<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Internal Medicine Clinical Reference Guide</title>
    <style>
        * {
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Arial, sans-serif;
            font-size: 10pt;
            line-height: 1.4;
            margin: 0;
            padding: 0;
            color: #24292e;
            background: #f6f8fa;
        }
        
        /* Search Styles */
        .toc-search-wrapper {
            position: relative;
            max-width: 500px;
            margin: 15px auto 20px auto;
        }
        .toc-search {
            width: 100%;
            padding: 12px 45px 12px 15px;
            border: 2px solid #e1e4e8;
            border-radius: 10px;
            font-size: 14px;
            background: #fff;
            -webkit-appearance: none;
        }
        .toc-search:focus {
            outline: none;
            border-color: #0366d6;
            box-shadow: 0 0 0 3px rgba(3, 102, 214, 0.1);
        }
        .toc-search::placeholder { color: #959da5; }
        .toc-search-clear {
            position: absolute;
            right: 12px;
            top: 50%;
            transform: translateY(-50%);
            background: #e1e4e8;
            border: none;
            width: 24px;
            height: 24px;
            border-radius: 50%;
            cursor: pointer;
            font-size: 12px;
            display: none;
            align-items: center;
            justify-content: center;
            color: #586069;
        }
        .toc-search-clear:hover { background: #d1d5da; }
        .toc-search-results {
            text-align: center;
            color: #586069;
            font-size: 12px;
            margin-bottom: 10px;
        }
        .toc-item.hidden { display: none; }
        .no-search-results {
            text-align: center;
            padding: 30px 20px;
            color: #586069;
            font-size: 14px;
        }
        
        .calculator {
            background: #fff3cd;
            border: 2px solid #ffc107;
            border-radius: 8px;
            padding: 15px;
            margin: 15px 0;
        }
        
        .calculator.collapsed .calculator-content {
            display: none;
        }
        
        .calculator-title {
            font-weight: 600;
            color: #856404;
            font-size: 11pt;
            margin-bottom: 10px;
            cursor: pointer;
            user-select: none;
        }
        
        .calculator-title:hover {
            color: #6c5303;
        }
        
        .calculator-title::before {
            content: 'â–¼ ';
            font-size: 9pt;
            display: inline-block;
            transition: transform 0.2s;
        }
        
        .calculator.collapsed .calculator-title::before {
            transform: rotate(-90deg);
        }
        
        .calculator.collapsed .calculator-title {
            margin-bottom: 0;
        }
        
        .calculator-content {
            /* Content wrapper */
        }
        
        .calc-item {
            margin: 12px 0;
            padding: 8px;
            background: white;
            border-radius: 4px;
            border: 1px solid #e8e8e8;
        }
        
        .calc-item label {
            display: block;
            font-weight: 600;
            margin-bottom: 6px;
            color: #333;
            font-size: 9.5pt;
        }
        
        .calc-item .hint {
            display: block;
            font-size: 8pt;
            color: #666;
            font-weight: normal;
            margin-top: 2px;
            font-style: italic;
        }
        
        .calc-item select, .calc-item input[type="number"] {
            width: 100%;
            padding: 8px 10px;
            border: 2px solid #ddd;
            border-radius: 4px;
            font-size: 9.5pt;
            background: white;
            transition: border-color 0.2s;
        }
        
        .calc-item select:focus, .calc-item input[type="number"]:focus {
            outline: none;
            border-color: #0366d6;
            box-shadow: 0 0 0 3px rgba(3, 102, 214, 0.1);
        }
        
        .calc-item input[type="number"]::placeholder {
            color: #999;
            font-style: italic;
        }
        
        .calc-item input[type="checkbox"] {
            width: 18px;
            height: 18px;
            margin-right: 8px;
            cursor: pointer;
            vertical-align: middle;
        }
        
        .calc-item.checkbox-item {
            padding: 10px;
            cursor: pointer;
            transition: background 0.2s;
        }
        
        .calc-item.checkbox-item:hover {
            background: #f8f9fa;
        }
        
        .calc-item.checkbox-item label {
            cursor: pointer;
            margin: 0;
            display: inline;
            font-weight: 500;
        }
        
        .calc-result {
            background: #d4edda;
            border: 2px solid #28a745;
            padding: 12px;
            margin-top: 12px;
            border-radius: 6px;
            font-weight: 600;
        }
        
        .calc-result.high-risk {
            background: #f8d7da;
            border-color: #dc3545;
        }
        
        .calc-button {
            background: #0366d6;
            color: white;
            border: none;
            padding: 8px 16px;
            border-radius: 6px;
            cursor: pointer;
            font-size: 9pt;
            margin-top: 10px;
        }
        
        .calc-button:hover {
            background: #0256c7;
        }
        
        .calc-description {
            font-size: 9pt;
            color: #666;
            margin-top: 8px;
            padding: 8px;
            background: #f9f9f9;
            border-radius: 4px;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            box-shadow: 0 1px 3px rgba(0,0,0,0.12);
        }
        
        .nav-header {
            background: #24292e;
            color: white;
            padding: 20px 30px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }
        
        .nav-header h1 {
            margin: 0;
            font-size: 22pt;
        }
        
        .nav-header p {
            margin: 5px 0 0 0;
            opacity: 0.9;
            font-size: 10pt;
        }
        
        .back-to-top {
            display: inline-block;
            background: #0366d6;
            color: white;
            padding: 8px 16px;
            text-decoration: none;
            border-radius: 6px;
            font-size: 9pt;
            margin-top: 10px;
            transition: background 0.2s;
        }
        
        .back-to-top:hover {
            background: #0256c7;
        }
        
        .toc {
            padding: 30px;
            background: #f6f8fa;
            border-bottom: 3px solid #e1e4e8;
            scroll-margin-top: 0;
        }
        
        .toc h2 {
            margin-top: 0;
            color: #24292e;
            font-size: 18pt;
            border-bottom: 2px solid #e1e4e8;
            padding-bottom: 10px;
        }
        
        .toc-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(280px, 1fr));
            gap: 12px;
            margin-top: 20px;
        }
        
        .toc-item {
            background: white;
            border: 1px solid #e1e4e8;
            border-radius: 6px;
            transition: all 0.2s;
        }
        
        .toc-item:hover {
            border-color: #0366d6;
            box-shadow: 0 2px 8px rgba(3,102,214,0.15);
            transform: translateY(-2px);
        }
        
        .toc-item a {
            text-decoration: none;
            color: #0366d6;
            font-weight: 600;
            font-size: 10pt;
            display: block;
            padding: 12px;
            -webkit-tap-highlight-color: rgba(3,102,214,0.2);
        }
        
        .toc-item a:hover {
            text-decoration: underline;
        }
        
        .toc-number {
            color: #586069;
            font-size: 9pt;
            font-weight: normal;
        }
        
        .condition-page {
            padding: 0px 30px 30px 30px;
            border-bottom: 3px solid #e1e4e8;
            scroll-margin-top: 0;
        }
        
        .page-header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 20px 25px;
            margin: 0 -30px 25px -30px;
            border-radius: 0;
        }
        
        .page-header h2 {
            margin: 0;
            font-size: 20pt;
        }
        
        .page-header .subtitle {
            font-size: 10pt;
            margin-top: 5px;
            opacity: 0.95;
        }
        
        .section {
            margin-bottom: 18px;
        }
        
        .section-title {
            background: #0366d6;
            color: white;
            padding: 6px 12px;
            font-weight: 600;
            font-size: 11pt;
            margin-bottom: 8px;
            border-radius: 4px;
        }
        
        .section-content {
            padding-left: 12px;
        }
        
        .label {
            font-weight: 600;
            color: #24292e;
        }
        
        .two-column {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 15px;
            margin: 15px 0;
        }
        
        @media (max-width: 768px) {
            .two-column {
                grid-template-columns: 1fr;
            }
            .toc-grid {
                grid-template-columns: 1fr;
            }
        }
        
        .box {
            border: 2px solid #d73a49;
            background: #ffeef0;
            padding: 12px;
            border-radius: 6px;
        }
        
        .box-title {
            font-weight: 600;
            color: #d73a49;
            margin-bottom: 6px;
            font-size: 11pt;
        }
        
        .pearl-box {
            border: 2px solid #28a745;
            background: #dcffe4;
            padding: 12px;
            margin: 15px 0;
            border-radius: 6px;
        }
        
        .pearl-title {
            font-weight: 600;
            color: #28a745;
            margin-bottom: 6px;
            font-size: 11pt;
        }
        
        ul {
            margin: 6px 0;
            padding-left: 20px;
        }
        
        li {
            margin: 4px 0;
        }
        
        p {
            margin: 6px 0;
        }
        
        .footer-section {
            background: #24292e;
            color: white;
            padding: 30px;
            text-align: center;
        }
        
        .footer-section p {
            margin: 5px 0;
            opacity: 0.8;
        }
        
        @media print {
            .nav-header, .back-to-top {
                display: none;
            }
            .condition-page {
                page-break-after: always;
            }
            body {
                background: white;
            }
            .container {
                box-shadow: none;
            }
        }
    </style>
</head>
<body>

    <div class="container">
        <div class="nav-header">
            <h1>Internal Medicine Clinical Reference Guide</h1>
            <p>338 Essential Conditions for Hospital Medicine</p>
            <a href="#toc" class="back-to-top">â†‘ Table of Contents</a>
        </div>
        
                <!-- TABLE OF CONTENTS -->
        <div id="toc" class="toc">
            <h1 class="toc-title">ðŸ“š Internal Medicine Clinical Reference Guide (IMCRG)</h1>
            <p class="toc-subtitle">Comprehensive iPad-Optimized Clinical Decision Support</p>
            <p class="toc-subtitle">Version 3.6 â€¢ 338 Conditions â€¢ <strong style="color: #e74c3c;">BUILD #27</strong></p>
            <p class="toc-subtitle"><em>Tap any condition below to jump to its management protocol.</em></p>
            <p class="toc-subtitle" style="margin-top: 10px;"><a href="#system-toc" style="color: #0366d6; font-weight: 600;">Or browse by Organ System â†’</a></p>
            
            <div class="toc-search-wrapper">
                <input type="text" class="toc-search" id="tocSearch" placeholder="Search conditions (e.g., ACS, sepsis, DKA...)" autocomplete="off" autocorrect="off" autocapitalize="off" spellcheck="false">
                <button class="toc-search-clear" id="tocSearchClear" type="button">âœ•</button>
            </div>
            <div class="toc-search-results" id="tocSearchResults"></div>
            
            <div class="toc-grid" id="tocGrid">
                <div class="toc-item">
                    <a href="#acs">
                        <span class="toc-number">1</span>
                        <span class="toc-title">ACUTE CORONARY SYNDROME (ACS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#heart-failure">
                        <span class="toc-number">2</span>
                        <span class="toc-title">ACUTE DECOMPENSATED HEART FAILURE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#afib">
                        <span class="toc-number">3</span>
                        <span class="toc-title">ATRIAL FIBRILLATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#htn-emergency">
                        <span class="toc-number">4</span>
                        <span class="toc-title">HYPERTENSIVE EMERGENCY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cap">
                        <span class="toc-number">5</span>
                        <span class="toc-title">COMMUNITY-ACQUIRED PNEUMONIA (CAP)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#copd">
                        <span class="toc-number">6</span>
                        <span class="toc-title">COPD EXACERBATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#asthma">
                        <span class="toc-number">7</span>
                        <span class="toc-title">ASTHMA EXACERBATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pe">
                        <span class="toc-number">8</span>
                        <span class="toc-title">PULMONARY EMBOLISM (PE)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#sepsis">
                        <span class="toc-number">9</span>
                        <span class="toc-title">SEPSIS/SEPTIC SHOCK</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#aki">
                        <span class="toc-number">10</span>
                        <span class="toc-title">ACUTE KIDNEY INJURY (AKI)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hyperkalemia">
                        <span class="toc-number">11</span>
                        <span class="toc-title">HYPERKALEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hyponatremia">
                        <span class="toc-number">12</span>
                        <span class="toc-title">HYPONATREMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#dka">
                        <span class="toc-number">13</span>
                        <span class="toc-title">DIABETIC KETOACIDOSIS (DKA)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hhs">
                        <span class="toc-number">14</span>
                        <span class="toc-title">HYPEROSMOLAR HYPERGLYCEMIC STATE (HHS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ugib">
                        <span class="toc-number">15</span>
                        <span class="toc-title">UPPER GI BLEED</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cirrhosis">
                        <span class="toc-number">16</span>
                        <span class="toc-title">CIRRHOSIS WITH ASCITES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#sbp">
                        <span class="toc-number">17</span>
                        <span class="toc-title">SPONTANEOUS BACTERIAL PERITONITIS (SBP)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#he">
                        <span class="toc-number">18</span>
                        <span class="toc-title">HEPATIC ENCEPHALOPATHY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pancreatitis">
                        <span class="toc-number">19</span>
                        <span class="toc-title">ACUTE PANCREATITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cellulitis">
                        <span class="toc-number">20</span>
                        <span class="toc-title">CELLULITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#uti">
                        <span class="toc-number">21</span>
                        <span class="toc-title">URINARY TRACT INFECTION / PYELONEPHRITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cdiff">
                        <span class="toc-number">22</span>
                        <span class="toc-title">C. DIFFICILE INFECTION (CDI)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#dvt">
                        <span class="toc-number">23</span>
                        <span class="toc-title">DEEP VEIN THROMBOSIS (DVT)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#stroke">
                        <span class="toc-number">24</span>
                        <span class="toc-title">ACUTE ISCHEMIC STROKE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#seizure">
                        <span class="toc-number">25</span>
                        <span class="toc-title">SEIZURE / STATUS EPILEPTICUS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#meningitis">
                        <span class="toc-number">26</span>
                        <span class="toc-title">BACTERIAL MENINGITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#anemia">
                        <span class="toc-number">27</span>
                        <span class="toc-title">ANEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#neutropenic-fever">
                        <span class="toc-number">28</span>
                        <span class="toc-title">NEUTROPENIC FEVER</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#etoh-withdrawal">
                        <span class="toc-number">29</span>
                        <span class="toc-title">ALCOHOL WITHDRAWAL</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#delirium">
                        <span class="toc-number">30</span>
                        <span class="toc-title">DELIRIUM</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hyperthyroid">
                        <span class="toc-number">31</span>
                        <span class="toc-title">HYPERTHYROIDISM / THYROID STORM</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hypothyroid">
                        <span class="toc-number">32</span>
                        <span class="toc-title">HYPOTHYROIDISM / MYXEDEMA COMA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#adrenal">
                        <span class="toc-number">33</span>
                        <span class="toc-title">ADRENAL INSUFFICIENCY / CRISIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hypercalcemia">
                        <span class="toc-number">34</span>
                        <span class="toc-title">HYPERCALCEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hypomag">
                        <span class="toc-number">35</span>
                        <span class="toc-title">HYPOMAGNESEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#rhabdo">
                        <span class="toc-number">36</span>
                        <span class="toc-title">RHABDOMYOLYSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#transfusion">
                        <span class="toc-number">37</span>
                        <span class="toc-title">TRANSFUSION REACTIONS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pleural-effusion">
                        <span class="toc-number">38</span>
                        <span class="toc-title">PLEURAL EFFUSION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pneumothorax">
                        <span class="toc-number">39</span>
                        <span class="toc-title">PNEUMOTHORAX</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#syncope">
                        <span class="toc-number">40</span>
                        <span class="toc-title">SYNCOPE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pericarditis">
                        <span class="toc-number">41</span>
                        <span class="toc-title">PERICARDITIS/PERICARDIAL EFFUSION/CARDIAC TAMPONADE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#endocarditis">
                        <span class="toc-number">42</span>
                        <span class="toc-title">INFECTIVE ENDOCARDITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#myocarditis">
                        <span class="toc-number">43</span>
                        <span class="toc-title">MYOCARDITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cardiogenic-shock">
                        <span class="toc-number">44</span>
                        <span class="toc-title">CARDIOGENIC SHOCK</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#bradycardia">
                        <span class="toc-number">45</span>
                        <span class="toc-title">SYMPTOMATIC BRADYCARDIA/HEART BLOCK (PACING)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#vt-vf">
                        <span class="toc-number">46</span>
                        <span class="toc-title">VENTRICULAR TACHYCARDIA/VENTRICULAR FIBRILLATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#limb-ischemia">
                        <span class="toc-number">47</span>
                        <span class="toc-title">ACUTE LIMB ISCHEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ild">
                        <span class="toc-number">48</span>
                        <span class="toc-title">ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASE (ILD)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hemoptysis">
                        <span class="toc-number">49</span>
                        <span class="toc-title">HEMOPTYSIS (MASSIVE)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hypercapnic-failure">
                        <span class="toc-number">50</span>
                        <span class="toc-title">ACUTE HYPERCAPNIC RESPIRATORY FAILURE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#tia">
                        <span class="toc-number">51</span>
                        <span class="toc-title">TRANSIENT ISCHEMIC ATTACK (TIA)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#gbs">
                        <span class="toc-number">52</span>
                        <span class="toc-title">GUILLAIN-BARRÃ‰ SYNDROME (GBS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#myasthenia">
                        <span class="toc-number">53</span>
                        <span class="toc-title">MYASTHENIA GRAVIS CRISIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#increased-icp">
                        <span class="toc-number">54</span>
                        <span class="toc-title">INCREASED INTRACRANIAL PRESSURE (ICP)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cord-compression">
                        <span class="toc-number">55</span>
                        <span class="toc-title">SPINAL CORD COMPRESSION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#influenza">
                        <span class="toc-number">56</span>
                        <span class="toc-title">INFLUENZA/SEVERE VIRAL PNEUMONIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#covid">
                        <span class="toc-number">57</span>
                        <span class="toc-title">COVID-19 SEVERE DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ssti">
                        <span class="toc-number">58</span>
                        <span class="toc-title">SKIN/SOFT TISSUE INFECTIONS (CELLULITIS, NECROTIZING FASCIITIS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#tb">
                        <span class="toc-number">59</span>
                        <span class="toc-title">TUBERCULOSIS (ACTIVE DISEASE)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hiv-aids">
                        <span class="toc-number">60</span>
                        <span class="toc-title">HIV/AIDS COMPLICATIONS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#opportunistic">
                        <span class="toc-number">61</span>
                        <span class="toc-title">OPPORTUNISTIC INFECTIONS IN IMMUNOCOMPROMISED HOST</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#siadh">
                        <span class="toc-number">62</span>
                        <span class="toc-title">SIADH (SYNDROME OF INAPPROPRIATE ADH)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#bowel-obstruction">
                        <span class="toc-number">63</span>
                        <span class="toc-title">BOWEL OBSTRUCTION (SMALL/LARGE)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ibd">
                        <span class="toc-number">64</span>
                        <span class="toc-title">INFLAMMATORY BOWEL DISEASE (IBD) FLARE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#tls">
                        <span class="toc-number">65</span>
                        <span class="toc-title">TUMOR LYSIS SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#thrombocytopenia">
                        <span class="toc-number">66</span>
                        <span class="toc-title">THROMBOCYTOPENIA (ITP, HIT, TTP/HUS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#dic">
                        <span class="toc-number">67</span>
                        <span class="toc-title">DISSEMINATED INTRAVASCULAR COAGULATION (DIC)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#gout">
                        <span class="toc-number">68</span>
                        <span class="toc-title">ACUTE GOUT/PSEUDOGOUT (CRYSTAL ARTHROPATHY)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#anaphylaxis">
                        <span class="toc-number">69</span>
                        <span class="toc-title">ANAPHYLAXIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#overdose">
                        <span class="toc-number">70</span>
                        <span class="toc-title">DRUG OVERDOSE/TOXIDROMES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#opioid">
                        <span class="toc-number">71</span>
                        <span class="toc-title">OPIOID OVERDOSE/WITHDRAWAL</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#appendicitis">
                        <span class="toc-number">72</span>
                        <span class="toc-title">ACUTE APPENDICITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cholangitis">
                        <span class="toc-number">73</span>
                        <span class="toc-title">ACUTE CHOLANGITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cholecystitis">
                        <span class="toc-number">74</span>
                        <span class="toc-title">ACUTE CHOLECYSTITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#encephalitis">
                        <span class="toc-number">75</span>
                        <span class="toc-title">ENCEPHALITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ich">
                        <span class="toc-number">76</span>
                        <span class="toc-title">INTRACEREBRAL HEMORRHAGE (ICH)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#perforation">
                        <span class="toc-number">77</span>
                        <span class="toc-title">GI PERFORATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#sah">
                        <span class="toc-number">78</span>
                        <span class="toc-title">SUBARACHNOID HEMORRHAGE (SAH)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#esophageal-spasm">
                        <span class="toc-number">79</span>
                        <span class="toc-title">ESOPHAGEAL SPASM</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#gastritis-erosions">
                        <span class="toc-number">80</span>
                        <span class="toc-title">GASTRITIS / GASTRIC EROSIONS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hemorrhoids">
                        <span class="toc-number">81</span>
                        <span class="toc-title">HEMORRHOIDS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#intraabdominal-abscess">
                        <span class="toc-number">82</span>
                        <span class="toc-title">INTRA-ABDOMINAL ABSCESS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#mallory-weiss">
                        <span class="toc-number">83</span>
                        <span class="toc-title">MALLORY-WEISS TEAR</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#neurogenic-shock">
                        <span class="toc-number">84</span>
                        <span class="toc-title">NEUROGENIC SHOCK</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ruptured-aaa">
                        <span class="toc-number">85</span>
                        <span class="toc-title">RUPTURED ABDOMINAL AORTIC ANEURYSM</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#b12-folate-deficiency">
                        <span class="toc-number">86</span>
                        <span class="toc-title">B12 / FOLATE DEFICIENCY ANEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#bone-marrow-failure">
                        <span class="toc-number">87</span>
                        <span class="toc-title">BONE MARROW FAILURE / MDS / APLASTIC ANEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#drug-induced-thrombocytopenia">
                        <span class="toc-number">88</span>
                        <span class="toc-title">DRUG-INDUCED THROMBOCYTOPENIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#acute-leukemia-lymphoma">
                        <span class="toc-number">89</span>
                        <span class="toc-title">ACUTE LEUKEMIA / LYMPHOMA (Acute Presentations)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cerebral-salt-wasting">
                        <span class="toc-number">90</span>
                        <span class="toc-title">CEREBRAL SALT WASTING (CSW)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#glomerulonephritis">
                        <span class="toc-number">91</span>
                        <span class="toc-title">ACUTE GLOMERULONEPHRITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#psychogenic-polydipsia">
                        <span class="toc-number">92</span>
                        <span class="toc-title">PSYCHOGENIC POLYDIPSIA (PRIMARY POLYDIPSIA)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#rta">
                        <span class="toc-number">93</span>
                        <span class="toc-title">RENAL TUBULAR ACIDOSIS (RTA)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#burns-third-spacing">
                        <span class="toc-number">94</span>
                        <span class="toc-title">BURNS / THIRD-SPACING</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hemiplegic-migraine">
                        <span class="toc-number">95</span>
                        <span class="toc-title">HEMIPLEGIC MIGRAINE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#todds-paralysis">
                        <span class="toc-number">96</span>
                        <span class="toc-title">TODD'S PARALYSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#traumatic-brain-injury">
                        <span class="toc-number">97</span>
                        <span class="toc-title">TRAUMATIC BRAIN INJURY (TBI)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#malaria">
                        <span class="toc-number">98</span>
                        <span class="toc-title">MALARIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#musculoskeletal-chest-pain">
                        <span class="toc-number">99</span>
                        <span class="toc-title">MUSCULOSKELETAL CHEST PAIN</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#diabetes-insipidus">
                        <span class="toc-number">100</span>
                        <span class="toc-title">DIABETES INSIPIDUS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pheo">
                        <span class="toc-number">101</span>
                        <span class="toc-title">PHEOCHROMOCYTOMA CRISIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#acute-diarrhea">
                        <span class="toc-number">102</span>
                        <span class="toc-title">SEVERE ACUTE DIARRHEA / VOLUME DEPLETION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#diverticulitis">
                        <span class="toc-number">103</span>
                        <span class="toc-title">DIVERTICULITIS (COMPLICATED)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cirrhosis-complications">
                        <span class="toc-number">104</span>
                        <span class="toc-title">CIRRHOSIS COMPLICATIONS (VARICEAL BLEEDING, HEPATORENAL SYNDROME)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#aclf">
                        <span class="toc-number">105</span>
                        <span class="toc-title">ACUTE-ON-CHRONIC LIVER FAILURE (ACLF)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#mesenteric-ischemia">
                        <span class="toc-number">106</span>
                        <span class="toc-title">ISCHEMIC BOWEL / MESENTERIC ISCHEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ckd-complications">
                        <span class="toc-number">107</span>
                        <span class="toc-title">CHRONIC KIDNEY DISEASE COMPLICATIONS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#uremia">
                        <span class="toc-number">108</span>
                        <span class="toc-title">UREMIC SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hypocalcemia">
                        <span class="toc-number">109</span>
                        <span class="toc-title">HYPOCALCEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#magnesium-disorders">
                        <span class="toc-number">110</span>
                        <span class="toc-title">HYPERMAGNESEMIA / HYPOMAGNESEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#phosphate">
                        <span class="toc-number">111</span>
                        <span class="toc-title">HYPERPHOSPHATEMIA / HYPOPHOSPHATEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#metabolic-alkalosis">
                        <span class="toc-number">112</span>
                        <span class="toc-title">METABOLIC ALKALOSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#sickle-cell">
                        <span class="toc-number">113</span>
                        <span class="toc-title">SICKLE CELL CRISIS (VASO-OCCLUSIVE, ACUTE CHEST SYNDROME)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hemolytic-anemia">
                        <span class="toc-number">114</span>
                        <span class="toc-title">HEMOLYTIC ANEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#onc-emergencies">
                        <span class="toc-number">115</span>
                        <span class="toc-title">ONCOLOGIC EMERGENCIES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#anticoag-reversal">
                        <span class="toc-number">116</span>
                        <span class="toc-title">ANTICOAGULATION REVERSAL / MAJOR BLEEDING</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#sle">
                        <span class="toc-number">117</span>
                        <span class="toc-title">SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) FLARE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#gca">
                        <span class="toc-number">118</span>
                        <span class="toc-title">GIANT CELL ARTERITIS / TEMPORAL ARTERITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ards">
                        <span class="toc-number">119</span>
                        <span class="toc-title">ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pulmonary-edema">
                        <span class="toc-number">120</span>
                        <span class="toc-title">ACUTE PULMONARY EDEMA / FLASH PULMONARY EDEMA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#viral-hepatitis">
                        <span class="toc-number">121</span>
                        <span class="toc-title">VIRAL HEPATITIS (ACUTE)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ischemic-hepatitis">
                        <span class="toc-number">122</span>
                        <span class="toc-title">ISCHEMIC HEPATITIS (SHOCK LIVER)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#aortic-dissection">
                        <span class="toc-number">123</span>
                        <span class="toc-title">AORTIC DISSECTION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cardiac-tamponade">
                        <span class="toc-number">124</span>
                        <span class="toc-title">CARDIAC TAMPONADE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#lower-gi-bleed">
                        <span class="toc-number">125</span>
                        <span class="toc-title">LOWER GI BLEED</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ttp-hus">
                        <span class="toc-number">126</span>
                        <span class="toc-title">TTP/HUS (THROMBOTIC MICROANGIOPATHY)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hit">
                        <span class="toc-number">127</span>
                        <span class="toc-title">HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#wernicke">
                        <span class="toc-number">128</span>
                        <span class="toc-title">WERNICKE ENCEPHALOPATHY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#nephrotic-syndrome">
                        <span class="toc-number">129</span>
                        <span class="toc-title">NEPHROTIC SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#aspiration-pneumonia">
                        <span class="toc-number">130</span>
                        <span class="toc-title">ASPIRATION PNEUMONIA / PNEUMONITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hap-vap">
                        <span class="toc-number">131</span>
                        <span class="toc-title">HOSPITAL-ACQUIRED / VENTILATOR-ASSOCIATED PNEUMONIA (HAP/VAP)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#critical-as">
                        <span class="toc-number">132</span>
                        <span class="toc-title">CRITICAL AORTIC STENOSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#acute-mr">
                        <span class="toc-number">133</span>
                        <span class="toc-title">ACUTE MITRAL REGURGITATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#svt">
                        <span class="toc-number">134</span>
                        <span class="toc-title">SUPRAVENTRICULAR TACHYCARDIA (SVT)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#massive-hemoptysis">
                        <span class="toc-number">135</span>
                        <span class="toc-title">MASSIVE HEMOPTYSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ph-crisis">
                        <span class="toc-number">136</span>
                        <span class="toc-title">PULMONARY HYPERTENSION CRISIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#dic">
                        <span class="toc-number">137</span>
                        <span class="toc-title">DISSEMINATED INTRAVASCULAR COAGULATION (DIC)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#tls">
                        <span class="toc-number">138</span>
                        <span class="toc-title">TUMOR LYSIS SYNDROME (TLS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hyperviscosity">
                        <span class="toc-number">139</span>
                        <span class="toc-title">HYPERVISCOSITY SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#myasthenic-crisis">
                        <span class="toc-number">140</span>
                        <span class="toc-title">MYASTHENIC CRISIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#gbs">
                        <span class="toc-number">141</span>
                        <span class="toc-title">GUILLAIN-BARRÃ‰ SYNDROME (GBS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#spinal-cord-compression">
                        <span class="toc-number">142</span>
                        <span class="toc-title">SPINAL CORD COMPRESSION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#apap-overdose">
                        <span class="toc-number">143</span>
                        <span class="toc-title">ACETAMINOPHEN OVERDOSE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#salicylate-toxicity">
                        <span class="toc-number">144</span>
                        <span class="toc-title">SALICYLATE TOXICITY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#toxic-alcohol">
                        <span class="toc-number">145</span>
                        <span class="toc-title">TOXIC ALCOHOL INGESTION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#opioid-overdose">
                        <span class="toc-number">146</span>
                        <span class="toc-title">OPIOID OVERDOSE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#vasculitis-emergency">
                        <span class="toc-number">147</span>
                        <span class="toc-title">VASCULITIS EMERGENCIES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#scleroderma-renal">
                        <span class="toc-number">148</span>
                        <span class="toc-title">SCLERODERMA RENAL CRISIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#gerd">
                        <span class="toc-number">149</span>
                        <span class="toc-title">GERD / ESOPHAGITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#barretts">
                        <span class="toc-number">150</span>
                        <span class="toc-title">BARRETT'S ESOPHAGUS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#esophageal-spasm">
                        <span class="toc-number">151</span>
                        <span class="toc-title">ESOPHAGEAL SPASM / MOTILITY DISORDERS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#costochondritis">
                        <span class="toc-number">152</span>
                        <span class="toc-title">COSTOCHONDRITIS / CHEST WALL PAIN</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#urosepsis">
                        <span class="toc-number">153</span>
                        <span class="toc-title">UROSEPSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#acute-respiratory-failure">
                        <span class="toc-number">154</span>
                        <span class="toc-title">ACUTE RESPIRATORY FAILURE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#acute-liver-failure">
                        <span class="toc-number">155</span>
                        <span class="toc-title">ACUTE LIVER FAILURE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#alcoholic-hepatitis">
                        <span class="toc-number">156</span>
                        <span class="toc-title">ALCOHOLIC HEPATITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ischemic-colitis">
                        <span class="toc-number">157</span>
                        <span class="toc-title">ISCHEMIC COLITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#choledocholithiasis">
                        <span class="toc-number">158</span>
                        <span class="toc-title">CHOLEDOCHOLITHIASIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#gastroparesis">
                        <span class="toc-number">159</span>
                        <span class="toc-title">GASTROPARESIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#serotonin-syndrome">
                        <span class="toc-number">160</span>
                        <span class="toc-title">SEROTONIN SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hypoglycemia">
                        <span class="toc-number">161</span>
                        <span class="toc-title">HYPOGLYCEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#nms">
                        <span class="toc-number">162</span>
                        <span class="toc-title">NEUROLEPTIC MALIGNANT SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#osteomyelitis">
                        <span class="toc-number">163</span>
                        <span class="toc-title">OSTEOMYELITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#septic-arthritis">
                        <span class="toc-number">164</span>
                        <span class="toc-title">SEPTIC ARTHRITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#epidural-abscess">
                        <span class="toc-number">165</span>
                        <span class="toc-title">SPINAL EPIDURAL ABSCESS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#clabsi">
                        <span class="toc-number">166</span>
                        <span class="toc-title">CLABSI</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#diabetic-foot-infection">
                        <span class="toc-number">167</span>
                        <span class="toc-title">DIABETIC FOOT INFECTION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#bb-ccb-toxicity">
                        <span class="toc-number">168</span>
                        <span class="toc-title">BETA BLOCKER / CCB TOXICITY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#digoxin-toxicity">
                        <span class="toc-number">169</span>
                        <span class="toc-title">DIGOXIN TOXICITY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#lithium-toxicity">
                        <span class="toc-number">170</span>
                        <span class="toc-title">LITHIUM TOXICITY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#tick-borne">
                        <span class="toc-number">171</span>
                        <span class="toc-title">TICK-BORNE ILLNESS (LYME, ANAPLASMOSIS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pid">
                        <span class="toc-number">172</span>
                        <span class="toc-title">PELVIC INFLAMMATORY DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#empyema">
                        <span class="toc-number">173</span>
                        <span class="toc-title">EMPYEMA / PARAPNEUMONIC EFFUSION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#lung-abscess">
                        <span class="toc-number">174</span>
                        <span class="toc-title">LUNG ABSCESS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#herpes-zoster">
                        <span class="toc-number">175</span>
                        <span class="toc-title">HERPES ZOSTER (SHINGLES)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#prostatitis">
                        <span class="toc-number">176</span>
                        <span class="toc-title">ACUTE BACTERIAL PROSTATITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#brain-abscess">
                        <span class="toc-number">177</span>
                        <span class="toc-title">BRAIN ABSCESS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#prosthetic-joint-infection">
                        <span class="toc-number">178</span>
                        <span class="toc-title">PROSTHETIC JOINT INFECTION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cied-infection">
                        <span class="toc-number">179</span>
                        <span class="toc-title">CIED INFECTION (PACEMAKER/ICD)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#transfusion-reactions">
                        <span class="toc-number">180</span>
                        <span class="toc-title">TRANSFUSION REACTIONS (TRALI/TACO)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#toxic-megacolon">
                        <span class="toc-number">181</span>
                        <span class="toc-title">TOXIC MEGACOLON</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pmr">
                        <span class="toc-number">182</span>
                        <span class="toc-title">POLYMYALGIA RHEUMATICA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#mdd">
                        <span class="toc-number">183</span>
                        <span class="toc-title">MAJOR DEPRESSIVE DISORDER</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#anxiety">
                        <span class="toc-number">184</span>
                        <span class="toc-title">ANXIETY DISORDERS (GAD / PANIC)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#bipolar">
                        <span class="toc-number">185</span>
                        <span class="toc-title">BIPOLAR DISORDER</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#chronic-urticaria">
                        <span class="toc-number">186</span>
                        <span class="toc-title">CHRONIC URTICARIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hae">
                        <span class="toc-number">187</span>
                        <span class="toc-title">HEREDITARY ANGIOEDEMA (HAE)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#allergic-rhinitis">
                        <span class="toc-number">188</span>
                        <span class="toc-title">ALLERGIC RHINITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#food-allergy">
                        <span class="toc-number">189</span>
                        <span class="toc-title">FOOD ALLERGY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#geriatric-syndromes">
                        <span class="toc-number">190</span>
                        <span class="toc-title">GERIATRIC SYNDROMES (FALLS / BEERS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#preventive-care">
                        <span class="toc-number">191</span>
                        <span class="toc-title">PREVENTIVE CARE & SCREENING</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ethics-capacity">
                        <span class="toc-number">192</span>
                        <span class="toc-title">MEDICAL ETHICS & CAPACITY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pcos">
                        <span class="toc-number">193</span>
                        <span class="toc-title">POLYCYSTIC OVARY SYNDROME (PCOS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#mononucleosis">
                        <span class="toc-number">194</span>
                        <span class="toc-title">INFECTIOUS MONONUCLEOSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#adult-still">
                        <span class="toc-number">195</span>
                        <span class="toc-title">ADULT-ONSET STILL'S DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#behcet">
                        <span class="toc-number">196</span>
                        <span class="toc-title">BEHÃ‡ET'S DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#rheumatoid-arthritis">
                        <span class="toc-number">197</span>
                        <span class="toc-title">RHEUMATOID ARTHRITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#spondyloarthropathy">
                        <span class="toc-number">198</span>
                        <span class="toc-title">SPONDYLOARTHROPATHIES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#osteoarthritis">
                        <span class="toc-number">199</span>
                        <span class="toc-title">OSTEOARTHRITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#lupus-nephritis">
                        <span class="toc-number">200</span>
                        <span class="toc-title">LUPUS NEPHRITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#drug-induced-lupus">
                        <span class="toc-number">201</span>
                        <span class="toc-title">DRUG-INDUCED LUPUS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#systemic-sclerosis">
                        <span class="toc-number">202</span>
                        <span class="toc-title">SYSTEMIC SCLEROSIS / SCLERODERMA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#inflammatory-myopathy">
                        <span class="toc-number">203</span>
                        <span class="toc-title">INFLAMMATORY MYOPATHIES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#sjogren">
                        <span class="toc-number">204</span>
                        <span class="toc-title">SJÃ–GREN'S SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#mctd">
                        <span class="toc-number">205</span>
                        <span class="toc-title">MIXED CONNECTIVE TISSUE DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#aps">
                        <span class="toc-number">206</span>
                        <span class="toc-title">ANTIPHOSPHOLIPID SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#sarcoidosis">
                        <span class="toc-number">207</span>
                        <span class="toc-title">SARCOIDOSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#igg4">
                        <span class="toc-number">208</span>
                        <span class="toc-title">IgG4-RELATED DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#amyloidosis">
                        <span class="toc-number">209</span>
                        <span class="toc-title">AMYLOIDOSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#osteoporosis">
                        <span class="toc-number">210</span>
                        <span class="toc-title">OSTEOPOROSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#paget">
                        <span class="toc-number">211</span>
                        <span class="toc-title">PAGET'S DISEASE OF BONE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#osteonecrosis">
                        <span class="toc-number">212</span>
                        <span class="toc-title">OSTEONECROSIS (AVN)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#fibromyalgia">
                        <span class="toc-number">213</span>
                        <span class="toc-title">FIBROMYALGIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cauda-equina">
                        <span class="toc-number">214</span>
                        <span class="toc-title">CAUDA EQUINA SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cushing">
                        <span class="toc-number">215</span>
                        <span class="toc-title">CUSHING SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#primary-aldosteronism">
                        <span class="toc-number">216</span>
                        <span class="toc-title">PRIMARY ALDOSTERONISM</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#prolactinoma">
                        <span class="toc-number">217</span>
                        <span class="toc-title">PROLACTINOMA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#acromegaly">
                        <span class="toc-number">218</span>
                        <span class="toc-title">ACROMEGALY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#men-syndromes">
                        <span class="toc-number">219</span>
                        <span class="toc-title">MEN SYNDROMES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pbc">
                        <span class="toc-number">220</span>
                        <span class="toc-title">PRIMARY BILIARY CHOLANGITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#nafld">
                        <span class="toc-number">221</span>
                        <span class="toc-title">NAFLD / NASH / MASLD</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#chronic-cad">
                        <span class="toc-number">222</span>
                        <span class="toc-title">CHRONIC CORONARY DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#stress-testing">
                        <span class="toc-number">223</span>
                        <span class="toc-title">STRESS TESTING SELECTION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pci-cabg">
                        <span class="toc-number">224</span>
                        <span class="toc-title">PCI vs CABG INDICATIONS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#icd-crt">
                        <span class="toc-number">225</span>
                        <span class="toc-title">ICD / CRT DEVICE THERAPY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hcm">
                        <span class="toc-number">226</span>
                        <span class="toc-title">HYPERTROPHIC CARDIOMYOPATHY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cardiomyopathies">
                        <span class="toc-number">227</span>
                        <span class="toc-title">DILATED & RESTRICTIVE CARDIOMYOPATHY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#constrictive-pericarditis">
                        <span class="toc-number">228</span>
                        <span class="toc-title">CONSTRICTIVE PERICARDITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#bradyarrhythmias">
                        <span class="toc-number">229</span>
                        <span class="toc-title">BRADYARRHYTHMIAS & PACING</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#scd-prevention">
                        <span class="toc-number">230</span>
                        <span class="toc-title">SUDDEN CARDIAC DEATH PREVENTION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pad">
                        <span class="toc-number">231</span>
                        <span class="toc-title">PERIPHERAL ARTERY DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#statin-guidelines">
                        <span class="toc-number">232</span>
                        <span class="toc-title">STATIN THERAPY GUIDELINES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#inpatient-insulin">
                        <span class="toc-number">233</span>
                        <span class="toc-title">INPATIENT INSULIN MANAGEMENT</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#insulin-types">
                        <span class="toc-number">234</span>
                        <span class="toc-title">INSULIN TYPES & PHARMACOLOGY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#euglycemic-dka">
                        <span class="toc-number">235</span>
                        <span class="toc-title">EUGLYCEMIC DKA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#diabetic-complications">
                        <span class="toc-number">236</span>
                        <span class="toc-title">DIABETIC MICROVASCULAR COMPLICATIONS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#subclinical-hypothyroid">
                        <span class="toc-number">237</span>
                        <span class="toc-title">SUBCLINICAL HYPOTHYROIDISM</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#thyroid-nodules">
                        <span class="toc-number">238</span>
                        <span class="toc-title">THYROID NODULES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#thyroiditis">
                        <span class="toc-number">239</span>
                        <span class="toc-title">THYROIDITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hypogonadism">
                        <span class="toc-number">240</span>
                        <span class="toc-title">MALE HYPOGONADISM</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#zes">
                        <span class="toc-number">241</span>
                        <span class="toc-title">ZOLLINGER-ELLISON SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#sibo">
                        <span class="toc-number">242</span>
                        <span class="toc-title">SIBO</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#malabsorption">
                        <span class="toc-number">243</span>
                        <span class="toc-title">MALABSORPTION SYNDROMES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#microscopic-colitis">
                        <span class="toc-number">244</span>
                        <span class="toc-title">MICROSCOPIC COLITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hereditary-crc">
                        <span class="toc-number">245</span>
                        <span class="toc-title">HEREDITARY CRC SYNDROMES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#psc">
                        <span class="toc-number">246</span>
                        <span class="toc-title">PRIMARY SCLEROSING CHOLANGITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#wilson">
                        <span class="toc-number">247</span>
                        <span class="toc-title">WILSON DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hemochromatosis">
                        <span class="toc-number">248</span>
                        <span class="toc-title">HEREDITARY HEMOCHROMATOSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#eoe">
                        <span class="toc-number">249</span>
                        <span class="toc-title">EOSINOPHILIC ESOPHAGITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ipf">
                        <span class="toc-number">250</span>
                        <span class="toc-title">IDIOPATHIC PULMONARY FIBROSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cystic-fibrosis">
                        <span class="toc-number">251</span>
                        <span class="toc-title">CYSTIC FIBROSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#a1at">
                        <span class="toc-number">252</span>
                        <span class="toc-title">ALPHA-1 ANTITRYPSIN DEFICIENCY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#bronchiectasis">
                        <span class="toc-number">253</span>
                        <span class="toc-title">BRONCHIECTASIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hp">
                        <span class="toc-number">254</span>
                        <span class="toc-title">HYPERSENSITIVITY PNEUMONITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pulm-nodule">
                        <span class="toc-number">255</span>
                        <span class="toc-title">PULMONARY NODULE EVALUATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#thalassemia">
                        <span class="toc-number">256</span>
                        <span class="toc-title">THALASSEMIAS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#mpn">
                        <span class="toc-number">257</span>
                        <span class="toc-title">MYELOPROLIFERATIVE NEOPLASMS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cml">
                        <span class="toc-number">258</span>
                        <span class="toc-title">CHRONIC MYELOID LEUKEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cll">
                        <span class="toc-number">259</span>
                        <span class="toc-title">CHRONIC LYMPHOCYTIC LEUKEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#myeloma">
                        <span class="toc-number">260</span>
                        <span class="toc-title">MULTIPLE MYELOMA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#vwd">
                        <span class="toc-number">261</span>
                        <span class="toc-title">VON WILLEBRAND DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hemophilia">
                        <span class="toc-number">262</span>
                        <span class="toc-title">HEMOPHILIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ms">
                        <span class="toc-number">263</span>
                        <span class="toc-title">MULTIPLE SCLEROSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#parkinsons">
                        <span class="toc-number">264</span>
                        <span class="toc-title">PARKINSON DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#essential-tremor">
                        <span class="toc-number">265</span>
                        <span class="toc-title">ESSENTIAL TREMOR</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#als">
                        <span class="toc-number">266</span>
                        <span class="toc-title">ALS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#nph">
                        <span class="toc-number">267</span>
                        <span class="toc-title">NORMAL PRESSURE HYDROCEPHALUS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#headache-syndromes">
                        <span class="toc-number">268</span>
                        <span class="toc-title">HEADACHE SYNDROMES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#peripheral-neuropathy">
                        <span class="toc-number">269</span>
                        <span class="toc-title">PERIPHERAL NEUROPATHY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#dementia">
                        <span class="toc-number">270</span>
                        <span class="toc-title">DEMENTIA SYNDROMES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#vertigo">
                        <span class="toc-number">271</span>
                        <span class="toc-title">VERTIGO</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#anca-vasculitis">
                        <span class="toc-number">272</span>
                        <span class="toc-title">ANCA VASCULITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pan">
                        <span class="toc-number">273</span>
                        <span class="toc-title">POLYARTERITIS NODOSA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#reactive-arthritis">
                        <span class="toc-number">274</span>
                        <span class="toc-title">REACTIVE ARTHRITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#raynaud">
                        <span class="toc-number">275</span>
                        <span class="toc-title">RAYNAUD PHENOMENON</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cryoglobulinemia">
                        <span class="toc-number">276</span>
                        <span class="toc-title">CRYOGLOBULINEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#invasive-candida">
                        <span class="toc-number">277</span>
                        <span class="toc-title">INVASIVE CANDIDIASIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pcp">
                        <span class="toc-number">278</span>
                        <span class="toc-title">PNEUMOCYSTIS PNEUMONIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#aspergillosis">
                        <span class="toc-number">279</span>
                        <span class="toc-title">INVASIVE ASPERGILLOSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cryptococcus">
                        <span class="toc-number">280</span>
                        <span class="toc-title">CRYPTOCOCCAL MENINGITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#endemic-mycoses">
                        <span class="toc-number">281</span>
                        <span class="toc-title">ENDEMIC MYCOSES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#sjs-ten">
                        <span class="toc-number">282</span>
                        <span class="toc-title">SJS / TEN</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#dress">
                        <span class="toc-number">283</span>
                        <span class="toc-title">DRESS SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cvid">
                        <span class="toc-number">284</span>
                        <span class="toc-title">PRIMARY IMMUNODEFICIENCIES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#eating-disorders">
                        <span class="toc-number">285</span>
                        <span class="toc-title">EATING DISORDERS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#sleep-disorders">
                        <span class="toc-number">286</span>
                        <span class="toc-title">SLEEP DISORDERS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#glomerular-diseases">
                        <span class="toc-number">287</span>
                        <span class="toc-title">GLOMERULAR DISEASES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#goodpasture">
                        <span class="toc-number">288</span>
                        <span class="toc-title">ANTI-GBM / GOODPASTURE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#contrast-nephropathy">
                        <span class="toc-number">289</span>
                        <span class="toc-title">CONTRAST-INDUCED NEPHROPATHY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#perioperative">
                        <span class="toc-number">290</span>
                        <span class="toc-title">PERIOPERATIVE EVALUATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#vte-prophylaxis">
                        <span class="toc-number">291</span>
                        <span class="toc-title">VTE PROPHYLAXIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#obesity-mgmt">
                        <span class="toc-number">292</span>
                        <span class="toc-title">OBESITY MANAGEMENT</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#smoking-cessation">
                        <span class="toc-number">293</span>
                        <span class="toc-title">SMOKING CESSATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#aud-oud">
                        <span class="toc-number">294</span>
                        <span class="toc-title">ALCOHOL & OPIOID USE DISORDERS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#variceal-bleeding">
                        <span class="toc-number">295</span>
                        <span class="toc-title">VARICEAL BLEEDING</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#ogilvie">
                        <span class="toc-number">296</span>
                        <span class="toc-title">OGILVIE SYNDROME (COLONIC PSEUDO-OBSTRUCTION)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#acalculous-cholecystitis">
                        <span class="toc-number">297</span>
                        <span class="toc-title">ACALCULOUS CHOLECYSTITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#liver-coagulopathy">
                        <span class="toc-number">298</span>
                        <span class="toc-title">COAGULOPATHY OF LIVER DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#takotsubo">
                        <span class="toc-number">299</span>
                        <span class="toc-title">TAKOTSUBO CARDIOMYOPATHY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#mitral-stenosis">
                        <span class="toc-number">300</span>
                        <span class="toc-title">MITRAL STENOSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#aortic-regurgitation">
                        <span class="toc-number">301</span>
                        <span class="toc-title">AORTIC REGURGITATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#prosthetic-valve">
                        <span class="toc-number">302</span>
                        <span class="toc-title">PROSTHETIC VALVE DYSFUNCTION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pres">
                        <span class="toc-number">303</span>
                        <span class="toc-title">PRES (POSTERIOR REVERSIBLE ENCEPHALOPATHY)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#osmotic-demyelination">
                        <span class="toc-number">304</span>
                        <span class="toc-title">OSMOTIC DEMYELINATION SYNDROME (CPM)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#iih">
                        <span class="toc-number">305</span>
                        <span class="toc-title">IIH (PSEUDOTUMOR CEREBRI)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#medication-overuse-headache">
                        <span class="toc-number">306</span>
                        <span class="toc-title">MEDICATION OVERUSE HEADACHE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hlh">
                        <span class="toc-number">307</span>
                        <span class="toc-title">HLH (HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#iron-deficiency-anemia">
                        <span class="toc-number">308</span>
                        <span class="toc-title">IRON DEFICIENCY ANEMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#paraneoplastic">
                        <span class="toc-number">309</span>
                        <span class="toc-title">PARANEOPLASTIC SYNDROMES</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#primary-hyperaldosteronism">
                        <span class="toc-number">310</span>
                        <span class="toc-title">PRIMARY HYPERALDOSTERONISM</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#carcinoid">
                        <span class="toc-number">311</span>
                        <span class="toc-title">CARCINOID SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hemothorax">
                        <span class="toc-number">312</span>
                        <span class="toc-title">HEMOTHORAX</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#chylothorax">
                        <span class="toc-number">313</span>
                        <span class="toc-title">CHYLOTHORAX</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#renal-vein-thrombosis">
                        <span class="toc-number">314</span>
                        <span class="toc-title">RENAL VEIN THROMBOSIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#atheroembolic-renal">
                        <span class="toc-number">315</span>
                        <span class="toc-title">ATHEROEMBOLIC RENAL DISEASE</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#catatonia">
                        <span class="toc-number">316</span>
                        <span class="toc-title">CATATONIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#malignant-hyperthermia">
                        <span class="toc-number">317</span>
                        <span class="toc-title">MALIGNANT HYPERTHERMIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hepatorenal-syndrome">
                        <span class="toc-number">318</span>
                        <span class="toc-title">HEPATORENAL SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#dili">
                        <span class="toc-number">319</span>
                        <span class="toc-title">DRUG-INDUCED LIVER INJURY (DILI)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#autoimmune-hepatitis">
                        <span class="toc-number">320</span>
                        <span class="toc-title">AUTOIMMUNE HEPATITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#budd-chiari">
                        <span class="toc-number">321</span>
                        <span class="toc-title">BUDD-CHIARI SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hepatopulmonary">
                        <span class="toc-number">322</span>
                        <span class="toc-title">HEPATOPULMONARY SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#contrast-nephropathy">
                        <span class="toc-number">323</span>
                        <span class="toc-title">CONTRAST-INDUCED NEPHROPATHY</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#acute-interstitial-nephritis">
                        <span class="toc-number">324</span>
                        <span class="toc-title">ACUTE INTERSTITIAL NEPHRITIS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#cppd">
                        <span class="toc-number">325</span>
                        <span class="toc-title">CPPD (PSEUDOGOUT)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#angioedema">
                        <span class="toc-number">326</span>
                        <span class="toc-title">ANGIOEDEMA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#trali">
                        <span class="toc-number">327</span>
                        <span class="toc-title">TRALI (TRANSFUSION-RELATED ACUTE LUNG INJURY)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#taco">
                        <span class="toc-number">328</span>
                        <span class="toc-title">TACO (TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD)</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#endemic-fungal">
                        <span class="toc-number">329</span>
                        <span class="toc-title">ENDEMIC FUNGAL INFECTIONS</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#pulmonary-hypertension">
                        <span class="toc-number">330</span>
                        <span class="toc-title">PULMONARY HYPERTENSION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#osa">
                        <span class="toc-number">331</span>
                        <span class="toc-title">OBSTRUCTIVE SLEEP APNEA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hyperparathyroidism">
                        <span class="toc-number">332</span>
                        <span class="toc-title">HYPERPARATHYROIDISM</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#hypoparathyroidism">
                        <span class="toc-number">333</span>
                        <span class="toc-title">HYPOPARATHYROIDISM</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#tricuspid-regurgitation">
                        <span class="toc-number">334</span>
                        <span class="toc-title">TRICUSPID REGURGITATION</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#long-qt">
                        <span class="toc-number">335</span>
                        <span class="toc-title">LONG QT SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#brugada">
                        <span class="toc-number">336</span>
                        <span class="toc-title">BRUGADA SYNDROME</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#vap">
                        <span class="toc-number">337</span>
                        <span class="toc-title">VENTILATOR-ASSOCIATED PNEUMONIA</span>
                    </a>
                </div>
                <div class="toc-item">
                    <a href="#fat-embolism">
                        <span class="toc-number">338</span>
                        <span class="toc-title">FAT EMBOLISM SYNDROME</span>
                    </a>
                </div>
            </div>
            
            <!-- SYSTEM-BASED TABLE OF CONTENTS -->
            <div id="system-toc" style="margin-top: 30px; padding-top: 20px; border-top: 2px solid #e1e4e8;">
                <h2 style="color: #24292e; font-size: 14pt; margin-bottom: 15px;">Browse by Organ System</h2>
                
                <div style="display: grid; grid-template-columns: repeat(auto-fill, minmax(180px, 1fr)); gap: 20px;">
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Cardiology</strong>
                        <a href="#acs" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">ACS</a>
                        <a href="#heart-failure" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Heart Failure</a>
                        <a href="#afib" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Atrial Fibrillation</a>
                        <a href="#htn-emergency" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">HTN Emergency</a>
                        <a href="#syncope" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Syncope</a>
                        <a href="#pericarditis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Pericarditis</a>
                        <a href="#costochondritis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Costochondritis</a>
                        <a href="#endocarditis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Endocarditis</a>
                        <a href="#cardiogenic-shock" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Cardiogenic Shock</a>
                        <a href="#vt-vf" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">VT/VF</a>
                        <a href="#svt" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">SVT</a>
                        <a href="#aortic-dissection" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Aortic Dissection</a>
                        <a href="#cardiac-tamponade" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Cardiac Tamponade</a>
                        <a href="#critical-as" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Critical AS</a>
                        <a href="#acute-mr" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Acute MR</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Pulmonology</strong>
                        <a href="#acute-respiratory-failure" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Acute Respiratory Failure</a>
                        <a href="#cap" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">CAP</a>
                        <a href="#copd" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">COPD Exacerbation</a>
                        <a href="#asthma" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Asthma Exacerbation</a>
                        <a href="#pe" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Pulmonary Embolism</a>
                        <a href="#pleural-effusion" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Pleural Effusion</a>
                        <a href="#pneumothorax" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Pneumothorax</a>
                        <a href="#ards" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">ARDS</a>
                        <a href="#massive-hemoptysis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Massive Hemoptysis</a>
                        <a href="#hap-vap" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">HAP/VAP</a>
                        <a href="#ph-crisis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">PH Crisis</a>
                        <a href="#hypercapnic-failure" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Hypercapnic Failure</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">GI / Hepatology</strong>
                        <a href="#ugib" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Upper GI Bleed</a>
                        <a href="#lower-gi-bleed" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Lower GI Bleed</a>
                        <a href="#cirrhosis-complications" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Variceal Hemorrhage</a>
                        <a href="#gerd" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">GERD / Esophagitis</a>
                        <a href="#barretts" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Barrett's Esophagus</a>
                        <a href="#esophageal-spasm" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Esophageal Spasm</a>
                        <a href="#gastroparesis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Gastroparesis</a>
                        <a href="#cholecystitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Acute Cholecystitis</a>
                        <a href="#choledocholithiasis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Choledocholithiasis</a>
                        <a href="#cholangitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Cholangitis</a>
                        <a href="#pancreatitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Pancreatitis</a>
                        <a href="#appendicitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Appendicitis</a>
                        <a href="#diverticulitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Diverticulitis</a>
                        <a href="#bowel-obstruction" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Bowel Obstruction</a>
                        <a href="#ischemic-colitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Ischemic Colitis</a>
                        <a href="#mesenteric-ischemia" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Mesenteric Ischemia</a>
                        <a href="#ibd" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">IBD Flare</a>
                        <a href="#toxic-megacolon" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Toxic Megacolon</a>
                        <a href="#cdiff" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">C. diff</a>
                        <a href="#cirrhosis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Cirrhosis</a>
                        <a href="#acute-liver-failure" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Acute Liver Failure</a>
                        <a href="#alcoholic-hepatitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Alcoholic Hepatitis</a>
                        <a href="#sbp" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">SBP</a>
                        <a href="#he" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Hepatic Encephalopathy</a>
                        <a href="#cirrhosis-complications" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Hepatorenal Syndrome</a>
                        <a href="#pbc" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Primary Biliary Cholangitis</a>
                        <a href="#nafld" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">NAFLD / NASH</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Nephrology</strong>
                        <a href="#aki" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">AKI</a>
                        <a href="#hyperkalemia" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Hyperkalemia</a>
                        <a href="#hyponatremia" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Hyponatremia</a>
                        <a href="#ckd-complications" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">CKD Complications</a>
                        <a href="#uremia" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Uremia</a>
                        <a href="#glomerulonephritis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Glomerulonephritis</a>
                        <a href="#nephrotic-syndrome" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Nephrotic Syndrome</a>
                        <a href="#rhabdo" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Rhabdomyolysis</a>
                        <a href="#uti" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">UTI / Pyelonephritis</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Endocrine</strong>
                        <a href="#dka" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">DKA</a>
                        <a href="#hhs" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">HHS</a>
                        <a href="#hypoglycemia" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Hypoglycemia</a>
                        <a href="#hyperthyroid" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Thyroid Storm</a>
                        <a href="#hypothyroid" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Myxedema Coma</a>
                        <a href="#adrenal" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Adrenal Crisis</a>
                        <a href="#hypercalcemia" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Hypercalcemia</a>
                        <a href="#hypocalcemia" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Hypocalcemia</a>
                        <a href="#siadh" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">SIADH</a>
                        <a href="#diabetes-insipidus" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Diabetes Insipidus</a>
                        <a href="#pcos" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">PCOS</a>
                        <a href="#cushing" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Cushing Syndrome</a>
                        <a href="#primary-aldosteronism" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Primary Aldosteronism</a>
                        <a href="#prolactinoma" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Prolactinoma</a>
                        <a href="#acromegaly" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Acromegaly</a>
                        <a href="#men-syndromes" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">MEN Syndromes</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Neurology</strong>
                        <a href="#stroke" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Ischemic Stroke</a>
                        <a href="#ich" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">ICH</a>
                        <a href="#sah" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">SAH</a>
                        <a href="#seizure" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Seizure / Status</a>
                        <a href="#meningitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Meningitis</a>
                        <a href="#encephalitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Encephalitis</a>
                        <a href="#gbs" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Guillain-BarrÃ©</a>
                        <a href="#myasthenic-crisis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Myasthenic Crisis</a>
                        <a href="#increased-icp" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Increased ICP</a>
                        <a href="#delirium" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Delirium</a>
                        <a href="#wernicke" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Wernicke Encephalopathy</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Infectious Disease</strong>
                        <a href="#sepsis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Sepsis</a>
                        <a href="#urosepsis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Urosepsis</a>
                        <a href="#cellulitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Cellulitis</a>
                        <a href="#ssti" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Necrotizing Fasciitis</a>
                        <a href="#osteomyelitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Osteomyelitis</a>
                        <a href="#septic-arthritis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Septic Arthritis</a>
                        <a href="#epidural-abscess" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Epidural Abscess</a>
                        <a href="#clabsi" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">CLABSI</a>
                        <a href="#diabetic-foot-infection" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Diabetic Foot Infection</a>
                        <a href="#neutropenic-fever" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Neutropenic Fever</a>
                        <a href="#tb" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">TB</a>
                        <a href="#hiv-aids" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">HIV/AIDS</a>
                        <a href="#covid" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">COVID-19</a>
                        <a href="#influenza" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Influenza</a>
                        <a href="#tick-borne" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Tick-borne Illness</a>
                        <a href="#pid" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">PID</a>
                        <a href="#empyema" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Empyema</a>
                        <a href="#lung-abscess" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Lung Abscess</a>
                        <a href="#herpes-zoster" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Herpes Zoster</a>
                        <a href="#mononucleosis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Mononucleosis</a>
                        <a href="#prostatitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Prostatitis</a>
                        <a href="#brain-abscess" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Brain Abscess</a>
                        <a href="#prosthetic-joint-infection" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Prosthetic Joint Infection</a>
                        <a href="#cied-infection" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">CIED Infection</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Heme / Onc</strong>
                        <a href="#anemia" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Anemia</a>
                        <a href="#dvt" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">DVT</a>
                        <a href="#thrombocytopenia" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Thrombocytopenia</a>
                        <a href="#ttp-hus" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">TTP/HUS</a>
                        <a href="#hit" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">HIT</a>
                        <a href="#dic" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">DIC</a>
                        <a href="#tls" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Tumor Lysis Syndrome</a>
                        <a href="#sickle-cell" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Sickle Cell Crisis</a>
                        <a href="#transfusion" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Transfusion Medicine</a>
                        <a href="#transfusion-reactions" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Transfusion Reactions</a>
                        <a href="#anticoag-reversal" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Anticoag Reversal</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Rheumatology</strong>
                        <a href="#gout" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Gout / Pseudogout</a>
                        <a href="#rheumatoid-arthritis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Rheumatoid Arthritis</a>
                        <a href="#osteoarthritis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Osteoarthritis</a>
                        <a href="#spondyloarthropathy" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Spondyloarthropathies</a>
                        <a href="#sle" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">SLE Flare</a>
                        <a href="#lupus-nephritis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Lupus Nephritis</a>
                        <a href="#drug-induced-lupus" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Drug-Induced Lupus</a>
                        <a href="#systemic-sclerosis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Systemic Sclerosis</a>
                        <a href="#inflammatory-myopathy" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Inflammatory Myopathies</a>
                        <a href="#sjogren" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">SjÃ¶gren's Syndrome</a>
                        <a href="#aps" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Antiphospholipid Syndrome</a>
                        <a href="#gca" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Giant Cell Arteritis</a>
                        <a href="#pmr" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Polymyalgia Rheumatica</a>
                        <a href="#adult-still" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Adult Still's Disease</a>
                        <a href="#behcet" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">BehÃ§et's Disease</a>
                        <a href="#vasculitis-emergency" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Vasculitis</a>
                        <a href="#sarcoidosis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Sarcoidosis</a>
                        <a href="#igg4" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">IgG4-Related Disease</a>
                        <a href="#amyloidosis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Amyloidosis</a>
                        <a href="#fibromyalgia" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Fibromyalgia</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Bone / Orthopedic</strong>
                        <a href="#osteoporosis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Osteoporosis</a>
                        <a href="#paget" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Paget's Disease</a>
                        <a href="#osteonecrosis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Osteonecrosis (AVN)</a>
                        <a href="#cauda-equina" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Cauda Equina Syndrome</a>
                        <a href="#spinal-cord-compression" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Spinal Cord Compression</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Toxicology</strong>
                        <a href="#overdose" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Toxidromes</a>
                        <a href="#opioid" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Opioid Overdose</a>
                        <a href="#apap-overdose" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Acetaminophen</a>
                        <a href="#salicylate-toxicity" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Salicylate Toxicity</a>
                        <a href="#toxic-alcohol" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Toxic Alcohols</a>
                        <a href="#serotonin-syndrome" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Serotonin Syndrome</a>
                        <a href="#nms" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Neuroleptic Malignant Syndrome</a>
                        <a href="#bb-ccb-toxicity" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">BB / CCB Toxicity</a>
                        <a href="#digoxin-toxicity" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Digoxin Toxicity</a>
                        <a href="#lithium-toxicity" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Lithium Toxicity</a>
                        <a href="#anaphylaxis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Anaphylaxis</a>
                        <a href="#etoh-withdrawal" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Alcohol Withdrawal</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Psychiatry</strong>
                        <a href="#mdd" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Depression (MDD)</a>
                        <a href="#anxiety" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Anxiety / Panic / PTSD</a>
                        <a href="#bipolar" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Bipolar Disorder</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Allergy / Immunology</strong>
                        <a href="#chronic-urticaria" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Chronic Urticaria</a>
                        <a href="#hae" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Hereditary Angioedema</a>
                        <a href="#allergic-rhinitis" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Allergic Rhinitis</a>
                        <a href="#food-allergy" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Food Allergy</a>
                    </div>
                    
                    <div>
                        <strong style="color: #24292e; display: block; margin-bottom: 6px; padding-bottom: 4px; border-bottom: 1px solid #e1e4e8;">Geriatrics / Preventtic Care</strong>
                        <a href="#geriatric-syndromes" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Falls / Beers / Elder Abuse</a>
                        <a href="#preventive-care" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Cancer Screening</a>
                        <a href="#ethics-capacity" style="display: block; padding: 2px 0; color: #0366d6; text-decoration: none;">Ethics / Capacity</a>
                    </div>
                </div>
            </div>
            
<p style="margin-top: 20px; text-align: center;">
                <a href="#toc" style="color: #0366d6; text-decoration: none; font-weight: 600;">â†‘ Back to Numerical Table of Contents</a>
                &nbsp;&nbsp;|&nbsp;&nbsp;
                <a href="#system-toc" style="color: #0366d6; text-decoration: none; font-weight: 600;">â†‘ Back to System-Based ToC</a>
            </p>
        </div>

<div id="acs" class="condition-page">
            <div class="page-header">
                <h2>1. ACUTE CORONARY SYNDROME (ACS)</h2>
                <div class="subtitle">STEMI â€¢ NSTEMI â€¢ Unstable Angina</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Substernal chest pain/pressure >20 minutes, radiation to jaw/left arm/back, diaphoresis, nausea, dyspnea. Pain not relieved by rest or nitroglycerin.</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Diabetics/Elderly/Women:</strong> Atypical symptoms - dyspnea alone, weakness, epigastric pain, syncope</li>
                        <li><strong>Silent MI:</strong> No chest pain (30% of diabetics)</li>
                        <li><strong>RV Infarction:</strong> Hypotension with clear lungs, JVD, Kussmaul sign</li>
                        <li><strong>Posterior MI:</strong> Isolated ST depression V1-V3, need posterior leads (V7-V9)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate:</span> ECG within 10 minutes, troponin (repeat at 3 and 6 hours if initial negative), CBC, BMP, PT/INR, lipid panel, CXR</p>
                    <p><span class="label">STEMI Criteria:</span> ST elevation â‰¥1mm in 2+ contiguous leads OR new LBBB OR ST depression V1-V3 (posterior MI)</p>
                    <p><span class="label">Calculations:</span> <a href="#calc-heart" style="color: #0366d6;">HEART Score</a>, <a href="#calc-timi-stemi" style="color: #0366d6;">TIMI STEMI</a>, <a href="#calc-timi-nstemi" style="color: #0366d6;">TIMI NSTEMI</a>, <a href="#calc-grace" style="color: #0366d6;">GRACE Score</a></p>
                    
                    <!-- HEART Score Calculator -->
                    <div id="calc-heart" class="calculator collapsed">
                        <div class="calculator-title" onclick="this.parentElement.classList.toggle('collapsed')">ðŸ§® HEART Score Calculator</div>
                        <div class="calculator-content">
                        <div class="calc-description">
                            <strong>Use:</strong> Risk stratification for chest pain patients to determine if safe for outpatient evaluation. Score 0-3 = low risk (outpatient), 4-6 = moderate risk (observe), 7-10 = high risk (admit).
                        </div>
                        
                        <div class="calc-item">
                            <label>History
                                <span class="hint">How suspicious is the patient's story for ACS?</span>
                            </label>
                            <select id="heart-history">
                                <option value="" disabled selected>-- Select --</option>
                                <option value="0">Slightly suspicious - probably not cardiac (0)</option>
                                <option value="1">Moderately suspicious - could be cardiac (1)</option>
                                <option value="2">Highly suspicious - typical angina (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>ECG
                                <span class="hint">Initial ECG findings</span>
                            </label>
                            <select id="heart-ecg">
                                <option value="" disabled selected>-- Select --</option>
                                <option value="0">Normal (0)</option>
                                <option value="1">Non-specific repolarization changes (1)</option>
                                <option value="2">Significant ST deviation (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>Age
                                <span class="hint">Patient's age in years</span>
                            </label>
                            <select id="heart-age">
                                <option value="" disabled selected>-- Select --</option>
                                <option value="0">&lt;21 years (0)</option>
                                <option value="1">21-45 years (1)</option>
                                <option value="2">45-65 years (2)</option>
                                <option value="2">&gt;65 years (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>Risk Factors
                                <span class="hint">Count: HTN, DM, smoking, high cholesterol, family history, obesity</span>
                            </label>
                            <select id="heart-risk">
                                <option value="" disabled selected>-- Select --</option>
                                <option value="0">None (0)</option>
                                <option value="1">1-2 risk factors (1)</option>
                                <option value="2">â‰¥3 risk factors or history of atherosclerotic disease (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>Troponin
                                <span class="hint">Initial troponin level relative to upper limit of normal</span>
                            </label>
                            <select id="heart-trop">
                                <option value="" disabled selected>-- Select --</option>
                                <option value="0">Normal - below upper limit (0)</option>
                                <option value="1">1-3Ã— upper limit of normal (1)</option>
                                <option value="2">&gt;3Ã— upper limit of normal (2)</option>
                            </select>
                        </div>
                        
                        <button class="calc-button" onclick="calculateHEART()">Calculate HEART Score</button>
                        <div id="heart-result" class="calc-result" style="display:none;"></div>
                        </div>
                    </div>
                    
                    <!-- TIMI STEMI Calculator -->
                    <div id="calc-timi-stemi" class="calculator collapsed">
                        <div class="calculator-title" onclick="this.parentElement.classList.toggle('collapsed')">ðŸ§® TIMI Risk Score - STEMI</div>
                        <div class="calculator-content">
                        <div class="calc-description">
                            <strong>Use:</strong> Predicts 30-day mortality in STEMI patients. Score 0-2 = 2% mortality, 3-4 = 5%, 5-6 = 12%, >6 = 36%.
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-age65"> Age 65-74 years
                                <span class="hint">+2 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-age75"> Age â‰¥75 years
                                <span class="hint">+3 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-dm"> Diabetes, Hypertension, or Angina history
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-bp"> Systolic BP <100 mmHg
                                <span class="hint">+3 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-hr"> Heart rate >100 bpm
                                <span class="hint">+2 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-killip"> Killip class II-IV (rales, S3, pulmonary edema, shock)
                                <span class="hint">+2 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-weight"> Weight <67 kg (150 lbs)
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-anterior"> Anterior STEMI or LBBB
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-time"> Time to treatment >4 hours
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateTIMI_STEMI()">Calculate TIMI STEMI Score</button>
                        <div id="timi-stemi-result" class="calc-result" style="display:none;"></div>
                        </div>
                    </div>
                    
                    <!-- TIMI NSTEMI Calculator -->
                    <div id="calc-timi-nstemi" class="calculator collapsed">
                        <div class="calculator-title" onclick="this.parentElement.classList.toggle('collapsed')">ðŸ§® TIMI Risk Score - NSTEMI/UA</div>
                        <div class="calculator-content">
                        <div class="calc-description">
                            <strong>Use:</strong> Risk of death, MI, or urgent revascularization within 14 days. Score 0-2 = 5% risk (low), 3-4 = 13% (moderate), 5-7 = 41% (high).
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-age"> Age â‰¥65 years
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-risk"> â‰¥3 CAD risk factors
                                <span class="hint">HTN, DM, smoking, high cholesterol, family history (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-cad"> Known CAD (stenosis â‰¥50%)
                                <span class="hint">Prior cath showing >50% stenosis (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-asa"> Aspirin use in past 7 days
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-angina"> Severe angina
                                <span class="hint">â‰¥2 episodes within 24 hours (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-ecg"> ST changes â‰¥0.5mm
                                <span class="hint">ST elevation or depression (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-trop"> Elevated cardiac markers
                                <span class="hint">Troponin or CK-MB elevated (+1 point)</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateTIMI_NSTEMI()">Calculate TIMI NSTEMI Score</button>
                        <div id="timi-nstemi-result" class="calc-result" style="display:none;"></div>
                        </div>
                    </div>
                    
                    <!-- GRACE Score Calculator -->
                    <div id="calc-grace" class="calculator collapsed">
                        <div class="calculator-title" onclick="this.parentElement.classList.toggle('collapsed')">ðŸ§® GRACE Score Calculator</div>
                        <div class="calculator-content">
                        <div class="calc-description">
                            <strong>Use:</strong> Estimates in-hospital and 6-month mortality in ACS. Low risk <109, intermediate 109-140, high >140. More accurate than TIMI for mortality prediction.
                        </div>
                        
                        <div class="calc-item">
                            <label>Age (years)
                                <span class="hint">Patient's age - typical range 40-80</span>
                            </label>
                            <input type="number" id="grace-age" placeholder="e.g., 65" min="18" max="120" >
                        </div>
                        
                        <div class="calc-item">
                            <label>Heart Rate (bpm)
                                <span class="hint">Beats per minute - typical range 60-100</span>
                            </label>
                            <input type="number" id="grace-hr" placeholder="e.g., 85" min="30" max="250" >
                        </div>
                        
                        <div class="calc-item">
                            <label>Systolic Blood Pressure (mmHg)
                                <span class="hint">SBP at presentation - typical range 100-160</span>
                            </label>
                            <input type="number" id="grace-sbp" placeholder="e.g., 130" min="50" max="250" >
                        </div>
                        
                        <div class="calc-item">
                            <label>Creatinine (mg/dL)
                                <span class="hint">Serum creatinine - normal 0.6-1.2 mg/dL</span>
                            </label>
                            <input type="number" id="grace-cr" placeholder="e.g., 1.0" step="0.1" min="0.1" max="15" >
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="grace-arrest"> Cardiac arrest at admission
                                <span class="hint">+39 points</span>
                            </label>
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="grace-st"> ST segment deviation on ECG
                                <span class="hint">ST elevation or depression (+28 points)</span>
                            </label>
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="grace-enzymes" checked> Elevated cardiac enzymes
                                <span class="hint">Troponin or CK-MB elevated (+14 points)</span>
                            </label>
                        </div>
                        
                        <div class="calc-item">
                            <label>Killip Class
                                <span class="hint">Clinical heart failure classification</span>
                            </label>
                            <select id="grace-killip">
                                <option value="" disabled selected>-- Select --</option>
                                <option value="0">I - No heart failure signs (0)</option>
                                <option value="20">II - Rales or S3 gallop (+20)</option>
                                <option value="39">III - Pulmonary edema (+39)</option>
                                <option value="59">IV - Cardiogenic shock (+59)</option>
                            </select>
                        </div>
                        
                        <button class="calc-button" onclick="calculateGRACE()">Calculate GRACE Score</button>
                        <div id="grace-result" class="calc-result" style="display:none;"></div>
                        </div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Initial Management (MONA-BAH):</span></p>
                    <ul>
                        <li><strong>Morphine:</strong> 2-4mg IV PRN (use cautiously, may worsen outcomes)</li>
                        <li><strong>Oxygen:</strong> Only if SpO2 <90%</li>
                        <li><strong>Nitroglycerin:</strong> 0.4mg SL q5min Ã— 3 (avoid if RV infarct, SBP <90, recent PDE5 inhibitor)</li>
                        <li><strong>Aspirin:</strong> 325mg PO chewed immediately</li>
                        <li><strong>Î²-Blocker:</strong> Metoprolol 25-50mg PO (avoid if HF, bradycardia, hypotension)</li>
                        <li><strong>Anticoagulation:</strong> Heparin bolus + infusion or enoxaparin</li>
                        <li><strong>High-intensity statin:</strong> Atorvastatin 80mg</li>
                    </ul>
                    <p><span class="label">P2Y12 Inhibitor:</span> Ticagrelor 180mg load (preferred) or clopidogrel 600mg load</p>
                    <p><span class="label">STEMI Specific:</span> Door-to-balloon <90 minutes. Call cath lab immediately. If PCI unavailable within 120 min, consider fibrinolytics (tPA, reteplase, tenecteplase)</p>
                    <p><span class="label">NSTEMI Specific:</span> Risk stratify with TIMI/GRACE. High-risk â†’ early invasive strategy (<24hr). Low-risk â†’ medical management, stress test before discharge</p>
                    
                    <p><span class="label">Post-MI Arrhythmia Monitoring:</span></p>
                    <ul>
                        <li><strong>48-Hour Standard:</strong> Continuous cardiac telemetry monitoring for minimum 48 hours is the standard post-MI observation period. Life-threatening arrhythmias (VF, VT, high-grade AV blocks) are most common in first 48 hours post-infarction, with peak risk in first 24 hours</li>
                        <li><strong>Early Discharge Considerations:</strong> Hemodynamically stable, low-risk patients without complications may be considered for discharge after 24 hours. However, patients discharged before 48 hours remain at elevated risk for arrhythmias and require careful patient selection, thorough education about warning signs, and clear return precautions</li>
                        <li><strong>Extended Monitoring (>48hr) indicated if:</strong> Arrhythmias detected, hemodynamic instability, large infarct, reduced EF (<40%), high-risk features, or persistent ischemia</li>
                        <li><strong>Serial troponins:</strong> Peak at 12-24 hours, trend until downtrending</li>
                        <li><strong>Daily ECG:</strong> Assess for evolution of infarct, new ischemia, conduction abnormalities</li>
                        <li><strong>Echo before discharge:</strong> Assess LV function (EF), wall motion abnormalities, mechanical complications, LV thrombus</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>48-hour arrhythmia window:</strong> Standard telemetry monitoring is 48 hours post-MI. Low-risk patients MAY be discharged at 24 hours if stable, but they remain at elevated arrhythmia risk until 48 hours. Early discharge requires careful patient selection and thorough education about warning signs (palpitations, syncope, chest pain)</li>
                    <li><strong>Sgarbossa Criteria:</strong> Diagnose STEMI with LBBB: ST elevation â‰¥1mm concordant with QRS (5 points), ST depression â‰¥1mm V1-V3 (3 points), ST elevation â‰¥5mm discordant (2 points). Score â‰¥3 = STEMI</li>
                    <li><strong>Wellens Syndrome:</strong> Biphasic or deep inverted T waves V2-V3 in pain-free patient = critical LAD stenosis, high risk of anterior STEMI. No stress test! Go to cath.</li>
                    <li><strong>RV Infarction Pearl:</strong> If inferior STEMI with hypotension, always get right-sided leads (V4R). Treat with aggressive IVF, avoid nitrates/diuretics</li>
                    <li><strong>Troponin timing:</strong> Can be negative first 2-4 hours. Serial troponins essential if high suspicion</li>
                    <li><strong>Don't forget:</strong> Type 2 MI (supply-demand mismatch from anemia, sepsis, tachyarrhythmia) - treat underlying cause, not necessarily cath</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability (SBP <90, shock)</li>
                        <li>Malignant arrhythmias (VT/VF, high-grade AV block)</li>
                        <li>Mechanical complications (papillary rupture, VSD, free wall rupture)</li>
                        <li>Acute heart failure/cardiogenic shock</li>
                        <li>Need for pressors or mechanical support (IABP, Impella)</li>
                        <li>Post-cardiac arrest</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable >24 hours (minimum for early discharge in low-risk patients; standard 48-hour telemetry monitoring preferred)</li>
                        <li>No recurrent chest pain or ischemic symptoms</li>
                        <li>No arrhythmias requiring intervention during monitoring period</li>
                        <li>LVEF assessed (echo)</li>
                        <li>Successful revascularization (if indicated)</li>
                        <li>On DAPT, statin, Î²-blocker, ACE-I (if EF <40%)</li>
                        <li>Cardiac rehab referral arranged</li>
                        <li>Patient educated on arrhythmia warning signs if discharged <48 hours</li>
                        <li>Clear return precautions given</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early (hours-days):</strong> Arrhythmias (VF, VT, bradycardia), cardiogenic shock, mechanical complications (papillary muscle rupture, VSD, free wall rupture), acute MR</p>
                    <p><strong>Late (days-weeks):</strong> Heart failure, LV thrombus, pericarditis (early: Dressler's syndrome 2-10 weeks), recurrent ischemia</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#hematology" style="color: #8e44ad;">ðŸ’Š Antiplatelets</a>, <a href="drug_reference_guide.html#unfractionated-heparin-ufh" style="color: #8e44ad;">ðŸ’Š Unfractionated Heparin</a>, <a href="drug_reference_guide.html#atorvastatin" style="color: #8e44ad;">ðŸ’Š Atorvastatin</a>, <a href="drug_reference_guide.html#metoprolol" style="color: #8e44ad;">ðŸ’Š Metoprolol</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="heart-failure" class="condition-page">
            <div class="page-header">
                <h2>2. ACUTE DECOMPENSATED HEART FAILURE</h2>
                <div class="subtitle">HFrEF â€¢ HFpEF â€¢ Acute Exacerbation</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Progressive dyspnea, orthopnea, PND, lower extremity edema, weight gain. Physical exam: JVD, bibasilar rales, S3 gallop, peripheral edema, hepatomegaly.</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Flash Pulmonary Edema:</strong> Acute onset, often with HTN emergency, minimal peripheral edema</li>
                        <li><strong>High Output HF:</strong> Warm extremities, bounding pulses (thyrotoxicosis, AV fistula, severe anemia)</li>
                        <li><strong>RV Failure:</strong> Isolated lower extremity edema, ascites, hepatic congestion without pulmonary edema</li>
                        <li><strong>Elderly:</strong> Confusion, fatigue, decreased appetite may predominate over dyspnea</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> BNP/NT-proBNP (BNP >400 or NT-proBNP >900 suggests HF), troponin (r/o ACS), BMP (assess renal function), CBC, Mg, TSH, LFTs</p>
                    <p><span class="label">Imaging:</span> CXR (cardiomegaly, pulmonary edema, pleural effusions), Echo (assess EF, valves, wall motion)</p>
                    <p><span class="label">ECG:</span> Look for ischemia, LVH, arrhythmias</p>
                    <p><span class="label">Calculations:</span> NYHA Class, EF%, fluid balance (daily weights), creatinine clearance</p>
                    <p><span class="label">Classify Hemodynamics:</span> Warm vs cold (perfusion), wet vs dry (volume status)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Initial Management:</span></p>
                    <ul>
                        <li><strong>O2:</strong> Maintain SpO2 >90%. Consider NIPPV (BiPAP/CPAP) if respiratory distress</li>
                        <li><strong>Diuresis (Wet):</strong> IV furosemide 40mg (or 2Ã— home dose) bolus, then assess response. Consider continuous infusion if poor response. Goal negative 1-2L/day</li>
                        <li><strong>Vasodilators (if SBP >90):</strong> Nitroglycerin IV for afterload reduction, especially if hypertensive</li>
                        <li><strong>Sodium/Fluid Restriction:</strong> <2g sodium/day, <2L fluid/day</li>
                        <li><strong>Daily weights:</strong> Essential for monitoring</li>
                    </ul>
                    
                    <p><span class="label">Cold & Wet (Low Output):</span> Consider inotropes (dobutamine, milrinone) with invasive monitoring</p>
                    
                    <p><span class="label">Chronic HF Management (Initiate/Optimize):</span></p>
                    <ul>
                        <li><strong>HFrEF (EF <40%):</strong> Guideline-directed medical therapy (GDMT)</li>
                        <li>ACE-I/ARB or ARNI (sacubitril-valsartan)</li>
                        <li>Î²-blocker (carvedilol, metoprolol succinate, bisoprolol) - start low when stable</li>
                        <li>Aldosterone antagonist (spironolactone, eplerenone) if EF <35%</li>
                        <li>SGLT2 inhibitor (dapagliflozin, empagliflozin) - proven mortality benefit</li>
                        <li><strong>HFpEF (EF â‰¥50%):</strong> Treat HTN, AF, ischemia. SGLT2i now indicated</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>BNP Pearls:</strong> Obesity lowers BNP. Renal failure raises it. Age-adjust NT-proBNP: <50yo: >450, 50-75yo: >900, >75yo: >1800</li>
                    <li><strong>Diuretic Resistance:</strong> If poor response to IV lasix, try: (1) Increase dose, (2) Continuous infusion, (3) Add thiazide (metolazone 2.5-5mg 30min before lasix), (4) Add acetazolamide</li>
                    <li><strong>Cardiorenal Syndrome:</strong> Cr bump with diuresis is often acceptable if congestion improving. Monitor BUN:Cr ratio (>20:1 suggests prerenal)</li>
                    <li><strong>Don't stop GDMT:</strong> Avoid stopping ACE-I/Î²-blocker acutely unless cardiogenic shock. Can hold during diuresis, restart before discharge</li>
                    <li><strong>B-type natriuretic peptide diuretics:</strong> Nesiritide (BNP analog) has no mortality benefit and increases hypotension - rarely used</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Cardiogenic shock (SBP <90, cool extremities, AMS, oliguria)</li>
                        <li>Need for inotropes or mechanical support</li>
                        <li>Acute respiratory failure requiring intubation</li>
                        <li>Refractory pulmonary edema</li>
                        <li>Malignant arrhythmias</li>
                        <li>ACS with hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Euvolemic (at or near dry weight)</li>
                        <li>No dyspnea at rest</li>
                        <li>Stable vital signs, O2 sat on room air</li>
                        <li>Transition to PO diuretics established</li>
                        <li>On optimized GDMT (HFrEF)</li>
                        <li>BMP stable, Cr at acceptable baseline</li>
                        <li>Patient education completed</li>
                        <li>Close follow-up arranged (within 7 days)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>During Admission:</strong> Cardiorenal syndrome (<a href="#aki" style="color: #0366d6;">AKI</a>), electrolyte abnormalities (<a href="#hyponatremia" style="color: #0366d6;">hyponatremia</a>), arrhythmias (<a href="#afib" style="color: #0366d6;">AF</a> most common), worsening renal function</p>
                    <p><strong>Long-term:</strong> Recurrent admissions (50% at 6 months), progressive renal dysfunction, sudden cardiac death, need for advanced therapies (LVAD, transplant)</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#furosemide" style="color: #8e44ad;">ðŸ’Š Furosemide</a>, <a href="drug_reference_guide.html#lisinopril" style="color: #8e44ad;">ðŸ’Š Lisinopril</a>, <a href="drug_reference_guide.html#carvedilol" style="color: #8e44ad;">ðŸ’Š Carvedilol</a>, <a href="drug_reference_guide.html#spironolactone" style="color: #8e44ad;">ðŸ’Š Spironolactone</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="afib" class="condition-page">
            <div class="page-header">
                <h2>3. ATRIAL FIBRILLATION</h2>
                <div class="subtitle">RVR â€¢ New-Onset â€¢ Chronic AF Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Palpitations, irregular pulse, dyspnea, chest discomfort, fatigue, lightheadedness. Irregularly irregular rhythm on exam.</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic:</strong> 30-40% discovered incidentally on exam or ECG</li>
                        <li><strong>Embolic stroke:</strong> First presentation in some patients</li>
                        <li><strong>Tachycardia-induced cardiomyopathy:</strong> Chronic RVR leading to heart failure</li>
                        <li><strong>Hyperthyroid AF:</strong> Lone AF in young patient, check TSH</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> TSH (always), BMP, Mg, CBC, troponin (if chest pain), digoxin level (if on digoxin)</p>
                    <p><span class="label">Imaging:</span> ECG (confirm AF, assess rate, look for ischemia/WPW), CXR, TTE (assess for structural disease, valve disease, LV function, LA size)</p>
                    <p><span class="label">TEE:</span> Before cardioversion if AF >48hr or unknown duration (r/o LA thrombus), unless patient on therapeutic anticoagulation â‰¥3 weeks</p>
                    <p><span class="label">Calculations:</span></p>
                    <ul>
                        <li><strong>CHAâ‚‚DSâ‚‚-VASc:</strong> Stroke risk (CHF, HTN, Age â‰¥75 [2pts], DM, Stroke/TIA [2pts], Vascular disease, Age 65-74, Sex [female]). Score â‰¥2 (â™‚) or â‰¥3 (â™€) â†’ anticoagulate</li>
                        <li><strong>HAS-BLED:</strong> Bleeding risk (HTN, Abnormal renal/liver, Stroke, Bleeding, Labile INR, Elderly, Drugs/alcohol). Score â‰¥3 = high bleeding risk</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Rate Control (First-line for most):</span></p>
                    <ul>
                        <li><strong>Î²-Blockers:</strong> Metoprolol 25-50mg PO q6h or 2.5-5mg IV, esmolol gtt (ICU). Goal HR <110 at rest</li>
                        <li><strong>Non-dihydropyridine CCB:</strong> Diltiazem 0.25mg/kg IV over 2min, then 5-15mg/hr gtt OR 30-60mg PO q6h</li>
                        <li><strong>Digoxin:</strong> 0.25mg IV/PO (less effective, use if HF or sedentary patients). Loading: 0.5mg â†’ 0.25mg q6h Ã— 2</li>
                        <li><strong>Avoid:</strong> Î²-blockers and CCBs together (risk of heart block), rate control in WPW (can precipitate VF)</li>
                    </ul>
                    
                    <p><span class="label">Rhythm Control:</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Hemodynamic instability, highly symptomatic despite rate control, first episode, young patient preference</li>
                        <li><strong>Cardioversion:</strong> If AF <48hr OR on anticoagulation â‰¥3 weeks OR TEE negative</li>
                        <li>Synchronized DC cardioversion: 120-200J biphasic (under sedation)</li>
                        <li>Chemical: Flecainide 300mg PO (if no CAD), ibutilide 1mg IV over 10min (monitor QT)</li>
                        <li><strong>Antiarrhythmics:</strong> Amiodarone (safest in structural disease), sotalol, dofetilide (in-hospital initiation)</li>
                    </ul>
                    
                    <p><span class="label">Anticoagulation:</span></p>
                    <ul>
                        <li><strong>CHAâ‚‚DSâ‚‚-VASc â‰¥2 (â™‚) or â‰¥3 (â™€):</strong> Anticoagulate (DOACs preferred over warfarin)</li>
                        <li><strong>DOACs:</strong> Apixaban, rivaroxaban, edoxaban, dabigatran (avoid if mechanical valve or severe MS)</li>
                        <li><strong>Post-cardioversion:</strong> Anticoagulate Ã— 4 weeks minimum, longer if stroke risk factors</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>WPW + AF = Emergency:</strong> Irregular wide-complex tachycardia. DO NOT use AV nodal blockers (can precipitate VF). Cardiovert or procainamide</li>
                    <li><strong>Rate vs Rhythm:</strong> AFFIRM/RACE trials show no mortality difference. Most patients do fine with rate control alone</li>
                    <li><strong>Anticoagulation paradox:</strong> HAS-BLED â‰¥3 means high bleeding risk, but often same patients who need anticoagulation most. Don't withhold if CHAâ‚‚DSâ‚‚-VASc high</li>
                    <li><strong>Holiday Heart:</strong> Alcohol-induced AF. Often converts spontaneously with abstinence</li>
                    <li><strong>TEE before cardioversion:</strong> Even if on anticoagulation <3 weeks, consider TEE strategy to expedite cardioversion safely</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability (SBP <90, shock)</li>
                        <li>Acute heart failure/pulmonary edema with RVR</li>
                        <li>Acute MI with RVR</li>
                        <li>Need for continuous IV rate control infusions</li>
                        <li>Post-cardioversion complications</li>
                        <li>RVR refractory to multiple agents</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Rate controlled (HR <110 at rest, <120 with activity)</li>
                        <li>Hemodynamically stable â‰¥24 hours</li>
                        <li>Transitioned to oral rate control meds</li>
                        <li>Anticoagulation started (if indicated)</li>
                        <li>No signs of heart failure</li>
                        <li>Follow-up arranged (cardiology if new-onset)</li>
                        <li>If cardioverted: Stable rhythm â‰¥24hr</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Stroke/TIA (most feared), hemodynamic compromise, heart failure, ACS (demand ischemia from RVR)</p>
                    <p><strong>Chronic:</strong> Tachycardia-induced cardiomyopathy (EF improves with rate/rhythm control), thromboembolism, bleeding (if anticoagulated)</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#metoprolol" style="color: #8e44ad;">ðŸ’Š Metoprolol</a>, <a href="drug_reference_guide.html#diltiazem" style="color: #8e44ad;">ðŸ’Š Diltiazem</a>, <a href="drug_reference_guide.html#amiodarone" style="color: #8e44ad;">ðŸ’Š Amiodarone</a>, <a href="drug_reference_guide.html#apixaban" style="color: #8e44ad;">ðŸ’Š Apixaban</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="htn-emergency" class="condition-page">
            <div class="page-header">
                <h2>4. HYPERTENSIVE EMERGENCY</h2>
                <div class="subtitle">End-Organ Damage â€¢ ICU Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Severe hypertension (typically SBP >180 or DBP >120) WITH acute end-organ damage</p>
                    <p><span class="label">Classic:</span> Severe headache, visual changes, chest pain, dyspnea, altered mental status, focal neurologic deficits</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Neurologic:</strong> Hypertensive encephalopathy (HA, confusion, seizures), stroke (ischemic/hemorrhagic), PRES</li>
                        <li><strong>Cardiac:</strong> Acute MI, acute pulmonary edema, aortic dissection</li>
                        <li><strong>Renal:</strong> Acute kidney injury, hematuria, proteinuria</li>
                        <li><strong>Microangiopathic:</strong> Hemolytic anemia, thrombocytopenia</li>
                    </ul>
                    <p><span class="label">Hypertensive Urgency:</span> Severe HTN WITHOUT end-organ damage. Managed outpatient with PO meds</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> BMP, troponin, CBC, UA, peripheral smear if hemolysis suspected, BNP if APE concern</p>
                    <p><span class="label">Imaging:</span> ECG, CXR, Head CT if neuro symptoms, CT chest if dissection suspected</p>
                    <p><span class="label">Fundoscopic:</span> Look for papilledema, hemorrhages, exudates</p>
                    <p><span class="label">Calculate Target BP:</span> Initial reduction 10-20% in 1st hour, then 5-15% over next 23 hours. Avoid >25% reduction in first 24hr</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General:</span> ICU admission, continuous BP monitoring (arterial line often needed), IV antihypertensives</p>
                    <p><span class="label">IV Agents:</span></p>
                    <ul>
                        <li><strong>Nicardipine:</strong> 5mg/hr, titrate by 2.5mg/hr q5-15min (max 15mg/hr). First-line</li>
                        <li><strong>Labetalol:</strong> 20mg IV bolus, then 20-80mg q10min OR 0.5-2mg/min infusion</li>
                        <li><strong>Clevidipine:</strong> 1-2mg/hr, double q90sec (max 21mg/hr). Short-acting</li>
                        <li><strong>Esmolol:</strong> Î²-blocker for dissection. 500mcg/kg load, then 50-300mcg/kg/min</li>
                        <li><strong>Nitroprusside:</strong> 0.25-10mcg/kg/min. For APE. Watch cyanide toxicity</li>
                    </ul>
                    <p><span class="label">Specific Scenarios:</span></p>
                    <ul>
                        <li><strong>Aortic Dissection:</strong> SBP <120 in 20min. Esmolol FIRST, then nicardipine</li>
                        <li><strong>Ischemic Stroke:</strong> Permissive HTN! Allow SBP up to 220 (or 185 if tPA)</li>
                        <li><strong>Hemorrhagic Stroke:</strong> Goal SBP 140-160</li>
                        <li><strong>Eclampsia:</strong> Mag sulfate + hydralazine/labetalol. Deliver baby!</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Urgency vs Emergency:</strong> Only EMERGENCY needs ICU/IV meds. Urgency = oral meds over hours-days</li>
                    <li><strong>Don't drop too fast:</strong> Cerebral autoregulation reset in chronic HTN. Rapid drop â†’ stroke/MI</li>
                    <li><strong>Ischemic stroke exception:</strong> Brain needs perfusion! Only lower if SBP >220 or giving tPA</li>
                    <li><strong>PRES:</strong> Headache, confusion, seizures, vision loss + posterior white matter edema. Usually reversible</li>
                    <li><strong>Transition to PO:</strong> Start long-acting oral agents before stopping IV to prevent rebound</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL hypertensive emergencies require ICU</li>
                        <li>Need for continuous IV infusion</li>
                        <li>Acute end-organ damage</li>
                        <li>Altered mental status</li>
                        <li>Arterial line needed</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>BP controlled on oral regimen â‰¥24hr</li>
                        <li>End-organ damage stabilized</li>
                        <li>Off IV medications</li>
                        <li>Patient educated on compliance</li>
                        <li>Close follow-up arranged (within 1 week)</li>
                        <li>Secondary causes evaluated if indicated</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Hypertension:</strong> Stroke, MI, aortic dissection, acute renal failure, retinopathy, heart failure</p>
                    <p><strong>From Treatment:</strong> Hypotension, stroke from rapid BP drop, rebound HTN, cyanide toxicity (nitroprusside)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="cap" class="condition-page">
            <div class="page-header">
                <h2>5. COMMUNITY-ACQUIRED PNEUMONIA (CAP)</h2>
                <div class="subtitle">Outpatient â€¢ Inpatient â€¢ ICU Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Fever, cough (productive/dry), dyspnea, pleuritic chest pain. Exam: Tachypnea, rales/crackles, bronchial breath sounds, dullness, egophony</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> Minimal fever, confusion/delirium, weakness, falls. May lack respiratory symptoms</li>
                        <li><strong>Atypical Organisms:</strong> Dry cough, headache, myalgias, diarrhea (Legionella, Mycoplasma)</li>
                        <li><strong>Aspiration:</strong> Witnessed event, right lower lobe/posterior segments, foul sputum</li>
                        <li><strong>Immunocompromised:</strong> PCP, CMV, TB</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span> CXR (PA and lateral) - infiltrate confirms diagnosis</p>
                    <p><span class="label">Labs (if admitted):</span> CBC, BMP, procalcitonin, blood cultures Ã— 2, sputum Gram stain/culture, ABG if hypoxic</p>
                    <p><span class="label">Special:</span> Legionella urinary Ag, Strep pneumo urinary Ag (if severe), respiratory viral panel, HIV if risk factors</p>
                    <p><span class="label">Severity Scores:</span></p>
                    <ul>
                        <li><strong>CURB-65:</strong> Confusion, Urea >20, RR â‰¥30, BP (SBP <90 or DBP â‰¤60), Age â‰¥65. Score 0-1: outpatient, 2: admit, â‰¥3: ICU</li>
                        <li><strong>PSI/PORT:</strong> More complex. Classes I-II outpatient, III consider admit, IV-V admit</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Outpatient (CURB-65 0-1):</span></p>
                    <ul>
                        <li><strong>Previously healthy:</strong> Amoxicillin 1g TID Ã— 5d OR doxycycline 100mg BID Ã— 5d</li>
                        <li><strong>With comorbidities:</strong> Amoxicillin-clavulanate + macrolide OR levofloxacin 750mg daily</li>
                    </ul>
                    
                    <p><span class="label">Inpatient Non-ICU:</span></p>
                    <ul>
                        <li><strong>Standard:</strong> Ceftriaxone 1-2g IV daily + azithromycin 500mg IV/PO daily</li>
                        <li><strong>Alternative:</strong> Levofloxacin 750mg daily or moxifloxacin 400mg daily</li>
                        <li><strong>Duration:</strong> Minimum 5 days if afebrile Ã— 48-72hr and stable</li>
                    </ul>
                    
                    <p><span class="label">ICU (Severe CAP):</span></p>
                    <ul>
                        <li><strong>Standard:</strong> Ceftriaxone 2g IV daily + azithromycin 500mg IV daily</li>
                        <li><strong>MRSA Risk:</strong> Add vancomycin or linezolid</li>
                        <li><strong>Pseudomonas Risk:</strong> Pip-tazo or cefepime + fluoroquinolone</li>
                    </ul>
                    
                    <p><span class="label">Supportive:</span> O2 to SpO2 >90%, IV fluids, VTE prophylaxis</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Legionella clues:</strong> Hyponatremia, elevated LFTs, GI symptoms, relative bradycardia. Urinary antigen test. Need 10-14d abx</li>
                    <li><strong>PCP Pneumonia:</strong> Subacute, dry cough, exertional dyspnea in HIV. Bilateral interstitial infiltrates. LDH >500. TMP-SMX + prednisone if PaO2 <70</li>
                    <li><strong>Step-down criteria:</strong> HR <100, RR <24, SBP >90, SpO2 >90%, temp <37.8Â°C, able to take PO</li>
                    <li><strong>Macrolide resistance:</strong> S. pneumoniae resistance ~30-40%. Always pair with Î²-lactam for inpatients</li>
                    <li><strong>Vaccines:</strong> PPSV23 and PCV20 after recovery per CDC schedule</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe CAP (CURB-65 â‰¥3)</li>
                        <li>Need for mechanical ventilation</li>
                        <li>Septic shock requiring pressors</li>
                        <li>Multilobar infiltrates</li>
                        <li>PaO2/FiO2 <250</li>
                        <li>Confusion, AMS</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile Ã— 48-72 hours</li>
                        <li>Hemodynamically stable</li>
                        <li>O2 sat >90% on room air/baseline</li>
                        <li>Able to tolerate PO</li>
                        <li>Completed minimum 5 days antibiotics</li>
                        <li>Follow-up CXR arranged (6 weeks)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early:</strong> Respiratory failure, sepsis/septic shock, parapneumonic effusion, empyema, lung abscess</p>
                    <p><strong>Late:</strong> Organizing pneumonia, fibrosis, recurrent pneumonia (consider malignancy)</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#ceftriaxone" style="color: #8e44ad;">ðŸ’Š Ceftriaxone</a>, <a href="drug_reference_guide.html#azithromycin" style="color: #8e44ad;">ðŸ’Š Azithromycin</a>, <a href="drug_reference_guide.html#vancomycin" style="color: #8e44ad;">ðŸ’Š Vancomycin</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="copd" class="condition-page">
            <div class="page-header">
                <h2>6. COPD EXACERBATION</h2>
                <div class="subtitle">AECOPD â€¢ Acute on Chronic</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Increased dyspnea, cough, sputum production/purulence beyond baseline. Wheezing, accessory muscle use, pursed-lip breathing</p>
                    <p><span class="label">Anthonisen Criteria:</span> (1) Increased dyspnea, (2) Increased sputum volume, (3) Increased sputum purulence. Type I = all 3, Type II = 2 of 3, Type III = 1 symptom</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Hypercapnic Encephalopathy:</strong> Confusion, asterixis, somnolence from CO2 retention</li>
                        <li><strong>Right Heart Failure:</strong> Peripheral edema, JVD from cor pulmonale</li>
                        <li><strong>Elderly:</strong> Fatigue, decreased functional status, falls</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> ABG (assess hypercapnia, acidosis), CBC, BMP, BNP if HF concern, sputum culture if severe/recurrent</p>
                    <p><span class="label">Imaging:</span> CXR (r/o pneumonia, PTX, CHF), consider CT if recurrent or PE concern</p>
                    <p><span class="label">ECG:</span> Evaluate for MI, arrhythmia, right heart strain</p>
                    <p><span class="label">Calculations:</span> A-a gradient, FiO2 requirements</p>
                    <p><span class="label">Triggers:</span> Infection (most common), medication noncompliance, PE, pneumothorax, MI, pneumonia</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Bronchodilators:</span></p>
                    <ul>
                        <li><strong>SABA:</strong> Albuterol 2.5-5mg nebulized q4h or continuous</li>
                        <li><strong>SAMA:</strong> Ipratropium 0.5mg nebulized q6h OR combined albuterol-ipratropium (DuoNeb)</li>
                        <li>Note: Ipratropium added to albuterol shows additive benefit in COPD (unlike asthma)</li>
                    </ul>
                    
                    <p><span class="label">Systemic Corticosteroids:</span></p>
                    <ul>
                        <li><strong>Dose:</strong> Prednisone 40mg PO daily Ã— 5 days (or methylprednisolone 125mg IV if severe/unable PO)</li>
                        <li><strong>Evidence:</strong> 5-7 days as effective as longer courses with fewer side effects</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics (if â‰¥2 cardinal symptoms or purulent sputum):</span></p>
                    <ul>
                        <li><strong>First-line:</strong> Azithromycin 500mg daily Ã— 5d OR doxycycline 100mg BID Ã— 5-7d</li>
                        <li><strong>Second-line:</strong> Amoxicillin-clavulanate, respiratory fluoroquinolone, cephalosporin</li>
                        <li><strong>Pseudomonas risk:</strong> (FEV1 <50%, recent hospitalization, >4 exacerbations/year) â†’ fluoroquinolone or cephalosporin</li>
                    </ul>
                    
                    <p><span class="label">Oxygen Therapy:</span> Goal SpO2 88-92% (avoid higher - can worsen hypercapnia). Titrate carefully in CO2 retainers</p>
                    
                    <p><span class="label">Ventilatory Support:</span></p>
                    <ul>
                        <li><strong>NIPPV (BiPAP):</strong> First-line for hypercapnic respiratory failure (pH 7.25-7.35). Reduces intubation rate and mortality</li>
                        <li><strong>Intubation:</strong> If unable to tolerate NIPPV, worsening acidosis (pH <7.25), decreased mental status</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>O2-induced hypercapnia:</strong> High O2 in COPD â†’ worsens V/Q mismatch and Haldane effect â†’ CO2 retention. Keep SpO2 88-92%</li>
                    <li><strong>BiPAP is magic:</strong> NIPPV reduces intubation by 65%, mortality by 55% in AECOPD with respiratory acidosis. Use early!</li>
                    <li><strong>Steroid duration:</strong> REDUCE trial showed 5 days = 14 days for outcomes. Don't give longer courses</li>
                    <li><strong>Antibiotics debate:</strong> Only benefit if purulent sputum or â‰¥2 cardinal symptoms. Type III (1 symptom) may not need abx</li>
                    <li><strong>Home oxygen criteria:</strong> Resting PaO2 <55 or SpO2 <88% OR PaO2 56-59 with cor pulmonale/polycythemia</li>
                    <li><strong>Prevention:</strong> Vaccinations (flu, pneumococcal), smoking cessation, maintenance inhalers, pulmonary rehab</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe respiratory acidosis (pH <7.30)</li>
                        <li>Need for intubation/mechanical ventilation</li>
                        <li>Hemodynamic instability</li>
                        <li>Altered mental status despite treatment</li>
                        <li>Failed NIPPV trial on floor</li>
                        <li>Life-threatening comorbidity (MI, sepsis)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Return to baseline dyspnea/function</li>
                        <li>Tolerating SABA q4h or less</li>
                        <li>SpO2 >90% on room air or baseline O2</li>
                        <li>Able to sleep and walk without severe dyspnea</li>
                        <li>pH >7.35 if acidotic on admission</li>
                        <li>On maintenance inhalers (LABA/LAMA combo)</li>
                        <li>Inhaler technique verified</li>
                        <li>Pulmonary follow-up within 1 month</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Respiratory failure requiring intubation, pneumothorax (bullous disease), pneumonia, arrhythmias, myocardial ischemia</p>
                    <p><strong>Chronic:</strong> Cor pulmonale, progressive lung function decline, long-term oxygen need, recurrent exacerbations</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#albuterol" style="color: #8e44ad;">ðŸ’Š Albuterol</a>, <a href="drug_reference_guide.html#prednisone" style="color: #8e44ad;">ðŸ’Š Prednisone</a>, <a href="drug_reference_guide.html#azithromycin" style="color: #8e44ad;">ðŸ’Š Azithromycin</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="asthma" class="condition-page">
            <div class="page-header">
                <h2>7. ASTHMA EXACERBATION</h2>
                <div class="subtitle">Acute Bronchospasm â€¢ Status Asthmaticus</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Dyspnea, wheezing, chest tightness, cough, accessory muscle use, prolonged expiration</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Silent Chest:</strong> Severe obstruction with minimal air movement - ominous sign!</li>
                        <li><strong>Cough-Variant Asthma:</strong> Persistent cough without wheezing</li>
                        <li><strong>Exercise-Induced:</strong> Symptoms during/after exercise</li>
                        <li><strong>Children:</strong> May present with only cough or difficulty feeding</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate:</span> Peak flow, O2 saturation, vital signs</p>
                    <p><span class="label">If Severe:</span> CXR (r/o pneumothorax, infiltrate), ABG if critically ill, VBG acceptable</p>
                    <p><span class="label">Calculations:</span> Peak flow % predicted (compare to personal best), FEV1 if available</p>
                    <p><span class="label">Severity Assessment:</span></p>
                    <ul>
                        <li><strong>Mild:</strong> Speaks full sentences, HR <100, PEF >70%</li>
                        <li><strong>Moderate:</strong> Speaks phrases, HR 100-120, PEF 40-70%</li>
                        <li><strong>Severe:</strong> Speaks words, HR >120, PEF <40%, accessory muscles</li>
                        <li><strong>Life-threatening:</strong> Unable to speak, altered mental status, silent chest, bradycardia, hypotension</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Bronchodilators:</span></p>
                    <ul>
                        <li><strong>Albuterol:</strong> 2.5-5mg nebulized q20min Ã— 3, then reassess. Consider continuous nebulization if severe</li>
                        <li><strong>Ipratropium:</strong> 0.5mg nebulized Ã— 3 doses (add to albuterol for moderate-severe exacerbations)</li>
                    </ul>
                    
                    <p><span class="label">Systemic Corticosteroids (ALL patients except mildest):</span></p>
                    <ul>
                        <li><strong>Prednisone:</strong> 40-60mg PO daily Ã— 5 days OR</li>
                        <li><strong>Methylprednisolone:</strong> 125mg IV if unable to take PO or severe</li>
                        <li>No taper needed for short course</li>
                    </ul>
                    
                    <p><span class="label">Oxygen:</span> Maintain SpO2 >90%</p>
                    
                    <p><span class="label">Severe/Refractory (not responding to above):</span></p>
                    <ul>
                        <li><strong>Magnesium sulfate:</strong> 2g IV over 20 minutes (relaxes bronchial smooth muscle)</li>
                        <li><strong>Epinephrine:</strong> 0.3-0.5mg IM (or subQ) if anaphylaxis component or impending respiratory failure</li>
                        <li><strong>Terbutaline:</strong> 0.25mg subQ (use with caution - cardiac side effects)</li>
                        <li><strong>Heliox:</strong> May reduce work of breathing (helium-oxygen mixture)</li>
                    </ul>
                    
                    <p><span class="label">Do NOT Give:</span> Sedatives (can suppress respiratory drive), antibiotics (unless clear bacterial infection)</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Silent chest = BAD:</strong> Means severe obstruction with minimal air movement. This is life-threatening!</li>
                    <li><strong>Ipratropium in asthma:</strong> Unlike COPD, only add for moderate-severe exacerbations (first 3 doses only)</li>
                    <li><strong>Magnesium mechanism:</strong> Competes with calcium in smooth muscle â†’ bronchodilation. Number needed to treat = 8</li>
                    <li><strong>Normal PCO2 is concerning:</strong> Asthma patients should be hypocapnic (from hyperventilation). Normal/high CO2 = respiratory fatigue</li>
                    <li><strong>Steroid timing:</strong> Takes 4-6 hours to work. Give early! Don't wait for severe deterioration</li>
                    <li><strong>Discharge medication:</strong> Always send home with short course PO steroids, albuterol inhaler, and controller if not already on one</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Status asthmaticus (not improving despite aggressive treatment)</li>
                        <li>Respiratory failure requiring intubation</li>
                        <li>Altered mental status, confusion, lethargy</li>
                        <li>Silent chest</li>
                        <li>PCO2 >45 (respiratory fatigue)</li>
                        <li>Need for continuous nebulization</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>PEF or FEV1 >70% predicted or personal best</li>
                        <li>SpO2 >90% on room air</li>
                        <li>No accessory muscle use, speaks full sentences</li>
                        <li>Sustained improvement â‰¥60 min after last treatment</li>
                        <li>On appropriate controller medication</li>
                        <li>Has action plan and follow-up arranged</li>
                        <li>Prescribed albuterol + oral steroids Ã— 5 days</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Status asthmaticus, respiratory failure, pneumothorax, pneumomediastinum, cardiac arrest</p>
                    <p><strong>Iatrogenic:</strong> Hypokalemia (from Î²-agonists), tremor, tachycardia, hyperglycemia (from steroids)</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#albuterol" style="color: #8e44ad;">ðŸ’Š Albuterol</a>, <a href="drug_reference_guide.html#prednisone" style="color: #8e44ad;">ðŸ’Š Prednisone</a>, <a href="drug_reference_guide.html#magnesium" style="color: #8e44ad;">ðŸ’Š Magnesium</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="pe" class="condition-page">
            <div class="page-header">
                <h2>8. PULMONARY EMBOLISM (PE)</h2>
                <div class="subtitle">VTE â€¢ Massive PE â€¢ Submassive PE</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Dyspnea, pleuritic chest pain, tachycardia, tachypnea, hemoptysis, unilateral leg swelling</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Massive PE:</strong> Hypotension, syncope, cardiac arrest (obstructive shock)</li>
                        <li><strong>Submassive PE:</strong> Hemodynamically stable but RV strain on echo or biomarkers</li>
                        <li><strong>Chronic PE:</strong> Progressive dyspnea, may be misdiagnosed as heart failure</li>
                        <li><strong>Small PE:</strong> May be asymptomatic or minimal symptoms</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Calculate Pre-test Probability:</span> Wells Score or PERC Rule (see calculators below)</p>
                    <p><span class="label">Labs:</span> D-dimer (if low probability - high sensitivity, low specificity), troponin, BNP (assess RV strain), ABG (may show hypoxemia, A-a gradient)</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CTPA (CT Pulmonary Angiography):</strong> Gold standard, shows filling defects</li>
                        <li><strong>V/Q Scan:</strong> If contrast contraindicated</li>
                        <li><strong>Lower Extremity Doppler US:</strong> Look for DVT source</li>
                        <li><strong>Echo:</strong> Assess RV function, strain (McConnell's sign = RV dysfunction with apical sparing)</li>
                    </ul>
                    <p><span class="label">ECG:</span> Sinus tachycardia most common. Classic S1Q3T3 pattern rare. Right heart strain pattern</p>
                    
                    <!-- Wells Score Calculator -->
                    <div id="calc-wells-pe" class="calculator collapsed">
                        <div class="calculator-title" onclick="this.parentElement.classList.toggle('collapsed')">ðŸ§® Wells Score for PE</div>
                        <div class="calculator-content">
                        <div class="calc-description">
                            <strong>Use:</strong> Pre-test probability of PE. Score â‰¤4 = PE unlikely (consider D-dimer), >4 = PE likely (proceed to CTPA).
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-dvt"> Clinical signs of DVT
                                <span class="hint">Leg swelling, unilateral pain (+3 points)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-alt"> PE most likely diagnosis (no alternative)
                                <span class="hint">+3 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-hr"> Heart rate >100 bpm
                                <span class="hint">+1.5 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-immob"> Immobilization â‰¥3 days or surgery within 4 weeks
                                <span class="hint">+1.5 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-prior"> Previous DVT or PE
                                <span class="hint">+1.5 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-hemo"> Hemoptysis
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-cancer"> Malignancy (treatment within 6 months or palliative)
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateWells()">Calculate Wells Score</button>
                        <div id="wells-result" class="calc-result" style="display:none;"></div>
                        </div>
                    </div>
                    
                    <!-- PERC Rule Calculator -->
                    <div id="calc-perc" class="calculator collapsed">
                        <div class="calculator-title" onclick="this.parentElement.classList.toggle('collapsed')">ðŸ§® PERC Rule (Pulmonary Embolism Rule-out Criteria)</div>
                        <div class="calculator-content">
                        <div class="calc-description">
                            <strong>Use:</strong> In LOW pre-test probability patients only. If ALL criteria are ABSENT (unchecked), PE is ruled out without D-dimer.
                        </div>
                        
                        <p style="font-weight: 600; margin: 10px 0 5px 0;">Check if ANY of these are PRESENT:</p>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="perc-age"> Age â‰¥50 years</label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="perc-hr"> Heart rate â‰¥100 bpm</label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="perc-spo2"> SpO2 &lt;95% on room air</label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="perc-hemo"> Hemoptysis</label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="perc-estrogen"> Estrogen use (OCP, HRT)</label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="perc-vte"> Prior DVT or PE</label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="perc-surgery"> Surgery or trauma within 4 weeks</label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="perc-leg"> Unilateral leg swelling</label>
                        </div>
                        
                        <button class="calc-button" onclick="calculatePERC()">Apply PERC Rule</button>
                        <div id="perc-result" class="calc-result" style="display:none;"></div>
                        </div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Anticoagulation (Most Patients):</span></p>
                    <ul>
                        <li><strong>LMWH:</strong> Enoxaparin 1mg/kg subQ q12h (preferred if renal function normal)</li>
                        <li><strong>Unfractionated Heparin:</strong> 80 units/kg bolus, then 18 units/kg/hr infusion (if CrCl <30 or high bleeding risk)</li>
                        <li><strong>Fondaparinux:</strong> Weight-based subQ dosing</li>
                        <li><strong>DOACs:</strong> Rivaroxaban or apixaban can be started immediately (no bridging needed)</li>
                    </ul>
                    
                    <p><span class="label">Thrombolytics (Massive PE with hemodynamic instability):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> SBP <90 for >15 min OR shock requiring pressors OR cardiac arrest</li>
                        <li><strong>Alteplase (tPA):</strong> 100mg IV over 2 hours OR 0.6mg/kg over 15 min (max 50mg)</li>
                        <li><strong>Contraindications:</strong> Recent surgery, active bleeding, stroke, intracranial pathology</li>
                    </ul>
                    
                    <p><span class="label">Catheter-Directed Therapy:</span> For submassive PE with RV dysfunction but contraindications to systemic lysis</p>
                    
                    <p><span class="label">IVC Filter:</span> Only if absolute contraindication to anticoagulation (active bleeding)</p>
                    
                    <p><span class="label">Supportive:</span> O2, judicious IVF (avoid overload - worsens RV strain), pressors if shock</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>PERC Rule:</strong> If all 8 criteria negative (age <50, HR <100, SpO2 â‰¥95%, no hemoptysis, no estrogen, no prior VTE, no surgery/trauma, no unilateral leg swelling) AND low clinical suspicion â†’ PE excluded, no D-dimer needed</li>
                    <li><strong>D-dimer pitfalls:</strong> Elevated in many conditions (infection, cancer, pregnancy, age >50). Only useful to rule OUT PE in low-probability patients</li>
                    <li><strong>Massive vs Submassive:</strong> Massive = hypotension/shock (needs thrombolytics). Submassive = RV strain but stable BP (controversial management)</li>
                    <li><strong>Anticoagulation duration:</strong> Provoked (surgery, trauma) = 3 months. Unprovoked or cancer = â‰¥6 months, consider indefinite</li>
                    <li><strong>Don't give IVF blindly:</strong> PE is RV failure - RV already volume overloaded. Excessive fluids worsen RV strain</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Massive PE (hypotension, shock)</li>
                        <li>Submassive PE with worsening RV function</li>
                        <li>Need for thrombolytics or mechanical intervention</li>
                        <li>Hemodynamic instability</li>
                        <li>Respiratory failure</li>
                        <li>Cardiac arrest</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable â‰¥24 hours</li>
                        <li>O2 sat >90% on room air or baseline</li>
                        <li>No RV dysfunction or resolved</li>
                        <li>Adequate pain control</li>
                        <li>On therapeutic anticoagulation</li>
                        <li>Safe for outpatient management (PESI score)</li>
                        <li>Follow-up arranged with anticoagulation clinic</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> RV failure, cardiac arrest, recurrent PE, bleeding (from anticoagulation)</p>
                    <p><strong>Chronic:</strong> Chronic thromboembolic pulmonary hypertension (CTEPH), post-thrombotic syndrome</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#unfractionated-heparin-ufh" style="color: #8e44ad;">ðŸ’Š Unfractionated Heparin</a>, <a href="drug_reference_guide.html#enoxaparin" style="color: #8e44ad;">ðŸ’Š Enoxaparin</a>, <a href="drug_reference_guide.html#apixaban" style="color: #8e44ad;">ðŸ’Š Apixaban</a>, <a href="drug_reference_guide.html#rivaroxaban" style="color: #8e44ad;">ðŸ’Š Rivaroxaban</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="sepsis" class="condition-page">
            <div class="page-header">
                <h2>9. SEPSIS/SEPTIC SHOCK</h2>
                <div class="subtitle">Life-Threatening Organ Dysfunction â€¢ Sepsis-3</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Sepsis Definition (Sepsis-3):</span> Life-threatening organ dysfunction caused by dysregulated host response to infection. SOFA score â‰¥2</p>
                    <p><span class="label">Classic:</span> Fever/hypothermia, tachycardia, tachypnea, altered mental status, hypotension</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> May lack fever, present with confusion or falls only</li>
                        <li><strong>Immunocompromised:</strong> Blunted fever response, rapid progression</li>
                        <li><strong>Cryptic Shock:</strong> Normal BP but elevated lactate (tissue hypoperfusion)</li>
                        <li><strong>Cold Sepsis:</strong> Hypothermia, cool extremities (late, poor prognosis)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> Blood cultures Ã— 2 (different sites, before antibiotics), CBC, CMP, lactate (repeat q2-4h), procalcitonin, coagulation studies</p>
                    <p><span class="label">Source Identification:</span> UA/urine culture, CXR, wound cultures, consider abdominal imaging if source unclear</p>
                    <p><span class="label">Calculate:</span> qSOFA score (see below), SOFA score, lactate clearance</p>
                    
                    <!-- qSOFA Calculator -->
                    <div id="calc-qsofa" class="calculator collapsed">
                        <div class="calculator-title" onclick="this.parentElement.classList.toggle('collapsed')">ðŸ§® qSOFA Calculator</div>
                        <div class="calculator-content">
                        <div class="calc-description">
                            <strong>Use:</strong> Quick screening for sepsis outside ICU. Score â‰¥2 suggests high risk for poor outcomes. NOT diagnostic, but prompts further evaluation.
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="qsofa-rr"> Respiratory Rate â‰¥22/min
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="qsofa-ams"> Altered Mental Status (GCS <15)
                                <span class="hint">Any confusion, disorientation, or decreased LOC (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="qsofa-sbp"> Systolic BP â‰¤100 mmHg
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateQSOFA()">Calculate qSOFA Score</button>
                        <div id="qsofa-result" class="calc-result" style="display:none;"></div>
                        </div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL (Sepsis Bundle - Within 1 Hour)</div>
                <div class="section-content">
                    <p><span class="label">1. Measure Lactate:</span> Remeasure if initial lactate >2 mmol/L</p>
                    
                    <p><span class="label">2. Obtain Blood Cultures BEFORE Antibiotics:</span> But don't delay antibiotics >45 min</p>
                    
                    <p><span class="label">3. Administer Broad-Spectrum Antibiotics:</span></p>
                    <ul>
                        <li><strong>Sepsis (no source identified):</strong> Vancomycin + pip-tazo OR cefepime + metronidazole</li>
                        <li><strong>Pulmonary source:</strong> Vancomycin + cefepime (or pip-tazo)</li>
                        <li><strong>Abdominal source:</strong> Pip-tazo OR ceftriaxone + metronidazole</li>
                        <li><strong>Urinary source:</strong> Ceftriaxone or fluoroquinolone (add ampicillin if Enterococcus risk)</li>
                        <li><strong>Skin/soft tissue:</strong> Vancomycin + pip-tazo</li>
                        <li><strong>Immunocompromised:</strong> Add antifungal (micafungin) and consider antivirals</li>
                    </ul>
                    
                    <p><span class="label">4. Rapid Administration of 30 mL/kg Crystalloid for Hypotension or Lactate â‰¥4:</span></p>
                    <ul>
                        <li>Use balanced crystalloids (LR or Plasma-Lyte) preferred over NS</li>
                        <li>Reassess after fluid bolus - repeat PRN based on hemodynamics</li>
                    </ul>
                    
                    <p><span class="label">5. Vasopressors if Hypotensive During or After Fluid Resuscitation:</span></p>
                    <ul>
                        <li><strong>Norepinephrine:</strong> First-line, start 0.05-0.1 mcg/kg/min, titrate to MAP â‰¥65</li>
                        <li><strong>Vasopressin:</strong> Add 0.03-0.04 units/min if inadequate response</li>
                        <li><strong>Epinephrine:</strong> Second-line if refractory</li>
                        <li><strong>Phenylephrine:</strong> Only if tachyarrhythmia or norepinephrine shortage</li>
                    </ul>
                    
                    <p><span class="label">Source Control:</span> Drain abscesses, remove infected devices, debride necrotic tissue - within 6-12 hours</p>
                    
                    <p><span class="label">Additional Considerations:</span></p>
                    <ul>
                        <li><strong>Stress-dose steroids:</strong> Hydrocortisone 200mg/day if refractory shock despite fluids + pressors</li>
                        <li><strong>Avoid:</strong> Hetastarch, gelatin (increase mortality), albumin for routine resuscitation</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Sepsis-3 vs Old Criteria:</strong> No more SIRS criteria. Focus on organ dysfunction (SOFA â‰¥2). qSOFA is screening tool, not diagnostic</li>
                    <li><strong>Time is tissue:</strong> Every hour delay in antibiotics increases mortality by 7.6%. Door-to-antibiotic <1 hour!</li>
                    <li><strong>Lactate clearance:</strong> >10% reduction in lactate within 2-4 hours associated with improved survival. Trend it!</li>
                    <li><strong>Balanced crystalloids:</strong> LR/Plasma-Lyte associated with lower mortality than NS. NS causes hyperchloremic acidosis</li>
                    <li><strong>Early vasopressors OK:</strong> Don't wait to "finish" 30cc/kg if patient still hypotensive. Start pressors concurrently</li>
                    <li><strong>Procalcitonin use:</strong> Can help determine if infection present and guide antibiotic duration. <0.5 = low likelihood bacterial</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL septic shock (hypotension requiring pressors)</li>
                        <li>Lactate â‰¥4 mmol/L</li>
                        <li>Respiratory failure requiring ventilation</li>
                        <li>Acute mental status changes</li>
                        <li>Oliguria/anuria despite fluids</li>
                        <li>Multiorgan dysfunction</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile Ã— 24-48 hours</li>
                        <li>Hemodynamically stable off pressors â‰¥24hr</li>
                        <li>Lactate normalized</li>
                        <li>Source controlled</li>
                        <li>Mental status at baseline</li>
                        <li>Tolerating PO, able to take antibiotics</li>
                        <li>No new organ dysfunction</li>
                        <li>Close follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> ARDS, <a href="#aki" style="color: #0366d6;">AKI</a> requiring dialysis, <a href="#dic" style="color: #0366d6;">DIC</a>, multiorgan failure, cardiac dysfunction, death (mortality 10-40%)</p>
                    <p><strong>Long-term:</strong> Post-sepsis syndrome (cognitive impairment, weakness, PTSD), recurrent infections, chronic organ dysfunction</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#vancomycin" style="color: #8e44ad;">ðŸ’Š Vancomycin</a>, <a href="drug_reference_guide.html#piperacillin-tazobactam" style="color: #8e44ad;">ðŸ’Š Piperacillin Tazobactam</a>, <a href="drug_reference_guide.html#norepinephrine" style="color: #8e44ad;">ðŸ’Š Norepinephrine</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="aki" class="condition-page">
            <div class="page-header">
                <h2>10. ACUTE KIDNEY INJURY (AKI)</h2>
                <div class="subtitle">Prerenal â€¢ Intrinsic â€¢ Postrenal</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Increase in Cr â‰¥0.3 mg/dL within 48hr OR increase to â‰¥1.5Ã— baseline OR urine output <0.5 mL/kg/hr for 6hr</p>
                    <p><span class="label">Classic:</span> Oliguria, fluid overload, edema, uremic symptoms (N/V, confusion, asterixis, pericarditis)</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Non-oliguric AKI:</strong> Cr rising but urine output preserved (often ATN from nephrotoxins)</li>
                        <li><strong>Hyperkalemia:</strong> May be presenting sign, can be life-threatening. <a href="#hyperkalemia" style="color: #0366d6;">See Hyperkalemia management</a></li>
                        <li><strong>Metabolic Acidosis:</strong> High anion gap from uremia</li>
                        <li><strong>Elderly:</strong> Minimal symptoms despite significant Cr elevation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> BMP (Cr, BUN, K+), baseline Cr for comparison, UA with microscopy, urine electrolytes (Na+, Cr, osmolality)</p>
                    <p><span class="label">Imaging:</span> Renal US (assess for obstruction, kidney size, hydronephrosis)</p>
                    <p><span class="label">Consider:</span> Renal biopsy if diagnosis unclear or concern for glomerulonephritis</p>
                    
                    <p><span class="label">Categorize AKI:</span></p>
                    <ul>
                        <li><strong>Prerenal (60-70%):</strong> Decreased renal perfusion - volume depletion, heart failure, cirrhosis, NSAIDs</li>
                        <li><strong>Intrinsic (25-40%):</strong> Acute tubular necrosis (ischemia, nephrotoxins), acute interstitial nephritis, glomerulonephritis</li>
                        <li><strong>Postrenal (5-10%):</strong> Obstruction - BPH, kidney stones, malignancy, neurogenic bladder</li>
                    </ul>
                    
                    <!-- FENa Calculator -->
                    <div id="calc-fena" class="calculator collapsed">
                        <div class="calculator-title" onclick="this.parentElement.classList.toggle('collapsed')">ðŸ§® FENa Calculator</div>
                        <div class="calculator-content">
                        <div class="calc-description">
                            <strong>Use:</strong> Differentiate prerenal AKI (<1%) from ATN (>2%). FENa 1-2% is indeterminate. If on diuretics, use FEUrea instead.
                        </div>
                        
                        <div class="calc-item">
                            <label>Urine Sodium (mEq/L)
                                <span class="hint">From random urine sample</span>
                            </label>
                            <input type="number" id="fena-urine-na" placeholder="e.g., 20" min="0" step="1">
                        </div>
                        
                        <div class="calc-item">
                            <label>Serum Sodium (mEq/L)
                                <span class="hint">From BMP - typically 135-145</span>
                            </label>
                            <input type="number" id="fena-serum-na" placeholder="e.g., 140" min="100" max="180" >
                        </div>
                        
                        <div class="calc-item">
                            <label>Urine Creatinine (mg/dL)
                                <span class="hint">From random urine sample</span>
                            </label>
                            <input type="number" id="fena-urine-cr" placeholder="e.g., 80" min="0" step="0.1">
                        </div>
                        
                        <div class="calc-item">
                            <label>Serum Creatinine (mg/dL)
                                <span class="hint">From BMP</span>
                            </label>
                            <input type="number" id="fena-serum-cr" placeholder="e.g., 2.5" min="0" step="0.1">
                        </div>
                        
                        <button class="calc-button" onclick="calculateFENa()">Calculate FENa</button>
                        <div id="fena-result" class="calc-result" style="display:none;"></div>
                        </div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li>Treat underlying cause</li>
                        <li>Stop nephrotoxins (NSAIDs, ACE-I/ARB if AKI severe, aminoglycosides, contrast)</li>
                        <li>Adjust all medication doses for GFR</li>
                        <li>Avoid further insults (hypotension, contrast, nephrotoxic drugs)</li>
                    </ul>
                    
                    <p><span class="label">Prerenal AKI:</span></p>
                    <ul>
                        <li><strong>Volume Depletion:</strong> IV fluids (LR or NS), correct hypotension</li>
                        <li><strong>Cardiorenal:</strong> Diuresis if volume overloaded, optimize cardiac output</li>
                        <li><strong>Hepatorenal:</strong> Albumin + midodrine + octreotide, or terlipressin</li>
                    </ul>
                    
                    <p><span class="label">Intrinsic AKI:</span></p>
                    <ul>
                        <li><strong>ATN:</strong> Supportive care, avoid nephrotoxins, optimize hemodynamics. Usually resolves in 1-3 weeks</li>
                        <li><strong>AIN (Acute Interstitial Nephritis):</strong> Stop offending drug, consider steroids if severe/not improving</li>
                        <li><strong>Glomerulonephritis:</strong> Nephrology consult, may need steroids/immunosuppression Â± plasmapheresis</li>
                    </ul>
                    
                    <p><span class="label">Postrenal AKI:</span></p>
                    <ul>
                        <li><strong>Relieve Obstruction:</strong> Foley catheter (if bladder outlet obstruction), nephrostomy tubes, ureteral stents</li>
                        <li>Watch for post-obstructive diuresis - may need aggressive fluid replacement</li>
                    </ul>
                    
                    <p><span class="label">Indications for Dialysis (AEIOU):</span></p>
                    <ul>
                        <li><strong>A</strong>cidosis - severe metabolic acidosis (pH <7.1) refractory to medical management</li>
                        <li><strong>E</strong>lectrolytes - <a href="#hyperkalemia" style="color: #0366d6;">hyperkalemia</a> refractory to medical therapy</li>
                        <li><strong>I</strong>ngestions - toxic alcohols, lithium, salicylates</li>
                        <li><strong>O</strong>verload - <a href="#pulmonary-edema" style="color: #0366d6;">volume overload</a> refractory to diuretics, pulmonary edema</li>
                        <li><strong>U</strong>remia - <a href="#uremia" style="color: #0366d6;">uremic pericarditis</a>, encephalopathy, bleeding</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>FENa limitations:</strong> Not valid if on diuretics (falsely elevated), chronic kidney disease, or contrast nephropathy. Use FEUrea if on diuretics (prerenal <35%)</li>
                    <li><strong>BUN:Cr ratio:</strong> >20:1 suggests prerenal (BUN reabsorbed more than Cr). <15:1 suggests intrinsic renal disease</li>
                    <li><strong>Muddy brown casts:</strong> Pathognomonic for ATN on urine microscopy</li>
                    <li><strong>Triple whammy:</strong> ACE-I/ARB + diuretic + NSAID = high risk for AKI. Avoid this combination!</li>
                    <li><strong>Contrast-induced AKI:</strong> Peak Cr at 3-5 days. Prevent with IV fluids before/after contrast. No evidence for NAC or bicarb</li>
                    <li><strong>Post-obstructive diuresis:</strong> Can lose massive amounts of fluid after obstruction relieved. Replace half of UOP with 0.45% NS</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li><a href="#hyperkalemia" style="color: #0366d6;">Hyperkalemia</a> >6.5 with ECG changes</li>
                        <li>Severe metabolic acidosis (pH <7.2)</li>
                        <li><a href="#pulmonary-edema" style="color: #0366d6;">Volume overload</a> with respiratory failure</li>
                        <li><a href="#uremia" style="color: #0366d6;">Uremic encephalopathy/pericarditis</a></li>
                        <li>Need for emergent dialysis</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Cr downtrending or stable</li>
                        <li>No dialysis-requiring complications</li>
                        <li>Electrolytes controlled (K+ <5.5)</li>
                        <li>Volume status optimized</li>
                        <li>Cause identified and addressed</li>
                        <li>Nephrotoxins stopped</li>
                        <li>Close nephrology follow-up if Cr not at baseline</li>
                        <li>Patient educated on medication adjustments</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> <a href="#hyperkalemia" style="color: #0366d6;">Hyperkalemia</a>, metabolic acidosis, <a href="#pulmonary-edema" style="color: #0366d6;">volume overload</a>, <a href="#uremia" style="color: #0366d6;">uremia</a>, need for dialysis, death</p>
                    <p><strong>Chronic:</strong> Chronic kidney disease, progression to ESRD, recurrent AKI episodes</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="hyperkalemia" class="condition-page">
            <div class="page-header">
                <h2>11. HYPERKALEMIA</h2>
                <div class="subtitle">K+ >5.5 mEq/L â€¢ Life-Threatening Arrhythmias</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Often asymptomatic until severe. Weakness, paresthesias, palpitations</p>
                    <p><span class="label">ECG Changes (Progressive):</span></p>
                    <ul>
                        <li><strong>Mild (5.5-6.5):</strong> Peaked T waves (tall, narrow, symmetric)</li>
                        <li><strong>Moderate (6.5-8):</strong> PR prolongation, P wave flattening/loss, QRS widening</li>
                        <li><strong>Severe (>8):</strong> Sine wave pattern, ventricular fibrillation, asystole</li>
                    </ul>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Pseudohyperkalemia:</strong> Hemolysis during blood draw, severe leukocytosis/thrombocytosis, fist clenching</li>
                        <li><strong>Acute on Chronic:</strong> Patients on ACE-I/ARB with CKD who take NSAIDs or get dehydrated</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> Repeat K+ to confirm (rule out pseudohyperkalemia), BMP, Mg, Ca, VBG, consider digoxin level if on digoxin</p>
                    <p><span class="label">ECG:</span> CRITICAL - assess for cardiotoxicity. ECG changes indicate true emergency</p>
                    <p><span class="label">Identify Cause:</span></p>
                    <ul>
                        <li><strong>Increased Intake:</strong> K+ supplements, salt substitutes, IV K+</li>
                        <li><strong>Transcellular Shift:</strong> Acidosis, insulin deficiency, Î²-blocker, digoxin toxicity, succinylcholine, tumor lysis</li>
                        <li><strong>Decreased Excretion:</strong> AKI/CKD, hypoaldosteronism, ACE-I/ARB, K+-sparing diuretics, NSAIDs, heparin, TMP-SMX</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL (Sequence Matters!)</div>
                <div class="section-content">
                    <p><span class="label">Step 1: Cardiac Membrane Stabilization (if ECG changes or K >6.5):</span></p>
                    <ul>
                        <li><strong>Calcium Gluconate:</strong> 1-2 amps (10-20 mL of 10% solution) IV over 2-3 min</li>
                        <li>OR <strong>Calcium Chloride:</strong> 0.5-1g (5-10 mL of 10%) IV via central line (more potent, sclerosing)</li>
                        <li>Effect: Immediate (1-3 min), duration 30-60 min</li>
                        <li>Does NOT lower K+, only protects heart</li>
                        <li>Can repeat dose if persistent ECG changes</li>
                    </ul>
                    
                    <p><span class="label">Step 2: Shift K+ Intracellularly (Temporary):</span></p>
                    <ul>
                        <li><strong>Insulin + Dextrose:</strong> Regular insulin 10 units IV + D50 50mL (25g dextrose) IV push
                            <ul>
                                <li>If glucose >250: give insulin alone, no dextrose</li>
                                <li>Effect: 15-30 min, duration 4-6 hours</li>
                                <li>Lowers K+ by 0.5-1.5 mEq/L</li>
                                <li>Check glucose in 1hr (risk hypoglycemia)</li>
                            </ul>
                        </li>
                        <li><strong>Albuterol:</strong> 10-20mg nebulized (or 0.5mg IV)
                            <ul>
                                <li>Effect: 30 min, duration 2-4 hours</li>
                                <li>Lowers K+ by 0.5-1 mEq/L</li>
                                <li>Additive with insulin</li>
                            </ul>
                        </li>
                        <li><strong>Sodium Bicarbonate:</strong> 50-100 mEq (1-2 amps) IV over 5 min (only if concurrent metabolic acidosis)
                            <ul>
                                <li>Controversial efficacy if pH normal</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Step 3: Remove K+ from Body (Definitive):</span></p>
                    <ul>
                        <li><strong>Loop Diuretic:</strong> Furosemide 40-80mg IV (if adequate renal function)</li>
                        <li><strong>Sodium Polystyrene Sulfonate (Kayexalate):</strong> 15-30g PO/PR
                            <ul>
                                <li>Effect: Hours, lowers K+ by 0.5-1 mEq/L</li>
                                <li>Avoid if ileus (risk colonic necrosis)</li>
                            </ul>
                        </li>
                        <li><strong>Patiromer or Sodium Zirconium:</strong> Newer K+ binders, better tolerated but slower onset</li>
                        <li><strong>Hemodialysis:</strong> Most effective. Indications:
                            <ul>
                                <li>K+ >6.5 with ECG changes refractory to medical management</li>
                                <li>Severe AKI/ESRD</li>
                                <li>Ongoing tissue breakdown (rhabdo, tumor lysis)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Step 4: Stop Exacerbating Factors:</span> Hold ACE-I/ARB, K+-sparing diuretics, NSAIDs, K+ supplements</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>ECG trumps K+ level:</strong> If ECG shows changes, treat aggressively regardless of exact K+ value. ECG changes = cardiac emergency!</li>
                    <li><strong>Calcium first!</strong> If ECG changes, give calcium before anything else. Protects heart immediately while you arrange other therapies</li>
                    <li><strong>Insulin hypoglycemia:</strong> Very common! Check glucose 30min and 1hr after insulin. Have D50 ready. Consider dextrose infusion</li>
                    <li><strong>Kayexalate controversy:</strong> Limited evidence for efficacy, risk of colonic necrosis esp with sorbitol. Consider newer agents</li>
                    <li><strong>Repeat K+ frequently:</strong> Check K+ q2-4h during acute management. Temporizing measures wear off!</li>
                    <li><strong>Chronic management:</strong> Low K+ diet, loop diuretics, K+ binders. Avoid "hyperkalemia cocktail" (ACE-I + spironolactone + NSAIDs)</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>K+ >6.5 with ECG changes</li>
                        <li>Hemodynamically significant arrhythmias</li>
                        <li>Need for emergent dialysis</li>
                        <li>Rapidly rising K+ despite treatment</li>
                        <li>Cardiac arrest from hyperkalemia</li>
                        <li>Requires continuous cardiac monitoring</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>K+ <5.5 mEq/L and downtrending</li>
                        <li>ECG normalized (no peaked T waves)</li>
                        <li>Cause identified and addressed</li>
                        <li>K+-raising medications stopped/adjusted</li>
                        <li>Patient educated on low K+ diet</li>
                        <li>Close follow-up with repeat K+ within 2-3 days</li>
                        <li>If CKD: nephrology follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Cardiac:</strong> Ventricular arrhythmias (VT, VF), heart block, asystole, sudden cardiac death</p>
                    <p><strong>From Treatment:</strong> Hypoglycemia (insulin), hypokalemia rebound, volume overload (from IVF), GI complications (kayexalate)</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#calcium-gluconate-chloride" style="color: #8e44ad;">ðŸ’Š Calcium Gluconate Chloride</a>, <a href="drug_reference_guide.html#regular-insulin" style="color: #8e44ad;">ðŸ’Š Regular Insulin</a>, <a href="drug_reference_guide.html#sodium-polystyrene-sulfonate" style="color: #8e44ad;">ðŸ’Š Sodium Polystyrene Sulfonate</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="hyponatremia" class="condition-page">
            <div class="page-header">
                <h2>12. HYPONATREMIA</h2>
                <div class="subtitle">Na+ <135 mEq/L â€¢ Osmotic Demyelination Risk</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Nausea, headache, confusion, lethargy, seizures (if severe/acute)</p>
                    <p><span class="label">Severity by Symptoms:</span></p>
                    <ul>
                        <li><strong>Mild (Na 130-135):</strong> Often asymptomatic or mild nausea</li>
                        <li><strong>Moderate (125-129):</strong> Nausea, confusion, headache</li>
                        <li><strong>Severe (<125):</strong> Vomiting, seizures, coma, respiratory arrest</li>
                    </ul>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> Falls, gait instability, cognitive impairment</li>
                        <li><strong>Athletes:</strong> Exercise-associated hyponatremia from excessive free water intake</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Step 1 - Check Serum Osmolality:</span></p>
                    <ul>
                        <li><strong>Isotonic (280-295):</strong> Pseudohyponatremia (hyperglycemia, hyperlipidemia, hyperproteinemia)</li>
                        <li><strong>Hypertonic (>295):</strong> Hyperglycemia, mannitol</li>
                        <li><strong>Hypotonic (<280):</strong> True hyponatremia - proceed to step 2</li>
                    </ul>
                    
                    <p><span class="label">Step 2 - Assess Volume Status:</span></p>
                    <ul>
                        <li><strong>Hypovolemic:</strong> Dry mucous membranes, â†“skin turgor, orthostatic hypotension
                            <ul>
                                <li>Urine Na <20: GI losses, third-spacing, skin losses</li>
                                <li>Urine Na >40: Diuretics, salt-wasting nephropathy, adrenal insufficiency</li>
                            </ul>
                        </li>
                        <li><strong>Euvolemic:</strong> Normal volume status
                            <ul>
                                <li>SIADH (most common), hypothyroidism, adrenal insufficiency, psychogenic polydipsia</li>
                            </ul>
                        </li>
                        <li><strong>Hypervolemic:</strong> Edema, elevated JVP, ascites
                            <ul>
                                <li>CHF, cirrhosis, nephrotic syndrome, advanced CKD</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Labs:</span> Serum osmolality, urine osmolality, urine Na, BMP, TSH, cortisol if indicated</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">âš ï¸ CRITICAL:</span> Correct slowly! Maximum 8-10 mEq/L in first 24 hours. Faster correction â†’ osmotic demyelination syndrome</p>
                    
                    <p><span class="label">Acute Symptomatic (<48hr onset with seizures/coma):</span></p>
                    <ul>
                        <li><strong>3% Hypertonic Saline:</strong> 100 mL IV bolus over 10 min, can repeat Ã— 2 if needed</li>
                        <li>Goal: Raise Na by 4-6 mEq/L (enough to stop seizures), then slow correction</li>
                        <li>Check Na q2-4h</li>
                    </ul>
                    
                    <p><span class="label">Chronic or Asymptomatic:</span></p>
                    <ul>
                        <li><strong>Hypovolemic:</strong> NS at 0.5-1 mL/kg/hr. Na will auto-correct with volume repletion</li>
                        <li><strong>Euvolemic (SIADH):</strong> 
                            <ul>
                                <li>Fluid restriction (800-1000 mL/day)</li>
                                <li>Treat underlying cause</li>
                                <li>Salt tabs + loop diuretic if needed</li>
                                <li>Tolvaptan (vasopressin antagonist) for refractory cases</li>
                            </ul>
                        </li>
                        <li><strong>Hypervolemic:</strong> Fluid + sodium restriction, diuretics, treat underlying (CHF, cirrhosis)</li>
                    </ul>
                    
                    <p><span class="label">Correction Rate Calculation:</span></p>
                    <ul>
                        <li>Target: 6-8 mEq/L in 24 hours, 12-14 mEq/L in 48 hours</li>
                        <li>High-risk patients (chronic, malnourished, cirrhosis, K+ <3): Limit to 6 mEq/L in 24hr</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Osmotic demyelination (ODS):</strong> From overly rapid correction. Presents 2-6 days later with dysarthria, dysphagia, quadriplegia, locked-in syndrome. PREVENT by slow correction!</li>
                    <li><strong>SIADH criteria:</strong> Hyponatremia + low serum osm (<280) + inappropriately concentrated urine (>100) + euvolemic + normal thyroid/adrenal</li>
                    <li><strong>Beer potomania:</strong> Hyponatremia from excessive beer intake with poor solute intake. Na can rise dangerously fast when solute repleted!</li>
                    <li><strong>Tea and toast diet:</strong> Similar to beer potomania - inadequate solute intake in elderly</li>
                    <li><strong>Exercise-associated:</strong> From drinking too much water during endurance events. Treat with hypertonic saline, NOT more water!</li>
                    <li><strong>Hyperglycemia correction:</strong> For every 100 mg/dL glucose >100, add 1.6 mEq/L to measured Na to get "true" Na</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Seizures or coma</li>
                        <li>Na <120 mEq/L</li>
                        <li>Acute symptomatic hyponatremia</li>
                        <li>Need for 3% hypertonic saline</li>
                        <li>Rapid changes requiring q2h monitoring</li>
                        <li>Respiratory compromise</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Na >125 mEq/L and stable/improving</li>
                        <li>Asymptomatic or symptoms resolved</li>
                        <li>Underlying cause identified/treated</li>
                        <li>Can comply with fluid restriction if needed</li>
                        <li>Follow-up arranged with Na check in 2-3 days</li>
                        <li>Patient educated on risks</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Hyponatremia:</strong> Seizures, cerebral edema, respiratory arrest, death</p>
                    <p><strong>From Overcorrection:</strong> Osmotic demyelination syndrome (irreversible neurologic damage)</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#electrolytes" style="color: #8e44ad;">ðŸ’Š Electrolytes</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="dka" class="condition-page">
            <div class="page-header">
                <h2>13. DIABETIC KETOACIDOSIS (DKA)</h2>
                <div class="subtitle">Hyperglycemia â€¢ Acidosis â€¢ Ketones</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> (1) Hyperglycemia (>250), (2) Anion gap metabolic acidosis, (3) Ketones</p>
                    <p><span class="label">Classic Symptoms:</span> Polyuria, polydipsia, N/V, abdominal pain, Kussmaul respirations (deep, rapid), fruity breath odor, altered mental status</p>
                    <p><span class="label">Precipitants (5 I's):</span></p>
                    <ul>
                        <li><strong>Infection:</strong> Most common (UTI, pneumonia, etc)</li>
                        <li><strong>Insulin:</strong> Non-compliance or inadequate dosing</li>
                        <li><strong>Ischemia:</strong> MI, stroke</li>
                        <li><strong>Intoxication:</strong> Alcohol, drugs</li>
                        <li><strong>Infant:</strong> Pregnancy</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">DKA Criteria:</span></p>
                    <ul>
                        <li>Glucose >250 mg/dL (or known diabetic)</li>
                        <li>pH <7.3 (arterial) or HCO3 <18</li>
                        <li>Anion gap >10</li>
                        <li>Positive serum/urine ketones</li>
                    </ul>
                    
                    <p><span class="label">Labs:</span> VBG (pH, HCO3), BMP, anion gap, Î²-hydroxybutyrate (preferred over urine ketones), phosphate, Mg, CBC, blood cultures, UA/CXR if infection suspected</p>
                    <p><span class="label">Calculate:</span> Anion gap = Na - (Cl + HCO3). Normal 8-12. Also calculate osmolality if altered mental status</p>
                    <p><span class="label">Severity:</span></p>
                    <ul>
                        <li><strong>Mild:</strong> pH 7.25-7.30, HCO3 15-18</li>
                        <li><strong>Moderate:</strong> pH 7.0-7.24, HCO3 10-14</li>
                        <li><strong>Severe:</strong> pH <7.0, HCO3 <10</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">1. Fluids (MOST IMPORTANT):</span></p>
                    <ul>
                        <li><strong>Initial:</strong> NS 1-1.5 L over first hour (15-20 mL/kg/hr)</li>
                        <li><strong>Subsequent:</strong> 
                            <ul>
                                <li>If Na normal/high: 0.45% NS at 250-500 mL/hr</li>
                                <li>If Na low: NS at 250-500 mL/hr</li>
                            </ul>
                        </li>
                        <li><strong>Once glucose <250:</strong> Switch to D5 0.45% NS to prevent hypoglycemia while continuing insulin</li>
                        <li>Total deficit usually 5-10 L - replace over 24-48 hours</li>
                    </ul>
                    
                    <p><span class="label">2. Insulin:</span></p>
                    <ul>
                        <li><strong>Regular insulin IV infusion:</strong> 0.1 units/kg/hr (usually 5-10 units/hr)</li>
                        <li>Optional bolus: 0.1 units/kg IV if severe DKA</li>
                        <li>Goal: Decrease glucose by 50-75 mg/dL/hr</li>
                        <li><strong>Do NOT stop insulin</strong> when glucose reaches 250! Switch to D5-containing fluids and continue insulin until anion gap closes</li>
                        <li>Once anion gap closed: Transition to subQ insulin, overlap by 1-2 hours before stopping gtt</li>
                    </ul>
                    
                    <p><span class="label">3. Potassium Repletion (CRITICAL):</span></p>
                    <ul>
                        <li><strong>If K+ <3.3:</strong> Hold insulin, give K+ 20-30 mEq/hr until K >3.3</li>
                        <li><strong>If K+ 3.3-5.2:</strong> Add 20-30 mEq K+ to each liter of fluids</li>
                        <li><strong>If K+ >5.2:</strong> No K+ initially, check q2-4h (will drop with insulin)</li>
                        <li>Goal: K+ 4-5 mEq/L</li>
                    </ul>
                    
                    <p><span class="label">4. Phosphate (if <1.0 mg/dL):</span> K-phos 20-30 mEq/L in fluids</p>
                    
                    <p><span class="label">5. Bicarbonate (controversial, only if pH <6.9):</span> 100 mEq in 400 mL H2O + 20 mEq KCl over 2 hours</p>
                    
                    <p><span class="label">6. Treat Precipitant:</span> Antibiotics if infection, adjust insulin regimen, etc</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>DKA resolution:</strong> Glucose <200 AND anion gap <12 AND HCO3 >18 AND pH >7.3. Don't stop insulin just because glucose normalized!</li>
                    <li><strong>Two-bag system:</strong> Run two IV bags (one NS, one D5-NS) through Y-connector. Adjust ratio to maintain glucose 150-200 while continuing insulin</li>
                    <li><strong>Euglycemic DKA:</strong> Can occur with SGLT2 inhibitors. Check ketones even if glucose <250!</li>
                    <li><strong>K+ shifts:</strong> Total body K+ depleted despite normal/high initial K+. With insulin, K+ shifts into cells â†’ life-threatening hypokalemia. Monitor closely!</li>
                    <li><strong>Cerebral edema:</strong> Rare but fatal. More common in kids. From too-rapid correction. Symptoms: Headache, AMS, bradycardia. Give mannitol/3% saline</li>
                    <li><strong>Anion gap:</strong> Closes before ketones clear. Don't discharge until ketones clearing and patient eating</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>pH <7.0</li>
                        <li>HCO3 <10</li>
                        <li>Altered mental status</li>
                        <li>Hemodynamic instability</li>
                        <li>Need for continuous insulin infusion</li>
                        <li>Severe electrolyte derangements</li>
                        <li>Cerebral edema concern</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>DKA resolved (AG <12, HCO3 >18, pH >7.3)</li>
                        <li>Tolerating PO intake</li>
                        <li>Transitioned to subQ insulin</li>
                        <li>Ketones clearing</li>
                        <li>Precipitant identified and treated</li>
                        <li>Patient educated on sick day management</li>
                        <li>Diabetes follow-up arranged</li>
                        <li>No ongoing complications</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Cerebral edema (1%), hypokalemia, hypoglycemia, ARDS, thrombosis, mucormycosis</p>
                    <p><strong>From Treatment:</strong> Hyperchloremic non-gap acidosis (from NS), volume overload</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#regular-insulin" style="color: #8e44ad;">ðŸ’Š Regular Insulin</a>, <a href="drug_reference_guide.html#potassium-chloride" style="color: #8e44ad;">ðŸ’Š Potassium Chloride</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="hhs" class="condition-page">
            <div class="page-header">
                <h2>14. HYPEROSMOLAR HYPERGLYCEMIC STATE (HHS)</h2>
                <div class="subtitle">Extreme Hyperglycemia â€¢ Hyperosmolarity â€¢ Type 2 DM</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Key Differences from DKA:</span> More extreme hyperglycemia (>600), higher osmolality (>320), NO significant ketoacidosis, more profound dehydration</p>
                    <p><span class="label">Classic:</span> Altered mental status, severe dehydration, hypotension. Often insidious onset over days-weeks</p>
                    <p><span class="label">Typical Patient:</span> Elderly Type 2 diabetic with infection or medication non-compliance</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">HHS Criteria:</span></p>
                    <ul>
                        <li>Glucose >600 mg/dL</li>
                        <li>Effective serum osmolality >320 mOsm/kg</li>
                        <li>pH >7.30</li>
                        <li>HCO3 >15</li>
                        <li>Minimal ketones (can have trace)</li>
                    </ul>
                    <p><span class="label">Calculate Osmolality:</span> 2(Na) + glucose/18 + BUN/2.8. Normal 280-295</p>
                    <p><span class="label">Labs:</span> Same as DKA - VBG, BMP, identify precipitant</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">1. Aggressive Fluid Resuscitation (MORE than DKA):</span></p>
                    <ul>
                        <li>Initial: NS 1-1.5 L first hour</li>
                        <li>Subsequent: 250-500 mL/hr based on volume status</li>
                        <li>Total deficit often 8-12 L (more than DKA)</li>
                        <li>Goal: Replace half of deficit in first 12-24 hours</li>
                    </ul>
                    
                    <p><span class="label">2. Insulin (LOWER rates than DKA):</span></p>
                    <ul>
                        <li>Wait 1-2 hours, give fluids first to avoid vascular collapse</li>
                        <li>Then start insulin 0.05-0.1 units/kg/hr (lower than DKA)</li>
                        <li>Goal: Decrease glucose by 50-75 mg/dL/hr</li>
                        <li>Once glucose <300: Add dextrose to fluids, continue insulin</li>
                    </ul>
                    
                    <p><span class="label">3. Potassium:</span> Same principles as DKA</p>
                    
                    <p><span class="label">4. Correct Slowly:</span> Osmolality should decrease by <3 mOsm/kg/hr to avoid cerebral edema</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>HHS vs DKA:</strong> HHS = Type 2 DM, more dehydration, higher glucose (>600), no ketosis. DKA = Type 1, ketoacidosis</li>
                    <li><strong>Why no ketosis?</strong> Type 2 patients have enough insulin to prevent lipolysis but not enough to control glucose</li>
                    <li><strong>Mortality higher:</strong> HHS mortality 10-20% (vs 1-5% for DKA) - sicker, older patients</li>
                    <li><strong>Fluids first!</strong> Give 1-2 L NS before starting insulin to prevent cardiovascular collapse</li>
                    <li><strong>Slower correction:</strong> Osmolality built up over longer time, correct more slowly to avoid cerebral edema</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Altered mental status/coma</li>
                        <li>Osmolality >350</li>
                        <li>Hemodynamic instability</li>
                        <li>Need for insulin infusion</li>
                        <li>Severe electrolyte abnormalities</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Glucose <250 and stable</li>
                        <li>Mental status at baseline</li>
                        <li>Osmolality <310</li>
                        <li>Taking PO</li>
                        <li>On appropriate diabetes regimen</li>
                        <li>Precipitant treated</li>
                    </ul>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#regular-insulin" style="color: #8e44ad;">ðŸ’Š Regular Insulin</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="ugib" class="condition-page">
            <div class="page-header">
                <h2>15. UPPER GI BLEED</h2>
                <div class="subtitle">Hematemesis â€¢ Melena â€¢ Variceal vs Non-Variceal</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Hematemesis (bright red or coffee-ground), melena (black tarry stool), syncope, hemodynamic instability</p>
                    <p><span class="label">Common Causes:</span></p>
                    <ul>
                        <li><strong>Non-Variceal (90%):</strong> PUD (H. pylori, NSAIDs), erosive gastritis/esophagitis, Mallory-Weiss tear, Dieulafoy lesion</li>
                        <li><strong>Variceal (10%):</strong> Esophageal or gastric varices (cirrhosis, portal hypertension)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate:</span> Two large-bore IVs, CBC, type & cross (4 units), BMP, coags, LFTs</p>
                    <p><span class="label">Risk Stratification:</span> Glasgow-Blatchford Score (score 0 = safe for outpatient, â‰¥1 consider admission)</p>
                    <p><span class="label">EGD:</span> Within 24 hours (within 12 hours if high risk/variceal suspected)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Resuscitation:</span></p>
                    <ul>
                        <li><strong>Transfusion:</strong> Goal Hgb 7-9 (restrictive strategy). Higher target (9-10) if active cardiac disease</li>
                        <li><strong>Fluids:</strong> Crystalloids for volume resuscitation</li>
                        <li><strong>Correct coagulopathy:</strong> Reverse anticoagulation if active bleeding, give FFP/PCC if INR >1.8</li>
                    </ul>
                    
                    <p><span class="label">Pharmacotherapy:</span></p>
                    <ul>
                        <li><strong>PPI:</strong> Pantoprazole 80mg IV bolus, then 8mg/hr infusion Ã— 72hr (for non-variceal)</li>
                        <li><strong>If Variceal Suspected:</strong> Octreotide 50 mcg bolus, then 50 mcg/hr infusion</li>
                        <li><strong>Antibiotics (if cirrhotic):</strong> Ceftriaxone 1g IV daily Ã— 7 days (reduces mortality)</li>
                    </ul>
                    
                    <p><span class="label">Endoscopic Management:</span></p>
                    <ul>
                        <li><strong>PUD:</strong> Epinephrine injection + thermal coagulation Â± clips</li>
                        <li><strong>Varices:</strong> Band ligation (preferred) or sclerotherapy</li>
                        <li><strong>If refractory variceal bleeding:</strong> Balloon tamponade (Blakemore tube), TIPS</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Don't over-transfuse:</strong> Target Hgb 7-9. Higher targets worsen outcomes (increased rebleeding)</li>
                    <li><strong>Rockall score:</strong> Post-EGD risk score. Predicts rebleeding and mortality</li>
                    <li><strong>PPI timing:</strong> Pre-EGD PPI doesn't reduce mortality but may reduce stigmata of recent hemorrhage</li>
                    <li><strong>Mallory-Weiss:</strong> Longitudinal tear at GE junction from forceful vomiting. Usually self-limited</li>
                    <li><strong>NG tube controversial:</strong> Not routinely needed. Doesn't improve outcomes, uncomfortable for patient</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability despite resuscitation</li>
                        <li>Massive transfusion (>4 units in 24hr)</li>
                        <li>Variceal bleeding</li>
                        <li>Rebleeding after endoscopic intervention</li>
                        <li>Need for airway protection</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable Ã— 24hr</li>
                        <li>Hgb stable (no transfusion need)</li>
                        <li>Post-EGD with low-risk lesion</li>
                        <li>Tolerating PO</li>
                        <li>On PPI BID Ã— 2 weeks, then daily</li>
                        <li>H. pylori testing sent/treated</li>
                        <li>GI follow-up arranged</li>
                    </ul>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#pantoprazole" style="color: #8e44ad;">ðŸ’Š Pantoprazole</a>, <a href="drug_reference_guide.html#octreotide" style="color: #8e44ad;">ðŸ’Š Octreotide</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="cirrhosis" class="condition-page">
            <div class="page-header">
                <h2>16. CIRRHOSIS WITH ASCITES</h2>
                <div class="subtitle">Portal Hypertension â€¢ Decompensated Cirrhosis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Abdominal distension, weight gain, peripheral edema, early satiety, dyspnea from diaphragm elevation</p>
                    <p><span class="label">Physical Exam:</span> Shifting dullness, fluid wave, bulging flanks. Stigmata of chronic liver disease: jaundice, spider angiomas, palmar erythema, gynecomastia, caput medusae, asterixis</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>SBP:</strong> Fever, abdominal pain/tenderness, altered mental status without obvious peritonitis</li>
                        <li><strong>Hepatic Hydrothorax:</strong> Right-sided pleural effusion (usually) without cardiopulmonary disease</li>
                        <li><strong>Tense Ascites:</strong> Respiratory compromise, severe discomfort, umbilical/inguinal hernias</li>
                        <li><strong>Hepatorenal Syndrome:</strong> Progressive AKI despite volume resuscitation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span> Ultrasound (detects >100mL ascites, evaluates liver texture, portal vein), CT abdomen if unclear etiology or concern for HCC</p>
                    <p><span class="label">Diagnostic Paracentesis (ALWAYS on first presentation OR any clinical deterioration):</span></p>
                    <ul>
                        <li><strong>Cell count with differential:</strong> PMN >250 = SBP</li>
                        <li><strong>Albumin:</strong> For SAAG calculation</li>
                        <li><strong>Total protein:</strong> <1g/dL = high SBP risk</li>
                        <li><strong>Gram stain and culture:</strong> Inoculate blood culture bottles at bedside (improves yield)</li>
                        <li><strong>Consider:</strong> Glucose, LDH, cytology (if malignancy suspected), TB studies, amylase (if pancreatitis concern)</li>
                    </ul>
                    
                    <p><span class="label">SAAG (Serum-Ascites Albumin Gradient):</span></p>
                    <ul>
                        <li>Calculate: Serum albumin - Ascitic fluid albumin</li>
                        <li><strong>â‰¥1.1 g/dL:</strong> Portal hypertension (97% accuracy) - cirrhosis, cardiac ascites, Budd-Chiari syndrome, sinusoidal obstruction syndrome</li>
                        <li><strong><1.1 g/dL:</strong> Non-portal causes - peritoneal carcinomatosis, TB peritonitis, pancreatic ascites, nephrotic syndrome, serositis</li>
                        <li>SAAG unaffected by diuretics or albumin infusions</li>
                    </ul>
                    
                    <p><span class="label">Labs:</span> CBC, CMP, albumin, PT/INR, hepatitis panel (HBsAg, anti-HCV), AFP (HCC screening), lipid panel</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Sodium Restriction:</span> <2g/day (88 mEq/day). This is THE most important intervention! Effective in 10-20% as monotherapy</p>
                    
                    <p><span class="label">Diuretic Therapy:</span></p>
                    <ul>
                        <li><strong>Initial regimen:</strong> Spironolactone 100mg PO daily + Furosemide 40mg PO daily (100:40 ratio)</li>
                        <li><strong>Titration:</strong> Increase both medications together every 3-5 days maintaining the 100:40 ratio
                            <ul>
                                <li>Step 2: Spironolactone 200mg + Furosemide 80mg</li>
                                <li>Step 3: Spironolactone 300mg + Furosemide 120mg</li>
                                <li>Maximum: Spironolactone 400mg + Furosemide 160mg</li>
                            </ul>
                        </li>
                        <li><strong>Goal weight loss:</strong> 0.5kg/day if ascites alone, 1kg/day if peripheral edema present</li>
                        <li><strong>Monitoring:</strong> Daily weights, BMP at least 2Ã—/week initially (watch Na, K, Cr)</li>
                        <li><strong>Hold diuretics if:</strong> Na <120, K >6, Cr rise >2mg/dL above baseline, encephalopathy worsens, severe hypovolemia</li>
                    </ul>
                    
                    <p><span class="label">Large Volume Paracentesis (LVP):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Tense/refractory ascites, respiratory compromise, severe discomfort, new-onset ascites for diagnosis</li>
                        <li>Safe to remove 10-12 liters in single session</li>
                        <li><strong>Albumin replacement:</strong> 6-8g IV per liter removed if >5 liters removed (prevents post-paracentesis circulatory dysfunction)</li>
                        <li>Can use 20% or 25% albumin (20% is more cost-effective)</li>
                        <li>Complications rare: bleeding <1%, infection <1%, bowel perforation <0.1%</li>
                    </ul>
                    
                    <p><span class="label">Refractory Ascites:</span></p>
                    <ul>
                        <li><strong>Definition:</strong> Unresponsive to maximum diuretics + sodium restriction OR development of diuretic-induced complications</li>
                        <li><strong>Management options:</strong>
                            <ul>
                                <li>Serial large volume paracentesis q2-4 weeks + albumin</li>
                                <li>TIPS (transjugular intrahepatic portosystemic shunt) - if appropriate candidate (MELD <18, no encephalopathy)</li>
                                <li>Liver transplant evaluation</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Fluid Restriction:</span> Generally NOT needed unless Na <120-125 mEq/L</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>100:40 ratio maintains normokalemia:</strong> Spironolactone (K-sparing) + furosemide (K-wasting) balance each other</li>
                    <li><strong>SAAG is gospel:</strong> â‰¥1.1 = portal hypertension with 97% accuracy. Unaffected by diuretics, paracentesis, or albumin</li>
                    <li><strong>Paracentesis is safe:</strong> Can tap with INR 2-3, platelets >20k. Prophylactic FFP/platelets NOT needed. Bleeding risk <1%</li>
                    <li><strong>SBP prophylaxis indications:</strong> Primary (never had SBP): ascitic protein <1.5 g/dL + Child-Pugh B/C OR GI bleeding. Secondary (prior SBP): lifelong</li>
                    <li><strong>Medications to AVOID:</strong> NSAIDs (precipitate HRS, worsen ascites), ACE-I/ARBs (hypotension, HRS), aminoglycosides (nephrotoxic)</li>
                    <li><strong>TIPS considerations:</strong> Reduces ascites and variceal bleeding but increases hepatic encephalopathy. Best for refractory ascites with MELD <18</li>
                    <li><strong>Hepatorenal syndrome triggers:</strong> SBP, GI bleeding, large volume paracentesis without albumin, overdiuresis</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability/shock</li>
                        <li>Respiratory failure from tense ascites</li>
                        <li>HRS type 1 (rapidly progressive AKI)</li>
                        <li>Grade 3-4 hepatic encephalopathy</li>
                        <li>Variceal bleeding</li>
                        <li>Severe SBP with sepsis</li>
                        <li>Need for mechanical ventilation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Ascites improved/controlled on oral diuretics</li>
                        <li>No evidence of SBP (if tapped)</li>
                        <li>Renal function stable (Cr not rising)</li>
                        <li>Electrolytes acceptable (Na >125, K 3.5-5.5)</li>
                        <li>Encephalopathy grade 0-1</li>
                        <li>Patient/family educated on 2g sodium diet</li>
                        <li>Daily weight monitoring arranged</li>
                        <li>Hepatology follow-up within 1-2 weeks</li>
                        <li>Transplant evaluation if MELD â‰¥15</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Disease:</strong> <a href="#sbp" style="color: #0366d6;">SBP</a>, hepatorenal syndrome, hepatic hydrothorax, umbilical/inguinal hernia rupture, respiratory compromise, <a href="#he" style="color: #0366d6;">hepatic encephalopathy</a></p>
                    <p><strong>From Treatment:</strong> <a href="#hyponatremia" style="color: #0366d6;">Hyponatremia</a>, <a href="#hyperkalemia" style="color: #0366d6;">hyperkalemia</a>, hypokalemia, <a href="#aki" style="color: #0366d6;">AKI</a>, muscle cramps, gynecomastia (spironolactone), metabolic alkalosis</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#furosemide" style="color: #8e44ad;">ðŸ’Š Furosemide</a>, <a href="drug_reference_guide.html#spironolactone" style="color: #8e44ad;">ðŸ’Š Spironolactone</a>, <a href="drug_reference_guide.html#lactulose" style="color: #8e44ad;">ðŸ’Š Lactulose</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="sbp" class="condition-page">
            <div class="page-header">
                <h2>17. SPONTANEOUS BACTERIAL PERITONITIS (SBP)</h2>
                <div class="subtitle">Infected Ascites â€¢ Cirrhotic Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> Fever, abdominal pain/tenderness, altered mental status in patient with ascites. BUT symptoms may be very subtle!</p>
                    <p><span class="label">High Index of Suspicion:</span> Any cirrhotic patient with ascites who clinically deteriorates (worsening encephalopathy, AKI, ileus, hypothermia, unexplained acidosis)</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic SBP:</strong> 10-30% have NO symptoms at all. Diagnosed on routine surveillance paracentesis</li>
                        <li><strong>Hypothermia:</strong> Temperature <36Â°C. Poor prognostic sign (mortality >50%)</li>
                        <li><strong>Isolated Worsening Encephalopathy:</strong> May be the ONLY presenting sign</li>
                        <li><strong>Acute Kidney Injury:</strong> SBP frequently triggers hepatorenal syndrome</li>
                        <li><strong>Ileus/Decreased Bowel Sounds:</strong> Without obvious mechanical obstruction</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Diagnostic Paracentesis:</span> MANDATORY with low threshold! Any clinical suspicion warrants immediate tap</p>
                    
                    <p><span class="label">SBP Diagnostic Criteria (any ONE equals SBP):</span></p>
                    <ul>
                        <li><strong>PMN â‰¥250 cells/mmÂ³:</strong> This alone is DIAGNOSTIC. Start antibiotics immediately!</li>
                        <li><strong>Culture-positive with PMN <250:</strong> "Culture-negative neutrocytic ascites" - treat as SBP</li>
                        <li><strong>Monomicrobial culture with PMN <250:</strong> "Bacterascites" - consider treatment if symptomatic</li>
                    </ul>
                    
                    <p><span class="label">Ascitic Fluid Studies:</span></p>
                    <ul>
                        <li><strong>Cell count with differential (STAT):</strong> PMN is the key number</li>
                        <li><strong>Gram stain:</strong> Usually negative (low sensitivity ~10%)</li>
                        <li><strong>Culture:</strong> Inoculate 10mL into blood culture bottles AT BEDSIDE (increases yield from 40% to 80%)</li>
                        <li><strong>Albumin:</strong> For SAAG if new ascites</li>
                        <li><strong>Total protein:</strong> <1 g/dL = high risk for SBP</li>
                        <li><strong>Glucose and LDH:</strong> Help distinguish primary from secondary peritonitis</li>
                    </ul>
                    
                    <p><span class="label">Blood Studies:</span> CBC, CMP, blood cultures Ã— 2, lactate</p>
                    
                    <p><span class="label">Common Organisms:</span></p>
                    <ul>
                        <li>E. coli (40%)</li>
                        <li>Klebsiella species (7%)</li>
                        <li>Streptococcus species (15%)</li>
                        <li>Enterococcus</li>
                        <li>Usually monomicrobial</li>
                    </ul>
                    
                    <p><span class="label">Secondary Bacterial Peritonitis (Bowel Perforation):</span> Consider if:
                        <ul>
                            <li>Polymicrobial culture</li>
                            <li>Protein >1 g/dL</li>
                            <li>Glucose <50 mg/dL</li>
                            <li>LDH > upper limit of serum normal</li>
                            <li>If suspected â†’ get CT abdomen/pelvis STAT</li>
                        </ul>
                    </p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Empiric Antibiotics (start IMMEDIATELY if PMN â‰¥250):</span></p>
                    <ul>
                        <li><strong>First-line (community-acquired):</strong> Ceftriaxone 2g IV daily Ã— 5-7 days</li>
                        <li><strong>Alternative:</strong> Cefotaxime 2g IV q8h</li>
                        <li><strong>If nosocomial or recent Î²-lactam exposure:</strong> Piperacillin-tazobactam 3.375g IV q6h OR Meropenem 1g IV q8h (for MDRO coverage)</li>
                        <li><strong>Penicillin allergy:</strong> Fluoroquinolone (but increasing resistance) or discuss with ID</li>
                        <li><strong>Duration:</strong> 5-7 days, or until ascitic PMN <250 on repeat tap</li>
                    </ul>
                    
                    <p><span class="label">Albumin Infusion (CRITICAL - Reduces Mortality by 30%):</span></p>
                    <ul>
                        <li><strong>Day 1:</strong> 1.5 g/kg IV (give within 6 hours of diagnosis)</li>
                        <li><strong>Day 3:</strong> 1.0 g/kg IV</li>
                        <li><strong>Example:</strong> 70kg patient â†’ 105g on day 1, 70g on day 3</li>
                        <li><strong>Mechanism:</strong> Prevents hepatorenal syndrome and improves circulatory function</li>
                        <li><strong>Evidence:</strong> Reduces HRS by 70%, mortality by 30%. This is NOT optional!</li>
                    </ul>
                    
                    <p><span class="label">Follow-up Paracentesis:</span></p>
                    <ul>
                        <li>At 48 hours if patient not improving clinically</li>
                        <li>PMN count should decrease by â‰¥25%</li>
                        <li>If not improving â†’ consider resistant organism, secondary peritonitis, or inadequate antibiotic</li>
                    </ul>
                    
                    <p><span class="label">Secondary Prophylaxis (After SBP Episode Resolves):</span></p>
                    <ul>
                        <li><strong>Duration:</strong> LIFELONG (until transplant or death)</li>
                        <li><strong>Options:</strong>
                            <ul>
                                <li>Norfloxacin 400mg PO daily (first choice) OR</li>
                                <li>Ciprofloxacin 750mg PO weekly OR</li>
                                <li>Trimethoprim-sulfamethoxazole DS daily</li>
                            </ul>
                        </li>
                        <li>Reduces 1-year recurrence from 70% to 20%</li>
                    </ul>
                    
                    <p><span class="label">Primary Prophylaxis (Never Had SBP):</span></p>
                    <ul>
                        <li><strong>Indication 1:</strong> Ascitic protein <1.5 g/dL + Child-Pugh â‰¥9 or impaired renal function</li>
                        <li><strong>Indication 2:</strong> Acute GI bleeding (give for 7 days regardless of ascitic protein)</li>
                        <li>Use same antibiotics as secondary prophylaxis</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>PMN â‰¥250 = Treat NOW:</strong> Don't wait for culture. Only 40% of true SBP will have positive culture</li>
                    <li><strong>Albumin saves lives:</strong> Reduces hepatorenal syndrome by 70%, mortality by 30%. Give on day 1 AND day 3. Not optional!</li>
                    <li><strong>Low threshold to tap:</strong> When in doubt, tap. Complications are rare (<1% bleeding). Missing SBP is worse than "unnecessary" paracentesis</li>
                    <li><strong>Bedside inoculation:</strong> Putting ascitic fluid in blood culture bottles AT BEDSIDE increases yield from 50% to 80%</li>
                    <li><strong>Secondary peritonitis clues:</strong> If polymicrobial, protein >1, glucose <50, or LDH >ULN â†’ think bowel perforation. Get CT!</li>
                    <li><strong>Recurrence without prophylaxis:</strong> 70% recur within 1 year. Secondary prophylaxis is lifelong</li>
                    <li><strong>No prophylaxis for everyone:</strong> Primary prophylaxis only for very high risk (protein <1.5 + advanced disease or GI bleed)</li>
                    <li><strong>Don't blame antibiotics for encephalopathy:</strong> Quinolones for SBP prophylaxis do NOT worsen encephalopathy (old myth)</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Septic shock requiring vasopressors</li>
                        <li>Respiratory failure needing intubation</li>
                        <li>Severe hepatic encephalopathy (grade 3-4)</li>
                        <li>Rapidly progressive AKI/HRS</li>
                        <li>Hypothermia or severe sepsis</li>
                        <li>No clinical improvement despite 48hr treatment</li>
                        <li>Suspected secondary peritonitis</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Completed minimum 5 days antibiotics</li>
                        <li>Afebrile Ã— 24-48 hours</li>
                        <li>Clinical symptoms resolved</li>
                        <li>Renal function stable or improving</li>
                        <li>Repeat paracentesis (if done) with PMN <250</li>
                        <li>Started on secondary prophylaxis</li>
                        <li>Close hepatology follow-up arranged</li>
                        <li>Transplant evaluation if not already listed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Hepatorenal syndrome (occurs in 30%), septic shock, paralytic ileus, worsening hepatic encephalopathy, death (in-hospital mortality 20-40%)</p>
                    <p><strong>Recurrence:</strong> 70% within 1 year without secondary prophylaxis. 20% with prophylaxis. Each recurrence increases mortality risk</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#ceftriaxone" style="color: #8e44ad;">ðŸ’Š Ceftriaxone</a>, <a href="drug_reference_guide.html#albumin" style="color: #8e44ad;">ðŸ’Š Albumin</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="he" class="condition-page">
            <div class="page-header">
                <h2>18. HEPATIC ENCEPHALOPATHY</h2>
                <div class="subtitle">Altered Mental Status in Cirrhosis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">West Haven Grading:</span></p>
                    <ul>
                        <li><strong>Grade 0 (Minimal):</strong> Normal mental status, subtle psychometric abnormalities</li>
                        <li><strong>Grade 1:</strong> Trivial confusion, euphoria/anxiety, shortened attention span, impaired addition/subtraction</li>
                        <li><strong>Grade 2:</strong> Lethargy, disorientation to time, obvious personality change, inappropriate behavior, asterixis</li>
                        <li><strong>Grade 3:</strong> Somnolent but arousable, gross disorientation, bizarre behavior</li>
                        <li><strong>Grade 4:</strong> Coma, unresponsive to painful stimuli</li>
                    </ul>
                    
                    <p><span class="label">Physical Exam Findings:</span></p>
                    <ul>
                        <li><strong>Asterixis:</strong> "Flapping tremor" - extend arms with dorsiflexed wrists, observe for irregular flapping. Present in grades 2-3</li>
                        <li><strong>Hyperreflexia:</strong> Increased deep tendon reflexes</li>
                        <li><strong>Fetor hepaticus:</strong> Sweet, musty breath odor</li>
                        <li><strong>Stigmata of cirrhosis:</strong> Jaundice, spider angiomas, palmar erythema, ascites</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Acute Change:</strong> Sudden worsening in previously stable patient suggests precipitant</li>
                        <li><strong>Post-TIPS:</strong> Can develop weeks after TIPS procedure</li>
                        <li><strong>Subclinical:</strong> Patient/family report subtle changes not apparent to clinicians</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Diagnosis of Exclusion:</span> Rule out other causes of altered mental status first!</p>
                    
                    <p><span class="label">Essential Studies:</span></p>
                    <ul>
                        <li><strong>Labs:</strong> CBC, CMP, ammonia level (correlates poorly but >200 suggests HE), venous pH/lactate</li>
                        <li><strong>Infection workup:</strong> UA, CXR, diagnostic paracentesis if ascites present (rule out SBP!)</li>
                        <li><strong>Toxicology screen:</strong> Especially in acute change</li>
                        <li><strong>Head CT:</strong> If focal neurologic signs, trauma, first episode, or atypical presentation</li>
                    </ul>
                    
                    <p><span class="label">Identify Precipitants (The "5 I's" + more):</span></p>
                    <ul>
                        <li><strong>Infection:</strong> SBP (most common), UTI, pneumonia, any infection</li>
                        <li><strong>GI bleed:</strong> Protein load from blood</li>
                        <li><strong>Constipation:</strong> Increased colonic transit time â†’ more ammonia absorption</li>
                        <li><strong>Medications:</strong> Benzos, opioids, diuretic-induced hypokalemia/alkalosis</li>
                        <li><strong>Dehydration/Azotemia:</strong> From overdiuresis</li>
                        <li><strong>Electrolyte abnormalities:</strong> Hyponatremia, hypokalemia</li>
                        <li><strong>TIPS:</strong> Increased porto-systemic shunting</li>
                        <li><strong>Hepatocellular carcinoma:</strong> Tumor burden</li>
                        <li><strong>Dietary indiscretion:</strong> Large protein meal</li>
                        <li><strong>Non-compliance:</strong> Stopping lactulose</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">1. Identify and Treat Precipitant (MOST IMPORTANT!):</span></p>
                    <ul>
                        <li>Tap ascites (rule out SBP)</li>
                        <li>Check for GI bleeding</li>
                        <li>Treat infections</li>
                        <li>Review medication list - stop sedatives/opioids</li>
                        <li>Correct electrolyte abnormalities</li>
                    </ul>
                    
                    <p><span class="label">2. Lactulose (First-line Therapy):</span></p>
                    <ul>
                        <li><strong>Initial dose:</strong> 30mL (20g) PO q1-2 hours until first bowel movement</li>
                        <li><strong>Maintenance:</strong> 30mL PO TID, titrate to 2-3 soft bowel movements per day</li>
                        <li><strong>Goal:</strong> Acidify colon, decrease ammonia production/absorption</li>
                        <li><strong>If cannot take PO:</strong> 300mL lactulose in 700mL water as retention enema, hold 30-60 min</li>
                        <li><strong>Watch for:</strong> Dehydration, hypernatremia (diarrhea), cramping</li>
                    </ul>
                    
                    <p><span class="label">3. Rifaximin (Add-on Therapy for Recurrent/Chronic HE):</span></p>
                    <ul>
                        <li><strong>Dose:</strong> 550mg PO BID</li>
                        <li><strong>Mechanism:</strong> Non-absorbable antibiotic, reduces ammonia-producing gut bacteria</li>
                        <li><strong>Evidence:</strong> Reduces HE recurrence by 58% when added to lactulose</li>
                        <li><strong>Cost:</strong> Expensive (~$2000/month), often requires prior auth</li>
                        <li>Use for patients with â‰¥2 HE episodes requiring hospitalization</li>
                    </ul>
                    
                    <p><span class="label">4. Zinc Supplementation:</span></p>
                    <ul>
                        <li><strong>Dose:</strong> Zinc sulfate 220mg PO daily</li>
                        <li>Many cirrhotics are zinc deficient</li>
                        <li>Zinc is cofactor for urea cycle enzymes</li>
                    </ul>
                    
                    <p><span class="label">5. Supportive Care:</span></p>
                    <ul>
                        <li>Airway protection if grade 3-4 (consider intubation)</li>
                        <li>Avoid sedatives (worsen encephalopathy)</li>
                        <li>If agitated: low-dose haloperidol 0.5-2mg (avoid benzos)</li>
                        <li>Nutrition: Don't restrict protein! Give 1.2-1.5 g/kg/day. Protein restriction is OUTDATED</li>
                    </ul>
                    
                    <p><span class="label">What NOT to Do:</span></p>
                    <ul>
                        <li><strong>Do NOT restrict protein:</strong> Outdated practice, worsens malnutrition</li>
                        <li><strong>Do NOT use neomycin:</strong> Nephrotoxic, ototoxic. Rifaximin is better</li>
                        <li><strong>Ammonia level:</strong> Don't follow serial levels - correlates poorly with clinical status</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Always find the precipitant:</strong> HE rarely occurs without a trigger. Treat the cause, not just the symptom</li>
                    <li><strong>Ammonia level controversy:</strong> Poor correlation with severity. Level >200 supports diagnosis but normal level doesn't exclude HE</li>
                    <li><strong>Protein restriction is WRONG:</strong> Old dogma. Cirrhotics need ADEQUATE protein (1.2-1.5g/kg/day) to prevent sarcopenia</li>
                    <li><strong>Vegetable protein better than animal:</strong> May be better tolerated but don't eliminate meat entirely</li>
                    <li><strong>Lactulose goals:</strong> 2-3 soft BMs/day. Too much = dehydration. Too little = constipation worsens HE</li>
                    <li><strong>Rifaximin not for acute:</strong> Add only for chronic/recurrent HE. Takes days to work. Not for initial episodes</li>
                    <li><strong>Post-TIPS HE:</strong> Occurs in 30-50%. May need TIPS revision or consider transplant if refractory</li>
                    <li><strong>Asterixis is NOT specific:</strong> Also seen in uremia, hypercapnia, other metabolic encephalopathies</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Grade 3-4 encephalopathy (coma)</li>
                        <li>Inability to protect airway</li>
                        <li>Rapidly progressive deterioration</li>
                        <li>Hemodynamic instability</li>
                        <li>Severe concurrent illness (sepsis, GI bleed)</li>
                        <li>Need for mechanical ventilation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Mental status at baseline (grade 0-1)</li>
                        <li>Precipitant identified and treated</li>
                        <li>Established bowel regimen (2-3 BM/day)</li>
                        <li>On appropriate lactulose dose</li>
                        <li>Rifaximin added if recurrent HE</li>
                        <li>Family educated on HE signs, lactulose use</li>
                        <li>Hepatology follow-up within 1 week</li>
                        <li>Transplant evaluation if not listed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Aspiration pneumonia, falls/trauma, pressure ulcers, malnutrition, inability to take medications</p>
                    <p><strong>Chronic:</strong> Recurrent HE episodes (50% recur within 6 months), cognitive decline, poor quality of life, increased mortality</p>
                    <p><strong>From Treatment:</strong> Dehydration and hypernatremia from excessive lactulose, diarrhea, abdominal cramping</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#lactulose" style="color: #8e44ad;">ðŸ’Š Lactulose</a>, <a href="drug_reference_guide.html#rifaximin" style="color: #8e44ad;">ðŸ’Š Rifaximin</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="pancreatitis" class="condition-page">
            <div class="page-header">
                <h2>19. ACUTE PANCREATITIS</h2>
                <div class="subtitle">Gallstones â€¢ Alcohol â€¢ Hypertriglyceridemia</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Epigastric pain radiating to back, nausea/vomiting, anorexia. Pain may be relieved by leaning forward</p>
                    <p><span class="label">Physical Exam:</span> Epigastric tenderness, decreased bowel sounds, tachycardia, fever, Cullen sign (periumbilical ecchymosis) or Grey Turner sign (flank ecchymosis) in hemorrhagic pancreatitis</p>
                    <p><span class="label">Common Causes (GET SMASHED):</span></p>
                    <ul>
                        <li><strong>G</strong>allstones (40%)</li>
                        <li><strong>E</strong>thanol (30%)</li>
                        <li><strong>T</strong>rauma</li>
                        <li><strong>S</strong>teroids</li>
                        <li><strong>M</strong>umps/other infections</li>
                        <li><strong>A</strong>utoimmune (IgG4)</li>
                        <li><strong>S</strong>corpion/snake bites</li>
                        <li><strong>H</strong>ypertriglyceridemia (>1000 mg/dL), Hypercalcemia</li>
                        <li><strong>E</strong>RCP</li>
                        <li><strong>D</strong>rugs (azathioprine, 6-MP, valproic acid, thiazides, furosemide, sulfonamides, tetracycline)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Diagnosis Requires 2 of 3:</span></p>
                    <ul>
                        <li><strong>1. Characteristic abdominal pain</strong></li>
                        <li><strong>2. Serum lipase >3Ã— upper limit normal</strong> (more specific than amylase)</li>
                        <li><strong>3. Imaging findings</strong></li>
                    </ul>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>Lipase:</strong> More sensitive/specific than amylase. Stays elevated longer</li>
                        <li>CBC (leukocytosis common), CMP (assess calcium, glucose), lipid panel (TG), LFTs (assess biliary etiology)</li>
                        <li><strong>If ALT >150:</strong> 95% PPV for gallstone pancreatitis</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>RUQ ultrasound:</strong> Look for gallstones, CBD dilation (do in ALL patients)</li>
                        <li><strong>CT abdomen with IV contrast:</strong> If diagnosis unclear OR severe disease. Delay 48-72hr if possible (pancreatic necrosis takes time to develop)</li>
                        <li><strong>MRCP:</strong> If concern for choledocholithiasis</li>
                    </ul>
                    
                    <p><span class="label">Severity Scoring:</span></p>
                    <ul>
                        <li><strong>Ranson Criteria:</strong> On admission + at 48 hours. Score â‰¥3 = severe</li>
                        <li><strong>BISAP Score:</strong> Simpler. 1 point each for: BUN >25, Impaired mental status, SIRS, Age >60, Pleural effusion. Score â‰¥3 = severe</li>
                        <li><strong>APACHE-II:</strong> Complex but accurate</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Fluid Resuscitation (MOST IMPORTANT):</span></p>
                    <ul>
                        <li><strong>Aggressive IVF:</strong> Lactated Ringer's preferred over NS (reduces SIRS, mortality)</li>
                        <li><strong>Rate:</strong> 250-500 mL/hr initially (15-20 mL/kg bolus, then 250-500 mL/hr)</li>
                        <li><strong>Goal:</strong> UOP >0.5 mL/kg/hr, HR <120, MAP 65-85</li>
                        <li><strong>Caution:</strong> Watch for volume overload in elderly/cardiac disease</li>
                        <li>Early aggressive hydration (within 24hr) reduces organ failure and mortality</li>
                    </ul>
                    
                    <p><span class="label">Nutrition:</span></p>
                    <ul>
                        <li><strong>Early oral feeding:</strong> Start within 24 hours if tolerated (even in severe pancreatitis!)</li>
                        <li><strong>Diet:</strong> Low-fat solid diet as tolerated. No need for clear liquids first</li>
                        <li><strong>If cannot tolerate PO:</strong> Enteral nutrition via NG/NJ tube preferred over TPN</li>
                        <li><strong>NPO only if:</strong> Intractable vomiting, ileus, or altered mental status</li>
                    </ul>
                    
                    <p><span class="label">Pain Control:</span></p>
                    <ul>
                        <li>IV opioids PRN (morphine, hydromorphone)</li>
                        <li>Myth: Opioids don't worsen pancreatitis via sphincter of Oddi spasm</li>
                    </ul>
                    
                    <p><span class="label">ERCP (Urgent <24hr):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Cholangitis OR biliary obstruction with bilirubin rising</li>
                        <li><strong>NOT indicated:</strong> Mild gallstone pancreatitis without obstruction (just do cholecystectomy later)</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics:</span></p>
                    <ul>
                        <li><strong>NOT routinely indicated</strong> for prophylaxis</li>
                        <li><strong>Give only if:</strong> Infected necrosis (proven by aspiration or gas on CT), cholangitis, or extrapancreatic infection</li>
                        <li>If infected necrosis: Carbapenems or fluoroquinolone + metronidazole</li>
                    </ul>
                    
                    <p><span class="label">Cholecystectomy (for Gallstone Pancreatitis):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> During SAME admission once acute inflammation resolves (pancreatic enzymes normalizing)</li>
                        <li>Usually safe after 48-72 hours if improving</li>
                        <li>Recurrence rate 30-60% if not done</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>LR > NS:</strong> Lactated Ringer's reduces SIRS and mortality compared to normal saline</li>
                    <li><strong>Early feeding is safe:</strong> Outdated to keep NPO. Start low-fat diet within 24hr</li>
                    <li><strong>No prophylactic antibiotics:</strong> Don't reduce infection or mortality. Only treat proven infection</li>
                    <li><strong>CT timing:</strong> Necrosis takes 48-72hr to develop. Early CT often non-diagnostic</li>
                    <li><strong>Lipase > Amylase:</strong> Lipase more sensitive/specific. Can skip amylase entirely</li>
                    <li><strong>Hypertriglyceridemia:</strong> If TG >1000, this can CAUSE pancreatitis. Treat with insulin gtt + fibrates</li>
                    <li><strong>Sterile vs infected necrosis:</strong> Infected = fever, leukocytosis, gas on CT. Needs drainage. Sterile necrosis = conservative management</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe pancreatitis (BISAP â‰¥3, Ranson â‰¥3)</li>
                        <li>Organ failure (respiratory, renal, cardiovascular)</li>
                        <li>Hemodynamic instability</li>
                        <li>Persistent SIRS >48 hours</li>
                        <li>Pancreatic necrosis with infection</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Pain controlled on PO medications</li>
                        <li>Tolerating regular diet</li>
                        <li>Lipase trending down</li>
                        <li>No organ dysfunction</li>
                        <li>Cholecystectomy done (if gallstone etiology)</li>
                        <li>Alcohol cessation counseling (if EtOH cause)</li>
                        <li>Follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early:</strong> Pancreatic necrosis (10-20%), infected necrosis, ARDS, AKI, shock, hypocalcemia</p>
                    <p><strong>Late:</strong> Pseudocyst (4 weeks), splenic/portal vein thrombosis, chronic pancreatitis, pancreatic insufficiency, diabetes</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="cellulitis" class="condition-page">
            <div class="page-header">
                <h2>20. CELLULITIS</h2>
                <div class="subtitle">Skin/Soft Tissue Infection</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Acute onset of erythema, warmth, edema, and tenderness in affected area. Usually unilateral lower extremity. Pain typically present. Systemic symptoms: fever, chills, malaise in 40-60% of hospitalized patients</p>
                    <p><span class="label">Physical Exam:</span> Ill-defined borders spreading centrifugally (vs erysipelas which has raised sharp borders), no fluctuance (vs abscess), lymphangitic streaking in 15-20%, regional lymphadenopathy. Measure and mark borders with pen. Look for portal of entry (trauma, tinea pedis, fissures)</p>
                    <p><span class="label">Common Organisms:</span> Î²-hemolytic Streptococcus (Group A Strep, most common in non-purulent), Staphylococcus aureus (especially MRSA if purulent/abscess present)</p>
                    <p><span class="label">Risk Factors:</span> Obesity, diabetes mellitus, venous insufficiency, chronic lymphedema, tinea pedis (toe web intertrigo), immunosuppression, prior cellulitis (20-30% recurrence rate), skin barrier disruption</p>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Erysipelas:</strong> Superficial cellulitis with sharply demarcated, raised, indurated borders. "Orange peel" appearance. Almost always Group A Strep. Face and legs most common</li>
                        <li><strong>Periorbital Cellulitis:</strong> Eyelid edema, erythema WITHOUT vision changes or pain with eye movement (vs orbital cellulitis which needs emergent CT/ENT). Can progress to orbital cellulitis</li>
                        <li><strong>Facial Cellulitis:</strong> Consider dental source (odontogenic), sinusitis. Higher risk of cavernous sinus thrombosis if near nasolabial triangle</li>
                        <li><strong>Diabetic Patients:</strong> More likely polymicrobial, higher risk of progression to necrotizing infection. Check for gas on imaging</li>
                        <li><strong>Immunocompromised:</strong> Consider atypical organisms (fungi, mycobacteria, Pseudomonas). May lack fever/leukocytosis despite severe infection</li>
                        <li><strong>Post-Surgical:</strong> If within 48 hours, consider Group A Strep (rapidly progressive, very painful). If days later, S. aureus more likely</li>
                        <li><strong>Water Exposure:</strong> Vibrio vulnificus (salt water), Aeromonas (fresh water) - both can cause necrotizing fasciitis. Ask about water exposure!</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis:</span> Based on appearance - culture/biopsy rarely needed for typical cellulitis. Positive predictive value of clinical diagnosis >70% by experienced clinicians</p>
                    
                    <p><span class="label">Labs (Obtain if systemic symptoms or severe):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis common (WBC >12k in 50%), left shift. Leukopenia concerning for overwhelming sepsis</li>
                        <li><strong>Blood Cultures:</strong> Low yield (<5% positive) but obtain if: fever >38.5Â°C, hypotension, immunocompromised, suspected bacteremia, failed outpatient therapy</li>
                        <li><strong>ESR/CRP:</strong> Elevated but non-specific. Can be useful if diagnosis uncertain or to follow treatment response</li>
                        <li><strong>BMP:</strong> If systemic toxicity (assess renal function before vancomycin/aminoglycosides)</li>
                        <li><strong>Lactate:</strong> If concern for sepsis or necrotizing infection</li>
                    </ul>
                    
                    <p><span class="label">Imaging (NOT routinely needed):</span></p>
                    <ul>
                        <li><strong>Ultrasound:</strong> Can differentiate cellulitis from abscess. "Cobblestoning" of subcutaneous tissue seen in cellulitis. Can identify fluid collections needing drainage</li>
                        <li><strong>CT with IV contrast:</strong> If necrotizing fasciitis suspected (gas in tissues, fascial involvement), deep abscess, osteomyelitis concern</li>
                        <li><strong>MRI:</strong> Gold standard for osteomyelitis, deep space infections, necrotizing fasciitis. Use if diagnosis unclear and high clinical suspicion</li>
                        <li><strong>X-ray:</strong> Can identify foreign body, subcutaneous gas (necrotizing infection), osteomyelitis (after 2 weeks)</li>
                    </ul>
                    
                    <p><span class="label">Culture/Biopsy (Consider if):</span></p>
                    <ul>
                        <li>Purulent drainage present â†’ Send for culture & sensitivity (guides antibiotic de-escalation)</li>
                        <li>Failed initial therapy</li>
                        <li>Immunocompromised (atypical organisms)</li>
                        <li>Penetrating trauma or water exposure (atypical organisms)</li>
                        <li>Punch biopsy/aspiration: Low yield (20-40% positive), painful, generally not recommended for uncomplicated cellulitis</li>
                    </ul>
                    
                    <p><span class="label">Mark Borders:</span> Draw around erythema with marker, date/time. Essential for tracking progression/regression. Take photo for documentation</p>
                    
                    <p><span class="label">Differential Diagnosis to Consider:</span></p>
                    <ul>
                        <li><strong>Stasis Dermatitis:</strong> Bilateral, chronic, hyperpigmentation, varicose veins. Often misdiagnosed as cellulitis</li>
                        <li><strong>DVT:</strong> Asymmetric edema but typically no erythema. Get duplex if uncertain</li>
                        <li><strong>Contact Dermatitis:</strong> Pruritic, vesicular, bilateral distribution, exposure history</li>
                        <li><strong>Necrotizing Fasciitis:</strong> Pain out of proportion, hemorrhagic bullae, crepitus, systemic toxicity, rapid progression</li>
                        <li><strong>Gout/Pseudogout:</strong> Acute monoarticular arthritis, usually joint-based</li>
                        <li><strong>Lipodermatosclerosis:</strong> Chronic, indurated, inverted champagne bottle appearance of lower leg</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Key Decision: Purulent vs Non-Purulent</span></p>
                    <ul>
                        <li><strong>Non-Purulent:</strong> No drainable abscess, no purulent discharge â†’ Target Streptococcus, NO MRSA coverage needed</li>
                        <li><strong>Purulent:</strong> Abscess, furuncle, carbuncle, purulent drainage â†’ MUST cover MRSA</li>
                    </ul>
                    
                    <p><span class="label">Non-Purulent Cellulitis (No Abscess/Furuncle) - Streptococcal Coverage:</span></p>
                    <ul>
                        <li><strong>Mild (Outpatient):</strong>
                            <ul>
                                <li>Cephalexin 500mg PO QID Ã— 5-10 days (first-line)</li>
                                <li>Dicloxacillin 500mg PO QID Ã— 5-10 days</li>
                                <li>Amoxicillin-clavulanate 875mg BID Ã— 5-10 days</li>
                            </ul>
                        </li>
                        <li><strong>Moderate (Inpatient/Observation):</strong>
                            <ul>
                                <li>Cefazolin 1-2g IV q8h (excellent Strep/MSSA coverage)</li>
                                <li>Ceftriaxone 1-2g IV q24h (good for once-daily dosing)</li>
                            </ul>
                        </li>
                        <li><strong>PCN Allergy (Non-anaphylaxis):</strong>
                            <ul>
                                <li>Cephalosporins safe if non-IgE mediated reaction (~98% safe)</li>
                            </ul>
                        </li>
                        <li><strong>Severe PCN Allergy (Anaphylaxis):</strong>
                            <ul>
                                <li>Clindamycin 600mg IV q8h OR 300-450mg PO TID (covers Strep/MSSA, not MRSA reliably)</li>
                                <li>Doxycycline 100mg PO/IV BID</li>
                                <li>Levofloxacin 750mg PO/IV daily (avoid if other options available)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Purulent Cellulitis (WITH Abscess/Drainage) - MRSA Coverage Required:</span></p>
                    <ul>
                        <li><strong>Mild (Outpatient):</strong>
                            <ul>
                                <li>TMP-SMX DS 1-2 tabs PO BID Ã— 5-10 days (excellent MRSA coverage)</li>
                                <li>Doxycycline 100mg PO BID Ã— 5-10 days</li>
                                <li>Clindamycin 300-450mg PO TID Ã— 5-10 days (if local resistance <10%)</li>
                            </ul>
                        </li>
                        <li><strong>Moderate-Severe (Inpatient):</strong>
                            <ul>
                                <li>Vancomycin 15-20mg/kg IV q8-12h (goal trough 15-20 for complicated infections)</li>
                                <li>Daptomycin 4mg/kg IV q24h (skin infections, not if pulmonary involvement)</li>
                                <li>Linezolid 600mg PO/IV BID (excellent bioavailability, reserve for VRE risk)</li>
                            </ul>
                        </li>
                        <li><strong>I&D (Incision & Drainage):</strong> Drain abscess if present. Send purulent material for culture & sensitivity. I&D alone may be sufficient for small abscesses <5cm without surrounding cellulitis</li>
                    </ul>
                    
                    <p><span class="label">Severe/Complicated Cellulitis:</span></p>
                    <ul>
                        <li><strong>Septic/Toxic appearance:</strong> Vancomycin 15-20mg/kg IV q8-12h + Pip-tazo 3.375g IV q6h</li>
                        <li><strong>Necrotizing Fasciitis Concern:</strong> Vancomycin + Pip-tazo + Clindamycin 900mg IV q8h (clindamycin inhibits toxin production). IMMEDIATE surgical consultation</li>
                        <li><strong>Immunocompromised:</strong> Broader coverage - consider Vancomycin + Cefepime or Vancomycin + Meropenem</li>
                        <li><strong>Water Exposure:</strong>
                            <ul>
                                <li>Salt water (Vibrio): Doxycycline 100mg IV BID + Ceftriaxone 1g IV q24h</li>
                                <li>Fresh water (Aeromonas): Ceftriaxone + Ciprofloxacin 400mg IV q12h</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Special Populations:</span></p>
                    <ul>
                        <li><strong>Diabetes:</strong> Lower threshold to admit. Check for gas on imaging. Consider broader coverage if severe or neuropathy present</li>
                        <li><strong>Cirrhosis:</strong> Higher risk of Vibrio if shellfish exposure. Consider ceftriaxone + doxycycline</li>
                        <li><strong>Neutropenic:</strong> Cefepime or meropenem + vancomycin. Consider antifungal if not improving</li>
                        <li><strong>Bite Wounds:</strong>
                            <ul>
                                <li>Human/Animal: Amoxicillin-clavulanate 875mg BID OR Ampicillin-sulbactam 3g IV q6h</li>
                                <li>PCN allergic: Doxycycline + Metronidazole OR Moxifloxacin</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Adjunct Measures:</span></p>
                    <ul>
                        <li><strong>Elevation:</strong> Keep affected limb elevated above heart level. CRITICAL for reducing edema and speeding recovery</li>
                        <li><strong>Analgesia:</strong> NSAIDs (ibuprofen 600mg q6h) or acetaminophen 1g q6h. NSAIDs have anti-inflammatory benefit</li>
                        <li><strong>Treat Underlying Conditions:</strong>
                            <ul>
                                <li>Tinea pedis: Topical antifungal (terbinafine cream BID Ã— 2 weeks)</li>
                                <li>Venous insufficiency: Compression stockings after acute infection resolves</li>
                                <li>Edema: Diuretics if appropriate, elevation, compression</li>
                            </ul>
                        </li>
                        <li><strong>Wound Care:</strong> Keep clean and dry. Gentle cleansing with soap and water. No need for topical antibiotics</li>
                    </ul>
                    
                    <p><span class="label">Duration of Therapy:</span></p>
                    <ul>
                        <li><strong>Standard:</strong> 5-10 days typical. Minimum 5 days if rapidly improving</li>
                        <li><strong>Severe:</strong> 10-14 days if slow response, extensive disease, or immunocompromised</li>
                        <li><strong>Transition to PO:</strong> When afebrile >24hr, improving cellulitis, tolerating PO, stable vitals</li>
                        <li><strong>Response Time:</strong> Expect improvement within 48-72 hours. Erythema may initially expand first 24-48hr despite appropriate antibiotics (inflammatory response). If not improving by 72hr, re-evaluate</li>
                    </ul>
                    
                    <p><span class="label">Recurrent Cellulitis Prevention:</span></p>
                    <ul>
                        <li><strong>â‰¥2 episodes/year or â‰¥3 lifetime:</strong> Consider prophylaxis</li>
                        <li>Penicillin VK 250mg PO BID OR Erythromycin 250mg PO BID (indefinitely or seasonally)</li>
                        <li>Address predisposing factors: Treat tinea pedis aggressively, compression for lymphedema/venous insufficiency, good skin hygiene</li>
                        <li>Patient education: Early recognition and treatment at first sign reduces hospitalizations</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>MRSA coverage ONLY if purulent:</strong> Overuse of vancomycin drives resistance. Non-purulent cellulitis = Î²-lactam monotherapy. Don't reflexively add vanc!</li>
                    <li><strong>Mark borders religiously:</strong> Date and time your marking. Simple intervention that objectively tracks progression/regression and improves clinical decision-making</li>
                    <li><strong>Elevation is NOT optional:</strong> Elevating the affected limb above heart level significantly speeds recovery by reducing venous congestion and edema. It's as important as antibiotics!</li>
                    <li><strong>Recurrent cellulitis screening questions:</strong> Ask about tinea pedis (toe web maceration = portal of entry), lymphedema, venous insufficiency. Treating these reduces recurrence dramatically</li>
                    <li><strong>Purpura = NOT cellulitis:</strong> If non-blanching purpura present, think necrotizing fasciitis, meningococcemia, septic emboli, vasculitis. Blanching erythema = cellulitis</li>
                    <li><strong>Pain out of proportion = Surgical Emergency:</strong> If pain is much worse than exam findings suggest, think necrotizing fasciitis. Also: hemorrhagic bullae, crepitus, "wooden" induration, rapid progression, systemic toxicity â†’ STAT surgical consult + broad antibiotics + clindamycin</li>
                    <li><strong>Initial expansion doesn't mean failure:</strong> Cellulitis commonly gets worse in first 24-48 hours despite appropriate antibiotics due to inflammatory response. Don't panic and broaden coverage unless systemic symptoms worsen</li>
                    <li><strong>Stasis dermatitis masquerader:</strong> #1 cellulitis mimic. Clues: Bilateral (cellulitis usually unilateral), chronic course, hyperpigmentation, varicose veins, hemosiderin deposition, pruritus > pain. Don't treat with antibiotics!</li>
                    <li><strong>LRINEC score for necrotizing fasciitis:</strong> CRP, WBC, Hgb, Na, Cr, glucose. Score â‰¥6 â†’ 50% PPV for NF. Score â‰¥8 â†’ 75% PPV. But don't wait for lab results if clinical suspicion high!</li>
                    <li><strong>Blood cultures low yield:</strong> Only 5% positive in cellulitis, but still obtain if fever >38.5Â°C or concern for bacteremia. Don't withhold antibiotics waiting for culture results</li>
                    <li><strong>Prophylaxis pearls:</strong> For recurrent cellulitis (â‰¥2/year), continuous penicillin prophylaxis reduces recurrence by 50%. But address underlying causes first (tinea pedis treatment, compression, lymphedema therapy)</li>
                    <li><strong>Failed therapy checklist:</strong> Wrong diagnosis (stasis dermatitis, DVT)? Inadequate coverage (MRSA not covered)? Abscess needing drainage? Underlying osteomyelitis? Deep space infection? Non-infectious cause?</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Necrotizing fasciitis suspected or confirmed (pain out of proportion, crepitus, bullae, "wooden" feel)</li>
                        <li>Septic shock (SBP <90 despite fluids, lactate >4)</li>
                        <li>Rapidly progressive cellulitis despite IV antibiotics (expanding >5cm/hr)</li>
                        <li>Compartment syndrome (tense compartment, pain with passive stretch, paresthesias, pulselessness)</li>
                        <li>Streptococcal toxic shock syndrome (hypotension + multi-organ dysfunction)</li>
                        <li>Airway compromise (facial/neck cellulitis, Ludwig's angina)</li>
                        <li>Need for vasopressors or aggressive resuscitation</li>
                        <li>Hemodynamic instability with failed floor management</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile Ã— 24 hours (Temp <38Â°C)</li>
                        <li>Hemodynamically stable (SBP >90, HR <110)</li>
                        <li>Erythema/edema clearly improving (borders regressing)</li>
                        <li>Pain controlled on oral analgesics</li>
                        <li>Tolerating PO intake and oral antibiotics</li>
                        <li>No evidence of abscess requiring drainage</li>
                        <li>No concern for necrotizing infection</li>
                        <li>Adequate home support for elevation/wound care</li>
                        <li>Close follow-up arranged within 2-3 days</li>
                        <li>Patient educated on: limb elevation, signs of worsening, medication adherence</li>
                        <li>If diabetes: glucose controlled, good perfusion to affected area</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Local Complications:</strong> Abscess formation (fluctuance, purulent drainage - needs I&D), necrotizing fasciitis (pain out of proportion, bullae, crepitus, rapid progression), compartment syndrome (increased pressure in fascial compartment - surgical emergency), lymphangitis (red streaking), chronic lymphedema (after repeated episodes), post-infectious scarring/hyperpigmentation</p>
                    <p><strong>Systemic Complications:</strong> Bacteremia/sepsis (5-10% of hospitalized patients), septic shock, endocarditis (especially MRSA bacteremia), osteomyelitis (if bone involvement), septic arthritis (if joint nearby), glomerulonephritis (post-Streptococcal), toxic shock syndrome (Strep or Staph toxins)</p>
                    <p><strong>Treatment-Related:</strong> Antibiotic-associated diarrhea, C. difficile infection, drug allergy/rash, nephrotoxicity (vancomycin, aminoglycosides), red man syndrome (vancomycin infusion reaction), thrombophlebitis (IV site)</p>
                    <p><strong>Recurrence:</strong> 20-30% recurrence rate, higher with lymphedema. Monitor for: inadequately treated portal of entry (tinea pedis), unaddressed edema/venous insufficiency, immunosuppression</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="uti" class="condition-page">
            <div class="page-header">
                <h2>21. URINARY TRACT INFECTION / PYELONEPHRITIS</h2>
                <div class="subtitle">Cystitis â€¢ Pyelonephritis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Cystitis (Lower UTI):</span> Acute onset of dysuria, urinary frequency, urgency, suprapubic pain/pressure, hematuria (gross or microscopic). NO fever (Temp <38Â°C) or flank pain. Symptoms typically develop over hours to 1-2 days</p>
                    <p><span class="label">Pyelonephritis (Upper UTI):</span> Fever >38.5Â°C, rigors, unilateral flank/back pain, costovertebral angle (CVA) tenderness on exam, nausea/vomiting. Often accompanied by dysuria and frequency. Can progress to sepsis</p>
                    <p><span class="label">Complicated UTI Definition:</span> Structural/functional abnormality of GU tract, instrumentation, immunosuppression, pregnancy, males, indwelling catheter, recent antimicrobial use, diabetes, renal transplant, hospital-acquired. Higher risk of treatment failure and complications</p>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly Patients:</strong> May present with altered mental status, confusion, falls, functional decline, or generalized weakness WITHOUT classic UTI symptoms. Fever often absent or blunted. Dysuria may not be reported. High index of suspicion needed</li>
                        <li><strong>Diabetic Patients:</strong> Higher risk of emphysematous pyelonephritis (gas-forming infection - E. coli, Klebsiella), papillary necrosis, perinephric abscess. Worse outcomes, longer treatment needed. May have poor glucose control as only manifestation</li>
                        <li><strong>Pregnancy:</strong> 20-30% of untreated asymptomatic bacteriuria progresses to pyelonephritis. Pyelonephritis can trigger preterm labor, low birth weight. Must screen ALL pregnant women and treat asymptomatic bacteriuria. Higher risk of recurrence during pregnancy</li>
                        <li><strong>Men (Any Age):</strong> Almost always complicated UTI. Assume prostatic involvement until proven otherwise. Need 7-14 days of treatment. Evaluate for structural abnormalities, BPH, prostatitis. First UTI in young man = red flag for anatomic defect</li>
                        <li><strong>Catheter-Associated (CAUTI):</strong> New fever, flank pain, suprapubic pain, altered mental status in catheterized patient. Often polymicrobial. Pyuria alone is NOT diagnostic (50% of catheterized patients have asymptomatic pyuria). Need symptoms to treat</li>
                        <li><strong>Perinephric/Renal Abscess:</strong> Persistent fever despite 48-72 hours appropriate antibiotics. Unilateral flank pain, palpable flank mass. Risk factors: diabetes, IV drug use, renal stones, obstruction. CT diagnostic. May need percutaneous or surgical drainage</li>
                        <li><strong>Xanthogranulomatous Pyelonephritis:</strong> Rare chronic infection causing granulomatous destruction of kidney. Mimics renal mass on imaging. Presents with persistent flank pain, fever, weight loss. Kidney non-functional, requires nephrectomy</li>
                        <li><strong>Emphysematous Pyelonephritis:</strong> Life-threatening gas-forming infection. 90% diabetics. Presents with severe sepsis, CVA tenderness. CT shows gas in renal parenchyma. High mortality (20-40%). Requires IV antibiotics + possible nephrectomy</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Urinalysis (Essential for ALL):</span></p>
                    <ul>
                        <li><strong>Pyuria:</strong> >10 WBC/hpf highly suggestive. >5 WBC/hpf = abnormal. Absence of pyuria makes UTI unlikely (95% NPV)</li>
                        <li><strong>Bacteriuria:</strong> Any bacteria on unspun urine microscopy = â‰¥10^5 CFU/mL</li>
                        <li><strong>Leukocyte Esterase:</strong> Sensitive (75-96%) but less specific. Produced by WBCs. Can be false positive with contamination</li>
                        <li><strong>Nitrites:</strong> Highly specific (90-100%) but only 50% sensitive. Many uropathogens (Enterococcus, Staph saprophyticus, Pseudomonas) don't produce nitrites. Requires bacteria in bladder â‰¥4 hours</li>
                        <li><strong>Hematuria:</strong> Present in 40-60% of UTIs but non-specific</li>
                        <li><strong>WBC Casts:</strong> Pathognomonic for pyelonephritis (indicates renal parenchymal involvement). Differentiates from cystitis</li>
                    </ul>
                    
                    <p><span class="label">Urine Culture & Sensitivity (When to Send):</span></p>
                    <ul>
                        <li><strong>ALWAYS send before antibiotics if:</strong> Pyelonephritis, complicated UTI, pregnant, recent antibiotic use, healthcare-associated, symptoms >7 days, recurrent UTI, immunocompromised</li>
                        <li><strong>NOT needed for:</strong> Uncomplicated cystitis in young women (treat empirically)</li>
                        <li><strong>Collection:</strong> Mid-stream clean catch (not catheter unless catheter present <2 hours). First morning void best</li>
                        <li><strong>Interpretation:</strong>
                            <ul>
                                <li>â‰¥10^5 CFU/mL = diagnostic for cystitis</li>
                                <li>â‰¥10^4 CFU/mL = diagnostic for pyelonephritis</li>
                                <li>â‰¥10^2 CFU/mL = diagnostic if catheter specimen</li>
                                <li>Multiple organisms = contamination (repeat culture)</li>
                            </ul>
                        </li>
                        <li><strong>Common Organisms:</strong> E. coli (75-95%), Klebsiella pneumoniae (5-10%), Proteus mirabilis (5%), Enterococcus (5%), Staphylococcus saprophyticus (5-15% in young women)</li>
                    </ul>
                    
                    <p><span class="label">Blood Cultures:</span></p>
                    <ul>
                        <li><strong>Obtain if:</strong> Pyelonephritis with sepsis/hemodynamic instability, immunocompromised, persistent fever despite 48-72hr of antibiotics, concern for bacteremia</li>
                        <li>Positive in 15-25% of hospitalized pyelonephritis patients</li>
                        <li>Usually same organism as urine culture</li>
                    </ul>
                    
                    <p><span class="label">Additional Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis common in pyelonephritis (WBC often 12-20k with left shift). Leukopenia suggests severe sepsis</li>
                        <li><strong>BMP:</strong> Assess renal function (baseline Cr), check for AKI. Evaluate electrolytes</li>
                        <li><strong>Pregnancy test:</strong> ALL women of childbearing age (ectopic can present as flank pain, UTI changes management in pregnancy)</li>
                        <li><strong>Lactate:</strong> If sepsis suspected (goal <2, elevated suggests tissue hypoperfusion)</li>
                    </ul>
                    
                    <p><span class="label">Imaging (NOT routine, but obtain if):</span></p>
                    <ul>
                        <li><strong>CT Abdomen/Pelvis WITH IV Contrast (Test of Choice):</strong>
                            <ul>
                                <li>No clinical improvement after 48-72 hours of appropriate antibiotics</li>
                                <li>Sepsis/septic shock</li>
                                <li>Immunocompromised (evaluate for abscess)</li>
                                <li>Concern for urinary obstruction (hydronephrosis, stones)</li>
                                <li>Recurrent pyelonephritis (>2 episodes)</li>
                                <li>Men with pyelonephritis (evaluate for anatomic abnormality)</li>
                                <li>Suspected emphysematous pyelonephritis (gas in tissues)</li>
                                <li>Suspected perinephric/renal abscess</li>
                            </ul>
                        </li>
                        <li><strong>Renal Ultrasound:</strong> First-line if pregnant or contraindication to IV contrast. Can detect hydronephrosis (obstruction) but less sensitive for abscess than CT. Good for assessing kidney size/echogenicity</li>
                        <li><strong>KUB X-ray:</strong> Limited utility. Can identify radiopaque stones (calcium) but misses 10-20% of stones</li>
                    </ul>
                    
                    <p><span class="label">Special Diagnostic Considerations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic Bacteriuria (ASB):</strong> Positive culture (â‰¥10^5 CFU/mL) WITHOUT symptoms. Very common in elderly, catheterized patients. <strong>DO NOT TREAT</strong> except in pregnancy or before urologic procedures. Treatment causes antibiotic resistance without benefit</li>
                        <li><strong>Sterile Pyuria:</strong> WBCs in urine but negative culture. Differential: TB (send AFB culture Ã— 3), fungal infection, interstitial nephritis, appendicitis, recent antibiotic use, urethritis (chlamydia, gonorrhea), kidney stones</li>
                        <li><strong>Catheter-Associated UTI Diagnosis:</strong> Catheterized patient with fever (>38Â°C) OR new onset suprapubic pain OR flank pain OR altered mental status WITHOUT other source PLUS positive culture â‰¥10^3 CFU/mL. Pyuria alone is NOT diagnostic</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Uncomplicated Cystitis (Healthy Non-Pregnant Women):</span></p>
                    <ul>
                        <li><strong>First-Line Options:</strong>
                            <ul>
                                <li>Nitrofurantoin monohydrate/macrocrystals 100mg PO BID Ã— 5 days (preferred)</li>
                                <li>TMP-SMX DS (160/800mg) PO BID Ã— 3 days (only if local E. coli resistance <20%)</li>
                            </ul>
                        </li>
                        <li><strong>Second-Line Options:</strong>
                            <ul>
                                <li>Fosfomycin 3g PO Ã— single dose (convenient but slightly lower cure rate ~90%)</li>
                                <li>Pivmecillinam 400mg PO TID Ã— 3-5 days (not available in US)</li>
                            </ul>
                        </li>
                        <li><strong>When Î²-lactams Necessary:</strong>
                            <ul>
                                <li>Amoxicillin-clavulanate 875/125mg PO BID Ã— 5-7 days</li>
                                <li>Cefpodoxime 100mg PO BID Ã— 5-7 days</li>
                                <li>Less effective than nitrofurantoin/TMP-SMX - use only if alternatives unavailable</li>
                            </ul>
                        </li>
                        <li><strong>AVOID Fluoroquinolones:</strong> Reserve for pyelonephritis due to serious adverse effects (C. diff, tendon rupture, neuropathy) and resistance concerns</li>
                        <li><strong>Contraindications:</strong>
                            <ul>
                                <li>Nitrofurantoin: CrCl <30 mL/min, pregnancy at term (risk of hemolytic anemia in newborn), G6PD deficiency</li>
                                <li>TMP-SMX: Pregnancy (especially 1st trimester - neural tube defects), severe sulfa allergy, CrCl <15</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Acute Pyelonephritis - Outpatient (Mild, Tolerates PO, Reliable):</span></p>
                    <ul>
                        <li><strong>Fluoroquinolone (if local resistance <10%):</strong>
                            <ul>
                                <li>Ciprofloxacin 500mg PO BID Ã— 7 days OR 1000mg XR daily Ã— 7 days</li>
                                <li>Levofloxacin 750mg PO daily Ã— 5 days</li>
                                <li>Can give single dose ceftriaxone 1g IM in ED before starting oral quinolone</li>
                            </ul>
                        </li>
                        <li><strong>If Fluoroquinolone Resistance or Contraindicated:</strong>
                            <ul>
                                <li>Ceftriaxone 1g IM/IV Ã— 1 dose, THEN oral step-down based on culture susceptibility</li>
                                <li>If susceptible: TMP-SMX DS BID Ã— 14 days OR Amoxicillin-clavulanate 875mg BID Ã— 10-14 days</li>
                                <li>Cefpodoxime 200mg PO BID Ã— 10-14 days (if susceptible)</li>
                            </ul>
                        </li>
                        <li><strong>Duration:</strong> 7-14 days depending on agent and clinical response. Fluoroquinolones 5-7 days, Î²-lactams 10-14 days</li>
                    </ul>
                    
                    <p><span class="label">Acute Pyelonephritis - Inpatient (Toxic, Septic, Unable to Tolerate PO):</span></p>
                    <ul>
                        <li><strong>Moderate Severity:</strong>
                            <ul>
                                <li>Ceftriaxone 1-2g IV q24h (excellent E. coli, Klebsiella, Proteus coverage)</li>
                                <li>Ciprofloxacin 400mg IV q12h OR Levofloxacin 750mg IV q24h</li>
                            </ul>
                        </li>
                        <li><strong>Severe/Septic/Complicated:</strong>
                            <ul>
                                <li>Cefepime 2g IV q8h (broader than ceftriaxone, covers Pseudomonas)</li>
                                <li>Piperacillin-tazobactam 3.375g IV q6h or 4.5g IV q8h</li>
                            </ul>
                        </li>
                        <li><strong>If Gram-Positive Cocci on Culture:</strong> Add Ampicillin 2g IV q4h (for Enterococcus - VRE risk if amp-resistant)</li>
                        <li><strong>ESBL Risk Factors Present:</strong> Previous ESBL infection, recent hospitalization, healthcare exposure, international travel, chronic care facility resident
                            <ul>
                                <li>Ertapenem 1g IV q24h OR Meropenem 1g IV q8h</li>
                                <li>Avoid cephalosporins/fluoroquinolones if ESBL confirmed</li>
                            </ul>
                        </li>
                        <li><strong>Transition to Oral:</strong> When afebrile Ã— 24 hours, improved symptoms, tolerating PO, hemodynamically stable
                            <ul>
                                <li>Ciprofloxacin 500mg BID or Levofloxacin 750mg daily</li>
                                <li>TMP-SMX DS BID (if susceptible)</li>
                                <li>Amoxicillin-clavulanate 875mg BID (if susceptible)</li>
                            </ul>
                        </li>
                        <li><strong>Total Duration:</strong> 7-14 days
                            <ul>
                                <li>7 days if uncomplicated, rapid response to treatment</li>
                                <li>10-14 days if complicated, bacteremia, slow response, immunocompromised, male</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Complicated UTI/Urosepsis:</span></p>
                    <ul>
                        <li><strong>Broad-Spectrum Initial Coverage:</strong>
                            <ul>
                                <li>Pip-tazo 4.5g IV q6h OR Cefepime 2g IV q8h</li>
                                <li>If MRSA suspected (skin breakdown, recent healthcare): ADD Vancomycin 15-20mg/kg IV q8-12h</li>
                                <li>If critically ill: Meropenem 1g IV q8h (covers ESBL, Pseudomonas)</li>
                            </ul>
                        </li>
                        <li><strong>De-escalate Based on Cultures:</strong> Narrow to organism-specific therapy once susceptibilities available</li>
                        <li><strong>Duration:</strong> 10-14 days minimum. Extend if slow response, abscess, obstruction</li>
                        <li><strong>Source Control:</strong> Remove catheters if possible. Drain abscesses. Relieve obstruction (nephrostomy, stent)</li>
                    </ul>
                    
                    <p><span class="label">Special Populations:</span></p>
                    <ul>
                        <li><strong>Pregnancy:</strong>
                            <ul>
                                <li><strong>Screen ALL pregnant women</strong> for ASB at 12-16 weeks (treat if positive)</li>
                                <li>Cystitis: Nitrofurantoin 100mg BID Ã— 5-7 days (avoid at term) OR Amoxicillin-clavulanate 875mg BID Ã— 5-7 days OR Cephalexin 500mg QID Ã— 5-7 days</li>
                                <li>Pyelonephritis: <strong>ADMIT</strong> - Ceftriaxone 1-2g IV q24h until afebrile Ã— 24-48hr, then Cephalexin 500mg QID Ã— 10-14 days total</li>
                                <li><strong>AVOID:</strong> Fluoroquinolones (cartilage toxicity), TMP in 1st trimester (neural tube defects), nitrofurantoin at term</li>
                            </ul>
                        </li>
                        <li><strong>Men (Always Complicated):</strong>
                            <ul>
                                <li>Assume prostatic involvement</li>
                                <li>Fluoroquinolone Ã— 10-14 days (penetrates prostate): Ciprofloxacin 500mg BID or Levofloxacin 750mg daily</li>
                                <li>Alternative: TMP-SMX DS BID Ã— 14 days (if susceptible)</li>
                                <li>If severe: Start IV (ceftriaxone, cefepime), transition to PO quinolone</li>
                                <li>Urology referral for: recurrent UTI, first UTI in young man, concern for obstruction</li>
                            </ul>
                        </li>
                        <li><strong>Catheter-Associated UTI (CAUTI):</strong>
                            <ul>
                                <li><strong>Remove or replace catheter</strong> if possible before starting antibiotics</li>
                                <li>Often polymicrobial, resistant organisms (Pseudomonas, Enterococcus, Candida)</li>
                                <li>Empiric: Ceftriaxone 1g IV daily OR Ciprofloxacin 400mg IV q12h</li>
                                <li>If severe: Cefepime or Pip-tazo (Pseudomonas coverage)</li>
                                <li>Duration: 7 days if catheter removed, 10-14 days if catheter remains in place</li>
                                <li>De-escalate based on cultures</li>
                            </ul>
                        </li>
                        <li><strong>Renal Impairment:</strong>
                            <ul>
                                <li>Avoid nitrofurantoin if CrCl <30 (inadequate levels)</li>
                                <li>Dose-adjust fluoroquinolones, Î²-lactams based on CrCl</li>
                                <li>TMP-SMX: Avoid if CrCl <15</li>
                            </ul>
                        </li>
                        <li><strong>Elderly/Nursing Home:</strong>
                            <ul>
                                <li>Do NOT treat asymptomatic bacteriuria</li>
                                <li>If symptomatic: Consider atypical presentations (AMS, falls)</li>
                                <li>Higher resistance rates - obtain culture before treating</li>
                                <li>Lower threshold to admit (dehydration, frailty, poor PO intake)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Recurrent UTI Management (â‰¥2 in 6 months or â‰¥3 in 12 months):</span></p>
                    <ul>
                        <li><strong>Non-Antibiotic Strategies:</strong>
                            <ul>
                                <li>Increase fluid intake (2-3 L/day)</li>
                                <li>Void after intercourse</li>
                                <li>Avoid spermicides, diaphragms</li>
                                <li>Cranberry products (modest benefit - 500-1500mg proanthocyanidins daily)</li>
                                <li>D-mannose 2g daily (prevents E. coli adhesion)</li>
                                <li>Vaginal estrogen cream (post-menopausal women) - Estradiol 0.5g intravaginally 2x/week</li>
                            </ul>
                        </li>
                        <li><strong>Antibiotic Prophylaxis:</strong>
                            <ul>
                                <li><strong>Continuous:</strong> TMP-SMX SS (40/200mg) daily OR Nitrofurantoin 50-100mg daily at bedtime</li>
                                <li><strong>Post-coital:</strong> Single dose TMP-SMX SS or nitrofurantoin 50-100mg within 2 hours of intercourse</li>
                                <li><strong>Self-start therapy:</strong> Patient-initiated 3-day course at first symptom if reliable patient</li>
                            </ul>
                        </li>
                        <li><strong>Further Workup:</strong> Consider urologic evaluation (cystoscopy, renal US) if: recurrent pyelonephritis, hematuria, men, young children, suspicion of anatomic abnormality</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Pyuria alone is NOT infection:</strong> 30-50% of catheterized patients have asymptomatic pyuria. Need SYMPTOMS to diagnose and treat CAUTI. Don't treat labs, treat patients!</li>
                    <li><strong>Asymptomatic bacteriuria - DON'T treat (with 2 exceptions):</strong> Treating ASB in elderly, catheterized, or diabetic patients drives resistance without benefit. ONLY treat in pregnancy or before urologic procedures. This is one of the most common antibiotic stewardship errors</li>
                    <li><strong>E. coli is the usual suspect:</strong> Causes 75-95% of community-acquired UTIs. Klebsiella, Proteus, Enterococcus are next. If unusual organism (Pseudomonas, Staph aureus), think catheter, recent healthcare exposure, or structural abnormality</li>
                    <li><strong>Men = complicated until proven otherwise:</strong> Almost all UTIs in men involve prostate. Need 10-14 days treatment (vs 3-5 days women). First UTI in young man = red flag for anatomic abnormality (posterior urethral valves, etc) - needs urologic workup</li>
                    <li><strong>Nitrofurantoin doesn't work for pyelonephritis:</strong> Doesn't achieve therapeutic levels in renal parenchyma or blood. Excellent for cystitis only. Using for pyelo = treatment failure</li>
                    <li><strong>Emphysematous pyelonephritis = life-threatening:</strong> Gas in kidney on CT. 90% in diabetics. E. coli or Klebsiella ferment glucose â†’ gas production. High mortality (20-40%). Needs IV antibiotics Â± nephrectomy if refractory. Never miss this on imaging!</li>
                    <li><strong>WBC casts are pathognomonic for pyelonephritis:</strong> If WBC casts on UA = renal parenchymal involvement (vs cystitis which is bladder only). This finding confirms pyelonephritis diagnosis</li>
                    <li><strong>Post-treatment UA not needed:</strong> If symptoms resolve, don't recheck UA/culture. Pyuria can persist for weeks after successful treatment. Only reculture if persistent symptoms. "Test of cure" is symptom resolution, not negative UA</li>
                    <li><strong>Pregnancy ASB MUST be treated:</strong> 30% of untreated ASB in pregnancy progresses to pyelonephritis â†’ preterm labor. Screen ALL pregnant women at 12-16 weeks and treat positive cultures even if asymptomatic. This is the ONLY population where ASB treatment is indicated</li>
                    <li><strong>Fluoroquinolone resistance is rising:</strong> E. coli resistance now 20-30% in many areas. Check local antibiogram. If resistance >10%, avoid empiric quinolones for pyelonephritis - use ceftriaxone instead</li>
                    <li><strong>Perinephric abscess if fever persists despite antibiotics:</strong> Still febrile after 48-72 hours of appropriate antibiotics? Get CT - look for abscess. Abscess >3cm usually needs percutaneous drainage. Antibiotics alone often insufficient</li>
                    <li><strong>Recurrent UTI red flags needing urologic evaluation:</strong> Recurrent pyelonephritis, men, young children, painless hematuria, suspicion of stones/obstruction/anatomic defect. These need cystoscopy and/or imaging to find underlying cause</li>
                    <li><strong>Sterile pyuria differential:</strong> WBCs but negative culture = TB (get AFB culture Ã— 3), partially treated UTI, urethritis (STI - test for chlamydia/gonorrhea), interstitial nephritis (NSAIDs, antibiotics), kidney stones, appendicitis, fungal infection (Candida in catheterized/diabetics)</li>
                    <li><strong>Nitrites are specific but not sensitive:</strong> If positive = infection. But 50% of UTIs are nitrite-negative because many organisms (Enterococcus, Staph saprophyticus, Pseudomonas, Acinetobacter) don't convert nitrate to nitrite. Don't rule out UTI based on negative nitrites alone</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Urosepsis with septic shock (SBP <90 despite fluids, lactate >4, requiring pressors)</li>
                        <li>Respiratory failure requiring mechanical ventilation</li>
                        <li>Severe sepsis with multi-organ dysfunction (AKI, AMS, coagulopathy)</li>
                        <li>Obstructive uropathy with sepsis (needs emergent decompression)</li>
                        <li>Perinephric or renal abscess with hemodynamic instability</li>
                        <li>Emphysematous pyelonephritis with shock (may need nephrectomy)</li>
                        <li>Papillary necrosis with obstruction and sepsis</li>
                        <li>Fournier's gangrene (necrotizing perineal infection - surgical emergency)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile Ã— 24-48 hours (temperature <38Â°C)</li>
                        <li>Hemodynamically stable (SBP >100, HR <100)</li>
                        <li>Tolerating PO intake without nausea/vomiting</li>
                        <li>Pain controlled on oral analgesics</li>
                        <li>Able to take oral antibiotics and reliable for adherence</li>
                        <li>Improving leukocytosis (if initially elevated, downtrending WBC)</li>
                        <li>Stable or improving renal function (if AKI, Cr trending toward baseline)</li>
                        <li>No evidence of obstruction requiring intervention (if imaging done)</li>
                        <li>No abscess, or abscess drained and improving</li>
                        <li>Urine culture results available and organism susceptible to oral agent</li>
                        <li>Patient educated on: completing full antibiotic course, adequate hydration (2-3 L/day), return precautions</li>
                        <li>PCP follow-up arranged within 1 week (urology if recurrent, male, or anatomic concern)</li>
                        <li>Plan for repeat culture if: pregnant, recurrent infection, initial blood culture positive</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early Complications (Hours-Days):</strong> Sepsis/septic shock (15-25% of hospitalized pyelonephritis), bacteremia with metastatic seeding (endocarditis, vertebral osteomyelitis, septic arthritis), acute kidney injury (from sepsis, obstruction, or bilateral pyelonephritis), urinary retention (from UTI-induced detrusor dysfunction), severe hematuria (can cause clot retention requiring continuous bladder irrigation)</p>
                    <p><strong>Late Complications (Days-Weeks):</strong> Perinephric abscess (persistent fever >72hr despite antibiotics, needs CT diagnosis and drainage), intrarenal abscess, emphysematous pyelonephritis (diabetics - gas-forming infection, 20-40% mortality, may need nephrectomy), renal papillary necrosis (diabetics, sickle cell disease, analgesic abuse - presents with flank pain, hematuria, AKI), chronic pyelonephritis with renal scarring (recurrent infections â†’ CKD), xanthogranulomatous pyelonephritis (rare chronic granulomatous destruction of kidney)</p>
                    <p><strong>Treatment-Related Complications:</strong> C. difficile infection (fluoroquinolones highest risk), antibiotic-associated diarrhea, allergic reactions (rash, anaphylaxis), tendon rupture (fluoroquinolones - Achilles tendon), peripheral neuropathy (fluoroquinolones - can be irreversible), QT prolongation (fluoroquinolones, especially if other QT drugs), photosensitivity (fluoroquinolones), pulmonary fibrosis (nitrofurantoin with chronic use >6 months), hemolytic anemia (nitrofurantoin in G6PD deficiency)</p>
                    <p><strong>Pregnancy-Related:</strong> Preterm labor and delivery (pyelonephritis), low birth weight, intrauterine growth restriction, maternal sepsis, respiratory failure (ARDS from pyelonephritis in pregnancy)</p>
                    <p><strong>Recurrence:</strong> 25-30% recurrence within 6 months if underlying factors not addressed (kidney stones, obstruction, vesicoureteral reflux, anatomic abnormality, poor hygiene, sexual activity with spermicide use, post-menopausal atrophic vaginitis, BPH in men, neurogenic bladder, immunosuppression)</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#ceftriaxone" style="color: #8e44ad;">ðŸ’Š Ceftriaxone</a>, <a href="drug_reference_guide.html#ciprofloxacin" style="color: #8e44ad;">ðŸ’Š Ciprofloxacin</a>, <a href="drug_reference_guide.html#nitrofurantoin" style="color: #8e44ad;">ðŸ’Š Nitrofurantoin</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="cdiff" class="condition-page">
            <div class="page-header">
                <h2>22. C. DIFFICILE INFECTION (CDI)</h2>
                <div class="subtitle">Clostridioides difficile â€¢ Antibiotic-Associated Diarrhea â€¢ Pseudomembranous Colitis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> â‰¥3 unformed (loose or watery) stools in 24 hours in setting of recent antibiotic exposure (typically within past 3 months). Crampy abdominal pain, low-grade fever. Diarrhea is NOT bloody in most cases. Leukocytosis often pronounced (WBC 15-30k)</p>
                    <p><span class="label">Physical Exam:</span> Diffuse abdominal tenderness (worse in left lower quadrant), abdominal distension, hyperactive bowel sounds. If peritoneal signs present â†’ concerning for toxic megacolon or perforation</p>
                    
                    <p><span class="label">Risk Factors:</span></p>
                    <ul>
                        <li><strong>Antibiotic exposure:</strong> #1 risk factor. Highest risk: clindamycin, fluoroquinolones, cephalosporins, carbapenems. Even single dose can trigger. Usually within 3 months but can be up to 3 years</li>
                        <li><strong>Healthcare exposure:</strong> Hospitalization, nursing home, recent admission</li>
                        <li><strong>Advanced age:</strong> >65 years (decreased immunity, increased exposure)</li>
                        <li><strong>Medications:</strong> PPIs (impair gastric acid barrier), H2 blockers, chemotherapy</li>
                        <li><strong>Immunosuppression:</strong> IBD, transplant, malignancy, HIV</li>
                        <li><strong>GI surgery/manipulation:</strong> Recent abdominal surgery, NG tube, PEG tube</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Severe CDI:</strong> WBC â‰¥15k, Cr â‰¥1.5Ã— baseline. Presents with high fever (>38.5Â°C), severe abdominal pain, hypotension. May have minimal diarrhea (ileus develops)</li>
                        <li><strong>Fulminant CDI (2-3% of cases):</strong> Hypotension requiring pressors, shock, ileus, megacolon, perforation, multi-organ failure. WBC >35k or <2k (leukemoid reaction or leukopenia both bad signs). High mortality (30-50%)</li>
                        <li><strong>Toxic Megacolon:</strong> Abdominal distension, absent bowel sounds, peritoneal signs. Colon >6cm on imaging. Life-threatening - requires surgical evaluation</li>
                        <li><strong>Elderly Patients:</strong> May present with only altered mental status, functional decline, or minimal diarrhea. Lower threshold for testing</li>
                        <li><strong>IBD Patients:</strong> Difficult to distinguish from IBD flare. C. diff superinfection in 5-10% of IBD hospitalizations. Always test IBD patients with worsening symptoms</li>
                        <li><strong>Community-Acquired CDI:</strong> No recent healthcare or antibiotic exposure (15-25% of cases). Often younger, healthier patients. Associated with PPI use, outpatient antibiotics</li>
                        <li><strong>Asymptomatic Carriage:</strong> 3-15% of healthy adults, 20-40% of hospitalized patients colonized without symptoms. Do NOT test or treat asymptomatic patients (even if formed stool sent for testing comes back positive)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">When to Test:</span> ONLY test patients with â‰¥3 unformed stools in 24 hours. Do NOT test formed stools or asymptomatic patients (high false positive rate from colonization)</p>
                    
                    <p><span class="label">Diagnostic Testing (Multi-Step Algorithm Preferred):</span></p>
                    <ul>
                        <li><strong>NAAT (Nucleic Acid Amplification Test/PCR):</strong>
                            <ul>
                                <li>Detects toxin genes (tcdB). Most sensitive test (>95%)</li>
                                <li>Problem: Can't distinguish active infection from colonization</li>
                                <li>If positive â†’ need clinical correlation (symptoms + risk factors)</li>
                            </ul>
                        </li>
                        <li><strong>EIA for Toxins A/B:</strong>
                            <ul>
                                <li>Detects actual toxins in stool. High specificity (>95%) but poor sensitivity (60-80%)</li>
                                <li>If positive â†’ definite infection (can start treatment)</li>
                                <li>If negative â†’ doesn't rule out (may need NAAT or repeat testing)</li>
                            </ul>
                        </li>
                        <li><strong>GDH (Glutamate Dehydrogenase) Antigen:</strong>
                            <ul>
                                <li>Screening test. Sensitive but not specific (detects organism, not toxin)</li>
                                <li>If negative â†’ C. diff ruled out</li>
                                <li>If positive â†’ need confirmatory toxin testing</li>
                            </ul>
                        </li>
                        <li><strong>Recommended 2-Step Algorithm:</strong>
                            <ul>
                                <li>Step 1: GDH + Toxin EIA</li>
                                <li>If both positive â†’ Treat</li>
                                <li>If GDH positive but Toxin negative â†’ Send NAAT (if high suspicion, can empirically treat while awaiting)</li>
                                <li>If both negative â†’ C. diff excluded</li>
                            </ul>
                        </li>
                        <li><strong>Do NOT send repeat testing:</strong> If initially negative but high clinical suspicion persists, can repeat once after 24-48 hours. More than 2 tests in 7 days is excessive</li>
                        <li><strong>Test of cure NOT recommended:</strong> Patients can shed toxin for weeks. Treat symptoms, not test results</li>
                    </ul>
                    
                    <p><span class="label">Labs (Assess Severity):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis common (15-30k). WBC >15k = severe. WBC >35k or <2k = very high risk for complications/death</li>
                        <li><strong>BMP:</strong> Cr >1.5Ã— baseline = severe. Check for AKI, electrolyte abnormalities (hypokalemia from diarrhea)</li>
                        <li><strong>Albumin:</strong> Hypoalbuminemia from protein-losing enteropathy</li>
                        <li><strong>Lactate:</strong> Elevated if sepsis/shock</li>
                    </ul>
                    
                    <p><span class="label">Imaging (If Severe or Complications Suspected):</span></p>
                    <ul>
                        <li><strong>CT Abdomen/Pelvis WITH IV Contrast:</strong>
                            <ul>
                                <li>Indications: Severe CDI, fulminant presentation, concern for megacolon/perforation, ileus, peritoneal signs</li>
                                <li>Findings: Colonic wall thickening (>4mm), pericolonic stranding, "accordion sign" (contrast trapped in thickened colonic folds), ascites, megacolon (>6cm), pneumatosis</li>
                                <li>Helps determine need for surgery</li>
                            </ul>
                        </li>
                        <li><strong>KUB X-ray:</strong> Can identify megacolon, free air (perforation), but CT preferred if available</li>
                        <li><strong>Colonoscopy:</strong> Generally NOT needed. Consider if diagnosis uncertain or refractory to treatment. Pseudomembranes (yellow-white plaques) are pathognomonic but only present in 50% of cases. Risk of perforation - avoid if severe colitis</li>
                    </ul>
                    
                    <p><span class="label">Severity Classification (Guides Treatment):</span></p>
                    <ul>
                        <li><strong>Non-Severe (Mild-Moderate):</strong> WBC <15k, Cr <1.5 mg/dL</li>
                        <li><strong>Severe:</strong> WBC â‰¥15k OR Cr â‰¥1.5Ã— baseline</li>
                        <li><strong>Fulminant:</strong> Hypotension, shock, ileus, megacolon, perforation, ICU admission, WBC >35k or <2k</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li><strong>Stop offending antibiotics immediately</strong> if medically possible (single most important intervention)</li>
                        <li><strong>Discontinue PPIs/H2 blockers</strong> if possible</li>
                        <li><strong>Contact isolation:</strong> Private room, gloves and gown for all contact. Soap and water hand hygiene (alcohol doesn't kill spores)</li>
                        <li><strong>Avoid anti-motility agents:</strong> Loperamide, opiates can precipitate toxic megacolon. Contraindicated</li>
                        <li><strong>Avoid unnecessary antibiotics:</strong> But continue life-saving antibiotics if needed (C. diff treatment will work alongside)</li>
                    </ul>
                    
                    <p><span class="label">Initial Episode - Non-Severe/Severe:</span></p>
                    <ul>
                        <li><strong>FIRST-LINE: Oral Vancomycin 125mg PO QID Ã— 10 days</strong>
                            <ul>
                                <li>Preferred for both non-severe AND severe CDI (2021 IDSA guidelines changed recommendation)</li>
                                <li>Acts locally in gut (not absorbed systemically)</li>
                                <li>Higher doses (500mg QID) do NOT improve outcomes for non-fulminant disease</li>
                            </ul>
                        </li>
                        <li><strong>ALTERNATIVE: Fidaxomicin 200mg PO BID Ã— 10 days</strong>
                            <ul>
                                <li>Narrow-spectrum, preserves gut flora better</li>
                                <li>Lower recurrence rate than vancomycin (15% vs 25%)</li>
                                <li>Very expensive - reserve for: recurrent CDI, high risk for recurrence, immunocompromised</li>
                            </ul>
                        </li>
                        <li><strong>If Oral Vanc/Fidaxomicin Unavailable: Metronidazole 500mg PO TID Ã— 10 days</strong>
                            <ul>
                                <li>No longer first-line (inferior to vancomycin)</li>
                                <li>Only use if vanc/fidaxomicin not available</li>
                                <li>Systemic side effects (neuropathy with prolonged use)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Severe CDI (WBC â‰¥15k OR Cr â‰¥1.5Ã— baseline):</span></p>
                    <ul>
                        <li><strong>Oral Vancomycin 125mg PO QID Ã— 10 days</strong> (same dose as non-severe)</li>
                        <li>Some experts use 500mg QID for severe, but 125mg QID likely equivalent</li>
                        <li>Monitor closely for progression to fulminant</li>
                    </ul>
                    
                    <p><span class="label">Fulminant CDI (Shock, Ileus, Megacolon, ICU):</span></p>
                    <ul>
                        <li><strong>Oral Vancomycin 500mg PO/NG QID</strong></li>
                        <li><strong>PLUS IV Metronidazole 500mg IV q8h</strong> (for systemic absorption since gut may not absorb oral meds)</li>
                        <li><strong>If Ileus Present: ADD Vancomycin 500mg in 500mL NS PR q6h</strong> (rectal enema to reach colon)</li>
                        <li><strong>Surgery consult immediately:</strong> Subtotal colectomy with end ileostomy if:
                            <ul>
                                <li>Refractory shock despite pressors</li>
                                <li>Perforation or peritonitis</li>
                                <li>Worsening lactate despite treatment</li>
                                <li>WBC >50k or <2k with clinical deterioration</li>
                                <li>Mental status decline</li>
                            </ul>
                        </li>
                        <li><strong>Mortality without surgery:</strong> 80% if meet criteria. With surgery: 40-50%</li>
                    </ul>
                    
                    <p><span class="label">Recurrent CDI (Most Challenging Aspect):</span></p>
                    <ul>
                        <li><strong>First Recurrence (20-30% of patients):</strong>
                            <ul>
                                <li>If metronidazole used initially â†’ Switch to Vancomycin 125mg QID Ã— 10 days</li>
                                <li>If vancomycin used initially â†’ Repeat Vancomycin 125mg QID Ã— 10 days OR Fidaxomicin 200mg BID Ã— 10 days (preferred - lower re-recurrence)</li>
                            </ul>
                        </li>
                        <li><strong>Second or Later Recurrence (40-60% after 2nd episode):</strong>
                            <ul>
                                <li><strong>Option 1: Vancomycin Taper/Pulse</strong>
                                    <ul>
                                        <li>125mg QID Ã— 10-14 days</li>
                                        <li>Then 125mg BID Ã— 7 days</li>
                                        <li>Then 125mg daily Ã— 7 days</li>
                                        <li>Then 125mg every 2-3 days Ã— 2-8 weeks</li>
                                    </ul>
                                </li>
                                <li><strong>Option 2: Fidaxomicin 200mg BID Ã— 10 days</strong> (preferred if available - 13% re-recurrence vs 25% with vanc)</li>
                                <li><strong>Option 3: Fecal Microbiota Transplant (FMT)</strong>
                                    <ul>
                                        <li>90% cure rate after â‰¥2 recurrences</li>
                                        <li>Restores normal gut flora</li>
                                        <li>Usually via colonoscopy (can also do via capsules, NG tube)</li>
                                        <li>Screening of donor required</li>
                                    </ul>
                                </li>
                                <li><strong>Option 4: Bezlotoxumab (Zinplava)</strong>
                                    <ul>
                                        <li>Monoclonal antibody against C. diff toxin B</li>
                                        <li>Given as single 10mg/kg IV infusion during antibiotic treatment</li>
                                        <li>Reduces recurrence from 26% to 17%</li>
                                        <li>Expensive - reserve for high-risk recurrent patients</li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Special Situations:</span></p>
                    <ul>
                        <li><strong>Unable to Take PO:</strong> Vancomycin via NG/OG tube + IV metronidazole + consider vanc enemas</li>
                        <li><strong>Pregnancy/Breastfeeding:</strong> Vancomycin safe (not absorbed). Avoid metronidazole in 1st trimester</li>
                        <li><strong>Renal Failure:</strong> Vancomycin dose unchanged (not absorbed). Metronidazole - monitor for neuropathy</li>
                        <li><strong>Concomitant Antibiotics Needed:</strong> Continue C. diff treatment alongside. Stop offending antibiotics if possible, but don't withhold life-saving antibiotics</li>
                        <li><strong>Prevention in High-Risk:</strong> Antibiotic stewardship (limit unnecessary antibiotics), avoid PPIs, probiotics NOT recommended for prevention</li>
                    </ul>
                    
                    <p><span class="label">Duration and Monitoring:</span></p>
                    <ul>
                        <li><strong>Standard duration:</strong> 10 days for initial/first recurrence</li>
                        <li><strong>Expect improvement:</strong> Within 3-5 days (decreased diarrhea, resolution of fever). If no improvement by day 5-7 â†’ re-evaluate</li>
                        <li><strong>Do NOT retest stool:</strong> Can remain PCR positive for 6 weeks. Treat symptoms, not tests</li>
                        <li><strong>Resolution defined as:</strong> â‰¤3 formed stools per day OR return to baseline bowel pattern</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Test ONLY liquid stool:</strong> If stool takes shape of container = test. If stool holds its own shape = don't test. Testing formed stool leads to false positives from asymptomatic colonization (10-15% of hospitalized patients colonized)</li>
                    <li><strong>PCR can't distinguish infection from colonization:</strong> NAAT detects toxin genes, not actual toxins. Positive PCR + no symptoms = colonization, not infection. Need clinical correlation always</li>
                    <li><strong>One antibiotic dose can trigger CDI:</strong> Even single perioperative dose. Symptoms typically 5-10 days after starting antibiotics but can be up to 3 months (or longer). Any antibiotic can cause it, but clinda/FQ/cephalosporins are worst</li>
                    <li><strong>Vancomycin 125mg = 500mg for non-fulminant:</strong> Higher doses don't improve outcomes. Save 500mg QID for fulminant only. This saves money and prevents unnecessary dose escalation</li>
                    <li><strong>Metronidazole is NOT first-line anymore:</strong> 2021 IDSA guidelines downgraded metronidazole. Vancomycin superior and should be used for initial treatment. Metronidazole only if vanc unavailable</li>
                    <li><strong>Fidaxomicin costs 100Ã— more than vancomycin:</strong> ~$3,000 vs $30 for 10-day course. Lower recurrence (15% vs 25%) but reserve for recurrent CDI or high-risk patients due to cost</li>
                    <li><strong>FMT is incredibly effective for recurrent CDI:</strong> 85-90% cure rate after â‰¥2 recurrences. Should be offered to all patients with multiple recurrences. Colonoscopy method preferred (highest success)</li>
                    <li><strong>Never use anti-diarrheal agents:</strong> Loperamide and opiates retain toxin in colon â†’ toxic megacolon. Absolutely contraindicated. Let the diarrhea clear the toxin</li>
                    <li><strong>Soap and water, not alcohol:</strong> Alcohol hand sanitizer doesn't kill C. diff spores. Healthcare workers must use soap and water + contact precautions (gown and gloves)</li>
                    <li><strong>WBC >35k or <2k = bad prognostic sign:</strong> Leukemoid reaction (>35k) or leukopenia (<2k) both associated with fulminant disease and high mortality. These patients need ICU + surgery consult</li>
                    <li><strong>Stop PPIs in CDI patients:</strong> PPIs increase CDI risk and recurrence. Discontinue unless absolutely necessary (active bleeding ulcer). Gastric acid is natural defense</li>
                    <li><strong>Bezlotoxumab for recurrent disease prevention:</strong> Single IV dose during antibiotic treatment reduces recurrence from 26% to 17%. Expensive but worth considering for patients with â‰¥2 recurrences or high risk (age >65, immunocompromised, severe disease)</li>
                    <li><strong>Surgery for fulminant = life-saving:</strong> Subtotal colectomy with ileostomy. Mortality 80% without surgery vs 40-50% with surgery if meet criteria. Don't delay if indicated</li>
                    <li><strong>Probiotics NOT recommended:</strong> No evidence for prevention or treatment. Don't use routinely. May increase infection risk in immunocompromised</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Fulminant CDI: hypotension requiring pressors, shock, lactate >4</li>
                        <li>WBC >35k or <2k (leukemoid reaction or leukopenia)</li>
                        <li>Toxic megacolon (colon >6cm, peritoneal signs)</li>
                        <li>Perforation or peritonitis</li>
                        <li>Ileus with severe abdominal distension</li>
                        <li>AKI with Cr >2Ã— baseline or requiring dialysis</li>
                        <li>Mental status decline despite treatment</li>
                        <li>Worsening lactate despite resuscitation</li>
                        <li>Need for mechanical ventilation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Diarrhea significantly improved (â‰¤3 unformed stools/day or return to baseline)</li>
                        <li>Afebrile Ã— 24 hours (temperature <38Â°C)</li>
                        <li>Hemodynamically stable (no tachycardia, normotensive)</li>
                        <li>Tolerating PO intake and medications</li>
                        <li>Abdominal pain resolved or minimal</li>
                        <li>WBC downtrending (if initially elevated)</li>
                        <li>No signs of complications (megacolon, perforation, ileus)</li>
                        <li>Able to complete antibiotic course as outpatient</li>
                        <li>Prescription for remaining vancomycin provided</li>
                        <li>Patient/family educated on: completing full course, hand hygiene, contact precautions at home if immunocompromised household members</li>
                        <li>PCP follow-up arranged within 1-2 weeks</li>
                        <li>Patient instructed on recurrence symptoms and when to return</li>
                        <li>If recurrent CDI: discussed prevention strategies (avoid unnecessary antibiotics/PPIs, FMT referral if multiple recurrences)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications (During Treatment):</strong> Toxic megacolon (colon dilation >6cm - 3-8% of cases, high mortality), colonic perforation (peritonitis, free air, requires emergency colectomy), fulminant colitis with shock (hypotension, multi-organ failure, 2-3% of cases), ileus (paradoxical decrease in diarrhea with worsening distension), sepsis/septic shock, acute kidney injury (from hypovolemia or sepsis)</p>
                    <p><strong>Metabolic/Nutritional:</strong> Severe dehydration and electrolyte imbalances (hypokalemia, hypomagnesemia from diarrhea), protein-losing enteropathy with hypoalbuminemia (<2.5 g/dL), malnutrition from prolonged illness</p>
                    <p><strong>Recurrence (Most Common Complication):</strong> First recurrence 20-30%, second recurrence 40-60% (cumulative). Usually within 2-8 weeks of completing treatment. Risk factors: age >65, continued antibiotics, PPI use, immunosuppression, initial severe infection, hospitalization. Each recurrence increases risk of subsequent recurrence</p>
                    <p><strong>Post-Infection:</strong> Post-infectious IBS (10-25% develop chronic diarrhea/abdominal pain even after CDI cured), chronic diarrhea from dysbiosis, small intestinal bacterial overgrowth (SIBO) from gut flora disruption</p>
                    <p><strong>Treatment-Related:</strong> Metronidazole peripheral neuropathy (with prolonged use >2 weeks - can be irreversible), disulfiram-like reaction with alcohol (metronidazole), vancomycin-resistant Enterococcus (VRE) colonization (prolonged oral vanc), microbiome disruption from prolonged treatment</p>
                    <p><strong>Surgical:</strong> Need for colectomy (1-3% of cases - fulminant colitis, perforation, toxic megacolon), post-surgical complications (wound infection, ileus, short bowel syndrome), high mortality with surgery (30-50%) but higher without surgery if indicated (80%)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="dvt" class="condition-page">
            <div class="page-header">
                <h2>23. DEEP VEIN THROMBOSIS (DVT)</h2>
                <div class="subtitle">Venous Thromboembolism â€¢ Lower Extremity â€¢ Pulmonary Embolism Risk</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Unilateral leg swelling, pain, warmth, erythema. Calf tenderness, palpable cord. Swelling typically involves entire leg if proximal DVT (iliofemoral), calf only if distal DVT</p>
                    <p><span class="label">Physical Exam:</span> Measure calf/thigh circumference (>3cm difference = significant), assess for pitting edema, erythema, warmth. Homan's sign (calf pain with dorsiflexion) is unreliable - do NOT use for diagnosis</p>
                    
                    <p><span class="label">Anatomic Classification:</span></p>
                    <ul>
                        <li><strong>Proximal DVT:</strong> Popliteal vein or above (femoral, iliofemoral). High PE risk (50% if untreated). ALWAYS requires anticoagulation</li>
                        <li><strong>Distal DVT:</strong> Calf veins only (peroneal, tibial, gastrocnemius). Lower PE risk (10%). May monitor without anticoagulation if low risk</li>
                        <li><strong>Upper Extremity DVT:</strong> Axillary, subclavian, internal jugular. 10% of DVTs. Often catheter-related</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic DVT:</strong> 50% of DVTs have minimal symptoms. May present as PE. Screen high-risk hospitalized patients</li>
                        <li><strong>Phlegmasia Alba Dolens:</strong> "Milk leg" - pale, swollen leg from extensive iliofemoral DVT with spasm. Painful but pulses intact</li>
                        <li><strong>Phlegmasia Cerulea Dolens:</strong> Blue, painful, massively swollen leg from complete venous occlusion. Arterial compromise, gangrene risk. Surgical emergency</li>
                        <li><strong>May-Thurner Syndrome:</strong> Left common iliac vein compression by right common iliac artery. Young women with left leg DVT</li>
                        <li><strong>Upper Extremity DVT:</strong> Arm swelling, pain. Paget-Schroetter syndrome (effort thrombosis) in athletes. Central line-associated in hospitalized</li>
                        <li><strong>Superficial Thrombophlebitis:</strong> Palpable tender cord, erythema along superficial vein. Low PE risk but can extend to deep system. If >5cm or near saphenofemoral junction, consider anticoagulation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Decision Rule - Wells Score for DVT:</span></p>
                    <ul>
                        <li>Active cancer (treatment within 6 months or palliative): +1</li>
                        <li>Paralysis, paresis, or recent immobilization of lower extremity: +1</li>
                        <li>Recently bedridden >3 days or major surgery within 4 weeks: +1</li>
                        <li>Localized tenderness along deep venous system: +1</li>
                        <li>Entire leg swollen: +1</li>
                        <li>Calf swelling >3cm compared to other leg (10cm below tibial tuberosity): +1</li>
                        <li>Pitting edema (greater in symptomatic leg): +1</li>
                        <li>Collateral superficial veins (non-varicose): +1</li>
                        <li>Alternative diagnosis as likely or more likely than DVT: -2</li>
                        <li><strong>Score interpretation:</strong> â‰¤0 = Low probability (5% DVT), 1-2 = Moderate (17%), â‰¥3 = High (53%)</li>
                    </ul>
                    
                    <p><span class="label">Diagnostic Algorithm:</span></p>
                    <ul>
                        <li><strong>Low Probability (Wells â‰¤0):</strong> D-dimer first. If negative â†’ DVT excluded (99% NPV). If positive â†’ Ultrasound</li>
                        <li><strong>Moderate-High Probability (Wells â‰¥1):</strong> Proceed directly to ultrasound (don't wait for D-dimer)</li>
                    </ul>
                    
                    <p><span class="label">D-Dimer:</span></p>
                    <ul>
                        <li><strong>High sensitivity (95-98%), low specificity (40-50%)</strong></li>
                        <li>Excellent negative predictive value - if negative, DVT/PE ruled out in low-risk patients</li>
                        <li>Many false positives: infection, malignancy, pregnancy, post-op, elderly, hospitalization</li>
                        <li><strong>Age-adjusted D-dimer:</strong> Age Ã— 10 mcg/L if age >50 (improves specificity in elderly)</li>
                        <li><strong>When NOT to use:</strong> High pretest probability, active cancer, recent surgery, pregnancy (always elevated)</li>
                    </ul>
                    
                    <p><span class="label">Compression Ultrasonography (Test of Choice):</span></p>
                    <ul>
                        <li><strong>Technique:</strong> 2-point compression (common femoral vein, popliteal vein). Add full duplex if high suspicion</li>
                        <li><strong>Positive = Non-compressibility of vein</strong> (vein doesn't collapse with probe pressure)</li>
                        <li><strong>Sensitivity/Specificity:</strong> >95% for proximal DVT, 50-70% for distal (calf) DVT</li>
                        <li><strong>If negative but high suspicion:</strong> Repeat ultrasound in 1 week (5-10% of distal DVTs extend proximally)</li>
                        <li><strong>Limitations:</strong> Operator-dependent, difficult with edema/obesity, poor for iliac veins and calf veins</li>
                    </ul>
                    
                    <p><span class="label">Additional Imaging (Special Situations):</span></p>
                    <ul>
                        <li><strong>CT/MR Venography:</strong> If ultrasound non-diagnostic and high suspicion. Better for pelvic/IVC thrombus</li>
                        <li><strong>Contrast Venography:</strong> Gold standard but invasive, rarely used now. Reserved for cases where diagnosis remains uncertain</li>
                    </ul>
                    
                    <p><span class="label">Labs (Assess for Complications and Etiology):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Baseline hemoglobin (before anticoagulation), platelet count (baseline for HIT monitoring)</li>
                        <li><strong>PT/INR, aPTT:</strong> Baseline coagulation studies</li>
                        <li><strong>BMP, Cr:</strong> Renal function (affects anticoagulant dosing)</li>
                        <li><strong>Hypercoagulability Workup:</strong> Generally NOT needed for provoked DVT. Consider if: age <50, recurrent VTE, strong family history, unusual sites
                            <ul>
                                <li>Factor V Leiden, Prothrombin G20210A mutation, Protein C/S deficiency, Antithrombin deficiency</li>
                                <li>Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-Î²2-glycoprotein)</li>
                                <li>Test AFTER acute phase and OFF anticoagulation (if possible) - results unreliable during acute DVT</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immediate Anticoagulation (Start Immediately if High Suspicion - Don't Wait for Imaging):</span></p>
                    
                    <p><span class="label">Direct Oral Anticoagulants (DOACs) - FIRST-LINE for Most Patients:</span></p>
                    <ul>
                        <li><strong>Rivaroxaban (Xarelto):</strong> 15mg PO BID Ã— 21 days, then 20mg PO daily
                            <ul>
                                <li>Advantages: Single drug, no LMWH bridge, BID dosing only first 3 weeks</li>
                            </ul>
                        </li>
                        <li><strong>Apixaban (Eliquis):</strong> 10mg PO BID Ã— 7 days, then 5mg PO BID
                            <ul>
                                <li>Advantages: Single drug, no LMWH bridge, lowest bleeding risk of DOACs</li>
                                <li>Preferred if high bleeding risk</li>
                            </ul>
                        </li>
                        <li><strong>Edoxaban (Savaysa):</strong> LMWH Ã— 5-10 days FIRST, then Edoxaban 60mg PO daily
                            <ul>
                                <li>Requires bridge - less convenient</li>
                            </ul>
                        </li>
                        <li><strong>Dabigatran (Pradaxa):</strong> LMWH Ã— 5-10 days FIRST, then Dabigatran 150mg PO BID
                            <ul>
                                <li>Requires bridge - less convenient</li>
                                <li>Advantage: Reversible with idarucizumab (Praxbind)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">DOAC Contraindications (Use LMWH/Warfarin Instead):</span></p>
                    <ul>
                        <li>Severe renal impairment (CrCl <30 mL/min for most DOACs, <25 for apixaban)</li>
                        <li>Mechanical heart valves</li>
                        <li>Antiphospholipid syndrome (high recurrence with DOACs - use warfarin)</li>
                        <li>Active malignancy (LMWH preferred - see below)</li>
                        <li>Extremes of body weight (<50kg or >120kg - limited data)</li>
                    </ul>
                    
                    <p><span class="label">Low Molecular Weight Heparin (LMWH):</span></p>
                    <ul>
                        <li><strong>Enoxaparin (Lovenox):</strong> 1mg/kg SC q12h OR 1.5mg/kg SC q24h
                            <ul>
                                <li>Bridge to warfarin Ã— 5-10 days (until INR 2-3 Ã— 2 consecutive days)</li>
                                <li>Or continue as monotherapy (especially cancer patients)</li>
                            </ul>
                        </li>
                        <li><strong>Dalteparin:</strong> 200 units/kg SC daily (max 18,000 units) Ã— 1 month, then 150 units/kg daily</li>
                        <li><strong>Advantages:</strong> No monitoring needed, predictable dosing, safe in renal impairment (CrCl >30)</li>
                        <li><strong>Dosing adjustments:</strong>
                            <ul>
                                <li>Obesity (>150kg): Consider anti-Xa levels</li>
                                <li>Renal impairment (CrCl 15-30): Reduce dose by 50% or switch to UFH</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Unfractionated Heparin (UFH):</span></p>
                    <ul>
                        <li><strong>Use when:</strong> Severe renal failure (CrCl <15), high bleeding risk (short half-life, reversible), possible need for procedure, massive PE</li>
                        <li><strong>Dosing:</strong> 80 units/kg IV bolus, then 18 units/kg/hr infusion</li>
                        <li><strong>Goal aPTT:</strong> 1.5-2.5Ã— control (60-80 seconds typically)</li>
                        <li><strong>Monitor:</strong> aPTT q6h until therapeutic, then daily. Platelet count q2-3 days (HIT risk)</li>
                    </ul>
                    
                    <p><span class="label">Warfarin (Coumadin):</span></p>
                    <ul>
                        <li><strong>Start 5mg PO daily</strong> (overlap with LMWH/UFH Ã— 5-10 days)</li>
                        <li><strong>Goal INR:</strong> 2-3 (2.5-3.5 for antiphospholipid syndrome)</li>
                        <li><strong>Monitor:</strong> INR daily until stable, then weekly, then monthly</li>
                        <li><strong>Advantages:</strong> Cheapest option, long track record, reversible with vitamin K/FFP/PCC</li>
                        <li><strong>Disadvantages:</strong> Requires monitoring, drug-food interactions, narrow therapeutic window</li>
                    </ul>
                    
                    <p><span class="label">Special Populations:</span></p>
                    <ul>
                        <li><strong>Cancer-Associated VTE:</strong>
                            <ul>
                                <li><strong>LMWH preferred over warfarin/DOACs</strong> (lower recurrence rate)</li>
                                <li>Enoxaparin 1mg/kg SC BID Ã— 3-6 months minimum, often lifelong</li>
                                <li>Alternative: Apixaban or rivaroxaban if LMWH not tolerated (recent trials show non-inferiority)</li>
                            </ul>
                        </li>
                        <li><strong>Pregnancy:</strong>
                            <ul>
                                <li>LMWH throughout pregnancy (enoxaparin 1mg/kg SC q12h)</li>
                                <li>DOACs and warfarin are teratogenic - CONTRAINDICATED</li>
                                <li>Switch to UFH at 36 weeks (shorter half-life for delivery)</li>
                                <li>Resume anticoagulation 6-12 hours postpartum, continue Ã— 6 weeks minimum postpartum</li>
                            </ul>
                        </li>
                        <li><strong>Obesity:</strong> Weight-based LMWH dosing, DOACs have limited data >120kg</li>
                        <li><strong>Elderly:</strong> Apixaban preferred (lowest bleeding risk)</li>
                        <li><strong>Renal Failure:</strong>
                            <ul>
                                <li>CrCl >30: Any anticoagulant</li>
                                <li>CrCl 15-30: Apixaban (dose-adjust), warfarin, or reduced-dose LMWH</li>
                                <li>CrCl <15 or dialysis: UFH or warfarin</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Duration of Anticoagulation:</span></p>
                    <ul>
                        <li><strong>Provoked DVT (surgery, immobilization, estrogen, pregnancy):</strong> 3 months</li>
                        <li><strong>Unprovoked DVT:</strong> 3-6 months, then reassess. Consider indefinite if:
                            <ul>
                                <li>Low bleeding risk</li>
                                <li>Proximal DVT or PE</li>
                                <li>Male sex (higher recurrence)</li>
                                <li>Elevated D-dimer 1 month after stopping anticoagulation</li>
                            </ul>
                        </li>
                        <li><strong>Recurrent VTE:</strong> Lifelong anticoagulation</li>
                        <li><strong>Active cancer:</strong> 3-6 months minimum, often indefinite while cancer active</li>
                        <li><strong>Thrombophilia:</strong> Duration depends on specific deficiency and circumstances</li>
                    </ul>
                    
                    <p><span class="label">IVC Filter:</span></p>
                    <ul>
                        <li><strong>Indications:</strong>
                            <ul>
                                <li>Absolute contraindication to anticoagulation (active bleeding)</li>
                                <li>Recurrent VTE despite therapeutic anticoagulation</li>
                                <li>Complication of anticoagulation (major bleeding)</li>
                            </ul>
                        </li>
                        <li><strong>Retrievable filters preferred:</strong> Remove once anticoagulation safe (ideally within 3 months)</li>
                        <li><strong>NOT indicated for:</strong> Large DVT, free-floating thrombus, prophylaxis</li>
                        <li><strong>Complications:</strong> IVC thrombosis, filter migration, perforation</li>
                    </ul>
                    
                    <p><span class="label">Thrombolysis (Catheter-Directed or Systemic):</span></p>
                    <ul>
                        <li><strong>Consider for:</strong> Phlegmasia cerulea dolens (limb-threatening), massive iliofemoral DVT in young patients with low bleeding risk</li>
                        <li><strong>Goal:</strong> Reduce post-thrombotic syndrome risk</li>
                        <li><strong>Contraindications:</strong> Recent surgery, stroke, bleeding, pregnancy</li>
                        <li><strong>Not routine:</strong> Bleeding risk usually outweighs benefit</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Homan's sign is useless:</strong> Neither sensitive (10-50%) nor specific. Don't use it. Make diagnosis with Wells score + imaging</li>
                    <li><strong>D-dimer rules OUT, doesn't rule IN:</strong> Excellent negative predictive value (99%) in low-risk patients. But positive D-dimer doesn't confirm DVT - need imaging. Many false positives</li>
                    <li><strong>Proximal vs distal DVT treatment differs:</strong> Proximal DVT (popliteal+) = ALWAYS anticoagulate (high PE risk). Distal (calf only) = can monitor with serial ultrasounds if low risk</li>
                    <li><strong>DOACs are now first-line:</strong> Rivaroxaban and apixaban don't require LMWH bridge. Easier, equally effective, possibly safer than warfarin. Use unless contraindicated</li>
                    <li><strong>Cancer = LMWH preferred:</strong> LMWH superior to warfarin for cancer-associated VTE (50% lower recurrence). DOACs now reasonable alternative (CARAVAGGIO, ADAM-VTE trials)</li>
                    <li><strong>Don't wait for imaging if high suspicion:</strong> Start anticoagulation immediately while awaiting ultrasound. Risk of bleeding from 1 dose < risk of PE extension</li>
                    <li><strong>Unprovoked DVT often needs indefinite anticoagulation:</strong> 30% 5-year recurrence risk off anticoagulation. Reassess at 3-6 months. If continuing, use lower dose apixaban/rivaroxaban (reduces bleeding)</li>
                    <li><strong>IVC filter is NOT a substitute for anticoagulation:</strong> Filters DON'T treat DVT, just prevent PE. Still need anticoagulation once safe. Filters have complications (IVC thrombosis). Only use if bleeding contraindication</li>
                    <li><strong>Superficial thrombophlebitis can extend to deep system:</strong> If >5cm or near saphenofemoral junction, needs anticoagulation (or at least prophylactic dose Ã— 45 days). Don't ignore it</li>
                    <li><strong>May-Thurner syndrome:</strong> Left leg DVT in young woman = think May-Thurner (left iliac vein compression by right iliac artery). May need endovascular stenting. Right leg DVT more common overall, but left leg in young = red flag</li>
                    <li><strong>Post-thrombotic syndrome is common:</strong> 20-50% of DVT patients develop chronic leg swelling, pain, skin changes. Prevented by immediate anticoagulation and compression stockings (30-40 mmHg Ã— 2 years)</li>
                    <li><strong>Wells score -2 points for alternative diagnosis:</strong> Cellulitis, Baker's cyst, muscle strain can mimic DVT. If alternative equally likely, subtract 2 points from Wells score</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Phlegmasia cerulea dolens (limb-threatening DVT with arterial compromise)</li>
                        <li>Massive PE with hemodynamic instability</li>
                        <li>Major bleeding complication from anticoagulation</li>
                        <li>Need for thrombolysis (catheter-directed or systemic)</li>
                        <li>Acute limb ischemia requiring urgent intervention</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>DVT confirmed on ultrasound and anticoagulation initiated</li>
                        <li>Hemodynamically stable</li>
                        <li>No signs of PE (no dyspnea, normal O2 sat, no tachycardia)</li>
                        <li>Pain controlled with oral analgesics</li>
                        <li>Patient able to take oral anticoagulants (or self-inject LMWH)</li>
                        <li>No active bleeding or high bleeding risk</li>
                        <li>Patient educated on: anticoagulation adherence, bleeding precautions, leg elevation, compression stockings, return precautions (dyspnea = PE)</li>
                        <li>Appropriate anticoagulant prescribed with clear instructions</li>
                        <li>Follow-up arranged: PCP within 1 week, hematology if unprovoked/recurrent</li>
                        <li>Compression stockings fitted (30-40 mmHg knee-high)</li>
                        <li>If distal DVT being monitored: repeat ultrasound scheduled in 1 week</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications:</strong> Pulmonary embolism (most feared - occurs in 50% of untreated proximal DVT), phlegmasia cerulea dolens (complete venous occlusion with arterial compromise, limb-threatening), venous gangrene, acute limb ischemia</p>
                    <p><strong>Bleeding from Anticoagulation:</strong> Major bleeding (intracranial hemorrhage, GI bleed, retroperitoneal bleed, any bleeding requiring transfusion or hospitalization), minor bleeding (epistaxis, easy bruising, hematuria, menorrhagia), HIT (heparin-induced thrombocytopenia - paradoxical thrombosis, check platelets if on heparin >4 days)</p>
                    <p><strong>Post-Thrombotic Syndrome (20-50% of DVT patients):</strong> Chronic leg swelling, pain, heaviness, skin hyperpigmentation, venous stasis dermatitis, venous ulcers (severe cases). Develops months to years after DVT. Prevention: immediate anticoagulation + compression stockings 30-40 mmHg Ã— 2 years</p>
                    <p><strong>Recurrent VTE:</strong> 5-10% per year off anticoagulation (unprovoked DVT), 30% cumulative 5-year risk. Higher risk if: unprovoked, proximal, male sex, obesity, residual thrombus. Provoked DVT: 1-3% per year recurrence</p>
                    <p><strong>From IVC Filter:</strong> IVC thrombosis (2-10%), filter migration, IVC perforation, failure to retrieve (50% of retrievable filters never removed), recurrent DVT below filter</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#unfractionated-heparin-ufh" style="color: #8e44ad;">ðŸ’Š Unfractionated Heparin</a>, <a href="drug_reference_guide.html#enoxaparin" style="color: #8e44ad;">ðŸ’Š Enoxaparin</a>, <a href="drug_reference_guide.html#apixaban" style="color: #8e44ad;">ðŸ’Š Apixaban</a>, <a href="drug_reference_guide.html#rivaroxaban" style="color: #8e44ad;">ðŸ’Š Rivaroxaban</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="stroke" class="condition-page">
            <div class="page-header">
                <h2>24. ACUTE ISCHEMIC STROKE</h2>
                <div class="subtitle">CVA â€¢ tPA â€¢ Mechanical Thrombectomy â€¢ Time Is Brain</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> SUDDEN onset focal neurologic deficit. Maximal deficit at onset (not progressive). FAST mnemonic: Face droop (ask to smile), Arm weakness (raise both arms), Speech difficulty (slurred/aphasia), Time = brain (1.9 million neurons die per minute untreated). "Last known well" time is critical for tPA eligibility</p>
                    
                    <p><span class="label">Presentations by Vascular Territory:</span></p>
                    <ul>
                        <li><strong>Middle Cerebral Artery (MCA - 50% of strokes):</strong> Contralateral hemiparesis/hemianesthesia (face and arm > leg), aphasia (if dominant/left hemisphere), neglect (if non-dominant/right hemisphere), gaze preference toward lesion, homonymous hemianopia</li>
                        <li><strong>Anterior Cerebral Artery (ACA):</strong> Contralateral leg weakness > arm, behavioral/personality changes, abulia, urinary incontinence, grasp reflex</li>
                        <li><strong>Posterior Cerebral Artery (PCA):</strong> Contralateral homonymous hemianopia, alexia without agraphia, visual agnosia, memory impairment (if bilateral thalamic involvement)</li>
                        <li><strong>Vertebrobasilar (Posterior Circulation):</strong> Dizziness, vertigo, diplopia, dysphagia, dysarthria, ataxia, crossed sensory/motor deficits (face one side, body opposite), bilateral symptoms, altered consciousness</li>
                        <li><strong>Lacunar (Small Vessel - 25%):</strong> Pure motor hemiparesis, pure sensory stroke, ataxic hemiparesis, dysarthria-clumsy hand syndrome. NO cortical signs (aphasia, neglect, visual field cuts)</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Wake-Up Stroke (25% of strokes):</strong> Patient wakes with deficits. Last known well = bedtime. Can still be tPA eligible if MRI shows DWI/FLAIR mismatch (DWI positive, FLAIR negative = likely <4.5 hours old)</li>
                        <li><strong>Large Vessel Occlusion (LVO):</strong> Severe deficits (NIHSS >6), gaze deviation, dense hemiplegia, global aphasia or severe neglect. These need mechanical thrombectomy urgently - activate stroke team immediately</li>
                        <li><strong>Posterior Circulation Stroke:</strong> Often misdiagnosed as "just dizziness" or vertigo. Red flags: sudden vertigo + HINTS exam abnormal (Head Impulse, Nystagmus, Test of Skew), inability to walk, severe headache</li>
                        <li><strong>Basilar Artery Occlusion:</strong> Decreased consciousness, quadriplegia, locked-in syndrome, respiratory failure. Devastating if untreated. Needs emergent thrombectomy even beyond 24 hours</li>
                        <li><strong>Stroke Mimics (20-30% of "stroke" activations):</strong> Hypoglycemia (<40 mg/dL - CHECK GLUCOSE FIRST), seizure with Todd's paralysis (post-ictal), complicated migraine with aura, conversion disorder, functional neurologic disorder, brain tumor, subdural hematoma</li>
                        <li><strong>Hemorrhagic Stroke:</strong> Progressive symptoms (not maximal at onset), severe headache, nausea/vomiting, decreased consciousness. Must rule out with CT before tPA</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate - STAT (Door-to-Needle Goal <60 Minutes):</span></p>
                    <ul>
                        <li><strong>Non-Contrast CT Head:</strong> FIRST TEST - rules out hemorrhage (absolute tPA contraindication). Only 60% sensitive for acute ischemia in first 6 hours. Look for: hyperdense MCA sign (visible clot), loss of gray-white differentiation, sulcal effacement, insular ribbon sign. If negative CT but high suspicion â†’ still likely ischemic stroke</li>
                        <li><strong>NIHSS Score (National Institutes of Health Stroke Scale):</strong> 0=normal, 1-4=minor, 5-15=moderate, 16-20=moderate-severe, >20=severe. Score >6 suggests large vessel occlusion - get CTA immediately. Repeat NIHSS to track improvement/worsening</li>
                        <li><strong>Fingerstick Glucose:</strong> MANDATORY FIRST - hypoglycemia (<60) mimics stroke perfectly and is immediately reversible. Never give tPA to hypoglycemia. If <60 â†’ give D50, reassess</li>
                        <li><strong>CT Angiography (CTA) Head/Neck:</strong> If NIHSS >6 or clinical suspicion for LVO. Identifies: ICA occlusion, M1/M2 MCA occlusion, basilar occlusion. Guides thrombectomy decision. Don't delay tPA waiting for CTA - can do simultaneously</li>
                    </ul>
                    
                    <p><span class="label">Labs (Send Immediately but Don't Delay tPA):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Platelets must be >100k for tPA. Severe anemia can cause neurologic deficits</li>
                        <li><strong>BMP:</strong> Severe hyperglycemia (>400) or renal failure impacts outcomes</li>
                        <li><strong>PT/INR, aPTT:</strong> INR must be <1.7 for tPA. Therapeutic heparin (aPTT >40) contraindication</li>
                        <li><strong>Troponin:</strong> 10-15% have MI with stroke. Check for concurrent ACS</li>
                        <li><strong>Hemoglobin A1c:</strong> Assess chronic glucose control</li>
                        <li><strong>Lipid panel:</strong> For secondary prevention</li>
                    </ul>
                    
                    <p><span class="label">Advanced Imaging:</span></p>
                    <ul>
                        <li><strong>MRI Brain with DWI:</strong> Gold standard for acute ischemia (>95% sensitive within hours). DWI bright = acute infarct. ADC dark = restricted diffusion (acute). Use for: unclear timing (wake-up stroke), TIA vs stroke, posterior circulation (CT misses 20% of posterior strokes), suspected mimics</li>
                        <li><strong>MR/CT Perfusion:</strong> Identifies salvageable penumbra (ischemic but not dead). Mismatch between perfusion deficit and infarct core = tissue to save. Extends thrombectomy window to 24 hours if large penumbra present</li>
                        <li><strong>Carotid Doppler or CTA Neck:</strong> Identify carotid stenosis. >70% symptomatic stenosis = CEA/stenting candidate (must be done within 2 weeks)</li>
                        <li><strong>Echocardiogram:</strong> TTE for LV thrombus, EF, wall motion abnormalities. TEE if suspicion for: endocarditis, atrial thrombus, PFO with significant shunt, aortic arch atheroma</li>
                    </ul>
                    
                    <p><span class="label">Stroke Etiology Workup (TOAST Classification):</span></p>
                    <ul>
                        <li><strong>Large Artery Atherosclerosis:</strong> Carotid stenosis >50%, intracranial stenosis</li>
                        <li><strong>Cardioembolism:</strong> Atrial fibrillation (most common), mechanical valve, recent MI with LV thrombus, dilated cardiomyopathy (EF <30%), endocarditis, atrial myxoma</li>
                        <li><strong>Small Vessel/Lacunar:</strong> Hypertension, diabetes. Small infarcts (<1.5cm) in basal ganglia, thalamus, pons</li>
                        <li><strong>Other Determined Cause:</strong> Dissection (carotid/vertebral), vasculitis, hypercoagulable state, drug-related (cocaine, amphetamines)</li>
                        <li><strong>Cryptogenic (30%):</strong> No clear cause. Consider: occult atrial fibrillation (30-day monitor), patent foramen ovale (PFO), atrial cardiopathy, cancer-associated</li>
                    </ul>
                    
                    <p><span class="label">Additional Workup:</span></p>
                    <ul>
                        <li><strong>Telemetry Ã— 48 hours minimum:</strong> Detect paroxysmal atrial fibrillation (20% of cryptogenic strokes)</li>
                        <li><strong>Extended cardiac monitoring:</strong> If no cause found, 30-day event monitor or implantable loop recorder</li>
                        <li><strong>Hypercoagulable workup:</strong> Only if young (<50), recurrent, family history, or unusual site. Test AFTER acute phase: Factor V Leiden, prothrombin mutation, protein C/S, antithrombin, lupus anticoagulant, anticardiolipin antibodies</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Time Is Brain - Every Second Counts:</span></p>
                    <ul>
                        <li>Door-to-imaging goal: <25 minutes</li>
                        <li>Door-to-needle (tPA) goal: <60 minutes</li>
                        <li>Door-to-groin (thrombectomy) goal: <90 minutes</li>
                    </ul>
                    
                    <p><span class="label">Intravenous tPA (Alteplase) - "Clot Buster":</span></p>
                    <ul>
                        <li><strong>Eligibility Window:</strong> <4.5 hours from symptom onset (or last known well time)</li>
                        <li><strong>Dose:</strong> 0.9 mg/kg IV (maximum 90mg total)
                            <ul>
                                <li>Give 10% as bolus over 1 minute</li>
                                <li>Remaining 90% as infusion over 60 minutes</li>
                            </ul>
                        </li>
                        <li><strong>Benefit:</strong> NNT = 6 to prevent dependency at 3 months. Benefits persist even with symptomatic ICH risk</li>
                        <li><strong>Absolute Contraindications:</strong>
                            <ul>
                                <li>Intracranial hemorrhage on CT (any amount)</li>
                                <li>Ischemic stroke within 3 months</li>
                                <li>Intracranial/spinal surgery within 3 months</li>
                                <li>Head trauma within 3 months</li>
                                <li>History of intracranial hemorrhage ever</li>
                                <li>GI or GU hemorrhage within 21 days</li>
                                <li>Arterial puncture at non-compressible site within 7 days</li>
                                <li>SBP >185 or DBP >110 despite aggressive treatment</li>
                                <li>Active internal bleeding or acute trauma/fracture</li>
                                <li>INR >1.7, aPTT >40 seconds, platelets <100,000</li>
                                <li>Glucose <50 mg/dL (treat and reassess)</li>
                            </ul>
                        </li>
                        <li><strong>Relative Contraindications:</strong> Seizure at stroke onset, glucose >400, large infarct on CT (>1/3 MCA territory), minor/rapidly improving symptoms (though recent data supports treating these), pregnancy (relative - can give if severe stroke)</li>
                    </ul>
                    
                    <p><span class="label">Blood Pressure Management (CRITICAL - Most Common Error):</span></p>
                    <ul>
                        <li><strong>If Giving tPA - Must Lower BP:</strong>
                            <ul>
                                <li>Goal: <185/110 mmHg BEFORE starting tPA</li>
                                <li>Labetalol 10-20mg IV push q10-20min (up to 300mg total) OR</li>
                                <li>Nicardipine drip: Start 5mg/hr, titrate by 2.5mg/hr q5-15min to goal (max 15mg/hr)</li>
                                <li>AFTER tPA: Keep BP <180/105 Ã— 24 hours (prevent hemorrhagic transformation)</li>
                            </ul>
                        </li>
                        <li><strong>If NOT Giving tPA - Permissive Hypertension:</strong>
                            <ul>
                                <li>ALLOW SBP up to 220 mmHg (brain needs perfusion pressure)</li>
                                <li>Only treat if: SBP >220 OR DBP >120 OR signs of end-organ damage (ACS, aortic dissection, acute pulmonary edema)</li>
                                <li>Goal: Lower by 15% over first 24 hours (NOT to normal)</li>
                                <li>Don't reflexively normalize BP - can extend infarct</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Mechanical Thrombectomy - "Most Effective Stroke Treatment":</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Large vessel occlusion (ICA, M1/M2 MCA, basilar artery) + salvageable tissue</li>
                        <li><strong>Time Window:</strong>
                            <ul>
                                <li>Up to 6 hours: All LVO eligible</li>
                                <li>6-16 hours: If good collaterals on CTA or small infarct core</li>
                                <li>16-24 hours: If perfusion imaging shows large penumbra (mismatch)</li>
                                <li>Basilar occlusion: Consider even beyond 24 hours (devastating if untreated)</li>
                            </ul>
                        </li>
                        <li><strong>Benefit:</strong> NNT = 3 for functional independence (best intervention in all of medicine)</li>
                        <li><strong>Transfer immediately if LVO identified</strong> at non-thrombectomy-capable center</li>
                        <li><strong>Can give tPA AND thrombectomy</strong> - not mutually exclusive</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>NPO until swallow screen passed:</strong> 30-50% have dysphagia. Aspiration pneumonia is leading complication</li>
                        <li><strong>Oxygen:</strong> Only if SpO2 <94% (hyperoxia may worsen outcomes)</li>
                        <li><strong>Normothermia:</strong> Fever worsens outcomes. Treat aggressively (acetaminophen, cooling)</li>
                        <li><strong>Euglycemia:</strong> Avoid hypoglycemia (<70) and severe hyperglycemia (>180). Both worsen outcomes</li>
                        <li><strong>Head of bed:</strong> 30 degrees (improves venous drainage, reduces aspiration)</li>
                        <li><strong>DVT prophylaxis:</strong> Pneumatic compression boots immediately. If no tPA given â†’ heparin 5000 units SQ TID. If tPA given â†’ wait 24 hours before starting heparin</li>
                    </ul>
                    
                    <p><span class="label">Antiplatelet Therapy:</span></p>
                    <ul>
                        <li><strong>If tPA Given:</strong> Hold aspirin Ã— 24 hours (hemorrhage risk), then ASA 162-325mg daily</li>
                        <li><strong>If NO tPA Given:</strong> Aspirin 325mg immediately (or within 48 hours)</li>
                        <li><strong>Minor Stroke (NIHSS â‰¤3) within 24 hours:</strong> Dual Antiplatelet Therapy (DAPT)
                            <ul>
                                <li>ASA 162-325mg load + Clopidogrel 600mg load on day 1</li>
                                <li>Then ASA 81mg + Clopidogrel 75mg daily Ã— 21 days</li>
                                <li>Then ASA 81mg alone lifelong</li>
                                <li>Reduces 90-day stroke recurrence by 30% (CHANCE, POINT trials)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Anticoagulation (For Atrial Fibrillation):</span></p>
                    <ul>
                        <li><strong>Timing is critical - too early = hemorrhagic transformation:</strong>
                            <ul>
                                <li>Small stroke (NIHSS <8): Start at 3-4 days</li>
                                <li>Moderate stroke (NIHSS 8-15): Start at 6-8 days</li>
                                <li>Large stroke (NIHSS >15): Start at 12-14 days</li>
                            </ul>
                        </li>
                        <li><strong>DOACs preferred over warfarin:</strong> Apixaban 5mg BID, rivaroxaban 20mg daily, edoxaban 60mg daily, dabigatran 150mg BID</li>
                        <li><strong>Reduce dose if:</strong> Age >80, weight <60kg, Cr >1.5 (apixaban 2.5mg BID)</li>
                    </ul>
                    
                    <p><span class="label">Secondary Prevention:</span></p>
                    <ul>
                        <li><strong>High-Intensity Statin:</strong> Atorvastatin 80mg daily regardless of LDL (plaque stabilization, anti-inflammatory). Start immediately</li>
                        <li><strong>Blood Pressure Control:</strong> Goal <140/90 (<130/80 if diabetic). Start after acute phase (don't lower acutely unless >220)</li>
                        <li><strong>Carotid Stenosis >70% Symptomatic:</strong> CEA or carotid stenting within 2 weeks (stroke risk 20% at 2 weeks without intervention)</li>
                        <li><strong>PFO Closure:</strong> Consider if cryptogenic stroke, age <60, large shunt, atrial septal aneurysm. Reduces recurrent stroke by 50%</li>
                        <li><strong>Lifestyle:</strong> Smoking cessation (doubles stroke risk), exercise, Mediterranean diet, weight loss</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Time is brain - 1.9 million neurons per minute:</strong> Every 15 minutes of delay in tPA = 1 month of disability. Door-to-needle <60 min, door-to-groin <90 min are achievable goals</li>
                    <li><strong>CHECK GLUCOSE FIRST:</strong> Hypoglycemia is the great stroke mimic and it's 100% reversible with D50. Never give tPA to a glucose of 45</li>
                    <li><strong>Permissive hypertension unless giving tPA:</strong> Brain needs perfusion in acute stroke. Allow SBP <220. Only lower if giving tPA (then <185) or signs of end-organ damage. Don't reflexively normalize BP</li>
                    <li><strong>tPA works - don't be afraid to use it:</strong> NNT=6 for preventing disability. Yes, 6% symptomatic ICH risk, but functional outcomes still better. Benefits extend to 4.5 hours</li>
                    <li><strong>Thrombectomy revolutionized stroke care:</strong> NNT=3 for independence. Extends to 24 hours with perfusion imaging. Transfer immediately if LVO - don't let them sit</li>
                    <li><strong>NIHSS >6 = think large vessel occlusion:</strong> Get CTA and activate interventional team immediately. These need thrombectomy within 6 hours (ideally)</li>
                    <li><strong>Wake-up strokes can still get tPA:</strong> If MRI shows DWI/FLAIR mismatch (DWI+, FLAIR-), likely <4.5hr old and eligible (WAKE-UP trial)</li>
                    <li><strong>Dual antiplatelets for minor stroke:</strong> ASA + clopidogrel Ã— 21 days if NIHSS â‰¤3 and within 24 hours. 30% reduction in recurrence (CHANCE, POINT). Don't use for moderate-severe stroke</li>
                    <li><strong>Delay anticoagulation in Afib stroke:</strong> Wait 3-14 days (size-dependent) before starting DOAC. Too early = hemorrhagic transformation. Use 1-2-2 week rule (small-medium-large)</li>
                    <li><strong>Posterior strokes are sneaky:</strong> "Just dizziness" can be fatal basilar occlusion. HINTS exam: Head Impulse Normal = central (stroke). Vertical/direction-changing Nystagmus = central. Test of Skew = central</li>
                    <li><strong>Carotid stenosis >70% needs urgent intervention:</strong> CEA or stent within 2 weeks. Stroke risk is 20% in first 2 weeks without treatment. Don't delay</li>
                    <li><strong>Blood pressure control is for AFTER acute phase:</strong> Lower gradually over days-weeks. Acutely, permissive hypertension preserves penumbra. Target <140/90 long-term</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Large stroke (NIHSS >15) with decreased consciousness</li>
                        <li>Basilar artery occlusion (high mortality, needs close monitoring)</li>
                        <li>Hemorrhagic transformation with mass effect</li>
                        <li>Malignant MCA syndrome (cerebral edema, herniation risk - peaks day 3-5)</li>
                        <li>Received tPA (monitor Ã— 24hr for ICH, strict BP control <180/105)</li>
                        <li>Post-thrombectomy (monitor for reperfusion injury, hemorrhage)</li>
                        <li>Unstable blood pressure requiring IV drips</li>
                        <li>Respiratory failure or airway compromise</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Neurologically stable or improving Ã— 24-48 hours</li>
                        <li>Swallow screen passed - safe for PO (or feeding tube placed)</li>
                        <li>Aspiration precautions in place if dysphagia present</li>
                        <li>PT/OT completed - mobility/ADL assessment done</li>
                        <li>Secondary prevention initiated (antiplatelet or anticoagulation, statin)</li>
                        <li>Blood pressure controlled and on appropriate regimen</li>
                        <li>If tPA given: >24 hours post-tPA, no hemorrhagic transformation on repeat CT</li>
                        <li>If carotid stenosis >70%: CEA/stent scheduled within 2 weeks</li>
                        <li>Outpatient rehabilitation arranged (acute rehab facility, subacute, home PT)</li>
                        <li>Neurology follow-up within 1-2 weeks</li>
                        <li>Patient/family educated on: stroke warning signs (FAST), when to call 911, medication adherence, risk factor modification</li>
                        <li>DME provided: walker, wheelchair, hospital bed if needed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early (Hours-Days):</strong> Hemorrhagic transformation (6% with tPA, 2% without - peaks at 24-36hr), cerebral edema with herniation (peaks day 3-5, especially large MCA strokes - malignant edema 10% mortality), seizures (5-10%, higher with cortical involvement), aspiration pneumonia (30-50% have dysphagia), DVT/PE (immobility), recurrent stroke (highest risk first 48hr - 5% risk at 2 weeks)</p>
                    <p><strong>Post-tPA Specific:</strong> Symptomatic intracranial hemorrhage (6% - half are fatal), angioedema (1-5%, especially if on ACE-I - can compromise airway), systemic bleeding (epistaxis, hematuria, GI bleed), reperfusion injury</p>
                    <p><strong>Late (Weeks-Months):</strong> Recurrent stroke (10% first year, 30% at 5 years without secondary prevention), disability and dependence (30-40% need assistance with ADLs), depression (30-50% develop post-stroke depression), vascular dementia (doubles risk), falls and hip fractures (hemiparesis, neglect), chronic pain syndromes, spasticity requiring botulinum toxin</p>
                    <p><strong>Specific Syndromes:</strong> Central post-stroke pain (thalamic pain syndrome - burning dysesthesia, 10% of strokes), shoulder subluxation (hemiplegic shoulder, 25%), complex regional pain syndrome, dysphagia persisting >6 months (10%), aphasia (permanent in 20-40% of left hemisphere strokes)</p>
                    <p><strong>Malignant MCA Syndrome:</strong> Large MCA infarct with massive edema, herniation, coma. Peaks day 3-5. Mortality 80% without decompressive hemicraniectomy, 30% with surgery. Consider surgery if age <60, within 48hr of symptom onset</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="seizure" class="condition-page">
            <div class="page-header">
                <h2>25. SEIZURE / STATUS EPILEPTICUS</h2>
                <div class="subtitle">Convulsive â€¢ Non-Convulsive â€¢ Neurologic Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Status Epilepticus Definition:</span> Seizure lasting >5 minutes OR recurrent seizures without return to baseline consciousness between episodes. TRUE MEDICAL EMERGENCY - mortality 10-20% if untreated</p>
                    
                    <p><span class="label">Types of Seizures:</span></p>
                    <ul>
                        <li><strong>Generalized Tonic-Clonic (Grand Mal):</strong> Loss of consciousness, tonic phase (muscle rigidity 10-30 sec), clonic phase (rhythmic jerking 30-60 sec), postictal confusion/somnolence (minutes to hours). May have tongue biting (lateral tongue = specific), incontinence, foaming at mouth</li>
                        <li><strong>Focal (Partial) Seizures:</strong> Originates one brain region. Can be motor (Jacksonian march up extremity), sensory, or with impaired awareness (staring, automatisms like lip-smacking). May secondarily generalize</li>
                        <li><strong>Absence:</strong> Brief staring spells 5-10 seconds. Child stops mid-activity, stares, resumes. No postictal confusion. Pediatric primarily (petit mal)</li>
                        <li><strong>Myoclonic:</strong> Brief muscle jerks. Can be benign (everyone has on falling asleep) or pathologic (juvenile myoclonic epilepsy)</li>
                        <li><strong>Atonic (Drop Attacks):</strong> Sudden loss of muscle tone, falls. Lennox-Gastaut syndrome</li>
                    </ul>
                    
                    <p><span class="label">Non-Convulsive Status Epilepticus (NCSE):</span></p>
                    <ul>
                        <li>Altered mental status WITHOUT obvious motor activity</li>
                        <li>10-20% of ICU patients with unexplained AMS have NCSE on EEG</li>
                        <li>Subtle findings: eye deviation, nystagmus, facial twitching, automatisms</li>
                        <li><strong>Diagnosis requires EEG</strong> - have high suspicion in ICU patients with AMS</li>
                    </ul>
                    
                    <p><span class="label">Seizure vs Syncope - Key Differences:</span></p>
                    <ul>
                        <li><strong>Seizure:</strong> Tonic-clonic >15 seconds, lateral tongue biting (specific), incontinence common, prolonged postictal confusion (30 min - hours)</li>
                        <li><strong>Syncope:</strong> Brief myoclonic jerks <15 seconds, no tongue biting (or central only), incontinence rare, rapid recovery (<1 min), no postictal confusion</li>
                    </ul>
                    
                    <p><span class="label">Etiology - "VITAMINS" Mnemonic:</span></p>
                    <ul>
                        <li><strong>V</strong>ascular: Ischemic stroke, hemorrhage, venous sinus thrombosis</li>
                        <li><strong>I</strong>nfection: Meningitis, encephalitis, brain abscess, neurocysticercosis</li>
                        <li><strong>T</strong>rauma: Prior TBI, subdural hematoma, DAI</li>
                        <li><strong>A</strong>utoimmune: SLE cerebritis, anti-NMDA receptor encephalitis, Hashimoto's encephalopathy</li>
                        <li><strong>M</strong>etabolic: Hypoglycemia <40 (most common reversible cause), hyponatremia <120, hypocalcemia, hypomagnesemia, uremia, hepatic encephalopathy</li>
                        <li><strong>I</strong>atrogenic/Intoxication: Tramadol, bupropion, fluoroquinolones, imipenem, isoniazid. Cocaine, amphetamines. WITHDRAWAL: alcohol, benzodiazepines, baclofen</li>
                        <li><strong>N</strong>eoplasm: Primary brain tumor, metastases (lung, breast, melanoma, renal)</li>
                        <li><strong>S</strong>tructural: Remote stroke, prior TBI, congenital malformation, mesial temporal sclerosis</li>
                    </ul>
                    
                    <p><span class="label">First Seizure Workup Approach:</span></p>
                    <ul>
                        <li><strong>Provoked Seizure:</strong> Clear reversible cause (metabolic, infection, drug). Treat cause, may not need chronic AED. Recurrence risk low if cause corrected</li>
                        <li><strong>Unprovoked Seizure:</strong> No identifiable acute cause. 40-50% recurrence risk. Consider starting AED after first unprovoked seizure, especially if: abnormal MRI, abnormal EEG, nocturnal seizure, focal seizure</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate Bedside:</span></p>
                    <ul>
                        <li><strong>Fingerstick Glucose:</strong> FIRST TEST - hypoglycemia (<40) causes seizures and is immediately reversible with D50. Never miss this</li>
                        <li><strong>Accucheck if on floor:</strong> While waiting for labs</li>
                    </ul>
                    
                    <p><span class="label">Labs (STAT):</span></p>
                    <ul>
                        <li><strong>BMP:</strong> Sodium (<120 causes seizures), calcium, magnesium, glucose, BUN/Cr (uremia)</li>
                        <li><strong>CBC:</strong> Infection, anemia</li>
                        <li><strong>LFTs:</strong> Hepatic encephalopathy</li>
                        <li><strong>Toxicology Screen:</strong> Cocaine, amphetamines, PCP</li>
                        <li><strong>Alcohol Level:</strong> If suspect withdrawal</li>
                        <li><strong>Anti-Epileptic Drug (AED) Levels:</strong> If known epileptic (phenytoin, valproate, carbamazepine). Levetiracetam levels not clinically useful</li>
                        <li><strong>Serum Prolactin:</strong> Peaks 10-20 min after seizure, normal by 60 min. >3Ã— baseline supports seizure (but normal doesn't rule out). Not routinely needed</li>
                        <li><strong>CK:</strong> Rhabdomyolysis common after prolonged seizure (CK >1000 in 50%)</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Non-Contrast CT Head:</strong> FIRST imaging - rules out bleed, mass, stroke. Get immediately if: first seizure, trauma, focal deficits, immunocompromised, persistent AMS</li>
                        <li><strong>MRI Brain:</strong> More sensitive for: hippocampal sclerosis, cortical dysplasia, small tumors, encephalitis, posterior reversible encephalopathy syndrome (PRES). Get within 24-48hr for first seizure</li>
                    </ul>
                    
                    <p><span class="label">Lumbar Puncture:</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Fever, immunocompromised, concern for meningitis/encephalitis, first seizure with no clear cause</li>
                        <li><strong>Get CT first if:</strong> Focal deficits, papilledema, immunocompromised (to rule out mass/herniation risk)</li>
                        <li><strong>Send:</strong> Cell count, glucose, protein, Gram stain, culture, HSV PCR, consider autoimmune encephalitis panel</li>
                    </ul>
                    
                    <p><span class="label">EEG (Electroencephalogram):</span></p>
                    <ul>
                        <li><strong>Routine EEG (30 min):</strong> All first-time seizure patients. Identifies: epileptiform discharges (spikes, sharp waves), focal slowing (structural lesion), generalized slowing (encephalopathy). Yield increases if done within 24-48 hours</li>
                        <li><strong>Continuous EEG Monitoring:</strong>
                            <ul>
                                <li>Status epilepticus (confirms cessation after treatment)</li>
                                <li>Unexplained AMS in ICU (r/o non-convulsive status)</li>
                                <li>Burst suppression monitoring (if on pentobarbital/propofol for refractory status)</li>
                            </ul>
                        </li>
                        <li><strong>Limitations:</strong> Single EEG only captures epileptiform activity in 50% of epileptics. Repeat EEG or prolonged monitoring increases yield to 80-90%</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Active Seizure Management (Non-Status):</span></p>
                    <ul>
                        <li>Position on SIDE (prevent aspiration)</li>
                        <li>Protect from injury (pad head, move objects away)</li>
                        <li>Do NOT restrain</li>
                        <li>Do NOT place anything in mouth (can break teeth, cause aspiration)</li>
                        <li>Supplemental O2 via NC or face mask</li>
                        <li>Establish IV access</li>
                        <li>Most seizures self-terminate in 1-3 minutes</li>
                        <li><strong>If seizure >5 minutes â†’ STATUS EPILEPTICUS â†’ Start treatment algorithm</strong></li>
                    </ul>
                    
                    <p><span class="label">STATUS EPILEPTICUS TREATMENT ALGORITHM (Time-Sensitive!):</span></p>
                    
                    <p><strong>STAGE 1 (0-5 minutes): First-Line Benzodiazepines</strong></p>
                    <ul>
                        <li><strong>Lorazepam (Ativan):</strong> 4mg IV over 2 minutes. Repeat once if continued seizure after 5 min (max 8mg)
                            <ul>
                                <li>Preferred over diazepam (longer duration of action)</li>
                                <li>Success rate: 60-80%</li>
                            </ul>
                        </li>
                        <li><strong>OR Midazolam (Versed):</strong> 10mg IM (if no IV access - absorbed well IM)
                            <ul>
                                <li>Alternative: 0.2mg/kg IV (typical 10-15mg)</li>
                                <li>Faster onset than lorazepam</li>
                                <li>IM route as effective as IV lorazepam in prehospital setting</li>
                            </ul>
                        </li>
                        <li><strong>OR Diazepam (Valium):</strong> 10mg IV or 20mg PR (rectal gel - useful prehospital/nursing home)
                            <ul>
                                <li>Rapid onset but shorter duration than lorazepam</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><strong>STAGE 2 (5-20 minutes): Second-Line Anti-Epileptic Drugs (If Benzos Fail)</strong></p>
                    <p>Choose ONE of the following:</p>
                    <ul>
                        <li><strong>Levetiracetam (Keppra):</strong> 60 mg/kg IV over 10 min (max 4500mg, typical dose 3000-4500mg)
                            <ul>
                                <li>Advantages: No drug interactions, safe profile, no cardiac monitoring needed, preferred by many</li>
                                <li>Disadvantages: May be slightly less effective than fosphenytoin (debated)</li>
                                <li>Side effects: Minimal. Rare psychiatric symptoms</li>
                            </ul>
                        </li>
                        <li><strong>Fosphenytoin:</strong> 20 PE/kg IV at max rate 150 PE/min (typical 1500-2000 PE, takes 10-15 min)
                            <ul>
                                <li>Advantages: Long track record, effective</li>
                                <li>Disadvantages: Cardiac monitoring required (bradycardia, hypotension, arrhythmias), purple glove syndrome, drug interactions (induces CYP450), can't use in heart block</li>
                                <li>Slower infusion if elderly or cardiac disease</li>
                                <li>Check ECG before and during infusion</li>
                            </ul>
                        </li>
                        <li><strong>Valproate (Depacon):</strong> 40 mg/kg IV over 10 min (max 3000mg)
                            <ul>
                                <li>Advantages: Well-tolerated, no cardiac effects</li>
                                <li>Disadvantages: Contraindicated in pregnancy (teratogenic), liver disease, pancreatitis history. Hyperammonemia, thrombocytopenia</li>
                            </ul>
                        </li>
                        <li><strong>Phenobarbital:</strong> 15 mg/kg IV at 50-100 mg/min
                            <ul>
                                <li>Advantages: Effective, cheap</li>
                                <li>Disadvantages: Sedation, respiratory depression (have airway equipment ready), long half-life</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><strong>STAGE 3 (20-40 minutes): Refractory Status Epilepticus</strong></p>
                    <ul>
                        <li>If seizure continues despite 2 first-line agents â†’ REFRACTORY status</li>
                        <li><strong>Intubate for airway protection</strong> (will need continuous sedation)</li>
                        <li><strong>ICU admission</strong></li>
                        <li><strong>Continuous EEG monitoring</strong></li>
                        <li><strong>Choose continuous infusion:</strong>
                            <ul>
                                <li><strong>Midazolam:</strong> 0.2 mg/kg bolus, then 0.05-2 mg/kg/hr infusion
                                    <ul>
                                        <li>First-line for refractory status (preferred by most)</li>
                                        <li>Titrate to seizure cessation on EEG or burst suppression</li>
                                    </ul>
                                </li>
                                <li><strong>Propofol:</strong> 1-2 mg/kg bolus, then 20-200 mcg/kg/min (2-10 mg/kg/hr)
                                    <ul>
                                        <li>Rapid on/off</li>
                                        <li>Watch for propofol infusion syndrome (rhabdo, metabolic acidosis, cardiac arrest) if >48hr or high doses</li>
                                        <li>Check CK, lactate, triglycerides daily</li>
                                    </ul>
                                </li>
                                <li><strong>Pentobarbital:</strong> 5-15 mg/kg load over 1hr, then 0.5-10 mg/kg/hr
                                    <ul>
                                        <li>Most effective but most side effects</li>
                                        <li>Severe hypotension (need pressors), ileus</li>
                                        <li>Reserved for super-refractory status</li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                        <li><strong>Goal:</strong> Seizure suppression on EEG. Some aim for burst suppression (flat periods between bursts)</li>
                        <li><strong>Duration:</strong> 24-48 hours, then attempt to wean. If seizures recur â†’ another 24 hours</li>
                    </ul>
                    
                    <p><span class="label">Starting Maintenance Anti-Epileptic Drug (After First Unprovoked Seizure):</span></p>
                    <ul>
                        <li><strong>Levetiracetam (Keppra):</strong> 500mg BID, increase to 1000-1500mg BID
                            <ul>
                                <li>FIRST-LINE for most patients</li>
                                <li>No drug interactions, no monitoring needed</li>
                                <li>Side effects: Irritability, depression (10-15%)</li>
                            </ul>
                        </li>
                        <li><strong>Lamotrigine (Lamictal):</strong> Start 25mg daily, slow titration
                            <ul>
                                <li>Must titrate SLOWLY (increase by 25mg every 2 weeks)</li>
                                <li>Fast titration â†’ Stevens-Johnson syndrome risk</li>
                                <li>Good for generalized epilepsy, well-tolerated</li>
                                <li>Final dose: 200-400mg daily (divided BID)</li>
                            </ul>
                        </li>
                        <li><strong>Lacosamide (Vimpat):</strong> 50mg BID, increase to 200-400mg daily
                            <ul>
                                <li>Good for focal seizures</li>
                                <li>Side effects: Dizziness, ataxia, PR interval prolongation (check ECG)</li>
                            </ul>
                        </li>
                        <li><strong>Older Options (More Side Effects/Interactions):</strong>
                            <ul>
                                <li>Phenytoin: Gingival hyperplasia, hirsutism, CYP450 inducer, narrow therapeutic window</li>
                                <li>Carbamazepine: Hyponatremia (SIADH), aplastic anemia (rare), CYP450 inducer</li>
                                <li>Valproate: Weight gain, hair loss, tremor, hepatotoxicity, teratogenic</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Special Considerations:</span></p>
                    <ul>
                        <li><strong>Provoked Seizures (Reversible Cause):</strong>
                            <ul>
                                <li>Alcohol withdrawal: Benzos (lorazepam, diazepam), thiamine</li>
                                <li>Hyponatremia: Correct slowly (risk of osmotic demyelination). If <120 with seizure, can give 100mL 3% saline bolus</li>
                                <li>Hypoglycemia: D50 50mL IV push</li>
                                <li>Hypocalcemia: Calcium gluconate 1-2g IV</li>
                                <li>Isoniazid overdose: Pyridoxine (vitamin B6) gram-for-gram match to INH dose</li>
                            </ul>
                        </li>
                        <li><strong>Pregnancy (Eclampsia):</strong> Magnesium sulfate 4-6g IV load, then 1-2g/hr. If seizures continue â†’ lorazepam</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Status epilepticus = >5 minutes, not 30:</strong> Old definition was 30 min. Now ANY seizure >5 min = status. Start treatment aggressively - every minute increases risk of refractory status and permanent neuronal injury</li>
                    <li><strong>Benzos first, AED second:</strong> Don't skip benzos and go straight to fosphenytoin. Benzos stop 60-80% of seizures. Give lorazepam 4mg IV immediately</li>
                    <li><strong>Midazolam IM if no IV access:</strong> 10mg IM works as well as IV lorazepam. Don't delay trying to get IV - give IM midazolam immediately</li>
                    <li><strong>Non-convulsive status is common in ICU:</strong> 10-20% of unexplained AMS in ICU is NCSE on EEG. Have low threshold for continuous EEG monitoring</li>
                    <li><strong>Levetiracetam is now first-line AED:</strong> Safer, fewer interactions than phenytoin. Equally effective for status epilepticus (ESETT trial). Start with keppra for most patients</li>
                    <li><strong>Provoked seizures may not need chronic AED:</strong> If clear reversible cause (alcohol withdrawal, severe hyponatremia <120, hypoglycemia <40), treat the cause. May not need lifelong AED</li>
                    <li><strong>Check glucose ALWAYS:</strong> Hypoglycemia causes seizures and is immediately reversible with D50. Never miss this - it's the most treatable cause</li>
                    <li><strong>Lateral tongue bite is specific for seizure:</strong> Central tongue bite can happen with any loss of consciousness (syncope, head trauma). LATERAL tongue bite is specific for tonic-clonic seizure</li>
                    <li><strong>Propofol infusion syndrome is real:</strong> Rhabdomyolysis, metabolic acidosis, cardiac arrest. Risk with >48hr use or high doses (>80 mcg/kg/min). Check CK, lactate, triglycerides daily</li>
                    <li><strong>Don't start multiple AEDs simultaneously:</strong> Use monotherapy first. Only add second AED if inadequate seizure control on max tolerated dose of first. Polypharmacy increases side effects and interactions</li>
                    <li><strong>First unprovoked seizure has 40-50% recurrence risk:</strong> Consider starting AED, especially if: abnormal MRI, abnormal EEG, nocturnal seizure, patient has high-risk occupation (pilot, driver)</li>
                    <li><strong>Todd's paralysis mimics stroke:</strong> Post-ictal focal weakness lasting 24-48 hours. MRI/CT normal. Resolves completely. Don't give tPA for this</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Status epilepticus (seizure >5 min or recurrent without baseline recovery)</li>
                        <li>Refractory status requiring continuous infusion (midazolam, propofol, pentobarbital)</li>
                        <li>Intubated for airway protection</li>
                        <li>Multiple seizures without return to baseline</li>
                        <li>Non-convulsive status on EEG requiring continuous monitoring</li>
                        <li>Hypoxia or respiratory compromise from seizure</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>No seizures Ã— 24-48 hours</li>
                        <li>Back to neurologic baseline (or new baseline established if stroke/bleed)</li>
                        <li>Anti-epileptic drug started (if unprovoked seizure or epilepsy)</li>
                        <li>AED levels checked if applicable (phenytoin, valproate, carbamazepine)</li>
                        <li>Provoking factors addressed/corrected (alcohol withdrawal treated, electrolytes normalized)</li>
                        <li>Safe to drive per state law (typically 3-12 months seizure-free required - varies by state)</li>
                        <li>Fall precautions at home if recurrent seizure risk</li>
                        <li>Neurology follow-up arranged within 1-2 weeks</li>
                        <li>Patient educated on: taking AED daily (don't miss doses), avoiding seizure triggers (sleep deprivation, alcohol), seizure precautions (no swimming alone, no heights, caution with driving), when to call 911 (seizure >5 min)</li>
                        <li>MRI completed or scheduled (if first seizure)</li>
                        <li>EEG completed or scheduled</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Seizure Activity:</strong> Aspiration pneumonia (30-50% if prolonged seizure or decreased consciousness), rhabdomyolysis (CK >1000 in 50% of status epilepticus, can cause AKI), acute kidney injury (from rhabdomyolysis, hypotension), lactic acidosis (from muscle activity), hyperthermia (from muscle activity, increases neuronal injury), posterior shoulder dislocation (tonic phase - anterior more common in most trauma but posterior in seizures), vertebral compression fractures (from violent muscle contractions), oral trauma (tongue biting, broken teeth)</p>
                    <p><strong>From Status Epilepticus:</strong> Permanent neuronal injury if >30 minutes (excitotoxicity from glutamate), cerebral edema, Todd's paralysis (post-ictal focal weakness lasting 24-48hr, mimics stroke), cognitive impairment, development of refractory epilepsy, death (10-20% mortality for status epilepticus)</p>
                    <p><strong>From Treatment:</strong> Respiratory depression (benzodiazepines, barbiturates - have airway equipment ready), hypotension (propofol, phenytoin, barbiturates), propofol infusion syndrome (rhabdo, acidosis, cardiac arrest after >48hr high-dose propofol), cardiac arrhythmias (phenytoin - especially if infused too fast), purple glove syndrome (phenytoin extravasation causing limb ischemia), hepatotoxicity (valproate), thrombocytopenia (valproate), hyponatremia (carbamazepine causing SIADH), Steven-Johnson syndrome (lamotrigine if titrated too fast, carbamazepine)</p>
                    <p><strong>Psychosocial:</strong> Loss of driving privileges (state-dependent, typically 3-12 months seizure-free required), job limitations (can't be pilot, commercial driver, work at heights), stigma, depression (30% of epileptics), medication non-adherence (leading cause of breakthrough seizures)</p>
                    <p><strong>SUDEP (Sudden Unexpected Death in Epilepsy):</strong> 1 in 1000 epilepsy patients per year. Higher risk if: poorly controlled seizures, generalized tonic-clonic, young age, non-adherence to AEDs, nocturnal seizures. Mechanism: likely cardiac arrhythmia or respiratory arrest during seizure</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#levetiracetam" style="color: #8e44ad;">ðŸ’Š Levetiracetam</a>, <a href="drug_reference_guide.html#phenytoin-fosphenytoin" style="color: #8e44ad;">ðŸ’Š Phenytoin Fosphenytoin</a>, <a href="drug_reference_guide.html#lorazepam" style="color: #8e44ad;">ðŸ’Š Lorazepam</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="meningitis" class="condition-page">
            <div class="page-header">
                <h2>26. BACTERIAL MENINGITIS</h2>
                <div class="subtitle">CNS Emergency â€¢ Give Antibiotics BEFORE LP â€¢ Dexamethasone</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad (44% have all 3):</span> Fever + headache + nuchal rigidity. 95% have â‰¥2 of: fever, headache, stiff neck, altered mental status</p>
                    <p><span class="label">Physical Exam:</span> Nuchal rigidity (passive neck flexion causes resistance), Kernig sign (hip flexed 90Â° then extend knee â†’ pain/resistance), Brudzinski sign (neck flexion â†’ involuntary hip flexion), jolt accentuation (turning head worsens HA). Altered MS 69%, focal deficits 10-30%, seizures 20-30%, papilledema rare (<1%). Petechial/purpuric rash = N. meningitidis</p>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly/Immunocompromised:</strong> Subtle - only AMS, weakness, falls. May lack fever/meningismus. Low threshold for LP</li>
                        <li><strong>Listeria (>50yo, pregnant, immunocompromised):</strong> More indolent. May have rhombencephalitis (brainstem - ataxia, CN palsies). Unpasteurized dairy/deli meats</li>
                        <li><strong>Meningococcemia:</strong> Fulminant - petechiae/purpura, shock, DIC, multi-organ failure. Health-to-death <24hr. Waterhouse-Friderichsen (adrenal hemorrhage)</li>
                        <li><strong>Post-neurosurgery/VP shunt:</strong> Healthcare-associated (S. aureus, coag-neg Staph, Pseudomonas). Fever + HA = shunt infection until proven otherwise</li>
                        <li><strong>Partially treated:</strong> Prior antibiotics (even 1-2 doses oral) sterilize CSF culture but leave inflammatory profile. Use PCR. Treat as bacterial</li>
                        <li><strong>Chronic meningitis (>4 weeks):</strong> TB, fungal (Cryptococcus in HIV), Lyme, syphilis, malignancy. Lymphocytic CSF</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">CRITICAL PRINCIPLE:</span> <strong>DO NOT DELAY ANTIBIOTICS for LP or CT!</strong> Door-to-antibiotic <1 hour improves outcomes. Antibiotics before LP don't affect yield if LP within 2-4 hours</p>
                    
                    <p><span class="label">CT Head BEFORE LP if:</span> Immunocompromised, history CNS disease, new seizure (<1 week), papilledema, GCS â‰¤10, focal deficit. Algorithm: Give antibiotics â†’ CT â†’ LP. If mass effect on CT, discuss LP with neurology</p>
                    
                    <p><span class="label">LP Procedure:</span> Lateral (measure OP) or sitting. L3-L4 or L4-L5. Opening pressure with manometer (normal 10-20 cm H2O, bacterial >25). Collect 4 tubes: (1) Gram/culture/PCR, (2) glucose/protein, (3) cell count/diff, (4) hold for extras. Traumatic tap: subtract 1 WBC per 700 RBCs</p>
                    
                    <p><span class="label">CSF Interpretation - Bacterial vs Viral:</span></p>
                    <ul>
                        <li><strong>Bacterial:</strong> WBC >1000 (often >5000), PMN >80%, glucose <40 or <50% serum, protein >200 (often >1000), opening pressure >25</li>
                        <li><strong>Viral:</strong> WBC 10-500, lymphs >50%, glucose normal (>45), protein 50-100</li>
                        <li><strong>Normal:</strong> WBC 0-5, glucose 50-80, protein 15-45</li>
                    </ul>
                    
                    <p><span class="label">CSF Studies:</span> Cell count/diff, glucose (+ simultaneous serum glucose for ratio), protein, Gram stain (60-90% positive depending on organism), culture (gold standard, 24-48hr), PCR/BioFire FilmArray (rapid ~1hr, detects S. pneumo, N. meningitidis, H. flu, Listeria, viruses - helpful when antibiotics given before LP), CSF lactate (>4 mmol/L = bacterial, 95% sens/spec). Add AFB/TB PCR, fungal culture, Crypto Ag, VDRL, Lyme if chronic presentation</p>
                    
                    <p><span class="label">Blood Studies:</span> Cultures Ã— 2 (positive 50-80%), CBC (leukocytosis, bands, thrombocytopenia if DIC), BMP (hyponatremia from SIADH common), coags if DIC suspected, lactate, serum glucose (for CSF ratio), procalcitonin (>0.5 suggests bacterial)</p>
                    
                    <p><span class="label">Common Pathogens by Age:</span></p>
                    <ul>
                        <li><strong>Adults <50yo:</strong> S. pneumoniae (50%), N. meningitidis (25%), rarely H. influenzae</li>
                        <li><strong>Adults â‰¥50yo:</strong> S. pneumoniae, Listeria, gram-negatives (E. coli, Klebsiella)</li>
                        <li><strong>Post-neurosurgery/shunt:</strong> S. aureus/epidermidis, Pseudomonas, Acinetobacter</li>
                        <li><strong>Immunocompromised:</strong> Listeria, gram-negatives, Cryptococcus, TB</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">EMPIRIC ANTIBIOTICS (START IMMEDIATELY, Within 1 Hour):</span></p>
                    <ul>
                        <li><strong>Adults <50yo, immunocompetent:</strong> Vancomycin 15-20 mg/kg IV q8-12h + Ceftriaxone 2g IV q12h (or Cefotaxime 2g q4-6h). Covers S. pneumo (including resistant), N. meningitidis, H. flu</li>
                        <li><strong>Adults â‰¥50yo OR immunocompromised OR alcoholism:</strong> Add Ampicillin 2g IV q4h for Listeria coverage. Triple therapy: Vanc + Ceftriaxone + Ampicillin</li>
                        <li><strong>Post-neurosurgery/VP shunt:</strong> Vancomycin + Cefepime 2g IV q8h (or Meropenem 2g q8h) for Pseudomonas coverage</li>
                        <li><strong>Severe PCN allergy:</strong> Vancomycin + Moxifloxacin 400mg IV daily. Can use Aztreonam + Moxifloxacin if needed</li>
                    </ul>
                    
                    <p><span class="label">DEXAMETHASONE:</span> 10mg IV q6h Ã— 4 days. MUST give BEFORE or WITH first antibiotic dose (not after). Reduces mortality/hearing loss in pneumococcal meningitis. Discontinue if organism not S. pneumoniae</p>
                    
                    <p><span class="label">Targeted Therapy (once organism/sensitivities known):</span></p>
                    <ul>
                        <li><strong>S. pneumoniae PCN-sensitive (MIC <0.06):</strong> Penicillin G 4 million units IV q4h. If resistant: continue Vanc + Ceftriaxone. Duration 10-14 days. Continue dexamethasone Ã— 4d</li>
                        <li><strong>N. meningitidis:</strong> Ceftriaxone 2g IV q12h Ã— 7 days (or Penicillin G if sensitive). Droplet precautions Ã— 24hr after antibiotics. Chemoprophylaxis close contacts: Cipro 500mg PO Ã— 1 or Ceftriaxone 250mg IM Ã— 1</li>
                        <li><strong>Listeria:</strong> Ampicillin 2g IV q4h + Gentamicin 5-7 mg/kg IV daily Ã— 21 days (synergy). TMP-SMX 5 mg/kg IV q8h if PCN allergy. Don't use ceftriaxone (no Listeria coverage)</li>
                        <li><strong>H. influenzae:</strong> Ceftriaxone 2g IV q12h Ã— 7-10 days</li>
                        <li><strong>Pseudomonas:</strong> Cefepime 2g IV q8h or Meropenem 2g IV q8h Ã— 21 days. Consider intrathecal/intraventricular aminoglycoside if refractory</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>ICP management:</strong> Elevate HOB 30Â°, avoid hypotonic fluids, treat fever/pain aggressively. If severe â†‘ICP: Mannitol 0.25-1 g/kg IV or 3% saline bolus. Neurosurgery for ventriculostomy if hydrocephalus</li>
                        <li><strong>Seizures:</strong> Treat acutely (lorazepam 2-4mg IV). Prophylactic AEDs not recommended unless seizure occurred. Load levetiracetam if recurrent</li>
                        <li><strong>SIADH (common):</strong> Fluid restrict 1-1.5 L/day. Hypertonic saline if severe symptomatic hyponatremia (Na <120, seizures, severe AMS)</li>
                        <li><strong>Isolation:</strong> Droplet precautions for N. meningitidis until 24hr after antibiotics. Standard precautions for other organisms</li>
                    </ul>
                    
                    <p><span class="label">Repeat LP at 48hr if:</span> Persistent fever, worsening neurologic status, concern for resistant organism. Should see â†“WBC, â†“protein, sterile cultures</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
                <ul>
                    <li><strong>Antibiotics before LP saves lives:</strong> Every hour delay increases mortality. If high suspicion, give empiric antibiotics immediately - don't wait. Diagnostic yield minimally affected if LP within 2-4 hours</li>
                    <li><strong>Classic triad is the minority:</strong> Only 44% have fever + HA + stiff neck. 95% have â‰¥2 of: fever, HA, stiff neck, AMS. Don't wait for "classic" presentation</li>
                    <li><strong>Dexamethasone timing critical:</strong> BEFORE or WITH first antibiotic (not after). Reduces mortality/hearing loss in pneumococcal. Don't forget it!</li>
                    <li><strong>Low CSF glucose = bacterial:</strong> CSF glucose <40 or <50% serum highly specific for bacterial meningitis. Viral/aseptic has normal glucose</li>
                    <li><strong>PCR is game-changer:</strong> BioFire results ~1hr vs 24-48hr culture. Helpful when antibiotics given before LP. High sensitivity/specificity</li>
                    <li><strong>Listeria loves extremes:</strong> Neonates, elderly >50, pregnant, immunocompromised. MUST add ampicillin empirically - ceftriaxone doesn't cover Listeria</li>
                    <li><strong>Meningococcus kills fast:</strong> Petechial rash + shock = urgent antibiotics + ICU + prophylaxis contacts (Cipro 500mg Ã— 1). Health-to-death <24hr</li>
                    <li><strong>Shunt infection = neurosurgery consult:</strong> Fever + HA in VP shunt = infection until proven otherwise. Often coag-neg Staph. Needs vancomycin + shunt removal/externalization</li>
                    <li><strong>Hearing screen everyone:</strong> 30% get hearing loss with pneumococcal meningitis. Audiology screening before discharge + follow-up mandatory</li>
                    <li><strong>Normal CT doesn't rule out â†‘ICP:</strong> CT may be normal even with elevated ICP from meningitis. Only delays LP if mass effect/shift. Give antibiotics first!</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>GCS <12 or rapidly declining mental status</li>
                        <li>Hemodynamic instability requiring vasopressors</li>
                        <li>Respiratory failure requiring intubation</li>
                        <li>Refractory or recurrent seizures</li>
                        <li>Signs of increased ICP (Cushing triad, papilledema)</li>
                        <li>Need for ICP monitoring or ventriculostomy</li>
                        <li>Meningococcemia with septic shock/DIC</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile >24-48 hours off antibiotics</li>
                        <li>Clinical improvement (HA resolving, AMS cleared, ambulating)</li>
                        <li>Tolerating PO intake</li>
                        <li>Neurologic exam stable or improved</li>
                        <li>Completed appropriate IV antibiotic duration (7-21d depending on organism)</li>
                        <li>CSF sterilized if repeat LP performed</li>
                        <li>Hearing screen performed (audiology follow-up arranged)</li>
                        <li>Close outpatient follow-up with ID/neurology</li>
                        <li>No complications requiring ongoing inpatient management</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Neurologic:</strong> Seizures (20-30% - treat acutely, consider prophylaxis if recurrent), stroke (15% from vasculitis/venous thrombosis), brain abscess, subdural empyema, ventriculitis, cerebral edema with herniation, hydrocephalus (communicating or obstructive requiring VP shunt), cranial nerve palsies (CN VI, VII, VIII most common - especially hearing loss)</p>
                    <p><strong>Systemic Complications:</strong> Septic shock (especially meningococcemia), DIC with bleeding, ARDS requiring mechanical ventilation, multi-organ failure, adrenal crisis (Waterhouse-Friderichsen syndrome in meningococcemia), SIADH with severe hyponatremia</p>
                    <p><strong>Long-term Sequelae:</strong> Sensorineural hearing loss (30% with S. pneumoniae - permanent, requires hearing aids/cochlear implants), cognitive impairment (memory, executive function), motor deficits/hemiparesis, post-infectious epilepsy, hydrocephalus requiring permanent shunt</p>
                    <p><strong>Mortality:</strong> Overall 15-20%. S. pneumoniae 20-30%, N. meningitidis 5-10%, Listeria 20-30%, gram-negatives 20-40%. Poor prognostic factors: elderly, delayed treatment, GCS <10, seizures, shock, focal deficits</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#ceftriaxone" style="color: #8e44ad;">ðŸ’Š Ceftriaxone</a>, <a href="drug_reference_guide.html#vancomycin" style="color: #8e44ad;">ðŸ’Š Vancomycin</a>, <a href="drug_reference_guide.html#ampicillin" style="color: #8e44ad;">ðŸ’Š Ampicillin</a>, <a href="drug_reference_guide.html#dexamethasone" style="color: #8e44ad;">ðŸ’Š Dexamethasone</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="anemia" class="condition-page">
            <div class="page-header">
                <h2>27. ANEMIA</h2>
                <div class="subtitle">Microcytic â€¢ Normocytic â€¢ Macrocytic</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">General Symptoms (severity depends on acuity and degree):</span> Fatigue, weakness, dyspnea on exertion, dizziness, headache, tinnitus, palpitations, chest pain (angina if severe anemia + CAD). Pallor (conjunctivae, palmar creases), tachycardia, systolic flow murmur, orthostatic hypotension if acute blood loss</p>
                    
                    <p><span class="label">Alternate Presentations by Etiology:</span></p>
                    <ul>
                        <li><strong>Iron Deficiency:</strong> Koilonychia (spoon nails), glossitis, angular cheilitis, pica (ice chips/starch/dirt craving), restless leg syndrome, dysphagia (Plummer-Vinson syndrome with esophageal webs)</li>
                        <li><strong>B12 Deficiency:</strong> Neurologic symptoms - paresthesias (glove-stocking), ataxia, decreased proprioception/vibratory sense, dementia, psychiatric changes. Glossitis (beefy red tongue). Subacute combined degeneration of spinal cord (dorsal columns + lateral corticospinal tracts)</li>
                        <li><strong>Folate Deficiency:</strong> Similar to B12 but NO neurologic symptoms. Glossitis, diarrhea. Often in alcoholics, malnutrition</li>
                        <li><strong>Hemolysis:</strong> Jaundice (â†‘unconjugated bilirubin), dark urine (hemoglobinuria), splenomegaly. If intravascular: hemoglobinuria, hemosiderinuria. If extravascular: splenomegaly, gallstones (pigmented)</li>
                        <li><strong>Acute Blood Loss:</strong> Tachycardia, hypotension, orthostatic changes, melena/hematochezia (GI bleed), hematemesis, vaginal bleeding. Hgb may be normal initially (takes hours for equilibration)</li>
                        <li><strong>Anemia of Chronic Disease:</strong> Underlying inflammatory condition (RA, IBD, malignancy, CKD). Usually mild-moderate anemia (Hgb 9-11)</li>
                        <li><strong>Thalassemia:</strong> Mild microcytic anemia often asymptomatic. Family history Mediterranean/Asian descent. Splenomegaly if thalassemia major</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Initial Labs:</span> CBC with differential, reticulocyte count (assess bone marrow response), peripheral smear, iron studies, B12/folate, LDH/haptoglobin/bilirubin (if hemolysis suspected)</p>
                    
                    <p><span class="label">Approach by MCV (Mean Corpuscular Volume):</span></p>
                    
                    <p><strong>MICROCYTIC (MCV <80 fL) - "TAILS":</strong></p>
                    <ul>
                        <li><strong>Thalassemia:</strong> Hgb electrophoresis (â†‘HbA2 in Î²-thal trait), family hx, ethnicity. MCV often <75, RBC count elevated despite low Hgb (RBC >5 million). RDW normal. Mentzer index (MCV/RBC count) <13 suggests thalassemia</li>
                        <li><strong>Anemia of chronic disease:</strong> Ferritin elevated (>100) or normal, TIBC low, transferrin saturation low-normal. Inflammatory markers elevated (CRP, ESR). Look for underlying chronic condition</li>
                        <li><strong>Iron deficiency:</strong> Ferritin <30 ng/mL (most specific). Serum iron low, TIBC elevated, transferrin saturation <20%. RDW elevated. Peripheral smear: hypochromic microcytic cells, pencil cells. Investigate source of blood loss (GI workup if no obvious source)</li>
                        <li><strong>Lead poisoning:</strong> Basophilic stippling on smear, elevated blood lead level. Occupational exposure, pica</li>
                        <li><strong>Sideroblastic anemia:</strong> Ring sideroblasts on bone marrow. Elevated ferritin, normal/high iron. Causes: alcohol, isoniazid, lead, copper deficiency, myelodysplasia</li>
                    </ul>
                    
                    <p><strong>NORMOCYTIC (MCV 80-100 fL):</strong></p>
                    <ul>
                        <li><strong>Check reticulocyte count to distinguish:</strong></li>
                        <li><strong>Elevated reticulocyte count (>2-3%) = Appropriate Response:</strong>
                            <ul>
                                <li><strong>Acute blood loss:</strong> Obvious source (GI bleed, trauma, surgery, menorrhagia). Hgb may be normal initially</li>
                                <li><strong>Hemolysis:</strong> Elevated LDH, low haptoglobin, elevated indirect bilirubin, +/- hemoglobinuria. Smear: schistocytes (TTP, HUS, DIC, mechanical valves), spherocytes (autoimmune, hereditary spherocytosis), sickle cells, bite cells (G6PD). Coombs test for autoimmune hemolytic anemia</li>
                            </ul>
                        </li>
                        <li><strong>Low reticulocyte count (<2%) = Inadequate Response:</strong>
                            <ul>
                                <li><strong>Anemia of chronic disease/inflammation:</strong> Ferritin normal/high, low TIBC. Underlying chronic illness (CKD, cancer, infection, autoimmune)</li>
                                <li><strong>CKD:</strong> Low EPO production. Cr elevated, usually Hgb 9-11. Start EPO if Hgb <10</li>
                                <li><strong>Bone marrow failure:</strong> Pancytopenia (â†“WBC, â†“platelets, â†“RBC). Aplastic anemia, myelodysplasia, leukemia, myelofibrosis. Needs bone marrow biopsy</li>
                                <li><strong>Early iron/B12/folate deficiency:</strong> May be normocytic before becoming micro/macrocytic. Check iron studies, B12, folate</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><strong>MACROCYTIC (MCV >100 fL):</strong></p>
                    <ul>
                        <li><strong>B12 deficiency:</strong> B12 <200 pg/mL (or <300 if high clinical suspicion). Elevated methylmalonic acid and homocysteine (more sensitive). Hypersegmented neutrophils on smear. Causes: pernicious anemia (anti-IF antibodies), malabsorption (Crohn's, celiac, gastric bypass), strict vegan diet, metformin</li>
                        <li><strong>Folate deficiency:</strong> Folate <2 ng/mL. Elevated homocysteine but normal methylmalonic acid. No neurologic symptoms (vs B12). Causes: poor diet (alcoholics, elderly), malabsorption, medications (methotrexate, phenytoin, TMP-SMX), pregnancy/lactation (increased demand)</li>
                        <li><strong>Alcohol:</strong> Direct marrow suppression. Often with folate deficiency. MCV 100-110. Elevated GGT, AST>ALT</li>
                        <li><strong>Hypothyroidism:</strong> Check TSH. MCV usually 100-110</li>
                        <li><strong>Medications:</strong> Hydroxyurea, zidovudine (AZT), azathioprine, 5-FU, methotrexate</li>
                        <li><strong>Myelodysplastic syndrome (MDS):</strong> Elderly, refractory anemia, dysplastic cells on smear, cytopenias. Bone marrow biopsy shows dysplasia. Risk of transformation to AML</li>
                        <li><strong>Reticulocytosis:</strong> Young RBCs are larger. If brisk hemolysis/blood loss with appropriate reticulocyte response, MCV may be elevated</li>
                    </ul>
                    
                    <p><span class="label">Additional Workup for Specific Situations:</span></p>
                    <ul>
                        <li><strong>GI workup if iron deficiency with no obvious source:</strong> EGD + colonoscopy to evaluate for occult GI bleeding (gastritis, ulcer, colon cancer, AVM). Celiac serologies. H. pylori testing</li>
                        <li><strong>Hemolysis workup:</strong> Coombs (direct antiglobulin test) for autoimmune hemolytic anemia. G6PD level (if bite cells, acute hemolysis after oxidative stress). Osmotic fragility (hereditary spherocytosis). PNH flow cytometry if intravascular hemolysis</li>
                        <li><strong>Bone marrow biopsy if:</strong> Pancytopenia, suspected malignancy (leukemia, lymphoma, myeloma), unexplained anemia, MDS suspected</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Transfusion Thresholds:</span></p>
                    <ul>
                        <li><strong>Stable, no CAD:</strong> Transfuse if Hgb <7 g/dL (restrictive strategy)</li>
                        <li><strong>CAD or high cardiac risk:</strong> Transfuse if Hgb <8 g/dL</li>
                        <li><strong>Acute MI/ACS:</strong> Transfuse if Hgb <10 g/dL (some say <8, controversial - individualize)</li>
                        <li><strong>Symptomatic (dyspnea, angina, orthostasis):</strong> Transfuse regardless of Hgb if symptomatic</li>
                        <li><strong>Chronic anemia:</strong> Often tolerate lower Hgb (compensatory mechanisms). Treat underlying cause, transfuse only if symptomatic or Hgb <7</li>
                        <li><strong>Each unit pRBC raises Hgb by ~1 g/dL</strong> (or Hct by ~3%)</li>
                    </ul>
                    
                    <p><span class="label">Specific Treatments by Etiology:</span></p>
                    
                    <p><strong>Iron Deficiency:</strong></p>
                    <ul>
                        <li><strong>Oral iron (first-line):</strong> Ferrous sulfate 325mg PO TID (65mg elemental iron per tablet). Take on empty stomach with vitamin C (enhances absorption). Common SE: constipation, dark stools, nausea. Response in 2-4 weeks (â†‘reticulocytes), full repletion 3-6 months. Continue 3 months after Hgb normalized to replete stores</li>
                        <li><strong>IV iron (if oral intolerance, malabsorption, CKD, need rapid repletion):</strong> Iron sucrose 200mg IV Ã— 5 doses or Ferric carboxymaltose 750mg IV Ã— 2 doses or Iron dextran (test dose required). Risk: anaphylaxis (rare with newer formulations), hypophosphatemia</li>
                        <li><strong>Treat underlying cause:</strong> GI bleeding (PPI for ulcer, colonoscopy for polyp/cancer removal), menorrhagia (NSAIDs, OCPs, IUD, ablation)</li>
                    </ul>
                    
                    <p><strong>B12 Deficiency:</strong></p>
                    <ul>
                        <li><strong>Cyanocobalamin 1000 mcg IM daily Ã— 7 days, then weekly Ã— 4 weeks, then monthly lifelong</strong> (if pernicious anemia or malabsorption)</li>
                        <li><strong>Oral B12 1000-2000 mcg daily:</strong> Alternative if dietary deficiency or mild malabsorption (compliance issue - less reliable)</li>
                        <li><strong>Neurologic symptoms may be irreversible if prolonged deficiency:</strong> Treat urgently</li>
                        <li><strong>NEVER give folate without B12</strong> in macrocytic anemia - can worsen B12 neuropathy!</li>
                    </ul>
                    
                    <p><strong>Folate Deficiency:</strong></p>
                    <ul>
                        <li><strong>Folic acid 1mg PO daily Ã— 1-4 months</strong> until replete</li>
                        <li><strong>Treat underlying cause:</strong> Alcohol cessation, improve diet</li>
                        <li><strong>Pregnancy:</strong> All women of childbearing age should take 400-800 mcg daily (prevent neural tube defects)</li>
                    </ul>
                    
                    <p><strong>Anemia of Chronic Disease:</strong></p>
                    <ul>
                        <li><strong>Treat underlying condition</strong> (control inflammation, treat cancer, manage CKD)</li>
                        <li><strong>If concurrent iron deficiency</strong> (ferritin <100 in setting of inflammation): IV iron (oral poorly absorbed)</li>
                        <li><strong>EPO (erythropoietin):</strong> If CKD with Hgb <10, or cancer-related anemia. Epoetin alfa 50-100 units/kg SC 3Ã—/week. Target Hgb 10-11 (don't overcorrect - â†‘thrombosis risk). Requires adequate iron stores</li>
                    </ul>
                    
                    <p><strong>Hemolytic Anemia:</strong></p>
                    <ul>
                        <li><strong>Autoimmune (warm AIHA):</strong> Prednisone 1mg/kg daily, taper over weeks-months. If refractory: Rituximab, IVIG, splenectomy. Folic acid 1mg daily (increased RBC turnover)</li>
                        <li><strong>Cold agglutinin disease:</strong> Avoid cold exposure. Rituximab. Don't transfuse unless life-threatening (can worsen hemolysis)</li>
                        <li><strong>G6PD deficiency:</strong> Avoid oxidative triggers (sulfa drugs, dapsone, antimalarials, fava beans). Supportive care, transfuse if severe</li>
                        <li><strong>TTP:</strong> URGENT plasmapheresis (see TTP section)</li>
                    </ul>
                    
                    <p><strong>Thalassemia:</strong></p>
                    <ul>
                        <li><strong>Trait (minor):</strong> No treatment needed. Avoid unnecessary iron supplementation. Genetic counseling</li>
                        <li><strong>Major:</strong> Chronic transfusions (maintain Hgb >9-10), iron chelation (deferoxamine, deferasirox) to prevent iron overload. Splenectomy if hypersplenism. Bone marrow transplant curative</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
                <ul>
                    <li><strong>MCV is your roadmap:</strong> Microcytic â†’ think iron/thalassemia/chronic disease. Normocytic â†’ check retic count (high = bleeding/hemolysis, low = bone marrow problem). Macrocytic â†’ B12/folate/alcohol/hypothyroid</li>
                    <li><strong>Ferritin <30 = iron deficiency:</strong> Most specific test. But ferritin is acute phase reactant - may be falsely normal/elevated with inflammation. If ferritin 30-100 with chronic disease, still suspect iron deficiency</li>
                    <li><strong>RDW helps distinguish:</strong> High RDW = iron deficiency (mixed cell sizes). Normal RDW = thalassemia, chronic disease (uniform small cells)</li>
                    <li><strong>Thalassemia has HIGH RBC count:</strong> Despite low Hgb/MCV, RBC count often >5 million (vs iron deficiency with low RBC count). Mentzer index <13 suggests thalassemia</li>
                    <li><strong>B12 deficiency causes neuro symptoms, folate doesn't:</strong> Paresthesias, ataxia, dementia = B12. Never give folate without checking B12 first in macrocytic anemia - can worsen neuropathy!</li>
                    <li><strong>Acute blood loss: Hgb lags:</strong> Initial Hgb may be normal because both RBCs and plasma lost equally. Takes hours for equilibration. Treat based on clinical status (hypotension, tachycardia)</li>
                    <li><strong>Hemolysis triad:</strong> Elevated LDH + low haptoglobin + elevated indirect bilirubin. If all three present, hemolysis confirmed. Then figure out cause (Coombs, smear)</li>
                    <li><strong>Restrictive transfusion saves lives:</strong> Transfuse <7 in stable patients (or <8 if CAD). Overtransfusion increases mortality, volume overload, immunosuppression</li>
                    <li><strong>Each unit pRBC raises Hgb ~1 g/dL:</strong> Don't transfuse more than needed. Reassess after each unit</li>
                    <li><strong>Iron pills cause constipation/GI upset:</strong> Take with food if intolerant (absorption slightly decreased but better than not taking). Try every-other-day dosing (absorption actually better). Black stools are expected</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Hemodynamic instability (hypotension, tachycardia unresponsive to fluids/transfusion)</li>
                        <li>Active massive hemorrhage requiring massive transfusion protocol</li>
                        <li>Severe symptomatic anemia (Hgb <5-6) with angina, AMS, respiratory distress</li>
                        <li>TTP/HUS with neurologic changes or renal failure</li>
                        <li>Severe autoimmune hemolytic anemia with rapid decompensation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable</li>
                        <li>Hgb stable or improving</li>
                        <li>No active bleeding</li>
                        <li>Tolerating PO intake (including iron/B12 if applicable)</li>
                        <li>Underlying cause identified and treated (or plan in place)</li>
                        <li>Appropriate outpatient follow-up arranged (PCP, hematology, GI)</li>
                        <li>Patient educated on medications, dietary recommendations</li>
                        <li>Transfusion reactions ruled out if transfused</li>
                        <li>Safe for discharge from functional standpoint</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications:</strong> High-output heart failure (severe chronic anemia - Hgb <6-7 with inadequate compensation), angina/MI (demand ischemia from anemia in patient with CAD), syncope, falls (orthostasis, weakness), transfusion reactions (see transfusion section)</p>
                    <p><strong>From Iron Deficiency:</strong> Restless leg syndrome (improves with iron repletion), cognitive impairment (especially children), increased risk infection (impaired immune function), pica complications (lead poisoning from paint chips, bowel obstruction)</p>
                    <p><strong>From B12 Deficiency:</strong> Irreversible neurologic damage (subacute combined degeneration - ataxia, spasticity, paresthesias), dementia, depression, increased homocysteine â†’ thrombosis risk</p>
                    <p><strong>From Treatment:</strong> Iron overload (chronic transfusions - hemochromatosis, cardiac/liver damage, requires chelation), transfusion reactions, infection from immunosuppression (rituximab, steroids for AIHA)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="neutropenic-fever" class="condition-page">
            <div class="page-header">
                <h2>28. NEUTROPENIC FEVER</h2>
                <div class="subtitle">Oncologic Emergency â€¢ Empiric Antibiotics Within 1 Hour</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Single oral temperature â‰¥38.3Â°C (101Â°F) OR temperature â‰¥38Â°C (100.4Â°F) for â‰¥1 hour WITH absolute neutrophil count (ANC) <500 cells/ÂµL OR ANC expected to decline to <500 within 48 hours</p>
                    <p><span class="label">Calculation:</span> ANC = WBC Ã— (% neutrophils + % bands) / 100</p>
                    
                    <p><span class="label">Typical Presentation:</span> Fever may be ONLY sign of infection (neutropenic patients lack inflammatory response - no pus, minimal symptoms). Subtle findings: mild hypotension, tachycardia, confusion. Absence of fever does NOT rule out infection</p>
                    
                    <p><span class="label">Common Sources (often no clear source found 50-60%):</span></p>
                    <ul>
                        <li><strong>GI tract (most common):</strong> Oral mucositis, esophagitis, typhlitis (cecal inflammation), C. diff, perirectal abscess</li>
                        <li><strong>Lungs:</strong> Pneumonia (bacterial, fungal - Aspergillus, PCP)</li>
                        <li><strong>Skin/soft tissue:</strong> Cellulitis, catheter site infection, perirectal abscess</li>
                        <li><strong>Bloodstream:</strong> Catheter-related bloodstream infection (CRBSI - coag-neg Staph, S. aureus)</li>
                        <li><strong>Urinary tract:</strong> Less common (neutrophils needed for pyuria - may have negative UA despite UTI)</li>
                        <li><strong>Sinusitis:</strong> Especially if prolonged neutropenia (fungal - Mucor, Aspergillus)</li>
                    </ul>
                    
                    <p><span class="label">Alternate/High-Risk Presentations:</span></p>
                    <ul>
                        <li><strong>Septic shock:</strong> Hypotension, tachycardia, AMS, lactate elevation. Requires urgent resuscitation + antibiotics</li>
                        <li><strong>Typhlitis (neutropenic enterocolitis):</strong> RLQ pain, diarrhea, distension. CT shows bowel wall thickening cecum/ascending colon. High mortality if perforation. Needs surgical consult</li>
                        <li><strong>Perirectal abscess:</strong> Severe perianal pain, tenderness. Often NO fluctuance (neutropenic - can't form pus). Needs exam under anesthesia + drainage + antibiotics</li>
                        <li><strong>Invasive fungal infection (if prolonged neutropenia >7-10 days):</strong> Persistent fever despite antibiotics. Aspergillus (pulmonary nodules, halo sign on CT), Candida (bloodstream, hepatosplenic candidiasis), Mucormycosis (sinusitis, black eschar)</li>
                        <li><strong>Atypical pneumonia:</strong> PCP (HIV/lymphoma), CMV, viral (RSV, influenza)</li>
                        <li><strong>CNS infection:</strong> Headache, AMS, focal deficits. Listeria, Aspergillus, Toxoplasma, Cryptococcus</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs (STAT):</span></p>
                    <ul>
                        <li><strong>CBC with differential:</strong> Confirm ANC. Trend daily. Platelets (thrombocytopenia common)</li>
                        <li><strong>Blood cultures Ã— 2 sets:</strong> One from EACH lumen of central line (if present) + peripheral. Label which lumen. Positive in 20-30%</li>
                        <li><strong>CMP:</strong> Renal function (for antibiotic dosing), electrolytes, LFTs</li>
                        <li><strong>Lactate:</strong> If concern for sepsis</li>
                        <li><strong>UA with culture:</strong> Even if UA negative (neutropenia â†’ may not have WBCs in urine despite UTI)</li>
                        <li><strong>Stool culture, C. diff if diarrhea</strong></li>
                        <li><strong>Procalcitonin:</strong> May help distinguish bacterial vs non-bacterial (not routinely recommended)</li>
                        <li><strong>Fungal markers if prolonged fever (>4-7 days) or high risk:</strong> Serum (1â†’3)-Î²-D-glucan (Candida, Aspergillus, PCP), Galactomannan (Aspergillus), Cryptococcal antigen</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Chest X-ray:</strong> All patients. But CXR may be normal early (neutropenia â†’ no infiltrate). If negative but respiratory symptoms, get CT chest</li>
                        <li><strong>CT Chest (if respiratory symptoms, hypoxia, or persistent fever):</strong> More sensitive for pneumonia, fungal nodules. Look for: infiltrates, nodules, halo sign (Aspergillus), cavitation</li>
                        <li><strong>CT Abdomen/Pelvis (if abdominal pain or no clear source):</strong> Evaluate for typhlitis, abscess, colitis</li>
                        <li><strong>CT Sinuses (if sinus symptoms, especially prolonged neutropenia):</strong> Rule out invasive fungal sinusitis</li>
                    </ul>
                    
                    <p><span class="label">Other Studies:</span></p>
                    <ul>
                        <li><strong>Respiratory viral panel (if respiratory symptoms):</strong> Influenza, RSV, COVID</li>
                        <li><strong>Lumbar puncture (if CNS symptoms):</strong> After platelets >50k. CSF for cell count, protein, glucose, Gram stain, culture, Crypto Ag, fungal culture</li>
                        <li><strong>Skin biopsy (if skin lesions):</strong> Culture and histology. Rule out disseminated fungal (Fusarium, Mucor)</li>
                    </ul>
                    
                    <p><span class="label">Risk Stratification (MASCC Score - guides inpatient vs outpatient, intensity):</span></p>
                    <ul>
                        <li><strong>MASCC Score â‰¥21:</strong> Low risk (mortality <5%). May consider outpatient management in select patients</li>
                        <li><strong>MASCC Score <21:</strong> High risk (mortality >20%). Requires inpatient management + aggressive treatment</li>
                        <li><strong>High-risk features:</strong> Prolonged neutropenia (>7 days expected), ANC <100, hemodynamic instability, pneumonia, mucositis grade 3-4, neurologic changes, abdominal pain, renal/liver dysfunction, age >60</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">EMPIRIC ANTIBIOTICS (START WITHIN 1 HOUR):</span></p>
                    
                    <p><strong>Initial Monotherapy (Preferred):</strong></p>
                    <ul>
                        <li><strong>Cefepime 2g IV q8h</strong> (antipseudomonal cephalosporin, preferred)</li>
                        <li><strong>OR Piperacillin-Tazobactam 4.5g IV q6h</strong> (broader spectrum)</li>
                        <li><strong>OR Meropenem 1g IV q8h</strong> (if PCN allergy or resistant organisms suspected)</li>
                        <li>Monotherapy covers: Pseudomonas, E. coli, Klebsiella, Enterobacter, Proteus, Staph (not MRSA), Strep</li>
                    </ul>
                    
                    <p><strong>ADD Vancomycin 15-20 mg/kg IV q8-12h if:</strong></p>
                    <ul>
                        <li>Central line/catheter infection suspected (erythema, tenderness at site)</li>
                        <li>Severe mucositis (oral, esophageal, GI - â†‘Strep viridans, Enterococcus risk)</li>
                        <li>Hemodynamic instability/septic shock</li>
                        <li>Skin/soft tissue infection</li>
                        <li>Known MRSA colonization</li>
                        <li>Pneumonia (cover MRSA)</li>
                    </ul>
                    
                    <p><strong>ADD Antifungal Coverage if:</strong></p>
                    <ul>
                        <li><strong>Persistent fever >4-7 days despite broad-spectrum antibiotics</strong> (empiric antifungal)</li>
                        <li><strong>Clinical/radiographic evidence of invasive fungal infection:</strong> Pulmonary nodules, halo sign, sinusitis</li>
                        <li><strong>Positive fungal markers:</strong> Î²-D-glucan, galactomannan</li>
                        <li><strong>Options:</strong> Micafungin 100mg IV daily (Candida), Voriconazole 6mg/kg q12h Ã— 2 then 4mg/kg q12h (Aspergillus), Liposomal Amphotericin B 3-5mg/kg IV daily (broad spectrum, if refractory)</li>
                    </ul>
                    
                    <p><strong>Special Situations:</strong></p>
                    <ul>
                        <li><strong>Perirectal abscess/typhlitis:</strong> Pip-tazo + Vancomycin (or Meropenem + Vanc). Metronidazole 500mg IV q8h if extensive bowel involvement. Surgical consult</li>
                        <li><strong>PCP suspected (HIV, lymphoma):</strong> TMP-SMX 5mg/kg IV q8h. Prednisone if severe (PaO2 <70 or A-a gradient >35)</li>
                        <li><strong>Viral respiratory infection (influenza):</strong> Oseltamivir 75mg PO BID Ã— 5d if within 48hr symptom onset (or longer if immunocompromised)</li>
                        <li><strong>HSV/VZV (mucositis, vesicular rash):</strong> Acyclovir 5-10mg/kg IV q8h</li>
                    </ul>
                    
                    <p><span class="label">Duration of Antibiotics:</span></p>
                    <ul>
                        <li><strong>If source identified:</strong> Treat for appropriate duration (7-14 days typical)</li>
                        <li><strong>If NO source, clinically improving, afebrile >48hr:</strong> Continue until ANC >500 (at least 7 days total)</li>
                        <li><strong>If persistent fever but stable:</strong> Continue antibiotics until ANC >500 or until fungal workup complete</li>
                        <li><strong>Do NOT stop antibiotics just because fever persists</strong> - fever may persist due to tumor, drugs, blood products, non-bacterial causes</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>G-CSF (filgrastim 5 mcg/kg SC daily):</strong> Consider if high-risk (MASCC <21, pneumonia, septic shock, invasive fungal, prolonged neutropenia expected >7-10 days). Shortens duration neutropenia. NOT needed routinely low-risk patients</li>
                        <li><strong>Fluid resuscitation:</strong> NS boluses if hypotensive. Early aggressive hydration improves outcomes</li>
                        <li><strong>Avoid rectal temps/exams, suppositories, enemas:</strong> Risk of bacteremia from mucosal trauma</li>
                        <li><strong>Transfusion support:</strong> pRBCs if Hgb <7-8, platelets if <10k (or <50k if bleeding/procedure)</li>
                        <li><strong>Oral care:</strong> Chlorhexidine or salt/soda rinses QID. Pain control (opiates if severe mucositis)</li>
                        <li><strong>Isolate patient:</strong> Private room, hand hygiene, avoid fresh flowers/plants (fungal spores), low-microbial diet controversial</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
                <ul>
                    <li><strong>Door-to-antibiotic <1 hour saves lives:</strong> Mortality increases 18% for each hour delay. Don't wait for cultures - empiric antibiotics immediately</li>
                    <li><strong>Fever may be only sign:</strong> Neutropenic patients can't mount inflammatory response. No pus, minimal symptoms despite severe infection. Low threshold to treat</li>
                    <li><strong>ANC <100 is very high risk:</strong> "Profound neutropenia." Mortality >20%. Need aggressive treatment, GCSF, close monitoring</li>
                    <li><strong>Persistent fever >4-7 days â†’ add antifungal:</strong> Empiric coverage for invasive fungal (Aspergillus, Candida). Don't wait for positive cultures/markers</li>
                    <li><strong>Don't forget perirectal exam:</strong> But be gentle! Perirectal abscess common, may not have fluctuance. Severe tenderness = likely abscess. Needs drainage</li>
                    <li><strong>CXR can be falsely negative:</strong> Neutropenia â†’ no infiltrate despite pneumonia. If respiratory symptoms, get CT chest even if CXR normal</li>
                    <li><strong>Mucositis = add vancomycin:</strong> Oral/GI mucositis â†‘risk Strep viridans bacteremia. Must add vancomycin to empiric regimen</li>
                    <li><strong>Typhlitis is surgical emergency:</strong> RLQ pain + fever + neutropenia = typhlitis until proven otherwise. CT shows cecal wall thickening. High mortality if perforation. Surgical consult urgently</li>
                    <li><strong>Don't remove central line unless CRBSI confirmed:</strong> Lines are precious in chemo patients. Can treat through line unless Staph aureus, Candida, or persistent bacteremia</li>
                    <li><strong>GCSF shortens duration:</strong> Use if high-risk (MASCC <21). Shortens neutropenia by ~2-3 days, reduces infection complications. NOT needed routinely</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Septic shock requiring vasopressors</li>
                        <li>Respiratory failure requiring intubation</li>
                        <li>Multi-organ dysfunction (renal failure, hepatic failure)</li>
                        <li>Hemodynamic instability despite fluid resuscitation</li>
                        <li>Profound neutropenia (ANC <100) with sepsis</li>
                        <li>Typhlitis with concern for perforation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile >24-48 hours off antibiotics (or on PO antibiotics if continued)</li>
                        <li>Hemodynamically stable</li>
                        <li>ANC recovering (>200-500 and rising)</li>
                        <li>No evidence of active infection requiring IV therapy</li>
                        <li>Able to tolerate PO intake</li>
                        <li>Close outpatient follow-up arranged (oncology within 48-72hr)</li>
                        <li>Patient education on infection precautions, when to return</li>
                        <li>Low-risk by MASCC score if outpatient management planned</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Infectious Complications:</strong> Septic shock (mortality 30-50%), invasive fungal infection (Aspergillus pneumonia, disseminated candidiasis - high mortality), typhlitis with perforation (requires surgery, high mortality), perirectal abscess with necrotizing fasciitis, catheter-related bloodstream infection (S. aureus, Candida - may require line removal), PCP pneumonia with respiratory failure</p>
                    <p><strong>Non-Infectious:</strong> Tumor lysis syndrome (especially with treatment of hematologic malignancies), mucositis (severe pain, inability to eat/swallow, TPN required), bleeding (thrombocytopenia), VTE (hypercoagulable from cancer), drug toxicity (nephrotoxicity, hepatotoxicity from antibiotics/antifungals)</p>
                    <p><strong>Mortality:</strong> Overall 5-20% depending on risk factors. Low-risk (MASCC â‰¥21) <5%, High-risk (MASCC <21) >20%. Mortality higher if: ANC <100, septic shock, pneumonia, invasive fungal infection, age >60</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="etoh-withdrawal" class="condition-page">
            <div class="page-header">
                <h2>29. ALCOHOL WITHDRAWAL</h2>
                <div class="subtitle">CIWA-Ar Protocol â€¢ Delirium Tremens â€¢ Thiamine BEFORE Glucose</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Timeline of Symptoms:</span></p>
                    <ul>
                        <li><strong>Minor withdrawal (6-12 hours after last drink):</strong> Tremor, anxiety, agitation, diaphoresis, nausea/vomiting, headache, insomnia, mild tachycard ia, mild hypertension</li>
                        <li><strong>Withdrawal seizures (12-48 hours):</strong> Generalized tonic-clonic, typically brief (<2 min), single or clustered (2-4 seizures), self-limited. If prolonged or focal â†’ think other cause (structural lesion, infection)</li>
                        <li><strong>Alcoholic hallucinosis (12-24 hours):</strong> Visual, auditory, or tactile hallucinations WITH intact orientation (patient knows hallucinations aren't real). No autonomic instability. Benign, self-limited</li>
                        <li><strong>Delirium Tremens/DTs (48-72 hours, can be up to 7-10 days):</strong> Life-threatening. Severe autonomic instability (tachycardia >120, hypertension, hyperthermia >38.5Â°C, profound diaphoresis), delirium (disoriented, agitated, hallucinations), tremor. Mortality 5-15% if untreated, <1-5% with treatment</li>
                    </ul>
                    
                    <p><span class="label">Risk Factors for Severe Withdrawal/DTs:</span> History of DTs/severe withdrawal, concurrent illness (pneumonia, pancreatitis, trauma), advanced age, multiple prior detoxifications (kindling phenomenon), prolonged heavy drinking, abrupt cessation, metabolic abnormalities (â†“K, â†“Mg, â†“PO4)</p>
                    
                    <p><span class="label">Alternate/Complicated Presentations:</span></p>
                    <ul>
                        <li><strong>Occult withdrawal in hospitalized patients:</strong> Admitted for other reason (trauma, surgery, infection), develops withdrawal 24-72hr into admission. High suspicion if unexplained tachycardia, hypertension, agitation</li>
                        <li><strong>Concurrent Wernicke encephalopathy:</strong> Acute thiamine deficiency. Triad: confusion, ataxia, ophthalmoplegia (nystagmus, gaze palsy). Often only 1-2 of triad present. Needs urgent IV thiamine BEFORE glucose</li>
                        <li><strong>Co-ingestion:</strong> Benzodiazepines (may mask withdrawal initially then rebound), opioids (can have concurrent withdrawal), stimulants (confound tachycardia/hypertension assessment)</li>
                        <li><strong>Hepatic encephalopathy mimicking DTs:</strong> Both have AMS, but HE has asterixis, elevated ammonia, slower onset. Can coexist</li>
                        <li><strong>Seizure complications:</strong> Status epilepticus (rare but life-threatening), aspiration pneumonia, traumatic injury from fall</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis:</span> Based on history, timeline, CIWA-Ar score. No specific diagnostic test</p>
                    
                    <p><span class="label">CIWA-Ar Score (Clinical Institute Withdrawal Assessment - Alcohol, revised):</span></p>
                    <p>10-item scale, max score 67. Assess q1-2h initially:</p>
                    <ul>
                        <li>Nausea/vomiting (0-7)</li>
                        <li>Tremor (0-7)</li>
                        <li>Paroxysmal sweats (0-7)</li>
                        <li>Anxiety (0-7)</li>
                        <li>Agitation (0-7)</li>
                        <li>Tactile disturbances (0-7)</li>
                        <li>Auditory disturbances (0-7)</li>
                        <li>Visual disturbances (0-7)</li>
                        <li>Headache (0-7)</li>
                        <li>Orientation/clouding of sensorium (0-4)</li>
                    </ul>
                    <p><strong>Interpretation:</strong> <8 = minimal withdrawal, 8-15 = moderate, >15 = severe, >20 = very severe (high DT risk)</p>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>BMP:</strong> Hypokalemia, hypomagnesemia, hypophosphatemia common. Anion gap metabolic acidosis (lactic acidosis, ketoacidosis). Renal function</li>
                        <li><strong>CBC:</strong> Macrocytosis (MCV >100), thrombocytopenia. Leukocytosis if infection</li>
                        <li><strong>LFTs:</strong> Elevated AST>ALT (2:1 ratio), GGT elevated. Assess for cirrhosis, hepatitis</li>
                        <li><strong>Albumin, INR:</strong> Synthetic liver function (low albumin, elevated INR = advanced liver disease)</li>
                        <li><strong>Magnesium, phosphate:</strong> Correct deficiencies (affect seizure threshold, cardiac arrhythmias)</li>
                        <li><strong>Thiamine level:</strong> Usually not sent (takes days, unreliable). Just give empiric thiamine</li>
                        <li><strong>Ethanol level:</strong> Helpful to know if still intoxicated vs pure withdrawal. But low/negative ethanol doesn't rule out withdrawal</li>
                        <li><strong>Lipase, troponin if abdominal pain/chest pain:</strong> Pancreatitis and ACS common in alcoholics</li>
                        <li><strong>Ammonia if concern for hepatic encephalopathy</strong></li>
                        <li><strong>Blood cultures if fever:</strong> Rule out infection (pneumonia, SBP, bacteremia)</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CT Head (if first seizure, focal seizure, persistent AMS, focal neurologic deficit, head trauma):</strong> Rule out ICH, subdural, stroke, mass</li>
                        <li><strong>CXR:</strong> Aspiration pneumonia common (especially post-seizure), eval for other pulmonary pathology</li>
                        <li><strong>EEG (if prolonged seizure or concern for non-convulsive status):</strong> Withdrawal seizures are brief, self-limited. If prolonged â†’ other etiology</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Benzodiazepines (Cornerstone of Treatment):</span></p>
                    
                    <p><strong>CIWA-Ar Protocol (Symptom-Triggered):</strong></p>
                    <ul>
                        <li><strong>Assess CIWA-Ar q1-2h (or q4h if stable/asleep)</strong></li>
                        <li><strong>If CIWA â‰¥8:</strong> Lorazepam 2-4mg IV/PO OR Diazepam 10-20mg IV/PO OR Chlordiazepoxide 50-100mg PO</li>
                        <li><strong>Reassess 1 hour after dose, repeat if CIWA still â‰¥8</strong></li>
                        <li><strong>Goal:</strong> CIWA <8, patient calm but arousable</li>
                        <li><strong>IV preferred if severe withdrawal, NPO, vomiting, or poor absorption</strong></li>
                    </ul>
                    
                    <p><strong>Fixed-Dose Protocol (if CIWA not feasible - ICU, intubated):</strong></p>
                    <ul>
                        <li><strong>Lorazepam 2mg IV q6h scheduled + 2mg q1h PRN breakthrough</strong></li>
                        <li><strong>OR Diazepam 10mg IV q6h scheduled + 10mg q1h PRN</strong></li>
                        <li><strong>Taper over 3-5 days once stable</strong></li>
                    </ul>
                    
                    <p><strong>Choice of Benzodiazepine:</strong></p>
                    <ul>
                        <li><strong>Lorazepam (Ativan):</strong> Intermediate-acting. No active metabolites. Safe in liver disease. Predictable IM absorption. PREFERRED if: liver disease, elderly, need IM route</li>
                        <li><strong>Diazepam (Valium):</strong> Long-acting, active metabolites (smoother withdrawal, less breakthrough). Preferred by some for DTs. Accumulates in liver disease. PREFERRED if: normal liver function, severe withdrawal/DTs</li>
                        <li><strong>Chlordiazepoxide (Librium):</strong> Long-acting, PO only. Good for mild-moderate withdrawal outpatient. NOT for severe/DTs</li>
                    </ul>
                    
                    <p><span class="label">Delirium Tremens (DTs) - Aggressive Management:</span></p>
                    <ul>
                        <li><strong>ICU admission</strong></li>
                        <li><strong>High-dose benzodiazepines:</strong> Lorazepam 2-4mg IV q10-15min or Diazepam 10-20mg IV q10-15min until symptoms controlled. May need 100s of mg/day</li>
                        <li><strong>Phenobarbital (if refractory to benzos):</strong> Phenobarbital 130-260mg IV q15-20min (max 10-15 mg/kg loading dose) then 30-60mg IV q6-8h maintenance. Synergistic with benzos, works on different GABA receptor</li>
                        <li><strong>Propofol/dexmedetomidine infusion (if refractory, intubated):</strong> Propofol 20-80 mcg/kg/min, Dexmedetomidine 0.2-1.5 mcg/kg/hr. Adjuncts, not replacements for benzos</li>
                        <li><strong>Avoid antipsychotics (haloperidol) as monotherapy:</strong> Lower seizure threshold, don't treat withdrawal. Can use low-dose as adjunct for hallucinations if needed (haloperidol 0.5-2mg)</li>
                        <li><strong>Aggressive supportive care:</strong> IVF, cooling for hyperthermia, electrolyte repletion</li>
                    </ul>
                    
                    <p><span class="label">Thiamine & Nutritional Repletion (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Thiamine 100mg IV daily Ã— 3-5 days, then 100mg PO daily</strong></li>
                        <li><strong>MUST give thiamine BEFORE glucose</strong> (glucose depletes thiamine, can precipitate Wernicke encephalopathy)</li>
                        <li><strong>If concern for Wernicke:</strong> Thiamine 500mg IV TID Ã— 3 days (higher dose)</li>
                        <li><strong>Folic acid 1mg PO daily</strong></li>
                        <li><strong>Multivitamin daily</strong></li>
                        <li><strong>Magnesium repletion:</strong> Mag sulfate 2-4g IV (or Mag oxide 400-800mg PO TID). Recheck and replete until >2 mg/dL. Hypomagnesemia â†“efficacy of benzos, â†‘seizure risk</li>
                        <li><strong>Phosphate repletion:</strong> K-phos or NaPhos based on K level. Goal >2.5 mg/dL</li>
                        <li><strong>Potassium repletion:</strong> 40-80 mEq IV (if <3.5). Recheck q4-6h until >3.5</li>
                    </ul>
                    
                    <p><span class="label">Seizure Management:</span></p>
                    <ul>
                        <li><strong>Acute seizure:</strong> Lorazepam 2-4mg IV (treat seizure + withdrawal). Usually self-limited</li>
                        <li><strong>NO prophylactic AEDs:</strong> Benzodiazepines prevent seizures. AEDs (phenytoin, levetiracetam) don't prevent withdrawal seizures</li>
                        <li><strong>If status epilepticus or prolonged seizure:</strong> Standard status protocol (lorazepam, then phenytoin/fosphenytoin or levetiracetam loading)</li>
                        <li><strong>Replete magnesium aggressively</strong> (low Mg lowers seizure threshold)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>Hydration:</strong> NS 100-150 mL/hr (many patients volume depleted). Monitor for volume overload if cirrhosis/cardiomyopathy</li>
                        <li><strong>Cooling for hyperthermia:</strong> Ice packs, cooling blanket. Acetaminophen (avoid NSAIDs if cirrhosis/varices)</li>
                        <li><strong>Aspiration precautions:</strong> NPO if AMS, HOB elevated, monitor for pneumonia</li>
                        <li><strong>Restraints only if necessary:</strong> Can worsen agitation, rhabdomyolysis. Verbal de-escalation, sitter, adequate sedation preferred</li>
                        <li><strong>Treat concurrent conditions:</strong> Pancreatitis, pneumonia, GI bleed common</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
                <ul>
                    <li><strong>Thiamine BEFORE glucose:</strong> Glucose depletes thiamine stores, can precipitate Wernicke encephalopathy (irreversible). Always give thiamine first in alcoholic patients</li>
                    <li><strong>Withdrawal seizures are 12-48hr, self-limited:</strong> If seizure <12hr (still intoxicated?) or >48hr (other cause?), broaden differential. No need for AED prophylaxis - benzos prevent withdrawal seizures</li>
                    <li><strong>DTs peak 48-72hr:</strong> Life-threatening. Autonomic storm (tachy, HTN, fever, diaphoresis) + delirium. Needs ICU, massive doses of benzos. Mortality 5-15% if untreated</li>
                    <li><strong>Magnesium is key:</strong> Hypomagnesemia lowers seizure threshold, reduces benzo efficacy. Aggressively replete Mg until >2 mg/dL</li>
                    <li><strong>CIWA doesn't work if intubated/ICU:</strong> Need fixed-dose protocol. CIWA requires patient cooperation</li>
                    <li><strong>Phenobarbital for refractory DTs:</strong> If benzos failing (which is rare), add phenobarbital. Different GABA receptor, synergistic. Works when benzos don't</li>
                    <li><strong>Don't confuse with hepatic encephalopathy:</strong> Both have AMS in alcoholic. HE has asterixis, elevated ammonia, responds to lactulose/rifaximin. Can coexist. If unsure, treat both</li>
                    <li><strong>Occult withdrawal in hospital:</strong> Patient admitted for trauma/surgery/infection, becomes unexplained tachy/HTN/agitated 24-72hr later. Think withdrawal, check alcohol history</li>
                    <li><strong>Restraints worsen outcomes:</strong> Increase agitation, rhabdomyolysis, aspiration. Use adequate sedation instead. Chemical > physical restraint</li>
                    <li><strong>Can't oversedatewith benzos in withdrawal:</strong> Respiratory drive preserved until massive doses. Goal is calm but arousable. Don't underdose - prevents DTs</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Delirium tremens (autonomic instability + delirium)</li>
                        <li>Refractory withdrawal requiring high-dose benzos or phenobarbital</li>
                        <li>Seizures (especially if recurrent or status epilepticus)</li>
                        <li>Severe agitation requiring intubation for airway protection</li>
                        <li>Hemodynamic instability, severe hypertension</li>
                        <li>Concurrent critical illness (sepsis, GI bleed, pancreatitis)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>CIWA <8-10 for >24 hours</li>
                        <li>Stable vital signs off benzodiazepines</li>
                        <li>No seizure activity</li>
                        <li>Tolerating PO intake</li>
                        <li>Ambulating safely</li>
                        <li>Completed thiamine/vitamin repletion (or on PO regimen)</li>
                        <li>Substance use treatment/counseling initiated or arranged</li>
                        <li>Outpatient follow-up arranged (PCP, addiction medicine)</li>
                        <li>Safe discharge environment</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications:</strong> Delirium tremens (mortality 5-15% if untreated), seizures (aspiration, trauma, status epilepticus), Wernicke encephalopathy (irreversible if not treated - ataxia, confusion, ophthalmoplegia â†’ Korsakoff syndrome with permanent memory impairment), aspiration pneumonia, rhabdomyolysis (from agitation, seizures, restraints - can cause AKI)</p>
                    <p><strong>Cardiovascular:</strong> Arrhythmias (especially if hypokalemia/hypomagnesemia), cardiomyopathy exacerbation (alcoholic CMP), hypertensive crisis, MI (demand ischemia from tachycardia)</p>
                    <p><strong>From Underlying Alcoholism:</strong> GI bleed (varices, gastritis, Mallory-Weiss), pancreatitis, hepatic encephalopathy, hepatorenal syndrome, coagulopathy (low platelets, elevated INR), infections (pneumonia, SBP)</p>
                    <p><strong>From Treatment:</strong> Over-sedation with respiratory depression (rare with benzos alone), paradoxical agitation, delirium from benzodiazepines</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#lorazepam" style="color: #8e44ad;">ðŸ’Š Lorazepam</a>, <a href="drug_reference_guide.html#lorazepam" style="color: #8e44ad;">ðŸ’Š Lorazepam</a>, <a href="drug_reference_guide.html#thiamine-vitamin-b1" style="color: #8e44ad;">ðŸ’Š Thiamine (Vitamin B1)</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="delirium" class="condition-page">
            <div class="page-header">
                <h2>30. DELIRIUM</h2>
                <div class="subtitle">Acute Confusional State â€¢ CAM Criteria â€¢ Treat Underlying Cause</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION & DIAGNOSIS</div>
                <div class="section-content">
                    <p><span class="label">CAM Criteria (Confusion Assessment Method) - ALL required:</span></p>
                    <ul>
                        <li><strong>(1) Acute onset + fluctuating course:</strong> Symptoms developed acutely (hours-days), wax/wane throughout day</li>
                        <li><strong>(2) Inattention:</strong> Difficulty focusing, easily distracted, can't follow conversation</li>
                        <li><strong>PLUS EITHER:</strong> (3) Disorganized thinking (rambling, illogical) OR (4) Altered level of consciousness (hyperalert, lethargic, stuporous)</li>
                    </ul>
                    
                    <p><span class="label">Types:</span> Hyperactive (25% - agitated, combative, hallucinations), Hypoactive (25% - lethargic, withdrawn, often missed), Mixed (50%)</p>
                    
                    <p><span class="label">Common Causes - "I WATCH DEATH":</span> Infections, Withdrawal, Acute metabolic, Trauma/CNS, Hypoxia, Deficiencies (B12, thiamine), Endocrine, Acute vascular, Toxins/drugs, Heavy metals</p>
                    
                    <p><span class="label">High-Risk Medications (Avoid):</span> Anticholinergics (diphenhydramine, TCAs), benzodiazepines (paradoxical), opioids, H2 blockers, corticosteroids, dopamine agonists</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">WORKUP & TREATMENT</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> CBC, CMP, UA/culture, blood cultures if fever, TSH, B12, drug screen, ammonia if liver disease, ABG if hypoxia</p>
                    <p><span class="label">Imaging:</span> CT head if focal signs, fall, anticoagulated, new-onset</p>
                    <p><span class="label">LP if:</span> Fever + AMS with no clear source (meningitis/encephalitis)</p>
                    
                    <p><span class="label">Non-Pharmacologic (FIRST-LINE):</span></p>
                    <ul>
                        <li>Reorient frequently (clocks, calendars, familiar objects)</li>
                        <li>Normalize sleep-wake cycle (lights on during day, dark/quiet at night)</li>
                        <li>Early mobilization (PT/OT daily)</li>
                        <li>Sensory aids (glasses, hearing aids)</li>
                        <li>Avoid restraints (worsen delirium)</li>
                        <li>Family/sitter presence</li>
                    </ul>
                    
                    <p><span class="label">Pharmacologic (ONLY if severe agitation, danger to self/others):</span></p>
                    <ul>
                        <li><strong>Haloperidol 0.5-2mg IV/PO q4-6h PRN</strong> (low-dose). Avoid if QTc >500, Parkinson's, Lewy body dementia</li>
                        <li><strong>Quetiapine 25-50mg PO q12h</strong> (if hyperactive, sundowning). Better for elderly</li>
                        <li><strong>Avoid benzodiazepines</strong> (except alcohol/benzo withdrawal)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
                <ul>
                    <li><strong>Delirium vs Dementia:</strong> Delirium = acute onset (hours-days), fluctuating, inattention. Dementia = chronic (months-years), stable throughout day, memory loss predominates</li>
                    <li><strong>Hypoactive delirium often missed:</strong> Quiet, withdrawn, "pleasantly confused." Worse outcomes than hyperactive. Screen all elderly admissions with CAM</li>
                    <li><strong>Anticholinergics are enemy #1:</strong> Diphenhydramine, TCAs, scopolamine, first-gen antihistamines. Avoid in elderly</li>
                    <li><strong>Restraints worsen delirium:</strong> Increase agitation, prolong delirium, cause injury. Use sitters, reorientation instead</li>
                    <li><strong>Every delirious patient needs infection workup:</strong> UTI, pneumonia, bacteremia most common. Even if afebrile</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Severe agitation refractory to medications</li>
                        <li>Respiratory compromise requiring intubation for airway protection</li>
                        <li>Hemodynamic instability</li>
                        <li>Concern for life-threatening cause (meningitis, severe sepsis)</li>
                    </ul>
                </div>
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Delirium resolved or significantly improved</li>
                        <li>Underlying cause identified and treated</li>
                        <li>Safe functional status (ambulation, ADLs)</li>
                        <li>Medication reconciliation (d/c deliriogenic meds)</li>
                        <li>Adequate support at discharge (may need rehab/SNF)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Falls, aspiration, pressure ulcers, prolonged hospitalization (â†‘LOS by 5-10 days), functional decline</p>
                    <p><strong>Long-term:</strong> Persistent cognitive impairment (30-40%), increased mortality (11% at 1 month), institutionalization, progression to dementia</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="hyperthyroid" class="condition-page">
            <div class="page-header">
                <h2>31. HYPERTHYROIDISM / THYROID STORM</h2>
                <div class="subtitle">Graves â€¢ Toxic Adenoma â€¢ Storm = Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Presentation:</span> Weight loss despite â†‘appetite, tremor, palpitations/AFib, heat intolerance, diarrhea, anxiety, proximal weakness. Graves: exophthalmos, pretibial myxedema, diffuse goiter</p>
                    <p><span class="label">Storm (Life-Threatening):</span> Fever >40Â°C (104Â°F), severe tachycardia (>140), AMS, agitation/psychosis, heart failure, vomiting/diarrhea. Burch-Wartofsky score â‰¥45 = storm. Mortality 10-20%</p>
                    <p><span class="label">Labs:</span> TSH suppressed (<0.01), Free T4 elevated (>1.8), Free T3 elevated. TSI/TRAb positive (Graves). Radioiodine uptake scan if etiology unclear</p>
                    
                    <p><span class="label">Storm Treatment (Order Matters!):</span></p>
                    <ol>
                        <li><strong>Î²-blocker FIRST:</strong> Propranolol 60-80mg PO q4-6h (or 1mg IV q10min) OR Esmolol infusion. Blocks peripheral T4â†’T3 conversion + controls symptoms</li>
                        <li><strong>Thionamide (1hr after Î²-blocker):</strong> PTU 600mg PO load then 200mg q6h OR Methimazole 20mg q6h. PTU preferred (blocks T4â†’T3 conversion)</li>
                        <li><strong>Iodine (1hr AFTER thionamide):</strong> SSKI 5 drops PO q6h OR Lugol's solution 10 drops q8h. Blocks thyroid hormone release. Must give after thionamide (prevents iodine from being used for hormone synthesis)</li>
                        <li><strong>Steroid:</strong> Hydrocortisone 100mg IV q8h (blocks T4â†’T3, treats possible adrenal insufficiency)</li>
                        <li><strong>Supportive:</strong> Cooling (acetaminophen, cooling blanket - NOT aspirin, displaces T4 from binding proteins), IVF, treat precipitant</li>
                    </ol>
                    
                    <p><span class="label">Outpatient Hyperthyroidism:</span> Methimazole 10-20mg daily (first-line) OR PTU 50mg TID (if pregnant 1st trimester, intolerant to methimazole). Propranolol 20-40mg TID for symptoms. Definitive: Radioiodine ablation or thyroidectomy after euthyroid</p>
                </div>
            </div>
            
            <div class="section">
                <div class="box warning-box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Thyroid storm (Burch-Wartofsky â‰¥45)</li>
                        <li>Hemodynamic instability or arrhythmias (AFib with RVR, VT)</li>
                        <li>Altered mental status, seizures</li>
                        <li>High-output heart failure</li>
                        <li>Hyperthermia not responding to treatment</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Heart rate controlled (<100 at rest)</li>
                        <li>Afebrile, mentating normally</li>
                        <li>Tolerating oral medications</li>
                        <li>On appropriate thionamide dose with Î²-blocker</li>
                        <li>Endocrinology follow-up arranged within 1-2 weeks</li>
                        <li>Labs improving (repeat TFTs in 4-6 weeks)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž PEARLS</div>
                <ul>
                    <li><strong>Order matters in storm:</strong> Î²-blocker first, thionamide 1hr later, iodine 1hr after that. Wrong order = worsened storm</li>
                    <li><strong>Iodine without thionamide = bad:</strong> Provides substrate for more hormone synthesis. Always give thionamide first</li>
                    <li><strong>PTU in pregnancy 1st trimester:</strong> Methimazole causes aplasia cutis. Switch to methimazole 2nd/3rd trimester</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="hypothyroid" class="condition-page">
            <div class="page-header">
                <h2>32. HYPOTHYROIDISM / MYXEDEMA COMA</h2>
                <div class="subtitle">Severe Hypothyroidism â€¢ Rare but Lethal</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Chronic Hypothyroidism:</span> Fatigue, weight gain, cold intolerance, constipation, hair loss, dry skin, bradycardia, delayed DTRs, periorbital edema. Labs: TSH elevated (>10), Free T4 low (<0.8)</p>
                    <p><span class="label">Treatment Outpatient:</span> Levothyroxine 1.6 mcg/kg/day PO (typical 75-125 mcg daily). Start 25-50 mcg if elderly/>65yo or CAD (risk MI from increased demand). Recheck TSH 6-8 weeks, titrate to normal TSH</p>
                    
                    <p><span class="label">Myxedema Coma (Emergency, Mortality 30-60%):</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Profound hypothermia (<95Â°F), severe bradycardia (<50), hypoventilation (â†“CO2 drive, respiratory failure), hyponatremia, hypoglycemia, AMSâ†’coma, non-pitting edema, pericardial/pleural effusions</li>
                        <li><strong>Precipitants:</strong> Infection, MI, stroke, hypothermia, sedatives/narcotics, surgery</li>
                        <li><strong>Diagnosis:</strong> Clinical + TSH elevated (>20), Free T4 very low. Don't wait for labs - treat empirically if high suspicion</li>
                    </ul>
                    
                    <p><span class="label">Myxedema Coma Treatment:</span></p>
                    <ul>
                        <li><strong>T4 (levothyroxine) 200-400 mcg IV load</strong> then 100 mcg IV daily. Larger, slower onset but safer</li>
                        <li><strong>PLUS T3 (liothyronine) 10 mcg IV q8h:</strong> Faster onset (hours vs days). Use both T4+T3</li>
                        <li><strong>Hydrocortisone 100mg IV q8h:</strong> Rule out adrenal insufficiency (can coexist). Give steroids BEFORE thyroid hormone (thyroid hormone can precipitate crisis if AI present)</li>
                        <li><strong>Supportive:</strong> Passive rewarming (NOT active - can cause vascular collapse), mechanical ventilation if respiratory failure, hypertonic saline if severe hyponatremia (usually improves with treatment), treat precipitant (infection)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="box warning-box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Myxedema coma or impending coma</li>
                        <li>Hypothermia (<95Â°F/35Â°C)</li>
                        <li>Respiratory failure or hypoventilation</li>
                        <li>Hemodynamic instability, severe bradycardia (<40)</li>
                        <li>Severe hyponatremia (<120 mEq/L)</li>
                        <li>Altered mental status</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Mentating normally, afebrile</li>
                        <li>Hemodynamically stable, HR >50</li>
                        <li>Tolerating oral levothyroxine</li>
                        <li>Sodium >130 mEq/L and stable</li>
                        <li>Precipitating cause treated</li>
                        <li>Endocrinology follow-up arranged</li>
                        <li>TSH recheck scheduled in 6-8 weeks</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž PEARLS</div>
                <ul>
                    <li><strong>Steroid BEFORE thyroid hormone in crisis:</strong> Prevents adrenal crisis from increased cortisol metabolism</li>
                    <li><strong>Passive rewarming only:</strong> Active rewarming (warm blankets, heating) causes peripheral vasodilation â†’ cardiovascular collapse</li>
                    <li><strong>Hyponatremia improves with treatment:</strong> Due to SIADH from hypothyroidism. Don't over correct</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="adrenal" class="condition-page">
            <div class="page-header">
                <h2>33. ADRENAL INSUFFICIENCY / CRISIS</h2>
                <div class="subtitle">Primary (Addison's) â€¢ Secondary â€¢ Crisis = Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Chronic AI Presentation:</span> Fatigue, weight loss, hypotension, hyponatremia, hypoglycemia. PRIMARY (Addison's) ALSO has: hyperkalemia, hyperpigmentation (â†‘ACTH stimulates melanocytes), salt craving. SECONDARY: no hyperK/hyperpigmentation</p>
                    
                    <p><span class="label">Adrenal Crisis (Emergency):</span> Shock (refractory hypotension), abdominal pain/vomiting (mimics acute abdomen), fever, severe dehydration, AMS/confusion. Precipitants: Infection, surgery, trauma, stopping steroids abruptly</p>
                    
                    <p><span class="label">Diagnosis:</span></p>
                    <ul>
                        <li><strong>Random cortisol:</strong> <3 mcg/dL = AI, >18 = excludes, 3-18 = indeterminate (do stim test)</li>
                        <li><strong>Cosyntropin stimulation test:</strong> Give cosyntropin 250 mcg IV, check cortisol at 30 and 60 min. Normal: cortisol >18-20. Abnormal: <18 = AI</li>
                        <li><strong>DON'T WAIT for test in crisis - treat empirically!</strong> Can do test later</li>
                        <li><strong>Distinguish primary vs secondary:</strong> ACTH level. Primary: ACTH >100 (pituitary trying to stimulate failed adrenals). Secondary: ACTH <10 (pituitary failure)</li>
                    </ul>
                    
                    <p><span class="label">Crisis Treatment (DON'T DELAY):</span></p>
                    <ul>
                        <li><strong>Hydrocortisone 100mg IV bolus immediately,</strong> then 50-100mg IV q6-8h (or 200mg/24hr continuous infusion)</li>
                        <li><strong>Aggressive IVF:</strong> NS 1-2L rapidly, then 200-300 mL/hr. Patients profoundly volume depleted</li>
                        <li><strong>Dextrose if hypoglycemic:</strong> D50 1-2 amps IV</li>
                        <li><strong>Treat precipitant:</strong> Antibiotics if infection, stress-dose steroids perioperatively</li>
                        <li><strong>NO fludrocortisone initially:</strong> High-dose hydrocortisone has mineralocorticoid activity. Add fludrocortisone once stable on oral therapy</li>
                    </ul>
                    
                    <p><span class="label">Chronic Replacement (After Crisis):</span></p>
                    <ul>
                        <li><strong>Hydrocortisone 15-25mg/day divided BID-TID</strong> (give 2/3 AM, 1/3 afternoon - mimic diurnal rhythm)</li>
                        <li><strong>Fludrocortisone 0.1mg PO daily if PRIMARY</strong> (mineralocorticoid replacement). Not needed if secondary</li>
                        <li><strong>Stress dosing:</strong> Double-triple dose for illness, surgery. Fever/infection: double dose. Major surgery: hydrocortisone 100mg IV q8h Ã— 24-48hr</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="box warning-box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Adrenal crisis with refractory hypotension</li>
                        <li>Shock requiring vasopressors</li>
                        <li>Severe altered mental status</li>
                        <li>Severe electrolyte abnormalities (K >6.5, Na <120)</li>
                        <li>Hypoglycemia not responding to dextrose</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable off pressors</li>
                        <li>Tolerating oral hydrocortisone Â± fludrocortisone</li>
                        <li>Electrolytes normalized (Na >130, K <5.5)</li>
                        <li>Precipitating cause treated</li>
                        <li>Patient educated on stress dosing and MedicAlert bracelet</li>
                        <li>Endocrinology follow-up arranged</li>
                        <li>Emergency injection kit prescribed if indicated</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž PEARLS</div>
                <ul>
                    <li><strong>Don't wait to treat crisis:</strong> If suspected, give hydrocortisone 100mg IV immediately. Can do cosyntropin test after (use dexamethasone 4mg if need test, doesn't interfere)</li>
                    <li><strong>Hyperkalemia + hyponatremia = PRIMARY:</strong> Aldosterone deficiency. Secondary AI has normal K (aldosterone intact)</li>
                    <li><strong>Hyperpigmentation = PRIMARY:</strong> â†‘ACTH stimulates melanocytes. Look: knuckles, palmar creases, scars, mucous membranes</li>
                    <li><strong>Most common cause chronic AI:</strong> Iatrogenic (stopping steroids abruptly after chronic use). Need slow taper</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="hypercalcemia" class="condition-page">
            <div class="page-header">
                <h2>34. HYPERCALCEMIA</h2>
                <div class="subtitle">"Stones, Bones, Groans, Psychiatric Overtones"</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Symptoms:</span> Mild (Ca 10.5-12): Often asymptomatic. Moderate-Severe (Ca >12): Polyuria/polydipsia (nephrogenic DI), constipation, nausea/vomiting, weakness, confusion, lethargy, shortened QT interval. Very severe (>14): AMS, coma, arrhythmias</p>
                    
                    <p><span class="label">Causes (90% are these 2):</span></p>
                    <ul>
                        <li><strong>Primary hyperparathyroidism:</strong> Outpatient, mild-moderate (Ca 10.5-11.5). PTH elevated or "inappropriately normal" with high Ca. Adenoma usually. Treatment: Parathyroidectomy if symptomatic</li>
                        <li><strong>Malignancy:</strong> Inpatient, moderate-severe (Ca >12). PTH suppressed (<20). Mechanisms: PTHrP (squamous cell, renal, breast), osteolytic mets (multiple myeloma, breast), calcitriol production (lymphoma). Treatment: Treat cancer, aggressive hydration, bisphosphonates</li>
                        <li><strong>Other:</strong> Granulomatous disease (sarcoid, TB - â†‘calcitriol), meds (thiazides, lithium, vitamin D intoxication), immobilization</li>
                    </ul>
                    
                    <p><span class="label">Treatment (Severe Hypercalcemia Ca >12-14):</span></p>
                    <ol>
                        <li><strong>IV Fluids:</strong> NS 200-300 mL/hr (goal UOP 100-150 mL/hr). Rehydrate (hypercalcemia causes dehydration from nephrogenic DI). Works in hours, lowers Ca 1-3 mg/dL. FIRST-LINE</li>
                        <li><strong>Calcitonin 4 units/kg subQ or IM q12h:</strong> Rapid onset (4-6hr), modest effect (â†“Ca 1-2 mg/dL). Tachyphylaxis in 48-72hr. Use as bridge while waiting for bisphosphonate</li>
                        <li><strong>Bisphosphonates (MOST effective):</strong> Pamidronate 60-90mg IV over 2-4hr OR Zoledronic acid 4mg IV over 15min. Onset 2-4 days, peak 5-7 days, lasts weeks. Lowers Ca 2-3 mg/dL. Dose-adjust if CrCl <30</li>
                        <li><strong>Dialysis:</strong> If refractory, severe renal failure, or Ca >18. Rapidly effective</li>
                        <li><strong>Avoid thiazides, lithium, vitamin D/calcium supplements</strong></li>
                    </ol>
                    
                    <p><span class="label">Special Cases:</span></p>
                    <ul>
                        <li><strong>Granulomatous (sarcoid):</strong> Prednisone 20-40mg daily (â†“calcitriol production)</li>
                        <li><strong>Lymphoma:</strong> Treat malignancy, steroids help</li>
                        <li><strong>Vitamin D intoxication:</strong> Stop vitamin D, steroids, fluids, bisphosphonates</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="box warning-box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe hypercalcemia (Ca >14 mg/dL)</li>
                        <li>Altered mental status, obtundation, coma</li>
                        <li>Cardiac arrhythmias (short QT, bradycardia, heart block)</li>
                        <li>Hemodynamic instability</li>
                        <li>Refractory to IV fluids and bisphosphonates</li>
                        <li>Need for emergent dialysis</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Calcium <12 mg/dL and downtrending</li>
                        <li>Mentally at baseline, tolerating PO</li>
                        <li>Hemodynamically stable, euvolemic</li>
                        <li>Underlying cause addressed (malignancy workup initiated if indicated)</li>
                        <li>Offending medications stopped</li>
                        <li>Appropriate follow-up (oncology, endocrinology) arranged</li>
                        <li>Recheck calcium in 1-2 weeks scheduled</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž PEARLS</div>
                <ul>
                    <li><strong>PTH tells you the cause:</strong> PTH elevated/normal = hyperparathyroidism. PTH suppressed = malignancy or other</li>
                    <li><strong>Outpatient vs inpatient:</strong> Outpatient mild hypercalcemia = hyperparathyroidism. Inpatient severe = malignancy</li>
                    <li><strong>Calcitonin is bridge:</strong> Works fast (hours) but tachyphylaxis (stops working after 2-3 days). Use while waiting for bisphosphonate to kick in</li>
                    <li><strong>Bisphosphonates most effective:</strong> But slow (2-4 days). Lasts weeks. Don't give if AKI (wait for rehydration)</li>
                    <li><strong>Furosemide does NOT help:</strong> Old teaching. Causes dehydration, worsens. Only if volume overload</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="hypomag" class="condition-page">
            <div class="page-header">
                <h2>35. HYPOMAGNESEMIA</h2>
                <div class="subtitle">Mg <1.5 â€¢ Often With HypoK/HypoCa</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Causes:</span> GI losses (diarrhea, malabsorption), renal losses (diuretics - loops/thiazides, PPIs, aminoglycosides, cisplatin, amphotericin), alcohol, DKA, refeeding syndrome, chronic PPI use</p>
                    <p><span class="label">Symptoms:</span> Often asymptomatic until Mg <1. Tremor, muscle fasciculations, weakness, tetany (Trousseau/Chvostek signs), seizures, arrhythmias (torsades de pointes, afib, PVCs), personality changes. Refractory hypokalemia/hypocalcemia (Mg needed for K/Ca homeostasis)</p>
                    <p><span class="label">ECG:</span> Prolonged QT, widened QRS, peaked T waves, torsades de pointes</p>
                    
                    <p><span class="label">Treatment:</span></p>
                    <ul>
                        <li><strong>Asymptomatic/Mild (Mg >1):</strong> Magnesium oxide 400-800mg PO BID-TID (poorly absorbed, causes diarrhea). OR Mag glycinate/citrate better tolerated</li>
                        <li><strong>Moderate (Mg <1) or Symptomatic:</strong> Magnesium sulfate 2g IV over 15-30min, repeat q6h until Mg >1.5. Then transition to PO</li>
                        <li><strong>Severe/Life-Threatening (Torsades, seizure, tetany):</strong> Magnesium sulfate 2-4g IV over 10-15min, then continuous infusion 1-2g/hr. Monitor DTRs (loss = hypermagnesemia). Cardiac monitor</li>
                        <li><strong>Replete K and Ca simultaneously:</strong> Won't normalize until Mg corrected. Check all three, replete together</li>
                        <li><strong>Monitor serum Mg q6-12h</strong> during repletion. Goal >1.5-2 mg/dL</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="box warning-box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Torsades de pointes or other malignant arrhythmias</li>
                        <li>Seizures</li>
                        <li>Severe tetany or respiratory muscle weakness</li>
                        <li>Mg <1.0 mg/dL with symptoms</li>
                        <li>Refractory arrhythmias despite repletion</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Mg >1.5 mg/dL and stable</li>
                        <li>Potassium and calcium normalized</li>
                        <li>No arrhythmias on telemetry</li>
                        <li>Tolerating oral magnesium supplementation</li>
                        <li>Underlying cause addressed (medication adjusted, PPI stopped)</li>
                        <li>Recheck labs in 1 week arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž PEARLS</div>
                <ul>
                    <li><strong>Refractory hypokalemia = check Mg:</strong> Can't fix K until Mg replete. Mg needed for K channel function</li>
                    <li><strong>Hypocalcemia with Mg deficiency:</strong> Mg needed for PTH secretion/action. Replete Mg first, Ca will follow</li>
                    <li><strong>Torsades de pointes:</strong> 2g Mg IV over 1-2min (even if Mg normal). First-line treatment</li>
                    <li><strong>Monitor DTRs:</strong> Loss of reflexes = hypermagnesemia (>4-5). Stop infusion if DTRs lost</li>
                    <li><strong>PPI-induced hypomagnesemia:</strong> Chronic PPI use (months-years) â†’ severe hypomagnesemia. Stop PPI, switch to H2 blocker</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="rhabdo" class="condition-page">
            <div class="page-header">
                <h2>36. RHABDOMYOLYSIS</h2>
                <div class="subtitle">CK >1000 â€¢ Myoglobinuria â€¢ AKI Risk</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Causes - "CRAMPS":</span> Crush injury/trauma, Recreational drugs (cocaine, PCP, MDMA, amphetamines), Alcohol/Anesthetics (malignant hyperthermia, NMS), Meds (statins, fibrates, colchicine), Prolonged immobilization/seizures, Strenuous exercise, Heat stroke, Infections (influenza, HIV)</p>
                    <p><span class="label">Classic Triad (only 10% have all 3):</span> Myalgias, weakness, dark urine (tea/cola-colored from myoglobinuria)</p>
                    <p><span class="label">Presentation:</strong> Muscle pain/tenderness/swelling, weakness, dark urine. May have compartment syndrome (tense compartments, pain out of proportion, 5 P's). Severe: <a href="#aki" style="color: #0366d6;">AKI</a>, <a href="#hyperkalemia" style="color: #0366d6;">hyperkalemia</a>, arrhythmias</p>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CK (creatine kinase):</strong> >1000 (often >5000, can be >100,000). Peak 24-36hr, normalize in 3-5 days. Trend daily</li>
                        <li><strong>Urine:</strong> Dipstick positive for blood (myoglobin cross-reacts) but NO RBCs on microscopy. Urine myoglobin (rarely sent, not needed)</li>
                        <li><strong>BMP:</strong> <a href="#aki" style="color: #0366d6;">AKI</a> (Cr rising), <a href="#hyperkalemia" style="color: #0366d6;">hyperkalemia</a> (released from muscle - LIFE-THREATENING), hypocalcemia early (Ca deposits in necrotic muscle), hypercalcemia late (resorption), hyperphosphatemia (released from muscle), elevated anion gap (lactate)</li>
                        <li><strong>ABG:</strong> Metabolic acidosis</li>
                        <li><strong>Check:</strong> LDH, AST/ALT (elevated from muscle, not liver), uric acid (elevated)</li>
                    </ul>
                    
                    <p><span class="label">Treatment (Aggressive IVF is Key):</span></p>
                    <ul>
                        <li><strong>IV Fluids:</strong> NS 200-300 mL/hr (or 1-1.5 L/hr if severe). Goal: UOP >200-300 mL/hr (flush myoglobin before it precipitates in tubules). Continue until CK downtrending <5000 AND Cr improving</li>
                        <li><strong>Monitor:</strong> Strict I/Os, UOP hourly, daily CK/BMP/Ca/Phos, cardiac telemetry (hyperK risk)</li>
                        <li><strong>Alkalinize urine (controversial, not routinely recommended):</strong> Some add NaHCO3 to IVF (3 amps in 1L D5W at 200 mL/hr) to maintain urine pH >6.5 (prevents myoglobin precipitation). But no proven benefit, risks volume overload/alkalosis</li>
                        <li><strong>Avoid:</strong> NSAIDs, nephrotoxins</li>
                        <li><strong>Hyperkalemia:</strong> Treat aggressively (insulin/dextrose, calcium, kayexalate, dialysis if severe)</li>
                        <li><strong>Hypocalcemia (early):</strong> DO NOT treat unless symptomatic (seizures, tetany, long QT). Repleting Ca can worsen later hypercalcemia</li>
                        <li><strong>Dialysis if:</strong> Severe AKI (oliguric, Cr >5-6), refractory hyperkalemia, severe acidosis, volume overload</li>
                        <li><strong>Compartment syndrome:</strong> Ortho/surgery consult URGENTLY. Fasciotomy if pressures >30 mmHg</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="box warning-box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>CK >100,000 or rapidly rising</li>
                        <li>Severe hyperkalemia (K >6.5) or cardiac arrhythmias</li>
                        <li>AKI with oliguria (<0.5 mL/kg/hr) or need for RRT</li>
                        <li>Compartment syndrome (surgical emergency)</li>
                        <li>Severe metabolic acidosis (pH <7.2)</li>
                        <li>Volume overload from aggressive resuscitation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>CK downtrending <5000 U/L</li>
                        <li>Creatinine stable or improving</li>
                        <li>Potassium normalized</li>
                        <li>Good urine output maintained</li>
                        <li>Underlying cause addressed (medication stopped, dehydration corrected)</li>
                        <li>No compartment syndrome concerns</li>
                        <li>Recheck CK/BMP in 2-3 days arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž PEARLS</div>
                <ul>
                    <li><strong>IVF, IVF, IVF:</strong> Aggressive volume expansion is treatment. Prevents AKI by flushing myoglobin. Goal UOP >200 mL/hr</li>
                    <li><strong>Hyperkalemia kills:</strong> Released from necrotic muscle. Check K q6-12h initially. Cardiac monitor. Treat aggressively</li>
                    <li><strong>Don't treat early hypocalcemia:</strong> Ca deposits in muscle. Later, gets resorbed â†’ hypercalcemia. Treating early worsens late</li>
                    <li><strong>Dipstick + but no RBCs = myoglobinuria:</strong> Myoglobin cross-reacts with hemoglobin on dipstick. Microscopy negative for RBCs</li>
                    <li><strong>Statin-induced rhabdo:</strong> Risk factors: Asian, elderly, CKD, drug interactions (gemfibrozil, azoles, macrolides). Check CK before starting if high risk</li>
                    <li><strong>Compartment syndrome:</strong> Tense compartment, pain out of proportion, pain with passive stretch. Pressures >30 mmHg. SURGICAL EMERGENCY - fasciotomy</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="transfusion" class="condition-page">
            <div class="page-header">
                <h2>37. TRANSFUSION REACTIONS</h2>
                <div class="subtitle">Acute Hemolytic â€¢ TRALI â€¢ TACO â€¢ Febrile</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Acute Hemolytic (ABO Incompatibility) - WORST:</span></p>
                    <ul>
                        <li><strong>Timing:</strong> Within minutes of transfusion</li>
                        <li><strong>Symptoms:</strong> Fever, chills, back/chest/flank pain, dyspnea, hypotension, hemoglobinuria (red/dark urine), DIC, AKI. IF INTUBATED: unexplained fever, hypotension, hemoglobinuria, oozing from surgical sites</li>
                        <li><strong>Cause:</strong> Clerical error (wrong blood to wrong patient). ABO antibodies lyse donor RBCs</li>
                        <li><strong>Treatment:</strong> STOP transfusion immediately! Maintain UOP >100 mL/hr (IVF, diuretics, alkalinize urine). Pressors if shock. Check: Coombs (DAT), LDH, haptoglobin, bilirubin, coags (DIC screen). Send blood bag + patient blood back to blood bank</li>
                    </ul>
                    
                    <p><span class="label">Febrile Non-Hemolytic (FNHTR) - Most Common:</span></p>
                    <ul>
                        <li><strong>Timing:</strong> During or within 4hr of transfusion</li>
                        <li><strong>Symptoms:</strong> Fever (>1Â°C rise or >38Â°C), chills, rigors. No hemolysis</li>
                        <li><strong>Cause:</strong> Recipient antibodies against donor WBCs/platelets, or cytokines released from donor WBCs</li>
                        <li><strong>Treatment:</strong> STOP transfusion. Check hemolysis labs (rule out hemolytic). If negative, give acetaminophen, can cautiously resume transfusion slowly. Prevent: Leukoreduced blood for future transfusions, pre-med with acetaminophen</li>
                    </ul>
                    
                    <p><span class="label">TRALI (Transfusion-Related Acute Lung Injury):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> Within 6hr of transfusion</li>
                        <li><strong>Symptoms:</strong> Acute hypoxemia, dyspnea, bilateral infiltrates on CXR (looks like ARDS), fever, hypotension. Normal CVP/PCWP (vs TACO)</li>
                        <li><strong>Cause:</strong> Donor antibodies against recipient WBCs â†’ capillary leak, non-cardiogenic pulmonary edema</li>
                        <li><strong>Treatment:</strong> Supportive - O2, may need intubation/mechanical ventilation. Diuretics NOT helpful (not volume overload). Usually resolves 48-96hr</li>
                    </ul>
                    
                    <p><span class="label">TACO (Transfusion-Associated Circulatory Overload):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> During or within 6hr</li>
                        <li><strong>Symptoms:</strong> Dyspnea, tachycardia, hypertension, JVD, pulmonary edema, bilateral crackles. Elevated BNP/NT-proBNP</li>
                        <li><strong>Cause:</strong> Volume overload (especially in CHF, renal failure, elderly)</li>
                        <li><strong>Treatment:</strong> Slow/stop transfusion. Diuretics (furosemide 20-40mg IV). O2, upright position. Prevent: Slow transfusion rate (<1 unit per 2-4hr), furosemide between units if high risk</li>
                    </ul>
                    
                    <p><span class="label">Allergic:</span></p>
                    <ul>
                        <li><strong>Mild (urticaria):</strong> Stop transfusion, antihistamine (diphenhydramine 25-50mg). Can resume if improves. Pre-med with antihistamine for future</li>
                        <li><strong>Severe (anaphylaxis):</strong> Angioedema, bronchospasm, hypotension. STOP transfusion. Epinephrine 0.3-0.5mg IM, antihistamines, steroids, IVF, pressors. Washed RBCs for future (removes plasma proteins)</li>
                    </ul>
                    
                    <p><span class="label">Delayed Hemolytic (Days to Weeks):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> 3-10 days post-transfusion</li>
                        <li><strong>Symptoms:</strong> Unexplained fever, jaundice, falling Hgb, dark urine. Less severe than acute hemolytic</li>
                        <li><strong>Cause:</strong> Anamnestic antibody response (patient previously sensitized, antibody level low â†’ transfusion boosts antibody production)</li>
                        <li><strong>Labs:</strong> Positive DAT, elevated bilirubin, LDH, low haptoglobin</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="box warning-box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Acute hemolytic reaction with shock or DIC</li>
                        <li>TRALI with respiratory failure requiring intubation</li>
                        <li>Anaphylaxis not responding to epinephrine</li>
                        <li>TACO with severe respiratory distress not responding to diuretics</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Reaction resolved, hemodynamically stable</li>
                        <li>No evidence of ongoing hemolysis (labs stable)</li>
                        <li>Respiratory status at baseline</li>
                        <li>Blood bank notified and documentation complete</li>
                        <li>Future transfusion recommendations documented (leukoreduced, premedication, washed cells if indicated)</li>
                        <li>Original indication for transfusion addressed</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž PEARLS</div>
                <ul>
                    <li><strong>STOP transfusion first:</strong> For ANY reaction (except very mild urticaria). Check vitals, send hemolysis labs, notify blood bank</li>
                    <li><strong>Acute hemolytic is clerical error:</strong> Wrong blood to wrong patient. Double-check patient ID before transfusion. Devastating complication</li>
                    <li><strong>TRALI vs TACO:</strong> Both have pulmonary edema within 6hr. TRALI = hypotension, normal CVP. TACO = hypertension, JVD, elevated BNP. TRALI = supportive, TACO = diuretics</li>
                    <li><strong>Febrile reaction most common:</strong> Benign. Rule out hemolysis (check labs), then acetaminophen, resume transfusion. Prevent with leukoreduced blood</li>
                    <li><strong>Pre-med selectively:</strong> Acetaminophen if prior febrile reactions. Diphenhydramine if prior allergic. NOT routinely for everyone</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="pleural-effusion" class="condition-page">
            <div class="page-header">
                <h2>38. PLEURAL EFFUSION</h2>
                <div class="subtitle">Transudate vs Exudate â€¢ Light's Criteria</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Presentation:</span> Dyspnea, pleuritic chest pain, cough. Exam: Decreased breath sounds, dullness to percussion, decreased tactile fremitus</p>
                    <p><span class="label">CXR:</span> Blunted costophrenic angle (requires ~200 mL). Lateral decubitus view (layering confirms free-flowing fluid). If loculated, doesn't layer</p>
                    <p><span class="label">Ultrasound:</span> More sensitive than CXR (detects 50 mL). Guides thoracentesis</p>
                    
                    <p><span class="label">Light's Criteria (Exudate if â‰¥1 of 3):</span></p>
                    <ul>
                        <li>Pleural fluid protein / Serum protein >0.5</li>
                        <li>Pleural fluid LDH / Serum LDH >0.6</li>
                        <li>Pleural fluid LDH >2/3 upper limit of normal serum LDH</li>
                    </ul>
                    <p><strong>Sensitivity 98%, Specificity 80%.</strong> Misclassifies ~20% transudates as exudates (especially if on diuretics). If clinically transudate but meets Light's, calculate serum-albumin gradient: Serum albumin - Pleural albumin >1.2 = transudate</p>
                    
                    <p><span class="label">Transudate (â†“Capillary Hydrostatic Pressure or â†“Oncotic Pressure):</span></p>
                    <ul>
                        <li><strong>CHF (most common):</strong> Bilateral, symmetric. Treat CHF (diuretics). Thoracentesis only if asymmetric, fever, or not responding to diuresis</li>
                        <li><strong>Cirrhosis/Hepatic hydrothorax:</strong> Usually right-sided. Treat ascites (diuretics, TIPS if refractory)</li>
                        <li><strong>Nephrotic syndrome:</strong> Hypoalbuminemia (<2.5), proteinuria >3.5 g/day</li>
                        <li><strong>PE:</strong> Can be transudate OR exudate. If high suspicion, get CTPA</li>
                    </ul>
                    
                    <p><span class="label">Exudate (Inflammation, Infection, Malignancy):</span></p>
                    <ul>
                        <li><strong>Pneumonia/Parapneumonic:</strong> Most common exudate. Thoracentesis if fluid >10mm on lateral decubitus or loculated. Simple parapneumonic: pH >7.2, glucose >60, LDH <1000, negative Gram/culture â†’ antibiotics alone. Complicated: pH <7.2, glucose <60, LDH >1000, or positive Gram/culture â†’ chest tube drainage</li>
                        <li><strong>Empyema:</strong> Pus in pleural space. Frank pus, positive Gram stain/culture, pH <7.2, glucose <40. Needs chest tube + antibiotics +/- VATS/surgery</li>
                        <li><strong>Malignancy:</strong> Lung cancer, breast, lymphoma, ovarian. Often bloody, exudative. Cytology positive in 60%. Thoracentesis for diagnosis + symptom relief. Pleurodesis if recurrent</li>
                        <li><strong>TB:</strong> Lymphocytic predominance (>50%), elevated ADA (>40 U/L), positive AFB culture (50-80% if also send pleural biopsy). Pleural biopsy for culture + histology (granulomas)</li>
                        <li><strong>PE:</strong> 1/3 transudates, 2/3 exudates. Often bloody. If suspected, get CTPA</li>
                        <li><strong>Pancreatitis:</strong> Left-sided, elevated pleural fluid amylase (>serum)</li>
                    </ul>
                    
                    <p><span class="label">Send Pleural Fluid for:</span></p>
                    <ul>
                        <li><strong>Always:</strong> pH, protein, LDH, cell count/diff, Gram stain, culture (aerobic/anaerobic)</li>
                        <li><strong>If concern for malignancy:</strong> Cytology (3 samples â†‘yield)</li>
                        <li><strong>If suspect TB:</strong> AFB smear/culture, ADA, pleural biopsy</li>
                        <li><strong>If bloody:</strong> Hematocrit (Hct >50% of serum Hct = hemothorax)</li>
                        <li><strong>If concern for pancreatitis, esophageal rupture:</strong> Amylase</li>
                        <li><strong>If milky appearance:</strong> Triglycerides (>110 = chylothorax)</li>
                    </ul>
                    
                    <p><span class="label">Treatment:</span></p>
                    <ul>
                        <li><strong>Treat underlying cause</strong></li>
                        <li><strong>Therapeutic thoracentesis:</strong> If symptomatic (dyspnea). Remove 1-1.5L max at a time (risk re-expansion pulmonary edema if >1.5L). Repeatthorax as needed</li>
                        <li><strong>Chest tube:</strong> If empyema, complicated parapneumonic, hemothorax</li>
                        <li><strong>Pleurodesis:</strong> If recurrent malignant effusion (talc, doxycycline, bleomycin). Prevents reaccumulation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="box warning-box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Empyema with sepsis/septic shock</li>
                        <li>Massive effusion with respiratory failure</li>
                        <li>Re-expansion pulmonary edema after thoracentesis</li>
                        <li>Hemodynamic instability</li>
                        <li>Hemothorax requiring surgical intervention</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Dyspnea improved, stable oxygen requirements</li>
                        <li>Underlying cause addressed (CHF optimized, infection treated)</li>
                        <li>If chest tube placed, removed with no reaccumulation on CXR</li>
                        <li>No signs of complicated parapneumonic/empyema</li>
                        <li>Follow-up imaging and appointments arranged</li>
                        <li>Outpatient thoracentesis arranged if needed for symptomatic malignant effusion</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž PEARLS</div>
                <ul>
                    <li><strong>Light's Criteria rules in exudate:</strong> Sens 98%, but 20% false positives (transudate called exudate). Use serum-albumin gradient if doesn't fit clinically</li>
                    <li><strong>CHF effusions are bilateral/symmetric:</strong> If unilateral or asymmetric, tap it (could be empyema, malignancy, PE)</li>
                    <li><strong>pH <7.2 or glucose <60 = drain it:</strong> Complicated parapneumonic/empyema. Won't resolve with antibiotics alone. Needs chest tube</li>
                    <li><strong>TB effusion is lymphocytic:</strong> >50% lymphs. ADA >40 suggestive. Pleural biopsy â†‘yield (culture + granulomas)</li>
                    <li><strong>Don't remove >1.5L at once:</strong> Risk re-expansion pulmonary edema (chest pain, cough, hypoxia after thoracentesis). Stop if patient develops symptoms or pressure drops >20 cm H2O</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="pneumothorax" class="condition-page">
            <div class="page-header">
                <h2>39. PNEUMOTHORAX</h2>
                <div class="subtitle">Primary â€¢ Secondary â€¢ Iatrogenic â€¢ TENSION = Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Types:</span></p>
                    <ul>
                        <li><strong>Primary Spontaneous (PSP):</strong> Tall, thin, young men (15-35yo). Smokers. Rupture apical bleb/bullae. No underlying lung disease</li>
                        <li><strong>Secondary Spontaneous (SSP):</strong> Underlying lung disease - COPD (most common), CF, PCP pneumonia, necrotizing pneumonia, TB, Marfan's</li>
                        <li><strong>Iatrogenic:</strong> Central line placement (subclavian>IJ), thoracentesis, transbronchial biopsy, mechanical ventilation (barotrauma), CPR</li>
                        <li><strong>Traumatic:</strong> Blunt/penetrating chest trauma, rib fractures</li>
                    </ul>
                    
                    <p><span class="label">Presentation:</span> Acute-onset pleuritic chest pain, dyspnea. Exam: Decreased breath sounds, hyperresonance to percussion, decreased tactile fremitus on affected side. Tracheal deviation toward affected side (simple PTX) or AWAY (tension PTX)</p>
                    
                    <p><span class="label">TENSION PNEUMOTHORAX - EMERGENCY:</span></p>
                    <ul>
                        <li><strong>Pathophys:</strong> One-way valve â†’ air enters pleural space but can't escape â†’ â†‘pressure collapses lung, shifts mediastinum, compresses contralateral lung + great vessels â†’ â†“venous return â†’ shock</li>
                        <li><strong>Presentation:</strong> Severe respiratory distress, hypotension, tachycardia, JVD, tracheal deviation AWAY from affected side, absent breath sounds, hyperresonance, cyanosis</li>
                        <li><strong>CLINICAL DIAGNOSIS - DON'T WAIT FOR CXR!</strong></li>
                        <li><strong>Treatment:</strong> Immediate needle decompression: 14-16 gauge angiocath, 2nd intercostal space, midclavicular line (or 4th-5th ICS anterior axillary line). Insert needle over rib (avoid neurovascular bundle under rib). Rush of air = confirms diagnosis. THEN get CXR and place chest tube</li>
                    </ul>
                    
                    <p><span class="label">CXR Findings:</span> Visceral pleural line (edge of collapsed lung), absent lung markings peripherally. Upright film more sensitive. Deep sulcus sign on supine (air collects anteriorly). Quantify size: Measure distance from chest wall to lung edge at hilum level. Small <2cm, Large >2cm</p>
                    
                    <p><span class="label">Treatment Algorithm (Non-Tension):</span></p>
                    <ul>
                        <li><strong>Small (<2cm or <20%), stable, minimal symptoms:</strong>
                            <ul>
                                <li>Observation + supplemental O2 (hastens resorption - 4Ã— faster with O2)</li>
                                <li>Repeat CXR in 6hr. If stable/improving, discharge with outpatient follow-up CXR 1-2 weeks</li>
                                <li>PSP: Resorbs ~1-2% per day (10-14 days). SSP: Higher risk progression, lower threshold to place tube</li>
                                <li>Instruct: Return if increased dyspnea, chest pain. No flying until resolved (pressure changes expand PTX)</li>
                            </ul>
                        </li>
                        <li><strong>Large (>2cm or >20%) OR symptomatic:</strong>
                            <ul>
                                <li><strong>Aspiration (PSP, first episode, age <50, stable):</strong> 16-18 gauge IV catheter, 2nd ICS midclavicular line or 4th-5th ICS midaxillary line. Aspirate with 60 mL syringe + 3-way stopcock. Max 2.5L (if not successful, place chest tube). If successful (PTX <2cm, symptoms improved), observe 4hr, repeat CXR. Discharge if stable. Success ~60-80% PSP</li>
                                <li><strong>Chest tube (SSP, large PSP failing aspiration, recurrent, bilateral, hemodynamic instability):</strong> 16-28Fr pigtail (small) or 28-32Fr tube (large). 4th-5th ICS, anterior axillary line, directed posteroapically. Connect to water seal +/- suction (-20 cm H2O). Keep tube until no air leak Ã— 24hr + lung re-expanded on CXR</li>
                            </ul>
                        </li>
                        <li><strong>Recurrent PTX (20-50% recur within 2 years):</strong> Video-assisted thoracoscopic surgery (VATS) with bleb resection + pleurodesis. Reduces recurrence to <5%. Consider after 1st SSP or 2nd PSP</li>
                    </ul>
                    
                    <p><span class="label">Special Situations:</span></p>
                    <ul>
                        <li><strong>Mechanical ventilation:</strong> If PTX develops, place chest tube immediately (positive pressure worsens). Don't wait/observe</li>
                        <li><strong>Bilateral PTX:</strong> Higher risk respiratory compromise. Usually place bilateral tubes</li>
                        <li><strong>Persistent air leak (tube in, still bubbling >7 days):</strong> Bronchopleural fistula. Consult thoracic surgery</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="box warning-box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Tension pneumothorax</li>
                        <li>Bilateral pneumothorax</li>
                        <li>Respiratory failure requiring intubation</li>
                        <li>Hemodynamic instability</li>
                        <li>Hemopneumothorax</li>
                        <li>SSP with severe underlying lung disease</li>
                        <li>Persistent large air leak</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Lung fully re-expanded on CXR</li>
                        <li>Chest tube removed (if placed) with no reaccumulation at 4-6 hours</li>
                        <li>Stable oxygen requirements, minimal dyspnea</li>
                        <li>No air leak Ã— 24 hours (if tube was in place)</li>
                        <li>Patient educated on return precautions</li>
                        <li>No flying for 1-2 weeks post-resolution</li>
                        <li>Follow-up CXR in 1-2 weeks arranged</li>
                        <li>Smoking cessation counseling provided</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
                <ul>
                    <li><strong>Tension PTX is clinical diagnosis:</strong> Don't wait for CXR! Respiratory distress + hypotension + absent breath sounds + hyperresonance = needle decompression NOW</li>
                    <li><strong>Tracheal deviation:</strong> Simple PTX â†’ toward affected side (volume loss). Tension PTX â†’ away from affected side (mass effect pushing mediastinum)</li>
                    <li><strong>PSP = tall thin young men:</strong> "Walking around with time bombs." Apical blebs. Smoking â†‘risk 20Ã—. Often rupture at rest. Recurrence 20-50%</li>
                    <li><strong>SSP more dangerous than PSP:</strong> Underlying lung disease â†’ less reserve. Lower threshold to place chest tube. Higher morbidity/mortality</li>
                    <li><strong>O2 speeds resolution 4Ã—:</strong> Creates nitrogen gradient â†’ resorption. Give O2 even if saturating well</li>
                    <li><strong>No flying until resolved:</strong> Pressure changes at altitude expand PTX. Wait 1-2 weeks post-resolution before flying</li>
                    <li><strong>Aspiration vs tube:</strong> PSP, young, stable â†’ try aspiration first (60-80% success, less invasive). SSP â†’ chest tube (higher failure rate, don't waste time)</li>
                    <li><strong>Recurrent PTX needs surgery:</strong> VATS pleurodesis after 1st SSP or 2nd PSP. Reduces recurrence <5%</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="syncope" class="condition-page">
            <div class="page-header">
                <h2>40. SYNCOPE</h2>
                <div class="subtitle">Vasovagal â€¢ Cardiac â€¢ Orthostatic â€¢ Neurologic</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Transient loss of consciousness (LOC) with loss of postural tone, followed by spontaneous complete recovery. Caused by global cerebral hypoperfusion. Duration typically <20 seconds</p>
                    <p><span class="label">Classic:</span> Sudden LOC, fall, rapid spontaneous recovery without intervention. Patient recalls events before and after (vs seizure with postictal confusion)</p>
                    
                    <p><span class="label">Key Historical Questions:</span></p>
                    <ul>
                        <li><strong>Prodrome:</strong> Nausea, diaphoresis, tunnel vision, lightheadedness = vasovagal. No warning = cardiac</li>
                        <li><strong>Position:</strong> Standing â†’ orthostatic or vasovagal. Supine â†’ cardiac (very concerning!)</li>
                        <li><strong>Activity:</strong> Exertional syncope = cardiac until proven otherwise (HOCM, AS, arrhythmia, PE)</li>
                        <li><strong>Triggers:</strong> Pain, emotion, standing, prolonged standing, hot environment = vasovagal. Post-micturition/defecation = situational</li>
                        <li><strong>Recovery:</strong> Immediate = syncope. Confusion/lethargy = seizure or stroke</li>
                        <li><strong>Witnesses:</strong> Tonic-clonic movements? (can occur in syncope but brief <15sec, vs prolonged in seizure). Tongue biting/incontinence more typical of seizure</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations by Etiology:</span></p>
                    <ul>
                        <li><strong>Vasovagal (Neurocardiogenic):</strong> Most common (40-50%). Prodrome of nausea, diaphoresis, visual changes. Triggered by emotional stress, pain, prolonged standing, hot environment. Young patients. Benign</li>
                        <li><strong>Orthostatic Hypotension:</strong> Syncope upon standing from sitting/supine. Elderly, autonomic dysfunction, medications (Î±-blockers, diuretics, vasodilators), volume depletion. BP drop â‰¥20/10 mmHg within 3 minutes of standing</li>
                        <li><strong>Cardiac Arrhythmia:</strong> No warning, sudden collapse. Palpitations before/after. High-risk: age >60, exertional, supine, no prodrome, heart disease. Bradyarrhythmias (sick sinus, AV block) or tachyarrhythmias (VT, SVT)</li>
                        <li><strong>Structural Cardiac:</strong> Aortic stenosis (exertional syncope, systolic murmur), HOCM (young athletes, exertional, family history sudden death), cardiac tamponade, myxoma, PE (dyspnea, pleuritic chest pain)</li>
                        <li><strong>Neurologic (RARE cause):</strong> Vertebrobasilar TIA (diplopia, ataxia, vertigo), subclavian steal, seizure (postictal confusion differentiates from syncope)</li>
                        <li><strong>Situational:</strong> Specific triggers - micturition (post-void), defecation, cough, swallow. Vasovagal-mediated</li>
                        <li><strong>Carotid Sinus Hypersensitivity:</strong> Elderly men, triggered by tight collar, head turning, shaving. Bradycardia/hypotension with carotid massage</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">ALL Patients Must Have:</span></p>
                    <ul>
                        <li><strong>Detailed History:</strong> Events before/during/after, position, activity, prodrome, recovery time, witnesses, prior episodes, medications, cardiac history</li>
                        <li><strong>Physical Exam:</strong> Complete cardiac exam (murmurs, JVD, edema), neurologic exam (focal deficits?), orthostatic vitals (supine â†’ standing at 1 and 3 min)</li>
                        <li><strong>ECG (MANDATORY for ALL):</strong> Look for: prolonged QT (>480ms = high risk for Torsades), Brugada pattern (ST elevation V1-V3), pre-excitation (WPW = short PR, delta wave), epsilon wave (ARVC), pathologic Q waves (old MI), heart block, SVT/VT</li>
                    </ul>
                    
                    <p><span class="label">Risk Stratification - San Francisco Syncope Rule (HIGH RISK if ANY):</span></p>
                    <ul>
                        <li><strong>H</strong>istory of CHF</li>
                        <li><strong>E</strong>CG abnormal (any non-sinus rhythm or new changes)</li>
                        <li><strong>A</strong>nemia (Hct <30%)</li>
                        <li><strong>R</strong>espiratory - Shortness of breath</li>
                        <li><strong>T</strong>riage systolic BP <90 mmHg</li>
                        <li>If ANY present â†’ 7-10% risk of serious outcome at 30 days â†’ ADMIT</li>
                    </ul>
                    
                    <p><span class="label">Labs (Based on Clinical Suspicion):</span></p>
                    <ul>
                        <li><strong>Basic:</strong> CBC (anemia?), BMP (electrolytes - hypokalemia can cause QT prolongation), glucose (hypoglycemia?)</li>
                        <li><strong>If cardiac suspected:</strong> Troponin (ACS?), BNP (heart failure?), D-dimer if PE suspected</li>
                        <li><strong>If volume depletion suspected:</strong> BUN/Cr ratio, orthostatic vitals</li>
                        <li><strong>Pregnancy test:</strong> All women of childbearing age (ectopic pregnancy can present as syncope)</li>
                    </ul>
                    
                    <p><span class="label">Advanced Testing (If Indicated):</span></p>
                    <ul>
                        <li><strong>Echocardiography:</strong> If structural heart disease suspected (murmur, abnormal ECG, exertional syncope, known heart disease). Assess for AS, HOCM, RV strain (PE), tamponade, LV function</li>
                        <li><strong>Telemetry/Holter Monitor:</strong> If arrhythmia suspected. Admit for telemetry if high-risk features. Outpatient Holter (24-48hr) or event monitor (30 days) for recurrent syncope</li>
                        <li><strong>Exercise Stress Test:</strong> If exertional syncope (evaluate for ischemia, arrhythmias). Contraindicated if severe AS suspected</li>
                        <li><strong>Tilt Table Test:</strong> If recurrent syncope, no cardiac cause found. Reproduces vasovagal response. Positive = BP drop >25mmHg or HR <60 with symptoms</li>
                        <li><strong>Electrophysiology Study (EP Study):</strong> For unexplained syncope with structural heart disease or high suspicion for arrhythmia. Can induce/document VT, assess sinus/AV node function</li>
                        <li><strong>CT Head:</strong> Only if focal neurologic deficits, head trauma, persistent altered mental status. Syncope alone does NOT require head CT</li>
                        <li><strong>Carotid Ultrasound:</strong> Generally low yield. Consider if carotid bruit or vertebrobasilar symptoms</li>
                        <li><strong>CT PE Protocol:</strong> If dyspnea, pleuritic chest pain, hypoxia, tachycardia, RV strain on ECG</li>
                    </ul>
                    
                    <p><span class="label">Orthostatic Vitals Technique:</span></p>
                    <ul>
                        <li>Supine Ã— 5 minutes â†’ measure BP/HR</li>
                        <li>Stand immediately â†’ measure at 1 minute and 3 minutes</li>
                        <li><strong>Positive:</strong> SBP drop â‰¥20 mmHg OR DBP drop â‰¥10 mmHg OR HR increase â‰¥30 bpm (or HR >120)</li>
                        <li>Symptoms (lightheadedness, presyncope) with standing = clinical orthostasis even if BP criteria not met</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li>Treatment depends on underlying cause</li>
                        <li>Admit if high-risk features (see San Francisco Syncope Rule, cardiac cause suspected)</li>
                        <li>Discharge if low-risk and clear benign etiology (young, vasovagal, normal ECG, normal exam)</li>
                    </ul>
                    
                    <p><span class="label">Vasovagal Syncope (Reflex/Neurocardiogenic):</span></p>
                    <ul>
                        <li><strong>Reassurance:</strong> Benign condition, excellent prognosis. Explain pathophysiology</li>
                        <li><strong>Trigger Avoidance:</strong> Avoid prolonged standing, hot environments, dehydration, emotional stress. Sit/lie down at first prodromal symptom</li>
                        <li><strong>Hydration:</strong> Increase fluid intake to 2-3 L/day. Liberal salt intake (6-10g/day) if no contraindications</li>
                        <li><strong>Physical Counterpressure Maneuvers:</strong> At first sign of prodrome: leg crossing + tensing, squatting, arm tensing. Can abort episode</li>
                        <li><strong>Tilt Training:</strong> Gradual exposure to prolonged standing (start 5 min, increase to 30+ min)</li>
                        <li><strong>Pharmacologic (Refractory cases only):</strong>
                            <ul>
                                <li>Midodrine 5-10mg TID (Î±-agonist, increases BP) - first-line medication</li>
                                <li>Fludrocortisone 0.1-0.2mg daily (volume expansion)</li>
                                <li>Î²-blockers (metoprolol) - controversial, limited evidence</li>
                            </ul>
                        </li>
                        <li><strong>Pacemaker:</strong> Very rarely indicated. Only if severe cardioinhibitory response (asystole >3 sec) on tilt table and failed medical therapy</li>
                    </ul>
                    
                    <p><span class="label">Orthostatic Hypotension:</span></p>
                    <ul>
                        <li><strong>Identify and Address Causes:</strong>
                            <ul>
                                <li>Volume depletion â†’ IV fluids, oral hydration</li>
                                <li>Medications â†’ stop/reduce Î±-blockers, diuretics, vasodilators, antihypertensives, antidepressants</li>
                                <li>Autonomic dysfunction â†’ treat underlying (diabetes, Parkinson's, amyloidosis)</li>
                            </ul>
                        </li>
                        <li><strong>Non-Pharmacologic:</strong>
                            <ul>
                                <li>Rise slowly from supine/sitting (sit at edge of bed Ã— 1 min before standing)</li>
                                <li>Increase fluid intake (2-3 L/day) and salt (6-10g/day if no CHF)</li>
                                <li>Compression stockings (waist-high, 30-40 mmHg) - wear before rising</li>
                                <li>Elevate head of bed 10-20 degrees at night (reduces nocturnal diuresis)</li>
                                <li>Avoid large meals (can cause postprandial hypotension)</li>
                                <li>Physical counterpressure maneuvers</li>
                            </ul>
                        </li>
                        <li><strong>Pharmacologic:</strong>
                            <ul>
                                <li>Midodrine 2.5-10mg TID (last dose before 6 PM to avoid supine hypertension)</li>
                                <li>Fludrocortisone 0.1-0.3mg daily (watch for hypokalemia, edema, supine hypertension)</li>
                                <li>Droxidopa 100-600mg TID (norepinephrine precursor, for neurogenic OH)</li>
                                <li>Pyridostigmine 60mg TID (if autonomic failure)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Cardiac Syncope - ADMIT for Telemetry:</span></p>
                    <ul>
                        <li><strong>Arrhythmia Management:</strong>
                            <ul>
                                <li>Bradycardia (sick sinus, AV block) â†’ Cardiology consult, consider pacemaker</li>
                                <li>Tachyarrhythmia (VT, SVT) â†’ Antiarrhythmics, ablation, ICD evaluation</li>
                                <li>Long QT syndrome â†’ Remove offending drugs, electrolyte repletion (Mg, K), Î²-blockers, ICD if high risk</li>
                                <li>Brugada, ARVC â†’ EP study, ICD placement</li>
                            </ul>
                        </li>
                        <li><strong>Structural Disease:</strong>
                            <ul>
                                <li>Aortic stenosis â†’ Cardiology/CT surgery referral for valve replacement if severe + symptomatic</li>
                                <li>HOCM â†’ Î²-blockers, avoid volume depletion/vasodilators. ICD if high risk. Septal reduction if refractory</li>
                                <li>Pulmonary embolism â†’ Anticoagulation, thrombolytics if massive PE</li>
                                <li>Cardiac tamponade â†’ Pericardiocentesis</li>
                            </ul>
                        </li>
                        <li><strong>Ischemia:</strong> If syncope due to ACS â†’ treat per ACS protocol (aspirin, heparin, cath lab)</li>
                    </ul>
                    
                    <p><span class="label">Situational Syncope:</span></p>
                    <ul>
                        <li>Micturition syncope â†’ Sit to void, avoid straining, stay hydrated</li>
                        <li>Defecation syncope â†’ Avoid straining (stool softeners), adequate hydration</li>
                        <li>Cough/swallow syncope â†’ Treat underlying cause (GERD, cough), maneuvers to reduce triggering</li>
                    </ul>
                    
                    <p><span class="label">Neurologic Syncope (Rare):</span></p>
                    <ul>
                        <li>Vertebrobasilar TIA â†’ Neurology consult, antiplatelet therapy, imaging (MRA/CTA neck)</li>
                        <li>Subclavian steal â†’ Vascular surgery referral</li>
                        <li>Seizure (if postictal confusion suggests) â†’ Neurology consult, antiepileptics, EEG</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>ECG is MANDATORY for ALL syncope patients:</strong> Single most important test. Can diagnose Brugada, long QT, WPW, ARVC, heart block, old MI. Never discharge syncope patient without ECG</li>
                    <li><strong>Syncope while supine = cardiac until proven otherwise:</strong> Vasovagal almost never occurs supine. If patient syncopizes lying down, think arrhythmia and admit for telemetry</li>
                    <li><strong>Exertional syncope = high-risk:</strong> Think HOCM (young athletes), AS (elderly), VT, coronary ischemia. These patients need echo, stress test, and cardiology evaluation</li>
                    <li><strong>Red flags for cardiac syncope:</strong> Age >60, exertional, supine position, no prodrome, known heart disease, abnormal ECG, family history sudden cardiac death. Admit these patients</li>
                    <li><strong>Vasovagal has a prodrome, cardiac doesn't:</strong> If patient describes nausea, diaphoresis, tunnel vision before passing out = vasovagal (low risk). No warning, sudden collapse = cardiac (high risk)</li>
                    <li><strong>Don't confuse syncope with seizure:</strong> Syncope = brief LOC (<20 sec), rapid complete recovery, may have brief myoclonic jerks (<15 sec). Seizure = prolonged LOC, tonic-clonic movements, tongue biting, incontinence, postictal confusion/lethargy. But can be tough to distinguish!</li>
                    <li><strong>Head CT rarely useful:</strong> Only if focal neurologic findings, head trauma, or persistent altered mental status. Syncope is due to global hypoperfusion, not focal brain lesion. Don't reflexively order head CT</li>
                    <li><strong>San Francisco Syncope Rule is your friend:</strong> If none of the 5 criteria (CHF, abnormal ECG, Hct <30%, SOB, SBP <90), patient is low-risk (<1% serious outcome) and can likely be discharged with outpatient follow-up if vasovagal etiology clear</li>
                    <li><strong>Orthostatic vitals technique matters:</strong> Must be supine Ã— 5 min first, then check at 1 and 3 minutes standing. Immediate standing without adequate supine time can give false positives</li>
                    <li><strong>Young healthy patient with classic vasovagal story needs minimal workup:</strong> Prodrome, triggered by standing/heat/emotion, quick recovery, normal ECG = can discharge with reassurance and anticipatory guidance. Don't over-test these patients</li>
                    <li><strong>Medications are a common culprit:</strong> Î±-blockers (BPH meds), diuretics, antihypertensives, TCAs, antipsychotics, PDE5 inhibitors. Always review medication list carefully</li>
                    <li><strong>Carotid massage to diagnose carotid sinus hypersensitivity:</strong> Only perform if safe (no carotid bruits, no recent stroke/TIA). Massage one side Ã— 5 seconds. Positive = >3 sec asystole or >50 mmHg BP drop. Never massage both sides simultaneously!</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Syncope with ongoing chest pain suggesting acute MI</li>
                        <li>Hemodynamically unstable (persistent hypotension, shock)</li>
                        <li>Malignant arrhythmia (sustained VT/VF requiring cardioversion)</li>
                        <li>High-grade AV block (Mobitz II, complete heart block) requiring pacing</li>
                        <li>Massive pulmonary embolism with hypotension</li>
                        <li>Cardiac tamponade</li>
                        <li>Aortic dissection</li>
                        <li>Ruptured ectopic pregnancy with hemorrhagic shock</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Clear benign etiology identified (vasovagal, orthostatic)</li>
                        <li>NO high-risk features (San Francisco Syncope Rule negative)</li>
                        <li>Normal or unchanged ECG</li>
                        <li>Normal vital signs and orthostatics</li>
                        <li>No concerning cardiac exam findings</li>
                        <li>Labs normal (if obtained)</li>
                        <li>No recurrent episodes during observation</li>
                        <li>Able to ambulate safely without recurrence</li>
                        <li>Patient counseled on trigger avoidance (if vasovagal)</li>
                        <li>Close follow-up arranged (PCP within 1 week, Cardiology if needed)</li>
                        <li>Clear return precautions: recurrent syncope, chest pain, palpitations, dyspnea</li>
                        <li>Driving restrictions discussed (varies by state, typically 3-6 months abstinence after cardiac syncope)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Syncope Episode:</strong> Trauma from fall (head injury, fractures, lacerations), motor vehicle accidents (if driving), sudden cardiac death (if malignant arrhythmia), prolonged cerebral hypoperfusion causing ischemia (rare)</p>
                    <p><strong>From Underlying Cardiac Cause:</strong> Sudden cardiac death (VT/VF, complete heart block), acute MI/ACS, cardiac arrest, stroke from arrhythmia with thrombus formation, progression of structural heart disease (AS, HOCM)</p>
                    <p><strong>From Recurrent Episodes:</strong> Injury from repeated falls, impaired quality of life, anxiety/depression, loss of driving privileges, loss of employment (especially if operate machinery), social isolation</p>
                    <p><strong>From Treatment:</strong> Supine hypertension (midodrine, fludrocortisone - can cause nocturnal HTN), hypokalemia (fludrocortisone), edema (fludrocortisone), bradycardia (Î²-blockers), pacemaker complications (infection, lead malfunction), ICD shocks (appropriate or inappropriate)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="pericarditis" class="condition-page">
            <div class="page-header">
                <h2>41. PERICARDITIS/PERICARDIAL EFFUSION/CARDIAC TAMPONADE</h2>
                <div class="subtitle">Inflammatory â€¢ Effusion â€¢ Tamponade Physiology</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Pericarditis:</span> Sharp, pleuritic chest pain worse with inspiration and lying flat, relieved by sitting forward. Friction rub (scratchy, triphasic sound)</p>
                    <p><span class="label">Pericardial Effusion:</span> Often asymptomatic if slow-accumulating. Dyspnea, muffled heart sounds, enlarged cardiac silhouette on CXR</p>
                    <p><span class="label">Cardiac Tamponade:</span> Beck's triad (hypotension, JVD, muffled heart sounds), pulsus paradoxus >10mmHg, tachycardia, dyspnea, shock</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Uremic pericarditis:</strong> ESRD patients, often painless. May indicate need for urgent dialysis</li>
                        <li><strong>Post-MI (Dressler syndrome):</strong> 1-3 weeks post-MI. Fever, pleurisy, pericarditis</li>
                        <li><strong>Malignant effusion:</strong> Gradual dyspnea, weight loss. Lung/breast cancer, lymphoma most common</li>
                        <li><strong>TB pericarditis:</strong> Endemic areas, HIV patients. Chronic symptoms, large effusions</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> CBC, CRP/ESR (elevated), troponin (mildly elevated if myopericarditis), BUN/Cr, TSH, ANA if autoimmune suspected</p>
                    <p><span class="label">ECG:</span> Diffuse ST elevation with PR depression (90%), upright T waves. Stage 1â†’4: ST elevation â†’ normalization â†’ T inversion â†’ resolution</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CXR:</strong> Enlarged cardiac silhouette if >250mL effusion ("water bottle heart")</li>
                        <li><strong>Echocardiogram:</strong> GOLD STANDARD. Quantify effusion, assess for tamponade physiology (RA/RV collapse, respiratory variation, IVC plethora)</li>
                        <li><strong>CT chest:</strong> If imaging for etiology (malignancy, TB, trauma)</li>
                    </ul>
                    <p><span class="label">Pericardiocentesis:</span> If tamponade, purulent/TB suspected, or large effusion not responding to NSAIDs. Send fluid for cell count, cultures, cytology, adenosine deaminase (TB)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Acute Pericarditis (no effusion/tamponade):</span></p>
                    <ul>
                        <li><strong>First-line:</strong> NSAIDs + Colchicine. Ibuprofen 600-800mg TID Ã— 1-2 weeks, taper over 1-2 weeks. Colchicine 0.6mg BID Ã— 3 months (reduces recurrence 50%)</li>
                        <li><strong>Alternative:</strong> Aspirin 750-1000mg TID (if post-MI or ASA allergy)</li>
                        <li><strong>Steroids:</strong> AVOID unless refractory or contraindication to NSAIDs (increases recurrence risk). Prednisone 0.25-0.5mg/kg/day</li>
                        <li><strong>Activity restriction:</strong> No strenuous exercise until symptoms resolve and CRP normalizes (risk of recurrence/tamponade)</li>
                    </ul>
                    
                    <p><span class="label">Pericardial Effusion (no tamponade):</span></p>
                    <ul>
                        <li><strong>Small/moderate:</strong> Treat underlying cause, anti-inflammatory therapy, serial echos q48-72hr</li>
                        <li><strong>Large (>20mm):</strong> Admit for monitoring, daily echos, consider pericardiocentesis if symptomatic or not responding</li>
                    </ul>
                    
                    <p><span class="label">Cardiac Tamponade (EMERGENCY):</span></p>
                    <ul>
                        <li><strong>Immediate:</strong> Aggressive IV fluids (increase preload), avoid diuretics/vasodilators</li>
                        <li><strong>Definitive:</strong> Urgent pericardiocentesis (echo or fluoro-guided). Drain 50mL often enough for immediate improvement</li>
                        <li><strong>Approach:</strong> Subxiphoid (most common). Leave pigtail catheter if large volume or suspected recurrence</li>
                        <li><strong>Refractory:</strong> Surgical drainage (pericardial window) if loculated, recurrent, or traumatic</li>
                        <li><strong>Post-procedure:</strong> Monitor for re-accumulation. Echo in 24-48hr</li>
                    </ul>
                    
                    <p><span class="label">Specific Etiologies:</span></p>
                    <ul>
                        <li><strong>Uremic:</strong> Urgent dialysis. Most resolve after adequate dialysis</li>
                        <li><strong>Malignant:</strong> Drainage for symptoms, often recurs. Consider pericardial window or sclerosis</li>
                        <li><strong>Purulent:</strong> Pericardiocentesis + broad-spectrum antibiotics (vanco + ceftriaxone). Often needs surgical drainage</li>
                        <li><strong>TB:</strong> Rifampin, isoniazid, pyrazinamide, ethambutol (RIPE) Ã— 2 months, then RIF/INH Ã— 4 months. Consider steroids (reduce constriction)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Pericarditis ECG vs STEMI:</strong> Pericarditis has diffuse ST elevation (multiple leads) with PR depression, STEMI has localized ST elevation with reciprocal changes. Pericarditis ST is concave ("smiling"), STEMI is convex ("frowning")</li>
                    <li><strong>Pulsus paradoxus:</strong> >10mmHg drop in SBP with inspiration. Normal <10mmHg. Also seen in COPD, PE, severe asthma</li>
                    <li><strong>Colchicine is key:</strong> Reduces recurrence from 30-50% to 10-15%. Use in all cases unless contraindicated</li>
                    <li><strong>Low-pressure tamponade:</strong> Can occur with hypovolemia or RV dysfunction. Tamponade physiology without elevated JVP</li>
                    <li><strong>Electrical alternans:</strong> Beat-to-beat variation in QRS amplitude. Classic for large effusion/tamponade but uncommon (10-20%)</li>
                    <li><strong>Avoid steroids if possible:</strong> 2-4Ã— increased risk of recurrence. Reserve for refractory cases or contraindication to NSAIDs</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Cardiac tamponade (SBP <90, pulsus paradoxus >20mmHg)</li>
                        <li>Hemodynamic instability</li>
                        <li>Large/rapidly accumulating effusion</li>
                        <li>Need for urgent pericardiocentesis</li>
                        <li>Myopericarditis with arrhythmias or reduced EF</li>
                        <li>Purulent pericarditis</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Pain controlled on oral NSAIDs</li>
                        <li>Hemodynamically stable</li>
                        <li>No evidence of tamponade on echo</li>
                        <li>CRP trending down</li>
                        <li>If effusion: Small/stable on repeat echo</li>
                        <li>Follow-up arranged (repeat echo in 1 week if effusion present)</li>
                        <li>Activity restrictions counseled</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Cardiac tamponade (most feared), myopericarditis (troponin â†‘, EF â†“), arrhythmias (rare)</p>
                    <p><strong>Chronic:</strong> Recurrent pericarditis (15-30%, higher without colchicine), constrictive pericarditis (chronic inflammation â†’ calcification â†’ restricted filling, often post-TB/radiation/cardiac surgery)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="endocarditis" class="condition-page">
            <div class="page-header">
                <h2>42. INFECTIVE ENDOCARDITIS</h2>
                <div class="subtitle">Native Valve â€¢ Prosthetic Valve â€¢ Duke Criteria</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Fever (90%), new or changing murmur (85%), embolic phenomena, positive blood cultures. Subacute: weeks of constitutional symptoms</p>
                    <p><span class="label">Acute Presentation:</span> Rapid valve destruction, heart failure, septic shock. More common with S. aureus</p>
                    <p><span class="label">Peripheral Stigmata (classic but rare <10%):</span></p>
                    <ul>
                        <li><strong>Osler nodes:</strong> Painful, raised, red nodules on fingers/toes (immunologic)</li>
                        <li><strong>Janeway lesions:</strong> Painless, red macules on palms/soles (septic emboli)</li>
                        <li><strong>Splinter hemorrhages:</strong> Linear red-brown streaks under nails</li>
                        <li><strong>Roth spots:</strong> Retinal hemorrhages with pale centers (rare)</li>
                    </ul>
                    <p><span class="label">Complications at Presentation:</span></p>
                    <ul>
                        <li><strong>Heart failure:</strong> Acute regurgitation from valve destruction (most common cause of death)</li>
                        <li><strong>Embolic stroke:</strong> 15-30%, highest risk with mitral valve and S. aureus</li>
                        <li><strong>Mycotic aneurysm:</strong> Brain, splenic, coronary arteries</li>
                        <li><strong>Perivalvular abscess:</strong> New heart block (AV node near aortic valve)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP (Duke Criteria)</div>
                <div class="section-content">
                    <p><span class="label">Blood Cultures:</span> 3 sets from separate sites BEFORE antibiotics. Time spacing less critical than previously thought (can obtain all within 1-2hr if clinically unstable)</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>TTE:</strong> First-line. Sensitivity 60-70% for vegetations. Excellent for assessment of valve function and complications</li>
                        <li><strong>TEE:</strong> Gold standard. Sensitivity 90-95%. REQUIRED if: prosthetic valve, negative TTE with high suspicion, suspected abscess/perforation, S. aureus bacteremia</li>
                        <li><strong>Cardiac CT/MRI:</strong> If TEE contraindicated or to evaluate perivalvular extension</li>
                        <li><strong>Brain MRI:</strong> If neurologic symptoms (ischemic stroke, hemorrhage, abscess, mycotic aneurysm)</li>
                    </ul>
                    <p><span class="label">Labs:</span> CBC (anemia of chronic disease), ESR/CRP (elevated), UA (hematuria/proteinuria), RF (positive in subacute), creatinine, LFTs</p>
                    <p><span class="label">Duke Criteria (Definite IE = 2 major OR 1 major + 3 minor OR 5 minor):</span></p>
                    <ul>
                        <li><strong>Major:</strong> (1) Positive blood cultures with typical organisms in â‰¥2 separate cultures, OR persistently positive cultures; (2) Echocardiographic evidence (vegetation, abscess, new dehiscence of prosthetic valve, new valvular regurgitation)</li>
                        <li><strong>Minor:</strong> Predisposing condition, fever >38Â°C, vascular phenomena (emboli, mycotic aneurysm), immunologic phenomena (Osler nodes, Roth spots, RF), microbiologic evidence not meeting major criteria</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Empiric Antibiotics (start after blood cultures Ã— 3):</span></p>
                    <ul>
                        <li><strong>Native valve:</strong> Vancomycin 15mg/kg IV q12h + ceftriaxone 2g IV q24h</li>
                        <li><strong>Prosthetic valve:</strong> Vancomycin + ceftriaxone + gentamicin 1mg/kg IV q8h (or cefepime instead of ceftriaxone)</li>
                        <li><strong>IVDU:</strong> Same as native valve (covers S. aureus, Streptococcus, gram-negatives)</li>
                    </ul>
                    
                    <p><span class="label">Organism-Specific Therapy:</span></p>
                    <ul>
                        <li><strong>Viridans Streptococcus (most common, ~30%):</strong> Penicillin G 4 million units IV q4h OR ceftriaxone 2g IV q24h Ã— 4 weeks. Can add gentamicin Ã— 2 weeks for synergy</li>
                        <li><strong>S. aureus (MSSA):</strong> Nafcillin/oxacillin 2g IV q4h Ã— 4-6 weeks. Consider adding gentamicin Ã— 3-5 days for synergy</li>
                        <li><strong>S. aureus (MRSA):</strong> Vancomycin 15mg/kg IV q12h Ã— 6 weeks. Consider daptomycin 8-10mg/kg if persistent bacteremia</li>
                        <li><strong>Enterococcus:</strong> Ampicillin 2g IV q4h + gentamicin 1mg/kg q8h (or ceftriaxone 2g q12h instead of gent) Ã— 4-6 weeks</li>
                        <li><strong>HACEK (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella):</strong> Ceftriaxone 2g IV q24h Ã— 4 weeks</li>
                        <li><strong>Culture-negative (10-15%):</strong> Continue empiric therapy. Consider Bartonella, Coxiella, Brucella, fungi in specific epidemiology</li>
                    </ul>
                    
                    <p><span class="label">Duration:</span> Native valve 4-6 weeks (S. aureus 6 weeks), prosthetic valve 6 weeks minimum. Time from FIRST negative blood culture</p>
                    
                    <p><span class="label">Surgical Indications (Cardiothoracic Surgery Consult):</span></p>
                    <ul>
                        <li><strong>Heart failure:</strong> From severe acute regurgitation or valve obstruction (Class I indication, emergent)</li>
                        <li><strong>Uncontrolled infection:</strong> Perivalvular abscess, persistent bacteremia >5-7 days on appropriate antibiotics, fungal endocarditis</li>
                        <li><strong>Prevention of embolism:</strong> Large mobile vegetation (>10mm) with embolic event, especially anterior mitral valve</li>
                        <li><strong>Prosthetic valve:</strong> Early prosthetic valve endocarditis (<1 year), heart failure, dehiscence, persistent bacteremia</li>
                        <li><strong>Timing:</strong> Emergent (heart failure/cardiogenic shock), urgent (uncontrolled infection, abscess), elective (large vegetation, embolic prevention)</li>
                    </ul>
                    
                    <p><span class="label">Post-Stroke Timing for Surgery:</span> If intracranial hemorrhage, delay surgery if possible. If ischemic stroke without hemorrhage, surgery can proceed but discuss risk/benefit</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>S. aureus bacteremia = TEE:</strong> 25% have IE even without murmur. Always get TEE for S. aureus bacteremia unless clear alternative source + no cardiac risk factors</li>
                    <li><strong>Culture first, antibiotics second:</strong> Don't delay cultures waiting for fever spike. Get 3 sets ASAP then start empiric therapy (unless stable subacute presentation)</li>
                    <li><strong>Right-sided endocarditis:</strong> IVDU, indwelling catheters. Tricuspid valve most common. Septic pulmonary emboli (not stroke). Better prognosis than left-sided</li>
                    <li><strong>New heart block = perivalvular abscess:</strong> AV node near aortic valve. High-grade block indicates abscess until proven otherwise. Surgical emergency</li>
                    <li><strong>Anticoagulation controversy:</strong> If on warfarin for other indication (prosthetic valve, AFib), continue but avoid starting new anticoagulation (doesn't prevent emboli, may increase hemorrhagic stroke)</li>
                    <li><strong>Mycotic aneurysm:</strong> Not fungal! Bacterial infection of arterial wall. Can rupture. Brain MRA if headache or neurologic symptoms</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability/cardiogenic shock</li>
                        <li>Acute heart failure (pulmonary edema)</li>
                        <li>High-grade heart block (perivalvular abscess)</li>
                        <li>Embolic stroke with decreased level of consciousness</li>
                        <li>Septic shock despite antibiotics</li>
                        <li>Perioperative (cardiac surgery for IE)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Appropriate IV antibiotics for â‰¥7-14 days (bloodstream clearance documented)</li>
                        <li>Hemodynamically stable</li>
                        <li>Blood cultures negative Ã— 2-3 sets</li>
                        <li>No indication for urgent surgery</li>
                        <li>Plan for completion of IV antibiotics (home IV, long-term facility, or outpatient infusion)</li>
                        <li>Follow-up with Infectious Disease and Cardiology arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Cardiac:</strong> Heart failure (most common cause of death, 50-60%), perivalvular abscess (10-40% prosthetic, 10-15% native), valve perforation, fistula formation</p>
                    <p><strong>Neurologic:</strong> Ischemic stroke (15-30%), intracerebral hemorrhage (5%), mycotic aneurysm rupture (rare but devastating), brain abscess</p>
                    <p><strong>Embolic:</strong> Spleen (abdominal pain), kidneys (hematuria, infarction), bones (osteomyelitis, vertebral), coronary arteries (MI)</p>
                    <p><strong>Immunologic:</strong> Glomerulonephritis (immune complex deposition), arthritis, splinter hemorrhages</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#vancomycin" style="color: #8e44ad;">ðŸ’Š Vancomycin</a>, <a href="drug_reference_guide.html#ceftriaxone" style="color: #8e44ad;">ðŸ’Š Ceftriaxone</a>, <a href="drug_reference_guide.html#nafcillin" style="color: #8e44ad;">ðŸ’Š Nafcillin</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="myocarditis" class="condition-page">
            <div class="page-header">
                <h2>43. MYOCARDITIS</h2>
                <div class="subtitle">Viral â€¢ Immune-mediated â€¢ Fulminant</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Chest pain (mimics MI), dyspnea, fatigue, palpitations. Often recent viral URI or gastroenteritis (1-3 weeks prior)</p>
                    <p><span class="label">Severity Spectrum:</span></p>
                    <ul>
                        <li><strong>Mild:</strong> Chest pain, elevated troponin, preserved EF. May be asymptomatic</li>
                        <li><strong>Moderate:</strong> Heart failure symptoms, reduced EF, arrhythmias</li>
                        <li><strong>Fulminant:</strong> Cardiogenic shock, severe LV dysfunction, arrhythmias. Higher mortality but survivors often recover completely</li>
                    </ul>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Sudden cardiac death:</strong> Ventricular arrhythmias in young, previously healthy patients</li>
                        <li><strong>Dilated cardiomyopathy:</strong> Chronic presentation after subclinical acute phase</li>
                        <li><strong>Pericardial involvement:</strong> Myopericarditis (chest pain, friction rub, ST elevation + troponin elevation)</li>
                        <li><strong>Post-COVID:</strong> Multisystem inflammatory syndrome (MIS-C in children, MIS-A in adults)</li>
                        <li><strong>Vaccine-related:</strong> mRNA COVID vaccines (rare, ~12 cases/million, mostly young males, mild)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> Troponin (elevated, often markedly), BNP, CBC, CRP/ESR, BMP, LFTs. Viral PCR if clinically indicated</p>
                    <p><span class="label">ECG:</span> ST elevation (diffuse, not localized), T wave changes, conduction abnormalities. May mimic STEMI or pericarditis</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Echocardiogram:</strong> Assess EF, regional wall motion abnormalities, pericardial effusion, LV thrombus</li>
                        <li><strong>Cardiac MRI:</strong> GOLD STANDARD for diagnosis (when stable). Late gadolinium enhancement in mid-wall/epicardial distribution (vs subendocardial in MI). T2-weighted imaging shows edema</li>
                        <li><strong>Coronary angiography:</strong> If concern for ACS (especially if STEMI-like presentation, risk factors). Normal coronaries support myocarditis</li>
                    </ul>
                    <p><span class="label">Endomyocardial Biopsy:</span> Gold standard but rarely done. Consider if: fulminant myocarditis, giant cell myocarditis suspected, not improving with supportive care, concern for infiltrative disease</p>
                    <p><span class="label">Etiologies:</span></p>
                    <ul>
                        <li><strong>Viral (most common):</strong> Coxsackie B, adenovirus, parvovirus B19, HHV-6, COVID-19, influenza</li>
                        <li><strong>Autoimmune:</strong> Giant cell myocarditis, cardiac sarcoidosis, lupus, eosinophilic myocarditis</li>
                        <li><strong>Toxic:</strong> Cocaine, alcohol, chemotherapy (anthracyclines), clozapine</li>
                        <li><strong>Immune checkpoint inhibitors:</strong> Pembrolizumab, nivolumab. High mortality if not recognized early</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Supportive Care (Mainstay):</span></p>
                    <ul>
                        <li><strong>Activity restriction:</strong> CRITICAL. Bed rest, no exercise for â‰¥3-6 months (even if feeling better). Exercise during acute phase increases mortality</li>
                        <li><strong>Heart failure management:</strong> ACE-I/ARB, Î²-blockers (start low, go slow when stable), diuretics, aldosterone antagonist</li>
                        <li><strong>Arrhythmia monitoring:</strong> Telemetry. Treat ventricular arrhythmias per ACLS. Consider temporary pacing if high-grade block</li>
                        <li><strong>Anticoagulation:</strong> If EF <35%, consider prophylaxis for LV thrombus prevention</li>
                    </ul>
                    
                    <p><span class="label">Immunosuppression (CONTROVERSIAL):</span></p>
                    <ul>
                        <li><strong>Generally NOT recommended for viral myocarditis</strong> (may worsen outcomes)</li>
                        <li><strong>Consider for:</strong> Giant cell myocarditis, cardiac sarcoidosis, eosinophilic myocarditis, immune checkpoint inhibitor myocarditis</li>
                        <li><strong>Regimen (if indicated):</strong> High-dose steroids Â± other immunosuppression (azathioprine, cyclosporine). Consult cardiology/rheumatology</li>
                    </ul>
                    
                    <p><span class="label">Fulminant Myocarditis (ICU Management):</span></p>
                    <ul>
                        <li><strong>Inotropes:</strong> Dobutamine or milrinone if low cardiac output</li>
                        <li><strong>Mechanical support:</strong> IABP, Impella, VA-ECMO if cardiogenic shock. Bridge to recovery (most improve) or transplant</li>
                        <li><strong>Temporary pacing:</strong> If complete heart block</li>
                        <li><strong>AVOID:</strong> NSAIDs (may worsen myocardial inflammation and increase mortality). Use acetaminophen for pain</li>
                    </ul>
                    
                    <p><span class="label">Specific Etiologies:</span></p>
                    <ul>
                        <li><strong>Giant cell:</strong> High-dose steroids + immunosuppression. Transplant evaluation</li>
                        <li><strong>Immune checkpoint inhibitor:</strong> STOP immunotherapy immediately. High-dose methylprednisolone 1g/day Ã— 3 days. Consider other immunosuppression if refractory</li>
                        <li><strong>Eosinophilic:</strong> Steroids. Check for hypereosinophilic syndrome</li>
                        <li><strong>Chagas:</strong> Benznidazole or nifurtimox (if acute). Treat heart failure in chronic phase</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Myocarditis vs MI:</strong> Younger age, no CAD risk factors, normal coronaries on angiography, diffuse ST elevation, troponin often disproportionately high for degree of ECG changes</li>
                    <li><strong>Cardiac MRI is diagnostic:</strong> Mid-wall/epicardial late gadolinium enhancement (vs subendocardial in MI). T2 signal for edema. Sensitivity/specificity >85%</li>
                    <li><strong>Fulminant paradox:</strong> Worse acute presentation but BETTER long-term outcomes (if survive). More likely to recover completely. Chronic myocarditis has worse prognosis</li>
                    <li><strong>Activity restriction saves lives:</strong> Athletes who return to sports too early have increased risk of sudden death. Minimum 3-6 months rest, longer if EF reduced</li>
                    <li><strong>NSAIDs are contraindicated:</strong> Animal studies show increased mortality. Use acetaminophen instead</li>
                    <li><strong>Troponin levels don't predict outcomes:</strong> Very high troponin can be seen in mild cases. EF and hemodynamics are better prognostic markers</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Fulminant myocarditis (cardiogenic shock, EF <30%)</li>
                        <li>Hemodynamic instability</li>
                        <li>Sustained ventricular arrhythmias</li>
                        <li>High-grade AV block</li>
                        <li>Need for inotropes or mechanical support</li>
                        <li>Respiratory failure</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable off inotropes</li>
                        <li>No sustained arrhythmias â‰¥48hr</li>
                        <li>On appropriate heart failure meds</li>
                        <li>Activity restrictions counseled (critical!)</li>
                        <li>Follow-up arranged (cardiology in 1-2 weeks, repeat echo in 1-3 months)</li>
                        <li>If EF reduced: Wearable defibrillator (LifeVest) until reassessment</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Cardiogenic shock (10-15% fulminant cases), sustained VT/VF (sudden death risk), complete heart block, acute heart failure</p>
                    <p><strong>Chronic:</strong> Dilated cardiomyopathy (10-30% of acute cases progress), chronic heart failure, need for transplant, recurrent myocarditis (rare), ventricular aneurysm</p>
                    <p><strong>Recovery:</strong> Most patients with preserved EF recover completely. Reduced EF may improve over 6-12 months with aggressive medical therapy. Repeat imaging essential</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="cardiogenic-shock" class="condition-page">
            <div class="page-header">
                <h2>44. CARDIOGENIC SHOCK</h2>
                <div class="subtitle">Pump Failure â€¢ Mechanical Complications â€¢ MCS</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Sustained hypotension (SBP <90mmHg) + end-organ hypoperfusion + cardiac dysfunction. Cardiac index <2.2 L/min/mÂ², PCWP >15mmHg</p>
                    <p><span class="label">Classic:</span> Hypotension, cool extremities, altered mental status, oliguria, elevated lactate. Following acute MI, myocarditis, or acute decompensated heart failure</p>
                    <p><span class="label">Clinical Signs:</span></p>
                    <ul>
                        <li><strong>Hypoperfusion:</strong> Cold, clammy skin, delayed capillary refill (>3 sec), weak pulses, confusion, oliguria (<0.5mL/kg/hr)</li>
                        <li><strong>Congestion:</strong> Elevated JVP, pulmonary edema, hepatomegaly, peripheral edema (often "cold and wet")</li>
                        <li><strong>Compensatory:</strong> Tachycardia (attempt to maintain cardiac output), tachypnea</li>
                    </ul>
                    <p><span class="label">SCAI Shock Stages:</span></p>
                    <ul>
                        <li><strong>Stage A (At risk):</strong> No hypotension but risk factors present</li>
                        <li><strong>Stage B (Beginning):</strong> Relative hypotension, tachycardia, without hypoperfusion</li>
                        <li><strong>Stage C (Classic):</strong> Hypotension requiring intervention, tissue hypoperfusion</li>
                        <li><strong>Stage D (Deteriorating):</strong> Not responding to initial interventions, worsening hypoperfusion</li>
                        <li><strong>Stage E (Extremis):</strong> Circulatory collapse, cardiac arrest, requiring CPR or multiple interventions</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> Lactate (>2 suggests shock), BMP (creatinine rising), LFTs (hepatic hypoperfusion, transaminitis), CBC, troponin, BNP, blood gas (metabolic acidosis)</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>ECG:</strong> Assess for acute MI (most common cause), arrhythmia</li>
                        <li><strong>Echocardiogram:</strong> URGENT. Assess EF, wall motion, valvular pathology, mechanical complications (VSD, acute MR, free wall rupture), pericardial effusion/tamponade, RV function</li>
                        <li><strong>CXR:</strong> Pulmonary edema, cardiomegaly</li>
                        <li><strong>Coronary angiography:</strong> If STEMI/NSTEMI. Revascularization is cornerstone of treatment for MI-related shock</li>
                    </ul>
                    <p><span class="label">Hemodynamic Monitoring (consider PA catheter or advanced monitoring):</span></p>
                    <ul>
                        <li><strong>Cardiogenic shock:</strong> CI <2.2, PCWP >15, SVR elevated</li>
                        <li><strong>Helps differentiate:</strong> From distributive shock (high CI, low SVR), hypovolemic shock (low PCWP)</li>
                    </ul>
                    <p><span class="label">Etiologies:</span></p>
                    <ul>
                        <li><strong>Acute MI (80%):</strong> Large anterior MI, mechanical complications (VSR, acute MR, free wall rupture)</li>
                        <li><strong>Acute decompensated HF:</strong> On chronic cardiomyopathy</li>
                        <li><strong>Acute valvular:</strong> Acute severe MR (papillary muscle rupture, endocarditis), acute severe AR (endocarditis, dissection)</li>
                        <li><strong>Myocarditis:</strong> Fulminant, usually viral or autoimmune</li>
                        <li><strong>RV failure:</strong> Massive PE, RV infarction</li>
                        <li><strong>Arrhythmia:</strong> Sustained VT, bradycardia, uncontrolled AFib with RVR</li>
                        <li><strong>Tako-tsubo (stress cardiomyopathy):</strong> Apical ballooning, mimics MI</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li><strong>Treat underlying cause:</strong> Emergent revascularization (PCI/CABG) for MI, surgery for mechanical complications, cardioversion for arrhythmia</li>
                        <li><strong>Optimize preload:</strong> Careful fluid management (avoid overload if already congested, give fluids if underfilled - esp RV MI)</li>
                        <li><strong>Improve contractility:</strong> Inotropes</li>
                        <li><strong>Reduce afterload:</strong> Vasodilators (if adequate BP)</li>
                        <li><strong>Mechanical circulatory support:</strong> If refractory to medical therapy</li>
                    </ul>
                    
                    <p><span class="label">Inotropes (ICU - arterial line required):</span></p>
                    <ul>
                        <li><strong>Dobutamine:</strong> 2.5-20mcg/kg/min. First-line. Î²â‚ agonist, increases contractility and reduces afterload. Risk: tachycardia, arrhythmias</li>
                        <li><strong>Milrinone:</strong> Load 50mcg/kg over 10min, then 0.375-0.75mcg/kg/min. PDE-3 inhibitor, inotrope + vasodilator. Avoid if hypotensive. Risk: hypotension, arrhythmias</li>
                        <li><strong>Dopamine:</strong> 5-20mcg/kg/min. Î² and Î± effects at higher doses (vasoconstriction). More arrhythmogenic than dobutamine</li>
                        <li><strong>Epinephrine:</strong> 0.05-0.5mcg/kg/min. For refractory shock. Potent inotrope + vasoconstrictor. Risk: tachycardia, ischemia, lactic acidosis</li>
                        <li><strong>Norepinephrine:</strong> Add if persistent hypotension despite inotropes (provides vasoconstriction)</li>
                    </ul>
                    
                    <p><span class="label">Vasodilators (only if adequate BP, SBP >90):</span></p>
                    <ul>
                        <li><strong>Nitroprusside:</strong> 0.25-10mcg/kg/min. Reduces afterload, improves forward flow. Watch for cyanide toxicity (>48hr high doses)</li>
                        <li><strong>Nitroglycerin:</strong> Reduces preload (less afterload reduction than nitroprusside)</li>
                    </ul>
                    
                    <p><span class="label">Mechanical Circulatory Support (MCS) - Cardiology/CT Surgery Consult:</span></p>
                    <ul>
                        <li><strong>Intra-aortic balloon pump (IABP):</strong> Inflates in diastole (improves coronary perfusion), deflates in systole (reduces afterload). Modest improvement in hemodynamics. No mortality benefit per IABP-SHOCK II trial, but still used as bridge</li>
                        <li><strong>Impella:</strong> Percutaneous ventricular assist device. Greater hemodynamic support than IABP. Can be placed at catheterization</li>
                        <li><strong>VA-ECMO:</strong> Veno-arterial ECMO. Complete cardiopulmonary support. For refractory shock. Bridge to recovery, bridge to decision, or bridge to durable VAD/transplant</li>
                        <li><strong>Surgical VAD:</strong> For bridge to transplant or destination therapy in refractory chronic cardiogenic shock</li>
                    </ul>
                    
                    <p><span class="label">Specific Scenarios:</span></p>
                    <ul>
                        <li><strong>STEMI with shock:</strong> Emergent PCI (or CABG if anatomy requires). Revascularization reduces mortality 50%. Consider MCS if refractory</li>
                        <li><strong>Mechanical complications post-MI:</strong> Surgery (VSD repair, MV repair/replacement, free wall rupture repair). Temporize with IABP/Impella until surgery</li>
                        <li><strong>RV MI/shock:</strong> AVOID diuretics/nitrates (need preload). Give IV fluids aggressively, maintain preload. Revascularization of RCA. May need inotropes</li>
                        <li><strong>Fulminant myocarditis:</strong> Supportive, mechanical support (ECMO). Most recover with bridge support</li>
                    </ul>
                    
                    <p><span class="label">Avoid in Cardiogenic Shock:</span></p>
                    <ul>
                        <li><strong>Î²-blockers:</strong> Worsen contractility and shock (restart when stabilized)</li>
                        <li><strong>ACE-I/ARB:</strong> Worsen hypotension acutely (restart when stabilized)</li>
                        <li><strong>Excessive fluids:</strong> If already volume overloaded (worsens pulmonary edema). Tailor to individual (RV MI needs fluids!)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>"Time is muscle":</strong> In MI-related cardiogenic shock, door-to-balloon time <90min reduces mortality. Revascularization is MOST important intervention</li>
                    <li><strong>Warm vs Cold, Dry vs Wet:</strong> Cold = hypoperfused (needs inotropes Â± MCS), Warm = adequate perfusion. Wet = congested (needs diuresis), Dry = needs volume. Most CS is "cold and wet"</li>
                    <li><strong>Lactate trends matter:</strong> Elevated and rising lactate = worsening shock, need for escalation. Clearing lactate = improving</li>
                    <li><strong>RV MI is different:</strong> Hypotension + clear lungs + JVD. Give fluids, NOT diuretics. Revascularize RCA</li>
                    <li><strong>Mechanical complications timing:</strong> VSR (1-5 days post-MI), free wall rupture (3-5 days), papillary muscle rupture (2-7 days). New murmur + shock = echo STAT!</li>
                    <li><strong>Mortality remains high:</strong> Despite advances, CS mortality 40-50%. Early recognition and aggressive treatment (revascularization, MCS) improve outcomes</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL cardiogenic shock patients require ICU</li>
                        <li>Need for inotropes/pressors</li>
                        <li>Hypotension (SBP <90mmHg)</li>
                        <li>End-organ hypoperfusion (oliguria, AMS, lactate >2)</li>
                        <li>Mechanical circulatory support</li>
                        <li>Post-cardiac catheterization/surgery</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ ICU â†’ FLOOR CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable off inotropes â‰¥24hr</li>
                        <li>SBP >90-100mmHg consistently</li>
                        <li>Adequate end-organ perfusion (normal lactate, UOP, mentation)</li>
                        <li>No mechanical support</li>
                        <li>Underlying cause treated (revascularized, etc)</li>
                        <li>Transitioned to oral heart failure medications</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Death (40-50% mortality), multi-organ failure (renal, hepatic, intestinal ischemia), arrhythmias, cardiac arrest, limb ischemia (from MCS), stroke</p>
                    <p><strong>MCS-related:</strong> Bleeding, vascular injury, infection, hemolysis (ECMO), limb ischemia (IABP, Impella), LV distension/thrombus (VA-ECMO)</p>
                    <p><strong>Chronic (survivors):</strong> Chronic heart failure, need for transplant, durable VAD, recurrent ischemic events, chronic kidney disease</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="bradycardia" class="condition-page">
            <div class="page-header">
                <h2>45. SYMPTOMATIC BRADYCARDIA/HEART BLOCK (PACING)</h2>
                <div class="subtitle">Sinus Bradycardia â€¢ AV Block â€¢ Pacing Indications</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Lightheadedness, presyncope, syncope, dyspnea, chest pain, fatigue with bradycardia (HR <50-60). May be asymptomatic if chronic and compensated</p>
                    <p><span class="label">Emergency Presentations:</span></p>
                    <ul>
                        <li><strong>Syncope:</strong> Sudden loss of consciousness from inadequate cerebral perfusion</li>
                        <li><strong>Shock/hypotension:</strong> Bradycardia-induced low cardiac output</li>
                        <li><strong>Heart failure:</strong> Pulmonary edema from inadequate heart rate compensation</li>
                        <li><strong>Ventricular escape rhythms:</strong> Wide-complex slow rhythms (unreliable, unstable)</li>
                    </ul>
                    <p><span class="label">Types of Bradycardia:</span></p>
                    <ul>
                        <li><strong>Sinus bradycardia:</strong> Normal P waves, normal PR, slow rate. Can be physiologic (athletes) or pathologic</li>
                        <li><strong>1Â° AV block:</strong> PR >200ms. Every P conducted. Usually benign, no treatment needed</li>
                        <li><strong>2Â° AV block Mobitz I (Wenckebach):</strong> Progressive PR prolongation until dropped QRS. Usually benign unless symptomatic</li>
                        <li><strong>2Â° AV block Mobitz II:</strong> Fixed PR with intermittent dropped QRS. High risk of complete heart block. Often needs pacing</li>
                        <li><strong>3Â° AV block (complete):</strong> No AV conduction. Atria and ventricles beat independently. Always pathologic</li>
                        <li><strong>High-grade AV block:</strong> â‰¥2 consecutive P waves not conducted. Unstable, high-risk</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">ECG:</span> Characterize rhythm, measure intervals, identify level of block (AV node vs infranodal)</p>
                    <ul>
                        <li><strong>Narrow QRS escape:</strong> Block at AV node (more benign, responds to atropine)</li>
                        <li><strong>Wide QRS escape:</strong> Infranodal block (His-Purkinje). More unstable, less responsive to atropine, needs pacing</li>
                    </ul>
                    <p><span class="label">Labs:</span> Electrolytes (K, Mg, Ca), digoxin level if on digoxin, TSH, troponin (if concern for MI)</p>
                    <p><span class="label">Imaging:</span> Echocardiogram (assess for structural disease, pericardial effusion/tamponade if suspected)</p>
                    <p><span class="label">Identify Reversible Causes:</span></p>
                    <ul>
                        <li><strong>Medications:</strong> Î²-blockers, CCBs (diltiazem/verapamil), digoxin, antiarrhythmics (amiodarone, sotalol)</li>
                        <li><strong>Ischemia:</strong> Inferior MI (RCA â†’ AV node), anterior MI with BBB/complete heart block (LAD â†’ His-Purkinje)</li>
                        <li><strong>Infiltrative:</strong> Sarcoid, amyloid, hemochromatosis</li>
                        <li><strong>Inflammatory:</strong> Lyme disease (endemic areas), endocarditis (perivalvular abscess)</li>
                        <li><strong>Metabolic:</strong> Hypothyroidism, hyperkalemia, hypoxia</li>
                        <li><strong>Increased vagal tone:</strong> Athletes, sleep, vasovagal</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">ACLS for Unstable Bradycardia:</span></p>
                    <ul>
                        <li><strong>Atropine:</strong> 1mg IV (can repeat q3-5min, max 3mg). First-line for symptomatic bradycardia. Blocks vagal tone. Works for AV nodal block, not infranodal</li>
                        <li><strong>Transcutaneous pacing (TCP):</strong> If atropine ineffective or severe symptoms. Apply pads, set rate 60-80, increase output until capture (usually 50-100mA). Sedate if conscious!</li>
                        <li><strong>Dopamine:</strong> 5-20mcg/kg/min. If atropine ineffective and TCP not available/not working</li>
                        <li><strong>Epinephrine:</strong> 2-10mcg/min infusion. Alternative to dopamine</li>
                    </ul>
                    
                    <p><span class="label">Transvenous Pacing (Temporary):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Symptomatic bradycardia refractory to medical therapy, unstable 2Â° Mobitz II or 3Â° AVB, post-MI with high-grade block</li>
                        <li><strong>Approach:</strong> Central venous access (IJ or subclavian), fluoroscopy-guided wire into RV apex. Set rate 60-80, output 2Ã— threshold</li>
                        <li><strong>Temporary bridge:</strong> To permanent pacemaker or until reversible cause resolves</li>
                    </ul>
                    
                    <p><span class="label">Permanent Pacemaker Indications (Cardiology Consult):</span></p>
                    <ul>
                        <li><strong>Class I (Definite):</strong></li>
                        <ul>
                            <li>3Â° AVB or advanced 2Â° AVB (any level) with symptomatic bradycardia, pauses >3sec while awake, or escape rate <40</li>
                            <li>3Â° AVB or advanced 2Â° AVB at any anatomic level associated with arrhythmias or medical conditions requiring drugs that result in symptomatic bradycardia</li>
                            <li>Persistent 2Â° Mobitz II AVB or 3Â° AVB after MI (even if asymptomatic)</li>
                            <li>Sinus node dysfunction with symptomatic bradycardia or pauses</li>
                            <li>Symptomatic chronotropic incompetence</li>
                            <li>Alternating BBB</li>
                        </ul>
                        <li><strong>Post-MI:</strong> Persistent 2Â° Mobitz II, 3Â° AVB, alternating BBB (even if asymptomatic) - permanent pacemaker indicated. Transient block with inferior MI usually resolves</li>
                        <li><strong>Type of pacemaker:</strong> Dual-chamber (DDD) vs single-chamber (VVI) depending on underlying rhythm and conduction</li>
                    </ul>
                    
                    <p><span class="label">Treating Reversible Causes:</span></p>
                    <ul>
                        <li><strong>Medications:</strong> Hold or reduce offending agents (Î²-blockers, CCBs, digoxin). Consider digibind for digoxin toxicity</li>
                        <li><strong>Ischemia:</strong> Revascularization. Inferior MI with AV block often temporary (RCA supplies AV node). Anterior MI with high-grade block is more permanent (LAD supplies His bundle)</li>
                        <li><strong>Hypothyroidism:</strong> Levothyroxine replacement (bradycardia improves over weeks)</li>
                        <li><strong>Lyme carditis:</strong> Ceftriaxone 2g IV daily Ã— 14-21 days. Often resolves, may need temporary pacing</li>
                        <li><strong>Hyperkalemia:</strong> Treat hyperkalemia (calcium, insulin/D50, kayexelate, dialysis)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Mobitz I vs Mobitz II:</strong> Mobitz I (Wenckebach) = progressive PR prolongation, block at AV node, usually benign. Mobitz II = sudden dropped beat without PR change, infranodal block, high risk of complete heart block, often needs pacing</li>
                    <li><strong>Atropine can worsen infranodal block:</strong> By increasing sinus rate, more beats reach diseased His-Purkinje â†’ paradoxical worsening. Use cautiously if wide-complex escape or known infranodal disease</li>
                    <li><strong>Inferior MI vs Anterior MI:</strong> Inferior (RCA occlusion) â†’ AV nodal ischemia â†’ transient block, usually resolves. Anterior (LAD) â†’ septal infarct, His-Purkinje damage â†’ often permanent, needs PPM</li>
                    <li><strong>High-grade AV block â‰  3Â° AVB:</strong> High-grade = â‰¥2 consecutive non-conducted P waves but occasional conduction still present. Still dangerous, often progresses to complete</li>
                    <li><strong>PPM after MI timing:</strong> If persistent block (not resolved by day 5-7), permanent pacemaker indicated. Transient block with inferior MI often resolves</li>
                    <li><strong>Lyme carditis can cause ANY degree of AV block:</strong> Think Lyme in endemic areas (Northeast US) with new AV block, especially if young, no CAD. Usually reversible with antibiotics</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Unstable vital signs (hypotension, shock)</li>
                        <li>Syncope/presyncope</li>
                        <li>3Â° AV block or high-grade 2Â° AV block</li>
                        <li>Mobitz II 2Â° AV block</li>
                        <li>Need for temporary pacing (TCP or transvenous)</li>
                        <li>Bradycardia + acute MI</li>
                        <li>Ventricular escape rhythm</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Asymptomatic on telemetry monitoring</li>
                        <li>Reversible cause identified and treated</li>
                        <li>If permanent pacemaker placed: functioning appropriately, no complications</li>
                        <li>Stable heart rate and rhythm â‰¥24-48hr</li>
                        <li>No syncope/presyncope episodes</li>
                        <li>Device check arranged (if PPM placed)</li>
                        <li>Cardiology follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Syncope/falls, progression to complete heart block, asystole, ventricular escape rhythms (unstable), cardiogenic shock</p>
                    <p><strong>Post-PPM:</strong> Pneumothorax (CXR post-placement), lead dislodgment, infection (pocket or endocarditis), hematoma, venous thrombosis, pacemaker syndrome (AV dyssynchrony in VVI pacing)</p>
                    <p><strong>Chronic:</strong> Pacemaker-dependent (if complete heart block), need for generator replacement (battery life 5-15 years), lead complications, heart failure (if excessive RV pacing)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="vt-vf" class="condition-page">
            <div class="page-header">
                <h2>46. VENTRICULAR TACHYCARDIA/VENTRICULAR FIBRILLATION</h2>
                <div class="subtitle">Wide Complex Tachycardia â€¢ Sudden Cardiac Arrest â€¢ ICD</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">VT (Ventricular Tachycardia):</span> Wide-complex (QRS >120ms) tachycardia at rate >100bpm. Can be stable or unstable</p>
                    <ul>
                        <li><strong>Stable (Monomorphic VT):</strong> Palpitations, dyspnea, chest pain, presyncope. Hemodynamically stable, conscious</li>
                        <li><strong>Unstable:</strong> Syncope, hypotension (SBP <90), altered mental status, pulmonary edema, shock</li>
                        <li><strong>Pulseless VT:</strong> Cardiac arrest. No pulse, unconscious. Treat as VF</li>
                    </ul>
                    <p><span class="label">VF (Ventricular Fibrillation):</span> Chaotic ventricular activity, no organized QRS complexes. Cardiac arrest. Pulseless, unconscious. Rapidly fatal without defibrillation</p>
                    <p><span class="label">Special Types:</span></p>
                    <ul>
                        <li><strong>Polymorphic VT:</strong> Varying QRS morphology. Often degenerates to VF. If QT prolonged = Torsades de Pointes</li>
                        <li><strong>Torsades de Pointes:</strong> Polymorphic VT with prolonged QT (>500ms). "Twisting of the points". Caused by QT-prolonging drugs, electrolyte abnormalities</li>
                        <li><strong>Ischemic VT:</strong> Post-MI scar-related reentry. Most common in adults</li>
                        <li><strong>Non-ischemic VT:</strong> Dilated cardiomyopathy, sarcoid, ARVD, genetic (Brugada, Long QT)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate (During Event):</span></p>
                    <ul>
                        <li><strong>ECG/Telemetry:</strong> Document rhythm. Assess QRS width, morphology, rate, AV dissociation</li>
                        <li><strong>Differentiate VT from SVT with aberrancy:</strong> Brugada criteria, AV dissociation (diagnostic of VT), capture/fusion beats, very wide QRS (>140ms), extreme axis deviation</li>
                        <li><strong>Pearl:</strong> If wide-complex tachycardia and unsure, assume VT (safer). "When in doubt, it's VT"</li>
                    </ul>
                    <p><span class="label">Post-Event Workup:</span></p>
                    <ul>
                        <li><strong>Labs:</strong> Troponin (MI trigger?), BMP (K, Mg - correct abnormalities), CBC, digoxin level if on digoxin</li>
                        <li><strong>ECG:</strong> Baseline rhythm, assess for MI, QT interval, epsilon wave (ARVD), Brugada pattern, pre-excitation</li>
                        <li><strong>Echo:</strong> Assess EF, wall motion (scar), structural disease</li>
                        <li><strong>Coronary angiography:</strong> If concern for ischemia/MI as trigger</li>
                        <li><strong>Cardiac MRI:</strong> Assess for scar, infiltrative disease (sarcoid, ARVD), myocarditis</li>
                        <li><strong>EP study:</strong> If recurrent VT, to map and potentially ablate VT circuit</li>
                    </ul>
                    <p><span class="label">Identify Triggers/Causes:</span></p>
                    <ul>
                        <li><strong>Ischemia/MI:</strong> Most common. VT/VF in first 48hr of MI is electrical instability. VT >48hr post-MI is scar-related</li>
                        <li><strong>Cardiomyopathy:</strong> Low EF (<35%) is strongest predictor of sudden death</li>
                        <li><strong>Electrolytes:</strong> Hypokalemia, hypomagnesemia, hypocalcemia (prolong QT â†’ Torsades)</li>
                        <li><strong>Medications:</strong> QT-prolonging drugs (antiarrhythmics, antipsychotics, fluoroquinolones, macrolides)</li>
                        <li><strong>Genetic:</strong> Long QT syndrome, Brugada, ARVD, catecholaminergic polymorphic VT (CPVT), hypertrophic cardiomyopathy</li>
                        <li><strong>Toxic:</strong> Cocaine, methamphetamine, digoxin toxicity</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Pulseless VT/VF (Cardiac Arrest - ACLS):</span></p>
                    <ul>
                        <li><strong>Immediate defibrillation:</strong> 200J biphasic (or 360J monophasic). Resume CPR immediately after shock</li>
                        <li><strong>CPR:</strong> High-quality compressions (â‰¥100/min, depth â‰¥2 inches), minimize interruptions</li>
                        <li><strong>Epinephrine:</strong> 1mg IV/IO q3-5min</li>
                        <li><strong>Amiodarone:</strong> 300mg IV/IO first dose, then 150mg if recurrent VF/VT</li>
                        <li><strong>Treat reversible causes:</strong> H's and T's (Hypovolemia, Hypoxia, Hâº [acidosis], Hypo/Hyperkalemia, Hypothermia, Toxins, Tamponade, Tension pneumothorax, Thrombosis [coronary or pulmonary], Trauma)</li>
                    </ul>
                    
                    <p><span class="label">Unstable VT (With Pulse, SBP <90, AMS, pulmonary edema):</span></p>
                    <ul>
                        <li><strong>Synchronized cardioversion:</strong> 100J, then 150J, 200J if unsuccessful. Sedate if conscious!</li>
                        <li><strong>If polymorphic VT:</strong> Treat as VF (unsynchronized high-energy shock 200J)</li>
                        <li><strong>Post-cardioversion:</strong> Amiodarone 150mg IV over 10min, then 1mg/min Ã— 6hr, then 0.5mg/min</li>
                    </ul>
                    
                    <p><span class="label">Stable Monomorphic VT (With Pulse, Hemodynamically Stable):</span></p>
                    <ul>
                        <li><strong>Amiodarone:</strong> 150mg IV over 10min (can repeat), then 1mg/min Ã— 6hr, then 0.5mg/min Ã— 18hr</li>
                        <li><strong>Procainamide:</strong> Alternative if normal EF. 20-50mg/min IV (max 17mg/kg). Monitor QT and BP</li>
                        <li><strong>Sotalol:</strong> Another alternative. 1.5mg/kg IV over 5min. Monitor QT</li>
                        <li><strong>If refractory:</strong> Synchronized cardioversion (consider sedation)</li>
                    </ul>
                    
                    <p><span class="label">Torsades de Pointes (Polymorphic VT with Long QT):</span></p>
                    <ul>
                        <li><strong>Magnesium sulfate:</strong> 2g IV over 5-20min (even if Mg normal). First-line. Stabilizes membrane</li>
                        <li><strong>Correct electrolytes:</strong> K >4.5, Mg >2</li>
                        <li><strong>Increase heart rate:</strong> Isoproterenol infusion (1-4mcg/min) or overdrive pacing (rate 100-120) to shorten QT</li>
                        <li><strong>STOP QT-prolonging agents:</strong> Review medication list, discontinue offending drugs</li>
                        <li><strong>If unstable:</strong> Unsynchronized defibrillation (as VF)</li>
                    </ul>
                    
                    <p><span class="label">VT Storm (Recurrent VT, â‰¥3 episodes in 24hr):</span></p>
                    <ul>
                        <li><strong>Amiodarone infusion:</strong> Load 150mg, then continuous infusion</li>
                        <li><strong>Î²-blockers:</strong> Metoprolol or esmolol (reduce sympathetic drive)</li>
                        <li><strong>Sedation:</strong> Reduce sympathetic tone (propofol, benzodiazepines)</li>
                        <li><strong>Correct triggers:</strong> Ischemia (revascularization), electrolytes, medications</li>
                        <li><strong>Catheter ablation:</strong> Consider urgent EP study and ablation if refractory</li>
                    </ul>
                    
                    <p><span class="label">Secondary Prevention (ICD Placement - Cardiology/EP Consult):</span></p>
                    <ul>
                        <li><strong>Class I Indications (Definite):</strong></li>
                        <ul>
                            <li>Cardiac arrest due to VF/VT not due to reversible cause</li>
                            <li>Spontaneous sustained VT with structural heart disease</li>
                            <li>Unexplained syncope with inducible VT/VF at EP study</li>
                        </ul>
                        <li><strong>Primary Prevention ICD:</strong> EF â‰¤35% despite optimal medical therapy â‰¥3 months (ischemic) or â‰¥3 months (non-ischemic), NYHA Class II-III</li>
                        <li><strong>Wearable defibrillator (LifeVest):</strong> Bridge to ICD assessment if not ready for permanent device (e.g., waiting for EF reassessment, infection, etc)</li>
                    </ul>
                    
                    <p><span class="label">Treating Underlying Causes:</span></p>
                    <ul>
                        <li><strong>Ischemia:</strong> Urgent PCI/CABG. VT/VF in acute MI is electrical, may not recur after revascularization</li>
                        <li><strong>Electrolytes:</strong> K >4, Mg >2 (higher targets in setting of VT/VF)</li>
                        <li><strong>Long QT syndrome:</strong> Î²-blockers (propranolol, nadolol). ICD if syncope/VT despite therapy</li>
                        <li><strong>Brugada:</strong> ICD. No proven pharmacologic therapy. Avoid drugs that unmask (procainamide, flecainide)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Wide complex tachycardia = VT until proven otherwise:</strong> Especially with structural heart disease. Treating VT as SVT can be fatal (e.g., adenosine in VT can cause VF). When in doubt, use amiodarone</li>
                    <li><strong>AV dissociation proves VT:</strong> P waves and QRS complexes independent. Capture beats (narrow QRS when P captures ventricle) and fusion beats also diagnostic</li>
                    <li><strong>Early post-MI VT/VF (first 48hr) doesn't need ICD:</strong> Electrical instability of ischemic myocardium. Treat with revascularization. VT >48hr post-MI is scar-related and needs ICD</li>
                    <li><strong>Torsades = Magnesium first:</strong> Even if serum Mg normal. Increases heart rate to shorten QT</li>
                    <li><strong>Never give adenosine for wide-complex tachycardia unless certain it's SVT:</strong> Can cause VF in VT, can precipitate AF with rapid conduction in WPW</li>
                    <li><strong>ICD is NOT primary treatment:</strong> ICD prevents sudden death but doesn't treat VT. Still need optimal medical therapy (Î²-blockers, ACE-I, etc) and treatment of underlying cause</li>
                    <li><strong>VT storm is an emergency:</strong> Recurrent shocks from ICD, severe sympathetic surge. Sedate, amiodarone, consider urgent ablation</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Pulseless VT/VF (post-ROSC)</li>
                        <li>Unstable VT (hypotension, AMS, pulmonary edema)</li>
                        <li>VT storm (recurrent episodes)</li>
                        <li>Post-cardioversion/defibrillation</li>
                        <li>Continuous antiarrhythmic infusions</li>
                        <li>Acute MI with ventricular arrhythmias</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Stable rhythm â‰¥24-48hr on telemetry</li>
                        <li>No recurrent VT/VF</li>
                        <li>Hemodynamically stable</li>
                        <li>Underlying cause identified and treated</li>
                        <li>If ICD candidate: Device placed or LifeVest prescribed</li>
                        <li>Optimal medical therapy initiated (Î²-blockers, etc)</li>
                        <li>Cardiology/EP follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Sudden cardiac death (if not defibrillated), cardiogenic shock, hypoxic brain injury (post-arrest), recurrent VT/VF (VT storm), ICD shocks (painful, psychological impact)</p>
                    <p><strong>Post-ICD:</strong> Inappropriate shocks (lead malfunction, SVT misdetected), infection (pocket or lead endocarditis), lead dislodgment, pneumothorax, psychological impact of living with ICD</p>
                    <p><strong>Chronic:</strong> Recurrent VT (may need ablation), progression of heart failure, need for transplant, complications of underlying disease (CAD, cardiomyopathy)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="limb-ischemia" class="condition-page">
            <div class="page-header">
                <h2>47. ACUTE LIMB ISCHEMIA</h2>
                <div class="subtitle">Vascular Emergency â€¢ 6 P's â€¢ Revascularization</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic 6 P's:</span></p>
                    <ul>
                        <li><strong>Pain:</strong> Severe, sudden onset. Often at rest</li>
                        <li><strong>Pallor:</strong> White, mottled appearance</li>
                        <li><strong>Pulselessness:</strong> Absent distal pulses (femoral, popliteal, DP, PT)</li>
                        <li><strong>Paresthesias:</strong> Numbness, tingling. Early sign of nerve ischemia</li>
                        <li><strong>Paralysis:</strong> Weakness, inability to move limb. LATE finding, indicates severe ischemia</li>
                        <li><strong>Poikilothermia:</strong> Cool to touch compared to contralateral limb</li>
                    </ul>
                    <p><span class="label">Severity Classification (Rutherford):</span></p>
                    <ul>
                        <li><strong>Class I (Viable):</strong> No immediate threat. No sensory/motor deficit. Audible Doppler signals</li>
                        <li><strong>Class IIA (Marginally threatened):</strong> Salvageable if promptly treated. Minimal sensory loss, no motor deficit. Inaudible Doppler</li>
                        <li><strong>Class IIB (Immediately threatened):</strong> Salvageable with immediate revascularization. Sensory loss beyond toes, mild-moderate motor deficit. Inaudible Doppler</li>
                        <li><strong>Class III (Irreversible):</strong> Major tissue loss inevitable. Profound sensory/motor deficit, rigor. Skin marbling. Amputation likely</li>
                    </ul>
                    <p><span class="label">Etiologies:</span></p>
                    <ul>
                        <li><strong>Embolism (40%):</strong> Sudden onset, no prior claudication. AF (cardiac source), MI (LV thrombus), endocarditis, paradoxical embolus. Typically lodges at arterial bifurcations</li>
                        <li><strong>Thrombosis (40%):</strong> Progressive onset, history of claudication/PAD. Atherosclerotic disease with superimposed thrombosis</li>
                        <li><strong>Trauma:</strong> Fracture, dislocation, penetrating injury, iatrogenic (catheterization)</li>
                        <li><strong>Other:</strong> Aortic dissection, compartment syndrome, popliteal aneurysm thrombosis, hypercoagulable state</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Exam:</span> Vascular exam (pulses, capillary refill, temperature, color), neurologic exam (sensation, motor function), compare to contralateral limb</p>
                    <p><span class="label">Doppler Ultrasound:</span> Bedside assessment of flow. Audible signals suggest viability. Inaudible signals in threatened/irreversible ischemia</p>
                    <p><span class="label">Labs:</span> CBC, BMP (creatinine - may worsen with revascularization/rhabdo), CK (rhabdomyolysis if elevated), lactate, coagulation studies, type & screen</p>
                    <p><span class="label">ECG:</span> Assess for AF (cardioembolic source), recent MI</p>
                    <p><span class="label">Imaging (don't delay revascularization if Class IIB/III):</span></p>
                    <ul>
                        <li><strong>CT Angiography (CTA):</strong> Gold standard for anatomy. Identifies level of occlusion, collaterals, assess for aneurysm/dissection. Fast</li>
                        <li><strong>Conventional angiography:</strong> Diagnostic + therapeutic (catheter-directed thrombolysis). Done in angio suite</li>
                        <li><strong>Duplex ultrasound:</strong> If concern for DVT, popliteal aneurysm</li>
                    </ul>
                    <p><span class="label">Echocardiogram:</span> If embolic source suspected (AF, LV thrombus, endocarditis, PFO)</p>
                    <p><span class="label">Embolism vs Thrombosis Clues:</span></p>
                    <ul>
                        <li><strong>Embolism:</strong> Sudden onset, no prior symptoms, AF, normal contralateral pulses, emboli elsewhere</li>
                        <li><strong>Thrombosis:</strong> Progressive symptoms, history of claudication, abnormal contralateral pulses, chronic PAD</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immediate Management (All Patients):</span></p>
                    <ul>
                        <li><strong>URGENT Vascular Surgery Consult:</strong> Time = limb! Revascularization within 6 hours optimal</li>
                        <li><strong>IV Heparin:</strong> Bolus 80 units/kg, then 18 units/kg/hr. Prevents propagation of thrombus/embolus. DO NOT delay for imaging</li>
                        <li><strong>Analgesia:</strong> IV opioids for severe pain</li>
                        <li><strong>IV fluids:</strong> Aggressive hydration (prevent contrast-induced nephropathy, prepare for reperfusion injury)</li>
                        <li><strong>Keep limb in dependent position:</strong> Improves blood flow. Do NOT elevate</li>
                        <li><strong>Keep warm:</strong> Room warm, but avoid direct heat to limb (can increase metabolic demand)</li>
                        <li><strong>Avoid flexing knee:</strong> Can worsen ischemia by compressing popliteal artery</li>
                    </ul>
                    
                    <p><span class="label">Revascularization Strategies (Vascular Surgery):</span></p>
                    <ul>
                        <li><strong>Catheter-directed thrombolysis:</strong> For Class I/IIA. Infuse tPA directly into thrombus. Takes 12-24hr. For less severe ischemia, or if patient not surgical candidate</li>
                        <li><strong>Surgical thromboembolectomy:</strong> For Class IIB/III (immediate threat). Fogarty catheter to remove clot. Faster than thrombolysis</li>
                        <li><strong>Bypass surgery:</strong> If severe underlying PAD, long-segment occlusion, or failed endovascular approach</li>
                        <li><strong>Hybrid approach:</strong> Combination of surgical and endovascular techniques</li>
                    </ul>
                    
                    <p><span class="label">Reperfusion Injury Prevention:</span></p>
                    <ul>
                        <li><strong>IV fluids:</strong> Aggressive hydration to maintain UOP >1mL/kg/hr (prevent myoglobin-induced AKI)</li>
                        <li><strong>Bicarbonate:</strong> Consider alkalinizing urine if rhabdomyolysis (keeps myoglobin soluble)</li>
                        <li><strong>Monitor electrolytes:</strong> Watch for hyperkalemia (reperfusion releases K from ischemic muscle)</li>
                        <li><strong>Fasciotomy:</strong> If compartment syndrome develops (swelling, pain, palpable tension). Prophylactic if prolonged ischemia (>6hr)</li>
                    </ul>
                    
                    <p><span class="label">Post-Revascularization Care:</span></p>
                    <ul>
                        <li><strong>Monitor for compartment syndrome:</strong> Severe pain (out of proportion), pain with passive stretch, tense compartments, paresthesias. SURGICAL EMERGENCY - fasciotomy</li>
                        <li><strong>Continue anticoagulation:</strong> Heparin bridge to warfarin or DOAC (if embolic source). Lifelong if AF, LV thrombus</li>
                        <li><strong>Antiplatelet:</strong> ASA + P2Y12 inhibitor (clopidogrel) if thrombotic/PAD</li>
                        <li><strong>Statin:</strong> High-intensity (PAD management)</li>
                        <li><strong>Monitor CK, potassium, creatinine:</strong> For rhabdomyolysis and AKI</li>
                    </ul>
                    
                    <p><span class="label">If Irreversible (Class III):</span></p>
                    <ul>
                        <li><strong>Amputation:</strong> To prevent systemic complications (rhabdomyolysis, sepsis from necrotic tissue)</li>
                        <li><strong>Supportive care:</strong> Aggressive hydration, treat hyperkalemia, monitor for systemic toxicity</li>
                        <li><strong>Do NOT revascularize:</strong> Reperfusion of necrotic tissue releases toxins (K, myoglobin, lactate) â†’ systemic collapse</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>"Time is limb":</strong> Revascularization within 6 hours gives best outcomes. Muscle tolerates 4-6hr ischemia, nerves 2-4hr. Paralysis = LATE finding, needs emergent revascularization</li>
                    <li><strong>Heparin first, imaging second:</strong> Start heparin immediately based on clinical diagnosis. Don't delay for imaging confirmation</li>
                    <li><strong>Paralysis is bad:</strong> Motor deficit indicates advanced ischemia (nerve damage). Urgent revascularization needed. Sensation goes before motor</li>
                    <li><strong>Compartment syndrome after revascularization:</strong> Reperfusion causes swelling. High index of suspicion. Pain out of proportion, pain with passive stretch. Don't wait for pulselessness or pressure measurement - clinical diagnosis!</li>
                    <li><strong>Blue toe syndrome:</strong> Emboli to digital arteries from proximal atherosclerotic plaque. Still palpable pulses. Suggests proximal source (aorta, iliac, popliteal aneurysm)</li>
                    <li><strong>Don't revascularize Class III:</strong> Reperfusion of necrotic tissue causes systemic toxicity (hyperkalemia, myoglobin â†’ cardiac arrest, AKI). Amputation is life-saving</li>
                    <li><strong>Check for bilateral involvement:</strong> Emboli can lodge in multiple locations. Assess contralateral limb, visceral arteries</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Class IIB/III (threatened or irreversible ischemia)</li>
                        <li>Hemodynamic instability</li>
                        <li>Post-revascularization (monitor for reperfusion injury)</li>
                        <li>Rhabdomyolysis (CK >5000, rising creatinine)</li>
                        <li>Severe hyperkalemia</li>
                        <li>Compartment syndrome requiring fasciotomy</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Successful revascularization with palpable pulses</li>
                        <li>No signs of compartment syndrome</li>
                        <li>Stable renal function (no rhabdo-induced AKI)</li>
                        <li>Electrolytes normalized</li>
                        <li>On appropriate anticoagulation/antiplatelet</li>
                        <li>Vascular surgery follow-up arranged</li>
                        <li>If embolic: Cardiology follow-up, address source (AF, LV thrombus)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Limb loss (amputation 10-30% depending on severity), compartment syndrome (post-reperfusion swelling), rhabdomyolysis â†’ AKI, hyperkalemia â†’ cardiac arrest, sepsis from necrotic tissue, death (15-20% in-hospital mortality)</p>
                    <p><strong>Post-reperfusion:</strong> Compartment syndrome, reperfusion injury (release of toxins â†’ systemic inflammation), AKI (myoglobin), cardiac arrhythmias (hyperkalemia), recurrent thrombosis/embolism</p>
                    <p><strong>Chronic:</strong> Chronic limb ischemia (incomplete revascularization), nerve damage (foot drop from peroneal nerve), chronic pain, graft/stent thrombosis, recurrent events if embolic source not addressed</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="ild" class="condition-page">
    <div class="page-header">
        <h2>48. ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASE (ILD)</h2>
        <div class="subtitle">Progressive Dyspnea â€¢ Ground-Glass Opacities â€¢ High Mortality</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with known ILD (idiopathic pulmonary fibrosis, connective tissue disease-related ILD, hypersensitivity pneumonitis) presenting with acute worsening of dyspnea, new or worsening hypoxemia, and new radiographic infiltrates not fully explained by infection, heart failure, or other causes.</p>
            
            <ul>
                <li><strong>Diagnostic Criteria for Acute Exacerbation:</strong>
                    <ul>
                        <li>Previous or concurrent diagnosis of ILD (usually IPF)</li>
                        <li>Acute worsening of dyspnea within 1 month</li>
                        <li>New bilateral ground-glass opacities and/or consolidation on CT</li>
                        <li>Worsening hypoxemia (PaO2/FiO2 <300 or need for supplemental O2)</li>
                        <li>Absence of alternative causes (infection, heart failure, PE, pneumothorax)</li>
                    </ul>
                </li>
                <li><strong>Symptoms:</strong>
                    <ul>
                        <li>Rapidly progressive dyspnea (over days to weeks)</li>
                        <li>Dry cough (non-productive)</li>
                        <li>Fever (in 50%, may mimic infection)</li>
                        <li>Fatigue, malaise</li>
                        <li>No response to usual ILD medications</li>
                    </ul>
                </li>
                <li><strong>Physical Exam:</strong>
                    <ul>
                        <li>Tachypnea, hypoxemia (often severe)</li>
                        <li>Bibasilar inspiratory crackles (Velcro-like)</li>
                        <li>Digital clubbing (if chronic ILD present)</li>
                        <li>Cyanosis in severe cases</li>
                        <li>Signs of respiratory distress (accessory muscle use, tripod position)</li>
                    </ul>
                </li>
                <li><strong>Risk Factors for Acute Exacerbation:</strong>
                    <ul>
                        <li>IPF subtype (highest risk, ~20% annual incidence)</li>
                        <li>Lung biopsy or other surgical procedures</li>
                        <li>Aspiration</li>
                        <li>High-dose oxygen therapy</li>
                        <li>Viral respiratory infections</li>
                        <li>Recent drug changes</li>
                    </ul>
                </li>
                <li><strong>Prognosis:</strong> Poor - in-hospital mortality 50-90%, median survival 3-4 months if survive hospitalization</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>High-Resolution CT Chest (HRCT):</strong></p>
            <ul>
                <li><strong>Typical Findings:</strong>
                    <ul>
                        <li>New bilateral ground-glass opacities (diffuse or peripheral)</li>
                        <li>Often superimposed on existing fibrotic changes (honeycombing, traction bronchiectasis)</li>
                        <li>Consolidation in some cases</li>
                        <li>Distribution: Bilateral, predominantly basal and peripheral</li>
                    </ul>
                </li>
                <li><strong>Rule Out Alternative Diagnoses:</strong> Pneumonia (focal consolidation), heart failure (pleural effusions, interlobular septal thickening), PE (filling defects on CTA)</li>
            </ul>
            
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>ABG:</strong> Hypoxemia (PaO2 <60 mmHg), elevated A-a gradient, respiratory alkalosis (early) or acidosis (late)</li>
                <li><strong>CBC:</strong> Leukocytosis common (even without infection)</li>
                <li><strong>BNP:</strong> Helps differentiate from heart failure (usually normal to mildly elevated in AE-ILD)</li>
                <li><strong>Inflammatory Markers:</strong> CRP, ESR elevated (non-specific)</li>
                <li><strong>LDH:</strong> Often elevated (correlates with severity)</li>
                <li><strong>KL-6 (Krebs von den Lungen-6):</strong> Elevated in acute exacerbations (if available, not widely used in US)</li>
            </ul>
            
            <p><strong>Microbiologic Studies:</strong></p>
            <ul>
                <li><strong>Blood Cultures:</strong> Rule out bacteremia</li>
                <li><strong>Sputum Culture/Gram Stain:</strong> If productive cough</li>
                <li><strong>Respiratory Viral Panel:</strong> PCR for influenza, RSV, COVID-19, other viruses</li>
                <li><strong>Urine Antigens:</strong> Legionella, Pneumococcus</li>
                <li><strong>Fungal Studies:</strong> Beta-D-glucan, galactomannan if immunosuppressed</li>
            </ul>
            
            <p><strong>Bronchoscopy with BAL (Bronchoalveolar Lavage):</strong></p>
            <ul>
                <li><strong>Indications:</strong> Rule out infection, especially if considering immunosuppression</li>
                <li><strong>BAL Findings in AE-ILD:</strong>
                    <ul>
                        <li>Elevated neutrophils (typically >50%)</li>
                        <li>May have increased eosinophils or lymphocytes</li>
                        <li>Negative cultures (by definition, not infection)</li>
                    </ul>
                </li>
                <li><strong>Cultures:</strong> Bacterial, fungal, viral, mycobacterial (AFB), PCP</li>
                <li><strong>Risk:</strong> Bronchoscopy may worsen hypoxemia; use caution</li>
            </ul>
            
            <p><strong>Echocardiogram:</strong></p>
            <ul>
                <li><strong>Purpose:</strong> Assess for heart failure, pulmonary hypertension (common complication of ILD)</li>
                <li><strong>Findings:</strong> May show elevated RVSP (pulmonary HTN), RV dysfunction, but preserved LV function</li>
            </ul>
            
            <p><strong>Lung Biopsy:</strong></p>
            <ul>
                <li><strong>Role:</strong> Usually NOT performed in acute setting (high risk, unlikely to change management)</li>
                <li><strong>Histology (if performed):</strong> Diffuse alveolar damage (DAD) pattern - hyaline membranes, fibroblast proliferation, superimposed on background fibrosis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Supportive Care (Foundation of Treatment):</strong></p>
            <ul>
                <li><strong>Oxygen Therapy:</strong>
                    <ul>
                        <li>Goal SpO2 88-92% (avoid hyperoxia, may worsen lung injury)</li>
                        <li>Start with nasal cannula or face mask</li>
                        <li>Escalate to high-flow nasal cannula (HFNC) if inadequate</li>
                        <li>Non-invasive ventilation (BiPAP) may be attempted but often fails</li>
                        <li>Mechanical ventilation if respiratory failure despite maximal support</li>
                    </ul>
                </li>
                <li><strong>Mechanical Ventilation (if required):</strong>
                    <ul>
                        <li>Low tidal volume strategy (6 mL/kg IBW)</li>
                        <li>PEEP to prevent atelectasis</li>
                        <li>Plateau pressure <30 cm H2O</li>
                        <li>Prognosis extremely poor once intubated (mortality >90%)</li>
                        <li>Consider goals of care discussion BEFORE intubation</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Pharmacologic Treatment:</strong></p>
            <ul>
                <li><strong>Corticosteroids (First-Line, Despite Limited Evidence):</strong>
                    <ul>
                        <li><strong>Methylprednisolone:</strong> 500-1000 mg IV daily Ã— 3 days (pulse dose), then prednisone 0.5-1 mg/kg/day PO with taper over weeks to months</li>
                        <li>Alternative: Prednisone 1 mg/kg/day PO (if not critically ill)</li>
                        <li>Evidence: No RCTs, but widely used based on observational data</li>
                        <li>Some patients respond, others do not; response unpredictable</li>
                    </ul>
                </li>
                <li><strong>Immunosuppression (Controversial, Limited Evidence):</strong>
                    <ul>
                        <li><strong>Cyclophosphamide:</strong> 500-600 mg/mÂ² IV monthly (case reports, no RCT data)</li>
                        <li><strong>Cyclosporine:</strong> 2-3 mg/kg/day PO divided BID (some case series suggest benefit)</li>
                        <li><strong>Tacrolimus:</strong> Alternative to cyclosporine</li>
                        <li>Use ONLY after ruling out infection with BAL</li>
                        <li>Most evidence from Japanese studies, not widely adopted in US</li>
                    </ul>
                </li>
                <li><strong>Antimicrobials (Empiric, Until Infection Ruled Out):</strong>
                    <ul>
                        <li>Broad-spectrum antibiotics: Ceftriaxone 1-2g IV daily + azithromycin 500mg IV daily (or respiratory fluoroquinolone)</li>
                        <li>Add PCP prophylaxis if not already on: TMP-SMX DS 1 tab daily or atovaquone 1500mg daily</li>
                        <li>Antiviral therapy if influenza/COVID suspected</li>
                        <li>Discontinue once infection ruled out by BAL</li>
                    </ul>
                </li>
                <li><strong>Antifibrotics (for Underlying IPF, NOT for Acute Exacerbation):</strong>
                    <ul>
                        <li>Nintedanib, pirfenidone: Slow progression of IPF but NO role in acute exacerbation</li>
                        <li>Hold during acute illness, resume if patient stabilizes</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Experimental/Rescue Therapies (Limited Data, Case Reports Only):</strong></p>
            <ul>
                <li><strong>Direct Hemoperfusion with Polymyxin B (PMX-DHP):</strong> Removes cytokines, used in Japan, not FDA-approved in US</li>
                <li><strong>ECMO:</strong> Case reports of success as bridge to lung transplant, but very high mortality</li>
                <li><strong>Lung Transplant:</strong> Definitive treatment if eligible, but often too sick for transplant during acute exacerbation</li>
            </ul>
            
            <p><strong>Palliative Care:</strong></p>
            <ul>
                <li><strong>Early Involvement:</strong> Given high mortality, involve palliative care early</li>
                <li><strong>Goals of Care Discussion:</strong> Clarify code status, mechanical ventilation wishes, comfort measures</li>
                <li><strong>Symptom Management:</strong> Opioids for dyspnea, anxiolytics for anxiety</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Acute Exacerbation = Clinical Diagnosis of Exclusion:</strong> Must rule out infection, heart failure, PE, pneumothorax before diagnosing AE-ILD. No single test confirms itâ€”diagnosis based on clinical course + imaging + negative workup for alternatives.</li>
            <li><strong>IPF Has Highest Acute Exacerbation Risk:</strong> ~5-20% annual incidence in IPF patients. Other ILDs (NSIP, CTD-ILD, HP) have lower risk. IPF patients should be counseled about this risk.</li>
            <li><strong>Prognosis Is Dismal:</strong> In-hospital mortality 50-90%, median survival 3-4 months even if discharged. Mechanical ventilation = >90% mortality. Have goals of care discussions EARLY, before crisis.</li>
            <li><strong>Ground-Glass Opacities on Background Fibrosis = Key Imaging Clue:</strong> New bilateral GGO superimposed on pre-existing honeycombing/traction bronchiectasis is classic for AE-ILD. Helps distinguish from new-onset ILD.</li>
            <li><strong>Steroids Are Standard Despite Lack of RCT Evidence:</strong> No randomized trials prove steroids work, but they're first-line based on observational data and biologic plausibility. Pulse-dose methylprednisolone (500-1000mg daily Ã— 3 days) commonly used.</li>
            <li><strong>BAL Before Immunosuppression:</strong> If considering steroids or other immunosuppression, must rule out infection first with BAL. Immunosuppressing an infection is catastrophic. BAL shows increased neutrophils in AE-ILD.</li>
            <li><strong>Avoid Hyperoxia:</strong> Target SpO2 88-92%, not normoxia. High FiO2 may worsen diffuse alveolar damage. Use lowest FiO2 to achieve acceptable saturations.</li>
            <li><strong>Intubation Is Often Futile:</strong> Once requiring mechanical ventilation, mortality exceeds 90%. Discuss code status and ventilation wishes BEFORE intubating. Many patients/families prefer comfort measures over intubation.</li>
            <li><strong>Recurrence Is Common:</strong> Survivors of one acute exacerbation are at very high risk for subsequent exacerbations. Median survival after first AE is 3-4 months. Emphasize close follow-up and early intervention for future episodes.</li>
            <li><strong>Lung Transplant Evaluation Should Happen Early:</strong> If patient has IPF and is transplant-eligible, refer for evaluation BEFORE acute exacerbation occurs. During AE, often too sick for transplant. Transplant is only definitive treatment for IPF.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Respiratory failure requiring high-flow oxygen or non-invasive ventilation</li>
            <li>Hypoxemia refractory to supplemental oxygen (SpO2 <88% on >6L NC)</li>
            <li>Need for mechanical ventilation</li>
            <li>Hemodynamic instability</li>
            <li>Rapid clinical deterioration</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Hemodynamically stable</li>
            <li>Oxygen requirements improved and stable (ideally <4L NC or back to baseline)</li>
            <li>Able to ambulate without severe desaturation</li>
            <li>Infection ruled out</li>
            <li>On stable corticosteroid taper regimen</li>
            <li>Close pulmonology follow-up arranged (within 1-2 weeks)</li>
            <li>Patient/family educated on poor prognosis, recurrence risk</li>
            <li>Palliative care involvement arranged if appropriate</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="hemoptysis" class="condition-page">
    <div class="page-header">
        <h2>49. HEMOPTYSIS (MASSIVE)</h2>
        <div class="subtitle">Life-Threatening Airway â€¢ Bronchial Artery Source â€¢ Emergent Intervention</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient coughing up blood (>100-600 mL in 24 hours, or any amount causing airway compromise or hemodynamic instability). Massive hemoptysis is a medical emergency with mortality up to 50-80% if untreated, primarily from asphyxiation (not exsanguination).</p>
            
            <ul>
                <li><strong>Definitions:</strong>
                    <ul>
                        <li><strong>Mild hemoptysis:</strong> <100 mL/24h (blood-streaked sputum)</li>
                        <li><strong>Moderate:</strong> 100-600 mL/24h</li>
                        <li><strong>Massive (life-threatening):</strong> >600 mL/24h OR >100-150 mL/hr OR any amount causing airway compromise or hemodynamic instability</li>
                        <li>Note: Definitions vary; focus on clinical impact (airway threat, shock) rather than volume</li>
                    </ul>
                </li>
                <li><strong>Mechanism of Death:</strong> Asphyxiation from blood filling alveoli (hypoxemia), NOT exsanguination. Airway protection is priority.</li>
                <li><strong>Common Etiologies (90% from Bronchial Arteries):</strong>
                    <ul>
                        <li><strong>Bronchiectasis (50%):</strong> Most common cause worldwide, chronic inflammation â†’ bronchial artery hypertrophy</li>
                        <li><strong>Tuberculosis (TB):</strong> Active or prior TB with cavitation, Rasmussen aneurysm (pulmonary artery erosion by cavity)</li>
                        <li><strong>Lung cancer:</strong> Primary (squamous most common) or metastatic, tumor eroding into vessels</li>
                        <li><strong>Aspergilloma (fungus ball):</strong> In pre-existing cavity (old TB, sarcoid), causes bleeding from friable vessels in cavity wall</li>
                        <li><strong>Pulmonary abscess:</strong> Necrotizing pneumonia with vessel erosion</li>
                        <li><strong>Mycetoma:</strong> Fungal ball in cavity</li>
                    </ul>
                </li>
                <li><strong>Less Common Causes (10% from Pulmonary Arteries):</strong>
                    <ul>
                        <li><strong>Pulmonary embolism:</strong> Pulmonary infarction</li>
                        <li><strong>AVM (arteriovenous malformation):</strong> Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu)</li>
                        <li><strong>Pulmonary artery rupture:</strong> Swan-Ganz catheter, trauma, BehÃ§et's disease, vasculitis</li>
                        <li><strong>Diffuse alveolar hemorrhage (DAH):</strong> Goodpasture, Wegener granulomatosis, lupus, but typically presents as anemia/hypoxemia, not massive hemoptysis</li>
                    </ul>
                </li>
                <li><strong>Iatrogenic Causes:</strong> Post-bronchoscopy, transbronchial biopsy, Swan-Ganz catheter placement</li>
                <li><strong>Presentation:</strong>
                    <ul>
                        <li>Coughing up frank blood (bright red)</li>
                        <li>Blood-tinged frothy sputum (from alveoli)</li>
                        <li>Sensation of warmth/bubbling in chest preceding cough</li>
                        <li>Dyspnea, tachypnea (airway obstruction from blood)</li>
                        <li>Hypoxemia (SpO2 drop from blood in alveoli)</li>
                        <li>Hemodynamic instability if massive volume loss (rare, late sign)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Initial Assessment (EMERGENT):</strong></p>
            <ul>
                <li><strong>ABCs:</strong> Airway patency (can they talk?), breathing (oxygen saturation), circulation (BP, HR)</li>
                <li><strong>Distinguish from Hematemesis:</strong>
                    <ul>
                        <li>Hemoptysis: Cough, frothy/bright red, alkaline pH, mixed with air/sputum</li>
                        <li>Hematemesis: Vomiting, dark/coffee-ground, acidic pH, mixed with food</li>
                        <li>Nasopharyngeal bleed: Usually obvious source, blood drips posteriorly</li>
                    </ul>
                </li>
                <li><strong>Lateralize Bleeding Side:</strong> Ask patient which side they feel bleeding from, listen for unilateral decreased breath sounds or crackles (blood-filled lung)</li>
            </ul>
            
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>CBC:</strong> Hemoglobin (baseline, check for anemia from blood loss), platelets (thrombocytopenia?)</li>
                <li><strong>Coagulation Studies:</strong> PT/INR, PTT (anticoagulation, coagulopathy)</li>
                <li><strong>Type & Screen:</strong> Prepare for transfusion</li>
                <li><strong>ABG:</strong> Assess oxygenation, ventilation</li>
                <li><strong>BMP:</strong> Renal function (contrast for CT, uremia affects platelets)</li>
            </ul>
            
            <p><strong>Chest X-ray (Portable if Unstable):</strong></p>
            <ul>
                <li><strong>Findings:</strong> May show infiltrate (blood/underlying pathology), cavity (aspergilloma, TB), mass (cancer), normal (30% of cases)</li>
                <li><strong>Lateralization:</strong> Helps identify bleeding side (position patient with suspected side down to protect good lung)</li>
            </ul>
            
            <p><strong>CT Chest with IV Contrast (Once Stabilized):</strong></p>
            <ul>
                <li><strong>Purpose:</strong> Identify source of bleeding (mass, cavity, bronchiectasis, AVM), localize for bronchoscopy/embolization</li>
                <li><strong>CT Angiography (CTA):</strong> Visualizes bronchial arteries, pulmonary arteries, identifies active extravasation</li>
                <li><strong>Timing:</strong> Only when hemodynamically stable; don't delay resuscitation for CT</li>
            </ul>
            
            <p><strong>Bronchoscopy (Flexible or Rigid):</strong></p>
            <ul>
                <li><strong>Rigid Bronchoscopy (Preferred for Massive Hemoptysis):</strong>
                    <ul>
                        <li>Advantages: Large-bore suction, better visualization, allows tamponade with scope, can ventilate through scope</li>
                        <li>Performed by thoracic surgery or interventional pulmonology in OR</li>
                        <li>Gold standard for massive hemoptysis</li>
                    </ul>
                </li>
                <li><strong>Flexible Bronchoscopy:</strong>
                    <ul>
                        <li>Can be done at bedside, ICU, or OR</li>
                        <li>Localizes bleeding site, allows focal therapy (cold saline, epinephrine, thrombin)</li>
                        <li>Limitations: Smaller suction channel (clots obstruct), difficult to control massive bleeding</li>
                    </ul>
                </li>
                <li><strong>Timing:</strong> Urgent/emergent once airway secured</li>
                <li><strong>Diagnostic Yield:</strong> Identifies bleeding site in 90% if performed during active bleeding</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Resuscitation (PRIORITY = AIRWAY):</strong></p>
            <ul>
                <li><strong>Positioning:</strong>
                    <ul>
                        <li>Place patient in <strong>lateral decubitus position with bleeding side DOWN</strong> (protects non-bleeding lung from aspiration of blood)</li>
                        <li>If side unknown, place in Trendelenburg or semi-upright to prevent aspiration</li>
                    </ul>
                </li>
                <li><strong>Oxygen:</strong> High-flow O2 via non-rebreather mask (goal SpO2 >90%)</li>
                <li><strong>Large-Bore IV Access:</strong> Two 18g IVs for resuscitation, blood transfusion</li>
                <li><strong>IV Fluids:</strong> Normal saline or LR bolus if hypotensive</li>
                <li><strong>Correct Coagulopathy:</strong>
                    <ul>
                        <li>Reverse anticoagulation: Vitamin K + 4-factor PCC for warfarin, andexanet alfa for factor Xa inhibitors, idarucizumab for dabigatran</li>
                        <li>Platelet transfusion if <50,000/Î¼L</li>
                        <li>FFP if INR >1.5 and bleeding</li>
                        <li>Desmopressin (DDAVP) 0.3 mcg/kg IV if uremic platelet dysfunction</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Airway Management (CRITICAL):</strong></p>
            <ul>
                <li><strong>Indications for Intubation:</strong>
                    <ul>
                        <li>Massive hemoptysis with airway compromise</li>
                        <li>Respiratory failure (hypoxemia despite high-flow O2)</li>
                        <li>Altered mental status, inability to protect airway</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </li>
                <li><strong>Intubation Strategy:</strong>
                    <ul>
                        <li>Use <strong>largest ETT possible</strong> (8.0-9.0 mm) to allow suctioning of blood clots</li>
                        <li>Consider awake fiberoptic intubation if time permits (maintain spontaneous ventilation)</li>
                        <li>Prepare for difficult intubation (blood obscures view)</li>
                        <li>Have rigid bronchoscopy available as backup</li>
                    </ul>
                </li>
                <li><strong>Lung Isolation (Advanced Airway Management):</strong>
                    <ul>
                        <li><strong>Double-Lumen ETT:</strong> Allows selective ventilation of non-bleeding lung, protects non-bleeding lung from blood aspiration</li>
                        <li><strong>Bronchial Blocker:</strong> Balloon catheter placed via bronchoscope to occlude bleeding bronchus</li>
                        <li><strong>Selective Mainstem Intubation:</strong> Intubate into non-bleeding mainstem bronchus (right for left-sided bleed, vice versa)</li>
                        <li>Requires expertise; consult anesthesia or interventional pulmonology</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Pharmacologic Hemostasis (Temporizing Measures):</strong></p>
            <ul>
                <li><strong>Tranexamic Acid (TXA):</strong> 1 gram IV over 10 min, then 1 gram IV over 8 hours (antifibrinolytic, stabilizes clots)</li>
                <li><strong>Topical Therapies via Bronchoscopy:</strong>
                    <ul>
                        <li>Cold saline lavage (vasoconstriction)</li>
                        <li>Epinephrine 1:10,000 (1-2 mL aliquots) via bronchoscope</li>
                        <li>Thrombin (topical)</li>
                        <li>Balloon tamponade with bronchial blocker</li>
                    </ul>
                </li>
                <li><strong>Vasopressin:</strong> 0.2-0.4 units/min IV infusion (causes bronchial artery vasoconstriction; case reports, not standard)</li>
            </ul>
            
            <p><strong>Definitive Treatment:</strong></p>
            <ul>
                <li><strong>Bronchial Artery Embolization (BAE) - FIRST-LINE for Massive Hemoptysis:</strong>
                    <ul>
                        <li><strong>Success Rate:</strong> 90% immediate hemostasis, ~20% rebleeding within 1 year</li>
                        <li><strong>Procedure:</strong> Interventional radiology, selective catheterization of bronchial arteries, embolize with coils or particles</li>
                        <li><strong>Indications:</strong> Massive hemoptysis, hemodynamically stable enough for procedure, bleeding from bronchial arteries (90% of cases)</li>
                        <li><strong>Complications:</strong> Spinal artery embolization (paraplegia, <5%), chest pain, dysphagia, transient fever</li>
                    </ul>
                </li>
                <li><strong>Surgery (Lung Resection) - Second-Line or Definitive:</strong>
                    <ul>
                        <li><strong>Indications:</strong> BAE failure/not available, localized disease (resectable tumor, destroyed lung lobe), recurrent hemoptysis</li>
                        <li><strong>Procedure:</strong> Lobectomy or pneumonectomy</li>
                        <li><strong>Mortality:</strong> High in emergency setting (10-40%), lower if elective</li>
                        <li><strong>Timing:</strong> Prefer elective surgery after hemoptysis controlled rather than emergency</li>
                    </ul>
                </li>
                <li><strong>Pulmonary Artery Embolization:</strong> If bleeding from pulmonary artery (rare, 10% of cases) - Rasmussen aneurysm, AVM, catheter injury</li>
            </ul>
            
            <p><strong>Supportive Care:</strong></p>
            <ul>
                <li><strong>Blood Transfusion:</strong> PRBC to maintain Hgb >7 g/dL (liberal transfusion may be needed if ongoing bleeding)</li>
                <li><strong>Antibiotics:</strong> If infection suspected (TB, pneumonia, abscess)</li>
                <li><strong>Bronchodilators:</strong> Avoid in setting of active bleeding (may worsen bleeding by increasing bronchial blood flow)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Death from Asphyxiation, Not Exsanguination:</strong> Massive hemoptysis kills by drowning in blood (hypoxemia from alveoli filling with blood), not from bleeding out. Priority is AIRWAY protection, not just volume resuscitation. Position bleeding side down to protect good lung.</li>
            <li><strong>90% of Bleeding Is from Bronchial Arteries, Not Pulmonary Arteries:</strong> Bronchial arteries are high-pressure systemic vessels (arise from aorta), not low-pressure pulmonary circulation. This is why bronchial artery embolization (BAE) is first-line treatment.</li>
            <li><strong>Bronchiectasis Is #1 Cause Worldwide:</strong> Chronic inflammation and infection cause bronchial artery hypertrophy and tortuous vessels prone to rupture. CF, post-TB bronchiectasis, chronic aspiration are common culprits.</li>
            <li><strong>Aspergilloma = Fungus Ball in Cavity:</strong> Aspergilloma grows in pre-existing cavities (old TB scars, sarcoidosis). The fungal ball itself bleeds from friable vessels in cavity wall. Treatment is resection or embolization, NOT antifungals (fungus is extravascular).</li>
            <li><strong>Rigid Bronchoscopy > Flexible for Massive Hemoptysis:</strong> Rigid scope has large-bore suction, can clear clots, allows tamponade with scope itself, and can ventilate through it. Flexible scopes clot quickly. Rigid scope requires OR and specialized training (thoracic surgery, interventional pulmonology).</li>
            <li><strong>Bronchial Artery Embolization (BAE) Has 90% Success but 20% Rebleed Rate:</strong> BAE is first-line for massive hemoptysis (if patient stable enough for procedure). Immediate hemostasis in 90%, but ~20% rebleed within 1 year because collaterals develop or underlying disease persists. May need repeat BAE or eventual surgery.</li>
            <li><strong>Position Patient Bleeding Side Down:</strong> Gravity prevents blood from healthy lung filling with blood. If you know right lung is bleeding, place patient in right lateral decubitus. This is critical to prevent asphyxiation of good lung.</li>
            <li><strong>TB and Aspergilloma Can Cause Rasmussen Aneurysm:</strong> Pulmonary artery erosion by TB cavity creates pseudoaneurysm (Rasmussen aneurysm) that ruptures â†’ massive hemoptysis. High mortality. Requires pulmonary artery embolization or surgery, NOT bronchial artery embolization.</li>
            <li><strong>Surgery Has High Mortality in Emergency Setting:</strong> Emergency lung resection for massive hemoptysis has 10-40% mortality (patient is hypoxemic, in shock, poor surgical candidate). Prefer BAE to stabilize, then elective surgery later if needed.</li>
            <li><strong>Tranexamic Acid (TXA) Is a Reasonable Temporizing Measure:</strong> TXA stabilizes clots and reduces bleeding. Give 1g IV loading dose, then 1g over 8h. Not definitive treatment but may buy time for BAE or surgery. Similar rationale to TXA in trauma.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>ALL massive hemoptysis requires ICU admission</li>
            <li>Respiratory failure or airway compromise</li>
            <li>Need for mechanical ventilation or advanced airway</li>
            <li>Hemodynamic instability</li>
            <li>Ongoing bleeding requiring transfusion</li>
            <li>Post-bronchial artery embolization monitoring</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>No active bleeding for >48 hours</li>
            <li>Hemodynamically stable</li>
            <li>Hemoglobin stable without transfusion requirement</li>
            <li>Oxygenating adequately on room air or baseline oxygen</li>
            <li>Definitive intervention completed (BAE or surgery) OR bleeding clearly self-limited</li>
            <li>Underlying etiology identified and treated (antibiotics for infection, etc.)</li>
            <li>Close pulmonology follow-up arranged (within 1-2 weeks)</li>
            <li>If BAE performed: Interventional radiology follow-up arranged</li>
            <li>Patient educated on return precautions (recurrent hemoptysis)</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="hypercapnic-failure" class="condition-page">
    <div class="page-header">
        <h2>50. ACUTE HYPERCAPNIC RESPIRATORY FAILURE</h2>
        <div class="subtitle">Elevated PaCO2 â€¢ Respiratory Acidosis â€¢ Alveolar Hypoventilation</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with acute or acute-on-chronic elevation in arterial CO2 (PaCO2 >45 mmHg) causing respiratory acidosis (pH <7.35), typically presenting with altered mental status, dyspnea, and/or respiratory distress. Results from alveolar hypoventilation - inadequate minute ventilation to eliminate CO2 produced by metabolism.</p>
            
            <ul>
                <li><strong>Pathophysiology:</strong> Minute ventilation (VE) = Tidal Volume Ã— Respiratory Rate. If VE inadequate â†’ CO2 retention â†’ respiratory acidosis â†’ CNS depression â†’ further hypoventilation (vicious cycle)</li>
                <li><strong>Acute vs Chronic Hypercapnia:</strong>
                    <ul>
                        <li><strong>Acute:</strong> pH <7.35, elevated PaCO2, normal HCO3 (kidneys haven't compensated yet)</li>
                        <li><strong>Chronic:</strong> pH 7.35-7.40, elevated PaCO2, elevated HCO3 (renal compensation)</li>
                        <li><strong>Acute-on-Chronic:</strong> pH <7.35, very elevated PaCO2 (>55-60), elevated HCO3 (baseline compensation insufficient for acute rise)</li>
                    </ul>
                </li>
                <li><strong>Compensatory Response:</strong> Kidneys retain HCO3 to buffer respiratory acidosis; takes 3-5 days. For every 10 mmHg rise in PaCO2, HCO3 rises ~1 mEq/L acutely, ~3.5 mEq/L chronically</li>
            </ul>
            
            <p><strong>Common Etiologies (by Mechanism):</strong></p>
            <ul>
                <li><strong>Decreased Respiratory Drive (CNS Depression):</strong>
                    <ul>
                        <li>Opioid overdose (most common iatrogenic cause in hospitalized patients)</li>
                        <li>Sedative/hypnotic overdose (benzodiazepines, barbiturates)</li>
                        <li>CNS lesions (stroke, tumor, trauma)</li>
                        <li>Severe metabolic alkalosis (depresses respiratory drive)</li>
                    </ul>
                </li>
                <li><strong>Neuromuscular Weakness (Respiratory Muscle Failure):</strong>
                    <ul>
                        <li>Guillain-BarrÃ© syndrome</li>
                        <li>Myasthenia gravis crisis</li>
                        <li>ALS (amyotrophic lateral sclerosis)</li>
                        <li>Muscular dystrophy</li>
                        <li>Phrenic nerve injury</li>
                        <li>Spinal cord injury (C3-C5 affects diaphragm)</li>
                        <li>Critical illness myopathy/polyneuropathy</li>
                    </ul>
                </li>
                <li><strong>Increased Airway Resistance (Obstructive Lung Disease):</strong>
                    <ul>
                        <li><strong>COPD exacerbation (most common cause overall)</strong></li>
                        <li>Severe asthma exacerbation</li>
                        <li>Upper airway obstruction (foreign body, tumor, laryngospasm)</li>
                    </ul>
                </li>
                <li><strong>Restrictive Lung Disease / Chest Wall Disorders:</strong>
                    <ul>
                        <li>Severe obesity (obesity hypoventilation syndrome)</li>
                        <li>Kyphoscoliosis</li>
                        <li>Flail chest (trauma)</li>
                        <li>Pneumothorax, pleural effusion (large)</li>
                    </ul>
                </li>
                <li><strong>Increased CO2 Production (Rare Primary Cause, Usually Multifactorial):</strong>
                    <ul>
                        <li>Malignant hyperthermia, neuroleptic malignant syndrome</li>
                        <li>Thyroid storm</li>
                        <li>Sepsis, fever</li>
                        <li>Overfeeding (especially carbohydrates in critically ill)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Clinical Manifestations:</strong></p>
            <ul>
                <li><strong>CNS Effects (Hypercapnia = Cerebral Vasodilation + CNS Depression):</strong>
                    <ul>
                        <li>Altered mental status: Confusion, lethargy, somnolence</li>
                        <li><strong>CO2 narcosis:</strong> Progressive obtundation â†’ stupor â†’ coma (PaCO2 >70-90 mmHg)</li>
                        <li>Headache (from cerebral vasodilation)</li>
                        <li>Tremor, asterixis (flapping tremor), myoclonus</li>
                        <li>Papilledema (if severe, prolonged)</li>
                        <li>Seizures (rare, severe hypercapnia)</li>
                    </ul>
                </li>
                <li><strong>Respiratory:</strong>
                    <ul>
                        <li>Dyspnea, tachypnea (early, trying to compensate)</li>
                        <li>Bradypnea, shallow breathing (late, respiratory fatigue or CNS depression)</li>
                        <li>Use of accessory muscles, paradoxical abdominal breathing</li>
                    </ul>
                </li>
                <li><strong>Cardiovascular:</strong>
                    <ul>
                        <li>Tachycardia, hypertension (catecholamine surge from hypercapnia/hypoxemia)</li>
                        <li>Arrhythmias (acidosis lowers threshold)</li>
                        <li>Warm, flushed skin (peripheral vasodilation from hypercapnia)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Arterial Blood Gas (ABG) - GOLD STANDARD:</strong></p>
            <ul>
                <li><strong>Diagnostic Criteria:</strong> PaCO2 >45 mmHg with pH <7.35 (respiratory acidosis)</li>
                <li><strong>Interpretation:</strong>
                    <ul>
                        <li>Acute: pH low, PaCO2 high, HCO3 normal (22-26 mEq/L)</li>
                        <li>Chronic: pH near-normal (7.35-7.40), PaCO2 high, HCO3 high (>26 mEq/L, compensated)</li>
                        <li>Acute-on-chronic: pH very low (<7.30), PaCO2 very high (>55-60), HCO3 elevated (baseline compensation insufficient)</li>
                    </ul>
                </li>
                <li><strong>Assess Oxygenation:</strong> PaO2, calculate A-a gradient (elevated in V/Q mismatch, normal in pure hypoventilation)</li>
                <li><strong>Alveolar Gas Equation:</strong> PAO2 = FiO2 Ã— (Patm - PH2O) - PaCO2/0.8. A-a gradient = PAO2 - PaO2. Normal <10-15 mmHg.</li>
                <li><strong>Expected Compensation:</strong> For pure respiratory acidosis, HCO3 increases ~1 mEq/L per 10 mmHg rise in PaCO2 (acute) or ~3.5 mEq/L (chronic). If HCO3 doesn't fit, suspect mixed disorder.</li>
            </ul>
            
            <p><strong>Venous Blood Gas (VBG):</strong></p>
            <ul>
                <li><strong>Use:</strong> Can estimate arterial pH and PaCO2 (venous pH ~0.03-0.05 lower, venous PCO2 ~5-8 mmHg higher than arterial)</li>
                <li><strong>Limitation:</strong> Cannot assess oxygenation (PvO2 not useful); ABG preferred if available</li>
            </ul>
            
            <p><strong>Identify Underlying Cause:</strong></p>
            <ul>
                <li><strong>History:</strong>
                    <ul>
                        <li>COPD/asthma history (exacerbation?)</li>
                        <li>Medications: Opioids, benzodiazepines, sedatives</li>
                        <li>Neuromuscular disease (GBS, MG, ALS)</li>
                        <li>Recent trauma, surgery</li>
                        <li>Symptoms: Cough, fever (pneumonia), chest pain (PTX)</li>
                    </ul>
                </li>
                <li><strong>Physical Exam:</strong>
                    <ul>
                        <li>Respiratory: Wheezing (COPD, asthma), decreased breath sounds (PTX, effusion), crackles (pneumonia, pulmonary edema)</li>
                        <li>Neurologic: Weakness (neuromuscular), altered mental status (CNS cause), pupils (pinpoint = opioids)</li>
                        <li>Chest wall: Kyphoscoliosis, obesity, flail segment</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Chest X-ray:</strong></p>
            <ul>
                <li><strong>Findings:</strong> Pneumothorax, pneumonia, pleural effusion, COPD hyperinflation, pulmonary edema, aspiration</li>
            </ul>
            
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>BMP:</strong> Assess HCO3 (metabolic compensation), K+ (acidosis causes hyperkalemia), renal function</li>
                <li><strong>CBC:</strong> Leukocytosis (infection), polycythemia (chronic hypercapnia)</li>
                <li><strong>Toxicology Screen:</strong> If overdose suspected (opioids, benzodiazepines, barbiturates)</li>
                <li><strong>CK:</strong> Rhabdomyolysis (if prolonged immobility, seizures)</li>
            </ul>
            
            <p><strong>Additional Testing (Based on Suspected Etiology):</strong></p>
            <ul>
                <li><strong>Pulmonary Function Tests (PFTs):</strong> If stable, assess for obstructive or restrictive lung disease (not in acute setting)</li>
                <li><strong>Negative Inspiratory Force (NIF):</strong> Measures respiratory muscle strength; NIF <-20 cm H2O suggests neuromuscular weakness (normal -60 to -100)</li>
                <li><strong>EMG/Nerve Conduction Studies:</strong> If neuromuscular disease suspected (GBS, MG)</li>
                <li><strong>CT Chest:</strong> If CXR non-diagnostic and etiology unclear (PE, ILD, bronchiectasis)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>General Principles:</strong></p>
            <ul>
                <li><strong>Treat Underlying Cause:</strong> Bronchodilators for COPD/asthma, antibiotics for pneumonia, naloxone for opioids, etc.</li>
                <li><strong>Improve Alveolar Ventilation:</strong> Increase minute ventilation (non-invasive or invasive ventilation)</li>
                <li><strong>Avoid Over-Oxygenation in COPD:</strong> High FiO2 can worsen hypercapnia (loss of hypoxic drive, Haldane effect)</li>
            </ul>
            
            <p><strong>Oxygen Therapy:</strong></p>
            <ul>
                <li><strong>Target SpO2 88-92% in Chronic CO2 Retainers (COPD):</strong>
                    <ul>
                        <li>Chronic hypercapnia â†’ respiratory drive dependent on hypoxic stimulus (peripheral chemoreceptors)</li>
                        <li>High FiO2 â†’ removes hypoxic drive â†’ worsening hypoventilation â†’ â†‘â†‘ PaCO2 â†’ CO2 narcosis</li>
                        <li><strong>Controlled oxygen delivery:</strong> Use Venturi mask (24-28% FiO2) or nasal cannula 1-2 L/min</li>
                    </ul>
                </li>
                <li><strong>Exception:</strong> In acute life-threatening hypoxemia, give high FiO2 and prepare for ventilatory support</li>
            </ul>
            
            <p><strong>Non-Invasive Ventilation (NIV) - FIRST-LINE for Acute-on-Chronic Hypercapnic Failure:</strong></p>
            <ul>
                <li><strong>BiPAP (Bilevel Positive Airway Pressure):</strong>
                    <ul>
                        <li><strong>Mechanism:</strong> IPAP (inspiratory pressure) augments tidal volume, EPAP (expiratory pressure) prevents alveolar collapse</li>
                        <li><strong>Settings:</strong> Start IPAP 10-12 cm H2O, EPAP 4-5 cm H2O, titrate IPAP to improve tidal volume/VE and reduce PaCO2</li>
                        <li><strong>Benefits:</strong> Reduces work of breathing, improves gas exchange, avoids intubation (~50-80% success in COPD exacerbations)</li>
                        <li><strong>Evidence:</strong> Decreases intubation rate, mortality, ICU length of stay in COPD exacerbations (NNT ~4-8)</li>
                    </ul>
                </li>
                <li><strong>CPAP (Continuous Positive Airway Pressure):</strong>
                    <ul>
                        <li>Less effective than BiPAP for hypercapnia (provides pressure support but doesn't augment ventilation as much)</li>
                        <li>May help in obesity hypoventilation syndrome (OHS) or obstructive sleep apnea</li>
                    </ul>
                </li>
                <li><strong>Contraindications to NIV:</strong>
                    <ul>
                        <li>Inability to protect airway (GCS <10, coma, copious secretions)</li>
                        <li>Hemodynamic instability (shock)</li>
                        <li>Facial trauma, burns (mask can't seal)</li>
                        <li>Recent upper GI surgery (risk of anastomotic leak from positive pressure)</li>
                        <li>Non-cooperative patient</li>
                    </ul>
                </li>
                <li><strong>NIV Failure:</strong> If pH worsening, PaCO2 rising, or mental status declining after 1-2 hours of NIV â†’ intubate</li>
            </ul>
            
            <p><strong>Invasive Mechanical Ventilation (Intubation):</strong></p>
            <ul>
                <li><strong>Indications:</strong>
                    <ul>
                        <li>NIV failure or contraindications</li>
                        <li>Severe respiratory acidosis (pH <7.25) with altered mental status</li>
                        <li>Respiratory arrest or near-arrest</li>
                        <li>Hemodynamic instability</li>
                        <li>Inability to protect airway</li>
                    </ul>
                </li>
                <li><strong>Ventilator Settings for Hypercapnic Failure:</strong>
                    <ul>
                        <li><strong>Mode:</strong> Assist-control (volume or pressure) or SIMV</li>
                        <li><strong>Tidal Volume:</strong> 6-8 mL/kg IBW (lung-protective, especially if also has ARDS/ALI)</li>
                        <li><strong>Respiratory Rate:</strong> 12-20/min (adjust to normalize pH, not necessarily PaCO2)</li>
                        <li><strong>FiO2:</strong> Start 100%, then wean to SpO2 88-92% (in chronic CO2 retainers)</li>
                        <li><strong>PEEP:</strong> 5-8 cm H2O to prevent atelectasis</li>
                        <li><strong>Goal:</strong> Normalize pH (>7.30), NOT necessarily PaCO2. Permissive hypercapnia acceptable if pH adequate.</li>
                    </ul>
                </li>
                <li><strong>Avoid Rapid CO2 Correction in Chronic Hypercapnia:</strong>
                    <ul>
                        <li>If chronic CO2 retainer, kidneys have compensated (high HCO3)</li>
                        <li>Rapid PaCO2 drop â†’ pH overshoots â†’ metabolic alkalosis â†’ seizures, arrhythmias</li>
                        <li>Target: Reduce PaCO2 slowly over 24-48 hours, aim for pH 7.30-7.35 initially</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Etiology-Specific Treatment:</strong></p>
            <ul>
                <li><strong>COPD Exacerbation:</strong>
                    <ul>
                        <li>Bronchodilators: Albuterol/ipratropium nebulizers q4h or continuous</li>
                        <li>Corticosteroids: Prednisone 40 mg PO daily Ã— 5 days or methylprednisolone 125 mg IV q6h</li>
                        <li>Antibiotics: If increased sputum purulence (azithromycin, doxycycline, or amoxicillin-clavulanate)</li>
                        <li>BiPAP first-line for acute-on-chronic hypercapnic failure</li>
                    </ul>
                </li>
                <li><strong>Opioid/Sedative Overdose:</strong>
                    <ul>
                        <li>Naloxone 0.4-2 mg IV (opioids) or flumazenil 0.2 mg IV (benzodiazepines, use with cautionâ€”seizure risk)</li>
                        <li>Support ventilation until drug metabolized</li>
                    </ul>
                </li>
                <li><strong>Neuromuscular Weakness:</strong>
                    <ul>
                        <li>GBS: IVIG or plasmapheresis, supportive ventilation</li>
                        <li>Myasthenia gravis: Pyridostigmine, IVIG, plasmapheresis, avoid triggering drugs (aminoglycosides, beta-blockers)</li>
                        <li>Often require intubation (BiPAP less effective for neuromuscular causes)</li>
                    </ul>
                </li>
                <li><strong>Obesity Hypoventilation Syndrome (OHS):</strong>
                    <ul>
                        <li>Weight loss (long-term goal)</li>
                        <li>CPAP or BiPAP at night (treat OSA component)</li>
                        <li>Diuretics if concurrent right heart failure (cor pulmonale)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Adjunctive Therapies:</strong></p>
            <ul>
                <li><strong>Bronchodilators:</strong> If airway obstruction present (albuterol, ipratropium)</li>
                <li><strong>Diuretics:</strong> If volume overload contributing (pulmonary edema, cor pulmonale)</li>
                <li><strong>Treat Infection:</strong> Antibiotics for pneumonia, bronchitis</li>
                <li><strong>Avoid Respiratory Depressants:</strong> Minimize opioids, benzodiazepines, sedatives</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>CO2 Narcosis = Severe CNS Depression from Hypercapnia:</strong> PaCO2 >70-90 mmHg â†’ cerebral vasodilation + direct CNS depression â†’ obtundation, stupor, coma. Classic triad: altered mental status, hypercapnia (PaCO2 >70), respiratory acidosis (pH <7.25). Treat with ventilatory support, NOT just oxygen.</li>
            <li><strong>Don't Over-Oxygenate Chronic CO2 Retainers:</strong> In COPD patients with chronic hypercapnia, high FiO2 removes hypoxic respiratory drive â†’ worsening hypoventilation â†’ â†‘â†‘ PaCO2 â†’ CO2 narcosis. Target SpO2 88-92%, use controlled O2 delivery (Venturi mask 24-28%). This is "permissive hypoxemia."</li>
            <li><strong>BiPAP Reduces Intubation and Mortality in COPD Exacerbations:</strong> High-quality evidence shows NIV (BiPAP) in acute-on-chronic hypercapnic respiratory failure from COPD reduces need for intubation, ICU stay, and mortality (NNT 4-8). Start early (pH 7.25-7.35), don't wait until patient is moribund.</li>
            <li><strong>Normalize pH, NOT PaCO2:</strong> In chronic CO2 retainers (baseline PaCO2 50-60 mmHg), goal is NOT to normalize PaCO2 to 40 mmHg. Kidneys have compensated with high HCO3. Rapidly dropping PaCO2 â†’ metabolic alkalosis (pH >7.50) â†’ seizures, arrhythmias. Target pH >7.30, accept elevated PaCO2.</li>
            <li><strong>A-a Gradient Differentiates Cause:</strong> Normal A-a gradient (<15 mmHg) suggests pure hypoventilation (CNS depression, neuromuscular weakness, obesity). Elevated A-a gradient suggests V/Q mismatch (COPD, pneumonia, PE). Use alveolar gas equation: A-a gradient = PAO2 - PaO2, where PAO2 = FiO2Ã—(760-47) - PaCO2/0.8.</li>
            <li><strong>Opioids Are Leading Iatrogenic Cause in Hospitalized Patients:</strong> Pain management with opioids (morphine, fentanyl, hydromorphone) commonly causes respiratory depression â†’ hypercapnia, especially in elderly, renal failure (reduced clearance), or OSA. Use lowest effective dose, consider non-opioid alternatives.</li>
            <li><strong>Intubation Doesn't Cure Hypercapnia, It Buys Time:</strong> Mechanical ventilation provides temporary support while treating underlying cause (COPD exacerbation, pneumonia, neuromuscular crisis). If underlying disease is irreversible (end-stage COPD, ALS), discuss goals of care before intubationâ€”many may not extubate.</li>
            <li><strong>Permissive Hypercapnia Is Acceptable If pH Adequate:</strong> In severe ARDS or COPD, allowing PaCO2 to rise (50-60 mmHg) to avoid barotrauma (high tidal volumes, plateau pressures) is acceptable as long as pH >7.25-7.30. Kidneys will compensate over 3-5 days.</li>
            <li><strong>Acute vs Chronic Compensation Takes 3-5 Days:</strong> In acute hypercapnia, HCO3 rises ~1 mEq/L per 10 mmHg â†‘ PaCO2 (immediate buffering). In chronic hypercapnia, kidneys retain HCO3 â†’ HCO3 rises ~3.5 mEq/L per 10 mmHg â†‘ PaCO2 (takes 3-5 days). Use this to estimate acuity.</li>
            <li><strong>Obesity Hypoventilation Syndrome (OHS) = BMI >30 + Chronic Hypercapnia + OSA:</strong> Obese patients develop chronic hypercapnia from chest wall restriction + OSA. Treat with weight loss + nighttime BiPAP/CPAP. Often confused with "just OSA," but OHS has daytime hypercapnia even when awake.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Severe respiratory acidosis (pH <7.30) with altered mental status</li>
            <li>Need for non-invasive ventilation (BiPAP) or mechanical ventilation</li>
            <li>Rapidly worsening hypercapnia despite treatment</li>
            <li>CO2 narcosis (obtundation, coma from severe hypercapnia)</li>
            <li>Hemodynamic instability</li>
            <li>Respiratory arrest or peri-arrest</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>PaCO2 improved or back to baseline (if chronic CO2 retainer)</li>
            <li>pH normalized (>7.35) or back to compensated baseline</li>
            <li>Respiratory rate <24/min, no accessory muscle use</li>
            <li>SpO2 >88-90% on room air or baseline oxygen requirement</li>
            <li>Underlying cause treated (COPD exacerbation resolved, infection treated, etc.)</li>
            <li>Able to ambulate and perform ADLs without significant dyspnea</li>
            <li>Off BiPAP/CPAP for >24 hours (unless home BiPAP/CPAP prescribed)</li>
            <li>Close pulmonology follow-up arranged (within 1-2 weeks)</li>
            <li>If COPD: On appropriate home oxygen, inhalers optimized, smoking cessation counseling</li>
            <li>If obesity hypoventilation: Home CPAP/BiPAP arranged</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="tia" class="condition-page">
            <div class="page-header">
                <h2>51. TRANSIENT ISCHEMIC ATTACK (TIA)</h2>
                <div class="subtitle">Stroke Warning â€¢ ABCDÂ² Score â€¢ Urgent Workup</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Transient episode of neurologic dysfunction from focal brain, spinal cord, or retinal ischemia WITHOUT acute infarction. Symptoms resolve within 24hr (most <1hr)</p>
                    <p><span class="label">Classic Symptoms (sudden onset, focal):</span></p>
                    <ul>
                        <li><strong>Motor:</strong> Unilateral weakness (face, arm, leg). Arm drift, facial droop</li>
                        <li><strong>Sensory:</strong> Unilateral numbness, paresthesias</li>
                        <li><strong>Speech:</strong> Aphasia (expressive or receptive), dysarthria (slurred speech)</li>
                        <li><strong>Visual:</strong> Monocular vision loss (amaurosis fugax - retinal TIA), hemianopia, diplopia</li>
                        <li><strong>Ataxia:</strong> Unsteady gait, incoordination (posterior circulation)</li>
                        <li><strong>Vertigo:</strong> With other posterior circulation symptoms (NOT isolated vertigo)</li>
                    </ul>
                    <p><span class="label">TIA Mimics (NOT TIA):</span> Seizure with Todd's paralysis, migraine with aura, hypoglycemia, syncope, peripheral vertigo alone, isolated sensory symptoms without other deficits</p>
                    <p><span class="label">High-Risk Features:</span></p>
                    <ul>
                        <li>Multiple TIAs in short period (crescendo TIAs)</li>
                        <li>Symptoms >1 hour</li>
                        <li>Carotid stenosis >50%</li>
                        <li>AF or cardioembolic source</li>
                        <li>ABCDÂ² score â‰¥4</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Urgent Imaging (within 24hr, ideally emergently):</span></p>
                    <ul>
                        <li><strong>Brain MRI with DWI:</strong> GOLD STANDARD. Detects acute infarction in 30-50% of "TIAs". DWI-positive = stroke, not TIA</li>
                        <li><strong>CT head (if MRI unavailable):</strong> Rule out hemorrhage, large stroke. Less sensitive for acute ischemia</li>
                        <li><strong>CTA or MRA head/neck:</strong> Assess for large vessel stenosis/occlusion (carotid, vertebral, intracranial). Identify surgical candidates</li>
                    </ul>
                    <p><span class="label">Vascular Studies:</span></p>
                    <ul>
                        <li><strong>Carotid Doppler ultrasound:</strong> Screen for carotid stenosis. If >50% stenosis, confirm with CTA/MRA</li>
                        <li><strong>Consider CTA chest:</strong> If concern for aortic arch atheroma</li>
                    </ul>
                    <p><span class="label">Cardiac Workup:</span></p>
                    <ul>
                        <li><strong>ECG:</strong> Assess for AF (most important modifiable risk factor for cardioembolic stroke)</li>
                        <li><strong>Telemetry:</strong> 24hr minimum. Consider prolonged monitoring (30-day event monitor) if no AF found and high suspicion</li>
                        <li><strong>Transthoracic echo (TTE):</strong> Assess for cardioembolic source (LV thrombus, valvular disease, reduced EF)</li>
                        <li><strong>TEE:</strong> If high suspicion for cardioembolic source and TTE negative. Better visualization of LA appendage (thrombus), PFO, aortic arch atheroma</li>
                    </ul>
                    <p><span class="label">Labs:</span> CBC, BMP, lipid panel, HbA1c, PT/PTT (if anticoagulation planned), ESR (if vasculitis concern), hypercoagulable workup (if age <50, unprovoked, recurrent)</p>
                    <p><span class="label">ABCDÂ² Score (Stroke Risk Stratification):</span></p>
                    <ul>
                        <li><strong>Age â‰¥60:</strong> 1 point</li>
                        <li><strong>BP â‰¥140/90:</strong> 1 point</li>
                        <li><strong>Clinical features:</strong> Unilateral weakness (2 points), Speech impairment without weakness (1 point)</li>
                        <li><strong>Duration:</strong> â‰¥60min (2 points), 10-59min (1 point)</li>
                        <li><strong>Diabetes:</strong> 1 point</li>
                        <li><strong>Score 0-3:</strong> Low risk (1% 2-day stroke risk). Outpatient workup possible if reliable</li>
                        <li><strong>Score 4-5:</strong> Moderate risk (4% 2-day stroke risk). Admit for expedited workup</li>
                        <li><strong>Score 6-7:</strong> High risk (8% 2-day stroke risk). Admit for urgent workup</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immediate Management (Goal: Prevent stroke within 48-90 days):</span></p>
                    <ul>
                        <li><strong>Aspirin:</strong> 325mg loading dose immediately (if not already on antiplatelet). Reduces early stroke risk by 80%</li>
                        <li><strong>Dual antiplatelet therapy (DAPT):</strong> Aspirin 81mg + clopidogrel 75mg daily Ã— 21 days, then aspirin alone. Reduces stroke risk by 32% compared to aspirin alone (POINT/CHANCE trials). Start within 24hr of symptom onset</li>
                        <li><strong>BP management:</strong> Goal <140/90 long-term. Avoid aggressive lowering in acute phase unless hypertensive emergency</li>
                        <li><strong>Statin:</strong> High-intensity (atorvastatin 40-80mg or rosuvastatin 20-40mg). Start immediately regardless of LDL. Reduces recurrent stroke</li>
                    </ul>
                    
                    <p><span class="label">Etiology-Specific Treatment:</span></p>
                    <ul>
                        <li><strong>Atrial fibrillation:</strong> Anticoagulation (DOAC preferred: apixaban, rivaroxaban, edoxaban, dabigatran). Start within 4-14 days depending on stroke risk. CHAâ‚‚DSâ‚‚-VASc score guides decision</li>
                        <li><strong>Carotid stenosis 70-99% (symptomatic):</strong> Urgent CEA (carotid endarterectomy) within 2 weeks. NNT=6 to prevent stroke. Consider CAS (carotid artery stenting) if high surgical risk</li>
                        <li><strong>Carotid stenosis 50-69%:</strong> CEA beneficial (NNT=15). Consider if good surgical candidate</li>
                        <li><strong>Carotid stenosis <50%:</strong> Medical management. No benefit from CEA</li>
                        <li><strong>Intracranial stenosis:</strong> Aggressive medical management (dual antiplatelet Ã— 90 days, statin, BP control). Stenting NOT superior to medical therapy</li>
                        <li><strong>Cardioembolic (not AF):</strong> Antiplatelet vs anticoagulation depending on source. TEE to identify source</li>
                        <li><strong>Cryptogenic (no identified cause):</strong> Aspirin. Consider extended cardiac monitoring for paroxysmal AF. PFO closure if large PFO + no other cause (controversial, age <60)</li>
                    </ul>
                    
                    <p><span class="label">Risk Factor Modification (CRITICAL):</span></p>
                    <ul>
                        <li><strong>BP control:</strong> Goal <130/80 (ACC/AHA) or <140/90 (ESH/ESC). ACE-I or ARB preferred</li>
                        <li><strong>Diabetes control:</strong> HbA1c <7%</li>
                        <li><strong>Lipids:</strong> LDL <70mg/dL (consider <55 if very high risk)</li>
                        <li><strong>Smoking cessation:</strong> Doubles stroke risk. Counsel + pharmacotherapy (varenicline, bupropion, NRT)</li>
                        <li><strong>Exercise:</strong> 30min moderate activity 5Ã— week</li>
                        <li><strong>Diet:</strong> Mediterranean diet, low sodium</li>
                        <li><strong>Weight loss:</strong> If overweight/obese</li>
                    </ul>
                    
                    <p><span class="label">Admission vs Outpatient:</span></p>
                    <ul>
                        <li><strong>Admit:</strong> ABCDÂ² â‰¥4, crescendo TIAs, within 48hr of symptom onset, unreliable for follow-up, unable to complete workup as outpatient</li>
                        <li><strong>Outpatient:</strong> ABCDÂ² <3, reliable patient, can complete MRI/vascular imaging/echo within 48hr, no high-risk features</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>TIA = stroke until proven otherwise:</strong> 30-50% of "TIAs" have infarction on DWI-MRI. If DWI-positive, it's a stroke, not TIA. Treat aggressively either way</li>
                    <li><strong>Highest stroke risk is within 48hr:</strong> 5-10% have stroke within 90 days, half of those within 48hr. TIA is an EMERGENCY. Expedited workup prevents stroke</li>
                    <li><strong>Dual antiplatelet (ASA + clopidogrel) for 21 days:</strong> POINT and CHANCE trials showed 32% relative risk reduction. Start within 24hr. Then continue aspirin alone</li>
                    <li><strong>Amaurosis fugax = retinal TIA:</strong> Transient monocular blindness ("curtain coming down"). Ipsilateral carotid stenosis or emboli. Same stroke risk as hemispheric TIA</li>
                    <li><strong>NOT all transient neuro symptoms are TIA:</strong> Isolated vertigo, isolated diplopia, isolated sensory symptoms = low likelihood. Need focal symptoms (motor/speech/visual field loss)</li>
                    <li><strong>Carotid stenosis timing matters:</strong> Symptomatic stenosis 70-99% needs CEA within 2 weeks. Benefit diminishes after that. Asymptomatic stenosis has different indications</li>
                    <li><strong>Extended cardiac monitoring increases AF detection:</strong> 30-day monitors detect AF in 10-20% of cryptogenic TIA/stroke. Consider if no cause found</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE/ADMIT IF:</div>
                    <ul>
                        <li>ABCDÂ² score â‰¥4 (moderate-high risk)</li>
                        <li>Crescendo TIAs (multiple in short period)</li>
                        <li>Symptoms occurred within 48hr</li>
                        <li>Carotid stenosis >50% (needs urgent evaluation for CEA)</li>
                        <li>Atrial fibrillation (needs anticoagulation)</li>
                        <li>Unable to complete urgent outpatient workup</li>
                        <li>Unreliable for follow-up</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Imaging complete (MRI/CTA or CT/carotid Doppler)</li>
                        <li>Cardiac evaluation done (ECG, telemetry â‰¥24hr, echo)</li>
                        <li>Started on appropriate therapy (antiplatelet or anticoagulation + statin)</li>
                        <li>If carotid stenosis >50%: Vascular surgery consult, CEA scheduled</li>
                        <li>Risk factors addressed (BP, lipids, diabetes)</li>
                        <li>Neurology follow-up arranged (within 1-2 weeks)</li>
                        <li>Patient educated on stroke warning signs</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Stroke (5-10% within 90 days, highest risk first 48hr), recurrent TIA (15-20% have another TIA), progression to stroke during evaluation</p>
                    <p><strong>Procedural:</strong> CEA complications (stroke 2-3%, MI, cranial nerve injury, bleeding), CAS complications (stroke, dissection, access site complications)</p>
                    <p><strong>Chronic:</strong> Recurrent stroke/TIA (if risk factors not controlled), bleeding on antiplatelets/anticoagulation, cognitive decline (vascular dementia), disability from eventual stroke if not treated aggressively</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="gbs" class="condition-page">
            <div class="page-header">
                <h2>52. GUILLAIN-BARRÃ‰ SYNDROME (GBS)</h2>
                <div class="subtitle">Acute Inflammatory Demyelinating Polyneuropathy â€¢ Ascending Paralysis â€¢ IVIG/Plasmapheresis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> (1) Progressive symmetric weakness, (2) Areflexia/hyporeflexia, (3) Symptoms progress over days-weeks (peak at 2-4 weeks)</p>
                    <p><span class="label">Typical Presentation:</span> Ascending symmetric weakness starting in legs â†’ arms â†’ bulbar â†’ respiratory muscles. Paresthesias in hands/feet (glove-stocking distribution). Preceding illness 1-3 weeks prior (URI, GI infection)</p>
                    <p><span class="label">Motor Findings:</span></p>
                    <ul>
                        <li><strong>Weakness:</strong> Symmetric, ascending (legs before arms typically). Proximal and distal affected</li>
                        <li><strong>Areflexia:</strong> Absent or markedly diminished deep tendon reflexes (hallmark finding)</li>
                        <li><strong>Bulbar involvement:</strong> Facial weakness (bilateral), dysphagia, dysarthria (30-50%)</li>
                        <li><strong>Respiratory failure:</strong> 20-30% require mechanical ventilation. Progressive weakness of diaphragm/intercostals</li>
                    </ul>
                    <p><span class="label">Sensory Findings:</span> Paresthesias, numbness (glove-stocking). Pain (back, radicular) in 50%. Sensory exam often normal despite symptoms</p>
                    <p><span class="label">Autonomic Dysfunction (60%):</span> Tachycardia, bradycardia, arrhythmias, labile BP (hyper/hypotension), ileus, urinary retention, SIADH</p>
                    <p><span class="label">Variants:</span></p>
                    <ul>
                        <li><strong>AIDP (Acute Inflammatory Demyelinating Polyneuropathy):</strong> Most common in US/Europe (90%). Classic ascending paralysis</li>
                        <li><strong>AMAN/AMSAN (Axonal variants):</strong> More common in Asia. Axonal damage. Worse prognosis</li>
                        <li><strong>Miller Fisher syndrome:</strong> Triad of ataxia, areflexia, ophthalmoplegia. Anti-GQ1b antibodies (90%)</li>
                        <li><strong>Pharyngeal-cervical-brachial variant:</strong> Starts with bulbar/arm weakness</li>
                    </ul>
                    <p><span class="label">Triggers (preceding infection in 60-70%):</span></p>
                    <ul>
                        <li><strong>Campylobacter jejuni (30%):</strong> Most common. Diarrheal illness 1-3 weeks prior</li>
                        <li><strong>Upper respiratory infections:</strong> CMV, EBV, Mycoplasma</li>
                        <li><strong>Other:</strong> Zika virus, COVID-19, vaccines (rare, <1 per million), surgery, trauma</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis (primarily):</span> Brighton Criteria or Asbury & Cornblath Criteria. Diagnosis based on clinical features + CSF + EMG</p>
                    <p><span class="label">Lumbar Puncture (CSF Analysis):</span></p>
                    <ul>
                        <li><strong>Albuminocytologic dissociation (CLASSIC):</strong> Elevated protein (>45mg/dL) with normal or mildly elevated WBC (<10 cells/ÂµL)</li>
                        <li><strong>Timing:</strong> Protein elevation may not appear until week 2. If early and normal, repeat LP in 1 week if high suspicion</li>
                        <li><strong>WBC >50:</strong> Consider alternative diagnosis (infection, malignancy, sarcoid)</li>
                    </ul>
                    <p><span class="label">Electrodiagnostic Studies (EMG/NCS):</span></p>
                    <ul>
                        <li><strong>Findings:</strong> Prolonged distal latencies, slowed conduction velocities, conduction block, prolonged/absent F-waves (demyelination)</li>
                        <li><strong>Timing:</strong> Abnormalities may not appear until 2 weeks. Early studies may be normal</li>
                        <li><strong>Axonal variants (AMAN/AMSAN):</strong> Low-amplitude CMAPs with normal velocities</li>
                    </ul>
                    <p><span class="label">Bedside Respiratory Assessment (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Vital capacity (VC):</strong> Measure q4-6hr if progressive. VC <20mL/kg or rapidly declining = high risk for intubation</li>
                        <li><strong>Negative inspiratory force (NIF):</strong> <-30cmHâ‚‚O = respiratory muscle weakness</li>
                        <li><strong>Single-breath count:</strong> Unable to count to 20 in one breath = severe weakness</li>
                        <li><strong>20/30/40 rule:</strong> VC <20mL/kg, NIF >-30cmHâ‚‚O, MIP <40cmHâ‚‚O = likely need intubation</li>
                    </ul>
                    <p><span class="label">Labs:</span> CBC, CMP, LFTs (baseline before IVIG), ABG (if respiratory concern), serology for infections (Campylobacter, CMV, EBV, Mycoplasma), anti-ganglioside antibodies (anti-GM1, anti-GQ1b - supportive but not required)</p>
                    <p><span class="label">MRI spine:</strong> Consider to rule out mimics (cord compression, transverse myelitis). May show nerve root enhancement in GBS</p>
                    <p><span class="label">Mimics to Rule Out:</span> Spinal cord compression, transverse myelitis, myasthenia gravis, botulism, tick paralysis, acute intermittent porphyria, critical illness polyneuropathy, vasculitis, HIV, Lyme, West Nile virus</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immunotherapy (Equally Effective - choose one):</span></p>
                    <ul>
                        <li><strong>IVIG (Intravenous Immunoglobulin):</strong> 0.4g/kg/day Ã— 5 days (total 2g/kg). First-line in most centers. Easier to administer than plasmapheresis</li>
                        <li><strong>Plasmapheresis (Plasma Exchange):</strong> 5 exchanges over 7-14 days (200-250mL/kg total). Equally effective as IVIG. Use if IVIG contraindicated (IgA deficiency) or failed</li>
                        <li><strong>NO benefit to combination:</strong> IVIG + plasmapheresis NOT better than either alone</li>
                        <li><strong>Timing:</strong> Start within 2 weeks of symptom onset for maximum benefit. Still beneficial up to 4 weeks</li>
                        <li><strong>Steroids NOT beneficial:</strong> Corticosteroids do not work in GBS. Do NOT use</li>
                    </ul>
                    
                    <p><span class="label">Respiratory Management (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Monitor closely:</strong> Vital capacity, NIF q4-6hr if progressive weakness</li>
                        <li><strong>Indications for intubation:</strong> VC <15-20mL/kg, rapidly declining VC, NIF >-30cmHâ‚‚O, hypoxia, hypercapnia, inability to clear secretions, bulbar weakness with aspiration</li>
                        <li><strong>Intubation considerations:</strong> Avoid succinylcholine (hyperkalemia risk in denervation). Use non-depolarizing paralytics</li>
                        <li><strong>Ventilation strategy:</strong> Lung-protective ventilation. Avoid over-sedation (need to assess neuro status)</li>
                        <li><strong>Tracheostomy:</strong> Consider if anticipated ventilation >2 weeks (many GBS patients)</li>
                    </ul>
                    
                    <p><span class="label">Autonomic Management:</span></p>
                    <ul>
                        <li><strong>Cardiac monitoring:</strong> Telemetry for all patients. Risk of arrhythmias (brady, tachy, heart block)</li>
                        <li><strong>BP lability:</strong> Avoid aggressive treatment of transient hyper/hypotension. Short-acting agents if needed. Fluid boluses for hypotension</li>
                        <li><strong>Avoid:</strong> Î²-blockers (can worsen bradycardia), aggressive BP lowering (can precipitate hypotension)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>DVT prophylaxis:</strong> SCDs + heparin/LMWH (high risk due to immobility)</li>
                        <li><strong>GI:</strong> Proton pump inhibitor (stress ulcer prophylaxis), bowel regimen (ileus common)</li>
                        <li><strong>Bladder:</strong> Foley catheter if urinary retention</li>
                        <li><strong>Pain management:</strong> Gabapentin, pregabalin for neuropathic pain. Opioids if needed</li>
                        <li><strong>Physical therapy:</strong> Early mobilization when stable. Prevent contractures</li>
                        <li><strong>Nutrition:</strong> Consider NG/NJ tube if dysphagia. Assess swallow before PO</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Areflexia is the key finding:</strong> Absent reflexes + ascending weakness = GBS until proven otherwise. DTRs are lost early and universally</li>
                    <li><strong>Respiratory failure is the biggest risk:</strong> 20-30% need intubation. Monitor VC closely. Don't wait for hypoxia/hypercapnia (late findings). Intubate early if declining</li>
                    <li><strong>CSF protein may be normal early:</strong> Classic albuminocytologic dissociation may not appear until week 2. Repeat LP if high suspicion and initially normal</li>
                    <li><strong>IVIG = Plasmapheresis in efficacy:</strong> Both equally effective. IVIG easier to give. Combination NOT better. Start within 2 weeks of symptom onset</li>
                    <li><strong>Steroids don't work in GBS:</strong> Unlike most autoimmune conditions, corticosteroids are NOT beneficial and should NOT be used</li>
                    <li><strong>Prognosis overall good but slow:</strong> 80-85% recover fully, but takes months-year. 5-10% permanent disability. 3-5% mortality (respiratory failure, autonomic dysfunction)</li>
                    <li><strong>Campylobacter-associated GBS has worse prognosis:</strong> More likely to be axonal variant (AMAN). Slower recovery, more residual deficits</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL GBS patients need ICU or stepdown with close monitoring</li>
                        <li>VC <20mL/kg or rapidly declining</li>
                        <li>NIF >-30cmHâ‚‚O</li>
                        <li>Bulbar weakness (dysphagia, dysarthria)</li>
                        <li>Autonomic instability (arrhythmias, labile BP)</li>
                        <li>Rapid progression (can't walk â†’ respiratory failure in days)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Respiratory status stable (if intubated, successfully extubated)</li>
                        <li>No autonomic instability Ã— 72hr</li>
                        <li>Weakness plateaued or improving</li>
                        <li>Completed course of IVIG or plasmapheresis</li>
                        <li>Able to swallow safely (speech/swallow eval)</li>
                        <li>DVT prophylaxis in place</li>
                        <li>Inpatient rehab arranged (most need extensive PT/OT)</li>
                        <li>Neurology follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Respiratory failure (20-30%, #1 cause of death), autonomic dysfunction (arrhythmias, labile BP, sudden death), aspiration pneumonia, DVT/PE (immobility), ileus, urinary retention, pressure ulcers</p>
                    <p><strong>Treatment-related:</strong> IVIG (aseptic meningitis, hemolysis, thrombosis, renal failure), Plasmapheresis (hypotension, line infection, citrate toxicity, bleeding)</p>
                    <p><strong>Chronic:</strong> Residual weakness (10-15% permanent disability), chronic neuropathic pain (30%), fatigue (persistent in 50%), relapse (3-5%, usually within 2 months - consider CIDP if relapses), CIDP (chronic inflammatory demyelinating polyneuropathy - GBS-like but chronic/relapsing)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="myasthenia" class="condition-page">
            <div class="page-header">
                <h2>53. MYASTHENIA GRAVIS CRISIS</h2>
                <div class="subtitle">Neuromuscular Junction â€¢ Respiratory Failure â€¢ IVIG/PLEX</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Myasthenia Gravis (Baseline):</span> Autoimmune disorder causing fluctuating muscle weakness from antibodies blocking acetylcholine receptors at neuromuscular junction. Weakness worsens with activity, improves with rest</p>
                    <p><span class="label">Classic MG Symptoms:</span></p>
                    <ul>
                        <li><strong>Ocular (85% at presentation):</strong> Ptosis (drooping eyelids), diplopia (double vision). Often first symptoms</li>
                        <li><strong>Bulbar (60%):</strong> Dysphagia, dysarthria, nasal speech, difficulty chewing</li>
                        <li><strong>Limb weakness (50%):</strong> Proximal > distal. Arms > legs. Can't raise arms, difficulty climbing stairs</li>
                        <li><strong>Neck weakness:</strong> Head drop, difficulty holding head up</li>
                        <li><strong>Fatigable weakness:</strong> HALLMARK. Worse at end of day, after repeated activity. Improves with rest</li>
                    </ul>
                    <p><span class="label">Myasthenic Crisis (EMERGENCY):</span> Severe worsening of MG leading to respiratory failure requiring intubation. 15-20% of MG patients experience crisis at least once</p>
                    <p><span class="label">Crisis Presentation:</span></p>
                    <ul>
                        <li><strong>Respiratory failure:</strong> Dyspnea, tachypnea, inability to clear secretions, hypoxia, hypercapnia. Can progress rapidly</li>
                        <li><strong>Bulbar crisis:</strong> Severe dysphagia, aspiration risk, inability to manage secretions</li>
                        <li><strong>Generalized weakness:</strong> Unable to sit up, lift head, limb weakness</li>
                    </ul>
                    <p><span class="label">Crisis Triggers:</span></p>
                    <ul>
                        <li><strong>Infection (30-40%):</strong> Most common. Pneumonia, UTI, URI</li>
                        <li><strong>Medications:</strong> Aminoglycosides, fluoroquinolones, macrolides, Î²-blockers, CCBs, statins, steroids (paradoxical worsening first 2 weeks), neuromuscular blockers</li>
                        <li><strong>Surgery/anesthesia:</strong> Stress, medications</li>
                        <li><strong>Thyroid dysfunction:</strong> Hyper or hypothyroidism</li>
                        <li><strong>Pregnancy/postpartum:</strong> Hormonal changes</li>
                        <li><strong>Medication non-compliance:</strong> Stopped pyridostigmine or immunosuppressants</li>
                        <li><strong>Aspiration pneumonia:</strong> From bulbar weakness</li>
                    </ul>
                    <p><span class="label">Cholinergic Crisis (Rare):</span> Overdose of acetylcholinesterase inhibitors (pyridostigmine). Weakness from EXCESS acetylcholine. Associated with SLUDGE symptoms (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis) + miosis, bronchorrhea, bradycardia</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Bedside Respiratory Assessment (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Vital capacity (VC):</strong> <15-20mL/kg = high risk for intubation. Monitor q2-4hr</li>
                        <li><strong>Negative inspiratory force (NIF):</strong> >-30cmHâ‚‚O = severe weakness</li>
                        <li><strong>ABG:</strong> Hypercapnia (pCOâ‚‚ >45) and hypoxia = impending respiratory failure. Don't wait for ABG to intubate</li>
                        <li><strong>Single-breath count:</strong> Unable to count to 15-20 in one breath = severe weakness</li>
                        <li><strong>Signs of impending failure:</strong> Tachypnea, accessory muscle use, paradoxical breathing, inability to cough or clear secretions</li>
                    </ul>
                    <p><span class="label">Myasthenic vs Cholinergic Crisis (Differentiate):</span></p>
                    <ul>
                        <li><strong>Clinical:</strong> Cholinergic has SLUDGE symptoms + fasciculations + miosis. Myasthenic does not</li>
                        <li><strong>Edrophonium (Tensilon) test:</strong> Short-acting acetylcholinesterase inhibitor. Myasthenic crisis improves. Cholinergic crisis worsens. RARELY done (dangerous in crisis)</li>
                        <li><strong>Practical approach:</strong> Hold pyridostigmine in crisis. Treat with IVIG/PLEX (works for both). Restart pyridostigmine when improving</li>
                    </ul>
                    <p><span class="label">Confirm MG Diagnosis (if not already diagnosed):</span></p>
                    <ul>
                        <li><strong>Antibodies:</strong> Anti-AChR (acetylcholine receptor) antibodies (80-85% sensitivity). Anti-MuSK antibodies (5-10% if AChR-negative). Anti-LRP4 (<5%)</li>
                        <li><strong>Repetitive nerve stimulation (RNS):</strong> >10% decrement in CMAP amplitude with low-frequency (2-3Hz) stimulation. Sensitivity 50-75%</li>
                        <li><strong>Single-fiber EMG:</strong> Most sensitive (95%). Shows increased jitter. Not widely available</li>
                        <li><strong>Edrophonium test:</strong> Improves strength transiently (3-5min). Rarely used (can cause bradycardia, bronchospasm)</li>
                    </ul>
                    <p><span class="label">Labs:</span> CBC (infection), CMP (electrolytes), ABG (respiratory status), CK (normal in MG, unlike muscular dystrophy), TSH (thyroid disease common in MG), troponin (stress from respiratory failure)</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CT chest:</strong> Assess for thymoma (present in 10-15% of MG). Thymic hyperplasia in 60-70%</li>
                        <li><strong>CXR:</strong> Rule out pneumonia (common trigger)</li>
                    </ul>
                    <p><span class="label">Search for Triggers:</span> Blood cultures, UA/UCx, CXR, review medications, TSH</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Airway/Respiratory Management (Priority #1):</span></p>
                    <ul>
                        <li><strong>Intubation criteria:</strong> VC <15mL/kg, NIF >-30cmHâ‚‚O, hypercapnia, inability to protect airway/clear secretions, impending respiratory failure</li>
                        <li><strong>Intubation considerations:</strong> AVOID succinylcholine (unpredictable response). Use non-depolarizing agents at reduced dose (increased sensitivity). Rocuronium 0.3-0.6mg/kg (half normal dose)</li>
                        <li><strong>Ventilation:</strong> Lung-protective strategy. Low tidal volume (6mL/kg IBW). Adequate PEEP</li>
                        <li><strong>Extubation:</strong> When VC >15-20mL/kg, NIF <-30cmHâ‚‚O, able to protect airway. Often takes 1-2 weeks after treatment</li>
                    </ul>
                    
                    <p><span class="label">Immunotherapy for Crisis (Start Immediately):</span></p>
                    <ul>
                        <li><strong>IVIG (Intravenous Immunoglobulin):</strong> 0.4g/kg/day Ã— 5 days OR 1g/kg/day Ã— 2 days (total 2g/kg). First-line. Improvement in 3-7 days</li>
                        <li><strong>Plasmapheresis (Plasma Exchange):</strong> 5 exchanges over 7-14 days. Equivalent efficacy to IVIG. Improvement in 2-4 days (faster than IVIG). Use if IVIG failed or contraindicated</li>
                        <li><strong>Duration of benefit:</strong> Temporary (weeks-months). Need long-term immunosuppression</li>
                    </ul>
                    
                    <p><span class="label">Acetylcholinesterase Inhibitor Management:</span></p>
                    <ul>
                        <li><strong>HOLD pyridostigmine during crisis:</strong> Respiratory failure impairs clearance of secretions (cholinergic side effect). Resume when extubated</li>
                        <li><strong>When stable:</strong> Pyridostigmine 30-60mg PO q4-6hr (typical dose 60mg q4hr). Max 120mg/dose. Adjust based on response</li>
                    </ul>
                    
                    <p><span class="label">Corticosteroids (Long-term, NOT in acute crisis):</span></p>
                    <ul>
                        <li><strong>NOT for acute crisis:</strong> Can cause paradoxical worsening in first 1-2 weeks</li>
                        <li><strong>For chronic MG control:</strong> Prednisone 20-100mg daily (start low if outpatient to avoid worsening). Taper slowly after improvement</li>
                        <li><strong>Steroid-sparing agents:</strong> Azathioprine, mycophenolate, cyclosporine, tacrolimus. Takes months to work</li>
                    </ul>
                    
                    <p><span class="label">Treat Triggers:</span></p>
                    <ul>
                        <li><strong>Infection:</strong> Antibiotics. Avoid contraindicated agents (aminoglycosides, fluoroquinolones, macrolides)</li>
                        <li><strong>Aspiration pneumonia:</strong> NPO until swallow safe. Aspiration precautions</li>
                        <li><strong>Medication review:</strong> Stop all potentially exacerbating medications</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>DVT prophylaxis:</strong> SCDs + heparin/LMWH</li>
                        <li><strong>GI:</strong> PPI for stress ulcer prophylaxis. NPO if intubated or severe bulbar weakness</li>
                        <li><strong>Nutrition:</strong> NG tube for feeding if prolonged intubation or severe dysphagia</li>
                        <li><strong>Physical therapy:</strong> Early mobilization when stable</li>
                    </ul>
                    
                    <p><span class="label">Thymectomy:</span> Improves long-term outcomes in generalized MG, especially if thymoma present. Usually done electively, not during crisis. Discuss with neurology/thoracic surgery</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Fatigable weakness is pathognomonic:</strong> Worse with activity, improves with rest. Ptosis worsens when looking up Ã— 1min. This distinguishes MG from other causes of weakness</li>
                    <li><strong>Crisis can develop rapidly:</strong> Can go from stable to intubated within hours. Monitor VC closely. Don't wait for ABG abnormalities (late finding)</li>
                    <li><strong>Ice pack test for ptosis:</strong> Apply ice to closed eyelid Ã— 2min. Ptosis improves in MG (cold improves NMJ transmission). Simple bedside test</li>
                    <li><strong>Avoid succinylcholine:</strong> Unpredictable response in MG. May have prolonged paralysis. Use non-depolarizing agents at REDUCED doses (increased sensitivity)</li>
                    <li><strong>Hold pyridostigmine in crisis:</strong> Increases secretions which impairs ventilation. Resume when extubated and improving</li>
                    <li><strong>IVIG and PLEX are temporizing:</strong> Provide weeks-months of benefit. Need long-term immunosuppression (prednisone, azathioprine, etc) for disease control</li>
                    <li><strong>Seronegative MG exists (10-15%):</strong> Negative antibodies don't rule out MG. Use clinical features + EMG (RNS or single-fiber)</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL myasthenic crisis patients need ICU</li>
                        <li>VC <20mL/kg or rapidly declining</li>
                        <li>NIF >-30cmHâ‚‚O</li>
                        <li>Severe bulbar weakness (aspiration risk)</li>
                        <li>Inability to clear secretions</li>
                        <li>Respiratory distress (tachypnea, accessory muscle use)</li>
                        <li>Need for intubation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Successfully extubated with stable respiratory status</li>
                        <li>VC >20mL/kg, NIF <-30cmHâ‚‚O</li>
                        <li>Completed IVIG or plasmapheresis</li>
                        <li>Swallow safe (passed speech/swallow eval)</li>
                        <li>Pyridostigmine restarted at stable dose</li>
                        <li>Long-term immunosuppression plan in place</li>
                        <li>Trigger identified and treated (infection, etc)</li>
                        <li>Neurology follow-up arranged (close follow-up needed)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Respiratory failure (15-20% of MG patients have crisis), aspiration pneumonia (bulbar weakness), prolonged intubation, ventilator-associated pneumonia, DVT/PE, pressure ulcers</p>
                    <p><strong>Treatment-related:</strong> IVIG complications (aseptic meningitis, hemolysis, thrombosis, renal failure), Plasmapheresis complications (hypotension, line infection, citrate toxicity), Steroid complications (hyperglycemia, infection, osteoporosis, psychosis)</p>
                    <p><strong>Chronic:</strong> Recurrent crises (30% have >1 crisis), medication side effects (chronic steroids), thymoma (10-15%, can be malignant), need for chronic immunosuppression, disability from weakness</p>
                    <p><strong>Mortality:</strong> 4-8% mortality from myasthenic crisis (improved from 40% in pre-ICU era)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="increased-icp" class="condition-page">
            <div class="page-header">
                <h2>54. INCREASED INTRACRANIAL PRESSURE (ICP)</h2>
                <div class="subtitle">Cushing's Triad â€¢ Herniation Syndromes â€¢ Emergency Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Normal ICP:</span> 5-15 mmHg. Increased ICP = sustained elevation >20 mmHg. Life-threatening when >30 mmHg or when herniation occurs</p>
                    <p><span class="label">Cushing's Triad (LATE finding, indicates impending herniation):</span></p>
                    <ul>
                        <li><strong>Hypertension:</strong> Widened pulse pressure (elevated systolic, normal/low diastolic)</li>
                        <li><strong>Bradycardia:</strong> Reflex response to hypertension</li>
                        <li><strong>Irregular respirations:</strong> Cheyne-Stokes, apneustic, or ataxic breathing</li>
                        <li><strong>Pearl:</strong> Cushing's triad is a pre-terminal sign. Don't wait for it - treat earlier symptoms!</li>
                    </ul>
                    <p><span class="label">Early/Progressive Symptoms:</span></p>
                    <ul>
                        <li><strong>Headache:</strong> Severe, worse in morning, worse with Valsalva (cough, sneeze, straining)</li>
                        <li><strong>Nausea/vomiting:</strong> Projectile vomiting (without nausea sometimes)</li>
                        <li><strong>Altered mental status:</strong> Confusion, lethargy, obtundation â†’ coma</li>
                        <li><strong>Papilledema:</strong> Swollen optic discs on fundoscopy. Takes hours-days to develop</li>
                        <li><strong>Vision changes:</strong> Blurry vision, diplopia, transient visual obscurations</li>
                        <li><strong>Seizures:</strong> From mass effect or ischemia</li>
                    </ul>
                    <p><span class="label">Herniation Syndromes (EMERGENCY):</span></p>
                    <ul>
                        <li><strong>Uncal herniation (most common):</strong> Ipsilateral dilated pupil (CN III compression), contralateral hemiparesis (compression of cerebral peduncle), Cushing's triad, coma</li>
                        <li><strong>Central herniation:</strong> Small reactive pupils â†’ bilateral dilated pupils, decorticate â†’ decerebrate posturing, coma</li>
                        <li><strong>Tonsillar herniation:</strong> Cerebellar tonsils herniate through foramen magnum. Apnea, sudden death from medullary compression</li>
                        <li><strong>Subfalcine herniation:</strong> Often asymptomatic until late. Can cause ACA stroke</li>
                    </ul>
                    <p><span class="label">Common Causes:</span></p>
                    <ul>
                        <li><strong>Traumatic brain injury (TBI):</strong> Epidural hematoma, subdural hematoma, cerebral contusion, diffuse axonal injury</li>
                        <li><strong>Hemorrhagic stroke:</strong> Intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) with hydrocephalus</li>
                        <li><strong>Ischemic stroke:</strong> Large MCA territory infarct with edema (malignant MCA syndrome)</li>
                        <li><strong>Tumor:</strong> Primary or metastatic brain tumors with mass effect</li>
                        <li><strong>Infection:</strong> Brain abscess, meningitis, encephalitis</li>
                        <li><strong>Hydrocephalus:</strong> Obstructive (tumor, blood) or communicating</li>
                        <li><strong>Idiopathic intracranial hypertension (IIH):</strong> Pseudotumor cerebri. Young obese women. Chronic headache, papilledema, vision loss</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate Imaging (Don't Delay):</span></p>
                    <ul>
                        <li><strong>CT head (non-contrast):</strong> FIRST-LINE. Fast, identifies hemorrhage, mass lesions, hydrocephalus, midline shift, herniation. Signs of increased ICP: effaced sulci, compressed ventricles, loss of gray-white differentiation, midline shift</li>
                        <li><strong>MRI brain:</strong> Better detail but takes longer. Use if CT non-diagnostic or for specific concerns (abscess, posterior fossa, tumor characterization)</li>
                    </ul>
                    <p><span class="label">ICP Monitoring (Neurosurgery):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Severe TBI (GCS â‰¤8) with abnormal CT, intraparenchymal hemorrhage requiring surgery, SAH with poor grade, refractory elevated ICP</li>
                        <li><strong>Types:</strong> External ventricular drain (EVD) - gold standard, allows CSF drainage + monitoring. Intraparenchymal monitor (fiberoptic) - monitoring only</li>
                        <li><strong>Goal ICP:</strong> <20 mmHg. Treat if >22 sustained</li>
                        <li><strong>Cerebral perfusion pressure (CPP) = MAP - ICP:</strong> Goal CPP 60-70 mmHg</li>
                    </ul>
                    <p><span class="label">Fundoscopy:</span> Look for papilledema (blurred disc margins, disc elevation, venous engorgement). Absence doesn't rule out increased ICP (takes time to develop)</p>
                    <p><span class="label">Labs:</span> CBC, CMP, coags (before procedures), osmolality (if using hyperosmolar therapy), ABG (avoid hypercapnia - vasodilates cerebral vessels)</p>
                    <p><span class="label">DO NOT perform LP if increased ICP!</span> Risk of herniation. Only after imaging rules out mass lesion and no signs of herniation</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li><strong>Treat underlying cause:</strong> Evacuate hematoma, resect tumor, drain abscess, treat infection, drain CSF (EVD for hydrocephalus)</li>
                        <li><strong>Reduce ICP:</strong> Medical management + surgical if indicated</li>
                        <li><strong>Maintain cerebral perfusion:</strong> CPP = MAP - ICP. Goal CPP 60-70 mmHg</li>
                    </ul>
                    
                    <p><span class="label">Immediate Medical Management (if signs of herniation or ICP >22):</span></p>
                    <ul>
                        <li><strong>Head of bed elevation:</strong> 30 degrees. Improves venous drainage. Keep head midline (no neck rotation - obstructs jugular veins)</li>
                        <li><strong>Hyperosmolar therapy:</strong></li>
                        <ul>
                            <li><strong>Mannitol:</strong> 0.25-1g/kg IV bolus (typical 100g = 500mL of 20% solution). Repeat q4-6hr PRN. Monitor serum osmolality (keep <320 mOsm/kg). Watch for hypovolemia, AKI</li>
                            <li><strong>Hypertonic saline:</strong> 3% NaCl 250mL bolus over 10-20min. Or 23.4% NaCl 30mL bolus via central line. Repeat PRN. Monitor Na (keep <160 mEq/L). May be superior to mannitol</li>
                        </ul>
                        <li><strong>Hyperventilation (TEMPORIZING ONLY):</strong> Target pCOâ‚‚ 30-35 mmHg. Causes cerebral vasoconstriction â†’ reduces cerebral blood volume â†’ lowers ICP. ONLY for emergent herniation (buys time for definitive treatment). Prolonged use causes ischemia</li>
                        <li><strong>Sedation:</strong> Propofol or midazolam. Reduces cerebral metabolic demand. Intubate first if severe</li>
                        <li><strong>Seizure prophylaxis:</strong> Levetiracetam 500-1000mg IV. Seizures increase ICP</li>
                    </ul>
                    
                    <p><span class="label">Supportive ICU Care:</span></p>
                    <ul>
                        <li><strong>Intubation:</strong> If GCS â‰¤8, inability to protect airway, need for hyperventilation. Use RSI with lidocaine pretreatment (blunts ICP spike from intubation)</li>
                        <li><strong>Ventilation:</strong> Target pCOâ‚‚ 35-40 mmHg (normal). Avoid hypercapnia (vasodilates) and excessive hypocapnia (causes ischemia)</li>
                        <li><strong>Oxygenation:</strong> Keep Oâ‚‚ sat >90%. Hypoxia worsens cerebral edema</li>
                        <li><strong>Blood pressure:</strong> Maintain adequate MAP to achieve CPP 60-70 mmHg. May need vasopressors (norepinephrine)</li>
                        <li><strong>Temperature:</strong> Avoid hyperthermia (increases metabolic demand). Goal normothermia. Consider therapeutic hypothermia (32-36Â°C) if refractory (controversial)</li>
                        <li><strong>Glucose:</strong> Avoid hyper and hypoglycemia. Goal 140-180 mg/dL</li>
                        <li><strong>Avoid:</strong> Hypotonic fluids (worsens cerebral edema). Use isotonic (0.9% NaCl) or hypertonic</li>
                    </ul>
                    
                    <p><span class="label">Surgical Management (Neurosurgery Consult):</span></p>
                    <ul>
                        <li><strong>Hematoma evacuation:</strong> Epidural, subdural, or intraparenchymal hematoma with mass effect</li>
                        <li><strong>External ventricular drain (EVD):</strong> Drains CSF, reduces ICP. For hydrocephalus or as ICP monitor</li>
                        <li><strong>Decompressive craniectomy:</strong> Remove part of skull to allow brain to swell outward. For malignant MCA syndrome, refractory TBI. Reduces mortality but increases severe disability</li>
                        <li><strong>Tumor resection/abscess drainage:</strong> If mass lesion causing ICP</li>
                    </ul>
                    
                    <p><span class="label">Refractory ICP (if above measures fail):</span></p>
                    <ul>
                        <li><strong>Barbiturate coma:</strong> Pentobarbital load 5-10mg/kg, then 1-4mg/kg/hr. Reduces cerebral metabolic rate. Requires continuous EEG monitoring. High complication rate (hypotension, infection)</li>
                        <li><strong>Decompressive craniectomy:</strong> Last resort for refractory ICP</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Cushing's triad is a late/pre-terminal sign:</strong> Don't wait for it! Treat based on symptoms, imaging, and ICP monitoring. By the time Cushing's triad appears, herniation is imminent</li>
                    <li><strong>Herniation kills via brainstem compression:</strong> Respiratory centers (apnea), cardiovascular centers (shock), reticular activating system (coma). Uncal herniation â†’ ipsilateral blown pupil is classic</li>
                    <li><strong>Hyperventilation is temporizing only:</strong> Buys 15-30 minutes by vasoconstricting cerebral vessels. Prolonged use causes ischemia. Use only for emergent herniation while preparing for definitive treatment</li>
                    <li><strong>Mannitol vs hypertonic saline:</strong> Both work. Hypertonic saline may be superior (no osmotic diuresis, longer duration). Hypertonic saline preferred in hypovolemic patients</li>
                    <li><strong>Avoid LP if increased ICP:</strong> Removing CSF creates pressure gradient â†’ brainstem herniates through foramen magnum (tonsillar herniation) â†’ death. Always image first!</li>
                    <li><strong>Head of bed 30Â°, not flat:</strong> Improves venous drainage, reduces ICP. Keep head midline (turning neck obstructs jugular veins â†’ worsens ICP)</li>
                    <li><strong>CPP matters more than ICP:</strong> Brain needs perfusion. CPP = MAP - ICP. Goal CPP 60-70 mmHg. May need to increase MAP with pressors even if ICP elevated</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL increased ICP patients need ICU</li>
                        <li>GCS â‰¤8</li>
                        <li>Signs of herniation (blown pupil, posturing, Cushing's triad)</li>
                        <li>Need for ICP monitoring</li>
                        <li>Need for hyperosmolar therapy or hyperventilation</li>
                        <li>Neurosurgical emergency</li>
                        <li>Intubated for airway protection</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ ICU â†’ FLOOR CRITERIA</div>
                    <ul>
                        <li>ICP controlled (<20 mmHg sustained)</li>
                        <li>No herniation risk</li>
                        <li>Underlying cause treated (hematoma evacuated, CSF draining, etc)</li>
                        <li>Off hyperosmolar therapy Ã— 24hr</li>
                        <li>Extubated (if intubated)</li>
                        <li>Neurologically stable or improving</li>
                        <li>Can remove ICP monitor if placed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Herniation (uncal, central, tonsillar) â†’ death or severe disability, ischemic stroke (from low CPP or herniation-related vascular compression), seizures, vision loss (optic nerve compression from papilledema), brainstem injury</p>
                    <p><strong>Treatment-related:</strong> Hyperventilation â†’ cerebral ischemia, Mannitol â†’ hypovolemia, AKI, rebound cerebral edema, Hypertonic saline â†’ hypernatremia, central pontine myelinolysis (if Na corrected too fast), Decompressive craniectomy â†’ infection, seizures, need for cranioplasty</p>
                    <p><strong>Chronic:</strong> Cognitive impairment, motor deficits, vision loss (from chronic papilledema), seizure disorder, chronic disability, death (mortality varies by etiology: TBI 20-50%, malignant stroke 80% without craniectomy)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="cord-compression" class="condition-page">
            <div class="page-header">
                <h2>55. SPINAL CORD COMPRESSION</h2>
                <div class="subtitle">Oncologic Emergency â€¢ Cauda Equina â€¢ Urgent MRI/Decompression</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> (1) Back pain, (2) Motor weakness, (3) Sensory level. Autonomic dysfunction (bowel/bladder) is LATE finding</p>
                    <p><span class="label">Back Pain (>90%, often first symptom):</span></p>
                    <ul>
                        <li><strong>Characteristics:</strong> Severe, progressive, localized to site of compression. Worse with recumbency, Valsalva (cough, sneeze)</li>
                        <li><strong>Radicular pain:</strong> Shooting pain down extremity (dermatome distribution)</li>
                        <li><strong>Percussion tenderness:</strong> Tenderness over spinous process at level of compression</li>
                    </ul>
                    <p><span class="label">Motor Findings:</span></p>
                    <ul>
                        <li><strong>Weakness:</strong> Progressive, bilateral (though may start asymmetric). Upper motor neuron pattern (hyperreflexia, spasticity, upgoing Babinski) if compression above conus. Lower motor neuron if conus/cauda equina</li>
                        <li><strong>Gait disturbance:</strong> Difficulty walking, ataxia</li>
                        <li><strong>Severity:</strong> Can progress from subtle weakness to paraplegia in hours-days</li>
                    </ul>
                    <p><span class="label">Sensory Findings:</span></p>
                    <ul>
                        <li><strong>Sensory level:</strong> Decreased sensation below dermatome corresponding to compression level. Test pinprick from feet upward</li>
                        <li><strong>Paresthesias:</strong> Numbness, tingling in legs/arms</li>
                        <li><strong>Band-like sensation:</strong> Tight band around chest/abdomen at level of compression</li>
                    </ul>
                    <p><span class="label">Autonomic Dysfunction (LATE, indicates severe compression):</span></p>
                    <ul>
                        <li><strong>Bladder dysfunction:</strong> Urinary retention (most common), overflow incontinence, loss of urge sensation</li>
                        <li><strong>Bowel dysfunction:</strong> Constipation, fecal incontinence</li>
                        <li><strong>Sexual dysfunction:</strong> Erectile dysfunction, loss of sensation</li>
                        <li><strong>Loss of anal sphincter tone:</strong> Decreased rectal tone on exam (check rectal exam!)</li>
                    </ul>
                    <p><span class="label">Cauda Equina Syndrome (Compression Below L1-L2):</span></p>
                    <ul>
                        <li><strong>Classic:</strong> Severe back/leg pain, saddle anesthesia (perineum, buttocks, inner thighs), bilateral leg weakness (lower motor neuron - areflexia), bowel/bladder dysfunction, decreased anal tone</li>
                        <li><strong>Pearl:</strong> Lower motor neuron findings (flaccid weakness, areflexia, muscle atrophy) vs cord compression (upper motor neuron)</li>
                    </ul>
                    <p><span class="label">Etiologies:</span></p>
                    <ul>
                        <li><strong>Metastatic cancer (50-70%):</strong> Most common cause. Breast, lung, prostate, renal, melanoma, myeloma. Vertebral body â†’ epidural extension</li>
                        <li><strong>Epidural abscess (5-10%):</strong> Staph aureus most common. Preceding bacteremia, IVDU, spinal procedure, immunosuppression</li>
                        <li><strong>Epidural hematoma:</strong> Trauma, anticoagulation, spinal procedure (epidural, LP)</li>
                        <li><strong>Disc herniation:</strong> Large central or posterolateral disc. Acute (trauma) or chronic (degenerative)</li>
                        <li><strong>Spinal stenosis:</strong> Chronic compression from degenerative changes. Progressive symptoms</li>
                        <li><strong>Primary cord tumor:</strong> Astrocytoma, ependymoma (intramedullary)</li>
                        <li><strong>Trauma:</strong> Vertebral fracture, subluxation</li>
                        <li><strong>Other:</strong> Transverse myelitis, spinal AVM, spontaneous epidural hematoma</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">MRI Spine with Gadolinium (URGENT, <24hr):</span></p>
                    <ul>
                        <li><strong>GOLD STANDARD:</strong> Identifies level and cause of compression. Visualizes entire spine (metastases can be multiple levels)</li>
                        <li><strong>Image entire spine:</strong> Cervical, thoracic, lumbar. 20-30% have lesions at multiple non-contiguous levels</li>
                        <li><strong>Timing:</strong> STAT MRI if progressive motor weakness or bowel/bladder dysfunction (hours matter!). Within 24hr if concerning symptoms</li>
                        <li><strong>Contraindications:</strong> Pacemaker, metallic implants (some), severe claustrophobia</li>
                    </ul>
                    <p><span class="label">CT Myelography (if MRI contraindicated or unavailable):</span></p>
                    <ul>
                        <li><strong>Requires LP:</strong> Inject contrast into subarachnoid space, then CT spine. Shows obstruction to flow</li>
                        <li><strong>Risk:</strong> If complete block, LP can worsen compression. MRI preferred</li>
                    </ul>
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis (abscess), anemia (malignancy)</li>
                        <li><strong>ESR/CRP:</strong> Elevated (abscess, malignancy)</li>
                        <li><strong>Blood cultures:</strong> If concern for epidural abscess (fever, elevated WBC)</li>
                        <li><strong>PSA:</strong> If prostate cancer suspected</li>
                        <li><strong>Coags:</strong> If epidural hematoma suspected (anticoagulation, bleeding disorder)</li>
                    </ul>
                    <p><span class="label">Rectal Exam (MANDATORY):</span> Assess anal tone, perianal sensation. Decreased tone = cauda equina or severe cord compression</p>
                    <p><span class="label">Post-Void Residual (PVR):</span> Bladder scan after patient voids. PVR >100-200mL = retention (indicates autonomic dysfunction)</p>
                    <p><span class="label">Red Flags Requiring URGENT MRI:</span></p>
                    <ul>
                        <li>New bowel/bladder dysfunction</li>
                        <li>Saddle anesthesia</li>
                        <li>Progressive motor weakness</li>
                        <li>Known cancer with new back pain or neurologic symptoms</li>
                        <li>Fever + back pain (epidural abscess)</li>
                        <li>Severe back pain after trauma</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immediate Management (BEFORE definitive treatment):</span></p>
                    <ul>
                        <li><strong>Dexamethasone (if malignancy suspected):</strong> 10mg IV STAT, then 4mg IV q6hr. Reduces cord edema. Give IMMEDIATELY while arranging MRI. Do NOT delay for imaging</li>
                        <li><strong>Hold steroids if abscess suspected:</strong> Can worsen infection. Give antibiotics first</li>
                        <li><strong>Pain control:</strong> Opioids as needed. Pain can be severe</li>
                        <li><strong>Bladder catheterization:</strong> Foley if urinary retention</li>
                        <li><strong>Spinal precautions:</strong> If trauma, keep spine immobilized</li>
                    </ul>
                    
                    <p><span class="label">Definitive Treatment by Etiology:</span></p>
                    <ul>
                        <li><strong>Metastatic Epidural Spinal Cord Compression (MESCC):</strong></li>
                        <ul>
                            <li><strong>Surgery:</strong> Decompressive laminectomy + tumor resection. Indications: radiosensitive tumor, spinal instability, neurologic decline on radiation, unclear diagnosis needing biopsy. Better outcomes than radiation alone if ambulatory pre-op</li>
                            <li><strong>Radiation therapy:</strong> For radiosensitive tumors (lymphoma, myeloma, small cell lung, prostate). 8-10 Gy Ã— 1-2 fractions emergently. Can preserve ambulation</li>
                            <li><strong>Combination:</strong> Surgery followed by radiation for local control</li>
                            <li><strong>Dexamethasone:</strong> Continue Ã— 3-7 days, then taper over 2-4 weeks</li>
                        </ul>
                        <li><strong>Epidural Abscess:</strong></li>
                        <ul>
                            <li><strong>Antibiotics:</strong> Empiric vancomycin 15mg/kg IV q12hr + ceftriaxone 2g IV q24hr OR cefepime 2g IV q8hr. Adjust based on cultures</li>
                            <li><strong>Surgery:</strong> Urgent laminectomy and drainage if neurologic deficits, spinal instability, or failed medical therapy. Source control critical</li>
                            <li><strong>Medical management alone:</strong> Consider if no neuro deficits, small abscess, high surgical risk. Requires close monitoring</li>
                            <li><strong>Duration:</strong> 4-8 weeks IV antibiotics (longer if osteomyelitis)</li>
                        </ul>
                        <li><strong>Epidural Hematoma:</strong></li>
                        <ul>
                            <li><strong>Reverse anticoagulation:</strong> Vitamin K, FFP, PCC, or idarucizumab/andexanet depending on agent</li>
                            <li><strong>Surgery:</strong> Urgent decompression if neurologic deficits</li>
                            <li><strong>Conservative:</strong> Small hematoma without neuro deficits can be observed</li>
                        </ul>
                        <li><strong>Disc Herniation/Cauda Equina:</strong></li>
                        <ul>
                            <li><strong>Surgery:</strong> EMERGENT discectomy (within 24-48hr). Outcomes worsen with delay. Cauda equina = surgical emergency</li>
                            <li><strong>Medical management:</strong> Only if no red flags, no progressive deficits. NSAIDs, PT</li>
                        </ul>
                    </ul>
                    
                    <p><span class="label">Surgical Timing (Critical):</span></p>
                    <ul>
                        <li><strong>Cauda equina:</strong> Within 24-48hr. Every hour delay worsens outcomes (bowel/bladder recovery)</li>
                        <li><strong>Progressive motor weakness:</strong> Emergent (hours). Pre-op ambulatory status predicts post-op ambulation</li>
                        <li><strong>Paraplegia >48hr:</strong> Unlikely to recover ambulation even with surgery. Still decompress for pain, bowel/bladder</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>DVT prophylaxis:</strong> SCDs + heparin/LMWH (unless hematoma)</li>
                        <li><strong>Bowel regimen:</strong> Prevent constipation (ileus common)</li>
                        <li><strong>Bladder management:</strong> Foley if retention. Intermittent cath when stable</li>
                        <li><strong>Skin care:</strong> Turn q2hr, pressure ulcer prevention</li>
                        <li><strong>Physical therapy:</strong> Early mobilization when safe</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Back pain + cancer = MRI until proven otherwise:</strong> 95% of MESCC patients have back pain. Any cancer patient with new/worsening back pain needs urgent spine MRI</li>
                    <li><strong>Autonomic dysfunction = LATE finding:</strong> Bowel/bladder involvement indicates severe compression. Don't wait for it - intervene earlier based on motor/sensory findings</li>
                    <li><strong>Ambulatory status predicts outcome:</strong> If ambulatory before treatment, 90% remain ambulatory. If paraplegic, only 10-20% regain ambulation. TIMING MATTERS</li>
                    <li><strong>Give steroids BEFORE MRI if malignancy suspected:</strong> Dexamethasone 10mg IV immediately. Reduces cord edema while waiting for imaging/surgery. Don't delay for diagnosis</li>
                    <li><strong>Check rectal tone!</strong> Mandatory part of exam. Decreased tone = cauda equina or severe compression requiring emergent intervention</li>
                    <li><strong>Cauda equina = surgical emergency:</strong> Decompress within 24-48hr. Permanent bowel/bladder/sexual dysfunction if delayed. Saddle anesthesia + bladder retention + bilateral leg weakness = OR now</li>
                    <li><strong>Epidural abscess triad:</strong> Back pain + fever + neurologic deficits. But only 10-15% have all three. High index of suspicion in IVDU, recent spinal procedure, or bacteremia</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ URGENT NEUROSURGERY CONSULT IF:</div>
                    <ul>
                        <li>ANY cord compression on imaging with neurologic deficits</li>
                        <li>Cauda equina syndrome (surgical emergency)</li>
                        <li>Progressive motor weakness</li>
                        <li>Bowel/bladder dysfunction</li>
                        <li>Epidural abscess with neuro deficits</li>
                        <li>Epidural hematoma with neuro deficits</li>
                        <li>Large disc herniation with cauda equina</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Neurologically stable or improving</li>
                        <li>Post-surgical if operated (wound healing, no infection)</li>
                        <li>Pain controlled on oral regimen</li>
                        <li>Bladder function recovered OR able to self-cath</li>
                        <li>Bowel regimen established</li>
                        <li>If abscess: Appropriate antibiotics, plan for weeks-long course</li>
                        <li>Inpatient rehab arranged (many need extensive PT/OT)</li>
                        <li>Oncology follow-up (if malignancy)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Permanent paraplegia (if delayed treatment), respiratory failure (if high cervical lesion), neurogenic shock (spinal shock - hypotension, bradycardia from loss of sympathetic tone), DVT/PE (immobility), pressure ulcers, urinary retention â†’ hydronephrosis</p>
                    <p><strong>Surgical:</strong> Wound infection, CSF leak, worsening neurologic deficits, spinal instability, epidural hematoma</p>
                    <p><strong>Chronic:</strong> Permanent bowel/bladder dysfunction (30-70% if cauda equina), chronic pain, sexual dysfunction, spasticity, recurrent UTIs (neurogenic bladder), pressure ulcers, DVT, depression, need for lifelong assistance/wheelchair</p>
                    <p><strong>Prognosis:</strong> Depends on etiology, severity at presentation, and time to treatment. Pre-op ambulatory status is most important predictor. Paraplegia >48hr rarely recovers</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="influenza" class="condition-page">
            <div class="page-header">
                <h2>56. INFLUENZA/SEVERE VIRAL PNEUMONIA</h2>
                <div class="subtitle">Viral Respiratory Illness â€¢ Primary Viral Pneumonia â€¢ Oseltamivir/Supportive Care</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Influenza (Uncomplicated):</span> Abrupt onset fever, myalgias, headache, malaise, dry cough, sore throat. Self-limited in 3-7 days in healthy individuals</p>
                    <p><span class="label">Severe Influenza/Primary Viral Pneumonia:</span> Progressive dyspnea, hypoxemia, bilateral infiltrates despite antiviral therapy. Can rapidly progress to ARDS. More common in high-risk patients</p>
                    <p><span class="label">Classic Presentation:</span></p>
                    <ul>
                        <li><strong>Respiratory:</strong> Dyspnea, tachypnea, hypoxemia (Oâ‚‚ sat <90%), cough (initially dry, may become productive), pleuritic chest pain</li>
                        <li><strong>Systemic:</strong> High fever (>38.5Â°C), severe myalgias, fatigue, headache</li>
                        <li><strong>Timeline:</strong> Initial flu symptoms â†’ worsening respiratory status over 2-5 days â†’ ARDS (severe cases)</li>
                    </ul>
                    <p><span class="label">High-Risk Groups (for Severe Disease):</span></p>
                    <ul>
                        <li><strong>Age:</strong> <5 years (especially <2 years), â‰¥65 years</li>
                        <li><strong>Chronic conditions:</strong> Asthma, COPD, heart disease, diabetes, chronic kidney disease, liver disease, obesity (BMI â‰¥40)</li>
                        <li><strong>Immunocompromised:</strong> HIV, malignancy, transplant, chronic steroids</li>
                        <li><strong>Pregnancy/postpartum:</strong> Up to 2 weeks postpartum</li>
                        <li><strong>Nursing home residents:</strong> Frail, multiple comorbidities</li>
                    </ul>
                    <p><span class="label">Complications:</span></p>
                    <ul>
                        <li><strong>Primary viral pneumonia:</strong> Diffuse bilateral infiltrates, hypoxemia, rapid progression to ARDS</li>
                        <li><strong>Secondary bacterial pneumonia:</strong> S. aureus (including MRSA), S. pneumoniae, H. influenzae. Suspect if improvement followed by clinical worsening, new fever, purulent sputum</li>
                        <li><strong>ARDS:</strong> Acute respiratory distress syndrome. P/F ratio <300. Bilateral infiltrates. High mortality</li>
                        <li><strong>Myocarditis:</strong> Troponin elevation, arrhythmias, heart failure</li>
                        <li><strong>Rhabdomyolysis:</strong> Severe myalgias, elevated CK, acute kidney injury</li>
                        <li><strong>Encephalopathy/encephalitis:</strong> Altered mental status, seizures (more common in children)</li>
                    </ul>
                    <p><span class="label">Influenza Subtypes:</span> Type A (H1N1, H3N2 - cause pandemics), Type B (seasonal, less severe). Type A more virulent. Novel strains (e.g., H1N1 pdm09, avian H5N1, H7N9) can cause severe disease in previously healthy adults</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Rapid Influenza Testing:</span></p>
                    <ul>
                        <li><strong>Rapid antigen tests (RIDT):</strong> Results in 15-30min. Sensitivity 50-70% (low). Specificity >90%. Negative test does NOT rule out influenza</li>
                        <li><strong>Molecular tests (PCR):</strong> GOLD STANDARD. High sensitivity (90-95%). Results in 1-8hr. Can differentiate influenza A vs B, subtypes. Preferred in hospitalized patients</li>
                        <li><strong>Multiplex respiratory panel:</strong> Tests for influenza + RSV, adenovirus, parainfluenza, coronavirus, others. Useful for ruling in/out other pathogens. Helps determine need for isolation precautions</li>
                        <li><strong>Timing:</strong> Test within first 4 days of illness (viral shedding highest). Can test up to 7 days if hospitalized or immunocompromised</li>
                        <li><strong>Sample:</strong> Nasopharyngeal swab (preferred), nasal swab, throat swab. Lower respiratory samples (BAL, sputum) if intubated</li>
                    </ul>
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukopenia or normal WBC (lymphopenia common). Leukocytosis suggests bacterial superinfection</li>
                        <li><strong>CMP:</strong> Assess renal function (before antivirals), electrolytes</li>
                        <li><strong>Blood cultures:</strong> If bacterial superinfection suspected (fever after initial improvement, leukocytosis)</li>
                        <li><strong>Sputum culture:</strong> If productive cough, suspicion for bacterial pneumonia</li>
                        <li><strong>Procalcitonin:</strong> Low in viral infection (<0.25). Elevated in bacterial co-infection (>0.5)</li>
                        <li><strong>CK:</strong> If severe myalgias (check for rhabdomyolysis)</li>
                        <li><strong>Troponin:</strong> If chest pain, ECG changes (myocarditis/myopericarditis can occur)</li>
                    </ul>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CXR:</strong> May be normal early. Bilateral interstitial infiltrates (viral pneumonia). Lobar consolidation (bacterial superinfection). Diffuse bilateral infiltrates (ARDS)</li>
                        <li><strong>CT chest:</strong> Ground-glass opacities (viral), tree-in-bud (bronchiolitis), consolidation. More sensitive than CXR but not routinely needed</li>
                    </ul>
                    <p><span class="label">ABG:</span> If hypoxemia (Oâ‚‚ sat <90%). Assess P/F ratio (PaOâ‚‚/FiOâ‚‚). <300 = ARDS</p>
                    <p><span class="label">Clinical Diagnosis:</span> In outbreak setting with typical symptoms, clinical diagnosis is acceptable. Testing confirms diagnosis and guides treatment/isolation</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Antiviral Therapy (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Oseltamivir (Tamiflu):</strong> 75mg PO BID Ã— 5 days. FIRST-LINE. Neuraminidase inhibitor. Reduces duration of illness by 1-2 days. Reduces complications and mortality in hospitalized patients</li>
                        <li><strong>Zanamivir (Relenza):</strong> 10mg inhaled BID Ã— 5 days. Alternative if oseltamivir not available. Contraindicated in asthma/COPD (bronchospasm risk)</li>
                        <li><strong>Peramivir (Rapivab):</strong> 600mg IV once daily Ã— 5 days. For hospitalized patients unable to take PO/inhaled</li>
                        <li><strong>Baloxavir (Xofluza):</strong> Single dose (40-80mg PO based on weight). Newer agent. Polymerase inhibitor. Not preferred in hospitalized patients (limited data)</li>
                        <li><strong>Timing:</strong> START WITHIN 48 HOURS of symptom onset for maximum benefit. Still beneficial if started >48hr in hospitalized/severe cases. DO NOT delay treatment for test results in hospitalized patients</li>
                        <li><strong>Who to treat:</strong> ALL hospitalized patients with confirmed or suspected influenza, regardless of illness duration. Outpatients with high-risk conditions. Severe illness (pneumonia, hypoxemia, respiratory failure)</li>
                        <li><strong>Duration:</strong> Standard 5 days. Consider longer course (10 days) in immunocompromised, severe disease, or persistent viral shedding</li>
                    </ul>
                    
                    <p><span class="label">Respiratory Support:</span></p>
                    <ul>
                        <li><strong>Supplemental oxygen:</strong> Target Oâ‚‚ sat â‰¥90-92%. Nasal cannula â†’ face mask â†’ high-flow nasal cannula â†’ NIPPV</li>
                        <li><strong>High-flow nasal cannula (HFNC):</strong> 40-60L/min, FiOâ‚‚ 0.4-1.0. May avoid intubation in hypoxemic respiratory failure</li>
                        <li><strong>NIPPV (BiPAP/CPAP):</strong> Consider if HFNC insufficient. Caution: increased risk of aerosolization (use negative pressure room)</li>
                        <li><strong>Mechanical ventilation:</strong> If refractory hypoxemia, work of breathing, altered mental status. Lung-protective ventilation (TV 6mL/kg IBW, plateau pressure <30cmHâ‚‚O, PEEP titrated)</li>
                        <li><strong>Prone positioning:</strong> Consider if P/F <150 (severe ARDS). Improves oxygenation and mortality</li>
                        <li><strong>ECMO:</strong> Consider in refractory ARDS despite maximal support. Transfer to ECMO center if available</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics (for Bacterial Superinfection):</span></p>
                    <ul>
                        <li><strong>When to add:</strong> Lobar consolidation on imaging, purulent sputum, leukocytosis, clinical worsening after initial improvement, procalcitonin >0.5, positive bacterial cultures</li>
                        <li><strong>Community-acquired pneumonia coverage:</strong> Ceftriaxone 1-2g IV daily + azithromycin 500mg IV daily OR levofloxacin 750mg IV daily</li>
                        <li><strong>MRSA coverage (if suspected):</strong> ADD vancomycin 15-20mg/kg IV q8-12hr OR linezolid 600mg IV q12hr. Post-influenza MRSA pneumonia is severe (necrotizing, high mortality)</li>
                        <li><strong>Duration:</strong> 5-7 days for CAP. Longer if slow response or complicated (empyema, abscess)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>Hydration:</strong> IV fluids (NS or LR) for dehydration. Maintain euvolemia (avoid fluid overload in ARDS)</li>
                        <li><strong>Antipyretics:</strong> Acetaminophen 650-1000mg q6hr PRN or ibuprofen 400-600mg q6hr PRN for fever/myalgias</li>
                        <li><strong>Cough suppressants:</strong> Dextromethorphan or benzonatate PRN (use sparingly - cough clears secretions)</li>
                        <li><strong>DVT prophylaxis:</strong> Heparin 5000 units SQ q8-12hr or LMWH (unless contraindicated)</li>
                        <li><strong>Stress ulcer prophylaxis:</strong> PPI if mechanically ventilated or high bleeding risk</li>
                    </ul>
                    
                    <p><span class="label">Corticosteroids (CONTROVERSIAL):</span></p>
                    <ul>
                        <li><strong>NOT routinely recommended:</strong> May prolong viral shedding, increase secondary infections</li>
                        <li><strong>Consider in refractory shock:</strong> Hydrocortisone 50mg IV q6hr if vasopressor-dependent shock</li>
                        <li><strong>Consider in ARDS:</strong> Low-dose methylprednisolone (1mg/kg/day) in severe ARDS (P/F <150) - controversial, mixed data</li>
                    </ul>
                    
                    <p><span class="label">Infection Control:</span></p>
                    <ul>
                        <li><strong>Droplet precautions:</strong> Surgical mask for healthcare workers. Private room preferred. Respirators (N95) for aerosol-generating procedures</li>
                        <li><strong>Duration of isolation:</strong> Until 24hr afebrile without antipyretics AND improvement in respiratory symptoms. Immunocompromised: may shed virus for weeks (consult ID)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Don't delay antivirals:</strong> Start oseltamivir empirically in hospitalized patients with suspected influenza BEFORE test results. Greatest benefit if started within 48hr, but still beneficial in severe cases started later</li>
                    <li><strong>Post-influenza S. aureus pneumonia is deadly:</strong> Classic scenario: Patient improves, then worsens 3-7 days later with new fever, leukocytosis, necrotizing pneumonia. Add vancomycin or linezolid immediately</li>
                    <li><strong>Negative rapid flu test doesn't rule out influenza:</strong> RIDT sensitivity only 50-70%. If high clinical suspicion, send PCR and treat empirically</li>
                    <li><strong>Primary viral pneumonia can cause ARDS rapidly:</strong> Young, healthy patients can deteriorate quickly (24-72hr). Early ICU transfer and aggressive respiratory support</li>
                    <li><strong>Procalcitonin helps guide antibiotics:</strong> Low PCT (<0.25) = viral. High PCT (>0.5) = bacterial co-infection. Can help avoid unnecessary antibiotics</li>
                    <li><strong>Influenza myocarditis is underrecognized:</strong> Check troponin in severe cases, especially with chest pain or arrhythmias. Can cause acute heart failure</li>
                    <li><strong>Zanamivir is inhaled - avoid in lung disease:</strong> Can cause bronchospasm in asthma/COPD patients. Use oseltamivir instead</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hypoxemic respiratory failure (Oâ‚‚ sat <90% despite supplemental Oâ‚‚)</li>
                        <li>Need for HFNC, NIPPV, or mechanical ventilation</li>
                        <li>Septic shock (hypotension requiring vasopressors)</li>
                        <li>ARDS (P/F ratio <300)</li>
                        <li>Altered mental status, encephalopathy</li>
                        <li>Lactic acidosis (lactate >4mmol/L)</li>
                        <li>Rapid clinical deterioration despite therapy</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile â‰¥24hr without antipyretics</li>
                        <li>Oâ‚‚ sat â‰¥90% on room air (or back to baseline if chronic lung disease)</li>
                        <li>Respiratory rate <24/min at rest</li>
                        <li>Tolerating PO intake and medications</li>
                        <li>Completed 5-day course of oseltamivir (or at least 48hr and improving)</li>
                        <li>No evidence of bacterial superinfection (or completed appropriate antibiotic course)</li>
                        <li>Able to perform ADLs or return to baseline function</li>
                        <li>Follow-up arranged (PCP within 1 week)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Primary viral pneumonia â†’ ARDS (P/F <200, high mortality), secondary bacterial pneumonia (S. aureus, S. pneumoniae - most common), septic shock, myocarditis (troponin elevation, arrhythmias, cardiogenic shock), rhabdomyolysis (CK >10,000, AKI), encephalitis/encephalopathy (altered mental status, seizures, especially children), exacerbation of underlying conditions (asthma, COPD, heart failure)</p>
                    <p><strong>Chronic:</strong> Post-viral chronic cough (weeks-months), persistent fatigue, prolonged recovery in elderly/frail patients, cardiovascular events (MI, stroke in first 2 weeks post-infection - 3-5x increased risk)</p>
                    <p><strong>Prevention:</strong> Annual influenza vaccine (inactivated or live attenuated). Highest priority: healthcare workers, elderly, chronic disease, pregnant women, young children. Vaccine reduces risk of hospitalization by 40-60%. Post-exposure prophylaxis with oseltamivir 75mg daily Ã— 10 days for high-risk unvaccinated contacts</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="covid" class="condition-page">
            <div class="page-header">
                <h2>57. COVID-19 SEVERE DISEASE</h2>
                <div class="subtitle">SARS-CoV-2 â€¢ Viral Pneumonia â†’ ARDS â€¢ Dexamethasone + Supportive Care</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Disease Severity Classification (NIH):</span></p>
                    <ul>
                        <li><strong>Mild:</strong> Any symptoms (fever, cough, fatigue) without dyspnea or abnormal imaging</li>
                        <li><strong>Moderate:</strong> Evidence of lower respiratory disease (clinical or imaging) + Oâ‚‚ sat â‰¥94% on room air</li>
                        <li><strong>SEVERE:</strong> Oâ‚‚ sat <94% on room air, P/F ratio <300, RR >30/min, or lung infiltrates >50%</li>
                        <li><strong>CRITICAL:</strong> Respiratory failure (requiring mechanical ventilation, HFNC, NIPPV), septic shock, multiorgan dysfunction</li>
                    </ul>
                    <p><span class="label">Severe/Critical COVID-19 Presentation:</span></p>
                    <ul>
                        <li><strong>Respiratory:</strong> Progressive dyspnea (typically 5-10 days after symptom onset), tachypnea (RR >30/min), hypoxemia (Oâ‚‚ sat <94%), increased work of breathing, bilateral pneumonia</li>
                        <li><strong>Systemic:</strong> Persistent fever, fatigue, myalgias, anorexia</li>
                        <li><strong>GI:</strong> Diarrhea (20-30%), nausea, abdominal pain</li>
                        <li><strong>Neurologic:</strong> Confusion, delirium, headache, anosmia/ageusia (loss of smell/taste)</li>
                        <li><strong>Thromboembolic:</strong> DVT, PE, stroke, MI (hypercoagulable state)</li>
                    </ul>
                    <p><span class="label">High-Risk Groups (for Severe Disease):</span></p>
                    <ul>
                        <li><strong>Age:</strong> â‰¥65 years (risk increases exponentially with age)</li>
                        <li><strong>Chronic conditions:</strong> Obesity (BMI â‰¥30), diabetes, hypertension, cardiovascular disease, chronic lung disease (COPD, asthma), chronic kidney disease, liver disease</li>
                        <li><strong>Immunocompromised:</strong> Solid organ transplant, hematologic malignancy, chemotherapy, HIV (CD4 <200), chronic high-dose steroids (â‰¥20mg prednisone daily), immunosuppressive medications</li>
                        <li><strong>Pregnancy:</strong> Increased risk of severe disease, preterm birth, ICU admission</li>
                        <li><strong>Other:</strong> Smoking, sickle cell disease, Down syndrome, neurologic conditions, tuberculosis</li>
                    </ul>
                    <p><span class="label">Typical Timeline:</span> Symptom onset (day 0) â†’ fever/cough/fatigue (days 1-4) â†’ hypoxemia/dyspnea (days 5-8) â†’ ARDS/critical illness (days 8-12) â†’ recovery or multiorgan failure (weeks 2-4+)</p>
                    <p><span class="label">Key Features Distinguishing COVID-19 ARDS:</span> "Silent hypoxemia" (profound hypoxemia with minimal dyspnea), preserved lung compliance early, hypercoagulability (elevated D-dimer), inflammatory cytokine storm (elevated CRP, ferritin, IL-6)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">SARS-CoV-2 Testing:</span></p>
                    <ul>
                        <li><strong>Nucleic acid amplification (NAAT/PCR):</strong> GOLD STANDARD. Nasopharyngeal swab. Sensitivity 80-90%. Detects active infection</li>
                        <li><strong>Rapid antigen test:</strong> Results in 15-30min. Sensitivity 60-80% (lower than PCR). Best within first 5-7 days of symptoms. False negatives common</li>
                        <li><strong>Timing:</strong> Test all hospitalized patients with respiratory symptoms. PCR preferred. Antigen OK for screening, but confirm negatives with PCR if high suspicion</li>
                        <li><strong>Repeat testing:</strong> If initial negative but high suspicion, repeat in 24-48hr or send lower respiratory sample (sputum, BAL)</li>
                    </ul>
                    <p><span class="label">Labs (for Severity Assessment & Prognostication):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Lymphopenia (common, correlates with severity), thrombocytopenia (severe disease)</li>
                        <li><strong>CMP:</strong> BUN/Cr (AKI in 20-40% of hospitalized), transaminitis (ALT/AST elevation), hypoalbuminemia (poor prognosis)</li>
                        <li><strong>Inflammatory markers:</strong> CRP, ferritin, LDH (elevated in severe disease, correlate with mortality), IL-6 (if available - very high in cytokine storm)</li>
                        <li><strong>D-dimer:</strong> Elevated in >70% of severe cases. Markedly elevated (>5,000ng/mL) = poor prognosis, high VTE risk</li>
                        <li><strong>Procalcitonin:</strong> Usually low-normal in viral infection. Elevation suggests bacterial superinfection</li>
                        <li><strong>Troponin:</strong> Elevated in 20-30% of hospitalized patients (myocardial injury, myocarditis). Associated with increased mortality</li>
                        <li><strong>BNP:</strong> If heart failure suspected (COVID-19 can precipitate HF)</li>
                    </ul>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CXR:</strong> Bilateral patchy infiltrates, consolidation, ground-glass opacities. Peripheral distribution. Normal CXR does NOT exclude COVID-19 pneumonia</li>
                        <li><strong>CT chest:</strong> More sensitive. Bilateral ground-glass opacities (GGO) with peripheral distribution, "crazy-paving" pattern, consolidation. Useful if CXR nondiagnostic. CT not needed for diagnosis/management in typical cases</li>
                    </ul>
                    <p><span class="label">ABG:</span> Assess P/F ratio if hypoxemic. <300 = ARDS. A-a gradient typically elevated</p>
                    <p><span class="label">Other Testing (as indicated):</span></p>
                    <ul>
                        <li><strong>ECG:</strong> If chest pain, troponin elevation (check for STEMI, arrhythmias, myocarditis)</li>
                        <li><strong>Blood cultures:</strong> If bacterial superinfection suspected</li>
                        <li><strong>Respiratory viral panel:</strong> Rule out co-infections (influenza, RSV) if early in illness</li>
                        <li><strong>VTE workup:</strong> CT-PE if high suspicion (tachycardia, hypoxemia out of proportion to lung findings, elevated D-dimer >5,000)</li>
                    </ul>
                    <p><span class="label">Poor Prognostic Indicators:</span> Age >65, oxygen requirement, elevated inflammatory markers (CRP >100mg/L, D-dimer >5,000ng/mL, ferritin >1,000ng/mL, LDH >400U/L), lymphopenia (<800/ÂµL), thrombocytopenia, AKI, troponin elevation, obesity (BMI â‰¥35)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Corticosteroids (PROVEN MORTALITY BENEFIT - MAINSTAY):</span></p>
                    <ul>
                        <li><strong>Dexamethasone 6mg IV/PO daily Ã— 10 days (or until discharge):</strong> RECOVERY trial showed 30% reduction in mortality at 28 days in patients requiring oxygen. Number needed to treat = 8 (for supplemental Oâ‚‚), 4 (for mechanical ventilation)</li>
                        <li><strong>Alternatives (if dexamethasone unavailable):</strong> Prednisone 40mg daily, methylprednisolone 32mg daily, hydrocortisone 160mg daily (divided doses)</li>
                        <li><strong>Who to treat:</strong> ALL patients requiring supplemental oxygen or mechanical ventilation</li>
                        <li><strong>Who NOT to treat:</strong> Mild COVID-19 not requiring oxygen (may cause harm)</li>
                        <li><strong>Duration:</strong> 10 days or until discharge (whichever comes first). Can stop earlier if no longer requiring oxygen</li>
                    </ul>
                    
                    <p><span class="label">Antiviral Therapy:</span></p>
                    <ul>
                        <li><strong>Remdesivir (Veklury):</strong> 200mg IV loading dose, then 100mg IV daily Ã— 4 days (total 5 days). Modest benefit - reduces time to recovery by 5 days in hospitalized patients requiring oxygen (not ventilated). Consider in severe COVID-19 within 10 days of symptom onset. Less effective in mechanically ventilated patients. NOT a mortality benefit drug</li>
                        <li><strong>Timing:</strong> Start within 10 days of symptom onset for maximum benefit</li>
                        <li><strong>Contraindications:</strong> eGFR <30mL/min, ALT >10Ã— ULN. Use cautiously if eGFR 30-60</li>
                        <li><strong>Note:</strong> Other antivirals (nirmatrelvir-ritonavir/Paxlovid, molnupiravir) are for OUTPATIENTS only (within 5 days of symptoms). NOT for hospitalized patients with severe disease</li>
                    </ul>
                    
                    <p><span class="label">IL-6 Receptor Antagonists (Anti-Cytokine Therapy):</span></p>
                    <ul>
                        <li><strong>Tocilizumab (Actemra) 8mg/kg IV once (max 800mg):</strong> Consider in patients with rapidly increasing oxygen requirements, CRP >75mg/L, within 24hr of ICU admission. Reduces mortality in severe/critical COVID-19 when combined with dexamethasone</li>
                        <li><strong>Baricitinib (Olumiant) 4mg PO daily Ã— 14 days:</strong> JAK inhibitor. Alternative to tocilizumab. Reduces mortality when combined with dexamethasone. Easier administration (oral). Contraindicated if ALC <200/ÂµL, ANC <500/ÂµL</li>
                        <li><strong>Use ONE (not both):</strong> Tocilizumab OR baricitinib, in combination with dexamethasone</li>
                        <li><strong>Screen for infections:</strong> Before use, rule out active bacterial/fungal infections</li>
                    </ul>
                    
                    <p><span class="label">Respiratory Support:</span></p>
                    <ul>
                        <li><strong>Supplemental oxygen:</strong> Target Oâ‚‚ sat 92-96% (or 88-92% if COPD). Start with nasal cannula</li>
                        <li><strong>High-flow nasal cannula (HFNC):</strong> 40-60L/min, FiOâ‚‚ 0.4-1.0. Effective in preventing intubation in many patients. ROX index (SpOâ‚‚/FiOâ‚‚ Ã— RR) <3.85 after 12hr = high risk of HFNC failure</li>
                        <li><strong>Prone positioning (AWAKE PRONING):</strong> Patient prone for 2-4hr several times daily while on HFNC. Improves oxygenation, may prevent intubation</li>
                        <li><strong>NIPPV (BiPAP/CPAP):</strong> Use cautiously (risk of aerosolization, delayed intubation). Consider in select patients who decline intubation or as bridge</li>
                        <li><strong>Mechanical ventilation:</strong> Intubate if worsening hypoxemia (P/F <150), work of breathing, or altered mental status. LUNG-PROTECTIVE VENTILATION: TV 6mL/kg IBW, plateau pressure <30cmHâ‚‚O, PEEP 10-15cmHâ‚‚O (higher PEEP in COVID-19), driving pressure <15cmHâ‚‚O</li>
                        <li><strong>Prone positioning (INTUBATED):</strong> For P/F <150 (moderate-severe ARDS). 16hr prone daily. Improves mortality</li>
                        <li><strong>ECMO:</strong> Consider for refractory hypoxemia despite maximal support. Transfer to ECMO center</li>
                    </ul>
                    
                    <p><span class="label">Anticoagulation (CRITICAL - Hypercoagulable State):</span></p>
                    <ul>
                        <li><strong>Prophylactic anticoagulation:</strong> ALL hospitalized patients unless contraindicated. Enoxaparin 40mg SQ daily (preferred) or heparin 5000 units SQ TID. Consider higher prophylactic dose (enoxaparin 0.5mg/kg BID) if BMI >40 or D-dimer >5,000</li>
                        <li><strong>Therapeutic anticoagulation:</strong> If confirmed VTE (PE, DVT). NOT routinely for all severe COVID-19 patients (trials showed no benefit, increased bleeding in non-ICU patients)</li>
                        <li><strong>Monitor D-dimer:</strong> Trending D-dimer useful. Persistently elevated or rising = higher VTE risk</li>
                        <li><strong>Low threshold for CT-PE:</strong> If worsening hypoxemia, tachycardia, elevated D-dimer</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics (for Bacterial Superinfection ONLY):</span></p>
                    <ul>
                        <li><strong>When to add:</strong> Clinical worsening after 7-10 days, new fever, leukocytosis, procalcitonin >0.5, positive bacterial cultures, lobar consolidation (new or worsening)</li>
                        <li><strong>Initial therapy:</strong> Ceftriaxone 1-2g IV daily + azithromycin 500mg IV daily (community-acquired pneumonia coverage). Consider vancomycin if MRSA risk (ICU, prior MRSA, necrotizing pneumonia)</li>
                        <li><strong>De-escalate:</strong> Stop antibiotics if procalcitonin <0.25 and no bacterial source identified. COVID-19 itself does NOT require antibiotics</li>
                        <li><strong>Bacterial co-infection uncommon:</strong> Only 8-15% of hospitalized COVID-19 patients have bacterial co-infection. Secondary bacterial pneumonia more common after 7-10 days (S. aureus, Pseudomonas, Enterobacterales)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>Fluids:</strong> Conservative fluid strategy (avoid fluid overload - worsens ARDS). Target euvolemia. Use vasopressors early if shock</li>
                        <li><strong>Vasopressors:</strong> Norepinephrine first-line for shock. Target MAP â‰¥65mmHg</li>
                        <li><strong>Sedation/analgesia:</strong> Light sedation if mechanically ventilated (target RASS -1 to 0). Daily sedation interruption</li>
                        <li><strong>Neuromuscular blockade:</strong> Consider in severe ARDS (P/F <150) with ventilator dyssynchrony. Time-limited (â‰¤48hr). Increased risk of ICU weakness</li>
                        <li><strong>Nutrition:</strong> Early enteral nutrition (within 48hr). NG/NJ tube if unable to tolerate PO</li>
                        <li><strong>Stress ulcer prophylaxis:</strong> PPI for mechanically ventilated patients</li>
                        <li><strong>Glycemic control:</strong> Target glucose 140-180mg/dL (avoid hypoglycemia). Hyperglycemia common with dexamethasone</li>
                    </ul>
                    
                    <p><span class="label">Therapies NO LONGER RECOMMENDED (Ineffective or Harmful):</span></p>
                    <ul>
                        <li><strong>Hydroxychloroquine:</strong> NO benefit. DO NOT USE</li>
                        <li><strong>Ivermectin:</strong> NO benefit. DO NOT USE</li>
                        <li><strong>Convalescent plasma:</strong> NO mortality benefit. Not recommended</li>
                        <li><strong>Vitamin C, vitamin D, zinc:</strong> No proven benefit in treatment (prevention data mixed)</li>
                        <li><strong>Azithromycin alone:</strong> NO antiviral effect. Only use if bacterial superinfection</li>
                    </ul>
                    
                    <p><span class="label">Infection Control:</span></p>
                    <ul>
                        <li><strong>Airborne + contact precautions:</strong> N95 respirator, gown, gloves, eye protection for all healthcare workers</li>
                        <li><strong>Negative pressure room:</strong> Preferred for hospitalized patients, especially if aerosol-generating procedures</li>
                        <li><strong>Duration of isolation:</strong> â‰¥10 days from symptom onset AND â‰¥24hr afebrile without antipyretics AND improvement in symptoms. Immunocompromised: â‰¥20 days (or negative PCR). Consult infection control</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Dexamethasone saves lives in severe COVID-19:</strong> 30% mortality reduction if requiring oxygen. Give to ALL patients on Oâ‚‚. Don't give to mild cases not requiring Oâ‚‚</li>
                    <li><strong>"Silent hypoxemia" is real:</strong> Patients can have Oâ‚‚ sat 70-80% with minimal dyspnea. Check pulse ox on ALL suspected COVID-19 patients</li>
                    <li><strong>Timing matters for progression:</strong> Most patients who worsen do so around days 7-10. Close monitoring during this window</li>
                    <li><strong>COVID-19 is a hypercoagulable state:</strong> Elevated D-dimer in 70%. High VTE risk (10-30%). Low threshold for CT-PE. Prophylactic anticoagulation for all hospitalized patients</li>
                    <li><strong>Bacterial co-infection is uncommon:</strong> Only 8-15% at admission. Don't reflexively start antibiotics. Check procalcitonin. Stop if <0.25 and no bacterial source</li>
                    <li><strong>Awake proning works:</strong> Have patients on HFNC lie prone 2-4hr multiple times daily. Improves oxygenation and may prevent intubation</li>
                    <li><strong>Most antivirals don't work in severe disease:</strong> Remdesivir has modest benefit. Paxlovid is for OUTPATIENTS only (within 5 days). Dexamethasone is the most important drug</li>
                    <li><strong>Avoid fluid overload:</strong> COVID-19 ARDS - keep patients dry. Aggressive fluids worsen respiratory status. Use vasopressors early if needed</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Oâ‚‚ sat <90% despite supplemental Oâ‚‚ >6L/min</li>
                        <li>Need for HFNC, NIPPV, or mechanical ventilation</li>
                        <li>Rapidly increasing oxygen requirements (>2L/hr escalation)</li>
                        <li>RR >30/min with accessory muscle use</li>
                        <li>Altered mental status, confusion, obtundation</li>
                        <li>Septic shock (hypotension requiring vasopressors)</li>
                        <li>P/F ratio <200</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Oâ‚‚ sat â‰¥92% on room air at rest and with ambulation (or baseline if chronic lung disease)</li>
                        <li>Afebrile â‰¥24hr without antipyretics</li>
                        <li>Respiratory rate <24/min at rest</li>
                        <li>Clinical improvement (resolving symptoms)</li>
                        <li>Completed minimum 5 days of treatment (dexamethasone)</li>
                        <li>Able to perform ADLs independently</li>
                        <li>Adequate home support, especially if elderly/high-risk</li>
                        <li>Follow-up arranged (telehealth or in-person within 3-7 days)</li>
                        <li>Pulse oximeter for home monitoring if marginal Oâ‚‚ sats</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute (During Hospitalization):</strong> ARDS (20-40% of hospitalized patients, high mortality), secondary bacterial/fungal infections (aspergillosis, candidemia after prolonged steroids/ICU stay), thromboembolic disease (PE, DVT, stroke, MI - 10-30% incidence), acute kidney injury (20-40%, poor prognosis), myocardial injury (troponin elevation, myocarditis, stress cardiomyopathy), arrhythmias, shock (septic, cardiogenic), multiorgan failure</p>
                    <p><strong>Subacute/Chronic (Post-Discharge):</strong> Post-COVID syndrome/"Long COVID" (30% of hospitalized patients - fatigue, dyspnea, cognitive impairment, lasting months), pulmonary fibrosis (after severe ARDS), chronic thromboembolic disease, persistent cardiac dysfunction (reduced EF, myocarditis sequelae), post-ICU syndrome (weakness, PTSD, depression), organizing pneumonia (can occur weeks post-infection)</p>
                    <p><strong>Follow-up:</strong> All hospitalized patients should have follow-up within 1-2 weeks post-discharge. Assess for persistent symptoms, oxygen needs, functional status. Chest imaging (CXR or CT) at 4-12 weeks if severe disease or persistent symptoms. Pulmonary function testing if dyspnea persists. Consider post-COVID clinic referral for prolonged symptoms</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="ssti" class="condition-page">
            <div class="page-header">
                <h2>58. SKIN/SOFT TISSUE INFECTIONS (CELLULITIS, NECROTIZING FASCIITIS)</h2>
                <div class="subtitle">Bacterial Skin Infection â€¢ Cellulitis vs Necrotizing â€¢ Early Surgery Saves Lives</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Cellulitis (Non-Necrotizing SSTI):</span> Acute bacterial infection of dermis and subcutaneous tissue. Characterized by erythema, warmth, swelling, tenderness. Usually unilateral lower extremity</p>
                    <p><span class="label">Cellulitis Presentation:</span></p>
                    <ul>
                        <li><strong>Erythema:</strong> Red, poorly demarcated area. Spreads centrifugally from entry site</li>
                        <li><strong>Warmth:</strong> Affected area warm to touch compared to surrounding skin</li>
                        <li><strong>Swelling:</strong> Edema of affected limb. May have peau d'orange appearance</li>
                        <li><strong>Tenderness:</strong> Pain with palpation. Pain usually proportionate to appearance</li>
                        <li><strong>Systemic symptoms (50%):</strong> Fever, chills, malaise. More common in severe cases</li>
                        <li><strong>Regional lymphadenopathy:</strong> Inguinal nodes (lower extremity cellulitis), axillary nodes (upper extremity)</li>
                        <li><strong>Lymphangitis (30%):</strong> Red linear streaking from site toward regional lymph nodes</li>
                    </ul>
                    <p><span class="label">Common Sites:</span> Lower extremities (60-70%), upper extremities (20%), face (5-10%), trunk (rare). Look for portal of entry (trauma, insect bite, tinea pedis, chronic venous insufficiency, lymphedema)</p>
                    <p><span class="label">Risk Factors for Cellulitis:</span> Tinea pedis (athlete's foot - toe web spaces), venous insufficiency, lymphedema (prior surgery, radiation), obesity, diabetes, peripheral vascular disease, chronic kidney disease, immunosuppression, IV drug use, prior cellulitis (recurrence rate 20-30%)</p>
                    
                    <p><span class="label">NECROTIZING SOFT TISSUE INFECTIONS (SURGICAL EMERGENCY):</span></p>
                    <ul>
                        <li><strong>Necrotizing Fasciitis (NF):</strong> Rapidly progressive infection of fascia and subcutaneous tissue with necrosis. High mortality (20-30%). REQUIRES URGENT SURGICAL DEBRIDEMENT</li>
                        <li><strong>Type I NF (Polymicrobial, 70-80%):</strong> Mixed aerobic + anaerobic bacteria (Streptococcus, E. coli, Bacteroides, Clostridium). Risk factors: diabetes, peripheral vascular disease, obesity, immunocompromised. Often post-surgical, perineal (Fournier's gangrene)</li>
                        <li><strong>Type II NF (Monomicrobial, 20-30%):</strong> Group A Streptococcus (Strep pyogenes) OR Staphylococcus aureus (including CA-MRSA). Younger, healthier patients. Post-trauma, varicella, NSAIDs use</li>
                    </ul>
                    <p><span class="label">RED FLAGS for Necrotizing Fasciitis (Think NF!):</span></p>
                    <ul>
                        <li><strong>Severe pain OUT OF PROPORTION to physical findings:</strong> CLASSIC. Severe pain but skin may look relatively benign initially</li>
                        <li><strong>Rapidly progressive erythema/swelling:</strong> Spreads within hours, not days</li>
                        <li><strong>Systemic toxicity:</strong> High fever, tachycardia (HR >120), hypotension, altered mental status, septic shock</li>
                        <li><strong>Skin changes (LATE findings):</strong> Dusky/purple discoloration, hemorrhagic bullae (blood-filled blisters), crepitus (gas in soft tissue), skin necrosis, anesthesia (nerve involvement)</li>
                        <li><strong>Wooden hard induration:</strong> Firm, boardlike feel to subcutaneous tissue</li>
                        <li><strong>Gas on imaging:</strong> Crepitus on exam or gas in soft tissue on X-ray/CT</li>
                        <li><strong>Lab abnormalities:</strong> WBC >15,000, lactate >4, Cr elevated, CK elevated (myonecrosis), severe metabolic acidosis, thrombocytopenia</li>
                    </ul>
                    <p><span class="label">LRINEC Score (Laboratory Risk Indicator for Necrotizing Fasciitis):</span> CRP â‰¥150mg/L (4 pts), WBC <15 or >25K (1-2 pts), Hgb <11g/dL (2 pts), Na <135mEq/L (2 pts), Cr >1.6mg/dL (2 pts), glucose >180mg/dL (1 pt). Score â‰¥6 = intermediate risk (50% PPV), â‰¥8 = high risk (75% PPV) for NF. HOWEVER: Clinical suspicion trumps score. Don't delay surgery for scoring</p>
                    
                    <p><span class="label">Other Necrotizing Infections:</span></p>
                    <ul>
                        <li><strong>Fournier's Gangrene:</strong> Necrotizing fasciitis of perineum/genitalia. Diabetics, elderly men. Polymicrobial. Extremely high mortality (20-40%)</li>
                        <li><strong>Clostridial Myonecrosis (Gas Gangrene):</strong> Clostridium perfringens. Post-trauma (crush injury), post-surgical, spontaneous (malignancy, immunocompromised). Crepitus, serosanguinous discharge, rapid progression. Very high mortality</li>
                        <li><strong>Streptococcal Toxic Shock Syndrome (STSS):</strong> Group A Strep with necrotizing fasciitis + shock + multiorgan failure. Mortality >30%</li>
                    </ul>
                    
                    <p><span class="label">Common Pathogens by Infection Type:</span></p>
                    <ul>
                        <li><strong>Non-purulent cellulitis:</strong> Î²-hemolytic Streptococcus (Group A, C, G most common), S. aureus (less common)</li>
                        <li><strong>Purulent cellulitis (abscess):</strong> S. aureus (including MRSA)</li>
                        <li><strong>Water exposure:</strong> Vibrio vulnificus (seawater), Aeromonas (freshwater)</li>
                        <li><strong>Animal bites:</strong> Pasteurella (cats/dogs), Capnocytophaga (dogs), Eikenella (human bites)</li>
                        <li><strong>Immunocompromised:</strong> Pseudomonas, fungal (Mucor, Rhizopus)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis (Cellulitis):</span> Diagnosis is clinical based on characteristic findings (erythema, warmth, swelling, tenderness). Imaging and lab tests NOT routinely needed for uncomplicated cellulitis</p>
                    <p><span class="label">Labs (for Severe or Complicated Infections):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis (WBC >15,000 suggests severe infection or necrotizing process). Bandemia (left shift). Thrombocytopenia (in sepsis, necrotizing infection)</li>
                        <li><strong>CMP:</strong> BUN/Cr (assess renal function, AKI in sepsis), glucose (hyperglycemia in stress/infection, especially diabetes)</li>
                        <li><strong>CRP:</strong> Elevated in bacterial infection. CRP >150mg/L increases suspicion for necrotizing infection (LRINEC score component)</li>
                        <li><strong>CK:</strong> Markedly elevated (>1,000) suggests myonecrosis (muscle involvement). Concerning for clostridial myonecrosis or necrotizing infection</li>
                        <li><strong>Lactate:</strong> >2mmol/L suggests hypoperfusion. >4mmol/L = severe sepsis. Associated with necrotizing infection</li>
                        <li><strong>Blood cultures:</strong> Obtain in: fever + systemic toxicity, immunocompromised, diabetic with severe infection, suspected necrotizing infection, hemodynamic instability. Positive in only 5-10% of cellulitis cases</li>
                    </ul>
                    <p><span class="label">Microbiology (Limited Role in Cellulitis):</span></p>
                    <ul>
                        <li><strong>Blood cultures:</strong> Low yield (5-10%) in uncomplicated cellulitis. Obtain if septic, immunocompromised, or severe infection</li>
                        <li><strong>Wound culture:</strong> Only if purulent drainage present (abscess). Swab of intact skin NOT useful (contaminated). Aspirate of abscess preferred</li>
                        <li><strong>Tissue biopsy/culture:</strong> Reserved for: (1) Failed empiric therapy, (2) Immunocompromised (atypical organisms), (3) Surgical debridement (send tissue for culture)</li>
                    </ul>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Plain X-ray:</strong> Limited utility. Can detect gas in soft tissue (crepitus), foreign body, osteomyelitis (if concern for bone involvement). ALWAYS obtain if crepitus present</li>
                        <li><strong>Ultrasound:</strong> Can differentiate cellulitis from abscess (hypoechoic fluid collection). Useful at bedside. "Cobblestoning" pattern suggests abscess. Can guide drainage</li>
                        <li><strong>CT with IV contrast:</strong> GOLD STANDARD for necrotizing infections. Obtain urgently if high suspicion for NF. Findings: gas in fascial planes, fascial thickening, fluid tracking along fascial planes, lack of enhancement (necrosis), muscle involvement</li>
                        <li><strong>MRI:</strong> Most sensitive for soft tissue infections. Can differentiate cellulitis, abscess, necrotizing fasciitis, myositis. Useful for deep infections, spinal/pelvic infections. NOT needed for routine cellulitis. Too slow if suspecting NF (do CT, then OR)</li>
                    </ul>
                    <p><span class="label">When to Image:</span></p>
                    <ul>
                        <li><strong>URGENT CT (within 1-2hr):</strong> Suspected necrotizing fasciitis (pain out of proportion, crepitus, skin necrosis, septic shock, LRINEC â‰¥6)</li>
                        <li><strong>Ultrasound:</strong> Suspected abscess (fluctuance, purulent drainage). Guide I&D</li>
                        <li><strong>X-ray:</strong> Crepitus on exam, foreign body, suspected osteomyelitis (bone tenderness, chronic wound)</li>
                        <li><strong>NO imaging needed:</strong> Uncomplicated cellulitis with clear diagnosis, no red flags</li>
                    </ul>
                    <p><span class="label">Surgical Exploration (Diagnostic & Therapeutic):</span> If high suspicion for NF but CT equivocal, proceed to OR for direct visualization. "Finger test" - blunt dissection along fascial planes. In NF, fascia separates easily ("dishwater" fluid, necrotic tissue, lack of bleeding). Don't delay surgery waiting for imaging</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">CELLULITIS (Non-Necrotizing) Management:</span></p>
                    <p><span class="label">Non-Purulent Cellulitis (No Abscess):</span></p>
                    <ul>
                        <li><strong>Mild (outpatient):</strong> Cephalexin 500mg PO QID Ã— 5-7 days OR Dicloxacillin 500mg PO QID OR Cefadroxil 1g PO BID</li>
                        <li><strong>Moderate-Severe (hospitalized, no MRSA risk):</strong></li>
                        <ul>
                            <li><strong>Cefazolin 1-2g IV q8hr:</strong> First-line. Excellent Strep/MSSA coverage</li>
                            <li><strong>Alternatives:</strong> Nafcillin 1-2g IV q4-6hr, Oxacillin 1-2g IV q4-6hr</li>
                            <li><strong>Penicillin allergy (non-anaphylactic):</strong> Ceftriaxone 1-2g IV daily (low cross-reactivity)</li>
                            <li><strong>Penicillin anaphylaxis:</strong> Clindamycin 600-900mg IV q8hr OR Vancomycin 15-20mg/kg IV q8-12hr</li>
                        </ul>
                    </ul>
                    <p><span class="label">MRSA Risk Factors:</span> Prior MRSA infection, injection drug use, incarceration, close contact with MRSA-infected person, purulent drainage, abscess</p>
                    <p><span class="label">Purulent Cellulitis/Abscess OR MRSA Risk:</span></p>
                    <ul>
                        <li><strong>Abscess management:</strong> Incision & drainage (I&D) is PRIMARY treatment. Antibiotics are ADJUNCT if surrounding cellulitis or systemic symptoms</li>
                        <li><strong>Empiric MRSA coverage (if systemic symptoms or extensive cellulitis):</strong></li>
                        <ul>
                            <li><strong>Vancomycin 15-20mg/kg IV q8-12hr (target trough 15-20):</strong> First-line IV MRSA coverage</li>
                            <li><strong>Alternatives:</strong> Linezolid 600mg IV/PO q12hr, Daptomycin 4-6mg/kg IV daily (NOT for pneumonia), Ceftaroline 600mg IV q12hr</li>
                        </ul>
                        <li><strong>Outpatient MRSA coverage (mild purulent cellulitis post-I&D):</strong> TMP-SMX 1-2 DS PO BID + Cephalexin 500mg QID (for Strep coverage) OR Doxycycline 100mg PO BID OR Clindamycin 300-450mg PO TID</li>
                    </ul>
                    
                    <p><span class="label">NECROTIZING FASCIITIS Management (SURGICAL EMERGENCY):</span></p>
                    <p><span class="label">Step 1: URGENT SURGICAL CONSULTATION (STAT):</span> Surgery is LIFE-SAVING. Time to OR directly correlates with mortality. Goal: debridement within 6 hours of diagnosis. "Time is tissue, tissue is life"</p>
                    <p><span class="label">Step 2: Aggressive Resuscitation & Support:</span></p>
                    <ul>
                        <li><strong>IV fluids:</strong> 30mL/kg crystalloid bolus (NS or LR) within first hour. Continue aggressive fluid resuscitation. May need 4-10L in first 24hr</li>
                        <li><strong>Vasopressors:</strong> Norepinephrine if hypotensive despite fluids. Target MAP â‰¥65mmHg</li>
                        <li><strong>ICU admission:</strong> ALL suspected/confirmed NF patients</li>
                        <li><strong>Blood cultures:</strong> 2 sets before antibiotics</li>
                        <li><strong>Lactate:</strong> Follow serial lactates q2-4hr. Goal: lactate clearance (normalize within 6hr)</li>
                    </ul>
                    <p><span class="label">Step 3: BROAD-SPECTRUM Antibiotics (Start IMMEDIATELY, before OR):</span></p>
                    <ul>
                        <li><strong>Empiric Regimen for Necrotizing Fasciitis:</strong></li>
                        <ul>
                            <li><strong>Vancomycin 15-20mg/kg IV q8-12hr (for MRSA, Strep)</strong></li>
                            <li><strong>PLUS Piperacillin-tazobactam 4.5g IV q6hr (broad Gram-neg, anaerobic coverage)</strong></li>
                            <li><strong>PLUS Clindamycin 600-900mg IV q8hr (CRITICAL - stops toxin production in Group A Strep, covers anaerobes, penetrates necrotic tissue)</strong></li>
                        </ul>
                        <li><strong>Alternative regimens:</strong></li>
                        <ul>
                            <li>Vancomycin + Meropenem 1g IV q8hr + Clindamycin (if severe sepsis, immunocompromised)</li>
                            <li>Vancomycin + Ceftriaxone 2g IV daily + Metronidazole 500mg IV q8hr + Clindamycin</li>
                        </ul>
                        <li><strong>If Clostridial myonecrosis suspected (gas gangrene):</strong></li>
                        <ul>
                            <li><strong>Penicillin G 4 million units IV q4hr + Clindamycin 900mg IV q8hr</strong></li>
                            <li>Consider hyperbaric oxygen therapy (HBOT) if available (controversial, delays surgery)</li>
                        </ul>
                    </ul>
                    <p><span class="label">Step 4: Surgical Debridement (URGENT):</span></p>
                    <ul>
                        <li><strong>Aggressive wide debridement:</strong> Remove ALL necrotic tissue, fascia, muscle. May require multiple trips to OR (second-look within 24-48hr). Debride until healthy bleeding tissue</li>
                        <li><strong>Amputation:</strong> May be necessary for limb salvage if extensive involvement or refractory sepsis</li>
                        <li><strong>Fournier's gangrene:</strong> Debride perineum, scrotum. Diverting colostomy if rectal involvement</li>
                        <li><strong>Negative pressure wound therapy (VAC):</strong> After debridement. Promotes healing, facilitates subsequent closures</li>
                    </ul>
                    <p><span class="label">Step 5: Adjunctive Therapies (for Streptococcal Toxic Shock):</span></p>
                    <ul>
                        <li><strong>IVIG (Intravenous Immunoglobulin) 1-2g/kg IV once:</strong> Consider in Group A Strep NF with toxic shock syndrome. Neutralizes streptococcal superantigens. May reduce mortality (controversial, limited data)</li>
                        <li><strong>Clindamycin is ESSENTIAL:</strong> Inhibits toxin production (unlike Î²-lactams which increase toxin release as bacteria lyse)</li>
                    </ul>
                    
                    <p><span class="label">Duration of Antibiotics:</span></p>
                    <ul>
                        <li><strong>Uncomplicated cellulitis:</strong> 5-7 days (or until clinical improvement + afebrile 48hr)</li>
                        <li><strong>Severe cellulitis:</strong> 7-10 days</li>
                        <li><strong>Necrotizing fasciitis:</strong> 10-14 days (or longer until all necrotic tissue debrided and clinically improving)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care for Cellulitis:</span></p>
                    <ul>
                        <li><strong>Elevation:</strong> Elevate affected limb above heart level. Reduces edema, improves lymphatic drainage</li>
                        <li><strong>Mark borders:</strong> Outline erythema with marker to track progression/improvement</li>
                        <li><strong>Analgesia:</strong> NSAIDs (ibuprofen 400-600mg PO q6-8hr) or acetaminophen 650-1000mg q6hr. Avoid NSAIDs in Group A Strep (theoretical increased risk of NF progression - controversial)</li>
                        <li><strong>Treat predisposing conditions:</strong> Tinea pedis (antifungal cream), venous stasis (compression), edema (diuretics if CHF), optimize diabetes control</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Pain out of proportion = necrotizing fasciitis until proven otherwise:</strong> Don't be fooled by benign-appearing skin. Severe pain with minimal skin findings is CLASSIC for NF. Call surgery immediately</li>
                    <li><strong>Crepitus = gas in tissue = EMERGENCY:</strong> Crepitus (crackling feel) on palpation indicates gas-forming organisms (Clostridium, Streptococcus, polymicrobial NF). Get imaging (X-ray or CT) and call surgery STAT</li>
                    <li><strong>Time to OR = survival in NF:</strong> Mortality increases 7-9% for every hour delay to surgery. Don't wait for CT if high clinical suspicion. "Stabilize in the OR, not the ICU"</li>
                    <li><strong>Clindamycin is critical in Group A Strep NF:</strong> Stops toxin production (Î²-lactams don't). Add clindamycin to all suspected NF empiric regimens</li>
                    <li><strong>Most cellulitis is streptococcal, not MRSA:</strong> Non-purulent cellulitis without risk factors â†’ don't need MRSA coverage. Cefazolin is appropriate. Reserve vancomycin for purulent infections or MRSA risk factors</li>
                    <li><strong>Blood cultures are low-yield in cellulitis:</strong> Only 5-10% positive. Reserve for severe cases, sepsis, immunocompromised</li>
                    <li><strong>Abscess = I&D, not just antibiotics:</strong> Antibiotics don't penetrate abscesses well. I&D is primary treatment. Antibiotics only needed if surrounding cellulitis or systemic symptoms</li>
                    <li><strong>LRINEC score helps but don't rely on it:</strong> Score â‰¥6 raises suspicion for NF. But NF can occur with low scores. Clinical gestalt and imaging trump the score</li>
                    <li><strong>Treat the source:</strong> Tinea pedis (athlete's foot) is the most common portal of entry for lower extremity cellulitis. Treat with topical antifungals to prevent recurrence</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ANY suspicion for necrotizing fasciitis</li>
                        <li>Septic shock (hypotension requiring vasopressors)</li>
                        <li>Severe pain out of proportion to exam findings</li>
                        <li>Skin necrosis, hemorrhagic bullae, crepitus</li>
                        <li>Lactate >4mmol/L</li>
                        <li>Altered mental status, confusion</li>
                        <li>WBC >25,000 or <4,000</li>
                        <li>Rapidly progressive erythema (spreading over hours)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile â‰¥24hr without antipyretics</li>
                        <li>Erythema improving (use marked borders to track)</li>
                        <li>Decreased swelling and tenderness</li>
                        <li>Able to ambulate (if lower extremity)</li>
                        <li>Tolerating PO antibiotics</li>
                        <li>Appropriate outpatient antibiotic regimen selected</li>
                        <li>Source control achieved (abscess drained, if applicable)</li>
                        <li>Follow-up arranged (PCP or ID within 3-5 days)</li>
                        <li>Patient educated on warning signs (worsening erythema, fever, systemic symptoms)</li>
                        <li>Predisposing factors addressed (tinea pedis treatment, wound care)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Cellulitis Complications:</strong> Abscess formation (requires I&D), bacteremia/sepsis (5-10%), lymphangitis (ascending infection toward lymph nodes), recurrent cellulitis (20-30% within 3 years - higher if lymphedema, chronic venous insufficiency, or tinea pedis not treated), chronic lymphedema (from repeated episodes damaging lymphatics), post-cellulitis venous thrombosis (thrombophlebitis)</p>
                    <p><strong>Necrotizing Fasciitis Complications:</strong> Septic shock (30-50%, high mortality), multiorgan failure (renal, respiratory, cardiac), limb loss (amputation needed in 20-30%), extensive scarring/disfigurement, chronic pain (neuropathic from nerve damage), functional impairment (prolonged rehabilitation), mortality (overall 20-30%, up to 50% if shock, 70-80% if clostridial myonecrosis)</p>
                    <p><strong>Prevention of Recurrent Cellulitis:</strong> Treat tinea pedis aggressively (topical or oral antifungals - terbinafine 250mg daily Ã— 2-4 weeks), compression stockings for venous insufficiency/lymphedema, elevate legs regularly, emollients for dry/cracked skin, prompt treatment of skin injuries/wounds, consider antibiotic prophylaxis if â‰¥3 episodes per year (penicillin VK 250-500mg daily OR erythromycin 250mg daily)</p>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#vancomycin" style="color: #8e44ad;">ðŸ’Š Vancomycin</a>, <a href="drug_reference_guide.html#cefazolin" style="color: #8e44ad;">ðŸ’Š Cefazolin</a>, <a href="drug_reference_guide.html#doxycycline" style="color: #8e44ad;">ðŸ’Š Doxycycline</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="tb" class="condition-page">
            <div class="page-header">
                <h2>59. TUBERCULOSIS (ACTIVE DISEASE)</h2>
                <div class="subtitle">Mycobacterium tuberculosis â€¢ Pulmonary + Extrapulmonary â€¢ Multi-Drug Regimen â€¢ Airborne Isolation</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Tuberculosis (TB) Overview:</span> Infectious disease caused by Mycobacterium tuberculosis. Transmitted via airborne droplets. Can affect lungs (pulmonary TB, 80-85%) or other organs (extrapulmonary TB, 15-20%). Highly contagious. Public health emergency requiring isolation and reporting</p>
                    <p><span class="label">Latent TB vs Active TB:</span></p>
                    <ul>
                        <li><strong>Latent TB Infection (LTBI):</strong> Infected with M. tuberculosis but no symptoms, not contagious. Positive TST/IGRA, normal CXR. 5-10% lifetime risk of reactivation (higher if immunocompromised)</li>
                        <li><strong>Active TB Disease:</strong> Symptomatic, contagious (if pulmonary/laryngeal), abnormal CXR, positive AFB smear/culture. Requires multi-drug treatment</li>
                    </ul>
                    
                    <p><span class="label">PULMONARY TB (Most Common, 80-85%):</span></p>
                    <p><span class="label">Classic Presentation (Subacute/Chronic):</span></p>
                    <ul>
                        <li><strong>Chronic cough:</strong> â‰¥3 weeks duration. Initially dry, becomes productive. Hallmark symptom</li>
                        <li><strong>Hemoptysis:</strong> Blood-tinged sputum (25-50%). Can be massive in cavitary disease</li>
                        <li><strong>Constitutional symptoms ("B symptoms"):</strong> Fever (low-grade, evening), night sweats (drenching, change clothes), weight loss (>10% body weight), anorexia, malaise, fatigue</li>
                        <li><strong>Chest pain:</strong> Pleuritic (if pleural involvement), dull ache</li>
                        <li><strong>Dyspnea:</strong> If extensive disease, pleural effusion, or miliary TB</li>
                    </ul>
                    <p><span class="label">Physical Exam (Often Unremarkable):</span> May have rales/crackles over involved lung fields, dullness to percussion (consolidation, effusion), amphoric breath sounds (cavity), cachexia (advanced disease). Exam may be entirely normal despite extensive radiographic disease</p>
                    
                    <p><span class="label">EXTRAPULMONARY TB (15-20%, Higher in HIV/Immunocompromised):</span></p>
                    <ul>
                        <li><strong>Tuberculous Lymphadenitis (Most Common EPTB):</strong> Painless, firm, matted cervical or supraclavicular lymph nodes. May suppurate (cold abscess). Slow progression over weeks-months</li>
                        <li><strong>Pleural TB:</strong> Exudative pleural effusion. Pleuritic chest pain, dyspnea. Effusion often lymphocyte-predominant. Pleural fluid ADA (adenosine deaminase) >40 U/L highly suggestive</li>
                        <li><strong>Tuberculous Meningitis (TB Meningitis):</strong> Subacute headache, fever, altered mental status, cranial nerve palsies (especially CN VI), seizures. CSF: lymphocytic pleocytosis, low glucose, high protein. HIGH MORTALITY (20-50%) even with treatment</li>
                        <li><strong>Miliary TB (Disseminated):</strong> Hematogenous spread to multiple organs. High fever, weight loss, hepatosplenomegaly. CXR: bilateral diffuse miliary (millet seed) nodules (1-3mm). Often in HIV, elderly, immunocompromised</li>
                        <li><strong>Skeletal TB (Pott's Disease):</strong> Vertebral osteomyelitis (thoracic/lumbar spine most common). Back pain, paravertebral abscess, cord compression, gibbus deformity. MRI shows vertebral destruction, abscess</li>
                        <li><strong>Genitourinary TB:</strong> Dysuria, hematuria, flank pain, sterile pyuria. Can cause ureteral strictures, hydronephrosis, chronic kidney disease</li>
                        <li><strong>Pericardial TB:</strong> Pericardial effusion, tamponade, constrictive pericarditis (chronic). High mortality</li>
                        <li><strong>Abdominal TB:</strong> Peritonitis (ascites, abdominal pain), intestinal involvement (chronic diarrhea, obstruction, perforation). Ascites: high protein, lymphocyte-predominant, ADA >39 U/L</li>
                    </ul>
                    
                    <p><span class="label">High-Risk Populations:</span></p>
                    <ul>
                        <li><strong>HIV/AIDS (CD4 <200):</strong> 10-20x increased risk. More likely disseminated/extrapulmonary TB. TB accelerates HIV progression</li>
                        <li><strong>Immunosuppression:</strong> TNF-Î± inhibitors (infliximab, adalimumab - screen before starting), transplant recipients, chronic steroids (â‰¥15mg prednisone daily), chemotherapy</li>
                        <li><strong>Close contact:</strong> Household contact with active TB case (20-30% infection rate)</li>
                        <li><strong>Endemic areas:</strong> India, China, Southeast Asia, Sub-Saharan Africa, Latin America, Eastern Europe</li>
                        <li><strong>Congregate settings:</strong> Homeless shelters, prisons, nursing homes</li>
                        <li><strong>Healthcare workers:</strong> Exposure to undiagnosed TB patients</li>
                        <li><strong>Other:</strong> Diabetes, chronic kidney disease, silicosis, malignancy, malnutrition, alcoholism, IV drug use</li>
                    </ul>
                    
                    <p><span class="label">Drug-Resistant TB:</span></p>
                    <ul>
                        <li><strong>Multidrug-Resistant TB (MDR-TB):</strong> Resistant to isoniazid (INH) + rifampin (RIF). 5% of new cases globally. Higher in HIV, prior TB treatment. Requires â‰¥18-24 months treatment. Lower cure rates (50-70%)</li>
                        <li><strong>Extensively Drug-Resistant TB (XDR-TB):</strong> MDR-TB + resistance to fluoroquinolones + second-line injectable (amikacin, kanamycin, capreomycin). Very poor prognosis. Mortality 30-50%</li>
                        <li><strong>Risk factors for resistance:</strong> Prior TB treatment, non-adherence, endemic areas (Russia, South Africa, India), HIV co-infection, close contact with known drug-resistant case</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Tuberculin Skin Test (TST) & Interferon-Gamma Release Assay (IGRA):</span></p>
                    <ul>
                        <li><strong>Use:</strong> Screen for LATENT TB infection. NOT for diagnosis of active TB disease</li>
                        <li><strong>TST (Mantoux test):</strong> Intradermal injection. Read at 48-72hr. Induration â‰¥5mm (HIV, immunocompromised, close contact), â‰¥10mm (immigrants, healthcare workers, high-risk), â‰¥15mm (low-risk) considered positive</li>
                        <li><strong>IGRA (QuantiFERON-TB Gold, T-SPOT):</strong> Blood test. Measures T-cell response to TB antigens. Not affected by BCG vaccination (unlike TST). Preferred in BCG-vaccinated individuals</li>
                        <li><strong>Both can be negative in active TB:</strong> Anergy from severe illness, immunosuppression. Don't rule out active TB based on negative TST/IGRA alone</li>
                    </ul>
                    
                    <p><span class="label">Chest X-Ray (CXR) - Essential:</span></p>
                    <ul>
                        <li><strong>Primary TB (children, recent infection):</strong> Hilar/mediastinal lymphadenopathy, middle/lower lobe infiltrates, Ghon complex (calcified granuloma + lymph node)</li>
                        <li><strong>Reactivation TB (adults):</strong> Upper lobe infiltrates (apical/posterior segments), cavitary lesions (thin-walled cavities with air-fluid levels), fibronodular opacities, volume loss. Right upper lobe most common</li>
                        <li><strong>Miliary TB:</strong> Bilateral diffuse miliary (millet seed) nodules, 1-3mm</li>
                        <li><strong>Pleural effusion:</strong> Unilateral, moderate-large. May be only finding</li>
                        <li><strong>Advanced disease:</strong> Fibrosis, traction bronchiectasis, destroyed lung</li>
                    </ul>
                    <p><span class="label">Note:</span> CXR can be normal in early disease or extrapulmonary TB. HIV patients may have atypical or normal CXR despite active pulmonary TB</p>
                    
                    <p><span class="label">Sputum Testing (GOLD STANDARD for Pulmonary TB):</span></p>
                    <ul>
                        <li><strong>Collection:</strong> 3 separate sputum samples on 3 different days (ideally early morning, deep cough). If unable to produce sputum: induced sputum (nebulized hypertonic saline), bronchoscopy with BAL, gastric aspirate (children)</li>
                        <li><strong>AFB Smear (Acid-Fast Bacilli):</strong> Ziehl-Neelsen or Auramine-rhodamine stain. Results in 24hr. Positive = patient is infectious. Sensitivity 50-60% (needs 5,000-10,000 organisms/mL). Negative smear does NOT rule out TB. Semi-quantitative: 1+ to 4+ (higher = more infectious)</li>
                        <li><strong>Mycobacterial Culture (GOLD STANDARD):</strong> Solid media (Lowenstein-Jensen) takes 3-8 weeks. Liquid media (MGIT) faster (1-3 weeks). Definitive diagnosis. Allows drug susceptibility testing (DST). ESSENTIAL</li>
                        <li><strong>Nucleic Acid Amplification Test (NAAT):</strong></li>
                        <ul>
                            <li><strong>Xpert MTB/RIF (GeneXpert):</strong> Rapid PCR test (results in 2 hours). Detects M. tuberculosis + rifampin resistance. Sensitivity 80-90% (higher if smear-positive). WHO-recommended. Use on first sputum sample</li>
                            <li><strong>Cepheid Xpert MTB/RIF Ultra:</strong> Improved sensitivity (90-95%). Detects lower bacterial loads</li>
                        </ul>
                        <li><strong>Histopathology (if tissue available):</strong> Caseating granulomas with Langhans giant cells. Supportive but not specific (fungi, sarcoid can mimic)</li>
                    </ul>
                    
                    <p><span class="label">Extrapulmonary TB Diagnosis:</span></p>
                    <ul>
                        <li><strong>Pleural fluid:</strong> Lymphocyte-predominant exudate, ADA >40 U/L (90% sensitivity), low glucose, high protein. Pleural biopsy (caseating granulomas, culture) more sensitive than pleural fluid culture</li>
                        <li><strong>CSF (TB meningitis):</strong> Lymphocytic pleocytosis (50-500 cells/ÂµL), low glucose (<45mg/dL or <50% serum), high protein (>100mg/dL). AFB smear low sensitivity (10-20%). Culture takes weeks. Large volume (6-10mL) increases yield. Xpert MTB/RIF on CSF (sensitivity 50-60%)</li>
                        <li><strong>Lymph node:</strong> Fine-needle aspiration (FNA) for AFB smear/culture, or excisional biopsy (caseating granulomas, culture)</li>
                        <li><strong>Urine:</strong> 3 early morning urine samples for AFB culture. Xpert MTB/RIF on urine (moderate sensitivity)</li>
                        <li><strong>Biopsy:</strong> Any suspected site (bone, peritoneum, pericardium) - send for AFB smear, culture, histopathology</li>
                    </ul>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Anemia of chronic disease, lymphopenia (miliary TB), monocytosis</li>
                        <li><strong>CMP:</strong> Hyponatremia (SIADH in TB meningitis, miliary TB), elevated alkaline phosphatase (hepatic TB, drug toxicity)</li>
                        <li><strong>ESR/CRP:</strong> Elevated (nonspecific inflammatory markers)</li>
                        <li><strong>HIV test:</strong> Obtain in ALL TB patients. HIV/TB co-infection common</li>
                        <li><strong>Baseline LFTs:</strong> Before starting treatment (INH, RIF, PZA are hepatotoxic)</li>
                    </ul>
                    
                    <p><span class="label">Drug Susceptibility Testing (DST):</span> CRITICAL. Perform on all initial isolates. Guides therapy. Tests susceptibility to INH, RIF, PZA, ethambutol, fluoroquinolones, second-line drugs. Takes 2-4 weeks. Don't wait for results to start treatment. Adjust regimen when results available</p>
                    
                    <p><span class="label">Additional Testing:</span></p>
                    <ul>
                        <li><strong>CT chest:</strong> If CXR abnormal or high suspicion with normal CXR. Better delineates cavities, lymphadenopathy, complications</li>
                        <li><strong>Bronchoscopy with BAL:</strong> If unable to produce sputum, high suspicion with negative sputum, suspected endobronchial TB</li>
                        <li><strong>MRI spine:</strong> If Pott's disease suspected (back pain, neurologic deficits)</li>
                        <li><strong>Ophthalmology exam:</strong> Check for choroidal tubercles (miliary TB), before starting ethambutol (monitor for optic neuritis)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">ISOLATION (CRITICAL - Airborne Precautions):</span></p>
                    <ul>
                        <li><strong>Airborne isolation room:</strong> Negative pressure, â‰¥6 air changes/hour, HEPA filtration. Private room. Door closed</li>
                        <li><strong>N95 respirators:</strong> For all healthcare workers entering room. Fit-tested. Surgical mask for patient when leaving room</li>
                        <li><strong>Duration:</strong> Until 3 consecutive negative AFB smears (usually 2-4 weeks of treatment) OR clinically improving + receiving appropriate therapy Ã— 2 weeks. TB meningitis/extrapulmonary TB (non-pulmonary) generally NOT infectious - standard precautions</li>
                        <li><strong>Reporting:</strong> TB is REPORTABLE to public health department. Contact investigation for close contacts</li>
                    </ul>
                    
                    <p><span class="label">STANDARD TREATMENT REGIMEN (Drug-Susceptible TB):</span></p>
                    <p><span class="label">Intensive Phase (First 2 Months) - RIPE:</span></p>
                    <ul>
                        <li><strong>Rifampin (R): 600mg PO daily (or 10mg/kg/day, max 600mg)</strong></li>
                        <li><strong>Isoniazid (I/INH): 300mg PO daily (or 5mg/kg/day, max 300mg) + Pyridoxine (Vitamin B6) 25-50mg daily (prevent peripheral neuropathy)</strong></li>
                        <li><strong>Pyrazinamide (P/PZA): 1000-2000mg PO daily (weight-based: 40-55kg = 1000mg, 56-75kg = 1500mg, 76-90kg = 2000mg, >90kg = 2000mg)</strong></li>
                        <li><strong>Ethambutol (E): 800-1600mg PO daily (weight-based: 40-55kg = 800mg, 56-75kg = 1200mg, 76-90kg = 1600mg, >90kg = 1600mg)</strong></li>
                        <li><strong>Duration:</strong> 2 months (8 weeks) OR until AFB smear-negative and clinical improvement</li>
                    </ul>
                    
                    <p><span class="label">Continuation Phase (Next 4-7 Months) - Rifampin + Isoniazid:</span></p>
                    <ul>
                        <li><strong>Rifampin 600mg PO daily + Isoniazid 300mg PO daily (+ pyridoxine 25-50mg daily)</strong></li>
                        <li><strong>Duration:</strong></li>
                        <ul>
                            <li><strong>Uncomplicated pulmonary TB (cavitary disease, smear-negative at 2 months):</strong> 4 months continuation (total 6 months therapy)</li>
                            <li><strong>Cavitary disease + positive smear at 2 months:</strong> 7 months continuation (total 9 months)</li>
                            <li><strong>TB meningitis, miliary TB, bone/joint TB:</strong> 10-12 months continuation (total 12 months therapy)</li>
                        </ul>
                    </ul>
                    
                    <p><span class="label">Total Treatment Duration:</span></p>
                    <ul>
                        <li><strong>Drug-susceptible pulmonary TB:</strong> 6 months (2 months RIPE, then 4 months RI)</li>
                        <li><strong>Extrapulmonary TB (lymph nodes, pleura):</strong> 6 months (same as pulmonary)</li>
                        <li><strong>TB meningitis, miliary TB, bone/spine TB:</strong> 9-12 months</li>
                        <li><strong>MDR-TB:</strong> 18-24 months (complex regimen, consult ID/TB specialist)</li>
                    </ul>
                    
                    <p><span class="label">Directly Observed Therapy (DOT):</span> STRONGLY RECOMMENDED for all TB patients. Healthcare worker observes patient taking medications (3-5 times/week or daily). Ensures adherence, prevents resistance, improves cure rates. Public health department coordinates DOT</p>
                    
                    <p><span class="label">Alternative Dosing (Intermittent Therapy):</span> 3 times weekly dosing (after initial 2 weeks daily therapy) acceptable if DOT ensured. Used in resource-limited settings. Doses higher than daily dosing (consult ID/TB expert for dosing)</p>
                    
                    <p><span class="label">Drug-Resistant TB:</span></p>
                    <ul>
                        <li><strong>Rifampin-Resistant (RR-TB):</strong> Detected by Xpert MTB/RIF. Treat as MDR-TB until full DST results</li>
                        <li><strong>MDR-TB (INH + RIF resistant):</strong> Requires 4-5 drugs including fluoroquinolone (levofloxacin, moxifloxacin) + second-line injectable (amikacin, capreomycin) + pyrazinamide + ethambutol + others (linezolid, bedaquiline, delamanid). CONSULT ID/TB SPECIALIST. Treatment 18-24 months</li>
                        <li><strong>XDR-TB:</strong> MDR + resistant to fluoroquinolones + injectable. Very limited options. Newer drugs: bedaquiline, delamanid, pretomanid. MUST consult TB expert</li>
                    </ul>
                    
                    <p><span class="label">HIV Co-Infection (TB-HIV):</span></p>
                    <ul>
                        <li><strong>Start TB treatment immediately:</strong> Don't delay for ART initiation</li>
                        <li><strong>When to start ART:</strong></li>
                        <ul>
                            <li><strong>CD4 <50:</strong> Start ART within 2 weeks of starting TB treatment (balance immune reconstitution vs TB treatment)</li>
                            <li><strong>CD4 >50:</strong> Start ART within 8 weeks of TB treatment</li>
                            <li><strong>TB meningitis:</strong> DELAY ART until 8 weeks (risk of IRIS with neurologic worsening)</li>
                        </ul>
                        <li><strong>Drug interactions:</strong> Rifampin induces CYP450 (decreases ART levels). Integrase inhibitors (dolutegravir, raltegravir) or efavirenz preferred. Avoid protease inhibitors with rifampin. Consider rifabutin (less CYP induction) instead of rifampin if needed</li>
                    </ul>
                    
                    <p><span class="label">TB Meningitis (Special Considerations):</span></p>
                    <ul>
                        <li><strong>Adjunctive corticosteroids:</strong> Dexamethasone 0.3-0.4mg/kg/day IV Ã— 4 weeks, then taper over 4 weeks. Reduces mortality and disability. START WITH FIRST DOSE OF TB DRUGS</li>
                        <li><strong>Duration:</strong> 9-12 months total treatment</li>
                        <li><strong>Monitor:</strong> Repeat lumbar punctures if worsening symptoms (hydrocephalus, increased ICP). Shunt if needed</li>
                    </ul>
                    
                    <p><span class="label">Monitoring During Treatment:</span></p>
                    <ul>
                        <li><strong>Clinical:</strong> Weekly initially, then monthly. Assess adherence, symptoms, side effects</li>
                        <li><strong>Sputum smears:</strong> Monthly until 2 consecutive negatives, then at end of treatment</li>
                        <li><strong>LFTs:</strong> Baseline, then monthly (or sooner if symptoms of hepatitis). Hold drugs if ALT >3Ã— ULN with symptoms or >5Ã— ULN asymptomatic</li>
                        <li><strong>CMP:</strong> Monitor creatinine (ethambutol cleared renally), uric acid (pyrazinamide causes hyperuricemia)</li>
                        <li><strong>Visual acuity & color vision:</strong> Monthly (ethambutol optic neuritis). Baseline ophthalmology exam</li>
                        <li><strong>CXR:</strong> At 2 months, end of treatment, then as needed. Improvement may lag clinical improvement</li>
                    </ul>
                    
                    <p><span class="label">Treatment Failure:</span> Persistent positive sputum cultures after 4 months of treatment. Suggests drug resistance, non-adherence, malabsorption. Repeat DST. Consult ID/TB specialist. Do NOT add single drug to failing regimen (creates resistance)</p>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>Nutrition:</strong> High-calorie, high-protein diet. Many patients malnourished</li>
                        <li><strong>Diabetes control:</strong> Rifampin decreases efficacy of oral hypoglycemics. May need insulin</li>
                        <li><strong>Symptom management:</strong> Cough suppressants, antipyretics, analgesics PRN</li>
                        <li><strong>Contact investigation:</strong> Public health screens close contacts (TST/IGRA, CXR). Treat LTBI if indicated</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>TB is "the great mimicker":</strong> Can present as pneumonia, lymphoma, cancer, chronic meningitis, osteomyelitis. High index of suspicion in endemic areas, immunocompromised, chronic symptoms</li>
                    <li><strong>Don't wait for culture to treat:</strong> Cultures take weeks. Start treatment based on clinical/radiographic suspicion and positive AFB smear or Xpert. Adjust when DST results available</li>
                    <li><strong>Never add a single drug to a failing regimen:</strong> Creates resistance. If treatment failing, add â‰¥2 new drugs and consult TB specialist</li>
                    <li><strong>Rifampin turns body fluids orange:</strong> Warn patients (urine, tears, sweat). Contact lenses permanently stained. Not harmful</li>
                    <li><strong>INH peripheral neuropathy is preventable:</strong> Give pyridoxine (vitamin B6) 25-50mg daily with INH to ALL patients. Essential in diabetics, HIV, pregnant women, alcoholics, malnourished</li>
                    <li><strong>Ethambutol optic neuritis is dose-dependent:</strong> Monitor visual acuity and color vision monthly. Mostly reversible if caught early. Higher risk if renal insufficiency (dose-adjust) or >2 months use</li>
                    <li><strong>TB-HIV co-infection is deadly but treatable:</strong> Start TB treatment first, then ART (within 2-8 weeks depending on CD4). Watch for IRIS (immune reconstitution inflammatory syndrome) - paradoxical worsening when starting ART</li>
                    <li><strong>TB meningitis needs steroids:</strong> Dexamethasone reduces mortality and disability. Start with first dose of TB drugs. Delay ART until 8 weeks (risk of IRIS neurologic worsening)</li>
                    <li><strong>Sputum cultures must be done:</strong> Only way to confirm diagnosis and perform drug susceptibility testing. Negative smears don't rule out TB (sensitivity only 50-60%). Culture is gold standard</li>
                    <li><strong>Adherence is everything:</strong> Non-adherence â†’ treatment failure â†’ drug resistance â†’ MDR-TB/XDR-TB. DOT (directly observed therapy) is highly effective and recommended for ALL patients</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Respiratory failure requiring mechanical ventilation (extensive TB pneumonia, ARDS)</li>
                        <li>TB meningitis with decreased consciousness (GCS <13), increased ICP, neurologic deterioration</li>
                        <li>Hemodynamically unstable (septic shock rare but possible)</li>
                        <li>Massive hemoptysis (>200mL in 24hr)</li>
                        <li>Drug-induced hepatotoxicity (ALT >10Ã— ULN, coagulopathy, encephalopathy)</li>
                        <li>Severe IRIS (immune reconstitution inflammatory syndrome) in HIV patients starting ART</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Clinically stable and improving (no fever, improved symptoms)</li>
                        <li>Tolerating PO medications</li>
                        <li>3 consecutive negative AFB smears (pulmonary TB) OR clinically improving on treatment Ã— 2 weeks</li>
                        <li>Appropriate outpatient TB regimen prescribed (DOT arranged)</li>
                        <li>Public health notified (contact investigation underway)</li>
                        <li>Close follow-up arranged (ID clinic, public health DOT program)</li>
                        <li>Patient counseled on adherence, side effects, infectivity</li>
                        <li>Isolation precautions no longer needed (3 negative smears or appropriate duration on therapy)</li>
                        <li>Directly Observed Therapy (DOT) arranged through public health</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute (During Active Disease):</strong> Respiratory failure (extensive pneumonia, ARDS), massive hemoptysis (eroded pulmonary artery - requires bronchial artery embolization or surgery), pneumothorax (cavitary disease rupture), empyema (pleural space infection), pericardial tamponade (pericardial TB), spinal cord compression (Pott's disease with epidural abscess), obstructive hydrocephalus (TB meningitis - may need shunt), ARDS (miliary TB, severe pneumonia)</p>
                    <p><strong>Treatment-Related Complications:</strong></p>
                    <ul>
                        <li><strong>Hepatotoxicity (INH, RIF, PZA):</strong> Transaminitis (10-20%), symptomatic hepatitis (1-3%). Monitor LFTs monthly. Hold drugs if ALT >5Ã— ULN or >3Ã— ULN with symptoms. Rechallenge drugs sequentially when LFTs normalize. INH most hepatotoxic</li>
                        <li><strong>Peripheral neuropathy (INH):</strong> Prevented by pyridoxine (vitamin B6). Higher risk in diabetes, HIV, alcohol, malnutrition</li>
                        <li><strong>Optic neuritis (Ethambutol):</strong> Decreased visual acuity, red-green color blindness. Monitor monthly. Usually reversible if caught early. Dose-adjust in renal insufficiency</li>
                        <li><strong>Hyperuricemia/gout (Pyrazinamide):</strong> Elevated uric acid. Treat with NSAIDs, colchicine. Allopurinol if recurrent gout (but wait until after PZA phase)</li>
                        <li><strong>Thrombocytopenia (Rifampin):</strong> Immune-mediated. Stop rifampin. Can use rifabutin instead</li>
                        <li><strong>Orange discoloration (Rifampin):</strong> Body fluids (urine, tears, sweat) turn orange-red. Harmless. Warn patients (contact lenses stained)</li>
                        <li><strong>Drug interactions (Rifampin):</strong> CYP450 inducer. Decreases levels of: oral contraceptives (use barrier method), warfarin, anticonvulsants, antiretrovirals, immunosuppressants</li>
                        <li><strong>IRIS (Immune Reconstitution Inflammatory Syndrome):</strong> Paradoxical worsening when starting ART in HIV patients on TB treatment. Inflammatory reaction to dead/dying TB. Can be severe (lymph node enlargement, worsening infiltrates, fever). Manage with NSAIDs or steroids. Don't stop ART or TB drugs</li>
                    </ul>
                    <p><strong>Chronic (Post-Treatment):</strong> Chronic pulmonary sequelae (fibrosis, bronchiectasis, destroyed lung, aspergilloma in old cavities - hemoptysis risk), chronic pericarditis (constrictive - may need pericardiectomy), chronic meningitis sequelae (hydrocephalus, seizures, cranial nerve palsies, cognitive impairment), skeletal deformities (gibbus deformity from vertebral collapse), chronic kidney disease (GU TB), relapse (5% after adequate treatment - usually within 1 year, higher if HIV, drug-resistant TB, non-adherence)</p>
                    <p><strong>Prevention:</strong> Treat LTBI (latent TB infection) in high-risk individuals: INH 300mg daily Ã— 9 months OR rifampin 600mg daily Ã— 4 months OR INH-rifapentine weekly Ã— 3 months (3HP). BCG vaccine (limited efficacy in adults, not used in US). Infection control (airborne precautions, N95 respirators). Contact investigation and treatment of close contacts</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="hiv-aids" class="condition-page">
            <div class="page-header">
                <h2>60. HIV/AIDS COMPLICATIONS</h2>
                <div class="subtitle">Advanced HIV Disease â€¢ CD4 <200 â€¢ Opportunistic Infections â€¢ Antiretroviral Therapy</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">HIV/AIDS Overview:</span> Advanced HIV disease occurs when CD4 count <200 cells/Î¼L (AIDS-defining) or presence of opportunistic infections. Patients vulnerable to infections, malignancies, and complications related to severe immunosuppression</p>
                    
                    <p><span class="label">Common AIDS-Defining Illnesses by CD4 Count:</span></p>
                    <ul>
                        <li><strong>CD4 <500:</strong> Herpes zoster (shingles), tuberculosis reactivation, recurrent bacterial pneumonia, oral/vaginal candidiasis</li>
                        <li><strong>CD4 <200:</strong> Pneumocystis jirovecii pneumonia (PCP), candidal esophagitis, CNS toxoplasmosis, disseminated histoplasmosis/coccidioidomycosis, chronic cryptosporidiosis</li>
                        <li><strong>CD4 <50:</strong> Cytomegalovirus (CMV) retinitis/colitis, Mycobacterium avium complex (MAC) disseminated infection, primary CNS lymphoma, progressive multifocal leukoencephalopathy (PML)</li>
                    </ul>
                    
                    <p><span class="label">PNEUMOCYSTIS JIROVECII PNEUMONIA (PCP) - Most Common AIDS-Defining Illness:</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Subacute onset (weeks) of dyspnea, dry cough, fever. Progressive hypoxemia. Typically CD4 <200</li>
                        <li><strong>Physical exam:</strong> Tachypnea, hypoxemia (Oâ‚‚ sat low, often 80s-90s on room air), clear lung sounds or fine crackles. NO consolidation</li>
                        <li><strong>CXR:</strong> Diffuse bilateral interstitial infiltrates ("ground glass"). Can be normal in 10-20%. Pneumothorax can occur</li>
                        <li><strong>Diagnosis:</strong> Induced sputum (methenamine silver stain, DFA), bronchoscopy with BAL (gold standard, sensitivity >95%)</li>
                        <li><strong>LDH:</strong> Markedly elevated (>500, often >1000). Nonspecific but sensitive</li>
                    </ul>
                    
                    <p><span class="label">CANDIDAL ESOPHAGITIS:</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Odynophagia (painful swallowing), dysphagia, retrosternal chest pain. Usually oral thrush present (white plaques on tongue/buccal mucosa). CD4 typically <200</li>
                        <li><strong>Diagnosis:</strong> Clinical (presence of oral thrush + odynophagia highly specific). Endoscopy if atypical or no response to treatment (shows white plaques in esophagus)</li>
                    </ul>
                    
                    <p><span class="label">CNS TOXOPLASMOSIS (Toxoplasma encephalitis):</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Altered mental status, focal neurologic deficits (hemiparesis, aphasia, ataxia), seizures, headache, fever. CD4 typically <100</li>
                        <li><strong>MRI brain:</strong> Multiple ring-enhancing lesions (80%), typically at gray-white junction, basal ganglia. Mass effect, edema</li>
                        <li><strong>Toxoplasma IgG:</strong> Positive in 90% (past exposure). Negative IgG makes toxoplasmosis less likely</li>
                        <li><strong>Diagnosis:</strong> Presumptive based on imaging + CD4 <100 + positive Toxoplasma IgG. Empiric treatment trial (if improvement in 7-14 days â†’ confirms diagnosis). Brain biopsy if no response or IgG negative</li>
                    </ul>
                    
                    <p><span class="label">CMV RETINITIS:</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Painless vision loss, floaters, visual field defects. CD4 <50</li>
                        <li><strong>Fundoscopy:</strong> "Pizza pie" or "cottage cheese and ketchup" appearance. Hemorrhagic necrosis along retinal vessels</li>
                        <li><strong>Risk:</strong> Retinal detachment, permanent blindness if untreated. OPHTHALMOLOGY EMERGENCY</li>
                    </ul>
                    
                    <p><span class="label">CMV COLITIS:</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Chronic diarrhea (watery or bloody), abdominal pain, fever, weight loss. CD4 <50</li>
                        <li><strong>Diagnosis:</strong> Colonoscopy with biopsy (CMV inclusion bodies, immunostaining)</li>
                    </ul>
                    
                    <p><span class="label">MYCOBACTERIUM AVIUM COMPLEX (MAC):</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Disseminated disease. High fever, night sweats, weight loss, anemia, hepatosplenomegaly, lymphadenopathy. Chronic diarrhea (GI involvement). CD4 <50</li>
                        <li><strong>Labs:</strong> Pancytopenia, elevated alkaline phosphatase</li>
                        <li><strong>Diagnosis:</strong> Blood cultures (mycobacterial blood cultures - takes 2-4 weeks). Positive in 90%</li>
                    </ul>
                    
                    <p><span class="label">CRYPTOCOCCAL MENINGITIS:</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Subacute headache (weeks), fever, altered mental status, nausea/vomiting. Minimal meningeal signs. CD4 <100</li>
                        <li><strong>CSF:</strong> Elevated opening pressure (>25cmHâ‚‚O in 75%), lymphocytic pleocytosis, low glucose, high protein. India ink (encapsulated yeast), cryptococcal antigen (CrAg) nearly 100% sensitive</li>
                        <li><strong>Serum CrAg:</strong> Also highly sensitive. Positive in disseminated disease</li>
                        <li><strong>Imaging:</strong> MRI may be normal or show hydrocephalus, cryptococcomas</li>
                    </ul>
                    
                    <p><span class="label">IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS):</span></p>
                    <ul>
                        <li><strong>Definition:</strong> Paradoxical worsening of opportunistic infection after starting ART (antiretroviral therapy). Occurs as CD4 count rises and immune system "awakens"</li>
                        <li><strong>Timing:</strong> Typically 2-12 weeks after starting ART</li>
                        <li><strong>Presentation:</strong> Fever, worsening symptoms/imaging of prior infection (e.g., TB lymphadenitis enlarges, PCP infiltrates worsen). Can be severe (respiratory failure, neurologic deterioration)</li>
                        <li><strong>Management:</strong> Continue ART + continue OI treatment. Corticosteroids if severe (prednisone 0.5-1mg/kg/day)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Essential Labs:</span></p>
                    <ul>
                        <li><strong>CD4 count:</strong> Determines risk of opportunistic infections. <200 = AIDS. <50 = highest risk</li>
                        <li><strong>HIV viral load:</strong> Assesses disease control, treatment response. Goal <20-50 copies/mL (undetectable)</li>
                        <li><strong>CBC:</strong> Anemia, leukopenia, thrombocytopenia common in advanced disease. Pancytopenia (think MAC, disseminated infection)</li>
                        <li><strong>CMP:</strong> Renal function (before nephrotoxic drugs), electrolytes, liver enzymes</li>
                        <li><strong>LDH:</strong> Elevated in PCP, lymphoma, hemolysis</li>
                        <li><strong>Blood cultures:</strong> Bacterial (if fever/sepsis), mycobacterial (if CD4 <50 with fever/night sweats - rule out MAC, TB)</li>
                    </ul>
                    
                    <p><span class="label">Imaging Based on Presentation:</span></p>
                    <ul>
                        <li><strong>CXR:</strong> If respiratory symptoms (PCP, TB, bacterial pneumonia, Kaposi sarcoma)</li>
                        <li><strong>CT chest:</strong> If CXR nondiagnostic but high suspicion for PCP or other pulmonary process</li>
                        <li><strong>MRI brain (with contrast):</strong> If altered mental status, focal deficits, seizures (toxoplasmosis, lymphoma, PML, cryptococcoma)</li>
                        <li><strong>CT abdomen/pelvis:</strong> If abdominal pain, diarrhea, hepatosplenomegaly (CMV colitis, MAC, lymphoma, Kaposi sarcoma)</li>
                    </ul>
                    
                    <p><span class="label">Specific OI Diagnostics:</span></p>
                    <ul>
                        <li><strong>PCP:</strong> ABG (A-a gradient), induced sputum or BAL (methenamine silver stain, DFA, PCR). Î²-D-glucan elevated</li>
                        <li><strong>Toxoplasmosis:</strong> MRI brain, Toxoplasma IgG serology</li>
                        <li><strong>Cryptococcus:</strong> Serum CrAg (screening if CD4 <100), lumbar puncture (opening pressure, CSF CrAg, India ink, fungal culture)</li>
                        <li><strong>CMV:</strong> Ophthalmology exam (retinitis), colonoscopy with biopsy (colitis), CMV PCR (viremia)</li>
                        <li><strong>MAC:</strong> Mycobacterial blood cultures (hold 4-6 weeks)</li>
                        <li><strong>TB:</strong> Sputum AFB smear/culture/PCR (Xpert MTB/RIF), mycobacterial blood cultures if disseminated</li>
                    </ul>
                    
                    <p><span class="label">Lumbar Puncture Indications:</span> Headache, altered mental status, seizures, fever with neurologic symptoms. Check opening pressure, cell count, protein, glucose, Gram stain/culture, CrAg, VDRL (syphilis), consider Toxoplasma PCR, JC virus PCR (PML)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">ANTIRETROVIRAL THERAPY (ART) - Foundation:</span></p>
                    <ul>
                        <li><strong>Start ART in ALL patients:</strong> Regardless of CD4 count. Reduces mortality, prevents disease progression, reduces transmission</li>
                        <li><strong>Timing:</strong> Start within 2 weeks of OI diagnosis (balance immune recovery vs IRIS risk). EXCEPTION: TB meningitis (delay ART 8 weeks to reduce IRIS-related neurologic complications), cryptococcal meningitis (delay 4-6 weeks after starting antifungals)</li>
                        <li><strong>Regimen:</strong> Integrase inhibitor-based (dolutegravir, bictegravir) + 2 NRTIs (tenofovir/emtricitabine). Consult HIV specialist for regimen selection</li>
                        <li><strong>Drug interactions:</strong> Many ART drugs interact with rifampin (TB treatment), azoles (fungal treatment). Adjust doses or choose alternative agents</li>
                    </ul>
                    
                    <p><span class="label">PCP TREATMENT:</span></p>
                    <ul>
                        <li><strong>First-line:</strong> Trimethoprim-sulfamethoxazole (Bactrim) 15-20mg/kg/day (based on TMP component) IV or PO divided TID-QID Ã— 21 days. Example: 2 DS tablets PO TID</li>
                        <li><strong>Alternative (if sulfa allergy):</strong> Pentamidine 4mg/kg IV daily Ã— 21 days (nephrotoxic, pancreatitis, hypoglycemia), OR clindamycin 600mg IV q6h + primaquine 15-30mg PO daily Ã— 21 days (check G6PD first)</li>
                        <li><strong>Adjunctive corticosteroids:</strong> Prednisone 40mg PO BID Ã— 5 days, then 40mg daily Ã— 5 days, then 20mg daily Ã— 11 days (total 21 days). INDICATION: PaOâ‚‚ <70mmHg on room air OR A-a gradient >35mmHg. START WITHIN 72 HOURS of antibiotics. Reduces mortality and respiratory failure</li>
                        <li><strong>Secondary prophylaxis:</strong> After completion, continue TMP-SMX 1 DS tablet PO daily until CD4 >200 Ã— 3 months</li>
                    </ul>
                    
                    <p><span class="label">CANDIDAL ESOPHAGITIS TREATMENT:</span></p>
                    <ul>
                        <li><strong>First-line:</strong> Fluconazole 200-400mg PO/IV daily Ã— 14-21 days</li>
                        <li><strong>Alternative (fluconazole-refractory):</strong> Itraconazole 200mg PO daily, posaconazole 400mg PO BID, voriconazole 200mg PO BID, OR micafungin 150mg IV daily, caspofungin 70mg IV load then 50mg daily</li>
                        <li><strong>Response:</strong> Symptoms improve in 3-5 days. If no improvement by 7 days â†’ endoscopy (confirm diagnosis, rule out CMV/HSV co-infection)</li>
                    </ul>
                    
                    <p><span class="label">CNS TOXOPLASMOSIS TREATMENT:</span></p>
                    <ul>
                        <li><strong>First-line (acute therapy Ã— 6 weeks):</strong> Pyrimethamine 200mg PO load, then 50-75mg PO daily (weight-based) + sulfadiazine 1-1.5g PO QID + leucovorin (folinic acid) 10-25mg PO daily (prevents bone marrow toxicity)</li>
                        <li><strong>Alternative:</strong> Pyrimethamine + leucovorin + clindamycin 600mg IV/PO q6h (if sulfa allergy)</li>
                        <li><strong>Second-line:</strong> TMP-SMX 5mg/kg (TMP component) IV q12h</li>
                        <li><strong>Anticonvulsants:</strong> If seizures occur. Levetiracetam preferred (fewer drug interactions than phenytoin)</li>
                        <li><strong>Corticosteroids:</strong> Dexamethasone if significant mass effect/edema. Use cautiously (can mask treatment failure)</li>
                        <li><strong>Clinical response:</strong> 80-90% improve by 7-14 days. Repeat MRI at 2 weeks. If worsening â†’ consider brain biopsy (lymphoma vs other diagnosis)</li>
                        <li><strong>Secondary prophylaxis:</strong> After acute treatment, continue pyrimethamine 25-50mg daily + sulfadiazine 2-4g daily (divided) + leucovorin 10-25mg daily until CD4 >200 Ã— 6 months</li>
                    </ul>
                    
                    <p><span class="label">CRYPTOCOCCAL MENINGITIS TREATMENT:</span></p>
                    <ul>
                        <li><strong>Induction (2 weeks):</strong> Amphotericin B lipid complex 3-4mg/kg IV daily + flucytosine 25mg/kg PO QID. Goal: sterilize CSF</li>
                        <li><strong>Consolidation (8 weeks):</strong> Fluconazole 400mg PO daily</li>
                        <li><strong>Maintenance (â‰¥1 year):</strong> Fluconazole 200mg PO daily until CD4 >200 Ã— 6 months AND undetectable viral load</li>
                        <li><strong>Elevated ICP management (CRITICAL):</strong> Daily therapeutic lumbar punctures (remove 20-30mL CSF) to maintain opening pressure <20cmHâ‚‚O. Persistent elevated ICP â†’ lumbar drain. Untreated elevated ICP causes blindness, death</li>
                        <li><strong>Monitor:</strong> Creatinine (amphotericin nephrotoxic), potassium/magnesium (wasting), CBC (flucytosine bone marrow suppression)</li>
                    </ul>
                    
                    <p><span class="label">CMV RETINITIS TREATMENT:</span></p>
                    <ul>
                        <li><strong>Induction (2-3 weeks):</strong> Ganciclovir 5mg/kg IV q12h OR foscarnet 90mg/kg IV q12h OR valganciclovir 900mg PO BID (if can tolerate PO)</li>
                        <li><strong>Maintenance:</strong> Valganciclovir 900mg PO daily OR ganciclovir 5mg/kg IV 5-7Ã—/week until immune recovery (CD4 >100 Ã— 6 months)</li>
                        <li><strong>Ophthalmology:</strong> Urgent consultation. Consider intravitreal injections if sight-threatening</li>
                    </ul>
                    
                    <p><span class="label">CMV COLITIS TREATMENT:</span></p>
                    <ul>
                        <li><strong>Induction:</strong> Ganciclovir 5mg/kg IV q12h Ã— 3-6 weeks (until symptoms resolve)</li>
                        <li><strong>Maintenance:</strong> Valganciclovir 900mg PO daily until CD4 >100 Ã— 6 months</li>
                    </ul>
                    
                    <p><span class="label">MAC TREATMENT:</span></p>
                    <ul>
                        <li><strong>Therapy:</strong> Clarithromycin 500mg PO BID + ethambutol 15mg/kg PO daily + rifabutin 300mg PO daily (if ART allows). Continue until CD4 >100 Ã— 12 months AND â‰¥12 months treatment AND asymptomatic</li>
                        <li><strong>Alternative:</strong> Azithromycin 500-600mg daily (instead of clarithromycin)</li>
                    </ul>
                    
                    <p><span class="label">IRIS MANAGEMENT:</span></p>
                    <ul>
                        <li><strong>Continue ART:</strong> Do not stop (benefit of immune recovery outweighs IRIS risk in most cases)</li>
                        <li><strong>Continue OI treatment:</strong> Ensure adequately treating underlying infection</li>
                        <li><strong>Corticosteroids if severe:</strong> Prednisone 0.5-1mg/kg/day Ã— 2 weeks, then taper. Consider if respiratory failure, neurologic deterioration, or life-threatening symptoms</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TEACHING PEARLS</div>
                <div class="pearls-box">
                    <p>ðŸ’¡ <strong>Start ART early:</strong> Within 2 weeks of OI diagnosis in most cases (except TB meningitis, cryptococcal meningitis). Early ART reduces mortality</p>
                    <p>ðŸ’¡ <strong>PCP prophylaxis indications:</strong> CD4 <200, prior PCP, or CD4 <14%. TMP-SMX 1 DS tablet daily or 3Ã—/week. Prevents #1 AIDS-defining illness</p>
                    <p>ðŸ’¡ <strong>Toxoplasmosis prophylaxis:</strong> CD4 <100 + positive Toxoplasma IgG. TMP-SMX 1 DS daily (also covers PCP)</p>
                    <p>ðŸ’¡ <strong>MAC prophylaxis:</strong> CD4 <50. Azithromycin 1200mg weekly or clarithromycin 500mg BID</p>
                    <p>ðŸ’¡ <strong>Ring-enhancing brain lesions in HIV:</strong> #1 = Toxoplasmosis (multiple lesions, CD4 <100). #2 = Primary CNS lymphoma (solitary, CD4 <50, EBV-associated). Empiric toxo treatment trial for 2 weeks; if no response â†’ biopsy</p>
                    <p>ðŸ’¡ <strong>Cryptococcal meningitis ICP crisis:</strong> Elevated opening pressure (>25cmHâ‚‚O) is the rule, not exception. Daily LPs to drain CSF are MANDATORY. Failure to control ICP â†’ blindness, death despite antifungals</p>
                    <p>ðŸ’¡ <strong>PCP in pregnancy:</strong> TMP-SMX contraindicated in 1st trimester (folate antagonist). Use pentamidine. After 1st trimester, TMP-SMX is safe</p>
                    <p>ðŸ’¡ <strong>CMV viremia vs disease:</strong> Positive CMV PCR alone is not disease. Need end-organ involvement (retinitis, colitis, esophagitis, pneumonitis). Don't treat viremia alone</p>
                    <p>ðŸ’¡ <strong>Rifampin drug interactions:</strong> Rifampin is potent CYP450 inducer. Decreases levels of protease inhibitors, NNRTIs, many other drugs. Use rifabutin (less induction) or integrase inhibitors (less affected) with HIV treatment</p>
                    <p>ðŸ’¡ <strong>Diarrhea in AIDS:</strong> Broad differential. Infectious (CMV, MAC, Cryptosporidium, Microsporidium, Isospora, C. diff), medication-related (protease inhibitors), HIV enteropathy. Workup: stool cultures, ova & parasites, CMV PCR, colonoscopy if refractory</p>
                    <p>ðŸ’¡ <strong>PML (progressive multifocal leukoencephalopathy):</strong> JC virus reactivation. CD4 <50. Progressive focal neurologic deficits, no fever, no enhancement on MRI. White matter lesions. CSF JC virus PCR diagnostic. NO specific treatment. Only ART (immune restoration)</p>
                    <p>ðŸ’¡ <strong>Kaposi sarcoma:</strong> HHV-8 associated. Violaceous skin lesions, oral lesions, GI/pulmonary involvement. Can occur at any CD4 but more common <200. Treatment: ART (causes regression in most)</p>
                </div>
            </div>
            
            <div class="two-column-section">
                <div class="column">
                    <div class="section-title">ICU ESCALATION CRITERIA</div>
                    <ul>
                        <li>Respiratory failure requiring mechanical ventilation (severe PCP, ARDS)</li>
                        <li>Septic shock (bacterial sepsis, disseminated infection)</li>
                        <li>Altered mental status with airway compromise (meningitis, encephalitis)</li>
                        <li>Seizures refractory to treatment (toxoplasmosis, CNS infection)</li>
                        <li>Hemodynamic instability (MAC with bacteremia, overwhelming sepsis)</li>
                        <li>Severe electrolyte abnormalities from treatment (amphotericin-induced hypokalemia/hypomagnesemia)</li>
                    </ul>
                </div>
                <div class="column">
                    <div class="section-title">DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Clinical improvement of OI on appropriate therapy</li>
                        <li>Tolerating oral medications (or has outpatient IV access for continued treatment)</li>
                        <li>No longer requiring IV medications that cannot be given outpatient</li>
                        <li>ART started (if treatment-naive) or regimen optimized</li>
                        <li>Prophylaxis medications prescribed for OI prevention</li>
                        <li>Follow-up arranged with HIV specialist</li>
                        <li>Social support/housing stable (critical for medication adherence)</li>
                        <li>Patient educated on warning signs, medication adherence, side effects</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>IRIS (Immune Reconstitution Inflammatory Syndrome):</strong> Paradoxical worsening of OI after starting ART (2-12 weeks). Can be life-threatening. Continue ART, continue OI treatment, add corticosteroids if severe</p>
                    <p><strong>Medication Toxicities:</strong> Amphotericin (nephrotoxicity, hypokalemia, hypomagnesemia, infusion reactions), ganciclovir/valganciclovir (bone marrow suppression), TMP-SMX (rash, hyperkalemia, renal dysfunction), pentamidine (hypoglycemia, pancreatitis, nephrotoxicity)</p>
                    <p><strong>ART Side Effects:</strong> GI intolerance, hepatotoxicity, nephrotoxicity (tenofovir), neuropsychiatric effects (efavirenz), rash (nevirapine, abacavir - check HLA-B*5701), lipodystrophy, metabolic syndrome</p>
                    <p><strong>Drug Interactions:</strong> ART interacts with many medications (azoles, rifamycins, anticonvulsants, PPIs, statins). Consult pharmacist/HIV specialist for regimen selection</p>
                    <p><strong>Non-adherence:</strong> Complex regimens, side effects, social issues â†’ resistance development. Directly observed therapy, social work support, simplify regimens</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="opportunistic" class="condition-page">
            <div class="page-header">
                <h2>61. OPPORTUNISTIC INFECTIONS IN IMMUNOCOMPROMISED HOST</h2>
                <div class="subtitle">Non-HIV Immunosuppression â€¢ Transplant â€¢ Chemotherapy â€¢ Biological Agents</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Immunocompromised Host Overview:</span> Patients with impaired immune function due to underlying disease (hematologic malignancy, solid organ/stem cell transplant), medications (chemotherapy, high-dose steroids, biologics), or inherited immunodeficiency. Susceptible to infections by organisms that rarely cause disease in immunocompetent hosts</p>
                    
                    <p><span class="label">Types of Immunosuppression:</span></p>
                    <ul>
                        <li><strong>Neutropenia:</strong> ANC <500 cells/Î¼L (severe <100). Risk of bacterial/fungal infections. Duration and depth critical</li>
                        <li><strong>Cell-mediated immunity defects:</strong> Solid organ transplant, chronic steroids (>20mg prednisone daily Ã— >2 weeks), TNF-Î± inhibitors, lymphoma. Risk: intracellular pathogens (Listeria, Nocardia, mycobacteria), fungi (Cryptococcus, Pneumocystis), viruses (CMV, VZV)</li>
                        <li><strong>Humoral immunity defects:</strong> Multiple myeloma, CLL, splenectomy, complement deficiencies. Risk: encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)</li>
                        <li><strong>Combined defects:</strong> Stem cell transplant, intensive chemotherapy regimens, HIV/AIDS</li>
                    </ul>
                    
                    <p><span class="label">INVASIVE FUNGAL INFECTIONS (Most Feared Complications):</span></p>
                    
                    <p><span class="label">Invasive Aspergillosis:</span></p>
                    <ul>
                        <li><strong>Risk factors:</strong> Prolonged neutropenia, hematologic malignancy (AML, allogeneic stem cell transplant), high-dose steroids, lung transplant</li>
                        <li><strong>Pulmonary aspergillosis (most common):</strong> Fever, cough, pleuritic chest pain, hemoptysis. CT chest: nodules with surrounding ground-glass opacity ("halo sign" early, "air-crescent sign" late), cavitation</li>
                        <li><strong>Invasive sinusitis:</strong> Facial pain, nasal congestion, black necrotic eschars in nasal cavity, cranial nerve palsies (cavernous sinus extension)</li>
                        <li><strong>CNS aspergillosis:</strong> Altered mental status, focal deficits, seizures. MRI: ring-enhancing lesions, hemorrhage</li>
                        <li><strong>Diagnosis:</strong> Galactomannan (serum/BAL - sensitivity 70-80% in high-risk), Î²-D-glucan (nonspecific but sensitive), CT-guided biopsy (gold standard - septate hyphae with acute-angle branching)</li>
                    </ul>
                    
                    <p><span class="label">Invasive Candidiasis:</span></p>
                    <ul>
                        <li><strong>Risk factors:</strong> Central lines, TPN, broad-spectrum antibiotics, GI surgery/perforation, neutropenia</li>
                        <li><strong>Candidemia:</strong> Fever unresponsive to antibiotics, hemodynamic instability. Blood cultures positive (but can be negative in tissue-invasive disease)</li>
                        <li><strong>Hepatosplenic candidiasis (chronic disseminated):</strong> Persistent fever during neutropenia recovery. RUQ pain, elevated alkaline phosphatase. Imaging: "bulls-eye" or target lesions in liver/spleen</li>
                        <li><strong>Candida endophthalmitis:</strong> Chorioretinal lesions (white fluffy infiltrates) on fundoscopy. Screen all candidemia patients</li>
                    </ul>
                    
                    <p><span class="label">Mucormycosis (Zygomycosis):</span></p>
                    <ul>
                        <li><strong>Risk factors:</strong> Diabetic ketoacidosis, neutropenia, hematologic malignancy, deferoxamine use, iron overload</li>
                        <li><strong>Rhinocerebral mucormycosis:</strong> AGGRESSIVE. Facial/periorbital swelling, facial pain, black necrotic eschars (palate, nasal turbinates), proptosis, ophthalmoplegia, vision loss. Can invade brain (cavernous sinus thrombosis, stroke). HIGH MORTALITY (>50%)</li>
                        <li><strong>Pulmonary mucormycosis:</strong> Fever, cough, hemoptysis, pleuritic chest pain. CT: nodules, consolidation, cavitation. Angioinvasive â†’ infarction</li>
                        <li><strong>Diagnosis:</strong> Tissue biopsy (broad, ribbon-like, non-septate hyphae with right-angle branching). Cultures often negative</li>
                    </ul>
                    
                    <p><span class="label">Pneumocystis jirovecii Pneumonia (PCP):</span></p>
                    <ul>
                        <li><strong>Risk factors:</strong> Prolonged high-dose steroids (>20mg prednisone Ã— >1 month), hematologic malignancy, solid organ transplant, chemotherapy (especially fludarabine, alemtuzumab), TNF-Î± inhibitors. NOT just HIV</li>
                        <li><strong>Presentation:</strong> Subacute dyspnea, dry cough, fever. Progressive hypoxemia. CXR: bilateral interstitial infiltrates. LDH markedly elevated</li>
                        <li><strong>Diagnosis:</strong> Induced sputum, BAL (methenamine silver stain, DFA, PCR). Î²-D-glucan elevated (80-90% sensitive)</li>
                    </ul>
                    
                    <p><span class="label">VIRAL INFECTIONS:</span></p>
                    
                    <p><span class="label">CMV (Cytomegalovirus) Disease:</span></p>
                    <ul>
                        <li><strong>Risk factors:</strong> Solid organ transplant (especially lung, heart), stem cell transplant, high-dose steroids</li>
                        <li><strong>CMV viremia vs disease:</strong> Viremia = PCR positive without symptoms. Disease = end-organ involvement (pneumonitis, colitis, retinitis, hepatitis, encephalitis)</li>
                        <li><strong>CMV pneumonitis:</strong> Dyspnea, fever, hypoxemia. CXR/CT: bilateral interstitial infiltrates. BAL: CMV by culture/PCR + cytopathic inclusions. HIGH MORTALITY in stem cell transplant</li>
                        <li><strong>CMV colitis:</strong> Diarrhea (bloody), abdominal pain, fever. Colonoscopy: ulcers, biopsy shows inclusions</li>
                        <li><strong>Monitoring:</strong> Weekly CMV PCR in high-risk transplant patients (preemptive therapy if viral load rising)</li>
                    </ul>
                    
                    <p><span class="label">Varicella-Zoster Virus (VZV) - Disseminated/Severe:</span></p>
                    <ul>
                        <li><strong>Risk:</strong> Can disseminate in immunocompromised (visceral involvement: pneumonitis, hepatitis, encephalitis)</li>
                        <li><strong>Presentation:</strong> Dermatomal zoster BUT lesions outside dermatome (disseminated), hemorrhagic vesicles, visceral symptoms</li>
                        <li><strong>Treatment:</strong> Acyclovir 10mg/kg IV q8h (vs PO for immunocompetent shingles)</li>
                    </ul>
                    
                    <p><span class="label">BK Virus (Polyomavirus):</span></p>
                    <ul>
                        <li><strong>Risk:</strong> Kidney transplant recipients. Can cause BK nephropathy â†’ graft loss</li>
                        <li><strong>Presentation:</strong> Rising creatinine, proteinuria, hematuria (mimics rejection)</li>
                        <li><strong>Diagnosis:</strong> Urine/plasma BK PCR (high viral load), kidney biopsy (viral inclusions, tubular injury)</li>
                    </ul>
                    
                    <p><span class="label">BACTERIAL INFECTIONS:</span></p>
                    
                    <p><span class="label">Nocardia:</span></p>
                    <ul>
                        <li><strong>Risk:</strong> Solid organ transplant (especially lung), chronic steroids, pulmonary alveolar proteinosis</li>
                        <li><strong>Presentation:</strong> Pulmonary (most common): cough, fever, nodules/cavitation on imaging. Can disseminate to CNS (brain abscess), skin (subcutaneous abscesses)</li>
                        <li><strong>Diagnosis:</strong> Sputum/tissue culture (slow-growing, modified AFB stain positive, Gram-positive branching filaments)</li>
                    </ul>
                    
                    <p><span class="label">Listeria monocytogenes:</span></p>
                    <ul>
                        <li><strong>Risk:</strong> Cell-mediated immunity defects (transplant, steroids, TNF-Î± inhibitors, elderly)</li>
                        <li><strong>Presentation:</strong> Meningitis (headache, fever, altered mental status), bacteremia. CSF: lymphocytic or neutrophilic pleocytosis. Blood cultures often positive</li>
                    </ul>
                    
                    <p><span class="label">Mycobacteria (TB, NTM):</span></p>
                    <ul>
                        <li><strong>Risk:</strong> TNF-Î± inhibitors (screen with IGRA/TST before starting), solid organ transplant, high-dose steroids</li>
                        <li><strong>Nontuberculous mycobacteria (NTM):</strong> M. avium complex, M. abscessus. Pulmonary disease (nodules, cavitation), disseminated disease (in severe immunosuppression)</li>
                    </ul>
                    
                    <p><span class="label">PARASITIC INFECTIONS:</span></p>
                    
                    <p><span class="label">Toxoplasma gondii:</span></p>
                    <ul>
                        <li><strong>Risk:</strong> Stem cell transplant (especially if donor seropositive/recipient seronegative), heart transplant (reactivation in donor heart)</li>
                        <li><strong>Presentation:</strong> Similar to HIV-related toxoplasmosis (CNS lesions, fever, altered mental status)</li>
                    </ul>
                    
                    <p><span class="label">Strongyloides stercoralis Hyperinfection:</span></p>
                    <ul>
                        <li><strong>Risk:</strong> Endemic exposure (tropical/subtropical regions) + immunosuppression (steroids). Parasite can persist for decades in immunocompetent, then hyperinfect</li>
                        <li><strong>Presentation:</strong> Abdominal pain, diarrhea, ileus, pulmonary symptoms. Can cause Gram-negative bacteremia (larvae carry gut bacteria). HIGH MORTALITY</li>
                        <li><strong>Diagnosis:</strong> Stool ova & parasites (multiple samples), serology. Larvae in sputum/BAL if pulmonary involvement</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">History - CRITICAL for Risk Stratification:</span></p>
                    <ul>
                        <li><strong>Type/duration of immunosuppression:</strong> Chemotherapy regimen, transplant type/date, biologic agents (infliximab, rituximab, etc.), steroid dose/duration</li>
                        <li><strong>Neutropenia:</strong> ANC, duration (>7 days = high risk)</li>
                        <li><strong>Prophylaxis medications:</strong> PCP prophylaxis (TMP-SMX), antifungal (fluconazole, voriconazole, posaconazole), antiviral (acyclovir, valganciclovir)</li>
                        <li><strong>Exposures:</strong> Travel (endemic fungi - Histoplasma, Coccidioides, Blastomyces), pets, construction sites (Aspergillus), undercooked meat (Toxoplasma), gardening/soil (Nocardia)</li>
                        <li><strong>Prior infections:</strong> Latent TB, endemic fungi, VZV, CMV serostatus</li>
                    </ul>
                    
                    <p><span class="label">Laboratory Studies:</span></p>
                    <ul>
                        <li><strong>CBC with differential:</strong> ANC (neutropenic fever defined as ANC <500 + fever â‰¥38.3Â°C once or â‰¥38Â°C Ã— 1hr), anemia, thrombocytopenia</li>
                        <li><strong>CMP:</strong> Renal function (before antifungals, antivirals), liver enzymes (hepatic involvement)</li>
                        <li><strong>Blood cultures Ã— 2 sets:</strong> Bacterial, fungal (if prolonged fever/neutropenia)</li>
                        <li><strong>Fungal biomarkers:</strong> Galactomannan (Aspergillus), Î²-D-glucan (Candida, Aspergillus, PCP - NOT Mucor), Cryptococcal antigen</li>
                        <li><strong>Viral studies:</strong> CMV PCR (quantitative), EBV PCR, BK virus PCR (transplant patients), respiratory viral panel</li>
                        <li><strong>Sputum:</strong> Gram stain/culture, AFB smear/culture, fungal culture, PCP stain (if indicated)</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CT chest (high-resolution):</strong> Preferred over CXR. Aspergillus (halo sign, air crescent, nodules), PCP (ground-glass), Mucor (nodules, infarction), Nocardia (cavitary nodules)</li>
                        <li><strong>CT sinus:</strong> If facial pain/congestion (Aspergillus, Mucor sinusitis)</li>
                        <li><strong>MRI brain (with contrast):</strong> If altered mental status, focal deficits (Toxoplasma, Aspergillus, Nocardia, Listeria, Cryptococcus)</li>
                        <li><strong>CT abdomen/pelvis:</strong> If abdominal pain (hepatosplenic candidiasis, CMV colitis, typhlitis)</li>
                    </ul>
                    
                    <p><span class="label">Invasive Diagnostics (Often Necessary):</span></p>
                    <ul>
                        <li><strong>Bronchoscopy with BAL:</strong> PCP, Aspergillus, viral pneumonitis (CMV). Send for bacterial/fungal/viral cultures, PCP stain, Galactomannan, cytology</li>
                        <li><strong>CT-guided biopsy:</strong> Lung nodules (Aspergillus, Mucor, Nocardia - definitive diagnosis). Liver/spleen lesions (hepatosplenic candidiasis)</li>
                        <li><strong>Lumbar puncture:</strong> Altered mental status. Cell count, protein, glucose, Gram stain/culture, cryptococcal antigen, Toxoplasma PCR, VZV/HSV PCR. Opening pressure (Cryptococcus)</li>
                        <li><strong>Endoscopy/colonoscopy:</strong> GI symptoms (CMV colitis, esophagitis). Biopsy for CMV inclusions, cultures</li>
                        <li><strong>Skin biopsy:</strong> Rash (disseminated fungal infection, Nocardia, cutaneous viruses)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">EMPIRIC THERAPY FOR NEUTROPENIC FEVER (ANC <500 + Fever):</span></p>
                    <ul>
                        <li><strong>Start within 1 hour:</strong> Delays increase mortality</li>
                        <li><strong>Regimen:</strong> Cefepime 2g IV q8h OR piperacillin-tazobactam 4.5g IV q6h OR meropenem 1g IV q8h (if prior ESBL, Pseudomonas, or critically ill)</li>
                        <li><strong>Add vancomycin 15-20mg/kg q8-12h IF:</strong> Hemodynamic instability, concern for catheter-related infection, skin/soft tissue infection, MRSA colonization, mucositis</li>
                        <li><strong>Duration:</strong> Continue until ANC >500 AND afebrile Ã— 48hr (minimum 7 days even if culture-negative)</li>
                        <li><strong>If persistent fever at 4-7 days:</strong> ADD empiric antifungal (voriconazole, caspofungin, or liposomal amphotericin B). Repeat imaging, fungal workup</li>
                    </ul>
                    
                    <p><span class="label">INVASIVE ASPERGILLOSIS:</span></p>
                    <ul>
                        <li><strong>First-line:</strong> Voriconazole 6mg/kg IV q12h Ã— 2 doses (loading), then 4mg/kg IV q12h (maintenance). Switch to PO when stable (200-300mg PO BID)</li>
                        <li><strong>Alternative:</strong> Isavuconazole 372mg IV q8h Ã— 6 doses (loading), then 372mg IV daily, OR liposomal amphotericin B 3-5mg/kg IV daily</li>
                        <li><strong>Salvage/combination:</strong> Voriconazole + anidulafungin (echinocandin) for severe/refractory disease</li>
                        <li><strong>Duration:</strong> Minimum 6-12 weeks. Continue until lesions resolve AND immune reconstitution (ANC recovery, reduced immunosuppression if possible)</li>
                        <li><strong>Monitor:</strong> Voriconazole levels (trough 1-5.5 mcg/mL - wide inter-patient variability, hepatotoxicity, visual changes)</li>
                    </ul>
                    
                    <p><span class="label">MUCORMYCOSIS:</span></p>
                    <ul>
                        <li><strong>Medical:</strong> Liposomal amphotericin B 5-10mg/kg IV daily. High-dose required. Alternative: posaconazole 300mg PO BID (loading Ã— 1 day, then 300mg daily) or isavuconazole</li>
                        <li><strong>Surgical debridement:</strong> MANDATORY for rhinocerebral, sino-orbital disease. Extensive debridement of necrotic tissue (repeat surgeries often needed). Medical therapy alone = FAILURE</li>
                        <li><strong>Reverse immunosuppression:</strong> Reduce steroids, optimize diabetes control, discontinue deferoxamine if applicable</li>
                        <li><strong>Duration:</strong> Several months (12+ weeks). Continue until clinical/radiographic resolution</li>
                        <li><strong>Mortality:</strong> 40-80% despite aggressive treatment</li>
                    </ul>
                    
                    <p><span class="label">INVASIVE CANDIDIASIS:</span></p>
                    <ul>
                        <li><strong>Candidemia/invasive candidiasis:</strong> Echinocandin (first-line): Micafungin 100mg IV daily, caspofungin 70mg IV load then 50mg daily, OR anidulafungin 200mg IV load then 100mg daily</li>
                        <li><strong>Alternative (if stable, Candida albicans):</strong> Fluconazole 800mg IV load, then 400mg IV/PO daily</li>
                        <li><strong>Remove central line:</strong> Candidemia requires line removal within 24-48hr (unless no alternative access)</li>
                        <li><strong>Ophthalmology exam:</strong> Within 1 week to rule out endophthalmitis (5-10% of candidemia)</li>
                        <li><strong>Duration:</strong> 14 days after first negative blood culture AND resolution of symptoms. Longer if endocarditis, osteomyelitis, or abscess (4-6 weeks minimum)</li>
                    </ul>
                    
                    <p><span class="label">PCP (Non-HIV):</span></p>
                    <ul>
                        <li><strong>Treatment:</strong> TMP-SMX 15-20mg/kg/day (TMP component) IV or PO divided TID-QID Ã— 21 days</li>
                        <li><strong>Alternative:</strong> Pentamidine 4mg/kg IV daily Ã— 21 days (if sulfa allergy)</li>
                        <li><strong>Adjunctive steroids:</strong> Prednisone 40mg BID Ã— 5 days â†’ 40mg daily Ã— 5 days â†’ 20mg daily Ã— 11 days. INDICATION: PaOâ‚‚ <70mmHg OR A-a gradient >35mmHg. START within 72 hours of antibiotics</li>
                        <li><strong>Note:</strong> PCP in non-HIV often MORE severe presentation, higher mortality than HIV-related PCP</li>
                    </ul>
                    
                    <p><span class="label">CMV DISEASE:</span></p>
                    <ul>
                        <li><strong>Treatment:</strong> Ganciclovir 5mg/kg IV q12h (induction Ã— 2-3 weeks) â†’ valganciclovir 900mg PO daily (maintenance until viremia clears + immune recovery)</li>
                        <li><strong>CMV pneumonitis in stem cell transplant:</strong> Ganciclovir + IV immunoglobulin (IVIG 0.5g/kg every other day Ã— 10 doses). HIGH MORTALITY despite treatment</li>
                        <li><strong>Alternative (if renal dysfunction, ganciclovir resistance):</strong> Foscarnet 90mg/kg IV q12h</li>
                        <li><strong>Monitoring:</strong> Weekly CMV PCR to assess treatment response. Monitor CBC (ganciclovir causes neutropenia)</li>
                    </ul>
                    
                    <p><span class="label">NOCARDIA:</span></p>
                    <ul>
                        <li><strong>Treatment:</strong> TMP-SMX 5-10mg/kg/day (TMP component) IV or PO divided BID-TID. High-dose required</li>
                        <li><strong>Duration:</strong> Prolonged. Pulmonary: 6-12 months. CNS: 12 months minimum. Often combined with other agents (imipenem, amikacin, linezolid) for severe/CNS disease</li>
                        <li><strong>Susceptibilities:</strong> Check antibiotic sensitivities (resistance patterns vary by species)</li>
                    </ul>
                    
                    <p><span class="label">LISTERIA MENINGITIS:</span></p>
                    <ul>
                        <li><strong>Treatment:</strong> Ampicillin 2g IV q4h + gentamicin 5-7mg/kg IV daily (synergistic) Ã— 21 days minimum</li>
                        <li><strong>Alternative (if penicillin allergy):</strong> TMP-SMX 5mg/kg (TMP component) IV q6h</li>
                        <li><strong>Note:</strong> Ceftriaxone does NOT cover Listeria. Ampicillin is mandatory</li>
                    </ul>
                    
                    <p><span class="label">STRONGYLOIDES HYPERINFECTION:</span></p>
                    <ul>
                        <li><strong>Treatment:</strong> Ivermectin 200 mcg/kg PO daily Ã— 2 days. Repeat in 2 weeks. For hyperinfection: continue daily until stool/sputum negative Ã— 2 weeks</li>
                        <li><strong>Add albendazole 400mg PO BID (if severe):</strong> Not proven but often used in combination</li>
                        <li><strong>Reduce immunosuppression:</strong> If possible (critical for cure)</li>
                        <li><strong>Treat Gram-negative bacteremia:</strong> Broad-spectrum antibiotics (often concurrent)</li>
                    </ul>
                    
                    <p><span class="label">REDUCING IMMUNOSUPPRESSION:</span></p>
                    <ul>
                        <li><strong>Balance:</strong> Need immune function to clear infection BUT must prevent organ rejection (transplant) or manage underlying disease</li>
                        <li><strong>Steroids:</strong> Taper if possible (cannot stop abruptly if chronic use - adrenal insufficiency). Life-threatening infections may require reduction</li>
                        <li><strong>Transplant immunosuppression:</strong> Reduce calcineurin inhibitors (tacrolimus, cyclosporine), hold antimetabolites (mycophenolate) temporarily. Maintain some immunosuppression to prevent rejection. Consult transplant team</li>
                        <li><strong>Biologic agents:</strong> Hold TNF-Î± inhibitors, rituximab during active infection</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TEACHING PEARLS</div>
                <div class="pearls-box">
                    <p>ðŸ’¡ <strong>Neutropenic fever = emergency:</strong> Start empiric antibiotics within 1 hour. Cefepime or piperacillin-tazobactam. Add vancomycin if unstable or catheter-related infection suspected</p>
                    <p>ðŸ’¡ <strong>Think Aspergillus if:</strong> Prolonged neutropenia + pulmonary nodules with halo sign on CT. Start voriconazole immediately while awaiting biopsy. Don't wait for culture (often negative)</p>
                    <p>ðŸ’¡ <strong>Mucor = aggressive surgical debridement + amphotericin:</strong> Medical therapy alone fails. Rhinocerebral mucor requires extensive ENT surgery, often multiple procedures</p>
                    <p>ðŸ’¡ <strong>Black necrotic eschar in immunocompromised:</strong> Mucormycosis until proven otherwise. Biopsy urgently. Broad, non-septate hyphae</p>
                    <p>ðŸ’¡ <strong>CMV viremia vs disease:</strong> Positive PCR alone is NOT disease. Need end-organ involvement (pneumonitis, colitis, retinitis). Preemptive therapy if rising viral load in transplant patients</p>
                    <p>ðŸ’¡ <strong>Listeria not covered by ceftriaxone:</strong> Ampicillin is mandatory for Listeria meningitis. Think Listeria in transplant/steroid patient with meningitis</p>
                    <p>ðŸ’¡ <strong>Nocardia mimics TB:</strong> Pulmonary nodules, cavitation. Weakly acid-fast positive. Long treatment course (6-12 months). Can disseminate to CNS (brain abscess)</p>
                    <p>ðŸ’¡ <strong>Screen for Strongyloides before immunosuppression:</strong> Serology in patients from endemic areas (tropics). Hyperinfection can occur decades after initial exposure when steroids started. Give ivermectin preemptively if positive</p>
                    <p>ðŸ’¡ <strong>Î²-D-glucan elevated in:</strong> Candida, Aspergillus, PCP. NOT Mucor or Cryptococcus. Use to monitor treatment response</p>
                    <p>ðŸ’¡ <strong>PCP in non-HIV:</strong> More severe presentation, worse outcomes than HIV-related PCP. Still use TMP-SMX + steroids if hypoxemic</p>
                    <p>ðŸ’¡ <strong>VZV in immunocompromised:</strong> Always treat with IV acyclovir 10mg/kg q8h. Can disseminate (visceral organs). Don't use oral therapy</p>
                    <p>ðŸ’¡ <strong>Duration of antifungal therapy:</strong> Aspergillosis requires months (minimum 6-12 weeks). Continue until immune recovery AND radiographic improvement. Early discontinuation = relapse</p>
                </div>
            </div>
            
            <div class="two-column-section">
                <div class="column">
                    <div class="section-title">ICU ESCALATION CRITERIA</div>
                    <ul>
                        <li>Septic shock requiring vasopressors</li>
                        <li>Respiratory failure requiring mechanical ventilation (severe PCP, Aspergillus pneumonia)</li>
                        <li>Neutropenic fever with hemodynamic instability</li>
                        <li>CNS infection with altered mental status/airway compromise</li>
                        <li>Mucormycosis requiring urgent surgical debridement + aggressive medical management</li>
                        <li>Refractory hypoxemia despite maximal support</li>
                    </ul>
                </div>
                <div class="column">
                    <div class="section-title">DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Clinical improvement on appropriate antimicrobial therapy</li>
                        <li>ANC recovering if neutropenic (>500 cells/Î¼L)</li>
                        <li>Hemodynamically stable, afebrile Ã— 48-72hr</li>
                        <li>Tolerating oral medications (or has outpatient IV access arranged)</li>
                        <li>Appropriate prophylaxis prescribed (if indicated)</li>
                        <li>Follow-up arranged with oncology/transplant/infectious disease</li>
                        <li>Immunosuppression regimen adjusted (if modifications needed)</li>
                        <li>Patient/family educated on warning signs, when to return</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Persistent/Recurrent Infections:</strong> Inadequate immune recovery (prolonged neutropenia, ongoing immunosuppression), resistance (fungi, bacteria), inadequate source control (abscess, catheter), wrong diagnosis (biopsy needed)</p>
                    <p><strong>Medication Toxicities:</strong> Amphotericin (nephrotoxicity, hypokalemia, hypomagnesemia, infusion reactions - rigors, fever), voriconazole (hepatotoxicity, visual changes, drug interactions), ganciclovir (bone marrow suppression), TMP-SMX (hyperkalemia, nephrotoxicity, rash)</p>
                    <p><strong>Organ Rejection (Transplant Patients):</strong> Reducing immunosuppression to treat infection can precipitate rejection. Monitor allograft function closely</p>
                    <p><strong>Secondary Infections:</strong> Broad-spectrum antibiotics â†’ C. difficile. Prolonged antifungals â†’ resistant organisms. Prophylaxis helps but doesn't eliminate risk</p>
                    <p><strong>Immune Reconstitution Inflammatory Syndrome (IRIS):</strong> Paradoxical worsening when ANC recovers or immunosuppression reduced. Especially with fungal infections (Aspergillus, Cryptococcus). May require steroids</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="siadh" class="condition-page">
            <div class="page-header">
                <h2>62. SIADH (SYNDROME OF INAPPROPRIATE ADH)</h2>
                <div class="subtitle">Euvolemic Hyponatremia â€¢ Dilutional Hyponatremia</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Asymptomatic hyponatremia discovered on routine labs OR neurologic symptoms (confusion, headache, nausea) in euvolemic patient with concentrated urine</p>
                    
                    <p><span class="label">Symptoms (Correlate with Na Level and Rate of Drop):</span></p>
                    <ul>
                        <li><strong>Mild (Na 130-135):</strong> Often asymptomatic, subtle cognitive changes</li>
                        <li><strong>Moderate (Na 125-129):</strong> Headache, nausea, confusion, lethargy</li>
                        <li><strong>Severe (Na <125):</strong> Vomiting, altered mental status, seizures, coma</li>
                        <li><strong>Critical (<120 or ACUTE drop):</strong> Cerebral edema â†’ seizures, respiratory arrest, brainstem herniation, death</li>
                    </ul>
                    
                    <p><span class="label">Physical Exam:</span> <strong>EUVOLEMIC</strong> - no edema, normal skin turgor, moist mucous membranes, normal JVP, no orthostatic vitals</p>
                    
                    <p><span class="label">Common Causes:</span></p>
                    <ul>
                        <li><strong>Malignancy (most common):</strong> SCLC (most classic), pancreatic/duodenal CA, lymphoma, head/neck cancers</li>
                        <li><strong>Pulmonary:</strong> Pneumonia, TB, COPD exacerbation, aspergillosis, positive pressure ventilation</li>
                        <li><strong>CNS:</strong> Meningitis, encephalitis, SAH, subdural hematoma, brain tumors, trauma, stroke</li>
                        <li><strong>Medications:</strong> SSRIs, carbamazepine, oxcarbazepine, vincristine, cyclophosphamide, NSAIDs, PPIs, MDMA/ecstasy</li>
                        <li><strong>Post-operative:</strong> Physiologic response to surgery (transient)</li>
                        <li><strong>Endocrine:</strong> Severe hypothyroidism, adrenal insufficiency (must exclude first!)</li>
                        <li><strong>Idiopathic:</strong> 10-15% of cases</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">SIADH Diagnostic Criteria (Must meet ALL):</span></p>
                    <ul>
                        <li><strong>Hyponatremia:</strong> Na <135 mEq/L (usually <130)</li>
                        <li><strong>Plasma hypo-osmolality:</strong> Serum osm <275 mOsm/kg</li>
                        <li><strong>Inappropriately concentrated urine:</strong> Urine osm >100 mOsm/kg (typically >300-400)</li>
                        <li><strong>Elevated urine sodium:</strong> Urine Na >40 mEq/L (on normal salt diet)</li>
                        <li><strong>Clinical euvolemia:</strong> No edema, no volume depletion</li>
                        <li><strong>Normal thyroid, adrenal, renal function:</strong> TSH, cortisol, Cr normal</li>
                        <li><strong>No diuretic use</strong></li>
                    </ul>
                    
                    <p><span class="label">Essential Labs:</span></p>
                    <ul>
                        <li><strong>Serum:</strong> BMP (Na, K, Cr), serum osmolality, glucose, TSH, cortisol (AM or random)</li>
                        <li><strong>Urine:</strong> Urine sodium, urine osmolality, specific gravity</li>
                        <li>Calculate serum osmolality: 2(Na) + Glucose/18 + BUN/2.8</li>
                    </ul>
                    
                    <p><span class="label">Workup for Underlying Cause:</span></p>
                    <ul>
                        <li><strong>Medication review:</strong> Stop offending agents if possible</li>
                        <li><strong>CT chest:</strong> Screen for SCLC, pneumonia</li>
                        <li><strong>Head CT/MRI:</strong> If neurologic symptoms or CNS cause suspected</li>
                        <li><strong>Consider:</strong> Lumbar puncture if meningitis/encephalitis suspected, CXR, additional malignancy workup</li>
                    </ul>
                    
                    <p><span class="label">Key Lab Pattern:</span></p>
                    <ul>
                        <li>â†“ Serum Na + â†“ Serum Osm + â†‘ Urine Osm + â†‘ Urine Na + Euvolemia = SIADH</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Treatment Depends on Severity and Acuity:</span></p>
                    
                    <p><span class="label">âš¡ SEVERE/SYMPTOMATIC (Na <120 OR seizures/coma/respiratory arrest):</span></p>
                    <ul>
                        <li><strong>3% Hypertonic Saline:</strong> 100 mL IV bolus over 10 minutes, can repeat Ã— 2-3 as needed</li>
                        <li>Alternative: 2 mL/kg bolus over 10-20 minutes</li>
                        <li><strong>Goal:</strong> Raise Na by 4-6 mEq/L acutely to abort seizures, then STOP acute correction</li>
                        <li>Check Na q2-4h during active correction</li>
                        <li>âš ï¸ <strong>DO NOT exceed 8-10 mEq/L rise in first 24 hours!</strong> Risk of osmotic demyelination syndrome (ODS)</li>
                    </ul>
                    
                    <p><span class="label">MODERATE (Na 125-129, mild symptoms):</span></p>
                    <ul>
                        <li><strong>Fluid restriction:</strong> 800-1000 mL/day (primary therapy)</li>
                        <li>Goal: Negative fluid balance of 500-1000 mL/day</li>
                        <li>Consider salt tablets 1-2g TID to increase osmolar load</li>
                        <li>Monitor Na daily initially</li>
                    </ul>
                    
                    <p><span class="label">CHRONIC/MILD (Na 130-135, asymptomatic):</span></p>
                    <ul>
                        <li><strong>Treat underlying cause first</strong></li>
                        <li>Fluid restriction 1000-1500 mL/day</li>
                        <li>High-salt, high-protein diet</li>
                        <li>Monitor outpatient</li>
                    </ul>
                    
                    <p><span class="label">Adjunct Pharmacotherapy:</span></p>
                    <ul>
                        <li><strong>Urea:</strong> 15-30g PO BID (osmotic diuretic, increases free water excretion) - rarely used in US</li>
                        <li><strong>Demeclocycline:</strong> 300-600 mg PO BID (induces nephrogenic DI) - slow onset (3-5 days), risk of photosensitivity, nephrotoxicity</li>
                        <li><strong>Vaptans (V2 receptor antagonists):</strong>
                            <ul>
                                <li><strong>Tolvaptan (Samsca):</strong> 15 mg PO daily (can increase to 30-60 mg). ONLY for euvolemic/hypervolemic hyponatremia</li>
                                <li>Reserved for severe, refractory SIADH</li>
                                <li>Very expensive, requires close monitoring (risk of overly rapid correction)</li>
                                <li>âš ï¸ <strong>Risk of osmotic demyelination if used incorrectly</strong></li>
                                <li><strong>Contraindicated:</strong> Hypovolemic hyponatremia, anuric renal failure, hepatic impairment</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">âš ï¸ CRITICAL CORRECTION LIMITS (Prevent Osmotic Demyelination Syndrome):</span></p>
                    <ul>
                        <li><strong>Maximum correction:</strong> 8-10 mEq/L in first 24 hours</li>
                        <li><strong>Maximum correction:</strong> 18 mEq/L in first 48 hours</li>
                        <li><strong>High-risk groups for ODS:</strong> Chronic hyponatremia (>48 hours), alcoholism, malnutrition, liver disease, hypokalemia</li>
                        <li>If overcorrect â†’ consider giving D5W to re-lower Na</li>
                    </ul>
                    
                    <p><span class="label">Treat Underlying Cause:</span></p>
                    <ul>
                        <li>Stop offending medications (SSRIs, carbamazepine)</li>
                        <li>Treat pneumonia, CNS infection</li>
                        <li>Oncology consult for malignancy-related SIADH</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Euvolemia is KEY:</strong> If patient has edema (CHF, cirrhosis) or volume depletion â†’ NOT SIADH. Must be euvolemic</li>
                    <li><strong>Osmotic demyelination syndrome (ODS):</strong> Caused by overly rapid Na correction. Presents 2-6 days later with dysarthria, dysphagia, paraplegia, "locked-in" syndrome. Irreversible and devastating</li>
                    <li><strong>"8 in 24" rule:</strong> Never raise Na >8-10 mEq/L in 24 hours, especially in chronic hyponatremia</li>
                    <li><strong>SCLC = classic:</strong> Ectopic ADH production. SIADH may be first presentation of lung cancer</li>
                    <li><strong>SSRIs underrecognized cause:</strong> Especially in elderly patients. Can occur weeks-months after starting</li>
                    <li><strong>Exercise-induced hyponatremia:</strong> Endurance athletes (marathons) drinking excessive hypotonic fluids. Treat with fluid restriction, NOT IV saline</li>
                    <li><strong>Don't give NS for SIADH:</strong> Makes it WORSE! Kidneys excrete the sodium, keep the water â†’ Na drops further. Exception: severe symptomatic needing 3% hypertonic</li>
                    <li><strong>Fluid restriction is hard:</strong> Most patients fail 800mL/day restriction. Compliance is poor</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe symptomatic hyponatremia (seizures, coma, respiratory arrest)</li>
                        <li>Na <120 mEq/L with symptoms</li>
                        <li>Need for 3% hypertonic saline</li>
                        <li>Rapidly dropping Na despite treatment</li>
                        <li>Altered mental status</li>
                        <li>Requiring q2h Na monitoring</li>
                        <li>Suspected or confirmed osmotic demyelination</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Na >125-130 mEq/L and stable/trending up</li>
                        <li>Asymptomatic or mild symptoms only</li>
                        <li>Underlying cause identified and addressed</li>
                        <li>Patient/family educated on fluid restriction</li>
                        <li>Offending medications discontinued</li>
                        <li>Close follow-up arranged (PCP or endocrine)</li>
                        <li>Discharge instructions include fluid restriction goal</li>
                        <li>Na recheck in 2-3 days</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="bowel-obstruction" class="condition-page">
            <div class="page-header">
                <h2>63. BOWEL OBSTRUCTION (SMALL/LARGE)</h2>
                <div class="subtitle">Mechanical Intestinal Blockage â€¢ Surgical Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Tetrad:</span> Abdominal pain, distension, nausea/vomiting, obstipation (inability to pass stool or flatus)</p>
                    
                    <p><span class="label">Small Bowel Obstruction (SBO) - 80% of obstructions:</span></p>
                    <ul>
                        <li><strong>Pain:</strong> Crampy, colicky, periumbilical, intermittent (initially)</li>
                        <li><strong>Vomiting:</strong> Early and prominent, bilious initially â†’ feculent if prolonged</li>
                        <li><strong>Distension:</strong> Variable (minimal if proximal obstruction)</li>
                        <li><strong>Bowel sounds:</strong> High-pitched, hyperactive "rushes" early â†’ absent if ischemia/perforation</li>
                        <li><strong>Most common causes:</strong> Adhesions (60%, especially post-surgical), hernias (20%), malignancy, Crohn's disease, radiation enteritis</li>
                    </ul>
                    
                    <p><span class="label">Large Bowel Obstruction (LBO) - 20% of obstructions:</span></p>
                    <ul>
                        <li><strong>Pain:</strong> Lower abdominal, constant, progressive</li>
                        <li><strong>Distension:</strong> MARKED, progressive</li>
                        <li><strong>Vomiting:</strong> Late finding (if competent ileocecal valve) or absent</li>
                        <li><strong>Bowel sounds:</strong> Decreased to absent</li>
                        <li><strong>Most common causes:</strong> Colorectal cancer (60%), diverticular disease (20%), volvulus (5%), fecal impaction</li>
                    </ul>
                    
                    <p><span class="label">âš ï¸ RED FLAGS for Complicated/Strangulated Bowel:</span></p>
                    <ul>
                        <li><strong>Fever:</strong> Suggests ischemia, perforation, or necrosis</li>
                        <li><strong>Tachycardia, hypotension:</strong> Sepsis, hypovolemia from third-spacing</li>
                        <li><strong>Peritoneal signs:</strong> Guarding, rigidity, rebound tenderness â†’ perforation/necrosis</li>
                        <li><strong>Severe, constant pain:</strong> Rather than colicky â†’ ischemia</li>
                        <li><strong>Bloody stool:</strong> Suggests mucosal ischemia</li>
                        <li><strong>Leukocytosis, metabolic acidosis:</strong> Ischemia, bacterial translocation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis suggests ischemia/perforation (WBC >15k concerning)</li>
                        <li><strong>CMP:</strong> Hypokalemia, hypochloremia (from vomiting), elevated BUN/Cr (dehydration), metabolic acidosis (ischemia)</li>
                        <li><strong>Lactate:</strong> Elevated in bowel ischemia/necrosis (>2.5-4 concerning)</li>
                        <li><strong>Lipase:</strong> To exclude pancreatitis</li>
                        <li><strong>Type & screen:</strong> If operative intervention likely</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Abdominal X-ray (initial screening):</strong>
                            <ul>
                                <li>SBO: Dilated small bowel (>3cm), air-fluid levels, paucity of colonic gas</li>
                                <li>LBO: Dilated colon (>6cm cecum, >9cm sigmoid), air-fluid levels</li>
                                <li>Free air under diaphragm â†’ perforation (upright or left lateral decubitus)</li>
                                <li>Sensitivity only 50-60% - negative X-ray does NOT exclude obstruction</li>
                            </ul>
                        </li>
                        <li><strong>CT Abdomen/Pelvis with IV contrast (GOLD STANDARD):</strong>
                            <ul>
                                <li>Sensitivity/specificity >95% for obstruction</li>
                                <li>Identifies transition point, cause, and complications</li>
                                <li>Signs of ischemia: Bowel wall thickening, pneumatosis, mesenteric stranding, portal venous gas</li>
                                <li>Can distinguish partial vs complete obstruction</li>
                                <li><strong>Key finding:</strong> "Transition point" where dilated bowel suddenly changes to collapsed bowel</li>
                            </ul>
                        </li>
                        <li><strong>Consider:</strong> CT enterography if Crohn's suspected, colonoscopy if LBO from malignancy suspected</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Initial Management (All Patients):</span></p>
                    <ul>
                        <li><strong>NPO:</strong> Nothing by mouth</li>
                        <li><strong>IV Fluids:</strong> Aggressive resuscitation with NS or LR (1-2L bolus, then 150-250 mL/hr). Third-spacing can cause massive fluid losses</li>
                        <li><strong>NG Tube:</strong> Decompress stomach, prevent aspiration, relieve symptoms
                            <ul>
                                <li>Consider long tube (Dobhoff, NG-J) for SBO if available</li>
                                <li>May prevent need for surgery in partial SBO</li>
                            </ul>
                        </li>
                        <li><strong>Correct electrolytes:</strong> Replace K, Cl aggressively (vomiting causes hypokalemic hypochloremic metabolic alkalosis)</li>
                        <li><strong>Pain control:</strong> Opioids acceptable (old teaching that they mask diagnosis is FALSE)</li>
                        <li><strong>Antiemetics:</strong> Ondansetron 4-8 mg IV q8h</li>
                    </ul>
                    
                    <p><span class="label">ðŸš¨ URGENT SURGICAL CONSULTATION for:</span></p>
                    <ul>
                        <li>Complete SBO with no prior abdominal surgery (likely hernia or mass)</li>
                        <li>Signs of strangulation/ischemia (fever, tachycardia, peritonitis, acidosis, elevated lactate)</li>
                        <li>Perforation (free air, peritonitis)</li>
                        <li>Large bowel obstruction (most require surgery)</li>
                        <li>Closed-loop obstruction (high risk of strangulation)</li>
                        <li>Cecal diameter >12 cm (risk of perforation)</li>
                        <li>Failure of conservative management after 48-72 hours</li>
                    </ul>
                    
                    <p><span class="label">Conservative Management (Partial SBO from Adhesions):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Partial SBO, no signs of strangulation, history of prior abdominal surgery (adhesions)</li>
                        <li>NPO + NG tube + IV fluids</li>
                        <li>Serial abdominal exams q4-6h</li>
                        <li>Water-soluble contrast study (Gastrografin) can be both diagnostic and therapeutic:
                            <ul>
                                <li>If contrast reaches colon in 24 hours â†’ ~90% resolve without surgery</li>
                                <li>Osmotic effect may help resolve partial obstruction</li>
                            </ul>
                        </li>
                        <li>Resolution typically within 24-72 hours</li>
                        <li><strong>If no improvement in 3-5 days â†’ surgery</strong></li>
                    </ul>
                    
                    <p><span class="label">Antibiotics:</span></p>
                    <ul>
                        <li><strong>Not routinely needed</strong> for simple uncomplicated obstruction</li>
                        <li><strong>Give if:</strong> Signs of ischemia, perforation, peritonitis, or preoperative prophylaxis</li>
                        <li>Regimen: Cefoxitin 2g IV q6h OR cefazolin 2g + metronidazole 500mg q8h OR pip-tazo 3.375g q6h</li>
                    </ul>
                    
                    <p><span class="label">Special Considerations:</span></p>
                    <ul>
                        <li><strong>Sigmoid volvulus:</strong> Flexible sigmoidoscopy for decompression (success rate 70-80%), then elective surgery</li>
                        <li><strong>Cecal volvulus:</strong> Usually requires surgery</li>
                        <li><strong>Malignant LBO:</strong> Consider stent as bridge to surgery or palliative if metastatic</li>
                        <li><strong>Adhesive SBO in virgin abdomen:</strong> High suspicion for incarcerated hernia - early surgery</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Adhesions = #1 cause SBO:</strong> 60% of cases. Usually in patients with prior abdominal surgery. Partial SBO from adhesions can often be managed conservatively</li>
                    <li><strong>Never-operated abdomen:</strong> SBO without prior surgery suggests hernia (check all hernial orifices!), malignancy, or Crohn's â†’ usually needs surgery</li>
                    <li><strong>Vomiting pattern:</strong> Early vomiting = proximal obstruction, late/absent vomiting = distal or large bowel obstruction</li>
                    <li><strong>Gastrografin challenge:</strong> Water-soluble contrast given via NG tube. Reaches colon in 24h = likely resolves without surgery. Also therapeutic</li>
                    <li><strong>"Rule of 3-6-9":</strong> Normal small bowel <3cm, normal large bowel <6cm, cecum <9cm. Cecum >12cm = impending perforation</li>
                    <li><strong>Closed-loop obstruction:</strong> Both ends of bowel segment obstructed â†’ rapid progression to ischemia. Classic example: sigmoid volvulus, internal hernia</li>
                    <li><strong>Strangulated bowel:</strong> Vascular compromise â†’ ischemia â†’ necrosis â†’ perforation. High mortality if delayed. Look for fever, peritonitis, acidosis</li>
                    <li><strong>Virgin abdomen LBO:</strong> Think cancer until proven otherwise. Needs colonoscopy/surgery for diagnosis and treatment</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Septic shock from perforation/ischemia</li>
                        <li>Peritonitis with hemodynamic instability</li>
                        <li>Severe metabolic acidosis (lactate >4)</li>
                        <li>Post-operative complications</li>
                        <li>Multi-organ dysfunction</li>
                        <li>Requiring vasopressors</li>
                        <li>Respiratory failure (aspiration, abdominal compartment syndrome)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li><strong>Conservative management successful:</strong></li>
                        <li>Resolution of symptoms (pain, nausea, vomiting)</li>
                        <li>Passing flatus and/or stool</li>
                        <li>Tolerating regular diet without N/V</li>
                        <li>Non-distended, soft abdomen with normal bowel sounds</li>
                        <li>No peritoneal signs</li>
                        <li><strong>Post-operative (if surgery):</strong></li>
                        <li>Return of bowel function</li>
                        <li>Tolerating diet, ambulating</li>
                        <li>Adequate pain control on PO meds</li>
                        <li>Surgical follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="ibd" class="condition-page">
            <div class="page-header">
                <h2>64. INFLAMMATORY BOWEL DISEASE (IBD) FLARE</h2>
                <div class="subtitle">Ulcerative Colitis â€¢ Crohn's Disease â€¢ Acute Exacerbation</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">General:</span> Acute worsening of chronic inflammatory bowel disease with increased bowel frequency, abdominal pain, and systemic symptoms</p>
                    
                    <p><span class="label">ULCERATIVE COLITIS (UC) FLARE:</span></p>
                    <ul>
                        <li><strong>Classic symptoms:</strong> Bloody diarrhea (hallmark), mucus in stool, tenesmus, urgency, lower abdominal cramping</li>
                        <li><strong>Frequency:</strong> 10-20+ bloody stools per day in severe flare</li>
                        <li><strong>Distribution:</strong> Continuous inflammation starting in rectum, extends proximally (rectum always involved)</li>
                        <li><strong>Systemic features:</strong> Fever, tachycardia, weight loss, fatigue, anemia</li>
                        <li><strong>Extraintestinal manifestations:</strong> Erythema nodosum, pyoderma gangrenosum, uveitis, arthritis, primary sclerosing cholangitis</li>
                    </ul>
                    
                    <p><span class="label">CROHN'S DISEASE FLARE:</span></p>
                    <ul>
                        <li><strong>Classic symptoms:</strong> Abdominal pain (RLQ common if terminal ileum involved), non-bloody diarrhea (unless colonic disease), weight loss</li>
                        <li><strong>Distribution:</strong> Skip lesions (patchy inflammation), can affect anywhere from mouth to anus. Terminal ileum most common (70%)</li>
                        <li><strong>Complications:</strong> Strictures (obstruction), fistulas (entero-enteric, entero-cutaneous, perianal), abscesses</li>
                        <li><strong>Perianal disease:</strong> Fissures, fistulas, abscesses (highly suggestive of Crohn's)</li>
                        <li><strong>Extraintestinal:</strong> Similar to UC plus oral aphthous ulcers</li>
                    </ul>
                    
                    <p><span class="label">SEVERE/FULMINANT COLITIS (UC or Crohn's Colitis) - Medical Emergency:</span></p>
                    <ul>
                        <li><strong>Truelove-Witts Criteria for Severe UC:</strong>
                            <ul>
                                <li>â‰¥6 bloody stools per day</li>
                                <li>PLUS â‰¥1 of: Fever >37.8Â°C, HR >90, Hgb <10.5 g/dL, ESR >30 mm/hr</li>
                            </ul>
                        </li>
                        <li><strong>Signs of toxicity:</strong> Severe abdominal pain, distension, peritoneal signs, hypotension, altered mental status</li>
                        <li><strong>Toxic megacolon:</strong> Colon dilation >6cm on X-ray + systemic toxicity (fever, tachycardia, leukocytosis). Risk of perforation (25% mortality)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Anemia (chronic disease Â± GI bleeding), leukocytosis (flare or steroids), thrombocytosis (inflammation)</li>
                        <li><strong>CMP:</strong> Hypokalemia, hypomagnesemia (diarrhea), elevated Cr (dehydration), hypoalbuminemia (malnutrition)</li>
                        <li><strong>Inflammatory markers:</strong> CRP, ESR elevated (correlate with disease activity)</li>
                        <li><strong>Stool studies:</strong>
                            <ul>
                                <li><strong>C. diff PCR:</strong> MANDATORY - exclude infectious trigger (common in IBD flares)</li>
                                <li><strong>Stool culture:</strong> Salmonella, Shigella, Campylobacter, E. coli O157:H7</li>
                                <li><strong>Ova & parasites:</strong> If travel history</li>
                                <li><strong>Fecal calprotectin:</strong> Marker of intestinal inflammation (>200-250 mcg/g suggests active disease)</li>
                            </ul>
                        </li>
                        <li><strong>Consider:</strong> CMV PCR (blood/stool) if steroid-refractory (CMV colitis common in severe UC), blood cultures if febrile</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Abdominal X-ray (first-line if severe):</strong>
                            <ul>
                                <li>Assess for toxic megacolon (colon >6 cm), free air (perforation), obstruction</li>
                                <li>Bowel wall thickening, "thumbprinting" (mucosal edema)</li>
                            </ul>
                        </li>
                        <li><strong>CT Abdomen/Pelvis with IV contrast:</strong>
                            <ul>
                                <li>UC: Bowel wall thickening, "target sign," continuous involvement starting rectum</li>
                                <li>Crohn's: Bowel wall thickening, "comb sign" (engorged mesenteric vessels), skip lesions, complications (abscess, fistula, stricture)</li>
                                <li>Evaluate for complications: perforation, abscess, obstruction</li>
                            </ul>
                        </li>
                        <li><strong>MR enterography:</strong> Better for small bowel Crohn's disease (preferred over CT for young patients)</li>
                    </ul>
                    
                    <p><span class="label">Endoscopy:</span></p>
                    <ul>
                        <li><strong>Flexible sigmoidoscopy (preferred over colonoscopy in acute severe colitis):</strong>
                            <ul>
                                <li>Safer than full colonoscopy (lower perforation risk)</li>
                                <li>Assess severity, obtain biopsies to exclude CMV</li>
                                <li>Appearance: UC = continuous erythema, friability, ulceration. Crohn's = skip lesions, cobblestoning</li>
                            </ul>
                        </li>
                        <li><strong>Colonoscopy:</strong> AVOID in severe acute colitis (high perforation risk). Defer until stabilized</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Initial Management (All Patients):</span></p>
                    <ul>
                        <li><strong>IV Fluids:</strong> Aggressive repletion (often 3-6L deficit from diarrhea)</li>
                        <li><strong>Electrolyte replacement:</strong> K, Mg aggressively</li>
                        <li><strong>Blood transfusion:</strong> If Hgb <7 g/dL or symptomatic anemia</li>
                        <li><strong>Bowel rest (NPO):</strong> If severe colitis, obstruction, or pre-operative</li>
                        <li><strong>VTE prophylaxis:</strong> IBD is hypercoagulable state - enoxaparin 40 mg SC daily (unless active bleeding)</li>
                        <li><strong>âš ï¸ AVOID:</strong>
                            <ul>
                                <li><strong>NSAIDs:</strong> Can worsen flares</li>
                                <li><strong>Antidiarrheals (loperamide):</strong> Risk of toxic megacolon</li>
                                <li><strong>Opioids:</strong> Risk of toxic megacolon, ileus</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Medical Therapy by Severity:</span></p>
                    
                    <p><span class="label">MILD-MODERATE FLARE (Outpatient Management Usually):</span></p>
                    <ul>
                        <li><strong>5-ASA (Mesalamine):</strong>
                            <ul>
                                <li>UC: Mainstay for mild-moderate disease. PO: 2.4-4.8 g/day divided. Rectal: Suppositories (proctitis) or enemas (left-sided)</li>
                                <li>Crohn's: Less effective, not routinely used</li>
                            </ul>
                        </li>
                        <li><strong>Prednisone:</strong> 40-60 mg PO daily Ã— 1-2 weeks, then taper over 8-12 weeks</li>
                        <li><strong>Budesonide (Crohn's ileal/right colon disease):</strong> 9 mg PO daily (lower systemic effects than prednisone)</li>
                    </ul>
                    
                    <p><span class="label">MODERATE-SEVERE FLARE (Hospitalization Required):</span></p>
                    <ul>
                        <li><strong>IV Corticosteroids (First-Line):</strong>
                            <ul>
                                <li><strong>Methylprednisolone:</strong> 40-60 mg IV daily OR Hydrocortisone 100 mg IV q6-8h</li>
                                <li>Response expected in 3-5 days</li>
                                <li>If no improvement by day 3 â†’ assess for steroid-refractory disease</li>
                            </ul>
                        </li>
                        <li><strong>Consider CMV testing:</strong> CMV colitis causes steroid-refractory UC. Treat with ganciclovir if positive</li>
                    </ul>
                    
                    <p><span class="label">SEVERE/STEROID-REFRACTORY DISEASE (Rescue Therapy):</span></p>
                    <ul>
                        <li><strong>Infliximab (Remicade):</strong>
                            <ul>
                                <li>Anti-TNF biologic, highly effective for steroid-refractory disease</li>
                                <li>Induction: 5 mg/kg IV at weeks 0, 2, 6, then q8 weeks maintenance</li>
                                <li>Response rate 60-70% in acute severe UC</li>
                                <li>Screen for TB, hepatitis B before starting</li>
                            </ul>
                        </li>
                        <li><strong>Cyclosporine:</strong>
                            <ul>
                                <li>Alternative to infliximab (especially if anti-TNF failure)</li>
                                <li>2 mg/kg/day IV continuous infusion</li>
                                <li>Bridge to maintenance therapy (thiopurines)</li>
                                <li>Requires monitoring: levels, Mg, renal function (nephrotoxic)</li>
                            </ul>
                        </li>
                        <li><strong>Consider earlier surgery</strong> if not responding to medical rescue therapy</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics:</span></p>
                    <ul>
                        <li><strong>Crohn's with perianal disease/abscess:</strong> Ciprofloxacin 500 mg PO BID + Metronidazole 500 mg PO TID</li>
                        <li><strong>UC:</strong> Not routinely indicated unless toxic megacolon, perforation, or sepsis concern</li>
                        <li><strong>If toxic megacolon:</strong> Broad-spectrum (pip-tazo 3.375g IV q6h or cefepime 2g q8h + metronidazole 500mg q8h)</li>
                    </ul>
                    
                    <p><span class="label">ðŸš¨ SURGICAL CONSULTATION for:</span></p>
                    <ul>
                        <li>Toxic megacolon (high perforation risk)</li>
                        <li>Perforation or peritonitis</li>
                        <li>Massive hemorrhage</li>
                        <li>Steroid-refractory disease failing rescue therapy</li>
                        <li>Crohn's complications: Abscess (for drainage), obstruction, fistulas</li>
                        <li><strong>UC surgery = Total colectomy with ileostomy (curative)</strong></li>
                        <li><strong>Crohn's surgery = Resection of diseased segment (NOT curative, high recurrence)</strong></li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>C. diff is common trigger:</strong> Always test! IBD patients have higher rates of C. diff, which can mimic or trigger flare</li>
                    <li><strong>UC = bloody diarrhea, Crohn's = pain/obstruction:</strong> Classic distinction but lots of overlap. Crohn's colitis can also have bloody diarrhea</li>
                    <li><strong>Toxic megacolon = surgical emergency:</strong> Colon >6cm + systemic toxicity. 25% mortality if perforation. Needs urgent surgery if medical therapy fails</li>
                    <li><strong>IBD is hypercoagulable:</strong> 3Ã— risk of VTE. Always give prophylactic anticoagulation unless active major bleeding</li>
                    <li><strong>CMV colitis in steroid-refractory UC:</strong> Up to 30% of steroid-refractory UC has CMV. Test for it! Treat with ganciclovir</li>
                    <li><strong>Avoid colonoscopy in acute severe colitis:</strong> High perforation risk. Use flexible sigmoidoscopy instead (just to rectosigmoid)</li>
                    <li><strong>UC surgery is curative:</strong> Total colectomy removes all disease. Crohn's surgery is NOT curative (can recur anywhere in GI tract)</li>
                    <li><strong>Smoking paradox:</strong> Smoking worsens Crohn's but protective for UC. Don't recommend smoking to UC patients though!</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Toxic megacolon</li>
                        <li>Hemodynamic instability/shock</li>
                        <li>Massive GI bleeding requiring transfusion</li>
                        <li>Severe sepsis</li>
                        <li>Peritonitis/perforation (surgical emergency)</li>
                        <li>Multi-organ dysfunction</li>
                        <li>Requiring vasopressors</li>
                        <li>Post-operative monitoring after colectomy</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Decreased stool frequency (<3-4/day)</li>
                        <li>Minimal/no blood in stool</li>
                        <li>Afebrile, hemodynamically stable</li>
                        <li>Tolerating oral diet</li>
                        <li>Pain controlled with oral medications</li>
                        <li>Hgb stable, no transfusion requirement</li>
                        <li>Transitioned to oral steroids (if needed)</li>
                        <li>C. diff negative (if tested)</li>
                        <li>GI follow-up arranged (within 1-2 weeks)</li>
                        <li>Patient educated on maintenance therapy</li>
                        <li>VTE prophylaxis plan if prolonged flare</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="tls" class="condition-page">
            <div class="page-header">
                <h2>65. TUMOR LYSIS SYNDROME</h2>
                <div class="subtitle">Oncologic Emergency â€¢ Metabolic Crisis from Tumor Cell Death</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Acute kidney injury, cardiac arrhythmias, seizures, or sudden death in patient with high-burden malignancy within hours-days of starting chemotherapy</p>
                    
                    <p><span class="label">Pathophysiology:</span> Massive tumor cell lysis â†’ release of intracellular contents â†’ hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia â†’ AKI, arrhythmias, seizures</p>
                    
                    <p><span class="label">Clinical Manifestations:</span></p>
                    <ul>
                        <li><strong>Renal:</strong> AKI (most common), oliguria/anuria, fluid overload, uremia. Uric acid and phosphate precipitate in tubules causing obstructive nephropathy</li>
                        <li><strong>Cardiac:</strong> Arrhythmias (peaked T-waves, widened QRS from hyperkalemia), cardiac arrest, QT prolongation (from hypocalcemia), heart failure</li>
                        <li><strong>Neurologic:</strong> Seizures (hypocalcemia), altered mental status, tetany, muscle cramps, paresthesias</li>
                        <li><strong>GI:</strong> Nausea, vomiting, diarrhea, anorexia</li>
                        <li><strong>Neuromuscular:</strong> Weakness, tetany, Chvostek/Trousseau signs (hypocalcemia)</li>
                    </ul>
                    
                    <p><span class="label">High-Risk Malignancies:</span></p>
                    <ul>
                        <li><strong>Highest risk:</strong> Burkitt lymphoma, lymphoblastic leukemia/lymphoma (ALL, T-cell ALL), DLBCL with high tumor burden</li>
                        <li><strong>Moderate-high risk:</strong> AML with WBC >25k (especially M4/M5), CLL, bulky solid tumors responsive to chemo (SCLC, germ cell)</li>
                        <li>Key feature: Rapidly dividing tumors with high proliferation rate and chemo-sensitivity</li>
                    </ul>
                    
                    <p><span class="label">Timing:</span> Usually 12-72 hours after chemotherapy initiation (can be up to 7 days), but can occur spontaneously in high-burden disease</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Cairo-Bishop Classification (Laboratory TLS):</span> â‰¥2 of following metabolic abnormalities within 3 days before or 7 days after chemotherapy:</p>
                    <ul>
                        <li><strong>Hyperuricemia:</strong> Uric acid >8 mg/dL or 25% increase from baseline</li>
                        <li><strong>Hyperkalemia:</strong> K >6 mEq/L or 25% increase</li>
                        <li><strong>Hyperphosphatemia:</strong> Phosphate >4.5 mg/dL (adults) or >6.5 mg/dL (children), or 25% increase</li>
                        <li><strong>Hypocalcemia:</strong> Corrected calcium <7 mg/dL or 25% decrease</li>
                    </ul>
                    
                    <p><span class="label">Clinical TLS:</span> Laboratory TLS PLUS one or more of:</p>
                    <ul>
                        <li>Increased creatinine (â‰¥1.5Ã— ULN or â‰¥1.5Ã— baseline)</li>
                        <li>Cardiac arrhythmia or sudden death</li>
                        <li>Seizure</li>
                    </ul>
                    
                    <p><span class="label">Essential Labs (q4-6h initially):</span></p>
                    <ul>
                        <li><strong>CMP:</strong> BUN, creatinine, potassium, calcium, phosphate</li>
                        <li><strong>Uric acid:</strong> Most sensitive early marker</li>
                        <li><strong>LDH:</strong> Marker of cell turnover (very high in TLS)</li>
                        <li><strong>Magnesium:</strong> Often low</li>
                        <li><strong>CBC:</strong> Track tumor burden (WBC if leukemia)</li>
                        <li><strong>ABG/VBG:</strong> Monitor acid-base status</li>
                    </ul>
                    
                    <p><span class="label">ECG:</span> For hyperkalemia monitoring (peaked T-waves, QRS widening) and hypocalcemia (QT prolongation)</p>
                    <p><span class="label">Urinalysis:</span> Uric acid crystals, phosphate crystals, pH</p>
                    <p><span class="label">Imaging:</span> Renal ultrasound if concern for obstruction</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">PREVENTION (Best Strategy for High-Risk Patients):</span></p>
                    <ul>
                        <li><strong>Aggressive IV hydration:</strong> NS at 200-300 mL/hr (3L/mÂ²/day) starting 24-48 hours BEFORE chemotherapy</li>
                        <li>Goal urine output 80-100 mL/hr (2-3 mL/kg/hr)</li>
                        <li>Continue for 48-72 hours after chemotherapy</li>
                        <li><strong>Avoid:</strong> Alkalinization with sodium bicarbonate (historical practice, no longer recommended - increases calcium phosphate precipitation)</li>
                    </ul>
                    
                    <p><span class="label">Uric Acid Management (Choose ONE):</span></p>
                    <ul>
                        <li><strong>Rasburicase (Elitek) - PREFERRED for high-risk TLS:</strong>
                            <ul>
                                <li>Dose: 0.1-0.2 mg/kg IV Ã— 1 dose (can repeat daily if needed)</li>
                                <li>Recombinant urate oxidase - converts uric acid to allantoin (10Ã— more soluble)</li>
                                <li>Rapidly lowers uric acid within 4 hours</li>
                                <li><strong>Contraindications:</strong> G6PD deficiency (causes severe hemolysis), pregnancy</li>
                                <li>More expensive but much more effective than allopurinol</li>
                            </ul>
                        </li>
                        <li><strong>Allopurinol - For LOW-RISK or prophylaxis:</strong>
                            <ul>
                                <li>Dose: 300 mg PO daily (or 100 mg/mÂ²/dose PO TID, max 800 mg/day)</li>
                                <li>Xanthine oxidase inhibitor - prevents NEW uric acid formation</li>
                                <li>Does NOT treat existing hyperuricemia (takes days to work)</li>
                                <li>Start 1-2 days before chemotherapy</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Electrolyte Management:</span></p>
                    <ul>
                        <li><strong>Hyperkalemia:</strong>
                            <ul>
                                <li>Calcium gluconate 1-2g IV if ECG changes</li>
                                <li>Insulin 10 units + D50 50mL IV</li>
                                <li>Kayexalate 30g PO/PR (slower onset)</li>
                                <li>Albuterol nebs (10-20 mg)</li>
                                <li><strong>Dialysis if refractory or K >6.5 with ECG changes</strong></li>
                            </ul>
                        </li>
                        <li><strong>Hyperphosphatemia:</strong>
                            <ul>
                                <li>Phosphate binders: Sevelamer 800-1600 mg PO TID with meals</li>
                                <li>Avoid calcium-based binders (risk calcium-phosphate precipitation)</li>
                                <li><strong>Dialysis if Phos >10 mg/dL or symptomatic</strong></li>
                            </ul>
                        </li>
                        <li><strong>Hypocalcemia:</strong>
                            <ul>
                                <li><strong>DO NOT give calcium unless symptomatic</strong> (seizures, tetany, severe QTc prolongation >500ms)</li>
                                <li>Giving calcium with high phosphate â†’ calcium-phosphate precipitation in tissues/kidneys</li>
                                <li>If must give: Calcium gluconate 1-2g IV slowly</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Renal Replacement Therapy:</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Refractory hyperkalemia (K >6.5), severe hyperphosphatemia (>10), volume overload, uremia, oliguria/anuria, acidosis</li>
                        <li><strong>CRRT preferred over HD:</strong> Continuous veno-venous hemofiltration (CVVH) or hemodialysis (CVVHD) for better hemodynamic stability</li>
                        <li>Intermittent HD acceptable if CRRT unavailable</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Prevention >>> Treatment:</strong> Identify high-risk patients BEFORE chemo and start aggressive hydration + rasburicase prophylactically</li>
                    <li><strong>Rasburicase black box:</strong> Must screen for G6PD deficiency before giving. Causes catastrophic hemolysis in G6PD patients</li>
                    <li><strong>Don't treat asymptomatic hypocalcemia:</strong> Giving calcium with high phosphate causes soft tissue calcification and worsens renal injury</li>
                    <li><strong>LDH as surrogate:</strong> Very high LDH (>2-3Ã— ULN) suggests massive tumor burden and high TLS risk</li>
                    <li><strong>Uric acid sampling artifact:</strong> If using rasburicase, must place specimen on ice immediately - sample continues to degrade uric acid ex vivo at room temp (falsely low)</li>
                    <li><strong>Alkalinization outdated:</strong> No longer recommended - historical practice. Increases calcium-phosphate precipitation</li>
                    <li><strong>TLS can occur spontaneously:</strong> Very high-burden tumors (Burkitt, ALL) can cause TLS even before chemotherapy starts</li>
                    <li><strong>Rasburicase Ã— 1 often sufficient:</strong> Single dose usually adequate due to long half-life (~16-20 hours)</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe hyperkalemia (K >6.5) with ECG changes</li>
                        <li>Cardiac arrhythmias</li>
                        <li>Seizures or altered mental status</li>
                        <li>Oliguric/anuric AKI requiring dialysis</li>
                        <li>Fluid overload with respiratory compromise</li>
                        <li>Need for CRRT/emergent HD</li>
                        <li>Rapidly worsening labs despite treatment</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Labs normalizing or stable (K <5.5, Phos <5, Uric acid <8, Ca >7.5)</li>
                        <li>Creatinine downtrending or at new baseline</li>
                        <li>Adequate urine output maintained</li>
                        <li>No cardiac arrhythmias</li>
                        <li>Tolerating PO (for oral phosphate binders)</li>
                        <li>Close oncology and nephrology follow-up arranged</li>
                        <li>Patient/family education on TLS monitoring</li>
                        <li>Consider if ongoing chemotherapy cycles planned</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="thrombocytopenia" class="condition-page">
            <div class="page-header">
                <h2>66. THROMBOCYTOPENIA (ITP, HIT, TTP/HUS)</h2>
                <div class="subtitle">Low Platelets â€¢ Bleeding Risk vs Thrombotic Risk</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Clinical Context is KEY to Diagnosis:</span> Platelets <150k/ÂµL, presentation varies by etiology</p>
                    
                    <p><span class="label">IMMUNE THROMBOCYTOPENIA (ITP) - Primary Platelet Destruction:</span></p>
                    <ul>
                        <li><strong>Classic patient:</strong> Otherwise healthy young adult (20-40s) or child presenting with isolated thrombocytopenia</li>
                        <li><strong>Presentation:</strong> Petechiae, purpura, mucosal bleeding (epistaxis, gingival bleeding), menorrhagia. Major bleeding rare unless platelets <10-20k</li>
                        <li><strong>Key features:</strong> NO other cytopenias, NO splenomegaly, patient feels well otherwise</li>
                        <li><strong>Diagnosis of exclusion:</strong> Must rule out other causes (HIV, HCV, H. pylori, SLE, drugs, bone marrow disorders)</li>
                    </ul>
                    
                    <p><span class="label">HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) - Prothrombotic Emergency:</span></p>
                    <ul>
                        <li><strong>Timing:</strong> Platelets drop 5-10 days after heparin exposure (any dose, any route including flushes!) OR <24 hours if recent heparin exposure (<100 days ago)</li>
                        <li><strong>Classic drop:</strong> Platelets fall >50% from baseline OR absolute count <150k</li>
                        <li><strong>ðŸš¨ PARADOX:</strong> Despite low platelets, HIGH risk of THROMBOSIS (30-50%), NOT bleeding!</li>
                        <li><strong>Thrombotic complications:</strong>
                            <ul>
                                <li>DVT/PE (most common)</li>
                                <li>Arterial thrombosis: Stroke, MI, limb ischemia, mesenteric ischemia</li>
                                <li>Skin necrosis at injection sites</li>
                                <li>Adrenal hemorrhage/infarction</li>
                            </ul>
                        </li>
                        <li><strong>4 T's Score:</strong> Thrombocytopenia, Timing, Thrombosis, oTher causes (use to assess pre-test probability)</li>
                    </ul>
                    
                    <p><span class="label">THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - Hematologic Emergency:</span></p>
                    <ul>
                        <li><strong>Classic pentad (only 40% have all 5):</strong>
                            <ul>
                                <li>Thrombocytopenia (100%)</li>
                                <li>Microangiopathic hemolytic anemia with schistocytes (100%)</li>
                                <li>Neurologic symptoms (60%): Confusion, headache, seizures, stroke, fluctuating mental status</li>
                                <li>Renal dysfunction (40%): Elevated Cr, hematuria, proteinuria</li>
                                <li>Fever (20%)</li>
                            </ul>
                        </li>
                        <li><strong>Key features:</strong> MAHA (schistocytes on smear) + thrombocytopenia + neuro symptoms = TTP until proven otherwise</li>
                        <li><strong>Demographics:</strong> Black females > others, age 30-40s</li>
                    </ul>
                    
                    <p><span class="label">HEMOLYTIC UREMIC SYNDROME (HUS) - TTP's Renal Cousin:</span></p>
                    <ul>
                        <li><strong>Triad:</strong> MAHA + thrombocytopenia + AKI (dominant feature)</li>
                        <li><strong>Classic (Shiga toxin-producing E. coli, STEC-HUS):</strong> Follows bloody diarrhea (E. coli O157:H7), predominantly affects children</li>
                        <li><strong>Atypical (aHUS):</strong> Complement-mediated, can occur at any age, more severe, worse prognosis</li>
                        <li>Less prominent neurologic symptoms than TTP</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Essential Labs for ALL:</span></p>
                    <ul>
                        <li><strong>CBC with diff and peripheral smear:</strong> Look for schistocytes (TTP/HUS), large platelets (ITP), other cytopenias</li>
                        <li><strong>Reticulocyte count:</strong> Elevated in hemolysis</li>
                        <li><strong>LDH:</strong> Markedly elevated in TTP/HUS (>1000), mildly elevated in ITP</li>
                        <li><strong>Haptoglobin:</strong> Low/undetectable in hemolysis</li>
                        <li><strong>Indirect bilirubin:</strong> Elevated in hemolysis</li>
                        <li><strong>Direct Coombs (DAT):</strong> Negative in TTP/HUS (confirms MAHA), positive in AIHA</li>
                        <li><strong>PT/PTT, fibrinogen:</strong> Normal in ITP/HIT/TTP (helps exclude DIC)</li>
                        <li><strong>BMP, Cr:</strong> Renal function</li>
                    </ul>
                    
                    <p><span class="label">ITP-Specific Workup:</span></p>
                    <ul>
                        <li>HIV, HCV, H. pylori testing</li>
                        <li>ANA, direct Coombs (exclude SLE, Evans syndrome)</li>
                        <li>TSH (associated autoimmune thyroid disease)</li>
                        <li><strong>Bone marrow biopsy:</strong> Consider if age >60, atypical features, failed to respond to steroids</li>
                    </ul>
                    
                    <p><span class="label">HIT-Specific Workup:</span></p>
                    <ul>
                        <li><strong>PF4 antibody (HIT antibody):</strong> High sensitivity (~95%) but poor specificity. Positive = confirms exposure, not necessarily disease</li>
                        <li><strong>Serotonin release assay (SRA):</strong> Gold standard, high specificity but not widely available</li>
                        <li><strong>Timing and clinical context often diagnostic</strong> - don't wait for antibody to act</li>
                        <li><strong>Doppler ultrasound:</strong> Screen for DVT even if asymptomatic</li>
                    </ul>
                    
                    <p><span class="label">TTP/HUS-Specific Workup:</span></p>
                    <ul>
                        <li><strong>ADAMTS13 activity:</strong> <10% diagnostic of TTP (send before plasmapheresis but don't wait for results)</li>
                        <li><strong>Stool culture/Shiga toxin PCR:</strong> For STEC-HUS</li>
                        <li><strong>Complement levels:</strong> For atypical HUS (low C3, C4, factor H)</li>
                        <li><strong>Urinalysis:</strong> Hematuria, proteinuria, RBC casts</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">IMMUNE THROMBOCYTOPENIA (ITP):</span></p>
                    <ul>
                        <li><strong>Treat if:</strong> Platelets <30k OR any bleeding OR high-risk patient (elderly, on anticoagulation)</li>
                        <li><strong>First-line:</strong>
                            <ul>
                                <li><strong>Corticosteroids:</strong> Prednisone 1 mg/kg/day (40-60 mg) Ã— 2-4 weeks, then taper OR Dexamethasone 40 mg PO daily Ã— 4 days</li>
                                <li>Â± <strong>IVIG:</strong> 1 g/kg IV Ã— 1-2 days (faster response, use if severe bleeding or high-risk)</li>
                            </ul>
                        </li>
                        <li><strong>Second-line (steroid-refractory):</strong> Rituximab, thrombopoietin receptor agonists (eltrombopag, romiplostim), splenectomy</li>
                        <li><strong>Platelet transfusions:</strong> Avoid unless life-threatening bleeding (will be consumed rapidly but may provide temporary hemostasis)</li>
                        <li><strong>If H. pylori positive:</strong> Eradication improves platelets in 50% of cases</li>
                    </ul>
                    
                    <p><span class="label">HEPARIN-INDUCED THROMBOCYTOPENIA (HIT):</span></p>
                    <ul>
                        <li><strong>ðŸš¨ IMMEDIATE ACTIONS:</strong>
                            <ul>
                                <li><strong>STOP ALL HEPARIN:</strong> IV, SC, flushes, heparin-coated catheters</li>
                                <li><strong>DO NOT give platelet transfusions</strong> (increases thrombosis risk)</li>
                                <li><strong>START alternative anticoagulation IMMEDIATELY</strong> (even without confirmed thrombosis - 30-50% will develop clots)</li>
                            </ul>
                        </li>
                        <li><strong>Alternative Anticoagulants (Choose ONE):</strong>
                            <ul>
                                <li><strong>Argatroban (preferred if hepatic/renal impairment):</strong> Direct thrombin inhibitor, start 2 mcg/kg/min, adjust to aPTT 1.5-3Ã— baseline</li>
                                <li><strong>Bivalirudin:</strong> Direct thrombin inhibitor, 0.15-0.2 mg/kg/hr</li>
                                <li><strong>Fondaparinux:</strong> 5-10 mg SC daily (based on weight), indirect Xa inhibitor</li>
                                <li><strong>DOACs (apixaban, rivaroxaban):</strong> Increasing evidence for use, easier to dose</li>
                            </ul>
                        </li>
                        <li><strong>Duration:</strong> Anticoagulate for â‰¥3 months (longer if thrombosis occurred)</li>
                        <li><strong>Warfarin:</strong> DO NOT start until platelets >150k and overlap with argatroban/bivalirudin for 5 days (risk of warfarin-induced limb gangrene)</li>
                        <li><strong>Future surgeries:</strong> Can use bivalirudin for cardiac surgery, AVOID all heparin products forever</li>
                    </ul>
                    
                    <p><span class="label">THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP):</span></p>
                    <ul>
                        <li><strong>ðŸš¨ THIS IS A MEDICAL EMERGENCY - >90% mortality if untreated!</strong></li>
                        <li><strong>URGENT PLASMAPHERESIS (Plasma Exchange):</strong>
                            <ul>
                                <li>Start immediately, within hours of diagnosis (don't wait for ADAMTS13)</li>
                                <li>Daily treatments (1-1.5 plasma volumes) until platelets normalize and LDH normalizes</li>
                                <li>Average duration: 5-7 days</li>
                                <li>Replaces missing ADAMTS13 enzyme</li>
                            </ul>
                        </li>
                        <li><strong>Caplacizumab:</strong> Anti-vWF antibody, 10 mg IV bolus before first PLEX, then 10 mg SC daily. Reduces time to platelet recovery</li>
                        <li><strong>Corticosteroids:</strong> Prednisone 1 mg/kg daily or methylprednisolone 1g IV daily Ã— 3 days</li>
                        <li><strong>Rituximab:</strong> For acquired TTP or refractory cases, 375 mg/mÂ² weekly Ã— 4</li>
                        <li><strong>Platelet transfusions CONTRAINDICATED:</strong> Can worsen thrombosis (except life-threatening bleeding)</li>
                        <li><strong>Red cell transfusions:</strong> OK if symptomatic anemia</li>
                    </ul>
                    
                    <p><span class="label">HEMOLYTIC UREMIC SYNDROME (HUS):</span></p>
                    <ul>
                        <li><strong>STEC-HUS (E. coli):</strong> Supportive care (hydration, dialysis if needed). Usually self-limited in children. <strong>NO antibiotics</strong> (may worsen by increasing toxin release)</li>
                        <li><strong>Atypical HUS:</strong> Eculizumab (complement C5 inhibitor), 900 mg weekly Ã— 4, then 1200 mg q2 weeks. Must vaccinate for meningococcus first (if time permits)</li>
                        <li><strong>Plasma exchange:</strong> Less effective than for TTP but consider in severe atypical HUS</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>MAHA + thrombocytopenia = TTP until proven otherwise:</strong> Start plasmapheresis emergently. >90% mortality if untreated</li>
                    <li><strong>HIT is prothrombotic, not bleeding:</strong> Paradoxically, low platelets cause clots, not bleeding. STOP heparin and START alternative anticoagulation immediately</li>
                    <li><strong>ITP is diagnosis of exclusion:</strong> Must rule out HIV, HCV, SLE, drugs, marrow disorders. Otherwise healthy patient with isolated low platelets</li>
                    <li><strong>Schistocytes = MAHA hallmark:</strong> Present in TTP, HUS, DIC, HELLP. Indicates RBC fragmentation from microvascular thrombi</li>
                    <li><strong>Never give platelets in TTP/HIT:</strong> Worsens thrombosis ("fuel for the fire")</li>
                    <li><strong>ADAMTS13 <10% = TTP:</strong> But don't wait for results - treat empirically if clinical suspicion. Takes days to result</li>
                    <li><strong>HIT 4 T's score:</strong> High score (â‰¥6) = ~50% probability of HIT. Low score (<4) = <5% probability. Helps guide testing</li>
                    <li><strong>ITP platelet goal:</strong> Treat to prevent bleeding, NOT to normalize counts. Goal >30k, not >150k</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li><strong>TTP:</strong> All patients until stable</li>
                        <li>Major bleeding (ICH, GI bleed)</li>
                        <li>Neurologic deterioration (TTP)</li>
                        <li>Severe AKI requiring dialysis (HUS)</li>
                        <li>HIT with arterial thrombosis (stroke, limb ischemia, MI)</li>
                        <li>ITP with platelets <10k and bleeding</li>
                        <li>Requiring plasmapheresis</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li><strong>ITP:</strong> Platelets >30k (or >50k if high bleeding risk), no active bleeding, tolerating oral steroids, heme f/u arranged</li>
                        <li><strong>HIT:</strong> Platelets >150k, on therapeutic alternative anticoagulation, no thrombosis, transitioned to warfarin/DOAC if appropriate</li>
                        <li><strong>TTP:</strong> Platelets normalized, LDH normalized, no neuro symptoms, completed PLEX course, heme f/u</li>
                        <li><strong>HUS:</strong> Cr improving/stable, no dialysis need, hemolysis resolving</li>
                        <li>Patient educated on avoiding triggers</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="dic" class="condition-page">
            <div class="page-header">
                <h2>67. DISSEMINATED INTRAVASCULAR COAGULATION (DIC)</h2>
                <div class="subtitle">Consumptive Coagulopathy â€¢ Thrombosis + Bleeding</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Bleeding (oozing from IV sites, venipuncture, mucosal bleeding, petechiae, ecchymoses) AND thrombosis (digital ischemia, renal failure, ARDS, stroke) in critically ill patient</p>
                    
                    <p><span class="label">Spectrum:</span></p>
                    <ul>
                        <li><strong>Acute DIC (decompensated):</strong> Severe bleeding Â± thrombosis, rapid onset, life-threatening</li>
                        <li><strong>Chronic DIC (compensated):</strong> Mild symptoms, often thrombotic >bleeding, seen in malignancy</li>
                    </ul>
                    
                    <p><span class="label">Clinical Features:</span></p>
                    <ul>
                        <li><strong>Bleeding (dominant in acute DIC):</strong> Diffuse petechiae, purpura, oozing from wounds/IV sites/mucosa, GI bleed, intracranial hemorrhage</li>
                        <li><strong>Thrombosis (microvascular):</strong> Digital/acral ischemia, renal failure, ARDS, hepatic dysfunction, altered mental status</li>
                        <li><strong>Multi-organ dysfunction:</strong> Due to microvascular thrombosis</li>
                    </ul>
                    
                    <p><span class="label">Common Underlying Causes (ALWAYS present):</span></p>
                    <ul>
                        <li><strong>Sepsis (most common):</strong> Gram-negative>gram-positive, especially meningococcemia</li>
                        <li><strong>Trauma:</strong> Massive tissue injury, burns, head trauma, crush injury</li>
                        <li><strong>Obstetric:</strong> Placental abruption, amniotic fluid embolism, retained dead fetus, HELLP syndrome</li>
                        <li><strong>Malignancy:</strong> Acute promyelocytic leukemia (APL), adenocarcinomas (pancreas, prostate, lung), mucin-producing tumors</li>
                        <li><strong>Vascular:</strong> Giant hemangioma (Kasabach-Merritt), aortic aneurysm, large vessel malformations</li>
                        <li><strong>Toxic:</strong> Snake venom, drug reactions, transfusion reactions</li>
                        <li><strong>Immunologic:</strong> Severe allergic reactions, ABO-incompatible transfusion</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">DIC Score (ISTH Criteria) - Score â‰¥5 = overt DIC:</span></p>
                    <ul>
                        <li><strong>Platelets:</strong> >100k (0 pts), 50-100k (1 pt), <50k (2 pts)</li>
                        <li><strong>D-dimer:</strong> No increase (0), moderate increase (2), strong increase (3)</li>
                        <li><strong>PT prolongation:</strong> <3 sec (0), 3-6 sec (1), >6 sec (2)</li>
                        <li><strong>Fibrinogen:</strong> >100 mg/dL (0), <100 mg/dL (1)</li>
                    </ul>
                    
                    <p><span class="label">Laboratory Findings (Typical Pattern):</span></p>
                    <ul>
                        <li><strong>Thrombocytopenia:</strong> Progressive decline, often <100k (hallmark finding)</li>
                        <li><strong>PT/PTT prolonged:</strong> Due to consumption of clotting factors</li>
                        <li><strong>Fibrinogen LOW:</strong> Usually <100 mg/dL (but can be normal initially as it's an acute phase reactant)</li>
                        <li><strong>D-dimer VERY elevated:</strong> Markedly increased (>10Ã— normal), indicates fibrinolysis</li>
                        <li><strong>Peripheral smear:</strong> Schistocytes (fragmented RBCs) present in 50% - suggests microangiopathic hemolytic anemia</li>
                        <li><strong>Factor levels LOW:</strong> Factors II, V, VIII, X consumed (rarely checked)</li>
                    </ul>
                    
                    <p><span class="label">Essential Labs:</span> CBC with diff, PT/INR, PTT, fibrinogen, D-dimer, peripheral smear, LDH, haptoglobin (hemolysis), DIC panel</p>
                    <p><span class="label">Identify Underlying Cause:</span> Blood cultures, imaging for trauma/malignancy, pregnancy test, evaluate for sepsis source</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">ðŸŽ¯ TREAT THE UNDERLYING CAUSE - This is PRIMARY therapy:</span></p>
                    <ul>
                        <li>Broad-spectrum antibiotics for sepsis</li>
                        <li>Delivery of fetus/placenta in obstetric emergencies</li>
                        <li>Chemotherapy for APL (all-trans retinoic acid)</li>
                        <li>Source control for trauma/surgery</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li>Aggressive hemodynamic support</li>
                        <li>Maintain tissue perfusion and oxygenation</li>
                        <li>Avoid unnecessary procedures/lines if possible</li>
                    </ul>
                    
                    <p><span class="label">Blood Product Replacement (Threshold-Based):</span></p>
                    <ul>
                        <li><strong>Platelets:</strong>
                            <ul>
                                <li>Transfuse if <10-20k (spontaneous bleeding risk)</li>
                                <li>OR <50k with active bleeding or planned procedure</li>
                                <li>Goal: Keep >50k if active bleeding</li>
                                <li>Give 1 apheresis unit or 4-6 units pooled platelets</li>
                            </ul>
                        </li>
                        <li><strong>FFP (Fresh Frozen Plasma):</strong>
                            <ul>
                                <li>If PT/PTT >1.5Ã— normal AND active bleeding or planned procedure</li>
                                <li>Dose: 15-20 mL/kg (typically 4 units for adults)</li>
                                <li>Replaces all clotting factors</li>
                            </ul>
                        </li>
                        <li><strong>Cryoprecipitate:</strong>
                            <ul>
                                <li>If fibrinogen <100 mg/dL AND active bleeding</li>
                                <li>Dose: 10 units (1 unit raises fibrinogen ~5-10 mg/dL)</li>
                                <li>Goal fibrinogen >100-150 mg/dL</li>
                            </ul>
                        </li>
                        <li><strong>PRBCs:</strong> Transfuse for symptomatic anemia or Hgb <7 g/dL</li>
                    </ul>
                    
                    <p><span class="label">Anticoagulation (Controversial, Limited Indications):</span></p>
                    <ul>
                        <li><strong>NOT routinely recommended</strong> in most DIC</li>
                        <li><strong>Consider heparin ONLY IF:</strong>
                            <ul>
                                <li>Chronic/compensated DIC with thrombosis (e.g., cancer-associated)</li>
                                <li>Acral ischemia with threatened limb loss</li>
                                <li>Purpura fulminans</li>
                            </ul>
                        </li>
                        <li>Dose: Unfractionated heparin 300-500 units/hr (no bolus) OR prophylactic LMWH</li>
                        <li><strong>Contraindications:</strong> Active major bleeding, intracranial hemorrhage, severe thrombocytopenia (<20k)</li>
                    </ul>
                    
                    <p><span class="label">Antifibrinolytics (Generally AVOID):</span></p>
                    <ul>
                        <li>Tranexamic acid/aminocaproic acid usually contraindicated</li>
                        <li>May worsen thrombosis</li>
                        <li>Exception: APL with severe hyperfibrinolysis (rare)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>DIC is NEVER a primary diagnosis:</strong> Always find and treat the underlying cause. DIC won't resolve until the trigger is addressed</li>
                    <li><strong>Lab pattern:</strong> â†“Plts + â†“Fibrinogen + â†‘D-dimer + â†‘PT/PTT = classic DIC tetrad</li>
                    <li><strong>Fibrinogen paradox:</strong> Can be normal/elevated early (acute phase reactant) - serial monitoring shows TREND down</li>
                    <li><strong>Schistocytes â‰  mandatory:</strong> Only 50% have schistocytes. Absence doesn't exclude DIC</li>
                    <li><strong>Don't chase numbers blindly:</strong> Transfuse based on clinical bleeding + thresholds, not just to normalize labs</li>
                    <li><strong>APL = special case:</strong> High risk of DIC at diagnosis. Start ATRA immediately, supportive with aggressive platelet/cryoprecipitate transfusions</li>
                    <li><strong>Heparin paradox:</strong> Despite being a clotting disorder, anticoagulation rarely helps and often harms</li>
                    <li><strong>Mortality high:</strong> 30-50% depending on cause. Septic DIC has worst prognosis</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Active major bleeding (GI, ICH, pulmonary)</li>
                        <li>Severe thrombocytopenia (<20k)</li>
                        <li>Multi-organ dysfunction (ARDS, AKI, altered mental status)</li>
                        <li>Refractory hypotension/shock</li>
                        <li>Requiring massive transfusion</li>
                        <li>Septic shock with DIC</li>
                        <li>Rapidly progressive coagulopathy</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li><strong>Unlikely for acute DIC</strong> - usually requires ICU-level care</li>
                        <li>For chronic/compensated DIC:</li>
                        <li>Underlying cause identified and treated</li>
                        <li>No active bleeding</li>
                        <li>Stable platelet count (>50k trending up)</li>
                        <li>Coagulation parameters improving</li>
                        <li>Hematology follow-up arranged</li>
                        <li>If malignancy-related: oncology follow-up</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="gout" class="condition-page">
            <div class="page-header">
                <h2>68. ACUTE GOUT/PSEUDOGOUT (CRYSTAL ARTHROPATHY)</h2>
                <div class="subtitle">Acute Monoarticular Arthritis â€¢ Crystal-Induced Synovitis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Acute-onset severe monoarticular joint pain, erythema, warmth, and swelling (develops over 6-12 hours) with exquisite tenderness and limited range of motion</p>
                    
                    <p><span class="label">GOUT (Monosodium Urate Crystals):</span></p>
                    <ul>
                        <li><strong>Most affected joints:</strong> 1st MTP joint (podagra - 50% of first attacks), midfoot, ankle, knee</li>
                        <li><strong>Presentation:</strong> "Worst pain of my life," cannot tolerate even bedsheet touching joint, pain peaks at 24 hours</li>
                        <li><strong>Timing:</strong> Often overnight/early morning, awakens patient from sleep</li>
                        <li><strong>Appearance:</strong> Red, hot, swollen, shiny skin over joint</li>
                        <li><strong>Chronic findings:</strong> Tophi (firm subcutaneous nodules) on ears, elbows, fingers, Achilles tendon</li>
                        <li><strong>Risk factors:</strong> Hyperuricemia (>7 mg/dL), obesity, HTN, CKD, diuretics, alcohol (beer), high purine diet (red meat, seafood)</li>
                        <li><strong>Precipitants:</strong> Surgery, acute illness, dehydration, alcohol binge, starting allopurinol/febuxostat</li>
                    </ul>
                    
                    <p><span class="label">PSEUDOGOUT (Calcium Pyrophosphate Deposition - CPPD):</span></p>
                    <ul>
                        <li><strong>Most affected joints:</strong> Knee (50%), wrist, shoulder, ankle</li>
                        <li><strong>Presentation:</strong> Similar to gout but often less severe, longer duration (days-weeks vs hours-days)</li>
                        <li><strong>Demographics:</strong> Elderly patients (>65 years), more common in women</li>
                        <li><strong>Associated conditions:</strong> Hyperparathyroidism, hemochromatosis, hypomagnesemia, hypothyroidism</li>
                        <li><strong>Chronic:</strong> Chondrocalcinosis on X-ray (calcium deposition in cartilage)</li>
                    </ul>
                    
                    <p><span class="label">Important:</span> Can mimic septic arthritis! Must differentiate. Consider septic arthritis if fever >39Â°C, systemic toxicity, immunocompromised, prosthetic joint</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">ðŸŽ¯ GOLD STANDARD: Arthrocentesis with Synovial Fluid Analysis</span></p>
                    <ul>
                        <li><strong>ALWAYS PERFORM if:</strong> First attack, uncertain diagnosis, concern for septic arthritis, fever, immunocompromised</li>
                        <li><strong>Safe to tap even on anticoagulation:</strong> Benefit >> risk</li>
                    </ul>
                    
                    <p><span class="label">Synovial Fluid Analysis:</span></p>
                    <ul>
                        <li><strong>Crystal analysis (polarized microscopy - DIAGNOSTIC):</strong>
                            <ul>
                                <li><strong>Gout:</strong> Needle-shaped, negatively birefringent (yellow under parallel light), intracellular and extracellular</li>
                                <li><strong>Pseudogout:</strong> Rhomboid-shaped, positively birefringent (blue under parallel light), often weakly birefringent</li>
                            </ul>
                        </li>
                        <li><strong>Cell count:</strong> WBC typically 20,000-100,000/ÂµL (inflammatory), predominantly PMNs (>80%)</li>
                        <li><strong>Gram stain and culture:</strong> MUST send to rule out septic arthritis (can coexist with gout ~5%!)</li>
                        <li><strong>Appearance:</strong> Cloudy to purulent</li>
                    </ul>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>Serum uric acid:</strong> Often elevated (>7 mg/dL) BUT can be normal during acute attack in 30-40%! Do NOT use to rule in/out</li>
                        <li><strong>CBC:</strong> May have mild leukocytosis (10-15k)</li>
                        <li><strong>CRP/ESR:</strong> Elevated (non-specific inflammatory markers)</li>
                        <li><strong>BMP:</strong> Check renal function before NSAIDs/colchicine</li>
                        <li><strong>For pseudogout:</strong> Calcium, phosphate, magnesium, PTH, TSH, iron studies (if <50 years old)</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>X-ray of affected joint:</strong>
                            <ul>
                                <li>Gout (chronic): Punched-out erosions with overhanging edges, soft tissue tophi</li>
                                <li>Pseudogout: Chondrocalcinosis (linear calcium in cartilage, "meniscus sign" in knee)</li>
                                <li>May be normal in acute flare</li>
                            </ul>
                        </li>
                        <li><strong>Ultrasound:</strong> Can show "double contour sign" (urate deposition on cartilage) - sensitive for gout</li>
                        <li><strong>Consider MRI:</strong> If concern for septic arthritis, osteomyelitis</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Acute Attack Treatment (Choose ONE anti-inflammatory):</span></p>
                    
                    <p><span class="label">Option 1: NSAIDs (First-line if no contraindications):</span></p>
                    <ul>
                        <li><strong>Indomethacin:</strong> 50 mg PO TID Ã— 2-3 days, then 25 mg TID until resolved (traditional choice)</li>
                        <li><strong>Naproxen:</strong> 500 mg PO BID</li>
                        <li><strong>Ibuprofen:</strong> 800 mg PO TID</li>
                        <li>Use for 5-7 days or until 1-2 days after complete resolution</li>
                        <li><strong>Contraindications:</strong> CKD (Cr >1.5), active PUD, heart failure, on anticoagulation</li>
                        <li>Add PPI for gastric protection</li>
                    </ul>
                    
                    <p><span class="label">Option 2: Colchicine (Effective if started within 36 hours of attack):</span></p>
                    <ul>
                        <li><strong>Loading dose:</strong> 1.2 mg PO, then 0.6 mg 1 hour later (total 1.8 mg day 1)</li>
                        <li><strong>Maintenance:</strong> 0.6 mg PO BID or daily until resolved</li>
                        <li><strong>Side effects:</strong> Diarrhea (dose-limiting), nausea - very common. GI symptoms often as bad as gout!</li>
                        <li><strong>Dose reduction needed:</strong> CKD (0.3-0.6 mg daily), hepatic impairment</li>
                        <li><strong>Interactions:</strong> Avoid with strong CYP3A4 inhibitors (clarithromycin, cyclosporine - risk of toxicity)</li>
                    </ul>
                    
                    <p><span class="label">Option 3: Corticosteroids (If NSAIDs/colchicine contraindicated):</span></p>
                    <ul>
                        <li><strong>Intra-articular injection (preferred for monoarticular):</strong>
                            <ul>
                                <li>Triamcinolone 40 mg for large joints (knee, shoulder)</li>
                                <li>20 mg for medium joints, 10 mg for small joints</li>
                                <li>Dramatic improvement within 24-48 hours</li>
                                <li>Must rule out septic arthritis first!</li>
                            </ul>
                        </li>
                        <li><strong>Systemic steroids:</strong>
                            <ul>
                                <li>Prednisone 30-40 mg PO daily Ã— 5-7 days (can taper over 10-14 days)</li>
                                <li>OR Methylprednisolone 100-150 mg IM Ã— 1</li>
                                <li>Good for polyarticular gout or when IA injection not feasible</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Adjunct Therapy:</span></p>
                    <ul>
                        <li><strong>Ice packs:</strong> 15-20 minutes several times daily</li>
                        <li><strong>Rest and elevation:</strong> Avoid weight-bearing on affected joint</li>
                        <li><strong>Adequate hydration:</strong> Helps uric acid excretion</li>
                    </ul>
                    
                    <p><span class="label">âš ï¸ DO NOT Start Uric Acid-Lowering Therapy (Allopurinol/Febuxostat) During Acute Attack:</span></p>
                    <ul>
                        <li>Will prolong or worsen acute flare</li>
                        <li><strong>Wait 2-4 weeks after flare resolves</strong></li>
                        <li><strong>If already on ULT:</strong> Continue it (don't stop)</li>
                        <li>When starting ULT: Always give prophylactic colchicine 0.6 mg daily Ã— 3-6 months to prevent flares</li>
                    </ul>
                    
                    <p><span class="label">Long-Term Management (Outpatient):</span></p>
                    <ul>
                        <li><strong>Indications for ULT:</strong> â‰¥2 attacks/year, tophi, chronic kidney disease, uric acid >9 mg/dL, urolithiasis</li>
                        <li><strong>Allopurinol:</strong> Start 100 mg daily, titrate up by 100 mg q2-4 weeks to goal uric acid <6 mg/dL (max 800 mg/day)</li>
                        <li><strong>Febuxostat:</strong> 40-80 mg daily (more expensive, alternative if allopurinol intolerant)</li>
                        <li><strong>Lifestyle:</strong> Weight loss, limit alcohol (especially beer), reduce red meat/seafood, stay hydrated</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Normal uric acid â‰  excludes gout:</strong> 30-40% have normal levels during acute attack due to uricosuria. Diagnosis is by crystals, not serum uric acid</li>
                    <li><strong>Tap before you treat:</strong> If first attack or uncertain diagnosis, arthrocentesis is essential. Septic arthritis can coexist with gout</li>
                    <li><strong>Never start allopurinol during flare:</strong> Will worsen/prolong attack. Wait until 2-4 weeks after resolution. But if already on it, continue</li>
                    <li><strong>Colchicine dosing changed:</strong> Old regimen (1.2 mg then 0.6 mg q1h) caused terrible diarrhea. New low-dose regimen (1.8 mg total day 1) equally effective with fewer GI side effects</li>
                    <li><strong>Intra-articular steroids are magic:</strong> Work fast (24-48h), avoid systemic effects, excellent for monoarticular flares. But must rule out infection first!</li>
                    <li><strong>Uric acid >9 = always treat:</strong> These patients will have recurrent attacks. Need chronic ULT</li>
                    <li><strong>Diuretics = gout trigger:</strong> Especially thiazides and loops. Cause uric acid retention. Consider stopping if recurrent gout</li>
                    <li><strong>Pseudogout in elderly:</strong> Think CPPD if knee arthritis in 70+ year old, especially women. X-ray shows chondrocalcinosis</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Septic arthritis cannot be ruled out with high clinical suspicion</li>
                        <li>Polyarticular flare with systemic toxicity</li>
                        <li>Severe pain refractory to multiple therapies</li>
                        <li><strong>Most gout patients do NOT need ICU</strong></li>
                        <li>Consider admission to floor for IV steroids if:</li>
                        <li>- Unable to take PO medications</li>
                        <li>- Failed outpatient management</li>
                        <li>- Severe polyarticular disease</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Pain controlled with oral medications</li>
                        <li>Septic arthritis excluded (if tapped)</li>
                        <li>Able to ambulate (or baseline mobility)</li>
                        <li>Discharge prescriptions:</li>
                        <li>- NSAID OR colchicine OR prednisone Ã— 5-7 days</li>
                        <li>- PPI if on NSAID</li>
                        <li>- Pain control (avoid opioids if possible)</li>
                        <li>Rheumatology or PCP follow-up in 2-4 weeks</li>
                        <li>Discussed avoiding ULT initiation until flare resolves</li>
                        <li>Lifestyle modifications reviewed</li>
                    </ul>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#colchicine" style="color: #8e44ad;">ðŸ’Š Colchicine</a>, <a href="drug_reference_guide.html#gout" style="color: #8e44ad;">ðŸ’Š Gout Medications</a>, <a href="drug_reference_guide.html#prednisone" style="color: #8e44ad;">ðŸ’Š Prednisone</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="anaphylaxis" class="condition-page">
            <div class="page-header">
                <h2>69. ANAPHYLAXIS</h2>
                <div class="subtitle">Systemic Type I Hypersensitivity â€¢ Life-Threatening Allergic Reaction</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> Acute-onset (<2 hours) involving â‰¥2 organ systems: skin/mucosa + respiratory/cardiovascular/GI</p>
                    <p><span class="label">Diagnostic Criteria (any ONE):</span></p>
                    <ul>
                        <li><strong>Criterion 1:</strong> Acute onset (minutes-hours) with skin/mucosa involvement PLUS â‰¥1 of: respiratory compromise OR hypotension/end-organ dysfunction</li>
                        <li><strong>Criterion 2:</strong> â‰¥2 of following after likely allergen exposure: skin/mucosa, respiratory compromise, hypotension, GI symptoms</li>
                        <li><strong>Criterion 3:</strong> Hypotension after exposure to KNOWN allergen</li>
                    </ul>
                    
                    <p><span class="label">Organ System Manifestations:</span></p>
                    <ul>
                        <li><strong>Skin (80-90%):</strong> Urticaria, pruritus, flushing, angioedema (lips, tongue, uvula). Note: 10-20% have NO skin findings!</li>
                        <li><strong>Respiratory (70%):</strong> Dyspnea, wheeze, stridor, throat tightness, hoarseness, cough. Upper airway edema can be LETHAL</li>
                        <li><strong>Cardiovascular (30-35%):</strong> Hypotension, tachycardia, dizziness, syncope, chest pain, cardiac arrest</li>
                        <li><strong>GI (25-30%):</strong> Nausea, vomiting, diarrhea, cramping abdominal pain</li>
                        <li><strong>Neurologic:</strong> Altered mental status, confusion, "sense of impending doom"</li>
                    </ul>
                    
                    <p><span class="label">Common Triggers:</span> Foods (peanuts, tree nuts, shellfish, fish), medications (Î²-lactams, NSAIDs, chemotherapy), venoms (Hymenoptera), radiocontrast, latex</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis:</span> Do NOT delay treatment for diagnostic testing! Anaphylaxis is a CLINICAL diagnosis</p>
                    
                    <p><span class="label">Serum Tryptase:</span></p>
                    <ul>
                        <li>Draw within 15 min - 3 hours of symptom onset (peak 1-2 hours)</li>
                        <li>Elevated >11.4 ng/mL suggests mast cell degranulation</li>
                        <li>Also draw baseline tryptase 24+ hours later for comparison</li>
                        <li>Sensitivity only 60-70%, so NORMAL level does NOT exclude anaphylaxis</li>
                    </ul>
                    
                    <p><span class="label">Initial Labs:</span> CBC, CMP, ABG/VBG if respiratory distress, troponin if chest pain/older patient</p>
                    <p><span class="label">Consider:</span> Chest X-ray if wheezing (to exclude other causes), ECG if cardiovascular symptoms</p>
                    <p><span class="label">Allergy Testing:</span> Outpatient referral for skin testing and allergen-specific IgE 4-6 weeks after event</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">âš¡ EPINEPHRINE IS FIRST-LINE - Give IMMEDIATELY:</span></p>
                    <ul>
                        <li><strong>Epinephrine 1:1000 (1 mg/mL) IM:</strong> 0.3-0.5 mg (0.3-0.5 mL) into anterolateral thigh, repeat q5-15min PRN</li>
                        <li>Pediatric: 0.01 mg/kg IM (max 0.3 mg), repeat q5-15min</li>
                        <li><strong>IM route preferred</strong> over SC (faster absorption)</li>
                        <li>NO absolute contraindications - benefits outweigh risks even with CV disease</li>
                        <li>If refractory after 2-3 doses â†’ consider IV epinephrine infusion</li>
                    </ul>
                    
                    <p><span class="label">Aggressive IV Fluid Resuscitation:</span></p>
                    <ul>
                        <li>1-2 liters NS rapid bolus (adults), then continue at 200-300 mL/hr</li>
                        <li>Massive capillary leak can cause 35% plasma volume loss in 10 minutes!</li>
                        <li>May need 4-6 liters in first hour</li>
                    </ul>
                    
                    <p><span class="label">Airway Management:</span></p>
                    <ul>
                        <li>Monitor closely for upper airway obstruction (stridor, voice changes, drooling)</li>
                        <li>Early intubation if signs of airway edema - can rapidly progress to complete obstruction</li>
                        <li>Have difficult airway equipment ready - angioedema makes intubation challenging</li>
                        <li>Consider cricothyrotomy if cannot intubate</li>
                    </ul>
                    
                    <p><span class="label">Adjunct Medications (NOT substitutes for epinephrine):</span></p>
                    <ul>
                        <li><strong>H1 antihistamine:</strong> Diphenhydramine 25-50 mg IV/IM/PO (peds: 1 mg/kg max 50mg)</li>
                        <li><strong>H2 antihistamine:</strong> Famotidine 20 mg IV or ranitidine 50 mg IV</li>
                        <li><strong>Corticosteroids:</strong> Methylprednisolone 125 mg IV or hydrocortisone 200 mg IV (may prevent biphasic reaction, but NOT acute therapy)</li>
                        <li><strong>Bronchodilators:</strong> Albuterol nebulizer for persistent bronchospasm</li>
                        <li><strong>Glucagon (if on Î²-blocker):</strong> 1-5 mg IV bolus over 5 min, then 5-15 mcg/min infusion (bypasses Î²-receptors)</li>
                    </ul>
                    
                    <p><span class="label">Refractory Hypotension:</span></p>
                    <ul>
                        <li>Epinephrine infusion: 0.1-1 mcg/kg/min (start low, titrate up)</li>
                        <li>Consider vasopressin 0.01-0.04 units/min if epinephrine-resistant</li>
                    </ul>
                    
                    <p><span class="label">Patient on Î²-Blocker:</span> May be refractory to epinephrine. Give glucagon AND higher/repeated doses of epinephrine</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Epinephrine has NO absolute contraindications:</strong> Even in elderly/cardiac patients, benefits far outweigh risks. Delay = death</li>
                    <li><strong>Biphasic reactions occur in 5-20%:</strong> Second wave 4-12 hours later. Observe ALL patients â‰¥4-6 hours (longer if severe)</li>
                    <li><strong>IM thigh > SC arm:</strong> Anterolateral thigh gives faster, more reliable absorption than subcutaneous deltoid</li>
                    <li><strong>Antihistamines/steroids are NOT first-line:</strong> They do not reverse anaphylaxis. Epinephrine is the ONLY life-saving drug</li>
                    <li><strong>Î²-blockers complicate treatment:</strong> Blunt response to epinephrine and may cause paradoxical bradycardia. Give glucagon</li>
                    <li><strong>ACE-I patients:</strong> More severe/prolonged reactions due to impaired bradykinin degradation</li>
                    <li><strong>Idiopathic anaphylaxis:</strong> 30-50% of cases - no identifiable trigger despite workup</li>
                    <li><strong>Tryptase timing:</strong> Peak 1-2 hours, returns to baseline by 12-24 hours. Too early or too late = false negative</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Requiring repeat IM epinephrine (â‰¥2 doses)</li>
                        <li>Need for continuous IV epinephrine</li>
                        <li>Respiratory distress/airway edema</li>
                        <li>Persistent hypotension despite fluids</li>
                        <li>Dysrhythmias or cardiac arrest</li>
                        <li>Severe presentation or delayed response to treatment</li>
                        <li>Patient on Î²-blocker with poor response</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Complete resolution of symptoms Ã— 4-6 hours minimum (longer if severe)</li>
                        <li>Hemodynamically stable without pressors</li>
                        <li>Normal respiratory status, no wheezing</li>
                        <li>Received steroids and antihistamines</li>
                        <li><strong>MUST PRESCRIBE:</strong> EpiPen Ã— 2 (0.3 mg for adults, 0.15 mg if <30 kg) with training on use</li>
                        <li>Anaphylaxis action plan provided</li>
                        <li>Allergy/immunology referral scheduled</li>
                        <li>Discussed trigger avoidance and medical alert bracelet</li>
                    </ul>
                </div>
            </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#epinephrine" style="color: #8e44ad;">ðŸ’Š Epinephrine</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="overdose" class="condition-page">
            <div class="page-header">
                <h2>70. DRUG OVERDOSE/TOXIDROMES</h2>
                <div class="subtitle">Acetaminophen â€¢ Salicylates â€¢ Tricyclic Antidepressants â€¢ Common Toxidromes</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">General Approach:</span> Identify toxidrome by vital signs and physical exam, then narrow differential and treat</p>
                    
                    <p><span class="label">COMMON TOXIDROMES:</span></p>
                    <ul>
                        <li><strong>Anticholinergic ("Hot as a hare, Blind as a bat, Dry as a bone, Red as a beet, Mad as a hatter"):</strong>
                            <ul>
                                <li>Causes: TCAs, antihistamines (diphenhydramine), atropine, scopolamine, jimson weed</li>
                                <li>Signs: Hyperthermia, mydriasis, dry skin/mucosa, flushed, urinary retention, decreased bowel sounds, altered mental status/delirium</li>
                            </ul>
                        </li>
                        <li><strong>Cholinergic ("SLUDGE" + "DUMBELS"):</strong>
                            <ul>
                                <li>Causes: Organophosphates, carbamates, nerve agents</li>
                                <li>SLUDGE: Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis</li>
                                <li>DUMBELS: Defecation, Urination, Miosis, Bradycardia/Bronchospasm, Emesis, Lacrimation, Salivation</li>
                                <li>Also: Fasciculations, muscle weakness, seizures</li>
                            </ul>
                        </li>
                        <li><strong>Sympathomimetic:</strong>
                            <ul>
                                <li>Causes: Cocaine, amphetamines, methamphetamine, synthetic cathinones ("bath salts"), MDMA</li>
                                <li>Signs: HTN, tachycardia, hyperthermia, mydriasis, diaphoresis, agitation, seizures</li>
                            </ul>
                        </li>
                        <li><strong>Sedative-Hypnotic:</strong>
                            <ul>
                                <li>Causes: Benzodiazepines, barbiturates, GHB, ethanol</li>
                                <li>Signs: CNS depression, respiratory depression, hypotension, hypothermia, normal pupils</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">ACETAMINOPHEN OVERDOSE - Silent Killer:</span></p>
                    <ul>
                        <li><strong>Stages:</strong>
                            <ul>
                                <li>Stage 1 (0-24h): Asymptomatic or N/V, malaise</li>
                                <li>Stage 2 (24-72h): RUQ pain, elevated LFTs/INR</li>
                                <li>Stage 3 (72-96h): Fulminant hepatic failure, encephalopathy, coagulopathy, death</li>
                                <li>Stage 4 (>5 days): Recovery OR need for transplant</li>
                            </ul>
                        </li>
                        <li><strong>Toxic dose:</strong> >7.5-10g in adults (>150 mg/kg in children) or >4g/day chronically</li>
                    </ul>
                    
                    <p><span class="label">SALICYLATE OVERDOSE (Aspirin):</span></p>
                    <ul>
                        <li><strong>Classic triad:</strong> Altered mental status, tachypnea (respiratory alkalosis), metabolic acidosis</li>
                        <li><strong>Symptoms:</strong> Tinnitus, vertigo, nausea, vomiting, diaphoresis, hyperpnea, confusion, seizures, pulmonary edema</li>
                        <li><strong>Lab findings:</strong> Mixed respiratory alkalosis + metabolic acidosis (HAGMA), hypokalemia, hypoglycemia (or hyperglycemia)</li>
                    </ul>
                    
                    <p><span class="label">TRICYCLIC ANTIDEPRESSANT (TCA) OVERDOSE:</span></p>
                    <ul>
                        <li><strong>Triad of death:</strong> Seizures, cardiac arrhythmias (wide-complex), hypotension</li>
                        <li><strong>Anticholinergic signs PLUS cardiac toxicity</strong></li>
                        <li><strong>ECG findings:</strong> QRS widening >100ms (predicts seizures/arrhythmias), terminal R wave in aVR, QTc prolongation</li>
                        <li><strong>Agents:</strong> Amitriptyline, nortriptyline, imipramine, doxepin</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">ALL Overdose Patients:</span></p>
                    <ul>
                        <li><strong>Vitals + repeat q15-30min:</strong> BP, HR, RR, temp, O2 sat, glucose</li>
                        <li><strong>ECG:</strong> QRS width, QTc, arrhythmias</li>
                        <li><strong>Labs:</strong> CBC, CMP, VBG (check pH, lactate), acetaminophen level, salicylate level, ethanol level</li>
                        <li><strong>Urine drug screen:</strong> Limited utility (many false +/-, doesn't detect levels). Don't let it guide treatment</li>
                        <li><strong>Specific levels when indicated:</strong> Digoxin, lithium, theophylline, iron, valproic acid, carbamazepine</li>
                    </ul>
                    
                    <p><span class="label">Acetaminophen Specific:</span></p>
                    <ul>
                        <li><strong>4-hour acetaminophen level:</strong> Plot on Rumack-Matthew nomogram to determine need for NAC</li>
                        <li>Level >150 mcg/mL at 4 hours = treat</li>
                        <li><strong>LFTs, PT/INR:</strong> Baseline and serial (q12-24h)</li>
                        <li>If unknown timing or chronic ingestion â†’ treat empirically if level >10 mcg/mL</li>
                    </ul>
                    
                    <p><span class="label">Salicylate Specific:</span></p>
                    <ul>
                        <li><strong>Salicylate level:</strong> >30 mg/dL = moderate, >70 mg/dL = severe. Repeat q2-4h until trending down (bezoar concern)</li>
                        <li><strong>ABG/VBG:</strong> Look for mixed acid-base (respiratory alkalosis + metabolic acidosis)</li>
                        <li>Urine pH (if available)</li>
                    </ul>
                    
                    <p><span class="label">TCA Specific:</span></p>
                    <ul>
                        <li><strong>Serial ECGs:</strong> QRS >100ms bad prognostic sign</li>
                        <li>TCA levels NOT helpful for acute management</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">GENERAL SUPPORTIVE CARE (All Patients):</span></p>
                    <ul>
                        <li><strong>ABCs:</strong> Airway protection, ventilatory support, IV access</li>
                        <li><strong>Dextrose:</strong> Check glucose, give D50 50mL IV if hypoglycemic or altered</li>
                        <li><strong>Naloxone:</strong> 0.4-2 mg IV/IM/IN if concern for opioid (see separate opioid section)</li>
                        <li><strong>Thiamine:</strong> 100 mg IV before dextrose (if concern for alcohol use/malnutrition)</li>
                        <li><strong>Benzodiazepines:</strong> For agitation, seizures (lorazepam 2-4 mg IV q5-10min PRN)</li>
                    </ul>
                    
                    <p><span class="label">GI DECONTAMINATION:</span></p>
                    <ul>
                        <li><strong>Activated charcoal:</strong> 1 g/kg (50-100g) PO/NGT if <1-2 hours since ingestion AND protected airway
                            <ul>
                                <li><strong>Contraindications:</strong> Unprotected airway, ileus, GI perforation/obstruction, caustic ingestion</li>
                                <li><strong>NOT effective for:</strong> Alcohols, lithium, iron, heavy metals</li>
                            </ul>
                        </li>
                        <li><strong>Gastric lavage:</strong> Rarely indicated (only massive life-threatening ingestion <1 hour)</li>
                        <li><strong>Whole bowel irrigation:</strong> Polyethylene glycol (GoLYTELY) for sustained-release pills, iron, lithium, body packers</li>
                    </ul>
                    
                    <p><span class="label">ACETAMINOPHEN OVERDOSE - N-Acetylcysteine (NAC):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> 4-hour level above treatment line on nomogram OR >10 mcg/mL with unknown time OR any evidence of hepatotoxicity</li>
                        <li><strong>IV Protocol (preferred):</strong>
                            <ul>
                                <li>Loading: 150 mg/kg in 200mL D5W over 60 minutes</li>
                                <li>Second: 50 mg/kg in 500mL D5W over 4 hours</li>
                                <li>Third: 100 mg/kg in 1000mL D5W over 16 hours</li>
                                <li>Total 21-hour protocol</li>
                            </ul>
                        </li>
                        <li><strong>PO Protocol:</strong> 140 mg/kg load, then 70 mg/kg q4h Ã— 17 doses (72 hours total)</li>
                        <li><strong>Anaphylactoid reactions common with IV NAC</strong> (15-20%) - slow/stop infusion, give antihistamines, restart slower</li>
                        <li><strong>Monitor:</strong> LFTs, PT/INR q12-24h. Can stop NAC once acetaminophen undetectable AND LFTs improving/normal</li>
                    </ul>
                    
                    <p><span class="label">SALICYLATE OVERDOSE:</span></p>
                    <ul>
                        <li><strong>IV Fluids:</strong> Aggressive hydration with D5 Â½ NS (dextrose to prevent CNS hypoglycemia despite normal serum glucose)</li>
                        <li><strong>Urinary Alkalinization (Key Treatment):</strong>
                            <ul>
                                <li>Goal urine pH 7.5-8.0 (traps ionized salicylate in urine â†’ increases excretion)</li>
                                <li>Add 150 mEq (3 amps) NaHCOâ‚ƒ to 1L D5W, run at 200-250 mL/hr</li>
                                <li>May need additional IV bicarbonate boluses</li>
                                <li>Replete potassium aggressively (hypokalemia prevents alkalinization)</li>
                            </ul>
                        </li>
                        <li><strong>Hemodialysis indications:</strong>
                            <ul>
                                <li>Salicylate level >100 mg/dL (acute) or >70 mg/dL (chronic)</li>
                                <li>Severe acidosis (pH <7.2)</li>
                                <li>AKI/ESRD</li>
                                <li>Pulmonary edema</li>
                                <li>Severe CNS symptoms (seizures, coma)</li>
                                <li>Failure of urinary alkalinization</li>
                            </ul>
                        </li>
                        <li><strong>Avoid:</strong> Aspirin-containing products, acidifying agents</li>
                    </ul>
                    
                    <p><span class="label">TRICYCLIC ANTIDEPRESSANT (TCA) OVERDOSE:</span></p>
                    <ul>
                        <li><strong>Sodium Bicarbonate (Antidote for QRS Widening):</strong>
                            <ul>
                                <li><strong>Indications:</strong> QRS >100ms, ventricular arrhythmias, hypotension</li>
                                <li>1-2 mEq/kg (1-2 amps = 50-100 mEq) IV bolus, repeat q3-5min until QRS narrows</li>
                                <li>Then continuous infusion: 150 mEq (3 amps) in 1L D5W</li>
                                <li>Goal: Serum pH 7.50-7.55 (alkalemia counteracts sodium channel blockade)</li>
                                <li>Monitor serial ECGs</li>
                            </ul>
                        </li>
                        <li><strong>Seizures:</strong> Benzodiazepines (lorazepam 2-4 mg IV), avoid phenytoin (may worsen cardiac toxicity)</li>
                        <li><strong>Hypotension:</strong> IV fluids + norepinephrine (vasopressor of choice)</li>
                        <li><strong>Arrhythmias:</strong>
                            <ul>
                                <li>Sodium bicarbonate (first-line)</li>
                                <li>Lidocaine for refractory VT</li>
                                <li>AVOID: Class IA (procainamide, quinidine) and IC (flecainide) antiarrhythmics</li>
                            </ul>
                        </li>
                        <li><strong>Intralipid emulsion:</strong> 20% lipid emulsion 1.5 mL/kg bolus for refractory cardiac arrest</li>
                    </ul>
                    
                    <p><span class="label">Poison Control:</span> Call 1-800-222-1222 for all serious overdoses</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Acetaminophen = #1 overdose in US:</strong> Often intentional, but also accidental from multiple sources (Tylenol + Percocet + cold meds). Low threshold to check level</li>
                    <li><strong>NAC is NOT toxic:</strong> Give liberally. If ANY doubt about toxicity â†’ treat. Can give even days later if hepatotoxicity present</li>
                    <li><strong>Salicylate paradox:</strong> Serum glucose normal/high but CNS hypoglycemia â†’ always give dextrose in fluids</li>
                    <li><strong>Urinary alkalinization KEY for salicylates:</strong> More important than dialysis for most cases. But can't alkalinize if hypokalemic â†’ repleteK aggressively</li>
                    <li><strong>TCA "3 C's of treatment":</strong> Charcoal (if early), Cardiac monitoring, biCarbonate (for wide QRS)</li>
                    <li><strong>QRS width predicts TCA toxicity:</strong> QRS >100ms = seizures and arrhythmias imminent. Push bicarb immediately</li>
                    <li><strong>Don't trust urine drug screens:</strong> Many false positives/negatives. Treat the patient, not the test</li>
                    <li><strong>Acetaminophen nomogram only works for single acute ingestion:</strong> If chronic ingestion or unknown time â†’ treat if level >10 mcg/mL</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Altered mental status or coma</li>
                        <li>Seizures</li>
                        <li>Hemodynamic instability/shock</li>
                        <li>Respiratory failure or need for intubation</li>
                        <li>Cardiac arrhythmias</li>
                        <li>TCA overdose with QRS widening</li>
                        <li>Severe salicylate toxicity needing dialysis</li>
                        <li>Acetaminophen with hepatotoxicity (elevated LFTs/INR)</li>
                        <li>Need for continuous cardiac monitoring</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li><strong>Acetaminophen:</strong> Completed NAC protocol, LFTs normal/improving, PT/INR normal, asymptomatic</li>
                        <li><strong>Salicylate:</strong> Level <30 mg/dL and trending down, normal acid-base, asymptomatic</li>
                        <li><strong>TCA:</strong> Asymptomatic Ã— 6 hours, normal ECG, no QRS widening</li>
                        <li><strong>General:</strong> Normal vital signs, mental status at baseline, no suicidal ideation</li>
                        <li><strong>Psych evaluation:</strong> Completed if intentional ingestion</li>
                        <li>Close follow-up arranged</li>
                        <li>Poison Control contacted (for intentional)</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="opioid" class="condition-page">
            <div class="page-header">
                <h2>71. OPIOID OVERDOSE/WITHDRAWAL</h2>
                <div class="subtitle">Opioid Toxicity â€¢ Opioid Withdrawal Syndrome</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">OPIOID OVERDOSE - "Classic Triad":</span></p>
                    <ul>
                        <li><strong>CNS depression:</strong> Altered mental status, drowsiness, coma (GCS <15)</li>
                        <li><strong>Respiratory depression:</strong> Bradypnea (RR <12), shallow breathing, hypoxia, apnea</li>
                        <li><strong>Miosis:</strong> Pinpoint pupils (2-3mm) - highly specific but not 100% sensitive</li>
                    </ul>
                    
                    <p><span class="label">Additional Features:</span></p>
                    <ul>
                        <li><strong>Cardiovascular:</strong> Bradycardia, hypotension (usually mild)</li>
                        <li><strong>Decreased bowel sounds</strong></li>
                        <li><strong>Hypothermia</strong></li>
                        <li><strong>Pulmonary edema:</strong> Can occur, especially with heroin ("heroin lung")</li>
                        <li><strong>Track marks:</strong> May be present in IV drug users</li>
                    </ul>
                    
                    <p><span class="label">Common Agents:</span></p>
                    <ul>
                        <li><strong>Prescription:</strong> Oxycodone, hydrocodone, morphine, hydromorphone (Dilaudid), fentanyl, methadone, tramadol</li>
                        <li><strong>Illicit:</strong> Heroin, illicit fentanyl (50-100Ã— more potent than morphine), carfentanil</li>
                        <li><strong>Special concern:</strong> Fentanyl-laced pills ("pressed pills" sold as oxycodone/Xanax) â†’ epidemic of overdose deaths</li>
                    </ul>
                    
                    <p><span class="label">Exceptions to Miosis:</span></p>
                    <ul>
                        <li><strong>Meperidine (Demerol):</strong> Can cause mydriasis</li>
                        <li><strong>Tramadol:</strong> Serotonergic properties, may have normal/dilated pupils</li>
                        <li><strong>Severe hypoxia/anoxia:</strong> Pupils dilate due to brain injury</li>
                        <li><strong>Co-ingestion with anticholinergics:</strong> Dilated pupils</li>
                    </ul>
                    
                    <p><span class="label">OPIOID WITHDRAWAL - Miserable but NOT Life-Threatening:</span></p>
                    <ul>
                        <li><strong>Timing:</strong> Onset 6-12 hours after last short-acting opioid (heroin), 24-48 hours for long-acting (methadone)</li>
                        <li><strong>Peak:</strong> 36-72 hours, duration 5-10 days</li>
                        <li><strong>Symptoms ("flu-like"):</strong>
                            <ul>
                                <li><strong>Early:</strong> Anxiety, restlessness, yawning, lacrimation, rhinorrhea, diaphoresis, mydriasis</li>
                                <li><strong>Late:</strong> Nausea, vomiting, diarrhea, abdominal cramping, myalgias, piloerection ("goose flesh"), tachycardia, HTN, fever</li>
                            </ul>
                        </li>
                        <li><strong>Key:</strong> Uncomfortable but NOT dangerous (unlike alcohol/benzo withdrawal which CAN be fatal)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">OVERDOSE - Clinical Diagnosis:</span></p>
                    <ul>
                        <li><strong>Don't wait for confirmatory testing - TREAT clinically!</strong></li>
                        <li><strong>Essential:</strong> Vitals (RR most important), pulse ox, glucose, ECG</li>
                        <li><strong>ABG/VBG:</strong> If severe respiratory depression (assess pCOâ‚‚, hypercapnia)</li>
                        <li><strong>Labs:</strong> CBC, CMP, lactate, acetaminophen level (co-ingestion common with prescription opioids), salicylate, ethanol</li>
                        <li><strong>Urine drug screen:</strong>
                            <ul>
                                <li>Often positive but NOT required for treatment</li>
                                <li><strong>Caveats:</strong> Fentanyl/methadone often NOT detected on standard screens. Screens typically only detect morphine, codeine, hydromorphone</li>
                                <li>Synthetic opioids require special testing</li>
                            </ul>
                        </li>
                        <li><strong>CXR:</strong> If hypoxia persists after naloxone (pulmonary edema, aspiration)</li>
                        <li><strong>Head CT:</strong> If no response to naloxone, concern for trauma/intracranial pathology</li>
                    </ul>
                    
                    <p><span class="label">WITHDRAWAL - Clinical Diagnosis + Assessment:</span></p>
                    <ul>
                        <li><strong>COWS (Clinical Opiate Withdrawal Scale):</strong> Objective scoring tool
                            <ul>
                                <li>Score 5-12 = mild, 13-24 = moderate, 25-36 = moderately severe, >36 = severe</li>
                                <li>Assesses: VS, GI upset, tremor, restlessness, pupil size, anxiety, gooseflesh, etc.</li>
                            </ul>
                        </li>
                        <li>Labs usually not needed unless concern for complications</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">OPIOID OVERDOSE:</span></p>
                    
                    <p><span class="label">Immediate Resuscitation:</span></p>
                    <ul>
                        <li><strong>Airway/Breathing:</strong>
                            <ul>
                                <li>Bag-valve-mask ventilation if apneic/severe respiratory depression</li>
                                <li>Supplemental Oâ‚‚ to maintain SpOâ‚‚ >90%</li>
                                <li>Consider intubation if no response to naloxone or prolonged</li>
                            </ul>
                        </li>
                        <li><strong>IV access, monitor</strong></li>
                    </ul>
                    
                    <p><span class="label">ðŸŽ¯ NALOXONE (Narcan) - Opioid Antagonist:</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Respiratory depression (RR <12) OR coma/unresponsive from suspected opioid</li>
                        <li><strong>IV/IM/SC dosing:</strong>
                            <ul>
                                <li>Start: 0.04-0.4 mg IV, titrate up by 0.4 mg q2-3min until respiratory drive restored</li>
                                <li>Goal: Adequate respiration (RR >12), NOT full reversal/consciousness</li>
                                <li>Maximum: 10 mg (if no response after 10 mg, reconsider diagnosis)</li>
                            </ul>
                        </li>
                        <li><strong>Intranasal:</strong> 4 mg (1 spray) in each nostril, repeat q2-3min PRN (easier for EMS/lay public)</li>
                        <li><strong>IM/SC:</strong> 0.4-2 mg, repeat q2-3min PRN (if no IV access)</li>
                        <li><strong>Duration:</strong> 30-90 minutes (shorter than most opioids!) â†’ re-sedation common
                            <ul>
                                <li>Especially with long-acting opioids (methadone, sustained-release formulations, fentanyl)</li>
                                <li>May need continuous naloxone infusion (2/3 of effective bolus dose per hour)</li>
                            </ul>
                        </li>
                        <li><strong>Caution:</strong> Naloxone precipitates acute withdrawal in opioid-dependent patients (uncomfortable but not dangerous). Use lowest effective dose</li>
                    </ul>
                    
                    <p><span class="label">Observation Period:</span></p>
                    <ul>
                        <li><strong>Short-acting opioids (heroin, oxycodone):</strong> Observe 4-6 hours after last naloxone dose</li>
                        <li><strong>Long-acting opioids (methadone, fentanyl, sustained-release):</strong> Admit for 24 hours monitoring</li>
                        <li>Watch for re-sedation, respiratory depression</li>
                    </ul>
                    
                    <p><span class="label">Post-Overdose Care:</span></p>
                    <ul>
                        <li><strong>Take-home naloxone kit:</strong> ALWAYS prescribe intranasal naloxone at discharge + educate patient/family</li>
                        <li><strong>Harm reduction counseling:</strong> Never use alone, avoid mixing with benzodiazepines/alcohol, fentanyl test strips</li>
                        <li><strong>Addiction treatment referral:</strong> Offer medication-assisted treatment (MAT) - buprenorphine, methadone, naltrexone</li>
                        <li>Social work consult</li>
                    </ul>
                    
                    <p><span class="label">OPIOID WITHDRAWAL TREATMENT:</span></p>
                    
                    <p><span class="label">Symptom Management (Supportive):</span></p>
                    <ul>
                        <li><strong>Clonidine:</strong> 0.1-0.2 mg PO q6h PRN (max 0.8 mg/day)
                            <ul>
                                <li>Î±â‚‚-agonist, reduces sympathetic hyperactivity</li>
                                <li>Helps: Anxiety, agitation, tachycardia, HTN, diaphoresis</li>
                                <li>Monitor BP (can cause hypotension)</li>
                            </ul>
                        </li>
                        <li><strong>Ondansetron:</strong> 4-8 mg IV/PO q8h PRN for N/V</li>
                        <li><strong>Loperamide:</strong> 4 mg PO initially, then 2 mg after each loose stool (max 16 mg/day) for diarrhea</li>
                        <li><strong>NSAIDs:</strong> Ibuprofen 600-800 mg PO q8h for myalgias</li>
                        <li><strong>Hydroxyzine or promethazine:</strong> 25-50 mg q6h PRN for anxiety/insomnia</li>
                        <li><strong>Avoid benzodiazepines</strong> (high abuse potential, unless severe anxiety/insomnia)</li>
                    </ul>
                    
                    <p><span class="label">Medication-Assisted Treatment (MAT) - PREFERRED Long-Term:</span></p>
                    <ul>
                        <li><strong>Buprenorphine (Suboxone):</strong>
                            <ul>
                                <li>Partial Î¼-opioid agonist - treats withdrawal, reduces cravings, low overdose risk</li>
                                <li>Can initiate in ED once patient in moderate withdrawal (COWS â‰¥8-12)</li>
                                <li>Start: 2-4 mg SL, repeat 2-4 mg q2-4h PRN (max 8-12 mg day 1)</li>
                                <li>Maintenance: 12-16 mg SL daily</li>
                                <li><strong>Requires X-waiver to prescribe outpatient</strong> (or prescribe 3-day bridge to clinic)</li>
                            </ul>
                        </li>
                        <li><strong>Methadone:</strong>
                            <ul>
                                <li>Full Î¼-opioid agonist - highly effective but requires special clinic</li>
                                <li>Start 10-30 mg PO daily, titrate slowly</li>
                                <li>Cannot prescribe for outpatient addiction treatment (only federally-licensed clinics)</li>
                            </ul>
                        </li>
                        <li><strong>Naltrexone (Vivitrol):</strong>
                            <ul>
                                <li>Opioid antagonist - blocks effects if relapse occurs</li>
                                <li>50 mg PO daily OR 380 mg IM monthly</li>
                                <li>Must be opioid-free â‰¥7-10 days before starting (will precipitate withdrawal)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Key Principle:</span> MAT (buprenorphine, methadone) is MORE effective than detox alone. Reduces mortality by 50-70%</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Naloxone goal = restore respiration, NOT consciousness:</strong> Overtitrating causes severe withdrawal and patient will leave AMA. Just enough to breathe (RR >12)</li>
                    <li><strong>Fentanyl epidemic:</strong> Illicit fentanyl now in everything (fake pills, heroin, cocaine). Much more potent â†’ may need higher/repeated naloxone doses</li>
                    <li><strong>Re-sedation is common:</strong> Naloxone wears off faster than most opioids. Long-acting opioids (methadone, fentanyl patch) require prolonged monitoring</li>
                    <li><strong>Withdrawal uncomfortable but NOT deadly:</strong> Unlike alcohol/benzo withdrawal. Can't die from opioid withdrawal (though it feels like you might!)</li>
                    <li><strong>Give naloxone kit at discharge:</strong> ~50% of OD patients will overdose again within 1 year. Take-home naloxone saves lives</li>
                    <li><strong>Start buprenorphine in the ED:</strong> Best time to engage patients in treatment. Can bridge to outpatient clinic with 3-day supply</li>
                    <li><strong>Urine drug screen limitations:</strong> Standard screens miss fentanyl, methadone, synthetic opioids. Clinical diagnosis >> lab test</li>
                    <li><strong>Stigma kills:</strong> Opioid use disorder is a medical disease, not a moral failure. Use non-judgmental language, offer treatment</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li><strong>Overdose:</strong></li>
                        <li>Persistent respiratory depression despite naloxone</li>
                        <li>Need for intubation</li>
                        <li>Hemodynamic instability</li>
                        <li>Pulmonary edema</li>
                        <li>Severe co-ingestion (benzos, alcohol)</li>
                        <li>Need for continuous naloxone infusion</li>
                        <li><strong>Withdrawal:</strong></li>
                        <li>Usually does NOT require ICU</li>
                        <li>Exception: Severe co-morbidities, elderly with cardiac disease</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li><strong>Overdose:</strong></li>
                        <li>Normal mental status and respiratory rate</li>
                        <li>Observed 4-6 hours (short-acting) or 24 hours (long-acting) after last naloxone</li>
                        <li>No re-sedation</li>
                        <li><strong>MUST provide:</strong> Take-home naloxone kit + training</li>
                        <li>Harm reduction counseling completed</li>
                        <li>Addiction treatment referral offered/accepted</li>
                        <li>Started on buprenorphine (if appropriate)</li>
                        <li><strong>Withdrawal:</strong></li>
                        <li>Symptoms controlled with outpatient meds</li>
                        <li>Tolerating PO, hydrated</li>
                        <li>Discharge Rx: Clonidine, ondansetron, loperamide</li>
                        <li>MAT arranged (buprenorphine or methadone clinic)</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="appendicitis" class="condition-page">
            <div class="page-header">
                <h2>72. ACUTE APPENDICITIS</h2>
                <div class="subtitle">RLQ Pain â€¢ Periumbilical â†’ RLQ Migration â€¢ Surgical Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic History:</span> Periumbilical pain migrating to RLQ over 12-24 hours, anorexia, nausea/vomiting (typically after pain onset)</p>
                    <p><span class="label">Physical Exam:</span></p>
                    <ul>
                        <li><strong>McBurney's point tenderness:</strong> 1/3 distance from ASIS to umbilicus</li>
                        <li><strong>Rovsing sign:</strong> RLQ pain with LLQ palpation</li>
                        <li><strong>Psoas sign:</strong> Pain with right hip extension (retrocecal appendix)</li>
                        <li><strong>Obturator sign:</strong> Pain with internal rotation of flexed right hip (pelvic appendix)</li>
                        <li><strong>Rebound/guarding:</strong> Suggests peritonitis (perforation)</li>
                    </ul>
                    <p><span class="label">Atypical Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> Blunted symptoms, often present with perforation</li>
                        <li><strong>Pregnant:</strong> Pain may be RUQ/flank (displaced appendix)</li>
                        <li><strong>Retrocecal:</strong> Flank pain, less peritoneal signs</li>
                        <li><strong>Pelvic:</strong> Suprapubic pain, urinary symptoms</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Alvarado Score (MANTRELS):</span></p>
                    <ul>
                        <li><strong>M</strong>igration of pain to RLQ (1)</li>
                        <li><strong>A</strong>norexia (1)</li>
                        <li><strong>N</strong>ausea/vomiting (1)</li>
                        <li><strong>T</strong>enderness in RLQ (2)</li>
                        <li><strong>R</strong>ebound pain (1)</li>
                        <li><strong>E</strong>levated temperature >37.3Â°C (1)</li>
                        <li><strong>L</strong>eukocytosis >10,000 (2)</li>
                        <li><strong>S</strong>hift to left >75% neutrophils (1)</li>
                        <li><strong>Interpretation:</strong> 0-4 low risk, 5-6 intermediate, 7-10 high risk</li>
                    </ul>
                    <p><span class="label">Labs:</span> CBC (leukocytosis with left shift), CMP, lipase, UA (rule out UTI, mild pyuria can occur from inflamed appendix), pregnancy test (all women of childbearing age)</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CT abdomen/pelvis with IV contrast:</strong> Gold standard (sensitivity 94%, specificity 95%)</li>
                        <li><strong>Findings:</strong> Dilated appendix >6mm, periappendiceal fat stranding, appendicolith, abscess</li>
                        <li><strong>Ultrasound:</strong> First-line in pediatrics, pregnancy. Noncompressible tubular structure >6mm</li>
                        <li><strong>MRI:</strong> Alternative in pregnancy if US inconclusive</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Surgical Consultation:</span> URGENT - appendectomy is definitive treatment</p>
                    <p><span class="label">Pre-operative:</span></p>
                    <ul>
                        <li><strong>NPO</strong></li>
                        <li><strong>IV fluids:</strong> Resuscitate if dehydrated</li>
                        <li><strong>Antibiotics:</strong> Start pre-operatively for surgical prophylaxis</li>
                        <li>Uncomplicated: Single dose cefazolin + metronidazole or cefoxitin</li>
                        <li>Perforated/complicated: Broader coverage (pip-tazo, ceftriaxone + metronidazole)</li>
                        <li><strong>Pain control:</strong> IV opioids (doesn't mask exam findings)</li>
                    </ul>
                    <p><span class="label">Operative Approach:</span></p>
                    <ul>
                        <li><strong>Laparoscopic appendectomy:</strong> Preferred approach</li>
                        <li><strong>Timing:</strong> Should occur within 24 hours of diagnosis</li>
                        <li><strong>Perforated with abscess:</strong> May require drainage + interval appendectomy</li>
                    </ul>
                    <p><span class="label">Non-operative Management:</span> In select cases, antibiotics alone may be considered (recent evidence), but recurrence rate 25-40%</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Anorexia is nearly universal:</strong> If patient is hungry, reconsider diagnosis</li>
                    <li><strong>Vomiting follows pain:</strong> If vomiting precedes pain, consider gastroenteritis</li>
                    <li><strong>Don't delay imaging for fear of perforation:</strong> CT doesn't cause perforation, delayed diagnosis does</li>
                    <li><strong>Pain medication doesn't mask diagnosis:</strong> Administer analgesia while awaiting imaging</li>
                    <li><strong>Consider in all RLQ pain:</strong> Including women with ovarian pathology as differential</li>
                </ul>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="cholangitis" class="condition-page">
            <div class="page-header">
                <h2>73. ACUTE CHOLANGITIS</h2>
                <div class="subtitle">Biliary Infection â€¢ Charcot's Triad â€¢ Biliary Drainage Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Charcot's Triad (50-70% sensitivity):</span></p>
                    <ul>
                        <li><strong>1. Fever/chills</strong></li>
                        <li><strong>2. RUQ pain</strong></li>
                        <li><strong>3. Jaundice</strong></li>
                    </ul>
                    <p><span class="label">Reynolds' Pentad (severe/suppurative cholangitis):</span></p>
                    <ul>
                        <li>Charcot's triad PLUS:</li>
                        <li><strong>4. Altered mental status</strong></li>
                        <li><strong>5. Hypotension</strong></li>
                    </ul>
                    <p><span class="label">Risk Factors:</span> Choledocholithiasis (most common), biliary strictures, malignancy, prior ERCP/biliary stents, parasites (endemic areas)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Tokyo Guidelines 2018 (TG18) Diagnostic Criteria:</span></p>
                    <ul>
                        <li><strong>A. Systemic inflammation:</strong> Fever >38Â°C and/or shaking chills, OR lab (WBC, CRP elevated)</li>
                        <li><strong>B. Cholestasis:</strong> Jaundice, OR abnormal LFTs (ALP, GGT, AST, ALT >1.5Ã— ULN)</li>
                        <li><strong>C. Imaging:</strong> Biliary dilation, OR evidence of etiology (stone, stent, stricture)</li>
                        <li><strong>Definite:</strong> A + B + C | <strong>Suspected:</strong> A + B or A + C</li>
                    </ul>
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li>CBC (leukocytosis), CMP, LFTs (cholestatic pattern: elevated ALP, GGT, direct bili)</li>
                        <li><strong>Blood cultures:</strong> Positive in 20-70% (E. coli, Klebsiella, Enterococcus most common)</li>
                        <li>Lipase (rule out pancreatitis)</li>
                    </ul>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>RUQ ultrasound:</strong> First-line. CBD dilation (>6mm, or >8mm post-cholecystectomy), stones</li>
                        <li><strong>MRCP:</strong> If US inconclusive, better stone detection</li>
                        <li><strong>CT:</strong> Good for complications, but less sensitive for CBD stones</li>
                    </ul>
                    <p><span class="label">Severity Grading (TG18):</span></p>
                    <ul>
                        <li><strong>Grade I (Mild):</strong> Does not meet Grade II/III criteria</li>
                        <li><strong>Grade II (Moderate):</strong> WBC >12K or <4K, fever â‰¥39Â°C, age â‰¥75, bili â‰¥5, albumin <0.7Ã— LLN</li>
                        <li><strong>Grade III (Severe):</strong> Organ dysfunction (cardiovascular, neuro, respiratory, renal, hepatic, hematologic)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Resuscitation:</span></p>
                    <ul>
                        <li>IV fluids, vasopressors if septic shock</li>
                        <li>Correct coagulopathy if present (vitamin K, FFP)</li>
                    </ul>
                    <p><span class="label">Antibiotics (start immediately):</span></p>
                    <ul>
                        <li><strong>Mild/Moderate:</strong> Ceftriaxone + metronidazole, OR pip-tazo, OR ertapenem</li>
                        <li><strong>Severe/septic shock:</strong> Pip-tazo, OR meropenem, OR cefepime + metronidazole</li>
                        <li>Add vancomycin if risk for resistant gram-positives (prior biliary intervention)</li>
                        <li><strong>Duration:</strong> 4-7 days after source control</li>
                    </ul>
                    <p><span class="label">Biliary Drainage (CRITICAL):</span></p>
                    <ul>
                        <li><strong>ERCP:</strong> First-line for decompression + stone extraction</li>
                        <li><strong>Timing by severity:</strong></li>
                        <li>Grade III: URGENT <12-24 hours (after initial resuscitation)</li>
                        <li>Grade II: EARLY 24-48 hours</li>
                        <li>Grade I: ELECTIVE 24-72 hours</li>
                        <li><strong>If ERCP not feasible:</strong> Percutaneous transhepatic biliary drainage (PTBD) or EUS-guided drainage</li>
                    </ul>
                    <p><span class="label">Cholecystectomy:</span> If gallstone etiology, perform during same admission or within 2 weeks once infection controlled</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Cholangitis is a biliary sepsis:</strong> Source control (drainage) is as important as antibiotics</li>
                    <li><strong>Charcot's triad has low sensitivity:</strong> Don't wait for all 3 to act</li>
                    <li><strong>Ascending infection:</strong> Bacteria ascend from duodenum when bile flow obstructed</li>
                    <li><strong>CBD stones cause cholangitis, GB stones cause cholecystitis:</strong> Different pathophysiology</li>
                    <li><strong>Biliary drainage saves lives:</strong> Mortality in severe cholangitis without drainage is very high</li>
                </ul>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="cholecystitis" class="condition-page">
            <div class="page-header">
                <h2>74. ACUTE CHOLECYSTITIS</h2>
                <div class="subtitle">Gallbladder Inflammation â€¢ RUQ Pain â€¢ Murphy's Sign</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Presentation:</span></p>
                    <ul>
                        <li>RUQ/epigastric pain lasting >6 hours (differentiates from biliary colic)</li>
                        <li>Fever, nausea, vomiting</li>
                        <li>Often precipitated by fatty meal</li>
                        <li>May radiate to right shoulder/scapula (referred pain)</li>
                    </ul>
                    <p><span class="label">Physical Exam:</span></p>
                    <ul>
                        <li><strong>Murphy's sign:</strong> Inspiratory arrest with RUQ palpation (deep breath while palpating GB area causes patient to stop breathing due to pain)</li>
                        <li>RUQ tenderness, possible palpable GB</li>
                        <li>Guarding (suggests perforation/gangrene)</li>
                    </ul>
                    <p><span class="label">Calculous vs Acalculous:</span></p>
                    <ul>
                        <li><strong>Calculous (90%):</strong> Gallstone impacted in cystic duct</li>
                        <li><strong>Acalculous (10%):</strong> ICU patients, burns, TPN, sepsis, vasculitis. Higher mortality (10-50%)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Tokyo Guidelines 2018 Diagnostic Criteria:</span></p>
                    <ul>
                        <li><strong>A. Local signs:</strong> Murphy's sign, RUQ mass/pain/tenderness</li>
                        <li><strong>B. Systemic signs:</strong> Fever, elevated CRP, elevated WBC</li>
                        <li><strong>C. Imaging:</strong> Characteristic findings on US/CT/MRI/HIDA</li>
                        <li><strong>Suspected:</strong> A + B | <strong>Definite:</strong> A + B + C</li>
                    </ul>
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li>CBC (leukocytosis), CMP, LFTs (usually mild elevation; if sig elevated, consider CBD stone)</li>
                        <li>Lipase (rule out pancreatitis)</li>
                        <li>Mildly elevated bilirubin common (inflammation, not obstruction)</li>
                    </ul>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>RUQ Ultrasound:</strong> First-line (sensitivity 88%, specificity 80%)</li>
                        <li>Findings: Gallstones, GB wall thickening (>3mm), pericholecystic fluid, sonographic Murphy's sign</li>
                        <li><strong>HIDA scan:</strong> If US inconclusive. Non-filling of GB = cystic duct obstruction (sensitivity 97%)</li>
                        <li><strong>CT:</strong> For complications (perforation, abscess, gangrene)</li>
                    </ul>
                    <p><span class="label">Severity Grading:</span></p>
                    <ul>
                        <li><strong>Grade I (Mild):</strong> No organ dysfunction, mild GB inflammation</li>
                        <li><strong>Grade II (Moderate):</strong> WBC >18K, palpable mass, symptoms >72hr, marked local inflammation (gangrenous, emphysematous, pericholecystic abscess)</li>
                        <li><strong>Grade III (Severe):</strong> Organ dysfunction (cardiovascular, neuro, respiratory, renal, hepatic, hematologic)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Initial Management:</span></p>
                    <ul>
                        <li><strong>NPO</strong></li>
                        <li><strong>IV fluids</strong></li>
                        <li><strong>Pain control:</strong> NSAIDs (ketorolac) + opioids PRN</li>
                        <li><strong>Antiemetics</strong></li>
                    </ul>
                    <p><span class="label">Antibiotics:</span></p>
                    <ul>
                        <li><strong>Mild (Grade I):</strong> Single-dose surgical prophylaxis may be sufficient if early cholecystectomy</li>
                        <li><strong>Moderate-Severe:</strong> Ceftriaxone + metronidazole, OR pip-tazo</li>
                        <li>Continue until cholecystectomy if delayed, or 24h post-op if uncomplicated</li>
                    </ul>
                    <p><span class="label">Cholecystectomy:</span></p>
                    <ul>
                        <li><strong>Early cholecystectomy preferred:</strong> Within 72 hours of symptom onset (or admission)</li>
                        <li>Grade I/II: Laparoscopic cholecystectomy during index admission</li>
                        <li>Grade III: Stabilize first, then cholecystectomy or cholecystostomy tube if too sick</li>
                        <li><strong>Delayed cholecystectomy:</strong> Higher complication rates, more difficult surgery</li>
                    </ul>
                    <p><span class="label">High-Risk/Poor Surgical Candidates:</span></p>
                    <ul>
                        <li><strong>Percutaneous cholecystostomy tube:</strong> Drainage procedure as bridge or definitive</li>
                        <li>Can perform interval cholecystectomy once patient optimized</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Biliary colic vs cholecystitis:</strong> Colic resolves in <6hr; cholecystitis pain is persistent</li>
                    <li><strong>Sonographic Murphy's:</strong> More specific than clinical Murphy's sign</li>
                    <li><strong>Acalculous cholecystitis:</strong> Think in ICU patients. High mortality, low threshold to treat</li>
                    <li><strong>Early surgery is safe:</strong> Within 72hr, easier dissection planes, shorter hospital stay</li>
                    <li><strong>Emphysematous cholecystitis:</strong> Gas in GB wall on CT. Clostridium, diabetics. Surgical emergency</li>
                </ul>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="encephalitis" class="condition-page">
            <div class="page-header">
                <h2>75. ENCEPHALITIS</h2>
                <div class="subtitle">Brain Parenchymal Inflammation â€¢ AMS + Fever â€¢ HSV Most Common</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span></p>
                    <ul>
                        <li><strong>1. Fever</strong></li>
                        <li><strong>2. Altered mental status</strong> (confusion, personality change, decreased LOC)</li>
                        <li><strong>3. Focal neurologic deficits</strong> (seizures, aphasia, hemiparesis, movement disorders)</li>
                    </ul>
                    <p><span class="label">Distinguishing Features (vs Meningitis):</span></p>
                    <ul>
                        <li>Encephalitis = brain parenchyma involvement â†’ altered mentation, seizures, focal deficits</li>
                        <li>Meningitis = meninges â†’ headache, stiff neck, photophobia</li>
                        <li>Often overlap (meningoencephalitis)</li>
                    </ul>
                    <p><span class="label">Common Etiologies:</span></p>
                    <ul>
                        <li><strong>HSV-1:</strong> Most common sporadic cause. Temporal lobe predilection</li>
                        <li><strong>Arboviruses:</strong> West Nile, Eastern equine, St. Louis (summer/fall, mosquito exposure)</li>
                        <li><strong>Enteroviruses:</strong> Summer/fall epidemics</li>
                        <li><strong>VZV:</strong> Immunocompromised, may have rash</li>
                        <li><strong>Autoimmune:</strong> Anti-NMDA receptor, LGI1, CASPR2 (consider if young, psychiatric symptoms)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Lumbar Puncture (ESSENTIAL):</span></p>
                    <ul>
                        <li><strong>CSF profile:</strong> Lymphocytic pleocytosis (usually 10-500 WBC), normal-mildly elevated protein, normal glucose</li>
                        <li><strong>HSV PCR:</strong> Sensitivity 96%, specificity 99%. SEND ON ALL PATIENTS</li>
                        <li><strong>Viral panel PCR:</strong> HSV, VZV, enteroviruses, West Nile, others based on exposure</li>
                        <li><strong>RBC in CSF:</strong> Suggests hemorrhagic encephalitis (HSV)</li>
                        <li><strong>Cytology, autoimmune panel:</strong> If no infectious cause identified</li>
                    </ul>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>MRI Brain with contrast:</strong> Study of choice</li>
                        <li><strong>HSV findings:</strong> T2/FLAIR hyperintensity in temporal lobes (medial > lateral), insular cortex, cingulate gyrus. Often asymmetric</li>
                        <li><strong>CT:</strong> May be normal early; temporal lobe hypodensity seen later</li>
                    </ul>
                    <p><span class="label">EEG:</span> Periodic lateralized epileptiform discharges (PLEDs) in temporal region suggests HSV</p>
                    <p><span class="label">Additional Labs:</span> CBC, CMP, HIV test, blood cultures, consider paraneoplastic/autoimmune panel if no infectious cause</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Empiric Therapy (START IMMEDIATELY - do not wait for LP/imaging):</span></p>
                    <ul>
                        <li><strong>Acyclovir 10 mg/kg IV q8h:</strong> Continue until HSV PCR negative. If HSV+, treat 14-21 days</li>
                        <li>Adjust for renal function</li>
                        <li>Ensure adequate hydration (prevent acyclovir crystalluria/AKI)</li>
                    </ul>
                    <p><span class="label">If Meningitis Also Suspected:</span></p>
                    <ul>
                        <li>Add empiric bacterial meningitis coverage (ceftriaxone + vancomycin Â± ampicillin)</li>
                        <li>Dexamethasone 0.15 mg/kg q6h if bacterial meningitis suspected (give before or with first abx dose)</li>
                    </ul>
                    <p><span class="label">Seizure Management:</span></p>
                    <ul>
                        <li>Load levetiracetam 20-30 mg/kg IV if seizures occur</li>
                        <li>Continuous EEG monitoring if persistent AMS</li>
                    </ul>
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li>ICU admission for severe cases</li>
                        <li>Manage cerebral edema (elevate HOB, osmotic therapy if needed)</li>
                        <li>DVT prophylaxis (mechanical preferred if seizures)</li>
                    </ul>
                    <p><span class="label">Autoimmune Encephalitis:</span></p>
                    <ul>
                        <li>If workup negative for infectious causes, consider autoimmune</li>
                        <li>Treatment: High-dose steroids, IVIG, plasmapheresis</li>
                        <li>Screen for underlying malignancy (ovarian teratoma in anti-NMDA receptor encephalitis)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Treat first, diagnose second:</strong> Start acyclovir immediately if encephalitis suspected. HSV mortality untreated 70%, treated <20%</li>
                    <li><strong>HSV PCR can be negative early:</strong> If high suspicion, repeat LP in 3-7 days. Continue acyclovir pending repeat</li>
                    <li><strong>Temporal lobe = HSV until proven otherwise:</strong> Classic MRI finding</li>
                    <li><strong>West Nile:</strong> Flaccid paralysis + encephalitis in summer should raise suspicion</li>
                    <li><strong>Don't forget autoimmune:</strong> Young patients with psychiatric symptoms, movement disorders, seizures - think anti-NMDA receptor encephalitis</li>
                </ul>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="ich" class="condition-page">
            <div class="page-header">
                <h2>76. INTRACEREBRAL HEMORRHAGE (ICH)</h2>
                <div class="subtitle">Hypertensive Hemorrhage â€¢ Acute Stroke â€¢ BP Control Critical</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Presentation:</span></p>
                    <ul>
                        <li>Sudden onset focal neurologic deficit (similar to ischemic stroke)</li>
                        <li>Headache (more common than ischemic stroke)</li>
                        <li>Vomiting, decreased LOC (suggests elevated ICP/larger hemorrhage)</li>
                        <li>Seizures (5-15% at onset)</li>
                    </ul>
                    <p><span class="label">Cannot Distinguish ICH from Ischemic Stroke Clinically:</span> MUST have imaging</p>
                    <p><span class="label">Location-Based Deficits:</span></p>
                    <ul>
                        <li><strong>Basal ganglia/putamen (most common):</strong> Contralateral hemiparesis, hemisensory loss</li>
                        <li><strong>Thalamus:</strong> Sensory > motor, eyes deviate downward ("looking at nose")</li>
                        <li><strong>Cerebellum:</strong> Ataxia, vertigo, nystagmus, can deteriorate rapidly</li>
                        <li><strong>Pons:</strong> Quadriparesis, pinpoint pupils, "locked-in" syndrome</li>
                        <li><strong>Lobar:</strong> Deficits depend on location (frontal, parietal, occipital, temporal)</li>
                    </ul>
                    <p><span class="label">Common Causes:</span></p>
                    <ul>
                        <li><strong>Hypertension (60-70%):</strong> Deep structures (basal ganglia, thalamus, pons, cerebellum)</li>
                        <li><strong>Cerebral amyloid angiopathy:</strong> Elderly, lobar hemorrhages, often recurrent</li>
                        <li><strong>Anticoagulation/coagulopathy</strong></li>
                        <li><strong>Vascular malformations:</strong> AVM, cavernous malformation (younger patients)</li>
                        <li><strong>Hemorrhagic transformation of ischemic stroke</strong></li>
                        <li><strong>Tumor, cocaine/sympathomimetics</strong></li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Non-contrast CT head:</strong> First-line. Hyperdense (bright) lesion with surrounding edema</li>
                        <li><strong>CT angiography:</strong> "Spot sign" (contrast extravasation) predicts hematoma expansion</li>
                        <li><strong>MRI:</strong> Better for underlying lesion (tumor, cavernoma, amyloid angiopathy)</li>
                        <li><strong>Conventional angiography:</strong> If vascular malformation suspected</li>
                    </ul>
                    <p><span class="label">ICH Score (Prognosis):</span></p>
                    <ul>
                        <li>GCS 3-4 (2 pts), GCS 5-12 (1 pt), GCS 13-15 (0 pts)</li>
                        <li>ICH volume â‰¥30 mL (1 pt)</li>
                        <li>Intraventricular extension (1 pt)</li>
                        <li>Infratentorial origin (1 pt)</li>
                        <li>Age â‰¥80 (1 pt)</li>
                        <li><strong>30-day mortality:</strong> Score 0 = 0%, Score 5 = 100%</li>
                    </ul>
                    <p><span class="label">Labs:</span> CBC, PT/INR, aPTT, fibrinogen, blood type/screen, CMP, troponin, toxicology screen</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Blood Pressure Management (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Target SBP <140 mmHg:</strong> Intensive BP lowering within 6 hours is safe and may improve outcomes (INTERACT2, ATACH-2)</li>
                        <li><strong>Agents:</strong> Nicardipine or clevidipine infusion (titratable). Labetalol IV bolus alternative</li>
                        <li><strong>Avoid:</strong> Precipitous drops (>60 mmHg in 1 hour)</li>
                        <li><strong>Exception:</strong> Avoid aggressive lowering if large infarct with hemorrhagic transformation</li>
                    </ul>
                    <p><span class="label">Anticoagulation Reversal (URGENT):</span></p>
                    <ul>
                        <li><strong>Warfarin:</strong> 4-factor PCC (25-50 units/kg) + Vitamin K 10mg IV. Goal INR <1.4</li>
                        <li><strong>Dabigatran:</strong> Idarucizumab 5g IV (if available) or 4-factor PCC</li>
                        <li><strong>Factor Xa inhibitors (rivaroxaban, apixaban):</strong> Andexanet alfa if available, or 4-factor PCC 50 units/kg</li>
                        <li><strong>Heparin:</strong> Protamine (1mg per 100 units heparin given in last 2-3 hours)</li>
                        <li><strong>Thrombocytopenia:</strong> Platelet transfusion if <100,000</li>
                    </ul>
                    <p><span class="label">ICP Management:</span></p>
                    <ul>
                        <li>Elevate head of bed 30Â°</li>
                        <li>Osmotic therapy: Mannitol 1g/kg or hypertonic saline 23.4% 30mL</li>
                        <li>Consider EVD if intraventricular hemorrhage with hydrocephalus</li>
                        <li>Avoid hyperthermia (increases ICP and poor outcomes)</li>
                    </ul>
                    <p><span class="label">Seizure Prophylaxis:</span></p>
                    <ul>
                        <li><strong>Not routinely recommended</strong> (AHA guidelines 2022)</li>
                        <li>Treat clinical seizures; consider continuous EEG if decreased LOC out of proportion to imaging</li>
                    </ul>
                    <p><span class="label">Surgical Consultation:</span></p>
                    <ul>
                        <li><strong>Cerebellar hemorrhage >3cm:</strong> Urgent surgical evacuation (can herniate rapidly)</li>
                        <li><strong>Supratentorial:</strong> Consider for superficial lobar hemorrhages, especially if deteriorating</li>
                        <li><strong>Minimally invasive surgery:</strong> Emerging option (MISTIE III trial)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>You cannot tell ICH from ischemic stroke without CT:</strong> Always image before thrombolytics</li>
                    <li><strong>Hematoma expansion is the enemy:</strong> 30-40% expand in first 3-6 hours. BP control and reversal critical</li>
                    <li><strong>Cerebellar hemorrhage is surgical emergency:</strong> Small posterior fossa, can herniate quickly</li>
                    <li><strong>SBP <140 is safe:</strong> Don't be afraid to aggressively treat BP</li>
                    <li><strong>ICH score is self-fulfilling:</strong> Don't withdraw care based solely on score</li>
                </ul>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="perforation" class="condition-page">
            <div class="page-header">
                <h2>77. GI PERFORATION</h2>
                <div class="subtitle">Surgical Emergency â€¢ Free Air â€¢ Peritonitis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Presentation:</span></p>
                    <ul>
                        <li>Sudden onset severe abdominal pain</li>
                        <li>Peritoneal signs: Rigidity, rebound tenderness, guarding</li>
                        <li>Fever, tachycardia, hypotension (septic shock)</li>
                        <li>Absent bowel sounds</li>
                    </ul>
                    <p><span class="label">Location-Based Features:</span></p>
                    <ul>
                        <li><strong>Peptic ulcer (gastric/duodenal):</strong> Sudden epigastric pain, may radiate to shoulder (diaphragmatic irritation), NSAIDs/H. pylori history</li>
                        <li><strong>Appendiceal:</strong> Initially RLQ, then diffuse</li>
                        <li><strong>Colonic (diverticular, tumor, ischemic):</strong> LLQ or diffuse, feculent peritonitis (higher mortality)</li>
                        <li><strong>Small bowel:</strong> Trauma, ischemia, foreign body, Crohn's disease</li>
                    </ul>
                    <p><span class="label">Special Populations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> May have blunted symptoms, minimal peritoneal signs despite perforation</li>
                        <li><strong>Immunocompromised/steroids:</strong> Masked inflammatory response</li>
                        <li><strong>Post-procedure:</strong> Colonoscopy, ERCP, endoscopy</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CT abdomen/pelvis with IV contrast:</strong> Study of choice (sensitivity >90% for free air)</li>
                        <li>Findings: Pneumoperitoneum (free air), extraluminal contrast, inflammatory changes at perforation site, abscess</li>
                        <li><strong>Upright CXR:</strong> Free air under diaphragm (70-80% sensitive). Quick bedside test</li>
                        <li><strong>Left lateral decubitus abdominal XR:</strong> If upright not possible</li>
                    </ul>
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li>CBC (leukocytosis), CMP, lactate (elevated suggests ischemia/shock)</li>
                        <li>Type and screen (prepare for OR)</li>
                        <li>Lipase (rule out pancreatitis)</li>
                        <li>Blood cultures</li>
                    </ul>
                    <p><span class="label">Free Air DDx:</span></p>
                    <ul>
                        <li>True perforation (most common)</li>
                        <li>Recent surgery/procedure</li>
                        <li>Barotrauma (mechanical ventilation)</li>
                        <li>Extension from pneumothorax/pneumomediastinum</li>
                        <li>Benign pneumatosis (less peritoneal signs)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Resuscitation (Parallel with Surgical Consult):</span></p>
                    <ul>
                        <li><strong>NPO</strong></li>
                        <li><strong>Large-bore IV access, aggressive fluid resuscitation</strong></li>
                        <li><strong>Vasopressors</strong> if refractory hypotension</li>
                        <li><strong>NG tube</strong> for decompression</li>
                        <li><strong>Foley catheter</strong> for UOP monitoring</li>
                    </ul>
                    <p><span class="label">Antibiotics (Start Immediately):</span></p>
                    <ul>
                        <li><strong>Upper GI perforation:</strong> Ceftriaxone + metronidazole (less fecal contamination)</li>
                        <li><strong>Lower GI/colonic perforation:</strong> Pip-tazo OR cefepime + metronidazole OR carbapenem</li>
                        <li>Continue for 4-7 days depending on source control</li>
                    </ul>
                    <p><span class="label">Surgical Intervention:</span></p>
                    <ul>
                        <li><strong>Emergent surgery</strong> is typically required</li>
                        <li><strong>Peptic ulcer:</strong> Graham patch (omental patch repair)</li>
                        <li><strong>Appendix:</strong> Appendectomy</li>
                        <li><strong>Colon:</strong> Resection with diversion (Hartmann procedure) vs primary anastomosis</li>
                        <li><strong>Small bowel:</strong> Resection and primary anastomosis</li>
                    </ul>
                    <p><span class="label">Conservative Management (Select Cases):</span></p>
                    <ul>
                        <li>Stable patient, contained perforation (walled off), no diffuse peritonitis</li>
                        <li>NPO, IV antibiotics, close monitoring</li>
                        <li>Percutaneous drainage of abscess if present</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>Free air = surgery until proven otherwise:</strong> Even small amounts are significant</li>
                    <li><strong>Elderly can have perforation without classic peritonitis:</strong> High index of suspicion</li>
                    <li><strong>Feculent peritonitis (colonic) is more lethal than gastric:</strong> Bacterial load much higher</li>
                    <li><strong>Lactate elevation + free air = surgical emergency:</strong> Don't delay for optimization</li>
                    <li><strong>Post-colonoscopy perforation:</strong> Can be delayed 24-48 hours. Always consider in recent procedure</li>
                </ul>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="sah" class="condition-page">
            <div class="page-header">
                <h2>78. SUBARACHNOID HEMORRHAGE (SAH)</h2>
                <div class="subtitle">Thunderclap Headache â€¢ Aneurysm Rupture â€¢ Neurosurgical Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Presentation:</span></p>
                    <ul>
                        <li><strong>"Worst headache of my life"</strong> - sudden onset, maximal intensity at onset (thunderclap)</li>
                        <li>Nausea, vomiting</li>
                        <li>Neck stiffness (meningismus)</li>
                        <li>Photophobia</li>
                        <li>Syncope at onset (25-50%)</li>
                        <li>Seizures</li>
                    </ul>
                    <p><span class="label">Sentinel Headache:</span> 20-50% report minor "warning leak" headache days-weeks before major rupture</p>
                    <p><span class="label">Hunt and Hess Grade:</span></p>
                    <ul>
                        <li><strong>Grade 1:</strong> Mild headache, no neurologic deficit</li>
                        <li><strong>Grade 2:</strong> Severe headache, stiff neck, no deficit other than cranial nerve palsy</li>
                        <li><strong>Grade 3:</strong> Drowsy, confused, mild focal deficit</li>
                        <li><strong>Grade 4:</strong> Stupor, hemiparesis</li>
                        <li><strong>Grade 5:</strong> Coma, decerebrate posturing</li>
                    </ul>
                    <p><span class="label">Causes:</span></p>
                    <ul>
                        <li><strong>Aneurysmal (85%):</strong> Most common locations - anterior communicating, posterior communicating, MCA bifurcation</li>
                        <li><strong>Non-aneurysmal perimesencephalic (10%):</strong> Benign, venous origin</li>
                        <li><strong>Other (5%):</strong> AVM, trauma, vasculitis, coagulopathy</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Non-contrast CT head:</strong> First-line. Sensitivity 95-100% within 6 hours, decreases over time</li>
                        <li>Look for: Hyperdensity in subarachnoid space (basilar cisterns, Sylvian fissures, interhemispheric fissure)</li>
                        <li><strong>CT Angiography:</strong> If CT positive, obtain immediately to identify aneurysm (sensitivity 95-100%)</li>
                    </ul>
                    <p><span class="label">Lumbar Puncture:</span></p>
                    <ul>
                        <li><strong>Indicated if:</strong> CT negative but clinical suspicion high</li>
                        <li><strong>Wait 6-12 hours from headache onset</strong> (allows RBC lysis â†’ xanthochromia)</li>
                        <li><strong>Positive findings:</strong> Elevated RBCs (not clearing from tube 1 to tube 4), xanthochromia (yellow CSF on visual inspection or spectrophotometry)</li>
                        <li><strong>Xanthochromia:</strong> Bilirubin from RBC breakdown. Most reliable indicator of true SAH vs traumatic tap</li>
                    </ul>
                    <p><span class="label">Ottawa SAH Rule (for clinical decision-making):</span></p>
                    <ul>
                        <li>Investigate for SAH if thunderclap headache + any of: Age â‰¥40, neck pain/stiffness, witnessed LOC, onset with exertion, limited neck flexion</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Initial Stabilization:</span></p>
                    <ul>
                        <li><strong>ABCs:</strong> Intubate if decreased LOC (GCS â‰¤8)</li>
                        <li><strong>BP control:</strong> SBP <160 mmHg before aneurysm secured (prevent rebleeding)</li>
                        <li><strong>Pain control:</strong> Avoid hypertensive spikes (use short-acting opioids)</li>
                        <li><strong>Seizure prophylaxis:</strong> Often given (levetiracetam), though controversial</li>
                        <li><strong>Stool softeners:</strong> Avoid Valsalva</li>
                    </ul>
                    <p><span class="label">Aneurysm Treatment (Within 24-72 hours):</span></p>
                    <ul>
                        <li><strong>Endovascular coiling:</strong> Preferred for many aneurysms (less invasive)</li>
                        <li><strong>Surgical clipping:</strong> For certain locations/morphologies</li>
                        <li><strong>Goal:</strong> Secure aneurysm before rebleeding (highest risk day 0-1)</li>
                    </ul>
                    <p><span class="label">Prevention of Complications:</span></p>
                    <ul>
                        <li><strong>Vasospasm (peak days 4-14):</strong></li>
                        <ul>
                            <li>Nimodipine 60mg PO/NG q4h for 21 days (only proven agent to improve outcomes)</li>
                            <li>Monitor with TCDs or CTA</li>
                            <li>Treat symptomatic vasospasm: Induced hypertension, endovascular intervention</li>
                        </ul>
                        <li><strong>Hydrocephalus:</strong> External ventricular drain (EVD) if needed</li>
                        <li><strong>Hyponatremia:</strong> Common (SIADH or cerebral salt wasting). Monitor sodium closely</li>
                        <li><strong>DVT prophylaxis:</strong> Mechanical first, then chemical after aneurysm secured</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
                <ul>
                    <li><strong>"Worst headache of life" = SAH until proven otherwise:</strong> Always investigate</li>
                    <li><strong>CT sensitivity drops over time:</strong> ~100% at 6hr, ~50% at 7 days. LP needed if CT negative and high suspicion</li>
                    <li><strong>Nimodipine is neuroprotective, not BP control:</strong> Continue even if hypotensive</li>
                    <li><strong>Rebleeding is catastrophic:</strong> Mortality 70%. Secure aneurysm early</li>
                    <li><strong>Vasospasm kills in the second week:</strong> Monitor closely days 4-14</li>
                    <li><strong>Sentinel headache:</strong> Mild headaches preceding SAH are often missed. High index of suspicion</li>
                </ul>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
        </div>
<div id="esophageal-spasm" class="condition-page">
    <div class="page-header">
        <h2>79. ESOPHAGEAL SPASM</h2>
        <div class="subtitle">Dysphagia â€¢ Chest Pain â€¢ Normal Endoscopy â€¢ Manometry Diagnosis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Intermittent dysphagia to both solids and liquids with non-cardiac chest pain, worse with hot/cold liquids or emotional stress. Often mimics cardiac chest pain with substernal pressure radiating to back or arms.</p>
            
            <ul>
                <li><strong>Symptoms:</strong>
                    <ul>
                        <li>Dysphagia: Intermittent, paradoxically worse with liquids than solids</li>
                        <li>Chest pain: Substernal, squeezing, can radiate to back/jaw/arms</li>
                        <li>Triggered by: Hot/cold liquids, rapid eating, emotional stress</li>
                        <li>Duration: Seconds to minutes, can last hours</li>
                        <li>Relief: May improve with warm liquids, calcium channel blockers, nitroglycerin</li>
                    </ul>
                </li>
                
                <li><strong>Types:</strong>
                    <ul>
                        <li>Distal Esophageal Spasm (DES): Multiple simultaneous contractions in distal esophagus</li>
                        <li>Jackhammer Esophagus: Hypercontractile peristalsis (>8000 mmHgÂ·sÂ·cm)</li>
                        <li>Nutcracker Esophagus: High-amplitude peristaltic contractions (>180 mmHg)</li>
                    </ul>
                </li>
                
                <li><strong>Associated Conditions:</strong> GERD (50%), anxiety disorders, diabetes, alcohol use</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Initial Evaluation:</span></p>
            <ul>
                <li><strong>Rule Out Cardiac:</strong> ECG, troponin if acute chest pain (cardiac workup first)</li>
                <li><strong>Upper Endoscopy:</strong> Normal or mild inflammation; excludes structural lesions, strictures, eosinophilic esophagitis</li>
                <li><strong>Barium Esophagram:</strong> "Corkscrew" or "rosary bead" appearance (simultaneous contractions), tertiary contractions</li>
            </ul>
            
            <p><span class="label">Definitive Testing:</span></p>
            <ul>
                <li><strong>High-Resolution Esophageal Manometry (Gold Standard):</strong>
                    <ul>
                        <li>Distal Esophageal Spasm: â‰¥20% premature contractions (DCI >450 mmHgÂ·sÂ·cm)</li>
                        <li>Jackhammer: â‰¥20% swallows with DCI >8000 mmHgÂ·sÂ·cm</li>
                        <li>Normal LES relaxation (distinguishes from achalasia)</li>
                        <li>Chicago Classification v4.0 criteria</li>
                    </ul>
                </li>
                
                <li><strong>pH Monitoring:</strong> If GERD suspected as trigger (24-hour pH-impedance)</li>
                
                <li><strong>Labs:</strong> Usually normal; TSH if thyroid dysfunction suspected</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">First-Line Medical Therapy:</span></p>
            <ul>
                <li><strong>Calcium Channel Blockers:</strong>
                    <ul>
                        <li>Diltiazem 30-60 mg PO TID-QID (before meals)</li>
                        <li>Nifedipine 10-30 mg PO TID-QID</li>
                        <li>Response rate: 50-70%</li>
                    </ul>
                </li>
                
                <li><strong>Nitrates:</strong>
                    <ul>
                        <li>Isosorbide dinitrate 5-10 mg SL PRN before meals</li>
                        <li>Long-acting: Isosorbide mononitrate 30-60 mg PO daily</li>
                        <li>Side effects: Headache, hypotension</li>
                    </ul>
                </li>
                
                <li><strong>PPI Therapy:</strong> If GERD component (omeprazole 20-40 mg PO daily)</li>
            </ul>
            
            <p><span class="label">Second-Line Therapy:</span></p>
            <ul>
                <li><strong>Tricyclic Antidepressants:</strong>
                    <ul>
                        <li>Imipramine 25-50 mg PO qHS (pain modulation)</li>
                        <li>Trazodone 100-150 mg PO qHS</li>
                    </ul>
                </li>
                
                <li><strong>Phosphodiesterase-5 Inhibitors:</strong> Sildenafil 50 mg PO prior to meals (emerging data)</li>
                
                <li><strong>Peppermint Oil:</strong> 0.2 mL enteric-coated capsules TID (natural smooth muscle relaxant)</li>
            </ul>
            
            <p><span class="label">Interventional Therapy (Refractory Cases):</span></p>
            <ul>
                <li><strong>Botulinum Toxin Injection:</strong> 100-200 units into esophageal body (temporary relief, 3-6 months)</li>
                
                <li><strong>Peroral Endoscopic Myotomy (POEM):</strong>
                    <ul>
                        <li>Success rate: 80-90% for spastic disorders</li>
                        <li>Lower esophageal myotomy length 6-10 cm</li>
                    </ul>
                </li>
                
                <li><strong>Surgical Myotomy:</strong> Rarely needed; reserved for failed POEM</li>
            </ul>
            
            <p><span class="label">Lifestyle Modifications:</span></p>
            <ul>
                <li>Avoid triggers: Very hot/cold foods, carbonated beverages, rapid eating</li>
                <li>Small, frequent meals</li>
                <li>Stress reduction techniques</li>
                <li>Avoid late-night eating</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Cardiac Mimicry:</strong> Up to 30% of patients with chest pain and normal coronary angiography have esophageal spasm. Always consider after cardiac workup is negative, especially if pain relieved by nitroglycerin (which relaxes esophageal smooth muscle).</li>
            
            <li><strong>The Nutcracker Paradox:</strong> Jackhammer/nutcracker esophagus may be asymptomatic. Symptom correlation on manometry is crucial - many patients have high-amplitude contractions without symptoms.</li>
            
            <li><strong>GERD Connection:</strong> 50% of spasm patients have GERD. Acid reflux can trigger spasm, so always treat reflux first before escalating to other therapies.</li>
            
            <li><strong>Manometry Timing:</strong> Perform manometry AFTER upper endoscopy and off PPI therapy (if possible) for accurate diagnosis. Requires specialized motility center.</li>
            
            <li><strong>Natural History:</strong> Only 3-5% of DES progresses to achalasia. Most patients have stable or improving symptoms over time, especially with treatment.</li>
            
            <li><strong>Drug-Induced Spasm:</strong> Bisphosphonates, NSAIDs, and potassium supplements can cause spasm. Review medication list before extensive workup.</li>
            
            <li><strong>Corkscrew Sign:</strong> Classic barium finding but only seen during symptomatic episodes (20-30% sensitivity). Normal barium swallow doesn't exclude diagnosis.</li>
            
            <li><strong>POEM vs. Heller:</strong> POEM has replaced Heller myotomy as first-line surgical therapy for refractory spastic disorders - less invasive, better outcomes, fewer complications.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe chest pain unresponsive to medical management</li>
                        <li>Unable to exclude acute coronary syndrome despite negative workup</li>
                        <li>Significant dehydration or inability to tolerate oral intake</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Pain controlled on oral medications</li>
                        <li>Able to tolerate oral intake without dysphagia</li>
                        <li>Cardiac causes excluded (negative troponin, normal ECG)</li>
                        <li>Follow-up arranged with GI/primary care</li>
                        <li>Prescription for calcium channel blockers or nitrates</li>
                        <li>Patient educated on trigger avoidance and medication use</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="gastritis-erosions" class="condition-page">
    <div class="page-header">
        <h2>80. GASTRITIS / GASTRIC EROSIONS</h2>
        <div class="subtitle">Epigastric Pain â€¢ NSAID Use â€¢ H. pylori â€¢ Endoscopic Diagnosis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Dyspepsia with epigastric pain, nausea, and early satiety. May be asymptomatic or present with upper GI bleeding (hematemesis, melena) if erosive/hemorrhagic.</p>
            
            <ul>
                <li><strong>Symptoms:</strong>
                    <ul>
                        <li>Epigastric pain/burning: Postprandial or fasting</li>
                        <li>Nausea/vomiting: May have coffee-ground emesis</li>
                        <li>Early satiety and bloating</li>
                        <li>Anorexia and weight loss (chronic cases)</li>
                        <li>GI bleeding: Melena, hematemesis (if erosive)</li>
                    </ul>
                </li>
                
                <li><strong>Types of Gastritis:</strong>
                    <ul>
                        <li><strong>Erosive (Acute):</strong> NSAIDs, alcohol, stress, bile reflux</li>
                        <li><strong>Non-Erosive (Chronic):</strong> H. pylori, autoimmune, eosinophilic</li>
                        <li><strong>Hemorrhagic:</strong> Stress-related mucosal disease (SRMD) in ICU</li>
                        <li><strong>Atrophic:</strong> Chronic H. pylori or autoimmune (pernicious anemia)</li>
                    </ul>
                </li>
                
                <li><strong>Risk Factors:</strong>
                    <ul>
                        <li>NSAIDs/aspirin (most common cause of erosive gastritis)</li>
                        <li>H. pylori infection (most common cause of chronic gastritis)</li>
                        <li>Alcohol (dose-dependent mucosal injury)</li>
                        <li>Stress: Critical illness, burns, trauma, post-surgical</li>
                        <li>Bile reflux (post-gastrectomy)</li>
                        <li>Autoimmune (pernicious anemia, type 1 DM, thyroiditis)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Initial Labs:</span></p>
            <ul>
                <li><strong>CBC:</strong> Anemia (acute blood loss or chronic B12 deficiency in atrophic gastritis)</li>
                <li><strong>BMP:</strong> Assess for dehydration, renal function</li>
                <li><strong>If Bleeding:</strong> Type & screen, coagulation studies</li>
            </ul>
            
            <p><span class="label">H. pylori Testing (All patients with gastritis):</span></p>
            <ul>
                <li><strong>Non-Invasive (First-Line if no alarm symptoms):</strong>
                    <ul>
                        <li>Urea Breath Test: Sensitivity/specificity >95% (gold standard non-invasive)</li>
                        <li>Stool Antigen: Sensitivity 91-98%, specificity 94-99%</li>
                        <li>Serology: IgG antibody (can't distinguish active from past infection, not for test-of-cure)</li>
                    </ul>
                </li>
                
                <li><strong>Invasive (At time of endoscopy):</strong>
                    <ul>
                        <li>Rapid Urease Test (CLO test): Sensitivity 90-95%</li>
                        <li>Histology: Gold standard, allows assessment of atrophy/metaplasia</li>
                        <li>Culture: For antibiotic resistance testing if multiple treatment failures</li>
                    </ul>
                </li>
                
                <li><strong>Testing Notes:</strong> Hold PPI Ã—2 weeks, antibiotics/bismuth Ã—4 weeks before testing to avoid false negatives</li>
            </ul>
            
            <p><span class="label">Endoscopy (EGD) - Indications:</span></p>
            <ul>
                <li><strong>Urgent:</strong> Active GI bleeding, hemodynamic instability</li>
                <li><strong>Prompt:</strong> Alarm symptoms (age >60, weight loss, dysphagia, anemia, family history gastric cancer)</li>
                <li><strong>Routine:</strong> Persistent symptoms despite PPI, confirm diagnosis, assess for complications</li>
            </ul>
            
            <p><span class="label">Endoscopic Findings:</span></p>
            <ul>
                <li><strong>Erosive Gastritis:</strong> Multiple shallow erosions, erythema, friability, may have active bleeding</li>
                <li><strong>Non-Erosive:</strong> Erythema, nodularity (H. pylori), pallor (atrophic)</li>
                <li><strong>Hemorrhagic:</strong> Petechiae, submucosal hemorrhage, overlying clot</li>
                <li><strong>Biopsy:</strong> Antrum and body for H. pylori, inflammation grade, atrophy, intestinal metaplasia</li>
            </ul>
            
            <p><span class="label">Additional Testing (Atrophic Gastritis):</span></p>
            <ul>
                <li><strong>Vitamin B12:</strong> <200 pg/mL indicates deficiency</li>
                <li><strong>Gastrin Level:</strong> Elevated (>500 pg/mL) in atrophic gastritis with achlorhydria</li>
                <li><strong>Antiparietal Cell Antibodies:</strong> Present in 90% of autoimmune gastritis</li>
                <li><strong>Anti-Intrinsic Factor Antibodies:</strong> Specific (98%) but less sensitive (50%) for pernicious anemia</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Acute Management:</span></p>
            <ul>
                <li><strong>Discontinue Offending Agents:</strong> NSAIDs, alcohol, smoking</li>
                
                <li><strong>Acid Suppression:</strong>
                    <ul>
                        <li><strong>PPI (First-Line):</strong> Omeprazole 40 mg PO BID or pantoprazole 40 mg IV BID (if NPO/bleeding)</li>
                        <li>Continue for 4-8 weeks for erosive gastritis</li>
                        <li>Can transition to once-daily after acute phase</li>
                    </ul>
                </li>
                
                <li><strong>If Active Bleeding:</strong>
                    <ul>
                        <li>Resuscitation: 2 large-bore IVs, crystalloid, pRBC as needed</li>
                        <li>Urgent EGD: Within 24 hours for hemodynamically significant bleeding</li>
                        <li>Endoscopic therapy: Epinephrine injection, thermal coagulation, hemostatic powder</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">H. pylori Eradication (If Positive):</span></p>
            <ul>
                <li><strong>First-Line: Clarithromycin-Based Triple Therapy (14 days):</strong>
                    <ul>
                        <li>PPI (omeprazole 20 mg or equivalent) PO BID</li>
                        <li>Clarithromycin 500 mg PO BID</li>
                        <li>Amoxicillin 1000 mg PO BID</li>
                        <li>Use only if local clarithromycin resistance <15% and no prior macrolide exposure</li>
                    </ul>
                </li>
                
                <li><strong>Alternative: Bismuth Quadruple Therapy (14 days, preferred if resistance >15%):</strong>
                    <ul>
                        <li>PPI (omeprazole 20 mg) PO BID</li>
                        <li>Bismuth subsalicylate 525 mg (2 tabs) PO QID</li>
                        <li>Metronidazole 250 mg (or 500 mg TID) PO QID</li>
                        <li>Tetracycline 500 mg PO QID</li>
                    </ul>
                </li>
                
                <li><strong>Concomitant Therapy (14 days, high efficacy):</strong>
                    <ul>
                        <li>PPI BID + Clarithromycin 500 mg BID + Amoxicillin 1000 mg BID + Metronidazole 500 mg BID</li>
                    </ul>
                </li>
                
                <li><strong>Test of Cure:</strong> Urea breath test or stool antigen â‰¥4 weeks after completion of therapy</li>
            </ul>
            
            <p><span class="label">Stress Ulcer Prophylaxis (ICU/Critically Ill):</span></p>
            <ul>
                <li><strong>Indications:</strong> Mechanical ventilation >48h, coagulopathy (PLT <50K, INR >1.5), history of GI bleeding</li>
                <li><strong>Agent:</strong> Pantoprazole 40 mg IV daily or famotidine 20 mg IV BID</li>
                <li><strong>Duration:</strong> While critically ill with risk factors; discontinue when ICU risk resolved</li>
            </ul>
            
            <p><span class="label">Autoimmune Atrophic Gastritis:</span></p>
            <ul>
                <li><strong>B12 Supplementation:</strong> 1000 mcg IM monthly (lifelong) for pernicious anemia</li>
                <li><strong>Surveillance:</strong> EGD every 3-5 years (increased gastric cancer risk)</li>
                <li><strong>PPI:</strong> Generally not needed (achlorhydria already present)</li>
            </ul>
            
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li>Antiemetics: Ondansetron 4-8 mg IV/PO Q8H PRN</li>
                <li>Sucralfate 1g PO QID: Mucosal protectant (if not on PPI)</li>
                <li>Dietary: Small frequent meals, avoid irritants (spicy, acidic foods, caffeine)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>NSAID Gastritis is Dose-Dependent:</strong> Even low-dose aspirin (81 mg) increases gastric erosion risk. COX-2 selective agents (celecoxib) reduce but don't eliminate risk. Always consider PPI co-therapy for high-risk patients (age >60, history of PUD, anticoagulation).</li>
            
            <li><strong>H. pylori Testing Strategy:</strong> Test-and-treat is appropriate for young patients (<60) with dyspepsia. Endoscopy first for alarm symptoms. Never use serology for test-of-cure (stays positive for years after eradication).</li>
            
            <li><strong>PPI Before Testing:</strong> PPIs decrease sensitivity of all H. pylori tests except serology. Hold Ã—2 weeks before urea breath test or stool antigen. Can cause false-negative endoscopic biopsies.</li>
            
            <li><strong>Clarithromycin Resistance Rising:</strong> Now >15% in many regions including US. Bismuth quadruple or concomitant therapy preferred first-line in high-resistance areas. Check local antibiograms.</li>
            
            <li><strong>Gastric Cancer Screening:</strong> Chronic H. pylori infection is the strongest risk factor for gastric adenocarcinoma. Eradication reduces risk by 50%. Atrophic gastritis and intestinal metaplasia warrant surveillance endoscopy.</li>
            
            <li><strong>Autoimmune Gastritis Triad:</strong> Pernicious anemia (B12 deficiency), achlorhydria (high gastrin), and increased risk of gastric carcinoid tumors (due to hypergastrinemia causing ECL cell hyperplasia).</li>
            
            <li><strong>Stress Gastropathy:</strong> Common in ICU patients but actual clinically significant bleeding is rare (3-5%). Target prophylaxis to high-risk patients only (ventilated, coagulopathic) to reduce C. diff and pneumonia risks from PPIs.</li>
            
            <li><strong>Erosions vs. Ulcers:</strong> Erosions are superficial (mucosa/submucosa), heal quickly, rarely bleed significantly. Ulcers penetrate muscularis, take longer to heal, have higher bleeding/perforation risk. Treatment differs.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Active GI bleeding with hemodynamic instability (SBP <90, HR >120)</li>
                        <li>Massive hematemesis or large-volume melena</li>
                        <li>Hemoglobin drop >3 g/dL despite transfusion</li>
                        <li>Need for >4 units PRBC transfusion</li>
                        <li>Signs of perforation (peritoneal signs, free air on imaging)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable for >24 hours</li>
                        <li>Hemoglobin stable without transfusion requirement</li>
                        <li>No evidence of active bleeding (no melena, stable Hgb)</li>
                        <li>Tolerating oral intake</li>
                        <li>On PPI therapy (omeprazole 40 mg daily or equivalent)</li>
                        <li>H. pylori treatment initiated if positive</li>
                        <li>Follow-up EGD arranged if indicated (within 4-8 weeks)</li>
                        <li>Patient educated on NSA ID avoidance, PPI compliance</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="hemorrhoids" class="condition-page">
    <div class="page-header">
        <h2>81. HEMORRHOIDS</h2>
        <div class="subtitle">Bright Red Blood Per Rectum â€¢ Anal Pain â€¢ Prolapse â€¢ Straining</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Painless bright red blood per rectum on toilet paper or coating stool, often with straining or constipation. External hemorrhoids may cause anal pain, especially if thrombosed.</p>
            
            <ul>
                <li><strong>Internal Hemorrhoids (Above Dentate Line):</strong>
                    <ul>
                        <li>Painless bleeding: Bright red, on paper or dripping into toilet</li>
                        <li>Prolapse: May reduce spontaneously or require manual reduction</li>
                        <li>Mucus discharge and pruritus</li>
                        <li>No pain (unless thrombosed or strangulated)</li>
                        <li>Covered by mucosa (insensate above dentate line)</li>
                    </ul>
                </li>
                
                <li><strong>External Hemorrhoids (Below Dentate Line):</strong>
                    <ul>
                        <li>Painful swelling: Especially if thrombosed</li>
                        <li>Skin tags: Residual from previous thrombosis</li>
                        <li>Itching and irritation</li>
                        <li>Acute thrombosis: Severe pain, purple/blue nodule</li>
                        <li>Covered by anoderm (sensate below dentate line)</li>
                    </ul>
                </li>
                
                <li><strong>Grades of Internal Hemorrhoids:</strong>
                    <ul>
                        <li><strong>Grade I:</strong> Bleeding only, no prolapse (confined to anal canal)</li>
                        <li><strong>Grade II:</strong> Prolapse with straining, spontaneously reduces</li>
                        <li><strong>Grade III:</strong> Prolapse with straining, requires manual reduction</li>
                        <li><strong>Grade IV:</strong> Irreducible prolapse, risk of strangulation</li>
                    </ul>
                </li>
                
                <li><strong>Risk Factors:</strong> Chronic constipation/straining, prolonged sitting, pregnancy, obesity, low-fiber diet, aging, portal hypertension (but rarely sole cause), chronic diarrhea</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Clinical Diagnosis (History and Examination):</span></p>
            <ul>
                <li><strong>History:</strong>
                    <ul>
                        <li>Bleeding pattern: Bright red, on paper vs. mixed with stool</li>
                        <li>Pain: Suggests external or thrombosed hemorrhoid</li>
                        <li>Prolapse: Timing (with defecation, constant), reducibility</li>
                        <li>Duration and severity of symptoms</li>
                        <li>Associated symptoms: Weight loss, change in bowel habits (red flags for malignancy)</li>
                    </ul>
                </li>
                
                <li><strong>Physical Examination:</strong>
                    <ul>
                        <li>Inspection: Look for external hemorrhoids, skin tags, thrombosis, prolapse, fissures</li>
                        <li>Digital rectal exam: Assess for masses, tenderness, tone</li>
                        <li>Anoscopy: Visualize internal hemorrhoids, classify grade</li>
                        <li>Note: Internal hemorrhoids typically not palpable on DRE</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Additional Evaluation:</span></p>
            <ul>
                <li><strong>Labs:</strong>
                    <ul>
                        <li>CBC: If significant bleeding or symptoms of anemia</li>
                        <li>Iron studies: If chronic bleeding suspected</li>
                    </ul>
                </li>
                
                <li><strong>Colonoscopy - Indications:</strong>
                    <ul>
                        <li>Age â‰¥45 (per colon cancer screening guidelines)</li>
                        <li>Red flag symptoms: Weight loss, change in bowel habits, anemia, family history</li>
                        <li>Occult blood positive (not just hemorrhoid bleeding)</li>
                        <li>Persistent bleeding despite treatment</li>
                        <li>Not routinely needed for young patients with typical hemorrhoid symptoms</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Differential Diagnosis:</span></p>
            <ul>
                <li>Anal fissure (painful, sentinel tag, visible tear)</li>
                <li>Colorectal cancer or polyp (older age, constitutional symptoms)</li>
                <li>Inflammatory bowel disease (diarrhea, abdominal pain)</li>
                <li>Rectal prolapse (circumferential, concentric rings)</li>
                <li>Abscess/fistula (fever, purulent drainage)</li>
                <li>Proctitis (tenesmus, mucus, urgency)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Conservative Medical Management (First-Line for Grades I-II):</span></p>
            <ul>
                <li><strong>Dietary Modifications:</strong>
                    <ul>
                        <li>High-fiber diet: 25-35 g daily (fruits, vegetables, whole grains)</li>
                        <li>Fiber supplementation: Psyllium 1 tablespoon BID or methylcellulose</li>
                        <li>Hydration: 8-10 glasses water daily</li>
                        <li>Improvement in 50-90% with fiber alone</li>
                    </ul>
                </li>
                
                <li><strong>Stool Softeners:</strong> Docusate 100-200 mg PO BID</li>
                
                <li><strong>Topical Therapy:</strong>
                    <ul>
                        <li>Hydrocortisone 1% cream: BID Ã—1 week (short-term only to avoid atrophy)</li>
                        <li>Witch hazel pads (Tucks): Cooling, anti-inflammatory</li>
                        <li>Lidocaine 5% ointment: For pain relief</li>
                        <li>Combination products: Preparation H, Anusol (limited evidence)</li>
                    </ul>
                </li>
                
                <li><strong>Sitz Baths:</strong> Warm water 15-20 minutes TID and after bowel movements</li>
                
                <li><strong>Bowel Habit Modification:</strong>
                    <ul>
                        <li>Avoid straining and prolonged sitting on toilet</li>
                        <li>Respond promptly to defecation urge</li>
                        <li>Limit bathroom time to <3-5 minutes</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Thrombosed External Hemorrhoid:</span></p>
            <ul>
                <li><strong>If Presenting <48-72 Hours:</strong>
                    <ul>
                        <li>Excision under local anesthesia (preferred, definitive)</li>
                        <li>Elliptical incision over thrombosis, remove clot and hemorrhoidal tissue</li>
                        <li>Faster pain relief than conservative management</li>
                    </ul>
                </li>
                
                <li><strong>If Presenting >72 Hours or Mild:</strong>
                    <ul>
                        <li>Conservative management: Pain control, sitz baths, stool softeners</li>
                        <li>Pain typically resolves in 7-14 days</li>
                        <li>May leave residual skin tag</li>
                    </ul>
                </li>
                
                <li><strong>Pain Control:</strong>
                    <ul>
                        <li>NSAIDs: Ibuprofen 600 mg PO Q8H or naproxen 500 mg PO BID</li>
                        <li>Acetaminophen: 650-1000 mg PO Q6H</li>
                        <li>Short course narcotics if severe (oxycodone 5 mg PO Q6H PRN Ã—3-5 days)</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Office-Based Procedures (Grades I-III):</span></p>
            <ul>
                <li><strong>Rubber Band Ligation:</strong>
                    <ul>
                        <li>Indications: Grades II-III with bleeding or prolapse</li>
                        <li>Technique: Place band at base of hemorrhoid column</li>
                        <li>Success rate: 70-80%, can repeat</li>
                        <li>Complications: Pain, bleeding, thrombosis (rare: pelvic sepsis)</li>
                        <li>Multiple hemorrhoids staged 2-4 weeks apart</li>
                    </ul>
                </li>
                
                <li><strong>Infrared Coagulation/Sclerotherapy:</strong>
                    <ul>
                        <li>Best for Grade I with bleeding</li>
                        <li>Lower efficacy than rubber band ligation</li>
                        <li>Fewer complications, less pain</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Surgical Management (Grades III-IV or Failed Conservative):</span></p>
            <ul>
                <li><strong>Hemorrhoidectomy (Excisional):</strong>
                    <ul>
                        <li>Indications: Grade IV, large external component, failed office procedures</li>
                        <li>Success rate: >95%</li>
                        <li>Recovery: 2-4 weeks, significant post-op pain</li>
                        <li>Complications: Pain, bleeding, infection, stenosis, incontinence (rare)</li>
                    </ul>
                </li>
                
                <li><strong>Stapled Hemorrhoidopexy (PPH):</strong>
                    <ul>
                        <li>Circular stapler repositions prolapsed tissue</li>
                        <li>Less pain than excision, faster recovery</li>
                        <li>Higher recurrence rate than hemorrhoidectomy</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Discharge Instructions:</span></p>
            <ul>
                <li>Continue high-fiber diet indefinitely</li>
                <li>Return if: Severe pain, fever, urinary retention, excessive bleeding</li>
                <li>Follow-up in 2-4 weeks to assess response</li>
                <li>Colonoscopy if indicated per age/symptoms</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Not All BRBPR is Hemorrhoids:</strong> Always consider colorectal cancer, especially age >45, family history, or associated symptoms (weight loss, change in bowel habits, anemia). Don't attribute all bleeding to hemorrhoids without appropriate screening.</li>
            
            <li><strong>Portal Hypertension Misconception:</strong> Hemorrhoids are NOT anorectal varices and don't decompress portal pressures. Patients with cirrhosis get hemorrhoids at the same rate as general population from straining, not portal hypertension.</li>
            
            <li><strong>Thrombosed External Timing:</strong> Excision is most beneficial within 48-72 hours of symptom onset. After 72 hours, thrombus is organizing and pain is improving - conservative management is equally effective with less procedure risk.</li>
            
            <li><strong>Rubber Band Ligation Risk:</strong> Rare but catastrophic complication is pelvic sepsis (incidence 1 in 55,000). Warn patients to return for fever, urinary retention, or severe pain. Occurs 2-9 days post-procedure.</li>
            
            <li><strong>Fiber is First-Line:</strong> Fiber supplementation alone improves symptoms in 50-90% of Grade I-II hemorrhoids. Start with 7-10g daily, increase gradually to 25-35g to minimize gas/bloating. Takes 4-6 weeks for full effect.</li>
            
            <li><strong>Steroid Cream Duration:</strong> Never use topical steroids >7 days - causes tissue atrophy, skin thinning, and can worsen symptoms long-term. Short burst for acute symptoms only.</li>
            
            <li><strong>Internal Hemorrhoids Don't Hurt:</strong> If patient has significant pain, think external hemorrhoid, thrombosis, fissure, or abscess. Internal hemorrhoids above dentate line lack somatic innervation (unless strangulated/necrotic).</li>
            
            <li><strong>Pregnancy Hemorrhoids:</strong> Common in 3rd trimester from pelvic pressure and constipation. Almost always resolve postpartum. Conservative management only during pregnancy - defer procedures until 3-6 months postpartum.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Massive hemorrhoidal bleeding causing hemodynamic instability (rare)</li>
                        <li>Thrombosed hemorrhoid with signs of systemic infection/sepsis</li>
                        <li>Post-operative hemorrhoidectomy complications requiring ICU monitoring</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Pain controlled on oral analgesics</li>
                        <li>No active bleeding or bleeding controlled</li>
                        <li>Able to tolerate oral intake and pass stool</li>
                        <li>Thrombosed hemorrhoid managed (either conservative or excised)</li>
                        <li>Patient educated on stool softeners, high-fiber diet, sitz baths</li>
                        <li>Follow-up with primary care or colorectal surgery if needed</li>
                        <li>Return precautions given (severe pain, fever, inability to urinate)</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="intraabdominal-abscess" class="condition-page">
    <div class="page-header">
        <h2>82. INTRA-ABDOMINAL ABSCESS</h2>
        <div class="subtitle">Fever â€¢ Abdominal Pain â€¢ Post-Operative â€¢ CT Diagnosis â€¢ Source Control</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Persistent fever with abdominal pain in patient with recent surgery, perforated viscus, or intra-abdominal infection. May present insidiously with non-specific symptoms.</p>
            
            <ul>
                <li><strong>Clinical Features:</strong>
                    <ul>
                        <li>Fever: Often persistent despite antibiotics</li>
                        <li>Abdominal pain: Localized or diffuse, depending on location</li>
                        <li>Ileus: Nausea, vomiting, decreased bowel sounds, distension</li>
                        <li>Systemic signs: Tachycardia, leukocytosis, sepsis</li>
                        <li>Subacute presentation: Anorexia, weight loss, failure to thrive</li>
                    </ul>
                </li>
                
                <li><strong>Common Locations:</strong>
                    <ul>
                        <li><strong>Subphrenic:</strong> Right/left upper quadrant, under diaphragm</li>
                        <li><strong>Perihepatlic:</strong> Morrison's pouch, perihepatic space</li>
                        <li><strong>Lesser Sac:</strong> Behind stomach, anterior to pancreas</li>
                        <li><strong>Pelvis:</strong> Pouch of Douglas (rectouterine/rectovesical)</li>
                        <li><strong>Paracolic Gutters:</strong> Right or left lateral</li>
                        <li><strong>Inter-loop:</strong> Between bowel loops</li>
                        <li><strong>Retroperitoneal:</strong> Perirenal, psoas, paraspinal</li>
                    </ul>
                </li>
                
                <li><strong>Etiologies:</strong>
                    <ul>
                        <li>Post-operative: Anastomotic leak, contamination (most common after colorectal surgery)</li>
                        <li>Perforated viscus: Appendicitis, diverticulitis, PUD, bowel perforation</li>
                        <li>Infected pancreatitis: Pancreatic necrosis (typically >2-3 weeks after onset)</li>
                        <li>Primary peritonitis: Cirrhosis with ascites (SBP)</li>
                        <li>Intra-abdominal sepsis: Cholecystitis, cholangitis</li>
                        <li>Trauma: Penetrating or blunt with hollow viscus injury</li>
                        <li>Crohn's disease: Penetrating disease with abscess formation</li>
                    </ul>
                </li>
                
                <li><strong>Risk Factors:</strong> Recent abdominal surgery, immunosuppression, diabetes, malignancy, prior abscess, IBD, complicated appendicitis/diverticulitis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Initial Labs:</span></p>
            <ul>
                <li><strong>CBC:</strong> Leukocytosis (may be normal in immunosuppressed), left shift, bandemia</li>
                <li><strong>CMP:</strong> Assess for electrolyte abnormalities, renal function, hepatic dysfunction</li>
                <li><strong>Liver Enzymes:</strong> Elevated if hepatobiliary or subphrenic abscess</li>
                <li><strong>Lactate:</strong> Elevated in sepsis, bowel ischemia</li>
                <li><strong>Blood Cultures:</strong> Send before antibiotics (positive in 20-30% of intra-abdominal infections)</li>
                <li><strong>Inflammatory Markers:</strong> ESR and CRP elevated (not specific but trend useful)</li>
            </ul>
            
            <p><span class="label">Imaging (CT Abdomen/Pelvis with IV Contrast - Gold Standard):</span></p>
            <ul>
                <li><strong>Findings Consistent with Abscess:</strong>
                    <ul>
                        <li>Fluid collection with enhancing wall ("rim enhancement")</li>
                        <li>Gas bubbles within collection (pathognomonic)</li>
                        <li>Mass effect on adjacent structures</li>
                        <li>Surrounding inflammation/fat stranding</li>
                    </ul>
                </li>
                
                <li><strong>Sensitivity/Specificity:</strong> >95% for abscess detection</li>
                
                <li><strong>Planning Drainage:</strong> CT guides percutaneous vs. surgical approach</li>
            </ul>
            
            <p><span class="label">Alternative Imaging:</span></p>
            <ul>
                <li><strong>Ultrasound:</strong>
                    <ul>
                        <li>Useful for hepatic, pelvic abscesses</li>
                        <li>Limited by bowel gas, obesity</li>
                        <li>Advantages: Bedside, no radiation, can guide drainage</li>
                    </ul>
                </li>
                
                <li><strong>MRI:</strong>
                    <ul>
                        <li>If contrast-allergy or pregnancy</li>
                        <li>Excellent for liver, pelvis, retroperitoneum</li>
                        <li>Time-consuming, limited availability</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Microbiologic Diagnosis:</span></p>
            <ul>
                <li><strong>Abscess Fluid Analysis:</strong>
                    <ul>
                        <li>Gram stain and culture (aerobic and anaerobic)</li>
                        <li>Cell count and differential</li>
                        <li>Consider fungal cultures if immunosuppressed or persistent fever</li>
                    </ul>
                </li>
                
                <li><strong>Common Organisms:</strong>
                    <ul>
                        <li>Polymicrobial (80%): Enteric gram-negatives (E. coli, Klebsiella) + anaerobes (Bacteroides fragilis)</li>
                        <li>Enterococcus (20-30%, controversial pathogenicity)</li>
                        <li>Fungi: Candida (immunosuppressed, prolonged antibiotics, post-op)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Source Control (Most Important):</span></p>
            <ul>
                <li><strong>Percutaneous Drainage (Preferred if feasible):</strong>
                    <ul>
                        <li>CT or ultrasound-guided catheter placement</li>
                        <li>Success rate: 70-90% for simple abscesses</li>
                        <li>Advantages: Less invasive, lower morbidity, can be repeated</li>
                        <li>Criteria: Safe access route, unilocular or few loculations, >3-4 cm size</li>
                        <li>Catheter management: Daily outputs, flush if needed, remove when <10-20 mL/day</li>
                    </ul>
                </li>
                
                <li><strong>Surgical Drainage (Indications):</strong>
                    <ul>
                        <li>No safe percutaneous access</li>
                        <li>Multiloculated or complex collections</li>
                        <li>Failed percutaneous drainage (persistent fever/leukocytosis >72h)</li>
                        <li>Associated with bowel perforation, fistula, or necrotic tissue</li>
                        <li>Phlegmon or organized infection requiring debridement</li>
                    </ul>
                </li>
                
                <li><strong>Timing:</strong> Urgent drainage for sepsis/septic shock; otherwise within 24 hours of diagnosis</li>
            </ul>
            
            <p><span class="label">Empiric Antibiotic Therapy:</span></p>
            <ul>
                <li><strong>Community-Acquired, Mild-Moderate Severity:</strong>
                    <ul>
                        <li>Piperacillin-tazobactam 3.375 g IV Q6H or 4.5g IV Q8H</li>
                        <li>Alternative: Ceftriaxone 2g IV Q24H + metronidazole 500 mg IV Q8H</li>
                        <li>Alternative: Ciprofloxacin 400 mg IV Q12H + metronidazole 500 mg IV Q8H</li>
                    </ul>
                </li>
                
                <li><strong>High Severity or Healthcare-Associated:</strong>
                    <ul>
                        <li>Meropenem 1g IV Q8H</li>
                        <li>Imipenem 500 mg IV Q6H or doripenem 500 mg IV Q8H</li>
                        <li>Piperacillin-tazobactam 4.5g IV Q6H (extended infusion)</li>
                        <li>Consider: Vancomycin 15-20 mg/kg IV Q8-12H if MRSA risk (penetrating trauma, prior MRSA)</li>
                    </ul>
                </li>
                
                <li><strong>Add Antifungal Coverage (if indicated):</strong>
                    <ul>
                        <li>Indications: Recent broad-spectrum antibiotics, immunosuppressed, recurrent abscess, Candida in cultures/operative findings</li>
                        <li>Fluconazole 800 mg IV Ã—1, then 400 mg IV Q24H</li>
                        <li>If azole-resistant: Echinocandin (micafungin 100 mg IV Q24H or caspofungin 70 mg IV Ã—1, then 50 mg Q24H)</li>
                    </ul>
                </li>
                
                <li><strong>Duration:</strong>
                    <ul>
                        <li>4-7 days if adequate source control achieved</li>
                        <li>Extend to 10-14 days if slow clinical response or incomplete drainage</li>
                        <li>Can transition to PO when afebrile Ã—24h, improving WBC, tolerating PO</li>
                    </ul>
                </li>
                
                <li><strong>De-escalation:</strong> Narrow based on culture results and clinical improvement</li>
            </ul>
            
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li><strong>Resuscitation:</strong> IV fluids, vasopressors for septic shock (norepinephrine first-line)</li>
                <li><strong>NPO/Bowel Rest:</strong> If ileus or concern for bowel involvement</li>
                <li><strong>NG Tube:</strong> For decompression if significant ileus or vomiting</li>
                <li><strong>Nutrition:</strong> Enteral if tolerated; TPN if prolonged NPO expected</li>
                <li><strong>DVT Prophylaxis:</strong> Heparin 5000 units SC TID or enoxaparin 40 mg SC daily</li>
                <li><strong>Monitor:</strong> Serial exams, vital signs, WBC, drain outputs</li>
            </ul>
            
            <p><span class="label">Follow-Up Imaging:</span></p>
            <ul>
                <li>Repeat CT if persistent fever/leukocytosis >72h despite drainage and antibiotics</li>
                <li>Confirm resolution if patient slow to improve or had complex abscess</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Source Control is Everything:</strong> Antibiotics alone fail in 90% of intra-abdominal abscesses. The KEY to successful treatment is adequate drainage - "pus somewhere, must go somewhere." Persistent fever on antibiotics = inadequate source control until proven otherwise.</li>
            
            <li><strong>The 72-Hour Rule:</strong> If no clinical improvement (defervescence, decreasing WBC) within 72 hours of drainage + antibiotics, assume inadequate drainage. Get repeat imaging and consider re-intervention or surgical drainage.</li>
            
            <li><strong>Post-Op Fever Timing:</strong> Intra-abdominal abscesses typically present 5-10 days post-operatively. Earlier fever (days 1-3) is more likely atelectasis, UTI, or wound infection. Later fever (>14 days) consider retained foreign body or anastomotic leak.</li>
            
            <li><strong>Pancreatic Abscess Exception:</strong> Infected pancreatic necrosis shouldn't be drained in first 2-3 weeks (worsens outcomes). Initial management is antibiotics alone. Delay intervention until necrosis is organized/walled-off (â‰¥4 weeks).</li>
            
            <li><strong>Enterococcus Dilemma:</strong> Enterococcus in intra-abdominal infections is often a colonizer, not a pathogen. IDSA guidelines don't recommend routine coverage unless immunosuppressed, valvular heart disease, or enterococcus bacteremia. Drain the abscess first.</li>
            
            <li><strong>Candida Coverage Controversies:</strong> Routine antifungal coverage not recommended for community-acquired infections. Reserve for high-risk patients: upper GI perforation, recurrent infection, immunosuppression, or Candida in perioperative cultures.</li>
            
            <li><strong>Drain Not Draining:</strong> If percutaneous drain outputs suddenly decrease with persistent fever, assume drain malfunction (kinked, clotted, malpositioned). Flush catheter and obtain repeat imaging. Don't pull drain until abscess resolved and output minimal.</li>
            
            <li><strong>Interloop Abscess Challenge:</strong> Small abscesses between bowel loops are difficult to drain percutaneously (bowel in the way). Often require surgical approach or prolonged antibiotic therapy with serial imaging to ensure resolution.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Septic shock requiring vasopressor support</li>
                        <li>Respiratory failure requiring mechanical ventilation</li>
                        <li>Acute renal failure requiring dialysis</li>
                        <li>Multi-organ dysfunction</li>
                        <li>Large abscess with impending perforation or rupture</li>
                        <li>Post-operative complications (anastomotic leak, bleeding)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable without vasopressors for >24 hours</li>
                        <li>Afebrile for >24 hours (or downtrending fever)</li>
                        <li>Improving leukocytosis and inflammatory markers</li>
                        <li>Abscess adequately drained (percutaneous or surgical)</li>
                        <li>Tolerating oral intake</li>
                        <li>Completed initial antibiotics course (typically 4-7 days IV, then transition to PO)</li>
                        <li>Drain output decreasing (if percutaneous drain placed)</li>
                        <li>Imaging shows resolution or improvement of abscess</li>
                        <li>Follow-up arranged with surgery and infectious disease</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="mallory-weiss" class="condition-page">
    <div class="page-header">
        <h2>83. MALLORY-WEISS TEAR</h2>
        <div class="subtitle">Hematemesis After Retching â€¢ Non-Variceal Bleeding â€¢ Usually Self-Limited</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Hematemesis following forceful or prolonged vomiting/retching episodes. Typically in patients with alcohol use, hyperemesis, or eating disorders.</p>
            
            <ul>
                <li><strong>Typical Presentation:</strong>
                    <ul>
                        <li>Initial non-bloody vomiting: Forceful retching from alcohol, gastroenteritis, hyperemesis</li>
                        <li>Hematemesis: Bright red blood after multiple vomiting episodes</li>
                        <li>Volume: Usually small to moderate (rarely massive)</li>
                        <li>Self-limited: 80-90% stop bleeding spontaneously</li>
                        <li>Epigastric/chest discomfort: From retching, not the tear itself</li>
                    </ul>
                </li>
                
                <li><strong>Associated Conditions:</strong>
                    <ul>
                        <li>Alcohol use (most common): Binge drinking with vomiting</li>
                        <li>Hyperemesis: Gravidarum, chemotherapy, gastroenteritis</li>
                        <li>Eating disorders: Bulimia with self-induced vomiting</li>
                        <li>Hiatal hernia (50% of patients)</li>
                        <li>Medications: Cough, NSAIDs (predispose to bleeding)</li>
                    </ul>
                </li>
                
                <li><strong>Pathophysiology:</strong>
                    <ul>
                        <li>Mucosal tear in gastroesophageal junction or distal esophagus</li>
                        <li>Caused by sudden increase in intra-abdominal pressure + negative intrathoracic pressure</li>
                        <li>Linear tear 5-40 mm long, usually single (can be multiple)</li>
                        <li>Location: 80% gastric side of GE junction, 20% esophageal side</li>
                    </ul>
                </li>
                
                <li><strong>Mallory-Weiss vs. Boerhaave:</strong>
                    <ul>
                        <li><strong>Mallory-Weiss:</strong> Mucosal tear only, bleeding, no perforation</li>
                        <li><strong>Boerhaave:</strong> Full-thickness perforation, pneumomediastinum, sepsis, surgical emergency</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Initial Assessment:</span></p>
            <ul>
                <li><strong>History:</strong>
                    <ul>
                        <li>Recent forceful vomiting/retching (key historical feature)</li>
                        <li>Alcohol consumption</li>
                        <li>NSAID/anticoagulant use</li>
                        <li>Prior GI bleeding, liver disease, coagulopathy</li>
                    </ul>
                </li>
                
                <li><strong>Physical Exam:</strong>
                    <ul>
                        <li>Vital signs: Usually stable (hematemesis typically limited)</li>
                        <li>Volume status: Orthostatics, skin turgor, mucous membranes</li>
                        <li>Abdominal exam: Epigastric tenderness common</li>
                        <li>Look for stigmata of chronic liver disease</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>CBC:</strong> Baseline hemoglobin/hematocrit, platelets</li>
                <li><strong>CMP:</strong> BUN:Cr ratio >30 suggests upper GI source (blood urea from protein digestion)</li>
                <li><strong>Coagulation Studies:</strong> PT/INR if anticoagulated or liver disease suspected</li>
                <li><strong>Type & Screen:</strong> Prepare for possible transfusion</li>
                <li><strong>Lactate:</strong> If concerned for shock/hypoperfusion</li>
            </ul>
            
            <p><span class="label">Risk Stratification (Glasgow-Blatchford Score):</span></p>
            <ul>
                <li><strong>Score 0-1:</strong> Low risk, possible outpatient management with close follow-up</li>
                <li><strong>Score â‰¥2:</strong> Hospitalization recommended</li>
                <li>Components: Hemoglobin, BUN, systolic BP, pulse, melena, syncope, hepatic/cardiac disease</li>
            </ul>
            
            <p><span class="label">Upper Endoscopy (EGD):</span></p>
            <ul>
                <li><strong>Timing:</strong>
                    <ul>
                        <li>Urgent (<12h): Active bleeding, hemodynamic instability</li>
                        <li>Early (12-24h): High-risk features (large volume hematemesis, coagulopathy, cirrhosis)</li>
                        <li>Routine: Stable patients without high-risk features</li>
                    </ul>
                </li>
                
                <li><strong>Endoscopic Findings:</strong>
                    <ul>
                        <li>Linear mucosal tear at GE junction (usually gastric side)</li>
                        <li>Active bleeding (rare, <10% at time of endoscopy)</li>
                        <li>Forrest Classification:</li>
                        <ul>
                            <li>Forrest Ia: Spurting arterial bleeding</li>
                            <li>Forrest Ib: Oozing bleeding</li>
                            <li>Forrest IIa: Visible vessel (non-bleeding)</li>
                            <li>Forrest IIb: Adherent clot</li>
                            <li>Forrest III: Clean-based tear (lowest rebleed risk)</li>
                        </ul>
                        <li>Often difficult to visualize if bleeding has stopped</li>
                    </ul>
                </li>
                
                <li><strong>Endoscopic Therapy (if indicated):</strong>
                    <ul>
                        <li>Epinephrine injection (1:10,000 dilution)</li>
                        <li>Thermal coagulation (bipolar or heater probe)</li>
                        <li>Hemoclipping</li>
                        <li>Hemospray (topical powder)</li>
                        <li>Combination therapy preferred for high-risk lesions</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Imaging (If Boerhaave Suspected):</span></p>
            <ul>
                <li><strong>CXR:</strong> Look for pneumomediastinum, pleural effusion, subcutaneous emphysema</li>
                <li><strong>CT Chest with Oral Contrast:</strong> Gold standard if perforation suspected (severe chest pain, fever, sepsis)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Initial Resuscitation:</span></p>
            <ul>
                <li><strong>IV Access:</strong> 2 large-bore IVs (18g or larger)</li>
                
                <li><strong>Fluid Resuscitation:</strong> NS or LR bolus, target MAP >65 mmHg</li>
                
                <li><strong>Blood Products (if indicated):</strong>
                    <ul>
                        <li>pRBC transfusion: Goal Hgb >7 g/dL (>8 g/dL if cardiovascular disease)</li>
                        <li>Platelets: If <50,000 and active bleeding</li>
                        <li>FFP: If INR >1.5 and active bleeding (goal INR <1.5)</li>
                        <li>Prothrombin complex concentrate (PCC): For rapid INR reversal if on warfarin</li>
                    </ul>
                </li>
                
                <li><strong>Reverse Anticoagulation (if applicable):</strong>
                    <ul>
                        <li>Warfarin: Vitamin K 10 mg IV + PCC (or FFP)</li>
                        <li>Dabigatran: Idarucizumab 5g IV</li>
                        <li>Factor Xa inhibitors: Andexanet alfa or PCC</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Medical Management:</span></p>
            <ul>
                <li><strong>Proton Pump Inhibitor:</strong>
                    <ul>
                        <li>Pantoprazole 80 mg IV bolus, then 8 mg/h continuous infusion Ã—72h</li>
                        <li>Alternative: Omeprazole 40-80 mg IV BID</li>
                        <li>Transition to PO: Omeprazole 40 mg PO BID after EGD, then 20-40 mg daily Ã—4-8 weeks</li>
                    </ul>
                </li>
                
                <li><strong>Antiemetics:</strong>
                    <ul>
                        <li>Ondansetron 4-8 mg IV/PO Q8H PRN</li>
                        <li>Prevent further vomiting to allow healing</li>
                    </ul>
                </li>
                
                <li><strong>Prokinetic (if gastroparesis contributing):</strong>
                    <ul>
                        <li>Metoclopramide 10 mg IV/PO TID (30 min before meals)</li>
                    </ul>
                </li>
                
                <li><strong>Avoid:</strong> NSAIDs, alcohol (counsel patient)</li>
            </ul>
            
            <p><span class="label">Endoscopic Intervention (Minority of Cases):</span></p>
            <ul>
                <li><strong>Indications for Therapy:</strong>
                    <ul>
                        <li>Active bleeding at endoscopy (Forrest Ia or Ib)</li>
                        <li>Visible vessel (Forrest IIa)</li>
                        <li>Adherent clot (Forrest IIb) - controversial, consider clot removal</li>
                    </ul>
                </li>
                
                <li><strong>No Therapy Needed:</strong> Clean-based tear (Forrest III) - most common finding</li>
            </ul>
            
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li><strong>NPO Initially:</strong> Advance to clear liquids after stabilization, then regular diet as tolerated</li>
                <li><strong>Monitor:</strong> Serial Hgb/Hct, vital signs, stool color (melena)</li>
                <li><strong>NG Tube:</strong> Not routinely recommended (may worsen tear); consider if massive bleeding or airway protection needed</li>
            </ul>
            
            <p><span class="label">Disposition:</span></p>
            <ul>
                <li><strong>ICU:</strong> Active bleeding, hemodynamic instability, significant comorbidities</li>
                <li><strong>Telemetry Floor:</strong> Most patients (stable, completed EGD)</li>
                <li><strong>Discharge:</strong> After 24h if stable, Hgb stable, tolerating PO, Glasgow-Blatchford score 0-1</li>
            </ul>
            
            <p><span class="label">Follow-Up:</span></p>
            <ul>
                <li>GI follow-up in 2-4 weeks</li>
                <li>Continue PPI for 4-8 weeks to allow healing</li>
                <li>Alcohol cessation counseling</li>
                <li>Address underlying cause (hyperemesis, bulimia, etc.)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Self-Limited Course:</strong> 80-90% of Mallory-Weiss tears stop bleeding spontaneously without intervention. Rebleeding rate is only 0-10%. This is one of the most benign causes of hematemesis - don't overtreat.</li>
            
            <li><strong>Classic History is Key:</strong> The diagnosis is strongly suggested by history of forceful vomiting followed by hematemesis. If history is atypical (no vomiting, chronic bleeding), consider alternative diagnoses (PUD, erosive gastritis, Cameron lesions).</li>
            
            <li><strong>High-Risk Features for Intervention:</strong> Rebleeding risk increased with: Coagulopathy (INR >2.5), thrombocytopenia (<50K), active bleeding at endoscopy, cirrhosis, large tears >2 cm. These patients warrant more aggressive management.</li>
            
            <li><strong>PPI Rationale:</strong> Unlike peptic ulcers, acid suppression doesn't directly heal Mallory-Weiss tears (they're mechanical). PPIs are given to (1) prevent further mucosal injury, (2) stabilize clot by raising gastric pH, and (3) treat coexistent gastritis/esophagitis.</li>
            
            <li><strong>Don't Confuse with Boerhaave:</strong> Boerhaave syndrome is full-thickness esophageal rupture (Mackler's triad: vomiting, chest pain, subcutaneous emphysema). It's a surgical emergency with 20-40% mortality. Mallory-Weiss is mucosal only.</li>
            
            <li><strong>Hiatal Hernia Association:</strong> 50% of Mallory-Weiss patients have hiatal hernia. The anatomic distortion at GE junction makes mucosa more vulnerable to shear forces during retching.</li>
            
            <li><strong>BUN:Cr Ratio Clue:</strong> Ratio >30 suggests upper GI bleed (blood is digested protein, producing urea). Lower ratio or normal ratio suggests lower GI source or non-GI cause of anemia.</li>
            
            <li><strong>Therapeutic Endoscopy Rare:</strong> Only 10-15% of Mallory-Weiss patients have active bleeding or high-risk stigmata requiring endoscopic therapy. Most endoscopies are diagnostic only (clean-based tear or already healed).</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Active bleeding with hemodynamic instability despite resuscitation</li>
                        <li>Hemoglobin <7 g/dL with ongoing transfusion requirements</li>
                        <li>Need for >4 units PRBC</li>
                        <li>Failed endoscopic hemostasis requiring repeat intervention or surgery</li>
                        <li>Esophageal perforation (rare complication)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable for >24 hours</li>
                        <li>Hemoglobin stable without transfusion requirement</li>
                        <li>No evidence of rebleeding</li>
                        <li>Tolerating oral intake</li>
                        <li>On PPI therapy (omeprazole 40 mg daily for 4-8 weeks)</li>
                        <li>Alcohol cessation counseling if applicable</li>
                        <li>Follow-up with GI and primary care arranged</li>
                        <li>Return precautions for recurrent hematemesis, melena, dizziness</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="neurogenic-shock" class="condition-page">
    <div class="page-header">
        <h2>84. NEUROGENIC SHOCK</h2>
        <div class="subtitle">Spinal Cord Injury â€¢ Bradycardia + Hypotension â€¢ Warm Extremities â€¢ Loss of Sympathetic Tone</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Hypotension with paradoxical bradycardia and warm, dry skin following acute spinal cord injury above T6. Results from loss of sympathetic tone with unopposed parasympathetic activity.</p>
            
            <ul>
                <li><strong>Clinical Triad (Distinguishes from other shock states):</strong>
                    <ul>
                        <li><strong>Hypotension:</strong> SBP <90 mmHg (variable severity)</li>
                        <li><strong>Bradycardia:</strong> HR 50-60 bpm (pathognomonic when combined with hypotension)</li>
                        <li><strong>Warm, Dry Skin:</strong> Peripheral vasodilation (unlike hypovolemic/cardiogenic shock)</li>
                    </ul>
                </li>
                
                <li><strong>Mechanism - Loss of Sympathetic Outflow:</strong>
                    <ul>
                        <li>Spinal sympathetic pathway disrupted (T1-L2 sympathetic chain)</li>
                        <li>Loss of vasomotor tone â†’ Peripheral vasodilation â†’ Decreased SVR</li>
                        <li>Loss of cardiac sympathetic innervation (T1-T4) â†’ Bradycardia</li>
                        <li>Unopposed vagal tone â†’ Further bradycardia</li>
                        <li>Venous pooling â†’ Decreased preload</li>
                    </ul>
                </li>
                
                <li><strong>Spinal Cord Injury Level:</strong>
                    <ul>
                        <li><strong>Above T6:</strong> Classic neurogenic shock (significant sympathetic disruption)</li>
                        <li><strong>Cervical (C3-C5):</strong> Most severe, includes diaphragm (respiratory failure)</li>
                        <li><strong>Below T6:</strong> Less likely to cause shock (preserved upper sympathetics)</li>
                    </ul>
                </li>
                
                <li><strong>Causes of Spinal Cord Injury:</strong>
                    <ul>
                        <li>Trauma: MVA, falls, sports injuries, penetrating injury</li>
                        <li>Non-traumatic: Epidural abscess, hematoma, tumor, cord infarction</li>
                        <li>Iatrogenic: Epidural anesthesia (rare high block), spinal surgery complication</li>
                    </ul>
                </li>
                
                <li><strong>Spinal Shock vs. Neurogenic Shock:</strong>
                    <ul>
                        <li><strong>Spinal Shock:</strong> Neurologic - flaccid paralysis, areflexia (lasts days-weeks)</li>
                        <li><strong>Neurogenic Shock:</strong> Hemodynamic - hypotension/bradycardia from sympathetic loss</li>
                        <li>These often coexist but are distinct entities</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Clinical Diagnosis (Key Features):</span></p>
            <ul>
                <li><strong>History:</strong> Recent trauma or acute neurologic event</li>
                <li><strong>Vital Signs:</strong> Hypotension + Bradycardia (or inappropriately normal HR for degree of hypotension)</li>
                <li><strong>Neurologic Exam:</strong>
                    <ul>
                        <li>Flaccid paralysis below level of injury</li>
                        <li>Loss of reflexes (spinal shock)</li>
                        <li>Sensory level</li>
                        <li>Priapism (pathognomonic in males)</li>
                        <li>Poikilothermia (inability to thermoregulate)</li>
                    </ul>
                </li>
                <li><strong>Skin:</strong> Warm, flushed, dry (vasodilated) above injury level; may be cool below injury</li>
            </ul>
            
            <p><span class="label">Rule Out Other Shock States (Critical):</span></p>
            <ul>
                <li><strong>Hypovolemic Shock:</strong>
                    <ul>
                        <li>Tachycardia, cold/clammy skin, narrow pulse pressure</li>
                        <li>Rule out: Hemorrhage (intra-abdominal, chest, pelvic/long bone fractures)</li>
                        <li>Neurogenic shock does NOT cause tachycardia or cold extremities</li>
                    </ul>
                </li>
                
                <li><strong>Cardiogenic Shock:</strong> Elevated JVP, pulmonary edema, cold extremities</li>
                
                <li><strong>Septic Shock:</strong> Fever, tachycardia (usually), warm extremities (early), altered mental status</li>
                
                <li><strong>Mixed Shock:</strong> Spinal injury patients may have concurrent hemorrhagic shock (polytrauma)</li>
            </ul>
            
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>CBC:</strong> Baseline hemoglobin (rule out hemorrhage)</li>
                <li><strong>CMP:</strong> Electrolytes, renal function</li>
                <li><strong>Lactate:</strong> May be elevated but less than hypovolemic/septic shock (if isolated neurogenic)</li>
                <li><strong>ABG:</strong> If respiratory compromise (high cervical injury)</li>
                <li><strong>Troponin:</strong> If concern for concurrent cardiac injury/MI</li>
                <li><strong>Blood Cultures:</strong> If sepsis cannot be excluded</li>
            </ul>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>CT Spine (Cervical/Thoracic):</strong>
                    <ul>
                        <li>Identify level and extent of spinal injury</li>
                        <li>Fractures, subluxation, epidural hematoma</li>
                        <li>STAT in trauma patients</li>
                    </ul>
                </li>
                
                <li><strong>MRI Spine (If stable):</strong>
                    <ul>
                        <li>Assess cord edema, contusion, compression</li>
                        <li>Evaluate for ligamentous injury, disc herniation</li>
                        <li>Gold standard for cord pathology</li>
                    </ul>
                </li>
                
                <li><strong>Trauma Imaging (Rule out concurrent injuries):</strong>
                    <ul>
                        <li>FAST exam or CT chest/abdomen/pelvis for hemorrhage</li>
                        <li>Chest X-ray</li>
                        <li>Pelvic X-ray if mechanism warrants</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Hemodynamic Monitoring:</span></p>
            <ul>
                <li><strong>Arterial Line:</strong> Continuous BP monitoring</li>
                <li><strong>Central Venous Catheter:</strong> CVP monitoring, vasopressor infusion</li>
                <li><strong>Foley Catheter:</strong> Urine output monitoring (neurogenic bladder common)</li>
                <li><strong>Consider PA Catheter or ECHO:</strong> If hemodynamics unclear or mixed shock</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">ABCs and Initial Resuscitation:</span></p>
            <ul>
                <li><strong>Airway:</strong>
                    <ul>
                        <li>C-spine precautions: In-line stabilization, avoid hyperextension</li>
                        <li>Intubate if: C5 or above injury (diaphragm paralysis), respiratory distress, GCS â‰¤8</li>
                        <li>Video laryngoscopy preferred (less neck manipulation)</li>
                    </ul>
                </li>
                
                <li><strong>Breathing:</strong>
                    <ul>
                        <li>High-flow O2 to maintain SpO2 >95%</li>
                        <li>Monitor for respiratory failure (cervical injuries)</li>
                        <li>Mechanical ventilation with lung-protective strategies if intubated</li>
                    </ul>
                </li>
                
                <li><strong>Circulation:</strong>
                    <ul>
                        <li>Large-bore IV access (2 peripheral IVs)</li>
                        <li>Spinal precautions during all procedures</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Hemodynamic Goals:</span></p>
            <ul>
                <li><strong>MAP Target: 85-90 mmHg (for 7 days post-injury)</strong>
                    <ul>
                        <li>Maintains spinal cord perfusion pressure</li>
                        <li>Higher MAP associated with improved neurologic outcomes</li>
                        <li>AANS/CNS guidelines recommend MAP 85-90 mmHg Ã—7 days</li>
                    </ul>
                </li>
                
                <li><strong>Heart Rate: 60-100 bpm</strong> (treat symptomatic bradycardia)</li>
            </ul>
            
            <p><span class="label">Fluid Resuscitation:</span></p>
            <ul>
                <li><strong>Initial Fluid Bolus:</strong>
                    <ul>
                        <li>NS or LR 500-1000 mL IV bolus</li>
                        <li>Reassess BP and perfusion</li>
                        <li>Caution: Excessive fluids worsen cord edema and pulmonary edema</li>
                    </ul>
                </li>
                
                <li><strong>Goal:</strong> Euvolemia (avoid both hypo- and hypervolemia)</li>
                
                <li><strong>Monitoring:</strong> CVP, urine output, clinical exam</li>
            </ul>
            
            <p><span class="label">Vasopressors (First-Line After Fluids):</span></p>
            <ul>
                <li><strong>Norepinephrine (Preferred):</strong>
                    <ul>
                        <li>Start: 0.01-0.05 mcg/kg/min (central line preferred)</li>
                        <li>Titrate to MAP 85-90 mmHg</li>
                        <li>Alpha-1 agonist (vasoconstriction) + beta-1 (inotropy/chronotropy)</li>
                    </ul>
                </li>
                
                <li><strong>Dopamine (Alternative):</strong>
                    <ul>
                        <li>Start: 5-10 mcg/kg/min</li>
                        <li>Increases HR and contractility (may help bradycardia)</li>
                        <li>Higher arrhythmia risk than norepinephrine</li>
                    </ul>
                </li>
                
                <li><strong>Phenylephrine (Pure Alpha Agonist):</strong>
                    <ul>
                        <li>If excessive tachycardia with norepinephrine/dopamine</li>
                        <li>May worsen bradycardia (reflex response)</li>
                    </ul>
                </li>
                
                <li><strong>Avoid:</strong> Excessive fluids as sole therapy (worsens cord edema)</li>
            </ul>
            
            <p><span class="label">Bradycardia Management:</span></p>
            <ul>
                <li><strong>Atropine:</strong>
                    <ul>
                        <li>0.5-1 mg IV bolus (can repeat Q3-5min, max 3 mg)</li>
                        <li>For symptomatic bradycardia (HR <50 with hypotension/altered mental status)</li>
                        <li>May have limited effect (denervated heart)</li>
                    </ul>
                </li>
                
                <li><strong>Transcutaneous Pacing:</strong>
                    <ul>
                        <li>If atropine fails or severe/persistent bradycardia</li>
                        <li>Temporary transvenous pacing for refractory cases</li>
                    </ul>
                </li>
                
                <li><strong>Dopamine or Epinephrine Infusion:</strong> For persistent symptomatic bradycardia</li>
            </ul>
            
            <p><span class="label">Spinal Cord Injury Specific Management:</span></p>
            <ul>
                <li><strong>Spinal Immobilization:</strong> C-spine collar until cleared by imaging</li>
                
                <li><strong>Neurosurgical Consultation:</strong> STAT for surgical evaluation/decompression</li>
                
                <li><strong>High-Dose Steroids (Controversial, Generally NOT Recommended):</strong>
                    <ul>
                        <li>Methylprednisolone was previously used (NASCIS protocols)</li>
                        <li>No longer recommended per AANS/CNS guidelines (no proven benefit, increased complications)</li>
                        <li>May be considered on case-by-case basis by neurosurgery</li>
                    </ul>
                </li>
                
                <li><strong>Early Surgical Decompression (If Indicated):</strong>
                    <ul>
                        <li>Within 24 hours improves outcomes</li>
                        <li>Indications: Compression, unstable fracture, progressive deficit</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li><strong>DVT Prophylaxis:</strong>
                    <ul>
                        <li>SCDs initially (within 24h)</li>
                        <li>Enoxaparin 30 mg SC BID (once hemorrhage ruled out, typically after 72h)</li>
                        <li>Spinal cord injury = VERY high DVT risk</li>
                    </ul>
                </li>
                
                <li><strong>Stress Ulcer Prophylaxis:</strong> PPI (pantoprazole 40 mg IV daily)</li>
                
                <li><strong>Foley Catheter:</strong> Neurogenic bladder common (monitor urine output, avoid over-distension)</li>
                
                <li><strong>Temperature Management:</strong> External warming/cooling (poikilothermia common)</li>
                
                <li><strong>Early Mobilization/Rehab:</strong> Once hemodynamically stable and spine cleared/stabilized</li>
            </ul>
            
            <p><span class="label">Disposition:</span></p>
            <ul>
                <li><strong>ICU Admission:</strong> All patients with neurogenic shock</li>
                <li><strong>Monitoring:</strong> Continuous cardiac, arterial line, central access, neuro checks Q1H</li>
                <li><strong>Duration:</strong> Shock typically resolves over days to weeks as sympathetic tone recovers (or doesn't)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Hypotension + Bradycardia = Neurogenic Until Proven Otherwise:</strong> This paradoxical combination is pathognomonic for neurogenic shock. All other shock states cause tachycardia (compensatory). If you see "HR 58, BP 85/50" after trauma, think spinal cord injury.</li>
            
            <li><strong>Don't Overcorrect the Bradycardia:</strong> HR 50-60 bpm is expected in neurogenic shock and does NOT need treatment unless symptomatic (hypotension, altered mental status, chest pain). Treat the MAP, not the number. Excessive atropine can cause tachycardia and worsen myocardial O2 demand.</li>
            
            <li><strong>Fluid Caution:</strong> Unlike hypovolemic shock, aggressive crystalloid resuscitation WORSENS outcomes in neurogenic shock by causing pulmonary/spinal cord edema. Give modest fluid bolus (1-2L), then start vasopressors early to achieve MAP goals.</li>
            
            <li><strong>MAP 85-90 mmHg for 7 Days:</strong> Specific guideline for acute SCI to maintain spinal cord perfusion. Higher than usual MAP goal. This is time-limited (7 days), then transition to standard goals (MAP 65+).</li>
            
            <li><strong>Rule Out Hemorrhage:</strong> Polytrauma patients can have BOTH neurogenic and hemorrhagic shock. Neurogenic shock alone doesn't cause narrow pulse pressure, cold extremities, or profound tachycardia (if present, assume hemorrhage). Get FAST/CT to rule out bleeding.</li>
            
            <li><strong>Priapism is Pathognomonic:</strong> Sustained erection in male patient with spinal injury is virtually diagnostic of cord injury and neurogenic shock. Results from loss of sympathetic tone with unopposed parasympathetic activity.</li>
            
            <li><strong>Methylprednisolone Controversy:</strong> Despite NASCIS trials, high-dose steroids are NO LONGER recommended per AANS/CNS guidelines (2013). Increased infection/complications, no proven benefit. Don't give unless neurosurgery specifically requests.</li>
            
            <li><strong>Sympathetic Recovery is Variable:</strong> Some patients regain sympathetic function over weeks-months. Others have permanent dysfunction (chronic orthostasis, thermoregulation issues, autonomic dysreflexia). Early rehab and education essential.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL patients with neurogenic shock require ICU admission</li>
                        <li>Vasopressor requirement (norepinephrine, phenylephrine)</li>
                        <li>Spinal cord injury (any level)</li>
                        <li>Hemodynamic instability (SBP <90, bradycardia <60 with hypotension)</li>
                        <li>Need for mechanical ventilation (high cervical injury)</li>
                        <li>Ongoing fluid resuscitation requirements</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable without vasopressor support for >48-72 hours</li>
                        <li>MAP consistently >65 mmHg</li>
                        <li>Heart rate normalized or stable (typically 60-80 with injury)</li>
                        <li>Spinal shock resolved (return of reflexes below lesion)</li>
                        <li>No further progression of neurologic deficits</li>
                        <li>Appropriate disposition arranged (acute rehab for spinal cord injury)</li>
                        <li>Urinary catheter management plan in place</li>
                        <li>DVT prophylaxis established (LMWH once spinal hematoma risk assessed)</li>
                        <li>Follow-up with neurosurgery and physical medicine/rehab arranged</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="ruptured-aaa" class="condition-page">
    <div class="page-header">
        <h2>85. RUPTURED ABDOMINAL AORTIC ANEURYSM</h2>
        <div class="subtitle">Abdominal/Back Pain â€¢ Hypotension â€¢ Pulsatile Mass â€¢ Surgical Emergency</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Triad (Only 50% Present):</span> Abdominal/back pain + Hypotension + Pulsatile abdominal mass. Ruptured AAA is a surgical emergency with mortality 50-80% overall, 90% if reaches ED alive.</p>
            
            <ul>
                <li><strong>Symptoms:</strong>
                    <ul>
                        <li><strong>Pain:</strong> Abdominal, back, or flank pain (sudden or gradually worsening)</li>
                        <li>Radiation: Back, groin, flank, or hip</li>
                        <li>Character: Tearing, ripping, or constant dull ache</li>
                        <li>May be painless in 30% (especially if contained/elderly)</li>
                    </ul>
                </li>
                
                <li><strong>Hemodynamic Status:</strong>
                    <ul>
                        <li><strong>Frank Rupture (Free Intraperitoneal):</strong> Profound hypotension/shock, rapid exsanguination</li>
                        <li><strong>Contained Rupture (Retroperitoneal):</strong> Relative hemodynamic stability initially, may compensate temporarily</li>
                        <li>Syncope or near-syncope (25%)</li>
                    </ul>
                </li>
                
                <li><strong>Physical Exam:</strong>
                    <ul>
                        <li><strong>Pulsatile Abdominal Mass:</strong> Palpable in 50-75% (sensitivity decreases with obesity, hypotension)</li>
                        <li>Abdominal distension and peritoneal signs</li>
                        <li>Hypotension or shock</li>
                        <li>Femoral pulses may be diminished or absent</li>
                        <li>Grey Turner sign: Flank ecchymosis (late, rare)</li>
                        <li>Cullen sign: Periumbilical ecchymosis (late, rare)</li>
                    </ul>
                </li>
                
                <li><strong>Atypical Presentations:</strong>
                    <ul>
                        <li>GI bleeding (aortoenteric fistula)</li>
                        <li>Lower extremity ischemia (distal embolization)</li>
                        <li>Isolated back pain mimicking renal colic/MSK pain</li>
                        <li>Syncope without obvious cause</li>
                    </ul>
                </li>
                
                <li><strong>Risk Factors for AAA:</strong>
                    <ul>
                        <li>Age >65 years (especially men)</li>
                        <li>Smoking (strongest modifiable risk factor)</li>
                        <li>Male sex (M:F = 4:1)</li>
                        <li>Family history (20% have first-degree relative with AAA)</li>
                        <li>Hypertension, hyperlipidemia, CAD, PAD</li>
                        <li>Known AAA (rupture risk increases with size: 1%/year if 5-5.9 cm, 10%/year if 6-6.9 cm, >20%/year if â‰¥7 cm)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Clinical Diagnosis in Unstable Patients:</span></p>
            <ul>
                <li><strong>High Clinical Suspicion + Hemodynamic Instability:</strong>
                    <ul>
                        <li>Do NOT delay for imaging if patient unstable</li>
                        <li>Bedside ultrasound if immediately available (see below)</li>
                        <li>Activate vascular surgery and go directly to OR</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Bedside Ultrasound (FAST Extended for AAA):</span></p>
            <ul>
                <li><strong>Indication:</strong> Unstable patient, rapid screening</li>
                <li><strong>Findings:</strong>
                    <ul>
                        <li>Aortic diameter >3 cm (normal â‰¤3 cm)</li>
                        <li>AAA defined as aortic diameter â‰¥3 cm</li>
                        <li>Intraperitoneal free fluid (ruptured)</li>
                        <li>Sensitivity: 95-100% for AAA presence, less sensitive for rupture</li>
                    </ul>
                </li>
                <li><strong>Limitation:</strong> Can't definitively diagnose rupture or assess proximal/distal extent</li>
            </ul>
            
            <p><span class="label">CT Angiography (CTA) Abdomen/Pelvis - Gold Standard:</span></p>
            <ul>
                <li><strong>Indication:</strong> Hemodynamically stable or stabilized patient</li>
                <li><strong>Findings:</strong>
                    <ul>
                        <li>AAA size and extent (infrarenal vs. suprarenal)</li>
                        <li>Active extravasation or contained rupture</li>
                        <li>Retroperitoneal hematoma</li>
                        <li>Vessel anatomy for surgical/endovascular planning</li>
                    </ul>
                </li>
                <li><strong>Sensitivity/Specificity:</strong> >95% for rupture</li>
                <li><strong>Contraindication:</strong> DO NOT send unstable patient to CT scanner</li>
            </ul>
            
            <p><span class="label">Labs (Don't Delay Surgery):</span></p>
            <ul>
                <li><strong>Type & Cross:</strong> 6-10 units pRBC (massive transfusion anticipated)</li>
                <li><strong>CBC:</strong> Baseline hemoglobin (may be normal acutely due to hemoconcentration)</li>
                <li><strong>CMP:</strong> Renal function (contrast), electrolytes</li>
                <li><strong>Coagulation Studies:</strong> PT/INR, PTT (baseline, anticipate coagulopathy)</li>
                <li><strong>Lactate:</strong> Assess perfusion/shock</li>
                <li><strong>Troponin:</strong> If concern for MI (may delay surgery)</li>
            </ul>
            
            <p><span class="label">ECG and CXR:</span></p>
            <ul>
                <li>Rule out MI/arrhythmia (if time permits and patient stable)</li>
                <li>Don't delay surgery for these tests if diagnosis clear</li>
            </ul>
            
            <p><span class="label">Differential Diagnosis (The Great Mimicker):</span></p>
            <ul>
                <li>Renal colic (unilateral, colicky, hematuria)</li>
                <li>Diverticulitis (LLQ pain, fever, CT shows colonic inflammation)</li>
                <li>Acute MI (chest pain radiating, ECG changes)</li>
                <li>Perforated viscus (peritonitis, free air)</li>
                <li>Pancreatitis (epigastric pain, elevated lipase)</li>
                <li>Mesenteric ischemia (pain out of proportion, lactate)</li>
                <li>Musculoskeletal back pain (no vascular symptoms)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Pre-Hospital and ED Resuscitation:</span></p>
            <ul>
                <li><strong>IV Access:</strong> 2 large-bore peripheral IVs (16g or larger) or intraosseous if unable</li>
                
                <li><strong>Permissive Hypotension (Key Concept):</strong>
                    <ul>
                        <li><strong>Goal SBP: 70-90 mmHg (or MAP 50-70 mmHg)</strong></li>
                        <li>Maintain perfusion to vital organs WITHOUT increasing bleeding</li>
                        <li>Overly aggressive resuscitation disrupts clot and worsens hemorrhage</li>
                        <li>"Pop the clot" phenomenon</li>
                    </ul>
                </li>
                
                <li><strong>Limited Fluid Resuscitation:</strong>
                    <ul>
                        <li>Give minimal crystalloid (250-500 mL boluses PRN for MAP 50-70)</li>
                        <li>Avoid large-volume resuscitation before surgical control</li>
                        <li>Immediate surgical intervention is priority, not normalization of BP</li>
                    </ul>
                </li>
                
                <li><strong>Blood Products (Once Activated):</strong>
                    <ul>
                        <li><strong>Massive Transfusion Protocol:</strong> 1:1:1 ratio pRBC:FFP:Platelets</li>
                        <li>Consider O-negative blood immediately if unstable</li>
                        <li>Tranexamic acid (TXA): 1g IV over 10 min, then 1g over 8h (if given <3h from injury)</li>
                    </ul>
                </li>
                
                <li><strong>Avoid:</strong>
                    <ul>
                        <li>NO chest compressions if cardiac arrest (futile and worsens bleeding)</li>
                        <li>NO palpation of abdomen if ruptured AAA suspected (may disrupt clot)</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Immediate Consultation:</span></p>
            <ul>
                <li><strong>Vascular Surgery:</strong> STAT consultation (as soon as diagnosis suspected)</li>
                <li><strong>Anesthesia:</strong> Activate OR, prepare for emergency surgery</li>
                <li><strong>Blood Bank:</strong> Massive transfusion protocol</li>
            </ul>
            
            <p><span class="label">Definitive Management - Surgical Repair:</span></p>
            <ul>
                <li><strong>Open Surgical Repair (OSR):</strong>
                    <ul>
                        <li>Traditional approach: Midline laparotomy, aortic cross-clamp, graft replacement</li>
                        <li>Advantages: Definitive repair, no anatomic limitations</li>
                        <li>Disadvantages: High physiologic stress, longer recovery</li>
                        <li>Perioperative mortality: 40-50% for ruptured AAA</li>
                    </ul>
                </li>
                
                <li><strong>Endovascular Aneurysm Repair (EVAR):</strong>
                    <ul>
                        <li>Minimally invasive: Femoral access, stent-graft deployment</li>
                        <li>Advantages: Lower physiologic stress, may reduce mortality (30-40%)</li>
                        <li>Disadvantages: Requires suitable anatomy, risk of endoleak, not always available emergently</li>
                        <li>Increasingly preferred if anatomically feasible and available</li>
                    </ul>
                </li>
                
                <li><strong>Decision Factors:</strong>
                    <ul>
                        <li>Hemodynamic stability (EVAR requires more time/setup)</li>
                        <li>Anatomic suitability (proximal/distal landing zones)</li>
                        <li>Institutional resources/expertise</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Intraoperative Management:</span></p>
            <ul>
                <li><strong>Rapid Sequence Intubation:</strong> Consider awake intubation if unstable</li>
                
                <li><strong>Permissive Hypotension Until Aortic Control:</strong> Avoid BP augmentation until cross-clamp applied</li>
                
                <li><strong>Massive Transfusion:</strong> 1:1:1 ratio, consider whole blood if available</li>
                
                <li><strong>Correct Coagulopathy:</strong>
                    <ul>
                        <li>Maintain temperature >36Â°C (warming devices)</li>
                        <li>Calcium replacement (citrate from transfusions)</li>
                        <li>Fibrinogen replacement if <150 mg/dL (cryoprecipitate or fibrinogen concentrate)</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Post-Operative Management (ICU):</span></p>
            <ul>
                <li><strong>Complications to Monitor:</strong>
                    <ul>
                        <li><strong>Abdominal Compartment Syndrome:</strong> Bladder pressure >20 mmHg, may require decompressive laparotomy</li>
                        <li><strong>Acute Kidney Injury:</strong> Contrast, ischemia, rhabdomyolysis (common, may need CRRT)</li>
                        <li><strong>Colonic Ischemia:</strong> Inferior mesenteric artery occlusion (bloody diarrhea, acidosis)</li>
                        <li><strong>Spinal Cord Ischemia:</strong> Paraplegia (1-3% risk, from spinal artery compromise)</li>
                        <li><strong>Lower Extremity Ischemia:</strong> Distal embolization or graft thrombosis</li>
                        <li><strong>ARDS/Multi-Organ Failure:</strong> From massive transfusion, shock</li>
                    </ul>
                </li>
                
                <li><strong>Supportive Care:</strong>
                    <ul>
                        <li>Mechanical ventilation (often prolonged)</li>
                        <li>Vasopressor support</li>
                        <li>Renal replacement therapy if needed</li>
                        <li>Nutrition (early enteral if tolerated)</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Prognosis:</span></p>
            <ul>
                <li>Overall mortality: 50-80% (includes pre-hospital deaths)</li>
                <li>If reaches ED alive: 40-50% mortality</li>
                <li>Better outcomes: Younger age, contained rupture, EVAR, expedient surgery</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Think AAA in "The Big Three":</strong> Any elderly patient with: (1) Abdominal/back pain, (2) Hypotension/syncope, or (3) Known AAA. Have extremely low threshold to image - ruptured AAA kills 50-80%, early diagnosis saves lives.</li>
            
            <li><strong>Permissive Hypotension is Counterintuitive but Lifesaving:</strong> Target SBP 70-90 mmHg UNTIL surgical control. Aggressively resuscitating to "normal" BP before aortic cross-clamp increases bleeding ("pops the clot") and worsens mortality. This goes against your instincts but is evidence-based.</li>
            
            <li><strong>Don't Send Unstable Patient to CT:</strong> If patient has hypotension + abdominal/back pain + pulsatile mass (or high suspicion), go directly to OR. Bedside ultrasound showing AAA is sufficient. Patient can die in scanner waiting for CT.</li>
            
            <li><strong>Ruptured AAA Mimics Renal Colic:</strong> Elderly patient with "renal colic" and hematuria may actually have ruptured AAA causing ureteral compression. Always consider AAA in older patients with flank/back pain, especially if hypotensive or no prior stone history.</li>
            
            <li><strong>Normal Hemoglobin Doesn't Exclude:</strong> Hgb may be normal initially after rupture due to hemoconcentration (blood loss not yet equilibrated). Don't be falsely reassured by "normal labs" in acute setting.</li>
            
            <li><strong>EVAR Improving Outcomes:</strong> Meta-analyses show 30-day mortality advantage for EVAR vs. OSR (30-35% vs. 45-50%). If center has EVAR capability and patient has suitable anatomy, this is increasingly preferred approach.</li>
            
            <li><strong>Don't Forget Screening Guidelines:</strong> Men age 65-75 with smoking history should get one-time ultrasound screening for AAA (USPSTF Grade B). Detection and elective repair of AAA before rupture has <5% mortality vs. 50-80% for ruptured.</li>
            
            <li><strong>Cardiac Arrest from Ruptured AAA is Futile:</strong> If patient arrests from exsanguination, CPR is ineffective (pushes blood out faster) and OR is only chance. Resuscitative thoracotomy with aortic cross-clamping is a Hail Mary but has been done with rare survival.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL patients with ruptured AAA require ICU (surgical ICU preferred)</li>
                        <li>Post-operative management after EVAR or open repair</li>
                        <li>Ongoing transfusion requirements or coagulopathy</li>
                        <li>Vasopressor support</li>
                        <li>Mechanical ventilation</li>
                        <li>Acute kidney injury or dialysis requirement</li>
                        <li>Abdominal compartment syndrome</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable without vasopressors for >72 hours</li>
                        <li>No evidence of ongoing bleeding or rebleeding</li>
                        <li>Stable hemoglobin without transfusion requirement</li>
                        <li>Extubated and breathing comfortably on room air or low-flow O2</li>
                        <li>Adequate renal function (or stable on dialysis with outpatient plan)</li>
                        <li>Tolerating oral intake, bowel function returned</li>
                        <li>Wound healing appropriately without signs of infection</li>
                        <li>Pain controlled on oral medications</li>
                        <li>Follow-up with vascular surgery arranged (typically 2-4 weeks)</li>
                        <li>CT angiography scheduled per surgery (usually 1 month post-op)</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="b12-folate-deficiency" class="condition-page">
    <div class="page-header">
        <h2>86. B12 / FOLATE DEFICIENCY ANEMIA</h2>
        <div class="subtitle">Macrocytic Anemia â€¢ Neurologic Symptoms (B12) â€¢ Hypersegmented Neutrophils</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Macrocytic anemia with fatigue, glossitis, and neurologic symptoms (B12 only). Often insidious onset over months to years.</p>
            
            <ul>
                <li><strong>General Anemia Symptoms:</strong>
                    <ul>
                        <li>Fatigue, weakness, dyspnea on exertion</li>
                        <li>Pallor</li>
                        <li>Tachycardia, heart failure (if severe)</li>
                        <li>Symptoms often develop slowly (compensated)</li>
                    </ul>
                </li>
                
                <li><strong>Specific to B12/Folate Deficiency:</strong>
                    <ul>
                        <li><strong>Glossitis:</strong> Beefy red, smooth tongue (atrophic papillae)</li>
                        <li><strong>Angular cheilitis:</strong> Cracks at corners of mouth</li>
                        <li><strong>Hyperpigmentation:</strong> Especially hands, knuckles (melanin deposition)</li>
                        <li><strong>Jaundice:</strong> Mild, from ineffective erythropoiesis (hemolysis of megaloblasts in marrow)</li>
                    </ul>
                </li>
                
                <li><strong>Neurologic Manifestations (B12 ONLY, NOT Folate):</strong>
                    <ul>
                        <li><strong>Subacute Combined Degeneration:</strong> Demyelination of dorsal/lateral columns
                            <ul>
                                <li>Posterior column: Loss of position/vibration sense, sensory ataxia</li>
                                <li>Lateral corticospinal: Weakness, spasticity, hyperreflexia, Babinski sign</li>
                                <li>Classic: Gait ataxia + paresthesias + weakness</li>
                            </ul>
                        </li>
                        <li><strong>Peripheral neuropathy:</strong> Stocking-glove distribution, paresthesias</li>
                        <li><strong>Cognitive/Psychiatric:</strong> Memory loss, dementia, depression, psychosis</li>
                        <li><strong>Optic neuropathy:</strong> Visual changes (rare)</li>
                        <li><strong>CRITICAL:</strong> Neuro damage may be irreversible if prolonged deficiency</li>
                    </ul>
                </li>
                
                <li><strong>Folate-Specific:</strong> Neural tube defects in pregnancy (if deficient periconceptionally)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">ETIOLOGIES</div>
        <div class="section-content">
            <p><span class="label">Vitamin B12 (Cobalamin) Deficiency:</span></p>
            <ul>
                <li><strong>Pernicious Anemia (Most Common in Developed Countries):</strong>
                    <ul>
                        <li>Autoimmune destruction of gastric parietal cells</li>
                        <li>Loss of intrinsic factor â†’ Impaired B12 absorption</li>
                        <li>Associated: Autoimmune disorders (thyroiditis, vitiligo, type 1 DM)</li>
                        <li>Antiparietal cell antibodies (85-90%), anti-intrinsic factor antibodies (50-70%, more specific)</li>
                        <li>Atrophic gastritis on endoscopy</li>
                    </ul>
                </li>
                
                <li><strong>Dietary Deficiency:</strong>
                    <ul>
                        <li>Strict vegans (B12 only in animal products)</li>
                        <li>Rare in developed countries (liver stores last 3-5 years)</li>
                    </ul>
                </li>
                
                <li><strong>Malabsorption:</strong>
                    <ul>
                        <li>Gastrectomy or gastric bypass (loss of intrinsic factor production)</li>
                        <li>Terminal ileum disease: Crohn's, resection, bacterial overgrowth</li>
                        <li>Pancreatic insufficiency (need pancreatic proteases to cleave R-protein)</li>
                        <li>Celiac disease</li>
                        <li>Diphyllobothrium latum (fish tapeworm)</li>
                    </ul>
                </li>
                
                <li><strong>Medications:</strong>
                    <ul>
                        <li>Metformin (decreases B12 absorption, 10-30% of users)</li>
                        <li>PPIs/H2 blockers (chronic use, impaired cleavage from food)</li>
                        <li>Nitrous oxide (inactivates B12, seen in anesthesia/recreational use)</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Folate (Folic Acid) Deficiency:</span></p>
            <ul>
                <li><strong>Dietary Deficiency (Most Common Cause):</strong>
                    <ul>
                        <li>Poor intake: Elderly, alcoholics, poverty</li>
                        <li>Folate depletes rapidly (body stores only 2-3 months)</li>
                    </ul>
                </li>
                
                <li><strong>Increased Demand:</strong>
                    <ul>
                        <li>Pregnancy and lactation</li>
                        <li>Hemolytic anemias (increased RBC turnover: sickle cell, thalassemia)</li>
                        <li>Malignancy, inflammatory states</li>
                        <li>Dialysis (folate removed)</li>
                    </ul>
                </li>
                
                <li><strong>Malabsorption:</strong>
                    <ul>
                        <li>Celiac disease, tropical sprue</li>
                        <li>Small bowel resection</li>
                    </ul>
                </li>
                
                <li><strong>Medications:</strong>
                    <ul>
                        <li>Methotrexate (dihydrofolate reductase inhibitor)</li>
                        <li>Trimethoprim, sulfasalazine, phenytoin</li>
                        <li>Alcohol (impairs absorption and utilization)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Complete Blood Count:</span></p>
            <ul>
                <li><strong>Anemia:</strong> Hemoglobin variable (may be severe, <7 g/dL)</li>
                <li><strong>Macrocytosis:</strong> MCV >100 fL (often 110-140 fL in severe deficiency)</li>
                <li><strong>Pancytopenia:</strong> May have leukopenia and thrombocytopenia (megaloblastic changes affect all cell lines)</li>
            </ul>
            
            <p><span class="label">Peripheral Blood Smear (Diagnostic):</span></p>
            <ul>
                <li><strong>Macro-ovalocytes:</strong> Large, oval RBCs</li>
                <li><strong>Hypersegmented Neutrophils (Pathognomonic):</strong> â‰¥5 lobes in neutrophil (normal â‰¤4)</li>
                <li><strong>Anisocytosis and poikilocytosis:</strong> Variable RBC size/shape</li>
                <li><strong>Howell-Jolly bodies:</strong> Nuclear remnants in RBCs</li>
            </ul>
            
            <p><span class="label">Vitamin Levels:</span></p>
            <ul>
                <li><strong>Serum B12:</strong>
                    <ul>
                        <li><150 pg/mL: Deficient</li>
                        <li>150-400 pg/mL: Borderline/low (consider methylmalonic acid if symptomatic)</li>
                        <li>>400 pg/mL: Normal</li>
                        <li>Note: Can be falsely normal in myeloproliferative disorders, liver disease</li>
                    </ul>
                </li>
                
                <li><strong>Serum Folate:</strong>
                    <ul>
                        <li><3 ng/mL: Deficient</li>
                        <li>Less reliable (reflects recent intake, not tissue stores)</li>
                    </ul>
                </li>
                
                <li><strong>RBC Folate:</strong>
                    <ul>
                        <li>Better reflects tissue stores than serum folate</li>
                        <li><150 ng/mL: Deficient</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Confirmatory Tests (If B12 Borderline or Normal with High Suspicion):</span></p>
            <ul>
                <li><strong>Methylmalonic Acid (MMA):</strong>
                    <ul>
                        <li>Elevated (>0.4 Âµmol/L) in B12 deficiency (NOT elevated in folate deficiency)</li>
                        <li>Most sensitive test for B12 deficiency</li>
                        <li>Also elevated in renal failure (confounding factor)</li>
                    </ul>
                </li>
                
                <li><strong>Homocysteine:</strong>
                    <ul>
                        <li>Elevated in BOTH B12 and folate deficiency (less specific)</li>
                        <li>Normal: <15 Âµmol/L</li>
                        <li>Also elevated in renal failure, hypothyroidism</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Etiology Workup (Once Deficiency Confirmed):</span></p>
            <ul>
                <li><strong>For B12 Deficiency:</strong>
                    <ul>
                        <li><strong>Anti-Intrinsic Factor Antibodies:</strong> Specific for pernicious anemia (50-70% sensitive)</li>
                        <li><strong>Anti-Parietal Cell Antibodies:</strong> Less specific (85-90% sensitive, but also in 10% of normal elderly)</li>
                        <li><strong>Gastrin Level:</strong> Elevated in pernicious anemia (achlorhydria)</li>
                        <li><strong>EGD:</strong> Consider if atrophic gastritis suspected (increased gastric cancer risk)</li>
                    </ul>
                </li>
                
                <li><strong>For Folate Deficiency:</strong>
                    <ul>
                        <li>Dietary history</li>
                        <li>Alcohol use screening</li>
                        <li>Consider celiac antibodies (TTG-IgA) if malabsorption suspected</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Additional Labs:</span></p>
            <ul>
                <li><strong>Reticulocyte Count:</strong> Inappropriately low for degree of anemia (ineffective erythropoiesis)</li>
                <li><strong>LDH:</strong> Elevated (intramedullary hemolysis)</li>
                <li><strong>Indirect Bilirubin:</strong> Mildly elevated (hemolysis)</li>
                <li><strong>Haptoglobin:</strong> Low (hemolysis)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">CRITICAL RULE: Always Treat B12 First (or Simultaneously) Before Folate:</span></p>
            <ul>
                <li><strong>Rationale:</strong> Giving folate alone to a B12-deficient patient can correct the anemia BUT precipitate/worsen neurologic damage (subacute combined degeneration)</li>
                <li><strong>Safe Approach:</strong> Treat both if unsure, or confirm B12 status before folate monotherapy</li>
            </ul>
            
            <p><span class="label">Vitamin B12 Replacement:</span></p>
            <ul>
                <li><strong>Acute/Severe Deficiency or Neurologic Symptoms:</strong>
                    <ul>
                        <li><strong>Cyanocobalamin (B12) 1000 mcg IM daily Ã—1 week</strong></li>
                        <li>Then: 1000 mcg IM weekly Ã—4 weeks</li>
                        <li>Then: 1000 mcg IM monthly (lifelong if pernicious anemia or malabsorption)</li>
                    </ul>
                </li>
                
                <li><strong>Maintenance or Mild Deficiency:</strong>
                    <ul>
                        <li><strong>Oral Cyanocobalamin 1000-2000 mcg PO daily</strong></li>
                        <li>Effective even in pernicious anemia (1-2% absorbed by mass action, bypasses intrinsic factor)</li>
                        <li>Requires patient adherence</li>
                    </ul>
                </li>
                
                <li><strong>Alternative Routes:</strong>
                    <ul>
                        <li>Sublingual cyanocobalamin 1000 mcg daily</li>
                        <li>Intranasal cyanocobalamin 500 mcg weekly (expensive, lower adherence)</li>
                    </ul>
                </li>
                
                <li><strong>Hydroxocobalamin:</strong> Alternative to cyanocobalamin (longer-acting, less commonly used in US)</li>
            </ul>
            
            <p><span class="label">Folate Replacement:</span></p>
            <ul>
                <li><strong>Treatment Dose:</strong>
                    <ul>
                        <li><strong>Folic Acid 1-5 mg PO daily</strong></li>
                        <li>Duration: Until deficiency corrected and underlying cause addressed (usually 1-4 months)</li>
                    </ul>
                </li>
                
                <li><strong>Prophylaxis (High-Risk Groups):</strong>
                    <ul>
                        <li>Pregnancy: 400-800 mcg daily (prenatal vitamins)</li>
                        <li>Chronic hemolysis: 1 mg daily</li>
                        <li>Dialysis: 1 mg daily</li>
                        <li>Methotrexate: Leucovorin (folinic acid) rescue or folic acid 1 mg daily</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Monitoring Response:</span></p>
            <ul>
                <li><strong>Reticulocytosis:</strong> Peaks at 5-7 days (indicates bone marrow response)</li>
                <li><strong>Hemoglobin:</strong> Begins to rise by 1 week, normalizes in 6-8 weeks</li>
                <li><strong>MCV:</strong> Gradually decreases to normal over 2-3 months</li>
                <li><strong>Neurologic Symptoms:</strong> May take weeks to months to improve (may be irreversible if longstanding)</li>
                <li><strong>Recheck B12/Folate:</strong> 4-8 weeks after starting treatment</li>
            </ul>
            
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li><strong>Transfusion:</strong>
                    <ul>
                        <li>If symptomatic (chest pain, dyspnea, CHF exacerbation) or Hgb <7 g/dL</li>
                        <li>Transfuse SLOWLY (1 unit over 3-4 hours) to avoid volume overload</li>
                        <li>Goal: Hgb 7-9 g/dL (NOT full correction acutely)</li>
                    </ul>
                </li>
                
                <li><strong>Potassium Supplementation:</strong>
                    <ul>
                        <li>Monitor K+ closely in first week of treatment</li>
                        <li>Rapid cell production depletes K+ ("refeeding hypokalemia")</li>
                        <li>Supplement if K+ <3.5 mEq/L</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Address Underlying Cause:</span></p>
            <ul>
                <li>Pernicious anemia: Lifelong B12 replacement</li>
                <li>Dietary: Nutrition counseling, supplementation</li>
                <li>Medications: Adjust/discontinue if possible, supplement as needed</li>
                <li>Malabsorption: Treat underlying condition (celiac, Crohn's), may need parenteral supplementation</li>
            </ul>
            
            <p><span class="label">Long-Term Follow-Up:</span></p>
            <ul>
                <li><strong>Pernicious Anemia:</strong> Lifelong replacement, surveillance EGD (increased gastric cancer risk - consider every 3-5 years)</li>
                <li><strong>Check B12/Folate Levels:</strong> Annually if on maintenance therapy</li>
                <li><strong>Screen for Autoimmune Disorders:</strong> If pernicious anemia (thyroid, diabetes, etc.)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Never Give Folate Without B12:</strong> Treating folate deficiency alone in a B12-deficient patient can WORSEN or PRECIPITATE irreversible neurologic damage (subacute combined degeneration). Always check B12 or treat both empirically if uncertain.</li>
            
            <li><strong>Hypersegmented Neutrophils are Pathognomonic:</strong> â‰¥5% of neutrophils with â‰¥5 lobes (or any with â‰¥6 lobes) is diagnostic for megaloblastic anemia. This finding persists even if patient already started replacement, making it useful diagnostically.</li>
            
            <li><strong>MMA is the Best Confirmatory Test:</strong> Methylmalonic acid is elevated in B12 deficiency but NOT folate deficiency, making it the most specific test. Use it when B12 level is borderline (150-400) but clinical suspicion is high.</li>
            
            <li><strong>Metformin and B12:</strong> 10-30% of long-term metformin users develop B12 deficiency. Check B12 annually in diabetics on metformin, especially if peripheral neuropathy develops (often attributed to diabetes but may be B12).</li>
            
            <li><strong>Oral B12 Works Even in Pernicious Anemia:</strong> High-dose oral B12 (1000-2000 mcg daily) is effective even without intrinsic factor because 1-2% is absorbed by passive diffusion. Cost-effective alternative to IM if patient adherent.</li>
            
            <li><strong>Nitrous Oxide = Instant B12 Deficiency:</strong> Nâ‚‚O inactivates B12 (oxidizes cobalt atom) within hours. Recreational "whippet" use or prolonged anesthesia exposure can cause acute subacute combined degeneration in previously borderline patients.</li>
            
            <li><strong>Neuro Damage May Be Irreversible:</strong> If subacute combined degeneration is present >6-12 months before treatment, neurologic recovery is often incomplete. Early recognition and treatment is critical. Anemia may be minimal but neuro symptoms prominent.</li>
            
            <li><strong>Pernicious Anemia = Gastric Cancer Risk:</strong> Atrophic gastritis and achlorhydria in pernicious anemia increase gastric adenocarcinoma risk 3-6 fold. Consider surveillance EGD every 3-5 years per ACG guidelines.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe neurologic compromise requiring ICU-level monitoring</li>
                        <li>Hemodynamic instability from severe anemia (Hgb <4-5 g/dL)</li>
                        <li>Heart failure or myocardial ischemia from severe anemia</li>
                        <li>Respiratory failure requiring mechanical ventilation</li>
                        <li>Multi-organ dysfunction from severe deficiency</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable</li>
                        <li>Hemoglobin improving or stable (typically >7-8 g/dL for discharge)</li>
                        <li>No active cardiac ischemia or heart failure</li>
                        <li>B12/folate replacement initiated (B12 1000 mcg IM or folate 1 mg PO daily)</li>
                        <li>No evidence of alternative causes requiring hospital-level care</li>
                        <li>Outpatient hematology follow-up arranged if needed</li>
                        <li>Patient educated on lifelong B12 replacement if pernicious anemia</li>
                        <li>Return precautions for worsening neurologic symptoms, severe fatigue</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="bone-marrow-failure" class="condition-page">
    <div class="page-header">
        <h2>87. BONE MARROW FAILURE / MDS / APLASTIC ANEMIA</h2>
        <div class="subtitle">Pancytopenia â€¢ Bone Marrow Hypoplasia â€¢ Transfusion-Dependent â€¢ Infection Risk</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Progressive pancytopenia with anemia symptoms, infections (neutropenia), and bleeding/bruising (thrombocytopenia). May present insidiously or acutely.</p>
            
            <ul>
                <li><strong>Symptoms by Cell Line Affected:</strong>
                    <ul>
                        <li><strong>Anemia (Low RBC):</strong> Fatigue, dyspnea, pallor, tachycardia</li>
                        <li><strong>Neutropenia (Low WBC):</strong> Recurrent infections, fever, oral ulcers</li>
                        <li><strong>Thrombocytopenia (Low Platelets):</strong> Petechiae, purpura, bleeding (gums, nose, GI, CNS)</li>
                    </ul>
                </li>
                
                <li><strong>Physical Exam:</strong>
                    <ul>
                        <li>Pallor, petechiae, ecchymoses</li>
                        <li>NO hepatosplenomegaly (distinguishes from leukemia/lymphoma)</li>
                        <li>NO lymphadenopathy (distinguishes from hematologic malignancies)</li>
                        <li>Fever if infection present</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">APLASTIC ANEMIA</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Bone marrow failure with pancytopenia and hypocellular marrow (<25% cellularity). Immune-mediated destruction of hematopoietic stem cells.</p>
            
            <ul>
                <li><strong>Severity Classification (Camitta Criteria):</strong>
                    <ul>
                        <li><strong>Severe (SAA):</strong> Marrow cellularity <25% AND â‰¥2 of:
                            <ul>
                                <li>ANC <500/ÂµL</li>
                                <li>Platelets <20,000/ÂµL</li>
                                <li>Reticulocytes <60,000/ÂµL (corrected <1%)</li>
                            </ul>
                        </li>
                        <li><strong>Very Severe (vSAA):</strong> SAA criteria + ANC <200/ÂµL</li>
                        <li><strong>Non-Severe (NSAA):</strong> Pancytopenia but doesn't meet SAA criteria</li>
                    </ul>
                </li>
                
                <li><strong>Etiologies:</strong>
                    <ul>
                        <li><strong>Idiopathic (70%):</strong> Presumed autoimmune, no identifiable cause</li>
                        <li><strong>Medications:</strong> Chloramphenicol, sulfonamides, gold, carbamazepine, NSAIDs, chemotherapy</li>
                        <li><strong>Toxins:</strong> Benzene, pesticides, organic solvents</li>
                        <li><strong>Viral:</strong> Hepatitis (seronegative hepatitis most common), EBV, CMV, parvovirus B19, HIV</li>
                        <li><strong>Radiation:</strong> Ionizing radiation exposure</li>
                        <li><strong>Inherited:</strong> Fanconi anemia, dyskeratosis congenita (usually present in childhood)</li>
                        <li><strong>Pregnancy:</strong> Rare, may resolve postpartum</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MYELODYSPLASTIC SYNDROMES (MDS)</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Clonal stem cell disorders with ineffective hematopoiesis, dysplastic changes, and risk of transformation to acute myeloid leukemia (AML).</p>
            
            <ul>
                <li><strong>Clinical Features:</strong>
                    <ul>
                        <li>Cytopenias (anemia most common, 80-85%)</li>
                        <li>Macrocytosis common (MCV >100 fL)</li>
                        <li>Progression to AML in 30% over time</li>
                        <li>Median age: 70+ years</li>
                    </ul>
                </li>
                
                <li><strong>WHO Classification (Selected Types):</strong>
                    <ul>
                        <li><strong>MDS with Single Lineage Dysplasia:</strong> One cell line affected</li>
                        <li><strong>MDS with Multilineage Dysplasia:</strong> â‰¥2 cell lines affected</li>
                        <li><strong>MDS with Excess Blasts (MDS-EB):</strong> 5-19% blasts in marrow (higher AML risk)</li>
                        <li><strong>MDS with del(5q):</strong> Isolated del(5q) cytogenetics, better prognosis</li>
                    </ul>
                </li>
                
                <li><strong>Risk Factors:</strong>
                    <ul>
                        <li>Prior chemotherapy/radiation (therapy-related MDS, poor prognosis)</li>
                        <li>Occupational exposures (benzene, pesticides)</li>
                        <li>Smoking</li>
                        <li>Inherited: Down syndrome, Fanconi anemia</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Complete Blood Count:</span></p>
            <ul>
                <li><strong>Pancytopenia:</strong> Anemia + leukopenia + thrombocytopenia</li>
                <li><strong>Reticulocyte Count:</strong> Low/inappropriately normal (indicates marrow failure)</li>
                <li><strong>MCV:</strong> May be elevated (especially MDS)</li>
            </ul>
            
            <p><span class="label">Peripheral Blood Smear:</span></p>
            <ul>
                <li><strong>Aplastic Anemia:</strong> Normocytic/normochromic RBCs, no dysplasia, no blasts</li>
                <li><strong>MDS:</strong> Dysplastic changes
                    <ul>
                        <li>RBCs: Macrocytosis, dimorphic population, basophilic stippling</li>
                        <li>WBCs: Hypogranular neutrophils, pseudo-Pelger-HuÃ«t anomaly (bilobed nucleus)</li>
                        <li>Platelets: Large/abnormal</li>
                        <li>May see blasts (if MDS-EB)</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Bone Marrow Biopsy and Aspirate (Definitive Diagnosis):</span></p>
            <ul>
                <li><strong>Aplastic Anemia:</strong>
                    <ul>
                        <li>Hypocellular marrow (<25% cellularity for age)</li>
                        <li>Fatty replacement</li>
                        <li>No dysplasia or abnormal cells</li>
                        <li>Cytogenetics: Normal</li>
                    </ul>
                </li>
                
                <li><strong>MDS:</strong>
                    <ul>
                        <li>Normo- to hypercellular marrow (paradoxically cellular despite cytopenias)</li>
                        <li>Dysplastic changes in â‰¥10% of cells in â‰¥1 lineage</li>
                        <li>Increased blasts (5-19% in MDS-EB)</li>
                        <li>Cytogenetics: Often abnormal (del(5q), trisomy 8, -7/del(7q), complex)</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Additional Labs:</span></p>
            <ul>
                <li><strong>B12/Folate:</strong> Rule out nutritional deficiency</li>
                <li><strong>LDH:</strong> Elevated in MDS (ineffective erythropoiesis)</li>
                <li><strong>EPO Level:</strong> Guide treatment (if <500 mU/mL, better response to ESA)</li>
                <li><strong>Viral Serologies:</strong> Hepatitis panel, HIV, EBV, CMV, parvovirus</li>
                <li><strong>Autoimmune Workup:</strong> ANA, RF (if concern for autoimmune etiology)</li>
                <li><strong>PNH Screen:</strong> Flow cytometry for CD55/CD59 (paroxysmal nocturnal hemoglobinuria, associated with aplastic anemia)</li>
                <li><strong>Fanconi Anemia Testing:</strong> Chromosome breakage test (if young patient or family history)</li>
            </ul>
            
            <p><span class="label">Prognostic Scoring:</span></p>
            <ul>
                <li><strong>IPSS-R (Revised International Prognostic Scoring System) for MDS:</strong>
                    <ul>
                        <li>Incorporates: Cytogenetics, marrow blast %, cytopenias</li>
                        <li>Predicts survival and AML transformation risk</li>
                        <li>Guides treatment intensity</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Supportive Care (All Patients):</span></p>
            <ul>
                <li><strong>Transfusions:</strong>
                    <ul>
                        <li><strong>pRBC:</strong> Goal Hgb >7 g/dL (or >8 if cardiac disease), use leukoreduced</li>
                        <li><strong>Platelets:</strong> Goal >10,000/ÂµL prophylactic, >50,000/ÂµL if bleeding or pre-procedure</li>
                        <li>CMV-negative blood products if transplant candidate</li>
                    </ul>
                </li>
                
                <li><strong>Infection Prophylaxis (if ANC <500/ÂµL):</strong>
                    <ul>
                        <li>Fluoroquinolone (levofloxacin 500 mg PO daily or ciprofloxacin 500 mg PO BID)</li>
                        <li>Antifungal: Fluconazole 400 mg PO daily or posaconazole 300 mg PO daily</li>
                        <li>Antiviral: Acyclovir 400 mg PO BID (HSV prophylaxis)</li>
                    </ul>
                </li>
                
                <li><strong>Febrile Neutropenia:</strong> Broad-spectrum antibiotics (see separate condition)</li>
                
                <li><strong>Growth Factors:</strong>
                    <ul>
                        <li><strong>Erythropoiesis-Stimulating Agents (ESA):</strong> Epoetin alfa or darbepoetin for anemia (if EPO <500 and MDS)</li>
                        <li><strong>G-CSF:</strong> Filgrastim for severe neutropenia with recurrent infections</li>
                    </ul>
                </li>
                
                <li><strong>Iron Chelation (if ferritin >1000 ng/mL from transfusions):</strong>
                    <ul>
                        <li>Deferasirox 20-30 mg/kg PO daily</li>
                        <li>Prevents organ damage from iron overload</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">APLASTIC ANEMIA - Definitive Treatment:</span></p>
            <ul>
                <li><strong>Hematopoietic Stem Cell Transplant (HSCT) - First-Line if Young with Matched Donor:</strong>
                    <ul>
                        <li>Indications: Age <40-50, severe/very severe AA, matched sibling donor</li>
                        <li>Success rate: 80-90% long-term survival if <20 years old</li>
                        <li>Refer to transplant center immediately</li>
                        <li>Minimize transfusions before transplant (reduces alloimmunization/GVHD risk)</li>
                    </ul>
                </li>
                
                <li><strong>Immunosuppressive Therapy (IST) - First-Line if No Donor or Older Age:</strong>
                    <ul>
                        <li><strong>Horse Anti-Thymocyte Globulin (h-ATG) + Cyclosporine:</strong>
                            <ul>
                                <li>h-ATG 40 mg/kg/day IV Ã—4 days</li>
                                <li>Cyclosporine 5-6 mg/kg/day PO BID (adjust to trough 200-400 ng/mL)</li>
                                <li>Continue cyclosporine 6-12 months, taper slowly</li>
                                <li>Response rate: 60-70% (hematologic improvement by 3-6 months)</li>
                            </ul>
                        </li>
                        <li><strong>Eltrombopag:</strong> Add to h-ATG/cyclosporine (improves response rate)</li>
                        <li><strong>Steroids:</strong> Methylprednisolone during ATG to prevent serum sickness</li>
                    </ul>
                </li>
                
                <li><strong>Eltrombopag Monotherapy (Refractory/Relapsed):</strong>
                    <ul>
                        <li>150 mg PO daily (TPO receptor agonist)</li>
                        <li>Response rate: 40% in refractory cases</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">MDS - Treatment by Risk Category:</span></p>
            <ul>
                <li><strong>Lower-Risk MDS (IPSS-R Low/Intermediate):</strong>
                    <ul>
                        <li><strong>Observation:</strong> If asymptomatic, minimal cytopenias</li>
                        <li><strong>ESA + G-CSF:</strong> For anemia (if EPO <500 mU/mL)</li>
                        <li><strong>Lenalidomide:</strong> If del(5q) cytogenetics, 10 mg PO daily Ã—21 days/cycle (67% transfusion independence)</li>
                        <li><strong>Luspatercept:</strong> For transfusion-dependent anemia with ring sideroblasts</li>
                        <li><strong>Immunosuppression:</strong> ATG/cyclosporine in selected cases (younger, hypocellular)</li>
                    </ul>
                </li>
                
                <li><strong>Higher-Risk MDS (IPSS-R Intermediate/High/Very High):</strong>
                    <ul>
                        <li><strong>HSCT:</strong> Only curative option if transplant-eligible</li>
                        <li><strong>Hypomethylating Agents (HMA):</strong>
                            <ul>
                                <li>Azacitidine 75 mg/mÂ² SC/IV days 1-7 every 28 days</li>
                                <li>Decitabine 20 mg/mÂ² IV daily Ã—5 days every 28 days</li>
                                <li>Response rate: 40-50%, median survival benefit 9-10 months</li>
                                <li>Continue until progression or intolerance</li>
                            </ul>
                        </li>
                        <li><strong>Intensive Chemotherapy:</strong> If fit and AML transformation (7+3 induction)</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Monitoring:</span></p>
            <ul>
                <li>CBC with differential weekly initially, then adjust based on stability</li>
                <li>Bone marrow biopsy: Every 6-12 months to assess response and monitor for progression</li>
                <li>Cytogenetics: Serially to detect clonal evolution</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Pancytopenia Without Organomegaly = Think Bone Marrow Failure:</strong> Aplastic anemia and MDS present with cytopenias but NO splenomegaly or lymphadenopathy (unlike leukemia/lymphoma). If pancytopenia with big spleen, think different diagnosis.</li>
            
            <li><strong>MDS is "Ineffective" Hematopoiesis:</strong> Paradoxically, MDS marrow is often hypercellular (lots of cells) but produces dysfunctional cells that die in marrow (intramedullary hemolysis). This is why you see cytopenias despite cellular marrow.</li>
            
            <li><strong>HSCT is Curative for Aplastic Anemia:</strong> If patient <40-50 years with severe AA and matched sibling donor, HSCT should be first-line (80-90% cure rate). Refer immediately and MINIMIZE transfusions beforehand to reduce alloimmunization.</li>
            
            <li><strong>Horse ATG > Rabbit ATG:</strong> Multiple trials show horse anti-thymocyte globulin superior to rabbit ATG for aplastic anemia (higher response rate, better survival). Always use h-ATG if available.</li>
            
            <li><strong>MDS with del(5q) = Lenalidomide:</strong> Isolated del(5q) cytogenetics predicts excellent response to lenalidomide (67% achieve transfusion independence). This is one of the few MDS subtypes with targeted therapy.</li>
            
            <li><strong>PNH Association:</strong> 30-50% of aplastic anemia patients have PNH clone detectable by flow cytometry. Screen all aplastic anemia patients for PNH (CD55/CD59 deficiency). Some will develop overt PNH later.</li>
            
            <li><strong>Seronegative Hepatitis â†’ Aplastic Anemia:</strong> Hepatitis-associated aplastic anemia typically occurs 2-3 months after acute hepatitis, and serologies are often NEGATIVE (non-A, non-B, non-C hepatitis). Young males most common.</li>
            
            <li><strong>MDS Transforms to AML:</strong> ~30% of MDS patients progress to AML over time. Higher-risk MDS (high blast count, poor cytogenetics) transforms faster. This is why close monitoring with serial bone marrow biopsies is essential.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Septic shock or severe infection with neutropenia (ANC <500)</li>
                        <li>Massive transfusion requirement or uncontrolled bleeding</li>
                        <li>Respiratory failure requiring mechanical ventilation</li>
                        <li>Multi-organ dysfunction</li>
                        <li>Tumor lysis syndrome (rare but can occur with MDS treatment)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable, afebrile >48 hours</li>
                        <li>ANC recovering or stable (ideally >500 if neutropenic)</li>
                        <li>Hemoglobin and platelets at safe baseline for patient</li>
                        <li>Any active infections controlled on appropriate antibiotics</li>
                        <li>Transfusion requirements met (target Hgb >7, platelets >10k if stable)</li>
                        <li>Outpatient hematology/oncology follow-up arranged (within 1-2 weeks)</li>
                        <li>Growth factor therapy initiated if indicated (G-CSF, EPO, TPO agonists)</li>
                        <li>Patient educated on fever precautions if neutropenic (return for temp >100.4Â°F)</li>
                        <li>Bone marrow biopsy completed or arranged</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="drug-induced-thrombocytopenia" class="condition-page">
    <div class="page-header">
        <h2>88. DRUG-INDUCED THROMBOCYTOPENIA</h2>
        <div class="subtitle">Platelet <100,000/ÂµL â€¢ Recent Medication â€¢ Bleeding Risk â€¢ Heparin/Quinine/Antibiotics</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Acute onset thrombocytopenia (platelets <100,000/ÂµL) temporally related to new medication exposure. May present with bleeding manifestations or incidentally discovered on labs.</p>
            
            <ul>
                <li><strong>Timing:</strong>
                    <ul>
                        <li><strong>Acute Onset:</strong> Within 1-2 weeks of starting new medication</li>
                        <li><strong>Re-exposure:</strong> Within hours to days if previously exposed (immune memory)</li>
                    </ul>
                </li>
                
                <li><strong>Clinical Manifestations:</strong>
                    <ul>
                        <li><strong>Asymptomatic:</strong> Platelets 50,000-100,000/ÂµL, found incidentally</li>
                        <li><strong>Mucocutaneous Bleeding:</strong> Platelets 10,000-50,000/ÂµL
                            <ul>
                                <li>Petechiae (pinpoint hemorrhages)</li>
                                <li>Purpura (larger bruises)</li>
                                <li>Gingival bleeding, epistaxis</li>
                                <li>Menorrhagia</li>
                            </ul>
                        </li>
                        <li><strong>Severe Bleeding:</strong> Platelets <10,000/ÂµL
                            <ul>
                                <li>GI bleeding (melena, hematemesis)</li>
                                <li>Hematuria</li>
                                <li>Intracranial hemorrhage (rare but life-threatening)</li>
                            </ul>
                        </li>
                    </ul>
                </li>
                
                <li><strong>Physical Exam:</strong>
                    <ul>
                        <li>Petechiae (especially lower extremities, dependent areas)</li>
                        <li>Purpura, ecchymoses</li>
                        <li>Wet purpura (blood blisters in mouth = high bleeding risk)</li>
                        <li>NO splenomegaly (distinguishes from ITP, liver disease)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MECHANISMS AND COMMON CAUSATIVE DRUGS</div>
        <div class="section-content">
            <p><span class="label">Immune-Mediated (Drug-Dependent Antibodies):</span></p>
            <ul>
                <li><strong>Mechanism:</strong> Drug or drug-platelet complex induces antibody formation â†’ Platelet destruction/consumption</li>
                
                <li><strong>Most Common Culprits:</strong>
                    <ul>
                        <li><strong>Quinine/Quinidine:</strong> Classic cause, found in tonic water, supplements</li>
                        <li><strong>Antibiotics:</strong>
                            <ul>
                                <li>Beta-lactams (penicillin, cephalosporins)</li>
                                <li>Sulfonamides (trimethoprim-sulfamethoxazole)</li>
                                <li>Vancomycin</li>
                                <li>Linezolid (dose-dependent + immune)</li>
                                <li>Rifampin</li>
                            </ul>
                        </li>
                        <li><strong>Anticonvulsants:</strong> Valproic acid, carbamazepine, phenytoin</li>
                        <li><strong>NSAIDs:</strong> Naproxen, ibuprofen, diclofenac</li>
                        <li><strong>Antiplatelet Agents:</strong> Abciximab, eptifibatide, tirofiban (GPIIb/IIIa inhibitors)</li>
                        <li><strong>H2 Blockers:</strong> Cimetidine, ranitidine</li>
                        <li><strong>Diuretics:</strong> Furosemide, HCTZ</li>
                        <li><strong>Antiretrovirals:</strong> Zidovudine (AZT)</li>
                        <li><strong>Immunosuppressants:</strong> Sirolimus, mycophenolate</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Heparin-Induced Thrombocytopenia (HIT) - Special Category:</span></p>
            <ul>
                <li><strong>Type I HIT (Non-immune):</strong>
                    <ul>
                        <li>Early (1-2 days), mild (platelets >100K), transient</li>
                        <li>Direct platelet aggregation</li>
                        <li>No clinical significance, heparin can continue</li>
                    </ul>
                </li>
                
                <li><strong>Type II HIT (Immune-mediated, SERIOUS):</strong>
                    <ul>
                        <li>Onset: 5-10 days (earlier if prior heparin exposure)</li>
                        <li>Mechanism: PF4-heparin antibodies â†’ Platelet activation â†’ Thrombosis</li>
                        <li>Platelets drop >50% from baseline (not necessarily <100K)</li>
                        <li><strong>PARADOX:</strong> Thrombocytopenia PLUS thrombosis (arterial/venous)</li>
                        <li>Mortality 20-30% if not recognized</li>
                        <li>Unfractionated heparin > LMWH risk</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Dose-Dependent Bone Marrow Suppression:</span></p>
            <ul>
                <li><strong>Chemotherapy:</strong> All cytotoxic agents</li>
                <li><strong>Immunosuppressants:</strong> Azathioprine, mycophenolate</li>
                <li><strong>Linezolid:</strong> Thrombocytopenia common with >2 weeks use</li>
                <li><strong>Valproic Acid:</strong> Dose-dependent, usually mild</li>
            </ul>
            
            <p><span class="label">TTP-Like (Thrombotic Microangiopathy):</span></p>
            <ul>
                <li><strong>Drugs:</strong> Quinine, ticlopidine, clopidogrel, cyclosporine, tacrolimus</li>
                <li><strong>Mechanism:</strong> Microangiopathic hemolytic anemia + thrombocytopenia + organ dysfunction</li>
                <li>See TTP/HUS section for full details</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">History (Most Important):</span></p>
            <ul>
                <li><strong>Medication Review:</strong> ALL medications including OTC, herbals, supplements (quinine in tonic water!)</li>
                <li><strong>Timing:</strong> When medication started, when platelets dropped</li>
                <li><strong>Prior Exposures:</strong> Has patient taken drug before? (Re-exposure â†’ rapid drop)</li>
                <li><strong>Bleeding Symptoms:</strong> Petechiae, epistaxis, GI/GU bleeding</li>
            </ul>
            
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>CBC with Differential:</strong>
                    <ul>
                        <li>Isolated thrombocytopenia (RBC/WBC normal in immune-mediated)</li>
                        <li>Pancytopenia suggests bone marrow suppression</li>
                    </ul>
                </li>
                
                <li><strong>Peripheral Blood Smear:</strong>
                    <ul>
                        <li>Rule out pseudothrombocytopenia (platelet clumping from EDTA)</li>
                        <li>Assess platelet size/morphology</li>
                        <li>Look for schistocytes (TTP/HUS)</li>
                        <li>No blasts (rule out leukemia)</li>
                    </ul>
                </li>
                
                <li><strong>PT/PTT:</strong> Normal (isolated platelet disorder)</li>
                
                <li><strong>If Bleeding:</strong> Type & screen, fibrinogen, D-dimer</li>
            </ul>
            
            <p><span class="label">HIT-Specific Testing (If Heparin Exposure):</span></p>
            <ul>
                <li><strong>4T Score (Pre-test Probability):</strong>
                    <ul>
                        <li>Thrombocytopenia magnitude</li>
                        <li>Timing of platelet fall</li>
                        <li>Thrombosis or other sequelae</li>
                        <li>Other causes of thrombocytopenia</li>
                        <li>Score 0-3: Low probability (HIT unlikely)</li>
                        <li>Score 4-5: Intermediate</li>
                        <li>Score 6-8: High probability (HIT likely)</li>
                    </ul>
                </li>
                
                <li><strong>HIT ELISA (PF4 Antibody):</strong>
                    <ul>
                        <li>High sensitivity (>95%), moderate specificity</li>
                        <li>Positive = may have HIT, confirm with functional assay</li>
                        <li>Negative = HIT excluded</li>
                    </ul>
                </li>
                
                <li><strong>Serotonin Release Assay (SRA) - Gold Standard:</strong>
                    <ul>
                        <li>Functional assay, high specificity</li>
                        <li>Send to reference lab, takes days</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Additional Testing (If Diagnosis Unclear):</span></p>
            <ul>
                <li><strong>Bone Marrow Biopsy:</strong> If pancytopenia, concern for marrow disorder, or diagnosis uncertain</li>
                <li><strong>HIV, Hepatitis C:</strong> Can cause thrombocytopenia</li>
                <li><strong>Autoimmune Workup:</strong> If considering ITP (ANA, RF)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Immediate Management:</span></p>
            <ul>
                <li><strong>DISCONTINUE OFFENDING DRUG (Most Important):</strong>
                    <ul>
                        <li>Stop ALL non-essential medications</li>
                        <li>If multiple suspects, stop all or use most likely culprit</li>
                        <li>Platelets typically recover within 1-2 weeks after stopping drug</li>
                    </ul>
                </li>
                
                <li><strong>Assess Bleeding Risk:</strong>
                    <ul>
                        <li>Mild (>50K): Observation, avoid trauma/procedures</li>
                        <li>Moderate (10-50K): Close monitoring, avoid NSAIDs/anticoagulants</li>
                        <li>Severe (<10K or active bleeding): Hospitalize, consider treatment</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li><strong>Platelet Transfusion:</strong>
                    <ul>
                        <li><strong>Indications:</strong>
                            <ul>
                                <li>Active bleeding + platelets <50,000/ÂµL</li>
                                <li>Severe thrombocytopenia (<10,000/ÂµL) with bleeding risk</li>
                                <li>Pre-procedure: Goal >50,000 (surgery) or >100,000 (CNS/ophthalmology)</li>
                            </ul>
                        </li>
                        <li><strong>Dose:</strong> 1 apheresis unit or 4-6 pooled units (should raise platelets ~30,000-50,000/ÂµL)</li>
                        <li><strong>NOTE:</strong> Transfusions often have SHORT duration in immune-mediated (antibodies destroy transfused platelets)</li>
                        <li><strong>AVOID in HIT:</strong> Worsens thrombosis risk</li>
                    </ul>
                </li>
                
                <li><strong>Avoid:</strong>
                    <ul>
                        <li>NSAIDs, aspirin (impair platelet function)</li>
                        <li>IM injections</li>
                        <li>Anticoagulation (unless HIT, see below)</li>
                        <li>Invasive procedures unless essential</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Specific Treatment for Severe Cases (Platelets <10K or Bleeding):</span></p>
            <ul>
                <li><strong>IVIG (If Life-Threatening Bleeding):</strong>
                    <ul>
                        <li>1 g/kg IV Ã—1-2 days</li>
                        <li>Rapid increase in platelets (within 24-48h)</li>
                        <li>Benefit temporary (days)</li>
                    </ul>
                </li>
                
                <li><strong>Corticosteroids:</strong>
                    <ul>
                        <li>Prednisone 1 mg/kg PO daily</li>
                        <li>Consider if platelets not recovering after stopping drug</li>
                        <li>Unclear benefit, often used empirically</li>
                    </ul>
                </li>
                
                <li><strong>Plasmapheresis:</strong> If TTP-like drug reaction (see TTP protocol)</li>
            </ul>
            
            <p><span class="label">HIT-Specific Management (Type II):</span></p>
            <ul>
                <li><strong>STOP ALL HEPARIN IMMEDIATELY:</strong>
                    <ul>
                        <li>All UFH and LMWH</li>
                        <li>Flush heparin lines</li>
                        <li>Remove heparin-coated catheters</li>
                    </ul>
                </li>
                
                <li><strong>Start NON-HEPARIN ANTICOAGULATION (Even Without Thrombosis):</strong>
                    <ul>
                        <li><strong>Rationale:</strong> HIT is prothrombotic state, 50% develop thrombosis if untreated</li>
                        <li><strong>First-Line Agents:</strong>
                            <ul>
                                <li><strong>Argatroban:</strong> 2 mcg/kg/min IV (adjust to aPTT 1.5-3Ã— baseline), preferred if hepatic dysfunction</li>
                                <li><strong>Bivalirudin:</strong> 0.15-0.2 mg/kg/h IV</li>
                                <li><strong>Fondaparinux:</strong> 7.5 mg SC daily (off-label, emerging evidence)</li>
                                <li><strong>DOACs:</strong> Apixaban, rivaroxaban (after platelets recover >150K)</li>
                            </ul>
                        </li>
                        <li><strong>Duration:</strong> 4 weeks minimum (or longer if thrombosis present)</li>
                        <li><strong>AVOID:</strong> Warfarin alone initially (increases thrombosis risk until therapeutic anticoagulation achieved)</li>
                    </ul>
                </li>
                
                <li><strong>DO NOT Transfuse Platelets:</strong> Increases thrombosis risk</li>
                
                <li><strong>Screen for Thrombosis:</strong> Duplex ultrasound (DVT), CTA chest (PE)</li>
            </ul>
            
            <p><span class="label">Monitoring:</span></p>
            <ul>
                <li>CBC daily initially, then every 2-3 days</li>
                <li>Platelets typically recover within 1-2 weeks after drug cessation</li>
                <li>If no recovery by 2-3 weeks, consider alternative diagnosis (ITP, bone marrow disorder)</li>
            </ul>
            
            <p><span class="label">Prevention/Avoidance:</span></p>
            <ul>
                <li><strong>Document Drug Allergy:</strong> In EMR, alert bracelet</li>
                <li><strong>Avoid Re-exposure:</strong> Will cause rapid recurrence (hours to days)</li>
                <li><strong>Cross-Reactivity:</strong> May occur within drug classes (e.g., beta-lactams)</li>
                <li><strong>Patient Education:</strong> Provide list of medications to avoid</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Think Drugs FIRST in New Thrombocytopenia:</strong> Drug-induced thrombocytopenia is diagnosis of exclusion but should be TOP of differential. Meticulous medication history (including OTC, herbals, supplements) is essential. Quinine in tonic water is a classic culprit.</li>
            
            <li><strong>HIT is Thrombosis WITH Thrombocytopenia:</strong> Unlike other drug-induced thrombocytopenias, HIT causes CLOTTING (arterial/venous thrombosis) despite low platelets. Don't be fooled - anticoagulate immediately, don't transfuse platelets. The "T" in HIT stands for thrombocytopenia but thrombosis is what kills.</li>
            
            <li><strong>4T Score Guides HIT Testing:</strong> Low 4T score (0-3) has high NPV - HIT is extremely unlikely, don't stop heparin or start alternate anticoagulation based on low score. Intermediate/high scores warrant HIT testing and empiric treatment while awaiting results.</li>
            
            <li><strong>Stop Drug = Cure:</strong> For most drug-induced thrombocytopenias, simply stopping the offending agent leads to recovery in 1-2 weeks. If platelets aren't improving by 2-3 weeks, reconsider diagnosis (may be ITP or bone marrow disorder).</li>
            
            <li><strong>GPIIb/IIIa Inhibitors = Rapid Onset:</strong> Abciximab, eptifibatide, tirofiban can cause severe thrombocytopenia within HOURS (not days). Always check platelet count 2-4 hours after starting these medications in catheterization lab.</li>
            
            <li><strong>IVIG Works Fast but Temporarily:</strong> In life-threatening bleeding with drug-induced thrombocytopenia, IVIG can raise platelets within 24-48 hours. But effect is temporary (days) - buys time while drug clears from system.</li>
            
            <li><strong>Never Re-challenge:</strong> Once patient has drug-induced thrombocytopenia, re-exposure causes RAPID recurrence (hours to days) because immune memory is present. Document as allergy and avoid forever, including cross-reactive drugs.</li>
            
            <li><strong>Warfarin Alone Worsens HIT:</strong> Starting warfarin without adequate alternative anticoagulation in HIT causes venous limb gangrene (warfarin-induced skin necrosis). Always anticoagulate with direct thrombin inhibitor or fondaparinux FIRST, overlap with warfarin once platelets recover >150K.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Active life-threatening bleeding (ICH, massive GI bleed, pulmonary hemorrhage)</li>
                        <li>Platelet count <10,000/Î¼L with high bleeding risk</li>
                        <li>Heparin-induced thrombocytopenia with thrombosis requiring anticoagulation</li>
                        <li>Multi-organ dysfunction from TTP/HUS</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable without active bleeding</li>
                        <li>Platelet count improving or stable (typically >30,000-50,000 for discharge depending on etiology)</li>
                        <li>Offending drug discontinued</li>
                        <li>No evidence of thrombotic complications (if HIT)</li>
                        <li>If HIT: transitioned to non-heparin anticoagulant (argatroban, fondaparinux)</li>
                        <li>If ITP: on appropriate treatment (IVIG, steroids) with outpatient hematology follow-up</li>
                        <li>Patient educated on avoiding offending drug in future</li>
                        <li>Medical alert bracelet recommended if severe reaction (especially HIT)</li>
                        <li>Follow-up with hematology arranged</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="acute-leukemia-lymphoma" class="condition-page">
    <div class="page-header">
        <h2>89. ACUTE LEUKEMIA / LYMPHOMA (Acute Presentations)</h2>
        <div class="subtitle">Cytopenias â€¢ Blasts â€¢ Lymphadenopathy â€¢ B-Symptoms â€¢ Oncologic Emergency</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Acute-onset cytopenias with or without leukocytosis, constitutional symptoms, and/or lymphadenopathy. May present with oncologic emergencies (hyperleukocytosis, tumor lysis, SVC syndrome).</p>
            
            <ul>
                <li><strong>Symptoms by Cytopenias:</strong>
                    <ul>
                        <li><strong>Anemia:</strong> Fatigue, dyspnea, pallor</li>
                        <li><strong>Thrombocytopenia:</strong> Petechiae, bruising, bleeding (gums, epistaxis, GI, CNS)</li>
                        <li><strong>Neutropenia:</strong> Recurrent infections, fever</li>
                    </ul>
                </li>
                
                <li><strong>B-Symptoms (Lymphoma):</strong>
                    <ul>
                        <li>Fever >38Â°C (without infection)</li>
                        <li>Drenching night sweats</li>
                        <li>Unintentional weight loss >10% body weight in 6 months</li>
                    </ul>
                </li>
                
                <li><strong>Physical Exam:</strong>
                    <ul>
                        <li><strong>Leukemia:</strong> Pallor, petechiae, hepatosplenomegaly (50%), gingival hypertrophy (AML-M5), chloromas (AML), NO significant lymphadenopathy</li>
                        <li><strong>Lymphoma:</strong> Lymphadenopathy (cervical, axillary, inguinal), hepatosplenomegaly, Waldeyer's ring involvement</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">ACUTE LEUKEMIAS</div>
        <div class="section-content">
            <p><span class="label">Acute Myeloid Leukemia (AML):</span></p>
            <ul>
                <li><strong>Definition:</strong> â‰¥20% blasts in bone marrow or peripheral blood (WHO criteria)</li>
                <li><strong>Peak Age:</strong> 65+ years (median 68)</li>
                <li><strong>Presentation:</strong>
                    <ul>
                        <li>Acute onset (days to weeks)</li>
                        <li>Cytopenias (anemia, thrombocytopenia, neutropenia)</li>
                        <li>Leukocytosis in 50% (may be low, normal, or high)</li>
                        <li>DIC (especially APL - M3 subtype)</li>
                        <li>Leukostasis if WBC >100,000/ÂµL</li>
                    </ul>
                </li>
                <li><strong>Subtypes of Note:</strong>
                    <ul>
                        <li><strong>Acute Promyelocytic Leukemia (APL, M3):</strong> t(15;17), DIC, tretinoin-responsive, curable</li>
                        <li><strong>AML with inv(16) or t(8;21):</strong> Better prognosis</li>
                        <li><strong>Therapy-related AML:</strong> Prior chemotherapy/radiation, poor prognosis</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Acute Lymphoblastic Leukemia (ALL):</span></p>
            <ul>
                <li><strong>Definition:</strong> â‰¥20% lymphoblasts in bone marrow</li>
                <li><strong>Peak Age:</strong> Children 2-5 years (80% pediatric), second peak in older adults</li>
                <li><strong>Presentation:</strong>
                    <ul>
                        <li>Cytopenias, bone pain (children)</li>
                        <li>Mediastinal mass (T-cell ALL)</li>
                        <li>CNS involvement (5-10%)</li>
                    </ul>
                </li>
                <li><strong>Subtypes:</strong>
                    <ul>
                        <li><strong>B-cell ALL:</strong> 75% of cases</li>
                        <li><strong>T-cell ALL:</strong> 25%, more common in adolescents/young adults, mediastinal mass</li>
                        <li><strong>Philadelphia chromosome-positive (Ph+):</strong> t(9;22), 25% of adult ALL, worse prognosis (but improved with TKIs)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">AGGRESSIVE LYMPHOMAS (Acute Presentations)</div>
        <div class="section-content">
            <p><span class="label">Diffuse Large B-Cell Lymphoma (DLBCL):</span></p>
            <ul>
                <li>Most common aggressive NHL (30% of all lymphomas)</li>
                <li>Rapidly enlarging lymphadenopathy</li>
                <li>Extranodal involvement common (40%): GI, bone, CNS, testes</li>
                <li>B-symptoms in 30%</li>
            </ul>
            
            <p><span class="label">Burkitt Lymphoma:</span></p>
            <ul>
                <li>Highly aggressive, very high proliferation rate (Ki-67 ~100%)</li>
                <li>Subtypes: Endemic (African, EBV+, jaw mass), sporadic (abdomen, GI), HIV-associated</li>
                <li>Tumor lysis syndrome risk with treatment</li>
                <li>Curable with intensive chemotherapy</li>
            </ul>
            
            <p><span class="label">Lymphoblastic Lymphoma:</span></p>
            <ul>
                <li>T-cell or B-cell, similar to ALL</li>
                <li>Mediastinal mass common (T-cell)</li>
                <li>Bone marrow <25% blasts (vs. â‰¥25% = ALL)</li>
                <li>Treated like ALL (intensive chemotherapy + CNS prophylaxis)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Initial Labs:</span></p>
            <ul>
                <li><strong>CBC with Differential:</strong>
                    <ul>
                        <li>Cytopenias (anemia, thrombocytopenia, neutropenia)</li>
                        <li>WBC: Variable (low, normal, or high)</li>
                        <li>BLAST count on differential</li>
                    </ul>
                </li>
                
                <li><strong>Peripheral Blood Smear:</strong>
                    <ul>
                        <li><strong>Leukemia:</strong> Circulating blasts, Auer rods (AML)</li>
                        <li><strong>Lymphoma:</strong> May see circulating lymphoma cells (rare)</li>
                    </ul>
                </li>
                
                <li><strong>Chemistry:</strong>
                    <ul>
                        <li>CMP, LDH (elevated, tumor burden marker)</li>
                        <li>Uric acid (tumor lysis risk)</li>
                        <li>Calcium, phosphorus (tumor lysis)</li>
                    </ul>
                </li>
                
                <li><strong>Coagulation:</strong>
                    <ul>
                        <li>PT/INR, PTT, fibrinogen, D-dimer</li>
                        <li>Rule out DIC (especially APL)</li>
                    </ul>
                </li>
                
                <li><strong>Type & Screen:</strong> Anticipate transfusion needs</li>
            </ul>
            
            <p><span class="label">Bone Marrow Biopsy and Aspirate (Definitive for Leukemia):</span></p>
            <ul>
                <li><strong>Morphology:</strong> â‰¥20% blasts for leukemia diagnosis</li>
                <li><strong>Flow Cytometry:</strong> Immunophenotyping (distinguish AML vs. ALL vs. lymphoma)</li>
                <li><strong>Cytogenetics:</strong> Prognostic information, guide therapy (e.g., APL t(15;17), Ph+ ALL t(9;22))</li>
                <li><strong>Molecular Studies:</strong> FLT3, NPM1, CEBPA (AML), BCR-ABL (Ph+ ALL)</li>
            </ul>
            
            <p><span class="label">Lymph Node Biopsy (Definitive for Lymphoma):</span></p>
            <ul>
                <li><strong>Excisional Biopsy Preferred:</strong> Whole lymph node (core needle if excisional not feasible)</li>
                <li><strong>Histology:</strong> Architecture, cell morphology</li>
                <li><strong>Immunohistochemistry:</strong> CD20, CD3, Ki-67, etc.</li>
                <li><strong>Flow Cytometry:</strong> B-cell vs. T-cell, clonality</li>
                <li><strong>Cytogenetics/FISH:</strong> t(14;18) (follicular), t(11;14) (mantle cell), MYC rearrangement (Burkitt)</li>
            </ul>
            
            <p><span class="label">Staging/Disease Assessment:</span></p>
            <ul>
                <li><strong>CT Chest/Abdomen/Pelvis:</strong> Lymphadenopathy, organomegaly, masses</li>
                <li><strong>PET/CT:</strong> For lymphoma staging (not routinely for leukemia)</li>
                <li><strong>Lumbar Puncture:</strong> CNS prophylaxis/staging for ALL, Burkitt, lymphoblastic lymphoma</li>
                <li><strong>Bone Marrow Biopsy:</strong> For lymphoma staging (especially aggressive)</li>
            </ul>
            
            <p><span class="label">Tumor Lysis Labs (If High Burden):</span></p>
            <ul>
                <li>K+, PO4, Ca2+, uric acid, LDH, Cr</li>
                <li>Check Q4-6H initially if high risk</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">ONCOLOGIC EMERGENCIES</div>
        <div class="section-content">
            <p><span class="label">Hyperleukocytosis / Leukostasis:</span></p>
            <ul>
                <li><strong>Definition:</strong> WBC >100,000/ÂµL with symptoms</li>
                <li><strong>Symptoms:</strong> Dyspnea, hypoxia, confusion, vision changes, priapism</li>
                <li><strong>Mechanism:</strong> Blast sludging in microcirculation â†’ tissue hypoxia</li>
                <li><strong>Treatment:</strong>
                    <ul>
                        <li>Urgent leukapheresis (if AML)</li>
                        <li>Hydroxyurea 50-100 mg/kg PO daily (cytoreduction)</li>
                        <li>Aggressive hydration</li>
                        <li>Allopurinol or rasburicase (prevent TLS)</li>
                        <li>AVOID transfusions initially (increases viscosity)</li>
                        <li>Start chemotherapy once WBC controlled</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Tumor Lysis Syndrome (TLS):</span></p>
            <ul>
                <li><strong>Definition (Cairo-Bishop):</strong> â‰¥2 of: Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia (within 3 days before or 7 days after chemotherapy)</li>
                <li><strong>High-Risk:</strong> Burkitt, lymphoblastic lymphoma, ALL, AML with WBC >100K</li>
                <li><strong>Treatment:</strong>
                    <ul>
                        <li><strong>Aggressive Hydration:</strong> NS 200-300 mL/hr (goal UOP 80-100 mL/hr)</li>
                        <li><strong>Rasburicase:</strong> 0.2 mg/kg IV Ã—1 (for uric acid >8 mg/dL or high risk)</li>
                        <li><strong>Allopurinol:</strong> 300-600 mg PO daily (if low risk or after rasburicase)</li>
                        <li>Manage hyperkalemia, hyperphosphatemia</li>
                        <li>Consider dialysis if refractory</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">DIC (Especially APL):</span></p>
            <ul>
                <li><strong>Presentation:</strong> Bleeding, thrombosis, coagulopathy</li>
                <li><strong>Labs:</strong> Low platelets, low fibrinogen, elevated PT/PTT, elevated D-dimer</li>
                <li><strong>Treatment:</strong>
                    <ul>
                        <li>Urgent hematology consultation</li>
                        <li>Start ATRA (all-trans retinoic acid) IMMEDIATELY if APL suspected (don't wait for confirmation)</li>
                        <li>Transfuse: pRBC, platelets, cryoprecipitate/FFP to maintain fibrinogen >100-150 mg/dL, platelets >30-50K</li>
                        <li>AVOID heparin</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">SVC Syndrome:</span></p>
            <ul>
                <li><strong>Presentation:</strong> Facial swelling, JVD, dyspnea, upper extremity edema</li>
                <li><strong>Cause:</strong> Mediastinal mass (lymphoma, esp. T-cell lymphoblastic)</li>
                <li><strong>Treatment:</strong>
                    <ul>
                        <li>Elevate head of bed, supplemental O2</li>
                        <li>Urgent tissue diagnosis (biopsy before steroids if possible)</li>
                        <li>Steroids: Dexamethasone 10 mg IV (if respiratory compromise)</li>
                        <li>Radiation or chemotherapy once diagnosis confirmed</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">INITIAL MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li><strong>Transfusions:</strong>
                    <ul>
                        <li>pRBC: Goal Hgb >7 g/dL (>8 if cardiac disease)</li>
                        <li>Platelets: >10K prophylactic, >50K if bleeding or pre-procedure</li>
                        <li>Use leukoreduced, irradiated, CMV-negative products</li>
                    </ul>
                </li>
                
                <li><strong>Infection Prophylaxis (Neutropenic):</strong>
                    <ul>
                        <li>Fluoroquinolone (levofloxacin 500 mg daily)</li>
                        <li>Antifungal (fluconazole 400 mg daily or posaconazole)</li>
                        <li>Antiviral (acyclovir 400 mg BID)</li>
                        <li>PJP prophylaxis (trimethoprim-sulfamethoxazole DS TIW or atovaquone)</li>
                    </ul>
                </li>
                
                <li><strong>Febrile Neutropenia:</strong> Broad-spectrum antibiotics (piperacillin-tazobactam or cefepime)</li>
            </ul>
            
            <p><span class="label">Urgent Hematology/Oncology Consultation:</span></p>
            <ul>
                <li>Arrange same-day consultation for new leukemia/aggressive lymphoma diagnosis</li>
                <li>Coordinate bone marrow biopsy, lymph node biopsy</li>
                <li>Discuss treatment plan (chemotherapy timing, clinical trials)</li>
            </ul>
            
            <p><span class="label">Disposition:</span></p>
            <ul>
                <li><strong>Admit:</strong> New leukemia or aggressive lymphoma diagnosis (ICU if unstable, oncologic emergency)</li>
                <li><strong>Goals:</strong> Stabilize, complete workup, initiate treatment</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>APL = Start ATRA Immediately:</strong> If you suspect APL (Acute Promyelocytic Leukemia - AML M3) based on clinical presentation and smear (Auer rods, promyelocytes), start ATRA (tretinoin) IMMEDIATELY without waiting for cytogenetics. APL causes life-threatening DIC and ATRA is life-saving. Delay kills.</li>
            
            <li><strong>Hyperleukocytosis Paradox:</strong> WBC >100,000/ÂµL with leukostasis causes tissue hypoxia. Transfusing pRBC/platelets BEFORE cytoreduction increases blood viscosity and worsens leukostasis. Cytoreduction (leukapheresis, hydroxyurea) FIRST, then transfuse.</li>
            
            <li><strong>Tumor Lysis Can Occur Before Chemo:</strong> High-burden cancers (Burkitt, lymphoblastic lymphoma, high WBC leukemia) can have spontaneous tumor lysis BEFORE treatment starts. Monitor labs closely, start hydration and rasburicase preemptively in high-risk patients.</li>
            
            <li><strong>Blasts on Smear = Urgent Workup:</strong> Circulating blasts on peripheral smear require immediate hematology consultation and bone marrow biopsy within 24 hours. Don't wait for outpatient follow-up - this is potentially life-threatening.</li>
            
            <li><strong>Lymphoma vs. Leukemia Physical Exam:</strong> Lymphoma = prominent lymphadenopathy, less hepatosplenomegaly. Leukemia = hepatosplenomegaly common, minimal lymphadenopathy. If confused, remember: lymphoma is lymph node disease, leukemia is bone marrow disease.</li>
            
            <li><strong>Philadelphia Chromosome Changes Everything:</strong> Ph+ ALL (t(9;22), BCR-ABL fusion) was historically dismal prognosis. Now with tyrosine kinase inhibitors (TKIs like imatinib, dasatinib), outcomes dramatically improved. Always check for Ph+ and add TKI to chemotherapy.</li>
            
            <li><strong>CNS Prophylaxis in ALL and Burkitt:</strong> Both have high risk of CNS involvement (5-10% at diagnosis, much higher without prophylaxis). Always do LP for staging and administer intrathecal chemotherapy (methotrexate, cytarabine) as part of treatment protocol.</li>
            
            <li><strong>Excisional Biopsy for Lymphoma Diagnosis:</strong> Core needle biopsies often insufficient for lymphoma subtyping (need architecture). Excisional lymph node biopsy is gold standard. If patient has mediastinal mass and you're considering lymphoma, get tissue diagnosis BEFORE giving steroids (destroys lymphocytes, makes diagnosis impossible).</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Septic shock or severe neutropenic fever unresponsive to antibiotics</li>
                        <li>Respiratory failure requiring mechanical ventilation</li>
                        <li>Tumor lysis syndrome with renal failure requiring dialysis</li>
                        <li>Leukostasis with end-organ damage (CNS symptoms, respiratory failure)</li>
                        <li>Disseminated intravascular coagulation with life-threatening bleeding</li>
                        <li>Multi-organ dysfunction</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable, afebrile >48 hours</li>
                        <li>Acute complications resolved (tumor lysis syndrome, leukostasis, infection)</li>
                        <li>Electrolytes normalized, renal function stable</li>
                        <li>Transfusion-dependent but at safe baseline (Hgb >7, platelets >10-20k)</li>
                        <li>Chemotherapy initiated or arranged with hematology/oncology</li>
                        <li>Central line placed if needed for chemotherapy</li>
                        <li>Outpatient hematology/oncology follow-up arranged (within days)</li>
                        <li>Patient educated on neutropenic precautions</li>
                        <li>Return precautions for fever >100.4Â°F, bleeding, severe weakness</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="cerebral-salt-wasting" class="condition-page">
    <div class="page-header">
        <h2>90. CEREBRAL SALT WASTING (CSW)</h2>
        <div class="subtitle">Hyponatremia â€¢ Volume Depletion â€¢ CNS Injury â€¢ High Urine Sodium</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Hyponatremia with clinical euvolemia or hypovolemia in patient with CNS pathology (SAH, TBI, meningitis, neurosurgery). Renal sodium wasting leads to volume depletion despite low serum sodium.</p>
            
            <ul>
                <li><strong>Timing:</strong> Typically occurs 2-10 days after CNS injury (peak 7-10 days)</li>
                
                <li><strong>Symptoms:</strong>
                    <ul>
                        <li><strong>Hyponatremia:</strong> Confusion, lethargy, headache, nausea, seizures (if severe/rapid)</li>
                        <li><strong>Volume Depletion:</strong> Orthostasis, tachycardia, decreased urine output, dry mucous membranes</li>
                        <li>May be masked by underlying CNS pathology</li>
                    </ul>
                </li>
                
                <li><strong>Associated CNS Conditions:</strong>
                    <ul>
                        <li><strong>Subarachnoid hemorrhage (Most Common):</strong> 30-40% incidence</li>
                        <li>Traumatic brain injury</li>
                        <li>Intracerebral hemorrhage</li>
                        <li>Meningitis/encephalitis</li>
                        <li>Brain tumors</li>
                        <li>Post-neurosurgery</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PATHOPHYSIOLOGY AND MECHANISM</div>
        <div class="section-content">
            <ul>
                <li><strong>Mechanism (Not Fully Understood):</strong>
                    <ul>
                        <li>CNS injury â†’ Release of natriuretic peptides (BNP, ANP, or "cerebral natriuretic peptide")</li>
                        <li>Natriuretic peptides â†’ Renal sodium wasting</li>
                        <li>Sodium loss â†’ Obligate water loss (isotonic fluid loss)</li>
                        <li>Net result: Hyponatremia + Hypovolemia</li>
                    </ul>
                </li>
                
                <li><strong>Distinction from SIADH (Critical):</strong>
                    <table style="width:100%; border-collapse: collapse;">
                        <tr style="background-color: #f0f0f0;">
                            <th style="border: 1px solid #ccc; padding: 8px;">Feature</th>
                            <th style="border: 1px solid #ccc; padding: 8px;">Cerebral Salt Wasting</th>
                            <th style="border: 1px solid #ccc; padding: 8px;">SIADH</th>
                        </tr>
                        <tr>
                            <td style="border: 1px solid #ccc; padding: 8px;">Volume Status</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">Hypovolemic</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">Euvolemic</td>
                        </tr>
                        <tr>
                            <td style="border: 1px solid #ccc; padding: 8px;">Urine Na+</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">>40 mEq/L (high)</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">>40 mEq/L (high)</td>
                        </tr>
                        <tr>
                            <td style="border: 1px solid #ccc; padding: 8px;">Serum Uric Acid</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">Low or normal</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">Low (<4 mg/dL)</td>
                        </tr>
                        <tr>
                            <td style="border: 1px solid #ccc; padding: 8px;">BUN</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">Elevated (â†‘BUN/Cr)</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">Low-normal</td>
                        </tr>
                        <tr>
                            <td style="border: 1px solid #ccc; padding: 8px;">Response to Saline</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">Improves Na+</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">Worsens/no change</td>
                        </tr>
                        <tr>
                            <td style="border: 1px solid #ccc; padding: 8px;">Treatment</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">IVF + Salt</td>
                            <td style="border: 1px solid #ccc; padding: 8px;">Fluid restrict</td>
                        </tr>
                    </table>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Serum Sodium:</strong> Typically 120-135 mEq/L (can be <120 if severe)</li>
                <li><strong>Serum Osmolality:</strong> Low (<280 mOsm/kg) - true hyponatremia</li>
                <li><strong>Urine Sodium:</strong> >40 mEq/L (inappropriately high for hypovolemic state)</li>
                <li><strong>Urine Osmolality:</strong> >100 mOsm/kg (concentrated urine despite hyponatremia)</li>
                <li><strong>BUN/Cr:</strong> BUN:Cr ratio >20:1 (prerenal from volume depletion)</li>
                <li><strong>Serum Uric Acid:</strong> Variable (low-normal, less reliable than in SIADH)</li>
            </ul>
            
            <p><span class="label">Volume Assessment (Key to Diagnosis):</span></p>
            <ul>
                <li><strong>Clinical Signs of Hypovolemia:</strong>
                    <ul>
                        <li>Orthostatic hypotension (SBP drop >20 mmHg or HR increase >20 bpm)</li>
                        <li>Tachycardia</li>
                        <li>Decreased skin turgor, dry mucous membranes</li>
                        <li>Flat neck veins</li>
                    </ul>
                </li>
                
                <li><strong>Objective Measures (if available):</strong>
                    <ul>
                        <li>CVP <5 mmHg (if central line present)</li>
                        <li>Negative fluid balance (intake < output)</li>
                        <li>Weight loss</li>
                    </ul>
                </li>
                
                <li><strong>CHALLENGE:</strong> Volume assessment difficult in ICU patients with CNS injury (sedated, on vasopressors, receiving IVF)</li>
            </ul>
            
            <p><span class="label">Response to Treatment (Diagnostic and Therapeutic):</span></p>
            <ul>
                <li><strong>Saline Challenge:</strong>
                    <ul>
                        <li>Give NS 500-1000 mL IV bolus</li>
                        <li>CSW: Sodium improves (positive response)</li>
                        <li>SIADH: Sodium worsens or no change (dilution)</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Rule Out Other Causes of Hyponatremia:</span></p>
            <ul>
                <li>Adrenal insufficiency: Cortisol, ACTH stimulation test</li>
                <li>Hypothyroidism: TSH, free T4</li>
                <li>Diuretic use: Medication review</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Goals of Treatment:</span></p>
            <ul>
                <li>Correct hypovolemia (restore normal volume status)</li>
                <li>Correct hyponatremia (prevent/treat symptoms)</li>
                <li>Prevent complications (cerebral vasospasm in SAH, seizures)</li>
            </ul>
            
            <p><span class="label">Fluid and Sodium Replacement:</span></p>
            <ul>
                <li><strong>Isotonic Saline (0.9% NS):</strong>
                    <ul>
                        <li>First-line therapy</li>
                        <li>Bolus: 500-1000 mL IV initially, assess response</li>
                        <li>Maintenance: 100-250 mL/hr continuous infusion</li>
                        <li>Goal: Restore euvolemia (CVP 8-12, MAP >65, UOP >0.5 mL/kg/hr)</li>
                    </ul>
                </li>
                
                <li><strong>Hypertonic Saline (3% NaCl) - If Severe or Symptomatic:</strong>
                    <ul>
                        <li><strong>Indications:</strong> Na+ <120 mEq/L with symptoms (confusion, seizures, coma)</li>
                        <li><strong>Dose:</strong> 100 mL IV bolus over 10 min (can repeat Ã—2-3)</li>
                        <li><strong>Infusion:</strong> 0.5-1 mL/kg/hr continuous (30-60 mL/hr for 70 kg patient)</li>
                        <li><strong>Target:</strong> Increase Na+ by 4-6 mEq/L in first few hours (just enough to stop symptoms)</li>
                        <li><strong>Maximum Correction:</strong>
                            <ul>
                                <li>8 mEq/L in first 24 hours</li>
                                <li>18 mEq/L in first 48 hours</li>
                                <li>Prevents osmotic demyelination syndrome (ODS)</li>
                            </ul>
                        </li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Oral Salt Supplementation:</span></p>
            <ul>
                <li><strong>Salt Tablets:</strong> 1-3 g PO TID (if patient able to take PO)</li>
                <li><strong>High-Salt Diet:</strong> Encourage salty foods, broths</li>
                <li>Used as adjunct to IV therapy or for long-term management</li>
            </ul>
            
            <p><span class="label">Fludrocortisone (Mineralocorticoid):</span></p>
            <ul>
                <li><strong>Dose:</strong> 0.1-0.2 mg PO BID</li>
                <li><strong>Mechanism:</strong> Promotes renal sodium retention</li>
                <li><strong>Use:</strong> Adjunct therapy if persistent CSW despite aggressive salt/fluid replacement</li>
                <li><strong>Side Effects:</strong> Hypertension, hypokalemia, fluid overload</li>
            </ul>
            
            <p><span class="label">Monitoring:</span></p>
            <ul>
                <li><strong>Serum Na+:</strong> Q4-6H initially, then Q8-12H once stable</li>
                <li><strong>Volume Status:</strong> Daily weights, I/O balance, orthostatics</li>
                <li><strong>Urine Output:</strong> Goal >0.5 mL/kg/hr</li>
                <li><strong>Neurologic Exam:</strong> Frequent assessments (q1-2h in ICU)</li>
            </ul>
            
            <p><span class="label">Special Consideration in SAH:</span></p>
            <ul>
                <li><strong>Euvolemia is Critical:</strong> Hypovolemia increases risk of cerebral vasospasm and delayed cerebral ischemia</li>
                <li><strong>Aggressive Volume Repletion:</strong> Target high-normal volume status</li>
                <li><strong>Monitor for Vasospasm:</strong> Transcranial Dopplers, CT perfusion</li>
                <li>CSW treatment aligns with SAH management goals (maintain perfusion)</li>
            </ul>
            
            <p><span class="label">Duration of Treatment:</span></p>
            <ul>
                <li>CSW typically self-limited, resolves over 2-4 weeks</li>
                <li>Continue salt supplementation until sodium stable off therapy</li>
                <li>Monitor for recurrence (uncommon)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>CSW vs. SIADH: The Million-Dollar Question:</strong> Both present with hyponatremia + high urine sodium in CNS injury patients. The KEY is volume status: CSW = hypovolemic (give fluids), SIADH = euvolemic (restrict fluids). Treating SIADH as CSW is safe (extra fluids), but treating CSW as SIADH is catastrophic (fluid restriction worsens hypovolemia and cerebral perfusion, especially in SAH).</li>
            
            <li><strong>When in Doubt, Give Saline:</strong> In neurocritical care, especially SAH, it's safer to err toward CSW diagnosis. Volume depletion increases vasospasm risk. Give isotonic saline and observe response: CSW improves, SIADH doesn't worsen significantly. This is the "therapeutic trial" approach.</li>
            
            <li><strong>SAH = High CSW Risk:</strong> 30-40% of SAH patients develop CSW, usually days 3-10 post-bleed (peak day 7). Hyponatremia in SAH patient should be assumed CSW until proven otherwise, especially if any signs of volume depletion.</li>
            
            <li><strong>Don't Overcorrect Sodium:</strong> Even though CSW requires aggressive salt/fluid replacement, you must still respect the 8/18 rule (8 mEq/L increase in 24h, 18 mEq/L in 48h) to prevent osmotic demyelination. Monitor Na+ closely, slow down fluids if correcting too fast.</li>
            
            <li><strong>Urine Sodium >40 in Both:</strong> High urine sodium is NOT specific for SIADH - it's also present in CSW (renal sodium wasting). Don't use urine sodium alone to distinguish. Volume status is king.</li>
            
            <li><strong>BUN:Cr Ratio is Helpful:</strong> Elevated BUN with preserved Cr (ratio >20:1) suggests prerenal azotemia from hypovolemia (CSW). Normal/low BUN suggests euvolemia (SIADH). Not perfect but useful adjunct.</li>
            
            <li><strong>Fludrocortisone is Adjunct, Not First-Line:</strong> Some centers use fludrocortisone routinely for CSW, but it's not necessary in most cases. IV saline + oral salt are usually sufficient. Fludrocortisone can cause hypertension (bad in SAH/ICH) and hypokalemia.</li>
            
            <li><strong>CSW is Self-Limited:</strong> Unlike SIADH (which may persist), CSW typically resolves spontaneously over 2-4 weeks as brain injury heals. You can wean salt supplementation and monitor for recurrence, which is rare.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe hyponatremia (Na <120 mEq/L) with altered mental status or seizures</li>
                        <li>Rapid sodium correction needed with close monitoring</li>
                        <li>Hemodynamic instability from hypovolemia</li>
                        <li>Ongoing neurosurgical issues requiring ICU-level care</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Sodium corrected to safe level (typically >130 mEq/L, or stable >125 mEq/L if chronic)</li>
                        <li>No seizures or severe neurologic symptoms</li>
                        <li>Euvolemic or volume replete</li>
                        <li>Underlying neurosurgical condition stable</li>
                        <li>On appropriate salt tablets (1-2g TID) and high-salt diet</li>
                        <li>If on fludrocortisone: outpatient endocrinology follow-up arranged</li>
                        <li>Patient educated on high-salt diet, liberal fluid intake</li>
                        <li>Follow-up with neurosurgery and primary care arranged</li>
                        <li>Recheck sodium within 2-3 days of discharge</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="glomerulonephritis" class="condition-page">
    <div class="page-header">
        <h2>91. ACUTE GLOMERULONEPHRITIS</h2>
        <div class="subtitle">Hematuria + Proteinuria + HTN + Edema â€¢ Nephritic Syndrome â€¢ Kidney Biopsy Definitive</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Nephritic Syndrome (Classic Presentation):</span> Hematuria + Hypertension + Edema + Proteinuria (sub-nephrotic range, usually <3.5 g/day) + AKI</p>
            
            <p><strong>Clinical Features:</strong></p>
            <ul>
                <li><strong>Hematuria:</strong>
                    <ul>
                        <li>Gross hematuria (tea-colored, cola-colored urine) or microscopic</li>
                        <li>Dysmorphic RBCs and RBC casts on urinalysis (pathognomonic for glomerular source)</li>
                    </ul>
                </li>
                <li><strong>Hypertension:</strong> New-onset or worsening HTN from fluid retention + decreased GFR</li>
                <li><strong>Edema:</strong>
                    <ul>
                        <li>Periorbital edema (morning, most specific for glomerular disease)</li>
                        <li>Lower extremity edema, weight gain</li>
                        <li>Pulmonary edema if severe (volume overload)</li>
                    </ul>
                </li>
                <li><strong>Acute Kidney Injury:</strong> Elevated creatinine, decreased GFR (from glomerular inflammation)</li>
                <li><strong>Oliguria:</strong> Urine output <400 mL/day (indicates severe disease)</li>
            </ul>
            
            <p><strong>DISTINGUISH NEPHRITIC FROM NEPHROTIC SYNDROME:</strong></p>
            <table>
                <tr>
                    <th>Feature</th>
                    <th>Nephritic Syndrome</th>
                    <th>Nephrotic Syndrome</th>
                </tr>
                <tr>
                    <td>Hematuria</td>
                    <td>+++  (prominent, RBC casts)</td>
                    <td>+ (mild or absent)</td>
                </tr>
                <tr>
                    <td>Proteinuria</td>
                    <td>&lt;3.5 g/day</td>
                    <td>&gt;3.5 g/day (heavy)</td>
                </tr>
                <tr>
                    <td>Hypertension</td>
                    <td>+++ (prominent)</td>
                    <td>+/- (mild or absent)</td>
                </tr>
                <tr>
                    <td>Edema</td>
                    <td>++ (moderate)</td>
                    <td>+++ (severe, anasarca)</td>
                </tr>
                <tr>
                    <td>AKI</td>
                    <td>+++ (common)</td>
                    <td>+ (less common)</td>
                </tr>
                <tr>
                    <td>Hypoalbuminemia</td>
                    <td>Mild</td>
                    <td>Severe (&lt;2.5 g/dL)</td>
                </tr>
            </table>
            
            <p><strong>COMMON CAUSES OF ACUTE GLOMERULONEPHRITIS:</strong></p>
            <ul>
                <li><strong>Post-Infectious GN (Most Common in Children):</strong>
                    <ul>
                        <li>Post-Streptococcal GN: 1-3 weeks after pharyngitis or 3-6 weeks after impetigo</li>
                        <li>Other infections: Staph, pneumococcus, viral (Hep B/C, HIV, endocarditis)</li>
                    </ul>
                </li>
                <li><strong>IgA Nephropathy (Most Common Worldwide, Especially in Adults):</strong>
                    <ul>
                        <li>Episodic gross hematuria concurrent with URI/GI infection ("synpharyngitic")</li>
                        <li>Mesangial IgA deposition on biopsy</li>
                    </ul>
                </li>
                <li><strong>Rapidly Progressive GN (RPGN):</strong>
                    <ul>
                        <li>Anti-GBM disease (Goodpasture's): Pulmonary hemorrhage + GN</li>
                        <li>ANCA-associated vasculitis: Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA)</li>
                        <li>Immune complex-mediated: Lupus nephritis, post-infectious, cryoglobulinemia</li>
                    </ul>
                </li>
                <li><strong>Lupus Nephritis:</strong> SLE with renal involvement (WHO Class III or IV)</li>
                <li><strong>Membranoproliferative GN (MPGN):</strong> Often with Hep C, cryoglobulinemia, or complement disorders</li>
                <li><strong>Alport Syndrome:</strong> Hereditary nephritis with deafness and ocular abnormalities</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Urinalysis (Critical First Step):</strong></p>
            <ul>
                <li><strong>Hematuria:</strong> RBCs (>3/hpf microscopic, or grossly visible)</li>
                <li><strong>RBC Casts:</strong> Pathognomonic for glomerulonephritis (vs. non-glomerular hematuria)</li>
                <li><strong>Dysmorphic RBCs:</strong> >5% suggests glomerular source</li>
                <li><strong>Proteinuria:</strong> Usually 1-3+ on dipstick (sub-nephrotic range)</li>
                <li><strong>WBCs/WBC casts:</strong> May be present (inflammatory)</li>
            </ul>
            
            <p><strong>Quantify Proteinuria:</strong></p>
            <ul>
                <li><strong>Urine Protein-to-Creatinine Ratio (UPCR):</strong> Spot urine; &lt;3.5 g/g in nephritic, &gt;3.5 g/g in nephrotic</li>
                <li><strong>24-Hour Urine Collection:</strong> Gold standard but cumbersome</li>
            </ul>
            
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>BMP:</strong> Elevated creatinine, hyperkalemia, metabolic acidosis (if AKI)</li>
                <li><strong>CBC:</strong> Anemia (from CKD or hemolysis if TMA), leukocytosis (if infection)</li>
                <li><strong>Albumin:</strong> Usually normal or mildly low in nephritic (vs. <2.5 g/dL in nephrotic)</li>
                <li><strong>Complement Levels (C3, C4):</strong>
                    <ul>
                        <li>**Low C3 and C4:** Lupus, cryoglobulinemia, endocarditis</li>
                        <li>**Low C3, Normal C4:** Post-streptococcal GN, MPGN, shunt nephritis</li>
                        <li>**Normal C3 and C4:** IgA nephropathy, ANCA vasculitis, anti-GBM disease</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Serologic Testing (Based on Clinical Suspicion):</strong></p>
            <ul>
                <li><strong>Post-Streptococcal:</strong>
                    <ul>
                        <li>ASO titer (anti-streptolysin O): Elevated if recent pharyngitis</li>
                        <li>Anti-DNase B: More sensitive if recent skin infection</li>
                        <li>Streptozyme: Composite of streptococcal antibodies</li>
                    </ul>
                </li>
                <li><strong>Rapidly Progressive GN:</strong>
                    <ul>
                        <li>**ANCA:** c-ANCA (GPA), p-ANCA (MPA, EGPA)</li>
                        <li>**Anti-GBM Antibodies:** Goodpasture's syndrome</li>
                    </ul>
                </li>
                <li><strong>Lupus Nephritis:</strong>
                    <ul>
                        <li>ANA, anti-dsDNA, complement (C3, C4)</li>
                    </ul>
                </li>
                <li><strong>Hepatitis Serologies:</strong> Hep B surface antigen, Hep C antibody (for MPGN, cryoglobulinemia)</li>
                <li><strong>Cryoglobulins:</strong> If suspect mixed cryoglobulinemia (Hep C, vasculitis)</li>
                <li><strong>HIV Testing:</strong> HIVAN (HIV-associated nephropathy) can present with nephritic features</li>
            </ul>
            
            <p><strong>Renal Ultrasound:</strong></p>
            <ul>
                <li>Assess kidney size (normal or enlarged in acute GN; small in chronic)</li>
                <li>Rule out obstruction</li>
                <li>Assess cortical echogenicity</li>
            </ul>
            
            <p><strong>Kidney Biopsy (DEFINITIVE DIAGNOSIS):</strong></p>
            <ul>
                <li><strong>Indications:</strong>
                    <ul>
                        <li>Unclear diagnosis (not classic post-infectious)</li>
                        <li>RPGN (creatinine doubling over days-weeks, crescents on UA)</li>
                        <li>Nephrotic-range proteinuria</li>
                        <li>Persistent hematuria/proteinuria for >4 weeks</li>
                        <li>Systemic disease (lupus, vasculitis)</li>
                    </ul>
                </li>
                <li><strong>Provides:</strong>
                    <ul>
                        <li>Light microscopy: Pattern (proliferative, crescentic, membranous)</li>
                        <li>Immunofluorescence: IgA, IgG, IgM, C3 deposition patterns</li>
                        <li>Electron microscopy: Location of deposits (subepithelial, subendothelial, mesangial)</li>
                    </ul>
                </li>
                <li><strong>Contraindications:</strong> Uncontrolled HTN, bleeding disorder, solitary kidney (relative)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>GENERAL SUPPORTIVE MANAGEMENT:</strong></p>
            <ul>
                <li><strong>Fluid and Sodium Restriction:</strong>
                    <ul>
                        <li>Fluid restrict to 1-1.5 L/day if oliguric or edematous</li>
                        <li>Sodium restrict to <2 g/day</li>
                    </ul>
                </li>
                <li><strong>Diuretics (for Volume Overload):</strong>
                    <ul>
                        <li><strong>Furosemide:</strong> 20-80 mg IV/PO daily (titrate to urine output and volume status)</li>
                        <li>Goal: Negative 0.5-1 L/day until euvolemic</li>
                        <li>Monitor electrolytes (hypokalemia, hyponatremia)</li>
                    </ul>
                </li>
                <li><strong>Hypertension Control:</strong>
                    <ul>
                        <li>Goal BP: <130/80 mmHg (lower if significant proteinuria)</li>
                        <li><strong>ACE Inhibitors or ARBs:</strong> First-line (reduce proteinuria, protect kidney)
                            <ul>
                                <li>Lisinopril 10-40 mg PO daily, or</li>
                                <li>Losartan 50-100 mg PO daily</li>
                                <li>**Caution:** Monitor creatinine (may rise initially) and potassium (risk of hyperkalemia)</li>
                            </ul>
                        </li>
                        <li><strong>Calcium Channel Blockers:</strong> Add if BP not controlled (amlodipine 5-10 mg daily)</li>
                        <li><strong>Avoid NSAIDs:</strong> Worsen renal function and fluid retention</li>
                    </ul>
                </li>
                <li><strong>Treat Hyperkalemia:</strong>
                    <ul>
                        <li>If K+ &gt;5.5 mEq/L: Calcium gluconate, insulin + dextrose, sodium polystyrene sulfonate</li>
                        <li>Consider dialysis if severe hyperkalemia refractory to medical management</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>SPECIFIC THERAPIES (Based on Etiology):</strong></p>
            
            <p><strong>1. Post-Streptococcal GN:</strong></p>
            <ul>
                <li><strong>Antibiotics:</strong> Penicillin or amoxicillin (to eradicate strep, not to treat GN itself)</li>
                <li><strong>Supportive Care:</strong> Fluid/sodium restriction, diuretics, BP control (as above)</li>
                <li><strong>Prognosis:</strong> Excellent in children (>95% full recovery); adults may develop CKD (10-20%)</li>
                <li><strong>Duration:</strong> Complement normalizes in 6-8 weeks; hematuria/proteinuria resolves in 3-6 months</li>
            </ul>
            
            <p><strong>2. IgA Nephropathy:</strong></p>
            <ul>
                <li><strong>ACE Inhibitor or ARB:</strong> First-line (reduce proteinuria)
                    <ul>
                        <li>Goal: UPCR <1 g/g</li>
                    </ul>
                </li>
                <li><strong>Corticosteroids:</strong> Consider if proteinuria >1 g/day despite ACEi/ARB for 3-6 months
                    <ul>
                        <li>Prednisone 0.5-1 mg/kg/day (max 60-80 mg) Ã— 2-3 months, then taper</li>
                        <li>**Evidence:** TESTING trial showed benefit in reducing kidney failure risk</li>
                    </ul>
                </li>
                <li><strong>Fish Oil (Omega-3):</strong> 4 g/day (modest benefit, anti-inflammatory)</li>
                <li><strong>Prognosis:</strong> Variable; 20-40% progress to ESRD over 20 years</li>
            </ul>
            
            <p><strong>3. Rapidly Progressive GN (RPGN):</strong></p>
            <ul>
                <li><strong>URGENT NEPHROLOGY CONSULTATION</strong> - this is a renal emergency</li>
                <li><strong>High-Dose Corticosteroids:</strong>
                    <ul>
                        <li>Methylprednisolone 500-1000 mg IV daily Ã— 3 days (pulse therapy), then prednisone 1 mg/kg/day PO Ã— 4-6 weeks, taper</li>
                    </ul>
                </li>
                <li><strong>Immunosuppression (ANCA Vasculitis or Lupus):</strong>
                    <ul>
                        <li><strong>Cyclophosphamide:</strong> 500-1000 mg/mÂ² IV monthly Ã— 6 months, or 2 mg/kg/day PO Ã— 3-6 months</li>
                        <li><strong>Rituximab:</strong> 375 mg/mÂ² weekly Ã— 4 doses (alternative to cyclophosphamide, especially in ANCA vasculitis)</li>
                        <li><strong>Mycophenolate Mofetil:</strong> 2-3 g/day PO (for lupus nephritis, after induction)</li>
                    </ul>
                </li>
                <li><strong>Plasmapheresis:</strong>
                    <ul>
                        <li>Indicated for: Anti-GBM disease (remove circulating antibodies), severe ANCA vasculitis with pulmonary hemorrhage or dialysis-dependent AKI</li>
                        <li>Protocol: Daily or every-other-day sessions Ã— 7-14 treatments</li>
                    </ul>
                </li>
                <li><strong>Prognosis:</strong> Without treatment, RPGN progresses to ESRD in weeks-months. Early aggressive treatment can preserve renal function.</li>
            </ul>
            
            <p><strong>4. Lupus Nephritis:</strong></p>
            <ul>
                <li><strong>Class III/IV (Proliferative):</strong>
                    <ul>
                        <li><strong>Induction:</strong> High-dose corticosteroids + cyclophosphamide (6 months) or mycophenolate (6-12 months)</li>
                        <li><strong>Maintenance:</strong> Mycophenolate or azathioprine + low-dose prednisone</li>
                    </ul>
                </li>
                <li><strong>Hydroxychloroquine:</strong> All lupus patients (reduces flares)</li>
            </ul>
            
            <p><strong>RENAL REPLACEMENT THERAPY (Dialysis):</strong></p>
            <ul>
                <li><strong>Indications:</strong>
                    <ul>
                        <li>Volume overload refractory to diuretics (pulmonary edema)</li>
                        <li>Severe hyperkalemia refractory to medical therapy</li>
                        <li>Severe metabolic acidosis (pH <7.1)</li>
                        <li>Uremic symptoms (pericarditis, encephalopathy, bleeding)</li>
                    </ul>
                </li>
                <li><strong>Modality:</strong> Hemodialysis (intermittent or CRRT if unstable)</li>
            </ul>
            
            <p><strong>NEPHROLOGY REFERRAL:</strong></p>
            <ul>
                <li>ALL patients with acute GN should be referred to nephrology</li>
                <li><strong>Urgent/Emergent:</strong> RPGN (creatinine doubling), oliguria, pulmonary hemorrhage, uncertain diagnosis requiring biopsy</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>RBC Casts = Glomerulonephritis:</strong> Finding RBC casts on urinalysis is pathognomonic for glomerular disease. No other condition causes RBC casts. If you see them, think GN, not kidney stones, UTI, or other non-glomerular causes of hematuria.</li>
            
            <li><strong>Nephritic vs. Nephrotic - Remember the "itic" vs. "otic":</strong> Nephritic = inflammatory (hematuria, HTN, RBC casts, sub-nephrotic proteinuria). Nephrotic = leaky (massive proteinuria >3.5 g/day, hypoalbuminemia, edema, hyperlipidemia). Both can coexist, but one usually predominates.</li>
            
            <li><strong>Complement Levels Point to Diagnosis:</strong> Low C3 + Low C4 = lupus or cryoglobulinemia. Low C3 + Normal C4 = post-strep GN or MPGN. Normal complements = IgA nephropathy or ANCA vasculitis. Complement patterns narrow your differential significantly.</li>
            
            <li><strong>Post-Strep GN Has a Latent Period:</strong> Symptoms appear 1-3 weeks after pharyngitis or 3-6 weeks after impetigo. The classic presentation is a child with tea-colored urine 2 weeks after a sore throat. ASO titers confirm recent strep infection.</li>
            
            <li><strong>RPGN is a Renal Emergency:</strong> Rapidly progressive GN (creatinine doubling over days-weeks, crescents on biopsy) requires URGENT diagnosis and treatment. Without aggressive immunosuppression Â± plasmapheresis, it progresses to ESRD within weeks-months. Call nephrology immediately.</li>
            
            <li><strong>IgA Nephropathy = Synpharyngitic Hematuria:</strong> Unlike post-strep GN (2-week delay), IgA nephropathy causes gross hematuria concurrent with or within 1-2 days of URI. "I get a cold, my urine turns red" is the classic history. It's the most common primary GN worldwide.</li>
            
            <li><strong>Goodpasture's = Pulmonary-Renal Syndrome:</strong> Anti-GBM disease causes both pulmonary hemorrhage (hemoptysis, dyspnea, alveolar infiltrates) and glomerulonephritis. Young male smokers are classic. Urgent plasmapheresis + immunosuppression can be life-saving. Test for anti-GBM antibodies immediately.</li>
            
            <li><strong>Kidney Biopsy is Definitive but Not Always Needed:</strong> Classic post-strep GN in a child (recent strep, low C3, hematuria, spontaneous improvement) doesn't need biopsy - manage supportively. But RPGN, unclear diagnosis, systemic disease, or lack of improvement ALWAYS warrants biopsy. When in doubt, consult nephrology.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe acute kidney injury requiring dialysis emergently</li>
                        <li>Pulmonary hemorrhage (diffuse alveolar hemorrhage)</li>
                        <li>Respiratory failure requiring mechanical ventilation</li>
                        <li>Hypertensive emergency with end-organ damage</li>
                        <li>Rapidly progressive glomerulonephritis with concern for dialysis-dependence</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable, blood pressure controlled (<140/90)</li>
                        <li>Renal function stable or improving (Cr stable or downtrending)</li>
                        <li>No dialysis requirement (or stable on outpatient dialysis)</li>
                        <li>Fluid status euvolemic (no significant edema or volume overload)</li>
                        <li>Urine output adequate</li>
                        <li>On appropriate immunosuppression if indicated (steroids, cyclophosphamide)</li>
                        <li>Outpatient nephrology follow-up arranged (within 1-2 weeks)</li>
                        <li>Kidney biopsy completed or arranged</li>
                        <li>Patient educated on low-sodium diet, fluid restriction if needed</li>
                        <li>Recheck labs arranged within 3-7 days</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="psychogenic-polydipsia" class="condition-page">
    <div class="page-header">
        <h2>92. PSYCHOGENIC POLYDIPSIA (PRIMARY POLYDIPSIA)</h2>
        <div class="subtitle">Compulsive Water Drinking â€¢ Hyponatremia â€¢ Psychiatric Illness â€¢ Low Urine Osmolality</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Excessive water intake (>3 L/day, often 10-20 L/day) from compulsive drinking behavior, leading to hyponatremia and dilute urine. Also called "primary polydipsia" or "dipsogenic diabetes insipidus."</p>
            
            <p><strong>Clinical Features:</strong></p>
            <ul>
                <li><strong>Polydipsia:</strong>
                    <ul>
                        <li>Excessive water drinking (often >10 L/day in severe cases)</li>
                        <li>Compulsive, non-physiologic (not driven by true thirst)</li>
                        <li>Patients may carry water bottles constantly, drink from taps/fountains excessively</li>
                    </ul>
                </li>
                <li><strong>Polyuria:</strong>
                    <ul>
                        <li>High urine output (often 5-15 L/day) - dilute urine from excessive intake</li>
                        <li>Nocturia (frequent nighttime urination)</li>
                    </ul>
                </li>
                <li><strong>Hyponatremia (If Intake Exceeds Renal Capacity to Excrete Free Water):</strong>
                    <ul>
                        <li>Mild: 130-135 mEq/L (often asymptomatic)</li>
                        <li>Moderate: 125-130 mEq/L (nausea, confusion, headache)</li>
                        <li>Severe: <125 mEq/L (seizures, coma, cerebral edema)</li>
                    </ul>
                </li>
                <li><strong>Other Symptoms:</strong>
                    <ul>
                        <li>Dizziness, lightheadedness</li>
                        <li>Weakness, fatigue</li>
                        <li>Weight fluctuations (water weight)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Typical Patient Profile:</strong></p>
            <ul>
                <li><strong>Psychiatric Illness (Most Common):</strong>
                    <ul>
                        <li>Schizophrenia (most common, 10-20% of patients)</li>
                        <li>Bipolar disorder, schizoaffective disorder</li>
                        <li>Obsessive-compulsive disorder (OCD)</li>
                        <li>Anxiety disorders</li>
                    </ul>
                </li>
                <li><strong>Developmental Disorders:</strong> Autism spectrum, intellectual disability</li>
                <li><strong>Medications:</strong>
                    <ul>
                        <li>Antipsychotics (especially clozapine, olanzapine) - can worsen polydipsia</li>
                        <li>Anticholinergics (dry mouth â†’ â†‘ drinking)</li>
                    </ul>
                </li>
                <li><strong>Less Common:</strong> "Health fad" excessive water intake (fitness/wellness culture), factitious disorder</li>
            </ul>
            
            <p><strong>Pathophysiology:</strong></p>
            <ul>
                <li>Normal kidneys can excrete up to ~15-20 L/day of free water (maximal dilution = urine osmolality ~50 mOsm/kg)</li>
                <li>If intake exceeds renal capacity â†’ positive free water balance â†’ hyponatremia</li>
                <li>Chronic polydipsia can cause "wash out" of medullary concentration gradient â†’ partial nephrogenic DI (impaired concentrating ability)</li>
            </ul>
            
            <p><strong>DISTINGUISH FROM DIABETES INSIPIDUS:</strong></p>
            <table>
                <tr>
                    <th>Feature</th>
                    <th>Psychogenic Polydipsia</th>
                    <th>Central DI</th>
                    <th>Nephrogenic DI</th>
                </tr>
                <tr>
                    <td>Mechanism</td>
                    <td>Excessive water intake</td>
                    <td>â†“ ADH secretion</td>
                    <td>Renal resistance to ADH</td>
                </tr>
                <tr>
                    <td>Serum Na+</td>
                    <td>Low or low-normal</td>
                    <td>High or high-normal</td>
                    <td>High or high-normal</td>
                </tr>
                <tr>
                    <td>Serum Osm</td>
                    <td>Low (<280)</td>
                    <td>High (>295)</td>
                    <td>High (>295)</td>
                </tr>
                <tr>
                    <td>Urine Osm</td>
                    <td>Very low (<100)</td>
                    <td>Low (<300)</td>
                    <td>Low (<300)</td>
                </tr>
                <tr>
                    <td>Water Deprivation Test</td>
                    <td>Urine concentrates normally</td>
                    <td>Urine stays dilute â†’ concentrates with desmopressin</td>
                    <td>Urine stays dilute, no response to desmopressin</td>
                </tr>
                <tr>
                    <td>Psychiatric History</td>
                    <td>Often present</td>
                    <td>Absent</td>
                    <td>Absent (unless drug-induced)</td>
                </tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Initial Laboratory Assessment:</strong></p>
            <ul>
                <li><strong>Serum Sodium:</strong> Low (125-135 mEq/L typical) or low-normal</li>
                <li><strong>Serum Osmolality:</strong> Low (<280 mOsm/kg)</li>
                <li><strong>Urine Osmolality:</strong>
                    <ul>
                        <li>Very dilute (<100 mOsm/kg) during active water drinking</li>
                        <li>Key diagnostic clue: Urine osm is LOWER than serum osm (inappropriate dilution)</li>
                    </ul>
                </li>
                <li><strong>Urine Sodium:</strong> Variable (often low due to volume expansion suppressing ADH/aldosterone)</li>
                <li><strong>BMP:</strong> Check for other electrolyte abnormalities, assess renal function</li>
            </ul>
            
            <p><strong>Assess Volume Status:</strong></p>
            <ul>
                <li>Patients are typically euvolemic or mildly hypervolemic (from water overload)</li>
                <li>No signs of hypovolemia (no orthostasis, tachycardia)</li>
                <li>No signs of severe hypervolemia (no edema, ascites)</li>
            </ul>
            
            <p><strong>Water Deprivation Test (Definitive Test to Distinguish from DI):</strong></p>
            <ul>
                <li><strong>Protocol:</strong>
                    <ul>
                        <li>Patient stops all fluid intake</li>
                        <li>Measure serum and urine osmolality hourly</li>
                        <li>Weigh patient hourly (stop if >3-5% body weight loss)</li>
                        <li>Monitor vital signs</li>
                        <li>Stop test when: Urine osm plateaus (2 consecutive values within 30 mOsm), serum osm >295-300 mOsm/kg, or clinical instability</li>
                    </ul>
                </li>
                <li><strong>Results:</strong>
                    <ul>
                        <li><strong>Psychogenic Polydipsia:</strong> Urine concentrates appropriately (urine osm >600-800 mOsm/kg)</li>
                        <li><strong>Central DI:</strong> Urine stays dilute (<300 mOsm/kg), then concentrates after desmopressin (DDAVP) given</li>
                        <li><strong>Nephrogenic DI:</strong> Urine stays dilute even after desmopressin</li>
                    </ul>
                </li>
                <li><strong>CAUTION:</strong>
                    <ul>
                        <li>Chronic polydipsia can cause partial nephrogenic DI ("medullary washout") â†’ blunted response on water deprivation test</li>
                        <li>May need prolonged abstinence from excess water intake (days-weeks) before testing to restore medullary gradient</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Serum ADH (Copeptin) - Not Routinely Done:</strong></p>
            <ul>
                <li>Copeptin (stable ADH surrogate) can help distinguish: Low in central DI, normal/high in nephrogenic DI and psychogenic polydipsia</li>
                <li>Rarely needed in clinical practice</li>
            </ul>
            
            <p><strong>Exclude Other Causes of Hyponatremia:</strong></p>
            <ul>
                <li><strong>Assess Volume Status:</strong> Hypovolemic, euvolemic, or hypervolemic?</li>
                <li><strong>Rule Out SIADH:</strong> Check urine osm (should be inappropriately HIGH in SIADH, LOW in psychogenic polydipsia)</li>
                <li><strong>TSH, Cortisol:</strong> Rule out hypothyroidism, adrenal insufficiency (causes of hyponatremia)</li>
                <li><strong>Medications:</strong> Review for diuretics, SSRIs, carbamazepine (cause SIADH or hyponatremia)</li>
            </ul>
            
            <p><strong>Psychiatric Evaluation:</strong></p>
            <ul>
                <li>Assess for underlying psychiatric disorders (schizophrenia, bipolar, OCD)</li>
                <li>Review medications (antipsychotics, anticholinergics)</li>
                <li>Assess insight into drinking behavior (many patients lack awareness of problem)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>ACUTE MANAGEMENT (If Symptomatic Hyponatremia):</strong></p>
            <ul>
                <li><strong>Stop Water Intake:</strong> Immediate cessation of oral intake (NPO or restrict to <1 L/day)</li>
                <li><strong>Treat Severe Symptomatic Hyponatremia (Na+ <120 mEq/L with seizures, coma):</strong>
                    <ul>
                        <li><strong>3% Hypertonic Saline:</strong> 100 mL IV bolus over 10 minutes, may repeat Ã— 2-3 if seizures persist</li>
                        <li>Goal: Increase Na+ by 4-6 mEq/L acutely (enough to stop seizures)</li>
                        <li>**CAUTION:** Do NOT correct too rapidly - risk of osmotic demyelination syndrome (ODS)
                            <ul>
                                <li>Limit correction to 6-8 mEq/L in 24 hours, 12-14 mEq/L in 48 hours</li>
                            </ul>
                        </li>
                    </ul>
                </li>
                <li><strong>Monitor Sodium Closely:</strong> Check Na+ every 2-4 hours during acute correction</li>
            </ul>
            
            <p><strong>CHRONIC MANAGEMENT (Behavioral and Pharmacologic):</strong></p>
            
            <p><strong>1. Fluid Restriction (Primary Treatment):</strong></p>
            <ul>
                <li><strong>Goal:</strong> Limit fluid intake to 1-1.5 L/day (less than renal free water clearance)</li>
                <li><strong>Implementation:</strong>
                    <ul>
                        <li>Supervised fluid intake in inpatient or residential settings</li>
                        <li>Remove access to excessive water (lock bathrooms, limit fountain access)</li>
                        <li>Behavioral modification, habit reversal training</li>
                    </ul>
                </li>
                <li><strong>Challenge:</strong> Compliance is poor, especially in unmonitored settings. Many patients compulsively seek water.</li>
            </ul>
            
            <p><strong>2. Treat Underlying Psychiatric Disorder:</strong></p>
            <ul>
                <li><strong>Optimize Antipsychotic Therapy:</strong>
                    <ul>
                        <li>Consider switching from high-risk antipsychotics (clozapine, olanzapine) to lower-risk agents</li>
                        <li>Ensure psychiatric symptoms are well-controlled (psychosis can worsen polydipsia)</li>
                    </ul>
                </li>
                <li><strong>Behavioral Therapy:</strong> Cognitive-behavioral therapy (CBT), habit reversal techniques</li>
                <li><strong>Address Anticholinergic Side Effects:</strong> If dry mouth contributing â†’ artificial saliva, sugar-free gum (avoid drinking)</li>
            </ul>
            
            <p><strong>3. Pharmacologic Interventions (Limited Evidence):</strong></p>
            <ul>
                <li><strong>Demeclocycline:</strong> 600-1200 mg/day PO (induces nephrogenic DI â†’ prevents hyponatremia)
                    <ul>
                        <li>Mechanism: Blocks ADH action in kidney â†’ impairs water reabsorption</li>
                        <li>Side effects: Photosensitivity, nephrotoxicity, esophagitis</li>
                        <li>**Caution:** Can cause hypernatremia if patient reduces intake; monitor Na+ closely</li>
                    </ul>
                </li>
                <li><strong>Urea:</strong> 15-60 g/day PO (osmotic diuresis)
                    <ul>
                        <li>Increases free water excretion</li>
                        <li>Unpalatable, poor compliance</li>
                    </ul>
                </li>
                <li><strong>Clozapine Dose Reduction:</strong> If on clozapine and polydipsia severe, consider reducing dose (but weigh risk of worsening psychosis)</li>
            </ul>
            
            <p><strong>MONITORING AND FOLLOW-UP:</strong></p>
            <ul>
                <li><strong>Frequent Sodium Monitoring:</strong>
                    <ul>
                        <li>Inpatient: Daily serum sodium</li>
                        <li>Outpatient: Weekly initially, then monthly once stable</li>
                    </ul>
                </li>
                <li><strong>Weight Monitoring:</strong> Daily weights (rapid fluctuations suggest excess water intake)</li>
                <li><strong>Urine Specific Gravity:</strong> Can monitor daily (specific gravity <1.005 indicates dilute urine from excess intake)</li>
                <li><strong>Close Coordination with Psychiatry:</strong> Ensure psychiatric stability, optimize medications</li>
            </ul>
            
            <p><strong>EDUCATION:</strong></p>
            <ul>
                <li>Educate patient (and caregivers) about risks of excessive water intake (hyponatremia, seizures, death)</li>
                <li>Explain that "more water is not always healthier" - dispel wellness myths</li>
                <li>Provide behavioral strategies to reduce drinking urges</li>
            </ul>
            
            <p><strong>PROGNOSIS:</strong></p>
            <ul>
                <li>Chronic, relapsing condition - very difficult to manage long-term</li>
                <li>Compliance with fluid restriction is poor, especially in outpatient settings</li>
                <li>Risk of recurrent severe hyponatremia and complications (seizures, falls, ODS from overly rapid correction)</li>
                <li>Best outcomes in supervised/residential psychiatric settings with strict fluid control</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Serum Osm < Urine Osm = Not Psychogenic Polydipsia:</strong> The hallmark of psychogenic polydipsia is very dilute urine (urine osm <100 mOsm/kg) with low serum osmolality (<280). If urine is concentrated (>300 mOsm/kg), think SIADH or other causes of hyponatremia, NOT psychogenic polydipsia.</li>
            
            <li><strong>Psychiatric Illness is the Key Clue:</strong> The vast majority of patients with psychogenic polydipsia have schizophrenia (10-20% of patients with schizophrenia), bipolar disorder, or other serious psychiatric illness. If you see polyuria + polydipsia + hyponatremia in a psychiatric patient, psychogenic polydipsia is top of the differential.</li>
            
            <li><strong>Water Deprivation Test Distinguishes from DI:</strong> Psychogenic polydipsia: urine concentrates normally (>600 mOsm/kg). Central DI: urine stays dilute, then concentrates with DDAVP. Nephrogenic DI: urine stays dilute despite DDAVP. BUT chronic polydipsia can cause "medullary washout" â†’ blunted response mimicking partial nephrogenic DI.</li>
            
            <li><strong>Don't Correct Sodium Too Fast:</strong> Even though psychogenic polydipsia causes hyponatremia from excess water intake, the same rules for correction apply: limit to 6-8 mEq/L in 24 hours to avoid osmotic demyelination syndrome (ODS). Overzealous correction can cause locked-in syndrome, quadriplegia, death.</li>
            
            <li><strong>Fluid Restriction is Primary Treatment:</strong> The key is limiting intake to <1.5 L/day. This is extremely difficult in unmonitored settings - patients compulsively seek water. Best managed in supervised psychiatric facilities with locked bathrooms and controlled water access. Outpatient compliance is abysmal.</li>
            
            <li><strong>Clozapine is a Common Culprit:</strong> Clozapine and olanzapine are strongly associated with polydipsia (mechanism unclear - may involve dry mouth, altered thirst regulation, or SIADH). Consider switching antipsychotics if polydipsia is severe and refractory.</li>
            
            <li><strong>Demeclocycline Induces Nephrogenic DI:</strong> Demeclocycline blocks ADH action in the kidneys â†’ prevents water reabsorption â†’ protects against hyponatremia. It's used off-label for psychogenic polydipsia and SIADH. But it can cause hypernatremia if intake decreases, and it's nephrotoxic - monitor closely.</li>
            
            <li><strong>This is a Chronic, Relapsing Condition:</strong> Unlike DI (which can be well-controlled with DDAVP or addressing the cause), psychogenic polydipsia is very difficult to manage long-term. Patients lack insight, compulsively drink despite education, and have frequent ER visits for symptomatic hyponatremia. It's frustrating for everyone involved.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe hyponatremia (Na <120 mEq/L) with seizures or coma</li>
                        <li>Acute water intoxication requiring close monitoring</li>
                        <li>Altered mental status requiring frequent neuro checks</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Sodium corrected to safe level (typically >130 mEq/L)</li>
                        <li>Mental status at baseline</li>
                        <li>No seizures during hospitalization</li>
                        <li>Underlying psychiatric condition addressed</li>
                        <li>Close monitoring of fluid intake established (behavioral plan, restricted access)</li>
                        <li>Psychiatry follow-up arranged (within days to week)</li>
                        <li>Outpatient psychiatry or case management to monitor fluid restriction</li>
                        <li>Patient/caregivers educated on risks of excessive water intake</li>
                        <li>Recheck sodium within 2-3 days of discharge</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="rta" class="condition-page">
    <div class="page-header">
        <h2>93. RENAL TUBULAR ACIDOSIS (RTA)</h2>
        <div class="subtitle">Non-Anion Gap Metabolic Acidosis â€¢ Normal GFR â€¢ Impaired Renal Acid Handling</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Overview:</span> Renal tubular acidosis (RTA) = group of disorders characterized by impaired renal acid excretion or bicarbonate reabsorption â†’ hyperchloremic (non-anion gap) metabolic acidosis with normal or near-normal GFR.</p>
            
            <p><strong>THREE MAIN TYPES:</strong></p>
            
            <p><strong>TYPE 1 RTA (DISTAL RTA):</strong></p>
            <ul>
                <li><strong>Mechanism:</strong> Impaired H+ secretion in distal tubule â†’ inability to acidify urine</li>
                <li><strong>Key Features:</strong>
                    <ul>
                        <li>Hyperchloremic metabolic acidosis (non-anion gap)</li>
                        <li>**Hypokalemia** (most common electrolyte abnormality)</li>
                        <li>**Urine pH >5.5** despite acidemia (pathognomonic - cannot acidify urine)</li>
                        <li>Nephrocalcinosis, kidney stones (calcium phosphate) - chronic complications</li>
                        <li>Bone disease (rickets in children, osteomalacia in adults) from chronic acidosis</li>
                    </ul>
                </li>
                <li><strong>Common Causes:</strong>
                    <ul>
                        <li>Autoimmune diseases: SjÃ¶gren's syndrome (most common), lupus, rheumatoid arthritis</li>
                        <li>Medications: Amphotericin B, lithium, ifosfamide</li>
                        <li>Genetic: Hereditary forms (mutations in H+-ATPase)</li>
                        <li>Obstructive uropathy, sickle cell disease</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>TYPE 2 RTA (PROXIMAL RTA):</strong></p>
            <ul>
                <li><strong>Mechanism:</strong> Impaired proximal tubule HCO3- reabsorption â†’ bicarbonate wasting</li>
                <li><strong>Key Features:</strong>
                    <ul>
                        <li>Hyperchloremic metabolic acidosis</li>
                        <li>**Hypokalemia** (from bicarbonaturia)</li>
                        <li>**Urine pH <5.5** once HCO3- is below reabsorptive threshold (can acidify urine, unlike Type 1)</li>
                        <li>Fractional excretion of HCO3- >15% (when HCO3- repleted to normal)</li>
                        <li>Often part of Fanconi syndrome (global proximal tubule dysfunction: also phosphaturia, glucosuria, aminoaciduria, uricosuria)</li>
                    </ul>
                </li>
                <li><strong>Common Causes:</strong>
                    <ul>
                        <li>Fanconi syndrome: Multiple myeloma, light chain deposition, cystinosis, Wilson's disease</li>
                        <li>Medications: Tenofovir, ifosfamide, aminoglycosides, cisplatin, valproic acid, topiramate</li>
                        <li>Genetic: Hereditary forms (rare)</li>
                        <li>Carbonic anhydrase inhibitors: Acetazolamide (iatrogenic Type 2 RTA)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>TYPE 4 RTA (HYPERKALEMIC RTA):</strong></p>
            <ul>
                <li><strong>Mechanism:</strong> Aldosterone deficiency or resistance â†’ impaired K+ and H+ secretion in distal tubule</li>
                <li><strong>Key Features:</strong>
                    <ul>
                        <li>Hyperchloremic metabolic acidosis (mild, usually HCO3- 18-22 mEq/L)</li>
                        <li>**HYPERKALEMIA** (distinguishes from Types 1 and 2)</li>
                        <li>Urine pH <5.5 (can acidify urine somewhat)</li>
                        <li>Often mild acidosis (vs. severe in Types 1 and 2)</li>
                    </ul>
                </li>
                <li><strong>Common Causes:</strong>
                    <ul>
                        <li><strong>Hypoaldosteronism:</strong>
                            <ul>
                                <li>Diabetes (hyporeninemic hypoaldosteronism, most common cause of Type 4 RTA)</li>
                                <li>CKD, NSAIDs, ACE inhibitors, ARBs, heparin</li>
                                <li>Adrenal insufficiency (Addison's disease)</li>
                            </ul>
                        </li>
                        <li><strong>Aldosterone Resistance:</strong>
                            <ul>
                                <li>Medications: K+-sparing diuretics (spironolactone, amiloride), trimethoprim, pentamidine</li>
                                <li>Urinary tract obstruction, sickle cell disease</li>
                            </ul>
                        </li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>COMPARISON OF RTA TYPES:</strong></p>
            <table>
                <tr>
                    <th>Feature</th>
                    <th>Type 1 (Distal)</th>
                    <th>Type 2 (Proximal)</th>
                    <th>Type 4</th>
                </tr>
                <tr>
                    <td>Urine pH</td>
                    <td>>5.5 (cannot acidify)</td>
                    <td><5.5 (can acidify)</td>
                    <td><5.5</td>
                </tr>
                <tr>
                    <td>Serum K+</td>
                    <td>Low (hypokalemia)</td>
                    <td>Low (hypokalemia)</td>
                    <td>High (hyperkalemia)</td>
                </tr>
                <tr>
                    <td>Severity of Acidosis</td>
                    <td>Severe (HCO3- <15)</td>
                    <td>Moderate (HCO3- 12-18)</td>
                    <td>Mild (HCO3- 18-22)</td>
                </tr>
                <tr>
                    <td>Stones/Nephrocalcinosis</td>
                    <td>Yes (common)</td>
                    <td>No</td>
                    <td>No</td>
                </tr>
                <tr>
                    <td>Fanconi Syndrome</td>
                    <td>No</td>
                    <td>Often present</td>
                    <td>No</td>
                </tr>
                <tr>
                    <td>Most Common Cause</td>
                    <td>SjÃ¶gren's syndrome</td>
                    <td>Medications (tenofovir)</td>
                    <td>Diabetic hypoaldosteronism</td>
                </tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Initial Laboratory Assessment:</strong></p>
            <ul>
                <li><strong>ABG or VBG:</strong>
                    <ul>
                        <li>Metabolic acidosis (pH <7.35, HCO3- <22 mEq/L)</li>
                        <li>Respiratory compensation (low pCO2)</li>
                    </ul>
                </li>
                <li><strong>Anion Gap:</strong>
                    <ul>
                        <li>Normal anion gap (8-12 mEq/L) - hyperchloremic acidosis</li>
                        <li>Formula: AG = Na+ - (Cl- + HCO3-)</li>
                        <li>**Key:** RTA is a non-anion gap acidosis (vs. anion gap acidosis from lactic acidosis, ketoacidosis, renal failure)</li>
                    </ul>
                </li>
                <li><strong>BMP:</strong>
                    <ul>
                        <li>Na+: Usually normal</li>
                        <li>K+: Low (Types 1 and 2) or HIGH (Type 4) - critical distinguishing feature</li>
                        <li>Cl-: Elevated (to maintain electroneutrality as HCO3- falls)</li>
                        <li>Creatinine: Normal or near-normal (RTA occurs with normal GFR; if GFR <20-30, acidosis is from renal failure, not RTA)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Urine Studies (Critical for Diagnosis):</strong></p>
            <ul>
                <li><strong>Urine pH:</strong>
                    <ul>
                        <li>**Type 1:** >5.5 despite acidemia (pathognomonic - cannot acidify urine)</li>
                        <li>**Type 2 and 4:** <5.5 (can acidify urine)</li>
                    </ul>
                </li>
                <li><strong>Urine Anion Gap (UAG):</strong>
                    <ul>
                        <li>Formula: UAG = (Urine Na+ + Urine K+) - Urine Cl-</li>
                        <li>**Positive UAG:** Suggests RTA (impaired NH4+ excretion)</li>
                        <li>**Negative UAG:** Suggests GI HCO3- loss (e.g., diarrhea) - normal renal response</li>
                    </ul>
                </li>
                <li><strong>Urine Osmolar Gap (Alternative to UAG):</strong>
                    <ul>
                        <li>Formula: Urine OG = Measured Osm - [2(Na+ + K+) + Urea/2.8 + Glucose/18]</li>
                        <li>Estimates NH4+ excretion: Low OG â†’ RTA; High OG â†’ normal renal acidification (GI losses)</li>
                    </ul>
                </li>
                <li><strong>Fractional Excretion of HCO3- (FE-HCO3-, for Type 2 Diagnosis):</strong>
                    <ul>
                        <li>Measure after HCO3- loading (give IV bicarbonate to raise serum HCO3- to ~24 mEq/L)</li>
                        <li>FE-HCO3- = (Urine HCO3- Ã— Serum Cr) / (Serum HCO3- Ã— Urine Cr) Ã— 100</li>
                        <li>**Type 2 RTA:** FE-HCO3- >15% (massive bicarbonaturia)</li>
                        <li>**Type 1 RTA:** FE-HCO3- <3% (minimal bicarbonaturia)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Additional Testing (Based on RTA Type):</strong></p>
            <ul>
                <li><strong>Type 1 RTA:</strong>
                    <ul>
                        <li>**Renal ultrasound:** Look for nephrocalcinosis, kidney stones</li>
                        <li>**Autoimmune workup:** ANA, anti-SSA (SjÃ¶gren's), anti-SSB, rheumatoid factor</li>
                        <li>**Genetic testing:** If family history or young age</li>
                    </ul>
                </li>
                <li><strong>Type 2 RTA:</strong>
                    <ul>
                        <li>**Urine studies:** Glucosuria, phosphaturia, aminoaciduria, uricosuria (Fanconi syndrome)</li>
                        <li>**Serum/urine protein electrophoresis (SPEP/UPEP):** Rule out multiple myeloma</li>
                        <li>**Ceruloplasmin:** If suspect Wilson's disease</li>
                    </ul>
                </li>
                <li><strong>Type 4 RTA:</strong>
                    <ul>
                        <li>**Renin and Aldosterone Levels:</strong>
                            <ul>
                                <li>Low renin + Low aldosterone = Hyporeninemic hypoaldosteronism (diabetic nephropathy, NSAIDs)</li>
                                <li>High renin + Low aldosterone = Primary adrenal insufficiency (Addison's)</li>
                                <li>High renin + High aldosterone with hyperkalemia = Aldosterone resistance (K+-sparing diuretics)</li>
                            </ul>
                        </li>
                        <li>**Cosyntropin stimulation test:** If suspect adrenal insufficiency</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>TYPE 1 RTA (DISTAL) TREATMENT:</strong></p>
            <ul>
                <li><strong>Alkali Therapy (Primary Treatment):</strong>
                    <ul>
                        <li><strong>Sodium Bicarbonate:</strong> 1-3 mEq/kg/day PO in divided doses (typically 650-1300 mg [7.8-15.5 mEq] PO TID-QID)
                            <ul>
                                <li>Goal: Maintain serum HCO3- >22 mEq/L</li>
                            </ul>
                        </li>
                        <li><strong>Alternative: Sodium Citrate/Citric Acid (Shohl's Solution):</strong> 1-3 mEq/kg/day
                            <ul>
                                <li>Better tolerated than bicarbonate (less GI upset)</li>
                                <li>Citrate is metabolized to bicarbonate</li>
                            </ul>
                        </li>
                        <li><strong>Alternative: Potassium Citrate:</strong> 30-100 mEq/day (if hypokalemic)
                            <ul>
                                <li>Dual benefit: Repletes K+ and provides alkali</li>
                            </ul>
                        </li>
                    </ul>
                </li>
                <li><strong>Potassium Supplementation:</strong>
                    <ul>
                        <li>Often needed (hypokalemia is common)</li>
                        <li>KCl 20-40 mEq PO daily-BID, or potassium citrate (as above)</li>
                    </ul>
                </li>
                <li><strong>Treat Underlying Cause:</strong>
                    <ul>
                        <li>Discontinue nephrotoxic medications (amphotericin B, lithium)</li>
                        <li>Treat autoimmune disease (SjÃ¶gren's, lupus)</li>
                    </ul>
                </li>
                <li><strong>Monitor:</strong>
                    <ul>
                        <li>Serum HCO3-, K+, Cl- every 1-3 months initially, then every 6-12 months</li>
                        <li>Renal ultrasound annually (monitor for nephrocalcinosis progression)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>TYPE 2 RTA (PROXIMAL) TREATMENT:</strong></p>
            <ul>
                <li><strong>Alkali Therapy (Higher Doses Needed Than Type 1):</strong>
                    <ul>
                        <li><strong>Sodium Bicarbonate:</strong> 5-15 mEq/kg/day PO in divided doses
                            <ul>
                                <li>Much higher doses needed because HCO3- is wasted in urine (poor efficacy)</li>
                                <li>Goal: Maintain HCO3- >18-20 mEq/L (complete correction often not achievable)</li>
                            </ul>
                        </li>
                        <li><strong>Potassium Citrate:</strong> Preferred if hypokalemic (provides both K+ and alkali)</li>
                    </ul>
                </li>
                <li><strong>Thiazide Diuretics (Paradoxically Helpful):</strong>
                    <ul>
                        <li><strong>Hydrochlorothiazide:</strong> 25-50 mg PO daily
                            <ul>
                                <li>Mechanism: Induces volume depletion â†’ â†‘ proximal HCO3- reabsorption â†’ less bicarbonaturia</li>
                                <li>**Caution:** Worsens hypokalemia - must supplement K+</li>
                            </ul>
                        </li>
                    </ul>
                </li>
                <li><strong>Potassium Supplementation:</strong>
                    <ul>
                        <li>Essential (bicarbonaturia causes K+ wasting)</li>
                        <li>KCl or potassium citrate 40-100 mEq/day</li>
                    </ul>
                </li>
                <li><strong>Treat Underlying Cause:</strong>
                    <ul>
                        <li>Discontinue causative medications (tenofovir, ifosfamide, topiramate)</li>
                        <li>Treat Fanconi syndrome causes (myeloma, Wilson's disease)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>TYPE 4 RTA TREATMENT:</strong></p>
            <ul>
                <li><strong>Treat Hyperkalemia (Primary Goal):</strong>
                    <ul>
                        <li><strong>Dietary K+ Restriction:</strong> <2-3 g (50-75 mEq)/day</li>
                        <li><strong>Loop Diuretics:</strong> Furosemide 20-80 mg PO daily (promotes K+ excretion)</li>
                        <li><strong>Potassium Binders:</strong>
                            <ul>
                                <li>**Patiromer (Veltassa):** 8.4-25.2 g PO daily (binds K+ in GI tract)</li>
                                <li>**Sodium Zirconium Cyclosilicate (Lokelma):** 10 g PO TID Ã— 48 hours, then 10 g daily</li>
                                <li>**Sodium Polystyrene Sulfonate (Kayexalate):** 15-60 g PO daily (less preferred - risk of colonic necrosis)</li>
                            </ul>
                        </li>
                    </ul>
                </li>
                <li><strong>Fludrocortisone (If Aldosterone Deficiency):</strong>
                    <ul>
                        <li>Dose: 0.1-0.2 mg PO daily</li>
                        <li>Indication: Hyporeninemic hypoaldosteronism, Addison's disease</li>
                        <li>**Caution:** Can worsen hypertension, heart failure, edema (monitor BP, volume status)</li>
                    </ul>
                </li>
                <li><strong>Sodium Bicarbonate (If Significant Acidosis):</strong>
                    <ul>
                        <li>Usually mild acidosis (HCO3- 18-22) - may not need treatment</li>
                        <li>If HCO3- <18 mEq/L: Give sodium bicarbonate 650-1300 mg PO TID</li>
                    </ul>
                </li>
                <li><strong>Discontinue Causative Medications:</strong>
                    <ul>
                        <li>K+-sparing diuretics (spironolactone, amiloride, triamterene)</li>
                        <li>NSAIDs, ACE inhibitors/ARBs (if safe to stop)</li>
                        <li>Trimethoprim, pentamidine, heparin</li>
                    </ul>
                </li>
                <li><strong>Tight Glycemic Control (If Diabetic):</strong>
                    <ul>
                        <li>Improves hyporeninemic hypoaldosteronism over time</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>GENERAL MONITORING:</strong></p>
            <ul>
                <li>Serum electrolytes (Na+, K+, Cl-, HCO3-) every 1-3 months initially, then every 6-12 months</li>
                <li>ABG/VBG if acidosis not improving</li>
                <li>Bone density (DEXA) if Type 1 RTA (risk of osteomalacia)</li>
                <li>Renal function (creatinine, GFR) - ensure RTA not progressing to CKD</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Hyperkalemia = Type 4, Hypokalemia = Types 1 and 2:</strong> The serum potassium immediately tells you which type of RTA. Type 4 causes hyperkalemia (aldosterone deficiency/resistance). Types 1 and 2 cause hypokalemia (renal K+ wasting). Check K+ first.</li>
            
            <li><strong>Urine pH >5.5 = Type 1 RTA:</strong> The pathognomonic finding of Type 1 RTA is inability to acidify urine despite systemic acidemia. If urine pH >5.5 with metabolic acidosis, it's Type 1 (distal RTA). Types 2 and 4 can acidify urine (pH <5.5).</li>
            
            <li><strong>Positive Urine Anion Gap = RTA, Negative = GI Loss:</strong> Hyperchloremic acidosis can be from RTA or GI HCO3- loss (diarrhea). Urine anion gap (UAG = [U-Na + U-K] - U-Cl) distinguishes: Positive UAG = RTA (impaired NH4+ excretion). Negative UAG = normal renal response to GI loss.</li>
            
            <li><strong>Type 1 RTA â†’ Kidney Stones:</strong> Type 1 RTA causes nephrocalcinosis and recurrent calcium phosphate kidney stones from chronic alkaline urine (pH >6), hypercalciuria, and low urinary citrate. If a patient has recurrent kidney stones + non-anion gap acidosis, check urine pH - it's probably Type 1 RTA.</li>
            
            <li><strong>Diabetics Get Type 4 RTA:</strong> The most common cause of Type 4 RTA is hyporeninemic hypoaldosteronism in diabetic nephropathy. If a diabetic has hyperkalemia + non-anion gap acidosis (HCO3- 18-22) with normal-ish GFR, think Type 4 RTA before blaming the kidney failure.</li>
            
            <li><strong>SjÃ¶gren's Causes Type 1, Tenofovir Causes Type 2:</strong> SjÃ¶gren's syndrome is the most common cause of Type 1 RTA (distal tubule dysfunction from autoimmune inflammation). Tenofovir is a classic cause of Type 2 RTA (proximal tubule toxicity causing Fanconi syndrome). Know the classic associations.</li>
            
            <li><strong>Type 2 RTA Needs HUGE Doses of Bicarbonate:</strong> Type 2 RTA wastes bicarbonate in the urine, so you need 5-15 mEq/kg/day (vs. 1-3 mEq/kg/day for Type 1). Despite high doses, you often can't fully correct HCO3- to normal. Adding a thiazide diuretic (induces volume depletion â†’ â†‘ proximal reabsorption) helps.</li>
            
            <li><strong>RTA Requires Normal GFR:</strong> By definition, RTA occurs with normal or near-normal GFR. If GFR <20-30 mL/min, the non-anion gap acidosis is from renal failure (uremic acidosis), not RTA. RTA = tubular dysfunction without glomerular failure.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe metabolic acidosis (pH <7.1, HCO3 <10) with hemodynamic compromise</li>
                        <li>Severe hyperkalemia (K >6.5 mEq/L) with ECG changes or dysrhythmias</li>
                        <li>Respiratory distress from metabolic acidosis</li>
                        <li>Need for dialysis for refractory acidosis or hyperkalemia</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Acid-base status corrected or stable (pH >7.30, HCO3 >18 mEq/L)</li>
                        <li>Electrolytes normalized (K normal if Type 4 RTA, K corrected if hypokalemic RTA)</li>
                        <li>Underlying cause identified (renal biopsy if needed, medication review)</li>
                        <li>On appropriate treatment (bicarbonate supplementation, potassium management)</li>
                        <li>Outpatient nephrology follow-up arranged</li>
                        <li>Patient educated on medication compliance (bicarbonate, potassium as indicated)</li>
                        <li>Recheck labs within 1 week</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="burns-third-spacing" class="condition-page">
    <div class="page-header">
        <h2>94. BURNS / THIRD-SPACING</h2>
        <div class="subtitle">Capillary Leak â€¢ Hypovolemia â€¢ Fluid Resuscitation</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with thermal, chemical, or electrical burn injury presenting with signs of intravascular volume depletion despite normal or increased total body water due to capillary leak and fluid sequestration into injured tissues.</p>
            
            <ul>
                <li><strong>Burn Classification by Depth:</strong>
                    <ul>
                        <li>Superficial (1st degree): Erythema, painful, no blisters (sunburn)</li>
                        <li>Superficial partial-thickness (2nd degree): Blisters, painful, blanches</li>
                        <li>Deep partial-thickness: White/yellow, decreased sensation</li>
                        <li>Full-thickness (3rd degree): Leathery, painless, does not blanch</li>
                        <li>Fourth degree: Extends to muscle, tendon, bone</li>
                    </ul>
                </li>
                <li><strong>Total Body Surface Area (TBSA):</strong> Calculated using Rule of Nines:
                    <ul>
                        <li>Head/neck: 9%</li>
                        <li>Each arm: 9%</li>
                        <li>Anterior trunk: 18%</li>
                        <li>Posterior trunk: 18%</li>
                        <li>Each leg: 18%</li>
                        <li>Perineum: 1%</li>
                        <li>Alternative: Patient's palm (including fingers) = 1% TBSA</li>
                    </ul>
                </li>
                <li><strong>Signs of Third-Spacing/Hypovolemia:</strong> Tachycardia, hypotension, decreased urine output (<0.5 mL/kg/hr), altered mental status, lactic acidosis, elevated hematocrit (hemoconcentration)</li>
                <li><strong>Inhalation Injury Red Flags:</strong> Facial burns, singed nasal hairs, carbonaceous sputum, hoarseness, stridor, enclosed space exposure, carboxyhemoglobin >10%</li>
                <li><strong>Electrical Injury Complications:</strong> Cardiac dysrhythmias, rhabdomyolysis, compartment syndrome, deeper tissue injury than apparent on surface</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Initial Assessment:</strong></p>
            <ul>
                <li><strong>TBSA Calculation:</strong> Use Rule of Nines or Lund-Browder chart for accurate assessment</li>
                <li><strong>Burn Center Transfer Criteria:</strong>
                    <ul>
                        <li>Partial-thickness burns >10% TBSA</li>
                        <li>Full-thickness burns any size</li>
                        <li>Burns involving face, hands, feet, genitalia, perineum, major joints</li>
                        <li>Electrical or chemical burns</li>
                        <li>Inhalation injury</li>
                        <li>Circumferential burns</li>
                        <li>Burns with trauma or medical comorbidities</li>
                        <li>Pediatric burns (consider >5% TBSA)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>CBC:</strong> Elevated hematocrit from hemoconcentration (fluid loss), leukocytosis</li>
                <li><strong>BMP:</strong> Hyperkalemia (cell lysis), hyponatremia (third-spacing), elevated BUN/Cr (prerenal from hypovolemia)</li>
                <li><strong>Arterial Blood Gas:</strong> Metabolic acidosis from hypoperfusion, carboxyhemoglobin level</li>
                <li><strong>CPK/Myoglobin:</strong> Rhabdomyolysis (especially electrical burns)</li>
                <li><strong>Lactate:</strong> Elevated in shock state</li>
                <li><strong>Coagulation Studies:</strong> May develop DIC in severe burns</li>
                <li><strong>Carboxyhemoglobin:</strong> >10% suggests inhalation injury (>25% serious toxicity)</li>
            </ul>
            
            <p><strong>Imaging/Additional Studies:</strong></p>
            <ul>
                <li><strong>Chest X-ray:</strong> Baseline for suspected inhalation injury (initially often normal)</li>
                <li><strong>ECG:</strong> Essential for electrical burns (dysrhythmias), continuous telemetry monitoring</li>
                <li><strong>Bronchoscopy:</strong> Gold standard for diagnosing inhalation injury if suspected</li>
                <li><strong>Compartment Pressure Measurement:</strong> If concern for compartment syndrome (circumferential burns, electrical injury)</li>
            </ul>
            
            <p><strong>Urine Output Monitoring:</strong></p>
            <ul>
                <li><strong>Goal:</strong> 0.5-1 mL/kg/hr adults, 1 mL/kg/hr children</li>
                <li><strong>Myoglobinuria:</strong> Tea-colored urine suggests rhabdomyolysis (electrical burns, extensive muscle injury)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management (First Hour):</strong></p>
            <ul>
                <li><strong>Airway Assessment:</strong>
                    <ul>
                        <li>Early intubation if signs of inhalation injury (edema progresses rapidly)</li>
                        <li>Lower threshold for intubation with facial burns, stridor, hoarseness</li>
                        <li>Use large ETT (7.5-8.0) due to anticipated secretions</li>
                    </ul>
                </li>
                <li><strong>Stop the Burning Process:</strong> Remove clothing, irrigate chemical burns for 20+ minutes, cool thermal burns with room temperature water (avoid hypothermia)</li>
                <li><strong>Large-Bore IV Access:</strong> Two large-bore peripheral IVs (through burned skin if necessary), central line if needed</li>
                <li><strong>Foley Catheter:</strong> Essential for monitoring urine output during resuscitation</li>
            </ul>
            
            <p><strong>Fluid Resuscitation (Parkland Formula):</strong></p>
            <ul>
                <li><strong>Parkland Formula:</strong> 4 mL Ã— kg Ã— %TBSA (only count partial and full-thickness burns)</li>
                <li><strong>First 24 Hours Fluid Distribution:</strong>
                    <ul>
                        <li>Give 50% of calculated volume in first 8 hours from time of burn</li>
                        <li>Give remaining 50% over next 16 hours</li>
                        <li>Use Lactated Ringer's solution (isotonic crystalloid)</li>
                    </ul>
                </li>
                <li><strong>Example:</strong> 80 kg patient with 40% TBSA burn:
                    <ul>
                        <li>Total 24h fluid = 4 Ã— 80 Ã— 40 = 12,800 mL</li>
                        <li>First 8 hours: 6,400 mL (800 mL/hr)</li>
                        <li>Next 16 hours: 6,400 mL (400 mL/hr)</li>
                    </ul>
                </li>
                <li><strong>Titrate to Urine Output:</strong> Goal 0.5-1 mL/kg/hr (30-50 mL/hr for 70 kg adult)</li>
                <li><strong>If Myoglobinuria Present:</strong>
                    <ul>
                        <li>Increase fluids to achieve urine output 1-2 mL/kg/hr</li>
                        <li>Consider sodium bicarbonate to alkalinize urine (goal pH >6.5)</li>
                        <li>Mannitol 12.5-25g IV if urine output inadequate despite fluids</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Pain Management:</strong></p>
            <ul>
                <li><strong>IV Opioids:</strong> Morphine 0.1-0.2 mg/kg IV or fentanyl 1-2 mcg/kg IV (avoid IM/SC due to poor absorption in third-spacing)</li>
                <li><strong>Anxiolytics:</strong> Lorazepam 0.5-2 mg IV for severe anxiety/agitation</li>
                <li><strong>Consider Ketamine:</strong> 0.1-0.3 mg/kg IV for dressing changes/procedures (preserves airway reflexes)</li>
            </ul>
            
            <p><strong>Wound Management:</strong></p>
            <ul>
                <li><strong>Sterile Technique:</strong> Cover burns with clean, dry dressings initially</li>
                <li><strong>Avoid Ice:</strong> Can worsen tissue injury and cause hypothermia</li>
                <li><strong>Tetanus Prophylaxis:</strong> Update if >5 years since last booster</li>
                <li><strong>Topical Antimicrobials:</strong> Silver sulfadiazine (avoid on face, pregnancy, sulfa allergy) or Silvadene alternatives</li>
                <li><strong>Escharotomy:</strong> Immediate if circumferential burns causing compartment syndrome or respiratory compromise</li>
            </ul>
            
            <p><strong>Specific Situations:</strong></p>
            <ul>
                <li><strong>Inhalation Injury:</strong>
                    <ul>
                        <li>100% oxygen (half-life of COHb: 90 min on 100% O2 vs 4 hours on room air)</li>
                        <li>Consider hyperbaric oxygen if COHb >25% or severe symptoms</li>
                        <li>Bronchodilators for bronchospasm</li>
                        <li>NO role for prophylactic antibiotics or steroids</li>
                    </ul>
                </li>
                <li><strong>Electrical Burns:</strong>
                    <ul>
                        <li>Cardiac monitoring for 24-48 hours if abnormal ECG or high-voltage exposure</li>
                        <li>Aggressive fluid resuscitation (tissue injury often deeper than apparent)</li>
                        <li>Early fasciotomy if compartment syndrome suspected</li>
                    </ul>
                </li>
                <li><strong>Chemical Burns:</strong>
                    <ul>
                        <li>Prolonged irrigation (20-60 minutes) with copious water/saline</li>
                        <li>Specific antidotes: Calcium gluconate for HF burns, irrigation with amphoteric solution for alkali burns</li>
                        <li>Avoid neutralizing agents (exothermic reactions can worsen injury)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Supportive Care:</strong></p>
            <ul>
                <li><strong>Temperature Regulation:</strong> Warm room, warming blankets (hypothermia common due to loss of skin barrier)</li>
                <li><strong>Nutrition:</strong> Early enteral nutrition (high caloric needs: 25-30 kcal/kg + 40 kcal per %TBSA burn)</li>
                <li><strong>GI Prophylaxis:</strong> PPI or H2-blocker (stress ulcer prophylaxis - Curling's ulcer)</li>
                <li><strong>DVT Prophylaxis:</strong> Subcutaneous heparin or LMWH once hemodynamically stable</li>
            </ul>
            
            <p><strong>Transfer to Burn Center:</strong></p>
            <ul>
                <li><strong>Early Communication:</strong> Contact burn center early in resuscitation</li>
                <li><strong>Continue Resuscitation During Transfer:</strong> Maintain IV access, continue fluids, monitor vitals</li>
                <li><strong>Transfer Documentation:</strong> TBSA calculation, fluid given, urine output, injuries, medical history</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Parkland Formula Pitfall:</strong> The formula is a starting point, NOT a rigid prescription. Titrate fluids to urine output (0.5-1 mL/kg/hr). Over-resuscitation causes abdominal compartment syndrome and pulmonary edema; under-resuscitation causes acute kidney injury and shock.</li>
            <li><strong>"8-Hour Clock" Starts at Time of Burn:</strong> NOT time of arrival to hospital. If patient arrives 3 hours after burn, you have only 5 hours to give the first half of calculated fluids. Adjust hourly rate accordingly to catch up.</li>
            <li><strong>Only Count Partial and Full-Thickness Burns:</strong> Do NOT include superficial (first-degree) burns in TBSA calculation for Parkland formula. Only blistering (partial-thickness) and worse are counted.</li>
            <li><strong>Hematocrit Paradox:</strong> Elevated hematocrit in burns indicates hemoconcentration from plasma loss into third-space, NOT polycythemia. It's a marker of hypovolemia requiring MORE fluid resuscitation.</li>
            <li><strong>Early Intubation for Inhalation Injury:</strong> Airway edema progresses rapidly over 12-24 hours. If you're debating intubation, intubate NOW. Delayed intubation with facial/airway edema can become a surgical airway emergency.</li>
            <li><strong>Tea-Colored Urine = Myoglobinuria Emergency:</strong> Indicates massive rhabdomyolysis (common in electrical burns). Requires aggressive fluid resuscitation (urine output goal 1-2 mL/kg/hr), urinary alkalinization with sodium bicarbonate, and mannitol if needed to prevent ATN.</li>
            <li><strong>Escharotomy vs Fasciotomy:</strong> Escharotomy releases constricting circumferential eschar (through skin only); fasciotomy releases deeper compartments (through fascia). Escharotomy is immediate bedside procedure; fasciotomy requires OR. Both are needed urgently if compartment syndrome develops.</li>
            <li><strong>No Role for Prophylactic Antibiotics:</strong> Prophylactic systemic antibiotics do NOT reduce infection rates and promote resistant organisms. Use topical antimicrobials (silver sulfadiazine) and treat infections when clinically evident with cultures.</li>
            <li><strong>Curling's Ulcer:</strong> Stress gastroduodenal ulceration is common complication of severe burns (>30% TBSA). Start PPI prophylaxis early. Named after Thomas Curling who first described it in burn patients in 1842.</li>
            <li><strong>Electrical Burns Are Icebergs:</strong> Surface injury dramatically underestimates tissue damage. Electricity follows path of least resistance (through nerves, vessels, muscles) causing deep tissue necrosis. Always assume worse injury than visible and monitor for compartment syndrome, rhabdomyolysis, dysrhythmias.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL severe burns (>20% TBSA) require ICU admission</li>
                        <li>Inhalation injury requiring mechanical ventilation</li>
                        <li>Burns involving face, airway, requiring close monitoring</li>
                        <li>Electrical burns with cardiac dysrhythmias</li>
                        <li>Hemodynamic instability despite fluid resuscitation</li>
                        <li>Rhabdomyolysis with acute kidney injury</li>
                        <li>Need for escharotomy or surgical intervention</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable without IV fluid resuscitation needs</li>
                        <li>Pain controlled on oral medications</li>
                        <li>Able to tolerate oral intake</li>
                        <li>Wound care manageable as outpatient (or home health arranged)</li>
                        <li>No signs of infection (afebrile, no purulent drainage)</li>
                        <li>Urine output adequate without IV fluids</li>
                        <li>Physical/occupational therapy arranged if needed</li>
                        <li>Follow-up with burn clinic or plastic surgery arranged (within 3-7 days)</li>
                        <li>Patient/family educated on wound care, dressing changes</li>
                        <li>Return precautions for fever, worsening pain, signs of infection</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="hemiplegic-migraine" class="condition-page">
    <div class="page-header">
        <h2>95. HEMIPLEGIC MIGRAINE</h2>
        <div class="subtitle">Motor Aura â€¢ Stroke Mimic â€¢ Genetic Mutations</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with history of migraine presenting with transient unilateral motor weakness (hemiparesis or hemiplegia) as part of migraine aura, typically followed by severe headache. Motor symptoms may persist for hours to days, mimicking acute stroke.</p>
            
            <ul>
                <li><strong>Motor Aura (Required):</strong> Fully reversible unilateral motor weakness, may range from mild hemiparesis to complete hemiplegia</li>
                <li><strong>Additional Aura Symptoms (Common):</strong>
                    <ul>
                        <li>Visual aura: Scintillating scotoma, fortification spectra, homonymous hemianopia (90%)</li>
                        <li>Sensory aura: Paresthesias, numbness in hemibody distribution (70%)</li>
                        <li>Speech/language disturbance: Aphasia, dysarthria (40%)</li>
                        <li>Brainstem symptoms: Diplopia, vertigo, ataxia, decreased consciousness (rare, suggests basilar-type)</li>
                    </ul>
                </li>
                <li><strong>Temporal Progression:</strong>
                    <ul>
                        <li>Aura symptoms develop gradually over 5-60 minutes (NOT sudden onset like stroke)</li>
                        <li>Each aura symptom lasts 5 minutes to 72 hours</li>
                        <li>Motor symptoms may persist longer than other aura types</li>
                        <li>Headache typically follows aura within 60 minutes (but may overlap or be absent)</li>
                    </ul>
                </li>
                <li><strong>Headache Characteristics:</strong> Severe, throbbing, unilateral (often contralateral to motor symptoms), associated with photophobia, phonophobia, nausea/vomiting</li>
                <li><strong>Age of Onset:</strong> Typically begins in childhood/adolescence (before age 20 in most cases), rarely presents de novo after age 40</li>
                <li><strong>Family History:</strong> 
                    <ul>
                        <li>Familial Hemiplegic Migraine (FHM): At least one first- or second-degree relative with hemiplegic migraine</li>
                        <li>Sporadic Hemiplegic Migraine (SHM): No affected relatives</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>ICHD-3 Diagnostic Criteria for Hemiplegic Migraine:</strong></p>
            <ul>
                <li><strong>A.</strong> At least two attacks fulfilling criteria B and C</li>
                <li><strong>B.</strong> Aura including both:
                    <ul>
                        <li>Fully reversible motor weakness</li>
                        <li>Fully reversible visual, sensory, and/or speech/language symptoms</li>
                    </ul>
                </li>
                <li><strong>C.</strong> At least three of the following:
                    <ul>
                        <li>At least one aura symptom spreads gradually over â‰¥5 minutes</li>
                        <li>Two or more aura symptoms occur in succession</li>
                        <li>Each aura symptom lasts 5-72 hours</li>
                        <li>At least one aura symptom is unilateral</li>
                        <li>At least one aura symptom is positive (e.g., flickering lights, tingling)</li>
                        <li>Headache accompanies or follows aura within 60 minutes</li>
                    </ul>
                </li>
                <li><strong>D.</strong> Not better accounted for by another diagnosis (stroke, seizure, etc.)</li>
            </ul>
            
            <p><strong>Initial Evaluation (First Presentation or Atypical Features):</strong></p>
            <ul>
                <li><strong>Neuroimaging (MRI Brain Preferred):</strong>
                    <ul>
                        <li>ESSENTIAL to rule out stroke, especially on first presentation</li>
                        <li>DWI/ADC sequences to exclude acute ischemia</li>
                        <li>MRA or CTA to evaluate for arterial dissection, vasculitis</li>
                        <li>May show T2/FLAIR hyperintensities in watershed zones or cerebellar atrophy (chronic FHM)</li>
                    </ul>
                </li>
                <li><strong>CT Head (if MRI unavailable):</strong> To exclude hemorrhage, mass lesion (less sensitive for acute ischemia)</li>
                <li><strong>Laboratory Studies:</strong>
                    <ul>
                        <li>CBC, CMP: Rule out metabolic causes (hypoglycemia, hyponatremia)</li>
                        <li>ESR/CRP: Elevated in vasculitis</li>
                        <li>Hypercoagulable workup: If stroke suspected (protein C/S, antiphospholipid antibodies, factor V Leiden, prothrombin gene mutation)</li>
                        <li>Toxicology screen: Rule out drug-induced causes</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Additional Testing (Based on Clinical Suspicion):</strong></p>
            <ul>
                <li><strong>EEG:</strong> If seizure suspected (may show spreading cortical depression during aura)</li>
                <li><strong>Lumbar Puncture:</strong> If meningoencephalitis, SAH, or CNS vasculitis suspected</li>
                <li><strong>Echocardiogram + Bubble Study:</strong> If concern for PFO/ASD with paradoxical embolism</li>
                <li><strong>Genetic Testing:</strong>
                    <ul>
                        <li>Consider in familial cases (mutations in CACNA1A, ATP1A2, SCN1A genes)</li>
                        <li>CACNA1A (FHM1): P/Q-type calcium channel, most common (50%), may have cerebellar signs</li>
                        <li>ATP1A2 (FHM2): Na+/K+-ATPase pump (20%), may have seizures</li>
                        <li>SCN1A (FHM3): Sodium channel (<10%), may have seizures</li>
                        <li>Typically sent by neurology, not emergently necessary</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Differentiating from Stroke:</strong></p>
            <ul>
                <li><strong>Favors Hemiplegic Migraine:</strong>
                    <ul>
                        <li>Gradual onset over 5-60 minutes (vs sudden in stroke)</li>
                        <li>Positive symptoms (tingling, visual phenomena) before negative symptoms</li>
                        <li>March of symptoms across body parts</li>
                        <li>Prior history of similar episodes</li>
                        <li>Younger age (<40), especially if childhood onset</li>
                        <li>Family history of hemiplegic migraine</li>
                    </ul>
                </li>
                <li><strong>Favors Stroke:</strong>
                    <ul>
                        <li>Sudden onset (maximal deficit at onset)</li>
                        <li>Only negative symptoms (weakness, numbness, vision loss)</li>
                        <li>Older age (>50), vascular risk factors</li>
                        <li>Alteration in consciousness</li>
                        <li>Persistent symptoms beyond 72 hours</li>
                    </ul>
                </li>
                <li><strong>Key Principle:</strong> When in doubt, treat as stroke until proven otherwise. Hemiplegic migraine is diagnosis of exclusion.</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Acute Management (First Presentation or Uncertain Diagnosis):</strong></p>
            <ul>
                <li><strong>Stroke Protocol:</strong>
                    <ul>
                        <li>Activate stroke team for first presentation with motor weakness</li>
                        <li>NIH Stroke Scale assessment</li>
                        <li>STAT neuroimaging (CT or MRI)</li>
                        <li><strong>AVOID tPA in hemiplegic migraine</strong> (case reports of worsening symptoms, hemorrhage)</li>
                        <li>If diagnosis uncertain, withhold thrombolytics and complete imaging workup</li>
                    </ul>
                </li>
                <li><strong>Observation:</strong> Admit for telemetry and neuro checks if first episode or prolonged symptoms (>1 hour)</li>
            </ul>
            
            <p><strong>Acute Treatment (Confirmed Hemiplegic Migraine):</strong></p>
            <ul>
                <li><strong>Triptans: CONTRAINDICATED in Hemiplegic Migraine</strong>
                    <ul>
                        <li>Risk of prolonged aura, vasoconstriction during vulnerable period</li>
                        <li>Absolute contraindication per FDA labeling</li>
                        <li>This includes sumatriptan, rizatriptan, all triptans</li>
                    </ul>
                </li>
                <li><strong>First-Line Abortive Therapy:</strong>
                    <ul>
                        <li><strong>NSAIDs:</strong> Ibuprofen 800 mg PO or ketorolac 30 mg IV</li>
                        <li><strong>Acetaminophen:</strong> 1000 mg PO</li>
                        <li><strong>Antiemetics:</strong> Metoclopramide 10 mg IV (also helps headache via central dopamine antagonism) or prochlorperazine 10 mg IV</li>
                    </ul>
                </li>
                <li><strong>Second-Line Options:</strong>
                    <ul>
                        <li><strong>IV Magnesium Sulfate:</strong> 2 grams IV over 15-30 minutes (may abort aura and improve headache)</li>
                        <li><strong>Chlorpromazine:</strong> 0.1 mg/kg IV (max 25 mg) for refractory headache</li>
                        <li><strong>IV Fluids:</strong> Normal saline 1-2L (dehydration common trigger)</li>
                        <li><strong>Corticosteroids:</strong> Dexamethasone 10-20 mg IV (for status migrainosus, prevents recurrence)</li>
                    </ul>
                </li>
                <li><strong>Supportive Care:</strong>
                    <ul>
                        <li>Dark, quiet room</li>
                        <li>Cold compress to head</li>
                        <li>Avoid sensory triggers</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Prophylactic Therapy (Recurrent Episodes):</strong></p>
            <ul>
                <li><strong>Indications for Prophylaxis:</strong> â‰¥2 attacks per month, attacks causing significant disability, attacks lasting >48 hours</li>
                <li><strong>First-Line Preventive Medications:</strong>
                    <ul>
                        <li><strong>Verapamil:</strong> 120-480 mg daily (calcium channel blocker, preferred for FHM1 with CACNA1A mutation)</li>
                        <li><strong>Topiramate:</strong> 25-100 mg BID (may worsen cognitive symptoms in some patients)</li>
                        <li><strong>Valproic Acid:</strong> 500-1000 mg daily (avoid in women of childbearing potential)</li>
                    </ul>
                </li>
                <li><strong>Alternative Preventives:</strong>
                    <ul>
                        <li><strong>Acetazolamide:</strong> 250-500 mg daily (especially if cerebellar signs present)</li>
                        <li><strong>Lamotrigine:</strong> 100-200 mg daily (particularly effective for aura)</li>
                        <li><strong>Flunarizine:</strong> 5-10 mg daily (not available in US, calcium channel blocker)</li>
                    </ul>
                </li>
                <li><strong>Newer Agents (Limited Data in Hemiplegic Migraine):</strong>
                    <ul>
                        <li><strong>CGRP Antagonists:</strong> Erenumab, fremanezumab, galcanezumab (case reports suggest safety and efficacy, but not FDA-approved for HM)</li>
                        <li>Avoid monoclonal antibodies targeting CGRP pathway until more data available</li>
                    </ul>
                </li>
                <li><strong>AVOID in Prophylaxis:</strong>
                    <ul>
                        <li>Beta-blockers (propranolol, metoprolol): May worsen aura</li>
                        <li>Triptans: Contraindicated</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Lifestyle Modifications:</strong></p>
            <ul>
                <li><strong>Trigger Avoidance:</strong> Sleep deprivation, stress, hormonal changes, certain foods (aged cheese, alcohol, MSG), bright lights</li>
                <li><strong>Regular Sleep Schedule:</strong> 7-9 hours nightly, consistent bedtime</li>
                <li><strong>Hydration:</strong> Adequate daily water intake</li>
                <li><strong>Stress Management:</strong> Cognitive behavioral therapy, biofeedback, relaxation techniques</li>
                <li><strong>Exercise:</strong> Regular aerobic exercise (but avoid triggering attacks)</li>
            </ul>
            
            <p><strong>Neurology Referral:</strong></p>
            <ul>
                <li><strong>Indications:</strong> All patients with hemiplegic migraine should have outpatient neurology follow-up</li>
                <li><strong>Purpose:</strong> Confirmation of diagnosis, genetic counseling, prophylactic management, monitoring for complications (rare: status migrainosus, migrainous infarction, permanent sequelae)</li>
            </ul>
            
            <p><strong>Complications:</strong></p>
            <ul>
                <li><strong>Migrainous Infarction:</strong> Aura symptoms lasting >7 days with neuroimaging showing ischemic infarction (RARE, <0.5% of hemiplegic migraine patients)</li>
                <li><strong>Persistent Aura:</strong> Aura symptoms lasting >1 week without infarction (may respond to steroids, antiepileptics)</li>
                <li><strong>Seizures:</strong> Slightly increased risk, especially in FHM2 and FHM3 (sodium/potassium channel mutations)</li>
                <li><strong>Cognitive Impairment:</strong> Rare, associated with recurrent severe attacks (cerebellar atrophy in some FHM1 patients)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Triptans Are Absolutely Contraindicated:</strong> All triptans (sumatriptan, rizatriptan, etc.) are contraindicated in hemiplegic migraine due to risk of prolonged aura and potential stroke. This is an FDA black box warning. NSAIDs, antiemetics, and magnesium are first-line instead.</li>
            <li><strong>Hemiplegic Migraine Is a Diagnosis of Exclusion:</strong> First presentation requires full stroke workup. Never diagnose hemiplegic migraine at bedside without neuroimaging excluding stroke, even with classic migraine history. Motor weakness = stroke until proven otherwise.</li>
            <li><strong>Gradual Onset Distinguishes from Stroke:</strong> Hemiplegic migraine aura develops gradually over 5-60 minutes with "march" of symptoms across body parts. Stroke is sudden (maximal at onset). This temporal profile is the key clinical differentiator.</li>
            <li><strong>Positive Symptoms Before Negative:</strong> Migraine aura typically starts with positive symptoms (tingling, visual sparkles) that evolve into negative symptoms (numbness, weakness). Stroke presents with only negative symptoms from the start.</li>
            <li><strong>Familial vs Sporadic Has Genetic Implications:</strong> Familial Hemiplegic Migraine (FHM) requires at least one first- or second-degree relative with hemiplegic migraine and has identified genetic mutations (CACNA1A, ATP1A2, SCN1A). Sporadic HM has no family history and genetic etiology is unclear. Genetic testing helpful for family planning.</li>
            <li><strong>FHM1 (CACNA1A) May Have Cerebellar Signs:</strong> Patients with CACNA1A mutations (most common FHM type) may develop progressive cerebellar atrophy with nystagmus, ataxia between attacks. Think of this if patient has "migraine plus cerebellar findings."</li>
            <li><strong>Don't Confuse with Basilar-Type Migraine:</strong> Basilar-type migraine (now called "migraine with brainstem aura") has brainstem symptoms (diplopia, dysarthria, vertigo, bilateral visual symptoms) but NO motor weakness. Motor weakness defines hemiplegic migraine.</li>
            <li><strong>Verapamil Is Prophylactic of Choice for FHM1:</strong> Calcium channel blockers (especially verapamil) are particularly effective for FHM1 (CACNA1A mutations affecting calcium channels). Start 120 mg daily, titrate to 480 mg as tolerated.</li>
            <li><strong>Prolonged Aura Can Last Days:</strong> Unlike typical migraine aura (5-60 minutes), hemiplegic migraine motor aura can persist for hours to days (up to 72 hours). This prolonged duration mimics stroke and causes diagnostic confusion. Document resolution over time to confirm diagnosis.</li>
            <li><strong>Migrainous Infarction Is a Real Entity:</strong> In rare cases (<0.5%), prolonged hemiplegic migraine aura can cause permanent ischemic stroke (migrainous infarction). Diagnosis requires aura lasting >7 days with MRI showing infarction in relevant territory. This is a medical emergency and changes management.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Inability to rule out stroke despite imaging (persistent diagnostic uncertainty with high-risk features)</li>
                        <li>Status migrainosus (severe headache >72 hours) unresponsive to treatment</li>
                        <li>Severe persistent neurologic deficits with unclear etiology</li>
                        <li>Complications from treatment (e.g., hypotension from aggressive medication)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Stroke definitively ruled out (MRI with DWI showing no restricted diffusion)</li>
                        <li>Motor weakness resolved or clearly improving</li>
                        <li>Headache improved or manageable on oral medications</li>
                        <li>Patient able to ambulate safely (or baseline function if chronic deficits)</li>
                        <li>Diagnosis confirmed as hemiplegic migraine by neurology</li>
                        <li>Prophylactic therapy initiated (verapamil, topiramate, or alternative)</li>
                        <li>Outpatient neurology follow-up arranged (within 1-2 weeks)</li>
                        <li>Patient educated on avoiding triptans, recognizing warning signs</li>
                        <li>Return precautions for recurrent weakness, persistent symptoms >72 hours</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="todds-paralysis" class="condition-page">
    <div class="page-header">
        <h2>96. TODD'S PARALYSIS</h2>
        <div class="subtitle">Postictal Weakness â€¢ Seizure Sequela â€¢ Transient Hemiparesis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with focal motor weakness (hemiparesis, monoparesis, or rarely quadriparesis) developing immediately after a focal or generalized tonic-clonic seizure, typically resolving within 48 hours. Most commonly presents as unilateral weakness contralateral to seizure focus.</p>
            
            <ul>
                <li><strong>Temporal Relationship to Seizure:</strong>
                    <ul>
                        <li>Onset: Immediately following cessation of seizure activity</li>
                        <li>Duration: Minutes to 48 hours (typically resolves within 24 hours)</li>
                        <li>Resolution: Gradual improvement over hours, complete recovery expected</li>
                        <li>Red flag: Weakness persisting >48 hours suggests stroke, not Todd's paralysis</li>
                    </ul>
                </li>
                <li><strong>Motor Deficits (Most Common):</strong>
                    <ul>
                        <li>Hemiparesis/hemiplegia (70%): Affects face, arm, leg on one side</li>
                        <li>Monoparesis (20%): Single limb weakness</li>
                        <li>Rarely: Focal weakness of specific muscle groups, quadriparesis</li>
                        <li>Distribution corresponds to seizure focus (contralateral to epileptogenic zone)</li>
                    </ul>
                </li>
                <li><strong>Other Postictal Neurologic Deficits:</strong>
                    <ul>
                        <li>Aphasia (10%): If seizure originates from dominant hemisphere language cortex</li>
                        <li>Visual field deficits: Homonymous hemianopia</li>
                        <li>Sensory deficits: Numbness, paresthesias (less common than motor)</li>
                        <li>Gaze deviation: Eyes deviate toward seizure focus (away from weak side)</li>
                        <li>Confusion, lethargy (expected postictal state)</li>
                    </ul>
                </li>
                <li><strong>Seizure Characteristics:</strong>
                    <ul>
                        <li>Type: Most commonly follows focal motor seizures with or without generalization (Jacksonian march)</li>
                        <li>Can occur after generalized tonic-clonic seizures (less common)</li>
                        <li>Duration: Longer seizure duration increases likelihood and severity of Todd's paralysis</li>
                        <li>Status epilepticus: High association with Todd's paralysis</li>
                    </ul>
                </li>
                <li><strong>Patient Population:</strong>
                    <ul>
                        <li>Known epilepsy: Most cases occur in patients with established seizure disorder</li>
                        <li>First seizure: Can be presenting sign of new-onset focal epilepsy</li>
                        <li>Structural lesions: Higher incidence in patients with stroke, tumor, AVM, trauma</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Critical Principle: Todd's Paralysis Is a Diagnosis of Exclusion</strong></p>
            <ul>
                <li>Must rule out acute stroke, particularly if first seizure or no witnessed seizure</li>
                <li>Weakness could represent stroke that caused seizure (stroke-induced seizure), NOT postictal paralysis</li>
                <li>Todd's paralysis should only be diagnosed with high confidence in witnessed seizure followed immediately by weakness</li>
            </ul>
            
            <p><strong>Initial Assessment:</strong></p>
            <ul>
                <li><strong>History (Critical):</strong>
                    <ul>
                        <li>WITNESSED seizure immediately preceding weakness? (if no witness, consider stroke)</li>
                        <li>Prior history of epilepsy? Previous Todd's paralysis?</li>
                        <li>Timing: How long after seizure did weakness begin? (immediate suggests Todd's)</li>
                        <li>Progression: Is weakness improving or stable/worsening? (improving suggests Todd's, stable/worsening suggests stroke)</li>
                        <li>Seizure type and duration (longer seizures â†’ more likely Todd's)</li>
                    </ul>
                </li>
                <li><strong>Physical Examination:</strong>
                    <ul>
                        <li>Neurologic exam: Document extent and severity of weakness (NIH Stroke Scale useful)</li>
                        <li>Look for tongue bite, incontinence, other trauma supporting seizure</li>
                        <li>Assess for confusion, postictal state (supports Todd's diagnosis)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Neuroimaging (ESSENTIAL):</strong></p>
            <ul>
                <li><strong>MRI Brain with DWI/ADC (Preferred):</strong>
                    <ul>
                        <li>Rule out acute ischemic stroke (restricted diffusion on DWI)</li>
                        <li>Todd's paralysis: NO restricted diffusion on DWI (key differentiator)</li>
                        <li>May show T2/FLAIR cortical hyperintensity or gyral swelling in seizure focus (transient, resolves)</li>
                        <li>Helps identify structural cause of seizure (old stroke, tumor, AVM, cortical dysplasia)</li>
                    </ul>
                </li>
                <li><strong>CT Head (if MRI unavailable/contraindicated):</strong>
                    <ul>
                        <li>Rules out hemorrhage, large infarct, mass</li>
                        <li>Less sensitive for acute ischemia and seizure-related changes</li>
                        <li>If CT negative but stroke still suspected, must follow with MRI</li>
                    </ul>
                </li>
                <li><strong>MRA or CTA:</strong> Consider if vascular abnormality suspected (dissection, vasculitis)</li>
            </ul>
            
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Basic Metabolic Panel:</strong> Hyponatremia, hypoglycemia can cause seizures and alter mentation</li>
                <li><strong>Antiepileptic Drug Levels:</strong> If on AEDs, check levels (subtherapeutic may explain breakthrough seizure)</li>
                <li><strong>Troponin:</strong> Seizure can cause demand ischemia, elevated troponin</li>
                <li><strong>CK:</strong> Elevated in prolonged seizures, rhabdomyolysis</li>
                <li><strong>Toxicology Screen:</strong> Rule out drug-induced seizures (cocaine, amphetamines, withdrawal states)</li>
                <li><strong>Prolactin:</strong> Elevated 10-20 minutes post-seizure (NOT specific, don't rely on this to diagnose seizure)</li>
            </ul>
            
            <p><strong>EEG:</strong></p>
            <ul>
                <li><strong>Indications:</strong> All patients with first seizure, unexplained weakness, or concern for ongoing subclinical seizures</li>
                <li><strong>Timing:</strong> Ideally within 24 hours of seizure (yield decreases over time)</li>
                <li><strong>Findings in Todd's Paralysis:</strong>
                    <ul>
                        <li>Focal slowing (delta waves) in hemisphere corresponding to weakness</li>
                        <li>Epileptiform discharges localize seizure focus</li>
                        <li>May be normal (postictal changes resolve quickly)</li>
                    </ul>
                </li>
                <li><strong>Role:</strong> Confirms seizure occurred, identifies epileptogenic focus, guides long-term management</li>
            </ul>
            
            <p><strong>Differentiating Todd's Paralysis from Stroke:</strong></p>
            <table style="width:100%; border-collapse: collapse; margin: 10px 0;">
                <tr style="background-color: #f0f0f0;">
                    <th style="border: 1px solid #ddd; padding: 8px;"></th>
                    <th style="border: 1px solid #ddd; padding: 8px;">Todd's Paralysis</th>
                    <th style="border: 1px solid #ddd; padding: 8px;">Acute Stroke</th>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;"><strong>Onset</strong></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Immediately after witnessed seizure</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Sudden, no seizure</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;"><strong>Progression</strong></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Gradual improvement over hours</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Stable or worsening</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;"><strong>Duration</strong></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Minutes to 48 hours (usually <24h)</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Persistent beyond 48 hours</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;"><strong>MRI DWI</strong></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">NO restricted diffusion</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Restricted diffusion (bright on DWI)</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;"><strong>Sensorium</strong></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Postictal confusion</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Alert (unless large stroke)</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;"><strong>EEG</strong></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Focal slowing, epileptiform activity</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Focal slowing, no epileptiform</td>
                </tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Acute Management:</strong></p>
            <ul>
                <li><strong>Observation:</strong>
                    <ul>
                        <li>Admit for telemetry and neurologic monitoring</li>
                        <li>Serial neurologic exams to document improvement (every 2-4 hours)</li>
                        <li>If weakness NOT improving after 12-24 hours, reconsider diagnosis (repeat imaging)</li>
                    </ul>
                </li>
                <li><strong>No Specific Treatment for Todd's Paralysis:</strong>
                    <ul>
                        <li>Supportive care only (spontaneous resolution expected)</li>
                        <li>Physical therapy/occupational therapy to prevent complications during weakness</li>
                        <li>DVT prophylaxis: Subcutaneous heparin or LMWH if prolonged weakness</li>
                    </ul>
                </li>
                <li><strong>DO NOT Give tPA:</strong>
                    <ul>
                        <li>Todd's paralysis is NOT an indication for thrombolysis</li>
                        <li>High risk of hemorrhage without benefit (no ischemia to treat)</li>
                        <li>If diagnosis uncertain, MUST rule out stroke with MRI before withholding tPA</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Seizure Management:</strong></p>
            <ul>
                <li><strong>Optimize Antiepileptic Therapy:</strong>
                    <ul>
                        <li>If on AEDs: Check levels, adjust doses to therapeutic range</li>
                        <li>If breakthrough seizure despite compliance: Increase dose or add second agent</li>
                        <li>If medication non-compliance: Counsel on adherence, simplify regimen</li>
                    </ul>
                </li>
                <li><strong>First Seizure Management:</strong>
                    <ul>
                        <li>Provoked seizure (hypoglycemia, hyponatremia, alcohol withdrawal, drug intoxication): Treat underlying cause, AED usually not needed long-term</li>
                        <li>Unprovoked seizure: Neurology consultation for AED initiation decision (typically start after second unprovoked seizure, or first seizure with high recurrence risk)</li>
                        <li>Structural lesion on imaging: Usually warrants AED initiation after first seizure</li>
                    </ul>
                </li>
                <li><strong>Common AED Options (Neurology to Guide):</strong>
                    <ul>
                        <li>Levetiracetam (Keppra): 500-1500 mg BID (broad-spectrum, well-tolerated, few drug interactions)</li>
                        <li>Phenytoin (Dilantin): Load 15-20 mg/kg IV, then 300 mg daily (narrow therapeutic index, many interactions)</li>
                        <li>Valproic acid: 250-500 mg BID (avoid in women of childbearing potential)</li>
                        <li>Lamotrigine: 25-200 mg BID (requires slow titration, Stevens-Johnson syndrome risk)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Identify and Treat Seizure Etiology:</strong></p>
            <ul>
                <li><strong>Metabolic:</strong> Correct hyponatremia, hypoglycemia, hypocalcemia, hypomagnesemia</li>
                <li><strong>Toxic:</strong> Cocaine, amphetamines, bupropion, tramadol, antidepressants â†’ supportive care, benzodiazepines</li>
                <li><strong>Withdrawal:</strong> Alcohol, benzodiazepines â†’ benzodiazepine taper, thiamine, folate</li>
                <li><strong>Infectious:</strong> Meningoencephalitis â†’ LP, empiric antibiotics/antivirals pending cultures</li>
                <li><strong>Structural:</strong> Stroke, hemorrhage, tumor, AVM â†’ neurosurgical consultation as indicated</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li><strong>Admission Indications:</strong>
                    <ul>
                        <li>Todd's paralysis (for observation until resolution)</li>
                        <li>First seizure with unclear etiology</li>
                        <li>Breakthrough seizure on AEDs</li>
                        <li>Status epilepticus</li>
                        <li>Structural lesion requiring intervention</li>
                    </ul>
                </li>
                <li><strong>Discharge Criteria:</strong>
                    <ul>
                        <li>Complete resolution of Todd's paralysis</li>
                        <li>Seizure clearly provoked with correctable cause</li>
                        <li>Therapeutic AED levels</li>
                        <li>Reliable follow-up arranged</li>
                    </ul>
                </li>
                <li><strong>Discharge Instructions:</strong>
                    <ul>
                        <li>Neurology follow-up within 1-2 weeks</li>
                        <li>Outpatient EEG if not done inpatient</li>
                        <li>Driving restrictions (varies by state, typically 3-6 months seizure-free)</li>
                        <li>Avoid high-risk activities (swimming alone, heights, operating heavy machinery)</li>
                        <li>Medication compliance counseling</li>
                        <li>Return precautions: Recurrent seizures, worsening weakness, new symptoms</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Long-Term Management (Neurology):</strong></p>
            <ul>
                <li><strong>Epilepsy Surgery Evaluation:</strong> If refractory epilepsy (seizures despite 2+ AEDs), consider referral to epilepsy center for surgery workup</li>
                <li><strong>VNS (Vagal Nerve Stimulator):</strong> Alternative for refractory epilepsy not amenable to surgery</li>
                <li><strong>Dietary Therapy:</strong> Ketogenic diet may reduce seizures in some patients</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Named After Robert Bentley Todd (1849):</strong> British physician who first described transient postictal paralysis in patients with epilepsy. His observations were fundamental to understanding focal seizures and their aftermath.</li>
            <li><strong>Todd's Paralysis Is Diagnosis of Exclusion:</strong> Never diagnose without imaging to rule out stroke. The clinical dilemma: weakness could be (1) Todd's paralysis after seizure, (2) stroke that caused a seizure, or (3) coincidental stroke unrelated to seizure. MRI DWI is gold standard to differentiate.</li>
            <li><strong>No Restricted Diffusion on MRI DWI:</strong> This is THE key imaging finding that distinguishes Todd's paralysis from acute ischemic stroke. Stroke shows restricted diffusion (bright on DWI, dark on ADC); Todd's paralysis shows NO restricted diffusion. May see transient T2/FLAIR cortical hyperintensity from seizure activity.</li>
            <li><strong>Duration >48 Hours â†’ Not Todd's Paralysis:</strong> By definition, Todd's paralysis resolves within 48 hours (most within 24 hours). Persistent weakness beyond 48 hours strongly suggests stroke or another structural lesion, not postictal phenomenon. Re-image and reconsider diagnosis.</li>
            <li><strong>Mechanism: Neuronal Exhaustion Theory:</strong> Exact pathophysiology unknown, but leading theory is temporary neuronal dysfunction and depletion of neurotransmitters after prolonged seizure activity. It's a "metabolic paralysis" from exhausted motor cortex, not ischemia. Neurons need time to recover.</li>
            <li><strong>Weakness Localizes the Seizure Focus:</strong> Todd's paralysis is contralateral to epileptogenic zone. Right-sided weakness â†’ left hemisphere seizure focus. This helps localize lesion for surgical workup in refractory epilepsy.</li>
            <li><strong>Longer Seizure = More Likely Todd's:</strong> Risk and severity of Todd's paralysis correlate with seizure duration. Status epilepticus has highest association. Brief (<1 minute) generalized seizures rarely cause Todd's paralysis.</li>
            <li><strong>EEG Shows Focal Slowing:</strong> During and immediately after Todd's paralysis, EEG typically shows focal slowing (delta waves) in affected hemisphere. This corresponds to "exhausted" neurons. Epileptiform discharges may also be present, localizing seizure focus. EEG helps confirm diagnosis.</li>
            <li><strong>DO NOT Give tPA for Todd's Paralysis:</strong> Thrombolysis is CONTRAINDICATEDâ€”it exposes patient to hemorrhage risk without benefit (no clot to lyse). This is a common ED dilemma: stroke mimic with weakness. Key is obtaining MRI before tPA decision when Todd's is suspected.</li>
            <li><strong>Recurrent Todd's Paralysis Suggests Poor Seizure Control:</strong> Patients with frequent Todd's paralysis have inadequately controlled epilepsy. Each episode indicates breakthrough seizure activity. Optimize AEDs or refer for epilepsy surgery evaluation if refractory to medications.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Status epilepticus requiring continuous EEG monitoring</li>
                        <li>Inability to rule out stroke despite imaging (diagnostic uncertainty)</li>
                        <li>Persistent altered mental status concerning for ongoing seizure activity</li>
                        <li>Hemodynamic instability post-seizure</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Stroke ruled out (MRI with DWI negative for restricted diffusion)</li>
                        <li>Todd's paralysis resolved completely</li>
                        <li>Seizures controlled on antiepileptic medication</li>
                        <li>Patient at neurologic baseline</li>
                        <li>Therapeutic AED levels if on chronic seizure medication</li>
                        <li>Outpatient neurology follow-up arranged (within 1-2 weeks)</li>
                        <li>EEG completed or arranged as outpatient</li>
                        <li>Patient educated on seizure precautions, medication compliance</li>
                        <li>Driving restrictions discussed (state-specific, typically 3-6 months seizure-free)</li>
                        <li>Return precautions for recurrent seizures, persistent weakness</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="traumatic-brain-injury" class="condition-page">
    <div class="page-header">
        <h2>97. TRAUMATIC BRAIN INJURY (TBI)</h2>
        <div class="subtitle">Concussion â€¢ Intracranial Hemorrhage â€¢ Glasgow Coma Scale</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with head trauma presenting with altered consciousness (ranging from brief confusion to prolonged coma), neurologic deficits, or signs of intracranial hemorrhage. Severity ranges from mild (concussion) to severe (coma, mass effect).</p>
            
            <ul>
                <li><strong>Mild TBI (Concussion, GCS 13-15):</strong>
                    <ul>
                        <li>Loss of consciousness: <30 minutes (or none)</li>
                        <li>Post-traumatic amnesia: <24 hours</li>
                        <li>Confusion, disorientation, difficulty concentrating</li>
                        <li>Headache, dizziness, nausea/vomiting</li>
                        <li>Photophobia, phonophobia</li>
                        <li>Emotional lability, irritability, sleep disturbances</li>
                        <li>Normal neurologic exam (or subtle deficits)</li>
                    </ul>
                </li>
                <li><strong>Moderate TBI (GCS 9-12):</strong>
                    <ul>
                        <li>Loss of consciousness: 30 minutes to 24 hours</li>
                        <li>Post-traumatic amnesia: 1-7 days</li>
                        <li>Confusion, lethargy, disorientation</li>
                        <li>Focal neurologic deficits possible</li>
                        <li>May have abnormal CT findings (small hemorrhage, edema)</li>
                    </ul>
                </li>
                <li><strong>Severe TBI (GCS 3-8):</strong>
                    <ul>
                        <li>Loss of consciousness: >24 hours</li>
                        <li>Coma, unresponsive or minimally responsive</li>
                        <li>Post-traumatic amnesia: >7 days</li>
                        <li>Focal deficits, posturing (decorticate, decerebrate)</li>
                        <li>Abnormal CT: Large hemorrhage, mass effect, midline shift</li>
                        <li>Elevated ICP signs (Cushing's triad: hypertension, bradycardia, irregular respirations)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Types of Intracranial Hemorrhage:</strong></p>
            <ul>
                <li><strong>Epidural Hematoma (EDH):</strong>
                    <ul>
                        <li>Mechanism: Skull fracture (temporal bone) â†’ middle meningeal artery rupture</li>
                        <li>Classic: "Lucid interval" (initial LOC, then alert period, then rapid deterioration)</li>
                        <li>CT: Biconvex (lens-shaped) hyperdensity, does NOT cross suture lines</li>
                        <li>Emergency: Neurosurgical evacuation if >30 mL or midline shift >5 mm</li>
                    </ul>
                </li>
                <li><strong>Subdural Hematoma (SDH):</strong>
                    <ul>
                        <li>Mechanism: Bridging vein tear (especially elderly, anticoagulated patients)</li>
                        <li>Acute: High-density crescent on CT, crosses suture lines</li>
                        <li>Chronic: Low-density crescent (weeks old), can rebleed</li>
                        <li>Risk factors: Elderly, alcoholism, anticoagulation, falls</li>
                    </ul>
                </li>
                <li><strong>Subarachnoid Hemorrhage (Traumatic SAH):</strong>
                    <ul>
                        <li>Blood in sulci, cisterns from cortical vessel injury</li>
                        <li>Usually mild, self-limited (vs aneurysmal SAH)</li>
                        <li>Monitor for delayed vasospasm (rare in traumatic SAH)</li>
                    </ul>
                </li>
                <li><strong>Intraparenchymal Hemorrhage / Contusion:</strong>
                    <ul>
                        <li>Bruising of brain parenchyma (coup or contrecoup injury)</li>
                        <li>Common locations: Frontal, temporal poles</li>
                        <li>CT: Mixed density (blood + edema), may expand over first 48 hours</li>
                    </ul>
                </li>
                <li><strong>Diffuse Axonal Injury (DAI):</strong>
                    <ul>
                        <li>Severe shearing injury from rapid acceleration-deceleration</li>
                        <li>CT: Often normal or small hemorrhages at grey-white junction</li>
                        <li>MRI: Microhemorrhages on GRE/SWI sequences, best for diagnosis</li>
                        <li>Poor prognosis: Coma, severe disability common</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Red Flags (High Risk for Intracranial Injury):</strong></p>
            <ul>
                <li>GCS <15 at 2 hours post-injury</li>
                <li>Loss of consciousness â‰¥5 minutes</li>
                <li>Focal neurologic deficits</li>
                <li>Persistent vomiting (â‰¥2 episodes)</li>
                <li>Age â‰¥65 years</li>
                <li>Skull fracture (palpable, Battle's sign, raccoon eyes, hemotympanum, CSF rhinorrhea/otorrhea)</li>
                <li>Anticoagulation (warfarin, DOACs, antiplatelets)</li>
                <li>Dangerous mechanism (fall >3 feet, high-speed MVC, pedestrian struck, assault)</li>
                <li>Post-traumatic seizure</li>
                <li>Severe persistent headache</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Glasgow Coma Scale (GCS):</strong></p>
            <table style="width:100%; border-collapse: collapse; margin: 10px 0;">
                <tr style="background-color: #f0f0f0;">
                    <th style="border: 1px solid #ddd; padding: 8px;">Component</th>
                    <th style="border: 1px solid #ddd; padding: 8px;">Response</th>
                    <th style="border: 1px solid #ddd; padding: 8px;">Score</th>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;" rowspan="4"><strong>Eye Opening</strong></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Spontaneous</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">4</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">To voice</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">3</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">To pain</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">2</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">None</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">1</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;" rowspan="5"><strong>Verbal Response</strong></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Oriented</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">5</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Confused conversation</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">4</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Inappropriate words</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">3</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Incomprehensible sounds</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">2</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">None</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">1</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;" rowspan="6"><strong>Motor Response</strong></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Obeys commands</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">6</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Localizes pain</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">5</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Withdraws from pain</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">4</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Flexion to pain (decorticate)</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">3</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Extension to pain (decerebrate)</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">2</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">None</td>
                    <td style="border: 1px solid #ddd; padding: 8px;">1</td>
                </tr>
            </table>
            <ul>
                <li><strong>Total Score:</strong> 3-15 (3 = worst, 15 = best)</li>
                <li><strong>Severity:</strong> Mild (13-15), Moderate (9-12), Severe (3-8)</li>
            </ul>
            
            <p><strong>CT Head Decision Rules:</strong></p>
            <ul>
                <li><strong>Canadian CT Head Rule (High Sensitivity):</strong>
                    <ul>
                        <li>High Risk (neurosurgical intervention needed): GCS <15 at 2h, suspected skull fracture, vomiting â‰¥2 episodes, age â‰¥65</li>
                        <li>Medium Risk (brain injury on CT): Amnesia >30 min, dangerous mechanism</li>
                        <li>If ANY risk factor present: CT indicated</li>
                    </ul>
                </li>
                <li><strong>New Orleans Criteria:</strong>
                    <ul>
                        <li>CT if ANY: Headache, vomiting, age >60, drug/alcohol intoxication, seizure, trauma visible above clavicles, anterograde amnesia</li>
                    </ul>
                </li>
                <li><strong>NEXUS II (Newer):</strong> Age â‰¥65, evidence of skull fracture, scalp hematoma, neurologic deficit, altered LOC, abnormal behavior, coagulopathy, persistent vomiting</li>
            </ul>
            
            <p><strong>CT Head (Non-Contrast):</strong></p>
            <ul>
                <li><strong>Indications:</strong> Any red flag or high-risk feature, GCS <15, focal deficits, anticoagulation</li>
                <li><strong>Findings:</strong>
                    <ul>
                        <li>Hemorrhage: EDH, SDH, SAH, IPH, IVH</li>
                        <li>Skull fracture: Linear, depressed, basilar</li>
                        <li>Midline shift, herniation, effacement of cisterns</li>
                        <li>Pneumocephalus (air in cranium, suggests skull fracture/dural tear)</li>
                    </ul>
                </li>
                <li><strong>Repeat CT Indications:</strong>
                    <ul>
                        <li>GCS decline â‰¥2 points</li>
                        <li>New focal deficits</li>
                        <li>Persistent or worsening headache</li>
                        <li>Routine repeat at 6-12 hours for initial hemorrhage (assess expansion)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>MRI Brain:</strong></p>
            <ul>
                <li><strong>Indications:</strong> Diffuse axonal injury suspected (GCS doesn't match CT findings), subacute/chronic TBI, detailed injury characterization</li>
                <li><strong>Sequences:</strong>
                    <ul>
                        <li>GRE/SWI: Detects microhemorrhages (DAI)</li>
                        <li>DWI: Identifies cytotoxic edema, ischemia</li>
                        <li>FLAIR: Cortical contusions, edema</li>
                    </ul>
                </li>
                <li><strong>NOT for acute management:</strong> CT is faster, more practical in trauma setting</li>
            </ul>
            
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>CBC:</strong> Baseline hemoglobin (ongoing hemorrhage), platelets (coagulopathy risk)</li>
                <li><strong>Coagulation Studies:</strong> PT/INR, PTT if anticoagulated or suspected coagulopathy</li>
                <li><strong>Type & Screen:</strong> If neurosurgery anticipated</li>
                <li><strong>Alcohol Level, Toxicology:</strong> Common confounders in altered mental status</li>
                <li><strong>Electrolytes, Glucose:</strong> Rule out metabolic causes of AMS</li>
            </ul>
            
            <p><strong>Cervical Spine Imaging:</strong></p>
            <ul>
                <li><strong>Indications:</strong> All patients with TBI should be evaluated for c-spine injury (10% have concomitant c-spine injury)</li>
                <li><strong>Canadian C-Spine Rule:</strong> High-risk mechanism, age â‰¥65, dangerous mechanism, paresthesias â†’ CT c-spine</li>
                <li><strong>CT C-Spine:</strong> Preferred in obtunded patients or those with high-risk features</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Initial Resuscitation (Severe TBI, GCS â‰¤8):</strong></p>
            <ul>
                <li><strong>Airway Management:</strong>
                    <ul>
                        <li>Early intubation for GCS â‰¤8 (unable to protect airway)</li>
                        <li>Rapid sequence intubation with inline stabilization (assume c-spine injury)</li>
                        <li>Avoid hypoxia (SpO2 goal >90%) and hypotension (SBP goal â‰¥100 mmHg)</li>
                        <li>Ventilator settings: Normocapnia (PaCO2 35-40 mmHg); avoid hyperventilation unless acute herniation</li>
                    </ul>
                </li>
                <li><strong>Circulation:</strong>
                    <ul>
                        <li>Maintain SBP â‰¥100 mmHg (age 50-69) or â‰¥110 mmHg (age 15-49, >70)</li>
                        <li>IV fluid resuscitation: Isotonic crystalloid (normal saline or LR), avoid hypotonic fluids (worsen cerebral edema)</li>
                        <li>Vasopressors if needed: Norepinephrine preferred</li>
                    </ul>
                </li>
                <li><strong>Treat Hypotension and Hypoxia FIRST:</strong> These are the two most harmful secondary insults in TBI (worse than elevated ICP)</li>
            </ul>
            
            <p><strong>ICP Management (Severe TBI with Signs of Elevated ICP):</strong></p>
            <ul>
                <li><strong>ICP Monitoring Indications:</strong>
                    <ul>
                        <li>Severe TBI (GCS 3-8) with abnormal CT (hematoma, contusion, edema, compressed cisterns)</li>
                        <li>Severe TBI with normal CT but â‰¥2 of: age >40, SBP <90, posturing</li>
                        <li>Goal ICP: <20-22 mmHg, CPP (cerebral perfusion pressure) 60-70 mmHg</li>
                    </ul>
                </li>
                <li><strong>Head of Bed Elevation:</strong> 30 degrees (improves venous drainage, reduces ICP)</li>
                <li><strong>Hyperosmolar Therapy:</strong>
                    <ul>
                        <li><strong>Hypertonic Saline (3% or 23.4%):</strong> 250 mL bolus 3% NaCl or 30 mL bolus 23.4% NaCl IV (preferred, more effective than mannitol)</li>
                        <li><strong>Mannitol:</strong> 0.25-1 g/kg IV bolus (onset 15-30 min, duration 4-6h; monitor serum osmolality <320 mOsm/kg)</li>
                        <li>Use for acute ICP elevation or signs of herniation (blown pupil, Cushing's triad, posturing)</li>
                    </ul>
                </li>
                <li><strong>Sedation:</strong>
                    <ul>
                        <li>Propofol infusion: 20-75 mcg/kg/min (reduces cerebral metabolic rate, lowers ICP)</li>
                        <li>Fentanyl: 25-100 mcg/hr (analgesia, reduces ICP from pain/agitation)</li>
                        <li>Avoid oversedation (masks neuro exam)</li>
                    </ul>
                </li>
                <li><strong>Avoid Hyperthermia:</strong> Fever worsens secondary brain injury; goal normothermia (acetaminophen, cooling blankets)</li>
                <li><strong>Seizure Prophylaxis:</strong>
                    <ul>
                        <li>Levetiracetam 500-1000 mg IV BID or phenytoin load 20 mg/kg for first 7 days (reduces early post-traumatic seizures)</li>
                        <li>No benefit for long-term prophylaxis beyond 7 days unless patient has actual seizure</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Hyperventilation (ONLY for Acute Herniation):</strong></p>
            <ul>
                <li><strong>Mechanism:</strong> Hypocapnia â†’ cerebral vasoconstriction â†’ reduced ICP (but also reduces cerebral blood flow â†’ ischemia)</li>
                <li><strong>Target:</strong> PaCO2 30-35 mmHg (NOT <30 mmHg)</li>
                <li><strong>Duration:</strong> Temporary bridge to definitive treatment (surgery, ICP monitor placement)</li>
                <li><strong>Avoid Prophylactic Hyperventilation:</strong> Worsens outcomes by causing ischemia</li>
            </ul>
            
            <p><strong>Surgical Intervention (Neurosurgery Consultation):</strong></p>
            <ul>
                <li><strong>Indications for Craniotomy/Craniectomy:</strong>
                    <ul>
                        <li>EDH >30 mL or midline shift >5 mm</li>
                        <li>SDH >10 mm thickness or midline shift >5 mm</li>
                        <li>Depressed skull fracture (>1 cm depression)</li>
                        <li>Large contusions with mass effect</li>
                        <li>Refractory elevated ICP despite medical management</li>
                    </ul>
                </li>
                <li><strong>Decompressive Craniectomy:</strong> Last resort for refractory ICP; improves survival but may leave severe disability</li>
            </ul>
            
            <p><strong>Reversal of Anticoagulation:</strong></p>
            <ul>
                <li><strong>Warfarin:</strong>
                    <ul>
                        <li>Vitamin K 10 mg IV PLUS 4-factor PCC (Kcentra) 25-50 units/kg IV (preferred over FFP)</li>
                        <li>Alternative: FFP 10-15 mL/kg if PCC unavailable (slower, less effective)</li>
                    </ul>
                </li>
                <li><strong>Dabigatran (Pradaxa):</strong> Idarucizumab (Praxbind) 5 grams IV</li>
                <li><strong>Factor Xa Inhibitors (rivaroxaban, apixaban):</strong> Andexanet alfa (Andexxa) 400-800 mg IV or 4-factor PCC 50 units/kg</li>
                <li><strong>Heparin:</strong> Protamine 1 mg per 100 units heparin (max 50 mg)</li>
                <li><strong>Antiplatelet Agents:</strong>
                    <ul>
                        <li>Platelet transfusion if neurosurgery planned</li>
                        <li>DDAVP 0.3 mcg/kg IV if uremic platelet dysfunction</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Mild TBI (Concussion) Management:</strong></p>
            <ul>
                <li><strong>Observation:</strong>
                    <ul>
                        <li>4-6 hours in ED if reliable home situation, normal CT (if obtained), GCS 15</li>
                        <li>Discharge with responsible adult for home observation</li>
                    </ul>
                </li>
                <li><strong>Return Precautions:</strong> Worsening headache, vomiting, confusion, seizures, weakness, vision changes â†’ return immediately</li>
                <li><strong>Cognitive Rest:</strong> Avoid screens, reading, work/school for 24-48 hours</li>
                <li><strong>Physical Rest:</strong> No sports, exercise, or activities with reinjury risk until cleared by physician</li>
                <li><strong>Graduated Return to Activity:</strong> Stepwise progression over days to weeks (no symptoms at each stage before advancing)</li>
                <li><strong>Follow-Up:</strong> Primary care or sports medicine in 1-2 weeks for clearance</li>
            </ul>
            
            <p><strong>Post-Concussion Syndrome (Symptoms >3 Months):</strong></p>
            <ul>
                <li><strong>Symptoms:</strong> Persistent headaches, dizziness, fatigue, difficulty concentrating, memory problems, mood changes</li>
                <li><strong>Management:</strong> Multidisciplinary (neurology, neuropsychology, physical therapy), symptom-directed treatment (headache meds, vestibular therapy, cognitive rehab)</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li><strong>ICU Admission:</strong> GCS â‰¤12, intracranial hemorrhage, elevated ICP, need for ICP monitoring, anticoagulation with ICH</li>
                <li><strong>Floor Admission:</strong> GCS 13-14, isolated skull fracture, need for serial neuro exams</li>
                <li><strong>Discharge:</strong> GCS 15, normal CT (or low-risk isolated finding), reliable follow-up, responsible adult at home</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Hypotension and Hypoxia Are the Deadliest Secondary Insults:</strong> Single episode of hypotension (SBP <90) or hypoxia (SpO2 <90%) doubles mortality in TBI. Airway, breathing, circulation BEFORE worrying about ICP. Maintain SBP â‰¥100-110 mmHg and SpO2 >90%.</li>
            <li><strong>"Talk and Die" Syndrome (Epidural Hematoma):</strong> Classic lucid interval: patient is initially unconscious, then wakes up and seems fine ("talks"), then rapidly deteriorates hours later ("dies" without intervention). High-pressure arterial bleeding (middle meningeal artery) â†’ rapid expansion â†’ herniation. Emergency craniotomy saves lives.</li>
            <li><strong>Lens-Shaped vs Crescent-Shaped on CT:</strong> Epidural hematoma is biconvex/lens-shaped (doesn't cross suture lines, limited by dura attachments). Subdural hematoma is crescent-shaped (crosses suture lines, follows brain contour). This distinction is high-yield for boards and clinical practice.</li>
            <li><strong>CPP = MAP - ICP (Cerebral Perfusion Pressure):</strong> Goal CPP 60-70 mmHg ensures adequate brain perfusion. If ICP rises or MAP drops, CPP falls â†’ brain ischemia. Maintain blood pressure AND reduce ICP. CPP <50 mmHg = bad news.</li>
            <li><strong>Cushing's Triad = Herniation Until Proven Otherwise:</strong> Hypertension (widened pulse pressure), bradycardia, irregular respirations = impending brainstem herniation from elevated ICP. This is a late, ominous sign. Immediate intervention required: hyperventilate, hyperosmolar therapy, neurosurgery.</li>
            <li><strong>Hypertonic Saline > Mannitol for ICP Reduction:</strong> 3% or 23.4% saline is more effective and safer than mannitol (no risk of hypovolemia, hypotension, or rebound ICP). Mannitol causes osmotic diuresis â†’ dehydration â†’ decreased CPP. Use saline first.</li>
            <li><strong>Avoid Prophylactic Hyperventilation:</strong> Hypocapnia causes cerebral vasoconstriction â†’ reduced cerebral blood flow â†’ ischemia. Only hyperventilate for acute herniation (PaCO2 30-35 mmHg) as temporary bridge to surgery. Target normocapnia (35-40 mmHg) otherwise.</li>
            <li><strong>Repeat CT at 6-12 Hours for Traumatic ICH:</strong> Hemorrhagic contusions and hematomas can expand in first 24-48 hours. Always repeat CT if clinical decline, but also routinely for any significant bleed to assess for expansion. Many bleeds enlarge even without GCS change.</li>
            <li><strong>Seizure Prophylaxis Only for First 7 Days:</strong> Levetiracetam or phenytoin reduces early post-traumatic seizures (first week) but NOT late seizures (>7 days). No benefit to prophylaxis beyond 7 days unless patient has actual seizure. If seizure occurs, continue AED long-term.</li>
            <li><strong>Diffuse Axonal Injury (DAI) = "Worst GCS for the CT":</strong> Patient in coma (GCS 4-6) but CT looks normal or shows only tiny punctate hemorrhages. MRI (GRE/SWI) reveals extensive microhemorrhages at grey-white junction from shearing forces. Poor prognosisâ€”severe disability common. DAI is hallmark of severe acceleration-deceleration injury (high-speed MVCs).</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL severe TBI (GCS â‰¤8) requires ICU admission</li>
                        <li>Intracranial hemorrhage with mass effect or midline shift</li>
                        <li>Need for ICP monitoring</li>
                        <li>Hemodynamic instability requiring vasopressor support</li>
                        <li>Respiratory failure requiring mechanical ventilation</li>
                        <li>Seizures requiring ongoing treatment</li>
                        <li>Signs of herniation (blown pupil, Cushing's triad, posturing)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable without vasopressors</li>
                        <li>Neurologically stable or improving (GCS â‰¥13-15 for mild TBI)</li>
                        <li>Repeat imaging stable (no expansion of hemorrhage, no new findings)</li>
                        <li>No seizures (or controlled on prophylactic AED for severe TBI)</li>
                        <li>Pain controlled on oral medications</li>
                        <li>Able to ambulate safely and perform ADLs (or baseline if chronic deficits)</li>
                        <li>Follow-up with neurosurgery arranged if indicated (within 1-4 weeks)</li>
                        <li>If concussion: graduated return-to-activity plan explained</li>
                        <li>Patient/family educated on return precautions (worsening headache, vomiting, confusion, seizures)</li>
                        <li>Repeat imaging arranged if indicated (typically 4-6 weeks for significant injury)</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="malaria" class="condition-page">
    <div class="page-header">
        <h2>98. MALARIA</h2>
        <div class="subtitle">Plasmodium Species â€¢ Fever Paroxysms â€¢ Blood Smear</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with recent travel to malaria-endemic area (Sub-Saharan Africa, South Asia, Latin America) presenting with fever, chills, headache, and myalgias. Fever classically occurs in paroxysms (cyclic pattern every 48-72 hours depending on species), though early infection often has irregular fever.</p>
            
            <ul>
                <li><strong>Five Plasmodium Species:</strong>
                    <ul>
                        <li><strong>P. falciparum:</strong> Most deadly (causes severe malaria), no relapse from liver (erythrocytic cycle only)</li>
                        <li><strong>P. vivax:</strong> Relapsing (hypnozoites in liver), causes severe anemia</li>
                        <li><strong>P. ovale:</strong> Relapsing (hypnozoites), clinically similar to P. vivax, less common</li>
                        <li><strong>P. malariae:</strong> Chronic low-grade parasitemia, can persist for years, no relapse</li>
                        <li><strong>P. knowlesi:</strong> Zoonotic (from monkeys), Southeast Asia, can cause severe disease</li>
                    </ul>
                </li>
                <li><strong>Transmission:</strong> Female Anopheles mosquito bite (typically dusk to dawn), rarely transfusion/needlestick/vertical transmission</li>
                <li><strong>Incubation Period:</strong> 7-30 days (P. falciparum), weeks to months (P. vivax/ovale), years (P. malariae)</li>
            </ul>
            
            <p><strong>Uncomplicated Malaria (Most Presentations):</strong></p>
            <ul>
                <li><strong>Fever:</strong> High fever (39-41Â°C), may have classic paroxysms (chills â†’ fever â†’ sweats), but early infection often irregular</li>
                <li><strong>Classic Paroxysm Timing by Species:</strong>
                    <ul>
                        <li>P. falciparum: Irregular or daily fever</li>
                        <li>P. vivax/ovale: Tertian fever (every 48 hours)</li>
                        <li>P. malariae: Quartan fever (every 72 hours)</li>
                    </ul>
                </li>
                <li><strong>Associated Symptoms:</strong>
                    <ul>
                        <li>Headache (severe, frontal)</li>
                        <li>Myalgias, arthralgias</li>
                        <li>Nausea, vomiting, diarrhea</li>
                        <li>Malaise, fatigue</li>
                        <li>Dry cough (mild)</li>
                    </ul>
                </li>
                <li><strong>Physical Exam:</strong>
                    <ul>
                        <li>Splenomegaly (50-75%, develops after 1-2 weeks)</li>
                        <li>Hepatomegaly (30-50%)</li>
                        <li>Jaundice (hemolytic anemia)</li>
                        <li>Pallor (anemia)</li>
                        <li>Tachycardia, tachypnea</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Severe Malaria (P. falciparum, Requires Hospitalization):</strong></p>
            <ul>
                <li><strong>Cerebral Malaria:</strong>
                    <ul>
                        <li>Altered mental status (confusion, delirium, coma)</li>
                        <li>Seizures (especially children)</li>
                        <li>GCS <11 or Blantyre Coma Score <3 (pediatric)</li>
                        <li>Mechanism: Sequestration of infected RBCs in cerebral microvasculature</li>
                        <li>High mortality (15-20% even with treatment)</li>
                    </ul>
                </li>
                <li><strong>Severe Anemia:</strong> Hemoglobin <7 g/dL or hematocrit <20%</li>
                <li><strong>Acute Respiratory Distress:</strong> Pulmonary edema, ARDS (often delayed, can occur after treatment started)</li>
                <li><strong>Renal Failure:</strong> Acute kidney injury (creatinine >3 mg/dL), "blackwater fever" (dark urine from massive hemolysis)</li>
                <li><strong>Metabolic Acidosis:</strong> Lactic acidosis (bicarbonate <15 mEq/L, lactate >5 mmol/L)</li>
                <li><strong>Hypoglycemia:</strong> Glucose <40 mg/dL (from parasite consumption + quinine-induced hyperinsulinemia)</li>
                <li><strong>Hyperparasitemia:</strong> >5% parasitemia (>250,000/Î¼L) or >2% with organ dysfunction</li>
                <li><strong>Shock:</strong> Hypotension, multiorgan failure</li>
                <li><strong>Disseminated Intravascular Coagulation (DIC):</strong> Bleeding, thrombocytopenia, elevated PT/PTT</li>
                <li><strong>Jaundice:</strong> Bilirubin >3 mg/dL with other signs of severity</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Clinical Suspicion (Who to Test):</strong></p>
            <ul>
                <li>ANY fever in patient with travel to malaria-endemic area in past year (especially past 3 months)</li>
                <li>Immigrants/refugees from endemic countries</li>
                <li>NO FEVER does NOT rule out malaria (some patients afebrile at presentation)</li>
            </ul>
            
            <p><strong>Definitive Diagnosis:</strong></p>
            <ul>
                <li><strong>Thick and Thin Blood Smears (Gold Standard):</strong>
                    <ul>
                        <li><strong>Thick smear:</strong> Higher sensitivity (concentrates parasites), used for screening</li>
                        <li><strong>Thin smear:</strong> Species identification, quantifies parasitemia</li>
                        <li>Repeat every 12-24 hours for 3 sets if initial negative but high suspicion</li>
                        <li>Timing: Can draw anytime (don't wait for fever spike)</li>
                        <li>Parasitemia calculation: (# parasites / # RBCs) Ã— 100</li>
                    </ul>
                </li>
                <li><strong>Rapid Diagnostic Tests (RDTs):</strong>
                    <ul>
                        <li>Detect parasite antigens (HRP-2 for P. falciparum, pLDH for all species)</li>
                        <li>Sensitivity 95% for P. falciparum, lower for other species</li>
                        <li>Results in 15-20 minutes</li>
                        <li>Limitation: Cannot quantify parasitemia, may stay positive for weeks after treatment</li>
                        <li>Use: Adjunct to blood smear, NOT replacement (always confirm with smear)</li>
                    </ul>
                </li>
                <li><strong>PCR:</strong> Most sensitive (detects low-level parasitemia), species identification, but not widely available, slow turnaround</li>
            </ul>
            
            <p><strong>Laboratory Findings:</strong></p>
            <ul>
                <li><strong>CBC:</strong>
                    <ul>
                        <li>Anemia: Normocytic, normochromic from hemolysis (Hgb often 7-10 g/dL)</li>
                        <li>Thrombocytopenia: 80-90% of cases (platelets 50,000-150,000/Î¼L), rarely causes bleeding</li>
                        <li>Leukopenia or normal WBC (leukocytosis suggests bacterial co-infection)</li>
                    </ul>
                </li>
                <li><strong>Comprehensive Metabolic Panel:</strong>
                    <ul>
                        <li>Elevated creatinine: Acute kidney injury in severe malaria</li>
                        <li>Hypoglycemia: Common in severe malaria and quinine treatment</li>
                        <li>Hyponatremia: SIADH-like picture</li>
                        <li>Elevated transaminases: Mild AST/ALT elevation (200-500 U/L)</li>
                        <li>Elevated bilirubin: Indirect (hemolysis)</li>
                    </ul>
                </li>
                <li><strong>Lactate:</strong> Elevated in severe malaria (>5 mmol/L indicates poor prognosis)</li>
                <li><strong>LDH:</strong> Elevated (hemolysis marker)</li>
                <li><strong>Haptoglobin:</strong> Low (intravascular hemolysis)</li>
                <li><strong>Arterial Blood Gas:</strong> Metabolic acidosis in severe malaria</li>
                <li><strong>Coagulation Studies:</strong> PT/PTT may be elevated in DIC</li>
            </ul>
            
            <p><strong>Determining Severity (Hospitalize vs Outpatient):</strong></p>
            <ul>
                <li><strong>Severe Malaria (ANY of the following = HOSPITALIZE):</strong>
                    <ul>
                        <li>Altered mental status, seizures, coma</li>
                        <li>Severe anemia (Hgb <7 g/dL)</li>
                        <li>Renal failure (Cr >3 mg/dL)</li>
                        <li>Pulmonary edema, ARDS</li>
                        <li>Hypoglycemia (<40 mg/dL)</li>
                        <li>Shock, acidosis (lactate >5)</li>
                        <li>Hyperparasitemia (>5% or >2% with organ dysfunction)</li>
                        <li>DIC, bleeding</li>
                        <li>Jaundice (bilirubin >3 mg/dL with other severity criteria)</li>
                    </ul>
                </li>
                <li><strong>Uncomplicated Malaria (Can Consider Outpatient if Reliable):</strong>
                    <ul>
                        <li>No severity criteria</li>
                        <li>Able to tolerate oral medications</li>
                        <li>Parasitemia <2%</li>
                        <li>Reliable for follow-up</li>
                        <li>Access to care if worsens</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Additional Testing:</strong></p>
            <ul>
                <li><strong>Glucose-6-Phosphate Dehydrogenase (G6PD) Testing:</strong> Before giving primaquine (can cause severe hemolysis in G6PD deficiency)</li>
                <li><strong>Chest X-ray:</strong> If respiratory symptoms (rule out ARDS, pulmonary edema)</li>
                <li><strong>Lumbar Puncture:</strong> If altered mental status to rule out meningitis/encephalitis (CSF usually normal in cerebral malaria)</li>
                <li><strong>Blood Cultures:</strong> If febrile and ill-appearing (rule out bacterial sepsis, co-infection common)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Treatment Selection Based on Species and Severity:</strong></p>
            
            <p><strong>SEVERE MALARIA (P. falciparum or Unknown Species):</strong></p>
            <ul>
                <li><strong>IV Artesunate (First-Line, Preferred):</strong>
                    <ul>
                        <li>Dose: 2.4 mg/kg IV at 0, 12, and 24 hours, then daily until oral therapy tolerated</li>
                        <li>Available through CDC Drug Service (770-488-7788)</li>
                        <li>20-30% reduction in mortality vs quinine</li>
                        <li>Switch to oral ACT (artemisinin-based combination therapy) when able to tolerate PO</li>
                    </ul>
                </li>
                <li><strong>IV Quinidine (Alternative if Artesunate Unavailable):</strong>
                    <ul>
                        <li>Loading dose: 10 mg/kg (max 600 mg) IV over 1-2 hours, then 0.02 mg/kg/min continuous infusion</li>
                        <li>PLUS doxycycline 100 mg IV/PO BID OR clindamycin 10 mg/kg IV TID</li>
                        <li>Cardiac monitoring required (QT prolongation, torsades risk)</li>
                        <li>Monitor glucose closely (causes hyperinsulinemia â†’ hypoglycemia)</li>
                    </ul>
                </li>
                <li><strong>Supportive Care (Critical):</strong>
                    <ul>
                        <li>ICU monitoring for severe malaria</li>
                        <li>IV fluids: Cautious hydration (risk of pulmonary edema), monitor I/Os closely</li>
                        <li>Correct hypoglycemia: Dextrose 50 mL D50 IV bolus, then maintenance D5W or D10W infusion</li>
                        <li>Transfuse PRBCs: If Hgb <7 g/dL or severe anemia with symptoms</li>
                        <li>Renal replacement therapy: Hemodialysis if acute kidney injury with uremia or fluid overload</li>
                        <li>Anticonvulsants: Benzodiazepines for seizures (do NOT use prophylactic phenobarbitalâ€”increases mortality)</li>
                        <li>Mechanical ventilation: If ARDS or respiratory failure</li>
                    </ul>
                </li>
                <li><strong>Adjunctive Therapies with NO BENEFIT (Avoid):</strong>
                    <ul>
                        <li>Steroids: NO benefit, may increase complications</li>
                        <li>Exchange transfusion: NOT routinely recommended (conflicting evidence)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>UNCOMPLICATED MALARIA:</strong></p>
            <ul>
                <li><strong>P. falciparum or Unknown Species (Chloroquine-Resistant):</strong>
                    <ul>
                        <li><strong>First-Line:</strong> Artemether-lumefantrine (Coartem): 4 tablets (20/120 mg) PO BID Ã— 3 days (with fatty food to improve absorption)</li>
                        <li><strong>Alternatives:</strong>
                            <ul>
                                <li>Atovaquone-proguanil (Malarone): 4 tablets (250/100 mg) PO daily Ã— 3 days</li>
                                <li>Quinine sulfate 542 mg PO TID Ã— 3-7 days PLUS doxycycline 100 mg PO BID Ã— 7 days OR clindamycin 20 mg/kg/day divided TID Ã— 7 days</li>
                                <li>Mefloquine 750 mg PO once, then 500 mg 6-12 hours later (neuropsychiatric side effects common)</li>
                            </ul>
                        </li>
                    </ul>
                </li>
                <li><strong>P. falciparum from Chloroquine-Sensitive Area (Rareâ€”Central America west of Panama Canal, Haiti, Dominican Republic):</strong>
                    <ul>
                        <li>Chloroquine phosphate: 600 mg base (1000 mg salt) PO, then 300 mg base at 6, 24, and 48 hours</li>
                    </ul>
                </li>
                <li><strong>P. vivax or P. ovale:</strong>
                    <ul>
                        <li><strong>Erythrocytic Stage (Blood Infection):</strong> Chloroquine 600 mg base PO, then 300 mg base at 6, 24, 48 hours</li>
                        <li><strong>PLUS Hepatic Stage (Hypnozoites, Prevents Relapse):</strong> Primaquine 30 mg base PO daily Ã— 14 days
                            <ul>
                                <li><strong>MUST check G6PD level first</strong> (primaquine causes severe hemolysis in G6PD deficiency)</li>
                                <li>If G6PD deficient: Use primaquine 45 mg weekly Ã— 8 weeks (slower regimen) OR avoid primaquine (accept relapse risk)</li>
                                <li>If chloroquine-resistant P. vivax (Southeast Asia, Oceania): Use artemether-lumefantrine or atovaquone-proguanil PLUS primaquine</li>
                            </ul>
                        </li>
                    </ul>
                </li>
                <li><strong>P. malariae or P. knowlesi:</strong>
                    <ul>
                        <li>Chloroquine (same as P. vivax) or artemether-lumefantrine</li>
                        <li>NO primaquine needed (no liver stage)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Monitoring During Treatment:</strong></p>
            <ul>
                <li><strong>Daily blood smears:</strong> Until parasitemia cleared (should decrease by 75% at 48 hours)</li>
                <li><strong>Daily labs:</strong> CBC, CMP, glucose (especially with quinine/quinidine)</li>
                <li><strong>Clinical assessment:</strong> Vital signs, mental status, urine output</li>
                <li><strong>Treatment failure:</strong> If parasitemia unchanged or worsening at 48-72 hours, consider resistance, change regimen</li>
            </ul>
            
            <p><strong>Special Populations:</strong></p>
            <ul>
                <li><strong>Pregnancy:</strong>
                    <ul>
                        <li>Severe malaria: IV artesunate (all trimesters), IV quinidine alternative</li>
                        <li>Uncomplicated: Quinine + clindamycin Ã— 7 days (avoid doxycycline), artemether-lumefantrine in 2nd/3rd trimester</li>
                        <li>Avoid primaquine (hemolysis risk to fetus if G6PD deficient)</li>
                        <li>Avoid atovaquone-proguanil (limited safety data)</li>
                    </ul>
                </li>
                <li><strong>Children:</strong>
                    <ul>
                        <li>Same drugs, dose by weight</li>
                        <li>Avoid doxycycline <8 years old (tooth staining)</li>
                        <li>Artemether-lumefantrine safe and effective</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Disposition and Follow-Up:</strong></p>
            <ul>
                <li><strong>Hospitalize:</strong> All severe malaria, pregnant women, young children, unable to tolerate oral medications, parasitemia >2%, unreliable for follow-up</li>
                <li><strong>Outpatient:</strong> Uncomplicated malaria in reliable patients, close follow-up (daily phone calls, recheck in 2-3 days)</li>
                <li><strong>Follow-Up Blood Smear:</strong> At day 7, 14, 28 to confirm cure and detect recrudescence/relapse</li>
            </ul>
            
            <p><strong>Prevention (Counseling for Future Travel):</strong></p>
            <ul>
                <li><strong>Chemoprophylaxis:</strong> Atovaquone-proguanil (Malarone), doxycycline, or mefloquine starting before travel</li>
                <li><strong>Mosquito Avoidance:</strong> Insect repellent (DEET), long sleeves/pants, bed nets (permethrin-treated), avoid dusk/dawn outdoor exposure</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>P. falciparum = The Killer:</strong> Responsible for 90% of malaria deaths. Causes severe malaria (cerebral malaria, severe anemia, ARDS, renal failure, acidosis). Other species (P. vivax, ovale, malariae, knowlesi) rarely cause death. Always assume P. falciparum in sick patient until proven otherwise.</li>
            <li><strong>Classic Fever Paroxysms Are Often Absent:</strong> Textbook cyclic fevers (chills-fever-sweats every 48-72 hours) occur in minority of cases, usually only after several weeks. Early malaria typically has irregular fevers. DO NOT rule out malaria because fever isn't cyclic.</li>
            <li><strong>Thrombocytopenia + Fever + Travel = Think Malaria (and Dengue):</strong> Malaria causes thrombocytopenia in 80-90% of cases but rarely causes bleeding. If fever + low platelets + recent travel to tropics, malaria and dengue are top differentials. Blood smear distinguishes them.</li>
            <li><strong>Always Get THREE Sets of Blood Smears if Suspicion High:</strong> Parasitemia can be low or fluctuate. Single negative smear does NOT rule out malaria. Repeat every 12-24 hours for 3 sets (thick and thin) before excluding diagnosis. Sensitivity of single smear ~70%, three smears ~95%.</li>
            <li><strong>IV Artesunate Saves Lives (20-30% Mortality Reduction):</strong> For severe malaria, IV artesunate is superior to quinine/quinidine. Faster parasite clearance, fewer complications. Available through CDC Drug Service 24/7 (770-488-7788). If artesunate delayed, start quinidine as bridge but switch to artesunate when available.</li>
            <li><strong>Primaquine Is for Liver Stage (Relapse Prevention) Only:</strong> P. vivax and P. ovale form dormant hypnozoites in liver that cause relapses months to years later. Primaquine is the ONLY drug that eradicates liver-stage parasites. Must give after treating blood stage to prevent relapse. Check G6PD FIRST (primaquine causes severe hemolysis if G6PD deficient).</li>
            <li><strong>Cerebral Malaria = Altered Mental Status + Malaria, NOT Meningitis:</strong> Cerebral malaria is impaired consciousness (coma) from sequestration of infected RBCs in brain microvasculature, NOT from meningitis/encephalitis. LP is usually normal (do it to rule out co-infection, but don't expect pleocytosis). Treat the malaria, not the "meningitis."</li>
            <li><strong>Blackwater Fever = Massive Intravascular Hemolysis:</strong> Dark/black urine from hemoglobinuria due to massive RBC lysis (usually P. falciparum). Historically associated with quinine treatment, but can occur from malaria itself. Leads to acute renal failure. Aggressive hydration, transfusion, dialysis if needed.</li>
            <li><strong>Hypoglycemia Is Common and Deadly in Severe Malaria:</strong> Occurs from (1) parasite consuming glucose, (2) quinine-induced hyperinsulinemia, (3) impaired gluconeogenesis. Check glucose frequently, especially during quinine/quinidine treatment. Empiric dextrose infusion may be life-saving.</li>
            <li><strong>Malaria vs Dengue vs Typhoid = The "Tropical Fever Triad":</strong> All three present with fever, headache, myalgias after tropical travel. Key differentiators: Malaria (blood smear shows parasites, thrombocytopenia, rigors), Dengue (severe myalgias, rash, leukopenia, positive serology), Typhoid (relative bradycardia, rose spots, positive blood culture). When in doubt, test for all three.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL severe malaria requires ICU admission</li>
                        <li>Cerebral malaria (altered mental status, seizures, coma)</li>
                        <li>Severe anemia (Hgb <7 g/dL)</li>
                        <li>Acute respiratory distress or pulmonary edema</li>
                        <li>Renal failure (Cr >3 mg/dL) or requiring dialysis</li>
                        <li>Hypoglycemia (<40 mg/dL) refractory or recurrent</li>
                        <li>Shock or metabolic acidosis (lactate >5 mmol/L)</li>
                        <li>Hyperparasitemia (>5% or >2% with organ dysfunction)</li>
                        <li>DIC or significant bleeding</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable, afebrile >48 hours</li>
                        <li>Parasitemia cleared or significantly reduced (<1%)</li>
                        <li>No signs of severe malaria (normal mental status, stable labs)</li>
                        <li>Tolerating oral antimalarial medication</li>
                        <li>Completed appropriate course of IV artesunate (if severe malaria) and transitioned to oral therapy</li>
                        <li>Hemoglobin stable (typically >7 g/dL)</li>
                        <li>Renal function stable or improving</li>
                        <li>Outpatient infectious disease follow-up arranged</li>
                        <li>Blood smear follow-up arranged (day 7, 14, 28 to confirm cure)</li>
                        <li>Patient educated on medication completion, return precautions for fever</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div id="musculoskeletal-chest-pain" class="condition-page">
    <div class="page-header">
        <h2>99. MUSCULOSKELETAL CHEST PAIN</h2>
        <div class="subtitle">Costochondritis â€¢ Chest Wall Tenderness â€¢ Benign Cause</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient presenting with chest pain that is reproducible with palpation of the chest wall, positional, or exacerbated by movement. Pain is typically sharp, well-localized, and NOT associated with exertion, dyspnea, diaphoresis, or other cardiac symptoms. Most common cause of chest pain in young, otherwise healthy patients.</p>
            
            <ul>
                <li><strong>Characteristics of Musculoskeletal Chest Pain:</strong>
                    <ul>
                        <li>Sharp, stabbing, or aching quality (rarely pressure-like)</li>
                        <li>Well-localized (patient can point with one finger)</li>
                        <li>Reproduced by palpation of chest wall or specific movements</li>
                        <li>Worsened by deep breathing, coughing, arm movement, twisting</li>
                        <li>Positional (better or worse in certain positions)</li>
                        <li>Duration: Seconds to minutes (fleeting) or constant for days</li>
                        <li>NOT related to exertion (key differentiator from angina)</li>
                        <li>NO associated dyspnea, diaphoresis, nausea (unlike ACS)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Common Musculoskeletal Causes:</strong></p>
            <ul>
                <li><strong>Costochondritis:</strong>
                    <ul>
                        <li>Inflammation of costal cartilage (rib-sternum junction)</li>
                        <li>Most commonly affects 2nd-5th ribs</li>
                        <li>Bilateral or unilateral chest pain</li>
                        <li>Exquisite tenderness to palpation over affected costochondral junctions</li>
                        <li>No swelling (vs Tietze syndrome which has visible swelling)</li>
                        <li>Etiology: Often idiopathic, sometimes post-viral illness, repetitive strain</li>
                    </ul>
                </li>
                <li><strong>Tietze Syndrome:</strong>
                    <ul>
                        <li>Similar to costochondritis but with visible swelling of costochondral junction</li>
                        <li>Typically affects single rib (2nd or 3rd most common)</li>
                        <li>Palpable, tender mass over costochondral junction</li>
                        <li>Less common than costochondritis, affects younger patients (20-40 years)</li>
                    </ul>
                </li>
                <li><strong>Intercostal Muscle Strain:</strong>
                    <ul>
                        <li>From overuse, vigorous coughing, trauma, heavy lifting, sudden twisting</li>
                        <li>Pain along rib cage, worsened by movement or deep breathing</li>
                        <li>Tenderness over affected intercostal muscles</li>
                        <li>May have bruising if traumatic</li>
                    </ul>
                </li>
                <li><strong>Rib Fracture:</strong>
                    <ul>
                        <li>From trauma, severe coughing (stress fracture), or osteoporosis</li>
                        <li>Severe, sharp pain worsened by breathing, coughing, movement</li>
                        <li>Point tenderness over fracture site</li>
                        <li>Palpable step-off or crepitus if displaced</li>
                        <li>Complications: Pneumothorax, hemothorax (if displaced), flail chest (if multiple adjacent ribs)</li>
                    </ul>
                </li>
                <li><strong>Sternoclavicular Joint Arthritis/Inflammation:</strong>
                    <ul>
                        <li>Pain at sternoclavicular junction (medial clavicle)</li>
                        <li>Tenderness, swelling over SC joint</li>
                        <li>Causes: Osteoarthritis, inflammatory arthritis (RA, psoriatic), infection (rare)</li>
                    </ul>
                </li>
                <li><strong>Precordial Catch Syndrome (Texidor's Twinge):</strong>
                    <ul>
                        <li>Sudden, sharp, fleeting chest pain (seconds to 3 minutes)</li>
                        <li>Left parasternal or apical region</li>
                        <li>Occurs at rest, worsened by deep breathing</li>
                        <li>Adolescents and young adults</li>
                        <li>Benign, self-limited (no treatment needed)</li>
                        <li>Etiology: Unknown, possibly intercostal muscle spasm</li>
                    </ul>
                </li>
                <li><strong>Xiphoidalgia (Xiphoid Process Syndrome):</strong>
                    <ul>
                        <li>Pain at xiphoid process (lower sternum)</li>
                        <li>Exquisite tenderness to palpation of xiphoid</li>
                        <li>Worsened by bending forward, eating large meals</li>
                        <li>Benign, often chronic/recurrent</li>
                    </ul>
                </li>
                <li><strong>Slipping Rib Syndrome:</strong>
                    <ul>
                        <li>Hypermobility of lower ribs (8-10) due to inadequate cartilage attachment</li>
                        <li>Sharp pain in lower chest/upper abdomen</li>
                        <li>"Hooking maneuver" reproduces pain (examiner hooks fingers under costal margin and pulls anteriorly)</li>
                        <li>Clicking or popping sensation</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Critical Principle: Must Rule Out Life-Threatening Causes FIRST</strong></p>
            <ul>
                <li>Musculoskeletal chest pain is a diagnosis of exclusion in the ED</li>
                <li>ALWAYS consider and rule out: ACS, PE, aortic dissection, pneumothorax, pericarditis, esophageal rupture</li>
                <li>Young, healthy patient with classic musculoskeletal features + normal ECG â†’ low probability of cardiac cause</li>
                <li>Older patient or cardiac risk factors â†’ must rule out cardiac cause despite musculoskeletal features</li>
            </ul>
            
            <p><strong>History (Key Questions):</strong></p>
            <ul>
                <li><strong>Reproducibility:</strong> "Can you push on your chest and make the pain worse?" (If yes, favors musculoskeletal)</li>
                <li><strong>Exertional:</strong> "Does the pain occur with walking, climbing stairs, or exertion?" (If yes, consider cardiac)</li>
                <li><strong>Radiation:</strong> Pain radiating to jaw, left arm, back (concerning for cardiac)</li>
                <li><strong>Associated Symptoms:</strong> Dyspnea, diaphoresis, nausea/vomiting (concerning for cardiac)</li>
                <li><strong>Triggers:</strong> Movement, position, breathing (favors musculoskeletal); exertion, stress (favors cardiac)</li>
                <li><strong>Recent Activity:</strong> Heavy lifting, new exercise routine, trauma, prolonged coughing</li>
            </ul>
            
            <p><strong>Physical Examination:</strong></p>
            <ul>
                <li><strong>Vital Signs:</strong> Normal HR, BP, RR, SpO2 (tachycardia, hypotension, hypoxia suggest serious pathology)</li>
                <li><strong>Chest Wall Palpation:</strong>
                    <ul>
                        <li>Systematically palpate sternum, ribs, costochondral junctions, intercostal spaces</li>
                        <li>Reproduce patient's pain with palpation (highly specific for musculoskeletal cause)</li>
                        <li>Note location, swelling, deformity, crepitus</li>
                    </ul>
                </li>
                <li><strong>Range of Motion:</strong> Ask patient to twist, reach overhead, bend forward (worsens musculoskeletal pain)</li>
                <li><strong>Cardiac Exam:</strong> Normal S1/S2, no murmurs, rubs, gallops</li>
                <li><strong>Lung Exam:</strong> Clear breath sounds bilaterally, no wheezes, rales, decreased breath sounds (rule out pneumonia, pneumothorax)</li>
            </ul>
            
            <p><strong>Electrocardiogram (ECG):</strong></p>
            <ul>
                <li><strong>Indications:</strong> All patients >30 years, cardiac risk factors, atypical features, cannot definitively rule out ACS clinically</li>
                <li><strong>Expected Findings in Musculoskeletal Pain:</strong> Normal sinus rhythm, no ST-T changes, no Q waves</li>
                <li><strong>Abnormal ECG:</strong> ST elevation/depression, T-wave inversions, new Q waves â†’ pursue cardiac workup (troponin, cardiology consult)</li>
            </ul>
            
            <p><strong>Laboratory Studies (Selective, Based on Suspicion):</strong></p>
            <ul>
                <li><strong>Troponin:</strong> NOT routinely needed for classic musculoskeletal pain in young, low-risk patients with normal ECG</li>
                <li><strong>Indications for Troponin:</strong>
                    <ul>
                        <li>Age >40 with cardiac risk factors (HTN, DM, smoking, family history)</li>
                        <li>Exertional component to pain</li>
                        <li>Any concern for ACS</li>
                        <li>Abnormal ECG</li>
                    </ul>
                </li>
                <li><strong>D-dimer:</strong> If concern for PE (dyspnea, tachycardia, hypoxia, risk factors)</li>
                <li><strong>CBC:</strong> If fever, concern for infection</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>Chest X-ray:</strong>
                    <ul>
                        <li>Indications: Trauma, concern for rib fracture, pneumothorax, or if pulmonary symptoms (cough, dyspnea)</li>
                        <li>Findings in musculoskeletal pain: Typically normal</li>
                        <li>May show rib fracture (but X-ray misses 50% of rib fractures)</li>
                        <li>NOT routinely needed for classic costochondritis</li>
                    </ul>
                </li>
                <li><strong>CT Chest:</strong> If concern for PE, aortic dissection, or to better characterize rib fractures/chest wall pathology</li>
                <li><strong>Ultrasound:</strong> Can identify rib fractures (more sensitive than X-ray), assess for pneumothorax at bedside (FAST exam)</li>
            </ul>
            
            <p><strong>Decision Tools:</strong></p>
            <ul>
                <li><strong>HEART Score (for Chest Pain Risk Stratification):</strong>
                    <ul>
                        <li>History, ECG, Age, Risk factors, Troponin</li>
                        <li>Score 0-3: Low risk (<2% MACE), consider discharge</li>
                        <li>Score 4-6: Moderate risk, admit for observation</li>
                        <li>Score â‰¥7: High risk, admit for aggressive workup</li>
                    </ul>
                </li>
                <li><strong>Reproducible Chest Pain + Normal ECG in Low-Risk Patient:</strong> Very low likelihood of ACS (<1%), can safely discharge without troponin in select cases</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Management of Musculoskeletal Chest Pain:</strong></p>
            <ul>
                <li><strong>Reassurance:</strong>
                    <ul>
                        <li>Explain that pain is from chest wall, NOT heart or lungs</li>
                        <li>Emphasize benign nature (not life-threatening)</li>
                        <li>Discuss expected course (may last days to weeks, gradual improvement)</li>
                    </ul>
                </li>
                <li><strong>Analgesia (First-Line):</strong>
                    <ul>
                        <li><strong>NSAIDs:</strong> Ibuprofen 400-600 mg PO TID or naproxen 500 mg PO BID (most effective due to anti-inflammatory properties)</li>
                        <li><strong>Acetaminophen:</strong> 650-1000 mg PO q6h (if NSAIDs contraindicated)</li>
                        <li>Typically 7-14 days course, then as needed</li>
                    </ul>
                </li>
                <li><strong>Topical Agents:</strong>
                    <ul>
                        <li>Lidocaine patches or diclofenac gel (Voltaren) applied to affected area</li>
                        <li>Heat or ice packs (whichever provides relief)</li>
                    </ul>
                </li>
                <li><strong>Activity Modification:</strong>
                    <ul>
                        <li>Avoid aggravating activities (heavy lifting, strenuous exercise) temporarily</li>
                        <li>Gentle stretching and range of motion exercises</li>
                        <li>Gradual return to normal activity as pain improves</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Specific Treatments by Diagnosis:</strong></p>
            <ul>
                <li><strong>Costochondritis / Tietze Syndrome:</strong>
                    <ul>
                        <li>NSAIDs Ã— 2-4 weeks</li>
                        <li>Reassurance (self-limited, typically resolves in weeks to months)</li>
                        <li>If refractory: Local corticosteroid injection (triamcinolone 40 mg + lidocaine into costochondral junction) by outpatient provider</li>
                    </ul>
                </li>
                <li><strong>Intercostal Muscle Strain:</strong>
                    <ul>
                        <li>NSAIDs, ice/heat, rest</li>
                        <li>Physical therapy if prolonged symptoms</li>
                    </ul>
                </li>
                <li><strong>Rib Fracture:</strong>
                    <ul>
                        <li><strong>Analgesia (Critical):</strong> Adequate pain control to prevent respiratory complications (atelectasis, pneumonia)
                            <ul>
                                <li>NSAIDs + acetaminophen scheduled (around-the-clock)</li>
                                <li>Opioids (oxycodone 5-10 mg q4-6h) if severe pain uncontrolled by NSAIDs</li>
                                <li>Consider intercostal nerve block (bupivacaine injection) for severe pain</li>
                            </ul>
                        </li>
                        <li><strong>Incentive Spirometry:</strong> Use every hour while awake to prevent atelectasis (pain â†’ shallow breathing â†’ atelectasis â†’ pneumonia)</li>
                        <li><strong>Rib Belt:</strong> NOT recommended (restricts breathing, increases pneumonia risk)</li>
                        <li><strong>Admission Indications:</strong>
                            <ul>
                                <li>Elderly (>65 years) or comorbidities (COPD, heart failure)</li>
                                <li>Multiple rib fractures (â‰¥3) or flail chest</li>
                                <li>Associated injuries (pneumothorax, hemothorax, pulmonary contusion)</li>
                                <li>Inadequate pain control or hypoxia</li>
                            </ul>
                        </li>
                        <li><strong>Discharge:</strong> Young, healthy patients with 1-2 simple rib fractures, adequate pain control, normal oxygen saturation</li>
                    </ul>
                </li>
                <li><strong>Precordial Catch Syndrome:</strong>
                    <ul>
                        <li>Reassurance only (benign, self-limited)</li>
                        <li>No treatment needed (pain lasts seconds to minutes)</li>
                        <li>Explain recurrence is common but harmless</li>
                    </ul>
                </li>
                <li><strong>Slipping Rib Syndrome:</strong>
                    <ul>
                        <li>Conservative: NSAIDs, activity modification</li>
                        <li>If refractory: Intercostal nerve block or surgical resection of hypermobile rib (rare)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li><strong>Discharge (Most Musculoskeletal Chest Pain):</strong>
                    <ul>
                        <li>Diagnosis: Musculoskeletal chest pain (costochondritis, muscle strain, etc.)</li>
                        <li>Medications: NSAIDs, acetaminophen as above</li>
                        <li>Follow-up: Primary care in 1-2 weeks if symptoms not improving</li>
                        <li><strong>Return Precautions:</strong> Worsening pain, dyspnea, fever, exertional chest pain, syncope â†’ return to ED immediately</li>
                    </ul>
                </li>
                <li><strong>Admit:</strong> Rib fractures in high-risk patients (see above), inability to rule out cardiac cause, persistent pain with concerning features</li>
            </ul>
            
            <p><strong>Follow-Up Management:</strong></p>
            <ul>
                <li><strong>Primary Care:</strong> 1-2 weeks if symptoms persist or worsen</li>
                <li><strong>Physical Therapy:</strong> For chronic or recurrent musculoskeletal pain (posture correction, strengthening, stretching)</li>
                <li><strong>Rheumatology:</strong> If suspicion for inflammatory arthritis (RA, ankylosing spondylitis) affecting costochondral joints</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Musculoskeletal Chest Pain Is the Most Common Cause in Young Patients:</strong> In patients <40 without cardiac risk factors, musculoskeletal pain accounts for 30-50% of ED chest pain presentations. Cardiac causes are rare (<5%) in this population, but must still be ruled out.</li>
            <li><strong>Reproducible Tenderness = Very Unlikely to Be Cardiac:</strong> If you can reproduce the patient's exact chest pain by palpating the chest wall, likelihood of ACS is <1-2%. This is a powerful clinical finding. However, reproducibility does NOT rule out serious causes (PE, pneumothorax still possible), so use clinical judgment.</li>
            <li><strong>Costochondritis vs Tietze Syndrome:</strong> Both cause chest wall pain and tenderness at costochondral junctions. Key difference: Tietze has visible/palpable swelling of the junction (true inflammation), while costochondritis has tenderness without swelling. Tietze is less common, affects younger patients, and typically involves only one rib (usually 2nd).</li>
            <li><strong>NSAIDs Are More Effective Than Acetaminophen:</strong> Costochondritis and other musculoskeletal pain respond better to NSAIDs (anti-inflammatory) than acetaminophen alone. Scheduled NSAIDs (not PRN) for 7-14 days provide best relief. Reserve acetaminophen for patients with NSAID contraindications (renal disease, bleeding risk, NSAID allergy).</li>
            <li><strong>Rib Fractures Can Cause Significant Morbidity:</strong> Pain from rib fractures causes splinting (shallow breathing) â†’ atelectasis â†’ pneumonia, especially in elderly. Adequate analgesia (NSAIDs + opioids if needed) and incentive spirometry are critical to prevent respiratory complications. Don't undertreated rib fracture pain.</li>
            <li><strong>X-ray Misses 50% of Rib Fractures:</strong> Plain chest X-rays have low sensitivity for rib fractures (especially non-displaced). If high suspicion but X-ray negative, consider ultrasound (more sensitive) or treat empirically. CT is gold standard but usually not necessary for clinical management.</li>
            <li><strong>Precordial Catch Syndrome = Texidor's Twinge:</strong> Sudden, sharp, fleeting chest pain lasting seconds to 3 minutes in adolescents/young adults. Left parasternal, worse with deep breathing, occurs at rest. Benign and self-limited. Just reassureâ€”no workup or treatment needed. Named after Miller and Texidor who first described it in 1955.</li>
            <li><strong>Slipping Rib Syndrome = "Hooking Maneuver":</strong> To diagnose, hook your fingers under the patient's lower costal margin (ribs 8-10) and pull anteriorly. If this reproduces pain and/or clicking sensation, positive test for slipping rib syndrome (hypermobile ribs). Conservative management usually effective.</li>
            <li><strong>Red Flags That Should Prompt Cardiac Workup:</strong> Age >40, exertional pain, radiation to jaw/arm, diaphoresis, dyspnea, cardiac risk factors (HTN, DM, smoking, family history), abnormal vital signs, abnormal ECG. Even if musculoskeletal features present, these require troponin and further evaluation.</li>
            <li><strong>Musculoskeletal Pain Can Coexist with Serious Pathology:</strong> Just because you can reproduce pain with palpation doesn't mean the patient can't also have PE, pneumothorax, or pneumonia. Use clinical gestalt. If patient looks sick, has dyspnea, hypoxia, or other concerning features, pursue appropriate workup even with chest wall tenderness.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Musculoskeletal chest pain does NOT require ICU admission</li>
                        <li>If ICU admission needed, it is for non-musculoskeletal etiology (MI, PE, dissection) that was initially missed</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Cardiac causes definitively excluded (normal ECG, negative troponin if obtained)</li>
                        <li>Pain controlled on oral NSAIDs/acetaminophen</li>
                        <li>Able to tolerate oral intake</li>
                        <li>If rib fracture: adequate pain control, normal oxygen saturation, incentive spirometry demonstrated</li>
                        <li>Patient educated on analgesic use, activity modification</li>
                        <li>Follow-up with primary care arranged if symptoms not improving in 1-2 weeks</li>
                        <li>Return precautions explained (worsening pain, dyspnea, fever, exertional chest pain)</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="diabetes-insipidus">
    <div class="page-header">
        <h2>100. DIABETES INSIPIDUS</h2>
        <div class="subtitle">Polyuria â€¢ Polydipsia â€¢ Hypernatremia â€¢ Dilute Urine</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Sudden onset of profound polyuria (>3 L/day, often 10-15 L/day) with intense thirst, preference for ice-cold water, and hypernatremia with inappropriately dilute urine (urine osmolality <300 mOsm/kg despite serum osmolality >300 mOsm/kg).</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Central DI results from inadequate ADH (vasopressin) secretion from posterior pituitary due to hypothalamic/pituitary damage. Nephrogenic DI results from renal resistance to ADH at the collecting duct level (aquaporin-2 dysfunction). Both lead to inability to concentrate urine and free water loss.</li>
                <li><strong>Risk Factors:</strong> Neurosurgery (especially transsphenoidal), traumatic brain injury, pituitary/hypothalamic tumors (craniopharyngioma, germinoma), infiltrative diseases (sarcoidosis, histiocytosis X, lymphoma), hypoxic brain injury, medications (lithium, demeclocycline, amphotericin, foscarnet), hypercalcemia, hypokalemia, pregnancy (vasopressinase), genetic (X-linked nephrogenic DI, autosomal AVPR2/AQP2 mutations)</li>
                <li><strong>Symptoms:</strong> Polyuria (large volume, dilute urine), intense thirst and polydipsia, nocturia (3-6 times/night), preference for ice-cold water, irritability, fatigue, confusion (if unable to maintain adequate intake), dehydration signs if fluid intake inadequate</li>
                <li><strong>Physical Exam:</strong> May appear normal if maintaining adequate oral intake. With inadequate intake: tachycardia, orthostatic hypotension, poor skin turgor, dry mucous membranes, altered mental status. Weight loss. Check for visual field defects (pituitary mass), signs of panhypopituitarism</li>
                <li><strong>Variants/Subtypes:</strong> Central DI (ADH deficiency) vs Nephrogenic DI (ADH resistance) vs Primary Polydipsia (psychogenic, compulsive water drinking). Triphasic response post-neurosurgery: initial DI (1-2 days), SIADH phase (days 3-10), permanent DI (>10 days). Partial DI (some residual ADH function)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Serum Sodium:</strong> Often elevated (>145 mEq/L, can be >160 mEq/L); may be normal if patient maintaining adequate intake</li>
                <li><strong>Serum Osmolality:</strong> Elevated (>300 mOsm/kg, normal 275-295); primary finding</li>
                <li><strong>Urine Osmolality:</strong> Inappropriately low (<300 mOsm/kg, often <100 mOsm/kg) despite elevated serum osmolality. Urine specific gravity <1.005</li>
                <li><strong>Urine Output:</strong> Typically >3 L/day (can be 10-20 L/day in severe cases); hourly output >200-300 mL/hr</li>
                <li><strong>24-Hour Urine Volume:</strong> Confirms polyuria; simultaneous osmolality measurement</li>
                <li><strong>Plasma ADH Level:</strong> Low/undetectable in central DI, elevated in nephrogenic DI (but test often unavailable acutely)</li>
                <li><strong>Other:</strong> BUN, creatinine, glucose (rule out hyperglycemia/DKA), calcium (hypercalcemia causes nephrogenic DI), potassium (hypokalemia causes nephrogenic DI)</li>
            </ul>
            
            <p><strong>Diagnostic Testing:</strong></p>
            <ul>
                <li><strong>Water Deprivation Test:</strong> Gold standard for diagnosis (requires close monitoring). Withhold fluids, measure hourly urine volume, osmolality, and serum osmolality. DI: urine osmolality remains <300 mOsm/kg despite rising serum osmolality >300 mOsm/kg. Then give desmopressin (DDAVP): Central DI shows >50% increase in urine osmolality; Nephrogenic DI shows <50% increase; Primary polydipsia shows already-concentrated urine before DDAVP</li>
                <li><strong>DDAVP Challenge Test:</strong> Can be done acutely in suspected DI with hypernatremia. Give desmopressin 2-4 mcg IV/SC, measure urine osmolality at 2 and 4 hours. Central DI: urine osmolality increases >600 mOsm/kg; Nephrogenic DI: minimal response</li>
                <li><strong>Copeptin Level:</strong> Emerging biomarker (stable ADH surrogate); low in central DI, elevated in nephrogenic DI</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>MRI Brain with Pituitary Protocol:</strong> Essential in central DI. Look for: loss of normal posterior pituitary "bright spot" on T1 (absent in central DI, present in nephrogenic DI and normal), hypothalamic/pituitary masses, infiltrative diseases, evidence of trauma/surgery, ectopic posterior pituitary. Evaluate entire pituitary stalk and hypothalamus</li>
                <li><strong>CT Head:</strong> If MRI contraindicated; less sensitive but can identify masses, hemorrhage, calcifications</li>
            </ul>
            
            <p><strong>Diagnostic Criteria:</strong></p>
            <ul>
                <li>DI Diagnosis: Polyuria (>3 L/24hr or >40-50 mL/kg/24hr) + dilute urine (osmolality <300 mOsm/kg) + serum hyperosmolality (>300 mOsm/kg) or hypernatremia (>145 mEq/L)</li>
                <li>Distinguish Central vs Nephrogenic: DDAVP response (>50% increase in urine osmolality = central; <50% = nephrogenic)</li>
                <li>Rule Out: Primary polydipsia (low serum osmolality), osmotic diuresis (glucose, urea, mannitol), post-obstructive diuresis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management:</strong></p>
            <ul>
                <li>Assess volume status and hemodynamics; establish IV access</li>
                <li>Strict I&O monitoring (hourly urine output initially, may need Foley catheter)</li>
                <li>Measure serum sodium, osmolality, urine osmolality STAT</li>
                <li>Calculate free water deficit: Free water deficit (L) = 0.6 Ã— body weight (kg) Ã— [(current Na/140) - 1]</li>
                <li>Allow oral free water intake if patient alert and able to drink (preferred)</li>
                <li>If hypernatremic with altered mental status or unable to drink: give hypotonic fluids IV (0.45% saline or D5W)</li>
                <li>CORRECT SODIUM SLOWLY: maximum 10-12 mEq/L per 24 hours to avoid cerebral edema (osmotic demyelination in reverse)</li>
            </ul>
            
            <p><strong>Pharmacologic Treatment (Central DI):</strong></p>
            <ul>
                <li><strong>Desmopressin (DDAVP) - First Line:</strong>
                    <ul>
                        <li>IV/SC: 1-4 mcg IV/SC q12-24h (acute); start 1-2 mcg, titrate based on response</li>
                        <li>Intranasal: 10-20 mcg (0.1-0.2 mL) once or twice daily</li>
                        <li>PO: 0.1-0.2 mg PO BID-TID (range 0.1-1.2 mg/day divided); start low, titrate up</li>
                        <li>Monitor sodium closely; risk of hyponatremia with overtreatment</li>
                    </ul>
                </li>
                <li><strong>Caution:</strong> In triphasic response post-neurosurgery, hold DDAVP during SIADH phase (days 3-10) to avoid severe hyponatremia</li>
            </ul>
            
            <p><strong>Pharmacologic Treatment (Nephrogenic DI):</strong></p>
            <ul>
                <li><strong>Thiazide Diuretics:</strong> Hydrochlorothiazide 25-50 mg PO daily. Causes mild volume depletion, increasing proximal tubule reabsorption, paradoxically reducing distal delivery and urine output by 30-50%</li>
                <li><strong>Amiloride:</strong> 5-10 mg PO BID, particularly for lithium-induced nephrogenic DI (blocks lithium entry into collecting duct cells)</li>
                <li><strong>NSAIDs:</strong> Indomethacin 50 mg PO TID, reduces GFR and increases ADH effect; use cautiously (GI/renal toxicity)</li>
                <li><strong>Low Sodium Diet:</strong> <2 g/day reduces urine output by decreasing solute excretion</li>
                <li><strong>Treat Underlying Cause:</strong> Discontinue lithium if possible, correct hypercalcemia, correct hypokalemia</li>
            </ul>
            
            <p><strong>Fluid Management:</strong></p>
            <ul>
                <li>Match urine output with free water replacement (PO preferred if possible)</li>
                <li>If IV fluids needed: D5W or 0.45% saline at rate matched to urine output losses</li>
                <li>Avoid rapid sodium correction (max 10-12 mEq/L per 24 hours)</li>
                <li>Check serum sodium q4-6h initially, then q12h once stable</li>
                <li>Daily weights to assess fluid balance</li>
            </ul>
            
            <p><strong>Endocrinology Consultation:</strong></p>
            <ul>
                <li>Consult for all cases of confirmed or suspected DI</li>
                <li>Assess for panhypopituitarism (check TSH, free T4, cortisol, LH, FSH, testosterone/estradiol, IGF-1)</li>
                <li>Central DI + anterior pituitary dysfunction suggests pituitary/hypothalamic disease</li>
                <li>Long-term management planning and DDAVP dosing adjustment</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU if: severe hypernatremia (>160 mEq/L), altered mental status, hemodynamic instability, post-neurosurgical patients, unable to maintain oral intake</li>
                <li>Floor with telemetry: moderate hypernatremia (148-160 mEq/L), new diagnosis requiring DDAVP titration, stable patients transitioning to oral therapy</li>
                <li>Discharge once: sodium normalized or stable (140-145 mEq/L), adequate oral intake maintained, DDAVP regimen established, endocrine follow-up arranged within 1-2 weeks</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Triphasic Response Post-Neurosurgery:</strong> Classic pattern after transsphenoidal surgery: (1) Initial DI (hours to 2 days) from surgical trauma/edema, (2) SIADH phase (days 3-10) from release of stored ADH from dying neurons, (3) Permanent DI (>10 days) if >80% of neurons destroyed. Must stop DDAVP during SIADH phase to avoid severe hyponatremia. About 30% develop permanent DI.</li>
            <li><strong>Loss of Posterior Pituitary Bright Spot:</strong> Normal posterior pituitary appears bright on T1 MRI (ADH-containing vesicles). In central DI, this "bright spot" is absent. In nephrogenic DI, it's present (ADH production intact). This finding is 80% sensitive for central DI. Also look for ectopic bright spot along pituitary stalk (ectopic neurohypophysis).</li>
            <li><strong>Central DI + Anterior Pituitary Dysfunction = Think Infiltrative Disease:</strong> Isolated central DI can be idiopathic or post-surgical. But if patient also has hypopituitarism (low TSH, ACTH, GH, gonadotropins), think infiltrative process: histiocytosis X (most common in children), sarcoidosis, lymphoma, metastases (especially breast, lung). Requires extensive pituitary imaging and sometimes biopsy.</li>
            <li><strong>Distinguish from Primary Polydipsia:</strong> Both cause polyuria and dilute urine, but primary polydipsia has LOW serum osmolality (<280 mOsm/kg) and LOW sodium (<138 mEq/L) from water overload. DI has HIGH serum osmolality (>300) and HIGH sodium (>145). Water deprivation test: polydipsia patients concentrate urine normally once water restricted.</li>
            <li><strong>Lithium-Induced Nephrogenic DI is Common and Often Irreversible:</strong> Occurs in 20-40% of patients on chronic lithium therapy. Lithium enters collecting duct principal cells via ENaC channels, accumulates, and downregulates aquaporin-2. Treat with amiloride (blocks ENaC, prevents lithium entry) 5-10 mg BID plus thiazide. Stopping lithium may improve but not fully resolve DI if damage is extensive (>10 years exposure).</li>
            <li><strong>Don't Overcorrect Hypernatremia Too Rapidly:</strong> Rapid sodium correction in DI can cause cerebral edema (reverse osmotic demyelination). The brain adapts to chronic hypernatremia by accumulating organic osmolytes. Rapid lowering of serum osmolality causes water shift into brain cells. Maximum correction rate: 10-12 mEq/L per 24 hours (0.5 mEq/L per hour). In chronic severe hypernatremia, consider 6-8 mEq/L per 24 hours.</li>
            <li><strong>Hypovolemic Patients May Not Show Severe Polyuria Initially:</strong> If patient is volume-depleted on presentation, reduced GFR may mask the full extent of polyuria. After IV fluid resuscitation, urine output may suddenly increase dramatically to 500-1000 mL/hour as GFR improves and the DI becomes clinically apparent. Anticipate this and have DDAVP ready.</li>
            <li><strong>Intranasal DDAVP Can Be Unreliable:</strong> Intranasal desmopressin absorption varies with nasal congestion, rhinitis, or upper respiratory infections. If patient not responding to intranasal DDAVP, switch to oral or SC route. Oral bioavailability is only 5-10% (vs 10-20% intranasal), so oral dose is 10-20 times higher than intranasal dose.</li>
            <li><strong>Risk of Hyponatremia with DDAVP Overtreatment:</strong> DDAVP has long half-life (8-12 hours for IV, 12-24 hours for oral). Giving too much or too frequently without allowing kidney to excrete free water causes dilutional hyponatremia. Monitor sodium q6-12h during dose titration. If Na drops below 135 mEq/L, hold next dose and allow natural diuresis to occur.</li>
            <li><strong>Nephrogenic DI from Hypercalcemia or Hypokalemia:</strong> Hypercalcemia (>11 mg/dL) causes nephrogenic DI by impairing collecting duct response to ADH and causing interstitial nephropathy. Hypokalemia (<3.0 mEq/L) downregulates aquaporin-2. Always check and correct calcium and potassium in patients with polyuria. Correcting the electrolyte abnormality often resolves the DI without need for specific DI treatment.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Severe hypernatremia (serum sodium >160 mEq/L)</li>
            <li>Altered mental status, confusion, seizures</li>
            <li>Hemodynamic instability (hypotension, tachycardia unresponsive to fluids)</li>
            <li>Post-neurosurgical patient (especially within 10 days of transphenoidal surgery)</li>
            <li>Urine output >500 mL/hour despite treatment</li>
            <li>Unable to maintain adequate oral intake despite thirst</li>
            <li>Rapid sodium changes requiring frequent monitoring and IV fluid adjustments</li>
            <li>Suspected panhypopituitarism with adrenal crisis</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Serum sodium normalized (138-145 mEq/L) or stable near-normal range</li>
            <li>Urine output controlled (<3 L/day) on DDAVP regimen</li>
            <li>Patient able to maintain adequate oral fluid intake (matching urine losses)</li>
            <li>Patient and family educated on DDAVP administration (timing, dose, route)</li>
            <li>Patient educated on monitoring for signs of overtreatment (hyponatremia: headache, nausea, confusion)</li>
            <li>Patient educated on monitoring for signs of undertreatment (recurrent polyuria, thirst)</li>
            <li>Endocrinology follow-up arranged within 1-2 weeks for DDAVP titration</li>
            <li>MRI brain completed (if central DI) or scheduled as outpatient</li>
            <li>If post-neurosurgical: cleared by neurosurgery, aware of triphasic response potential</li>
            <li>Written instructions including when to call doctor (urine output >4 L/day, severe thirst, confusion, headache)</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="pheo">
    <div class="page-header">
        <h2>101. PHEOCHROMOCYTOMA CRISIS</h2>
        <div class="subtitle">Hypertensive Emergency â€¢ Catecholamine Excess â€¢ Palpitations â€¢ Diaphoresis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Paroxysmal or sustained severe hypertension (BP often >220/120 mmHg) with episodic triad of severe headache, profuse diaphoresis, and palpitations, often triggered by anesthesia, surgery, medications (metoclopramide, opioids), or tumor manipulation.</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Catecholamine-secreting tumor of chromaffin cells (90% adrenal medulla, 10% extra-adrenal paragangliomas). Excessive release of epinephrine, norepinephrine, and/or dopamine causes severe hypertension, tachycardia, and hypermetabolic state. Crisis can be triggered by direct tumor stimulation (palpation, surgery, biopsy), medications, or spontaneous massive catecholamine release. Can cause catecholamine-induced cardiomyopathy (Takotsubo-like), cerebrovascular events, or multiorgan failure.</li>
                <li><strong>Risk Factors:</strong> Genetic syndromes: MEN 2A/2B (RET mutation), VHL syndrome (VHL gene), NF1 (neurofibromatosis type 1), familial paraganglioma syndromes (SDH gene mutations). About 40% of pheochromocytomas are hereditary. Known adrenal mass. Family history of pheochromocytoma or paraganglioma. History of refractory hypertension</li>
                <li><strong>Symptoms - Classic Triad (present in 50%):</strong> (1) Severe, pounding, occipital headache, (2) Profuse diaphoresis (soaking through clothes), (3) Palpitations or chest tightness. Other symptoms: Anxiety, sense of impending doom, pallor, tremor, nausea/vomiting, abdominal pain, chest pain (angina from coronary vasospasm), dyspnea. Episodes last minutes to hours, can occur multiple times daily or weekly</li>
                <li><strong>Physical Exam:</strong> Severe hypertension (often >220/120 mmHg, can be >300/150 mmHg in crisis), wide pulse pressure, tachycardia (HR 100-140), orthostatic hypotension (paradoxical - volume depletion from pressure natriuresis), pallor or flushing, diaphoresis, tremor, fever, retinopathy on fundoscopy (hypertensive changes), abdominal mass (if large tumor), cafÃ©-au-lait spots (NF1), thyroid nodules (MEN 2)</li>
                <li><strong>Variants/Subtypes:</strong> Pheochromocytoma (adrenal) vs Paraganglioma (extra-adrenal: bladder, organ of Zuckerkandl, thorax). Benign vs malignant (10% are malignant - metastases to bone, liver, lung, lymph nodes). Predominantly norepinephrine-secreting (sustained hypertension) vs epinephrine-secreting (paroxysmal hypertension with hypotension between episodes). Dopamine-secreting (rare, often malignant, may have normal BP)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies - Biochemical Testing (Definitive Diagnosis):</strong></p>
            <ul>
                <li><strong>Plasma Free Metanephrines:</strong> MOST SENSITIVE TEST (96-99% sensitivity). Measure plasma-free metanephrine and normetanephrine. Normal <0.5 nmol/L; >4 times upper limit of normal (ULN) is diagnostic. Draw with patient supine for 20 minutes. Nearly 100% negative predictive value - normal level rules out pheo</li>
                <li><strong>24-Hour Urine Fractionated Metanephrines and Catecholamines:</strong> Measure metanephrine, normetanephrine, epinephrine, norepinephrine, dopamine. >2 times ULN strongly suggests pheo. More specific than plasma testing but less sensitive. Interfering substances: acetaminophen, MAO inhibitors, tricyclic antidepressants</li>
                <li><strong>Plasma Catecholamines:</strong> Norepinephrine >2000 pg/mL highly suggestive. Less sensitive than metanephrines. Must be drawn during symptomatic episode for best yield</li>
                <li><strong>Chromogranin A:</strong> Elevated in most neuroendocrine tumors; non-specific but supports diagnosis. False elevation with PPI use</li>
                <li><strong>Supporting Labs:</strong> Hyperglycemia (catecholamine-induced insulin resistance), hypokalemia (increased renin), elevated hematocrit (volume contraction), leukocytosis, elevated calcium (MEN 2A with hyperparathyroidism)</li>
            </ul>
            
            <p><strong>Imaging - Tumor Localization:</strong></p>
            <ul>
                <li><strong>CT Abdomen/Pelvis with Contrast:</strong> First-line anatomic imaging. Pheochromocytomas appear as heterogeneous, enhancing adrenal masses 3-10 cm, often with areas of necrosis/hemorrhage. Measure Hounsfield units: typically >10 HU (distinguish from adenoma). Sensitivity 90-95% for adrenal tumors. Caution: IV contrast can precipitate crisis (ensure alpha blockade first)</li>
                <li><strong>MRI Abdomen:</strong> Preferred if CT contraindicated or in pregnancy. Characteristic "lightbulb" bright appearance on T2-weighted images (sensitivity 90-100%). Better for extra-adrenal paragangliomas and metastatic disease. No contrast-induced crisis risk</li>
                <li><strong>Functional Imaging (if biochemically positive but CT/MRI negative):</strong>
                    <ul>
                        <li><strong>I-123 MIBG Scan:</strong> Metaiodobenzylguanidine scintigraphy. Taken up by chromaffin cells. Sensitivity 80-90%, specificity 95-100%. Best for detecting metastatic disease and extra-adrenal paragangliomas</li>
                        <li><strong>FDG-PET:</strong> High sensitivity for malignant pheo and paragangliomas (especially SDH mutations)</li>
                        <li><strong>Ga-68 DOTATATE PET:</strong> Emerging modality with high sensitivity for SDH-mutated tumors</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Cardiac Evaluation:</strong></p>
            <ul>
                <li><strong>ECG:</strong> Sinus tachycardia, LVH, ST-T wave changes, QT prolongation, rarely MI pattern</li>
                <li><strong>Echocardiogram:</strong> Assess for catecholamine-induced cardiomyopathy (Takotsubo pattern with apical ballooning), LVH, systolic/diastolic dysfunction, valvular disease. Important for preoperative risk stratification</li>
                <li><strong>Troponin:</strong> May be elevated (myocardial strain, type 2 MI from demand ischemia)</li>
            </ul>
            
            <p><strong>Genetic Testing:</strong></p>
            <ul>
                <li>Recommended for all patients with pheochromocytoma/paraganglioma (40% have germline mutations)</li>
                <li>Test for: RET (MEN 2), VHL, NF1, SDHB, SDHD, TMEM127, MAX genes</li>
                <li>Genetic counseling referral for positive results</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management (Acute Crisis):</strong></p>
            <ul>
                <li>Transfer to ICU immediately; continuous cardiac monitoring and arterial line</li>
                <li>IV access (two large-bore IVs); avoid palpating abdomen (can trigger catecholamine release)</li>
                <li>ECG, cardiac enzymes, strict I&O</li>
                <li>Goal BP: <160/100 mmHg acutely, then gradual reduction to <140/90 mmHg</li>
                <li>NEVER give beta-blockers before alpha blockade (can cause unopposed alpha vasoconstriction and hypertensive crisis)</li>
            </ul>
            
            <p><strong>Pharmacologic Treatment - Acute Hypertensive Crisis:</strong></p>
            <ul>
                <li><strong>Phentolamine (Alpha-Blocker) - FIRST LINE for acute crisis:</strong>
                    <ul>
                        <li>Give 5-10 mg IV bolus, repeat q5-15min as needed</li>
                        <li>Or infusion: 0.5-1 mg/min IV, titrate to BP goal</li>
                        <li>Non-selective alpha-1 and alpha-2 antagonist, rapid onset (1-2 min), short duration (10-15 min)</li>
                    </ul>
                </li>
                <li><strong>Nicardipine (CCB) - Alternative or Adjunct:</strong>
                    <ul>
                        <li>Start 5 mg/hr IV infusion, titrate by 2.5 mg/hr q5-15min (max 15 mg/hr)</li>
                        <li>Good for BP control without reflex tachycardia</li>
                    </ul>
                </li>
                <li><strong>Sodium Nitroprusside:</strong>
                    <ul>
                        <li>0.5-10 mcg/kg/min IV infusion, titrate to BP goal</li>
                        <li>Effective but short-acting, requires close monitoring, cyanide toxicity risk if prolonged use</li>
                    </ul>
                </li>
                <li><strong>After Alpha Blockade, Add Beta-Blocker ONLY if tachycardia (HR >110):</strong>
                    <ul>
                        <li>Esmolol 50-200 mcg/kg/min IV infusion (short-acting, easily titratable)</li>
                        <li>Or labetalol 10-20 mg IV bolus q10min (but has alpha:beta ratio of 1:7, less ideal)</li>
                    </ul>
                </li>
                <li><strong>Volume Resuscitation:</strong> IV crystalloids 1-2 L bolus. Patients are often volume-depleted from chronic pressure natriuresis despite elevated BP</li>
            </ul>
            
            <p><strong>Preoperative Medical Preparation (Once Diagnosis Confirmed):</strong></p>
            <ul>
                <li><strong>Phenoxybenzamine (Non-Selective Alpha Blocker) - Gold Standard:</strong>
                    <ul>
                        <li>Start 10 mg PO BID, increase by 10-20 mg/day every 2-3 days</li>
                        <li>Target dose: 1 mg/kg/day divided BID-TID (typical 40-100 mg/day)</li>
                        <li>Goal: BP <140/90 mmHg with orthostatic hypotension (SBP drop >20 mmHg on standing)</li>
                        <li>Duration: Minimum 10-14 days before surgery</li>
                        <li>Long-acting (24-48 hrs), irreversible alpha blockade</li>
                    </ul>
                </li>
                <li><strong>Doxazosin or Prazosin (Selective Alpha-1 Blockers) - Alternative:</strong>
                    <ul>
                        <li>Doxazosin: Start 2 mg PO daily, titrate up to 16-32 mg daily</li>
                        <li>Shorter-acting, fewer side effects, but may be less effective for crisis prevention</li>
                    </ul>
                </li>
                <li><strong>Beta-Blocker (Add AFTER adequate alpha blockade):</strong>
                    <ul>
                        <li>Atenolol 25-50 mg PO daily or Metoprolol 25-50 mg PO BID</li>
                        <li>For persistent tachycardia (HR >90) or arrhythmias</li>
                    </ul>
                </li>
                <li><strong>CCB (If additional BP control needed):</strong>
                    <ul>
                        <li>Amlodipine 5-10 mg PO daily or Nifedipine XL 30-90 mg daily</li>
                    </ul>
                </li>
                <li><strong>High-Salt Diet:</strong> Encourage salt intake to expand intravascular volume</li>
            </ul>
            
            <p><strong>Definitive Treatment - Surgical Resection:</strong></p>
            <ul>
                <li>Laparoscopic adrenalectomy is treatment of choice for pheochromocytoma</li>
                <li>Open surgery if large tumor (>6 cm), malignant, or extra-adrenal paraganglioma</li>
                <li>Timing: Delay surgery until adequate preoperative alpha/beta blockade (10-14 days minimum)</li>
                <li>Perioperative management: Continue alpha-blocker until morning of surgery, have phentolamine available intraoperatively, anticipate hypotension post-tumor removal (loss of catecholamines), IV fluids 2-3 L perioperatively</li>
            </ul>
            
            <p><strong>Consultations:</strong></p>
            <ul>
                <li><strong>Endocrinology:</strong> Immediate consult for diagnosis confirmation, biochemical testing, preoperative optimization</li>
                <li><strong>Surgery (Endocrine Surgery):</strong> For definitive resection planning</li>
                <li><strong>Anesthesiology:</strong> Early involvement for perioperative planning (high-risk surgery)</li>
                <li><strong>Cardiology:</strong> If cardiomyopathy, severe arrhythmias, or CAD</li>
                <li><strong>Genetics:</strong> For germline mutation testing and family counseling</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: All patients in hypertensive crisis, catecholamine-induced cardiomyopathy, or perioperative period</li>
                <li>Floor with telemetry: Stable patients undergoing preoperative alpha/beta blockade titration</li>
                <li>Discharge: Only after successful tumor resection, postoperative recovery, stable BP off pressors, and confirmed biochemical cure (plasma metanephrines normalized 2-6 weeks post-op)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Never Beta-Block Before Alpha-Blockade ("Rule of Alpha First"):</strong> Giving beta-blocker first causes unopposed alpha-receptor stimulation (vasoconstriction), precipitating severe hypertensive crisis, potentially fatal. Always establish alpha blockade first, then add beta-blocker only if needed for tachycardia. Think: "A before B in the alphabet, alpha before beta in pheo."</li>
            <li><strong>The Classic Triad is Only 50% Sensitive:</strong> Headache + diaphoresis + palpitations occur together in only half of cases. Many patients present with isolated sustained hypertension without paroxysms. High index of suspicion needed: young patient with severe refractory hypertension, hypertension with orthostatic hypotension (paradoxical), hypertension triggered by anesthesia/surgery. The "rule of 10s": 10% extra-adrenal, 10% bilateral, 10% malignant, 10% in children, 10% familial (actually now 40%).</li>
            <li><strong>Plasma Free Metanephrines Have Near-Perfect Negative Predictive Value:</strong> Normal plasma-free metanephrines essentially rule out pheochromocytoma (NPV >99%). If high clinical suspicion but negative test, repeat testing after 6 months. Metanephrines (breakdown products of catecholamines) are continuously produced by tumor, whereas catecholamines are released episodically, making metanephrines more reliable screening test than catecholamines.</li>
            <li><strong>40% Are Hereditary - All Patients Need Genetic Testing:</strong> Previously thought rare, but germline mutations found in 40% of pheochromocytomas/paragangliomas. Most common: RET (MEN 2A/2B: medullary thyroid cancer + pheo + hyperparathyroidism), VHL (VHL syndrome: CNS/retinal hemangioblastomas + RCC + pheo), NF1 (cafÃ©-au-lait spots + neurofibromas), SDH mutations (familial paraganglioma). Genetic testing guides surveillance for syndromic features and family screening.</li>
            <li><strong>Orthostatic Hypotension in Hypertensive Patient is a Red Flag:</strong> Paradoxical finding: severe hypertension when supine but orthostatic drop >20 mmHg when standing. Caused by chronic catecholamine-induced pressure natriuresis leading to volume depletion and downregulated baroreceptor reflexes. If you see this combination (hypertension + orthostatic hypotension), think pheo until proven otherwise.</li>
            <li><strong>Perioperative Management is High-Risk:</strong> Tumor manipulation during surgery causes massive catecholamine release, risking hypertensive crisis, arrhythmias, MI, stroke. After tumor removal, BP can crash (loss of catecholamine drive, residual alpha blockade). Requires experienced anesthesia team with arterial line, have phentolamine boluses ready for intraoperative spikes, and anticipate need for 2-3 L IV fluids and possible pressors (norepinephrine) post-resection.</li>
            <li><strong>Phenoxybenzamine Causes Orthostatic Hypotension - That's the Goal:</strong> When titrating preoperative alpha blockade with phenoxybenzamine, target is not just BP <140/90 but achieving orthostatic hypotension (SBP drop >20 mmHg on standing). This indicates adequate alpha blockade and volume expansion has occurred. Patients need to increase salt/fluid intake during this period. Orthostasis confirms readiness for surgery.</li>
            <li><strong>Labetalol is NOT Ideal for Pheo Crisis:</strong> Despite being an alpha/beta blocker, labetalol has 1:7 alpha:beta ratio (much more beta blockade). In pheo crisis, this can worsen hypertension via unopposed alpha stimulation. Prefer pure alpha-blockers (phentolamine) followed by pure beta-blockers (esmolol) if needed. Labetalol can be used once adequate alpha blockade established, but not first-line.</li>
            <li><strong>Catecholamine-Induced Cardiomyopathy Can Mimic MI:</strong> Takotsubo (stress) cardiomyopathy pattern: apical ballooning, ST elevations, troponin elevation, but normal coronary arteries on angiography. Caused by catecholamine myocardial toxicity. Can also see true type 2 MI from demand ischemia. Echo shows wall motion abnormalities that typically resolve after tumor resection. Cardiac MRI can help distinguish from acute MI.</li>
            <li><strong>Lifelong Surveillance Required After "Cure":</strong> Even after complete tumor resection and biochemical cure, 5-15% recurrence rate over 10-20 years. Annual plasma metanephrine testing required indefinitely. Malignant pheochromocytomas (10%) can recur after many years. Hereditary cases require more intensive surveillance (imaging every 1-2 years). "Cure" is never truly confirmed - it's a lifetime diagnosis requiring ongoing monitoring.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Hypertensive emergency (BP >220/120 mmHg with end-organ damage)</li>
            <li>Hypertensive crisis requiring IV antihypertensive drip (phentolamine, nicardipine, nitroprusside)</li>
            <li>Acute coronary syndrome (chest pain, ECG changes, troponin elevation)</li>
            <li>Catecholamine-induced cardiomyopathy (Takotsubo, heart failure, pulmonary edema)</li>
            <li>Cerebrovascular event (stroke, hypertensive encephalopathy, seizures)</li>
            <li>Tachydysrhythmias (atrial fibrillation, ventricular tachycardia)</li>
            <li>Perioperative patients (during tumor resection or immediate post-op period)</li>
            <li>Suspected pheochromocytoma crisis triggered by surgery/anesthesia</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Successful tumor resection completed</li>
            <li>Postoperative recovery complete (typically 3-5 days)</li>
            <li>BP controlled (<140/90 mmHg) off IV medications, on oral regimen or no medications</li>
            <li>No ongoing chest pain, dyspnea, or neurologic symptoms</li>
            <li>Plasma metanephrines drawn 2 weeks post-op showing normalization (confirms cure)</li>
            <li>Patient educated on symptoms of recurrence (5-15% recurrence risk)</li>
            <li>Endocrinology follow-up scheduled for 6-12 weeks for repeat biochemical testing</li>
            <li>Genetic testing results discussed or scheduled for outpatient</li>
            <li>Family members referred for screening if hereditary syndrome identified</li>
            <li>Annual surveillance with plasma metanephrines arranged (lifelong monitoring required)</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="acute-diarrhea">
    <div class="page-header">
        <h2>102. SEVERE ACUTE DIARRHEA / VOLUME DEPLETION</h2>
        <div class="subtitle">Frequent Watery Stools â€¢ Dehydration â€¢ Electrolyte Abnormalities â€¢ Acute Kidney Injury</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Abrupt onset of â‰¥3 loose/watery stools per day lasting <14 days, often with nausea, vomiting, abdominal cramping, and signs of volume depletion (tachycardia, orthostatic hypotension, decreased urine output, acute kidney injury).</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Infectious (bacterial, viral, parasitic), medication-induced (antibiotics causing C. difficile), inflammatory, osmotic, or secretory mechanisms causing increased intestinal fluid secretion and decreased absorption. Volume depletion results from GI losses exceeding oral intake, with secondary renal hypoperfusion causing prerenal AKI. Electrolyte losses (Na, K, bicarbonate) can cause metabolic acidosis and dysrhythmias.</li>
                <li><strong>Risk Factors:</strong> Recent antibiotic use (C. difficile), recent travel (traveler's diarrhea), immunosuppression (HIV, chemotherapy, transplant), contaminated food/water, nursing home residence, hospitalization, inflammatory bowel disease, diabetes (autonomic neuropathy), laxative abuse, elderly age, chronic kidney disease</li>
                <li><strong>Symptoms:</strong> Frequent loose/watery stools (>3/day, can be 10-20/day in severe cases), abdominal cramping, nausea, vomiting, fever (infectious), tenesmus, fecal urgency, fecal incontinence, thirst, dizziness, weakness, decreased urine output, confusion (elderly)</li>
                <li><strong>Physical Exam:</strong> Tachycardia, orthostatic vital signs (BP drop >20 mmHg systolic or HR increase >20 bpm on standing), hypotension (if severe), dry mucous membranes, decreased skin turgor, delayed capillary refill, cool extremities, decreased urine output, altered mental status, abdominal tenderness (diffuse or focal), hyperactive bowel sounds, occult blood on rectal exam (inflammatory/invasive diarrhea)</li>
                <li><strong>Variants/Subtypes:</strong> Watery diarrhea (most common: viral, ETEC, cholera) vs Inflammatory/Bloody diarrhea (Shigella, Campylobacter, Salmonella, EHEC, C. difficile, IBD flare). Secretory (persists with fasting: VIPoma, carcinoid) vs Osmotic (stops with fasting: lactose intolerance, sorbitol). Hospital-acquired vs Community-acquired</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Basic Metabolic Panel:</strong> Assess volume status and electrolytes. Expect: elevated BUN/Cr ratio >20:1 (prerenal AKI), hyponatremia or hypernatremia, hypokalemia (<3.0 mEq/L common), non-anion gap metabolic acidosis (bicarbonate loss in stool), elevated creatinine</li>
                <li><strong>Complete Blood Count:</strong> Leukocytosis (bacterial infection), bandemia (sepsis), hemoconcentration (elevated Hgb/Hct if volume depleted), thrombocytosis (IBD), eosinophilia (parasites)</li>
                <li><strong>Lactate:</strong> Elevated if hypoperfusion, sepsis, or mesenteric ischemia. Lactate >4 mmol/L concerning for severe sepsis</li>
                <li><strong>Urinalysis:</strong> Concentrated urine (specific gravity >1.020), elevated urine sodium if volume depleted, urine osmolality >450 mOsm/kg</li>
                <li><strong>Stool Studies (if indicated):</strong>
                    <ul>
                        <li>C. difficile PCR (if antibiotic use within 3 months or healthcare exposure)</li>
                        <li>Stool culture (if fever >38.5Â°C, bloody diarrhea, severe illness, immunocompromised)</li>
                        <li>Stool ova & parasites (if travel history, persistent diarrhea >7 days)</li>
                        <li>Giardia/Cryptosporidium antigen (immunocompromised, waterborne exposure)</li>
                        <li>Fecal leukocytes or lactoferrin (suggests inflammatory diarrhea)</li>
                        <li>Fecal occult blood</li>
                    </ul>
                </li>
                <li><strong>Blood Cultures:</strong> If fever, severe illness, immunocompromised, signs of bacteremia/sepsis</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>CT Abdomen/Pelvis with IV Contrast:</strong> Indicated if severe abdominal pain, peritoneal signs, concern for toxic megacolon, ischemic colitis, colonic perforation, intra-abdominal abscess. Findings: colonic wall thickening (C. difficile, CMV colitis), pneumatosis, free air (perforation), "thumbprinting" (ischemic colitis)</li>
                <li><strong>Abdominal X-ray:</strong> If concern for toxic megacolon (colon diameter >6 cm), obstruction, free air</li>
            </ul>
            
            <p><strong>Endoscopy:</strong></p>
            <ul>
                <li><strong>Colonoscopy:</strong> Consider if bloody diarrhea of unclear etiology, suspected IBD flare, persistent diarrhea despite treatment, immunocompromised. Can visualize pseudomembranes (C. difficile), ulcerations (CMV, IBD), ischemia. Caution in acute severe colitis (perforation risk)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management:</strong></p>
            <ul>
                <li>Assess hemodynamic stability (orthostatic vitals, BP, HR)</li>
                <li>Establish IV access (two large-bore IVs if severe dehydration or hypotensive)</li>
                <li>Volume resuscitation: LR or NS 1-2 L bolus, reassess, repeat as needed</li>
                <li>Goal: normalize BP, HR <100, urine output >0.5 mL/kg/hr</li>
                <li>Monitor strict I&O (consider Foley catheter if critically ill)</li>
                <li>Contact isolation precautions if suspected infectious diarrhea</li>
            </ul>
            
            <p><strong>Fluid and Electrolyte Replacement:</strong></p>
            <ul>
                <li><strong>Oral Rehydration Solution (ORS) - Preferred if mild-moderate dehydration and tolerating PO:</strong> WHO-ORS formula or commercial products (Pedialyte). Contains glucose and sodium for coupled absorption. Goal: 50-100 mL/kg over 2-4 hours</li>
                <li><strong>IV Fluid Resuscitation - If severe dehydration, unable to tolerate PO, or hypotensive:</strong> 
                    <ul>
                        <li>Lactated Ringer's or 0.9% saline 1-2 L bolus initially</li>
                        <li>Continue IV fluids at 150-250 mL/hr, adjust based on ongoing losses</li>
                        <li>Match ongoing stool losses with IV fluids (may require 3-6 L/day)</li>
                    </ul>
                </li>
                <li><strong>Potassium Replacement:</strong> Most patients need K+ repletion. If K <3.0 mEq/L: give 40-80 mEq PO or 20-40 mEq IV (max rate 10 mEq/hr via peripheral line, 20 mEq/hr via central line). Check K q4-6h</li>
                <li><strong>Bicarbonate:</strong> Usually corrects with volume resuscitation. If severe acidosis (pH <7.2, HCO3 <10), consider sodium bicarbonate</li>
                <li><strong>Magnesium Replacement:</strong> Check and replace if Mg <1.5 mg/dL (2-4 g IV over 4 hours)</li>
            </ul>
            
            <p><strong>Antimicrobial Therapy (if indicated):</strong></p>
            <ul>
                <li><strong>C. difficile Infection:</strong> 
                    <ul>
                        <li>Fidaxomicin 200 mg PO BID x 10 days (preferred, lower recurrence)</li>
                        <li>Or Vancomycin 125 mg PO QID x 10 days</li>
                        <li>If fulminant/severe (WBC >15k, Cr â‰¥1.5x baseline, hypotension, ileus, toxic megacolon): Vancomycin 500 mg PO/NG QID + Metronidazole 500 mg IV q8h</li>
                        <li>Stop offending antibiotic if possible</li>
                    </ul>
                </li>
                <li><strong>Campylobacter:</strong> Azithromycin 500 mg daily x 3 days (if severe or immunocompromised)</li>
                <li><strong>Shigella:</strong> Ciprofloxacin 500 mg BID x 3 days or Azithromycin 500 mg daily x 3 days</li>
                <li><strong>Salmonella (non-typhi):</strong> Usually self-limited, antibiotics only if bacteremia, immunocompromised, or age >50 with high risk. Ciprofloxacin 500 mg BID x 7 days</li>
                <li><strong>Giardia:</strong> Metronidazole 250 mg TID x 5-7 days or Tinidazole 2 g single dose</li>
                <li><strong>Cryptosporidium:</strong> Nitazoxanide 500 mg BID x 3 days (immunocompetent); no effective treatment if HIV/immunocompromised (improve immune status)</li>
                <li><strong>Do NOT use antibiotics for EHEC/STEC (E. coli O157:H7):</strong> Increases risk of hemolytic uremic syndrome (HUS)</li>
            </ul>
            
            <p><strong>Symptomatic Management:</strong></p>
            <ul>
                <li><strong>Antimotility Agents - Use with EXTREME CAUTION:</strong>
                    <ul>
                        <li>Loperamide 4 mg initial, then 2 mg after each loose stool (max 16 mg/day)</li>
                        <li>CONTRAINDICATIONS: bloody diarrhea, fever >38.5Â°C, C. difficile, EHEC/STEC, severe colitis (risk of toxic megacolon)</li>
                        <li>Generally safe for uncomplicated watery diarrhea</li>
                    </ul>
                </li>
                <li><strong>Antiemetics:</strong> Ondansetron 4-8 mg IV/PO q8h PRN</li>
                <li><strong>Probiotics:</strong> Lactobacillus or Saccharomyces boulardii may reduce duration; evidence mixed</li>
            </ul>
            
            <p><strong>Nutrition:</strong></p>
            <ul>
                <li>Continue normal diet as tolerated; avoid prolonged fasting (delays recovery)</li>
                <li>BRAT diet (bananas, rice, applesauce, toast) is outdated - normal diet preferred</li>
                <li>Avoid dairy temporarily if lactose intolerance suspected</li>
                <li>Encourage oral fluids with electrolytes</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Septic shock, severe electrolyte disturbances, toxic megacolon, fulminant C. difficile</li>
                <li>Floor: Moderate-severe volume depletion requiring IV fluids, unable to tolerate adequate PO intake, elderly with comorbidities, AKI requiring monitoring</li>
                <li>Discharge: Mild-moderate diarrhea, tolerating PO, hemodynamically stable, improving symptoms, able to follow-up</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>BUN/Cr Ratio >20:1 Suggests Prerenal AKI from Volume Depletion:</strong> In severe diarrhea, GI losses cause hypovolemia and renal hypoperfusion. BUN rises disproportionately to creatinine due to increased proximal tubule urea reabsorption. Ratio >20:1 (e.g., BUN 60, Cr 2.0 = ratio 30:1) indicates prerenal etiology. After adequate IV fluid resuscitation, ratio normalizes (<15:1) and creatinine improves, confirming prerenal diagnosis.</li>
            <li><strong>Don't Withhold Antimotility Agents in All Cases - Know Your Contraindications:</strong> Loperamide is safe and effective for uncomplicated watery diarrhea (viral, traveler's diarrhea from ETEC). Absolute contraindications: bloody diarrhea, high fever (>38.5Â°C), suspected C. difficile, EHEC/STEC (E. coli O157:H7), severe colitis/IBD flare. Risk is precipitating toxic megacolon or prolonging infection by slowing bacterial clearance. If watery diarrhea without red flags, antimotility is appropriate and improves quality of life.</li>
            <li><strong>Antibiotics for EHEC/STEC (E. coli O157:H7) Increase Risk of HUS:</strong> Enterohemorrhagic E. coli (O157:H7 and other Shiga toxin-producing E. coli) causes bloody diarrhea, often from undercooked beef or contaminated produce. Antibiotics trigger Shiga toxin release, increasing risk of hemolytic uremic syndrome (HUS): microangiopathic hemolytic anemia, thrombocytopenia, AKI, can be fatal. If bloody diarrhea and suspect STEC: do NOT give antibiotics, send stool for Shiga toxin PCR, monitor CBC and renal function for HUS development (days 5-7 of illness).</li>
            <li><strong>Oral Rehydration Solution (ORS) is as Effective as IV Fluids for Mild-Moderate Dehydration:</strong> WHO-ORS contains precise glucose:sodium ratio (2:1) to maximize coupled absorption via SGLT1 transporters in small intestine. Glucose-facilitated sodium absorption pulls water into bloodstream. Equally effective as IV fluids if patient can tolerate oral intake, cheaper, no IV complications. Give 50-100 mL/kg over 2-4 hours. Transition to ORS from IV fluids as soon as patient tolerating PO.</li>
            <li><strong>Fulminant C. difficile Requires Dual Therapy (PO Vancomycin + IV Metronidazole):</strong> Severe/fulminant C. diff defined by: WBC >15k, Cr â‰¥1.5x baseline, hypotension, ileus, or toxic megacolon. Oral vancomycin alone may not reach colon if ileus present. Add IV metronidazole 500 mg q8h to ensure colonic antibiotic levels. If ileus: give vancomycin via NGT (500 mg QID) or rectal enema (vancomycin 500 mg in 100 mL NS q6h). Early surgical consultation for toxic megacolon or perforation (mortality 50% without colectomy).</li>
            <li><strong>Severe Hypokalemia is Common and Dangerous:</strong> Diarrhea causes massive potassium losses (normal stool K 75-90 mEq/L; diarrhea can lose 300+ mEq/day). Hypokalemia <3.0 mEq/L causes cardiac arrhythmias (prolonged QT, torsades de pointes), muscle weakness, ileus. Aggressively replace: if K 2.5-3.0, give 40-80 mEq PO; if K <2.5, give 40 mEq IV over 4 hours (central line preferred if giving >10 mEq/hr). Check K q4-6h until >3.5 mEq/L. Most patients need 120-200 mEq total replacement.</li>
            <li><strong>Lactate Elevation Can Be from Hypoperfusion, Sepsis, or Metformin + AKI:</strong> In severe diarrhea with volume depletion, lactate >2-4 mmol/L can result from tissue hypoperfusion (prerenal state), sepsis (if bacteremia), or lactic acidosis from metformin accumulation if AKI present (metformin renally excreted). Distinguish: if hypoperfusion alone, lactate clears with IV fluids; if sepsis, remains elevated and patient appears toxic; if metformin-induced, lactate very high (>10 mmol/L), hold metformin, consider dialysis if severe.</li>
            <li><strong>Non-Anion Gap Metabolic Acidosis is Expected in Diarrhea:</strong> Stool contains bicarbonate (20-40 mEq/L). Massive diarrhea causes bicarbonate loss, resulting in hyperchloremic non-anion gap metabolic acidosis (NAGMA). Example: pH 7.28, HCO3 14, Cl 112, anion gap 14 (normal). Distinguish from anion gap acidosis (lactic acidosis, ketoacidosis) which suggests more ominous process. NAGMA in diarrhea is expected and corrects with volume resuscitation and treating underlying cause.</li>
            <li><strong>Immunocompromised Patients Need Broader Stool Workup:</strong> HIV/AIDS (CD4 <200), chemotherapy, transplant, chronic steroids are at risk for atypical infections. Send expanded stool panel: CMV PCR/culture (most common in HIV), Mycobacterium avium complex (MAC), Cryptosporidium, Microsporidia, Cyclospora, Isospora. Consider colonoscopy with biopsies. CMV colitis: hemorrhagic colitis with ulcerations, treat with ganciclovir 5 mg/kg IV q12h. MAC: watery diarrhea, abdominal pain, treat with azithromycin + ethambutol.</li>
            <li><strong>Consider Ischemic Colitis in Elderly with Bloody Diarrhea:</strong> Acute onset bloody diarrhea with abdominal pain in elderly patient (especially with vascular disease, AF, hypotension, cocaine use). Results from decreased colonic blood flow, most often affecting "watershed" areas (splenic flexure, sigmoid). CT: colonic wall thickening, "thumbprinting". Mild cases: supportive care, bowel rest, resolve in 48-72 hours. Severe cases: gangrenous bowel, peritonitis, septic shock, require urgent surgical resection. Do NOT use antibiotics empirically for bloody diarrhea before considering ischemic colitis.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Septic shock (hypotension requiring vasopressors, lactate >4 mmol/L)</li>
            <li>Severe dehydration with persistent hypotension despite 3-4 L IV fluids</li>
            <li>Acute kidney injury with oliguria/anuria requiring urgent dialysis consideration</li>
            <li>Life-threatening electrolyte disturbances (K <2.5 or >6.5 mEq/L, severe acidosis pH <7.2)</li>
            <li>Toxic megacolon (colon diameter >6 cm with systemic toxicity)</li>
            <li>Fulminant C. difficile colitis (WBC >35k, lactate >5, ileus, peritoneal signs)</li>
            <li>Altered mental status, seizures from severe electrolyte abnormalities</li>
            <li>GI bleeding with hemodynamic instability</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Hemodynamically stable (BP >90/60, HR <100, normal orthostatics)</li>
            <li>Tolerating adequate oral fluids (>1-1.5 L/day) without vomiting</li>
            <li>Diarrhea frequency decreasing or stable (<5 stools/day)</li>
            <li>Electrolytes normalized or improving trend (K >3.5, Na 135-145, normal bicarb)</li>
            <li>Renal function improved or stable (Cr at or near baseline)</li>
            <li>Afebrile for 24 hours if infectious etiology</li>
            <li>Appropriate antibiotics prescribed if indicated (C. diff, Shigella, Giardia)</li>
            <li>Patient educated on hydration, signs of worsening, when to return (severe abdominal pain, bloody stools, fever, dizziness, decreased urine output)</li>
            <li>Follow-up arranged with PCP within 3-7 days</li>
            <li>If C. difficile: educated on recurrence risk (20-30%), hand hygiene, avoid PPIs if possible</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="diverticulitis">
    <div class="page-header">
        <h2>103. DIVERTICULITIS (COMPLICATED)</h2>
        <div class="subtitle">LLQ Pain â€¢ Fever â€¢ Leukocytosis â€¢ Abscess/Perforation/Fistula</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Acute left lower quadrant (LLQ) abdominal pain with fever and leukocytosis. Complicated diverticulitis involves abscess formation, perforation with peritonitis, fistula (colovesical, colovaginal), or stricture/obstruction.</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Diverticula are herniations of colonic mucosa through muscular wall at points of vascular penetration. Most common in sigmoid colon (90%). Microperforation or macroperforation leads to inflammation (diverticulitis). Complicated diverticulitis (20-25% of cases) includes: (1) Abscess formation (pericolic or distant), (2) Free perforation causing fecal peritonitis, (3) Fistula formation (most common colovesical: pneumaturia, fecaluria), (4) Stricture causing obstruction</li>
                <li><strong>Risk Factors:</strong> Age >40 years (prevalence 30% by age 60, 60% by age 80), Western diet (low fiber), obesity, smoking, NSAIDs/aspirin, immunosuppression, connective tissue disorders (Marfan, Ehlers-Danlos), polycystic kidney disease, chronic constipation</li>
                <li><strong>Symptoms:</strong> Acute LLQ abdominal pain (constant, may radiate to back/groin), fever >38Â°C, anorexia, nausea, change in bowel habits (diarrhea or constipation), dysuria/frequency if bladder involvement, pneumaturia/fecaluria (colovesical fistula), vaginal passage of stool/flatus (colovaginal fistula)</li>
                <li><strong>Physical Exam:</strong> LLQ tenderness (most sensitive finding), palpable tender mass (phlegmon or abscess), rebound tenderness, guarding, rigidity (if peritonitis), fever, tachycardia, hypotension (if septic), diminished bowel sounds, rectal exam: tenderness, palpable mass if low abscess</li>
                <li><strong>Variants/Subtypes:</strong> Uncomplicated diverticulitis (colonic inflammation only) vs Complicated diverticulitis: Hinchey Classification - Stage Ia (pericolic abscess <4 cm), Stage Ib (pericolic abscess >4 cm), Stage II (pelvic/distant abscess), Stage III (purulent peritonitis), Stage IV (fecal peritonitis - worst prognosis)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Complete Blood Count:</strong> Leukocytosis (WBC >11k, typical 12-18k), left shift (bandemia), thrombocytosis. Severe leukocytosis (>20k) suggests abscess or perforation</li>
                <li><strong>Basic Metabolic Panel:</strong> Acute kidney injury (prerenal from sepsis/dehydration), electrolyte abnormalities</li>
                <li><strong>Liver Function Tests:</strong> Usually normal; if elevated, consider liver abscess or biliary pathology</li>
                <li><strong>Lactate:</strong> Elevated (>2 mmol/L) if sepsis, mesenteric ischemia, or perforation. Lactate >4 mmol/L indicates severe sepsis/shock</li>
                <li><strong>Lipase:</strong> To rule out pancreatitis (similar presentation)</li>
                <li><strong>Urinalysis:</strong> May show pyuria, hematuria if colovesical fistula or bladder irritation from adjacent inflammation. True UTI vs sterile pyuria (inflammation without infection)</li>
                <li><strong>Blood Cultures:</strong> If fever >38.5Â°C, septic appearance, immunocompromised. Common organisms: E. coli, Bacteroides, Enterococcus</li>
            </ul>
            
            <p><strong>Imaging - CT Abdomen/Pelvis with IV Contrast (Gold Standard):</strong></p>
            <ul>
                <li><strong>Indications:</strong> All patients with suspected complicated diverticulitis. CT has 97% sensitivity, 100% specificity for diverticulitis</li>
                <li><strong>Classic CT Findings:</strong>
                    <ul>
                        <li>Colonic wall thickening (>4 mm)</li>
                        <li>Pericolic fat stranding (inflammation)</li>
                        <li>Diverticula visible</li>
                        <li>Abscess: loculated fluid collection with enhancing rim (Hinchey Ib/II)</li>
                        <li>Free air (pneumoperitoneum): perforation, requires emergent surgery</li>
                        <li>Extraluminal air/fecalith: microperforation contained by mesentery</li>
                        <li>Bowel obstruction: dilated bowel proximal to inflamed segment (stricture)</li>
                        <li>Colovesical fistula: air in bladder (pneumaturia) without urinary catheter</li>
                    </ul>
                </li>
                <li><strong>Contraindications:</strong> Renal insufficiency (relative; consider non-contrast CT or MRI), contrast allergy (can premedicate or use MRI)</li>
            </ul>
            
            <p><strong>Alternative Imaging:</strong></p>
            <ul>
                <li><strong>Ultrasound:</strong> Can be used (especially in pregnant patients or young adults), shows hypoechoic bowel wall thickening. Less sensitive than CT (61-85%)</li>
                <li><strong>MRI Abdomen/Pelvis:</strong> If pregnancy, renal insufficiency, contrast allergy. Excellent for evaluating pelvic abscesses and fistulas</li>
                <li><strong>Abdominal X-ray:</strong> Low sensitivity but can detect free air (upright CXR or left lateral decubitus), bowel obstruction, ileus. Not diagnostic for diverticulitis</li>
            </ul>
            
            <p><strong>Colonoscopy:</strong></p>
            <ul>
                <li><strong>CONTRAINDICATED in acute diverticulitis:</strong> Risk of perforation. Defer 6-8 weeks after acute episode</li>
                <li><strong>Indication for delayed colonoscopy (6-8 weeks post-resolution):</strong> To rule out colon cancer (can mimic diverticulitis), especially if first episode, age >50, alarm features (weight loss, anemia), or complicated diverticulitis with abscess/fistula. Cancer found in 2-11% of first diverticulitis episodes in patients >50</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management:</strong></p>
            <ul>
                <li>IV access, hemodynamic stabilization (IV fluids if tachycardic, hypotensive)</li>
                <li>NPO initially, advance diet as tolerated (clear liquids â†’ low-residue diet)</li>
                <li>Pain control: IV opioids (morphine 2-4 mg IV q2-4h, hydromorphone 0.5-1 mg IV q3-4h). Avoid NSAIDs (may worsen inflammation/perforation risk)</li>
                <li>Antiemetics: Ondansetron 4-8 mg IV q8h PRN</li>
                <li>Strict I&O monitoring</li>
            </ul>
            
            <p><strong>Antibiotic Therapy:</strong></p>
            <ul>
                <li><strong>Uncomplicated Diverticulitis (now controversial whether antibiotics needed):</strong> Recent data suggests select immunocompetent patients with CT-confirmed uncomplicated diverticulitis (no abscess, no perforation, WBC <15k, able to tolerate PO) can be managed without antibiotics. However, most still treat with antibiotics</li>
                <li><strong>Complicated Diverticulitis (ALWAYS require antibiotics):</strong> Abscess, perforation, fistula, immunocompromised, severe illness, sepsis</li>
                <li><strong>Empiric Antibiotic Regimens (broad-spectrum, cover GNR and anaerobes):</strong>
                    <ul>
                        <li><strong>Mild-Moderate (outpatient or floor):</strong> Ciprofloxacin 500 mg PO BID + Metronidazole 500 mg PO TID x 7-10 days. Or Amoxicillin-clavulanate 875 mg PO BID x 7-10 days. Or Moxifloxacin 400 mg PO daily x 7-10 days (monotherapy)</li>
                        <li><strong>Severe/Complicated (IV therapy):</strong>
                            <ul>
                                <li>Piperacillin-tazobactam 3.375 g IV q6h (or 4.5 g q8h for severe)</li>
                                <li>Or Ceftriaxone 1-2 g IV daily + Metronidazole 500 mg IV q8h</li>
                                <li>Or Ciprofloxacin 400 mg IV q12h + Metronidazole 500 mg IV q8h</li>
                                <li>Or Carbapenem (Meropenem 1 g IV q8h or Ertapenem 1 g IV daily) - if recent antibiotics, healthcare-associated, or very ill</li>
                            </ul>
                        </li>
                        <li>Duration: 4-7 days IV (if abscess drained or free perf), up to 7-14 days total</li>
                        <li>Transition to PO antibiotics once improving: afebrile 24-48 hours, WBC normalizing, tolerating PO, pain improved</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Abscess Management:</strong></p>
            <ul>
                <li><strong>Small Pericolic Abscess (<4 cm, Hinchey Ia):</strong> Antibiotics alone, no drainage needed. Success rate 70-85%</li>
                <li><strong>Large Abscess (>4 cm, Hinchey Ib/II):</strong> Percutaneous CT-guided drainage + antibiotics
                    <ul>
                        <li>Indications: abscess >4 cm, accessible for percutaneous approach, patient too unstable for surgery</li>
                        <li>Interventional radiology consultation for drain placement (usually 10-14 Fr pigtail catheter)</li>
                        <li>Drain to gravity, flush with 10-20 mL saline TID, remove when output <10 mL/day and patient clinically improved (typically 7-14 days)</li>
                        <li>Success rate 70-85%; avoids urgent surgery in most cases</li>
                        <li>Failed drainage (persistent sepsis, enlarging abscess): requires surgical intervention</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Surgical Management:</strong></p>
            <ul>
                <li><strong>EMERGENT Surgery Indications (immediate OR):</strong>
                    <ul>
                        <li>Hinchey III (purulent peritonitis) or IV (fecal peritonitis)</li>
                        <li>Diffuse peritonitis, free air on imaging</li>
                        <li>Hemodynamic instability/septic shock despite resuscitation</li>
                        <li>Clinical deterioration despite antibiotics Â± drainage</li>
                    </ul>
                </li>
                <li><strong>Surgical Options:</strong>
                    <ul>
                        <li><strong>Hartmann Procedure (most common emergent):</strong> Sigmoid resection, end colostomy, rectal stump (stapled or oversewn). Colostomy reversal in 3-6 months if patient recovers</li>
                        <li><strong>Primary Resection with Anastomosis:</strong> If minimal contamination, stable patient. Higher risk of anastomotic leak in acute setting</li>
                        <li><strong>Laparoscopic Peritoneal Lavage:</strong> Controversial, for Hinchey III (purulent peritonitis) without feculent peritonitis. Not standard of care</li>
                    </ul>
                </li>
                <li><strong>ELECTIVE Surgery Indications (post-resolution, 6-8 weeks later):</strong>
                    <ul>
                        <li>Recurrent diverticulitis (â‰¥2 episodes) - now controversial, individualize decision</li>
                        <li>Complicated diverticulitis (abscess, fistula, stricture, recurrent bleeding)</li>
                        <li>Immunocompromised (transplant, chronic steroids, chemotherapy) - even after first episode</li>
                        <li>Young age (<50 years) - previously standard, now individualized</li>
                        <li>Inability to exclude cancer</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Consultations:</strong></p>
            <ul>
                <li><strong>Surgery (General Surgery or Colorectal Surgery):</strong> Consult early for all complicated diverticulitis cases. Emergent consult if peritonitis, free air, septic shock</li>
                <li><strong>Interventional Radiology:</strong> For CT-guided abscess drainage (abscesses >4 cm)</li>
                <li><strong>Gastroenterology:</strong> For outpatient colonoscopy 6-8 weeks post-discharge (rule out colon cancer)</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Septic shock, Hinchey III/IV requiring emergent surgery, post-operative from emergent surgery</li>
                <li>Floor: Complicated diverticulitis (abscess, unable to tolerate PO, severe pain, immunocompromised), requiring IV antibiotics</li>
                <li>Discharge/Outpatient: Mild-moderate diverticulitis, CT-confirmed, able to tolerate PO, hemodynamically stable, reliable for follow-up, adequate oral antibiotic coverage</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Always Get CT with IV Contrast for Suspected Complicated Diverticulitis:</strong> Clinical diagnosis alone misses abscesses, microperforation, and alternative diagnoses (colon cancer, appendicitis, ovarian pathology, ischemic colitis). CT is 97% sensitive, 100% specific. Don't rely on physical exam alone - even with classic LLQ tenderness and fever, CT changes management in 30% of cases by identifying abscess needing drainage or perforation requiring surgery.</li>
            <li><strong>Hinchey Classification Guides Surgical vs Medical Management:</strong> Hinchey Ia (pericolic abscess <4 cm): antibiotics alone. Hinchey Ib (pericolic abscess >4 cm): percutaneous drainage + antibiotics. Hinchey II (distant/pelvic abscess): percutaneous drainage + antibiotics. Hinchey III (purulent peritonitis): emergent surgery (Hartmann). Hinchey IV (fecal peritonitis): emergent surgery, worst prognosis (mortality 20-40%). Know this classification - it dictates management and need for urgent surgical consultation.</li>
            <li><strong>Colovesical Fistula: Air in Bladder Without Foley = Diverticulitis Until Proven Otherwise:</strong> Most common fistula complication (65%). Patient presents with pneumaturia (air in urine), fecaluria (stool in urine), recurrent UTIs. CT shows air in bladder without urinary catheter. Occurs when inflamed sigmoid colon (left side) erodes into dome of bladder. Diagnosis: CT cystogram may show contrast in colon. Treatment requires sigmoid resection with bladder repair - antibiotics alone never cure fistula.</li>
            <li><strong>Antibiotics May NOT Be Needed for Uncomplicated Diverticulitis:</strong> Recent high-quality RCTs (AVOD, DIABOLO trials) show select patients with CT-confirmed uncomplicated diverticulitis (no abscess, no perforation, immunocompetent, WBC <15k) can be managed with supportive care alone without antibiotics. No difference in complication rates. However, this applies ONLY to uncomplicated cases. Complicated diverticulitis (abscess, perforation, fistula, immunosuppression, severe illness) ALWAYS requires antibiotics. This is evolving practice - many institutions still use antibiotics for all cases.</li>
            <li><strong>Defer Colonoscopy 6-8 Weeks Post-Resolution to Rule Out Colon Cancer:</strong> Colon cancer can present identically to diverticulitis (LLQ pain, fever, leukocytosis, CT showing colonic wall thickening). About 2-11% of first diverticulitis episodes in patients >50 are actually cancer. Colonoscopy during acute diverticulitis risks perforation. Wait 6-8 weeks to allow inflammation to resolve, then perform colonoscopy to visualize mucosa and rule out malignancy, especially if first episode, age >50, or alarm symptoms (weight loss, anemia, positive FOBT).</li>
            <li><strong>Immunosuppressed Patients Have Worse Outcomes and Need Surgery After First Episode:</strong> Transplant recipients, chronic steroids, chemotherapy, biologics (TNF-alpha inhibitors) have 3-5x higher perforation rate, higher mortality, and more aggressive disease. Even uncomplicated diverticulitis in immunosuppressed patient may progress to perforation rapidly. Strategy: lower threshold for admission, IV antibiotics, early surgical consultation, and consider elective sigmoid resection after first episode to prevent recurrence (unlike immunocompetent where surgery typically reserved for recurrent episodes).</li>
            <li><strong>Young Age (<40-50 Years) Does NOT Automatically Mean More Aggressive Disease:</strong> Old teaching: young patients have more virulent diverticulitis, need surgery after first episode. Recent data shows this is FALSE. Young patients have similar complication rates to older patients. Current approach: individualize surgical decision based on frequency of recurrence, impact on quality of life, presence of complications - NOT age alone. Don't tell 35-year-old they "need" prophylactic sigmoid resection after first uncomplicated episode.</li>
            <li><strong>Percutaneous Abscess Drainage Avoids Urgent Surgery in 70-85% of Cases:</strong> Abscess >4 cm (Hinchey Ib/II) traditionally required urgent surgery (Hartmann procedure). Now, CT-guided percutaneous drainage + antibiotics successfully treats abscess, allows acute inflammation to resolve, then patient can undergo elective one-stage sigmoid resection 6-8 weeks later (lower morbidity, higher primary anastomosis rate, avoid colostomy). Drainage "converts" complicated diverticulitis to uncomplicated, allowing definitive surgery to be done electively under optimal conditions.</li>
            <li><strong>High-Fiber Diet AFTER Resolution - Avoid During Acute Episode:</strong> During acute diverticulitis: low-residue diet or NPO initially (reduce colonic stimulation). After resolution (2-4 weeks): transition to high-fiber diet (25-30 g/day) to prevent recurrence. Fiber increases stool bulk, reduces intraluminal pressure, decreases diverticula formation. Old myth: avoid nuts, seeds, popcorn (no evidence they cause diverticulitis - DEBUNKED). High fiber reduces recurrence risk by 30-40%.</li>
            <li><strong>Hartmann Procedure is Emergency Surgery, NOT Definitive Treatment:</strong> Hartmann = sigmoid resection + end colostomy + rectal stump oversewn/stapled. Performed in emergency setting (Hinchey III/IV, peritonitis) because primary anastomosis too high-risk (leak rate 10-20% in contaminated field). Colostomy is temporary. Plan colostomy reversal in 3-6 months once patient recovered. Reversal surgery: reconnect colon to rectal stump, restore bowel continuity. About 50-60% of patients undergo successful reversal; others never reversed due to comorbidities, age, patient preference.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Septic shock (hypotension requiring vasopressors, lactate >4 mmol/L)</li>
            <li>Diffuse peritonitis with free air (Hinchey IV - fecal peritonitis)</li>
            <li>Purulent peritonitis (Hinchey III) requiring emergent surgery</li>
            <li>Hemodynamic instability despite aggressive fluid resuscitation</li>
            <li>Post-operative from emergent Hartmann procedure or bowel resection</li>
            <li>Clinical deterioration despite antibiotics and abscess drainage</li>
            <li>Severe lactic acidosis (lactate >4 mmol/L), concern for bowel ischemia/necrosis</li>
            <li>Respiratory failure from sepsis or abdominal compartment syndrome</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Afebrile for >24-48 hours (Temp <38Â°C without antipyretics)</li>
            <li>Tolerating regular or low-residue diet without nausea/vomiting</li>
            <li>Pain adequately controlled on oral analgesics</li>
            <li>WBC normalized or trending down (<12k, ideally <10k)</li>
            <li>Hemodynamically stable (normal vital signs without tachycardia)</li>
            <li>Able to ambulate independently</li>
            <li>Discharged on appropriate oral antibiotics (7-10 day course completed)</li>
            <li>Follow-up arranged with PCP or GI within 1-2 weeks</li>
            <li>Colonoscopy scheduled for 6-8 weeks post-discharge (to rule out colon cancer)</li>
            <li>Patient educated on high-fiber diet after resolution (25-30 g fiber/day), avoiding nuts/seeds NOT necessary</li>
            <li>Red flag symptoms discussed: worsening pain, fever, unable to tolerate PO, vomiting, distension (obstruction)</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="cirrhosis-complications">
    <div class="page-header">
        <h2>104. CIRRHOSIS COMPLICATIONS (VARICEAL BLEEDING, HEPATORENAL SYNDROME)</h2>
        <div class="subtitle">Portal Hypertension â€¢ GI Bleeding â€¢ Renal Failure â€¢ Ascites</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Decompensated cirrhosis presenting with acute variceal hemorrhage (hematemesis, melena, hemodynamic instability) or hepatorenal syndrome (rapidly progressive renal failure with oliguria, resistant ascites, without other cause of renal dysfunction).</p>
            <ul>
                <li><strong>Pathophysiology:</strong> <strong>Variceal Bleeding:</strong> Portal hypertension (HVPG >12 mmHg) causes portosystemic collaterals (varices in esophagus, stomach, rectum). Rupture causes massive GI bleeding (mortality 15-20% per episode). <strong>Hepatorenal Syndrome (HRS):</strong> Functional renal failure from severe hepatic dysfunction, splanchnic vasodilation, effective hypovolemia, and renal vasoconstriction. No intrinsic kidney damage - kidneys are structurally normal but failing due to hemodynamic changes. Reversible with liver transplant but rapidly fatal without treatment.</li>
                <li><strong>Risk Factors:</strong> Decompensated cirrhosis (any etiology: EtOH, NASH, viral hepatitis, autoimmune), MELD score >15, Child-Pugh class B/C, large varices on EGD, red whale markings on varices (high rupture risk), SBP, recent binge alcohol use, NSAIDs, anticoagulation</li>
                <li><strong>Symptoms - Variceal Bleeding:</strong> Hematemesis (bright red or coffee-ground), melena, hematochezia (if brisk bleeding), dizziness, syncope, dyspnea, chest pain (if severe anemia), altered mental status (hepatic encephalopathy from blood in GI tract)</li>
                <li><strong>Symptoms - Hepatorenal Syndrome:</strong> Oliguria (<400-500 mL/day), abdominal distension (ascites), confusion (hepatic encephalopathy), nausea, weakness. Patients often initially have type 2 HRS (slower, more chronic) then progress to type 1 HRS (rapid, <2 weeks)</li>
                <li><strong>Physical Exam:</strong> Stigmata of cirrhosis: jaundice, spider angiomata, palmar erythema, gynecomastia, testicular atrophy, caput medusae. Tense ascites (fluid wave, shifting dullness). Asterixis (hepatic encephalopathy). Hypotension, tachycardia (variceal bleeding). Splenomegaly (portal hypertension)</li>
                <li><strong>Variants/Subtypes:</strong> <strong>Variceal Bleeding:</strong> Esophageal (most common 80%), gastric (15%), rectal (5%). <strong>HRS:</strong> Type 1 (rapid, <2 weeks, doubling of Cr to >2.5 mg/dL, very poor prognosis) vs Type 2 (slower, moderate renal dysfunction, associated with refractory ascites)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Complete Blood Count:</strong> Anemia (acute blood loss or chronic disease), thrombocytopenia (<100k common in cirrhosis from splenic sequestration, bone marrow suppression), leukopenia</li>
                <li><strong>Comprehensive Metabolic Panel:</strong> Elevated BUN (GI bleeding), elevated Cr (HRS), hyponatremia (<130 mEq/L common in advanced cirrhosis), hypoglycemia possible, elevated bilirubin</li>
                <li><strong>Liver Function Tests:</strong> Elevated AST/ALT (usually <300 unless acute hepatitis superimposed), elevated alkaline phosphatase, hypoalbuminemia (<3.0 g/dL), hyperbilirubinemia (both direct and indirect)</li>
                <li><strong>Coagulation Studies:</strong> Prolonged PT/INR (INR often 1.5-3.0 or higher in decompensated cirrhosis from decreased synthetic function), prolonged PTT. Do NOT routinely correct INR unless active bleeding and performing procedure</li>
                <li><strong>Lactate:</strong> Elevated if hypovolemic shock, hepatic hypoperfusion, or mesenteric ischemia</li>
                <li><strong>Type & Screen / Crossmatch:</strong> Essential for variceal bleeding; anticipate transfusion needs</li>
                <li><strong>Ammonia Level:</strong> Often elevated in hepatic encephalopathy; useful to assess need for lactulose escalation</li>
                <li><strong>Blood Cultures:</strong> Draw before antibiotics if concern for SBP or bacteremia</li>
            </ul>
            
            <p><strong>HRS-Specific Laboratory Criteria:</strong></p>
            <ul>
                <li>Serum creatinine >1.5 mg/dL or doubling of baseline to >2.5 mg/dL (Type 1)</li>
                <li>Urine sodium <10 mEq/L (avid sodium retention)</li>
                <li>Urine osmolality > serum osmolality (kidneys concentrating urine)</li>
                <li>Urinalysis: bland sediment (no casts, minimal protein, no RBCs/WBCs)</li>
                <li>Fractional excretion of sodium (FENa) <1% (prerenal pattern)</li>
                <li>No improvement after 48-hour trial of albumin and diuretic withdrawal</li>
                <li>Absence of shock, nephrotoxic drugs, parenchymal renal disease</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>Renal Ultrasound:</strong> To rule out obstructive uropathy, assess kidney size (normal to slightly enlarged in HRS, small kidneys suggest chronic kidney disease)</li>
                <li><strong>CT Abdomen/Pelvis:</strong> If concern for other cause of renal failure (obstruction, abscess, hepatocellular carcinoma with vascular invasion)</li>
                <li><strong>Doppler Ultrasound of Liver:</strong> Assess portal vein patency (portal vein thrombosis can worsen portal hypertension, precipitate bleeding)</li>
            </ul>
            
            <p><strong>Endoscopy - URGENT Upper Endoscopy (EGD):</strong></p>
            <ul>
                <li>Perform within 12 hours of presentation for suspected variceal bleeding</li>
                <li>Diagnostic: confirms variceal source, grades varices (small vs large)</li>
                <li>Therapeutic: band ligation (preferred over sclerotherapy), bleeding control</li>
                <li>If not variceal: peptic ulcer, gastritis, Mallory-Weiss tear, portal hypertensive gastropathy</li>
            </ul>
            
            <p><strong>Paracentesis (if ascites present):</strong></p>
            <ul>
                <li>Rule out SBP (fluid PMN >250/ÂµL)</li>
                <li>Send ascitic fluid for: cell count with differential, culture (blood culture bottles at bedside), albumin, total protein, Gram stain</li>
                <li>Calculate serum-ascites albumin gradient (SAAG): Serum albumin minus ascitic fluid albumin. SAAG â‰¥1.1 g/dL confirms portal hypertension as cause of ascites</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>VARICEAL BLEEDING MANAGEMENT:</strong></p>
            
            <p><strong>Immediate Resuscitation:</strong></p>
            <ul>
                <li>IV access: Two large-bore IVs (18-gauge or larger)</li>
                <li>Hemodynamic monitoring: continuous telemetry, frequent vitals q15min initially</li>
                <li>Target BP: permissive hypotension initially (SBP 90-100 mmHg) to reduce variceal pressure before endoscopy</li>
                <li>Target Hemoglobin: 7-9 g/dL (restrictive transfusion strategy better outcomes). Transfuse PRBCs to Hgb 7-8 g/dL, avoid over-transfusion (increases portal pressure, rebleeding risk)</li>
                <li>Do NOT over-resuscitate with fluids (worsens portal hypertension and rebleeding)</li>
            </ul>
            
            <p><strong>Pharmacologic Therapy for Variceal Bleeding:</strong></p>
            <ul>
                <li><strong>Octreotide (Somatostatin Analog) - START IMMEDIATELY before endoscopy:</strong>
                    <ul>
                        <li>Bolus: 50 mcg IV push</li>
                        <li>Infusion: 50 mcg/hr continuous IV infusion</li>
                        <li>Duration: 2-5 days (until hemostasis confirmed)</li>
                        <li>Mechanism: splanchnic vasoconstriction, reduces portal pressure</li>
                    </ul>
                </li>
                <li><strong>Prophylactic Antibiotics (CRITICAL - reduces mortality):</strong>
                    <ul>
                        <li>Ceftriaxone 1 g IV daily x 7 days (preferred in advanced cirrhosis, prior quinolone use)</li>
                        <li>Or Ciprofloxacin 400 mg IV BID x 7 days</li>
                        <li>Or Norfloxacin 400 mg PO BID x 7 days (if can tolerate PO)</li>
                        <li>Prevents SBP and bacteremia (occurs in 20% of variceal bleeds)</li>
                    </ul>
                </li>
                <li><strong>Proton Pump Inhibitor:</strong> Pantoprazole 80 mg IV bolus, then 8 mg/hr infusion (reduces non-variceal bleeding, protects mucosa)</li>
            </ul>
            
            <p><strong>Endoscopic Therapy - URGENT (within 12 hours):</strong></p>
            <ul>
                <li><strong>Esophageal Variceal Band Ligation (EVL) - Preferred:</strong> Place bands on varices to achieve hemostasis. Success rate 80-90%. Repeat banding sessions q2-4 weeks until varices obliterated</li>
                <li><strong>Sclerotherapy:</strong> Inject sclerosant into varices. Alternative if banding not feasible. Higher complication rate than banding</li>
                <li><strong>If Bleeding Not Controlled with Above Measures:</strong> Consider rescue therapies below</li>
            </ul>
            
            <p><strong>Rescue Therapies (if endoscopic therapy fails):</strong></p>
            <ul>
                <li><strong>Balloon Tamponade (Minnesota or Sengstaken-Blakemore Tube):</strong>
                    <ul>
                        <li>Temporary measure (bridge to TIPS or surgery)</li>
                        <li>Inflate esophageal and gastric balloons to tamponade varices</li>
                        <li>High complication rate: esophageal perforation, aspiration, pressure necrosis</li>
                        <li>Use ONLY as last resort, max 24 hours inflation</li>
                        <li>Requires ICU, intubation for airway protection</li>
                    </ul>
                </li>
                <li><strong>TIPS (Transjugular Intrahepatic Portosystemic Shunt):</strong>
                    <ul>
                        <li>Interventional radiology creates shunt between portal and hepatic veins, reduces portal pressure</li>
                        <li>Indications: refractory variceal bleeding despite endoscopic therapy, rebleeding within 5 days, high-risk patients (Child-Pugh B/C with active bleeding at endoscopy)</li>
                        <li>Early TIPS (within 72 hours) in high-risk patients improves survival</li>
                        <li>Complications: hepatic encephalopathy (30-50%), shunt stenosis/thrombosis, liver failure</li>
                        <li>Contraindications: severe hepatic encephalopathy, heart failure, polycystic liver disease, hepatocellular carcinoma</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>HEPATORENAL SYNDROME MANAGEMENT:</strong></p>
            
            <p><strong>Diagnostic Confirmation (ensure criteria met):</strong></p>
            <ul>
                <li>Cirrhosis with ascites</li>
                <li>Cr >1.5 mg/dL or doubling to >2.5 mg/dL</li>
                <li>No improvement after 2 days of diuretic withdrawal + 1 g/kg albumin IV (max 100 g/day x 2 days)</li>
                <li>No shock, no nephrotoxins (NSAIDs, aminoglycosides, contrast), no parenchymal kidney disease</li>
                <li>Urine sodium <10 mEq/L, bland urinalysis</li>
            </ul>
            
            <p><strong>Pharmacologic Treatment (HRS-Specific):</strong></p>
            <ul>
                <li><strong>Albumin + Vasoconstrictors - FIRST LINE:</strong>
                    <ul>
                        <li><strong>Albumin:</strong> 1 g/kg IV on day 1 (max 100 g), then 20-40 g IV daily</li>
                        <li><strong>PLUS Midodrine + Octreotide (if no ICU bed):</strong>
                            <ul>
                                <li>Midodrine: 7.5 mg PO TID, increase by 2.5 mg TID every 3 days (max 15 mg TID). Goal MAP >15 mmHg increase or SBP >120 mmHg</li>
                                <li>Octreotide: 100-200 mcg SC TID (or 50 mcg/hr IV infusion if unable to take PO)</li>
                            </ul>
                        </li>
                        <li><strong>PLUS Norepinephrine (if ICU setting) - MOST EFFECTIVE:</strong>
                            <ul>
                                <li>Norepinephrine 0.5-3 mg/hr IV infusion, titrate to MAP >10 mmHg increase</li>
                                <li>More effective than midodrine/octreotide, preferred if ICU available</li>
                            </ul>
                        </li>
                        <li>Duration: Continue until Cr <1.5 mg/dL or liver transplant</li>
                        <li>Response rate: 40-50% with reversal of HRS</li>
                    </ul>
                </li>
                <li><strong>Terlipressin (Vasopressin Analog) - GOLD STANDARD (if available):</strong>
                    <ul>
                        <li>Dose: 1 mg IV bolus q4-6h, increase to 2 mg q4-6h if no response after 3 days</li>
                        <li>Most effective drug for HRS (reversal rate 40-50%)</li>
                        <li>Not FDA-approved in US but available in Europe, being considered for US approval</li>
                        <li>Complications: ischemic events (MI, mesenteric ischemia, limb ischemia) in 5-10%</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Supportive Care for HRS:</strong></p>
            <ul>
                <li><strong>Stop all diuretics</strong> (worsens renal perfusion)</li>
                <li><strong>Avoid nephrotoxins:</strong> NSAIDs, aminoglycosides, IV contrast</li>
                <li><strong>Maintain euvolemia:</strong> avoid aggressive diuresis and over-resuscitation</li>
                <li><strong>Treat precipitating factors:</strong> SBP (if present), GI bleeding, infections</li>
                <li><strong>Paracentesis:</strong> Large-volume paracentesis (>5 L) requires albumin 6-8 g per liter removed</li>
            </ul>
            
            <p><strong>Definitive Treatment (HRS):</strong></p>
            <ul>
                <li><strong>Liver Transplantation - ONLY CURE:</strong> HRS resolves after transplant (kidneys are structurally normal). List for transplant urgently. MELD score includes creatinine, so HRS improves transplant priority</li>
                <li><strong>Renal Replacement Therapy (Dialysis):</strong> Bridge to transplant. Continuous renal replacement therapy (CRRT) preferred over intermittent HD in hemodynamically unstable patients. Does not improve survival unless transplant occurs</li>
            </ul>
            
            <p><strong>Consultations:</strong></p>
            <ul>
                <li><strong>Gastroenterology/Hepatology:</strong> URGENT for variceal bleeding (endoscopy), HRS management, transplant evaluation</li>
                <li><strong>Interventional Radiology:</strong> For TIPS if refractory variceal bleeding</li>
                <li><strong>Nephrology:</strong> For HRS management, dialysis consideration</li>
                <li><strong>Transplant Surgery:</strong> For liver transplant evaluation (expedite if HRS Type 1)</li>
                <li><strong>Interventional Radiology:</strong> For TIPS placement</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Active variceal bleeding, hemodynamic instability, HRS Type 1 on vasopressors, post-TIPS, balloon tamponade, hepatic encephalopathy grade 3-4</li>
                <li>Floor with Telemetry: Controlled variceal bleeding post-endoscopy, HRS Type 2, moderate ascites, hepatic encephalopathy grade 1-2</li>
                <li>Discharge: Stable post-variceal bleed (after observation, repeat Hgb stable, no rebleeding x 48-72 hours), on appropriate prophylaxis (beta-blocker, repeated banding sessions scheduled)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Restrictive Transfusion Strategy (Target Hgb 7-9 g/dL) Reduces Rebleeding and Mortality:</strong> Over-transfusion increases portal venous pressure, precipitating rebleeding. Landmark study showed targeting Hgb 7-9 g/dL had 50% reduction in rebleeding and improved survival vs liberal strategy (Hgb 9-11 g/dL). Avoid over-resuscitation - permissive hypotension (SBP 90-100) acceptable before endoscopy. After hemostasis achieved, aim Hgb ~8 g/dL.</li>
            <li><strong>Start Octreotide and Antibiotics BEFORE Endoscopy:</strong> Don't wait for EGD to start octreotide (reduces bleeding, portal pressure) and prophylactic antibiotics (prevents SBP, bacteremia). Both improve mortality. Start in ED as soon as variceal bleeding suspected. Octreotide 50 mcg bolus then 50 mcg/hr infusion. Ceftriaxone 1 g IV x 7 days (more effective than quinolones in advanced cirrhosis). Antibiotics reduce mortality by 20% - this is standard of care.</li>
            <li><strong>Band Ligation Preferred Over Sclerotherapy:</strong> EVL (endoscopic variceal ligation) has higher success rate, lower rebleeding rate, fewer complications (strictures, ulcers, perforation) than sclerotherapy. Sclerotherapy involves injecting caustic sclerosant, causing inflammation, scarring, higher complication rate. Use EVL first-line. Sclerotherapy only if banding not technically feasible. Post-banding: schedule repeat sessions q2-4 weeks until varices eradicated.</li>
            <li><strong>Early TIPS (Within 72 Hours) in High-Risk Patients Improves Survival:</strong> Patients with Child-Pugh B/C with active bleeding at endoscopy or Child-Pugh C <14 points with active bleeding have high mortality. Early TIPS (within 72 hours) in this population reduces rebleeding and improves 1-year survival from 60% to 80%. Don't wait for rebleeding - consult IR for TIPS early if high-risk. Calculate Child-Pugh score at presentation.</li>
            <li><strong>HRS is Functional Renal Failure - Kidneys Are Structurally Normal:</strong> Unlike ATN or AIN, kidneys in HRS have no intrinsic damage - urinalysis is bland, kidney biopsy shows normal glomeruli. Renal failure is purely hemodynamic: severe hepatic dysfunction causes splanchnic vasodilation, effective hypovolemia, compensatory renal vasoconstriction, GFR drops. Kidneys work perfectly after liver transplant. But without transplant, HRS progresses to multiorgan failure and death. Median survival Type 1 HRS: 2 weeks without treatment.</li>
            <li><strong>Albumin Plus Vasoconstrictors (Norepinephrine or Midodrine/Octreotide) is Evidence-Based for HRS:</strong> Albumin alone doesn't reverse HRS. Need vasoconstrictor to increase systemic vascular resistance, counteract splanchnic vasodilation. Norepinephrine (ICU setting) most effective: 0.5-3 mg/hr IV, target MAP >10 mmHg increase. Alternative: midodrine (alpha-agonist) + octreotide (splanchnic vasoconstrictor). Give albumin 20-40 g IV daily. Response rate 40-50%. Continue until Cr <1.5 mg/dL or transplant.</li>
            <li><strong>Stop Diuretics in HRS - They Worsen Renal Perfusion:</strong> Common mistake: continuing spironolactone, furosemide in HRS patient with refractory ascites. Diuretics cause volume depletion, worsen renal hypoperfusion, accelerate renal failure. In HRS, hold ALL diuretics. Treat ascites with large-volume paracentesis + albumin (8 g per liter removed if >5 L removed). Accept some ascites - prioritize kidney function over comfort. Restart diuretics only if HRS resolves.</li>
            <li><strong>Large-Volume Paracentesis (>5 L) Requires Albumin Replacement:</strong> Removing >5 L ascites without albumin replacement causes post-paracentesis circulatory dysfunction (PPCD): effective hypovolemia, renal failure, hyponatremia. Give albumin 6-8 g per liter removed if >5 L total. Example: drain 8 L ascites, give 64 g albumin IV (8 L Ã— 8 g/L). Prevents PPCD, reduces mortality. <5 L: albumin not required.</li>
            <li><strong>Non-Selective Beta-Blockers (Propranolol, Nadolol) are First-Line for Primary and Secondary Variceal Prophylaxis:</strong> Reduce portal pressure by decreasing cardiac output (beta-1) and causing splanchnic vasoconstriction (beta-2 blockade on mesenteric vessels). Goal HR 55-60 bpm or 25% reduction from baseline. Start propranolol 20 mg PO BID or nadolol 20 mg daily, titrate up. Reduces bleeding risk by 40-50%. Contraindications: decompensated HF, severe COPD, severe bradycardia. Carvedilol (non-selective + alpha-blocker) may be more effective.</li>
            <li><strong>SAAG â‰¥1.1 g/dL Confirms Portal Hypertension as Cause of Ascites:</strong> Serum-Ascites Albumin Gradient = Serum albumin minus Ascitic fluid albumin. SAAG â‰¥1.1 g/dL (97% accurate) indicates portal hypertension etiology (cirrhosis, Budd-Chiari, cardiac ascites). SAAG <1.1 g/dL suggests non-portal hypertensive causes (peritoneal carcinomatosis, TB peritonitis, nephrotic syndrome, pancreatitis). Also check ascitic fluid PMN count: >250 cells/ÂµL = SBP (start ceftriaxone 2 g IV daily).</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Active variceal hemorrhage with hemodynamic instability (SBP <90, HR >120)</li>
            <li>Massive GI bleeding (Hgb <7 despite transfusion, ongoing hematemesis)</li>
            <li>Requires balloon tamponade (Minnesota/Sengstaken-Blakemore tube)</li>
            <li>Refractory bleeding despite endoscopic therapy (needs TIPS)</li>
            <li>HRS Type 1 requiring norepinephrine infusion for renal perfusion</li>
            <li>Hepatic encephalopathy grade 3-4 (stupor, coma)</li>
            <li>Acute liver failure or acute-on-chronic liver failure</li>
            <li>Septic shock from SBP or bacteremia</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Variceal bleeding controlled, no rebleeding for 48-72 hours</li>
            <li>Hemoglobin stable (>7 g/dL) without ongoing transfusion requirements</li>
            <li>Hemodynamically stable (SBP >90, HR <100)</li>
            <li>Tolerating PO diet without nausea/vomiting</li>
            <li>On non-selective beta-blocker (nadolol 20-40 mg daily or propranolol 20 mg BID, titrate to HR 55-60 bpm) for secondary prophylaxis</li>
            <li>Repeat EGD band ligation sessions scheduled (q2-4 weeks until varices eradicated)</li>
            <li>Patient educated on avoiding NSAIDs, alcohol, hepatotoxic drugs</li>
            <li>Hepatology follow-up within 1-2 weeks</li>
            <li>If HRS: NOT a discharge diagnosis - requires ongoing treatment, transplant evaluation, or hospice discussion</li>
            <li>Prophylactic antibiotics completed (7 days ceftriaxone)</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="aclf">
    <div class="page-header">
        <h2>105. ACUTE-ON-CHRONIC LIVER FAILURE (ACLF)</h2>
        <div class="subtitle">Acute Decompensation â€¢ Organ Failure â€¢ High Short-Term Mortality â€¢ Precipitating Event</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with known chronic liver disease presenting with acute decompensation and organ failure(s) - typically hepatic, renal, coagulation, circulatory, respiratory, or cerebral - triggered by a precipitating event (infection, alcohol binge, hepatotoxin), with high short-term mortality (28-day mortality 15-90% depending on grade).</p>
            <ul>
                <li><strong>Pathophysiology:</strong> ACLF is syndrome of acute deterioration in patients with chronic liver disease (cirrhosis or non-cirrhotic chronic liver disease) characterized by hepatic and/or extrahepatic organ failures and high short-term mortality. Unlike simple decompensated cirrhosis (ascites, variceal bleed, encephalopathy alone), ACLF involves systemic inflammatory response, multiorgan dysfunction. Precipitants: bacterial infections (SBP, pneumonia, UTI), alcohol binge, hepatotoxic drugs (acetaminophen), viral hepatitis superinfection (HBV reactivation, HEV, HSV), surgery/trauma, GI bleeding, portal vein thrombosis.</li>
                <li><strong>Risk Factors:</strong> Alcoholic cirrhosis (most common), chronic HBV/HCV, NASH, autoimmune hepatitis, active alcohol use, recent infection, immunosuppression, malnutrition, baseline MELD >15</li>
                <li><strong>Symptoms:</strong> Jaundice (rapid onset or worsening), abdominal pain/distension (ascites, peritonitis), confusion/altered mental status (hepatic encephalopathy grade 2-4), dyspnea (hepatopulmonary syndrome, pleural effusions, pulmonary edema), oliguria (HRS), hematemesis/melena (variceal bleeding), fever (infection)</li>
                <li><strong>Physical Exam:</strong> Jaundice, altered mental status (confusion, asterixis, obtundation, coma), signs of cirrhosis (spider angiomata, palmar erythema, gynecomastia, caput medusae), tense ascites, hypotension (circulatory failure, septic shock), tachypnea, hypoxia, decreased breath sounds (pleural effusions), bleeding (coagulopathy)</li>
                <li><strong>Variants/Subtypes:</strong> ACLF Grades (EASL-CLIF Consortium criteria): ACLF Grade 1 (single kidney failure, or single non-kidney organ failure with kidney dysfunction/hepatic encephalopathy), ACLF Grade 2 (2 organ failures), ACLF Grade 3 (â‰¥3 organ failures). 28-day mortality: Grade 1 (~22%), Grade 2 (~32%), Grade 3 (~76%)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Complete Blood Count:</strong> Leukocytosis (infection), leukopenia (sepsis, bone marrow suppression), thrombocytopenia (<50k), anemia</li>
                <li><strong>Comprehensive Metabolic Panel:</strong> Elevated bilirubin (>5 mg/dL, often >12 mg/dL), elevated AST/ALT (can be >300-500 if acute hepatitis superimposed), hyponatremia (<130 mEq/L), elevated creatinine (HRS), hypoglycemia possible, elevated BUN</li>
                <li><strong>Coagulation Studies:</strong> Prolonged PT/INR (INR >2.0, often >2.5), prolonged PTT, low fibrinogen</li>
                <li><strong>Lactate:</strong> Elevated (>4 mmol/L) in septic shock, hepatic hypoperfusion</li>
                <li><strong>Ammonia:</strong> Often very elevated (>100 mcg/dL), correlates with hepatic encephalopathy severity</li>
                <li><strong>Arterial Blood Gas:</strong> Metabolic acidosis (sepsis, lactic acidosis), respiratory alkalosis (hepatopulmonary syndrome), hypoxemia</li>
                <li><strong>Blood Cultures:</strong> Before antibiotics; positive in 30-40% if bacteremia/SBP</li>
            </ul>
            
            <p><strong>Organ Failure Assessment (CLIF-SOFA Criteria):</strong></p>
            <ul>
                <li><strong>Liver Failure:</strong> Bilirubin >12 mg/dL</li>
                <li><strong>Kidney Failure:</strong> Creatinine â‰¥2.0 mg/dL or RRT (dialysis)</li>
                <li><strong>Cerebral Failure:</strong> Hepatic encephalopathy grade 3-4 (West Haven criteria)</li>
                <li><strong>Coagulation Failure:</strong> INR >2.5 or platelets â‰¤20k/ÂµL</li>
                <li><strong>Circulatory Failure:</strong> MAP <70 mmHg or need for vasopressors</li>
                <li><strong>Respiratory Failure:</strong> PaO2/FiO2 <200 (or SpO2/FiO2 <214) or mechanical ventilation</li>
            </ul>
            
            <p><strong>Infectious Workup (CRITICAL - infection most common precipitant):</strong></p>
            <ul>
                <li><strong>Paracentesis (if ascites):</strong> Cell count, culture, Gram stain. SBP: PMN >250/ÂµL. Send 10 mL into blood culture bottles at bedside</li>
                <li><strong>Chest X-ray:</strong> Pneumonia, pleural effusions</li>
                <li><strong>Urinalysis and Urine Culture:</strong> UTI common</li>
                <li><strong>Blood Cultures:</strong> X 2 sets from separate sites</li>
                <li><strong>Other:</strong> Sputum culture if pneumonia, stool studies if diarrhea</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>Chest X-ray:</strong> Pneumonia, pleural effusions, pulmonary edema, ARDS</li>
                <li><strong>CT Abdomen/Pelvis:</strong> Assess for intra-abdominal abscess, portal vein thrombosis, hepatocellular carcinoma, bowel perforation</li>
                <li><strong>Liver Ultrasound with Doppler:</strong> Assess portal vein patency (thrombosis), hepatic vein patency (Budd-Chiari), hepatic masses</li>
            </ul>
            
            <p><strong>Additional Testing:</strong></p>
            <ul>
                <li><strong>Viral Hepatitis Panel:</strong> HBsAg, anti-HCV, HBV DNA/HCV RNA (check for reactivation), HEV IgM (acute hepatitis E - consider in travelers)</li>
                <li><strong>Acetaminophen Level:</strong> If concern for overdose (intentional or unintentional)</li>
                <li><strong>Alcohol Level:</strong> If intoxication suspected</li>
                <li><strong>Toxicology Screen:</strong> For other hepatotoxins</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management (ICU Level Care):</strong></p>
            <ul>
                <li>Transfer to ICU (ACLF Grade 2-3 always ICU, Grade 1 consider ICU)</li>
                <li>IV access, arterial line, central venous catheter if needed</li>
                <li>Hemodynamic monitoring: continuous telemetry, frequent vitals</li>
                <li>Airway protection: intubate if hepatic encephalopathy grade 3-4 (GCS <8)</li>
                <li>Strict I&O, Foley catheter for accurate urine output monitoring</li>
            </ul>
            
            <p><strong>Identify and Treat Precipitating Factor:</strong></p>
            <ul>
                <li><strong>Bacterial Infection (50-60% of ACLF cases):</strong>
                    <ul>
                        <li>Empiric broad-spectrum antibiotics (before culture results)</li>
                        <li>If SBP suspected/confirmed: Ceftriaxone 2 g IV daily or Piperacillin-tazobactam 3.375 g IV q6h</li>
                        <li>Add Albumin if SBP: 1.5 g/kg IV on day 1, then 1 g/kg on day 3 (reduces HRS, improves survival)</li>
                        <li>If healthcare-associated or prior antibiotic exposure: consider carbapenem (Meropenem 1 g IV q8h)</li>
                    </ul>
                </li>
                <li><strong>Alcohol-Related (30% of ACLF):</strong>
                    <ul>
                        <li>Abstinence counseling, addiction medicine consult</li>
                        <li>Nutritional support: thiamine 100 mg IV daily, folate 1 mg daily, multivitamin</li>
                        <li>Consider corticosteroids if alcoholic hepatitis (Maddrey Discriminant Function â‰¥32): Prednisolone 40 mg PO daily x 28 days</li>
                    </ul>
                </li>
                <li><strong>Hepatotoxic Drug (Acetaminophen, etc.):</strong>
                    <ul>
                        <li>N-acetylcysteine (NAC) if acetaminophen: 150 mg/kg IV loading dose over 1 hr, then 50 mg/kg over 4 hrs, then 100 mg/kg over 16 hrs</li>
                        <li>Stop all hepatotoxic medications</li>
                    </ul>
                </li>
                <li><strong>Viral Hepatitis Reactivation:</strong>
                    <ul>
                        <li>HBV: Entecavir 0.5 mg PO daily or Tenofovir 300 mg PO daily</li>
                        <li>HCV: Defer direct-acting antivirals until acute phase stabilizes</li>
                        <li>HSV hepatitis (rare): Acyclovir 10 mg/kg IV q8h</li>
                    </ul>
                </li>
                <li><strong>Variceal Bleeding:</strong> Octreotide, endoscopy, TIPS if refractory (see Condition 78)</li>
            </ul>
            
            <p><strong>Organ Support:</strong></p>
            <ul>
                <li><strong>Hepatic Encephalopathy:</strong>
                    <ul>
                        <li>Lactulose: 30-45 mL PO/NG q2-4h until 2-3 soft bowel movements per day. Goal: reduce ammonia</li>
                        <li>Rifaximin: 550 mg PO BID (adjunct to lactulose)</li>
                        <li>Avoid sedatives (benzodiazepines, opioids worsen encephalopathy)</li>
                        <li>Correct precipitants: GI bleeding, infection, constipation, hypokalemia</li>
                    </ul>
                </li>
                <li><strong>Renal Support (HRS):</strong>
                    <ul>
                        <li>Albumin + Midodrine/Octreotide or Norepinephrine (see Condition 78)</li>
                        <li>Continuous renal replacement therapy (CRRT) if severe AKI, volume overload, refractory hyperkalemia</li>
                    </ul>
                </li>
                <li><strong>Circulatory Support:</strong>
                    <ul>
                        <li>Fluid resuscitation: Albumin preferred over crystalloid (25% albumin 100 mL IV boluses)</li>
                        <li>Vasopressors: Norepinephrine first-line (0.1-1 mcg/kg/min), target MAP >65 mmHg</li>
                        <li>Avoid over-resuscitation (worsens ascites, portal pressure)</li>
                    </ul>
                </li>
                <li><strong>Respiratory Support:</strong>
                    <ul>
                        <li>Supplemental oxygen to maintain SpO2 >92%</li>
                        <li>Mechanical ventilation if severe hypoxemia (PaO2/FiO2 <200), hepatic encephalopathy grade 3-4</li>
                        <li>Lung-protective ventilation if ARDS</li>
                    </ul>
                </li>
                <li><strong>Coagulopathy:</strong>
                    <ul>
                        <li>Do NOT routinely correct INR (worsens outcomes, causes volume overload)</li>
                        <li>Transfuse FFP/platelets ONLY if active bleeding or procedure (goal platelets >50k, INR <2.0 for high-risk procedure)</li>
                        <li>Consider prothrombin complex concentrate (PCC) if urgent reversal needed</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Nutrition:</strong></p>
            <ul>
                <li>Early enteral nutrition (within 48 hours) improves outcomes</li>
                <li>High-protein diet (1.2-1.5 g/kg/day) - old myth about protein restriction is FALSE</li>
                <li>Branched-chain amino acids (BCAA) may help encephalopathy</li>
                <li>Avoid prolonged fasting (worsens muscle wasting, encephalopathy)</li>
            </ul>
            
            <p><strong>Liver Transplant Evaluation (URGENT):</strong></p>
            <ul>
                <li>Contact transplant center immediately for all ACLF Grade 2-3</li>
                <li>ACLF patients may improve with supportive care OR deteriorate rapidly - need early transplant assessment</li>
                <li>Criteria: Too sick to survive without transplant, not too sick to survive transplant (ACLF Grade 3 with multiorgan failure may have futile outcome even with transplant)</li>
                <li>Contraindications: Active alcohol/drug use, extrahepatic malignancy, severe cardiopulmonary disease, active septic shock (relative)</li>
            </ul>
            
            <p><strong>Consultations:</strong></p>
            <ul>
                <li><strong>Hepatology:</strong> Immediate consult for all ACLF, co-manage with ICU</li>
                <li><strong>Transplant Surgery:</strong> Urgent evaluation for Grade 2-3 ACLF</li>
                <li><strong>Nephrology:</strong> For HRS management, CRRT</li>
                <li><strong>Critical Care:</strong> ICU admission, multiorgan support</li>
                <li><strong>Infectious Disease:</strong> If multidrug-resistant organisms, fungal infection, or unusual infections</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: All ACLF Grade 2-3, ACLF Grade 1 with shock/encephalopathy, any organ failure requiring intensive monitoring/support</li>
                <li>Floor: NOT appropriate for ACLF - this is ICU-level disease by definition</li>
                <li>Hospice: Consider if ACLF Grade 3, not transplant candidate, multiorgan failure, poor prognosis despite maximal therapy</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>ACLF is NOT the Same as Simple Decompensated Cirrhosis:</strong> Decompensated cirrhosis (new onset ascites, variceal bleed, encephalopathy) is manageable on floor, has lower mortality. ACLF involves ORGAN FAILURES (hepatic, renal, cerebral, coag, circulatory, respiratory) and has very high short-term mortality (15-90%). ACLF Grade 3 with â‰¥3 organ failures has 28-day mortality 76%. ACLF requires ICU, aggressive intervention, urgent transplant evaluation. Don't confuse the two - ACLF is much more serious.</li>
            <li><strong>Infection is the Most Common Precipitant (50-60% of Cases):</strong> SBP, pneumonia, UTI, bacteremia trigger systemic inflammatory response, organ failures. Always have high suspicion for infection - do paracentesis if ascites (SBP), CXR (pneumonia), UA/UCx (UTI), blood cultures. Start empiric broad-spectrum antibiotics early (ceftriaxone 2 g IV daily). If SBP confirmed: add albumin 1.5 g/kg day 1, 1 g/kg day 3 (reduces HRS, improves survival by 30%). Don't delay antibiotics waiting for culture results.</li>
            <li><strong>ACLF Can Develop in Non-Cirrhotic Chronic Liver Disease:</strong> Most ACLF occurs in cirrhotic patients, but 30-40% develop in patients with chronic liver disease without established cirrhosis (chronic HBV/HCV, NASH, autoimmune hepatitis). Acute precipitant (HBV reactivation, alcohol binge, hepatotoxin) in patient with chronic liver disease causes acute hepatic injury, systemic inflammation, extrahepatic organ failures. These patients can still develop ACLF and have similar mortality to cirrhotic patients.</li>
            <li><strong>High-Protein Diet in Liver Disease is NOT Contraindicated:</strong> Old myth: protein restriction prevents hepatic encephalopathy. FALSE. Protein restriction causes malnutrition, sarcopenia, worse outcomes. Current guidelines: 1.2-1.5 g/kg/day protein for all liver disease patients. If encephalopathy develops: treat with lactulose/rifaximin, NOT protein restriction. Exception: acute hyperammonemia with hepatic encephalopathy grade 3-4 may temporarily reduce protein for 24-48 hours, then resume. Adequate nutrition is critical for survival in ACLF.</li>
            <li><strong>Albumin is More Than Just Volume Expander - It's Anti-Inflammatory in ACLF:</strong> Albumin has pleiotropic effects beyond oncotic pressure: binds endotoxins, reduces systemic inflammation, improves endothelial function, reduces oxidative stress. In SBP: albumin reduces HRS and improves survival. In large-volume paracentesis (>5 L): prevents circulatory dysfunction. In ACLF: albumin preferred over crystalloid for resuscitation. Dose: 25% albumin 100 mL (25 g) boluses. Don't just give saline - use albumin liberally in ACLF.</li>
            <li><strong>Grading ACLF (Grade 1, 2, 3) Predicts Mortality and Guides Transplant Urgency:</strong> CLIF-SOFA criteria define organ failures (liver, kidney, cerebral, coag, circulatory, respiratory). Grade 1 = 1 organ failure (22% mortality), Grade 2 = 2 organ failures (32% mortality), Grade 3 = â‰¥3 organ failures (76% mortality at 28 days). Grade 3 patients need urgent transplant evaluation but may be too sick to survive even with transplant. Grade 2 patients are ideal transplant candidates - sick enough to need it, well enough to survive it. Calculate ACLF grade on admission.</li>
            <li><strong>Do NOT Routinely Correct INR with FFP in ACLF:</strong> Elevated INR in cirrhosis reflects decreased synthesis of both pro-coagulant and anti-coagulant factors - patients are in rebalanced hemostasis, not actually "coagulopathic." Giving FFP causes volume overload, worsens ascites, increases portal pressure, no survival benefit. Transfuse FFP/platelets ONLY if active bleeding or high-risk procedure (goal platelets >50k, INR <2.0). Otherwise, accept elevated INR. Exception: severe coagulopathy (INR >5.0) with bleeding may warrant PCC (4-factor prothrombin complex concentrate).</li>
            <li><strong>Corticosteroids in Severe Alcoholic Hepatitis (Component of Some ACLF Cases):</strong> If ACLF precipitated by severe alcoholic hepatitis (AST:ALT ratio >2:1, bilirubin >5 mg/dL, recent heavy alcohol use), calculate Maddrey Discriminant Function (MDF) = 4.6 Ã— (PT patient - PT control) + Bilirubin. If MDF â‰¥32: consider prednisolone 40 mg PO daily x 28 days (reduces mortality). But corticosteroids controversial if active infection. Lille score at day 7 predicts response: if Lille score â‰¥0.45 (non-responder), stop steroids.</li>
            <li><strong>Liver Transplant is the Only Definitive Treatment for ACLF but Timing is Critical:</strong> ACLF patients are prioritized on transplant list (high MELD scores due to bilirubin, INR, creatinine). But transplanting patient in ACLF Grade 3 with â‰¥3 organ failures and septic shock has poor outcomes (may not survive surgery). Ideal candidates: ACLF Grade 2, improving with treatment but still need transplant, no active sepsis. Early transplant evaluation critical - don't wait until patient too sick. If ACLF Grade 3 persists despite maximal therapy, survival with or without transplant is dismal - consider palliative care.</li>
            <li><strong>N-Acetylcysteine (NAC) May Benefit Non-Acetaminophen ACLF:</strong> NAC traditionally used for acetaminophen overdose, but emerging data suggests benefit in non-acetaminophen acute liver failure and possibly ACLF (antioxidant, improves tissue oxygenation, reduces systemic inflammation). Some centers use NAC in ACLF patients even without acetaminophen exposure. Dose: 150 mg/kg IV over 1 hr, then 50 mg/kg over 4 hrs, then 100 mg/kg over 16 hrs (can continue longer). Low risk, may improve encephalopathy and survival. Not yet standard of care but consider in severe cases.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>ALL patients with ACLF Grade 2-3 (â‰¥2 organ failures) - ICU mandatory</li>
            <li>ACLF Grade 1 with hemodynamic instability, shock, hepatic encephalopathy grade 3-4</li>
            <li>Respiratory failure (PaO2/FiO2 <200, mechanical ventilation needed)</li>
            <li>Circulatory failure (MAP <70 mmHg, vasopressor requirement)</li>
            <li>Acute kidney injury requiring CRRT (Cr >2.0 mg/dL or oliguria)</li>
            <li>Severe hepatic encephalopathy (grade 3-4, obtundation, coma)</li>
            <li>Severe coagulopathy with active bleeding (INR >3.0, platelets <20k)</li>
            <li>Septic shock, lactate >4 mmol/L</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>ACLF is NOT a discharge diagnosis - most patients either improve (downgrade to compensated cirrhosis) or deteriorate (transplant or death)</li>
            <li>If patient improves from ACLF to compensated cirrhosis: precipitant treated, organ failures resolved, stable for 48-72 hours off organ support</li>
            <li>Close hepatology follow-up within 1 week</li>
            <li>Transplant evaluation completed or scheduled</li>
            <li>Abstinence from alcohol if relevant</li>
            <li>Medications optimized: diuretics, beta-blockers, lactulose/rifaximin if history of encephalopathy</li>
            <li>Patient/family educated on red flags: jaundice, confusion, abdominal pain, fever, bleeding, dyspnea</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="mesenteric-ischemia">
    <div class="page-header">
        <h2>106. ISCHEMIC BOWEL / MESENTERIC ISCHEMIA</h2>
        <div class="subtitle">Severe Abdominal Pain â€¢ Pain Out of Proportion â€¢ Lactic Acidosis â€¢ Bowel Necrosis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Acute onset of severe, diffuse abdominal pain that is "out of proportion to physical exam findings" (severe pain with minimal tenderness), often with bloody diarrhea, lactic acidosis, and rapid clinical deterioration. Most common in elderly with atrial fibrillation or atherosclerotic disease.</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Acute interruption of blood flow to intestines causes bowel ischemia, progressing to infarction and necrosis if not rapidly reversed. Four main types: (1) Arterial embolism (50%): AF, MI, valvular disease â†’ emboli to SMA; (2) Arterial thrombosis (15-25%): atherosclerotic plaque in SMA/celiac axis thromboses; (3) Non-occlusive mesenteric ischemia (NOMI, 20-30%): low cardiac output state (HF, shock, dialysis) causes mesenteric vasoconstriction; (4) Venous thrombosis (10%): hypercoagulable state â†’ SMV/portal vein thrombosis. Mortality 60-80% if bowel infarction occurs.</li>
                <li><strong>Risk Factors:</strong> <strong>Arterial:</strong> Atrial fibrillation (most important), recent MI, valvular heart disease (endocarditis), aortic atherosclerosis, prior embolism, hypotension, vasopressor use, cocaine. <strong>Venous:</strong> Hypercoagulable states (Factor V Leiden, protein C/S deficiency, malignancy, OCP use, pregnancy), portal hypertension, cirrhosis, pancreatitis, inflammatory bowel disease, intra-abdominal infection/abscess</li>
                <li><strong>Symptoms:</strong> Sudden onset severe, constant abdominal pain (often periumbilical or diffuse), early: pain out of proportion to exam (pathognomonic), nausea, vomiting, diarrhea (often bloody), urgency to defecate (early sign), abdominal distension (late - ileus, necrosis)</li>
                <li><strong>Physical Exam:</strong> Early (hours 0-6): Minimal abdominal tenderness despite severe pain (hallmark), normal or hypoactive bowel sounds, tachycardia, no peritoneal signs. Late (hours 6-24): Peritoneal signs develop (rebound, guarding, rigidity), absent bowel sounds (ileus), abdominal distension, hemodynamic instability (shock), bloody rectal exam (late finding). Classically described as "pain out of proportion" - patient writhing in agony but abdomen soft on exam (early).</li>
                <li><strong>Variants/Subtypes:</strong> Acute mesenteric ischemia (discussed here) vs Chronic mesenteric ischemia ("intestinal angina" - postprandial pain, weight loss, food fear, chronic). Colonic ischemia (separate entity, see pearl)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Lactate:</strong> MOST IMPORTANT. Elevated (>2 mmol/L) in 90% of cases. Lactate >3 mmol/L highly concerning. Lactate >4-5 mmol/L suggests transmural ischemia/necrosis. Serial lactates: rising lactate = worsening ischemia. NOTE: normal lactate does NOT rule out mesenteric ischemia - 10% have normal lactate early</li>
                <li><strong>Complete Blood Count:</strong> Leukocytosis (>15k common, >20k suggests necrosis), hemoconcentration, later: leukopenia (sepsis)</li>
                <li><strong>Basic Metabolic Panel:</strong> Metabolic acidosis (elevated anion gap from lactic acidosis), elevated BUN/Cr (prerenal from hypovolemia), hyperkalemia (cell death)</li>
                <li><strong>Liver Function Tests:</strong> Elevated AST/ALT (hepatic hypoperfusion), elevated alkaline phosphatase, elevated LDH (nonspecific)</li>
                <li><strong>Amylase/Lipase:</strong> Can be mildly elevated (nonspecific); helps rule out pancreatitis</li>
                <li><strong>D-dimer:</strong> Often very elevated (>1000 ng/mL) but non-specific. Normal D-dimer has high negative predictive value (helps rule out)</li>
                <li><strong>Arterial Blood Gas:</strong> Metabolic acidosis (pH <7.35, low HCO3), elevated lactate, base deficit</li>
                <li><strong>Coagulation Studies:</strong> If venous thrombosis suspected, check PT/INR, PTT, consider hypercoagulability workup (protein C/S, Factor V Leiden, antiphospholipid antibodies, JAK2 mutation)</li>
            </ul>
            
            <p><strong>Imaging - CT Angiography (CTA) Abdomen/Pelvis (GOLD STANDARD):</strong></p>
            <ul>
                <li><strong>Diagnostic test of choice - 90-95% sensitive and specific</strong></li>
                <li><strong>MUST be done with IV contrast in arterial phase</strong> to visualize mesenteric vessels</li>
                <li><strong>Findings - Arterial occlusion:</strong> SMA filling defect/occlusion, lack of contrast enhancement of bowel wall, pneumatosis intestinalis (air in bowel wall - ominous), portal venous gas (late sign, poor prognosis), free air (perforation)</li>
                <li><strong>Findings - Venous thrombosis:</strong> SMV or portal vein thrombus, bowel wall thickening, mesenteric edema/stranding, ascites</li>
                <li><strong>Findings - NOMI:</strong> Patent but narrowed mesenteric vessels, bowel wall thinning or thickening, no discrete occlusion</li>
                <li><strong>Contraindications:</strong> Renal insufficiency (risk vs benefit - ischemic bowel is fatal without diagnosis, contrast nephropathy is manageable)</li>
            </ul>
            
            <p><strong>Alternative Imaging:</strong></p>
            <ul>
                <li><strong>Abdominal X-ray (Supine and Upright):</strong> Low sensitivity (30%) but fast. Findings (late): pneumatosis intestinalis (air in bowel wall), portal venous gas, free air (perforation), ileus, "thumbprinting" (mucosal edema). Normal X-ray does NOT rule out mesenteric ischemia</li>
                <li><strong>Duplex Ultrasound:</strong> Can assess SMA/celiac artery stenosis, SMV thrombosis. Operator-dependent, bowel gas limits visualization. Not useful in acute setting</li>
                <li><strong>Conventional Angiography:</strong> Gold standard for diagnosis and potential intervention (intra-arterial vasodilators for NOMI, thrombolysis/embolectomy). Invasive, used therapeutically more than diagnostically now that CTA is excellent</li>
            </ul>
            
            <p><strong>Diagnostic Laparotomy/Laparoscopy:</strong></p>
            <ul>
                <li>If high clinical suspicion (severe pain, lactate elevated, peritonitis) but imaging non-diagnostic or unavailable, proceed to exploratory laparotomy</li>
                <li>"Don't let the sun set on mesenteric ischemia" - early surgery improves survival</li>
                <li>Directly visualize bowel: necrotic bowel (black, gangrenous), lack of peristalsis, lack of pulsations in mesenteric vessels</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management (TIME IS BOWEL - Urgent Action Required):</strong></p>
            <ul>
                <li>NPO, NGT to suction (decompress bowel)</li>
                <li>IV access: Two large-bore IVs</li>
                <li>Aggressive fluid resuscitation: LR or NS 1-2 L bolus, continue at 200-300 mL/hr (maintain perfusion pressure)</li>
                <li>Hemodynamic support: Target MAP >65 mmHg, maintain adequate perfusion</li>
                <li>Correct acidosis: IV fluids, treat underlying ischemia (acidosis corrects with reperfusion)</li>
                <li>URGENT Vascular Surgery + General Surgery Consultation (within 1 hour of suspected diagnosis)</li>
                <li>URGENT CTA if patient stable enough for imaging; if unstable or peritonitis â†’ direct to OR</li>
            </ul>
            
            <p><strong>Antibiotics (Broad-Spectrum - Start Immediately):</strong></p>
            <ul>
                <li>Ischemic bowel â†’ bacterial translocation, high risk of sepsis and peritonitis</li>
                <li>Piperacillin-tazobactam 3.375-4.5 g IV q6h</li>
                <li>Or Meropenem 1 g IV q8h (if severe sepsis or recent antibiotics)</li>
                <li>Or Ceftriaxone 2 g IV daily + Metronidazole 500 mg IV q8h</li>
                <li>Continue until after surgery, typically 5-7 days postoperatively</li>
            </ul>
            
            <p><strong>Anticoagulation:</strong></p>
            <ul>
                <li><strong>If Arterial Embolism or Thrombosis Confirmed (and no contraindications):</strong>
                    <ul>
                        <li>Heparin bolus 80 units/kg IV (max 5000 units), then infusion 18 units/kg/hr</li>
                        <li>Goal PTT 60-80 seconds</li>
                        <li>Prevents clot propagation, allows collateral flow to develop</li>
                        <li>Hold before surgery but restart postoperatively if feasible</li>
                    </ul>
                </li>
                <li><strong>If Venous Thrombosis (SMV/portal vein thrombosis):</strong>
                    <ul>
                        <li>Anticoagulation is primary treatment if NO bowel necrosis</li>
                        <li>Heparin drip (as above) or LMWH (enoxaparin 1 mg/kg SC q12h)</li>
                        <li>Transition to warfarin (INR 2-3) for 3-6 months minimum, possibly lifelong if unprovoked or hypercoagulable state</li>
                        <li>If bowel necrosis: surgery first, anticoagulate postoperatively</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Specific Treatments by Etiology:</strong></p>
            <ul>
                <li><strong>Arterial Embolism (50%):</strong>
                    <ul>
                        <li>EMERGENT SURGERY: Open embolectomy or bypass</li>
                        <li>Laparotomy â†’ SMA embolectomy via Fogarty catheter â†’ assess bowel viability â†’ resect necrotic segments</li>
                        <li>If viable bowel after revascularization: "second look" laparotomy in 24-48 hours to reassess (some bowel may declare itself non-viable later)</li>
                        <li>Postoperative anticoagulation (prevent recurrence)</li>
                    </ul>
                </li>
                <li><strong>Arterial Thrombosis (15-25%):</strong>
                    <ul>
                        <li>EMERGENT SURGERY: Bypass grafting (aorto-SMA bypass) or endarterectomy</li>
                        <li>More technically difficult than embolism (extensive atherosclerosis)</li>
                        <li>Higher mortality than embolic disease</li>
                    </ul>
                </li>
                <li><strong>Non-Occlusive Mesenteric Ischemia (NOMI, 20-30%):</strong>
                    <ul>
                        <li>Optimize hemodynamics: Fluids, stop vasopressors if possible, treat underlying shock/HF</li>
                        <li>Intra-arterial vasodilators via angiography: Papaverine 30-60 mg/hr continuous intra-arterial infusion into SMA (reverses vasoconstriction). Requires IR/angiography</li>
                        <li>If peritonitis or necrosis: SURGERY for bowel resection</li>
                        <li>NOMI has highest mortality (70-90%) because patients are critically ill at baseline</li>
                    </ul>
                </li>
                <li><strong>Venous Thrombosis (10%):</strong>
                    <ul>
                        <li>If NO peritonitis, NO bowel necrosis: MEDICAL management with anticoagulation alone (see above)</li>
                        <li>If peritonitis or suspected necrosis: SURGERY â†’ resect necrotic bowel â†’ postoperative anticoagulation</li>
                        <li>Better prognosis than arterial occlusion (slower onset, more collateral flow)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Surgical Principles:</strong></p>
            <ul>
                <li>Revascularization (embolectomy, thrombectomy, bypass) takes priority over resection</li>
                <li>After revascularization, wait 15-30 minutes, reassess bowel viability: look for peristalsis, pink color, arterial pulsations</li>
                <li>Resect clearly necrotic bowel (black, no pulses, no peristalsis)</li>
                <li>Leave questionable bowel â†’ "second look" laparotomy in 24-48 hours</li>
                <li>If extensive necrosis (>50% of small bowel): discuss prognosis with family, consider short bowel syndrome implications</li>
            </ul>
            
            <p><strong>Postoperative Care:</strong></p>
            <ul>
                <li>ICU monitoring</li>
                <li>Serial lactates (should normalize after successful reperfusion/resection)</li>
                <li>Broad-spectrum antibiotics continue 5-7 days</li>
                <li>Anticoagulation (arterial and venous cases)</li>
                <li>NPO, TPN until bowel function returns</li>
                <li>Scheduled "second look" laparotomy if planned (24-48 hours after initial surgery)</li>
            </ul>
            
            <p><strong>Consultations:</strong></p>
            <ul>
                <li><strong>Vascular Surgery:</strong> URGENT consult within 1 hour for arterial occlusion (embolectomy, bypass)</li>
                <li><strong>General Surgery:</strong> URGENT consult for bowel resection, exploratory laparotomy</li>
                <li><strong>Interventional Radiology:</strong> For angiography with papaverine infusion (NOMI), catheter-directed thrombolysis</li>
                <li><strong>Critical Care:</strong> ICU admission for hemodynamic support</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: ALL patients with mesenteric ischemia require ICU care (pre-op and post-op)</li>
                <li>Operating Room: EMERGENTLY if peritonitis, bowel necrosis, or arterial occlusion</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>"Pain Out of Proportion to Physical Exam" is the Hallmark:</strong> Early mesenteric ischemia (hours 0-6): patient writhing in severe, unrelenting abdominal pain, but exam shows soft abdomen with minimal tenderness, no rebound, no guarding. This discrepancy is pathognomonic. Why? Ischemia causes visceral pain (poorly localized, severe) but no peritoneal irritation yet (bowel wall hasn't necro sed). Once peritoneal signs develop (6-24 hours later), bowel is necrotic - prognosis much worse. If you see severe pain with benign exam in elderly patient with AF â†’ think mesenteric ischemia, get CTA immediately.</li>
            <li><strong>"Don't Let the Sun Set on Mesenteric Ischemia" - Time is Bowel:</strong> Mortality increases dramatically with delay. If revascularization occurs within 6 hours: mortality 30-50%. If 12-24 hours: mortality 70-90%. Bowel can tolerate ischemia for only 3-6 hours before irreversible necrosis. This is analogous to "time is brain" in stroke. High index of suspicion â†’ immediate CTA â†’ emergent surgery. Don't wait overnight, don't "observe." If strong clinical suspicion and patient has peritoneal signs, skip imaging and go directly to OR for exploratory laparotomy.</li>
            <li><strong>Atrial Fibrillation is the #1 Risk Factor for Arterial Mesenteric Ischemia:</strong> AF â†’ left atrial thrombus â†’ embolus to superior mesenteric artery (SMA). SMA supplies entire small bowel and proximal colon - occlusion is catastrophic. Elderly patient with AF who suddenly develops severe abdominal pain = mesenteric embolism until proven otherwise. 50% of acute mesenteric ischemia is embolic. Risk highest with AF not on anticoagulation, or new-onset AF (before anticoagulation started). Lesson: anticoagulate AF patients (prevents stroke AND mesenteric ischemia).</li>
            <li><strong>Lactate is the Most Important Lab but Normal Lactate Does NOT Rule Out Mesenteric Ischemia:</strong> 90% of mesenteric ischemia cases have elevated lactate (>2 mmol/L). Lactate >4 mmol/L strongly suggests transmural necrosis. BUT 10% have normal lactate in early stages. Why? Ischemia is patchy initially, limited anaerobic metabolism, collateral flow. So: elevated lactate in right clinical context = order CTA immediately. Normal lactate with high clinical suspicion = still order CTA, don't be falsely reassured. Serial lactates: rising = worsening, falling after surgery = good sign (successful reperfusion).</li>
            <li><strong>CTA Abdomen/Pelvis with IV Contrast in Arterial Phase is Diagnostic Test of Choice:</strong> 90-95% sensitive and specific. Shows SMA occlusion, SMV thrombosis, pneumatosis (air in bowel wall - ominous), portal venous gas (very late, poor prognosis). CTA has replaced conventional angiography for diagnosis (angiography still used therapeutically for papaverine infusion in NOMI). Order CTA if patient hemodynamically stable. If patient hypotensive, peritonitis, or CTA not immediately available â†’ skip imaging, go directly to OR (exploratory laparotomy).</li>
            <li><strong>NOMI (Non-Occlusive Mesenteric Ischemia) Has Worst Prognosis:</strong> 20-30% of mesenteric ischemia cases. Occurs in critically ill patients: cardiogenic shock, septic shock, post-cardiac surgery, dialysis patients, cocaine users. Low cardiac output â†’ mesenteric vasoconstriction â†’ bowel ischemia WITHOUT discrete arterial occlusion. CTA shows patent but narrowed vessels, no thrombus. Treatment: optimize hemodynamics (fluids, inotropes, avoid vasoconstrictors), intra-arterial papaverine via angiography (reverses vasospasm). Mortality 70-90% because underlying critical illness + bowel ischemia = dismal prognosis. Surgery if bowel necrosis.</li>
            <li><strong>Mesenteric Venous Thrombosis Can Be Treated Medically if Caught Early:</strong> Unlike arterial occlusion (always requires surgery unless purely NOMI), mesenteric venous thrombosis WITHOUT peritonitis or necrosis can be managed with anticoagulation alone. SMV/portal vein thrombosis develops more slowly (days to weeks), allows collateral flow. If caught early (abdominal pain, CT showing thrombus, no peritoneal signs, no free air): start heparin drip, transition to warfarin INR 2-3 x 3-6 months. Surgery only if necrosis suspected. Check for hypercoagulable states (Factor V Leiden, protein C/S deficiency, JAK2, cancer).</li>
            <li><strong>Second-Look Laparotomy is Often Necessary:</strong> After initial revascularization and resection of obviously necrotic bowel, surgeons often leave "questionable" bowel (dusky, no obvious necrosis but poor perfusion). Plan "second look" laparotomy in 24-48 hours to reassess viability. Why? Some ischemic bowel may recover with reperfusion; some borderline bowel may declare itself necrotic over next 24 hours. Second-look allows reassessment, resection of newly necrotic segments, avoids over-resection initially. Decreases short bowel syndrome risk. Second-look is standard of care in mesenteric ischemia surgery.</li>
            <li><strong>Acute Mesenteric Ischemia vs Colonic Ischemia Are Different Entities:</strong> Acute mesenteric ischemia (discussed here): SMA/IMA/celiac occlusion, involves small bowel Â± colon, severe, high mortality, requires surgery. Colonic ischemia: isolated ischemia of colon (usually "watershed" areas: splenic flexure, sigmoid), caused by hypotension, low cardiac output, NOT embolic. Presents with bloody diarrhea, mild abdominal pain, benign exam. Diagnosed by CT (colonic wall thickening, "thumbprinting"). Treatment: supportive care (fluids, bowel rest, broad-spectrum antibiotics). Most resolve spontaneously. Surgery only if perforation, gangrene. Don't confuse the two - colonic ischemia is much less severe.</li>
            <li><strong>Pneumatosis Intestinalis and Portal Venous Gas are Late, Ominous Findings:</strong> Pneumatosis = air in bowel wall (CT shows linear lucencies in bowel wall). Portal venous gas = air in portal vein/hepatic veins (CT shows branching lucencies in liver periphery). These findings indicate transmural necrosis, bacterial translocation. Pneumatosis has 40-50% mortality, portal venous gas 50-75% mortality. If you see these on CT â†’ patient needs emergency surgery (likely already has necrotic bowel). These are NOT incidental findings - they signify advanced disease.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>ALL patients with suspected or confirmed acute mesenteric ischemia â†’ ICU</li>
            <li>Severe abdominal pain out of proportion to exam</li>
            <li>Lactate >2 mmol/L with clinical suspicion</li>
            <li>Peritoneal signs (rebound, guarding, rigidity)</li>
            <li>Hemodynamic instability (hypotension, tachycardia, shock)</li>
            <li>Severe metabolic acidosis (pH <7.3, lactate >4 mmol/L)</li>
            <li>Post-operative from bowel resection/revascularization</li>
            <li>This is a surgical emergency with 60-80% mortality - ICU care is mandatory</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Mesenteric ischemia is NOT a discharge diagnosis - patients require surgery or die</li>
            <li>Post-operative patients discharge when:
                <ul>
                    <li>Bowel function returned (passing flatus/stool, tolerating PO diet)</li>
                    <li>No signs of infection (afebrile, WBC normalizing)</li>
                    <li>Adequate pain control on oral analgesics</li>
                    <li>Lactate normalized</li>
                    <li>Anticoagulation established if indicated (therapeutic INR 2-3 on warfarin, or DOAC started)</li>
                    <li>Cardiology follow-up for AF if relevant (rate/rhythm control, long-term anticoagulation)</li>
                    <li>Vascular surgery follow-up within 1-2 weeks</li>
                </ul>
            </li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="ckd-complications">
    <div class="page-header">
        <h2>107. CHRONIC KIDNEY DISEASE COMPLICATIONS</h2>
        <div class="subtitle">Hyperkalemia â€¢ Volume Overload â€¢ Metabolic Acidosis â€¢ Uremia â€¢ Dialysis Urgency</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with known CKD (GFR <60 mL/min/1.73mÂ²) presenting with acute decompensation: severe hyperkalemia, volume overload with pulmonary edema, worsening uremia, metabolic acidosis, or acute-on-chronic renal failure requiring urgent dialysis consideration.</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Progressive nephron loss leads to inability to maintain fluid/electrolyte homeostasis, acid-base balance, and toxin excretion. Acute decompensation triggered by: medication non-compliance (missed dialysis, dietary indiscretion), infection, volume overload, NSAIDs/nephrotoxins, obstruction, hypotension. Key complications: (1) Hyperkalemia (K >6.0 mEq/L, cardiac arrest risk), (2) Volume overload (pulmonary edema, hypertensive urgency), (3) Metabolic acidosis (HCO3 <15 mEq/L), (4) Uremia (pericarditis, encephalopathy, bleeding), (5) Mineral-bone disease (hypocalcemia, hyperphosphatemia, secondary hyperparathyroidism)</li>
                <li><strong>Risk Factors:</strong> CKD Stage 4-5 (GFR <30 mL/min), diabetes mellitus, hypertension, ESRD on dialysis (missed sessions), medication non-adherence, dietary indiscretion (high K, high Na, high fluid), ACE-I/ARB use, potassium-sparing diuretics, NSAIDs, contrast exposure, infections (UTI, sepsis), obstructive uropathy</li>
                <li><strong>Symptoms:</strong> Dyspnea (pulmonary edema), chest pain (pericarditis, ACS), muscle weakness (hyperkalemia), nausea/vomiting (uremia), confusion/altered mental status (uremic encephalopathy), pruritus (uremia), decreased urine output (oliguria/anuria), palpitations (arrhythmias from hyperkalemia)</li>
                <li><strong>Physical Exam:</strong> Hypertension (often severe, >180/110), rales/crackles (pulmonary edema), elevated JVP, peripheral edema (2-4+), pericardial friction rub (uremic pericarditis), altered mental status, asterixis, uremic frost (white crystalline deposits on skin - rare), pallor (anemia), excoriation marks (pruritus)</li>
                <li><strong>Variants/Subtypes:</strong> CKD Stage 3a (GFR 45-59, usually stable) vs Stage 3b (GFR 30-44) vs Stage 4 (GFR 15-29, pre-dialysis) vs Stage 5 (GFR <15, ESRD requiring RRT). Acute-on-chronic kidney injury (rapid GFR decline superimposed on CKD). Dialysis-dependent ESRD (missed dialysis sessions = acute decompensation)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Basic Metabolic Panel:</strong> Elevated BUN/Cr (baseline Cr varies; acute rise >0.3 mg/dL concerning), hyperkalemia (K >5.5 mEq/L concerning, >6.5 mEq/L emergency), metabolic acidosis (HCO3 <22 mEq/L in CKD, <15 mEq/L severe), hyperphosphatemia (PO4 >5.5 mg/dL), hyponatremia or hypernatremia, elevated anion gap (uremic acidosis)</li>
                <li><strong>Complete Blood Count:</strong> Normocytic anemia (low Hgb typical 8-10 g/dL in CKD from low EPO), thrombocytopenia if uremia severe</li>
                <li><strong>Calcium/Magnesium:</strong> Hypocalcemia (ionized Ca <1.0 mmol/L), hyperphosphatemia, elevated PTH (secondary hyperparathyroidism)</li>
                <li><strong>Arterial Blood Gas:</strong> Metabolic acidosis (pH <7.35, low HCO3, elevated anion gap), assess for respiratory compensation</li>
                <li><strong>ECG (CRITICAL for hyperkalemia):</strong> Peaked T waves (K 5.5-6.5), loss of P waves (K 6.5-7.0), widened QRS (K >7.0), sine wave pattern (K >8.0, pre-cardiac arrest), bradycardia, AV blocks, ventricular arrhythmias</li>
                <li><strong>Urinalysis:</strong> Assess for infection (pyuria, bacteria), obstruction, new proteinuria/hematuria</li>
                <li><strong>Other:</strong> PTH (elevated in CKD-MBD), albumin, troponin (if chest pain), BNP (if dyspnea/volume overload)</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>Chest X-ray:</strong> Pulmonary edema (perihilar infiltrates, Kerley B lines, pleural effusions), cardiomegaly, pericardial effusion (uremic pericarditis)</li>
                <li><strong>Renal Ultrasound:</strong> Assess kidney size (small echogenic kidneys = chronic disease), hydronephrosis (obstruction), renal artery stenosis (Doppler). Helps differentiate acute vs chronic kidney disease</li>
                <li><strong>Echocardiogram:</strong> If pericardial effusion suspected (pericardial friction rub, muffled heart sounds), assess LV function, valvular disease</li>
            </ul>
            
            <p><strong>Assessment of Acute vs Chronic Kidney Injury:</strong></p>
            <ul>
                <li>Acute-on-chronic: Rapid rise in Cr (>0.3 mg/dL in 48 hours or >1.5x baseline in 7 days)</li>
                <li>Chronic: Small kidneys (<9 cm), anemia, hyperphosphatemia, hypocalcemia, elevated PTH</li>
                <li>Review prior Cr values (establish baseline renal function)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management (Priority-Based):</strong></p>
            <ul>
                <li><strong>1. Hyperkalemia (MOST URGENT - cardiac arrest risk):</strong> See detailed protocol below</li>
                <li><strong>2. Volume Overload/Pulmonary Edema:</strong> Oxygen, diuresis, consider dialysis</li>
                <li><strong>3. Severe Metabolic Acidosis (pH <7.2):</strong> Sodium bicarbonate, consider dialysis</li>
                <li><strong>4. Uremic Complications:</strong> Urgent dialysis if pericarditis, encephalopathy, bleeding</li>
            </ul>
            
            <p><strong>HYPERKALEMIA MANAGEMENT (K >6.0 mEq/L or ECG changes):</strong></p>
            <ul>
                <li><strong>Step 1 - Cardiac Membrane Stabilization (if ECG changes present):</strong>
                    <ul>
                        <li>Calcium gluconate 10% 1-2 grams (10-20 mL) IV over 2-5 minutes</li>
                        <li>Or Calcium chloride 10% 0.5-1 gram (5-10 mL) IV over 2-5 minutes (via central line preferred)</li>
                        <li>Onset: 1-3 minutes, Duration: 30-60 minutes</li>
                        <li>Does NOT lower K, just stabilizes cardiac membranes</li>
                        <li>Repeat dose if ECG changes persist after 5 minutes</li>
                    </ul>
                </li>
                <li><strong>Step 2 - Shift Potassium Intracellularly:</strong>
                    <ul>
                        <li><strong>Insulin + Glucose:</strong> Regular insulin 10 units IV + D50 50 mL (25 grams dextrose) IV push. Onset: 15-30 minutes, Duration: 4-6 hours, Lowers K by 0.5-1.2 mEq/L. Check glucose q1h (risk of hypoglycemia). If glucose >250 mg/dL, give insulin without dextrose</li>
                        <li><strong>Albuterol Nebulized:</strong> 10-20 mg nebulized over 10 minutes (4-8 times standard dose). Onset: 30 minutes, Duration: 2 hours, Lowers K by 0.5-1.0 mEq/L. Synergistic with insulin</li>
                        <li><strong>Sodium Bicarbonate (if acidotic):</strong> 150 mEq (3 amps, 50 mEq each) in 1 L D5W over 2-4 hours. Only effective if metabolic acidosis present (pH <7.2, HCO3 <15). Lowers K by 0.5 mEq/L</li>
                    </ul>
                </li>
                <li><strong>Step 3 - Remove Potassium from Body:</strong>
                    <ul>
                        <li><strong>Diuretics (if residual kidney function):</strong> Furosemide 40-80 mg IV push (increase to 160-200 mg if CKD Stage 4-5). Promotes renal K excretion</li>
                        <li><strong>Patiromer (Veltassa):</strong> 8.4 g PO daily, increase to 25.2 g daily. Onset: 4-7 hours. GI K binder. For non-emergent or chronic management</li>
                        <li><strong>Sodium Zirconium Cyclosilicate (Lokelma):</strong> 10 g PO TID x 48 hours, then 10 g PO daily. Onset: 1 hour. Faster than patiromer</li>
                        <li><strong>Sodium Polystyrene Sulfonate (Kayexalate) - AVOID if possible:</strong> 15-30 g PO/PR. Onset: 2-4 hours. Risk of bowel necrosis (especially with sorbitol). Use only if other binders unavailable</li>
                        <li><strong>Hemodialysis:</strong> MOST EFFECTIVE. Removes 50-75 mEq K per session. Indicated if K >6.5 mEq/L with ECG changes, K >7.0 mEq/L, refractory to medical management, or anuric ESRD patient</li>
                    </ul>
                </li>
                <li><strong>Monitoring:</strong> Continuous telemetry, repeat K q2h until <5.5 mEq/L, repeat ECG after interventions</li>
            </ul>
            
            <p><strong>VOLUME OVERLOAD / PULMONARY EDEMA MANAGEMENT:</strong></p>
            <ul>
                <li><strong>Oxygen:</strong> Supplemental O2 to maintain SpO2 >92%</li>
                <li><strong>Positioning:</strong> Upright position (reduces preload)</li>
                <li><strong>Diuretics (if residual kidney function, GFR >15 mL/min):</strong>
                    <ul>
                        <li>Furosemide 80-200 mg IV push (higher doses in CKD)</li>
                        <li>If inadequate response: Furosemide continuous infusion 10-40 mg/hr</li>
                        <li>Add thiazide diuretic for synergy: Metolazone 5-10 mg PO 30 minutes before furosemide</li>
                    </ul>
                </li>
                <li><strong>Nitroglycerin (if hypertensive):</strong> 0.4 mg SL q5min x 3, or IV infusion 10-200 mcg/min</li>
                <li><strong>Ultrafiltration/Dialysis:</strong> If minimal urine output (<400 mL/day), refractory pulmonary edema, or GFR <15 mL/min. Can remove 2-4 L fluid per session</li>
            </ul>
            
            <p><strong>METABOLIC ACIDOSIS MANAGEMENT:</strong></p>
            <ul>
                <li><strong>Sodium Bicarbonate (if pH <7.2 or HCO3 <15 mEq/L):</strong>
                    <ul>
                        <li>Acute: 1-2 amps (50-100 mEq) IV push, can repeat</li>
                        <li>Infusion: 150 mEq (3 amps) in 1 L D5W at 100-150 mL/hr</li>
                        <li>Goal: pH >7.2, HCO3 >15-18 mEq/L (avoid over-correction)</li>
                        <li>Caution: worsens volume overload, hypernatremia</li>
                    </ul>
                </li>
                <li><strong>Dialysis:</strong> Most effective for severe acidosis in ESRD</li>
            </ul>
            
            <p><strong>URGENT DIALYSIS INDICATIONS ("AEIOU"):</strong></p>
            <ul>
                <li><strong>A</strong> - Acidosis (refractory metabolic acidosis, pH <7.2)</li>
                <li><strong>E</strong> - Electrolytes (severe hyperkalemia K >6.5 mEq/L with ECG changes, refractory to medical therapy)</li>
                <li><strong>I</strong> - Intoxication (dialyzable toxins: methanol, ethylene glycol, lithium, salicylates)</li>
                <li><strong>O</strong> - Overload (volume overload, pulmonary edema refractory to diuretics)</li>
                <li><strong>U</strong> - Uremia (pericarditis, encephalopathy, bleeding diathesis)</li>
            </ul>
            
            <p><strong>Nephrology Consultation:</strong></p>
            <ul>
                <li>STAT consult for urgent dialysis consideration</li>
                <li>All CKD Stage 4-5 admissions for ongoing management</li>
                <li>Acute-on-chronic kidney injury</li>
                <li>Dialysis catheter placement (if no AV fistula/graft available)</li>
            </ul>
            
            <p><strong>Chronic CKD Management (Once Stabilized):</strong></p>
            <ul>
                <li><strong>Anemia:</strong> ESA (epoetin alfa, darbepoetin) if Hgb <10 g/dL, goal Hgb 10-11.5 g/dL. Iron supplementation (IV iron preferred in CKD)</li>
                <li><strong>Mineral-Bone Disease:</strong> Phosphate binders (calcium acetate, sevelamer), vitamin D analogs (calcitriol, paricalcitol), calcimimetics (cinacalcet) if elevated PTH</li>
                <li><strong>Dietary:</strong> Low potassium (<2-3 g/day), low phosphorus (<800-1000 mg/day), fluid restriction (1-1.5 L/day if oliguric), sodium restriction (<2 g/day)</li>
                <li><strong>Medications to Avoid:</strong> NSAIDs, aminoglycosides, IV contrast (if possible), metformin (hold if GFR <30), digoxin (reduce dose), renally-cleared drugs (adjust for GFR)</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Severe hyperkalemia (K >7.0, ECG changes), pulmonary edema requiring BiPAP/intubation, hemodynamic instability, urgent dialysis needed, uremic pericarditis with tamponade</li>
                <li>Floor with Telemetry: Moderate hyperkalemia (K 6.0-7.0), volume overload managed with diuretics, acute-on-chronic kidney injury</li>
                <li>Discharge: Hyperkalemia resolved (K <5.5 mEq/L), euvolemic, stable renal function, follow-up arranged with nephrology</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>ECG Changes Predict Cardiac Arrest Risk Better Than Absolute K Level:</strong> Hyperkalemia is dangerous because of cardiac arrhythmias, not the number itself. K 6.5 mEq/L with peaked T waves is more dangerous than K 7.5 mEq/L with normal ECG. ECG progression: Peaked T waves (K 5.5-6.5) â†’ Loss of P waves + widened QRS (K 6.5-7.5) â†’ Sine wave pattern (K >8.0, pre-arrest). ANY ECG change from hyperkalemia = give calcium gluconate immediately to stabilize cardiac membrane, then shift K intracellularly (insulin+glucose, albuterol), then remove K (dialysis). Don't wait for "critical" K level.</li>
            <li><strong>Calcium Gluconate Does NOT Lower Potassium - It Stabilizes Cardiac Membranes:</strong> Common misconception: calcium lowers K. FALSE. Calcium antagonizes K's effect on cardiac myocyte membranes, preventing arrhythmias, but K level unchanged. Think of it as buying time (30-60 minutes) while you actually lower K with insulin/glucose, albuterol, dialysis. Give calcium if ANY ECG changes (peaked T, widened QRS), don't wait for sine wave. Can repeat calcium q5min if ECG changes persist. Calcium gluconate 1-2 g IV over 2-5 minutes (10-20 mL of 10% solution).</li>
            <li><strong>Insulin+Glucose+Albuterol is the Fastest Way to Lower K Acutely (Besides Dialysis):</strong> Insulin drives K into cells via Na-K-ATPase. Give regular insulin 10 units IV + D50 50 mL (if glucose <250 mg/dL). Lowers K by 0.5-1.2 mEq/L in 15-30 minutes, lasts 4-6 hours. Add albuterol 10-20 mg nebulized (4-8x standard dose) - synergistic, lowers K by another 0.5-1.0 mEq/L. Combined, can lower K by 1-2 mEq/L. Pitfall: insulin without glucose causes hypoglycemia (check glucose q1h x 4 hours). If glucose >250 mg/dL, give insulin alone without dextrose.</li>
            <li><strong>Hemodialysis is Most Effective K Removal - Lower Threshold in CKD Stage 4-5:</strong> Dialysis removes 50-75 mEq K per 4-hour session, lowering K by 2-3 mEq/L. Most definitive treatment. Indications: K >6.5 mEq/L with ECG changes, K >7.0 mEq/L regardless of ECG, refractory to medical therapy, or anuric ESRD patient (can't excrete K renally). Don't delay dialysis hoping medical management will work in CKD Stage 5 patient with K 7.0 - just dialyze. Medical management is temporizing; dialysis is definitive in these patients.</li>
            <li><strong>"AEIOU" Mnemonic for Urgent Dialysis Indications:</strong> A = Acidosis (pH <7.2 refractory), E = Electrolytes (severe hyperkalemia K >6.5 with ECG changes), I = Intoxication (methanol, ethylene glycol, lithium, salicylates - dialyzable toxins), O = Overload (volume overload, pulmonary edema refractory to diuretics), U = Uremia (pericarditis, encephalopathy, bleeding). If any AEIOU criterion met, consult nephrology STAT for urgent dialysis. Don't delay with prolonged medical management attempts.</li>
            <li><strong>Kayexalate (Sodium Polystyrene Sulfonate) is Obsolete and Dangerous:</strong> Old-school K binder with minimal efficacy (only lowers K by 0.5-1.0 mEq/L after 4-6 hours) and serious risk of bowel necrosis (especially with sorbitol). FDA black box warning. Newer K binders (patiromer, sodium zirconium cyclosilicate) are safer and faster. Use Lokelma (10 g PO, onset 1 hour) or Veltassa (8.4 g PO, onset 4-7 hours) instead. Reserve Kayexalate only if newer binders unavailable. Never give Kayexalate with sorbitol. For acute severe hyperkalemia, use insulin/glucose/albuterol/dialysis - not Kayexalate.</li>
            <li><strong>CKD Patients Need Much Higher Furosemide Doses for Diuresis:</strong> Loop diuretics work at thick ascending limb of loop of Henle. In CKD, reduced drug delivery to site of action (low GFR) + structural changes in nephrons = resistance to diuretics. Standard furosemide dose (20-40 mg IV) is inadequate. CKD Stage 3: 80 mg IV; Stage 4: 120-160 mg IV; Stage 5: 160-200 mg IV bolus. If inadequate diuresis, use continuous furosemide infusion 10-40 mg/hr or add metolazone 5-10 mg PO (thiazide + loop = synergistic diuresis). Alternatively, dialyze for volume removal (ultrafiltration).</li>
            <li><strong>Target Hgb 10-11.5 g/dL in CKD Anemia - Higher Targets Increase Mortality:</strong> CKD causes anemia (low erythropoietin production). Treat with ESAs (epoetin alfa, darbepoetin) + IV iron. But targeting higher Hgb (>13 g/dL) with aggressive ESA dosing increases stroke, MI, thrombosis, mortality (TREAT trial). Current guidelines: start ESA if Hgb <10 g/dL, target 10-11.5 g/dL. Never transfuse to Hgb >12 g/dL. Iron supplementation essential: check ferritin, TSAT; give IV iron if ferritin <500 ng/mL or TSAT <30% (oral iron poorly absorbed in CKD).</li>
            <li><strong>Secondary Hyperparathyroidism in CKD Requires Triple Therapy:</strong> CKD causes hyperphosphatemia (kidneys can't excrete PO4) â†’ binds Ca â†’ hypocalcemia â†’ elevated PTH â†’ bone disease. Management: (1) Phosphate binders with meals (calcium acetate, sevelamer, lanthanum) to reduce PO4 absorption, goal PO4 <5.5 mg/dL; (2) Vitamin D analogs (calcitriol 0.25-0.5 mcg daily or paricalcitol) to suppress PTH; (3) Calcimimetics (cinacalcet 30-180 mg daily) if PTH remains >300 pg/mL despite above. Goal PTH 150-300 pg/mL in CKD Stage 5. Uncontrolled secondary hyperparathyroidism causes renal osteodystrophy (bone pain, fractures) and vascular calcification.</li>
            <li><strong>Avoid Metformin if GFR <30 mL/min - Risk of Lactic Acidosis:</strong> Metformin is renally excreted. Accumulation in renal failure causes lactic acidosis (type B, non-hypoxic). Mortality 30-50% if metformin-associated lactic acidosis develops. FDA guidelines: Hold metformin if GFR <30 mL/min. If patient on metformin presents with AKI + lactic acidosis (lactate >5-10 mmol/L, pH <7.35, anion gap acidosis), assume metformin-induced until proven otherwise. Treatment: hemodialysis (removes metformin + lactate). Similarly, avoid contrast in CKD (risk of contrast-induced nephropathy); if unavoidable, IV fluids before/after, hold metformin 48 hours pre/post-contrast.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Severe hyperkalemia (K >7.0 mEq/L) or any hyperkalemia with ECG changes (peaked T, widened QRS, sine wave)</li>
            <li>Refractory hyperkalemia despite medical management (requires urgent dialysis)</li>
            <li>Pulmonary edema with respiratory failure (requiring BiPAP, intubation)</li>
            <li>Severe metabolic acidosis (pH <7.1) refractory to bicarbonate</li>
            <li>Uremic pericarditis with hemodynamic compromise or cardiac tamponade</li>
            <li>Altered mental status from uremic encephalopathy</li>
            <li>Hypertensive emergency (BP >220/120 with end-organ damage)</li>
            <li>Dialysis catheter placement needed emergently but no existing access</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Potassium normalized (<5.5 mEq/L) and stable for 24 hours</li>
            <li>Volume status optimized (euvolemic, no dyspnea at rest, SpO2 >92% on room air)</li>
            <li>Renal function stable or improved (Cr at or near baseline for patient)</li>
            <li>Metabolic acidosis corrected (HCO3 >18-20 mEq/L) or chronic compensated</li>
            <li>Blood pressure controlled (<160/100 mmHg on oral regimen)</li>
            <li>If new dialysis: first outpatient dialysis session scheduled within 48 hours, dialysis catheter functional</li>
            <li>Patient educated on low-potassium diet, fluid restriction, medication adherence</li>
            <li>Nephrology follow-up arranged within 1-2 weeks (sooner if dialysis-dependent)</li>
            <li>Medications reconciled (nephrotoxins stopped, doses adjusted for GFR)</li>
            <li>Patient/family understand signs of hyperkalemia, fluid overload, when to seek emergency care</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="uremia">
    <div class="page-header">
        <h2>108. UREMIC SYNDROME</h2>
        <div class="subtitle">End-Stage Renal Failure â€¢ Uremic Pericarditis â€¢ Encephalopathy â€¢ Bleeding â€¢ Dialysis Required</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with ESRD (GFR <15 mL/min) or acute severe kidney injury presenting with systemic manifestations of uremic toxin accumulation: nausea/vomiting, altered mental status, pericarditis, bleeding, pruritus, asterixis - indicating urgent need for renal replacement therapy.</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Accumulation of uremic toxins (urea, creatinine, guanidine compounds, middle molecules, protein-bound solutes) when kidneys fail to excrete metabolic waste. Affects multiple organ systems. Key manifestations: (1) Uremic pericarditis (fibrinous pericarditis, risk of tamponade), (2) Uremic encephalopathy (confusion, seizures, coma), (3) Platelet dysfunction (prolonged bleeding time despite normal platelet count), (4) Neuropathy (peripheral neuropathy, restless legs), (5) Pruritus, (6) GI symptoms (nausea, anorexia, uremic fetor - ammonia breath smell)</li>
                <li><strong>Risk Factors:</strong> ESRD (any cause: diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritis), missed dialysis sessions, acute kidney injury (AKI with BUN >100 mg/dL, Cr >8-10 mg/dL), delayed initiation of dialysis, malnutrition, elderly age</li>
                <li><strong>Symptoms:</strong> Nausea, vomiting, anorexia (early), metallic taste, uremic fetor (ammonia or "fishy" breath smell), confusion/lethargy (uremic encephalopathy), seizures, chest pain (pericarditis), dyspnea, pruritus (intense, generalized itching), fatigue, weakness, restless legs syndrome, hiccups (persistent, from diaphragmatic irritation)</li>
                <li><strong>Physical Exam:</strong> Altered mental status (confusion, somnolence), asterixis (flapping tremor, similar to hepatic encephalopathy), pericardial friction rub (pathognomonic for uremic pericarditis), tachycardia, hypotension (if tamponade), pallor (anemia), uremic frost (white crystalline urea deposits on skin - very rare, extreme uremia), excoriations from scratching (pruritus), peripheral edema, peripheral neuropathy (decreased reflexes, sensory loss)</li>
                <li><strong>Variants/Subtypes:</strong> Uremic pericarditis vs Uremic encephalopathy vs Uremic bleeding diathesis. Acute uremia (AKI with rapid toxin accumulation) vs Chronic uremia (ESRD with gradual onset)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Basic Metabolic Panel:</strong> Markedly elevated BUN (typically >80-100 mg/dL, can be >150-200 mg/dL), markedly elevated Cr (>8-10 mg/dL), hyperkalemia, metabolic acidosis, elevated anion gap</li>
                <li><strong>BUN/Cr Ratio:</strong> Usually >20:1 in uremia (indicates poor renal function with urea accumulation)</li>
                <li><strong>Complete Blood Count:</strong> Normocytic anemia (Hgb 6-10 g/dL), normal or elevated WBC, platelet count usually normal (dysfunction is qualitative, not quantitative)</li>
                <li><strong>Coagulation Studies:</strong> PT/INR normal, PTT normal, but <strong>bleeding time prolonged</strong> (platelet dysfunction from uremic toxins)</li>
                <li><strong>Arterial Blood Gas:</strong> Metabolic acidosis (pH <7.35, HCO3 <18 mEq/L)</li>
                <li><strong>Other:</strong> Elevated phosphate, low calcium, elevated PTH, hypoalbuminemia</li>
            </ul>
            
            <p><strong>ECG:</strong></p>
            <ul>
                <li>Pericarditis: Diffuse ST elevations (concave upward), PR depression (highly specific for pericarditis)</li>
                <li>Hyperkalemia: Peaked T waves, widened QRS, loss of P waves (see CKD complications)</li>
                <li>Low voltage (if pericardial effusion)</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>Echocardiogram (if pericarditis suspected):</strong> Pericardial effusion (can be small to large), fibrinous strands, assess for tamponade physiology (RV collapse, exaggerated respiratory variation in mitral inflow), assess LV function</li>
                <li><strong>Chest X-ray:</strong> Cardiomegaly (if effusion), pulmonary edema (if volume overload)</li>
            </ul>
            
            <p><strong>Diagnostic Criteria for Uremic Pericarditis:</strong></p>
            <ul>
                <li>Clinical: Chest pain, pericardial friction rub, dyspnea</li>
                <li>ECG: Diffuse ST elevations, PR depression</li>
                <li>Echo: Pericardial effusion</li>
                <li>Context: ESRD or severe AKI (BUN >60-80 mg/dL)</li>
                <li>Uremic pericarditis is "dialysis-requiring" pericarditis - absolute indication for urgent dialysis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management:</strong></p>
            <ul>
                <li>Assess hemodynamic stability (BP, HR, oxygen saturation)</li>
                <li>IV access, continuous telemetry</li>
                <li>NPO initially (nausea, vomiting common)</li>
                <li>Antiemetics: Ondansetron 4-8 mg IV q8h PRN</li>
                <li>URGENT Nephrology Consult for dialysis consideration</li>
            </ul>
            
            <p><strong>URGENT DIALYSIS - Primary Treatment for Uremic Syndrome:</strong></p>
            <ul>
                <li><strong>Indications (Absolute for Uremia):</strong>
                    <ul>
                        <li>Uremic pericarditis (MOST IMPORTANT - prevents cardiac tamponade)</li>
                        <li>Uremic encephalopathy (confusion, seizures, coma)</li>
                        <li>Uremic bleeding (platelet dysfunction causing GI bleeding, epistaxis)</li>
                        <li>Intractable nausea/vomiting despite antiemetics</li>
                        <li>BUN >100 mg/dL with symptoms</li>
                        <li>Also: AEIOU criteria (see CKD complications - acidosis, electrolytes, intoxication, overload)</li>
                    </ul>
                </li>
                <li><strong>Modality:</strong> Hemodialysis preferred for urgent indications (faster clearance than peritoneal dialysis)</li>
                <li><strong>Access:</strong> Temporary dialysis catheter (internal jugular or femoral vein) if no AV fistula/graft. Place urgently</li>
                <li><strong>Frequency:</strong> Initially daily or every other day until uremia resolves, then 3x/week (standard ESRD schedule)</li>
                <li><strong>Response:</strong> Symptoms typically improve within 24-48 hours of initiating dialysis. Pericarditis resolves over 1-2 weeks</li>
            </ul>
            
            <p><strong>Specific Management by Complication:</strong></p>
            <ul>
                <li><strong>Uremic Pericarditis:</strong>
                    <ul>
                        <li>Dialysis is PRIMARY treatment (resolves pericarditis in 85-90% of cases)</li>
                        <li>NSAIDs and Colchicine are CONTRAINDICATED (worsen renal function, ineffective for uremic pericarditis)</li>
                        <li>Heparin-free dialysis (avoid anticoagulation during dialysis if pericardial effusion, bleeding risk)</li>
                        <li>If large effusion (>2 cm on echo) or tamponade: Pericardiocentesis or pericardial window</li>
                        <li>Monitor with serial echos q2-3 days until effusion resolves</li>
                    </ul>
                </li>
                <li><strong>Uremic Encephalopathy:</strong>
                    <ul>
                        <li>Dialysis is treatment (clears uremic toxins)</li>
                        <li>Avoid sedatives (benzodiazepines worsen encephalopathy)</li>
                        <li>Seizures: Levetiracetam 500-1000 mg IV (renally cleared but safer than phenytoin in uremia)</li>
                        <li>Airway protection if altered mental status (GCS <8)</li>
                    </ul>
                </li>
                <li><strong>Uremic Bleeding (Platelet Dysfunction):</strong>
                    <ul>
                        <li>Dialysis improves platelet function (but takes days)</li>
                        <li>For acute bleeding:
                            <ul>
                                <li><strong>DDAVP (Desmopressin):</strong> 0.3 mcg/kg IV over 30 minutes. Increases vWF release, improves platelet adhesion. Onset 1-2 hours, duration 4-8 hours. Can repeat q12-24h</li>
                                <li><strong>Cryoprecipitate:</strong> 10 units IV. Contains vWF, Factor VIII. Onset 1 hour, duration 12-24 hours. More effective than DDAVP</li>
                                <li><strong>Conjugated Estrogens:</strong> 0.6 mg/kg IV daily x 5 days. Improves platelet function, but onset 6-12 hours, used for refractory bleeding</li>
                                <li><strong>Platelet Transfusion:</strong> Generally NOT effective (transfused platelets also become dysfunctional in uremic environment)</li>
                            </ul>
                        </li>
                        <li>Correct anemia: Transfuse PRBCs if Hgb <7 g/dL (improves platelet function by increasing RBC-platelet interactions)</li>
                    </ul>
                </li>
                <li><strong>Pruritus:</strong>
                    <ul>
                        <li>Dialysis (most effective)</li>
                        <li>Topical: Moisturizing creams, capsaicin cream</li>
                        <li>Oral: Gabapentin 100-300 mg post-dialysis, Pregabalin 25-75 mg post-dialysis (both renally cleared, dose after dialysis)</li>
                        <li>UVB phototherapy if refractory</li>
                    </ul>
                </li>
                <li><strong>Nausea/Vomiting:</strong>
                    <ul>
                        <li>Ondansetron 4-8 mg IV q8h</li>
                        <li>Metoclopramide 5-10 mg IV q6h (use cautiously, risk of extrapyramidal symptoms in uremia)</li>
                        <li>Dialysis improves nausea within 24-48 hours</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Supportive Care:</strong></p>
            <ul>
                <li>Nutrition: Protein restriction (0.8-1.0 g/kg/day pre-dialysis, 1.2 g/kg/day on dialysis), low potassium, low phosphorus</li>
                <li>Phosphate binders with meals (prevent hyperphosphatemia)</li>
                <li>Treat anemia: ESAs, IV iron</li>
                <li>Avoid nephrotoxins: NSAIDs, aminoglycosides, IV contrast</li>
            </ul>
            
            <p><strong>Consultations:</strong></p>
            <ul>
                <li><strong>Nephrology:</strong> URGENT - for dialysis initiation, access placement, ongoing management</li>
                <li><strong>Cardiology:</strong> If uremic pericarditis with large effusion or tamponade (may need pericardiocentesis)</li>
                <li><strong>Vascular Surgery:</strong> For AV fistula creation (long-term dialysis access)</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Uremic pericarditis with tamponade, severe uremic encephalopathy (GCS <12, seizures), active bleeding from uremia, hemodynamic instability</li>
                <li>Floor with Telemetry: Uremia requiring dialysis initiation, uremic encephalopathy (mild confusion), stable pericardial effusion</li>
                <li>Discharge: Only after dialysis initiated, symptoms improved, effusion (if present) stable/resolving, outpatient dialysis arranged (3x/week)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Uremic Pericarditis is an ABSOLUTE Indication for Urgent Dialysis:</strong> Unlike viral or idiopathic pericarditis (treated with NSAIDs/colchicine), uremic pericarditis ONLY responds to dialysis. NSAIDs and colchicine are contraindicated (worsen renal function, ineffective). Uremic pericarditis = fibrinous "bread-and-butter" pericarditis from direct toxic effect of uremic toxins on pericardium. Friction rub is pathognomonic. Can progress to large effusion and tamponade. Dialysis resolves pericarditis in 85-90% of cases over 1-2 weeks. If large effusion or tamponade: consider pericardiocentesis, but still need dialysis as primary treatment.</li>
            <li><strong>BUN >100 mg/dL is Not Diagnostic of Uremia - Symptoms Define Uremia:</strong> Uremic syndrome is clinical diagnosis: presence of uremic symptoms (nausea, encephalopathy, pericarditis, bleeding, pruritus) in setting of kidney failure. BUN >80-100 mg/dL typically correlates with symptoms, but some patients tolerate BUN >150 mg/dL without symptoms (chronic uremia, gradual rise). Conversely, acute rise to BUN 60-80 mg/dL can cause symptoms (acute uremia). Diagnosis uremia based on symptoms + elevated BUN/Cr, not BUN number alone. Dialysis indicated if symptomatic uremia regardless of exact BUN level.</li>
            <li><strong>Uremic Frost is Pathognomonic but Extremely Rare:</strong> White crystalline deposits on skin from evaporation of sweat with high urea content (urea crystallizes on skin surface). Looks like white powder, typically on face, neck. Only occurs with extreme uremia (BUN >200 mg/dL). Historical curiosity - almost never seen in modern medicine because dialysis initiated before BUN reaches such levels. If you see uremic frost, patient has been severely neglected (missed dialysis x weeks-months). Immediately initiate dialysis.</li>
            <li><strong>Asterixis is Not Specific to Hepatic Encephalopathy - Also Seen in Uremic Encephalopathy:</strong> Asterixis = "flapping tremor," best elicited by having patient extend arms/wrists with fingers spread (like "stop" sign), observe for irregular lapses in wrist extension. Results from disruption of diencephalic-brain stem pathways controlling postural tone. Seen in any metabolic encephalopathy: hepatic, uremic, hypercapnia, drug toxicity. Not specific but helpful clinical sign. In uremic encephalopathy, asterixis indicates moderate-severe uremia - need urgent dialysis.</li>
            <li><strong>Uremic Platelet Dysfunction Causes Prolonged Bleeding Time Despite Normal Platelet Count and PT/INR/PTT:</strong> Uremia causes qualitative platelet defect (impaired adhesion/aggregation from uremic toxins interfering with vWF-platelet binding), not quantitative defect. CBC shows normal platelet count. PT/INR/PTT normal (coagulation cascade intact). But bleeding time prolonged (>10 minutes, normal <10 min). Clinically: mucosal bleeding (epistaxis, GI bleeding, menorrhagia), easy bruising. Treatment: dialysis (most effective, but takes days), DDAVP 0.3 mcg/kg IV (rapid onset 1-2 hr, short duration 4-8 hr), cryoprecipitate (10 units IV, more effective than DDAVP).</li>
            <li><strong>DDAVP vs Cryoprecipitate for Uremic Bleeding:</strong> Both improve uremic platelet dysfunction by increasing vWF (platelet adhesion). DDAVP (desmopressin) stimulates endogenous vWF release from endothelial cells - easier to give, onset 1-2 hours, duration 4-8 hours, can repeat q12-24h. Cryoprecipitate provides exogenous vWF + Factor VIII - more effective than DDAVP, onset 1 hour, duration 12-24 hours, but requires blood product. Use DDAVP first-line for mild bleeding; cryoprecipitate for severe/refractory bleeding. Platelet transfusion NOT effective (transfused platelets become dysfunctional in uremic environment).</li>
            <li><strong>NSAIDs are Absolutely Contraindicated in Uremic Pericarditis:</strong> Common error: treating chest pain from uremic pericarditis with NSAIDs (ibuprofen, indomethacin) like viral pericarditis. BAD. NSAIDs worsen renal function (inhibit prostaglandin-mediated renal blood flow), cause further AKI, and are ineffective for uremic pericarditis (doesn't respond to anti-inflammatory drugs). Similarly, colchicine ineffective. Uremic pericarditis is NOT an inflammatory process - it's direct toxic effect of uremic toxins on pericardium. Only treatment: DIALYSIS (clears toxins, resolves pericarditis). Pain control: use opioids (fentanyl, hydromorphone) or acetaminophen, not NSAIDs.</li>
            <li><strong>Heparin-Free Dialysis is Required if Pericardial Effusion or Bleeding Risk:</strong> Standard hemodialysis uses heparin anticoagulation (prevents clotting in dialysis circuit). But if patient has uremic pericarditis with pericardial effusion or active bleeding, heparin worsens bleeding/hemorrhagic pericardial effusion. Use "heparin-free" or "minimal heparin" dialysis: saline flushes of circuit, regional citrate anticoagulation, or frequent circuit changes. Discuss with nephrology before first dialysis session if pericardial effusion on echo. Hemorrhagic pericardial effusion can progress to tamponade.</li>
            <li><strong>Dialysis Disequilibrium Syndrome is Risk with First Dialysis in Severe Uremia:</strong> Rapid reduction in BUN during aggressive first dialysis (BUN drops from 150 to 50 mg/dL in 4 hours) creates osmotic gradient - brain slower to equilibrate than serum, causing cerebral edema. Symptoms during or after dialysis: headache, nausea, confusion, seizures, coma. More common when BUN >150-175 mg/dL, rapid/aggressive dialysis, first dialysis session. Prevention: "gentle" first dialysis (2 hours instead of 4, lower blood flow rate, limit BUN reduction to <40% per session), use higher dialysate sodium. If symptoms develop: slow/stop dialysis, mannitol 0.5-1 g/kg IV, supportive care.</li>
            <li><strong>Uremic Fetor is Pathognomonic for Uremia:</strong> Characteristic ammonia or "fishy" smell to breath. Caused by breakdown of urea in saliva by bacterial urease â†’ ammonia. Described as "urinous" odor. Can smell from across room in severe cases. Highly specific for uremia (BUN >80-100 mg/dL). Also associated with metallic taste, decreased appetite. Resolves with dialysis. If you smell uremic fetor, patient needs dialysis ASAP.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Cardiac tamponade from uremic pericarditis (hypotension, JVD, muffled heart sounds, pulsus paradoxus >10 mmHg)</li>
            <li>Large pericardial effusion (>2 cm on echo) with hemodynamic compromise</li>
            <li>Severe uremic encephalopathy (GCS <12, stupor, coma)</li>
            <li>Seizures from uremic encephalopathy</li>
            <li>Active life-threatening bleeding (GI bleed, intracranial hemorrhage) from uremic platelet dysfunction</li>
            <li>Severe hyperkalemia (K >7.0 mEq/L) or ECG changes from hyperkalemia</li>
            <li>Respiratory failure requiring mechanical ventilation</li>
            <li>Hemodynamic instability requiring vasopressors</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Dialysis initiated with at least 2-3 sessions completed</li>
            <li>BUN trending down (goal <80 mg/dL, though may not fully normalize if ESRD)</li>
            <li>Uremic symptoms resolved: no nausea/vomiting, mental status at baseline, no chest pain</li>
            <li>If pericardial effusion: stable or decreasing in size, no tamponade physiology</li>
            <li>Hemodynamically stable (normal BP, HR)</li>
            <li>Tolerating PO intake without nausea</li>
            <li>Outpatient dialysis center arranged (3x/week schedule)</li>
            <li>Dialysis access functional (tunneled catheter or AV fistula/graft)</li>
            <li>Nephrology follow-up within 1 week</li>
            <li>Patient/family educated on dialysis schedule, dietary restrictions, medication compliance</li>
            <li>If uremic pericarditis: cardiology follow-up arranged for repeat echo in 2-4 weeks</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="hypocalcemia">
    <div class="page-header">
        <h2>109. HYPOCALCEMIA</h2>
        <div class="subtitle">Tetany â€¢ Paresthesias â€¢ QT Prolongation â€¢ Seizures â€¢ Trousseau/Chvostek Signs</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Acute onset of perioral paresthesias, finger/toe tingling, muscle cramps, carpopedal spasm (tetany), with positive Chvostek and Trousseau signs, QT prolongation on ECG, and serum calcium <8.0 mg/dL (ionized Ca <1.0 mmol/L).</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Hypocalcemia increases neuromuscular excitability (calcium normally stabilizes neuronal membranes). Low ionized calcium â†’ spontaneous neuronal depolarization â†’ tetany, paresthesias, seizures. Also impairs cardiac conduction (prolonged QT, torsades risk). Causes: (1) Hypoparathyroidism (post-thyroidectomy, autoimmune, genetic), (2) Vitamin D deficiency, (3) Hypomagnesemia (Mg required for PTH secretion and action), (4) CKD (hyperphosphatemia binds Ca), (5) Acute pancreatitis (fat saponification), (6) Tumor lysis syndrome, (7) Massive transfusion (citrate binds Ca), (8) Drugs (bisphosphonates, denosumab, cinacalcet, foscarnet)</li>
                <li><strong>Risk Factors:</strong> Post-thyroidectomy/parathyroidectomy surgery, CKD, vitamin D deficiency, malabsorption (Crohn's, celiac), chronic PPI use (impairs Ca absorption), alcoholism (low Mg), loop diuretics (renal Ca wasting), chemotherapy (tumor lysis), critical illness, sepsis, acute pancreatitis</li>
                <li><strong>Symptoms:</strong> Perioral paresthesias (numbness/tingling around mouth), acral paresthesias (fingers, toes), muscle cramps (calves, feet), carpopedal spasm (hand/foot spasms with flexion), laryngospasm (life-threatening - stridor, difficulty breathing), tetany, seizures (generalized tonic-clonic), confusion, irritability, anxiety, palpitations (arrhythmias)</li>
                <li><strong>Physical Exam:</strong> <strong>Chvostek Sign:</strong> Tap facial nerve anterior to ear â†’ ipsilateral facial muscle twitching (50% sensitive, can be positive in normals). <strong>Trousseau Sign:</strong> Inflate BP cuff above systolic BP for 3 minutes â†’ carpopedal spasm (hand contracts into flexion with thumb adduction, "obstetrician's hand" - 90% sensitive, more specific than Chvostek). Hyperreflexia, prolonged QT on ECG, papilledema (if chronic, increased ICP), cataracts (chronic hypocalcemia), basal ganglia calcifications (chronic), dry skin/brittle nails</li>
                <li><strong>Variants/Subtypes:</strong> Acute symptomatic hypocalcemia (tetany, seizures, laryngospasm - EMERGENCY) vs Chronic asymptomatic hypocalcemia (gradually compensated). Hypocalcemia with high PTH (secondary hyperparathyroidism from vit D deficiency, CKD) vs low PTH (hypoparathyroidism)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Serum Calcium (Total and Ionized):</strong>
                    <ul>
                        <li><strong>Total Calcium:</strong> Normal 8.5-10.5 mg/dL. Hypocalcemia <8.0 mg/dL. BUT must correct for albumin</li>
                        <li><strong>Corrected Calcium:</strong> Corrected Ca = measured Ca + 0.8 Ã— (4.0 - albumin). Accounts for protein-bound Ca</li>
                        <li><strong>Ionized Calcium (GOLD STANDARD):</strong> Normal 1.15-1.35 mmol/L (4.6-5.4 mg/dL). Hypocalcemia <1.0 mmol/L. Measures metabolically active (free) calcium, unaffected by albumin. Order ionized Ca if any doubt</li>
                    </ul>
                </li>
                <li><strong>Phosphate:</strong> Elevated in CKD, hypoparathyroidism, tumor lysis. Low in vitamin D deficiency, malabsorption</li>
                <li><strong>Magnesium:</strong> Check ALWAYS in hypocalcemia. Hypomagnesemia (<1.5 mg/dL) impairs PTH secretion and Ca reabsorption. Cannot correct hypocalcemia without correcting hypomagnesemia first</li>
                <li><strong>Parathyroid Hormone (PTH):</strong> 
                    <ul>
                        <li><strong>PTH Low/Inappropriately Normal:</strong> Hypoparathyroidism (post-surgical, autoimmune, genetic), hypomagnesemia</li>
                        <li><strong>PTH Elevated:</strong> Appropriate response to hypocalcemia - indicates secondary hyperparathyroidism from vitamin D deficiency, CKD, malabsorption</li>
                    </ul>
                </li>
                <li><strong>25-Hydroxyvitamin D:</strong> Assess vitamin D status. Deficiency <20 ng/mL (most common cause of hypocalcemia in general population)</li>
                <li><strong>1,25-Dihydroxyvitamin D (Calcitriol):</strong> Active form. Low in CKD (kidneys can't activate vit D)</li>
                <li><strong>Albumin:</strong> For corrected calcium calculation</li>
                <li><strong>BUN/Creatinine:</strong> CKD common cause of hypocalcemia</li>
                <li><strong>Alkaline Phosphatase:</strong> Elevated in vitamin D deficiency (bone disease)</li>
                <li><strong>Lipase:</strong> If acute pancreatitis suspected</li>
            </ul>
            
            <p><strong>ECG (CRITICAL):</strong></p>
            <ul>
                <li><strong>Prolonged QT interval (QTc >500 ms):</strong> Most important finding. Risk of torsades de pointes</li>
                <li>T wave changes (flattening, inversion)</li>
                <li>Bradycardia</li>
                <li>Heart block (rare, severe hypocalcemia)</li>
                <li>Compare to prior ECGs, calculate QTc (QT corrected for heart rate)</li>
            </ul>
            
            <p><strong>Imaging (if indicated):</strong></p>
            <ul>
                <li><strong>Head CT (non-contrast):</strong> If chronic hypocalcemia, seizures, movement disorder. May show basal ganglia calcifications (Fahr's syndrome), cerebral calcifications</li>
                <li><strong>Neck Ultrasound/Sestamibi Scan:</strong> If hypoparathyroidism, assess for parathyroid glands (absent after surgery vs auto immune destruction)</li>
            </ul>
            
            <p><strong>Diagnostic Algorithm:</strong></p>
            <ul>
                <li>Step 1: Confirm hypocalcemia (ionized Ca <1.0 mmol/L or corrected Ca <8.0 mg/dL)</li>
                <li>Step 2: Check Mg (if low, correct Mg first)</li>
                <li>Step 3: Check PTH
                    <ul>
                        <li>If PTH low/normal â†’ Hypoparathyroidism (post-surgical, autoimmune)</li>
                        <li>If PTH elevated â†’ Check 25-OH vit D (low = vit D deficiency), check PO4 (high = CKD), check renal function</li>
                    </ul>
                </li>
                <li>Step 4: Consider other causes (pancreatitis, tumor lysis, drugs)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>ACUTE SYMPTOMATIC HYPOCALCEMIA (Tetany, Seizures, Laryngospasm, QTc >500 ms) - EMERGENCY:</strong></p>
            <ul>
                <li><strong>Step 1 - IV Calcium (Immediate Treatment):</strong>
                    <ul>
                        <li><strong>Calcium Gluconate 10%:</strong> 1-2 grams (10-20 mL) IV over 10-20 minutes (SLOW push - rapid gives bradycardia, cardiac arrest). Can repeat q1-2h until symptoms resolve</li>
                        <li>Or <strong>Calcium Chloride 10%:</strong> 0.5-1 gram (5-10 mL) IV over 10 minutes via CENTRAL line only (scleroses peripheral veins, tissue necrosis if extravasation)</li>
                        <li>Calcium chloride has 3x more elemental calcium than gluconate (preferred for life-threatening hypocalcemia if central access)</li>
                        <li>Onset: 5-10 minutes, Duration: 2-4 hours</li>
                    </ul>
                </li>
                <li><strong>Step 2 - Continuous IV Calcium Infusion (if recurrent symptoms):</strong>
                    <ul>
                        <li>Calcium gluconate 10% 50-100 mL (5-10 grams) in 1000 mL D5W or NS at 50-100 mL/hr (0.5-1 mg/kg/hr elemental Ca)</li>
                        <li>Continue until symptoms controlled and able to transition to oral Ca</li>
                        <li>Monitor ionized Ca q4-6h, goal ionized Ca >1.0 mmol/L</li>
                        <li>Infuse via central line if possible (avoid phlebitis)</li>
                    </ul>
                </li>
                <li><strong>Step 3 - Correct Hypomagnesemia (CRITICAL):</strong>
                    <ul>
                        <li>If Mg <1.5 mg/dL: Magnesium sulfate 1-2 grams IV over 15-60 minutes, then 1-2 grams IV q6h until Mg >2.0 mg/dL</li>
                        <li>Or Magnesium sulfate 4-6 grams in 1000 mL NS at 100-150 mL/hr</li>
                        <li>CANNOT correct hypocalcemia without correcting hypomagnesemia first (Mg required for PTH secretion)</li>
                    </ul>
                </li>
                <li><strong>Airway Protection (if Laryngospasm):</strong>
                    <ul>
                        <li>Laryngospasm = vocal cord spasm, stridor, respiratory distress. LIFE-THREATENING</li>
                        <li>Immediate IV calcium (calcium gluconate 1-2 g IV push)</li>
                        <li>Bag-mask ventilation with 100% O2</li>
                        <li>If refractory: intubation (succinylcholine for paralysis), ICU</li>
                    </ul>
                </li>
                <li><strong>Seizure Management:</strong>
                    <ul>
                        <li>IV calcium (corrects underlying cause)</li>
                        <li>If ongoing seizure despite Ca: Lorazepam 2-4 mg IV</li>
                        <li>Avoid phenytoin (can worsen hypocalcemia, decreases Ca absorption)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>CHRONIC/ASYMPTOMATIC HYPOCALCEMIA (Ca 7.0-8.0 mg/dL, No Tetany/Seizures):</strong></p>
            <ul>
                <li><strong>Oral Calcium Supplementation:</strong>
                    <ul>
                        <li>Calcium carbonate 1000-1500 mg elemental Ca PO TID with meals (total 3000-4500 mg/day)</li>
                        <li>Or Calcium citrate 1000-1500 mg elemental Ca PO TID (better absorbed, preferred if achlorhydria, PPI use)</li>
                        <li>Start high dose, titrate based on Ca levels</li>
                    </ul>
                </li>
                <li><strong>Vitamin D Supplementation (if deficient):</strong>
                    <ul>
                        <li>Ergocalciferol (Vitamin D2) 50,000 units PO weekly x 8 weeks (if 25-OH vit D <20 ng/mL)</li>
                        <li>Or Cholecalciferol (Vitamin D3) 1000-2000 units PO daily (maintenance)</li>
                        <li>In CKD: Calcitriol (active vit D) 0.25-0.5 mcg PO daily (kidneys can't activate vit D)</li>
                    </ul>
                </li>
                <li><strong>Correct Hypomagnesemia:</strong> Magnesium oxide 400 mg PO BID or Magnesium chloride 500 mg PO BID</li>
            </ul>
            
            <p><strong>HYPOPARATHYROIDISM-SPECIFIC TREATMENT:</strong></p>
            <ul>
                <li>High-dose oral calcium (3000-6000 mg/day divided TID-QID)</li>
                <li>PLUS Active vitamin D (Calcitriol 0.5-2.0 mcg PO BID - higher doses than typical)</li>
                <li>Goal: Ca 8.0-8.5 mg/dL (low-normal to avoid hypercalciuria, nephrolithiasis)</li>
                <li>If refractory: Recombinant PTH (teriparatide, not FDA-approved for hypoparathyroidism but used off-label)</li>
            </ul>
            
            <p><strong>Monitoring:</strong></p>
            <ul>
                <li>Continuous telemetry (if QTc >500 ms or symptomatic)</li>
                <li>Ionized calcium q2-4h until stable (acute treatment)</li>
                <li>Serum Mg q4-6h until >2.0 mg/dL</li>
                <li>ECG q4-8h to monitor QTc</li>
                <li>Once transitioned to oral: Check Ca, Mg weekly x 4 weeks, then monthly</li>
                <li>24-hour urine calcium (monitor for hypercalciuria in hypoparathyroidism patients on high-dose Ca/vit D)</li>
            </ul>
            
            <p><strong>Cautions:</strong></p>
            <ul>
                <li>Do NOT give IV calcium in same line as bicarbonate or phosphate (precipitates)</li>
                <li>Calcium infusion via peripheral IV can cause phlebitis (use central line if prolonged infusion)</li>
                <li>Calcium chloride MUST go via central line (tissue necrosis if extravasation)</li>
                <li>Rapid IV calcium causes bradycardia, cardiac arrest (push slowly over 10-20 minutes)</li>
                <li>Avoid thiazide diuretics in hypocalcemia (decrease renal Ca excretion, risk of hypercalcemia once treated)</li>
            </ul>
            
            <p><strong>Consultations:</strong></p>
            <ul>
                <li><strong>Endocrinology:</strong> All cases of hypoparathyroidism, refractory hypocalcemia, complex cases</li>
                <li><strong>Nephrology:</strong> If CKD-related hypocalcemia</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Symptomatic hypocalcemia (tetany, seizures, laryngospasm), QTc >500 ms, requires continuous IV calcium infusion, hemodynamic instability</li>
                <li>Floor with Telemetry: Mild symptoms, ionized Ca 0.8-1.0 mmol/L, QTc 480-500 ms, able to take PO, requiring IV calcium boluses (not continuous infusion)</li>
                <li>Discharge: Asymptomatic, ionized Ca >1.0 mmol/L on oral regimen, Mg corrected, QTc <480 ms, follow-up arranged with endocrinology/PCP within 1 week</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Always Check Ionized Calcium - It's the Metabolically Active Form:</strong> Total calcium includes protein-bound (60%) and ionized/free (40%) calcium. Only ionized Ca is metabolically active. Hypoalbuminemia (common in hospitalized patients) causes low total Ca but normal ionized Ca - patient is NOT hypocalcemic. Corrected calcium formula estimates ionized Ca but is imperfect. GOLD STANDARD: measure ionized calcium directly (<1.0 mmol/L = true hypocalcemia). Order ionized Ca in all suspected hypocalcemia cases, especially critically ill, hypoalbuminemia, or if total Ca borderline low (8.0-8.5 mg/dL).</li>
            <li><strong>Cannot Correct Hypocalcemia Without Correcting Hypomagnesemia First:</strong> Magnesium is required for PTH secretion from parathyroid glands AND for PTH action on target tissues (bone, kidney). If Mg low, PTH secretion impaired â†’ hypocalcemia worsens. Also, low Mg directly impairs renal calcium reabsorption. Clinically: patient with hypocalcemia gets IV calcium, Ca normalizes transiently, then drops again hours later - check Mg. If Mg <1.5 mg/dL, give magnesium sulfate 2-4 grams IV, recheck Mg q6h, goal Mg >2.0 mg/dL. Only after Mg corrected will calcium stay normal. Hypomagnesemia common in alcoholics, diuretic use, diarrhea, PPI use.</li>
            <li><strong>Trousseau Sign is More Specific Than Chvostek Sign for Hypocalcemia:</strong> Chvostek sign (tap facial nerve â†’ facial twitching) is 50% sensitive, but 10-15% of normal people have positive Chvostek. Trousseau sign (inflate BP cuff above systolic BP x 3 minutes â†’ carpopedal spasm/"obstetrician's hand") is 90% sensitive and more specific. If Trousseau positive, hypocalcemia highly likely. Mechanism: ischemia from BP cuff + hypocalcemia â†’ increased neuromuscular excitability â†’ tetany. Trousseau takes 3 minutes to elicit (be patient), Chvostek is instant. Do Trousseau if suspecting hypocalcemia.</li>
            <li><strong>Rapid IV Calcium Causes Bradycardia and Cardiac Arrest - Always Push SLOWLY:</strong> IV calcium MUST be given slowly (over 10-20 minutes minimum). Rapid push causes transient severe hypercalcemia â†’ bradycardia, heart block, cardiac arrest (calcium overdose effect on cardiac conduction). Exception: life-threatening situations (laryngospasm, torsades) where you accept this risk. Standard: calcium gluconate 1-2 grams IV over 10-20 minutes. Monitor on telemetry during administration. If heart rate drops, slow/stop infusion. Never give calcium as rapid IV push unless imminently life-threatening.</li>
            <li><strong>Calcium Chloride vs Calcium Gluconate - Know the Difference:</strong> Both treat hypocalcemia but different potency and administration. Calcium gluconate 10%: 1 gram = 93 mg elemental Ca (10 mL ampule). Safe via peripheral IV. First-line. Calcium chloride 10%: 1 gram = 272 mg elemental Ca (10 mL ampule), 3x more potent. MUST give via central line (scleroses peripheral veins, causes tissue necrosis if extravasation). Use calcium chloride for severe symptomatic hypocalcemia if central access available, or in code situations (faster effect). Otherwise, use calcium gluconate. Never push calcium chloride peripherally.</li>
            <li><strong>Prolonged QT from Hypocalcemia Increases Torsades Risk - Monitor ECG Closely:</strong> Hypocalcemia prolongs phase 2 of cardiac action potential (plateau phase) â†’ prolonged QT interval (QTc >500 ms = high risk). Torsades de pointes can occur. Check ECG on all hypocalcemia patients. Calculate QTc (QT corrected for HR). If QTc >500 ms: continuous telemetry, IV calcium immediately, avoid other QT-prolonging drugs (antipsychotics, fluoroquinolones, azithromycin, ondansetron). Monitor QTc after calcium repletion - should shorten as Ca normalizes. Hypocalcemia is correctable cause of torsades (unlike congenital long QT syndrome).</li>
            <li><strong>Post-Thyroidectomy Hypocalcemia Peaks at 24-72 Hours Post-Op:</strong> Thyroidectomy can damage/remove parathyroid glands (inadvertent parathyroidectomy) â†’ hypoparathyroidism â†’ hypocalcemia. Transient (48-72 hours, parathyroids "stunned" from manipulation) in 20-30%, permanent in 1-2%. Typically becomes symptomatic 24-72 hours post-op (as circulating Ca depletes). Check Ca POD #1, POD #2. If Ca <8.0 mg/dL or symptomatic: start high-dose oral calcium (2000-3000 mg/day) + calcitriol 0.5-1.0 mcg BID. Transient cases resolve in weeks; permanent cases need lifelong Ca/vit D. Measure PTH at 6 months to determine if permanent.</li>
            <li><strong>Vitamin D Deficiency is Most Common Cause of Hypocalcemia in General Population:</strong> Vitamin D deficiency (25-OH vit D <20 ng/mL) is epidemic - 40-50% of US population. Causes: inadequate sun exposure, dark skin (melanin blocks UVB), obesity (vit D sequestered in fat), malabsorption, CKD, elderly. Low vit D â†’ decreased intestinal Ca absorption â†’ hypocalcemia â†’ secondary hyperparathyroidism (PTH elevated trying to compensate). Labs: low Ca, low vit D, elevated PTH, low/normal PO4. Treatment: Ergocalciferol 50,000 units weekly x 8 weeks, then maintenance 1000-2000 units daily. Plus oral calcium. Check 25-OH vit D in all hypocalcemia patients.</li>
            <li><strong>Tumor Lysis Syndrome Causes Hypocalcemia via Hyperphosphatemia:</strong> Rapid tumor cell lysis (chemotherapy for hematologic malignancies) â†’ massive release of intracellular contents â†’ hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia. Mechanism of hypocalcemia: High phosphate binds calcium â†’ calcium-phosphate precipitates in tissues â†’ hypocalcemia worsens. Also, high phosphate suppresses 1,25-vit D production. Labs: low Ca, very high PO4 (>6-8 mg/dL), high K, high uric acid, elevated LDH. Treatment: aggressive IV fluids, allopurinol/rasburicase (prevent uric acid nephropathy), correct electrolytes, dialysis if severe. Do NOT give calcium if PO4 very high (>6.5 mg/dL) - worsens tissue calcium-phosphate deposition, unless life-threatening hypocalcemia.</li>
            <li><strong>Hungry Bone Syndrome After Parathyroidectomy for Hyperparathyroidism:</strong> Patient with chronic primary hyperparathyroidism (high PTH, high Ca, bone resorption for years) undergoes parathyroidectomy â†’ PTH suddenly drops â†’ bone aggressively takes up calcium to remineralize ("hungry bones") â†’ severe hypocalcemia. Occurs in ~10-15% of parathyroidectomies, especially if pre-op Ca >12 mg/dL, elevated alkaline phosphatase (bone turnover), or vitamin D deficiency. Postoperative days 1-7: Ca can drop to 6-7 mg/dL, requires massive calcium repletion (IV calcium, then oral calcium 4-6 grams/day + calcitriol 1-2 mcg/day) for weeks to months. Monitor Ca closely post-parathyroidectomy.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Laryngospasm (stridor, respiratory distress) - airway emergency</li>
            <li>Seizures from hypocalcemia</li>
            <li>Tetany refractory to IV calcium boluses (requires continuous calcium infusion)</li>
            <li>QTc >500 ms (high risk of torsades de pointes)</li>
            <li>Hemodynamically significant arrhythmias (bradycardia, torsades)</li>
            <li>Ionized calcium <0.8 mmol/L with symptoms</li>
            <li>Requiring continuous cardiac monitoring and IV calcium infusion</li>
            <li>Heart block from severe hypocalcemia</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Ionized calcium >1.0 mmol/L (or total corrected calcium >8.0 mg/dL)</li>
            <li>Asymptomatic (no paresthesias, tetany, muscle cramps)</li>
            <li>Tolerating oral calcium and vitamin D supplementation</li>
            <li>Magnesium corrected (>1.8-2.0 mg/dL)</li>
            <li>QTc normalized (<480 ms)</li>
            <li>No seizures or arrhythmias</li>
            <li>Patient educated on oral calcium regimen (timing, dosing, take with food)</li>
            <li>Follow-up arranged with endocrinology (if hypoparathyroidism) or PCP within 1 week</li>
            <li>Recheck Ca, Mg, and PTH scheduled for 1 week</li>
            <li>If post-thyroidectomy: surgical team aware, monitoring calcium closely</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="magnesium-disorders">
    <div class="page-header">
        <h2>110. HYPERMAGNESEMIA / HYPOMAGNESEMIA</h2>
        <div class="subtitle">Muscle Weakness â€¢ Arrhythmias â€¢ Tetany â€¢ Deep Tendon Reflex Changes</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">HYPOMAGNESEMIA (Mg <1.5 mg/dL):</span> Muscle cramps, tremor, tetany, cardiac arrhythmias (especially torsades de pointes), concurrent hypocalcemia/hypokalemia that's refractory to replacement, seizures, and hyperreflexia.</p>
            <p><span class="label">HYPERMAGNESEMIA (Mg >2.5 mg/dL):</span> Muscle weakness, hyporeflexia, lethargy, bradycardia, hypotension, respiratory depression (Mg >5-6 mg/dL), cardiac arrest (Mg >12-15 mg/dL).</p>
            <ul>
                <li><strong>Pathophysiology:</strong> <strong>Hypomagnesemia:</strong> Impairs PTH secretion â†’ hypocalcemia. Increases renal potassium wasting â†’ hypokalemia. Destabilizes cardiac membranes â†’ arrhythmias (prolonged QT, torsades). Causes: GI losses (diarrhea, malabsorption, PPI use), renal losses (diuretics, aminoglycosides, cisplatin, amphotericin), alcoholism (most common), DKA, hungry bone syndrome. <strong>Hypermagnesemia:</strong> Excess Mg antagonizes calcium channels â†’ neuromuscular blockade, cardiac conduction delays. Usually iatrogenic (Mg infusions, laxatives/antacids in CKD) or renal failure (inability to excrete Mg). Severe hypermagnesemia (>12-15 mg/dL) causes cardiac arrest (asystole)</li>
                <li><strong>Risk Factors - HYPOMAGNESEMIA:</strong> Chronic diarrhea, Crohn's disease, celiac disease, chronic PPI use (decreases Mg absorption), alcoholism (decreased intake + increased losses), loop/thiazide diuretics, aminoglycosides, cisplatin, amphotericin B, foscarnet, DKA (osmotic diuresis), post-parathyroidectomy (hungry bone syndrome)</li>
                <li><strong>Risk Factors - HYPERMAGNESEMIA:</strong> CKD/ESRD (GFR <30 mL/min), excessive Mg administration (IV Mg for eclampsia/tocolysis, Mg-containing laxatives, antacids), rhabdomyolysis, tumor lysis syndrome, Addison's disease</li>
                <li><strong>Symptoms - HYPOMAGNESEMIA:</strong> Muscle cramps (calves, feet), fasciculations, tremor, tetany, paresthesias, weakness, palpitations, nausea, seizures (if severe), personality changes</li>
                <li><strong>Symptoms - HYPERMAGNESEMIA:</strong> Nausea, vomiting (Mg 3-5 mg/dL), flushing, warmth (vasodilation), muscle weakness, lethargy, confusion (Mg 5-7 mg/dL), respiratory depression (Mg >7-10 mg/dL), coma (Mg >10-12 mg/dL)</li>
                <li><strong>Physical Exam - HYPOMAGNESEMIA:</strong> Hyperreflexia, positive Chvostek/Trousseau signs (if concurrent hypocalcemia), tachycardia, arrhythmias</li>
                <li><strong>Physical Exam - HYPERMAGNESEMIA:</strong> Hyporeflexia (DTRs lost at Mg 4-6 mg/dL), bradycardia (Mg >5 mg/dL), hypotension, respiratory depression (decreased respiratory rate, shallow breathing at Mg >7 mg/dL), cardiac arrest (Mg >12-15 mg/dL)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Serum Magnesium:</strong> Normal 1.5-2.5 mg/dL (1.25-2.1 mEq/L or 0.6-1.0 mmol/L)
                    <ul>
                        <li>Hypomagnesemia: <1.5 mg/dL. Severe <1.0 mg/dL</li>
                        <li>Hypermagnesemia: >2.5 mg/dL. Moderate 2.5-5 mg/dL, Severe >5 mg/dL, Critical >7-10 mg/dL</li>
                    </ul>
                </li>
                <li><strong>Calcium (total and ionized):</strong> Check always with Mg abnormalities. Hypomagnesemia causes hypocalcemia (impaired PTH secretion). Mg and Ca often abnormal together</li>
                <li><strong>Potassium:</strong> Hypomagnesemia causes hypokalemia (renal K wasting). Check and correct</li>
                <li><strong>Phosphate:</strong> May be low in malnutrition/alcoholism (same causes as hypomagnesemia)</li>
                <li><strong>Basic Metabolic Panel:</strong> BUN/Cr (assess renal function - hypermagnesemia common in CKD)</li>
                <li><strong>ECG:</strong>
                    <ul>
                        <li><strong>Hypomagnesemia:</strong> Prolonged QT interval (risk of torsades de pointes), T wave flattening, U waves, atrial/ventricular arrhythmias</li>
                        <li><strong>Hypermagnesemia:</strong> Prolonged PR interval (Mg >5 mg/dL), widened QRS (Mg >7 mg/dL), heart block, bradycardia, asystole (Mg >12-15 mg/dL)</li>
                    </ul>
                </li>
                <li><strong>24-Hour Urine Magnesium (if hypomagnesemia etiology unclear):</strong> Distinguish renal vs GI losses
                    <ul>
                        <li>Urine Mg >24 mg/24hr (or fractional excretion >2%) with hypomagnesemia = Renal wasting (diuretics, drugs)</li>
                        <li>Urine Mg <12 mg/24hr = Appropriate renal conservation, GI losses (diarrhea, malabsorption)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>HYPOMAGNESEMIA TREATMENT:</strong></p>
            
            <p><strong>Severe Symptomatic Hypomagnesemia (Mg <1.0 mg/dL, Seizures, Arrhythmias):</strong></p>
            <ul>
                <li><strong>IV Magnesium Sulfate:</strong>
                    <ul>
                        <li>Loading dose: 2-4 grams (16-32 mEq) IV over 15-60 minutes (slower if not life-threatening)</li>
                        <li>Maintenance: 1-2 grams IV q6h or continuous infusion 1-2 grams/hr until Mg >1.5 mg/dL</li>
                        <li>Alternative: 6 grams (48 mEq) in 1000 mL NS at 100-150 mL/hr over 6-8 hours</li>
                        <li>Monitor: DTRs q2h (if lost, stop infusion - hypermagnesemia), Mg q6-12h</li>
                    </ul>
                </li>
                <li><strong>Torsades de Pointes from Hypomagnesemia:</strong> Magnesium sulfate 2 grams IV push over 2-5 minutes, can repeat x1. Then continuous infusion</li>
            </ul>
            
            <p><strong>Mild-Moderate Hypomagnesemia (Mg 1.0-1.5 mg/dL, Symptomatic):</strong></p>
            <ul>
                <li><strong>Oral Magnesium (if able to tolerate PO):</strong>
                    <ul>
                        <li>Magnesium oxide 400-800 mg PO BID-TID (poorly absorbed, causes diarrhea)</li>
                        <li>Or Magnesium chloride 500 mg PO BID (better absorbed)</li>
                        <li>Or Magnesium gluconate 500 mg PO TID</li>
                        <li>Or Magnesium citrate 300 mg PO BID (good absorption)</li>
                        <li>Total elemental Mg 300-600 mg/day divided doses</li>
                    </ul>
                </li>
                <li><strong>IV Magnesium (if NPO or severe GI losses):</strong> 1-2 grams IV q6-12h</li>
            </ul>
            
            <p><strong>Concurrent Electrolyte Correction (CRITICAL):</strong></p>
            <ul>
                <li><strong>Hypocalcemia:</strong> Correct Mg FIRST before giving calcium (hypocalcemia won't correct without Mg)</li>
                <li><strong>Hypokalemia:</strong> Correct Mg FIRST (hypokalemia won't correct without Mg, renal K wasting continues). Then give potassium</li>
                <li>Check Ca, K, Mg together; replace Mg first, then Ca/K</li>
            </ul>
            
            <p><strong>HYPERMAGNESEMIA TREATMENT:</strong></p>
            
            <p><strong>Immediate Management:</strong></p>
            <ul>
                <li>STOP all Mg sources (IV Mg, laxatives, antacids)</li>
                <li>Continuous cardiac monitoring</li>
                <li>IV access, assess airway/breathing</li>
            </ul>
            
            <p><strong>Severe Life-Threatening Hypermagnesemia (Mg >7-10 mg/dL, Respiratory Depression, Cardiac Toxicity):</strong></p>
            <ul>
                <li><strong>Calcium Gluconate (Immediate Antagonist):</strong>
                    <ul>
                        <li>Calcium gluconate 10% 1-2 grams (10-20 mL) IV over 5-10 minutes</li>
                        <li>Directly antagonizes Mg effects on neuromuscular junction and cardiac conduction</li>
                        <li>Does NOT lower Mg level, just reverses toxicity temporarily (30-60 minutes)</li>
                        <li>Can repeat q1h as needed while arranging definitive treatment</li>
                    </ul>
                </li>
                <li><strong>HEMODIALYSIS (Definitive Treatment):</strong>
                    <ul>
                        <li>MOST EFFECTIVE for severe hypermagnesemia</li>
                        <li>Rapidly removes Mg (can lower Mg by 50% in 3-4 hours)</li>
                        <li>Indications: Mg >7-10 mg/dL with symptoms, Mg >4-5 mg/dL in anuric patient, respiratory depression, cardiac toxicity</li>
                        <li>URGENT Nephrology consult</li>
                    </ul>
                </li>
                <li><strong>Supportive Care:</strong>
                    <ul>
                        <li>Respiratory support: Supplemental O2, BiPAP, intubation if respiratory failure (Mg >10 mg/dL)</li>
                        <li>Cardiac support: Atropine for bradycardia, pacing if high-grade AV block, pressors if hypotensive</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Moderate Hypermagnesemia (Mg 2.5-5 mg/dL, Asymptomatic or Mild Symptoms):</strong></p>
            <ul>
                <li><strong>IV Fluids + Diuresis (if normal renal function):</strong>
                    <ul>
                        <li>Normal saline 1-2 L bolus, then 150-250 mL/hr</li>
                        <li>PLUS Furosemide 40-80 mg IV q6-8h (promotes renal Mg excretion)</li>
                        <li>Monitor Mg q4-6h, goal Mg <2.5 mg/dL</li>
                        <li>Replace calcium/potassium losses from diuresis</li>
                    </ul>
                </li>
                <li><strong>If Renal Failure:</strong> Dialysis required (kidneys can't excrete Mg)</li>
            </ul>
            
            <p><strong>Monitoring:</strong></p>
            <ul>
                <li><strong>Hypomagnesemia:</strong> Recheck Mg q6-12h during repletion. Check DTRs q2h during IV Mg infusion (loss of DTRs = stop infusion, hypermagnesemia developing). Check concurrent Ca, K levels</li>
                <li><strong>Hypermagnesemia:</strong> Continuous telemetry if Mg >5 mg/dL. Recheck Mg q2-4h. Monitor respiratory rate, DTRs, level of consciousness. ECG q4-6h to assess conduction</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Severe hypomagnesemia with torsades, seizures; Severe hypermagnesemia (Mg >5-7 mg/dL) with respiratory depression, cardiac toxicity, requiring dialysis</li>
                <li>Floor with Telemetry: Symptomatic hypomagnesemia requiring IV Mg, moderate hypermagnesemia (Mg 4-5 mg/dL)</li>
                <li>Discharge: Asymptomatic or mild symptoms, Mg normalized, able to take oral Mg (if hypomagnesemia), underlying cause addressed</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Hypomagnesemia is Extremely Common but Often Missed (10-20% of Hospitalized Patients):</strong> Rarely checked unless specifically ordered. Causes refractory hypocalcemia, refractory hypokalemia. If patient has hypocalcemia or hypokalemia that won't correct despite aggressive replacement, CHECK MAGNESIUM. Hypomagnesemia impairs PTH secretion (hypocalcemia) and increases renal K wasting (hypokalemia). Cannot correct Ca or K without correcting Mg first. Clinical pearl: If giving IV calcium or potassium and levels won't stay up, think hypomagnesemia.</li>
            <li><strong>Loss of Deep Tendon Reflexes Indicates Mg >5-6 mg/dL - Stop Magnesium Immediately:</strong> DTRs are best clinical monitor for Mg toxicity. As Mg rises: Normal reflexes (Mg <4) â†’ Hyporeflexia (Mg 4-5) â†’ Loss of DTRs (Mg 5-6) â†’ Respiratory depression (Mg 7-10) â†’ Cardiac arrest (Mg >12-15). When giving IV Mg infusion, check patellar reflex (knee jerk) q2h. If reflex lost, STOP Mg infusion immediately (hypermagnesemia developing). DTRs lost BEFORE respiratory depression, so provides early warning. Bedside clinical sign that prevents iatrogenic hypermagnesemia during Mg repletion for eclampsia/pre-eclampsia.</li>
            <li><strong>Calcium is Immediate Antidote for Severe Hypermagnesemia:</strong> Calcium directly antagonizes Mg effects on neuromuscular junction and cardiac conduction. Give calcium gluconate 1-2 grams IV over 5-10 minutes if Mg >7 mg/dL with respiratory depression, bradycardia, heart block. Effect is immediate (within minutes) but temporary (30-60 minutes). Buys time while arranging dialysis (definitive treatment). Can repeat calcium q1h as needed. Mechanism: Calcium and Mg compete for same channels; calcium reverses Mg-induced neuromuscular blockade and cardiac conduction delays.</li>
            <li><strong>Chronic PPI Use is a Common Cause of Hypomagnesemia:</strong> PPIs (omeprazole, pantoprazole, esomeprazole) decrease intestinal Mg absorption (mechanism unclear, possibly involving TRPM6/7 channels). FDA warning in 2011 - chronic PPI use (>1 year) causes hypomagnesemia in 5-10% of users. Presents as muscle cramps, arrhythmias, concurrent hypocalcemia. If patient on chronic PPI with unexplained hypomagnesemia, try stopping PPI (switch to H2 blocker like famotidine) or increase oral Mg supplementation. Check Mg levels in all patients on chronic PPI who present with arrhythmias or tetany.</li>
            <li><strong>Loop Diuretics Cause Magnesium Wasting - Thiazides Spare Magnesium:</strong> Loop diuretics (furosemide, bumetanide, torsemide) inhibit Na-K-2Cl cotransporter in thick ascending limb â†’ increased Mg excretion â†’ hypomagnesemia (also causes hypokalemia, hypocalcemia). Chronic loop diuretic use in CHF patients commonly causes hypomagnesemia. Thiazide diuretics (hydrochlorothiazide) have less effect on Mg (primarily cause hypokalemia, hypercalcemia). If patient on chronic loops with hypomagnesemia, consider switching to thiazide or add Mg supplementation. Also consider K-sparing diuretic (spironolactone, amiloride) which reduces K wasting.</li>
            <li><strong>Torsades de Pointes from Hypomagnesemia - Give Magnesium Immediately Even if QT Not Prolonged:</strong> Hypomagnesemia prolongs QT interval (like hypocalcemia, hypokalemia) â†’ torsades de pointes (polymorphic VT with "twisting" QRS). If patient with hypomagnesemia develops torsades: Give magnesium sulfate 2 grams IV push over 2-5 minutes, can repeat x1, then continuous infusion 1-2 grams/hr. Magnesium is treatment of choice for torsades even if Mg level normal (stabilizes cardiac membranes). Magnesium shortens QT interval, suppresses early afterdepolarizations that trigger torsades. Also defibrillate if hemodynamically unstable.</li>
            <li><strong>Alcoholism is Most Common Cause of Hypomagnesemia:</strong> Chronic alcoholism causes hypomagnesemia via: (1) Decreased intake (poor nutrition), (2) Increased GI losses (diarrhea, vomiting), (3) Increased renal losses (alcohol directly increases urinary Mg excretion, secondary hyperaldosteronism), (4) Impaired intestinal Mg absorption. Alcoholics presenting with DTs, seizures, arrhythmias often have hypomagnesemia + hypocalcemia + hypokalemia + hypophosphatemia (refeeding syndrome if malnourished). Check and repletes all four electrolytes. Magnesium repletion may reduce alcohol withdrawal symptoms, seizure risk. Give thiamine (prevent Wernicke's), folate, multivitamin as well.</li>
            <li><strong>Aminoglycosides and Cisplatin Cause Renal Magnesium Wasting:</strong> Aminoglycosides (gentamicin, tobramycin) and cisplatin chemotherapy damage renal tubules â†’ urinary Mg wasting persists for weeks-months after drug stopped. Up to 50% of cisplatin patients develop hypomagnesemia. If patient on aminoglycosides/cisplatin develops muscle cramps, arrhythmias, check Mg (and Ca, K). May need aggressive oral Mg supplementation 400-800 mg/day. Hypomagnesemia can persist for months after cisplatin, requiring long-term supplementation. Also, amphotericin B, foscarnet, pentamidine cause renal Mg wasting.</li>
            <li><strong>Hypermagnesemia Almost Always Iatrogenic or Renal Failure:</strong> Healthy kidneys excrete excess Mg efficiently, so hypermagnesemia rare unless: (1) Excessive administration (IV Mg for eclampsia/tocolysis, Mg-containing laxatives/antacids in elderly), (2) CKD/ESRD (GFR <30, can't excrete Mg), (3) Rhabdomyolysis/tumor lysis (cellular release), (4) Addison's disease (rare). Most common scenario: Elderly patient with CKD taking Mg-containing laxatives (Milk of Magnesia) or antacids daily â†’ progressive hypermagnesemia over weeks. Always ask about laxative/antacid use in hypermagnesemia. Stop Mg sources, dialyze if severe.</li>
            <li><strong>Pregnant Women with Eclampsia Receiving IV Magnesium Need Close Monitoring:</strong> Magnesium sulfate is first-line for eclampsia seizure prophylaxis and treatment. Loading dose 4-6 grams IV over 15-20 minutes, then maintenance 1-2 grams/hr. Therapeutic range 4-6 mg/dL (prevents seizures). Risk of hypermagnesemia toxicity: Loss of DTRs (5-6 mg/dL), respiratory depression (7-10 mg/dL), cardiac arrest (>12-15 mg/dL). Monitor: DTRs q2h (if lost, stop Mg), respiratory rate q1h (if <12/min, stop Mg), Mg level q4-6h. Antidote: Calcium gluconate 1 gram IV push. Toxicity more common if renal insufficiency (pre-eclampsia can cause AKI). Mg infusion requires ICU/L&D with close monitoring.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li><strong>Hypomagnesemia:</strong> Torsades de pointes, refractory ventricular arrhythmias, seizures</li>
            <li><strong>Hypermagnesemia:</strong> Mg >7-10 mg/dL, respiratory depression/failure (RR <10, hypoxia), cardiac toxicity (bradycardia <40, heart block, hypotension), loss of deep tendon reflexes (Mg >5-6 mg/dL), altered mental status/coma, requiring urgent dialysis</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Magnesium normalized (1.5-2.5 mg/dL) and stable</li>
            <li>Concurrent electrolyte abnormalities corrected (Ca, K normalized)</li>
            <li>Asymptomatic (no arrhythmias, tetany, muscle weakness)</li>
            <li>If hypomagnesemia: on oral Mg supplementation, underlying cause addressed (stop PPI if possible, diuretic adjusted)</li>
            <li>If hypermagnesemia: Mg sources stopped (laxatives, antacids discontinued)</li>
            <li>Normal ECG (QT normalized if hypomagnesemia, conduction normalized if hypermagnesemia)</li>
            <li>Deep tendon reflexes normal</li>
            <li>Follow-up arranged to recheck Mg in 1 week</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="phosphate">
    <div class="page-header">
        <h2>111. HYPERPHOSPHATEMIA / HYPOPHOSPHATEMIA</h2>
        <div class="subtitle">Muscle Weakness â€¢ Rhabdomyolysis â€¢ Hemolysis â€¢ Cardiac Dysfunction â€¢ Tissue Calcification</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">HYPOPHOSPHATEMIA (PO4 <2.5 mg/dL):</span> Progressive muscle weakness, rhabdomyolysis, respiratory failure, hemolytic anemia, altered mental status, typically developing over hours-days with severe depletion (PO4 <1.0 mg/dL).</p>
            <p><span class="label">HYPERPHOSPHATEMIA (PO4 >4.5 mg/dL):</span> Often asymptomatic acutely, but causes secondary hypocalcemia (PO4 binds Ca), metastatic calcification (soft tissue, vascular), and long-term complications (CKD-mineral bone disease).</p>
            <ul>
                <li><strong>Pathophysiology:</strong> <strong>Hypophosphatemia:</strong> Phosphate essential for ATP production. Severe depletion (PO4 <1.0 mg/dL) causes cellular energy crisis â†’ muscle dysfunction (weakness, rhabdomyolysis, respiratory failure from diaphragm weakness), RBC dysfunction (hemolysis, decreased 2,3-DPG â†’ left-shifted O2 curve), WBC/platelet dysfunction. Causes: Refeeding syndrome (most dangerous), DKA treatment (insulin shifts PO4 into cells), alcoholism, chronic diarrhea, vitamin D deficiency, antacids. <strong>Hyperphosphatemia:</strong> Excess PO4 binds calcium â†’ hypocalcemia â†’ secondary hyperparathyroidism â†’ bone disease. Also causes metastatic calcification (calcium-phosphate precipitates in vessels, soft tissue, organs). Causes: CKD (most common - kidneys can't excrete PO4), tumor lysis syndrome, rhabdomyolysis (cellular release)</li>
                <li><strong>Risk Factors - HYPOPHOSPHATEMIA:</strong> Refeeding syndrome (malnourished patient restarted nutrition), DKA (insulin treatment shifts PO4 intracellularly), chronic alcoholism, vitamin D deficiency, chronic antacid use (aluminum/magnesium antacids bind PO4), chronic diarrhea, burns, sepsis, respiratory alkalosis (shifts PO4 into cells)</li>
                <li><strong>Risk Factors - HYPERPHOSPHATEMIA:</strong> CKD Stage 4-5 (GFR <30 mL/min), ESRD on dialysis, tumor lysis syndrome (chemotherapy for hematologic malignancies), rhabdomyolysis, acute kidney injury, hypoparathyroidism, excessive vitamin D supplementation, phosphate-containing enemas/laxatives</li>
                <li><strong>Symptoms - HYPOPHOSPHATEMIA:</strong> Mild (PO4 2.0-2.5 mg/dL): Asymptomatic. Moderate (PO4 1.0-2.0 mg/dL): Muscle weakness, myalgias. Severe (PO4 <1.0 mg/dL): Progressive generalized weakness, rhabdomyolysis (myoglobinuria, elevated CK), respiratory failure (diaphragm weakness), confusion, seizures, coma, hemolytic anemia, ileus</li>
                <li><strong>Symptoms - HYPERPHOSPHATEMIA:</strong> Usually asymptomatic acutely. Symptoms of hypocalcemia if PO4 very high (tetany, paresthesias). Chronic: pruritus, bone pain (CKD-MBD), soft tissue calcification (vascular calcification increases CV mortality)</li>
                <li><strong>Physical Exam - HYPOPHOSPHATEMIA:</strong> Muscle weakness (proximal > distal, difficulty standing from chair), hyporeflexia, confusion/delirium, tachypnea (compensating for weakness), rhabdomyolysis (muscle tenderness, dark urine)</li>
                <li><strong>Physical Exam - HYPERPHOSPHATEMIA:</strong> Usually normal. If severe hypocalcemia: Chvostek/Trousseau signs, tetany. Chronic: soft tissue calcifications (palpable), band keratopathy (corneal calcium deposits), calciphylaxis (painful skin lesions, ulcers - rare, in ESRD)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Serum Phosphate:</strong> Normal 2.5-4.5 mg/dL
                    <ul>
                        <li>Hypophosphatemia: <2.5 mg/dL. Mild 2.0-2.5, Moderate 1.0-2.0, Severe <1.0 mg/dL</li>
                        <li>Hyperphosphatemia: >4.5 mg/dL. Moderate 4.5-6.0, Severe >6.0 mg/dL</li>
                    </ul>
                </li>
                <li><strong>Calcium (total and ionized):</strong> Hyperphosphatemia causes hypocalcemia (PO4 binds Ca). Check together. If hypocalcemia with hyperphosphatemia: DO NOT give calcium if PO4 >6.5 mg/dL (worsens tissue calcium-phosphate deposition)</li>
                <li><strong>Magnesium:</strong> Hypomagnesemia often coexists with hypophosphatemia (same causes: alcoholism, malnutrition, refeeding)</li>
                <li><strong>Potassium:</strong> Check with phosphate disorders (often abnormal together in DKA, refeeding, tumor lysis)</li>
                <li><strong>BUN/Creatinine:</strong> CKD most common cause of hyperphosphatemia. AKI can cause both hyper- and hypophosphatemia</li>
                <li><strong>Creatine Kinase (CK):</strong> Elevated if rhabdomyolysis (from severe hypophosphatemia or cause of hyperphosphatemia)</li>
                <li><strong>PTH:</strong> Elevated in secondary hyperparathyroidism (response to hyperphosphatemia in CKD). Low in hypoparathyroidism (causes hyperphosphatemia)</li>
                <li><strong>25-Hydroxyvitamin D:</strong> Deficiency causes hypophosphatemia (decreased intestinal PO4 absorption)</li>
                <li><strong>LDH, Uric Acid, Potassium:</strong> If tumor lysis syndrome suspected (elevated in TLS)</li>
                <li><strong>Urinalysis:</strong> Myoglobinuria (rhabdomyolysis from severe hypophosphatemia)</li>
                <li><strong>24-Hour Urine Phosphate (if etiology unclear):</strong> Assess renal PO4 handling
                    <ul>
                        <li>FePO4 (Fractional Excretion of Phosphate) = (Urine PO4 Ã— Serum Cr) / (Serum PO4 Ã— Urine Cr) Ã— 100</li>
                        <li>FePO4 >5% with hypophosphatemia = Renal phosphate wasting</li>
                        <li>FePO4 <5% = Appropriate renal conservation, extrarenal losses</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Additional Testing Based on Suspected Etiology:</strong></p>
            <ul>
                <li><strong>Hypophosphatemia:</strong> Glucose (DKA), ABG (respiratory alkalosis), nutritional history (refeeding risk), alcohol use history</li>
                <li><strong>Hyperphosphatemia:</strong> Renal function, tumor lysis labs (LDH, uric acid, K, Ca), recent chemotherapy history</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>HYPOPHOSPHATEMIA TREATMENT:</strong></p>
            
            <p><strong>Severe Symptomatic Hypophosphatemia (PO4 <1.0 mg/dL, Weakness, Rhabdomyolysis, Respiratory Failure):</strong></p>
            <ul>
                <li><strong>IV Sodium Phosphate or Potassium Phosphate:</strong>
                    <ul>
                        <li>Dose: 0.08-0.16 mmol/kg (typically 15-30 mmol) IV over 6 hours</li>
                        <li>Sodium phosphate preferred if hyperkalemia; potassium phosphate if hypokalemia</li>
                        <li>Max rate: 7 mmol/hr (faster causes hypocalcemia, hypotension)</li>
                        <li>Can repeat dose q6-12h based on recheck PO4 levels</li>
                        <li>Monitor PO4 q6-8h during repletion</li>
                        <li>CAUTION: IV phosphate can cause severe hypocalcemia, hypotension, tissue calcification if given too rapidly. Always give slowly</li>
                    </ul>
                </li>
                <li><strong>Monitoring:</strong>
                    <ul>
                        <li>Check calcium (ionized Ca) before and during IV phosphate (risk of hypocalcemia)</li>
                        <li>Check magnesium, potassium (replace concurrently)</li>
                        <li>Monitor respiratory status (if ventilated from diaphragm weakness, may wean after PO4 corrected)</li>
                        <li>Monitor CK if rhabdomyolysis (should trend down as PO4 corrects)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Moderate Hypophosphatemia (PO4 1.0-2.0 mg/dL, Mild Symptoms or High-Risk Patients):</strong></p>
            <ul>
                <li><strong>Oral Phosphate (Preferred if GI Tract Functional):</strong>
                    <ul>
                        <li>Sodium/potassium phosphate (Neutra-Phos, K-Phos) 500 mg (16 mmol) PO TID-QID</li>
                        <li>Or Sodium phosphate/potassium phosphate packets: 1-2 packets PO TID</li>
                        <li>Total daily dose: 50-80 mmol/day divided</li>
                        <li>Side effect: Diarrhea (dose-limiting). Start lower dose, titrate up</li>
                    </ul>
                </li>
                <li><strong>IV Phosphate (if NPO or severe GI dysfunction):</strong> 15-30 mmol IV over 6 hours, repeat as needed</li>
            </ul>
            
            <p><strong>Mild Asymptomatic Hypophosphatemia (PO4 2.0-2.5 mg/dL):</strong></p>
            <ul>
                <li><strong>Dietary Supplementation:</strong> High-phosphate foods (dairy, meats, nuts, legumes, whole grains)</li>
                <li><strong>Oral Phosphate:</strong> 500 mg PO BID-TID if dietary insufficient</li>
                <li>Address underlying cause (stop antacids, treat vitamin D deficiency, optimize nutrition)</li>
            </ul>
            
            <p><strong>REFEEDING SYNDROME PREVENTION (HIGH-RISK PATIENTS):</strong></p>
            <ul>
                <li><strong>Risk Factors:</strong> Chronic malnutrition, alcoholism, anorexia nervosa, prolonged fasting, marasmus, chronic illness</li>
                <li><strong>Prevention Strategy:</strong>
                    <ul>
                        <li>Check baseline PO4, K, Mg, glucose before refeeding</li>
                        <li>Start nutrition slowly: 20-25 kcal/kg/day (50% of estimated needs), increase gradually over 4-7 days</li>
                        <li>Supplement thiamine 200-300 mg IV daily x 3 days (prevent Wernicke's), then 100 mg PO daily</li>
                        <li>Prophylactic supplementation: Phosphate 500 mg PO TID, Potassium 40 mEq PO BID, Magnesium 400 mg PO BID</li>
                        <li>Monitor electrolytes daily x 7 days (PO4, K, Mg, Ca)</li>
                        <li>If PO4 drops <2.0 mg/dL: slow/stop nutrition, give IV phosphate</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>HYPERPHOSPHATEMIA TREATMENT:</strong></p>
            
            <p><strong>Immediate Management:</strong></p>
            <ul>
                <li>Identify and treat underlying cause (CKD, tumor lysis, rhabdomyolysis)</li>
                <li>Stop phosphate sources (phosphate-containing laxatives/enemas, vitamin D supplements)</li>
                <li>Check calcium (expect hypocalcemia). If symptomatic hypocalcemia: hold IV calcium if PO4 >6.5 mg/dL (worsens tissue calcification)</li>
            </ul>
            
            <p><strong>Acute Severe Hyperphosphatemia (PO4 >6-7 mg/dL or Tumor Lysis Syndrome):</strong></p>
            <ul>
                <li><strong>IV Fluids:</strong> NS 150-250 mL/hr (promote renal PO4 excretion, dilute serum PO4)</li>
                <li><strong>Dialysis:</strong> If severe (PO4 >10 mg/dL), symptomatic hypocalcemia, renal failure, tumor lysis syndrome. Hemodialysis removes PO4 rapidly</li>
                <li><strong>Phosphate Binders (limited role acutely):</strong> Sevelamer 800 mg PO TID with meals, or Calcium acetate 667 mg PO TID with meals. Effect delayed (binds dietary PO4 in gut)</li>
            </ul>
            
            <p><strong>Chronic Hyperphosphatemia (CKD Patients):</strong></p>
            <ul>
                <li><strong>Dietary Phosphate Restriction:</strong> <800-1000 mg/day (avoid dairy, processed foods, cola, nuts)</li>
                <li><strong>Phosphate Binders (First-Line):</strong>
                    <ul>
                        <li><strong>Sevelamer (Renagel, Renvela):</strong> 800-1600 mg PO TID with meals. Non-calcium-based, doesn't worsen vascular calcification</li>
                        <li><strong>Calcium Acetate (PhosLo):</strong> 667-1334 mg PO TID with meals. Cheaper, but risk of hypercalcemia, vascular calcification</li>
                        <li><strong>Lanthanum Carbonate:</strong> 500-1000 mg PO TID with meals. Alternative if sevelamer not tolerated</li>
                        <li><strong>Aluminum Hydroxide:</strong> 300-600 mg PO TID with meals. Effective but risk of aluminum toxicity (encephalopathy, bone disease). Use short-term only (<4 weeks)</li>
                        <li>Take with meals (binds dietary PO4)</li>
                    </ul>
                </li>
                <li><strong>Dialysis:</strong> 3x/week HD removes PO4, maintains PO4 4.5-5.5 mg/dL</li>
                <li><strong>Goal:</strong> PO4 3.5-5.5 mg/dL in CKD (KDIGO guidelines)</li>
            </ul>
            
            <p><strong>Monitoring:</strong></p>
            <ul>
                <li><strong>Hypophosphatemia:</strong> Recheck PO4 q6-12h during IV repletion, daily once on oral. Monitor concurrent Ca, Mg, K</li>
                <li><strong>Hyperphosphatemia:</strong> Recheck PO4 q12-24h acutely, then weekly-monthly in chronic CKD. Monitor calcium, PTH, vitamin D</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Severe hypophosphatemia (PO4 <1.0 mg/dL) with respiratory failure, rhabdomyolysis, hemolysis; Severe hyperphosphatemia (PO4 >10 mg/dL) with symptomatic hypocalcemia, tumor lysis requiring dialysis</li>
                <li>Floor: Moderate hypophosphatemia requiring IV repletion, moderate hyperphosphatemia (PO4 5-7 mg/dL) in CKD</li>
                <li>Discharge: Phosphate corrected or stable on oral regimen, asymptomatic, follow-up arranged</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Refeeding Syndrome is a Lethal Complication of Restarting Nutrition in Malnourished Patients:</strong> Chronic starvation depletes total body PO4, K, Mg (though serum levels may be normal). When nutrition restarted, insulin surges â†’ glucose + PO4/K/Mg shift intracellularly â†’ severe hypophosphatemia, hypokalemia, hypomagnesemia within 24-72 hours. Can cause respiratory failure (diaphragm weakness), cardiac arrhythmias, rhabdomyolysis, seizures, death. High risk: anorexia nervosa, chronic alcoholism, marasmus, prolonged fasting, very low BMI (<16 kg/mÂ²). Prevention: Start nutrition slowly (20-25 kcal/kg/day), thiamine 200-300 mg IV, prophylactic PO4/K/Mg supplementation, monitor electrolytes daily x 7 days.</li>
            <li><strong>Severe Hypophosphatemia (PO4 <1.0 mg/dL) Causes Respiratory Failure from Diaphragm Weakness:</strong> Phosphate essential for ATP. Severe depletion causes cellular energy crisis, diaphragm muscle dysfunction â†’ respiratory failure. Patient may be intubated for "unknown reason," difficult to wean. Check PO4 in all intubated patients, especially if malnourished, alcoholic, or refeeding. Correcting PO4 (IV phosphate 15-30 mmol over 6 hours) improves respiratory muscle strength, enables weaning within 24-48 hours. Classic scenario: alcoholic patient intubated, PO4 0.8 mg/dL, after IV PO4 repletion successfully extubated next day.</li>
            <li><strong>IV Phosphate Can Cause Severe Hypocalcemia and Hypotension - Always Give Slowly:</strong> IV phosphate must be given over 6 hours minimum (max rate 7 mmol/hr). Rapid infusion causes: (1) Acute hypocalcemia (PO4 binds Ca â†’ calcium-phosphate precipitates), can cause tetany, cardiac arrhythmias, (2) Hypotension, (3) Tissue calcification (especially in kidneys, blood vessels). Before giving IV PO4: check calcium (have calcium gluconate available), give slowly, monitor calcium q6h during infusion. If hypocalcemia develops: slow/stop PO4 infusion, give calcium. Never push IV phosphate as bolus.</li>
            <li><strong>Hemolytic Anemia from Severe Hypophosphatemia is Rare but Specific:</strong> Phosphate needed for RBC 2,3-DPG production and ATP. Severe hypophosphatemia (PO4 <1.0 mg/dL) causes: (1) Hemolytic anemia (RBC membrane instability), (2) Left-shifted oxygen-hemoglobin dissociation curve (decreased 2,3-DPG â†’ poor tissue oxygen delivery despite normal SpO2). Labs: low Hgb, elevated LDH, elevated indirect bilirubin, low haptoglobin, schistocytes on smear (microangiopathic hemolysis). Correct PO4 â†’ hemolysis resolves. Also causes WBC/platelet dysfunction (increased infection risk, bleeding).</li>
            <li><strong>CKD Patients with Hyperphosphatemia Have Increased Cardiovascular Mortality from Vascular Calcification:</strong> Chronic hyperphosphatemia (PO4 >5.5 mg/dL) in CKD causes calcium-phosphate precipitation in blood vessels, heart valves, soft tissues. Vascular calcification â†’ coronary artery disease, MI, heart failure, stroke. Calcium-phosphate product (Ca Ã— PO4) >55 mgÂ²/dLÂ² increases calcification risk exponentially. Goal in CKD: PO4 3.5-5.5 mg/dL, Ca 8.5-10.5 mg/dL, Ca Ã— PO4 <55 mgÂ²/dLÂ². Treatment: phosphate binders (sevelamer preferred - doesn't add calcium), dietary PO4 restriction (<1000 mg/day), dialysis. Avoid excessive calcium-based binders (worsen vascular calcification).</li>
            <li><strong>Tumor Lysis Syndrome Causes Hyperphosphatemia + Hypocalcemia + Hyperkalemia + Hyperuricemia:</strong> Rapid tumor cell lysis (chemotherapy for hematologic malignancies) â†’ massive release of intracellular contents. Classic labs within 24-72 hours of chemotherapy: High PO4 (>6-8 mg/dL), low Ca (PO4 binds Ca), high K (>6 mEq/L), high uric acid (>10 mg/dL), high LDH, AKI (uric acid crystals, calcium-phosphate precipitates in kidneys). Prevention: aggressive IV fluids 3 L/day, allopurinol or rasburicase (prevent uric acid nephropathy), monitor electrolytes q6-8h. Treatment: IV fluids, correct electrolytes, dialysis if severe (PO4 >10 mg/dL, K >6.5 mEq/L, AKI). Do NOT give calcium unless life-threatening hypocalcemia (worsens kidney injury).</li>
            <li><strong>Phosphate Binders MUST Be Taken With Meals to Work:</strong> Phosphate binders (sevelamer, calcium acetate, lanthanum) work by binding dietary phosphate in GI tract, preventing absorption. If taken between meals, no dietary PO4 present â†’ ineffective. Always instruct patients: take phosphate binder WITH first bite of meal. Common error: patient takes binders morning/evening regardless of meals â†’ PO4 remains high â†’ doctor increases dose unnecessarily. Proper timing crucial. Also, sevelamer can bind other medications - separate dosing by 2 hours.</li>
            <li><strong>Respiratory Alkalosis Causes Intracellular Phosphate Shift â†’ Hypophosphatemia:</strong> Acute respiratory alkalosis (hyperventilation from pain, anxiety, sepsis, early ventilator settings) increases pH â†’ stimulates glycolysis â†’ increases intracellular PO4 consumption â†’ PO4 shifts into cells â†’ serum PO4 drops. Can see PO4 drop from 3.5 to 1.5 mg/dL within hours of intubation/hyperventilation. Usually asymptomatic (PO4 rarely drops <1.0 mg/dL). Resolves when respiratory alkalosis corrected. Don't aggressively replace PO4 unless severe (<1.0 mg/dL) or patient at risk (already malnourished, alcoholic). Fix the ventilator settings (decrease minute ventilation, allow pCO2 to normalize).</li>
            <li><strong>DKA Treatment Causes Hypophosphatemia - Monitor and Replace Carefully:</strong> DKA causes total body PO4 depletion (osmotic diuresis), but initial serum PO4 normal/high (cellular release from acidosis, insulin deficiency). When insulin given â†’ glucose + PO4 shift intracellularly â†’ serum PO4 drops precipitously within 4-6 hours of treatment. PO4 can drop to <1.0 mg/dL. Risk of respiratory failure, cardiac arrhythmias. Management: Check PO4 before insulin, then q4-6h during DKA treatment. If PO4 <1.0 mg/dL: give IV phosphate 15-30 mmol over 6 hours. If PO4 1.0-2.0 mg/dL: give oral phosphate or add potassium phosphate to IV fluids (instead of potassium chloride). Don't wait for PO4 to drop critically before replacing.</li>
            <li><strong>Aluminum-Based Phosphate Binders Cause Aluminum Toxicity - Avoid Long-Term Use:</strong> Aluminum hydroxide (Amphojel, AlternaGel) is very effective phosphate binder (binds more PO4 per mg than sevelamer). But aluminum accumulates in body, especially in CKD (kidneys can't excrete aluminum). Chronic use (>4 weeks) causes: (1) Aluminum-induced bone disease (osteomalacia, fractures), (2) Aluminum-induced encephalopathy (dementia, seizures, death), (3) Microcytic anemia (aluminum inhibits heme synthesis). Current recommendation: Use aluminum binders short-term only (<4 weeks) for severe acute hyperphosphatemia. Long-term: use sevelamer, calcium acetate, or lanthanum. If aluminum binders needed chronically, monitor serum aluminum levels (goal <20 mcg/L).</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li><strong>Hypophosphatemia:</strong> PO4 <1.0 mg/dL, respiratory failure from diaphragm weakness, rhabdomyolysis (CK >10,000), hemolytic anemia, altered mental status, seizures</li>
            <li><strong>Hyperphosphatemia:</strong> PO4 >10 mg/dL, tumor lysis syndrome with AKI, symptomatic hypocalcemia with PO4 >6.5 mg/dL, requiring urgent dialysis</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Phosphate normalized (2.5-4.5 mg/dL) or stable in acceptable range for patient (CKD patients may tolerate PO4 4-5.5 mg/dL)</li>
            <li>Asymptomatic (no weakness, rhabdomyolysis resolved, respiratory function normal)</li>
            <li>Concurrent electrolyte abnormalities corrected (Ca, Mg, K normalized)</li>
            <li>If hypophosphatemia: on oral phosphate or high-phosphate diet, underlying cause addressed</li>
            <li>If hyperphosphatemia (CKD): on phosphate binders, dietary restriction counseled</li>
            <li>If refeeding syndrome: nutrition plan established, thiamine supplemented</li>
            <li>Follow-up arranged (nephrology if CKD, PCP within 1 week)</li>
            <li>Recheck PO4, Ca, Mg scheduled for 1 week</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="metabolic-alkalosis">
    <div class="page-header">
        <h2>112. METABOLIC ALKALOSIS</h2>
        <div class="subtitle">Elevated pH â€¢ High Bicarbonate â€¢ Hypokalemia â€¢ Hypochloremia â€¢ Volume Depletion</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Arterial blood gas showing elevated pH (>7.45), elevated HCO3 (>28 mEq/L), typically with hypokalemia, hypochloremia, and either volume depletion (vomiting, diuretics) or volume expansion (mineralocorticoid excess). Often presents with muscle weakness, cramps, arrhythmias, confusion.</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Metabolic alkalosis results from net gain of bicarbonate or net loss of acid (H+). Requires two components: (1) <strong>Generation:</strong> Event that initiates alkalosis (vomiting, diuretics, alkali administration), (2) <strong>Maintenance:</strong> Factors preventing kidney from excreting excess HCO3 (volume depletion, hypokalemia, hypochloremia). Kidneys normally excrete HCO3 rapidly, so sustained alkalosis indicates maintenance factor present. Classification: Saline-responsive (urine Cl <20 mEq/L - volume depleted) vs Saline-resistant (urine Cl >20 mEq/L - mineralocorticoid excess, severe K depletion)</li>
                <li><strong>Risk Factors:</strong> Vomiting/NG suction (most common), loop/thiazide diuretics, primary hyperaldosteronism, Cushing's syndrome, licorice ingestion, massive blood transfusion (citrate converted to HCO3), alkali administration (sodium bicarbonate, citrate in TPN), milk-alkali syndrome, hypercalcemia, Bartter/Gitelman syndrome</li>
                <li><strong>Symptoms:</strong> Often asymptomatic if mild (pH 7.45-7.50). Moderate-severe (pH >7.50): confusion, lethargy, muscle weakness/cramps, paresthesias (perioral, fingers), nausea, polyuria, palpitations (arrhythmias from hypokalemia), tetany (rare, if concurrent hypocalcemia)</li>
                <li><strong>Physical Exam:</strong> Signs of volume depletion (vomiting, diuretics): orthostatic hypotension, tachycardia, dry mucous membranes, decreased skin turgor. Signs of volume expansion (mineralocorticoid excess): hypertension, edema. Neuromuscular: hyporeflexia, muscle weakness, Chvostek/Trousseau signs if severe alkalosis (alkalosis shifts ionized Ca down). Arrhythmias if severe hypokalemia</li>
                <li><strong>Variants/Subtypes:</strong> <strong>Saline-Responsive (Chloride-Responsive):</strong> Vomiting, NG suction, diuretics, post-hypercapnia. Urine Cl <20 mEq/L. Respond to saline + KCl. <strong>Saline-Resistant (Chloride-Resistant):</strong> Hyperaldosteronism, Cushing's, severe hypokalemia. Urine Cl >20 mEq/L. Do NOT respond to saline alone.</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Arterial Blood Gas (ABG) - Diagnostic:</strong></p>
            <ul>
                <li><strong>pH:</strong> Elevated >7.45 (7.45-7.55 mild-moderate, >7.55 severe)</li>
                <li><strong>HCO3:</strong> Elevated >28 mEq/L (can be >40-45 mEq/L in severe cases)</li>
                <li><strong>pCO2:</strong> Elevated (respiratory compensation). Expected pCO2 = 0.7 Ã— HCO3 + 20 (Â±5). For every 1 mEq/L rise in HCO3, expect pCO2 to rise 0.7 mmHg</li>
                <li><strong>Compensation:</strong> Respiratory compensation is LIMITED (pCO2 rarely >55 mmHg even with severe metabolic alkalosis - respiratory drive prevents further hypoventilation). If pCO2 >55 mmHg, consider mixed disorder (metabolic alkalosis + respiratory acidosis)</li>
            </ul>
            
            <p><strong>Serum Electrolytes:</strong></p>
            <ul>
                <li><strong>Hypokalemia:</strong> Almost always present (K <3.5 mEq/L, often <3.0 mEq/L). Alkalosis shifts K+ intracellularly. H+ and K+ inversely related</li>
                <li><strong>Hypochloremia:</strong> Cl <95 mEq/L (loss of HCl from vomiting, or Cl loss with diuretics). Chloride deficiency maintains alkalosis</li>
                <li><strong>Hyponatremia or Normal Sodium:</strong> Na can be low (diuretics), normal, or elevated (mineralocorticoid excess)</li>
                <li><strong>Elevated Bicarbonate:</strong> HCO3 >28 mEq/L (same as ABG)</li>
            </ul>
            
            <p><strong>Urine Chloride (MOST IMPORTANT TEST to Classify Etiology):</strong></p>
            <ul>
                <li><strong>Urine Cl <20 mEq/L:</strong> Saline-responsive (chloride-responsive) metabolic alkalosis
                    <ul>
                        <li>Causes: Vomiting, NG suction, remote diuretic use (>24 hours ago), post-hypercapnia, villous adenoma</li>
                        <li>Interpretation: Kidneys appropriately retaining chloride (volume depleted state)</li>
                        <li>Treatment: Normal saline + KCl</li>
                    </ul>
                </li>
                <li><strong>Urine Cl >20 mEq/L:</strong> Saline-resistant (chloride-resistant) metabolic alkalosis
                    <ul>
                        <li>Causes: Active diuretic use, primary hyperaldosteronism, Cushing's syndrome, severe hypokalemia (K <2.0 mEq/L), Bartter/Gitelman syndrome, licorice ingestion</li>
                        <li>Interpretation: Kidneys inappropriately wasting chloride despite alkalosis</li>
                        <li>Treatment: Treat underlying cause (stop diuretic, correct severe hypokalemia, treat hyperaldosteronism)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Additional Testing Based on Classification:</strong></p>
            <ul>
                <li><strong>If Saline-Responsive (Urine Cl <20):</strong> Clinical history usually sufficient (vomiting, NG suction, diuretics)</li>
                <li><strong>If Saline-Resistant (Urine Cl >20):</strong>
                    <ul>
                        <li>Check blood pressure: Hypertensive (think primary hyperaldosteronism, Cushing's, renovascular hypertension) vs Normotensive (think severe K depletion, Bartter/Gitelman syndrome, licorice, diuretic abuse)</li>
                        <li><strong>Plasma Renin and Aldosterone:</strong> If hypertensive + hypokalemia + metabolic alkalosis
                            <ul>
                                <li>Low renin + High aldosterone = Primary hyperaldosteronism (adrenal adenoma, bilateral adrenal hyperplasia)</li>
                                <li>High renin + High aldosterone = Secondary hyperaldosteronism (renovascular hypertension, renin-secreting tumor)</li>
                                <li>Low renin + Low aldosterone = Exogenous mineralocorticoid (licorice, Cushing's, exogenous steroids)</li>
                            </ul>
                        </li>
                        <li><strong>24-Hour Urine Cortisol or Dexamethasone Suppression Test:</strong> If concern for Cushing's syndrome</li>
                        <li><strong>Abdominal CT/MRI:</strong> If primary hyperaldosteronism confirmed (look for adrenal adenoma)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>ECG:</strong></p>
            <ul>
                <li>Hypokalemia findings: U waves, T wave flattening, prolonged QT, PVCs, atrial/ventricular arrhythmias</li>
                <li>Alkalosis itself can prolong QT interval</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>General Principles:</strong></p>
            <ul>
                <li>Metabolic alkalosis is rarely life-threatening (unlike severe acidosis)</li>
                <li>Focus on treating underlying cause and correcting maintenance factors</li>
                <li>Most cases respond to fluid + electrolyte repletion (saline-responsive)</li>
                <li>Do NOT attempt to directly lower pH (dangerous) - correct underlying disorder</li>
            </ul>
            
            <p><strong>SALINE-RESPONSIVE METABOLIC ALKALOSIS (Urine Cl <20 mEq/L) - MOST COMMON:</strong></p>
            <ul>
                <li><strong>Step 1 - Volume Repletion with Normal Saline:</strong>
                    <ul>
                        <li>0.9% Normal Saline 1-2 L bolus, then 100-200 mL/hr</li>
                        <li>Provides chloride (repletes chloride deficit) + volume (improves renal HCO3 excretion)</li>
                        <li>Monitor: Assess volume status clinically, goal orthostatic vitals resolved, good urine output</li>
                    </ul>
                </li>
                <li><strong>Step 2 - Potassium Chloride Repletion (CRITICAL):</strong>
                    <ul>
                        <li>Most patients have profound K depletion (K <3.0 mEq/L, often <2.5 mEq/L)</li>
                        <li><strong>KCl 40-80 mEq IV</strong> in first liter of NS (if K <3.0 mEq/L)</li>
                        <li>Then continue KCl 20-40 mEq in each liter NS until K >3.5 mEq/L</li>
                        <li>Or KCl 40-80 mEq PO q6-8h if able to tolerate PO</li>
                        <li>Goal: K >3.5 mEq/L (often need 200-400 mEq total replacement)</li>
                        <li><strong>Cannot correct alkalosis without correcting hypokalemia</strong> (low K maintains alkalosis via renal mechanisms)</li>
                    </ul>
                </li>
                <li><strong>Step 3 - Treat Underlying Cause:</strong>
                    <ul>
                        <li>Vomiting: Antiemetics (ondansetron 4-8 mg IV q8h), treat underlying GI pathology</li>
                        <li>NG suction: Reduce suction rate if possible, or give IV HCl (see below) if must continue suction</li>
                        <li>Diuretics: Stop diuretic if possible, or switch to K-sparing diuretic (spironolactone)</li>
                    </ul>
                </li>
                <li><strong>Monitoring:</strong>
                    <ul>
                        <li>ABG q6-12h to assess pH, HCO3, pCO2</li>
                        <li>BMP q6-12h to monitor K, Cl, HCO3</li>
                        <li>Continuous telemetry if K <2.5 mEq/L or arrhythmias present</li>
                        <li>Goal: pH <7.45, HCO3 <28 mEq/L, K >3.5 mEq/L, Cl >95 mEq/L</li>
                    </ul>
                </li>
                <li><strong>Expected Response:</strong> With adequate saline + KCl, alkalosis corrects within 24-48 hours</li>
            </ul>
            
            <p><strong>SALINE-RESISTANT METABOLIC ALKALOSIS (Urine Cl >20 mEq/L):</strong></p>
            <ul>
                <li><strong>Active Diuretic Use:</strong> Stop diuretic if possible. If must continue (CHF, cirrhosis), switch to acetazolamide (promotes HCO3 excretion) or add K-sparing diuretic (spironolactone 25-50 mg PO daily)</li>
                <li><strong>Severe Hypokalemia (K <2.0 mEq/L):</strong>
                    <ul>
                        <li>Aggressive KCl repletion: 40-80 mEq IV q4-6h until K >2.5 mEq/L (requires central line for higher rates)</li>
                        <li>Alkalosis persists until K >2.5 mEq/L (severe K depletion maintains alkalosis independent of volume status)</li>
                    </ul>
                </li>
                <li><strong>Primary Hyperaldosteronism:</strong>
                    <ul>
                        <li>Spironolactone (aldosterone antagonist) 50-100 mg PO BID, or Eplerenone 50-100 mg PO daily</li>
                        <li>Blocks aldosterone effect â†’ reduces K wasting, improves metabolic alkalosis</li>
                        <li>Definitive: Surgical adrenalectomy if unilateral adenoma (cures 50-60%)</li>
                    </ul>
                </li>
                <li><strong>Cushing's Syndrome:</strong> Treat underlying cause (pituitary adenoma, adrenal tumor, ectopic ACTH). May need ketoconazole or metyrapone to lower cortisol acutely</li>
                <li><strong>Bartter/Gitelman Syndrome:</strong> Chronic K supplementation, NSAIDs (reduce renal prostaglandin-mediated K wasting), K-sparing diuretics</li>
            </ul>
            
            <p><strong>SEVERE LIFE-THREATENING METABOLIC ALKALOSIS (pH >7.55-7.60):</strong></p>
            <ul>
                <li><strong>Indications for Aggressive Treatment:</strong> pH >7.55-7.60, seizures, severe arrhythmias, hemodynamic instability</li>
                <li><strong>Acetazolamide (Carbonic Anhydrase Inhibitor) - Promotes Bicarbonate Excretion:</strong>
                    <ul>
                        <li>Dose: 250-500 mg IV q6-12h</li>
                        <li>Mechanism: Inhibits proximal tubule HCO3 reabsorption â†’ increases renal HCO3 excretion â†’ lowers pH</li>
                        <li>Onset: 4-6 hours</li>
                        <li>Caution: Worsens hypokalemia (check K q4-6h, replace aggressively). Contraindicated if severe hypokalemia (K <2.5 mEq/L) - correct K first</li>
                    </ul>
                </li>
                <li><strong>Hydrochloric Acid (HCl) Infusion - MOST RAPID but HIGH RISK:</strong>
                    <ul>
                        <li>0.1-0.2 N HCl infusion via CENTRAL LINE ONLY (scleroses peripheral veins)</li>
                        <li>Dose: Calculate HCl needed = 0.5 Ã— body weight (kg) Ã— (HCO3 current - HCO3 goal). Infuse half this amount over 8-12 hours</li>
                        <li>Mechanism: Directly titrates HCO3 with H+</li>
                        <li>Complications: Tissue necrosis if extravasation, hemolysis, acidemia overshoot. Requires ICU, central line, close monitoring</li>
                        <li>Rarely used (reserved for life-threatening alkalosis refractory to other measures)</li>
                    </ul>
                </li>
                <li><strong>Hemodialysis with Low-Bicarbonate Dialysate:</strong>
                    <ul>
                        <li>If renal failure prevents renal HCO3 excretion</li>
                        <li>Dialysate with low HCO3 (e.g., 20 mEq/L instead of standard 35-40 mEq/L) removes HCO3</li>
                        <li>Consult nephrology</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Supportive Care:</strong></p>
            <ul>
                <li>Supplemental oxygen if hypoxemic (alkalosis shifts O2-Hgb curve left, impairs O2 release)</li>
                <li>Correct concurrent hypomagnesemia (impairs K correction)</li>
                <li>Treat arrhythmias (usually improve as K and pH normalize)</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Severe alkalosis (pH >7.55), severe hypokalemia (K <2.5 mEq/L) with arrhythmias, requiring HCl infusion or acetazolamide, altered mental status, seizures</li>
                <li>Floor with Telemetry: Moderate alkalosis (pH 7.45-7.55), hypokalemia (K 2.5-3.5 mEq/L), requiring IV KCl repletion</li>
                <li>Discharge: Alkalosis corrected or mild (pH <7.45, HCO3 <30 mEq/L), K >3.5 mEq/L, underlying cause addressed, able to maintain oral K supplementation if needed</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Urine Chloride is THE Key Test to Classify Metabolic Alkalosis Etiology:</strong> Not urine sodium, not urine pH - URINE CHLORIDE. Distinguishes saline-responsive (<20 mEq/L) from saline-resistant (>20 mEq/L). Saline-responsive (95% of cases): vomiting, NG suction, diuretics (>24 hours ago), post-hypercapnia. Treat with NS + KCl. Saline-resistant: active diuretics, primary hyperaldosteronism, Cushing's, severe hypokalemia. Treat underlying cause. Always send spot urine chloride in metabolic alkalosis before starting treatment - guides entire management.</li>
            <li><strong>Metabolic Alkalosis Requires Both Generation and Maintenance - Kidneys Normally Excrete HCO3 Rapidly:</strong> Healthy kidneys can excrete enormous amounts of HCO3 (thousands of mEq/day). So transient alkalosis (one-time vomiting, alkali load) self-corrects rapidly. Sustained metabolic alkalosis requires maintenance factor preventing renal HCO3 excretion: (1) Volume depletion (activates RAAS â†’ increases proximal HCO3 reabsorption), (2) Chloride depletion (impairs distal HCO3 secretion), (3) Hypokalemia (increases renal H+ secretion, generates new HCO3). Treatment must address maintenance factor, not just generation. Example: Patient vomiting x 1 day gets 1 L NS â†’ alkalosis resolves. Patient vomiting x 5 days needs NS + KCl for days to correct.</li>
            <li><strong>Cannot Correct Metabolic Alkalosis Without Correcting Hypokalemia:</strong> Hypokalemia maintains alkalosis via renal mechanisms: (1) Low serum K â†’ K shifts out of cells â†’ H+ shifts into cells â†’ intracellular acidosis â†’ kidney excretes H+ (generates HCO3, worsens alkalosis), (2) Hypokalemia increases proximal tubule H+ secretion (generates HCO3), (3) Aldosterone effect enhanced when K low. Clinically: giving NS without KCl in vomiting patient â†’ pH stays elevated, K stays low. Must give both NS and KCl. Typical requirement: 200-400 mEq KCl total to correct alkalosis + hypokalemia. Check K q6-8h during repletion.</li>
            <li><strong>Contraction Alkalosis from Diuretics is Due to Chloride Depletion, Not Just Volume Loss:</strong> Loop and thiazide diuretics cause metabolic alkalosis via: (1) Volume depletion (activates RAAS, increases HCO3 reabsorption), (2) Chloride depletion (kidneys cannot excrete HCO3 without Clâˆ’), (3) Hypokalemia (see above). The chloride depletion is key - giving dextrose in water (volume without Cl) won't correct alkalosis. Must give saline (provides Clâˆ’) + KCl. Urine Cl <20 mEq/L if diuretic stopped >24 hours ago (becomes saline-responsive). Urine Cl >20 mEq/L if actively taking diuretic (saline-resistant - stop diuretic).</li>
            <li><strong>Post-Hypercapnic Alkalosis Occurs After Rapid Correction of Chronic Respiratory Acidosis:</strong> Patient with chronic CO2 retention (COPD, obesity hypoventilation) has compensatory metabolic alkalosis (kidneys retain HCO3 to buffer chronic acidosis, HCO3 may be 35-45 mEq/L). If pCO2 corrected rapidly (intubation, BiPAP, treating exacerbation) â†’ pCO2 normalizes but HCO3 still elevated â†’ metabolic alkalosis (pH can be >7.50). Takes days for kidneys to excrete excess HCO3. Treatment: Saline + KCl (saline-responsive, urine Cl <20 mEq/L). Acetazolamide can speed correction. Don't over-ventilate COPD patients - causes post-hypercapnic alkalosis and difficult weaning.</li>
            <li><strong>Severe Metabolic Alkalosis (pH >7.55) is Dangerous - Causes Arrhythmias, Seizures, Decreased Coronary Blood Flow:</strong> Alkalosis shifts K+ and Ca2+ intracellularly (ionized Ca drops) â†’ arrhythmias (prolonged QT, VT, atrial fib), neuromuscular excitability (tetany, seizures). Alkalosis also causes cerebral vasoconstriction (decreased cerebral blood flow â†’ confusion, seizures), coronary vasoconstriction (angina in CAD patients), impaired oxygen delivery (left-shift O2-Hgb curve). pH >7.60 is medical emergency. Unlike metabolic acidosis (can tolerate pH 7.10-7.20), severe alkalosis poorly tolerated. If pH >7.55-7.60: consider acetazolamide or HCl infusion.</li>
            <li><strong>Acetazolamide Promotes Bicarbonate Excretion but Worsens Hypokalemia:</strong> Acetazolamide inhibits carbonic anhydrase in proximal tubule â†’ blocks HCO3 reabsorption â†’ increased renal HCO3 excretion (bicarbonaturia) â†’ lowers pH. Dose 250-500 mg IV q6-12h. Onset 4-6 hours, effective for pH >7.50. BUT acetazolamide also increases distal Na delivery â†’ K wasting â†’ worsens hypokalemia. Must check K q4-6h, give aggressive KCl (40-80 mEq q4-6h) while on acetazolamide. Do NOT use if K <2.5 mEq/L (correct K first, then use acetazolamide if still needed). Side effects: paresthesias, metabolic acidosis (if overdone).</li>
            <li><strong>Primary Hyperaldosteronism (Conn Syndrome) Classic Triad: Hypertension + Hypokalemia + Metabolic Alkalosis:</strong> Excess aldosterone â†’ renal K wasting + Na retention â†’ hypokalemia (K 2.5-3.5 mEq/L) + hypertension + metabolic alkalosis (HCO3 30-40 mEq/L). Urine Cl >20 mEq/L (saline-resistant). Screening: plasma aldosterone/renin ratio. If ratio >20-30 and aldosterone >15 ng/dL â†’ primary hyperaldosteronism. Confirm with saline suppression test or captopril test. Imaging: adrenal CT/MRI (look for adenoma). Treatment: spironolactone 50-100 mg BID (blocks aldosterone), or surgical adrenalectomy if unilateral adenoma. Classic scenario: 40-year-old with hypertension, K 2.8 mEq/L, HCO3 35 mEq/L, resistant to treatment.</li>
            <li><strong>Milk-Alkali Syndrome: Triad of Hypercalcemia + Metabolic Alkalosis + Acute Kidney Injury:</strong> From excessive calcium and alkali ingestion (calcium carbonate antacids, calcium supplements, calcium-fortified foods). Hypercalcemia â†’ nephrogenic DI, volume depletion, AKI. Calcium carbonate â†’ alkali load â†’ metabolic alkalosis. Classic patient: woman taking calcium carbonate 3000-5000 mg/day for osteoporosis prevention + vitamin D, presents with confusion, nausea, Ca 12-14 mg/dL, HCO3 32-38 mEq/L, Cr 2.5-4.0 mg/dL. Treatment: stop calcium/vitamin D, IV saline, calcitonin if Ca >14 mg/dL. Third most common cause of hypercalcemia (after primary hyperparathyroidism and malignancy).</li>
            <li><strong>Never Give Bicarbonate to "Correct" Metabolic Alkalosis - You'll Make It Worse:</strong> Common error: seeing "metabolic" and thinking "give opposite" (like giving bicarb for metabolic acidosis). NO. Giving bicarbonate in metabolic alkalosis adds more HCO3, worsens alkalosis, can cause pH >7.60 (life-threatening). Treatment is NOT to "neutralize" pH but to remove maintenance factors (give saline + KCl for volume/Cl/K repletion, stop diuretics, treat hyperaldosteronism). Only exception: if patient has MIXED disorder (metabolic alkalosis + severe metabolic acidosis from different cause, pH near normal, very sick) - but this is rare and complex.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Severe metabolic alkalosis (pH >7.55-7.60)</li>
            <li>Severe hypokalemia (K <2.5 mEq/L) with cardiac arrhythmias (PVCs, VT, atrial fibrillation)</li>
            <li>Altered mental status, confusion, seizures from alkalosis</li>
            <li>Requiring hydrochloric acid (HCl) infusion</li>
            <li>Respiratory depression from compensatory hypoventilation (pCO2 >55 mmHg, hypoxemia)</li>
            <li>Hemodynamic instability</li>
            <li>Requiring central line for rapid KCl infusion (>20 mEq/hr)</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>pH normalized (<7.45) or near-normal (7.42-7.45)</li>
            <li>Bicarbonate normalized (<28 mEq/L) or near-normal (26-28 mEq/L)</li>
            <li>Potassium corrected (>3.5 mEq/L, ideally >4.0 mEq/L)</li>
            <li>Chloride normalized (>95 mEq/L)</li>
            <li>Volume status optimized (euvolemic, normal orthostatics)</li>
            <li>Asymptomatic (no muscle weakness, cramps, palpitations, confusion)</li>
            <li>Underlying cause addressed (vomiting controlled, diuretic stopped/adjusted)</li>
            <li>If ongoing risk (e.g., continued diuretics for CHF): on oral KCl supplementation 20-40 mEq PO BID</li>
            <li>Follow-up arranged with PCP within 1 week</li>
            <li>Recheck BMP (K, Cl, HCO3) scheduled for 1 week</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="sickle-cell">
    <div class="page-header">
        <h2>113. SICKLE CELL CRISIS (VASO-OCCLUSIVE, ACUTE CHEST SYNDROME)</h2>
        <div class="subtitle">Severe Pain â€¢ Acute Chest Syndrome â€¢ Stroke Risk â€¢ Exchange Transfusion</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with known sickle cell disease presenting with severe, excruciating bone/joint pain (vaso-occlusive crisis), or fever, chest pain, hypoxia, and new infiltrate on chest X-ray (acute chest syndrome - leading cause of death in SCD).</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Hemoglobin S (HbS) polymerizes under hypoxic/acidotic conditions, causing RBC sickling. Sickled cells occlude microvasculature leading to tissue ischemia, infarction, and severe pain (vaso-occlusive crisis - VOC). Acute chest syndrome (ACS) results from pulmonary vaso-occlusion, fat embolism from bone marrow infarction, and/or infection, creating a cycle of hypoxia â†’ more sickling â†’ worsening pulmonary compromise. Can progress to ARDS, multiorgan failure, death. Other crises: aplastic crisis (parvovirus B19), splenic sequestration (massive splenomegaly, hypovolemic shock), hemolytic crisis</li>
                <li><strong>Risk Factors:</strong> Sickle cell disease (HbSS most severe, HbSC moderate, HbS-beta-thal variable), triggers: dehydration, infection (pneumonia, osteomyelitis, UTI), hypoxia, acidosis, cold exposure, extreme exertion, pregnancy, alcohol, noncompliance with hydroxyurea. VOC triggered by weather changes, physical stress, emotional stress. ACS often precipitated by VOC, post-operative state, fat embolism</li>
                <li><strong>Symptoms - Vaso-Occlusive Crisis:</strong> Severe, deep, aching bone pain (most common: long bones, back, chest, abdomen), pain intensity 8-10/10, often described as "worst pain imaginable," lasts hours to days. Dactylitis (hand-foot syndrome) in children. Abdominal pain (mesenteric ischemia, splenic infarction). Priapism (urologic emergency). Headache, altered mental status (stroke)</li>
                <li><strong>Symptoms - Acute Chest Syndrome:</strong> Fever (>38.5Â°C), chest pain (pleuritic), dyspnea, cough, hypoxia (O2 sat <90%), rapid respiratory decompensation. Often develops 24-72 hours after VOC or post-operatively. Progressive infiltrates on CXR</li>
                <li><strong>Physical Exam:</strong> Tachycardia, tachypnea, hypoxia, fever. Severe pain with minimal external findings (hallmark of VOC). Tenderness over affected bones/joints. ACS: decreased breath sounds, rales/crackles, dullness to percussion, respiratory distress. Jaundice, scleral icterus (chronic hemolysis). Splenomegaly (children; adults have autoinfarction). Stroke: focal neurologic deficits, altered mental status</li>
                <li><strong>Variants/Subtypes:</strong> VOC (most common crisis, 90%), Acute Chest Syndrome (ACS - second most common, leading cause of death), Splenic Sequestration (massive splenomegaly, hypovolemia, shock), Aplastic Crisis (parvovirus B19, profound anemia with reticulocytopenia), Hemolytic Crisis (accelerated hemolysis beyond baseline), Stroke (ischemic from large vessel occlusion or hemorrhagic), Multiorgan Failure Syndrome (MOFS - liver, kidney, lung failure)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Complete Blood Count:</strong> Baseline anemia (Hgb 6-9 g/dL in HbSS is typical; acute drop suggests sequestration or aplastic crisis). Elevated WBC (15,000-25,000/ÂµL common in VOC from demargination, not infection). Low platelets (<150,000/ÂµL) concerning for sequestration or sepsis. Reticulocyte count: elevated (5-15%) at baseline; LOW in aplastic crisis (<1%)</li>
                <li><strong>Hemolysis Labs:</strong> Elevated LDH (often 400-1000 U/L), elevated indirect bilirubin (2-5 mg/dL at baseline, higher in hemolytic crisis), low haptoglobin (<25 mg/dL or undetectable), elevated AST</li>
                <li><strong>Peripheral Smear:</strong> Sickled RBCs (elongated, crescent-shaped), target cells, Howell-Jolly bodies (asplenia), nucleated RBCs, polychromasia</li>
                <li><strong>Type and Screen:</strong> ALWAYS in preparation for transfusion. Extended phenotype matching (Rh, Kell, Duffy, Kidd antigens) to reduce alloimmunization</li>
                <li><strong>Basic Metabolic Panel:</strong> Assess renal function (Cr often mildly elevated at baseline), electrolytes, anion gap (lactic acidosis from tissue ischemia)</li>
                <li><strong>Hepatic Panel:</strong> Elevated transaminases (hepatic sequestration, ischemia), elevated bilirubin (hemolysis)</li>
                <li><strong>Arterial Blood Gas:</strong> If hypoxia or respiratory distress. Assess oxygenation, acidosis (pH <7.35 worsens sickling)</li>
                <li><strong>Lactate:</strong> Elevated in severe vaso-occlusion, tissue ischemia, multiorgan failure</li>
                <li><strong>Blood Cultures:</strong> If fever (>38.5Â°C) or ACS. Encapsulated organisms (S. pneumoniae, H. influenzae, Salmonella) due to functional asplenia</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>Chest X-ray:</strong> MANDATORY if fever, chest pain, dyspnea, hypoxia. ACS: new infiltrate (can be subtle initially, progresses over 24-48 hours), pleural effusion, consolidation. May be normal early in ACS</li>
                <li><strong>CT Chest (if CXR equivocal or severe):</strong> Better characterize infiltrates, assess for pulmonary embolism (increased risk in SCD)</li>
                <li><strong>MRI/MRA Brain (if stroke symptoms):</strong> Acute ischemic stroke (MCA territory most common), hemorrhagic stroke, chronic silent infarcts. STAT imaging for any focal neurologic deficit</li>
                <li><strong>Ultrasound Abdomen:</strong> If RUQ pain or elevated LFTs. Assess for cholelithiasis (pigment stones from chronic hemolysis), hepatic sequestration, splenic infarction/sequestration</li>
                <li><strong>X-rays of Painful Areas:</strong> Rule out osteomyelitis (difficult to distinguish from bone infarction; Salmonella osteomyelitis classic), pathologic fracture, avascular necrosis (femoral head, humeral head)</li>
            </ul>
            
            <p><strong>Special Considerations:</strong></p>
            <ul>
                <li><strong>Hemoglobin Electrophoresis:</strong> If new diagnosis or unknown SCD type. HbSS (Hb 6-9 g/dL, 85-95% HbS), HbSC (Hb 10-12 g/dL, HbS + HbC), HbS-beta-thal (variable based on beta-zero vs beta-plus)</li>
                <li><strong>Parvovirus B19 PCR/IgM:</strong> If aplastic crisis suspected (Hgb drop, low/absent reticulocytes)</li>
                <li><strong>Transcranial Doppler (TCD) Ultrasound:</strong> Screen for stroke risk in children (velocities >200 cm/s = high risk). Not acute test</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management - Vaso-Occlusive Crisis:</strong></p>
            <ul>
                <li>IV access, continuous pulse oximetry, cardiac monitoring</li>
                <li><strong>AGGRESSIVE HYDRATION:</strong> NS or D5Â½NS at 1.5-2Ã— maintenance (150-200 mL/hr initially). Target urine output 1-2 mL/kg/hr. Avoid overhydration (can precipitate ACS)</li>
                <li><strong>OXYGEN THERAPY:</strong> Maintain O2 sat >95% (hypoxia worsens sickling). Supplemental O2 via nasal cannula or face mask as needed. Do NOT over-oxygenate (suppresses erythropoiesis)</li>
                <li><strong>PAIN CONTROL (PRIORITY):</strong> Treat pain aggressively and immediately (delays worsen crisis):
                    <ul>
                        <li>Morphine 0.1-0.15 mg/kg IV q2-4h (preferred) or hydromorphone 0.01-0.02 mg/kg IV q2-4h</li>
                        <li>PCA pump if available (better pain control, reduces ED visits)</li>
                        <li>Adjunct: Ketorolac 15-30 mg IV q6h (if normal renal function, limit 5 days)</li>
                        <li>AVOID MEPERIDINE (neurotoxic metabolite normeperidine causes seizures)</li>
                        <li>Reassess pain q1-2h, uptitrate opioids as needed</li>
                    </ul>
                </li>
                <li>Correct acidosis (worsens sickling): Treat underlying cause, consider NaHCO3 if pH <7.25</li>
                <li>Antibiotics if fever: Ceftriaxone 1-2 g IV q24h (covers encapsulated organisms)</li>
            </ul>
            
            <p><strong>Management - Acute Chest Syndrome (MEDICAL EMERGENCY):</strong></p>
            <ul>
                <li><strong>Supplemental Oxygen:</strong> Maintain O2 sat >95%. Escalate to high-flow nasal cannula, BiPAP, or mechanical ventilation as needed</li>
                <li><strong>BROAD-SPECTRUM ANTIBIOTICS (START IMMEDIATELY):</strong>
                    <ul>
                        <li>Ceftriaxone 1-2 g IV q24h PLUS Azithromycin 500 mg IV/PO daily (covers atypical pathogens: Mycoplasma, Chlamydia)</li>
                        <li>OR: Ceftriaxone + Levofloxacin 750 mg IV daily</li>
                    </ul>
                </li>
                <li><strong>AGGRESSIVE HYDRATION:</strong> But AVOID overhydration (worsens pulmonary edema)</li>
                <li><strong>INCENTIVE SPIROMETRY:</strong> 10 breaths q2h while awake (prevents atelectasis, reduces ACS risk in VOC patients)</li>
                <li><strong>SIMPLE TRANSFUSION (if Hgb <8 g/dL):</strong> 1-2 units PRBCs to increase O2 carrying capacity. Target Hgb 9-10 g/dL (DO NOT exceed Hgb 10 g/dL - increases viscosity, worsens vaso-occlusion)</li>
                <li><strong>EXCHANGE TRANSFUSION (if severe ACS):</strong> Indications: rapidly progressive infiltrates, O2 sat <90% despite O2, severe hypoxia/respiratory distress, neurologic symptoms, multiorgan involvement. Goal: reduce HbS% to <30%, increase HbA to >70%. Hematology consult STAT for exchange transfusion</li>
                <li>Bronchodilators: Albuterol/ipratropium nebulizers if bronchospasm</li>
                <li>Pain control: Continue opioids as in VOC</li>
            </ul>
            
            <p><strong>Transfusion Therapy:</strong></p>
            <ul>
                <li><strong>Simple Transfusion:</strong> For symptomatic anemia (Hgb <6 g/dL or drop of 2+ g/dL from baseline), acute chest syndrome with Hgb <8 g/dL, pre-operative preparation, stroke prevention. Transfuse 1-2 units PRBCs to target Hgb 9-10 g/dL (NEVER >10 g/dL)</li>
                <li><strong>Exchange Transfusion (Urgent Hematology Consult):</strong> Severe ACS, acute stroke, multiorgan failure syndrome, severe priapism (>4 hours). Can be manual (phlebotomy + transfusion) or automated (apheresis). Goal: HbS <30%</li>
                <li>Use EXTENDED PHENOTYPE-MATCHED blood (Rh, Kell, Duffy, Kidd) to reduce alloimmunization (30-50% of SCD patients develop antibodies)</li>
            </ul>
            
            <p><strong>Specific Crisis Management:</strong></p>
            <ul>
                <li><strong>Stroke:</strong> STAT MRI/MRA, neurology consult, exchange transfusion (reduce HbS <30%). Treat as acute ischemic stroke (consider tPA if no contraindication, discuss with hematology). Chronic transfusion therapy to prevent recurrence</li>
                <li><strong>Priapism:</strong> Hydration, opioid analgesia, ice packs. If >4 hours: urology consult for aspiration/irrigation. Exchange transfusion if refractory</li>
                <li><strong>Splenic Sequestration:</strong> Acute splenomegaly, Hgb drop >2 g/dL, hypovolemia. IV fluids, emergent simple transfusion (1-2 units), monitor closely (can autoresolve and cause hyperviscosity). Splenectomy for recurrent episodes</li>
                <li><strong>Aplastic Crisis:</strong> Parvovirus B19 infection. Hgb <5-6 g/dL, reticulocytopenia (<1%). Simple transfusion to target Hgb 7-8 g/dL. Self-limited (bone marrow recovery in 7-10 days)</li>
            </ul>
            
            <p><strong>Chronic Disease-Modifying Therapy (Long-term):</strong></p>
            <ul>
                <li><strong>Hydroxyurea:</strong> Increases HbF (fetal hemoglobin), reduces sickling frequency by 50%, reduces VOC, ACS, mortality. Dose 15-35 mg/kg/day PO. All patients with SCD should be on hydroxyurea unless contraindicated</li>
                <li><strong>L-Glutamine (Endari):</strong> Reduces oxidative stress. 5-15 g PO BID. Adjunct to hydroxyurea</li>
                <li><strong>Voxelotor (Oxbryta):</strong> Increases Hgb oxygen affinity, reduces hemolysis. 1500 mg PO daily</li>
                <li><strong>Crizanlizumab (Adakveo):</strong> P-selectin inhibitor, reduces VOC frequency. 5 mg/kg IV q4 weeks</li>
                <li>Chronic transfusion therapy: For recurrent stroke, recurrent ACS</li>
            </ul>
            
            <p><strong>Hematology Consultation:</strong></p>
            <ul>
                <li>MANDATORY for all ACS, stroke, severe VOC requiring exchange transfusion, multiorgan failure, first SCD crisis presentation</li>
                <li>Consider for refractory pain, transfusion needs, management optimization</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Acute chest syndrome, respiratory failure (O2 sat <90%, requiring >4L O2), severe hypoxia, stroke, multiorgan failure, exchange transfusion needed, hemodynamic instability</li>
                <li>Floor: VOC requiring IV opioids, mild ACS (stable O2 sat), fever/infection requiring IV antibiotics</li>
                <li>Discharge: Pain well-controlled on PO opioids, normal O2 sat, tolerating PO intake, reliable follow-up</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Acute Chest Syndrome is the Leading Cause of Death in SCD:</strong> ACS causes 25% of SCD deaths and develops in 50% of SCD patients during their lifetime. Often precipitated by VOC, post-operative state, or infection. Diagnosis: fever + chest pain + new infiltrate on CXR + hypoxia. KEY: Can present initially as simple VOC, then develop ACS 24-72 hours later. Early recognition and aggressive treatment (antibiotics, O2, transfusion/exchange) are critical. Fat embolism from bone marrow infarction during VOC is a major contributor.</li>
            <li><strong>Do NOT Transfuse to Hemoglobin >10 g/dL:</strong> Increasing Hgb above 10 g/dL increases blood viscosity and worsens vaso-occlusion (hyperviscosity syndrome). Target Hgb is 9-10 g/dL maximum with simple transfusion. This is counterintuitive but critical - more is NOT better in SCD. For severe complications requiring exchange transfusion, goal is to REPLACE HbS with HbA (reduce HbS% to <30%), not just increase total hemoglobin.</li>
            <li><strong>Pain Crisis Delays Worsen Outcomes:</strong> Delayed or inadequate pain control leads to prolonged hospital stays, increased complications, and higher readmission rates. VOC pain is SEVERE (8-10/10) and requires aggressive opioid therapy immediately. Use morphine or hydromorphone IV q2-4h or PCA pump. Do NOT use meperidine (Demerol) - the metabolite normeperidine accumulates and causes seizures, especially in SCD patients with renal dysfunction. Reassess pain frequently and uptitrate aggressively.</li>
            <li><strong>Incentive Spirometry Prevents ACS:</strong> Patients with VOC (especially chest/rib pain) have shallow breathing from pain, leading to atelectasis and hypoventilation. This hypoxia triggers more sickling and can precipitate ACS. Incentive spirometry 10 breaths q2h while awake has been shown to reduce ACS incidence by 50% in hospitalized VOC patients. It's simple, low-cost, and highly effective - make it a standing order.</li>
            <li><strong>Functional Asplenia Increases Infection Risk:</strong> By age 5, most SCD patients have autoinfarction of the spleen (repeated splenic infarcts lead to fibrosis). This creates functional asplenia, increasing risk of sepsis from encapsulated organisms: S. pneumoniae (most common), H. influenzae, Salmonella (especially osteomyelitis). Fever >38.5Â°C requires immediate blood cultures and empiric antibiotics (ceftriaxone). Patients should receive pneumococcal, H. influenzae, and meningococcal vaccines, plus penicillin VK prophylaxis (250 mg PO BID) lifelong.</li>
            <li><strong>Exchange Transfusion vs Simple Transfusion:</strong> Simple transfusion increases Hgb by adding RBCs (for symptomatic anemia, Hgb <6-8 g/dL). Exchange transfusion REPLACES patient's HbS-containing RBCs with donor HbA-containing RBCs (goal: HbS% <30%, HbA% >70%). Indications for exchange: severe ACS, acute stroke, multiorgan failure, severe priapism. Exchange is preferred over simple transfusion in emergencies because it improves oxygen delivery AND reduces sickling without increasing viscosity. Requires hematology consult for apheresis or manual exchange.</li>
            <li><strong>Hydroxyurea is Disease-Modifying:</strong> Hydroxyurea increases fetal hemoglobin (HbF) levels, which inhibits HbS polymerization. Clinical benefits: 50% reduction in VOC frequency, 50% reduction in ACS episodes, reduced mortality, reduced transfusion needs. ALL patients with SCD (including HbSC and HbS-beta-thal) should be offered hydroxyurea starting in infancy. Dose 15-35 mg/kg/day, titrated to maintain WBC 4000-8000/ÂµL and ANC >2000/ÂµL. Common misconception: hydroxyurea is NOT chemotherapy; it's a safe, well-tolerated, disease-modifying therapy.</li>
            <li><strong>Avoid Over-Hydration in ACS:</strong> While aggressive hydration is critical for VOC (1.5-2Ã— maintenance), in ACS be cautious about overhydration which can worsen pulmonary edema and respiratory status. In ACS, maintain euvolemia with careful fluid balance monitoring. If patient is developing ACS from VOC, reduce IV fluids to maintenance rate and focus on oxygen therapy, antibiotics, and transfusion. Monitor intake/output closely and daily weights.</li>
            <li><strong>Stroke Risk and Prevention:</strong> 10% of children with SCD have a stroke by age 20. Transcranial Doppler (TCD) ultrasound screens for stroke risk by measuring cerebral blood flow velocities. TCD >200 cm/s = high risk (10% annual stroke rate if untreated). Prevention: chronic transfusion therapy to maintain HbS <30% reduces stroke risk by 90%. Acute stroke treatment: exchange transfusion STAT to reduce HbS <30%, then chronic transfusion therapy or hematopoietic stem cell transplant (curative).</li>
            <li><strong>Salmonella Osteomyelitis is Classic in SCD:</strong> SCD patients have 100Ã— increased risk of Salmonella osteomyelitis (vs S. aureus in general population). Mechanism: gut translocation of Salmonella during sickling episodes affecting mesenteric vessels, then hematogenous spread to infarcted bone. Presentation: fever, localized bone pain, difficulty distinguishing from bone infarction (both cause pain, elevated WBC, elevated ESR). Diagnosis requires MRI with contrast (shows abscess, periosteal reaction) and bone biopsy/culture. Treatment: prolonged antibiotics (ceftriaxone or fluoroquinolone Ã— 4-6 weeks).</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Acute chest syndrome (fever, chest pain, new infiltrate, hypoxia)</li>
            <li>Hypoxia: O2 saturation <90% on room air or requiring >4L O2 via nasal cannula</li>
            <li>Acute stroke or altered mental status (focal neurologic deficits, confusion, decreased consciousness)</li>
            <li>Severe respiratory distress or impending respiratory failure</li>
            <li>Multiorgan failure (acute kidney injury with Cr >2Ã— baseline, liver failure with INR >2, encephalopathy)</li>
            <li>Exchange transfusion required (ACS, stroke, multiorgan failure)</li>
            <li>Hemodynamic instability (hypotension SBP <90, tachycardia HR >120 unresponsive to fluids)</li>
            <li>Rapidly progressive infiltrates on chest X-ray</li>
            <li>Splenic sequestration with hypovolemic shock</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Pain controlled on oral opioids (pain score â‰¤4/10)</li>
            <li>Oxygen saturation â‰¥95% on room air</li>
            <li>Afebrile for â‰¥24 hours (if ACS or infection)</li>
            <li>Tolerating oral intake and adequate hydration (drinking 2-3 L/day)</li>
            <li>Chest X-ray stable or improving (if ACS)</li>
            <li>No signs of ACS, stroke, or other complications</li>
            <li>Hemoglobin stable (no further drop from admission)</li>
            <li>Patient/family educated on hydration, pain management, when to return</li>
            <li>Hematology follow-up arranged within 1-2 weeks</li>
            <li>Home medications reconciled (hydroxyurea, folic acid, opioids as needed)</li>
            <li>Prescription for oral opioids (hydrocodone/oxycodone) with clear instructions and limits</li>
            <li>Incentive spirometry instructions if recent VOC/ACS</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="hemolytic-anemia">
    <div class="page-header">
        <h2>114. HEMOLYTIC ANEMIA</h2>
        <div class="subtitle">Elevated LDH â€¢ Low Haptoglobin â€¢ Reticulocytosis â€¢ Jaundice â€¢ Schistocytes</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Acute onset of jaundice, dark urine (hemoglobinuria), and anemia with laboratory evidence of hemolysis: elevated LDH (>400 U/L), elevated indirect bilirubin (>2 mg/dL), low/undetectable haptoglobin (<25 mg/dL), and reticulocytosis (>2-3%).</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Hemolysis is premature RBC destruction (normal RBC lifespan 120 days). Can be INTRAVASCULAR (RBCs destroyed within vessels: PNH, microangiopathic hemolytic anemia like TTP/HUS/DIC, cold agglutinin disease, transfusion reactions) or EXTRAVASCULAR (RBCs destroyed by macrophages in spleen/liver: warm autoimmune hemolytic anemia, hereditary spherocytosis, G6PD deficiency). Intravascular releases free hemoglobin into plasma (hemoglobinemia, hemoglobinuria, low haptoglobin). Extravascular produces indirect hyperbilirubinemia, jaundice, splenomegaly. Bone marrow compensates with increased RBC production (reticulocytosis) unless bone marrow failure coexists.</li>
                <li><strong>Risk Factors - Immune:</strong> Autoimmune diseases (SLE, rheumatoid arthritis), lymphoproliferative disorders (CLL, lymphoma), medications (penicillins, cephalosporins, sulfonamides, methyldopa, quinine), infections (Mycoplasma pneumoniae, EBV, HIV), malignancies, transfusion reactions (ABO incompatibility)</li>
                <li><strong>Risk Factors - Non-Immune:</strong> G6PD deficiency (triggered by infections, fava beans, sulfa drugs, antimalarials), hereditary spherocytosis, sickle cell disease, paroxysmal nocturnal hemoglobinuria (PNH), mechanical heart valves, thrombotic microangiopathies (TTP, HUS), DIC, HELLP syndrome (pregnancy), burns, snake venom</li>
                <li><strong>Symptoms:</strong> Fatigue, weakness, dyspnea on exertion (anemia). Jaundice (extravascular hemolysis). Dark urine, tea-colored or cola-colored (hemoglobinuria in intravascular hemolysis). Abdominal pain (splenic infarction, cholelithiasis). Back pain, chest pain (intravascular hemolysis). Fever (AIHA, TTP). Pallor. Symptoms of underlying disorder (thrombosis in PNH, neurologic symptoms in TTP)</li>
                <li><strong>Physical Exam:</strong> Jaundice (scleral icterus), pallor, tachycardia, flow murmur. Splenomegaly (extravascular hemolysis, especially AIHA, hereditary spherocytosis). Hepatomegaly (if severe hemolysis). Petechiae/purpura (if thrombocytopenia coexists as in TTP, DIC). Lymphadenopathy (lymphoma, CLL). Dark urine on inspection (hemoglobinuria). Signs of underlying disease (SLE rash, prosthetic valve click)</li>
                <li><strong>Variants/Subtypes:</strong> 
                    <ul>
                        <li><strong>Autoimmune Hemolytic Anemia (AIHA):</strong> Warm (IgG, treated with steroids) vs Cold (IgM, cold agglutinins, treat with rituximab, avoid cold). Coombs-positive</li>
                        <li><strong>Microangiopathic Hemolytic Anemia (MAHA):</strong> TTP (fever, neurologic symptoms, renal failure, thrombocytopenia, hemolysis), HUS (diarrhea, renal failure, thrombocytopenia, hemolysis), DIC, HELLP, malignant hypertension, prosthetic valve hemolysis. Schistocytes on smear</li>
                        <li><strong>G6PD Deficiency:</strong> X-linked, episodic hemolysis after oxidative stress. Bite cells, Heinz bodies on smear</li>
                        <li><strong>Hereditary Spherocytosis:</strong> Autosomal dominant, chronic hemolysis, splenomegaly, cholelithiasis. Spherocytes on smear, positive osmotic fragility test</li>
                        <li><strong>Paroxysmal Nocturnal Hemoglobinuria (PNH):</strong> Acquired stem cell disorder, intravascular hemolysis (worse at night/morning), thrombosis, pancytopenia. Flow cytometry shows CD55/CD59 deficiency</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Initial Laboratory Studies - Confirm Hemolysis:</strong></p>
            <ul>
                <li><strong>Complete Blood Count:</strong> Anemia (Hgb often <10 g/dL in acute hemolysis, can be <6-7 g/dL in severe cases). MCV may be elevated if reticulocytosis (reticulocytes are larger than mature RBCs). Thrombocytopenia (concerning for TTP, DIC, HELLP)</li>
                <li><strong>Reticulocyte Count:</strong> ELEVATED (>2-3%, absolute count >100,000/ÂµL) indicating bone marrow response. If LOW reticulocytes with hemolysis, think aplastic crisis (parvovirus B19), bone marrow infiltration, or nutritional deficiency</li>
                <li><strong>Lactate Dehydrogenase (LDH):</strong> MARKEDLY ELEVATED (often >400-1000 U/L, can be >1500 U/L). Released from lysed RBCs. Most sensitive marker of hemolysis</li>
                <li><strong>Haptoglobin:</strong> LOW or UNDETECTABLE (<25 mg/dL). Haptoglobin binds free hemoglobin; depleted in intravascular hemolysis. Can be falsely normal in inflammation (acute phase reactant). Absent in 1-2% of population (genetic ahaptoglobinemia)</li>
                <li><strong>Indirect (Unconjugated) Bilirubin:</strong> ELEVATED (>1.2 mg/dL, often 2-5 mg/dL) from heme breakdown. Predominantly indirect hyperbilirubinemia (direct <0.3 mg/dL)</li>
                <li><strong>Direct Antiglobulin Test (DAT, Coombs Test):</strong> POSITIVE in autoimmune hemolytic anemia (AIHA). Detects antibodies or complement on RBC surface. Warm AIHA: IgG positive. Cold agglutinin disease: C3d positive. Negative DAT rules out autoimmune cause</li>
            </ul>
            
            <p><strong>Peripheral Blood Smear (CRITICAL for Diagnosis):</strong></p>
            <ul>
                <li><strong>Schistocytes (Fragmented RBCs):</strong> Microangiopathic hemolytic anemia (TTP, HUS, DIC, HELLP, prosthetic valve). Helmet cells, triangular cells. If schistocytes present, URGENT evaluation for TTP</li>
                <li><strong>Spherocytes:</strong> Warm AIHA, hereditary spherocytosis. Small, round RBCs without central pallor</li>
                <li><strong>Bite Cells, Blister Cells, Heinz Bodies:</strong> G6PD deficiency (after oxidative stress). Heinz bodies require supravital stain (crystal violet)</li>
                <li><strong>Agglutination:</strong> Cold agglutinin disease (IgM antibodies cause RBC clumping at room temperature)</li>
                <li><strong>Sickle Cells:</strong> Sickle cell disease</li>
                <li><strong>Target Cells:</strong> Liver disease, thalassemia, hemoglobinopathies</li>
                <li><strong>Polychromasia:</strong> Reticulocytes (bluish-gray tinge on Wright-Giemsa stain)</li>
            </ul>
            
            <p><strong>Specialized Testing to Determine Etiology:</strong></p>
            <ul>
                <li><strong>Direct Antiglobulin Test (DAT/Coombs):</strong> Positive = immune-mediated (AIHA, drug-induced). IgG positive = warm AIHA. C3 positive = cold agglutinin disease</li>
                <li><strong>Cold Agglutinin Titer:</strong> If DAT positive for C3. Titer >1:64 diagnostic of cold agglutinin disease</li>
                <li><strong>G6PD Level:</strong> If bite cells/Heinz bodies or hemolysis after oxidative stress (infection, fava beans, medications). NOTE: may be falsely normal during acute hemolysis (reticulocytes have normal G6PD); recheck 3 months after acute episode</li>
                <li><strong>Osmotic Fragility Test:</strong> If spherocytes and family history. Positive in hereditary spherocytosis</li>
                <li><strong>Flow Cytometry for CD55/CD59:</strong> If intravascular hemolysis (hemoglobinuria) + thrombosis + cytopenias. Diagnostic for PNH</li>
                <li><strong>Hemoglobin Electrophoresis:</strong> If sickle cells or family history. Diagnose sickle cell disease, thalassemia</li>
                <li><strong>ADAMTS13 Activity:</strong> If schistocytes + thrombocytopenia + neurologic symptoms. <10% diagnostic of TTP. SEND BEFORE PLASMAPHERESIS</li>
                <li><strong>Coagulation Studies (PT, PTT, Fibrinogen, D-dimer):</strong> If schistocytes or concern for DIC. DIC: prolonged PT/PTT, low fibrinogen (<200 mg/dL), elevated D-dimer (>500 ng/mL)</li>
                <li><strong>Free Hemoglobin (Plasma):</strong> Elevated in intravascular hemolysis (>25 mg/dL). Plasma appears pink or red</li>
                <li><strong>Urinalysis:</strong> Hemoglobinuria (positive blood without RBCs on microscopy). Indicates intravascular hemolysis. Also check for hemosiderinuria (chronic intravascular hemolysis)</li>
            </ul>
            
            <p><strong>Additional Testing Based on Clinical Suspicion:</strong></p>
            <ul>
                <li>Mycoplasma IgM, EBV serologies, HIV test (infection-triggered AIHA)</li>
                <li>ANA, anti-dsDNA, complement levels (SLE-associated AIHA)</li>
                <li>Peripheral lymphocyte flow cytometry (CLL, lymphoma)</li>
                <li>Medication review (drug-induced hemolysis: penicillins, cephalosporins, methyldopa, quinine, sulfonamides)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management:</strong></p>
            <ul>
                <li>Assess hemodynamic stability: BP, HR, orthostatics, signs of shock</li>
                <li>Supplemental oxygen if symptomatic anemia or hypoxia</li>
                <li>Type and screen, crossmatch (extended phenotyping if warm AIHA or history of alloantibodies)</li>
                <li>IV access, continuous monitoring if severe anemia (Hgb <7 g/dL)</li>
                <li>Identify and treat underlying cause (stop offending medication, treat infection, manage TTP/DIC)</li>
                <li>Folic acid 1 mg PO daily (increased demand from RBC turnover)</li>
            </ul>
            
            <p><strong>Transfusion Therapy:</strong></p>
            <ul>
                <li><strong>Indications:</strong> Symptomatic anemia (dyspnea, chest pain, altered mental status, hemodynamic instability), Hgb <7 g/dL, or rapid Hgb drop</li>
                <li><strong>Challenges in AIHA:</strong> Crossmatching difficult due to antibodies. All units may be "incompatible" but can still transfuse least incompatible units if life-threatening</li>
                <li><strong>Transfuse PRBCs slowly:</strong> 1 unit over 2-4 hours with close monitoring. Risk of hemolysis of transfused cells, transfusion reactions</li>
                <li><strong>Goal:</strong> Hgb 7-8 g/dL (avoid overtransfusion which suppresses reticulocyte response)</li>
                <li><strong>Washed RBCs:</strong> Consider if recurrent severe transfusion reactions</li>
            </ul>
            
            <p><strong>Treatment - Warm Autoimmune Hemolytic Anemia (IgG, DAT positive):</strong></p>
            <ul>
                <li><strong>First Line - Corticosteroids:</strong> Prednisone 1 mg/kg PO daily (60-80 mg daily) or methylprednisolone 1 mg/kg IV daily. Response in 7-14 days (reticulocyte count drops, Hgb stabilizes/rises). Taper slowly over 3-6 months once Hgb >10 g/dL</li>
                <li><strong>Second Line (if refractory or relapsing):</strong> Rituximab 375 mg/mÂ² IV weekly Ã— 4 weeks (anti-CD20 antibody depletes B cells). Response rate 80-90%, slower onset (4-8 weeks)</li>
                <li><strong>Third Line:</strong> Splenectomy (removes site of RBC destruction), immunosuppressants (azathioprine 1-2 mg/kg/day, mycophenolate 1000 mg BID, cyclophosphamide)</li>
                <li><strong>Refractory Severe:</strong> IVIG 1 g/kg IV daily Ã— 2 days (temporary response, days to weeks), plasmapheresis (limited efficacy in warm AIHA)</li>
            </ul>
            
            <p><strong>Treatment - Cold Agglutinin Disease (IgM, C3 positive DAT):</strong></p>
            <ul>
                <li><strong>Avoid Cold Exposure:</strong> Keep patient warm (blankets, warm IV fluids, warm room). Cold triggers IgM binding and complement activation</li>
                <li><strong>Corticosteroids:</strong> Generally INEFFECTIVE (unlike warm AIHA)</li>
                <li><strong>First Line:</strong> Rituximab 375 mg/mÂ² IV weekly Ã— 4 weeks. Response rate 50-60%</li>
                <li><strong>Second Line:</strong> Rituximab + bendamustine or rituximab + fludarabine</li>
                <li><strong>Supportive:</strong> Transfuse through blood warmer if needed</li>
                <li>Treat underlying disorder: Mycoplasma pneumoniae (azithromycin), lymphoproliferative disease</li>
            </ul>
            
            <p><strong>Treatment - Microangiopathic Hemolytic Anemia (TTP/HUS/DIC):</strong></p>
            <ul>
                <li><strong>TTP (Thrombotic Thrombocytopenic Purpura):</strong> MEDICAL EMERGENCY. Plasmapheresis (plasma exchange) IMMEDIATELY, before confirmatory ADAMTS13 results. Delay increases mortality. Plasma exchange daily until platelets >150,000/ÂµL and LDH normalizing. Adjunct: rituximab, caplacizumab (anti-vWF antibody)</li>
                <li><strong>HUS (Hemolytic Uremic Syndrome):</strong> Supportive care (hydration, avoid antibiotics in Shiga toxin HUS), dialysis if needed. Eculizumab for atypical HUS (complement-mediated)</li>
                <li><strong>DIC:</strong> Treat underlying cause (sepsis, malignancy). Transfuse platelets if bleeding, FFP/cryoprecipitate if coagulopathy and bleeding</li>
                <li><strong>DO NOT TRANSFUSE PLATELETS in TTP</strong> (unless life-threatening bleeding) - may worsen thrombosis</li>
            </ul>
            
            <p><strong>Treatment - G6PD Deficiency:</strong></p>
            <ul>
                <li>STOP offending agent: sulfa drugs, antimalarials (primaquine, dapsone), fava beans, naphthalene (mothballs), rasburicase</li>
                <li>Supportive care: hydration, transfuse if severe anemia</li>
                <li>Self-limited: hemolysis resolves once oxidative stress removed</li>
                <li>Patient education: avoid triggers lifelong</li>
            </ul>
            
            <p><strong>Treatment - Paroxysmal Nocturnal Hemoglobinuria (PNH):</strong></p>
            <ul>
                <li><strong>Eculizumab (Soliris):</strong> Monoclonal antibody inhibiting complement C5. 600 mg IV weekly Ã— 4 weeks, then 900 mg q2 weeks. Reduces hemolysis, thrombosis risk. MUST vaccinate against N. meningitidis before starting</li>
                <li><strong>Alternative:</strong> Ravulizumab (longer-acting C5 inhibitor), pegcetacoplan (C3 inhibitor)</li>
                <li>Anticoagulation: For history of thrombosis (warfarin INR 2-3)</li>
                <li>Transfuse for symptomatic anemia, treat iron deficiency</li>
                <li>Allogeneic stem cell transplant: Curative for young patients with severe disease</li>
            </ul>
            
            <p><strong>Treatment - Drug-Induced Hemolytic Anemia:</strong></p>
            <ul>
                <li>STOP offending medication immediately</li>
                <li>Hemolysis typically resolves within days to weeks after drug discontinuation</li>
                <li>Supportive care, transfuse if severe</li>
                <li>Corticosteroids if severe (prednisone 1 mg/kg/day)</li>
            </ul>
            
            <p><strong>Hematology Consultation:</strong></p>
            <ul>
                <li>MANDATORY for all cases of hemolytic anemia</li>
                <li>URGENT consultation for TTP, severe AIHA, PNH, refractory hemolysis</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Severe anemia (Hgb <5-6 g/dL), hemodynamic instability, TTP requiring plasmapheresis, acute kidney injury, transfusion-dependent, rapid hemolysis</li>
                <li>Floor: Moderate anemia (Hgb 6-8 g/dL) requiring transfusion or IV steroids, new diagnosis requiring workup</li>
                <li>Discharge: Mild hemolysis (Hgb >8-9 g/dL), chronic compensated hemolysis, hemolysis controlled on oral medications, close hematology follow-up arranged</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Haptoglobin is the Most Specific Marker for Intravascular Hemolysis:</strong> Haptoglobin binds free hemoglobin released from lysed RBCs. Low/undetectable haptoglobin (<25 mg/dL) is highly specific for hemolysis, particularly intravascular hemolysis. However, haptoglobin is an acute phase reactant - can be falsely elevated (normal) in inflammatory states even with hemolysis. Also, 1-2% of the population has genetic ahaptoglobinemia (congenitally absent haptoglobin). In these cases, rely on other markers: elevated LDH, indirect bilirubin, hemoglobinemia/hemoglobinuria.</li>
            <li><strong>Peripheral Smear is the Key to Diagnosis:</strong> The smear reveals the MECHANISM of hemolysis. Schistocytes = microangiopathic (TTP, HUS, DIC, prosthetic valve) - think mechanical destruction. Spherocytes = AIHA or hereditary spherocytosis - think membrane loss. Bite cells/Heinz bodies = G6PD deficiency - think oxidative damage. Sickle cells = sickle cell disease. Agglutination at room temperature = cold agglutinin disease. Always review the smear yourself or request hematopathology review - it guides the entire workup and treatment.</li>
            <li><strong>TTP is a "Do Not Miss" Emergency Requiring Immediate Plasmapheresis:</strong> Classic pentad: thrombocytopenia, microangiopathic hemolytic anemia (schistocytes), neurologic changes, renal failure, fever - but only 40% have full pentad. If you see thrombocytopenia + schistocytes + any neurologic change (confusion, headache, focal deficit), treat as TTP immediately. Send ADAMTS13 level (<10% confirms TTP) but START PLASMAPHERESIS BEFORE results return. Mortality is 90% without treatment, 10-20% with treatment. Every hour of delay increases mortality.</li>
            <li><strong>Warm AIHA Responds to Steroids, Cold Agglutinin Disease Does NOT:</strong> Warm AIHA (IgG antibodies, DAT IgG-positive) responds well to corticosteroids (prednisone 1 mg/kg/day) with 70-85% response rate. Cold agglutinin disease (IgM antibodies, DAT C3-positive) does NOT respond to steroids. Instead, treat cold agglutinin disease with avoidance of cold, rituximab, and keeping the patient warm (heated blankets, warm IV fluids, warm room). Do NOT waste time with steroids in cold agglutinin disease.</li>
            <li><strong>G6PD Testing Can Be Falsely Normal During Acute Hemolysis:</strong> G6PD deficiency is X-linked; older RBCs have lower G6PD activity. During acute hemolytic crisis, the oldest (most deficient) cells are destroyed, and young reticulocytes (which have NORMAL G6PD levels) predominate. Testing during crisis may show falsely normal G6PD. If clinical suspicion is high (acute hemolysis after oxidative trigger in African or Mediterranean male), presume G6PD deficiency and recheck G6PD level 3 months after acute event when RBC population normalizes.</li>
            <li><strong>Don't Overtransfuse in Hemolytic Anemia:</strong> In hemolytic anemia, the bone marrow is actively producing RBCs (reticulocytosis). Overtransfusion (targeting Hgb >10 g/dL) suppresses erythropoietin and shuts down this compensatory response, making the patient transfusion-dependent. Additionally, in AIHA, transfused RBCs may also be destroyed by autoantibodies. Transfuse only for symptoms or critical anemia (Hgb <7 g/dL), target Hgb 7-8 g/dL, and allow the body's own reticulocyte response to recover the Hgb over time with definitive treatment.</li>
            <li><strong>PNH Triad: Hemolysis + Thrombosis + Cytopenias:</strong> Paroxysmal nocturnal hemoglobinuria is an acquired clonal stem cell disorder causing deficiency of GPI-anchored complement regulatory proteins (CD55, CD59). Clinical triad: (1) intravascular hemolysis (worst at night/morning from nocturnal acidosis activating complement), (2) thrombosis in unusual sites (hepatic vein = Budd-Chiari, portal vein, cerebral venous sinus), (3) pancytopenia. Diagnose with flow cytometry showing absent CD55/CD59. Treat with eculizumab (complement inhibitor), which dramatically reduces hemolysis and thrombosis risk.</li>
            <li><strong>Crossmatching Blood is Difficult in AIHA:</strong> In warm AIHA, autoantibodies react with ALL donor RBCs, making crossmatch appear incompatible for every unit. Blood bank will provide "least incompatible" units. Transfuse these units if patient is symptomatic or critically anemic - they will be hemolyzed by autoantibodies but provide temporary oxygen-carrying capacity until definitive treatment (steroids, rituximab) takes effect. Communicate clearly with blood bank about diagnosis. Consider extended phenotype matching to avoid alloimmunization.</li>
            <li><strong>Drug-Induced Hemolytic Anemia Mechanisms Vary:</strong> Drugs cause hemolysis via three mechanisms: (1) Hapten mechanism - drug binds RBC, antibody forms against drug-RBC complex (penicillins, cephalosporins), (2) Immune complex mechanism - drug-antibody complexes activate complement (quinine, rifampin), (3) Autoantibody induction - drug induces true autoantibody formation (methyldopa, levodopa, fludarabine). All require DAT (Coombs) positive. Treatment: STOP THE DRUG. Hemolysis resolves in days to weeks. Corticosteroids may help if severe.</li>
            <li><strong>Splenectomy is Effective in Refractory Warm AIHA and Hereditary Spherocytosis:</strong> The spleen is the primary site of RBC destruction in warm AIHA and hereditary spherocytosis (extravascular hemolysis). Splenectomy has a 70-80% response rate in refractory warm AIHA (after failing steroids and rituximab) and is curative in hereditary spherocytosis. However, splenectomy increases lifelong risk of infection from encapsulated organisms (S. pneumoniae, H. influenzae, N. meningitidis) and venous thromboembolism. Vaccinate 2 weeks before splenectomy (pneumococcal, H. influenzae, meningococcal) and give lifelong penicillin VK prophylaxis (250-500 mg PO BID).</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Severe anemia with hemoglobin <5-6 g/dL</li>
            <li>Hemodynamic instability (hypotension SBP <90, tachycardia HR >120, shock)</li>
            <li>Symptomatic anemia with chest pain, dyspnea, altered mental status, syncope</li>
            <li>Suspected TTP (schistocytes + thrombocytopenia + neurologic changes) - requires urgent plasmapheresis</li>
            <li>Acute kidney injury with oliguria or rising creatinine (>2 mg/dL or 2Ã— baseline)</li>
            <li>Rapid hemolysis with Hgb dropping >2 g/dL per day despite treatment</li>
            <li>Transfusion-dependent hemolysis requiring multiple units PRBCs</li>
            <li>Severe hemoglobinuria with acute kidney injury (intravascular hemolysis)</li>
            <li>DIC with active bleeding and coagulopathy</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Hemoglobin stable and >8-9 g/dL (or stable at patient's baseline for chronic hemolysis)</li>
            <li>No symptoms of anemia (no dyspnea, chest pain, or significant fatigue at rest)</li>
            <li>Hemodynamically stable (normal BP, HR <100, no orthostatic hypotension)</li>
            <li>Hemolysis controlled or improving (LDH trending down, haptoglobin stabilizing)</li>
            <li>Underlying cause identified or under investigation with outpatient plan</li>
            <li>Appropriate therapy initiated (steroids for AIHA, eculizumab for PNH, offending drug stopped)</li>
            <li>No evidence of TTP, DIC, or other life-threatening complications</li>
            <li>Patient educated on medication compliance (steroids, immunosuppressants), avoidance of triggers (cold exposure, specific drugs)</li>
            <li>Hematology follow-up arranged within 1-2 weeks</li>
            <li>Folic acid 1 mg daily prescribed</li>
            <li>Clear instructions on when to return: worsening fatigue, dyspnea, chest pain, jaundice, dark urine, bleeding</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="onc-emergencies">
    <div class="page-header">
        <h2>115. ONCOLOGIC EMERGENCIES</h2>
        <div class="subtitle">SVC Syndrome â€¢ Spinal Cord Compression â€¢ Hypercalcemia of Malignancy â€¢ Tumor Lysis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Cancer patient presenting with life-threatening complication requiring urgent intervention: superior vena cava syndrome (facial edema, dilated chest veins), malignant spinal cord compression (back pain, weakness, bowel/bladder dysfunction), hypercalcemia of malignancy (confusion, polyuria), or tumor lysis syndrome (hyperkalemia, acute kidney injury).</p>
            <ul>
                <li><strong>Pathophysiology:</strong>
                    <ul>
                        <li><strong>Superior Vena Cava (SVC) Syndrome:</strong> Obstruction of SVC by external compression (lung cancer, lymphoma, mediastinal mass, thrombus). Impaired venous drainage from head, neck, upper extremities causes facial/upper body edema, venous distension. Can progress to cerebral edema, respiratory compromise, death if untreated</li>
                        <li><strong>Malignant Spinal Cord Compression (MSCC):</strong> Tumor invasion into epidural space (vertebral body metastases collapse onto cord, or direct invasion through intervertebral foramina). Compresses spinal cord causing ischemia and permanent neurologic damage. Irreversible paraplegia if not treated within 24-48 hours. Most common: thoracic spine (70%), then lumbar (20%), cervical (10%)</li>
                        <li><strong>Hypercalcemia of Malignancy:</strong> (1) PTHrP-mediated (squamous cell lung cancer, RCC, breast, bladder - 80% of cases) - tumor secretes PTHrP mimicking PTH, increasing bone resorption and renal calcium reabsorption, OR (2) Osteolytic bone metastases (breast, multiple myeloma, lymphoma - 20% of cases) - direct bone destruction releases calcium. Causes polyuria, dehydration, worsening hypercalcemia (vicious cycle), confusion, coma</li>
                        <li><strong>Tumor Lysis Syndrome (TLS):</strong> Massive tumor cell death (spontaneous or treatment-induced chemo/radiation) releases intracellular contents: potassium, phosphate, uric acid, nucleic acids. Causes hyperkalemia (cardiac arrhythmias), hyperphosphatemia â†’ hypocalcemia (tetany, seizures), hyperuricemia â†’ uric acid nephropathy (AKI), acute kidney injury from crystal deposition</li>
                    </ul>
                </li>
                <li><strong>Risk Factors:</strong> Lung cancer (SVC syndrome, MSCC, hypercalcemia), breast cancer (bone mets, MSCC, hypercalcemia), prostate cancer (bone mets, MSCC), multiple myeloma (hypercalcemia, MSCC), renal cell carcinoma (hypercalcemia), lymphoma (SVC syndrome, TLS), leukemia (TLS), cancers with high proliferation rates (Burkitt lymphoma, acute leukemias - highest TLS risk)</li>
                <li><strong>Symptoms by Emergency Type:</strong>
                    <ul>
                        <li><strong>SVC Syndrome:</strong> Facial swelling (worse in morning, improves when upright), neck swelling, upper extremity edema, dyspnea, cough, dysphagia, hoarseness, headache (worse when bending forward/lying down), visual changes, chest pain</li>
                        <li><strong>MSCC:</strong> Back pain (90% - progressive, severe, localized, worse at night or with Valsalva), lower extremity weakness (85%), sensory changes (paresthesias, numbness), bowel/bladder dysfunction (urinary retention, incontinence, constipation), gait difficulty</li>
                        <li><strong>Hypercalcemia:</strong> "Stones, bones, groans, psychiatric overtones" - polyuria, polydipsia, nausea, vomiting, constipation, abdominal pain, confusion, lethargy, weakness, bone pain</li>
                        <li><strong>TLS:</strong> Often asymptomatic initially, then nausea, vomiting, diarrhea, lethargy, muscle cramps/tetany (hypocalcemia), cardiac arrhythmias (hyperkalemia), decreased urine output, seizures</li>
                    </ul>
                </li>
                <li><strong>Physical Exam:</strong>
                    <ul>
                        <li><strong>SVC Syndrome:</strong> Facial edema (especially periorbital), plethora, cyanosis, distended neck veins, dilated chest wall veins (collaterals), upper extremity edema (non-pitting), Pemberton sign (raising arms above head causes facial plethora/cyanosis), stridor if severe tracheal compression</li>
                        <li><strong>MSCC:</strong> Focal tenderness to percussion over spinous processes, decreased strength (upper motor neuron pattern: spasticity, hyperreflexia, upgoing Babinski), sensory level, decreased rectal tone, saddle anesthesia</li>
                        <li><strong>Hypercalcemia:</strong> Altered mental status, dry mucous membranes (dehydration), decreased skin turgor, bradycardia, shortened QT interval on ECG</li>
                        <li><strong>TLS:</strong> Usually normal exam early, then lethargy, decreased urine output, muscle twitching/tetany (hypocalcemia), cardiac arrhythmias</li>
                    </ul>
                </li>
                <li><strong>Variants/Subtypes:</strong> Acute vs subacute presentation (SVC syndrome can present over days to weeks; MSCC can be acute/subacute). Complete vs incomplete cord compression. Symptomatic vs asymptomatic hypercalcemia (treatment based on symptoms AND calcium level). Laboratory TLS (abnormal labs only) vs Clinical TLS (labs + organ dysfunction)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Basic Metabolic Panel:</strong> Hypercalcemia (>11 mg/dL moderate, >14 mg/dL severe), hyperkalemia (K >5.5 mEq/L in TLS), elevated Cr (AKI from hypercalcemia or TLS), hyperphosphatemia (PO4 >4.5 mg/dL in TLS)</li>
                <li><strong>Ionized Calcium:</strong> More accurate than total calcium. Ionized Ca >1.35 mmol/L (5.4 mg/dL) diagnostic of hypercalcemia. Correct total calcium for albumin: Corrected Ca = measured Ca + 0.8 Ã— (4.0 - albumin)</li>
                <li><strong>Complete Blood Count:</strong> Anemia, leukocytosis or leukopenia (underlying malignancy), thrombocytopenia</li>
                <li><strong>PTH Level:</strong> Suppressed (<20 pg/mL) in hypercalcemia of malignancy (negative feedback from high calcium). Normal/elevated PTH suggests primary hyperparathyroidism</li>
                <li><strong>PTHrP Level:</strong> Elevated in PTHrP-mediated hypercalcemia (squamous cell cancers, RCC). Helps differentiate mechanism</li>
                <li><strong>Uric Acid:</strong> Elevated (>8 mg/dL) in TLS from purine metabolism of lysed tumor cells</li>
                <li><strong>LDH:</strong> Markedly elevated in TLS (tumor lysis releases LDH). Also elevated in lymphoma/leukemia at baseline</li>
                <li><strong>Phosphate:</strong> Elevated in TLS (>4.5 mg/dL, can be >10 mg/dL). Low in hypercalcemia (PTHrP increases renal phosphate wasting)</li>
                <li><strong>ECG:</strong> Shortened QT interval (hypercalcemia), peaked T waves/widened QRS (hyperkalemia in TLS), prolonged QT (hypocalcemia in TLS)</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>SVC Syndrome:</strong>
                    <ul>
                        <li><strong>CT Chest with IV Contrast (URGENT):</strong> Visualize SVC obstruction, identify cause (mass vs thrombus), assess collateral circulation, evaluate tracheal compression. Preferred initial test</li>
                        <li><strong>Chest X-ray:</strong> May show widened mediastinum, right hilar mass, pleural effusion. Less sensitive than CT but can be done immediately</li>
                        <li><strong>Venography or Doppler Ultrasound:</strong> If concern for SVC thrombus (for intervention planning)</li>
                    </ul>
                </li>
                <li><strong>Malignant Spinal Cord Compression:</strong>
                    <ul>
                        <li><strong>MRI Spine with Gadolinium (STAT WITHIN 1 HOUR):</strong> Gold standard. Visualize entire spine (tumor can be at multiple levels). Shows epidural mass, cord compression, vertebral body involvement. If MRI unavailable or contraindicated, CT myelography is alternative</li>
                        <li><strong>Plain X-rays Spine:</strong> Show vertebral body destruction (lytic or blastic lesions), compression fracture. Do NOT rule out cord compression - 10% of MSCC have normal X-rays. Cannot delay definitive imaging</li>
                    </ul>
                </li>
                <li><strong>Hypercalcemia/TLS:</strong>
                    <ul>
                        <li><strong>Renal Ultrasound:</strong> Assess for hydronephrosis (can worsen kidney function), nephrocalcinosis</li>
                        <li><strong>Skeletal Survey or PET-CT:</strong> Identify bone metastases (for hypercalcemia from osteolytic lesions)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>SUPERIOR VENA CAVA SYNDROME:</strong></p>
            <ul>
                <li><strong>Immediate Stabilization:</strong>
                    <ul>
                        <li>Elevate head of bed 30-45 degrees (improve venous drainage)</li>
                        <li>Supplemental oxygen as needed</li>
                        <li>AVOID IV access in upper extremities (impaired venous drainage). Use lower extremity or central line if needed</li>
                        <li>Diuretics: Furosemide 20-40 mg IV (reduce edema, but use cautiously to avoid dehydration)</li>
                    </ul>
                </li>
                <li><strong>Corticosteroids (if lymphoma or chemosensitive tumor):</strong> Dexamethasone 10 mg IV, then 4 mg IV q6h. Rapidly reduces tumor burden and edema. Do NOT give if diagnosis uncertain (obscures histology)</li>
                <li><strong>Radiation Therapy (Definitive Treatment for Most Cases):</strong> Consult radiation oncology URGENTLY. Fractionated radiation (2-4 Gy per day Ã— 10-20 fractions) to mediastinal mass. Improvement in 70-90% of patients within 3-7 days. Preferred for non-small cell lung cancer, small cell lung cancer</li>
                <li><strong>Chemotherapy:</strong> For chemosensitive tumors (lymphoma, small cell lung cancer, germ cell tumors). Consult oncology. Can result in rapid tumor shrinkage</li>
                <li><strong>Endovascular Stenting:</strong> For severe symptoms or lack of response to radiation/chemo. Interventional radiology places expandable metallic stent in SVC. Immediate symptom relief in 90% of cases. Consider if: severe symptoms (stridor, respiratory distress, cerebral edema), previously radiated mediastinum, SVC thrombus</li>
                <li><strong>Anticoagulation:</strong> If SVC thrombus identified. Heparin or LMWH. Thrombolysis for acute severe thrombosis</li>
            </ul>
            
            <p><strong>MALIGNANT SPINAL CORD COMPRESSION (TRUE EMERGENCY - HOURS MATTER):</strong></p>
            <ul>
                <li><strong>High-Dose Corticosteroids (START IMMEDIATELY, do not wait for MRI):</strong>
                    <ul>
                        <li><strong>Dexamethasone 10 mg IV STAT</strong>, then 4-6 mg IV q6h. Reduces vasogenic edema, stabilizes/improves neurologic function in 75% if given early. Continue until definitive treatment</li>
                        <li>PPI prophylaxis (pantoprazole 40 mg IV daily) for GI protection with high-dose steroids</li>
                    </ul>
                </li>
                <li><strong>URGENT Radiation Oncology Consult (within 2 hours):</strong> Emergent radiation therapy (EBRT) is the definitive treatment for most patients. 30 Gy in 10 fractions over 2 weeks typical. Start within 24 hours of diagnosis. Effective in 70-80% for pain relief and neurologic stabilization</li>
                <li><strong>URGENT Neurosurgery Consult (within 2 hours):</strong> Surgical decompression (laminectomy) indications: (1) Neurologic deterioration despite radiation, (2) Spinal instability or pathologic fracture, (3) Unknown primary cancer (need tissue diagnosis), (4) Previously radiated area (cannot re-radiate), (5) Radioresistant tumor (RCC, melanoma, sarcoma). Surgery followed by radiation improves outcomes vs radiation alone in selected patients</li>
                <li><strong>Medical Oncology Consult:</strong> For concurrent chemotherapy if chemosensitive tumor (lymphoma, myeloma, prostate cancer)</li>
                <li><strong>Bowel/Bladder Management:</strong> Foley catheter if urinary retention. Bowel regimen to prevent constipation. Physical therapy/rehab consultation</li>
            </ul>
            
            <p><strong>HYPERCALCEMIA OF MALIGNANCY:</strong></p>
            <ul>
                <li><strong>AGGRESSIVE IV HYDRATION (First-Line):</strong>
                    <ul>
                        <li>Normal saline 200-300 mL/hr initially (goal 3-4 L over first 24 hours). Enhances renal calcium excretion</li>
                        <li>Monitor for volume overload (especially in elderly, heart failure patients). Titrate based on urine output, clinical exam</li>
                        <li>Replace electrolytes: Hypomagnesemia (Mg <1.5 mg/dL) and hypokalemia common with saline diuresis</li>
                        <li>Goal urine output 100-150 mL/hr. This ALONE lowers calcium by 1-3 mg/dL over 24-48 hours</li>
                    </ul>
                </li>
                <li><strong>Bisphosphonates (Definitive Treatment):</strong>
                    <ul>
                        <li><strong>Zoledronic Acid (Zometa) 4 mg IV over 15-30 minutes:</strong> Preferred. Inhibits osteoclast-mediated bone resorption. Calcium normalizes in 4-7 days, effect lasts 2-4 weeks. Dose-adjust for renal impairment (use 3.5 mg if CrCl 50-60, 3.3 mg if CrCl 40-49, 3 mg if CrCl 30-39, avoid if CrCl <30)</li>
                        <li><strong>Pamidronate (Aredia) 60-90 mg IV over 2-4 hours:</strong> Alternative if zoledronic acid unavailable. Less potent. Normalizes calcium in 7-10 days</li>
                        <li><strong>Precautions:</strong> Can cause acute kidney injury (ensure adequate hydration first). Risk of osteonecrosis of jaw (rare, with prolonged use). Hold if CrCl <30 mL/min</li>
                    </ul>
                </li>
                <li><strong>Calcitonin (Rapid Onset but Short Duration):</strong>
                    <ul>
                        <li>Calcitonin 4 units/kg SC or IM q12h. Lowers calcium within 4-6 hours (vs 4-7 days for bisphosphonates). Effect modest (decrease calcium 1-2 mg/dL) and short-lived (tachyphylaxis after 48 hours)</li>
                        <li>Use as BRIDGE therapy while waiting for bisphosphonates to work, especially if severe symptomatic hypercalcemia (Ca >14 mg/dL with altered mental status)</li>
                    </ul>
                </li>
                <li><strong>Denosumab (if refractory to bisphosphonates):</strong> Denosumab 120 mg SC weekly Ã— 4 weeks, then monthly. Fully humanized monoclonal antibody against RANKL (inhibits osteoclast activation). More potent than bisphosphonates. Use if CrCl <30 or bisphosphonate failure</li>
                <li><strong>Loop Diuretics (Controversial, USE CAUTIOUSLY):</strong> Furosemide 20-40 mg IV q6-12h ONLY AFTER adequate hydration (euvolemic/hypervolemic). Increases renal calcium excretion. AVOID if hypovolemic (worsens dehydration and hypercalcemia). Modern guidelines de-emphasize routine use</li>
                <li><strong>Hemodialysis (Severe Refractory Hypercalcemia):</strong> If Ca >18 mg/dL with severe symptoms, AKI, or heart failure precluding aggressive hydration. Rapidly lowers calcium. Calcium-free dialysate</li>
                <li><strong>Treat Underlying Malignancy:</strong> Oncology consult for chemotherapy/targeted therapy (definitive long-term treatment)</li>
            </ul>
            
            <p><strong>TUMOR LYSIS SYNDROME:</strong></p>
            <ul>
                <li><strong>Prevention (High-Risk Patients Before Chemo):</strong>
                    <ul>
                        <li>Aggressive IV hydration: NS or D5Â½NS at 2-3 L/mÂ²/day (goal urine output >100 mL/mÂ²/hr or 2-3 mL/kg/hr)</li>
                        <li><strong>Allopurinol 300-600 mg PO daily (or 200-400 mg/mÂ² IV if unable to take PO):</strong> Xanthine oxidase inhibitor, prevents uric acid formation from purine breakdown. Start 24-48 hours before chemotherapy</li>
                        <li><strong>Rasburicase (Elitek) 0.2 mg/kg IV daily Ã— 1-7 days (HIGH RISK ONLY):</strong> Recombinant urate oxidase, converts uric acid to allantoin (10Ã— more soluble, easily excreted). Rapidly lowers uric acid within 4 hours. Indications: baseline uric acid >8 mg/dL, high tumor burden (Burkitt lymphoma, acute leukemias), baseline CrCl <60. Contraindications: G6PD deficiency (causes severe hemolysis), pregnancy</li>
                        <li>Avoid nephrotoxins (NSAIDs, contrast, aminoglycosides)</li>
                        <li>Monitor labs q6-8h during first 24-72 hours of chemotherapy: BMP, phosphate, uric acid, calcium, LDH</li>
                    </ul>
                </li>
                <li><strong>Treatment of Established TLS:</strong>
                    <ul>
                        <li><strong>Aggressive IV Hydration:</strong> NS at 200-300 mL/hr (3-4 L/day). Goal urine output >100 mL/hr. Promotes excretion of uric acid, phosphate, potassium</li>
                        <li><strong>Rasburicase (if not already given):</strong> 0.2 mg/kg IV Ã— 1 dose. Rapidly corrects hyperuricemia</li>
                        <li><strong>Allopurinol:</strong> 300-600 mg PO daily. Prevents NEW uric acid formation (does not lower existing levels - that's rasburicase)</li>
                        <li><strong>Manage Hyperkalemia:</strong> K >6.0 mEq/L or ECG changes:
                            <ul>
                                <li>Calcium gluconate 1-2 g (10-20 mL of 10% solution) IV over 2-3 min (cardiac membrane stabilization)</li>
                                <li>Insulin 10 units IV + Dextrose 50% 25 g (1 amp D50) IV (shifts K intracellularly)</li>
                                <li>Albuterol 10-20 mg nebulized (shifts K intracellularly)</li>
                                <li>Sodium polystyrene sulfonate (Kayexalate) 30 g PO or 50 g PR (GI K excretion, slow onset)</li>
                                <li>Hemodialysis if refractory or K >7.0 mEq/L</li>
                            </ul>
                        </li>
                        <li><strong>Manage Hyperphosphatemia:</strong> Phosphate binders: Sevelamer 800-1600 mg PO TID with meals, or calcium acetate 667 mg (169 mg elemental Ca) 2-3 tabs PO TID with meals. AVOID aluminum-based binders (neurotoxicity)</li>
                        <li><strong>Manage Hypocalcemia:</strong> Usually asymptomatic (from calcium-phosphate binding). Treat only if symptomatic (tetany, seizures, QTc >500 ms): Calcium gluconate 1-2 g IV over 10 min, then infusion. Avoid aggressive calcium repletion if phosphate >5 mg/dL (risk of metastatic calcification)</li>
                        <li><strong>Hemodialysis (if refractory):</strong> Indications: K >7 mEq/L despite treatment, severe AKI (Cr >5 mg/dL or oliguria), fluid overload, symptomatic hypocalcemia with high phosphate. Removes potassium, phosphate, uric acid rapidly</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Oncology Consultation:</strong></p>
            <ul>
                <li>MANDATORY for all oncologic emergencies</li>
                <li>URGENT consultation for SVC syndrome, MSCC, severe hypercalcemia, TLS</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: MSCC, severe SVC syndrome (respiratory distress, stridor, altered mental status), severe hypercalcemia (Ca >15 mg/dL or altered mental status), clinical TLS with AKI/hyperkalemia, need for emergent intervention (surgery, stenting, dialysis)</li>
                <li>Floor: SVC syndrome (mild-moderate symptoms), hypercalcemia (Ca 12-14 mg/dL without severe symptoms), laboratory TLS without organ dysfunction</li>
                <li>Discharge: Hypercalcemia resolved/controlled, close oncology follow-up for definitive treatment of underlying cancer</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Malignant Spinal Cord Compression is a "Hours Not Days" Emergency:</strong> Neurologic function at presentation predicts outcome. If patient is ambulatory at diagnosis, 80-90% remain ambulatory after treatment. If already paraplegic, only 10% regain ambulation. EVERY HOUR COUNTS. Give dexamethasone 10 mg IV IMMEDIATELY (even before MRI), get MRI within 1 hour, consult radiation oncology and neurosurgery within 2 hours. Do NOT delay for "routine" MRI scheduling - this is a STAT test. Back pain + new weakness = MSCC until proven otherwise.</li>
            <li><strong>SVC Syndrome is NOT Always an Emergency Requiring Immediate Biopsy:</strong> Classic teaching says "never biopsy before diagnosis" is WRONG. Most SVC syndrome cases develop gradually over days to weeks and are NOT immediately life-threatening. The vast majority of patients can safely undergo tissue diagnosis (biopsy, bronchoscopy) before definitive treatment. Tissue diagnosis is CRITICAL because treatment differs: lymphoma gets chemotherapy, NSCLC gets radiation, SCLC gets chemo+radiation. Only give empiric steroids/radiation for TRUE emergencies: stridor, respiratory failure, severe cerebral edema. Otherwise, GET TISSUE FIRST.</li>
            <li><strong>Hypercalcemia of Malignancy Has TWO Distinct Mechanisms Requiring Different Long-term Management:</strong> (1) PTHrP-mediated (80%): squamous cell lung, RCC, breast - tumor secretes PTHrP which is NOT detected on standard PTH assay (need specific PTHrP test). Treat with bisphosphonates + treat tumor. (2) Osteolytic metastases (20%): breast, myeloma - direct bone destruction. PTH suppressed in BOTH. Distinguish by PTHrP level, bone scan, or clinical context. Long-term: monthly bisphosphonates (zoledronic acid 4 mg IV) or denosumab 120 mg SC prevent recurrent hypercalcemia and reduce skeletal-related events.</li>
            <li><strong>Calcitonin Works Fast but Doesn't Last - Use as Bridge Therapy Only:</strong> Calcitonin lowers calcium within 4-6 hours (fastest acting agent) but effect is modest (1-2 mg/dL decrease) and short-lived (tachyphylaxis after 48 hours). Bisphosphonates take 4-7 days to work but last weeks. Strategy: Use calcitonin for severe symptomatic hypercalcemia (Ca >14 mg/dL with confusion) as a bridge while waiting for bisphosphonates to kick in. Give BOTH together initially. After 48-72 hours, calcitonin becomes ineffective so discontinue.</li>
            <li><strong>Tumor Lysis Syndrome Prevention is Better Than Treatment:</strong> High-risk patients (high tumor burden Burkitt lymphoma, acute leukemias with WBC >50,000/ÂµL, bulky lymphoma) should receive TLS prophylaxis BEFORE starting chemotherapy: aggressive hydration (3-4 L/day), allopurinol 300-600 mg daily, rasburicase for highest risk. Monitor labs q6-8h during first 48-72 hours after starting chemo. Once TLS develops with AKI, treatment is difficult and requires hemodialysis. Prevention saves kidneys.</li>
            <li><strong>Rasburicase is Contraindicated in G6PD Deficiency (Causes Severe Hemolysis):</strong> Rasburicase converts uric acid to hydrogen peroxide, which causes oxidative stress. In G6PD-deficient patients, this triggers massive hemolysis, methemoglobinemia, and can be fatal. ALWAYS check G6PD level before giving rasburicase. If G6PD deficient, use allopurinol + aggressive hydration only. African Americans, Mediterranean descent, Asians have higher G6PD deficiency prevalence.</li>
            <li><strong>Do NOT Aggressively Treat Hypocalcemia in Tumor Lysis Syndrome if Phosphate is Elevated:</strong> In TLS, calcium is LOW because it binds to phosphate (calcium-phosphate product). If you give IV calcium when phosphate is >5 mg/dL, you create metastatic calcification (calcium-phosphate crystals deposit in kidneys, heart, lungs, soft tissues), worsening organ damage. Only treat hypocalcemia if SYMPTOMATIC (tetany, seizures, QTc >500 ms) AND cautiously (small doses calcium gluconate 1 g IV slowly). Focus on lowering phosphate with binders and dialysis.</li>
            <li><strong>Loop Diuretics for Hypercalcemia Have Fallen Out of Favor:</strong> Old teaching: give aggressive saline PLUS furosemide to enhance calciuresis. Modern evidence shows loop diuretics provide minimal additional calcium lowering, increase risk of dehydration (which worsens hypercalcemia), cause electrolyte abnormalities, and may impair renal function. Current approach: aggressive saline hydration FIRST, then bisphosphonates. Only use furosemide if patient develops volume overload from aggressive fluids (CHF, renal failure). Do NOT use furosemide routinely.</li>
            <li><strong>Radiation Therapy is the Primary Treatment for MOST Malignant Spinal Cord Compression:</strong> Surgery is beneficial in SELECT patients: unknown primary (need tissue), spinal instability/fracture, radioresistant tumor (RCC, melanoma, sarcoma), previously irradiated spine, rapid neurologic decline despite radiation. For the majority of patients with known cancer and intact spine, EMERGENT radiation therapy (within 24 hours) is the standard. Exception: the landmark Patchell study showed surgical decompression FOLLOWED by radiation was superior to radiation alone in patients who were ambulatory, had good performance status, and had single-level compression from solid tumor metastases. Discuss with neurosurgery AND radiation oncology.</li>
            <li><strong>Denosumab is More Potent Than Bisphosphonates but Has Unique Toxicities:</strong> Denosumab (monoclonal antibody against RANKL) is superior to zoledronic acid for preventing skeletal-related events and treating hypercalcemia of malignancy. Advantages: can use in renal failure (unlike bisphosphonates), no renal toxicity, more potent. Disadvantages: (1) Rebound hypercalcemia when stopped (must transition to bisphosphonates if stopping), (2) Severe hypocalcemia if baseline low calcium or vitamin D deficiency (give calcium/vitamin D supplementation), (3) Increased osteonecrosis of jaw risk with long-term use. Dose: 120 mg SC weekly Ã— 4 weeks, then monthly.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Malignant spinal cord compression (ANY degree of weakness or bowel/bladder dysfunction) - neurosurgical emergency</li>
            <li>Severe SVC syndrome with respiratory distress, stridor, or altered mental status</li>
            <li>Severe hypercalcemia (ionized Ca >1.75 mmol/L or total Ca >15 mg/dL) with altered mental status</li>
            <li>Clinical tumor lysis syndrome with acute kidney injury (Cr >2 mg/dL or oliguria)</li>
            <li>Hyperkalemia >7.0 mEq/L or ECG changes (peaked T waves, widened QRS)</li>
            <li>Need for emergent hemodialysis (refractory hyperkalemia, severe AKI, fluid overload)</li>
            <li>Hemodynamic instability (hypotension, tachycardia)</li>
            <li>Respiratory failure requiring intubation</li>
            <li>Seizures (from hypercalcemia, hypocalcemia, or CNS involvement)</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>No acute life-threatening emergency (no MSCC, severe SVC syndrome, severe hypercalcemia/TLS)</li>
            <li>Hypercalcemia corrected or controlled (calcium <11.5 mg/dL, asymptomatic)</li>
            <li>Tumor lysis syndrome resolved (electrolytes normalized, renal function stable)</li>
            <li>SVC syndrome mild and stable (minimal symptoms, no respiratory compromise)</li>
            <li>Definitive treatment plan in place (radiation therapy scheduled, chemotherapy regimen determined)</li>
            <li>Close oncology follow-up arranged (within 1-7 days depending on urgency)</li>
            <li>Adequate hydration maintained (able to drink 2-3 L/day)</li>
            <li>No need for ongoing IV medications or interventions</li>
            <li>Patient/family educated on warning signs to return (worsening weakness, confusion, respiratory distress, severe nausea/vomiting)</li>
            <li>Pain controlled on oral medications</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="anticoag-reversal">
    <div class="page-header">
        <h2>116. ANTICOAGULATION REVERSAL / MAJOR BLEEDING</h2>
        <div class="subtitle">Warfarin Reversal â€¢ DOAC Reversal â€¢ Major Hemorrhage â€¢ Rapid Correction</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient on anticoagulation (warfarin, DOACs, heparin, LMWH) presenting with life-threatening bleeding (intracranial hemorrhage, GI bleed with hemodynamic instability, massive hemoptysis) OR need for urgent surgery/procedure requiring immediate anticoagulation reversal.</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Anticoagulants impair hemostasis by various mechanisms: warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X, protein C/S), DOACs directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban), heparins enhance antithrombin activity. Excessive anticoagulation or trauma/bleeding while therapeutic increases bleeding risk. Reversal strategies target the specific mechanism: vitamin K and coagulation factor replacement for warfarin, specific reversal agents for DOACs, protamine for heparins.</li>
                <li><strong>Risk Factors:</strong> Supratherapeutic anticoagulation (INR >4 on warfarin, peak DOAC levels), elderly (>75 years), renal impairment (DOACs accumulate, especially dabigatran), concurrent antiplatelet therapy (aspirin, clopidogrel), liver disease, thrombocytopenia, recent trauma/fall, alcohol use, drug interactions (antibiotics, antifungals, amiodarone increase warfarin effect), medication non-adherence (dose errors)</li>
                <li><strong>Symptoms - Major Bleeding:</strong> Intracranial hemorrhage (severe headache, vomiting, altered mental status, focal neurologic deficits), GI bleeding (hematemesis, melena, hematochezia, hemodynamic instability), hemoptysis (massive, compromising airway), gross hematuria (persistent, with clots, hemodynamic instability), retroperitoneal hematoma (flank/back pain, falling hematocrit, hypotension), hemarthrosis (painful swollen joint), prolonged bleeding from trauma/procedure</li>
                <li><strong>Physical Exam:</strong> Tachycardia, hypotension (SBP <90 mmHg from blood loss), pallor, altered mental status (if intracranial hemorrhage or shock), melena/hematochezia on rectal exam, hematemesis, ecchymoses/petechiae (excessive), hematoma (expanding, tense), decreased breath sounds (hemothorax), neurologic deficits (if ICH)</li>
                <li><strong>Variants/Subtypes:</strong> Life-threatening major bleeding (intracranial hemorrhage, massive GI bleed with shock) vs non-life-threatening major bleeding (clinically significant but stable) vs supratherapeutic anticoagulation without bleeding. Urgent surgery/procedure requiring reversal. Type of anticoagulant: warfarin vs DOAC (dabigatran vs Xa inhibitor) vs heparin vs LMWH determines reversal strategy</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Complete Blood Count:</strong> Hemoglobin/hematocrit (baseline and serial q2-4h to assess ongoing bleeding). Platelet count (thrombocytopenia worsens bleeding)</li>
                <li><strong>Coagulation Studies:</strong>
                    <ul>
                        <li><strong>PT/INR:</strong> Elevated in warfarin use (therapeutic INR 2-3 for most indications, 2.5-3.5 for mechanical valves). Supratherapeutic if >4. Also prolonged in factor deficiency, liver disease</li>
                        <li><strong>aPTT:</strong> Elevated in heparin use (therapeutic aPTT 60-80 sec or 1.5-2.5Ã— control). Also prolonged in hemophilia, factor deficiencies</li>
                        <li><strong>Thrombin Time (TT) or Ecarin Clotting Time (ECT):</strong> Prolonged with dabigatran (direct thrombin inhibitor). Useful to confirm dabigatran effect</li>
                        <li><strong>Anti-Xa Level:</strong> Elevated with Xa inhibitors (rivaroxaban, apixaban, edoxaban) and heparins (LMWH, UFH). Quantifies drug activity. Useful if uncertain about DOAC effect</li>
                    </ul>
                </li>
                <li><strong>Type and Screen/Crossmatch:</strong> Prepare for transfusion (order 4-6 units PRBCs if massive bleeding)</li>
                <li><strong>Basic Metabolic Panel:</strong> Renal function (CrCl affects DOAC clearance). BUN/Cr ratio (elevated in upper GI bleed from blood protein absorption)</li>
                <li><strong>Liver Function Tests:</strong> Baseline liver function (affects warfarin metabolism, coagulation factor synthesis)</li>
                <li><strong>Fibrinogen:</strong> If massive transfusion/DIC suspected (fibrinogen <150 mg/dL concerning)</li>
            </ul>
            
            <p><strong>Imaging (Based on Bleeding Source):</strong></p>
            <ul>
                <li><strong>CT Head Non-Contrast (STAT if altered mental status, headache, focal deficits):</strong> Rule out intracranial hemorrhage. ICH on anticoagulation has high mortality (40-50%)</li>
                <li><strong>CT Chest/Abdomen/Pelvis with IV Contrast:</strong> If retroperitoneal hematoma, hemothorax, or bleeding source uncertain. Can identify active arterial extravasation ("contrast blush") for IR embolization</li>
                <li><strong>Endoscopy (EGD/Colonoscopy):</strong> For upper/lower GI bleeding once hemodynamically stabilized. Therapeutic (can cauterize, clip, inject epinephrine)</li>
                <li><strong>Angiography:</strong> If active bleeding identified on CT and hemodynamically unstable. IR can perform embolization</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Resuscitation (All Patients with Major Bleeding):</strong></p>
            <ul>
                <li>2 large-bore IV access (18G or larger), consider central line if massive transfusion anticipated</li>
                <li>Aggressive IV fluid resuscitation: Bolus NS or LR 1-2 L (reassess after each liter)</li>
                <li>Maintain SBP >90 mmHg (permissive hypotension for trauma, higher target for ICH)</li>
                <li>Supplemental oxygen, continuous monitoring (telemetry, pulse ox)</li>
                <li>NPO (if endoscopy or surgery anticipated)</li>
                <li>STOP anticoagulant and antiplatelet agents immediately</li>
                <li>Treat underlying bleeding source: endoscopy (GI bleed), neurosurgery (ICH evacuation if indicated), IR embolization (active arterial bleeding)</li>
            </ul>
            
            <p><strong>Transfusion Therapy (Major Hemorrhage):</strong></p>
            <ul>
                <li><strong>Packed Red Blood Cells (PRBCs):</strong> Transfuse if Hgb <7 g/dL (or <8-9 g/dL if active bleeding/unstable). Massive transfusion protocol if hemodynamic instability despite 2 L crystalloid</li>
                <li><strong>Massive Transfusion Protocol (if ongoing massive bleeding):</strong> PRBCs : FFP : Platelets in 1:1:1 ratio. Example: 6 units PRBCs, 6 units FFP, 1 apheresis platelet unit (equivalent to 6 pooled platelets). Prevents dilutional coagulopathy</li>
                <li><strong>Platelets:</strong> Transfuse if platelet count <50,000/ÂµL and active bleeding (or <100,000/ÂµL for ICH or neurosurgery). Goal >50,000/ÂµL</li>
                <li><strong>Cryoprecipitate:</strong> If fibrinogen <150 mg/dL. 10 units cryoprecipitate raises fibrinogen ~50-70 mg/dL</li>
                <li><strong>Tranexamic Acid (TXA):</strong> 1 g IV over 10 min, then 1 g IV over 8 hours. Antifibrinolytic. Reduces mortality in trauma with hemorrhagic shock (CRASH-2 trial). Use within 3 hours of injury. Caution: increases VTE risk. Do NOT use in hematuria (risk of clot obstruction)</li>
            </ul>
            
            <p><strong>WARFARIN REVERSAL:</strong></p>
            <ul>
                <li><strong>Four-Factor Prothrombin Complex Concentrate (4F-PCC, Kcentra) - FIRST LINE for Life-Threatening Bleeding:</strong>
                    <ul>
                        <li>Contains factors II, VII, IX, X + protein C and S. Reverses warfarin within 15-30 minutes</li>
                        <li>Dose based on INR and body weight:
                            <ul>
                                <li>INR 2-4: 25 units/kg IV (max 2500 units)</li>
                                <li>INR 4-6: 35 units/kg IV (max 3500 units)</li>
                                <li>INR >6: 50 units/kg IV (max 5000 units)</li>
                            </ul>
                        </li>
                        <li>Give over 15 minutes (rate not to exceed 4 mL/min)</li>
                        <li>Recheck INR 30 min after infusion (goal INR <1.5). If still elevated, can repeat dose</li>
                        <li>Superior to FFP (faster, more reliable, no volume overload, no need for typing/crossmatch)</li>
                        <li>Risk: thrombosis (MI, CVA, PE, DVT - 1-3% incidence). Weigh risk vs benefit</li>
                    </ul>
                </li>
                <li><strong>Fresh Frozen Plasma (FFP) - Alternative if PCC Unavailable:</strong>
                    <ul>
                        <li>Dose 10-15 mL/kg (typically 4-6 units for 70 kg patient). Repeat INR after infusion</li>
                        <li>Slower reversal (requires thawing 30-45 min, typing/crossmatch), variable factor levels, volume overload risk (each unit = 250 mL), transfusion reactions</li>
                        <li>Use only if PCC not available or if coagulopathy from liver disease (FFP replaces ALL factors)</li>
                    </ul>
                </li>
                <li><strong>Vitamin K (Phytonadione) - ALWAYS GIVE WITH PCC/FFP:</strong>
                    <ul>
                        <li>Dose: 10 mg IV slow push over 10-30 minutes (or PO/SC if not bleeding). Prevents re-elevation of INR after PCC wears off (PCC half-life 6-8 hours, vitamin K restores factor production)</li>
                        <li>Onset 6-12 hours IV, peak effect 24 hours. Duration 1-2 weeks. Give with PCC/FFP for sustained reversal</li>
                        <li>IV vitamin K has anaphylaxis risk (0.1%) - give slow push, monitor closely. Do NOT give IM (hematoma risk)</li>
                    </ul>
                </li>
                <li><strong>Indications for Emergent Reversal:</strong> Intracranial hemorrhage, massive GI bleed with hemodynamic instability, retroperitoneal hematoma, need for urgent surgery/procedure, INR >10 with high bleeding risk</li>
            </ul>
            
            <p><strong>DOAC REVERSAL:</strong></p>
            <ul>
                <li><strong>Dabigatran (Pradaxa) - Direct Thrombin Inhibitor:</strong>
                    <ul>
                        <li><strong>Idarucizumab (Praxbind) - SPECIFIC REVERSAL AGENT (FIRST LINE):</strong>
                            <ul>
                                <li>Humanized monoclonal antibody fragment, binds dabigatran with 350Ã— higher affinity than thrombin</li>
                                <li>Dose: 5 g IV (two 2.5 g vials) given as two consecutive infusions 15 min apart, or as bolus</li>
                                <li>Reverses dabigatran effect within 5-10 minutes. Duration 24 hours</li>
                                <li>Check aPTT or thrombin time before and after (should normalize)</li>
                                <li>Very safe, no prothrombotic risk reported</li>
                            </ul>
                        </li>
                        <li><strong>Hemodialysis (if idarucizumab unavailable):</strong> Dabigatran is 35% protein-bound, can be dialyzed. 4-hour dialysis session removes ~60% of drug</li>
                        <li><strong>PCC (off-label, if no other option):</strong> 50 units/kg (max 5000 units). Less effective than for warfarin reversal. Use only if idarucizumab unavailable and cannot dialyze</li>
                    </ul>
                </li>
                <li><strong>Factor Xa Inhibitors (Rivaroxaban, Apixaban, Edoxaban):</strong>
                    <ul>
                        <li><strong>Andexanet Alfa (Andexxa) - SPECIFIC REVERSAL AGENT (FIRST LINE if available):</strong>
                            <ul>
                                <li>Modified recombinant factor Xa decoy protein, binds Xa inhibitors</li>
                                <li>Dose depends on DOAC, dose, and time since last dose:
                                    <ul>
                                        <li>LOW DOSE: 400 mg IV bolus over 15 min, then 4 mg/min infusion Ã— 2 hours (total 480 mg). For rivaroxaban â‰¤10 mg or apixaban â‰¤5 mg, last dose >8 hours ago</li>
                                        <li>HIGH DOSE: 800 mg IV bolus over 30 min, then 8 mg/min infusion Ã— 2 hours (total 960 mg). For rivaroxaban >10 mg, apixaban >5 mg, edoxaban, or unknown dose/time</li>
                                    </ul>
                                </li>
                                <li>Reduces anti-Xa activity by 90% within minutes. Duration 2 hours (may need repeat dosing)</li>
                                <li>Risk: thrombosis (10% within 30 days in trials). Reserve for life-threatening bleeding</li>
                                <li>Very expensive (~$50,000 per dose), not universally available</li>
                            </ul>
                        </li>
                        <li><strong>Four-Factor PCC (Kcentra) - ALTERNATIVE if Andexanet Unavailable:</strong>
                            <ul>
                                <li>Off-label use. Replaces consumed clotting factors, partially reverses Xa inhibitor effect</li>
                                <li>Dose: 50 units/kg IV (max 5000 units)</li>
                                <li>Less effective than andexanet but widely available and much less expensive</li>
                            </ul>
                        </li>
                        <li><strong>Activated Prothrombin Complex Concentrate (aPCC, FEIBA):</strong> 50 units/kg (max 5000 units). Contains activated factor VII. Use if 4F-PCC unavailable. Higher thrombosis risk than 4F-PCC</li>
                    </ul>
                </li>
                <li><strong>Supportive Measures for All DOACs:</strong>
                    <ul>
                        <li>Activated charcoal (50 g PO) if last dose within 2-4 hours (prevents further absorption)</li>
                        <li>Hemodialysis generally NOT effective (except dabigatran) - DOACs are >80% protein-bound</li>
                        <li>Transfuse PRBCs, platelets, consider TXA</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>HEPARIN / LMWH REVERSAL:</strong></p>
            <ul>
                <li><strong>Protamine Sulfate (Specific Reversal for Heparin):</strong>
                    <ul>
                        <li>Cationic protein, binds anionic heparin, neutralizes anticoagulant effect</li>
                        <li><strong>Unfractionated Heparin (UFH):</strong> 1 mg protamine per 100 units heparin. Give dose based on total heparin received in last 2 hours (UFH half-life 60-90 min). Example: If patient received 5000 units UFH 1 hour ago, give 50 mg protamine IV</li>
                        <li><strong>LMWH (enoxaparin, dalteparin):</strong> 1 mg protamine per 1 mg enoxaparin (or 100 units dalteparin) given in last 8 hours. If >8 hours, give 0.5 mg protamine per 1 mg enoxaparin. LMWH reversal is incomplete (~60% neutralization) because protamine only reverses anti-IIa activity, not anti-Xa</li>
                        <li>Max single dose: 50 mg protamine (risk of hypotension if faster)</li>
                        <li>Give slow IV push over 10 minutes (rate not to exceed 5 mg/min). Rapid infusion causes hypotension, bradycardia</li>
                        <li>Check aPTT (UFH) or anti-Xa level (LMWH) 5-15 min after dose. Repeat protamine if still prolonged</li>
                        <li>Adverse effects: Hypotension (slow infusion), anaphylaxis (fish allergy, prior protamine exposure from NPH insulin, prior vasectomy), pulmonary hypertension</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Consultation:</strong></p>
            <ul>
                <li>Hematology: Urgent consult for all major bleeding on anticoagulation, guidance on reversal strategy</li>
                <li>GI: Urgent endoscopy for upper/lower GI bleeding once stabilized</li>
                <li>Neurosurgery: STAT consult for intracranial hemorrhage (surgical evacuation if indicated)</li>
                <li>Interventional Radiology: For active arterial bleeding on CT (embolization)</li>
                <li>Surgery: For intra-abdominal, retroperitoneal bleeding requiring operative management</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Intracranial hemorrhage, hemodynamic instability (SBP <90, HR >120), massive transfusion, need for urgent surgery/procedure, ongoing bleeding despite reversal, need for serial neurologic exams</li>
                <li>Floor: Stable after reversal, minor bleeding controlled, supratherapeutic INR without bleeding (INR >4 but <10, no bleeding)</li>
                <li>Discharge: Supratherapeutic INR without bleeding, corrected with vitamin K, close follow-up arranged (INR recheck in 24 hours)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Four-Factor PCC is Superior to FFP for Warfarin Reversal:</strong> PCC reverses warfarin within 15-30 minutes (vs 6-12 hours for FFP), with smaller volume (100 mL vs 1-1.5 L), no need for typing/crossmatch (immediately available), and more predictable factor levels. FFP requires thawing (30-45 min delay), causes volume overload (especially problematic in elderly or CHF patients), and has variable factor content. For life-threatening bleeding (ICH, massive GI bleed), use PCC. FFP is reserved for situations where PCC is unavailable or if patient has liver disease with multifactorial coagulopathy needing ALL clotting factors replaced.</li>
            <li><strong>Always Give Vitamin K WITH PCC in Warfarin Reversal:</strong> PCC provides immediate reversal (factors II, VII, IX, X) but has short half-life (6-8 hours). Without vitamin K, warfarin continues to inhibit hepatic synthesis and INR re-elevates after PCC wears off. Vitamin K takes 6-12 hours to work but restores endogenous factor production and provides sustained reversal lasting 1-2 weeks. ALWAYS give vitamin K 10 mg IV (slow push) CONCURRENTLY with PCC. This combination prevents rebound INR elevation and need for repeat PCC dosing.</li>
            <li><strong>Idarucizumab (Praxbind) is Highly Effective and Safe for Dabigatran Reversal:</strong> Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran with 350Ã— higher affinity than thrombin, completely reversing its anticoagulant effect within 5-10 minutes. Dose is simple: 5 g IV (two 2.5 g vials). Unlike PCC, idarucizumab has NO prothrombotic risk - it's remarkably safe. Check aPTT or dilute thrombin time before and after (should normalize). If reversal incomplete, consider hemodialysis (dabigatran is dialyzable). Idarucizumab is now widely available and should be first-line for dabigatran-associated major bleeding or urgent surgery.</li>
            <li><strong>Andexanet Alfa is Expensive and Has Thrombosis Risk - Use Judiciously:</strong> Andexanet alfa (Andexxa) reverses factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) within minutes and reduces anti-Xa activity by 90%. However, it costs ~$50,000 per dose and is associated with 10% thrombosis rate (MI, stroke, VTE) within 30 days. Reserve for LIFE-THREATENING bleeding only (ICH, massive bleeding with shock). For non-life-threatening bleeding (e.g., stable GI bleed), consider supportive care Â± PCC rather than andexanet. Also, andexanet's effect wanes after 2 hours, so rebleeding is common.</li>
            <li><strong>PCC Has Thrombosis Risk - Balance Bleeding vs Thrombosis:</strong> Both 4F-PCC and andexanet alfa carry 1-3% thrombosis risk (arterial and venous). This creates a dilemma: patient is anticoagulated for a reason (atrial fibrillation, mechanical valve, prior VTE) so reversal increases thrombosis risk, but they're bleeding so need reversal. Clinical judgment: use reversal agents for LIFE-THREATENING bleeding (ICH, massive bleeding with hemodynamic instability) where immediate death risk outweighs delayed thrombosis risk. For minor bleeding or supratherapeutic INR without bleeding, use vitamin K alone or hold anticoagulation temporarily rather than PCC.</li>
            <li><strong>Protamine Reverses Unfractionated Heparin Completely, LMWH Only Partially:</strong> Protamine neutralizes UFH immediately and completely (1 mg protamine per 100 units heparin). However, LMWH reversal is incomplete - protamine only neutralizes ~60% of enoxaparin's anticoagulant effect because it reverses anti-IIa activity but NOT anti-Xa activity (which accounts for 40% of LMWH's effect). Dose: 1 mg protamine per 1 mg enoxaparin given in last 8 hours. For life-threatening LMWH-associated bleeding with incomplete protamine reversal, consider PCC or andexanet as adjunct.</li>
            <li><strong>Check INR 30 Minutes After PCC to Confirm Reversal:</strong> PCC effect is rapid but variable. After giving PCC for warfarin reversal, recheck INR 30 minutes later. Goal INR <1.5 for most bleeding, <1.3 for ICH or neurosurgery. If INR still elevated, can give additional PCC (25 units/kg). If INR normalized but patient continues bleeding, problem is NOT the INR - look for surgical bleeding source requiring intervention (endoscopy, IR embolization, surgery). Don't keep giving PCC if INR is <1.5 - you'll just increase thrombosis risk without additional benefit.</li>
            <li><strong>Massive Transfusion Protocol Uses 1:1:1 Ratio to Prevent Dilutional Coagulopathy:</strong> Massive transfusion (>10 units PRBCs in 24 hours) causes dilutional coagulopathy, thrombocytopenia, hypocalcemia, hypothermia, acidosis (trauma "lethal triad"). Modern massive transfusion protocols use 1:1:1 ratio: 1 unit PRBC : 1 unit FFP : 1 platelet unit (1 apheresis or 6 pooled). This prevents dilutional coagulopathy by replacing clotting factors and platelets proportionally. Old practice (crystalloid + PRBCs only) worsened coagulopathy and increased mortality. Activate massive transfusion protocol early if ongoing hemorrhage despite 2 L crystalloid.</li>
            <li><strong>Tranexamic Acid (TXA) Reduces Mortality in Trauma with Hemorrhagic Shock:</strong> The CRASH-2 trial showed TXA (1 g IV bolus, then 1 g infusion over 8 hours) given within 3 hours of traumatic injury reduced all-cause mortality by 10% without increasing VTE. Mechanism: antifibrinolytic (blocks plasminogen activation). Use for trauma patients with hemorrhagic shock (SBP <90 or HR >110) within 3 hours of injury. Do NOT use after 3 hours (increased mortality, possibly from late fibrinolysis impairing clot remodeling). Caution in hematuria (risk of ureteral clot obstruction).</li>
            <li><strong>When to Resume Anticoagulation After Major Bleeding:</strong> This is challenging. Balance thrombosis risk (stroke in atrial fibrillation, valve thrombosis, recurrent VTE) vs rebleeding risk. General approach: (1) ICH: usually permanently discontinue oral anticoagulation, consider left atrial appendage closure for atrial fibrillation. (2) Major GI bleed: resume in 7-14 days if source controlled endoscopically and hemostasis confirmed. (3) Mechanical heart valve: very high thrombosis risk - resume as soon as hemostasis achieved (24-48 hours), bridge with heparin. Consult hematology, cardiology, or neurology for individualized decision-making.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Intracranial hemorrhage (any size, any location) on anticoagulation</li>
            <li>Hemodynamic instability (SBP <90 mmHg, HR >120 bpm, shock index >1)</li>
            <li>Massive bleeding requiring massive transfusion protocol (>4 units PRBCs in 1 hour or >10 units in 24 hours)</li>
            <li>Hemoglobin drop >3-4 g/dL or <7 g/dL despite transfusion</li>
            <li>Active ongoing bleeding despite reversal and supportive measures</li>
            <li>Retroperitoneal hematoma with hemodynamic instability</li>
            <li>Need for urgent surgery or invasive procedure (neurosurgery, laparotomy)</li>
            <li>Altered mental status (from ICH or shock)</li>
            <li>Respiratory compromise (massive hemoptysis, hemothorax)</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Hemodynamically stable (SBP >100, HR <100, no orthostatic hypotension)</li>
            <li>Bleeding source controlled or minor</li>
            <li>Hemoglobin stable for >12-24 hours (no further drop)</li>
            <li>INR or coagulation studies corrected or therapeutic (if restarting anticoagulation)</li>
            <li>No signs of ongoing bleeding (stable Hgb, vital signs stable, no melena/hematochezia/hematuria)</li>
            <li>No indication for ICU-level care (no ICH, no need for serial transfusions)</li>
            <li>Clear plan for anticoagulation management (resume, change agent, or discontinue based on bleeding risk vs thrombosis risk)</li>
            <li>Close follow-up arranged (hematology, cardiology, PCP within 1-7 days)</li>
            <li>INR recheck scheduled if on warfarin (24-48 hours)</li>
            <li>Patient/family educated on signs of rebleeding and when to return</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="sle">
    <div class="page-header">
        <h2>117. SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) FLARE</h2>
        <div class="subtitle">Multisystem Autoimmune â€¢ Rash â€¢ Arthritis â€¢ Serositis â€¢ Lupus Nephritis â€¢ Cytopenias</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient with known SLE (or new diagnosis) presenting with acute exacerbation of multisystem autoimmune disease: malar/discoid rash, polyarthritis, serositis (pleuritis, pericarditis), acute kidney injury from lupus nephritis, cytopenias, or CNS lupus (psychosis, seizures).</p>
            <ul>
                <li><strong>Pathophysiology:</strong> SLE is a chronic autoimmune disease characterized by production of autoantibodies (ANA, anti-dsDNA, anti-Smith) causing immune complex deposition in multiple organs. Flares triggered by infections, UV exposure, medications (sulfa drugs, hydralazine), pregnancy, stress, medication non-compliance. Organ involvement: (1) Mucocutaneous (malar rash, discoid lesions, photosensitivity, oral ulcers), (2) Musculoskeletal (polyarthritis, myositis), (3) Renal (lupus nephritis - most serious, leading cause of morbidity), (4) Hematologic (autoimmune hemolytic anemia, thrombocytopenia, leukopenia), (5) Serositis (pleuritis, pericarditis), (6) Neuropsychiatric (psychosis, seizures, cognitive dysfunction, stroke from antiphospholipid antibodies), (7) Cardiac (Libman-Sacks endocarditis, myocarditis)</li>
                <li><strong>Risk Factors:</strong> Young women (90% of SLE patients), African American, Hispanic, Asian descent (higher prevalence and severity), family history (genetic predisposition), known SLE diagnosis, medication non-compliance (stopped hydroxychloroquine, steroids), triggers: infections (URI, UTI), UV light exposure, pregnancy (postpartum flares common), estrogen (OCPs, HRT), medications (sulfonamides, hydralazine, procainamide, isoniazid, minocycline)</li>
                <li><strong>Symptoms:</strong> Constitutional (fever, fatigue, weight loss), malar rash ("butterfly rash" across cheeks/nose), discoid rash (scarring, hyperpigmentation), photosensitive rash, oral/nasal ulcers (usually painless), polyarthralgia/polyarthritis (symmetric, non-erosive, hands/wrists/knees), pleuritic chest pain (pleuritis), pericardial chest pain (pericarditis), dyspnea (pleural effusion, pulmonary hemorrhage), Raynaud phenomenon, alopecia (non-scarring), headache, confusion/psychosis, seizures, vision changes (retinal vasculitis)</li>
                <li><strong>Physical Exam:</strong> Fever, malar rash (erythematous, flat or raised, spares nasolabial folds), discoid lesions (scarring alopecia, hyperpigmentation), oral ulcers, synovitis (swelling, tenderness in MCPs, PIPs, wrists, knees - symmetric), pleural friction rub, pericardial friction rub, muffled heart sounds (pericardial effusion), peripheral edema (nephrotic syndrome), hypertension (lupus nephritis), altered mental status, focal neurologic deficits, retinal hemorrhages/exudates on fundoscopy</li>
                <li><strong>Variants/Subtypes:</strong> Mild flare (rash, arthritis, mild serositis) vs Severe flare (lupus nephritis, CNS lupus, severe cytopenias, vasculitis, pulmonary hemorrhage). Lupus nephritis classes (I-VI): Class III/IV (proliferative) most severe, requires aggressive immunosuppression. Drug-induced lupus (procainamide, hydralazine, isoniazid, minocycline) - usually mild, resolves after stopping drug. Neonatal lupus (anti-Ro/La antibodies in pregnant mothers cross placenta, causes congenital heart block in fetus)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Complete Blood Count:</strong> Leukopenia (WBC <4000/ÂµL, often lymphopenia), autoimmune hemolytic anemia (Hgb <10 g/dL, Coombs positive), thrombocytopenia (platelets <100,000/ÂµL). Pancytopenia in severe cases</li>
                <li><strong>Basic Metabolic Panel:</strong> Elevated creatinine (AKI from lupus nephritis), hyperkalemia, metabolic acidosis (if severe renal involvement)</li>
                <li><strong>Urinalysis:</strong> CRITICAL for lupus nephritis. Proteinuria (>0.5 g/24hr or spot urine protein:creatinine ratio >0.5), hematuria (RBCs, RBC casts - pathognomonic for glomerulonephritis), pyuria (sterile, WBC casts). Active urine sediment (cellular casts) indicates active lupus nephritis</li>
                <li><strong>24-Hour Urine or Spot Urine Protein:Creatinine Ratio:</strong> Quantify proteinuria. Nephrotic range proteinuria (>3.5 g/24hr or spot ratio >3.5) indicates severe lupus nephritis</li>
                <li><strong>Complement Levels (C3, C4):</strong> LOW in active SLE (immune complex formation consumes complement). Low C3 (<90 mg/dL) and C4 (<16 mg/dL) correlate with disease activity, especially lupus nephritis. Normal complement makes SLE flare less likely</li>
                <li><strong>Anti-dsDNA Antibody:</strong> ELEVATED in active SLE (especially lupus nephritis). High specificity (95%) for SLE. Titer correlates with disease activity. Rising anti-dsDNA suggests flare</li>
                <li><strong>Antinuclear Antibody (ANA):</strong> Positive (>1:80) in 95% of SLE patients (sensitive but not specific). Negative ANA makes SLE unlikely. Do NOT trend - stays positive even in remission</li>
                <li><strong>Anti-Smith Antibody:</strong> Highly specific (99%) for SLE but only 30% sensitive. Does NOT correlate with disease activity. Used for diagnosis, not monitoring</li>
                <li><strong>Erythrocyte Sedimentation Rate (ESR):</strong> Often elevated (>30 mm/hr) in active SLE. Not specific but useful for trending</li>
                <li><strong>C-Reactive Protein (CRP):</strong> Usually NORMAL or mildly elevated in SLE flares (despite high ESR). Markedly elevated CRP (>10 mg/dL) suggests infection or serositis (pericarditis) rather than pure SLE flare</li>
                <li><strong>Hemolysis Labs (if anemia):</strong> Elevated LDH, indirect bilirubin, low haptoglobin, positive Coombs test (direct antiglobulin test). Indicates autoimmune hemolytic anemia</li>
                <li><strong>Antiphospholipid Antibodies:</strong> If thrombosis or recurrent pregnancy loss. Lupus anticoagulant, anticardiolipin IgG/IgM, anti-beta-2-glycoprotein I. Present in 30-40% of SLE patients (antiphospholipid syndrome)</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>Chest X-ray:</strong> Pleural effusion (pleuritis, common in SLE), pulmonary infiltrates (lupus pneumonitis, pulmonary hemorrhage, infection), cardiomegaly (pericardial effusion, myocarditis)</li>
                <li><strong>Echocardiogram:</strong> If pericardial chest pain, muffled heart sounds, or elevated JVP. Assess for pericardial effusion, tamponade physiology, Libman-Sacks endocarditis (verrucous vegetations, usually asymptomatic), myocarditis (reduced EF)</li>
                <li><strong>CT Chest (if pulmonary hemorrhage suspected):</strong> Ground-glass opacities (alveolar hemorrhage), consolidations. Diffuse alveolar hemorrhage is life-threatening SLE complication</li>
                <li><strong>MRI Brain (if CNS symptoms):</strong> Rule out stroke, posterior reversible encephalopathy syndrome (PRES), transverse myelitis, CNS vasculitis. May be normal in neuropsychiatric lupus (diagnosis of exclusion)</li>
            </ul>
            
            <p><strong>Special Studies:</strong></p>
            <ul>
                <li><strong>Kidney Biopsy (if lupus nephritis suspected):</strong> Indications: new-onset proteinuria >0.5 g/24hr, active urine sediment (RBC casts), rising creatinine. Biopsy determines lupus nephritis class (I-VI) and guides treatment. Class III (focal proliferative) and Class IV (diffuse proliferative) require aggressive immunosuppression (cyclophosphamide or mycophenolate + steroids)</li>
                <li><strong>Lumbar Puncture (if CNS lupus suspected):</strong> Elevated protein, lymphocytic pleocytosis. Rule out infection (bacterial, viral, fungal meningitis). CNS lupus is diagnosis of exclusion</li>
            </ul>
            
            <p><strong>Diagnostic Criteria (2019 EULAR/ACR Criteria):</strong></p>
            <ul>
                <li>Requires ANA â‰¥1:80 as entry criterion, then score â‰¥10 points from clinical/immunologic domains. Key features: arthritis, serositis, lupus nephritis, cytopenias, malar rash, fever, low complement, anti-dsDNA</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management:</strong></p>
            <ul>
                <li>Assess severity of flare: organ-threatening (lupus nephritis, CNS lupus, pulmonary hemorrhage, severe cytopenia) vs mild (rash, arthritis, mild serositis)</li>
                <li>IV access, continuous monitoring if severe</li>
                <li>RULE OUT INFECTION (fever in SLE can be flare OR infection - both common). Blood cultures, urinalysis/urine culture, chest X-ray, consider procalcitonin (elevated in infection, normal in SLE flare)</li>
                <li>Stop potential triggers (sulfa drugs, estrogens) if identified</li>
            </ul>
            
            <p><strong>Glucocorticoids (Cornerstone of Acute Flare Management):</strong></p>
            <ul>
                <li><strong>Mild-Moderate Flare (rash, arthritis, mild serositis):</strong> Prednisone 0.5-1 mg/kg PO daily (typically 40-60 mg daily). Taper slowly over 6-12 weeks based on response</li>
                <li><strong>Severe Flare (lupus nephritis, CNS lupus, severe cytopenias, pulmonary hemorrhage):</strong> High-dose IV methylprednisolone (pulse therapy) 500-1000 mg IV daily Ã— 3 days, then prednisone 1 mg/kg PO daily (60-80 mg). Dramatic improvement within days. Taper very slowly (months)</li>
                <li><strong>Steroid-Sparing Agents:</strong> Start or increase immunosuppression concurrently (see below) to allow steroid taper</li>
                <li><strong>PPI Prophylaxis:</strong> Pantoprazole 40 mg PO daily for GI protection with high-dose steroids</li>
                <li><strong>Pneumocystis Prophylaxis:</strong> TMP-SMX DS 1 tab PO 3Ã—/week (or dapsone, atovaquone if sulfa allergy) if prednisone >20 mg/day for >1 month</li>
                <li><strong>Calcium/Vitamin D:</strong> Calcium carbonate 1200 mg + vitamin D 800-1000 IU daily (osteoporosis prevention)</li>
            </ul>
            
            <p><strong>Immunosuppressive Therapy (Steroid-Sparing, Disease-Modifying):</strong></p>
            <ul>
                <li><strong>Hydroxychloroquine (Plaquenil) - BASELINE for ALL SLE Patients:</strong> 200-400 mg PO daily (â‰¤5 mg/kg/day). Reduces flares by 50%, improves survival, prevents thrombosis. Minimal side effects. Requires annual ophthalmology exam (rare retinal toxicity). If patient not on hydroxychloroquine, START IT. If already on it, CONTINUE (don't stop during flare)</li>
                <li><strong>Mycophenolate Mofetil (CellCept) - First Line for Lupus Nephritis:</strong> 1000-1500 mg PO BID (total 2-3 g/day). Inhibits purine synthesis, suppresses T/B cells. Preferred over cyclophosphamide (equal efficacy, less toxicity). Side effects: GI upset, leukopenia. Monitor CBC weekly initially</li>
                <li><strong>Cyclophosphamide (Cytoxan) - Alternative for Severe Lupus Nephritis:</strong> IV pulse: 500-1000 mg/mÂ² IV monthly Ã— 6 months (Euro-Lupus protocol), or 500-750 mg/mÂ² IV q2 weeks Ã— 6 doses (NIH protocol). More toxic than mycophenolate (hemorrhagic cystitis, infertility, bladder cancer). Reserved for refractory disease. Give with mesna (bladder protection), aggressive hydration</li>
                <li><strong>Azathioprine (Imuran) - Maintenance Therapy:</strong> 1-2 mg/kg/day PO (typically 100-150 mg daily). Less potent than mycophenolate. Used for maintenance after induction with mycophenolate or cyclophosphamide. Check TPMT activity before starting (TPMT deficiency causes severe myelosuppression)</li>
                <li><strong>Methotrexate:</strong> 15-25 mg PO/SC weekly. For refractory arthritis, cutaneous lupus. NOT for lupus nephritis. Give with folic acid 1 mg daily</li>
                <li><strong>Rituximab (Rituxan) - Refractory SLE:</strong> 1000 mg IV on day 1 and day 15, or 375 mg/mÂ² IV weekly Ã— 4 weeks. Monoclonal anti-CD20 antibody, depletes B cells. For refractory lupus nephritis, severe cytopenias, CNS lupus despite conventional therapy. Off-label use. Requires premedication (acetaminophen, diphenhydramine)</li>
                <li><strong>Belimumab (Benlysta) - Biologic for Refractory SLE:</strong> 10 mg/kg IV every 2 weeks Ã— 3 doses, then q4 weeks. Or 200 mg SC weekly. Monoclonal antibody against BLyS (B-lymphocyte stimulator). FDA-approved for active SLE despite standard therapy. Reduces flares, steroid requirements. Do NOT use in severe active lupus nephritis or CNS lupus</li>
            </ul>
            
            <p><strong>Specific Organ-Based Treatment:</strong></p>
            <ul>
                <li><strong>Lupus Nephritis (Class III/IV):</strong> URGENT nephrology consult. Induction: mycophenolate 2-3 g/day PO OR cyclophosphamide 500-1000 mg/mÂ² IV monthly Ã— 6 months, PLUS high-dose steroids (methylprednisolone 1 g IV daily Ã— 3 days, then prednisone 1 mg/kg). Maintenance: mycophenolate or azathioprine for 2-3 years. Target blood pressure <130/80. ACE-I/ARB for proteinuria (even if normotensive)</li>
                <li><strong>Neuropsychiatric Lupus:</strong> High-dose steroids (methylprednisolone 1 g IV daily Ã— 3-5 days), cyclophosphamide or rituximab. Rule out infection (LP), stroke (MRI). Anticoagulation if antiphospholipid antibodies. Psychiatric symptoms often require antipsychotics (quetiapine, olanzapine), antidepressants (SSRIs)</li>
                <li><strong>Severe Cytopenias (Hgb <7 g/dL, platelets <20,000/ÂµL):</strong> High-dose steroids, IVIG 1 g/kg IV daily Ã— 2 days (for thrombocytopenia), rituximab if refractory. Transfuse PRBCs if Hgb <7 g/dL, platelets if <10,000/ÂµL or bleeding</li>
                <li><strong>Pulmonary Hemorrhage:</strong> LIFE-THREATENING. High-dose steroids (methylprednisolone 1 g IV daily Ã— 3-5 days), cyclophosphamide 500-1000 mg/mÂ² IV, plasmapheresis (removes autoantibodies). Mechanical ventilation often required. ICU admission</li>
                <li><strong>Serositis (Pleuritis, Pericarditis):</strong> NSAIDs (indomethacin 50 mg PO TID, ibuprofen 600-800 mg PO TID) + prednisone 0.5 mg/kg/day. If pericardial effusion with tamponade: pericardiocentesis</li>
            </ul>
            
            <p><strong>Supportive Measures:</strong></p>
            <ul>
                <li>NSAIDs for arthritis/serositis (use cautiously if lupus nephritis - can worsen renal function)</li>
                <li>Hypertension control: ACE-I/ARB preferred (renoprotective in lupus nephritis). Target BP <130/80</li>
                <li>Thromboprophylaxis: Aspirin 81 mg daily for antiphospholipid antibodies (primary prevention). Warfarin INR 2-3 for history of thrombosis (secondary prevention)</li>
                <li>Sun protection: Sunscreen SPF 50+, protective clothing, avoid peak sun (UV triggers flares)</li>
                <li>Vaccinations: Pneumococcal, influenza (annual), Tdap. Give BEFORE starting immunosuppression if possible. Avoid live vaccines (MMR, varicella, yellow fever) on immunosuppression</li>
            </ul>
            
            <p><strong>Rheumatology Consultation:</strong></p>
            <ul>
                <li>MANDATORY for all SLE flares</li>
                <li>URGENT consultation for severe flares (lupus nephritis, CNS lupus, severe cytopenias, pulmonary hemorrhage)</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>ICU: Pulmonary hemorrhage, respiratory failure, severe CNS lupus (seizures, psychosis, coma), severe cytopenias with bleeding, hemodynamic instability, need for plasmapheresis</li>
                <li>Floor: Lupus nephritis requiring IV pulse steroids, moderate-severe flares requiring IV methylprednisolone, inability to tolerate PO medications</li>
                <li>Discharge: Mild flares (rash, arthritis, mild serositis), stable on oral prednisone/immunosuppression, close rheumatology follow-up (within 1-2 weeks)</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Lupus Nephritis is the Leading Cause of Morbidity and Mortality in SLE:</strong> 50% of SLE patients develop lupus nephritis, and it's the major determinant of long-term outcomes. Untreated proliferative lupus nephritis (Class III/IV) progresses to ESRD in 20-30% of patients. KEY: Screen ALL SLE patients with urinalysis and urine protein:creatinine ratio at EVERY visit. New proteinuria >0.5 g/24hr or active sediment (RBC casts) warrants kidney biopsy. Early aggressive treatment with mycophenolate or cyclophosphamide + high-dose steroids can prevent progression to ESRD. Don't wait - kidney damage is irreversible.</li>
            <li><strong>Low Complement (C3, C4) and High Anti-dsDNA Correlate with Active Disease, Especially Lupus Nephritis:</strong> SLE flares consume complement via immune complex formation, causing low C3 (<90 mg/dL) and C4 (<16 mg/dL). Anti-dsDNA antibodies are highly specific (95%) for SLE and titer rises during flares. Lupus nephritis almost always has low complement + elevated anti-dsDNA. Normal complement makes active SLE flare unlikely. Use complement and anti-dsDNA to TREND disease activity (unlike ANA which stays positive even in remission). Caveat: infections can also lower complement, so correlate with clinical picture.</li>
            <li><strong>Hydroxychloroquine is the Most Important Drug in SLE - Never Stop It:</strong> Hydroxychloroquine reduces SLE flares by 50%, reduces thrombosis (especially in antiphospholipid syndrome), improves survival, lowers cholesterol, and has minimal side effects. ALL SLE patients should be on hydroxychloroquine 200-400 mg daily unless contraindicated (retinopathy, G6PD deficiency). Common mistake: stopping hydroxychloroquine during pregnancy or flare. Don't do it - hydroxychloroquine is SAFE in pregnancy and should be CONTINUED during flares (add steroids/immunosuppression on top). Only toxicity: rare retinal toxicity requiring annual ophthalmology screening after 5 years.</li>
            <li><strong>Fever in SLE Can Be Flare OR Infection - Both Are Common:</strong> SLE patients are immunosuppressed from disease itself and from medications (steroids, mycophenolate, cyclophosphamide), increasing infection risk. Fever differential: (1) SLE flare (low-grade, associated with other flare symptoms like rash/arthritis, low CRP), (2) Infection (high CRP >10 mg/dL, procalcitonin elevated, focal source). ALWAYS rule out infection before attributing fever to SLE and starting high-dose steroids (which worsen infection). Get blood cultures, urinalysis/urine culture, chest X-ray. If uncertain, start antibiotics AND steroids, reassess in 24-48 hours.</li>
            <li><strong>Mycophenolate Has Replaced Cyclophosphamide as First-Line for Lupus Nephritis:</strong> The ALMS and MAINTAIN trials showed mycophenolate (2-3 g/day) is AS effective as cyclophosphamide for inducing and maintaining remission in lupus nephritis, with significantly fewer side effects. Cyclophosphamide causes hemorrhagic cystitis (give mesna), infertility (20-40% premature ovarian failure), bladder cancer (long-term risk), and severe infections. Reserve cyclophosphamide for mycophenolate-refractory disease or when fertility concerns are secondary. Mycophenolate side effects are mainly GI (nausea, diarrhea) and leukopenia - much more tolerable.</li>
            <li><strong>Neuropsychiatric Lupus is a Diagnosis of Exclusion:</strong> CNS lupus manifests as psychosis, seizures, stroke, cognitive dysfunction, cranial neuropathies, transverse myelitis. However, MANY other causes can mimic CNS lupus in SLE patients: (1) Infection (CNS infections from immunosuppression: cryptococcal meningitis, toxoplasmosis, PML), (2) Stroke from antiphospholipid antibodies (not inflammatory), (3) Posterior reversible encephalopathy syndrome (PRES from hypertension, especially with lupus nephritis), (4) Medication toxicity (steroids cause psychosis), (5) Metabolic (uremia from renal failure, hypercalcemia). MUST rule out these before diagnosing CNS lupus. Get MRI brain, LP (rule out infection), check antiphospholipid antibodies.</li>
            <li><strong>Libman-Sacks Endocarditis is Sterile Verrucous Vegetations, Not Bacterial:</strong> Libman-Sacks endocarditis is aseptic thrombotic vegetations on heart valves (usually mitral, aortic) in SLE and antiphospholipid syndrome. Caused by immune complex deposition, NOT infection. Key differences from bacterial endocarditis: (1) Blood cultures negative, (2) No fever/sepsis (unless concurrent infection), (3) Usually asymptomatic (incidental finding on echo), (4) Treat SLE with steroids/immunosuppression, NOT antibiotics. However, Libman-Sacks valves ARE at increased risk of superimposed bacterial endocarditis, so antibiotic prophylaxis for dental procedures is recommended in these patients.</li>
            <li><strong>Antiphospholipid Syndrome Complicates 30-40% of SLE Cases:</strong> Antiphospholipid syndrome (APS) causes arterial/venous thrombosis (DVT, PE, stroke, MI), recurrent pregnancy loss (â‰¥3 spontaneous abortions), and thrombocytopenia. Diagnosed by: (1) Clinical criterion (thrombosis or pregnancy morbidity) PLUS (2) Persistent positive antiphospholipid antibodies (lupus anticoagulant, anticardiolipin IgG/IgM, anti-beta-2-glycoprotein I) on TWO occasions 12 weeks apart. Treatment: lifelong anticoagulation with warfarin INR 2-3 for thrombosis history. Aspirin 81 mg daily for primary prevention if antibodies positive but no thrombosis. DOACs are NOT recommended for APS (inferior to warfarin in trials).</li>
            <li><strong>Drug-Induced Lupus Resolves After Stopping the Offending Drug:</strong> Classic drugs: procainamide (20% of patients), hydralazine (5-10%), isoniazid, minocycline, TNF-alpha inhibitors (infliximab, etanercept). Presents with arthralgia, myalgia, serositis (pleuritis, pericarditis), fever. Positive ANA and anti-histone antibodies (70-95%). KEY differences from idiopathic SLE: (1) NO renal involvement, (2) NO CNS involvement, (3) Rare rash, (4) Complement normal, (5) Anti-dsDNA and anti-Smith antibodies NEGATIVE. Treatment: STOP THE DRUG - symptoms resolve in weeks to months. May need short course of prednisone for symptomatic relief. No long-term immunosuppression needed.</li>
            <li><strong>Pulse-Dose IV Methylprednisolone for Severe Flares Provides Rapid Control:</strong> For life-threatening SLE flares (severe lupus nephritis, CNS lupus, pulmonary hemorrhage, severe cytopenias), give pulse-dose IV methylprednisolone 500-1000 mg IV daily Ã— 3 days. This provides MUCH higher tissue steroid levels than oral prednisone and results in dramatic improvement within 24-72 hours. After 3 days of IV pulse, transition to high-dose oral prednisone 1 mg/kg/day and taper slowly over months. Pulse steroids are generally safe (main risks: hyperglycemia, infection, avascular necrosis with chronic use). Always start steroid-sparing immunosuppression (mycophenolate, cyclophosphamide) concurrently.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Diffuse alveolar hemorrhage / pulmonary hemorrhage (hemoptysis, hypoxia, diffuse infiltrates on CXR)</li>
            <li>Respiratory failure requiring intubation or high-flow oxygen</li>
            <li>Severe neuropsychiatric lupus (seizures, coma, stroke, acute psychosis with agitation)</li>
            <li>Severe thrombocytopenia (<20,000/ÂµL) with active bleeding</li>
            <li>Severe autoimmune hemolytic anemia (Hgb <5-6 g/dL) with hemodynamic instability</li>
            <li>Cardiac tamponade from pericardial effusion</li>
            <li>Acute kidney injury with oliguria and need for urgent dialysis</li>
            <li>Hemodynamic instability (hypotension, shock)</li>
            <li>Need for plasmapheresis</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>Mild flare only (cutaneous, musculoskeletal, mild serositis without significant effusion)</li>
            <li>No organ-threatening manifestations (no lupus nephritis, CNS lupus, severe cytopenias, pulmonary hemorrhage)</li>
            <li>Able to tolerate oral medications (prednisone, immunosuppressants)</li>
            <li>Stable vital signs, no hypoxia, no fever (or infection ruled out)</li>
            <li>No evidence of infection (cultures negative or appropriate antibiotics started)</li>
            <li>Renal function stable or improving (if lupus nephritis, proteinuria not worsening)</li>
            <li>Hemoglobin stable (>8-9 g/dL if AIHA), platelets >30,000-50,000/ÂµL if ITP</li>
            <li>Close rheumatology follow-up arranged (within 1-2 weeks)</li>
            <li>Patient educated on medication compliance (hydroxychloroquine, prednisone taper), sun protection, when to return</li>
            <li>Prescriptions provided: prednisone with clear taper schedule, PPI, calcium/vitamin D, hydroxychloroquine</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<div class="condition-page" id="gca">
    <div class="page-header">
        <h2>118. GIANT CELL ARTERITIS / TEMPORAL ARTERITIS</h2>
        <div class="subtitle">Vision Loss Risk â€¢ Jaw Claudication â€¢ New Headache â€¢ Age >50 â€¢ ESR >50</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Patient >50 years old presenting with new-onset severe headache (temporal region), jaw claudication, vision changes (transient or permanent vision loss), and markedly elevated ESR (>50 mm/hr, often >100 mm/hr). This is a medical emergency due to risk of irreversible blindness.</p>
            <ul>
                <li><strong>Pathophysiology:</strong> Giant cell arteritis (GCA) is a large-vessel granulomatous vasculitis affecting medium and large arteries, particularly branches of the external carotid artery (temporal, ophthalmic, posterior ciliary arteries) and aorta. Inflammatory infiltrate with multinucleated giant cells causes intimal hyperplasia, vessel wall thickening, and luminal narrowing/occlusion. Ischemia to ophthalmic artery branches causes anterior ischemic optic neuropathy (AION) - the most feared complication. Untreated, 50-70% develop permanent vision loss. Systemic inflammation causes constitutional symptoms. Strongly associated with polymyalgia rheumatica (50% have concurrent PMR).</li>
                <li><strong>Risk Factors:</strong> Age >50 years (rare below 50, peak incidence 70-80 years), female (2-3:1), Northern European descent (especially Scandinavian), polymyalgia rheumatica (15-20% of PMR patients develop GCA), positive family history</li>
                <li><strong>Symptoms - Classic Triad:</strong> (1) New headache (temporal, severe, unilateral or bilateral, different from prior headaches), (2) Jaw claudication (pain/fatigue in jaw/tongue with chewing, resolves with rest - 50% of patients, HIGHLY SPECIFIC for GCA), (3) Vision changes (transient vision loss/amaurosis fugax, diplopia, or permanent vision loss - 15-20%). Other symptoms: scalp tenderness (combing hair painful), constitutional symptoms (fever, malaise, weight loss, anorexia), tongue claudication, neck/throat pain</li>
                <li><strong>Associated Polymyalgia Rheumatica (PMR):</strong> Bilateral shoulder and hip girdle pain/stiffness, worse in morning, difficulty raising arms or getting out of chair. 50% of GCA patients have concurrent PMR. PMR without GCA is more common</li>
                <li><strong>Physical Exam:</strong> Temporal artery abnormalities (prominent, tender, nodular, pulseless temporal artery - 50%), scalp tenderness over temporal region, visual field defects, decreased visual acuity, relative afferent pupillary defect (RAPD), fundoscopy shows swollen pale optic disc (AION) or normal (posterior AION), limited shoulder/hip range of motion (if PMR)</li>
                <li><strong>Variants/Subtypes:</strong> Cranial GCA (temporal artery involvement, classic symptoms) vs Large-vessel GCA (aorta, subclavian, axillary arteries, often subclinical but can cause limb claudication, aortic aneurysm/dissection). GCA with PMR vs GCA without PMR. Occult GCA (atypical presentation: fever of unknown origin, unexplained anemia, no headache)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Laboratory Studies:</strong></p>
            <ul>
                <li><strong>Erythrocyte Sedimentation Rate (ESR):</strong> Markedly elevated (>50 mm/hr, often 70-120 mm/hr). ESR >100 mm/hr is 90% specific but only 40% sensitive. Normal ESR (<40 mm/hr) makes GCA unlikely but does NOT rule it out (10% of biopsy-proven GCA have ESR <50)</li>
                <li><strong>C-Reactive Protein (CRP):</strong> Elevated (>10 mg/dL, often 20-50 mg/dL). More sensitive than ESR. CRP >2.45 mg/dL has 97% negative predictive value (normal CRP makes GCA very unlikely)</li>
                <li><strong>Complete Blood Count:</strong> Normocytic anemia (anemia of chronic disease, Hgb 9-11 g/dL), thrombocytosis (platelets >400,000/ÂµL common)</li>
                <li><strong>Basic Metabolic Panel:</strong> Usually normal. Assess baseline renal function before high-dose steroids</li>
                <li><strong>Liver Function Tests:</strong> Alkaline phosphatase often elevated (2-3Ã— ULN). Transaminases may be mildly elevated</li>
            </ul>
            
            <p><strong>Temporal Artery Biopsy (Gold Standard):</strong></p>
            <ul>
                <li><strong>Indications:</strong> All suspected GCA cases to confirm diagnosis (allows eventual steroid taper, confirms need for long-term treatment)</li>
                <li><strong>Timing:</strong> Can be done within 2 weeks of starting steroids (steroid effect on biopsy is delayed 2-4 weeks). Do NOT delay steroids to get biopsy - start prednisone immediately, then biopsy within 1-2 weeks</li>
                <li><strong>Technique:</strong> Excisional biopsy of 2-3 cm segment of temporal artery (skip lesions common, long segment needed). Bilateral biopsy increases yield by 10-15% if unilateral negative</li>
                <li><strong>Histopathology:</strong> Granulomatous inflammation with multinucleated giant cells (classic but present in only 50%), intimal hyperplasia, fragmentation of internal elastic lamina, transmural mononuclear infiltrate. Negative biopsy does NOT rule out GCA (skip lesions, sampling error)</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>Ultrasound Temporal Arteries:</strong> "Halo sign" - hypoechoic circumferential wall thickening around temporal artery lumen. 70-90% sensitive, 90-95% specific. Non-invasive, can be done at bedside. May replace biopsy in some centers if expertise available. Steroid therapy reduces sensitivity after 3-7 days</li>
                <li><strong>CT Angiography or MR Angiography (CTA/MRA):</strong> For large-vessel GCA. Shows aortic/subclavian/axillary artery wall thickening, stenosis, aneurysm. Useful if cranial symptoms absent but high clinical suspicion</li>
                <li><strong>PET-CT:</strong> Shows FDG uptake in inflamed large vessels (aorta, subclavian). High sensitivity for large-vessel GCA. Not readily available, expensive</li>
                <li><strong>Ophthalmology Evaluation (URGENT if vision symptoms):</strong> Visual acuity, visual fields, fundoscopy (optic disc edema/pallor), RAPD assessment. Repeat exams to monitor for progression</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>IMMEDIATE MANAGEMENT - START STEROIDS WITHOUT DELAY:</strong></p>
            <ul>
                <li><strong>CRITICAL: Do NOT wait for temporal artery biopsy to start treatment. Permanent blindness can occur within hours to days if untreated. Start prednisone IMMEDIATELY based on clinical suspicion.</strong></li>
                <li>Temporal artery biopsy remains positive for 2-4 weeks after starting steroids - there is NO urgency to get biopsy before steroids</li>
            </ul>
            
            <p><strong>Glucocorticoid Therapy (Cornerstone of Treatment):</strong></p>
            <ul>
                <li><strong>WITHOUT Vision Loss (Cranial Symptoms Only):</strong>
                    <ul>
                        <li><strong>Prednisone 1 mg/kg PO daily (typically 40-60 mg daily)</strong>. Start immediately</li>
                        <li>Clinical improvement (headache resolves) within 24-48 hours confirms diagnosis</li>
                        <li>Maintain 40-60 mg daily Ã— 4 weeks, then taper SLOWLY by 5-10 mg every 2-4 weeks</li>
                        <li>Total treatment duration: 12-24 months (or longer if relapse occurs)</li>
                        <li>Monitor ESR/CRP to guide taper (keep <20 mm/hr and <1 mg/dL)</li>
                    </ul>
                </li>
                <li><strong>WITH Vision Loss or Impending Vision Loss (Amaurosis Fugax, Diplopia):</strong>
                    <ul>
                        <li><strong>High-Dose IV Methylprednisolone ("Pulse Therapy"):</strong> 500-1000 mg IV daily Ã— 3 days</li>
                        <li>After 3 days IV, transition to prednisone 1 mg/kg PO daily (60-80 mg)</li>
                        <li>Rationale: Higher tissue steroid levels may prevent progression to complete vision loss or involvement of contralateral eye. Evidence is limited but standard practice</li>
                        <li>Ophthalmology consult URGENT (same day)</li>
                    </ul>
                </li>
                <li><strong>Steroid Taper (Very Gradual):</strong>
                    <ul>
                        <li>Month 1-2: 40-60 mg daily</li>
                        <li>Month 2-4: Taper by 5-10 mg every 2 weeks to 20 mg daily</li>
                        <li>Month 4-12: Taper by 2.5 mg every 2-4 weeks to 10 mg daily</li>
                        <li>Month 12-24: Taper by 1 mg every 1-2 months, goal discontinuation at 12-24 months</li>
                        <li>Relapse rate 50% during taper - increase dose if symptoms recur or ESR/CRP rise</li>
                    </ul>
                </li>
                <li><strong>Steroid-Related Prophylaxis:</strong>
                    <ul>
                        <li>PPI (pantoprazole 40 mg PO daily) for GI protection</li>
                        <li>Calcium 1200 mg + Vitamin D 800-1000 IU daily for osteoporosis prevention</li>
                        <li>Consider bisphosphonate (alendronate 70 mg PO weekly) if high fracture risk (DEXA T-score <-1.5, age >65, prednisone >7.5 mg/day for >3 months)</li>
                        <li>Pneumocystis prophylaxis (TMP-SMX DS 3Ã—/week) if prednisone >20 mg/day for >1 month</li>
                        <li>Blood glucose monitoring (steroids cause hyperglycemia)</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Steroid-Sparing Agents (For Relapsing Disease or Steroid Toxicity):</strong></p>
            <ul>
                <li><strong>Methotrexate:</strong> 10-25 mg PO/SC weekly. Reduces steroid requirement and relapse rate. Start when prednisone <20 mg/day during taper. Give with folic acid 1 mg daily. Monitor CBC, LFTs, creatinine</li>
                <li><strong>Tocilizumab (Actemra) - FDA Approved for GCA:</strong> IL-6 receptor antagonist. 162 mg SC weekly or every other week. GiACTA trial showed 50% steroid-free remission at 1 year vs 10% with prednisone alone. Consider for: refractory GCA, relapsing disease, or high steroid toxicity risk (diabetes, osteoporosis, prior fractures). Very expensive (~$40,000/year)</li>
                <li><strong>Azathioprine:</strong> 1-2 mg/kg/day PO (typically 100-150 mg daily). Alternative steroid-sparing agent if methotrexate contraindicated or ineffective</li>
            </ul>
            
            <p><strong>Aspirin (Antiplatelet Therapy):</strong></p>
            <ul>
                <li>Aspirin 81-100 mg PO daily. Observational data suggests reduced ischemic complications (vision loss, stroke, MI). No contraindication â†’ start aspirin</li>
            </ul>
            
            <p><strong>Rheumatology Consultation:</strong></p>
            <ul>
                <li>MANDATORY for all suspected or confirmed GCA</li>
                <li>Assists with diagnosis, steroid taper, management of relapses, steroid-sparing agents</li>
            </ul>
            
            <p><strong>Ophthalmology Consultation:</strong></p>
            <ul>
                <li>URGENT (same day) if ANY vision symptoms (vision loss, amaurosis fugax, diplopia)</li>
                <li>Baseline evaluation if no vision symptoms, repeat if symptoms develop</li>
            </ul>
            
            <p><strong>Temporal Artery Biopsy:</strong></p>
            <ul>
                <li>Schedule within 1-2 weeks of starting steroids (no urgency, biopsy positive for 2-4 weeks after steroids)</li>
                <li>Surgical/vascular surgery consultation for biopsy</li>
            </ul>
            
            <p><strong>Monitoring:</strong></p>
            <ul>
                <li>ESR/CRP at each visit (every 2-4 weeks during taper). Goal: ESR <20 mm/hr, CRP <1 mg/dL</li>
                <li>Clinical symptoms (headache, jaw claudication, vision changes, PMR symptoms)</li>
                <li>Monitor for steroid side effects: blood glucose, blood pressure, weight, mood, bone density (DEXA scan baseline and q1-2 years)</li>
                <li>Vision monitoring: Any new vision symptoms â†’ URGENT ophthalmology evaluation</li>
            </ul>
            
            <p><strong>Disposition:</strong></p>
            <ul>
                <li>Admission: Vision loss (any degree), impending vision loss (amaurosis fugax, diplopia), inability to take oral medications, need for IV pulse steroids, need for close monitoring</li>
                <li>Discharge: Stable without vision symptoms, able to take oral prednisone, close rheumatology follow-up arranged (within 1-2 weeks), temporal artery biopsy scheduled</li>
            </ul>
        </div>
    </div>
            <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Giant Cell Arteritis is an Ophthalmologic Emergency - Start Prednisone Immediately:</strong> Untreated GCA causes permanent blindness in 50-70% of patients (anterior ischemic optic neuropathy from ophthalmic artery occlusion). Vision loss is IRREVERSIBLE once it occurs. Time to blindness after symptom onset is unpredictable - can be days to weeks. If clinical suspicion is high (age >50, new headache, jaw claudication, elevated ESR >50), START PREDNISONE 1 mg/kg (40-60 mg daily) IMMEDIATELY. Do NOT wait for temporal artery biopsy - biopsy remains positive for 2-4 weeks after starting steroids. Delaying treatment to get biopsy first is malpractice.</li>
            <li><strong>Jaw Claudication is the Most Specific Symptom for GCA:</strong> Jaw/tongue pain or fatigue with chewing that resolves with rest (jaw claudication) is present in 50% of GCA patients and is 90% specific for the diagnosis. Mechanism: ischemia of masseter muscles from facial/maxillary artery involvement. If patient has jaw claudication + elevated ESR, think GCA. Other specific symptoms: scalp tenderness (painful to comb hair, tender temporal artery), tongue claudication, diplopia from ischemic ophthalmoplegia. Headache alone is sensitive but NOT specific.</li>
            <li><strong>Normal ESR Does NOT Rule Out GCA:</strong> Classic teaching: ESR >50 mm/hr (often >100) is required for GCA. However, 10-15% of biopsy-proven GCA have ESR <50 mm/hr. If clinical suspicion is high (age >70, new headache, jaw claudication, vision symptoms), do NOT rely on ESR alone. Check CRP (more sensitive) - CRP >2.45 mg/dL has 97% NPV. If both ESR and CRP are normal, GCA is very unlikely. But if high clinical suspicion persists despite normal labs, still consider treatment and pursue biopsy/imaging.</li>
            <li><strong>Temporal Artery Biopsy Can Be Done Up to 2-4 Weeks After Starting Steroids:</strong> Histologic changes persist for 2-4 weeks after steroid initiation. This allows time to schedule biopsy without urgency. DO NOT delay steroids to rush biopsy - vision loss can occur while waiting. Instead: start prednisone immediately, schedule biopsy for next 1-2 weeks. Biopsy confirms diagnosis, allowing eventual steroid taper with confidence. Negative biopsy does NOT rule out GCA (skip lesions, sampling error) - treat based on clinical picture. Some centers use temporal artery ultrasound (halo sign) instead of biopsy if expertise available.</li>
            <li><strong>High-Dose IV Methylprednisolone for Vision Loss or Impending Vision Loss:</strong> If patient has vision loss (any degree) or transient vision loss (amaurosis fugax) or diplopia, give IV methylprednisolone 500-1000 mg daily Ã— 3 days before transitioning to oral prednisone. Rationale: higher tissue steroid concentration may prevent progression to complete blindness or involvement of second eye (15% develop bilateral blindness if first eye already affected). Evidence is limited but this is standard practice. Urgently consult ophthalmology. Vision loss is often permanent despite steroids, but early treatment may salvage some vision.</li>
            <li><strong>Steroid Taper in GCA is VERY Slow (12-24 Months Total):</strong> GCA requires prolonged steroid therapy. Too-rapid taper causes relapse (50% relapse rate). Typical taper: start 40-60 mg prednisone daily Ã— 4 weeks, taper by 5-10 mg every 2 weeks to 20 mg, then taper by 2.5 mg every 2-4 weeks to 10 mg, then taper by 1 mg every 1-2 months. Total duration 12-24 months. Monitor ESR/CRP at each visit (goal ESR <20, CRP <1). If relapse (symptoms recur, ESR/CRP rise), increase prednisone back to last effective dose, then resume slower taper. Patients need extensive education on long-term steroids and side effects.</li>
            <li><strong>Tocilizumab (Actemra) is FDA-Approved Steroid-Sparing Agent for GCA:</strong> Tocilizumab is an IL-6 receptor antagonist (GCA is IL-6 driven). GiACTA trial showed 162 mg SC weekly or every other week achieved steroid-free remission in 50% at 1 year (vs 10% with prednisone alone) and reduced cumulative steroid dose by 50%. Indications: relapsing GCA (cannot taper steroids without flare), high steroid toxicity risk (diabetes, osteoporosis, prior fractures, steroid psychosis), or inability to tolerate prolonged steroids. Very expensive (~$40,000/year) but can prevent steroid-related complications. Alternative steroid-sparing agents: methotrexate 15-25 mg weekly (less effective than tocilizumab but much cheaper).</li>
            <li><strong>Polymyalgia Rheumatica and GCA are Related - 50% Overlap:</strong> PMR is bilateral shoulder/hip girdle pain and stiffness (worse in morning, difficulty raising arms or getting out of chair) with elevated ESR. 50% of GCA patients have concurrent PMR. 15-20% of PMR patients develop GCA. PMR without GCA is treated with lower-dose prednisone (15-20 mg daily), GCA requires higher dose (40-60 mg). If patient with "PMR" develops headache, jaw claudication, or vision symptoms â†’ think GCA, increase steroids to GCA dose immediately. Always ask PMR patients about cranial symptoms at each visit.</li>
            <li><strong>Large-Vessel GCA Can Be Occult Without Cranial Symptoms:</strong> GCA affects aorta and large vessels (subclavian, axillary, carotid) in 30-40% of cases. Large-vessel GCA can present without temporal headache or jaw claudication. Clues: unexplained fever of unknown origin, elevated ESR/CRP, unexplained anemia, upper extremity claudication (subclavian stenosis), asymmetric blood pressures between arms, aortic aneurysm/dissection. Diagnose with CTA/MRA chest showing arterial wall thickening, stenosis. Treat with prednisone like cranial GCA. Prognosis same if treated, but diagnosis often delayed.</li>
            <li><strong>Aspirin Reduces Ischemic Complications in GCA:</strong> Observational studies show aspirin 75-100 mg daily reduces cranial ischemic events (vision loss, stroke, TIA) by 70-80% in GCA. Mechanism: antiplatelet effect prevents thrombosis in inflamed stenotic vessels. All GCA patients should receive aspirin 81-100 mg daily UNLESS contraindications (active bleeding, severe thrombocytopenia). Combine with steroids from day 1. Low bleeding risk on low-dose aspirin + prednisone. Aspirin is not a substitute for steroids - always give both.</li>
        </ul>
    </div>
            
            <div class="two-column">
                <div class="box">
        <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
        <ul>
            <li>Acute vision loss (any degree) in one or both eyes</li>
            <li>Amaurosis fugax (transient vision loss) - high risk of permanent blindness</li>
            <li>Stroke or TIA from GCA-related vasculitis</li>
            <li>Aortic dissection or rupture (rare complication of aortic GCA)</li>
            <li>Severe hypertension requiring IV antihypertensives</li>
            <li>Hemodynamic instability</li>
            <li>Need for frequent neurologic or ophthalmologic monitoring</li>
        </ul>
    </div>
                
                <div class="box">
        <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
        <ul>
            <li>No vision loss or impending vision loss (no amaurosis fugax, no diplopia)</li>
            <li>Able to take oral prednisone (1 mg/kg/day, typically 40-60 mg daily)</li>
            <li>Clinical improvement of symptoms (headache improved within 24-48 hours confirms diagnosis and response)</li>
            <li>Temporal artery biopsy scheduled (within 1-2 weeks of steroid initiation)</li>
            <li>Close rheumatology follow-up arranged (within 1-2 weeks)</li>
            <li>Ophthalmology follow-up arranged if any vision concerns</li>
            <li>Patient educated on warning signs to return: vision changes, severe headache recurrence, jaw claudication recurrence</li>
            <li>Prescriptions provided: prednisone with clear instructions, PPI, calcium/vitamin D, aspirin</li>
            <li>Patient understands need for prolonged steroid therapy (12-24 months) with slow taper</li>
        </ul>
    </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="ards" class="condition-page">
    <div class="page-header">
        <h2>119. ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME)</h2>
        <div class="subtitle">Berlin Criteria â€¢ P/F Ratio â€¢ Lung-Protective Ventilation â€¢ Prone Positioning</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Acute onset of severe hypoxemic respiratory failure within 1 week of known clinical insult, with bilateral opacities on CXR/CT not fully explained by effusions, lobar collapse, or nodules.</p>
            <p><span class="label">Key Features:</span></p>
            <ul>
                <li><strong>Timing:</strong> Acute onset within 1 week of known clinical insult or new/worsening respiratory symptoms</li>
                <li><strong>Hypoxemia:</strong> PaO2/FiO2 ratio â‰¤300 mmHg with PEEP â‰¥5 cm H2O</li>
                <li><strong>Bilateral infiltrates:</strong> On CXR or CT, not fully explained by effusions, collapse, or nodules</li>
                <li><strong>Non-cardiogenic:</strong> Respiratory failure not fully explained by cardiac failure or fluid overload (may need echo to rule out)</li>
            </ul>
            <p><span class="label">Common Etiologies:</span></p>
            <ul>
                <li><strong>Pulmonary (Direct):</strong> Pneumonia (most common), aspiration, pulmonary contusion, inhalation injury, drowning</li>
                <li><strong>Extrapulmonary (Indirect):</strong> Sepsis (most common), pancreatitis, trauma, massive transfusion (TRALI), burns, drug overdose</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Berlin Criteria (2012) - All 4 Required:</span></p>
            <ul>
                <li><strong>Timing:</strong> Within 1 week of known clinical insult or new/worsening respiratory symptoms</li>
                <li><strong>Imaging:</strong> Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules</li>
                <li><strong>Origin of edema:</strong> Not fully explained by cardiac failure or fluid overload</li>
                <li><strong>Oxygenation (with PEEP â‰¥5):</strong> Mild (P/F 200-300), Moderate (P/F 100-200), Severe (P/F <100)</li>
            </ul>
            <p><span class="label">Labs:</span> ABG (P/F ratio calculation), CBC, CMP, lactate, procalcitonin, blood cultures, BNP/NT-proBNP (rule out cardiogenic)</p>
            <p><span class="label">Imaging:</span> CXR (bilateral infiltrates), CT chest if diagnostic uncertainty, Echo (rule out cardiogenic pulmonary edema, assess RV function)</p>
            <p><span class="label">Additional:</span> BAL if pneumonia suspected, respiratory viral panel, consider bronchoscopy</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">SEVERITY CLASSIFICATION (P/F Ratio with PEEP â‰¥5)</div>
        <div class="section-content">
            <ul>
                <li><strong>Mild ARDS:</strong> P/F 201-300 mmHg (mortality ~27%)</li>
                <li><strong>Moderate ARDS:</strong> P/F 101-200 mmHg (mortality ~32%)</li>
                <li><strong>Severe ARDS:</strong> P/F â‰¤100 mmHg (mortality ~45%)</li>
            </ul>
            <p><span class="label">P/F Ratio Calculation:</span> PaO2 (from ABG) Ã· FiO2 (as decimal). Example: PaO2 80 on 60% FiO2 = 80/0.6 = 133 (moderate ARDS)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Lung-Protective Ventilation (ARDSNet Protocol):</span></p>
            <ul>
                <li><strong>Low Tidal Volume:</strong> 6 mL/kg PREDICTED body weight (PBW), range 4-8 mL/kg</li>
                <li><strong>PBW Calculation:</strong> Male: 50 + 2.3 Ã— (height in inches - 60); Female: 45.5 + 2.3 Ã— (height in inches - 60)</li>
                <li><strong>Plateau Pressure Goal:</strong> â‰¤30 cm H2O (measure with inspiratory hold)</li>
                <li><strong>PEEP:</strong> Use ARDSNet PEEP/FiO2 tables, start moderate PEEP (8-12), titrate up for refractory hypoxemia</li>
                <li><strong>Driving Pressure:</strong> Target <15 cm H2O (Driving Pressure = Plateau Pressure - PEEP)</li>
                <li><strong>Permissive Hypercapnia:</strong> Accept pH >7.20, PaCO2 up to 60-80 if needed to maintain lung protection</li>
            </ul>
            <p><span class="label">Oxygenation Goals:</span></p>
            <ul>
                <li><strong>SpO2:</strong> 88-95% (avoid hyperoxia)</li>
                <li><strong>PaO2:</strong> 55-80 mmHg</li>
            </ul>
            <p><span class="label">Adjunctive Therapies for Moderate-Severe ARDS:</span></p>
            <ul>
                <li><strong>Prone Positioning:</strong> For P/F <150, prone for â‰¥16 hours/day. Reduces mortality by ~16% in severe ARDS (PROSEVA trial)</li>
                <li><strong>Neuromuscular Blockade:</strong> Consider cisatracurium for 48 hours in severe ARDS with ventilator dyssynchrony (controversial after ROSE trial)</li>
                <li><strong>Conservative Fluid Management:</strong> Target CVP <4 or PAOP <8 after initial resuscitation (FACTT trial - improved ventilator-free days)</li>
                <li><strong>Corticosteroids:</strong> Consider dexamethasone 20mg IV daily Ã— 5 days, then 10mg Ã— 5 days for moderate-severe ARDS (DEXA-ARDS trial)</li>
            </ul>
            <p><span class="label">Refractory Hypoxemia:</span></p>
            <ul>
                <li><strong>Recruitment Maneuvers:</strong> Brief sustained inflation (controversial, use with caution)</li>
                <li><strong>Inhaled Pulmonary Vasodilators:</strong> Inhaled nitric oxide or epoprostenol (rescue therapy, no mortality benefit)</li>
                <li><strong>ECMO:</strong> Consider VV-ECMO for refractory hypoxemia despite optimal ventilation (EOLIA trial)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREAT UNDERLYING CAUSE</div>
        <div class="section-content">
            <ul>
                <li><strong>Sepsis:</strong> Early antibiotics, source control</li>
                <li><strong>Pneumonia:</strong> Broad-spectrum antibiotics, consider fungal/viral coverage</li>
                <li><strong>Aspiration:</strong> Antibiotics only if clear infection (not routine for aspiration pneumonitis)</li>
                <li><strong>Pancreatitis:</strong> Supportive care, NPO, IV fluids</li>
                <li><strong>TRALI:</strong> Supportive care, avoid implicated donor</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>PREDICTED Body Weight is Critical:</strong> ALWAYS use predicted (ideal) body weight for tidal volume calculation, NOT actual weight. Obese patients don't have bigger lungs. Using actual weight in obesity leads to dangerous over-ventilation and VILI.</li>
            <li><strong>Driving Pressure May Be the Best Predictor:</strong> Driving pressure (Plateau - PEEP) <15 is associated with survival benefit. It reflects lung stress better than tidal volume or plateau pressure alone. If Pplat is 28 and PEEP is 16, driving pressure is only 12 - that's good!</li>
            <li><strong>Prone Early and Prone Long:</strong> Don't wait until patient is moribund to prone. Start when P/F <150 and prone for at least 16 hours/day. The PROSEVA trial showed 16% absolute mortality reduction - one of the largest benefits in critical care.</li>
            <li><strong>Conservative Fluids AFTER Resuscitation:</strong> FACTT trial showed benefit of conservative fluid strategy, but this is AFTER initial sepsis resuscitation. Don't withhold fluids from a hypotensive septic patient to "keep lungs dry."</li>
            <li><strong>ARDS is a Syndrome, Not a Disease:</strong> Always search for and treat the underlying cause. ARDS from pneumonia needs antibiotics; ARDS from pancreatitis needs supportive care. The ventilator strategy is the same, but disease-specific treatment differs.</li>
            <li><strong>High PEEP vs. Low PEEP:</strong> Three major trials (ALVEOLI, LOV, ExPress) showed no mortality difference. Use PEEP/FiO2 tables, individualize based on mechanics, and avoid over-distension (watch plateau pressure).</li>
            <li><strong>Don't Anchor on the CXR:</strong> Bilateral infiltrates can look identical in ARDS vs cardiogenic pulmonary edema. Use BNP, echo, clinical context to differentiate. If uncertain, treat both empirically while sorting it out.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>All ARDS patients require ICU care</li>
                <li>Need for invasive mechanical ventilation</li>
                <li>Refractory hypoxemia despite high-flow nasal cannula or NIV</li>
                <li>P/F ratio <200 (moderate-severe ARDS)</li>
                <li>Hemodynamic instability requiring vasopressors</li>
                <li>Need for prone positioning</li>
                <li>Consideration for ECMO</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Liberated from mechanical ventilation for >48 hours</li>
                <li>Stable on room air or low-flow O2 (â‰¤4L NC) with SpO2 >92%</li>
                <li>P/F ratio >300 on room air or minimal supplemental O2</li>
                <li>Underlying cause treated and resolving</li>
                <li>No ongoing need for ICU-level monitoring</li>
                <li>Pulmonary rehab referral if prolonged ventilation</li>
                <li>Follow-up arranged (pulmonary clinic in 2-4 weeks)</li>
                <li>Patient educated on gradual recovery timeline (weeks to months)</li>
            </ul>
        </div>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="pulmonary-edema" class="condition-page">
    <div class="page-header">
        <h2>120. ACUTE PULMONARY EDEMA / FLASH PULMONARY EDEMA</h2>
        <div class="subtitle">Cardiogenic vs Non-Cardiogenic â€¢ BiPAP â€¢ Diuresis â€¢ Afterload Reduction</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Acute onset severe dyspnea, orthopnea, pink frothy sputum, diffuse crackles/rales, hypoxemia. Often with hypertension, tachycardia, diaphoresis, and anxiety ("air hunger").</p>
            <p><span class="label">Flash Pulmonary Edema:</span> Rapid onset (minutes to hours), often with severe hypertension, may occur without significant fluid overload. Common in renal artery stenosis, acute MR, acute MI, and hypertensive crisis.</p>
            <p><span class="label">Key Features:</span></p>
            <ul>
                <li><strong>Symptoms:</strong> Severe dyspnea, orthopnea, PND, cough with pink frothy sputum</li>
                <li><strong>Signs:</strong> Tachypnea, hypoxemia, diffuse crackles, JVD, S3 gallop, lower extremity edema (may be absent in flash)</li>
                <li><strong>Vital Signs:</strong> Hypertension common (may be hypotensive if cardiogenic shock), tachycardia, low SpO2</li>
            </ul>
            <p><span class="label">Differentiate from ARDS:</span></p>
            <ul>
                <li><strong>Cardiogenic Pulmonary Edema:</strong> Elevated BNP (>500), elevated PCWP (>18), rapid response to diuretics/nitrates, cardiac history</li>
                <li><strong>ARDS/Non-cardiogenic:</strong> Normal/low BNP, normal PCWP, clear precipitant (sepsis, pneumonia), no response to diuretics</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Immediate:</span> SpO2, ECG (ischemia, arrhythmia), CXR (cardiomegaly, cephalization, Kerley B lines, effusions, bat-wing infiltrates)</p>
            <p><span class="label">Labs:</span> BNP/NT-proBNP (elevated in cardiogenic), troponin (rule out ACS), BMP (renal function, electrolytes), CBC, ABG if severe</p>
            <p><span class="label">Imaging:</span> CXR portable, bedside echo (LV function, valve pathology, pericardial effusion), lung ultrasound (B-lines)</p>
            <p><span class="label">Consider:</span> CT chest if uncertain etiology, cardiac catheterization if ACS suspected</p>
            <p><span class="label">BNP Interpretation:</span></p>
            <ul>
                <li>BNP <100 pg/mL or NT-proBNP <300 pg/mL: Heart failure unlikely</li>
                <li>BNP >400 pg/mL or NT-proBNP >900 pg/mL (age <50) / >1800 (age >50): Heart failure likely</li>
                <li>Gray zone values: Use clinical context</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Immediate Interventions (First 30 Minutes):</span></p>
            <ul>
                <li><strong>Position:</strong> Sit patient upright (reduces preload)</li>
                <li><strong>Oxygen:</strong> High-flow O2, target SpO2 >92%</li>
                <li><strong>BiPAP/CPAP:</strong> First-line respiratory support. BiPAP 10/5, titrate to 15/10. Reduces preload, afterload, and work of breathing. Decreases intubation rates by 50%</li>
                <li><strong>IV Access:</strong> Establish immediately for medications</li>
            </ul>
            <p><span class="label">Medical Therapy:</span></p>
            <ul>
                <li><strong>Furosemide:</strong> 40-80mg IV (or 2.5Ã— home dose if on chronic diuretics). Can repeat in 30-60 min if inadequate response. Target urine output 100-150 mL/hr initially</li>
                <li><strong>Nitroglycerin:</strong> 400mcg SL q5min Ã— 3, then IV infusion 10-20 mcg/min, titrate to 200 mcg/min for BP control. AVOID if SBP <90 or recent PDE5 inhibitor</li>
                <li><strong>Morphine:</strong> 2-4mg IV - controversial, may cause respiratory depression. Consider for severe anxiety/dyspnea only. Generally avoid</li>
            </ul>
            <p><span class="label">Hypertensive Pulmonary Edema (SBP >140):</span></p>
            <ul>
                <li><strong>Goal:</strong> Reduce SBP by 25% in first hour</li>
                <li><strong>Preferred agents:</strong> IV nitroglycerin (vasodilator), IV nicardipine (if refractory HTN), nitroprusside (if severe, watch for cyanide toxicity)</li>
                <li><strong>Avoid:</strong> Beta-blockers acutely (negative inotropy), excessive diuresis before afterload reduction</li>
            </ul>
            <p><span class="label">Hypotensive Pulmonary Edema (Cardiogenic Shock):</span></p>
            <ul>
                <li><strong>Vasopressors:</strong> Norepinephrine first-line if SBP <90</li>
                <li><strong>Inotropes:</strong> Dobutamine or milrinone if low output state</li>
                <li><strong>Mechanical support:</strong> IABP, Impella, or ECMO if refractory</li>
                <li><strong>Avoid:</strong> Aggressive diuresis without hemodynamic support</li>
            </ul>
            <p><span class="label">Refractory Cases:</span></p>
            <ul>
                <li><strong>Ultrafiltration:</strong> Consider if diuretic-resistant</li>
                <li><strong>Intubation:</strong> If failing BiPAP, declining mental status, or severe acidosis</li>
                <li><strong>Urgent cardiology/cardiac surgery:</strong> If acute valvular pathology (acute MR, acute AI)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">IDENTIFY AND TREAT PRECIPITANTS</div>
        <div class="section-content">
            <ul>
                <li><strong>ACS:</strong> Troponin, ECG â†’ cardiology/cath lab</li>
                <li><strong>Arrhythmia:</strong> Rate control for AF with RVR, cardioversion if unstable</li>
                <li><strong>Hypertensive crisis:</strong> Aggressive BP control</li>
                <li><strong>Acute valvular disease:</strong> Urgent echo, surgical evaluation</li>
                <li><strong>Medication non-adherence:</strong> Restart home medications</li>
                <li><strong>Dietary indiscretion:</strong> Sodium/fluid restriction education</li>
                <li><strong>Renal artery stenosis:</strong> Consider if flash pulmonary edema with minimal fluid overload</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>BiPAP is a Diuretic:</strong> Not really, but BiPAP reduces preload (positive intrathoracic pressure decreases venous return) and afterload (reduces LV transmural pressure). Many patients improve dramatically on BiPAP before diuretics even kick in. Don't skip BiPAP!</li>
            <li><strong>Flash Pulmonary Edema â‰  Fluid Overload:</strong> Flash pulmonary edema is often due to acute afterload increase (hypertensive crisis) or acute valvular pathology, NOT total body volume overload. These patients may have normal weight and no peripheral edema. Treat with vasodilators, not just diuretics.</li>
            <li><strong>Renal Artery Stenosis Pearl:</strong> Bilateral RAS is a classic cause of "flash pulmonary edema" - acute, severe pulmonary edema that resolves quickly but recurs. Suspect in patients with resistant hypertension, acute rise in creatinine with ACE-I, or minimal peripheral edema during episodes.</li>
            <li><strong>Morphine is Falling Out of Favor:</strong> Traditional teaching was "LMNOP" (Lasix, Morphine, Nitrates, Oxygen, Position). However, morphine may increase mortality in acute heart failure (observational data). Reserve for severe anxiety/dyspnea only, and use with caution.</li>
            <li><strong>Wet and Warm vs. Wet and Cold:</strong> "Wet and warm" (congested but adequate perfusion) - diurese aggressively. "Wet and cold" (congested AND hypoperfused) - need inotropes/vasopressors before aggressive diuresis or patient will crash.</li>
            <li><strong>The BNP Gray Zone:</strong> BNP 100-400 is the "gray zone." Use clinical context: obese patients have lower BNP, renal failure causes higher BNP, AF causes higher BNP. Trend from baseline is often more useful than absolute value.</li>
            <li><strong>Don't Forget the Echo:</strong> Bedside echo in the ED/ICU can rapidly differentiate cardiogenic (reduced EF, elevated E/e', valve pathology) from non-cardiogenic (normal LV function) pulmonary edema. This guides therapy immediately.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Requiring intubation or failing BiPAP</li>
                <li>Hypotension (SBP <90) or cardiogenic shock</li>
                <li>Need for IV vasoactive medications (pressors, inotropes, nitroprusside)</li>
                <li>Acute coronary syndrome as precipitant</li>
                <li>New/worsening acute valvular pathology</li>
                <li>Refractory hypoxemia despite BiPAP</li>
                <li>Hemodynamic instability or arrhythmias</li>
                <li>Need for mechanical circulatory support</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Symptoms resolved or returned to baseline</li>
                <li>Off supplemental O2 or at baseline O2 requirement</li>
                <li>Stable on oral diuretics with adequate urine output</li>
                <li>Weight stable or decreasing (not gaining)</li>
                <li>No IV vasoactive medications for >24 hours</li>
                <li>Precipitant identified and addressed</li>
                <li>Transitioned to oral heart failure medications</li>
                <li>Cardiology follow-up within 7 days</li>
                <li>Patient educated on daily weights, sodium restriction, medication adherence</li>
                <li>Clear return precautions given</li>
            </ul>
        </div>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="viral-hepatitis" class="condition-page">
    <div class="page-header">
        <h2>121. VIRAL HEPATITIS (ACUTE)</h2>
        <div class="subtitle">HAV â€¢ HBV â€¢ HCV â€¢ Acute Liver Failure Risk â€¢ Serologic Diagnosis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Prodrome of fatigue, malaise, anorexia, nausea, RUQ discomfort, followed by jaundice, dark urine (bilirubinuria), pale stools. May have low-grade fever. Many cases are anicteric (subclinical).</p>
            <p><span class="label">By Virus Type:</span></p>
            <ul>
                <li><strong>Hepatitis A (HAV):</strong> Fecal-oral transmission, travel to endemic areas, contaminated food/water, MSM, IVDU. Acute onset, self-limited, no chronic state. Peak ALT often >1000</li>
                <li><strong>Hepatitis B (HBV):</strong> Blood/body fluid exposure (sexual, perinatal, needlestick, IVDU). Incubation 6 weeks-6 months. May become chronic (90% if perinatal, 5% if adult-acquired)</li>
                <li><strong>Hepatitis C (HCV):</strong> Blood exposure (IVDU most common, transfusion before 1992, needlestick). Often asymptomatic acutely. 75-85% become chronic</li>
                <li><strong>Hepatitis D (HDV):</strong> Only with HBV co-infection (requires HBsAg). More severe disease</li>
                <li><strong>Hepatitis E (HEV):</strong> Fecal-oral, endemic in developing countries. Self-limited except in pregnancy (high mortality) and immunocompromised (can become chronic)</li>
            </ul>
            <p><span class="label">Severity Spectrum:</span></p>
            <ul>
                <li><strong>Mild:</strong> Elevated transaminases, no jaundice, preserved synthetic function</li>
                <li><strong>Moderate:</strong> Jaundice, symptoms, but normal INR and mental status</li>
                <li><strong>Severe/Fulminant:</strong> Coagulopathy (INR >1.5), encephalopathy â†’ acute liver failure (ALF)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Initial Labs:</span> AST/ALT (often >10Ã— ULN in acute viral), total/direct bilirubin, alkaline phosphatase, GGT, albumin, INR/PT, CBC</p>
            <p><span class="label">Viral Serologies:</span></p>
            <ul>
                <li><strong>Hepatitis A:</strong> IgM anti-HAV (acute), IgG anti-HAV (past infection/immunity)</li>
                <li><strong>Hepatitis B:</strong> HBsAg, anti-HBs, anti-HBc (IgM for acute, total for any exposure), HBeAg, anti-HBe, HBV DNA</li>
                <li><strong>Hepatitis C:</strong> Anti-HCV (screen), HCV RNA (confirmatory, also for acute infection before antibody develops)</li>
                <li><strong>Hepatitis D:</strong> Anti-HDV (only if HBsAg positive)</li>
                <li><strong>Hepatitis E:</strong> IgM anti-HEV (if travel to endemic area, pregnant, immunocompromised)</li>
            </ul>
            <p><span class="label">HBV Serology Interpretation:</span></p>
            <ul>
                <li><strong>Acute HBV:</strong> HBsAg+, IgM anti-HBc+, anti-HBs-</li>
                <li><strong>Chronic HBV:</strong> HBsAg+, IgM anti-HBc-, anti-HBs-</li>
                <li><strong>Resolved HBV:</strong> HBsAg-, anti-HBc+, anti-HBs+</li>
                <li><strong>Vaccinated:</strong> HBsAg-, anti-HBc-, anti-HBs+</li>
                <li><strong>Isolated anti-HBc:</strong> Window period, resolved with waned anti-HBs, occult HBV, or false positive</li>
            </ul>
            <p><span class="label">Additional Studies:</span> RUQ ultrasound (rule out biliary obstruction), consider other causes of acute hepatitis (autoimmune hepatitis panel, Wilson's, drug-induced)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">General Supportive Care (All Types):</span></p>
            <ul>
                <li><strong>Hydration:</strong> IV fluids if poor oral intake or vomiting</li>
                <li><strong>Antiemetics:</strong> Ondansetron for nausea</li>
                <li><strong>Avoid hepatotoxins:</strong> No alcohol, minimize acetaminophen, review all medications</li>
                <li><strong>Avoid sedatives:</strong> Risk of encephalopathy if liver function declining</li>
                <li><strong>Contact precautions:</strong> HAV and HEV (fecal-oral)</li>
            </ul>
            <p><span class="label">Hepatitis A:</span></p>
            <ul>
                <li>Supportive care only - self-limited</li>
                <li>Post-exposure prophylaxis for close contacts: HAV vaccine (preferred if age 1-40) or IG (if <1 or >40, immunocompromised)</li>
                <li>Rarely causes acute liver failure (<1%)</li>
            </ul>
            <p><span class="label">Hepatitis B (Acute):</span></p>
            <ul>
                <li>Most adults clear spontaneously (95%) - supportive care</li>
                <li><strong>Antiviral therapy indicated if:</strong> Severe/protracted course, acute liver failure, immunocompromised</li>
                <li><strong>Preferred antivirals:</strong> Tenofovir or entecavir</li>
                <li>Post-exposure prophylaxis: HBIG + vaccine series if unvaccinated exposure</li>
            </ul>
            <p><span class="label">Hepatitis C (Acute):</span></p>
            <ul>
                <li>Spontaneous clearance in 15-25%</li>
                <li>Consider antiviral therapy (direct-acting antivirals) in acute phase - may prevent chronicity</li>
                <li>Consult hepatology - timing of treatment debated (some wait 12-16 weeks to see if spontaneous clearance)</li>
            </ul>
            <p><span class="label">Acute Liver Failure Management:</span></p>
            <ul>
                <li>Transfer to liver transplant center</li>
                <li>Monitor for cerebral edema, coagulopathy, hypoglycemia, infection</li>
                <li>N-acetylcysteine may benefit even in non-acetaminophen ALF (grade I-II encephalopathy)</li>
                <li>Early transplant evaluation - King's College Criteria for prognosis</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>The "Hepatitis A Doesn't Kill" Myth:</strong> While rare (<1%), HAV CAN cause acute liver failure, especially in older adults and those with underlying liver disease. Mortality increases significantly with age. HAV superinfection in chronic HBV or HCV can be devastating - vaccinate these patients!</li>
            <li><strong>IgM Anti-HBc is the Key to Acute HBV:</strong> During the "window period" of acute HBV, HBsAg may be negative (cleared) but anti-HBs hasn't appeared yet. IgM anti-HBc will be positive and is diagnostic. Don't miss acute HBV because you only checked HBsAg.</li>
            <li><strong>Acute HCV is a Diagnosis of Exclusion... Sort Of:</strong> Anti-HCV takes 8-12 weeks to become positive. In acute HCV, you'll have HCV RNA positive with anti-HCV negative or newly positive (document seroconversion). Recent exposure history is key.</li>
            <li><strong>AST/ALT >10,000 is Usually Ischemic, Not Viral:</strong> While viral hepatitis causes very high transaminases, levels >10,000 U/L are more suggestive of ischemic hepatitis (shock liver) or acetaminophen toxicity. Viral hepatitis typically peaks in the 1,000-3,000 range.</li>
            <li><strong>Always Check INR, Not Just Transaminases:</strong> A patient with ALT 50 and INR 3.0 is sicker than a patient with ALT 5000 and INR 1.0. Synthetic function (INR, albumin) reflects true liver function. Transaminases just reflect hepatocyte injury.</li>
            <li><strong>HBV Reactivation is a Real and Preventable Problem:</strong> Always screen for HBsAg and anti-HBc before immunosuppressive therapy (chemo, biologics, high-dose steroids). HBsAg+ or even isolated anti-HBc+ patients need antiviral prophylaxis to prevent potentially fatal reactivation.</li>
            <li><strong>Hepatitis E in Pregnancy is an Emergency:</strong> HEV has 20-25% mortality in pregnant women (especially 3rd trimester). If pregnant patient presents with acute hepatitis and travel to endemic area, test for HEV and consult OB/hepatology immediately.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>INR >1.5 (indicates severe hepatic dysfunction)</li>
                <li>Any sign of hepatic encephalopathy (confusion, asterixis)</li>
                <li>Hypoglycemia (liver unable to maintain glucose)</li>
                <li>Acute kidney injury (hepatorenal physiology)</li>
                <li>Hemodynamic instability</li>
                <li>Need for frequent monitoring (q1-2h labs)</li>
                <li>Consideration for liver transplant evaluation</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Tolerating oral intake without significant nausea/vomiting</li>
                <li>INR â‰¤1.5 and stable or improving</li>
                <li>Bilirubin stable or downtrending (peak may take 1-2 weeks)</li>
                <li>No hepatic encephalopathy</li>
                <li>Transaminases downtrending (don't need to be normal)</li>
                <li>Hepatology/GI follow-up arranged within 1-2 weeks</li>
                <li>Patient educated on alcohol avoidance, hepatotoxic medication avoidance</li>
                <li>Close contacts notified/prophylaxed if HAV or HBV</li>
                <li>Return precautions: confusion, worsening jaundice, bleeding</li>
            </ul>
        </div>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="ischemic-hepatitis" class="condition-page">
    <div class="page-header">
        <h2>122. ISCHEMIC HEPATITIS (SHOCK LIVER)</h2>
        <div class="subtitle">Hypoperfusion Injury â€¢ Massive Transaminase Elevation â€¢ Rapid Resolution</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Dramatic transaminase elevation (often >10,000 U/L) occurring 24-72 hours after an episode of systemic hypoperfusion (cardiogenic shock, septic shock, cardiac arrest, severe hypoxemia). Patient is often critically ill with underlying cause.</p>
            <p><span class="label">The Triad:</span></p>
            <ul>
                <li><strong>Underlying condition causing hypoperfusion:</strong> Heart failure, shock, cardiac arrest, respiratory failure, severe hypotension</li>
                <li><strong>Dramatic transaminase elevation:</strong> AST/ALT often >20Ã— ULN (frequently >5,000-10,000 U/L)</li>
                <li><strong>Rapid improvement:</strong> Transaminases fall 50% within 24-72 hours once perfusion restored</li>
            </ul>
            <p><span class="label">Common Causes:</span></p>
            <ul>
                <li><strong>Cardiac:</strong> Acute heart failure, cardiogenic shock, cardiac arrest, acute MI, arrhythmias with hypotension</li>
                <li><strong>Sepsis:</strong> Septic shock with hypotension</li>
                <li><strong>Respiratory:</strong> Severe hypoxemia, pulmonary embolism, respiratory failure</li>
                <li><strong>Hypovolemic:</strong> Hemorrhagic shock, severe dehydration</li>
                <li><strong>Obstructive:</strong> Massive PE, cardiac tamponade</li>
            </ul>
            <p><span class="label">Key Differentiator:</span> Unlike viral hepatitis or drug-induced liver injury, ischemic hepatitis occurs in the setting of clear hemodynamic instability, and transaminases fall rapidly (often 50% decline in 24-48 hours) once perfusion is restored.</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Laboratory Pattern:</span></p>
            <ul>
                <li><strong>AST/ALT:</strong> Massively elevated, often >5,000-10,000 U/L (can exceed 20,000)</li>
                <li><strong>AST > ALT:</strong> Typically AST predominates early (zone 3 hepatocyte injury)</li>
                <li><strong>LDH:</strong> Markedly elevated (often >5,000 U/L) - released from ischemic hepatocytes</li>
                <li><strong>Bilirubin:</strong> Mildly elevated initially, may rise as transaminases fall (delayed hepatic processing)</li>
                <li><strong>INR:</strong> May be elevated if severe, but often preserved unless prolonged shock</li>
                <li><strong>Lactate:</strong> Often elevated due to underlying shock</li>
            </ul>
            <p><span class="label">Timeline:</span></p>
            <ul>
                <li><strong>Peak transaminases:</strong> 24-72 hours after hypotensive event</li>
                <li><strong>Peak bilirubin:</strong> 48-96 hours (lags behind transaminases)</li>
                <li><strong>Resolution:</strong> Transaminases fall 50% within 24-72 hours if perfusion restored</li>
            </ul>
            <p><span class="label">Exclude Other Causes:</span></p>
            <ul>
                <li><strong>Acetaminophen toxicity:</strong> Check level, history</li>
                <li><strong>Viral hepatitis:</strong> HAV IgM, HBsAg, IgM anti-HBc, HCV RNA</li>
                <li><strong>Budd-Chiari syndrome:</strong> RUQ ultrasound with Doppler (hepatic vein thrombosis)</li>
                <li><strong>Biliary obstruction:</strong> RUQ ultrasound</li>
                <li><strong>Autoimmune hepatitis:</strong> ANA, ASMA, IgG levels (in appropriate clinical context)</li>
            </ul>
            <p><span class="label">Imaging:</span> RUQ ultrasound with Doppler to rule out Budd-Chiari syndrome and biliary obstruction</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Primary Goal: Restore Hepatic Perfusion</span></p>
            <ul>
                <li><strong>Treat underlying cause:</strong> This is the definitive therapy</li>
                <li><strong>Optimize cardiac output:</strong> Treat heart failure, arrhythmias</li>
                <li><strong>Restore blood pressure:</strong> Vasopressors if shock (target MAP >65)</li>
                <li><strong>Correct hypoxemia:</strong> Oxygen, mechanical ventilation if needed</li>
                <li><strong>Volume resuscitation:</strong> If hypovolemic (caution if cardiogenic shock)</li>
            </ul>
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li><strong>Avoid hepatotoxins:</strong> Hold unnecessary medications, avoid acetaminophen</li>
                <li><strong>Monitor for complications:</strong> Hypoglycemia (check glucose q4-6h), coagulopathy (INR), encephalopathy</li>
                <li><strong>Nutrition:</strong> Enteral nutrition when stable, avoid excessive protein restriction unless encephalopathy</li>
                <li><strong>No specific liver-directed therapy:</strong> N-acetylcysteine not proven beneficial (unlike acetaminophen toxicity)</li>
            </ul>
            <p><span class="label">Monitoring:</span></p>
            <ul>
                <li>Daily LFTs initially - expect 50% reduction in transaminases within 24-72 hours</li>
                <li>Monitor INR, glucose, mental status for hepatic dysfunction</li>
                <li>If transaminases NOT falling as expected, reconsider diagnosis</li>
            </ul>
            <p><span class="label">Prognosis:</span></p>
            <ul>
                <li>Mortality primarily determined by underlying condition, not liver injury itself</li>
                <li>If patient survives underlying illness, liver typically recovers completely</li>
                <li>Persistent elevation beyond 7-14 days suggests ongoing injury or alternate diagnosis</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>The "Shock Liver" Misnomer:</strong> Ischemic hepatitis often occurs WITHOUT overt shock. Passive hepatic congestion (right heart failure) + transient hypotension can cause it. Look for JVD, hepatomegaly, and elevated CVP - even brief hypotension in a congested liver can cause massive injury.</li>
            <li><strong>LDH is Your Friend:</strong> Markedly elevated LDH (often >5,000 U/L) with equally elevated AST/ALT strongly suggests ischemic hepatitis over viral or drug-induced. In viral hepatitis, LDH is only mildly elevated. LDH >AST is classic for ischemic hepatitis.</li>
            <li><strong>The 50% Rule:</strong> If transaminases don't fall by ~50% within 48-72 hours of restoring perfusion, reconsider the diagnosis. Viral hepatitis has a more prolonged course. Ongoing shock/hypoperfusion will prevent improvement.</li>
            <li><strong>Don't Chase the Transaminases:</strong> AST 15,000 sounds terrifying, but the absolute number is less important than the trend and synthetic function. A patient with ALT 15,000 and INR 1.1 who is clinically improving will likely be fine. A patient with ALT 500 and INR 4.0 may need transplant evaluation.</li>
            <li><strong>Congestive Hepatopathy vs. Ischemic Hepatitis:</strong> Chronic right heart failure causes congestive hepatopathy (mild transaminase elevation, elevated bilirubin, elevated INR). Acute-on-chronic decompensation with hypotension can cause superimposed ischemic hepatitis (sudden spike in transaminases).</li>
            <li><strong>The Bilirubin Lag:</strong> Don't be surprised when bilirubin rises as transaminases fall - this is expected. Damaged hepatocytes release transaminases immediately but take time to process bilirubin. Peak bilirubin occurs 48-96 hours after the event.</li>
            <li><strong>Zone 3 Necrosis:</strong> The centrilobular hepatocytes (zone 3, around the central vein) are most susceptible to hypoxia because they receive blood AFTER zones 1 and 2 have extracted oxygen. This explains the pattern of injury in ischemic hepatitis and why AST often exceeds ALT early.</li>
            <li><strong>Cardiac Arrest Pearl:</strong> After cardiac arrest with ROSC, expect transaminases to peak at 24-72 hours. This does NOT necessarily predict poor neurologic outcome. The liver usually recovers if the patient survives.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>All patients with ischemic hepatitis require ICU-level care (underlying shock/instability)</li>
                <li>Hemodynamic instability requiring vasopressors</li>
                <li>Respiratory failure requiring mechanical ventilation</li>
                <li>INR >2.0 (suggests severe hepatic dysfunction)</li>
                <li>Hepatic encephalopathy</li>
                <li>Hypoglycemia requiring dextrose infusion</li>
                <li>Underlying cardiac arrest or cardiogenic shock</li>
                <li>Multi-organ failure</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Underlying cause treated and hemodynamically stable</li>
                <li>Transaminases clearly downtrending (usually >50% from peak)</li>
                <li>INR normal or stable/improving</li>
                <li>No hepatic encephalopathy</li>
                <li>Glucose stable without IV dextrose</li>
                <li>Off vasopressors and mechanical ventilation</li>
                <li>Able to tolerate oral medications and nutrition</li>
                <li>Follow-up arranged (may need cardiology, hepatology depending on underlying cause)</li>
                <li>Patient and family understand diagnosis and expected recovery</li>
            </ul>
        </div>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 123: AORTIC DISSECTION -->
<div id="aortic-dissection" class="condition-page">
    <div class="page-header">
        <h2>123. AORTIC DISSECTION</h2>
        <div class="subtitle">Stanford Type A â€¢ Type B â€¢ Hypertensive Emergency</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Sudden-onset severe "tearing" or "ripping" chest/back pain, often migratory (follows dissection propagation). Maximum intensity at onset (unlike ACS which crescendos).</p>
            <p><span class="label">Stanford Classification:</span></p>
            <ul>
                <li><strong>Type A:</strong> Involves ascending aorta (regardless of origin) â€“ SURGICAL EMERGENCY</li>
                <li><strong>Type B:</strong> Descending aorta only (distal to left subclavian) â€“ usually medical management</li>
            </ul>
            <p><span class="label">Associated Findings:</span></p>
            <ul>
                <li><strong>Pulse deficits:</strong> Unequal BPs between arms (>20 mmHg difference), absent pulses</li>
                <li><strong>Neurologic:</strong> Stroke (carotid involvement), syncope, altered mental status, paraplegia (spinal artery involvement)</li>
                <li><strong>Cardiac:</strong> Aortic regurgitation murmur (diastolic, Type A), tamponade, MI (coronary ostia involvement)</li>
                <li><strong>Abdominal:</strong> Mesenteric ischemia, renal failure</li>
            </ul>
            <p><span class="label">Risk Factors:</span> Hypertension (most common), Marfan syndrome, bicuspid aortic valve, Turner syndrome, pregnancy, cocaine use, recent aortic instrumentation, aortic aneurysm</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Imaging (Confirm Diagnosis):</span></p>
            <ul>
                <li><strong>CT Angiography (CTA):</strong> Gold standard, sensitivity >95%. Shows intimal flap, true and false lumens, extent of dissection, branch vessel involvement</li>
                <li><strong>TEE:</strong> Excellent for Type A, can be done at bedside in unstable patients</li>
                <li><strong>CXR:</strong> Widened mediastinum (suggestive but not diagnostic); NORMAL in 10-20%</li>
            </ul>
            <p><span class="label">Laboratory:</span></p>
            <ul>
                <li><strong>D-dimer:</strong> Often elevated (high sensitivity), but non-specific. Useful to rule out in low-risk patients.</li>
                <li><strong>Troponin:</strong> May be elevated if coronary involvement â€“ but elevated troponin does NOT rule out dissection</li>
                <li><strong>CBC, BMP, coags, type and screen:</strong> Baseline for potential surgery</li>
            </ul>
            <p><span class="label">ECG:</span> Often normal or non-specific. May show LVH, ischemic changes if coronary involvement. STEMI + dissection = catastrophic combination.</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Immediate Goals (First 20 Minutes):</span></p>
            <ul>
                <li><strong>Pain control:</strong> IV opioids (morphine 2-4 mg IV or fentanyl 25-50 mcg IV)</li>
                <li><strong>Target HR <60 bpm:</strong> Reduces aortic shear stress (dP/dt)</li>
                <li><strong>Target SBP 100-120 mmHg:</strong> Lowest BP that maintains end-organ perfusion</li>
                <li><strong>BETA-BLOCKER FIRST:</strong> Must reduce HR before vasodilators</li>
            </ul>
            <p><span class="label">Anti-Impulse Therapy (HR Control FIRST):</span></p>
            <ul>
                <li><strong>Esmolol:</strong> 500 mcg/kg bolus, then 50-200 mcg/kg/min â€“ preferred (short-acting, titratable)</li>
                <li><strong>Labetalol:</strong> 20 mg IV bolus, then 1-2 mg/min infusion</li>
                <li><strong>If beta-blocker contraindicated:</strong> Diltiazem 0.25 mg/kg IV bolus, then 5-15 mg/hr</li>
            </ul>
            <p><span class="label">Blood Pressure Control (After HR Controlled):</span></p>
            <ul>
                <li><strong>Nicardipine:</strong> 5-15 mg/hr IV (preferred)</li>
                <li><strong>Nitroprusside:</strong> 0.25-10 mcg/kg/min (ONLY after adequate beta blockade)</li>
            </ul>
            <p><span class="label">Type A Dissection â€“ SURGICAL EMERGENCY:</span></p>
            <ul>
                <li>IMMEDIATE cardiothoracic surgery consultation</li>
                <li>Mortality increases 1-2% per hour without surgery</li>
            </ul>
            <p><span class="label">Type B Dissection â€“ Usually Medical Management:</span></p>
            <ul>
                <li>Uncomplicated: HR/BP control, ICU monitoring, serial imaging</li>
                <li><strong>Complicated (requires intervention):</strong> Malperfusion, rupture, refractory pain, rapid expansion</li>
            </ul>
            <p><span class="label">AVOID:</span> Anticoagulation, thrombolytics (even if STEMI present â€“ catastrophic if dissection), vasodilators before beta-blockade</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>The STEMI-Dissection Trap:</strong> Type A dissection can cause STEMI by occluding coronary ostia. Giving thrombolytics without considering dissection can be fatal. If ANY features suggest dissection, get CTA BEFORE heparin/cath.</li>
            <li><strong>Beta-Blocker BEFORE Vasodilator:</strong> Vasodilators cause reflex tachycardia, which increases aortic shear stress and can propagate dissection. Always achieve HR <60 first.</li>
            <li><strong>Pain Onset:</strong> ACS pain typically crescendos over minutes; dissection is classically maximum intensity at onset.</li>
            <li><strong>Normal CXR Does NOT Rule Out Dissection:</strong> 10-20% of dissections have normal CXR. If clinical suspicion is high, proceed to CTA.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU / OR IF:</div>
            <ul>
                <li>ALL Type A dissections â€“ immediate surgical consult</li>
                <li>Hemodynamic instability</li>
                <li>Signs of tamponade or rupture</li>
                <li>End-organ malperfusion</li>
                <li>Refractory hypertension or pain</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA (Type B Only)</div>
            <ul>
                <li>Uncomplicated Type B with stable imaging</li>
                <li>Pain controlled on oral medications</li>
                <li>BP at goal on oral regimen (SBP <120)</li>
                <li>Reliable follow-up with vascular surgery</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 124: CARDIAC TAMPONADE -->
<div id="cardiac-tamponade" class="condition-page">
    <div class="page-header">
        <h2>124. CARDIAC TAMPONADE</h2>
        <div class="subtitle">Beck's Triad â€¢ Pulsus Paradoxus â€¢ Pericardiocentesis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Beck's Triad (Present in Only ~30%):</span></p>
            <ul>
                <li><strong>Hypotension:</strong> Due to decreased cardiac output</li>
                <li><strong>Jugular Venous Distension (JVD):</strong> Due to impaired venous return</li>
                <li><strong>Muffled Heart Sounds:</strong> Fluid dampens sound transmission</li>
            </ul>
            <p><span class="label">Pulsus Paradoxus:</span> >10 mmHg drop in systolic BP during inspiration. Most sensitive clinical sign.</p>
            <p><span class="label">Other Signs:</span> Dyspnea, tachypnea, tachycardia, cool extremities, anxiety</p>
            <p><span class="label">Acute vs. Chronic:</span></p>
            <ul>
                <li><strong>Acute (trauma, dissection):</strong> Small volumes (150-200 mL) can cause tamponade</li>
                <li><strong>Chronic (malignancy, uremia):</strong> May accumulate 1-2L before tamponade</li>
            </ul>
            <p><span class="label">Common Etiologies:</span> Malignancy (lung, breast, lymphoma), uremia, infection (viral, TB), post-cardiac surgery, post-MI, autoimmune, trauma, aortic dissection (Type A), idiopathic</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Echocardiography (Test of Choice):</span></p>
            <ul>
                <li><strong>Pericardial effusion:</strong> Anechoic space surrounding heart</li>
                <li><strong>Right atrial collapse:</strong> During late diastole â€“ earliest sign</li>
                <li><strong>Right ventricular diastolic collapse:</strong> More specific</li>
                <li><strong>IVC plethora:</strong> Dilated IVC with <50% inspiratory collapse</li>
                <li><strong>Respiratory variation:</strong> >25% mitral inflow variation</li>
            </ul>
            <p><span class="label">ECG:</span> Low voltage, electrical alternans (specific but not sensitive), sinus tachycardia</p>
            <p><span class="label">CXR:</span> "Water bottle" heart â€“ may be normal in acute tamponade</p>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ BMP Reference</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Hemodynamically UNSTABLE:</span></p>
            <ul>
                <li><strong>EMERGENT PERICARDIOCENTESIS:</strong> Cannot wait</li>
                <li><strong>Volume resuscitation:</strong> IV fluids to maintain preload while preparing for drainage</li>
                <li><strong>AVOID:</strong> Diuretics, vasodilators, positive pressure ventilation (all worsen tamponade)</li>
            </ul>
            <p><span class="label">Pericardiocentesis:</span></p>
            <ul>
                <li><strong>Echo guidance:</strong> Standard of care</li>
                <li><strong>Approach:</strong> Subxiphoid or apical</li>
                <li><strong>Leave catheter:</strong> For continued drainage in most cases</li>
            </ul>
            <p><span class="label">Specific Etiologies:</span></p>
            <ul>
                <li><strong>Malignancy:</strong> Pericardial window for recurrent effusions</li>
                <li><strong>Uremic:</strong> Intensify dialysis</li>
                <li><strong>Aortic dissection (Type A):</strong> Do NOT do pericardiocentesis â€“ emergent surgical repair</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Tamponade is CLINICAL, Not Radiographic:</strong> Large effusions can be well-tolerated; small acute effusions can kill. Treat the patient, not the echo.</li>
            <li><strong>Pulsus Paradoxus is KEY:</strong> >10 mmHg is abnormal. >20-25 mmHg strongly suggests tamponade.</li>
            <li><strong>Don't Rely on Beck's Triad:</strong> Classic triad is often incomplete. Trust pulsus paradoxus and echo findings.</li>
            <li><strong>NEVER Pericardiocentesis in Type A Dissection:</strong> Can cause exsanguination â€“ requires surgical repair.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU / CATH LAB IF:</div>
            <ul>
                <li>Hemodynamic instability</li>
                <li>Pulsus paradoxus >15-20 mmHg</li>
                <li>Echo evidence of chamber collapse</li>
                <li>Need for emergent pericardiocentesis</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Tamponade drained, no reaccumulation</li>
                <li>Underlying cause identified and being treated</li>
                <li>Stable vital signs</li>
                <li>Follow-up arranged</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 125: LOWER GI BLEED -->
<div id="lower-gi-bleed" class="condition-page">
    <div class="page-header">
        <h2>125. LOWER GI BLEED</h2>
        <div class="subtitle">Diverticular â€¢ Angiodysplasia â€¢ Risk Stratification</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Bleeding distal to the ligament of Treitz. Usually presents with hematochezia.</p>
            <p><span class="label">Key Point:</span> ~15% of patients with hematochezia have a brisk UPPER GI source. Always consider UGIB in unstable patients.</p>
            <p><span class="label">Common Etiologies:</span></p>
            <ul>
                <li><strong>Diverticulosis (30-40%):</strong> Painless, massive bleeding; stops spontaneously in 80%</li>
                <li><strong>Angiodysplasia (10-15%):</strong> Common in elderly, associated with CKD and aortic stenosis (Heyde syndrome)</li>
                <li><strong>Hemorrhoids (10-15%):</strong> Bright red blood on toilet paper/bowl</li>
                <li><strong>Colitis (10%):</strong> IBD, infectious, ischemic â€“ bloody diarrhea with pain</li>
                <li><strong>Neoplasm (5-10%):</strong> Polyps, colorectal cancer</li>
                <li><strong>Post-polypectomy (5%):</strong> 1-2 weeks post-procedure</li>
            </ul>
            <p><span class="label">Distinguishing LGIB from UGIB:</span></p>
            <ul>
                <li><strong>BUN/Cr ratio >30:</strong> Suggests UGIB</li>
                <li><strong>Melena:</strong> Usually UGIB</li>
                <li><strong>Hemodynamic instability + hematochezia:</strong> Consider brisk UGIB</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Laboratory:</span> CBC (trend q6-8h), BMP (BUN/Cr ratio), coags, type and screen/crossmatch, lactate if concern for ischemia</p>
            <p><span class="label">Risk Stratification â€“ Oakland Score:</span> Score â‰¤8 = low risk (may be candidate for outpatient management)</p>
            <p><span class="label">Colonoscopy:</span></p>
            <ul>
                <li><strong>Timing:</strong> Within 24 hours for most patients</li>
                <li><strong>Bowel prep:</strong> 4-6L polyethylene glycol over 3-4 hours</li>
                <li>Diagnostic AND therapeutic (clips, cautery, injection)</li>
            </ul>
            <p><span class="label">If Colonoscopy Non-Diagnostic:</span></p>
            <ul>
                <li><strong>Upper endoscopy:</strong> If UGIB not excluded</li>
                <li><strong>CT angiography:</strong> Detects bleeding >0.3-0.5 mL/min</li>
                <li><strong>Tagged RBC scan:</strong> Detects bleeding >0.1 mL/min (more sensitive, less specific)</li>
                <li><strong>Angiography:</strong> Detects >0.5-1 mL/min, can embolize</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ CBC Reference</a>, <a href="#ugib" style="color: #0366d6;">ðŸ“š Upper GI Bleed</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Initial Resuscitation:</span></p>
            <ul>
                <li><strong>IV access:</strong> Two large-bore IVs (18G or larger)</li>
                <li><strong>Crystalloid resuscitation:</strong> Target MAP >65</li>
                <li><strong>Blood transfusion:</strong> Target Hgb >7 g/dL (>8-9 if active CAD)</li>
                <li><strong>Correct coagulopathy:</strong> FFP if INR >2.0, platelets if <50k</li>
            </ul>
            <p><span class="label">Endoscopic Therapy:</span> Injection, thermal cautery, hemoclips, band ligation</p>
            <p><span class="label">Interventional Radiology:</span> Angiography with embolization for failed endoscopy or massive bleeding</p>
            <p><span class="label">Surgery:</span> For hemodynamic instability despite resuscitation, failed endoscopic/IR intervention, or >6 units PRBC in 24h</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Hematochezia â‰  LGIB:</strong> 15% have brisk UPPER GI bleed. Consider UGIB in unstable patients.</li>
            <li><strong>Most LGIB Stops Spontaneously:</strong> ~80% of diverticular bleeds stop on their own.</li>
            <li><strong>Hemoglobin Lag:</strong> Initial Hgb may be normal â€“ equilibration takes 8-24 hours.</li>
            <li><strong>Heyde Syndrome:</strong> Aortic stenosis + angiodysplasia + acquired vWF deficiency.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Hemodynamic instability</li>
                <li>Massive transfusion requirement</li>
                <li>Active ongoing hemorrhage</li>
                <li>Need for emergent intervention</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Bleeding stopped, stable hemoglobin</li>
                <li>Colonoscopy completed or follow-up arranged</li>
                <li>Tolerating oral intake</li>
                <li>GI follow-up arranged</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 126: TTP/HUS -->
<div id="ttp-hus" class="condition-page">
    <div class="page-header">
        <h2>126. TTP/HUS (THROMBOTIC MICROANGIOPATHY)</h2>
        <div class="subtitle">PLASMIC Score â€¢ Plasmapheresis â€¢ DO NOT Transfuse Platelets</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic "Pentad" (Full Pentad in <10%):</span></p>
            <ul>
                <li><strong>Microangiopathic Hemolytic Anemia (MAHA):</strong> Schistocytes, elevated LDH, low haptoglobin</li>
                <li><strong>Thrombocytopenia:</strong> Usually severe (median ~15,000)</li>
                <li><strong>Neurologic symptoms:</strong> Headache, confusion, seizures, focal deficits</li>
                <li><strong>Renal dysfunction:</strong> Mild in TTP, severe in HUS</li>
                <li><strong>Fever:</strong> Non-specific</li>
            </ul>
            <p><span class="label">TTP vs. HUS:</span></p>
            <ul>
                <li><strong>TTP:</strong> ADAMTS13 activity <10%. More neurologic, milder renal</li>
                <li><strong>STEC-HUS:</strong> Shiga toxin E. coli (O157:H7). Bloody diarrhea prodrome, severe renal</li>
                <li><strong>Atypical HUS:</strong> Complement dysregulation. Severe renal, no diarrhea</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Essential Labs:</span></p>
            <ul>
                <li><strong>CBC with smear:</strong> Thrombocytopenia + schistocytes (>1%)</li>
                <li><strong>Hemolysis labs:</strong> LDH (markedly elevated), haptoglobin (undetectable), indirect bilirubin, reticulocytes</li>
                <li><strong>Direct Coombs:</strong> NEGATIVE (rules out AIHA)</li>
                <li><strong>Coags:</strong> PT, PTT, fibrinogen â€“ typically NORMAL (vs. DIC)</li>
            </ul>
            <p><span class="label">ADAMTS13 Activity:</span> SEND BEFORE PLASMA. Activity <10% confirms TTP. Don't wait for results to treat.</p>
            <p><span class="label">PLASMIC Score (Predicts ADAMTS13 <10%):</span></p>
            <ul>
                <li><strong>P</strong>latelet <30k (+1)</li>
                <li><strong>L</strong>ysis (hemolysis markers) (+1)</li>
                <li><strong>A</strong>ctive cancer absent (+1)</li>
                <li><strong>S</strong>tem cell/organ transplant absent (+1)</li>
                <li><strong>M</strong>CV <90 (+1)</li>
                <li><strong>I</strong>NR <1.5 (+1)</li>
                <li><strong>C</strong>reatinine <2.0 (+1)</li>
                <li>Score â‰¥6 = High risk (~72% ADAMTS13 <10%)</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ CBC Reference</a>, <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ LDH Reference</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <div class="box">
                <div class="box-title">âš ï¸ CRITICAL: DO NOT TRANSFUSE PLATELETS</div>
                <p>Platelet transfusion can precipitate thrombosis and worsen disease. Only if life-threatening bleeding.</p>
            </div>
            <p><span class="label">Therapeutic Plasma Exchange (TPE):</span></p>
            <ul>
                <li><strong>START IMMEDIATELY:</strong> Don't wait for ADAMTS13. Mortality >90% untreated vs. <20% with TPE.</li>
                <li><strong>Regimen:</strong> Daily 1-1.5 plasma volumes until platelets >150k Ã— 2 days</li>
                <li><strong>If TPE not available:</strong> Give FFP 30 mL/kg as bridge</li>
            </ul>
            <p><span class="label">Corticosteroids:</span> Prednisone 1 mg/kg/day OR methylprednisolone 1g IV daily Ã— 3 days</p>
            <p><span class="label">Rituximab:</span> For refractory/relapsed TTP. 375 mg/mÂ² weekly Ã— 4 weeks</p>
            <p><span class="label">Caplacizumab:</span> Anti-vWF nanobody. 11 mg IV before first TPE, then 11 mg SQ daily</p>
            <p><span class="label">STEC-HUS:</span> Supportive care only. AVOID antibiotics (may worsen). NO TPE.</p>
            <p><span class="label">Atypical HUS:</span> Eculizumab (C5 inhibitor) â€“ treatment of choice. Vaccinate for meningococcus.</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Don't Wait for Pentad:</strong> MAHA + thrombocytopenia alone is enough to suspect TTP and start treatment.</li>
            <li><strong>Coags are NORMAL:</strong> Unlike DIC, PT/PTT/fibrinogen are normal in TTP.</li>
            <li><strong>Send ADAMTS13 BEFORE Plasma:</strong> Plasma contains ADAMTS13 and falsely elevates levels.</li>
            <li><strong>NO PLATELETS:</strong> Can trigger catastrophic thrombosis. Exception: life-threatening bleeding.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>All suspected TTP â€“ hematologic emergency</li>
                <li>Severe neurologic manifestations</li>
                <li>Severe thrombocytopenia (<10k)</li>
                <li>Need for emergent TPE</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Platelets >150k Ã— 2 consecutive days</li>
                <li>LDH normalizing</li>
                <li>No neurologic symptoms</li>
                <li>TPE course completed</li>
                <li>Hematology follow-up arranged</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 127: HIT -->
<div id="hit" class="condition-page">
    <div class="page-header">
        <h2>127. HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)</h2>
        <div class="subtitle">4T Score â€¢ Argatroban/Bivalirudin â€¢ Warfarin Bridging</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Immune-mediated thrombocytopenia from antibodies against PF4-heparin complexes. Causes THROMBOSIS, not bleeding.</p>
            <p><span class="label">Timing:</span></p>
            <ul>
                <li><strong>Typical HIT:</strong> Platelet drop 5-10 days after heparin exposure</li>
                <li><strong>Rapid-onset HIT:</strong> Within 24 hours if heparin in past 100 days</li>
            </ul>
            <p><span class="label">Key Features:</span></p>
            <ul>
                <li><strong>Thrombocytopenia:</strong> ~50% drop from baseline (nadir usually 20,000-150,000)</li>
                <li><strong>Thrombosis:</strong> 50% of untreated HIT develop thrombosis (DVT, PE, limb ischemia, stroke)</li>
                <li><strong>Skin necrosis:</strong> At injection sites</li>
            </ul>
            <p><span class="label">Risk Factors:</span> UFH > LMWH (10Ã— higher risk), surgical > medical patients, duration >4 days</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">4T Score:</span></p>
            <table style="width: 100%; border-collapse: collapse; margin: 10px 0; font-size: 9pt;">
                <tr style="background: #f0f0f0;">
                    <th style="border: 1px solid #ddd; padding: 6px;">Feature</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">2 Points</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">1 Point</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">0 Points</th>
                </tr>
                <tr><td style="border: 1px solid #ddd; padding: 6px;"><strong>Thrombocytopenia</strong></td><td style="border: 1px solid #ddd; padding: 6px;">>50% fall or nadir 20-100k</td><td style="border: 1px solid #ddd; padding: 6px;">30-50% fall or nadir 10-19k</td><td style="border: 1px solid #ddd; padding: 6px;"><30% fall or nadir <10k</td></tr>
                <tr><td style="border: 1px solid #ddd; padding: 6px;"><strong>Timing</strong></td><td style="border: 1px solid #ddd; padding: 6px;">Days 5-10 or â‰¤1 day if recent heparin</td><td style="border: 1px solid #ddd; padding: 6px;">Days 5-10 unclear</td><td style="border: 1px solid #ddd; padding: 6px;">â‰¤4 days without recent heparin</td></tr>
                <tr><td style="border: 1px solid #ddd; padding: 6px;"><strong>Thrombosis</strong></td><td style="border: 1px solid #ddd; padding: 6px;">New thrombosis or skin necrosis</td><td style="border: 1px solid #ddd; padding: 6px;">Progressive/suspected thrombosis</td><td style="border: 1px solid #ddd; padding: 6px;">None</td></tr>
                <tr><td style="border: 1px solid #ddd; padding: 6px;"><strong>Other causes</strong></td><td style="border: 1px solid #ddd; padding: 6px;">None evident</td><td style="border: 1px solid #ddd; padding: 6px;">Possible other cause</td><td style="border: 1px solid #ddd; padding: 6px;">Definite other cause</td></tr>
            </table>
            <p><strong>Score:</strong> 0-3 = Low (<5%); 4-5 = Intermediate (10-30%); 6-8 = High (40-80%)</p>
            <p><span class="label">Laboratory:</span></p>
            <ul>
                <li><strong>Anti-PF4/heparin ELISA:</strong> High sensitivity (~99%), lower specificity</li>
                <li><strong>Serotonin release assay (SRA):</strong> Gold standard, high specificity (~99%)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Immediate Actions:</span></p>
            <ul>
                <li><strong>STOP ALL HEPARIN:</strong> UFH, LMWH, heparin flushes, heparin-coated catheters</li>
                <li><strong>Start alternative anticoagulation:</strong> Even without thrombosis</li>
                <li><strong>Duplex legs:</strong> Screen for occult DVT</li>
            </ul>
            <p><span class="label">Alternative Anticoagulation:</span></p>
            <ul>
                <li><strong>Argatroban:</strong> 2 mcg/kg/min IV (no bolus), adjust to aPTT 1.5-3Ã— baseline. Hepatically cleared.</li>
                <li><strong>Bivalirudin:</strong> 0.15-0.2 mg/kg/hr IV. Renally cleared.</li>
                <li><strong>Fondaparinux:</strong> 7.5 mg SQ daily. No cross-reactivity with HIT antibodies.</li>
                <li><strong>DOACs:</strong> Can use in stable patients.</li>
            </ul>
            <p><span class="label">Warfarin Bridging (CRITICAL):</span></p>
            <ul>
                <li><strong>DO NOT start warfarin until platelets >150,000:</strong> Can cause venous limb gangrene</li>
                <li><strong>Start low dose (5 mg daily)</strong> when platelets recovered</li>
                <li><strong>Overlap â‰¥5 days</strong> with alternative anticoagulant until INR therapeutic Ã— 2 days</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>HIT Causes Thrombosis:</strong> Despite low platelets, HIT is hypercoagulable. Treat with anticoagulation.</li>
            <li><strong>4T Score is Essential:</strong> Low score (<4) essentially rules out HIT.</li>
            <li><strong>Timing is Everything:</strong> Classic HIT = days 5-10. Day 2 drop without recent heparin is NOT HIT.</li>
            <li><strong>Warfarin Danger:</strong> Never start warfarin while platelets are low â€“ causes limb gangrene.</li>
            <li><strong>Argatroban Elevates INR:</strong> Target INR >4 before stopping argatroban when bridging.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Acute arterial thrombosis</li>
                <li>Massive PE</li>
                <li>Venous limb gangrene</li>
                <li>Need for emergent surgery</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Platelets >150,000 and stable</li>
                <li>On oral anticoagulation</li>
                <li>No new thrombosis</li>
                <li>Patient educated to avoid heparin</li>
            </ul>
        </div>
    </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#argatroban" style="color: #8e44ad;">ðŸ’Š Argatroban</a>, <a href="drug_reference_guide.html#fondaparinux" style="color: #8e44ad;">ðŸ’Š Fondaparinux</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 128: WERNICKE ENCEPHALOPATHY -->
<div id="wernicke" class="condition-page">
    <div class="page-header">
        <h2>128. WERNICKE ENCEPHALOPATHY</h2>
        <div class="subtitle">Thiamine Deficiency â€¢ Give Thiamine BEFORE Glucose â€¢ Korsakoff Syndrome</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Triad (Present in Only ~30%):</span></p>
            <ul>
                <li><strong>Encephalopathy:</strong> Confusion, disorientation, apathy (most common, >80%)</li>
                <li><strong>Oculomotor dysfunction:</strong> Nystagmus, lateral rectus palsy, ophthalmoplegia</li>
                <li><strong>Gait ataxia:</strong> Wide-based, unsteady; may be unable to walk</li>
            </ul>
            <p><span class="label">High-Risk Populations:</span></p>
            <ul>
                <li><strong>Alcohol use disorder:</strong> Most common</li>
                <li><strong>Malnutrition:</strong> Anorexia, starvation, refeeding syndrome</li>
                <li><strong>Hyperemesis gravidarum</strong></li>
                <li><strong>Bariatric surgery</strong></li>
                <li><strong>Prolonged TPN</strong> without thiamine</li>
                <li><strong>Dialysis</strong></li>
            </ul>
            <p><span class="label">Korsakoff Syndrome:</span> Untreated Wernicke â†’ irreversible anterograde amnesia, confabulation. ~80% of untreated cases progress.</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">WERNICKE IS A CLINICAL DIAGNOSIS:</span> Do NOT wait for labs or imaging to treat.</p>
            <p><span class="label">Laboratory (Supportive):</span></p>
            <ul>
                <li><strong>Thiamine level:</strong> Can confirm deficiency but takes days</li>
                <li><strong>Magnesium:</strong> Often low; required for thiamine utilization</li>
            </ul>
            <p><span class="label">MRI Brain:</span> T2/FLAIR hyperintensities in medial thalami, mammillary bodies, periaqueductal gray. Sensitivity ~50% â€“ normal MRI does NOT rule out.</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <div class="box">
                <div class="box-title">âš ï¸ CRITICAL: THIAMINE BEFORE GLUCOSE</div>
                <p>Glucose consumes thiamine in glycolysis. Giving glucose without thiamine can precipitate or worsen Wernicke. ALWAYS give thiamine before or with glucose.</p>
            </div>
            <p><span class="label">Thiamine Dosing (TREATMENT):</span></p>
            <ul>
                <li><strong>High-dose IV:</strong> 500 mg IV TID Ã— 2-3 days</li>
                <li><strong>Then:</strong> 250 mg IV daily Ã— 3-5 days</li>
                <li><strong>Then:</strong> 100 mg PO TID until no longer at risk</li>
            </ul>
            <p><span class="label">Why IV and High-Dose?</span> Oral absorption limited (~5 mg/day max). Brain stores depleted â€“ need aggressive repletion.</p>
            <p><span class="label">Prophylaxis (At-Risk Without Symptoms):</span> 100-200 mg IV daily while NPO</p>
            <p><span class="label">Magnesium Repletion:</span> Cofactor for thiamine-dependent enzymes. Target Mg >2.0 mg/dL.</p>
            <p><span class="label">Expected Response:</span></p>
            <ul>
                <li>Oculomotor findings: Hours to days</li>
                <li>Ataxia: Days to weeks; may not fully resolve</li>
                <li>Encephalopathy: Days to weeks; may not fully resolve</li>
                <li>Korsakoff amnesia: Usually irreversible</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ Magnesium Reference</a>, <a href="#etoh-withdrawal" style="color: #0366d6;">ðŸ“š Alcohol Withdrawal</a></p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Clinical Diagnosis:</strong> Don't wait for labs. If you suspect it, treat it.</li>
            <li><strong>Triad is a Myth:</strong> Only ~30% present with classic triad. Suspect in ANY confused patient with risk factors.</li>
            <li><strong>THIAMINE BEFORE GLUCOSE:</strong> Boards-relevant and clinically critical.</li>
            <li><strong>Low-Dose is Inadequate:</strong> "Banana bag" (100 mg) insufficient for established Wernicke. Use 500 mg IV TID.</li>
            <li><strong>Korsakoff is Irreversible:</strong> Early aggressive treatment prevents progression.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Severe encephalopathy (coma)</li>
                <li>Concurrent severe alcohol withdrawal</li>
                <li>Respiratory compromise</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Mental status improved</li>
                <li>Gait stable</li>
                <li>Tolerating oral thiamine</li>
                <li>Magnesium repleted</li>
                <li>Alcohol cessation resources provided</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 129: NEPHROTIC SYNDROME -->
<div id="nephrotic-syndrome" class="condition-page">
    <div class="page-header">
        <h2>129. NEPHROTIC SYNDROME</h2>
        <div class="subtitle">>3.5g Proteinuria â€¢ Thrombosis Risk â€¢ Infection Risk</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Diagnostic Criteria:</span></p>
            <ul>
                <li><strong>Proteinuria >3.5 g/day</strong> (or UPCR >3.5)</li>
                <li><strong>Hypoalbuminemia</strong> (<3.0 g/dL)</li>
                <li><strong>Peripheral edema</strong></li>
                <li><strong>Hyperlipidemia</strong></li>
            </ul>
            <p><span class="label">Primary Causes:</span></p>
            <ul>
                <li><strong>Minimal Change:</strong> Most common in children; responds to steroids</li>
                <li><strong>FSGS:</strong> Most common primary cause in adults; often steroid-resistant</li>
                <li><strong>Membranous Nephropathy:</strong> Most common in older adults; high thrombosis risk; associated with malignancy</li>
            </ul>
            <p><span class="label">Secondary Causes:</span> Diabetes (most common overall), SLE, amyloidosis, hepatitis B/C, HIV, malignancy, drugs (NSAIDs)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Confirm Diagnosis:</span> 24-hour urine protein or spot UPCR, serum albumin, lipid panel</p>
            <p><span class="label">Workup for Etiology:</span></p>
            <ul>
                <li>HbA1c, fundoscopic exam (diabetes)</li>
                <li>ANA, anti-dsDNA, C3/C4 (SLE)</li>
                <li>Hepatitis B/C, HIV serologies</li>
                <li>Anti-PLA2R antibody (primary membranous)</li>
                <li>SPEP/UPEP, free light chains (amyloidosis)</li>
                <li>Age-appropriate cancer screening</li>
            </ul>
            <p><span class="label">Renal Biopsy:</span> Definitive diagnosis in most cases; not required if clear diabetic nephropathy</p>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ Albumin Reference</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Supportive Care (All Patients):</span></p>
            <ul>
                <li><strong>Sodium restriction:</strong> <2 g/day</li>
                <li><strong>Loop diuretics:</strong> Furosemide 40-80 mg daily; may need high doses</li>
                <li><strong>ACE-I or ARB:</strong> Reduces proteinuria; use even if BP normal</li>
                <li><strong>Statin:</strong> For hyperlipidemia</li>
            </ul>
            <p><span class="label">Thrombosis Prevention:</span></p>
            <ul>
                <li>High risk â€“ loss of antithrombin III, protein S</li>
                <li>VTE risk highest with membranous and albumin <2.5</li>
                <li>Consider prophylactic anticoagulation in high-risk patients</li>
                <li><strong>Renal vein thrombosis:</strong> Classic complication â€“ flank pain, hematuria</li>
            </ul>
            <p><span class="label">Infection Risk:</span> Loss of immunoglobulins â†’ increased infection risk. Ensure pneumococcal vaccination.</p>
            <p><span class="label">Disease-Specific:</span></p>
            <ul>
                <li>Minimal change: High-dose prednisone</li>
                <li>FSGS: Steroids; if resistant, calcineurin inhibitors or rituximab</li>
                <li>Membranous: Rituximab or cyclophosphamide + steroids if high-risk</li>
                <li>Diabetic: Glycemic control, ACE-I/ARB, <strong>SGLT2 inhibitors</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Nephrotic vs. Nephritic:</strong> Nephrotic = heavy proteinuria, low albumin, edema. Nephritic = hematuria, RBC casts, HTN.</li>
            <li><strong>Thrombosis is a Big Deal:</strong> VTE risk 10-40% in membranous. Consider DVT/PE in symptomatic patients.</li>
            <li><strong>Membranous + Cancer:</strong> In adults >50, consider occult malignancy workup.</li>
            <li><strong>SGLT2 Inhibitors:</strong> Standard of care for proteinuric CKD regardless of diabetes (DAPA-CKD, EMPA-KIDNEY).</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Massive PE</li>
                <li>Severe AKI requiring dialysis</li>
                <li>Severe pulmonary edema</li>
                <li>Sepsis</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Edema controlled with oral diuretics</li>
                <li>Renal function stable</li>
                <li>On ACE-I/ARB</li>
                <li>Nephrology follow-up arranged</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 130: ASPIRATION PNEUMONIA/PNEUMONITIS -->
<div id="aspiration-pneumonia" class="condition-page">
    <div class="page-header">
        <h2>130. ASPIRATION PNEUMONIA / PNEUMONITIS</h2>
        <div class="subtitle">Chemical Pneumonitis vs. Infection â€¢ Anaerobic Coverage Debate</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Pneumonitis vs. Pneumonia:</span></p>
            <table style="width: 100%; border-collapse: collapse; margin: 10px 0; font-size: 9pt;">
                <tr style="background: #f0f0f0;"><th style="border: 1px solid #ddd; padding: 6px;">Feature</th><th style="border: 1px solid #ddd; padding: 6px;">Aspiration Pneumonitis</th><th style="border: 1px solid #ddd; padding: 6px;">Aspiration Pneumonia</th></tr>
                <tr><td style="border: 1px solid #ddd; padding: 6px;"><strong>Pathophysiology</strong></td><td style="border: 1px solid #ddd; padding: 6px;">Chemical inflammation from gastric acid</td><td style="border: 1px solid #ddd; padding: 6px;">Bacterial infection</td></tr>
                <tr><td style="border: 1px solid #ddd; padding: 6px;"><strong>Onset</strong></td><td style="border: 1px solid #ddd; padding: 6px;">Hours after witnessed aspiration</td><td style="border: 1px solid #ddd; padding: 6px;">Days (often no witnessed event)</td></tr>
                <tr><td style="border: 1px solid #ddd; padding: 6px;"><strong>Course</strong></td><td style="border: 1px solid #ddd; padding: 6px;">Improves 24-48 hrs</td><td style="border: 1px solid #ddd; padding: 6px;">Progressive without antibiotics</td></tr>
                <tr><td style="border: 1px solid #ddd; padding: 6px;"><strong>Antibiotics</strong></td><td style="border: 1px solid #ddd; padding: 6px;">Usually NOT indicated</td><td style="border: 1px solid #ddd; padding: 6px;">Yes</td></tr>
            </table>
            <p><span class="label">Risk Factors:</span> Decreased consciousness, dysphagia, impaired gag reflex, NG tube, GERD, poor dentition</p>
            <p><span class="label">Location:</span> Right lower lobe (supine); dependent lung segments</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Aspiration Pneumonitis:</span></p>
            <ul>
                <li>Supportive care, observation</li>
                <li>Most resolve 24-48 hours</li>
                <li>Antibiotics only if: no improvement after 48h, worsening, grossly contaminated material</li>
            </ul>
            <p><span class="label">Aspiration Pneumonia:</span></p>
            <ul>
                <li><strong>Community-Acquired:</strong> Ceftriaxone + Azithro OR levofloxacin (standard CAP coverage)</li>
                <li><strong>Anaerobic Coverage Debate:</strong> Recent evidence suggests NOT routinely necessary</li>
                <li><strong>Add anaerobic coverage if:</strong> Lung abscess, empyema, foul sputum, severe periodontal disease</li>
                <li><strong>Anaerobic options:</strong> Ampicillin-sulbactam 3g IV q6h, Pip-tazo, Meropenem, or add Metronidazole</li>
            </ul>
            <p><span class="label">Prevention:</span> HOB elevation 30-45Â°, oral hygiene, swallowing evaluation, thickened liquids if dysphagia</p>
            <p><span class="label">Cross-link:</span> <a href="id_guide.html#respiratory" style="color: #0366d6;">ðŸ¦  ID Guide: Respiratory Infections</a></p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Pneumonitis â‰  Pneumonia:</strong> Pneumonitis is chemical, not infection. Usually resolves 24-48h without antibiotics.</li>
            <li><strong>48-Hour Rule:</strong> After witnessed aspiration, observe 48h. If worsening â†’ start antibiotics.</li>
            <li><strong>Anaerobic Coverage Overprescribed:</strong> Reserve for abscess, empyema, foul sputum, poor dentition.</li>
            <li><strong>Procalcitonin Can Help:</strong> Low procalcitonin argues against bacterial infection.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Severe hypoxemia</li>
                <li>Respiratory failure</li>
                <li>Septic shock</li>
                <li>ARDS</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Oxygenation adequate</li>
                <li>Afebrile</li>
                <li>Tolerating oral intake safely</li>
                <li>Aspiration precautions in place</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 131: HAP/VAP -->
<div id="hap-vap" class="condition-page">
    <div class="page-header">
        <h2>131. HOSPITAL-ACQUIRED / VENTILATOR-ASSOCIATED PNEUMONIA (HAP/VAP)</h2>
        <div class="subtitle">MDR Risk Factors â€¢ Empiric Coverage â€¢ De-escalation</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definitions:</span></p>
            <ul>
                <li><strong>HAP:</strong> Pneumonia â‰¥48 hours after admission</li>
                <li><strong>VAP:</strong> Pneumonia >48 hours after intubation</li>
            </ul>
            <p><span class="label">Common Pathogens:</span> Pseudomonas, Klebsiella, E. coli, Acinetobacter, MRSA, S. pneumoniae</p>
            <p><span class="label">MDR Risk Factors:</span></p>
            <ul>
                <li>IV antibiotics in prior 90 days</li>
                <li>Hospitalization â‰¥5 days</li>
                <li>Septic shock at time of VAP</li>
                <li>ARDS before VAP</li>
                <li>Renal replacement therapy</li>
                <li>Prior MRSA/Pseudomonas infection</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Clinical:</span> New infiltrate + â‰¥2 of: fever, leukocytosis/leukopenia, purulent secretions, declining oxygenation</p>
            <p><span class="label">Cultures:</span> Sputum/ETA, blood cultures, consider BAL if not responding</p>
            <p><span class="label">MRSA Nasal PCR:</span> High NPV (~95%). If negative, can discontinue MRSA coverage.</p>
            <p><span class="label">Cross-link:</span> <a href="id_guide.html#respiratory" style="color: #0366d6;">ðŸ¦  ID Guide: Respiratory Infections</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">NO MDR Risk Factors:</span></p>
            <ul>
                <li><strong>Single anti-pseudomonal beta-lactam:</strong> Pip-tazo 4.5g q6h, Cefepime 2g q8h, OR Meropenem 1g q8h</li>
            </ul>
            <p><span class="label">WITH MDR Risk Factors:</span></p>
            <ul>
                <li><strong>Two anti-pseudomonal agents:</strong> Beta-lactam + fluoroquinolone or aminoglycoside</li>
                <li><strong>PLUS MRSA coverage if risk factors:</strong> Vancomycin 15-20 mg/kg q8-12h OR Linezolid 600mg q12h</li>
            </ul>
            <p><span class="label">De-escalation (at 48-72h):</span></p>
            <ul>
                <li>Review cultures and narrow coverage</li>
                <li>If MRSA nasal PCR negative â†’ stop vancomycin</li>
                <li>If Pseudomonas not isolated â†’ narrow to single agent</li>
            </ul>
            <p><span class="label">Duration:</span> 7 days for most HAP/VAP. Longer for Pseudomonas, MRSA bacteremia, abscess, empyema.</p>
            <p><span class="label">VAP Prevention Bundle:</span> HOB elevation, daily sedation vacation, DVT/PUD prophylaxis, oral care with chlorhexidine</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>MDR Risk Assessment is Key:</strong> Not everyone needs double Pseudomonas coverage + vancomycin.</li>
            <li><strong>De-escalate Early:</strong> 48-72h culture review is critical. Narrow when possible.</li>
            <li><strong>MRSA Nasal PCR:</strong> Use it to stop unnecessary vancomycin.</li>
            <li><strong>7 Days is Usually Enough:</strong> Longer courses = more resistance, more C. diff.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Most HAP/VAP patients already in ICU</li>
                <li>Septic shock</li>
                <li>Severe hypoxemia</li>
                <li>Need for mechanical ventilation</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Afebrile >48 hours</li>
                <li>Stable oxygenation</li>
                <li>WBC normalizing</li>
                <li>Able to take oral medications</li>
                <li>Plan to complete antibiotic course</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 132: CRITICAL AORTIC STENOSIS -->
<div id="critical-as" class="condition-page">
    <div class="page-header">
        <h2>132. CRITICAL AORTIC STENOSIS</h2>
        <div class="subtitle">Valve Area <1.0 cmÂ² â€¢ Syncope/Angina/CHF â€¢ AVR Indications</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Symptom Triad:</span></p>
            <ul>
                <li><strong>Angina:</strong> Due to increased myocardial O2 demand + reduced coronary perfusion pressure. ~5 year survival once present.</li>
                <li><strong>Syncope:</strong> Exertional â€“ fixed cardiac output cannot meet demand. ~3 year survival.</li>
                <li><strong>Heart Failure:</strong> LV decompensation. ~2 year survival once symptomatic.</li>
            </ul>
            <p><span class="label">Physical Exam:</span></p>
            <ul>
                <li><strong>Murmur:</strong> Harsh crescendo-decrescendo systolic murmur at RUSB, radiates to carotids</li>
                <li><strong>Parvus et tardus:</strong> Weak and delayed carotid upstroke (classic but insensitive)</li>
                <li><strong>Paradoxical S2 split:</strong> Prolonged LV ejection delays A2</li>
                <li><strong>S4 gallop:</strong> Stiff, hypertrophied LV</li>
                <li><strong>Narrow pulse pressure:</strong> Reduced stroke volume</li>
            </ul>
            <p><span class="label">Severity Classification:</span></p>
            <ul>
                <li><strong>Severe AS:</strong> Valve area <1.0 cmÂ², mean gradient >40 mmHg, peak velocity >4 m/s</li>
                <li><strong>Critical AS:</strong> Valve area <0.6 cmÂ² (or indexed AVA <0.6 cmÂ²/mÂ²)</li>
            </ul>
            <p><span class="label">Etiologies:</span> Calcific/degenerative (most common in elderly), bicuspid aortic valve (younger patients), rheumatic (rare in developed countries)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Echocardiography (Diagnostic Standard):</span></p>
            <ul>
                <li>Valve area by continuity equation</li>
                <li>Mean and peak gradients</li>
                <li>Peak aortic jet velocity</li>
                <li>LV function (EF)</li>
                <li>LV wall thickness (concentric hypertrophy typical)</li>
            </ul>
            <p><span class="label">Low-Flow, Low-Gradient AS:</span></p>
            <ul>
                <li>Reduced EF with low gradient (<40 mmHg) but small valve area â€“ may be true severe AS or pseudo-severe AS</li>
                <li><strong>Dobutamine stress echo:</strong> Differentiates true severe from pseudo-severe</li>
            </ul>
            <p><span class="label">Other Studies:</span></p>
            <ul>
                <li><strong>ECG:</strong> LVH with strain pattern, LAE, conduction abnormalities</li>
                <li><strong>CXR:</strong> Cardiomegaly, calcified aortic valve, pulmonary congestion if decompensated</li>
                <li><strong>Cardiac cath:</strong> Pre-operative coronary assessment; direct gradient measurement if echo inconclusive</li>
                <li><strong>CT calcium scoring:</strong> Can help confirm severe AS in borderline cases</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ BNP Reference</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Medical Management (Temporizing Only):</span></p>
            <ul>
                <li><strong>No medical therapy prevents progression</strong> â€“ definitive treatment is valve replacement</li>
                <li><strong>Diuretics:</strong> Cautious use for pulmonary congestion. Avoid over-diuresis (preload dependent).</li>
                <li><strong>Avoid vasodilators:</strong> Can cause severe hypotension (fixed obstruction cannot increase CO)</li>
                <li><strong>Avoid negative inotropes:</strong> Beta-blockers should be used cautiously; avoid in decompensated state</li>
                <li><strong>Maintain sinus rhythm:</strong> Atrial kick contributes ~25% of LV filling in stiff ventricle</li>
            </ul>
            <p><span class="label">Indications for Intervention (2020 ACC/AHA Guidelines):</span></p>
            <ul>
                <li><strong>Class I:</strong> Symptomatic severe AS (angina, syncope, HF)</li>
                <li><strong>Class I:</strong> Asymptomatic severe AS with LVEF <50%</li>
                <li><strong>Class I:</strong> Severe AS undergoing other cardiac surgery</li>
                <li><strong>Class IIa:</strong> Asymptomatic very severe AS (Vmax â‰¥5 m/s)</li>
                <li><strong>Class IIa:</strong> Asymptomatic severe AS with exercise intolerance or BP drop on exercise testing</li>
            </ul>
            <p><span class="label">Intervention Options:</span></p>
            <ul>
                <li><strong>SAVR (Surgical AVR):</strong> Gold standard for low/intermediate surgical risk</li>
                <li><strong>TAVR (Transcatheter AVR):</strong> Preferred for high/prohibitive surgical risk; increasingly used in intermediate risk. Now approved for low-risk patients.</li>
                <li><strong>Balloon valvuloplasty:</strong> Bridge to definitive therapy in hemodynamically unstable patients. NOT definitive â€“ high restenosis rate.</li>
            </ul>
            <p><span class="label">Acute Decompensation Management:</span></p>
            <ul>
                <li>ICU admission</li>
                <li>Gentle diuresis (avoid hypotension)</li>
                <li>Inotropes if needed (dobutamine preferred)</li>
                <li>Avoid vasodilators</li>
                <li>Urgent cardiology/cardiac surgery consultation</li>
                <li>Consider emergent TAVR or balloon valvuloplasty as bridge</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Symptoms = Intervention:</strong> Once symptomatic, prognosis is poor without AVR. Median survival: angina 5yr, syncope 3yr, CHF 2yr.</li>
            <li><strong>Avoid Vasodilators:</strong> Nitrates, ACE-I, and other vasodilators can cause severe hypotension. The stenotic valve creates fixed obstruction â€“ CO cannot increase to compensate for decreased SVR.</li>
            <li><strong>The Murmur May Soften:</strong> As AS progresses and LV fails, the murmur may become softer (less flow across valve). Don't be fooled â€“ soft murmur â‰  mild AS in a failing ventricle.</li>
            <li><strong>Heyde Syndrome:</strong> AS + GI bleeding from angiodysplasia + acquired von Willebrand syndrome. Shear stress degrades vWF multimers. May resolve after AVR.</li>
            <li><strong>TAVR Revolution:</strong> TAVR now approved for all surgical risk categories. Discuss with heart team for optimal approach.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Cardiogenic shock</li>
                <li>Acute pulmonary edema</li>
                <li>Syncope with hemodynamic instability</li>
                <li>New arrhythmias (especially AF with RVR)</li>
                <li>Need for inotropic support</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Hemodynamically stable</li>
                <li>Euvolemic on oral diuretics</li>
                <li>Intervention plan established (SAVR/TAVR scheduled)</li>
                <li>Cardiology follow-up arranged</li>
                <li>Patient educated on activity restrictions and symptoms</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 133: ACUTE MITRAL REGURGITATION -->
<div id="acute-mr" class="condition-page">
    <div class="page-header">
        <h2>133. ACUTE MITRAL REGURGITATION</h2>
        <div class="subtitle">Papillary Muscle Rupture â€¢ Chordae Tendineae â€¢ Surgical Emergency</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Key Distinction from Chronic MR:</span> In acute MR, the LA is non-compliant (no time to dilate) â†’ acute elevation of LA pressure â†’ flash pulmonary edema. Chronic MR allows LA dilation, delaying symptoms.</p>
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li>Acute, severe dyspnea</li>
                <li>Flash pulmonary edema</li>
                <li>Hypotension, cardiogenic shock</li>
                <li>May have chest pain if ischemic etiology</li>
            </ul>
            <p><span class="label">Physical Exam:</span></p>
            <ul>
                <li><strong>Murmur may be SOFT or ABSENT:</strong> Rapid equilibration of LV and LA pressures limits murmur duration/intensity</li>
                <li><strong>S3 gallop:</strong> Volume overload</li>
                <li><strong>Rales:</strong> Pulmonary edema</li>
                <li><strong>Hypotension:</strong> Reduced forward cardiac output</li>
            </ul>
            <p><span class="label">Etiologies:</span></p>
            <ul>
                <li><strong>Papillary muscle rupture:</strong> Post-MI (usually 2-7 days after inferior MI, posteromedial papillary muscle most common)</li>
                <li><strong>Chordae tendineae rupture:</strong> Myxomatous degeneration (MVP), endocarditis, trauma</li>
                <li><strong>Infective endocarditis:</strong> Valve perforation, vegetation interference</li>
                <li><strong>Prosthetic valve dysfunction:</strong> Dehiscence, stuck leaflet</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Echocardiography (Urgent):</span></p>
            <ul>
                <li><strong>TTE:</strong> Initial study â€“ shows flail leaflet, ruptured chordae/papillary muscle, severe MR jet</li>
                <li><strong>TEE:</strong> Better visualization of mitral apparatus, essential for surgical planning</li>
                <li><strong>Findings:</strong> Hyperdynamic LV (volume overload), dilated LA (if any chronicity), pulmonary hypertension, flail leaflet</li>
            </ul>
            <p><span class="label">Other Studies:</span></p>
            <ul>
                <li><strong>CXR:</strong> Pulmonary edema, often asymmetric (MR jet directed posteriorly â†’ right-sided edema)</li>
                <li><strong>ECG:</strong> May show ischemia if post-MI; AF common</li>
                <li><strong>BNP:</strong> Markedly elevated</li>
                <li><strong>Coronary angiography:</strong> If ischemic etiology suspected and patient stable enough</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="#acs" style="color: #0366d6;">ðŸ“š Acute Coronary Syndrome</a>, <a href="#endocarditis" style="color: #0366d6;">ðŸ“š Infective Endocarditis</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Medical Stabilization (Bridge to Surgery):</span></p>
            <ul>
                <li><strong>Afterload reduction:</strong> Nitroprusside (if BP tolerates) â€“ reduces regurgitant fraction by promoting forward flow</li>
                <li><strong>Inotropes:</strong> Dobutamine if hypotensive</li>
                <li><strong>Diuretics:</strong> For pulmonary edema</li>
                <li><strong>IABP:</strong> Reduces afterload, augments diastolic coronary perfusion, stabilizes hemodynamics</li>
                <li><strong>Avoid:</strong> Pure vasoconstrictors (increase afterload, worsen MR)</li>
            </ul>
            <p><span class="label">Definitive Treatment = SURGERY:</span></p>
            <ul>
                <li><strong>Urgent/emergent mitral valve surgery</strong> â€“ repair preferred if feasible, replacement if not</li>
                <li><strong>Timing:</strong> As soon as possible once diagnosis confirmed. Delay increases mortality.</li>
                <li><strong>Post-MI papillary rupture:</strong> Extremely high mortality without surgery (~75% in 24h). Emergent OR.</li>
            </ul>
            <p><span class="label">Specific Etiologies:</span></p>
            <ul>
                <li><strong>Post-MI:</strong> Emergent surgery Â± CABG</li>
                <li><strong>Endocarditis:</strong> Surgery for hemodynamic instability, plus antibiotics</li>
                <li><strong>Prosthetic valve:</strong> Re-operation or transcatheter intervention depending on mechanism</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Murmur May Be Soft:</strong> Unlike chronic MR, acute severe MR may have a soft or short murmur due to rapid pressure equilibration. Don't rely on murmur intensity to assess severity.</li>
            <li><strong>Post-MI Timing:</strong> Papillary muscle rupture typically occurs 2-7 days post-MI. Patient may have been improving, then sudden deterioration.</li>
            <li><strong>Posteromedial > Anterolateral:</strong> Posteromedial papillary muscle (single blood supply from PDA) ruptures more often than anterolateral (dual supply).</li>
            <li><strong>IABP is Your Friend:</strong> In acute MR, IABP reduces afterload (decreases regurgitant fraction) and augments coronary perfusion. Use as bridge to OR.</li>
            <li><strong>Surgery is the Treatment:</strong> Medical therapy is temporizing only. Mortality without surgery is extremely high.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU/OR IF:</div>
            <ul>
                <li>All acute severe MR â€“ surgical emergency</li>
                <li>Cardiogenic shock</li>
                <li>Flash pulmonary edema</li>
                <li>Need for IABP or mechanical support</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ POST-OP CONSIDERATIONS</div>
            <ul>
                <li>ICU monitoring post-operatively</li>
                <li>Anticoagulation if mechanical valve</li>
                <li>Endocarditis prophylaxis education</li>
                <li>Cardiac rehab referral</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 134: SVT -->
<div id="svt" class="condition-page">
    <div class="page-header">
        <h2>134. SUPRAVENTRICULAR TACHYCARDIA (SVT)</h2>
        <div class="subtitle">AVNRT â€¢ AVRT â€¢ Adenosine â€¢ Cardioversion</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Narrow-complex tachycardia (QRS <120ms) originating above the ventricles, typically 150-250 bpm, regular rhythm.</p>
            <p><span class="label">Types of SVT:</span></p>
            <ul>
                <li><strong>AVNRT (60%):</strong> Re-entry circuit within AV node. Most common. P waves buried in QRS or pseudo-R' in V1.</li>
                <li><strong>AVRT (30%):</strong> Accessory pathway (e.g., WPW). Orthodromic (antegrade via AV node) = narrow complex. P waves after QRS.</li>
                <li><strong>Atrial tachycardia (10%):</strong> Focal or re-entrant atrial source. P wave morphology differs from sinus.</li>
            </ul>
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li>Palpitations (sudden onset, sudden offset)</li>
                <li>Lightheadedness, presyncope</li>
                <li>Chest discomfort, dyspnea</li>
                <li>Polyuria post-episode (ANP release from atrial stretch)</li>
                <li>Rarely syncope or hemodynamic collapse</li>
            </ul>
            <p><span class="label">Triggers:</span> Caffeine, alcohol, stress, decongestants, hyperthyroidism, electrolyte abnormalities</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">ECG During Tachycardia:</span></p>
            <ul>
                <li>Narrow QRS (<120ms) â€“ if wide, consider aberrancy or VT</li>
                <li>Regular R-R intervals</li>
                <li>Rate typically 150-250 bpm</li>
                <li>P wave location helps identify mechanism</li>
            </ul>
            <p><span class="label">Baseline ECG (After Conversion):</span></p>
            <ul>
                <li>Look for delta wave (WPW) â€“ short PR, slurred QRS upstroke</li>
                <li>Pre-excitation syndromes have risk of rapid AF with accessory pathway conduction</li>
            </ul>
            <p><span class="label">Labs:</span></p>
            <ul>
                <li>Electrolytes (K, Mg)</li>
                <li>TSH</li>
                <li>Troponin if chest pain or hemodynamic compromise</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ Electrolytes Reference</a>, <a href="im_guide.html#afib" style="color: #0366d6;">ðŸ©º Palpitations Framework</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Hemodynamically UNSTABLE:</span></p>
            <ul>
                <li><strong>Synchronized cardioversion:</strong> 50-100J biphasic, escalate as needed</li>
                <li>Don't delay for vagal maneuvers or adenosine if truly unstable</li>
            </ul>
            <p><span class="label">Hemodynamically STABLE â€“ Step-wise Approach:</span></p>
            <p><strong>Step 1: Vagal Maneuvers</strong></p>
            <ul>
                <li><strong>Valsalva (modified):</strong> Blow into 10mL syringe for 15 sec, then immediately lie supine with legs elevated 45Â° for 15 sec. Success rate ~40-50% with modified technique.</li>
                <li><strong>Carotid sinus massage:</strong> 5-10 sec unilateral pressure. Contraindicated if carotid bruit, recent stroke, known carotid disease.</li>
                <li><strong>Ice water to face:</strong> Dive reflex â€“ cold water or ice bag to face for 15-30 sec.</li>
            </ul>
            <p><strong>Step 2: Adenosine</strong></p>
            <ul>
                <li><strong>First dose:</strong> 6 mg rapid IV push through large proximal IV, followed immediately by 20 mL NS flush and arm elevation</li>
                <li><strong>Second dose:</strong> 12 mg if no response in 1-2 minutes</li>
                <li><strong>Third dose:</strong> 12 mg if needed</li>
                <li><strong>Warn patient:</strong> Transient chest discomfort, flushing, sense of "impending doom" â€“ resolves in seconds</li>
                <li><strong>Contraindications:</strong> Known WPW with pre-excited AF (can accelerate ventricular rate), severe asthma (relative)</li>
            </ul>
            <p><strong>Step 3: If Adenosine Fails</strong></p>
            <ul>
                <li><strong>Diltiazem:</strong> 0.25 mg/kg IV over 2 min (typically 15-20 mg), may repeat 0.35 mg/kg in 15 min. Then infusion 5-15 mg/hr.</li>
                <li><strong>Verapamil:</strong> 5-10 mg IV over 2 min</li>
                <li><strong>Beta-blockers:</strong> Metoprolol 5 mg IV q5min Ã— 3, or esmolol infusion</li>
                <li><strong>Avoid in WPW with pre-excitation:</strong> AV nodal blockers can accelerate accessory pathway conduction</li>
            </ul>
            <p><strong>Step 4: Cardioversion</strong></p>
            <ul>
                <li>If refractory to medications or patient decompensates</li>
                <li>Synchronized cardioversion 50-100J</li>
            </ul>
            <p><span class="label">Long-Term Management:</span></p>
            <ul>
                <li><strong>EP study and ablation:</strong> Curative for AVNRT and AVRT (~95% success)</li>
                <li><strong>Medical therapy:</strong> AV nodal blockers (beta-blocker, diltiazem) for rate control if ablation not desired</li>
                <li><strong>Pill-in-pocket:</strong> Diltiazem or propafenone for infrequent episodes</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Modified Valsalva Works Better:</strong> The modified Valsalva (strain then supine with leg elevation) has ~40% success vs. ~20% for standard Valsalva.</li>
            <li><strong>Adenosine Technique Matters:</strong> Must be rapid push through large, proximal IV with immediate flush. Slow administration = degradation before reaching heart.</li>
            <li><strong>WPW Danger:</strong> If pre-excited AF (irregular, wide-complex with varying morphology), AV nodal blockers (adenosine, diltiazem, digoxin) are CONTRAINDICATED â€“ can cause VF. Use procainamide or cardioversion.</li>
            <li><strong>Record the Strip:</strong> Always record continuous ECG during adenosine â€“ even if it doesn't terminate SVT, it may reveal underlying rhythm (flutter waves, P waves) during AV block.</li>
            <li><strong>Ablation is Curative:</strong> For recurrent SVT, refer to EP. Ablation success rate >95% for AVNRT/AVRT with low complication rate.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE IF:</div>
            <ul>
                <li>Hemodynamic instability</li>
                <li>Refractory to adenosine and rate control</li>
                <li>Wide-complex tachycardia (may be VT)</li>
                <li>Pre-excited AF (WPW with AF)</li>
                <li>Associated ischemia or heart failure</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Converted to sinus rhythm</li>
                <li>Hemodynamically stable</li>
                <li>No ongoing symptoms</li>
                <li>Rate control medication if recurrent</li>
                <li>EP/Cardiology follow-up for ablation discussion</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 135: MASSIVE HEMOPTYSIS -->
<div id="massive-hemoptysis" class="condition-page">
    <div class="page-header">
        <h2>135. MASSIVE HEMOPTYSIS</h2>
        <div class="subtitle">Airway Protection â€¢ Bronchial Artery Embolization â€¢ Positioning</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Variably defined as 100-600 mL/24h or any amount causing hemodynamic instability or respiratory compromise. Clinically, "massive" = life-threatening.</p>
            <p><span class="label">Key Point:</span> Death from massive hemoptysis is usually due to ASPHYXIATION (airway flooding), not exsanguination. Airway protection is priority #1.</p>
            <p><span class="label">Common Etiologies:</span></p>
            <ul>
                <li><strong>Bronchiectasis:</strong> Most common cause worldwide</li>
                <li><strong>Lung cancer:</strong> Common in developed countries</li>
                <li><strong>Tuberculosis:</strong> Active or post-TB bronchiectasis, Rasmussen aneurysm</li>
                <li><strong>Aspergilloma:</strong> Fungus ball in pre-existing cavity</li>
                <li><strong>Pulmonary arteriovenous malformation (AVM)</strong></li>
                <li><strong>Anticoagulation:</strong> May unmask underlying lesion</li>
                <li><strong>Iatrogenic:</strong> Post-biopsy, post-bronchoscopy, PA catheter rupture</li>
            </ul>
            <p><span class="label">Distinguishing Hemoptysis from Hematemesis:</span></p>
            <ul>
                <li>Hemoptysis: Bright red, frothy, alkaline pH, mixed with sputum, preceded by cough</li>
                <li>Hematemesis: Dark red/"coffee grounds", acidic pH, mixed with food, preceded by nausea</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Immediate Actions:</span></p>
            <ul>
                <li><strong>Position bleeding lung DOWN:</strong> If known laterality, place patient with bleeding side dependent to protect good lung from blood spillage</li>
                <li><strong>Supplemental O2:</strong> High-flow</li>
                <li><strong>Large-bore IV access:</strong> Prepare for resuscitation</li>
                <li><strong>Type and crossmatch:</strong> Have blood available</li>
                <li><strong>Reverse anticoagulation:</strong> If applicable (see <a href="#anticoag-reversal" style="color: #0366d6;">Anticoagulation Reversal</a>)</li>
                <li><strong>Avoid cough suppressants initially:</strong> May prevent clearing of blood from airways</li>
            </ul>
            <p><span class="label">Airway Management:</span></p>
            <ul>
                <li><strong>Early intubation if:</strong> Unable to protect airway, respiratory failure, ongoing massive bleeding</li>
                <li><strong>Use large ETT (â‰¥8.0):</strong> Allows bronchoscopy through tube</li>
                <li><strong>Mainstem intubation:</strong> If bleeding side known and bronchoscopy not immediately available, can intubate mainstem of non-bleeding lung to isolate</li>
                <li><strong>Double-lumen ETT:</strong> Allows lung isolation â€“ requires expertise</li>
            </ul>
            <p><span class="label">Diagnostic and Therapeutic Bronchoscopy:</span></p>
            <ul>
                <li><strong>Localize bleeding:</strong> Essential for directing therapy</li>
                <li><strong>Therapeutic options:</strong> Cold saline lavage, topical epinephrine (1:20,000), balloon tamponade, electrocautery</li>
                <li><strong>Rigid bronchoscopy:</strong> Better suction, airway control; requires anesthesia support</li>
            </ul>
            <p><span class="label">Bronchial Artery Embolization (BAE):</span></p>
            <ul>
                <li><strong>First-line definitive therapy</strong> for massive hemoptysis in most cases</li>
                <li>90%+ of hemoptysis from bronchial arteries (systemic circulation)</li>
                <li>Success rate 70-90% for immediate control</li>
                <li>Recurrence rate 10-30% â€“ may need repeat embolization or surgery</li>
            </ul>
            <p><span class="label">Surgery:</span></p>
            <ul>
                <li>Reserved for: BAE failure, recurrent hemoptysis, localized disease amenable to resection, Rasmussen aneurysm, AVM</li>
                <li>High operative mortality in emergency setting</li>
            </ul>
            <p><span class="label">Specific Etiologies:</span></p>
            <ul>
                <li><strong>TB:</strong> Anti-TB therapy + BAE</li>
                <li><strong>Aspergilloma:</strong> BAE; consider antifungals and surgical resection if localized</li>
                <li><strong>Malignancy:</strong> BAE for palliation; radiation therapy</li>
                <li><strong>AVM:</strong> Embolization or surgical resection</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="id_guide.html#fungal-infections" style="color: #0366d6;">ðŸ¦  ID Guide: Fungal Infections</a></p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Bleeding Lung DOWN:</strong> Position patient with suspected bleeding lung dependent. This protects the good lung from blood spillage. Asphyxiation, not exsanguination, is the main cause of death.</li>
            <li><strong>Don't Estimate Volume:</strong> Patients (and providers) are poor at estimating blood volume. Focus on physiologic impact: hemodynamic status, respiratory status, rate of bleeding.</li>
            <li><strong>Bronchial Arteries are the Source:</strong> 90%+ of massive hemoptysis is from bronchial arteries (high pressure, systemic). Pulmonary artery bleeding (low pressure) is rare but can occur (PA catheter rupture, Rasmussen aneurysm).</li>
            <li><strong>CT Before Bronchoscopy?</strong> If patient is stable enough, CTA chest can help localize bleeding and guide bronchoscopy/BAE. If unstable, proceed directly to bronchoscopy/OR.</li>
            <li><strong>Rasmussen Aneurysm:</strong> Pulmonary artery pseudoaneurysm in TB cavity. High mortality. Requires embolization or surgery.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>All massive hemoptysis â€“ ICU mandatory</li>
                <li>Respiratory failure</li>
                <li>Hemodynamic instability</li>
                <li>Need for intubation</li>
                <li>Urgent bronchoscopy or BAE needed</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ POST-STABILIZATION</div>
            <ul>
                <li>Identify and treat underlying cause</li>
                <li>Pulmonology and IR follow-up</li>
                <li>Consider thoracic surgery if recurrent</li>
                <li>Address anticoagulation needs</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 136: PULMONARY HYPERTENSION CRISIS -->
<div id="ph-crisis" class="condition-page">
    <div class="page-header">
        <h2>136. PULMONARY HYPERTENSION CRISIS</h2>
        <div class="subtitle">RV Failure â€¢ Avoid Systemic Hypotension â€¢ Pulmonary Vasodilators</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Acute RV failure in setting of pulmonary hypertension, often triggered by an acute event. Life-threatening emergency.</p>
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li>Severe dyspnea, worsening exercise intolerance</li>
                <li>Syncope or presyncope</li>
                <li>Chest pain (RV ischemia)</li>
                <li>Altered mental status (low cardiac output)</li>
            </ul>
            <p><span class="label">Signs:</span></p>
            <ul>
                <li>Hypotension, tachycardia</li>
                <li>Elevated JVP, RV heave</li>
                <li>Loud P2, TR murmur</li>
                <li>Peripheral edema, hepatomegaly</li>
                <li>Cool extremities (low output)</li>
            </ul>
            <p><span class="label">Common Triggers:</span></p>
            <ul>
                <li>Infection/sepsis</li>
                <li>Arrhythmia (especially AF)</li>
                <li>PE (acute-on-chronic)</li>
                <li>Non-compliance with PH therapy</li>
                <li>Anesthesia/surgery</li>
                <li>Pregnancy (high mortality in PH)</li>
                <li>Volume overload</li>
                <li>Hypoxemia</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Goals:</span></p>
            <ul>
                <li>Maintain systemic BP (RV coronary perfusion occurs in systole AND diastole â€“ need MAP)</li>
                <li>Reduce RV afterload (pulmonary vasodilation)</li>
                <li>Optimize RV preload (gentle diuresis if overloaded, avoid aggressive volume removal)</li>
                <li>Maintain contractility</li>
                <li>Treat underlying trigger</li>
            </ul>
            <p><span class="label">Immediate Interventions:</span></p>
            <ul>
                <li><strong>Oxygen:</strong> Hypoxic pulmonary vasoconstriction worsens PH. Target SpO2 >90%.</li>
                <li><strong>Avoid intubation if possible:</strong> Positive pressure ventilation reduces RV preload. If necessary, use low PEEP, avoid hypoxia, maintain systemic BP during induction.</li>
                <li><strong>IV access, arterial line:</strong> Close hemodynamic monitoring essential</li>
            </ul>
            <p><span class="label">Hemodynamic Support:</span></p>
            <ul>
                <li><strong>Norepinephrine:</strong> First-line vasopressor. Maintains systemic BP for RV perfusion.</li>
                <li><strong>Vasopressin:</strong> May add as second agent; causes systemic vasoconstriction with less pulmonary vasoconstriction than other agents.</li>
                <li><strong>Dobutamine:</strong> Inotropic support for RV; may cause systemic hypotension (vasodilation).</li>
                <li><strong>Avoid pure vasodilators:</strong> Will drop systemic BP without proportional drop in PVR â†’ RV ischemia.</li>
            </ul>
            <p><span class="label">Pulmonary Vasodilators:</span></p>
            <ul>
                <li><strong>Inhaled nitric oxide (iNO):</strong> Selective pulmonary vasodilator; no systemic hypotension. Start 10-20 ppm.</li>
                <li><strong>Inhaled epoprostenol:</strong> Alternative to iNO; cheaper, more available.</li>
                <li><strong>IV epoprostenol:</strong> Potent but causes systemic hypotension. Use with systemic vasopressor support.</li>
                <li><strong>Continue home PH medications:</strong> Do NOT stop chronic PH therapies (prostacyclins, ERA, PDE5i). Rebound PH can be fatal.</li>
            </ul>
            <p><span class="label">Diuresis:</span></p>
            <ul>
                <li>Gentle diuresis if RV volume overloaded (elevated CVP, peripheral edema)</li>
                <li>Avoid aggressive diuresis â€“ RV is preload-dependent</li>
            </ul>
            <p><span class="label">Treat Underlying Trigger:</span> Infection, PE, arrhythmia, etc.</p>
            <p><span class="label">Refractory Cases:</span></p>
            <ul>
                <li>ECMO (VA-ECMO) as bridge to recovery or transplant</li>
                <li>Atrial septostomy (decompresses RV)</li>
                <li>Urgent transplant evaluation</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>RV Needs Systemic Pressure:</strong> Unlike LV (perfused mainly in diastole), the RV is perfused throughout cardiac cycle. Systemic hypotension â†’ RV ischemia â†’ RV failure spiral.</li>
            <li><strong>Never Stop Home PH Meds:</strong> Abruptly stopping prostacyclins (especially IV) causes rebound PH and death. Ensure continuous infusion even in crisis.</li>
            <li><strong>Avoid Intubation if Possible:</strong> Positive pressure ventilation decreases RV preload and can precipitate cardiovascular collapse. If intubation required, use experienced provider, maintain BP, use low PEEP.</li>
            <li><strong>Inhaled Pulmonary Vasodilators:</strong> iNO and inhaled epoprostenol selectively vasodilate pulmonary vasculature without systemic hypotension. Ideal in PH crisis.</li>
            <li><strong>The Death Spiral:</strong> RV dilation â†’ TR worsens â†’ RV CO drops â†’ systemic hypotension â†’ RV ischemia â†’ RV fails further. Must break this cycle early.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>All PH crisis â€“ ICU mandatory</li>
                <li>Hypotension, shock</li>
                <li>Need for vasopressors or inotropes</li>
                <li>Respiratory failure</li>
                <li>Syncope</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ STABILIZATION GOALS</div>
            <ul>
                <li>MAP >65 mmHg</li>
                <li>SpO2 >90%</li>
                <li>Resolving end-organ dysfunction</li>
                <li>Weaning vasopressors</li>
                <li>PH specialist consultation</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 137: DIC -->
<div id="dic" class="condition-page">
    <div class="page-header">
        <h2>137. DISSEMINATED INTRAVASCULAR COAGULATION (DIC)</h2>
        <div class="subtitle">Consumption Coagulopathy â€¢ Treat Underlying Cause â€¢ ISTH Score</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Systemic activation of coagulation causing widespread microvascular thrombosis AND consumption of clotting factors/platelets â†’ simultaneous bleeding and clotting.</p>
            <p><span class="label">Clinical Features:</span></p>
            <ul>
                <li><strong>Bleeding:</strong> Oozing from IV sites, surgical wounds, mucosal bleeding, petechiae, ecchymoses</li>
                <li><strong>Thrombosis:</strong> Digital ischemia, skin necrosis, organ dysfunction (renal, hepatic)</li>
                <li><strong>Purpura fulminans:</strong> Large ecchymoses with central necrosis (protein C depletion)</li>
            </ul>
            <p><span class="label">Underlying Causes (DIC is ALWAYS Secondary):</span></p>
            <ul>
                <li><strong>Sepsis:</strong> Most common cause (~35%)</li>
                <li><strong>Malignancy:</strong> Solid tumors (mucin-secreting), acute leukemia (especially APL)</li>
                <li><strong>Trauma:</strong> Massive tissue injury, burns</li>
                <li><strong>Obstetric:</strong> Placental abruption, amniotic fluid embolism, HELLP, septic abortion</li>
                <li><strong>Vascular:</strong> Large aortic aneurysm, giant hemangioma (Kasabach-Merritt)</li>
                <li><strong>Toxic:</strong> Snake envenomation, transfusion reaction, drug reactions</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">No Single Test is Diagnostic:</span> DIC is diagnosed by pattern of abnormalities + clinical context.</p>
            <p><span class="label">Laboratory Findings:</span></p>
            <ul>
                <li><strong>Platelets:</strong> Low or rapidly falling</li>
                <li><strong>PT/INR:</strong> Prolonged (consumption of factors)</li>
                <li><strong>PTT:</strong> Prolonged (but may be normal early)</li>
                <li><strong>Fibrinogen:</strong> Low (consumed) â€“ but may be normal/elevated if acute phase reactant effect</li>
                <li><strong>D-dimer/FDP:</strong> Markedly elevated (fibrinolysis)</li>
                <li><strong>Peripheral smear:</strong> Schistocytes (microangiopathic hemolysis from fibrin strands)</li>
            </ul>
            <p><span class="label">ISTH DIC Score:</span></p>
            <ul>
                <li>Platelet count: >100k (0), 50-100k (1), <50k (2)</li>
                <li>D-dimer: No increase (0), moderate (2), strong (3)</li>
                <li>PT prolongation: <3 sec (0), 3-6 sec (1), >6 sec (2)</li>
                <li>Fibrinogen: >1 g/L (0), <1 g/L (1)</li>
                <li><strong>Score â‰¥5:</strong> Compatible with overt DIC</li>
            </ul>
            <p><span class="label">Distinguish from Other Conditions:</span></p>
            <ul>
                <li><strong>TTP/HUS:</strong> Coags (PT/PTT/fibrinogen) are NORMAL in TTP</li>
                <li><strong>Liver failure:</strong> Similar coagulopathy but different clinical context; factor VIII normal or elevated (synthesized outside liver)</li>
                <li><strong>HIT:</strong> Thrombocytopenia + thrombosis but coags usually normal</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ Coagulation Reference</a>, <a href="#ttp-hus" style="color: #0366d6;">ðŸ“š TTP/HUS</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Treat Underlying Cause:</span> This is the ONLY definitive treatment. DIC will not resolve until trigger is eliminated.</p>
            <ul>
                <li>Sepsis â†’ antibiotics, source control</li>
                <li>Obstetric â†’ delivery, surgical intervention</li>
                <li>Malignancy â†’ chemotherapy (especially APL â€“ ATRA)</li>
                <li>Trauma â†’ hemorrhage control, damage control surgery</li>
            </ul>
            <p><span class="label">Supportive Therapy (Replace What's Consumed):</span></p>
            <ul>
                <li><strong>Platelets:</strong> Transfuse if <10k (or <50k with bleeding/procedure). Don't chase a number â€“ will be consumed.</li>
                <li><strong>FFP:</strong> For active bleeding with prolonged PT/PTT. Give 15-30 mL/kg.</li>
                <li><strong>Cryoprecipitate:</strong> If fibrinogen <100-150 mg/dL. Target fibrinogen >100-150.</li>
                <li><strong>PRBC:</strong> For anemia/hemorrhage</li>
            </ul>
            <p><span class="label">Anticoagulation â€“ Controversial:</span></p>
            <ul>
                <li><strong>Generally NOT recommended</strong> in bleeding-predominant DIC</li>
                <li><strong>May consider:</strong> If thrombosis-predominant (e.g., purpura fulminans, acral ischemia) and bleeding controlled</li>
                <li><strong>APL with DIC:</strong> ATRA is treatment; heparin not beneficial</li>
            </ul>
            <p><span class="label">Antifibrinolytics (TXA, aminocaproic acid):</span></p>
            <ul>
                <li>Generally contraindicated (can worsen microvascular thrombosis)</li>
                <li>Exception: Hyperfibrinolytic DIC (trauma, APL) â€“ use with caution</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>DIC is Always Secondary:</strong> Never treat DIC in isolation. Find and treat the underlying cause â€“ DIC won't resolve otherwise.</li>
            <li><strong>Coags are Deranged in DIC, NOT in TTP:</strong> This is a key distinguishing feature. TTP has normal PT/PTT/fibrinogen; DIC has abnormal coags.</li>
            <li><strong>Don't Chase Numbers:</strong> Platelet and FFP transfusions are consumed rapidly in active DIC. Transfuse for active bleeding or procedures, not to normalize labs.</li>
            <li><strong>Fibrinogen Can Be Misleading:</strong> Fibrinogen is an acute phase reactant. In sepsis-associated DIC, fibrinogen may be "normal" even while being consumed. A "normal" fibrinogen in septic patient may actually represent significant consumption.</li>
            <li><strong>APL is Special:</strong> Acute promyelocytic leukemia has characteristic DIC. ATRA (all-trans retinoic acid) is treatment â€“ improves coagulopathy as it treats disease.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Active bleeding requiring transfusion</li>
                <li>End-organ dysfunction</li>
                <li>Hemodynamic instability</li>
                <li>Need for massive transfusion</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ RESOLUTION CRITERIA</div>
            <ul>
                <li>Underlying cause treated/resolving</li>
                <li>Improving platelet count</li>
                <li>Normalizing PT/PTT</li>
                <li>Rising fibrinogen</li>
                <li>Decreasing D-dimer</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 138: TUMOR LYSIS SYNDROME -->
<div id="tls" class="condition-page">
    <div class="page-header">
        <h2>138. TUMOR LYSIS SYNDROME (TLS)</h2>
        <div class="subtitle">Hyperuricemia â€¢ Hyperkalemia â€¢ Hyperphosphatemia â€¢ Hypocalcemia</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Metabolic emergency from rapid tumor cell death releasing intracellular contents. Can be spontaneous or treatment-induced.</p>
            <p><span class="label">Classic Metabolic Abnormalities:</span></p>
            <ul>
                <li><strong>Hyperuricemia:</strong> Nucleic acid breakdown â†’ uric acid</li>
                <li><strong>Hyperkalemia:</strong> Intracellular K+ release</li>
                <li><strong>Hyperphosphatemia:</strong> Intracellular PO4 release</li>
                <li><strong>Hypocalcemia:</strong> Ca binds to elevated phosphate â†’ precipitation</li>
            </ul>
            <p><span class="label">Clinical Manifestations:</span></p>
            <ul>
                <li><strong>AKI:</strong> Uric acid and calcium phosphate crystal deposition in tubules</li>
                <li><strong>Arrhythmias:</strong> From hyperkalemia and hypocalcemia</li>
                <li><strong>Seizures:</strong> Hypocalcemia</li>
                <li><strong>Muscle cramps, tetany:</strong> Hypocalcemia</li>
                <li><strong>Nausea, vomiting, diarrhea</strong></li>
            </ul>
            <p><span class="label">High-Risk Malignancies:</span></p>
            <ul>
                <li><strong>Highest risk:</strong> Burkitt lymphoma, ALL (especially with high WBC), AML (especially with high WBC)</li>
                <li><strong>Moderate risk:</strong> Other aggressive lymphomas, solid tumors with rapid response to therapy</li>
                <li><strong>Risk factors:</strong> High tumor burden, high LDH, high WBC, pre-existing renal impairment, dehydration</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC CRITERIA</div>
        <div class="section-content">
            <p><span class="label">Cairo-Bishop Criteria:</span></p>
            <p><strong>Laboratory TLS:</strong> â‰¥2 of the following within 3 days before or 7 days after chemotherapy:</p>
            <ul>
                <li>Uric acid â‰¥8 mg/dL or 25% increase from baseline</li>
                <li>Potassium â‰¥6.0 mEq/L or 25% increase</li>
                <li>Phosphorus â‰¥4.5 mg/dL (adults) or 25% increase</li>
                <li>Calcium â‰¤7.0 mg/dL or 25% decrease</li>
            </ul>
            <p><strong>Clinical TLS:</strong> Laboratory TLS + â‰¥1 of:</p>
            <ul>
                <li>Creatinine â‰¥1.5Ã— ULN</li>
                <li>Cardiac arrhythmia or sudden death</li>
                <li>Seizure</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ Electrolytes Reference</a>, <a href="#hyperkalemia" style="color: #0366d6;">ðŸ“š Hyperkalemia</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Prevention (High-Risk Patients):</span></p>
            <ul>
                <li><strong>IV hydration:</strong> 2-3 L/mÂ²/day NS. Target urine output 80-100 mL/mÂ²/hr (or ~200 mL/hr adult).</li>
                <li><strong>Allopurinol:</strong> 300-600 mg/day, start 1-2 days before chemotherapy. Prevents NEW uric acid formation.</li>
                <li><strong>Rasburicase:</strong> For high-risk patients or established hyperuricemia. 0.2 mg/kg IV Ã— 1. Breaks down EXISTING uric acid. Contraindicated in G6PD deficiency (hemolysis).</li>
                <li><strong>Avoid alkalinization:</strong> Previously used to increase uric acid solubility, but promotes calcium phosphate precipitation. Not routinely recommended.</li>
            </ul>
            <p><span class="label">Treatment of Established TLS:</span></p>
            <ul>
                <li><strong>Aggressive IV hydration:</strong> 3 L/mÂ²/day with close monitoring</li>
                <li><strong>Rasburicase:</strong> For hyperuricemia (0.2 mg/kg IV Ã— 1, may repeat)</li>
                <li><strong>Hyperkalemia management:</strong> Calcium gluconate (cardiac protection), insulin/glucose, kayexalate, diuretics, dialysis if severe (see <a href="#hyperkalemia" style="color: #0366d6;">Hyperkalemia</a>)</li>
                <li><strong>Hyperphosphatemia:</strong> Phosphate binders (sevelamer, calcium-free if hypocalcemic), dialysis if severe</li>
                <li><strong>Hypocalcemia:</strong> Treat only if symptomatic (tetany, seizures, arrhythmia). Asymptomatic hypocalcemia â€“ avoid Ca supplementation (can worsen calcium phosphate precipitation).</li>
            </ul>
            <p><span class="label">Dialysis Indications:</span></p>
            <ul>
                <li>Severe hyperkalemia refractory to medical management</li>
                <li>Severe hyperphosphatemia</li>
                <li>Volume overload</li>
                <li>Symptomatic hypocalcemia with high phosphate (can't give Ca without worsening precipitation)</li>
                <li>Uremia</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Prevention is Key:</strong> High-risk patients should receive prophylaxis (hydration + allopurinol or rasburicase) BEFORE chemotherapy. Once TLS is established, management is more difficult.</li>
            <li><strong>Rasburicase is a Game-Changer:</strong> Unlike allopurinol (prevents new uric acid), rasburicase breaks down existing uric acid. Works in hours, not days. First-line for established hyperuricemia or very high-risk patients.</li>
            <li><strong>G6PD and Rasburicase:</strong> Rasburicase is CONTRAINDICATED in G6PD deficiency â€“ causes severe hemolysis. Screen if possible, especially in high-risk populations.</li>
            <li><strong>Don't Treat Asymptomatic Hypocalcemia:</strong> Giving calcium when phosphate is high causes calcium phosphate precipitation â†’ worsens renal injury. Only treat symptomatic hypocalcemia.</li>
            <li><strong>Alkalinization is OUT:</strong> Old teaching was to alkalinize urine to solubilize uric acid. This promotes calcium phosphate precipitation and is NOT recommended.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Clinical TLS (AKI, arrhythmia, seizure)</li>
                <li>Severe hyperkalemia (>6.5 or ECG changes)</li>
                <li>Need for dialysis</li>
                <li>Symptomatic hypocalcemia</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ RESOLUTION CRITERIA</div>
            <ul>
                <li>Normalizing electrolytes</li>
                <li>Improving renal function</li>
                <li>Adequate urine output</li>
                <li>No arrhythmias</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 139: HYPERVISCOSITY SYNDROME -->
<div id="hyperviscosity" class="condition-page">
    <div class="page-header">
        <h2>139. HYPERVISCOSITY SYNDROME</h2>
        <div class="subtitle">Waldenstrom's â€¢ Multiple Myeloma â€¢ Plasmapheresis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Increased blood viscosity causing impaired microvascular flow. Classic triad: bleeding, neurologic symptoms, visual disturbances.</p>
            <p><span class="label">Classic Triad:</span></p>
            <ul>
                <li><strong>Bleeding:</strong> Mucosal bleeding (epistaxis, gingival), GI bleeding, menorrhagia. Paraprotein interferes with platelet function and coagulation factors.</li>
                <li><strong>Neurologic:</strong> Headache, confusion, altered mental status, ataxia, vertigo, hearing loss, stroke-like symptoms</li>
                <li><strong>Visual:</strong> Blurred vision, diplopia, vision loss. Fundoscopy shows "sausage-link" or "boxcar" retinal veins, retinal hemorrhages, papilledema.</li>
            </ul>
            <p><span class="label">Other Manifestations:</span></p>
            <ul>
                <li>Dyspnea, hypoxia (pulmonary infiltrates)</li>
                <li>Heart failure (increased cardiac workload)</li>
                <li>Cryoglobulinemia (if cryoglobulins present)</li>
            </ul>
            <p><span class="label">Common Causes:</span></p>
            <ul>
                <li><strong>Waldenstrom macroglobulinemia (IgM):</strong> Most common cause. IgM is large pentamer â€“ small increases cause large viscosity changes.</li>
                <li><strong>Multiple myeloma (IgA, IgG3):</strong> Less common than WM. IgA tends to polymerize.</li>
                <li><strong>Polycythemia vera / Leukostasis:</strong> Cellular hyperviscosity (WBC >100k or Hct >60%)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Serum Viscosity:</span></p>
            <ul>
                <li>Normal: 1.4-1.8 centipoise (relative to water)</li>
                <li>Symptoms typically occur at >4 cp (but varies by individual)</li>
                <li>Some patients symptomatic at lower levels; others asymptomatic at higher levels</li>
            </ul>
            <p><span class="label">Laboratory:</span></p>
            <ul>
                <li><strong>SPEP/UPEP:</strong> M-spike</li>
                <li><strong>Immunofixation:</strong> Identifies paraprotein type (IgM, IgA, IgG)</li>
                <li><strong>Quantitative immunoglobulins:</strong> Elevated monoclonal Ig</li>
                <li><strong>CBC:</strong> Anemia common (dilutional, marrow infiltration)</li>
                <li><strong>Coagulation studies:</strong> May be abnormal (paraprotein interference)</li>
            </ul>
            <p><span class="label">Fundoscopic Exam:</span> Essential â€“ look for retinal vein engorgement, hemorrhages, papilledema</p>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ SPEP Reference</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Emergent Treatment â€“ Plasmapheresis:</span></p>
            <ul>
                <li><strong>Removes circulating paraprotein</strong> â€“ rapidly reduces viscosity</li>
                <li>Single session can reduce IgM by 30-50%</li>
                <li>Usually 1-2 exchanges initially, then as needed</li>
                <li>Bridge to definitive chemotherapy</li>
            </ul>
            <p><span class="label">Supportive Measures:</span></p>
            <ul>
                <li><strong>IV hydration:</strong> Improves rheology</li>
                <li><strong>AVOID transfusion of PRBC:</strong> Will worsen viscosity. If anemia severe and transfusion necessary, do after plasmapheresis.</li>
                <li><strong>Treat bleeding:</strong> Supportive; may need platelet transfusion</li>
            </ul>
            <p><span class="label">Definitive Treatment â€“ Chemotherapy:</span></p>
            <ul>
                <li><strong>Waldenstrom:</strong> Rituximab-based regimens (but rituximab can cause IgM flare â€“ sometimes defer until after plasmapheresis), BTK inhibitors (ibrutinib)</li>
                <li><strong>Multiple myeloma:</strong> Bortezomib-based regimens, IMiDs</li>
            </ul>
            <p><span class="label">Rituximab Flare:</span> Rituximab can cause transient increase in IgM (tumor lysis or cytokine release). In hyperviscosity, may need plasmapheresis before rituximab.</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>IgM is the Worst Offender:</strong> IgM is a pentamer (large) â€“ small increases cause disproportionate viscosity increase. Waldenstrom's is more likely to cause hyperviscosity than myeloma at same paraprotein level.</li>
            <li><strong>Check the Eyes:</strong> Fundoscopic exam is essential. "Sausage-link" retinal veins are classic. Visual changes may be the presenting symptom.</li>
            <li><strong>Don't Transfuse RBCs:</strong> This will worsen viscosity. If patient needs blood, do plasmapheresis first.</li>
            <li><strong>Plasmapheresis is Temporary:</strong> Reduces paraprotein but doesn't treat underlying disease. Chemotherapy is definitive treatment.</li>
            <li><strong>Symptoms Don't Correlate Perfectly with Viscosity:</strong> Some patients are symptomatic at viscosity 3, others asymptomatic at 6. Treat symptoms, not just numbers.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Altered mental status, obtundation</li>
                <li>Stroke-like symptoms</li>
                <li>Severe bleeding</li>
                <li>Respiratory failure</li>
                <li>Urgent plasmapheresis needed</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Symptoms resolved</li>
                <li>Viscosity improved</li>
                <li>Chemotherapy plan established</li>
                <li>Hematology/Oncology follow-up</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 140: MYASTHENIC CRISIS -->
<div id="myasthenic-crisis" class="condition-page">
    <div class="page-header">
        <h2>140. MYASTHENIC CRISIS</h2>
        <div class="subtitle">Respiratory Failure â€¢ IVIG/Plasmapheresis â€¢ Avoid Certain Medications</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Life-threatening weakness in myasthenia gravis requiring mechanical ventilation or airway protection due to respiratory muscle or bulbar weakness.</p>
            <p><span class="label">Warning Signs of Impending Crisis:</span></p>
            <ul>
                <li>Worsening dyspnea, orthopnea</li>
                <li>Dysphagia, difficulty managing secretions</li>
                <li>Weak cough</li>
                <li>Rapid shallow breathing</li>
                <li>Use of accessory muscles</li>
            </ul>
            <p><span class="label">Common Triggers:</span></p>
            <ul>
                <li><strong>Infection:</strong> Most common trigger (especially respiratory infections)</li>
                <li><strong>Medications:</strong> Aminoglycosides, fluoroquinolones, beta-blockers, magnesium, neuromuscular blockers</li>
                <li><strong>Surgery/Anesthesia</strong></li>
                <li><strong>Medication changes:</strong> Reduction of immunotherapy, missed doses</li>
                <li><strong>Pregnancy/Postpartum</strong></li>
                <li><strong>Emotional/Physical stress</strong></li>
            </ul>
            <p><span class="label">Distinguish from Cholinergic Crisis:</span></p>
            <ul>
                <li>Cholinergic crisis = excessive acetylcholinesterase inhibitor (pyridostigmine)</li>
                <li>Features: SLUDGE (salivation, lacrimation, urination, defecation, GI cramping, emesis), miosis, bradycardia</li>
                <li>Both can cause weakness â€“ history and exam help differentiate</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Bedside Pulmonary Function:</span></p>
            <ul>
                <li><strong>FVC (Forced Vital Capacity):</strong> Most important parameter. <1 L or <15-20 mL/kg = impending respiratory failure</li>
                <li><strong>NIF (Negative Inspiratory Force):</strong> More negative is better. Less negative than -30 cmH2O = weakness</li>
                <li><strong>Trend is critical:</strong> Declining FVC even if still "normal" is concerning</li>
                <li><strong>20-30-40 Rule:</strong> Consider intubation if FVC <20 mL/kg, NIF > -30, or FVC decline >30% from baseline</li>
            </ul>
            <p><span class="label">Laboratory:</span></p>
            <ul>
                <li>ABG (late finding â€“ don't wait for hypercapnia)</li>
                <li>Infectious workup (CXR, UA, blood cultures)</li>
                <li>TSH (thyroid disease associated with MG)</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ ABG Reference</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Airway Management:</span></p>
            <ul>
                <li><strong>Low threshold for intubation:</strong> Don't wait for respiratory failure. Intubate early for declining FVC or bulbar dysfunction with aspiration risk.</li>
                <li><strong>Avoid depolarizing neuromuscular blockers:</strong> Succinylcholine â€“ MG patients are resistant (need higher dose) and may have prolonged weakness</li>
                <li><strong>Non-depolarizing NMBs:</strong> Use reduced dose (MG patients are very sensitive)</li>
            </ul>
            <p><span class="label">Immunomodulatory Therapy (Rescue Therapy):</span></p>
            <ul>
                <li><strong>Plasmapheresis:</strong> 5-7 exchanges over 10-14 days. Removes acetylcholine receptor antibodies. Effect in 2-5 days.</li>
                <li><strong>IVIG:</strong> 2 g/kg divided over 2-5 days. Similar efficacy to plasmapheresis. Effect in 4-5 days.</li>
                <li>Both are first-line for crisis â€“ choice often based on availability and patient factors (vascular access, renal function)</li>
            </ul>
            <p><span class="label">Medications to HOLD or AVOID:</span></p>
            <ul>
                <li><strong>HOLD pyridostigmine:</strong> During intubation â€“ reduces secretions, allows better assessment</li>
                <li><strong>Avoid:</strong> Aminoglycosides, fluoroquinolones, macrolides (use with caution), beta-blockers, magnesium, procainamide, lithium, phenytoin</li>
            </ul>
            <p><span class="label">Long-Term Immunotherapy (After Stabilization):</span></p>
            <ul>
                <li>Corticosteroids (may cause initial worsening â€“ start in hospital)</li>
                <li>Azathioprine, mycophenolate, cyclosporine</li>
                <li>Rituximab for refractory cases</li>
                <li>Thymectomy if thymoma or generalized MG</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>FVC is Your Friend:</strong> Serial FVC measurements are the best predictor of impending respiratory failure. ABG changes late â€“ don't wait for hypercarbia.</li>
            <li><strong>20-30-40 Rule:</strong> Intubate if FVC <20 mL/kg, NIF > -30 cmH2O (less negative than -30), or >30% decline from baseline.</li>
            <li><strong>Infection is the #1 Trigger:</strong> Aggressively look for and treat infection, but be mindful of antibiotic choice â€“ avoid aminoglycosides and fluoroquinolones if possible.</li>
            <li><strong>PLEX vs. IVIG:</strong> Both work. PLEX slightly faster onset. IVIG easier to administer. Choice often pragmatic.</li>
            <li><strong>Hold Pyridostigmine When Intubated:</strong> Reduces secretions, easier to manage. Restart when weaning.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>All myasthenic crisis â€“ ICU mandatory</li>
                <li>FVC <20 mL/kg or declining</li>
                <li>Bulbar weakness with aspiration risk</li>
                <li>Need for intubation</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ EXTUBATION CRITERIA</div>
            <ul>
                <li>FVC >15-20 mL/kg</li>
                <li>NIF < -30 cmH2O</li>
                <li>Adequate cough and secretion management</li>
                <li>Completed PLEX or IVIG course</li>
                <li>Underlying trigger treated</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- Continuing with conditions 141-148 in next section due to length -->
<!-- CONDITION 141: GUILLAIN-BARRÃ‰ SYNDROME -->
<div id="gbs" class="condition-page">
    <div class="page-header">
        <h2>141. GUILLAIN-BARRÃ‰ SYNDROME (GBS)</h2>
        <div class="subtitle">Ascending Paralysis â€¢ IVIG/Plasmapheresis â€¢ Autonomic Instability</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Features:</span></p>
            <ul>
                <li><strong>Ascending weakness:</strong> Starts distally in legs, progresses proximally over days to weeks</li>
                <li><strong>Areflexia:</strong> Absent or reduced deep tendon reflexes</li>
                <li><strong>Sensory symptoms:</strong> Paresthesias, pain (often less prominent than weakness)</li>
                <li><strong>Facial weakness:</strong> Bilateral in ~50%</li>
                <li><strong>Respiratory failure:</strong> 15-30% require ventilation</li>
            </ul>
            <p><span class="label">Preceding Illness:</span> 2/3 have antecedent infection 1-4 weeks prior (Campylobacter, CMV, EBV, Zika, influenza, COVID-19)</p>
            <p><span class="label">Variants:</span></p>
            <ul>
                <li><strong>AIDP:</strong> Classic demyelinating form (most common in Western countries)</li>
                <li><strong>AMAN/AMSAN:</strong> Axonal variants (more common in Asia, associated with Campylobacter)</li>
                <li><strong>Miller Fisher:</strong> Ophthalmoplegia, ataxia, areflexia (anti-GQ1b antibodies)</li>
            </ul>
            <p><span class="label">Red Flags for Respiratory Failure:</span></p>
            <ul>
                <li>Rapid progression (<7 days to unable to walk)</li>
                <li>Bulbar weakness</li>
                <li>Bilateral facial weakness</li>
                <li>Autonomic dysfunction</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">CSF Analysis (Lumbar Puncture):</span></p>
            <ul>
                <li><strong>Albuminocytologic dissociation:</strong> Elevated protein with normal cell count</li>
                <li>May be normal early (first week) â€“ repeat if negative and high suspicion</li>
            </ul>
            <p><span class="label">Electrodiagnostic Studies (EMG/NCS):</span></p>
            <ul>
                <li>Confirms diagnosis, distinguishes AIDP from axonal variants</li>
                <li>May be normal in first 1-2 weeks</li>
            </ul>
            <p><span class="label">Pulmonary Function:</span></p>
            <ul>
                <li>Serial FVC and NIF (same as myasthenic crisis)</li>
                <li>Same 20-30-40 rule applies</li>
            </ul>
            <p><span class="label">Anti-Ganglioside Antibodies:</span> GQ1b (Miller Fisher), GM1 (AMAN). Not required for diagnosis but can help classify.</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Immunomodulatory Therapy:</span></p>
            <ul>
                <li><strong>IVIG:</strong> 0.4 g/kg/day Ã— 5 days (total 2 g/kg). First-line in most centers.</li>
                <li><strong>Plasmapheresis:</strong> 5 exchanges over 1-2 weeks. Equally effective to IVIG.</li>
                <li><strong>Start within 2-4 weeks of symptom onset</strong> for best efficacy</li>
                <li><strong>Steroids are NOT effective</strong> (unlike other inflammatory neuropathies)</li>
            </ul>
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li><strong>Serial respiratory monitoring:</strong> FVC q4-6h initially</li>
                <li><strong>DVT prophylaxis:</strong> High risk due to immobility</li>
                <li><strong>Pain management:</strong> Gabapentin, opioids if needed</li>
                <li><strong>Physical therapy:</strong> Early mobilization</li>
            </ul>
            <p><span class="label">Autonomic Dysfunction:</span></p>
            <ul>
                <li>Occurs in 70% â€“ can be life-threatening</li>
                <li>Manifestations: Tachycardia, bradycardia, hypertension, hypotension, arrhythmias, ileus, urinary retention</li>
                <li>Continuous cardiac monitoring in ICU</li>
                <li>Use short-acting agents for BP management</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Ascending Weakness + Areflexia = GBS Until Proven Otherwise:</strong> Classic pattern. Sensory symptoms often present but less prominent than weakness.</li>
            <li><strong>Serial FVC is Critical:</strong> Same monitoring principles as myasthenic crisis. Don't wait for ABG abnormalities.</li>
            <li><strong>Steroids Don't Work:</strong> Unlike CIDP or other inflammatory conditions. Don't give steroids for GBS.</li>
            <li><strong>Autonomic Instability Kills:</strong> Cardiac arrhythmias are a major cause of death in GBS. Monitor continuously, use short-acting agents.</li>
            <li><strong>CSF Can Be Normal Early:</strong> Protein may not elevate until week 2. Don't exclude GBS based on normal early LP.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Declining FVC (<20-25 mL/kg)</li>
                <li>Bulbar weakness</li>
                <li>Autonomic instability</li>
                <li>Rapid progression</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ PROGNOSIS</div>
            <ul>
                <li>~80% walk independently at 6 months</li>
                <li>~5-10% mortality (respiratory, autonomic)</li>
                <li>Residual deficits common (fatigue, pain)</li>
                <li>Recovery can take months to years</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 142: SPINAL CORD COMPRESSION -->
<div id="spinal-cord-compression" class="condition-page">
    <div class="page-header">
        <h2>142. SPINAL CORD COMPRESSION</h2>
        <div class="subtitle">Oncologic Emergency â€¢ MRI Whole Spine â€¢ Dexamethasone</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Presentation:</span></p>
            <ul>
                <li><strong>Back pain:</strong> Most common initial symptom (90%+). Worse supine, with Valsalva</li>
                <li><strong>Weakness:</strong> Progresses over hours to days. Level depends on compression site.</li>
                <li><strong>Sensory level:</strong> Decreased sensation below level of compression</li>
                <li><strong>Bladder/bowel dysfunction:</strong> Late finding â€“ urinary retention, overflow incontinence, constipation</li>
            </ul>
            <p><span class="label">Etiologies:</span></p>
            <ul>
                <li><strong>Malignancy (Most Common):</strong> Metastatic (lung, breast, prostate, renal, lymphoma, myeloma). 5-10% of cancer patients.</li>
                <li><strong>Epidural abscess:</strong> Fever, back pain, risk factors (IVDU, bacteremia, spinal procedure)</li>
                <li><strong>Epidural hematoma:</strong> Anticoagulation, trauma, post-procedure</li>
                <li><strong>Disc herniation:</strong> Trauma, degenerative</li>
            </ul>
            <p><span class="label">Red Flags:</span> New back pain in cancer patient, fever + back pain, urinary retention, rapidly progressive weakness, saddle anesthesia</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">MRI Spine (URGENT):</span></p>
            <ul>
                <li><strong>WHOLE SPINE with and without contrast:</strong> Multiple levels of compression common in malignancy</li>
                <li>Gold standard for diagnosis</li>
                <li>Must be done EMERGENTLY â€“ prognosis depends on neurologic status at treatment initiation</li>
            </ul>
            <p><span class="label">CT Myelography:</span> Alternative if MRI contraindicated (pacemaker, etc.)</p>
            <p><span class="label">Laboratory:</span></p>
            <ul>
                <li>If epidural abscess suspected: Blood cultures, CBC, ESR, CRP</li>
                <li>If malignancy: Staging workup as indicated</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Immediate Management (Don't Delay for Imaging):</span></p>
            <ul>
                <li><strong>Dexamethasone:</strong> 10 mg IV bolus, then 4 mg IV q6h. Reduces edema, preserves neurologic function.</li>
                <li>Start immediately if high suspicion â€“ don't wait for MRI confirmation</li>
            </ul>
            <p><span class="label">Definitive Treatment â€“ Malignant Cord Compression:</span></p>
            <ul>
                <li><strong>Radiation therapy:</strong> First-line for most radiosensitive tumors (lymphoma, myeloma, small cell lung, breast, prostate)</li>
                <li><strong>Surgery (decompressive laminectomy) followed by radiation:</strong> Superior outcomes in selected patients (single site, radioresistant tumor, spinal instability, unknown primary, progression during/after RT)</li>
                <li><strong>Emergent surgery:</strong> If rapid neurologic decline</li>
            </ul>
            <p><span class="label">Epidural Abscess:</span></p>
            <ul>
                <li><strong>Emergent surgical decompression:</strong> Usually required</li>
                <li><strong>IV antibiotics:</strong> Broad-spectrum initially (vancomycin + cefepime or similar), then tailored to culture</li>
                <li><strong>Duration:</strong> 4-8 weeks IV antibiotics</li>
            </ul>
            <p><span class="label">Epidural Hematoma:</span></p>
            <ul>
                <li>Reverse anticoagulation (see <a href="#anticoag-reversal" style="color: #0366d6;">Anticoagulation Reversal</a>)</li>
                <li>Emergent surgical evacuation if neurologic deficits</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="id_guide.html#anatomic-infections" style="color: #0366d6;">ðŸ¦  ID Guide: Bone & Joint Infections</a></p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Time is Function:</strong> Neurologic status at treatment initiation predicts outcome. Ambulatory patients often remain ambulatory; paraplegic patients rarely recover. Treat urgently.</li>
            <li><strong>Give Steroids NOW:</strong> Don't wait for MRI. Dexamethasone is safe and can preserve function. Give it with first suspicion.</li>
            <li><strong>Image the WHOLE Spine:</strong> In malignancy, multiple levels of compression are common. Miss one, patient still has cord compression.</li>
            <li><strong>Epidural Abscess is Surgical:</strong> Unlike vertebral osteomyelitis, epidural abscess with neurologic deficits requires emergent surgery. Antibiotics alone are insufficient.</li>
            <li><strong>Bladder Dysfunction = Late Finding:</strong> Once present, prognosis for recovery is worse. Don't wait for this to act.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE IF:</div>
            <ul>
                <li>Any suspicion for cord compression</li>
                <li>Progressive neurologic deficits</li>
                <li>New bladder/bowel dysfunction</li>
                <li>Need for emergent surgery</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ PROGNOSIS FACTORS</div>
            <ul>
                <li>Pre-treatment ambulatory status</li>
                <li>Speed of deficit onset</li>
                <li>Duration of deficits before treatment</li>
                <li>Tumor type (radiosensitivity)</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 143-148: Toxicology and Rheum conditions - continuing -->
<!-- CONDITION 143: ACETAMINOPHEN OVERDOSE -->
<div id="apap-overdose" class="condition-page">
    <div class="page-header">
        <h2>143. ACETAMINOPHEN OVERDOSE</h2>
        <div class="subtitle">Rumack-Matthew Nomogram â€¢ N-Acetylcysteine â€¢ Acute Liver Failure</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Stages of Toxicity:</span></p>
            <ul>
                <li><strong>Stage 1 (0-24h):</strong> Often asymptomatic or nonspecific (nausea, vomiting, malaise). Labs normal.</li>
                <li><strong>Stage 2 (24-72h):</strong> RUQ pain, elevated AST/ALT. Stage 1 symptoms may resolve.</li>
                <li><strong>Stage 3 (72-96h):</strong> Peak hepatotoxicity. Markedly elevated transaminases, coagulopathy, encephalopathy, possible renal failure.</li>
                <li><strong>Stage 4 (4d-2wk):</strong> Recovery (if survived) or death from fulminant hepatic failure.</li>
            </ul>
            <p><span class="label">Key Point:</span> Patients may appear well initially. Don't be reassured by lack of early symptoms.</p>
            <p><span class="label">Toxic Dose:</span></p>
            <ul>
                <li>>150 mg/kg (or >7.5-10g in adults) acute ingestion â€“ potential for hepatotoxicity</li>
                <li>Chronic ingestion: lower thresholds, nomogram doesn't apply</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Serum Acetaminophen Level:</span></p>
            <ul>
                <li>Draw at 4 hours post-ingestion (or immediately if >4h since ingestion)</li>
                <li>Plot on Rumack-Matthew Nomogram</li>
            </ul>
            <p><span class="label">Rumack-Matthew Nomogram:</span></p>
            <ul>
                <li>Treatment line starts at 150 mcg/mL at 4h post-ingestion</li>
                <li>Level above the line â†’ treat with NAC</li>
                <li>Only valid for single acute ingestion with known time</li>
            </ul>
            <p><span class="label">Other Labs:</span></p>
            <ul>
                <li>AST/ALT (may be normal initially)</li>
                <li>INR, bilirubin</li>
                <li>BMP (creatinine â€“ renal failure can occur)</li>
                <li>Serum salicylate (common co-ingestant)</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ LFT Reference</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Decontamination:</span></p>
            <ul>
                <li><strong>Activated charcoal:</strong> If <4h from ingestion and patient alert. 1 g/kg (max 50g).</li>
            </ul>
            <p><span class="label">N-Acetylcysteine (NAC) â€“ The Antidote:</span></p>
            <ul>
                <li><strong>Indication:</strong> Level above treatment line, unknown ingestion time with detectable level and transaminitis, massive ingestion, late presentation with hepatotoxicity</li>
                <li><strong>Most effective if started within 8 hours</strong> â€“ but give even if late if hepatotoxicity present</li>
            </ul>
            <p><strong>IV NAC Protocol (21-hour):</strong></p>
            <ul>
                <li>Loading: 150 mg/kg in 200mL D5W over 1 hour</li>
                <li>Second dose: 50 mg/kg in 500mL D5W over 4 hours</li>
                <li>Third dose: 100 mg/kg in 1000mL D5W over 16 hours</li>
                <li>If ongoing hepatotoxicity, continue third dose rate until INR <2, AST/ALT declining, and no encephalopathy</li>
            </ul>
            <p><strong>Oral NAC Protocol (72-hour):</strong></p>
            <ul>
                <li>Loading: 140 mg/kg PO Ã— 1</li>
                <li>Maintenance: 70 mg/kg PO q4h Ã— 17 doses</li>
            </ul>
            <p><span class="label">Anaphylactoid Reactions to IV NAC:</span></p>
            <ul>
                <li>Common (10-20%) â€“ flushing, urticaria, bronchospasm</li>
                <li>Usually rate-related â€“ slow or pause infusion, give antihistamines</li>
                <li>True anaphylaxis rare â€“ can usually rechallenge at slower rate</li>
            </ul>
            <p><span class="label">Liver Transplant Criteria (King's College Criteria):</span></p>
            <ul>
                <li>pH <7.3 after resuscitation, OR</li>
                <li>All three: INR >6.5, Cr >3.4, Grade 3-4 encephalopathy</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>8-Hour Window:</strong> NAC is nearly 100% effective if started within 8 hours. Efficacy decreases after that but still give it.</li>
            <li><strong>Patients Look Well Initially:</strong> Stage 1 is asymptomatic. Don't discharge early based on how patient "looks."</li>
            <li><strong>Nomogram Only for Acute Single Ingestion:</strong> Chronic supratherapeutic ingestion, staggered dosing, or unknown time â†’ nomogram doesn't apply. Use clinical judgment, lower threshold to treat.</li>
            <li><strong>AST >1000:</strong> This should make you think of APAP toxicity (or ischemic/viral hepatitis). Not typical of other drug reactions.</li>
            <li><strong>Anaphylactoid â‰  Stop NAC:</strong> Slow the rate, give antihistamines, usually can resume. Don't withhold life-saving antidote.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Elevated INR or transaminases</li>
                <li>Encephalopathy</li>
                <li>Massive ingestion (>500 mg/kg)</li>
                <li>Concerning trajectory</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Level below treatment line at 4h+ post-ingestion</li>
                <li>Normal AST/ALT, INR</li>
                <li>Psychiatry clearance if intentional</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 144: SALICYLATE TOXICITY -->
<div id="salicylate-toxicity" class="condition-page">
    <div class="page-header">
        <h2>144. SALICYLATE TOXICITY</h2>
        <div class="subtitle">Mixed Acid-Base â€¢ Alkalinization â€¢ Dialysis Indications</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Early (Mild):</span> Tinnitus, nausea, vomiting, tachypnea (respiratory alkalosis from direct CNS stimulation)</p>
            <p><span class="label">Moderate:</span> Hyperthermia, diaphoresis, altered mental status, mixed acid-base disorder</p>
            <p><span class="label">Severe:</span> Seizures, coma, cerebral edema, pulmonary edema, cardiovascular collapse, hypoglycemia, coagulopathy</p>
            <p><span class="label">Classic Acid-Base Pattern:</span></p>
            <ul>
                <li><strong>Early:</strong> Respiratory alkalosis (CNS stimulation of respiratory center)</li>
                <li><strong>Later:</strong> Anion gap metabolic acidosis (uncoupled oxidative phosphorylation, lactate, ketones)</li>
                <li><strong>Mixed:</strong> Often see combined respiratory alkalosis + metabolic acidosis</li>
            </ul>
            <p><span class="label">Toxic Dose:</span> >150 mg/kg acute ingestion (single dose >6.5g in adults)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Decontamination:</span></p>
            <ul>
                <li><strong>Activated charcoal:</strong> Effective even several hours post-ingestion (enteric-coated formulations, bezoar formation)</li>
                <li>May repeat charcoal doses for significant ingestions</li>
            </ul>
            <p><span class="label">Urinary Alkalinization:</span></p>
            <ul>
                <li><strong>Goal:</strong> Urine pH 7.5-8.0. Traps ionized salicylate in urine, enhances elimination.</li>
                <li><strong>Method:</strong> Sodium bicarbonate 150 mEq in 1L D5W at 1.5-2Ã— maintenance</li>
                <li><strong>Monitor:</strong> Urine pH, serum K (alkalinization causes hypokalemia â€“ must replace K to achieve urinary alkalinization)</li>
            </ul>
            <p><span class="label">Hemodialysis Indications:</span></p>
            <ul>
                <li>Salicylate level >100 mg/dL (acute) or >80 mg/dL (chronic)</li>
                <li>Severe altered mental status or coma</li>
                <li>Pulmonary edema</li>
                <li>Seizures</li>
                <li>Renal failure (can't alkalinize)</li>
                <li>Clinical deterioration despite treatment</li>
            </ul>
            <p><span class="label">DO NOT INTUBATE without Good Reason:</span></p>
            <ul>
                <li>Patients with salicylate toxicity have massive compensatory hyperventilation</li>
                <li>If intubated, must match their minute ventilation â€“ otherwise pH drops rapidly, salicylate enters CNS, death</li>
                <li>If intubation required, use high RR and tidal volume</li>
            </ul>
            <p><span class="label">Cross-link:</span> <a href="dx_framework.html#aki" style="color: #0366d6;">ðŸ©º Acid-Base Framework</a></p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>The Intubation Trap:</strong> Salicylate-toxic patients hyperventilate massively to compensate. If you intubate and normalize their CO2, pH crashes, salicylate enters brain, they die. Avoid intubation if possible; if required, match their high minute ventilation.</li>
            <li><strong>Alkalemia is Protective:</strong> At alkaline pH, salicylate is ionized and can't cross blood-brain barrier. Acidemia allows uncharged salicylate into CNS â†’ cerebral toxicity.</li>
            <li><strong>Chronic Toxicity is More Dangerous:</strong> Chronic salicylate toxicity presents at lower levels with worse symptoms. Older patients on chronic aspirin are at high risk.</li>
            <li><strong>Check K Before Alkalinizing:</strong> Hypokalemia prevents urinary alkalinization. Must replace K aggressively.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Level >50 mg/dL</li>
                <li>Altered mental status</li>
                <li>Metabolic acidosis</li>
                <li>Need for dialysis</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Declining salicylate levels</li>
                <li>Resolved symptoms</li>
                <li>Normal pH</li>
                <li>Psychiatry clearance if intentional</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 145: TOXIC ALCOHOL INGESTION -->
<div id="toxic-alcohol" class="condition-page">
    <div class="page-header">
        <h2>145. TOXIC ALCOHOL INGESTION</h2>
        <div class="subtitle">Methanol â€¢ Ethylene Glycol â€¢ Osmol Gap â€¢ Fomepizole</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">General Features:</span> Inebriation without ethanol smell, anion gap metabolic acidosis, elevated osmol gap</p>
            <p><span class="label">Methanol:</span></p>
            <ul>
                <li>Sources: Windshield washer fluid, wood alcohol, moonshine</li>
                <li>Toxic metabolite: Formic acid</li>
                <li>Features: <strong>Visual disturbances</strong> (blurred vision, "snowfield" vision, blindness), headache, abdominal pain</li>
                <li>Classically causes basal ganglia hemorrhage</li>
            </ul>
            <p><span class="label">Ethylene Glycol:</span></p>
            <ul>
                <li>Sources: Antifreeze (sweet-tasting)</li>
                <li>Toxic metabolites: Glycolic acid, oxalic acid</li>
                <li>Features: <strong>Renal failure</strong> (calcium oxalate crystal deposition), hypocalcemia</li>
                <li>Calcium oxalate crystals on urinalysis (envelope-shaped)</li>
            </ul>
            <p><span class="label">Isopropanol:</span></p>
            <ul>
                <li>Sources: Rubbing alcohol</li>
                <li>Metabolite: Acetone (ketosis without acidosis)</li>
                <li>Features: CNS depression, GI irritation, <strong>NO anion gap acidosis</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Osmol Gap:</span></p>
            <ul>
                <li>Calculated Osm = 2[Na] + [Glucose]/18 + [BUN]/2.8 + [EtOH]/4.6</li>
                <li>Osmol gap = Measured Osm â€“ Calculated Osm</li>
                <li>Normal <10. Elevated in toxic alcohol ingestion (before metabolism)</li>
            </ul>
            <p><span class="label">Anion Gap:</span></p>
            <ul>
                <li>Elevated AG indicates toxic metabolites present</li>
                <li><strong>Early:</strong> High osmol gap, low/normal AG (parent compound present)</li>
                <li><strong>Late:</strong> Low osmol gap, high AG (metabolized to acids)</li>
            </ul>
            <p><span class="label">Specific Levels:</span> Methanol and ethylene glycol levels (send but don't wait for results to treat)</p>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ Electrolytes Reference</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Fomepizole (Antidote):</span></p>
            <ul>
                <li>Inhibits alcohol dehydrogenase â€“ prevents formation of toxic metabolites</li>
                <li><strong>Dosing:</strong> 15 mg/kg IV load, then 10 mg/kg IV q12h Ã— 4 doses, then 15 mg/kg q12h</li>
                <li>Continue until level <20 mg/dL and patient asymptomatic with normal pH</li>
            </ul>
            <p><span class="label">Ethanol (Alternative if Fomepizole Unavailable):</span></p>
            <ul>
                <li>Same mechanism (competitive ADH inhibition)</li>
                <li>Target serum ethanol 100-150 mg/dL</li>
                <li>More difficult to titrate, more side effects</li>
            </ul>
            <p><span class="label">Hemodialysis Indications:</span></p>
            <ul>
                <li>Severe metabolic acidosis (pH <7.25)</li>
                <li>Visual disturbances (methanol)</li>
                <li>Renal failure (ethylene glycol)</li>
                <li>Level >50 mg/dL</li>
                <li>Clinical deterioration</li>
            </ul>
            <p><span class="label">Adjunctive Therapy:</span></p>
            <ul>
                <li><strong>Methanol:</strong> Folic acid 50 mg IV q4h (enhances formate metabolism)</li>
                <li><strong>Ethylene glycol:</strong> Pyridoxine 100 mg IV q6h, Thiamine 100 mg IV q6h (enhance metabolism to nontoxic metabolites)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Osmol vs. Anion Gap Timing:</strong> Early = high osmol gap (parent compound). Late = high anion gap (metabolites). Both gaps may not be elevated simultaneously.</li>
            <li><strong>Visual Symptoms = Methanol:</strong> Formic acid is toxic to the optic nerve. Any visual symptoms â†’ think methanol.</li>
            <li><strong>Renal Failure + Crystals = Ethylene Glycol:</strong> Calcium oxalate crystals in urine are classic but not always present.</li>
            <li><strong>Fomepizole is First-Line:</strong> Easier to use than ethanol, fewer side effects. Give empirically if high suspicion â€“ don't wait for specific levels.</li>
            <li><strong>Isopropanol is Different:</strong> Causes ketosis (acetone) but NOT acidosis. Osmol gap without anion gap.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>All significant toxic alcohol ingestions</li>
                <li>Metabolic acidosis</li>
                <li>Need for dialysis</li>
                <li>Visual changes or AKI</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ TREATMENT ENDPOINTS</div>
            <ul>
                <li>Level <20 mg/dL</li>
                <li>Normal pH</li>
                <li>Resolved symptoms</li>
                <li>Improving renal function (EG)</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 146: OPIOID OVERDOSE -->
<div id="opioid-overdose" class="condition-page">
    <div class="page-header">
        <h2>146. OPIOID OVERDOSE</h2>
        <div class="subtitle">Naloxone â€¢ Respiratory Depression â€¢ Harm Reduction</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Triad:</span></p>
            <ul>
                <li><strong>Miosis:</strong> Pinpoint pupils</li>
                <li><strong>CNS depression:</strong> Decreased LOC, coma</li>
                <li><strong>Respiratory depression:</strong> Decreased RR, hypoxia, apnea</li>
            </ul>
            <p><span class="label">Other Features:</span> Hypotension, bradycardia, hypothermia, decreased bowel sounds, track marks</p>
            <p><span class="label">Complications:</span></p>
            <ul>
                <li>Aspiration pneumonia</li>
                <li>Non-cardiogenic pulmonary edema</li>
                <li>Rhabdomyolysis (from prolonged immobility)</li>
                <li>Compartment syndrome</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Immediate:</span></p>
            <ul>
                <li><strong>Airway:</strong> Open airway, provide ventilation if needed</li>
                <li><strong>Naloxone:</strong> See below</li>
            </ul>
            <p><span class="label">Naloxone (Narcan):</span></p>
            <ul>
                <li><strong>Initial dose:</strong> 0.04-0.4 mg IV/IM/SC/IN. Start low if opioid-dependent (avoid precipitating severe withdrawal).</li>
                <li><strong>Goal:</strong> Restore adequate spontaneous respiration â€“ NOT full alertness</li>
                <li><strong>Repeat:</strong> q2-3 min until adequate respiration (can give up to 10-15 mg total for synthetic opioids)</li>
                <li><strong>Half-life:</strong> 30-90 min â€“ shorter than most opioids. Watch for recurrent sedation.</li>
            </ul>
            <p><span class="label">Special Considerations:</span></p>
            <ul>
                <li><strong>Fentanyl and analogues:</strong> May require higher naloxone doses (2-10+ mg)</li>
                <li><strong>Long-acting opioids (methadone):</strong> May need naloxone infusion (2/3 of reversal dose per hour)</li>
                <li><strong>Precipitated withdrawal:</strong> Severe but not life-threatening. Supportive care.</li>
            </ul>
            <p><span class="label">Observation Period:</span></p>
            <ul>
                <li>Short-acting opioid (heroin): 4-6 hours post-naloxone</li>
                <li>Long-acting/sustained-release: 12-24 hours (consider admission)</li>
            </ul>
            <p><span class="label">Harm Reduction at Discharge:</span></p>
            <ul>
                <li>Prescribe naloxone kit (Narcan nasal spray)</li>
                <li>Offer MAT (medication-assisted treatment): buprenorphine, methadone</li>
                <li>Connect to addiction medicine resources</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Titrate to Respiration, Not Alertness:</strong> Goal is adequate breathing, not fully awake patient. Over-reversal causes severe withdrawal.</li>
            <li><strong>Fentanyl Needs More Naloxone:</strong> Synthetic opioids are highly potent. May need 10Ã— typical naloxone dose.</li>
            <li><strong>Watch for Re-sedation:</strong> Naloxone wears off before most opioids. Observe 4-6h minimum; longer for long-acting opioids.</li>
            <li><strong>Prescribe Naloxone at Discharge:</strong> This saves lives. Ensure patient and family have take-home naloxone.</li>
            <li><strong>Offer Treatment:</strong> Every overdose is an opportunity to offer MAT. ED-initiated buprenorphine improves outcomes.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ADMIT IF:</div>
            <ul>
                <li>Long-acting opioid ingestion</li>
                <li>Recurrent sedation</li>
                <li>Needed naloxone infusion</li>
                <li>Pulmonary edema</li>
                <li>Concern for co-ingestion</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Alert and oriented</li>
                <li>Adequate respiration off naloxone â‰¥4h</li>
                <li>Ambulating safely</li>
                <li>Naloxone kit prescribed</li>
                <li>Harm reduction resources provided</li>
            </ul>
        </div>
    </div>
            <div class="section" style="background: linear-gradient(135deg, #f5f0ff 0%, #ede4ff 100%); border-left: 4px solid #8e44ad; margin-top: 15px;">
                <div class="section-content" style="padding: 12px 15px;">
                    <span style="font-weight: 600; color: #6b21a8;">ðŸ“– Drug Reference:</span> <a href="drug_reference_guide.html#naloxone" style="color: #8e44ad;">ðŸ’Š Naloxone</a>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 147: VASCULITIS EMERGENCIES -->
<div id="vasculitis-emergency" class="condition-page">
    <div class="page-header">
        <h2>147. VASCULITIS EMERGENCIES</h2>
        <div class="subtitle">DAH â€¢ Rapidly Progressive GN â€¢ Pulse Steroids + Cyclophosphamide</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Life-Threatening Manifestations:</span></p>
            <ul>
                <li><strong>Diffuse Alveolar Hemorrhage (DAH):</strong> Hemoptysis (may be absent), dyspnea, hypoxia, diffuse infiltrates, dropping hemoglobin. BAL shows progressively bloodier returns.</li>
                <li><strong>Rapidly Progressive Glomerulonephritis (RPGN):</strong> AKI over days-weeks, hematuria, RBC casts, proteinuria</li>
                <li><strong>Pulmonary-Renal Syndrome:</strong> DAH + RPGN = classic for ANCA vasculitis or anti-GBM disease</li>
            </ul>
            <p><span class="label">Vasculitides Causing Emergencies:</span></p>
            <ul>
                <li><strong>GPA (Granulomatosis with Polyangiitis):</strong> cANCA/PR3+. Upper airway, lung, kidney involvement.</li>
                <li><strong>MPA (Microscopic Polyangiitis):</strong> pANCA/MPO+. Lung and kidney predominant.</li>
                <li><strong>Anti-GBM Disease (Goodpasture):</strong> Anti-GBM antibodies. Classic pulmonary-renal syndrome.</li>
                <li><strong>EGPA (Eosinophilic GPA):</strong> Asthma, eosinophilia, vasculitis.</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Serologies:</span></p>
            <ul>
                <li><strong>ANCA:</strong> cANCA/PR3 (GPA), pANCA/MPO (MPA)</li>
                <li><strong>Anti-GBM antibodies:</strong> Goodpasture syndrome</li>
                <li><strong>ANA, complement:</strong> Evaluate for SLE</li>
            </ul>
            <p><span class="label">Urinalysis:</span> RBC casts = glomerulonephritis</p>
            <p><span class="label">Bronchoscopy with BAL:</span> Confirms DAH (serial aliquots increasingly bloody, hemosiderin-laden macrophages)</p>
            <p><span class="label">Renal Biopsy:</span> Pauci-immune crescentic GN (ANCA vasculitis), linear IgG staining (anti-GBM)</p>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ Autoimmune Labs Reference</a>, <a href="#glomerulonephritis" style="color: #0366d6;">ðŸ“š Glomerulonephritis</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Pulse Steroids (First-Line):</span></p>
            <ul>
                <li><strong>Methylprednisolone:</strong> 500-1000 mg IV daily Ã— 3 days</li>
                <li>Then prednisone 1 mg/kg/day (max 80mg) with taper</li>
            </ul>
            <p><span class="label">Cyclophosphamide or Rituximab:</span></p>
            <ul>
                <li><strong>Cyclophosphamide:</strong> 15 mg/kg IV q2weeks Ã— 3, then q3weeks OR 2 mg/kg/day PO</li>
                <li><strong>Rituximab:</strong> 375 mg/mÂ² weekly Ã— 4 OR 1g Ã— 2 doses 2 weeks apart. Now considered first-line for many patients (RAVE trial).</li>
            </ul>
            <p><span class="label">Plasmapheresis:</span></p>
            <ul>
                <li><strong>Indications:</strong> Anti-GBM disease (removes antibody), severe ANCA vasculitis with DAH or dialysis-dependent renal failure</li>
                <li>PEXIVAS trial: Showed benefit primarily in patients with severe AKI</li>
            </ul>
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li>Respiratory support (may need intubation for DAH)</li>
                <li>Renal replacement therapy if needed</li>
                <li>PJP prophylaxis (TMP-SMX) with immunosuppression</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Pulmonary-Renal Syndrome:</strong> DAH + RPGN = think ANCA vasculitis or anti-GBM disease. Requires aggressive immunosuppression.</li>
            <li><strong>Anti-GBM Needs Plasmapheresis:</strong> Unlike ANCA vasculitis where PLEX is selective, anti-GBM disease benefits clearly from antibody removal.</li>
            <li><strong>Don't Wait for Biopsy:</strong> In life-threatening vasculitis, start treatment empirically based on clinical picture and serologies. Biopsy can confirm but shouldn't delay therapy.</li>
            <li><strong>Rituximab is an Option:</strong> RAVE trial showed rituximab non-inferior to cyclophosphamide. Often preferred in younger patients (fertility) and relapsing disease.</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Diffuse alveolar hemorrhage</li>
                <li>Respiratory failure</li>
                <li>Dialysis-dependent AKI</li>
                <li>Need for plasmapheresis</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ TREATMENT GOALS</div>
            <ul>
                <li>Stabilize respiratory status</li>
                <li>Preserve/recover renal function</li>
                <li>Induce remission with immunosuppression</li>
                <li>Transition to maintenance therapy</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONDITION 148: SCLERODERMA RENAL CRISIS -->
<div id="scleroderma-renal" class="condition-page">
    <div class="page-header">
        <h2>148. SCLERODERMA RENAL CRISIS</h2>
        <div class="subtitle">ACE Inhibitors â€¢ Malignant Hypertension â€¢ MAHA</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Life-threatening complication of systemic sclerosis (scleroderma) characterized by acute renal failure and severe hypertension.</p>
            <p><span class="label">Classic Presentation:</span></p>
            <ul>
                <li><strong>Severe hypertension:</strong> Often >150/90, may be malignant (>180/120 with end-organ damage)</li>
                <li><strong>Rapidly progressive AKI:</strong> Over days</li>
                <li><strong>MAHA:</strong> Microangiopathic hemolytic anemia (schistocytes, elevated LDH, low haptoglobin)</li>
                <li><strong>Thrombocytopenia:</strong> May mimic TTP/HUS</li>
            </ul>
            <p><span class="label">Associated Features:</span></p>
            <ul>
                <li>Hypertensive encephalopathy (headache, confusion, seizures)</li>
                <li>Flash pulmonary edema</li>
                <li>Cardiac involvement (pericardial effusion, arrhythmias)</li>
            </ul>
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li>Diffuse cutaneous systemic sclerosis (especially early, rapidly progressive skin disease)</li>
                <li>Anti-RNA polymerase III antibodies (strongest association)</li>
                <li>High-dose corticosteroids (may precipitate SRC)</li>
                <li>First 5 years of disease</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Laboratory:</span></p>
            <ul>
                <li>BMP (elevated creatinine, hyperkalemia)</li>
                <li>CBC with smear (MAHA â€“ schistocytes, thrombocytopenia)</li>
                <li>LDH, haptoglobin, bilirubin (hemolysis)</li>
                <li>Urinalysis (proteinuria, possible hematuria)</li>
                <li>Coagulation studies (usually normal, unlike DIC)</li>
            </ul>
            <p><span class="label">Differentiate from TTP:</span></p>
            <ul>
                <li>SRC has severe hypertension (TTP usually doesn't)</li>
                <li>SRC occurs in scleroderma patients</li>
                <li>ADAMTS13 normal in SRC</li>
            </ul>
            <p><span class="label">Renal Biopsy:</span> Not usually required for diagnosis. Shows thrombotic microangiopathy, "onion-skin" arterial lesions.</p>
            <p><span class="label">Cross-link:</span> <a href="lab_values.html" style="color: #0366d6;">ðŸ”¬ BMP Reference</a>, <a href="#ttp-hus" style="color: #0366d6;">ðŸ“š TTP/HUS</a></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <div class="box">
                <div class="box-title">âš ï¸ ACE INHIBITORS ARE LIFE-SAVING</div>
                <p>ACE inhibitors are the cornerstone of treatment. Start immediately and titrate aggressively. Do NOT withhold due to elevated creatinine.</p>
            </div>
            <p><span class="label">ACE Inhibitor Therapy:</span></p>
            <ul>
                <li><strong>Captopril:</strong> Preferred due to short half-life and rapid titration. Start 6.25-12.5 mg PO q8h, titrate up rapidly (can increase every few hours).</li>
                <li><strong>Goal:</strong> Normalize BP within 72 hours. May need very high doses (up to 450 mg/day).</li>
                <li><strong>Continue even if dialysis required:</strong> Renal recovery can occur weeks-months later if ACE-I continued.</li>
            </ul>
            <p><span class="label">If ACE-I Insufficient for BP Control:</span></p>
            <ul>
                <li>Add IV calcium channel blocker (nicardipine) or nitroprusside</li>
                <li>ARBs can be added but not first-line</li>
                <li>Avoid beta-blockers (can worsen Raynaud's and peripheral vasoconstriction)</li>
            </ul>
            <p><span class="label">Dialysis:</span></p>
            <ul>
                <li>Required in ~50% of patients acutely</li>
                <li><strong>Continue ACE-I even on dialysis</strong> â€“ 30-50% may recover renal function over months</li>
            </ul>
            <p><span class="label">Avoid or Use Cautiously:</span></p>
            <ul>
                <li><strong>Corticosteroids:</strong> May precipitate SRC. If needed for other scleroderma manifestations, use lowest effective dose.</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>ACE-I is THE Treatment:</strong> Before ACE inhibitors, SRC was uniformly fatal. Now ~80% survive. Do not withhold ACE-I due to creatinine â€“ it saves lives.</li>
            <li><strong>Steroids Can Precipitate SRC:</strong> High-dose corticosteroids are a risk factor. Use with extreme caution in scleroderma, especially early diffuse disease.</li>
            <li><strong>Continue ACE-I on Dialysis:</strong> Unlike typical AKI where ACE-I might be held, in SRC continue treatment. Renal recovery possible even after months of dialysis.</li>
            <li><strong>Normotensive SRC Exists:</strong> 10% of SRC patients have normal or only mildly elevated BP. Consider diagnosis in scleroderma patient with unexplained AKI + MAHA.</li>
            <li><strong>MAHA + Severe HTN + Scleroderma = SRC:</strong> This triad is essentially diagnostic. Don't confuse with TTP (no hypertension in TTP).</li>
        </ul>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Malignant hypertension</li>
                <li>Hypertensive encephalopathy</li>
                <li>Flash pulmonary edema</li>
                <li>Need for IV antihypertensives</li>
                <li>Severe hyperkalemia</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">âœ“ TREATMENT GOALS</div>
            <ul>
                <li>BP normalization within 72h</li>
                <li>Maximum-tolerated ACE-I dose</li>
                <li>Dialysis as needed</li>
                <li>Monitor for renal recovery (may take months)</li>
                <li>Rheumatology follow-up</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="gerd" class="condition-page">
    <div class="page-header">
        <h2>149. GERD / ESOPHAGITIS</h2>
        <div class="subtitle">Erosive â€¢ Non-Erosive â€¢ Eosinophilic â€¢ Pill-Induced</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Typical GERD Symptoms:</span> Heartburn (retrosternal burning, worse post-prandial/supine), regurgitation (sour/bitter taste), dysphagia. Worse with large meals, fatty/spicy food, alcohol, caffeine, chocolate, lying down after eating</p>
            <p><span class="label">Atypical/Extraesophageal:</span> Chronic cough (especially nocturnal), hoarseness/laryngitis, asthma exacerbation, dental erosions, globus sensation, chest pain (can mimic ACS)</p>
            <p><span class="label">Alarm Features (Need EGD):</span> Dysphagia (progressive), odynophagia, weight loss, GI bleeding/anemia, persistent vomiting, age >60 with new symptoms, family history esophageal/gastric cancer</p>
            
            <p><span class="label">Types of Esophagitis:</span></p>
            <ul>
                <li><strong>Erosive (GERD):</strong> Mucosal breaks visible on EGD. LA Classification A-D (A = <5mm, D = >75% circumference)</li>
                <li><strong>Non-Erosive Reflux Disease (NERD):</strong> Symptoms but normal EGD. 60% of GERD patients. pH testing confirms</li>
                <li><strong>Eosinophilic Esophagitis (EoE):</strong> Young men, atopy history, solid food dysphagia, food impaction. EGD: rings, furrows, strictures. Bx: >15 eos/hpf</li>
                <li><strong>Pill Esophagitis:</span></strong> NSAIDs, doxycycline, bisphosphonates, KCl, iron. Sharp odynophagia, discrete ulcer at aortic arch level</li>
                <li><strong>Infectious:</strong> Candida (immunocompromised, white plaques), HSV (punched-out ulcers), CMV (large shallow ulcers)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Clinical Diagnosis:</span> Typical symptoms (heartburn + regurgitation) without alarm features â†’ empiric PPI trial (8 weeks). If responds, confirms GERD</p>
            <p><span class="label">EGD Indications:</span> Alarm features, refractory to PPI (8 weeks bid), atypical symptoms, Barrett's surveillance, pre-fundoplication</p>
            <p><span class="label">pH/Impedance Testing:</span> Refractory symptoms, normal EGD, pre-surgical evaluation. Off PPI Ã— 7 days for diagnosis, on PPI if evaluating refractory symptoms</p>
            <p><span class="label">Esophageal Manometry:</span> Pre-fundoplication (rule out motility disorder), evaluate dysphagia if EGD negative</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Lifestyle Modifications:</span></p>
            <ul>
                <li>Weight loss (if overweight - most effective lifestyle change)</li>
                <li>Elevate head of bed 6-8 inches (blocks, not pillows)</li>
                <li>Avoid eating 2-3 hours before bedtime</li>
                <li>Avoid triggers: fatty foods, chocolate, caffeine, alcohol, mint, citrus, tomatoes</li>
                <li>Stop smoking</li>
                <li>Avoid tight-fitting clothes</li>
            </ul>
            
            <p><span class="label">Pharmacotherapy:</span></p>
            <ul>
                <li><strong>PPI (First-Line):</strong> Omeprazole 20mg, Pantoprazole 40mg, Esomeprazole 20-40mg daily. Take 30-60 min before breakfast. 8-week course for healing</li>
                <li><strong>Refractory:</strong> Increase to BID dosing (before breakfast AND dinner). If still refractory, confirm diagnosis with pH testing</li>
                <li><strong>H2 Blockers:</strong> Famotidine 20mg BID. Less effective than PPI. Use for mild/intermittent symptoms or nocturnal breakthrough</li>
                <li><strong>Antacids/Alginates:</strong> PRN for breakthrough. Calcium carbonate, Gaviscon (alginate forms raft)</li>
                <li><strong>Maintenance:</strong> Lowest effective PPI dose. Step-down to H2 blocker or on-demand PPI if controlled</li>
            </ul>
            
            <p><span class="label">PPI Long-Term Risks (generally overstated but consider):</span> C. diff, pneumonia, hypomagnesemia, B12 deficiency, hip fractures (osteoporosis), CKD. Benefits usually outweigh risks. Don't stop for fear of side effects if truly needed</p>
            
            <p><span class="label">Surgical:</span> Fundoplication (Nissen) if: refractory despite max medical therapy, intolerant of PPIs, large hiatal hernia, regurgitation-predominant. Requires manometry pre-op</p>
            
            <p><span class="label">Specific Esophagitis Treatment:</span></p>
            <ul>
                <li><strong>Eosinophilic:</strong> PPI trial first (PPI-responsive EoE), then swallowed fluticasone or budesonide slurry, elimination diet, dilation if stricture</li>
                <li><strong>Pill:</strong> Stop offending med, liquid alternatives, take pills with full glass water, stay upright 30 min</li>
                <li><strong>Candida:</strong> Fluconazole 200mg day 1, then 100mg Ã— 14 days</li>
                <li><strong>HSV:</strong> Acyclovir 400mg 5Ã—/day Ã— 14-21 days (or valacyclovir)</li>
                <li><strong>CMV:</strong> Ganciclovir or valganciclovir Ã— 3-6 weeks</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Upper GI bleeding with hemodynamic instability</li>
                <li>Esophageal perforation (Boerhaave's - post-vomiting chest pain, subcutaneous emphysema)</li>
                <li>Complete esophageal obstruction/food impaction with respiratory compromise</li>
                <li>Severe infectious esophagitis with sepsis</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Tolerating oral intake</li>
                <li>Pain controlled</li>
                <li>No signs of bleeding or perforation</li>
                <li>On appropriate PPI regimen</li>
                <li>EGD performed or scheduled if alarm features</li>
                <li>Lifestyle modifications reviewed</li>
                <li>GI follow-up if needed</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Chest pain workup:</strong> Always rule out cardiac cause first. GERD is diagnosis of exclusion for chest pain</li>
            <li><strong>PPI timing matters:</strong> Take 30-60 min before meal for maximum efficacy (needs acid to activate)</li>
            <li><strong>NERD is common:</strong> 60% have symptoms with normal EGD. pH testing confirms. May respond less well to PPI</li>
            <li><strong>Young man with food impaction = EoE:</strong> Think eosinophilic esophagitis. Get biopsies even if EGD looks normal</li>
            <li><strong>Doxycycline esophagitis:</strong> Always take with full glass of water, stay upright. Mid-esophagus (aortic arch level)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="barretts" class="condition-page">
    <div class="page-header">
        <h2>150. BARRETT'S ESOPHAGUS</h2>
        <div class="subtitle">Intestinal Metaplasia â€¢ Dysplasia â€¢ Cancer Surveillance</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Replacement of normal squamous esophageal epithelium with intestinal-type columnar epithelium (intestinal metaplasia with goblet cells). Complication of chronic GERD. Premalignant - risk of esophageal adenocarcinoma</p>
            <p><span class="label">Risk Factors:</span> Chronic GERD (>5 years), male sex (8:1), age >50, Caucasian, obesity (central), smoking, family history Barrett's/esophageal cancer, hiatal hernia</p>
            <p><span class="label">Presentation:</span> Often asymptomatic (GERD symptoms may actually improve as metaplastic epithelium is less sensitive). Found incidentally on EGD for GERD evaluation</p>
            <p><span class="label">Cancer Risk:</span> 0.5% per year progression to adenocarcinoma (without dysplasia). Higher with dysplasia. Esophageal adenocarcinoma has increased 6-fold in past 40 years</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">EGD Findings:</span> Salmon-colored mucosa extending above GE junction (replacing normal pale squamous mucosa). Described by length: short-segment (<3cm) vs long-segment (â‰¥3cm). Prague classification: C (circumferential) and M (maximum extent)</p>
            <p><span class="label">Histology (Required for Diagnosis):</span> Intestinal metaplasia with goblet cells. Must have goblet cells to diagnose Barrett's in US (European criteria differ)</p>
            <p><span class="label">Biopsy Protocol:</span> Seattle protocol - 4-quadrant biopsies every 1-2cm throughout Barrett's segment + any visible lesions. Look for dysplasia</p>
            
            <p><span class="label">Dysplasia Classification:</span></p>
            <ul>
                <li><strong>No dysplasia:</strong> Intestinal metaplasia only. Lowest risk</li>
                <li><strong>Indefinite for dysplasia:</strong> Inflammation makes interpretation difficult. Repeat after aggressive PPI</li>
                <li><strong>Low-grade dysplasia (LGD):</strong> Confirmed by expert GI pathologist. 0.5-1% annual progression to cancer</li>
                <li><strong>High-grade dysplasia (HGD):</strong> 6-19% annual progression to cancer. Often has occult cancer</li>
            </ul>
            
            <p><span class="label">Screening Recommendations:</span> Consider one-time screening EGD in patients with chronic GERD (>5 years) AND multiple risk factors (male, age >50, white, obesity, smoking, family history). Not recommended for general population</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">All Barrett's Patients:</span></p>
            <ul>
                <li>PPI daily (reduces progression, even if asymptomatic)</li>
                <li>Lifestyle modifications (weight loss, smoking cessation)</li>
                <li>Surveillance EGD per guidelines</li>
            </ul>
            
            <p><span class="label">Surveillance Intervals:</span></p>
            <ul>
                <li><strong>No dysplasia:</strong> EGD every 3-5 years (if segment <3cm and no risk factors, can extend to 5 years)</li>
                <li><strong>Indefinite for dysplasia:</strong> Optimize PPI, repeat EGD in 3-6 months</li>
                <li><strong>Low-grade dysplasia:</strong> Confirm with expert pathologist. Options: surveillance every 6-12 months OR endoscopic eradication therapy (preferred if confirmed LGD)</li>
                <li><strong>High-grade dysplasia:</strong> Endoscopic eradication therapy (radiofrequency ablation Â± EMR). Esophagectomy rarely needed now</li>
            </ul>
            
            <p><span class="label">Endoscopic Eradication Therapy:</span></p>
            <ul>
                <li><strong>Endoscopic mucosal resection (EMR):</strong> For visible lesions, nodules. Removes tissue for staging</li>
                <li><strong>Radiofrequency ablation (RFA):</strong> For flat dysplasia/Barrett's. Burns away metaplastic epithelium. Multiple sessions needed. 90%+ eradication rates</li>
                <li><strong>Cryotherapy:</strong> Alternative ablation technique</li>
                <li>Continue PPI after ablation. Surveillance continues (recurrence possible)</li>
            </ul>
            
            <p><span class="label">Surgery (Esophagectomy):</span> Reserved for: invasive cancer, failed endoscopic therapy, patient preference. High morbidity (leak, stricture, mortality 2-5% at high-volume centers)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Post-procedure perforation or bleeding</li>
                <li>Esophageal cancer with obstruction or bleeding</li>
                <li>Post-esophagectomy complications (anastomotic leak, respiratory failure)</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Tolerating diet after EGD/ablation</li>
                <li>No signs of perforation or bleeding</li>
                <li>On daily PPI</li>
                <li>Surveillance interval established</li>
                <li>GI follow-up scheduled</li>
                <li>Pathology results reviewed and plan communicated</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Barrett's doesn't reverse with PPI:</strong> Metaplasia persists. PPI reduces further damage and may reduce dysplasia/cancer progression</li>
            <li><strong>Long-segment = higher risk:</strong> â‰¥3cm has higher cancer risk than short-segment</li>
            <li><strong>Symptoms may improve:</strong> Metaplastic epithelium is less acid-sensitive. Fewer symptoms â‰  less disease</li>
            <li><strong>Expert pathology confirmation:</strong> Dysplasia diagnosis should be confirmed by second expert GI pathologist before treatment decisions</li>
            <li><strong>RFA changed management:</strong> Endoscopic therapy now standard for dysplasia. Esophagectomy rarely needed</li>
            <li><strong>Surveillance continues after ablation:</strong> Recurrence can occur. Lifelong follow-up needed</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="esophageal-spasm" class="condition-page">
    <div class="page-header">
        <h2>151. ESOPHAGEAL SPASM / MOTILITY DISORDERS</h2>
        <div class="subtitle">DES â€¢ Jackhammer â€¢ Achalasia â€¢ Nutcracker</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">General Features:</span> Chest pain (can be severe, mimic angina), dysphagia (to solids AND liquids - vs mechanical obstruction which is solids first), odynophagia. Symptoms often intermittent, triggered by stress, hot/cold foods</p>
            
            <p><span class="label">Specific Disorders:</span></p>
            <ul>
                <li><strong>Diffuse Esophageal Spasm (DES):</strong> Uncoordinated, simultaneous contractions. Intermittent dysphagia + chest pain. "Corkscrew esophagus" on barium swallow. Manometry: â‰¥20% premature (simultaneous) contractions</li>
                <li><strong>Hypercontractile Esophagus (Jackhammer):</strong> Extremely high-amplitude contractions. Severe chest pain. Manometry: distal contractile integral (DCI) >8000 mmHgÂ·sÂ·cm</li>
                <li><strong>Achalasia:</strong> Failure of LES relaxation + absent peristalsis. Progressive dysphagia (solids AND liquids), regurgitation of undigested food, weight loss, aspiration. "Bird's beak" on barium swallow. Manometry: absent peristalsis + impaired LES relaxation. EGD to rule out pseudoachalasia (GE junction cancer)</li>
                <li><strong>Ineffective Esophageal Motility:</strong> Weak contractions. Often with GERD. Dysphagia, heartburn</li>
            </ul>
            
            <p><span class="label">Important DDx:</span> Always rule out cardiac chest pain first! Also consider: GERD, eosinophilic esophagitis, esophageal cancer, stricture</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Step 1 - Rule Out Cardiac:</span> ECG, troponin if acute chest pain. Stress test/cath if indicated. Esophageal spasm is diagnosis of exclusion for chest pain</p>
            <p><span class="label">Step 2 - EGD:</span> Rule out mechanical obstruction, stricture, eosinophilic esophagitis, cancer (especially at GE junction for achalasia symptoms - pseudoachalasia)</p>
            <p><span class="label">Step 3 - Barium Swallow:</span> Corkscrew esophagus (DES), bird's beak with dilated proximal esophagus (achalasia), stricture</p>
            <p><span class="label">Step 4 - High-Resolution Manometry (Gold Standard):</span> Defines specific motility disorder per Chicago Classification. Required before surgical intervention</p>
            
            <p><span class="label">Manometry Findings:</span></p>
            <ul>
                <li><strong>Achalasia Type I:</strong> No esophageal pressurization, absent peristalsis</li>
                <li><strong>Achalasia Type II:</strong> Panesophageal pressurization (best prognosis for treatment)</li>
                <li><strong>Achalasia Type III:</strong> Spastic contractions (worst prognosis)</li>
                <li><strong>DES:</strong> â‰¥20% premature contractions, normal LES relaxation</li>
                <li><strong>Jackhammer:</strong> DCI >8000 mmHgÂ·sÂ·cm in â‰¥20% of swallows</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Diffuse Esophageal Spasm / Jackhammer:</span></p>
            <ul>
                <li><strong>First-line:</strong> Smooth muscle relaxants - nitrates (isosorbide dinitrate 10-20mg before meals), calcium channel blockers (diltiazem 60-90mg TID or nifedipine 10-30mg TID)</li>
                <li><strong>Second-line:</strong> Tricyclic antidepressants (imipramine 25-50mg qhs) - visceral pain modulation</li>
                <li><strong>PPI trial:</strong> Many have coexisting GERD</li>
                <li><strong>Botox injection:</strong> Temporary relief. Effect wanes in 6-12 months</li>
                <li><strong>POEM (peroral endoscopic myotomy):</strong> For refractory cases. Emerging therapy</li>
            </ul>
            
            <p><span class="label">Achalasia (Definitive Treatment Required):</span></p>
            <ul>
                <li><strong>Pneumatic dilation:</strong> 30-40mm balloon at LES. 60-90% effective. Risk perforation 2-5%. May need repeat</li>
                <li><strong>Heller myotomy (laparoscopic):</strong> Surgical division of LES muscle. 90% effective. Add partial fundoplication (Dor/Toupet) to prevent reflux. Durable</li>
                <li><strong>POEM:</strong> Endoscopic myotomy. Comparable efficacy to Heller. Higher GERD rates post-procedure. Growing experience</li>
                <li><strong>Botox injection:</strong> Temporary (3-12 months). Reserve for poor surgical candidates</li>
                <li><strong>Medical therapy (nitrates/CCB):</strong> Least effective. Bridge to definitive therapy or if not surgical candidate</li>
            </ul>
            
            <p><span class="label">Treatment Selection (Achalasia):</span> Type II responds best to all treatments. Young patients â†’ Heller myotomy (most durable). Older/comorbid â†’ pneumatic dilation or POEM. Poor surgical candidates â†’ Botox or medical</p>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Esophageal perforation (post-dilation or spontaneous)</li>
                <li>Aspiration pneumonia with respiratory failure</li>
                <li>Severe dehydration/malnutrition from inability to eat</li>
                <li>Chest pain with hemodynamic instability (rule out cardiac)</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Tolerating oral intake</li>
                <li>Chest pain controlled</li>
                <li>Cardiac causes excluded</li>
                <li>Treatment plan established (medications or procedure scheduled)</li>
                <li>No signs of perforation post-procedure</li>
                <li>GI follow-up arranged</li>
                <li>Dietary modifications reviewed (small bites, upright eating, avoid triggers)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Dysphagia to solids AND liquids = motility:</strong> Mechanical obstruction (stricture, cancer) â†’ solids first, then liquids. Motility â†’ both from start</li>
            <li><strong>Rule out cardiac first:</strong> Esophageal spasm can perfectly mimic angina. Even responds to nitrates! Always exclude cardiac before diagnosing</li>
            <li><strong>Pseudoachalasia:</strong> GE junction cancer mimics achalasia. EGD with biopsies mandatory. Older patient, rapid symptom onset, significant weight loss = red flags</li>
            <li><strong>Achalasia increases cancer risk:</strong> 3% lifetime risk of squamous cell carcinoma. Some recommend surveillance EGD</li>
            <li><strong>Type II achalasia = best prognosis:</strong> Responds well to all treatments. Type III (spastic) = worst outcomes</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="costochondritis" class="condition-page">
    <div class="page-header">
        <h2>152. COSTOCHONDRITIS / CHEST WALL PAIN</h2>
        <div class="subtitle">Tietze Syndrome â€¢ Musculoskeletal Chest Pain</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Costochondritis:</span> Inflammation of costochondral junctions (where ribs meet cartilage). Sharp, localized chest pain. Reproducible with palpation. Worse with movement, deep breathing, coughing. No swelling. Most common at ribs 2-5. Often bilateral</p>
            <p><span class="label">Tietze Syndrome:</span> Similar to costochondritis BUT with visible swelling at costochondral junction. Usually single site, ribs 2-3. Younger patients. Less common</p>
            
            <p><span class="label">Risk Factors/Triggers:</span> Recent upper respiratory infection (repetitive coughing), physical strain, repetitive activities, trauma, recent exercise, fibromyalgia, inflammatory arthritis</p>
            
            <p><span class="label">Key Features:</span></p>
            <ul>
                <li>Reproducible tenderness on palpation (most important finding)</li>
                <li>Sharp or pressure-like pain</li>
                <li>Worse with movement, twisting, deep breathing</li>
                <li>May radiate to arm or back</li>
                <li>Duration: weeks to months (often chronic/recurrent)</li>
            </ul>
            
            <p><span class="label">Differential Diagnosis (Must Exclude):</span></p>
            <ul>
                <li><strong>Cardiac:</strong> ACS, pericarditis, aortic dissection</li>
                <li><strong>Pulmonary:</strong> PE, pneumonia, pneumothorax, pleuritis</li>
                <li><strong>GI:</strong> GERD, esophageal spasm, PUD</li>
                <li><strong>Other MSK:</strong> Rib fracture, muscle strain, herpes zoster (pre-rash), xiphodynia, slipping rib syndrome</li>
                <li><strong>Malignancy:</strong> Metastatic disease to ribs/sternum</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Clinical Diagnosis:</span> Costochondritis is a clinical diagnosis of exclusion. Key: reproducible tenderness on palpation + no concerning features</p>
            
            <p><span class="label">When to Test:</span></p>
            <ul>
                <li><strong>ECG:</strong> If ANY cardiac concern (risk factors, exertional, associated symptoms). Low threshold</li>
                <li><strong>Troponin:</strong> If ACS concern</li>
                <li><strong>CXR:</strong> If pulmonary symptoms, trauma, concern for pneumothorax</li>
                <li><strong>D-dimer/CTPA:</strong> If PE concern (Wells score, risk factors)</li>
                <li><strong>CT chest/MRI:</strong> If concern for malignancy, persistent unexplained pain</li>
                <li><strong>Labs (ESR, CRP):</strong> If inflammatory arthritis suspected or Tietze syndrome</li>
            </ul>
            
            <p><span class="label">Red Flags Requiring Further Workup:</span></p>
            <ul>
                <li>Exertional chest pain</li>
                <li>Associated dyspnea, diaphoresis, nausea</li>
                <li>Cardiac risk factors (DM, HTN, smoking, family history, hyperlipidemia)</li>
                <li>Age >40 with new chest pain</li>
                <li>Abnormal vital signs</li>
                <li>Radiation to jaw/arm</li>
                <li>Recent immobilization/surgery (PE risk)</li>
                <li>Fever, weight loss (malignancy, infection)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">First-Line (Conservative):</span></p>
            <ul>
                <li><strong>NSAIDs:</strong> Ibuprofen 400-800mg TID or Naproxen 500mg BID Ã— 1-2 weeks. Most effective</li>
                <li><strong>Topical NSAIDs:</strong> Diclofenac gel to affected area TID-QID. Fewer systemic side effects</li>
                <li><strong>Heat/Ice:</strong> Local application for comfort</li>
                <li><strong>Rest:</strong> Avoid aggravating activities, repetitive movements</li>
                <li><strong>Acetaminophen:</strong> If NSAIDs contraindicated</li>
            </ul>
            
            <p><span class="label">Second-Line (Refractory):</span></p>
            <ul>
                <li><strong>Local corticosteroid injection:</strong> Triamcinolone 20-40mg + lidocaine into costochondral junction. Consider if failed NSAIDs Ã— 2-4 weeks</li>
                <li><strong>Physical therapy:</strong> Stretching exercises, posture correction</li>
                <li><strong>Intercostal nerve block:</strong> For severe refractory cases</li>
            </ul>
            
            <p><span class="label">Patient Education:</span></p>
            <ul>
                <li>Benign condition, not dangerous</li>
                <li>May take weeks to months to resolve</li>
                <li>Can be recurrent</li>
                <li>Activity modification during flares</li>
                <li>Return precautions: exertional pain, dyspnea, radiation, new symptoms</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Not applicable - costochondritis does not require ICU</li>
                <li>If patient has costochondritis AND develops cardiac symptoms, treat as ACS until proven otherwise</li>
                <li>Misdiagnosis concern: Always reconsider if patient deteriorates or develops new symptoms</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Cardiac causes confidently excluded</li>
                <li>Reproducible tenderness on exam</li>
                <li>No red flag symptoms</li>
                <li>Pain controlled with oral medications</li>
                <li>Clear return precautions provided</li>
                <li>PCP follow-up if symptoms persist >2-4 weeks</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Reproducible = reassuring:</strong> Pain reproduced by palpation strongly suggests MSK cause. BUT can coexist with cardiac disease - still need to exclude</li>
            <li><strong>Costochondritis is diagnosis of exclusion:</strong> Rule out life-threatening causes first, especially in patients with risk factors</li>
            <li><strong>Tietze has swelling:</strong> Visible/palpable swelling at costochondral junction. Costochondritis = tenderness without swelling</li>
            <li><strong>Can mimic ACS:</strong> Chest pain, radiation to arm, worse with exertion (if using arms). Low threshold to evaluate cardiac</li>
            <li><strong>Duration weeks-months:</strong> Set expectations. Not a quick fix. Recurrence common</li>
            <li><strong>NSAIDs work:</strong> First-line, most effective. Try for at least 1-2 weeks before declaring failure</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="urosepsis" class="condition-page">
    <div class="page-header">
        <h2>153. UROSEPSIS</h2>
        <div class="subtitle">Sepsis from Urinary Source â€¢ UTI with SIRS/Organ Dysfunction</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Sepsis (life-threatening organ dysfunction from dysregulated host response) caused by urinary tract infection. 20-30% of all sepsis cases. Second most common source after pneumonia</p>
            
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li>Urinary obstruction (kidney stones, BPH, stricture, tumor) - MOST IMPORTANT</li>
                <li>Indwelling urinary catheter</li>
                <li>Recent urologic procedure/instrumentation</li>
                <li>Diabetes mellitus</li>
                <li>Immunosuppression</li>
                <li>Neurogenic bladder</li>
                <li>Pregnancy</li>
                <li>Elderly, nursing home residents</li>
                <li>Anatomic abnormalities</li>
            </ul>
            
            <p><span class="label">Presentation:</span></p>
            <ul>
                <li><strong>Urinary symptoms:</strong> Dysuria, frequency, urgency, suprapubic pain, flank pain (pyelonephritis), CVA tenderness, hematuria. May be absent in elderly/catheterized</li>
                <li><strong>Sepsis features:</strong> Fever (or hypothermia), tachycardia, tachypnea, hypotension, altered mental status</li>
                <li><strong>Severe sepsis/Septic shock:</strong> Hypotension (SBP <90 or MAP <65) refractory to fluids, lactate >2 mmol/L, organ dysfunction (AKI, coagulopathy, altered mental status)</li>
            </ul>
            
            <p><span class="label">Common Organisms:</span></p>
            <ul>
                <li><strong>E. coli:</strong> Most common (50-80%)</li>
                <li><strong>Klebsiella, Proteus, Enterobacter:</strong> Other gram-negatives</li>
                <li><strong>Pseudomonas:</strong> Healthcare-associated, catheter-related</li>
                <li><strong>Enterococcus:</strong> Especially with instrumentation</li>
                <li><strong>Candida:</strong> Immunocompromised, prolonged antibiotics, catheters</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Laboratory:</span></p>
            <ul>
                <li><strong>Urinalysis:</strong> Pyuria (WBC), bacteriuria, nitrites (gram-negatives), leukocyte esterase. May be absent early</li>
                <li><strong>Urine culture:</strong> BEFORE antibiotics (but don't delay antibiotics). >10âµ CFU/mL significant (lower threshold with catheter or symptoms)</li>
                <li><strong>Blood cultures:</strong> Ã— 2 sets before antibiotics. Positive in 20-40% of pyelonephritis, higher in urosepsis</li>
                <li><strong>CBC:</strong> Leukocytosis (or leukopenia = worse prognosis), left shift, thrombocytopenia (DIC)</li>
                <li><strong>BMP:</strong> AKI (Cr elevation), electrolyte abnormalities</li>
                <li><strong>Lactate:</strong> >2 mmol/L indicates tissue hypoperfusion. Prognostic. Trend to assess response</li>
                <li><strong>Procalcitonin:</strong> Elevated in bacterial sepsis. Can guide antibiotic duration</li>
                <li><strong>Coagulation:</strong> PT/INR, fibrinogen, D-dimer if DIC concern</li>
            </ul>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>CT abdomen/pelvis with contrast:</strong> First-line if obstruction suspected. Identifies hydronephrosis, stones, abscess, emphysematous pyelonephritis</li>
                <li><strong>Renal ultrasound:</strong> If CT contraindicated (contrast allergy, AKI). Good for hydronephrosis, less sensitive for stones/abscess</li>
                <li><strong>Urgent imaging indications:</strong> Not responding to antibiotics 48-72hr, concern for obstruction, abscess, emphysematous infection</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Hour-1 Bundle (Sepsis):</span></p>
            <ul>
                <li><strong>Measure lactate</strong> - remeasure if initial >2</li>
                <li><strong>Blood cultures</strong> before antibiotics</li>
                <li><strong>Broad-spectrum antibiotics</strong> within 1 hour</li>
                <li><strong>IV crystalloid 30 mL/kg</strong> for hypotension or lactate â‰¥4</li>
                <li><strong>Vasopressors</strong> if hypotensive despite fluids (target MAP â‰¥65)</li>
            </ul>
            
            <p><span class="label">Empiric Antibiotics (Start Broad, Narrow Based on Culture):</span></p>
            <ul>
                <li><strong>Community-acquired, no risk factors:</strong> Ceftriaxone 1g IV daily OR Fluoroquinolone (ciprofloxacin 400mg IV q12h or levofloxacin 750mg IV daily) - check local resistance patterns</li>
                <li><strong>Healthcare-associated or resistant organism risk:</strong> Piperacillin-tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h OR Meropenem 1g IV q8h (if ESBL concern)</li>
                <li><strong>Pseudomonas risk (catheter, recent hospitalization, structural abnormality):</strong> Antipseudomonal coverage - pip-tazo, cefepime, or meropenem</li>
                <li><strong>MRSA risk (rare in UTI):</strong> Add vancomycin</li>
                <li><strong>Enterococcus concern:</strong> Ampicillin 2g IV q4h (if susceptible) or vancomycin</li>
            </ul>
            
            <p><span class="label">Source Control (CRITICAL):</span></p>
            <ul>
                <li><strong>Obstruction:</strong> Urgent decompression within 24 hours. Options: percutaneous nephrostomy (IR) or ureteral stent (urology). Antibiotics alone will fail</li>
                <li><strong>Abscess:</strong> Drainage (percutaneous or surgical) if >3-5 cm or not responding to antibiotics</li>
                <li><strong>Emphysematous pyelonephritis:</strong> Life-threatening. Drainage Â± nephrectomy. High mortality</li>
                <li><strong>Infected catheter:</strong> Replace or remove if possible</li>
            </ul>
            
            <p><span class="label">Duration:</span></p>
            <ul>
                <li>Uncomplicated pyelonephritis: 7-14 days (can be as short as 5-7 days with fluoroquinolones if responding)</li>
                <li>Complicated UTI/urosepsis: 10-14 days</li>
                <li>Abscess, prostatitis: 4-6 weeks</li>
                <li>Procalcitonin-guided discontinuation if available</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Septic shock (hypotension despite adequate fluid resuscitation requiring vasopressors)</li>
                <li>Lactate >4 mmol/L or rising despite treatment</li>
                <li>Respiratory failure requiring intubation</li>
                <li>Multi-organ dysfunction (AKI + coagulopathy + encephalopathy)</li>
                <li>Emphysematous pyelonephritis or necrotizing infection</li>
                <li>Failure to respond to initial resuscitation</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Afebrile >24-48 hours</li>
                <li>Hemodynamically stable off vasopressors</li>
                <li>Lactate normalized</li>
                <li>WBC normalizing</li>
                <li>Tolerating oral antibiotics and fluids</li>
                <li>Source control achieved (obstruction relieved, abscess drained)</li>
                <li>Creatinine at baseline or improving</li>
                <li>Culture sensitivities back, on appropriate narrow-spectrum oral antibiotic</li>
                <li>Urology follow-up if structural abnormality or stones</li>
                <li>Duration of antibiotics clearly documented</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Obstruction = emergency:</strong> Infected, obstructed kidney is urologic emergency. Antibiotics won't penetrate. Needs drainage within 24hr</li>
            <li><strong>E. coli is king:</strong> Causes 50-80% of UTI/urosepsis. But consider Pseudomonas, ESBL if healthcare-associated</li>
            <li><strong>Catheter = think Pseudomonas and Enterococcus:</strong> Broader coverage needed. Remove/replace catheter</li>
            <li><strong>CT if not improving at 48-72hr:</strong> Look for abscess, obstruction, emphysematous pyelonephritis</li>
            <li><strong>Emphysematous = high mortality:</strong> Gas in renal parenchyma on CT. Usually diabetics. Aggressive drainage, may need nephrectomy</li>
            <li><strong>Procalcitonin guides duration:</strong> Can shorten antibiotic course safely. Trend to assess response</li>
            <li><strong>Better prognosis than other sepsis:</strong> Urosepsis generally has lower mortality than pneumonia-related sepsis (with appropriate source control)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="acute-respiratory-failure" class="condition-page">
    <div class="page-header">
        <h2>154. ACUTE RESPIRATORY FAILURE</h2>
        <div class="subtitle">Type 1 (Hypoxic) â€¢ Type 2 (Hypercapnic) â€¢ Mixed â€¢ Oxygen Delivery â€¢ Ventilation</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Inability of the respiratory system to meet the metabolic demands of the body â€” failure to oxygenate (Type 1), failure to ventilate (Type 2), or both (Mixed)</p>
            
            <p><strong>Type 1 â€” Hypoxic Respiratory Failure:</strong></p>
            <ul>
                <li><strong>Definition:</strong> PaO2 <60 mmHg on room air (or P/F ratio <300 on supplemental O2)</li>
                <li><strong>Mechanism:</strong> V/Q mismatch, shunt, diffusion impairment, low FiO2</li>
                <li><strong>PaCO2:</strong> Normal or LOW (patient hyperventilating to compensate)</li>
                <li><strong>A-a Gradient:</strong> ELEVATED (>15 mmHg) â€” problem is at alveolar-capillary interface</li>
                <li><strong>Common Causes:</strong> Pneumonia, ARDS, pulmonary edema (cardiogenic), PE, ILD, atelectasis</li>
            </ul>
            
            <p><strong>Type 2 â€” Hypercapnic Respiratory Failure:</strong></p>
            <ul>
                <li><strong>Definition:</strong> PaCO2 >45 mmHg with respiratory acidosis (pH <7.35)</li>
                <li><strong>Mechanism:</strong> Alveolar hypoventilation â€” inadequate minute ventilation</li>
                <li><strong>PaO2:</strong> May be low (from hypoventilation) but responds well to supplemental O2</li>
                <li><strong>A-a Gradient:</strong> Often NORMAL â€” lungs are fine, ventilation is the problem</li>
                <li><strong>Common Causes:</strong> COPD exacerbation, opioid overdose, neuromuscular disease (GBS, MG), obesity hypoventilation, severe asthma</li>
                <li>â†’ See <a href="#hypercapnic-failure" style="color: #0366d6;">Condition 50: Acute Hypercapnic Respiratory Failure</a> for detailed management</li>
            </ul>
            
            <p><strong>Mixed (Type 1 + Type 2):</strong></p>
            <ul>
                <li><strong>Definition:</strong> Both hypoxemia AND hypercapnia</li>
                <li><strong>Mechanism:</strong> Severe parenchymal disease with respiratory muscle fatigue</li>
                <li><strong>Common Causes:</strong> Severe COPD with pneumonia, late-stage ARDS, cardiogenic shock with pulmonary edema, severe asthma with fatigue</li>
                <li><strong>Prognosis:</strong> Worse than isolated Type 1 or Type 2 â€” often indicates impending respiratory arrest</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">RAPID ASSESSMENT</div>
        <div class="section-content">
            <p><strong>ABCs + Vital Signs:</strong></p>
            <ul>
                <li><strong>Airway:</strong> Patent? Secretions? Stridor? Can patient speak in full sentences?</li>
                <li><strong>Breathing:</strong> RR (>30 = severe), accessory muscle use, paradoxical breathing, SpO2</li>
                <li><strong>Circulation:</strong> HR, BP (hypotension = shock, may need intubation for resuscitation)</li>
                <li><strong>Disability:</strong> Mental status (confusion, agitation, somnolence = ominous)</li>
            </ul>
            
            <p><strong>Immediate Red Flags (Consider Immediate Intubation):</strong></p>
            <ul>
                <li>Apnea or agonal breathing</li>
                <li>Severe altered mental status / inability to protect airway</li>
                <li>Refractory hypoxemia (SpO2 <88% despite high-flow O2)</li>
                <li>Hemodynamic instability / cardiac arrest</li>
                <li>Severe respiratory acidosis (pH <7.20) with declining mental status</li>
                <li>Respiratory muscle fatigue (paradoxical breathing, declining RR with worsening status)</li>
            </ul>
            
            <p><strong>ABG Interpretation:</strong></p>
            <ul>
                <li><strong>P/F Ratio (PaO2 Ã· FiO2):</strong>
                    <ul>
                        <li>Normal: >400</li>
                        <li>Mild impairment: 300-400</li>
                        <li>Moderate (mild ARDS): 200-300</li>
                        <li>Severe (moderate ARDS): 100-200</li>
                        <li>Very severe (severe ARDS): <100</li>
                    </ul>
                </li>
                <li><strong>A-a Gradient:</strong> PAO2 - PaO2, where PAO2 = (FiO2 Ã— 713) - (PaCO2 Ã· 0.8)
                    <ul>
                        <li>Normal: <15 mmHg (or Age/4 + 4)</li>
                        <li>Elevated = V/Q mismatch, shunt, diffusion defect (parenchymal disease)</li>
                        <li>Normal = pure hypoventilation (CNS, neuromuscular, chest wall)</li>
                    </ul>
                </li>
                <li><strong>Acute vs Chronic Respiratory Acidosis:</strong>
                    <ul>
                        <li>Acute: â†‘ HCO3 1 mEq/L per 10 mmHg â†‘ PaCO2</li>
                        <li>Chronic: â†‘ HCO3 3.5 mEq/L per 10 mmHg â†‘ PaCO2</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">OXYGEN DELIVERY LADDER</div>
        <div class="section-content">
            <p><strong>Escalate based on response. Don't delay escalation if patient deteriorating.</strong></p>
            
            <p><strong>1. Nasal Cannula (NC):</strong></p>
            <ul>
                <li><strong>Flow:</strong> 1-6 L/min â†’ ~24-44% FiO2 (variable, depends on patient's minute ventilation)</li>
                <li><strong>Use:</strong> Mild hypoxemia, stable patients</li>
                <li><strong>Limitation:</strong> FiO2 unreliable, max ~44% even at 6L</li>
            </ul>
            
            <p><strong>2. Simple Face Mask:</strong></p>
            <ul>
                <li><strong>Flow:</strong> 6-10 L/min â†’ ~35-55% FiO2</li>
                <li><strong>Use:</strong> Moderate hypoxemia, short-term (procedures, transport)</li>
                <li><strong>Limitation:</strong> Must run â‰¥5 L/min to avoid CO2 rebreathing</li>
            </ul>
            
            <p><strong>3. Venturi Mask:</strong></p>
            <ul>
                <li><strong>Flow:</strong> Set to specific FiO2 (24%, 28%, 31%, 35%, 40%, 50%)</li>
                <li><strong>Use:</strong> COPD / chronic CO2 retainers â€” need precise, controlled FiO2</li>
                <li><strong>Advantage:</strong> Reliable FiO2 regardless of patient's breathing pattern</li>
            </ul>
            
            <p><strong>4. Non-Rebreather Mask (NRB):</strong></p>
            <ul>
                <li><strong>Flow:</strong> 10-15 L/min â†’ ~60-90% FiO2</li>
                <li><strong>Use:</strong> Severe hypoxemia, CO poisoning, trauma</li>
                <li><strong>Limitation:</strong> Max FiO2 ~90% (not truly 100%), uncomfortable for prolonged use</li>
            </ul>
            
            <p><strong>5. High-Flow Nasal Cannula (HFNC):</strong></p>
            <ul>
                <li><strong>Flow:</strong> 20-60 L/min, FiO2 21-100%, heated/humidified</li>
                <li><strong>Mechanism:</strong> Matches/exceeds patient's inspiratory flow â†’ reliable FiO2, PEEP effect (2-5 cm H2O), dead space washout, reduced work of breathing</li>
                <li><strong>Use:</strong> Moderate-severe hypoxemia (P/F 100-300), post-extubation, may avoid intubation in some patients</li>
                <li><strong>Starting Settings:</strong> Flow 40-60 L/min, FiO2 titrate to SpO2 >92%</li>
                <li><strong>Evidence:</strong> FLORALI trial â€” reduced intubation vs NRB in hypoxic respiratory failure; ROX index predicts failure (SpO2/FiO2 Ã· RR; <4.88 at 12h = high failure risk)</li>
                <li><strong>Advantages over NIPPV:</strong> Better tolerated, allows eating/speaking, less claustrophobia</li>
                <li><strong>When to escalate:</strong> Persistent hypoxemia, rising FiO2 requirements, RR >30, ROX <4.88</li>
            </ul>
            
            <p><strong>6. Non-Invasive Positive Pressure Ventilation (NIPPV):</strong></p>
            <ul>
                <li><strong>CPAP:</strong> Single pressure throughout cycle (e.g., 5-10 cm H2O)
                    <ul>
                        <li>Best for: Cardiogenic pulmonary edema (reduces preload/afterload), OSA</li>
                    </ul>
                </li>
                <li><strong>BiPAP:</strong> IPAP (inspiratory) + EPAP (expiratory) â€” provides pressure support
                    <ul>
                        <li>Best for: Hypercapnic failure (COPD), provides ventilatory assistance</li>
                        <li>Starting settings: IPAP 10-12, EPAP 5, FiO2 to SpO2 >88-92%</li>
                        <li>Titrate: â†‘ IPAP to improve ventilation (â†“ CO2), â†‘ EPAP to improve oxygenation</li>
                    </ul>
                </li>
                <li><strong>Contraindications:</strong> Inability to protect airway, AMS (GCS <10), hemodynamic instability, facial trauma, recent upper GI surgery, copious secretions, uncooperative patient</li>
                <li><strong>Failure Signs:</strong> Worsening pH/PaCO2, declining mental status, persistent hypoxemia after 1-2 hours â†’ intubate</li>
            </ul>
            
            <p><strong>7. Intubation / Mechanical Ventilation:</strong></p>
            <ul>
                <li>See "Intubation Indications" and "Initial Vent Settings" below</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">INTUBATION</div>
        <div class="section-content">
            <p><strong>Indications (SOAP ME):</strong></p>
            <ul>
                <li><strong>S</strong>ecretions â€” unable to clear, aspiration risk</li>
                <li><strong>O</strong>xygenation failure â€” refractory hypoxemia despite max non-invasive support</li>
                <li><strong>A</strong>irway protection â€” GCS â‰¤8, loss of gag/cough, inability to protect from aspiration</li>
                <li><strong>P</strong>atient trajectory â€” worsening despite treatment, impending arrest</li>
                <li><strong>M</strong>echanical ventilation needed â€” severe acidosis, fatigue, anticipated prolonged failure</li>
                <li><strong>E</strong>xpected course â€” OR, procedures, transport of unstable patient</li>
            </ul>
            
            <p><strong>Clinical Triggers:</strong></p>
            <ul>
                <li>Respiratory rate >35-40/min with distress</li>
                <li>SpO2 <88% on maximal non-invasive O2</li>
                <li>PaO2 <60 mmHg on FiO2 >0.6</li>
                <li>PaCO2 >50 with pH <7.25 and declining mental status</li>
                <li>Signs of fatigue: paradoxical breathing, decreasing RR with worsening mental status</li>
                <li>"Intubate the trajectory, not the number" â€” if rapidly worsening, don't wait</li>
            </ul>
            
            <p><strong>Pre-Intubation Checklist:</strong></p>
            <ul>
                <li><strong>Prepare:</strong> Suction, BVM, ETT (7.0-8.0), laryngoscope, bougie, video laryngoscope if available</li>
                <li><strong>Preoxygenate:</strong> 3-5 min NRB or HFNC at 100% (denitrogenate), apneic oxygenation during attempt</li>
                <li><strong>Push-dose pressors:</strong> Have phenylephrine/epinephrine ready for post-induction hypotension</li>
                <li><strong>RSI Medications:</strong> Induction (etomidate, ketamine, propofol) + paralytic (succinylcholine or rocuronium)</li>
                <li><strong>Position:</strong> Sniffing position, ramped if obese</li>
                <li><strong>Plan B:</strong> Supraglottic airway (LMA), surgical airway equipment available</li>
            </ul>
            
            <p><strong>Initial Ventilator Settings (Post-Intubation):</strong></p>
            <ul>
                <li><strong>Mode:</strong> Volume-Assist Control (AC/VC) or Pressure-Assist Control (AC/PC)</li>
                <li><strong>Tidal Volume:</strong> 6-8 mL/kg IBW (lung-protective; use 6 mL/kg if ARDS)
                    <ul>
                        <li>IBW (kg): Males = 50 + 2.3 Ã— (height in inches - 60); Females = 45.5 + 2.3 Ã— (height in inches - 60)</li>
                    </ul>
                </li>
                <li><strong>Respiratory Rate:</strong> 14-20/min (adjust for pH/PaCO2)</li>
                <li><strong>FiO2:</strong> Start 100%, wean to SpO2 92-96% (88-92% if COPD)</li>
                <li><strong>PEEP:</strong> Start 5 cm H2O, increase if hypoxemia persists (ARDS may need 10-20)</li>
                <li><strong>Plateau Pressure Goal:</strong> <30 cm H2O (to avoid barotrauma)</li>
            </ul>
            
            <p><strong>Post-Intubation:</strong></p>
            <ul>
                <li>Confirm placement: End-tidal CO2 (gold standard), bilateral breath sounds, CXR</li>
                <li>Secure tube, note depth at teeth (typically 21-23 cm)</li>
                <li>Sedation: Propofol or fentanyl/midazolam drip (target RASS -2 to 0)</li>
                <li>ABG in 30-60 min, adjust vent settings</li>
                <li>OG/NG tube, DVT prophylaxis, stress ulcer prophylaxis, HOB 30-45Â°</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Immediate (Bedside):</strong></p>
            <ul>
                <li><strong>ABG:</strong> Defines type (hypoxic vs hypercapnic vs mixed), severity, acid-base status</li>
                <li><strong>CXR (portable):</strong> Infiltrates (pneumonia, ARDS, edema), effusion, pneumothorax, cardiomegaly</li>
                <li><strong>ECG:</strong> Ischemia, arrhythmia, RV strain (PE)</li>
                <li><strong>Bedside Echo (POCUS):</strong> LV function, RV dilation (PE), pericardial effusion, IVC for volume status</li>
            </ul>
            
            <p><strong>Laboratory:</strong></p>
            <ul>
                <li><strong>CBC:</strong> Anemia (reduced O2 carrying capacity), leukocytosis (infection)</li>
                <li><strong>BMP:</strong> Metabolic derangements, renal function</li>
                <li><strong>BNP/NT-proBNP:</strong> Elevated in cardiogenic pulmonary edema (>500 pg/mL suggestive)</li>
                <li><strong>Troponin:</strong> ACS, PE with RV strain, demand ischemia</li>
                <li><strong>Lactate:</strong> Tissue hypoxia, shock</li>
                <li><strong>Procalcitonin:</strong> Bacterial infection (pneumonia, sepsis)</li>
                <li><strong>D-dimer:</strong> If PE suspected (use Wells score first)</li>
            </ul>
            
            <p><strong>Advanced Imaging:</strong></p>
            <ul>
                <li><strong>CT Chest:</strong> Characterize infiltrates, ILD, malignancy</li>
                <li><strong>CTPA:</strong> If PE suspected</li>
                <li><strong>CT Pulmonary Angiogram:</strong> PE diagnosis</li>
                <li><strong>Formal Echo:</strong> Detailed cardiac assessment if cardiogenic cause suspected</li>
            </ul>
            
            <p><strong>Etiology-Based Workup:</strong></p>
            <table style="width:100%; border-collapse: collapse; margin-top: 10px; font-size: 9pt;">
                <tr style="background: #f0f0f0;">
                    <th style="border: 1px solid #ddd; padding: 8px; text-align: left;">Clinical Picture</th>
                    <th style="border: 1px solid #ddd; padding: 8px; text-align: left;">Consider</th>
                    <th style="border: 1px solid #ddd; padding: 8px; text-align: left;">Key Tests</th>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Fever + productive cough + infiltrate</td>
                    <td style="border: 1px solid #ddd; padding: 8px;"><a href="#cap" style="color: #0366d6;">Pneumonia</a></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Sputum Cx, blood Cx, procalcitonin, urine Legionella/pneumococcal Ag</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Orthopnea + JVD + crackles + edema</td>
                    <td style="border: 1px solid #ddd; padding: 8px;"><a href="#heart-failure" style="color: #0366d6;">CHF / Pulmonary Edema</a></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">BNP, TTE, CXR (cephalization, Kerley B lines)</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Pleuritic CP + hypoxia out of proportion to CXR</td>
                    <td style="border: 1px solid #ddd; padding: 8px;"><a href="#pe" style="color: #0366d6;">PE</a></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">D-dimer, CTPA, RV strain on echo/ECG</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Bilateral infiltrates + known risk factor + P/F <300</td>
                    <td style="border: 1px solid #ddd; padding: 8px;"><a href="#ards" style="color: #0366d6;">ARDS</a></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Berlin criteria, echo to exclude cardiogenic cause</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">COPD history + wheezing + â†‘ PaCO2</td>
                    <td style="border: 1px solid #ddd; padding: 8px;"><a href="#copd" style="color: #0366d6;">COPD Exacerbation</a></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">ABG, CXR, sputum if purulent</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Wheezing + air trapping + young patient</td>
                    <td style="border: 1px solid #ddd; padding: 8px;"><a href="#asthma" style="color: #0366d6;">Asthma Exacerbation</a></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Peak flow, ABG if severe</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Pinpoint pupils + â†“RR + â†‘ PaCO2</td>
                    <td style="border: 1px solid #ddd; padding: 8px;"><a href="#opioid-overdose" style="color: #0366d6;">Opioid Overdose</a></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Tox screen, response to naloxone</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Ascending weakness + â†“ NIF</td>
                    <td style="border: 1px solid #ddd; padding: 8px;"><a href="#gbs" style="color: #0366d6;">GBS / Neuromuscular</a></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">NIF, VC, LP, EMG/NCS</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 8px;">Absent breath sounds + tracheal deviation</td>
                    <td style="border: 1px solid #ddd; padding: 8px;"><a href="#pneumothorax" style="color: #0366d6;">Tension Pneumothorax</a></td>
                    <td style="border: 1px solid #ddd; padding: 8px;">Clinical diagnosis â†’ needle decompression before CXR</td>
                </tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT BY ETIOLOGY (QUICK REFERENCE)</div>
        <div class="section-content">
            <p><strong>All patients:</strong> Supplemental O2 to target SpO2 (92-96% most; 88-92% COPD), treat underlying cause, monitor closely for deterioration</p>
            
            <ul>
                <li><strong>Pneumonia:</strong> Antibiotics (CAP vs HAP/VAP coverage), supportive care â†’ <a href="#cap" style="color: #0366d6;">CAP</a>, <a href="#hap-vap" style="color: #0366d6;">HAP/VAP</a></li>
                <li><strong>CHF / Pulmonary Edema:</strong> Diuresis (furosemide), CPAP/BiPAP, nitrates if hypertensive, reduce afterload â†’ <a href="#heart-failure" style="color: #0366d6;">Heart Failure</a></li>
                <li><strong>PE:</strong> Anticoagulation, consider thrombolytics if massive/submassive â†’ <a href="#pe" style="color: #0366d6;">PE</a></li>
                <li><strong>ARDS:</strong> Lung-protective ventilation (6 mL/kg, Pplat <30), prone positioning, conservative fluids â†’ <a href="#ards" style="color: #0366d6;">ARDS</a></li>
                <li><strong>COPD Exacerbation:</strong> Bronchodilators, steroids, BiPAP, antibiotics if purulent sputum â†’ <a href="#copd" style="color: #0366d6;">COPD</a>, <a href="#hypercapnic-failure" style="color: #0366d6;">Hypercapnic Failure</a></li>
                <li><strong>Asthma:</strong> Bronchodilators, steroids, magnesium if severe â†’ <a href="#asthma" style="color: #0366d6;">Asthma</a></li>
                <li><strong>Opioid Overdose:</strong> Naloxone, support ventilation â†’ <a href="#opioid-overdose" style="color: #0366d6;">Opioid Overdose</a></li>
                <li><strong>Pneumothorax:</strong> Needle decompression (tension) or chest tube â†’ <a href="#pneumothorax" style="color: #0366d6;">Pneumothorax</a></li>
                <li><strong>Neuromuscular:</strong> IVIG/PLEX (GBS, MG crisis), intubation often needed â†’ <a href="#gbs" style="color: #0366d6;">GBS</a>, <a href="#myasthenia" style="color: #0366d6;">MG Crisis</a></li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Need for HFNC, NIPPV, or mechanical ventilation</li>
                <li>P/F ratio <200 (moderate-severe hypoxemia)</li>
                <li>Respiratory acidosis with pH <7.30</li>
                <li>Hemodynamic instability</li>
                <li>Altered mental status from respiratory failure</li>
                <li>High likelihood of deterioration / need for close monitoring</li>
                <li>Requiring FiO2 >50% to maintain adequate SpO2</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>SpO2 >92% on â‰¤2L NC (or baseline O2 requirement)</li>
                <li>Respiratory rate <24, no accessory muscle use</li>
                <li>Underlying cause treated or controlled</li>
                <li>ABG normalized or at baseline (chronic CO2 retainers)</li>
                <li>Off NIPPV/HFNC for >24 hours</li>
                <li>Able to ambulate without significant desaturation</li>
                <li>Home O2 arranged if needed</li>
                <li>Pulmonary/cardiology follow-up as appropriate</li>
                <li>Clear return precautions (worsening dyspnea, chest pain, fever)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Intubate the trajectory:</strong> If patient is rapidly deteriorating, don't wait for a specific number. A patient who "looks bad" and is getting worse needs the tube before they arrest.</li>
            <li><strong>HFNC is not just "fancy nasal cannula":</strong> It delivers reliable FiO2, provides PEEP effect (2-5 cm H2O), washes out dead space, and reduces work of breathing. Can prevent intubation in moderate hypoxic failure.</li>
            <li><strong>ROX index predicts HFNC failure:</strong> (SpO2/FiO2) Ã· RR. If <4.88 at 12 hours, high risk of needing intubation â€” escalate early.</li>
            <li><strong>BiPAP for CO2, CPAP for cardiogenic edema:</strong> BiPAP provides pressure support to augment ventilation (lowers CO2). CPAP reduces preload/afterload (treats pulmonary edema). Both provide PEEP.</li>
            <li><strong>Normal A-a gradient = hypoventilation:</strong> If A-a gradient is normal, the lungs are fine â€” problem is inadequate respiratory drive (opioids, CNS) or pump failure (neuromuscular). Give naloxone and support ventilation.</li>
            <li><strong>SpO2 88-92% for chronic CO2 retainers:</strong> High O2 in COPD can worsen hypercapnia (loss of hypoxic drive, Haldane effect). Target lower SpO2, use Venturi mask for precise FiO2.</li>
            <li><strong>6 mL/kg IBW saves lives in ARDS:</strong> Lung-protective ventilation reduces mortality. Use ideal body weight (based on height, not actual weight), keep plateau pressure <30.</li>
            <li><strong>Post-intubation hypotension is common:</strong> Loss of catecholamine surge, positive pressure reduces venous return, sedation causes vasodilation. Have push-dose pressors ready.</li>
            <li><strong>Don't forget the simple stuff:</strong> Before intubating, make sure you've tried positioning (upright), suctioning secretions, treating bronchospasm, and draining large effusions.</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="acute-liver-failure" class="condition-page">
    <div class="page-header">
        <h2>155. ACUTE LIVER FAILURE</h2>
        <div class="subtitle">Fulminant Hepatic Failure â€¢ Coagulopathy â€¢ Encephalopathy â€¢ Transplant Evaluation</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Severe acute liver injury with encephalopathy and coagulopathy (INR â‰¥1.5) in a patient WITHOUT pre-existing liver disease, developing within 26 weeks of initial symptoms. Hyperacute (<7 days), acute (7-21 days), subacute (21 days-26 weeks)</p>
            
            <p><strong>Etiologies:</strong></p>
            <ul>
                <li><strong>Acetaminophen Toxicity (46% in US):</strong> Intentional OD or unintentional (chronic use + alcohol, fasting). Dose-dependent hepatotoxicity >10g acute or >4g/day chronic</li>
                <li><strong>Drug-Induced (11%):</strong> Isoniazid, phenytoin, valproate, sulfonamides, statins, herbal supplements (kava, green tea extract), mushroom poisoning (Amanita phalloides)</li>
                <li><strong>Viral Hepatitis:</strong> Hepatitis A (rare), Hepatitis B (reactivation or acute), Hepatitis E (pregnant women), HSV, CMV, EBV</li>
                <li><strong>Autoimmune Hepatitis:</strong> May present acutely, check ANA, ASMA, IgG</li>
                <li><strong>Ischemic/Hypoxic:</strong> Shock liver, Budd-Chiari syndrome, acute portal vein thrombosis</li>
                <li><strong>Wilson's Disease:</strong> Young patients, hemolytic anemia, low alkaline phosphatase, Kayser-Fleischer rings</li>
                <li><strong>Pregnancy-Related:</strong> HELLP, acute fatty liver of pregnancy (AFLP)</li>
                <li><strong>Indeterminate (15%):</strong> No cause found despite workup</li>
            </ul>
            
            <p><strong>Clinical Features:</strong></p>
            <ul>
                <li><strong>Jaundice:</strong> Rapidly progressive</li>
                <li><strong>Coagulopathy:</strong> INR â‰¥1.5, bleeding diathesis</li>
                <li><strong>Hepatic Encephalopathy:</strong> Confusion â†’ somnolence â†’ coma (Grade I-IV)</li>
                <li><strong>Cerebral Edema:</strong> Major cause of death. Cushing's triad (HTN, bradycardia, irregular respirations)</li>
                <li><strong>Hypoglycemia:</strong> Impaired gluconeogenesis â€” check frequently</li>
                <li><strong>Infections:</strong> High risk (impaired immunity) â€” often bacterial, fungal</li>
                <li><strong>Multi-organ failure:</strong> AKI, ARDS, circulatory failure</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Confirm ALF:</strong></p>
            <ul>
                <li>INR â‰¥1.5 + hepatic encephalopathy + acute illness (<26 weeks)</li>
                <li>NO pre-existing cirrhosis (distinguishes from acute-on-chronic liver failure)</li>
            </ul>
            
            <p><strong>Etiology Workup:</strong></p>
            <ul>
                <li><strong>Acetaminophen level</strong> + Rumack-Matthew nomogram (if timed ingestion known)</li>
                <li><strong>Viral:</strong> HAV IgM, HBsAg, HBV DNA, HBc IgM, HCV Ab/RNA, HSV PCR, CMV, EBV</li>
                <li><strong>Autoimmune:</strong> ANA, ASMA, IgG levels</li>
                <li><strong>Wilson's:</strong> Ceruloplasmin, 24-hr urine copper, slit lamp exam</li>
                <li><strong>Pregnancy test</strong> in women of childbearing age</li>
                <li><strong>Toxicology screen</strong></li>
                <li><strong>Imaging:</strong> RUQ US with Doppler (Budd-Chiari, portal vein thrombosis), CT if needed</li>
            </ul>
            
            <p><strong>Severity/Prognosis:</strong></p>
            <ul>
                <li><strong>King's College Criteria (Non-Acetaminophen):</strong> INR >6.5 OR any 3 of: Age <10 or >40, etiology (non-A/non-B hepatitis, drug), jaundice >7 days before encephalopathy, INR >3.5, bilirubin >17.5 mg/dL</li>
                <li><strong>King's College Criteria (Acetaminophen):</strong> pH <7.3 (after resuscitation) OR all 3: INR >6.5, Cr >3.4, Grade III-IV encephalopathy</li>
                <li><strong>MELD score:</strong> Used for transplant listing</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate:</strong></p>
            <ul>
                <li><strong>ICU admission</strong> â€” all ALF patients</li>
                <li><strong>Contact transplant center early</strong> â€” even if uncertain; transfer before too unstable</li>
                <li><strong>N-acetylcysteine (NAC):</strong> Give to ALL ALF patients (not just acetaminophen). IV: 150 mg/kg over 1 hr, then 50 mg/kg over 4 hr, then 100 mg/kg over 16 hr. Continue until INR <1.5 or transplant</li>
            </ul>
            
            <p><strong>Supportive Care:</strong></p>
            <ul>
                <li><strong>Coagulopathy:</strong> Do NOT correct prophylactically (INR is prognostic marker). Give FFP/platelets only for active bleeding or procedures</li>
                <li><strong>Hypoglycemia:</strong> Check glucose q1-2h, D10 infusion to maintain >100 mg/dL</li>
                <li><strong>Cerebral Edema:</strong> HOB 30Â°, avoid stimulation, hypertonic saline (goal Na 145-155), mannitol 0.5-1 g/kg for herniation signs, consider ICP monitoring</li>
                <li><strong>Infections:</strong> Low threshold to culture and treat; surveillance cultures. Prophylactic antibiotics controversial but often given</li>
                <li><strong>Renal Failure:</strong> Avoid nephrotoxins, CRRT preferred over intermittent HD (less hemodynamic instability)</li>
                <li><strong>Avoid sedation</strong> if possible (obscures encephalopathy assessment)</li>
                <li><strong>Stress ulcer prophylaxis:</strong> PPI</li>
            </ul>
            
            <p><strong>Etiology-Specific:</strong></p>
            <ul>
                <li><strong>Acetaminophen:</strong> NAC (most effective <8-10 hr but give regardless of timing)</li>
                <li><strong>Mushroom (Amanita):</strong> Penicillin G, silibinin, NAC</li>
                <li><strong>Autoimmune:</strong> Steroids (controversial in ALF, consult hepatology)</li>
                <li><strong>HSV:</strong> Acyclovir</li>
                <li><strong>HBV reactivation:</strong> Nucleos(t)ide analogs (tenofovir, entecavir)</li>
                <li><strong>Wilson's:</strong> Plasmapheresis, transplant often needed</li>
                <li><strong>Budd-Chiari:</strong> Anticoagulation, TIPS, transplant</li>
                <li><strong>AFLP/HELLP:</strong> Emergent delivery</li>
            </ul>
            
            <p><strong>Transplant:</strong></p>
            <ul>
                <li>Liver transplant is definitive treatment for ALF not responding to medical therapy</li>
                <li>List as Status 1A (highest priority)</li>
                <li>Contraindications: Uncontrolled sepsis, severe cardiopulmonary disease, active malignancy, irreversible brain injury</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>ALL patients with acute liver failure require ICU</li>
                <li>Hepatic encephalopathy grade II or higher</li>
                <li>INR >2.0</li>
                <li>Hypoglycemia</li>
                <li>Hemodynamic instability</li>
                <li>Cerebral edema signs</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Rarely discharged â€” most require transplant or die</li>
                <li>If spontaneous recovery: INR normalizing, encephalopathy resolved, stable synthetic function</li>
                <li>Etiology identified and treated</li>
                <li>Close hepatology follow-up</li>
                <li>Acetaminophen: Psychiatric evaluation if intentional OD</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>NAC for ALL ALF:</strong> Not just acetaminophen. Improves transplant-free survival in non-acetaminophen ALF too (especially grade I-II encephalopathy)</li>
            <li><strong>Don't correct the INR:</strong> It's your best prognostic marker. Only give FFP for active bleeding or invasive procedures</li>
            <li><strong>Transfer early:</strong> Patients deteriorate rapidly. Transfer to transplant center before too unstable to move</li>
            <li><strong>Acetaminophen ALF has best prognosis:</strong> 65% spontaneous survival vs 25% for other causes</li>
            <li><strong>Hyperacute has paradoxically better prognosis:</strong> Often acetaminophen, higher spontaneous recovery rate</li>
            <li><strong>Wilson's ALF = emergent transplant:</strong> Almost never recovers spontaneously. Hemolytic anemia + low ALP:bilirubin ratio are clues</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="alcoholic-hepatitis" class="condition-page">
    <div class="page-header">
        <h2>156. ALCOHOLIC HEPATITIS</h2>
        <div class="subtitle">Acute Alcohol-Associated Hepatitis â€¢ Maddrey Score â€¢ Lille Model â€¢ Steroids</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Acute inflammatory liver injury from heavy alcohol use, typically presenting with jaundice, tender hepatomegaly, and systemic inflammation. Usually in setting of >40g/day (women) or >60g/day (men) alcohol for >6 months, often with recent heavy binge</p>
            
            <p><strong>Classic Presentation:</strong></p>
            <ul>
                <li><strong>Jaundice:</strong> Rapid onset, often severe (bilirubin >3 mg/dL, frequently >10-20)</li>
                <li><strong>Tender hepatomegaly:</strong> RUQ pain and tenderness</li>
                <li><strong>Fever:</strong> Low-grade, even without infection (inflammatory response)</li>
                <li><strong>Malnutrition:</strong> Muscle wasting, low albumin</li>
                <li><strong>Signs of chronic liver disease:</strong> Spider angiomata, palmar erythema, gynecomastia</li>
                <li><strong>Ascites, encephalopathy:</strong> If decompensated</li>
            </ul>
            
            <p><strong>Lab Pattern:</strong></p>
            <ul>
                <li><strong>AST:ALT ratio >2:1</strong> (classic, due to B6 deficiency and mitochondrial injury)</li>
                <li><strong>AST and ALT typically <300-500</strong> (if >500, consider other causes)</li>
                <li><strong>Elevated bilirubin</strong> (often >5-10 mg/dL, key prognostic marker)</li>
                <li><strong>Elevated INR</strong> (synthetic dysfunction)</li>
                <li><strong>Leukocytosis</strong> (often 12-20k, WBC >20k concerning for infection)</li>
                <li><strong>Low albumin</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Clinical Diagnosis (Biopsy Not Required If Classic Presentation):</strong></p>
            <ul>
                <li>Heavy alcohol use (>40g/day women, >60g/day men for >6 months)</li>
                <li>Rapid onset jaundice (bilirubin >3 mg/dL)</li>
                <li>AST 50-300, AST:ALT >1.5 (typically >2)</li>
                <li>No other explanation for liver disease</li>
            </ul>
            
            <p><strong>Rule Out Other Causes:</strong></p>
            <ul>
                <li>Viral hepatitis serologies (HBV, HCV)</li>
                <li>RUQ US: Rule out biliary obstruction, assess for cirrhosis</li>
                <li>Consider: Autoimmune markers (ANA, ASMA), ceruloplasmin if young</li>
            </ul>
            
            <p><strong>Rule Out Infection (Critical Before Steroids):</strong></p>
            <ul>
                <li>Blood cultures</li>
                <li>Urine culture</li>
                <li>Diagnostic paracentesis if ascites (rule out SBP)</li>
                <li>CXR</li>
            </ul>
            
            <p><strong>Severity Scoring:</strong></p>
            <ul>
                <li><strong>Maddrey Discriminant Function (mDF):</strong> 4.6 Ã— (PT - control PT) + bilirubin
                    <ul>
                        <li>mDF â‰¥32 = severe alcoholic hepatitis, ~35% 30-day mortality without treatment</li>
                        <li>mDF <32 = mild-moderate, supportive care</li>
                    </ul>
                </li>
                <li><strong>MELD Score:</strong> >20 indicates severe disease</li>
                <li><strong>Lille Score:</strong> Calculate at day 7 of steroids to assess response
                    <ul>
                        <li>Lille <0.45 = responder, complete 28 days steroids</li>
                        <li>Lille â‰¥0.45 = non-responder, stop steroids (futile, increases infection risk)</li>
                    </ul>
                </li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>All Patients:</strong></p>
            <ul>
                <li><strong>Alcohol cessation</strong> (most important long-term intervention)</li>
                <li><strong>Nutrition:</strong> 1.2-1.5 g/kg/day protein, 30-40 kcal/kg/day. Enteral preferred. Zinc supplementation</li>
                <li><strong>Thiamine:</strong> 100-250 mg IV/IM Ã— 3-5 days, then oral (prevent Wernicke's)</li>
                <li><strong>Folate, multivitamin</strong></li>
                <li><strong>Manage alcohol withdrawal:</strong> CIWA protocol, benzodiazepines PRN</li>
                <li><strong>Treat complications:</strong> Ascites (diuretics, paracentesis), encephalopathy (lactulose, rifaximin)</li>
            </ul>
            
            <p><strong>Severe Alcoholic Hepatitis (mDF â‰¥32 or MELD >20):</strong></p>
            <ul>
                <li><strong>Prednisolone 40 mg PO daily Ã— 28 days</strong> (or methylprednisolone 32 mg IV if unable to take PO)
                    <ul>
                        <li>Use prednisolone (not prednisone) â€” doesn't require hepatic conversion</li>
                        <li>Contraindications: Active infection (GI bleeding, sepsis, SBP), HBV, uncontrolled DM, GI bleeding</li>
                    </ul>
                </li>
                <li><strong>Calculate Lille score at day 7:</strong>
                    <ul>
                        <li>Lille <0.45: Continue steroids for full 28 days, then taper</li>
                        <li>Lille â‰¥0.45: Stop steroids (non-responder), consider transplant evaluation</li>
                    </ul>
                </li>
                <li><strong>Pentoxifylline:</strong> No longer recommended (STOPAH trial showed no benefit)</li>
            </ul>
            
            <p><strong>Transplant Evaluation:</strong></p>
            <ul>
                <li>Consider for steroid non-responders, severe AH not responding to medical therapy</li>
                <li>Traditionally required 6 months abstinence, but early transplant protocols exist at select centers for carefully selected patients</li>
                <li>Excellent outcomes in selected patients with severe AH failing medical therapy</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>MELD >30 or mDF >54 (very severe)</li>
                <li>Grade III-IV hepatic encephalopathy</li>
                <li>GI bleeding</li>
                <li>Sepsis or severe infection</li>
                <li>Renal failure (hepatorenal syndrome)</li>
                <li>Respiratory failure</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Bilirubin downtrending</li>
                <li>INR improving or stable</li>
                <li>Encephalopathy resolved or at baseline</li>
                <li>Tolerating oral nutrition</li>
                <li>No active infection</li>
                <li>Alcohol cessation resources arranged</li>
                <li>Hepatology follow-up within 1-2 weeks</li>
                <li>If on steroids: Clear taper plan, glucose monitoring</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>AST:ALT >2 is classic:</strong> Alcohol depletes B6 (pyridoxine) needed for ALT synthesis. If ratio <1, think viral or other causes</li>
            <li><strong>Transaminases NOT dramatically elevated:</strong> AST/ALT usually <300. If >500, look for acetaminophen, ischemia, viral superinfection</li>
            <li><strong>Lille at day 7 guides therapy:</strong> Don't continue steroids in non-responders â€” increases infection risk without benefit</li>
            <li><strong>Nutrition is critical:</strong> These patients are severely malnourished. High protein (1.5 g/kg) improves outcomes</li>
            <li><strong>Rule out infection before steroids:</strong> Steroids in setting of undiagnosed infection = disaster. Get cultures, paracentesis if ascites</li>
            <li><strong>Pentoxifylline doesn't work:</strong> STOPAH trial buried it. Don't use</li>
            <li><strong>Early transplant is evolving:</strong> Select centers offer transplant without 6-month abstinence for carefully chosen patients failing medical therapy</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="ischemic-colitis" class="condition-page">
    <div class="page-header">
        <h2>157. ISCHEMIC COLITIS</h2>
        <div class="subtitle">Colonic Ischemia â€¢ Watershed Areas â€¢ Thumbprinting â€¢ Supportive Care</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Ischemic injury to the colon from reduced blood flow. Most common form of GI ischemia. Usually transient and self-limited (80-85%), but can progress to gangrene/perforation</p>
            
            <p><strong>Classic Triad:</strong></p>
            <ul>
                <li><strong>Sudden crampy abdominal pain</strong> (usually left-sided)</li>
                <li><strong>Urgent need to defecate</strong></li>
                <li><strong>Bloody diarrhea</strong> (maroon or bright red) within 24 hours of pain onset</li>
            </ul>
            
            <p><strong>Risk Factors:</strong></p>
            <ul>
                <li><strong>Age >60</strong> (most common)</li>
                <li><strong>Cardiovascular disease:</strong> HTN, CAD, CHF, AFib, PVD</li>
                <li><strong>Hypotensive episodes:</strong> Surgery, sepsis, hemodialysis, cardiac arrest</li>
                <li><strong>Medications:</strong> Vasopressors, cocaine, digoxin, NSAIDs, oral contraceptives, immunosuppressants</li>
                <li><strong>Coagulopathy / Hypercoagulable states</strong></li>
                <li><strong>Constipation / Obstruction:</strong> Increased intraluminal pressure</li>
                <li><strong>Aortic surgery:</strong> IMA ligation</li>
                <li><strong>Long-distance running</strong> (marathon colitis)</li>
            </ul>
            
            <p><strong>Watershed Areas (Most Susceptible):</strong></p>
            <ul>
                <li><strong>Splenic flexure:</strong> Junction of SMA and IMA territories (Griffith's point)</li>
                <li><strong>Rectosigmoid junction:</strong> Junction of IMA and internal iliac (Sudeck's point)</li>
                <li>Rectum usually spared (dual blood supply from IMA and internal iliac)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Labs:</strong></p>
            <ul>
                <li><strong>CBC:</strong> Leukocytosis (WBC >15k concerning for severe ischemia)</li>
                <li><strong>BMP:</strong> Metabolic acidosis, elevated lactate = severe ischemia</li>
                <li><strong>Lactate:</strong> If elevated, concerning for transmural ischemia/necrosis</li>
                <li><strong>LDH, CPK:</strong> May be elevated in severe cases</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>CT Abdomen/Pelvis with IV Contrast:</strong> First-line imaging
                    <ul>
                        <li>Segmental colonic wall thickening</li>
                        <li>"Thumbprinting" (submucosal edema/hemorrhage)</li>
                        <li>Pericolonic fat stranding</li>
                        <li>Pneumatosis (air in bowel wall) = severe ischemia</li>
                        <li>Portal venous gas, free air = perforation/gangrene</li>
                    </ul>
                </li>
                <li><strong>CT Angiography:</strong> If concerned for acute mesenteric ischemia (isolated right colon involvement, severe presentation)</li>
            </ul>
            
            <p><strong>Colonoscopy (Gold Standard for Diagnosis):</strong></p>
            <ul>
                <li>Perform within 48 hours if diagnosis uncertain</li>
                <li>Findings: Segmental erythema, edema, hemorrhagic mucosa, ulcerations. Sharp demarcation between affected and normal mucosa</li>
                <li><strong>Contraindicated if:</strong> Peritonitis, pneumatosis, hemodynamic instability (risk of perforation)</li>
            </ul>
            
            <p><strong>Severity Classification:</strong></p>
            <ul>
                <li><strong>Mild:</strong> No risk factors, non-isolated right colon, no peritonitis</li>
                <li><strong>Moderate:</strong> 1-3 risk factors (right colon involvement, hypotension, tachycardia, male sex, BUN >20, Hgb <12, LDH >350, Na <136, WBC >15k)</li>
                <li><strong>Severe:</strong> â‰¥3 risk factors OR peritonitis OR pneumatosis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Supportive Care (Majority of Cases):</strong></p>
            <ul>
                <li><strong>Bowel rest:</strong> NPO initially</li>
                <li><strong>IV fluids:</strong> Gentle hydration (avoid hypotension)</li>
                <li><strong>Avoid/discontinue offending medications:</strong> Vasoconstrictors, NSAIDs, digoxin, diuretics</li>
                <li><strong>Optimize cardiac output:</strong> Treat CHF, arrhythmias</li>
                <li><strong>Antibiotics:</strong> If moderate-severe, signs of sepsis, or mucosal compromise. Ciprofloxacin + metronidazole or piperacillin-tazobactam</li>
                <li><strong>Serial abdominal exams:</strong> Monitor for peritonitis</li>
                <li><strong>DVT prophylaxis</strong></li>
            </ul>
            
            <p><strong>Surgical Consultation (Emergent if):</strong></p>
            <ul>
                <li>Peritonitis or free perforation</li>
                <li>Pneumatosis intestinalis or portal venous gas</li>
                <li>Hemodynamic instability despite resuscitation</li>
                <li>Worsening despite 24-48 hours of conservative management</li>
                <li>Massive GI bleeding</li>
                <li>Fulminant colitis with sepsis</li>
            </ul>
            
            <p><strong>Prognosis:</strong></p>
            <ul>
                <li>80-85% resolve with conservative management</li>
                <li>15-20% progress to gangrene, perforation, or stricture</li>
                <li>Surgery required in ~20%</li>
                <li>Mortality: 5% overall, 50-60% if surgery required</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Peritonitis or signs of perforation</li>
                <li>Hemodynamic instability</li>
                <li>Pneumatosis or portal venous gas on imaging</li>
                <li>Isolated right colon involvement (IMA not involved â€” suggests SMA occlusion)</li>
                <li>Severe sepsis</li>
                <li>Need for emergent surgery</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Abdominal pain resolved</li>
                <li>Tolerating regular diet</li>
                <li>Normal bowel function returning</li>
                <li>No fever, leukocytosis resolving</li>
                <li>Lactate normal (if previously elevated)</li>
                <li>Offending medications discontinued</li>
                <li>Follow-up colonoscopy in 1-2 weeks to assess healing (and rule out underlying mass/stricture)</li>
                <li>GI follow-up arranged</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Pain â†’ urge â†’ bloody stool:</strong> Classic sequence within 24 hours. Distinguishes from infectious colitis (diarrhea first, then bloody)</li>
            <li><strong>Isolated right colon = worrisome:</strong> Right colon supplied by SMA, not IMA. Isolated right colon ischemia suggests more proximal occlusion â€” higher mortality, often needs CTA and surgery</li>
            <li><strong>Rectal sparing:</strong> Rectum has dual blood supply. If rectum involved, consider other diagnoses (IBD, infectious)</li>
            <li><strong>Thumbprinting on imaging:</strong> Classic CT finding â€” thickened haustral folds from submucosal edema/hemorrhage</li>
            <li><strong>Most cases self-limited:</strong> 80-85% resolve with supportive care. Don't rush to surgery unless peritonitis</li>
            <li><strong>Follow-up colonoscopy important:</strong> Rule out underlying malignancy (especially in older patients) and assess for stricture formation</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="choledocholithiasis" class="condition-page">
    <div class="page-header">
        <h2>158. CHOLEDOCHOLITHIASIS</h2>
        <div class="subtitle">Common Bile Duct Stone â€¢ Obstructive Jaundice â€¢ ERCP â€¢ MRCP</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Gallstone(s) in the common bile duct (CBD). Usually migrated from gallbladder. Can cause biliary obstruction, jaundice, cholangitis, or pancreatitis</p>
            
            <p><strong>Presentation Spectrum:</strong></p>
            <ul>
                <li><strong>Asymptomatic:</strong> Found incidentally on imaging</li>
                <li><strong>Biliary colic:</strong> Episodic RUQ/epigastric pain, may be more prolonged than gallbladder colic</li>
                <li><strong>Obstructive jaundice:</strong> Painless or painful jaundice, dark urine, pale stools, pruritus</li>
                <li><strong>Acute cholangitis:</strong> â†’ See <a href="#cholangitis" style="color: #0366d6;">Cholangitis</a> (Charcot's triad: fever, jaundice, RUQ pain)</li>
                <li><strong>Gallstone pancreatitis:</strong> â†’ See <a href="#pancreatitis" style="color: #0366d6;">Pancreatitis</a></li>
            </ul>
            
            <p><strong>Lab Pattern:</strong></p>
            <ul>
                <li><strong>Elevated bilirubin:</strong> Direct (conjugated) > indirect</li>
                <li><strong>Elevated ALP and GGT:</strong> Cholestatic pattern</li>
                <li><strong>Transaminases:</strong> May be elevated (especially with acute obstruction â€” can be >1000 transiently)</li>
                <li><strong>If cholangitis:</strong> Leukocytosis, elevated inflammatory markers</li>
                <li><strong>If pancreatitis:</strong> Elevated lipase</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Risk Stratification (ASGE Guidelines):</strong></p>
            <ul>
                <li><strong>Very High Risk (Confirmed CBD Stone):</strong> Stone visible on US/CT, clinical cholangitis, bilirubin >4 + dilated CBD
                    <ul><li>â†’ Proceed directly to ERCP</li></ul>
                </li>
                <li><strong>High Risk:</strong> Dilated CBD (>6mm or >8mm post-cholecystectomy) + elevated bilirubin, OR any very high risk predictor
                    <ul><li>â†’ ERCP or intraoperative cholangiogram</li></ul>
                </li>
                <li><strong>Intermediate Risk:</strong> Abnormal LFTs (other than bilirubin), age >55, gallstone pancreatitis
                    <ul><li>â†’ EUS or MRCP first (avoid unnecessary ERCP)</li></ul>
                </li>
                <li><strong>Low Risk:</strong> None of the above
                    <ul><li>â†’ Proceed to cholecystectomy, no CBD evaluation needed</li></ul>
                </li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>RUQ Ultrasound:</strong> First-line. Sees dilated CBD (>6mm), gallstones. May not see CBD stones directly (50-70% sensitivity)</li>
                <li><strong>MRCP (Magnetic Resonance Cholangiopancreatography):</strong>
                    <ul>
                        <li>Non-invasive, no sedation, no radiation</li>
                        <li>Sensitivity 90-95% for CBD stones</li>
                        <li>Use for intermediate probability</li>
                    </ul>
                </li>
                <li><strong>EUS (Endoscopic Ultrasound):</strong>
                    <ul>
                        <li>Highest sensitivity (95%+) for CBD stones</li>
                        <li>Requires sedation but can proceed to ERCP in same session if stone found</li>
                        <li>Alternative to MRCP for intermediate risk</li>
                    </ul>
                </li>
                <li><strong>ERCP:</strong> Diagnostic AND therapeutic. Reserve for high probability (risk of pancreatitis 3-5%)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Definitive Treatment:</strong></p>
            <ul>
                <li><strong>ERCP with Sphincterotomy and Stone Extraction:</strong>
                    <ul>
                        <li>First-line therapeutic intervention</li>
                        <li>Success rate >90%</li>
                        <li>Balloon or basket extraction</li>
                        <li>Mechanical lithotripsy for large stones</li>
                        <li>Stent placement if incomplete clearance</li>
                    </ul>
                </li>
                <li><strong>Cholecystectomy:</strong> Should follow ERCP (same admission or within 2 weeks) to prevent recurrent stones</li>
            </ul>
            
            <p><strong>Alternative Approaches:</strong></p>
            <ul>
                <li><strong>Laparoscopic CBD exploration:</strong> Can be done during cholecystectomy at experienced centers</li>
                <li><strong>Choledochotomy:</strong> Open surgical CBD exploration (rarely needed now)</li>
                <li><strong>Percutaneous transhepatic cholangiography (PTC):</strong> If ERCP fails or inaccessible (altered anatomy)</li>
            </ul>
            
            <p><strong>If Cholangitis Present:</strong></p>
            <ul>
                <li>Urgent ERCP within 24-48 hours (emergent if severe/septic)</li>
                <li>IV antibiotics (piperacillin-tazobactam or ceftriaxone + metronidazole)</li>
                <li>Volume resuscitation, pressors if needed</li>
                <li>â†’ See <a href="#cholangitis" style="color: #0366d6;">Cholangitis</a></li>
            </ul>
            
            <p><strong>If Pancreatitis Present:</strong></p>
            <ul>
                <li>Urgent ERCP (within 24 hours) ONLY if concurrent cholangitis or biliary obstruction</li>
                <li>Otherwise, manage pancreatitis supportively, ERCP can be semi-elective</li>
                <li>Cholecystectomy during same admission (once pancreatitis resolved)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Concurrent cholangitis with sepsis/shock</li>
                <li>Severe gallstone pancreatitis</li>
                <li>Post-ERCP complications (perforation, severe pancreatitis, bleeding)</li>
                <li>Multi-organ dysfunction</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>CBD cleared (stone extracted or stent placed)</li>
                <li>Cholecystectomy completed (or scheduled)</li>
                <li>LFTs improving</li>
                <li>Tolerating diet</li>
                <li>Pain controlled</li>
                <li>Afebrile, WBC normalizing</li>
                <li>GI follow-up for stent removal if placed</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Transient transaminase spike:</strong> ALT/AST can spike >1000 with acute CBD obstruction (higher than typical biliary pattern), then fall rapidly. Don't assume viral hepatitis</li>
            <li><strong>CBD dilates with age:</strong> Normal CBD <6mm, but add 1mm per decade over age 60. Post-cholecystectomy CBD can be up to 10mm and still be normal</li>
            <li><strong>Don't ERCP everyone:</strong> ERCP has risks (pancreatitis, bleeding, perforation). Use MRCP or EUS for intermediate probability to avoid unnecessary procedures</li>
            <li><strong>Cholecystectomy on same admission:</strong> After ERCP, do cholecystectomy before discharge to prevent recurrence (unless patient too sick)</li>
            <li><strong>Gallstone pancreatitis + cholangitis = urgent ERCP:</strong> Pancreatitis alone doesn't need urgent ERCP, but if there's ongoing biliary obstruction or cholangitis, decompress urgently</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="gastroparesis" class="condition-page">
    <div class="page-header">
        <h2>159. GASTROPARESIS</h2>
        <div class="subtitle">Delayed Gastric Emptying â€¢ Diabetic Gastroparesis â€¢ Prokinetics â€¢ Gastric Stimulation</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Delayed gastric emptying in the absence of mechanical obstruction. Symptoms: nausea, vomiting, early satiety, bloating, abdominal pain</p>
            
            <p><strong>Etiologies:</strong></p>
            <ul>
                <li><strong>Diabetic (38%):</strong> Most common known cause. Usually longstanding DM with neuropathy. Type 1 > Type 2</li>
                <li><strong>Idiopathic (36%):</strong> No identifiable cause, often post-viral</li>
                <li><strong>Post-surgical:</strong> Vagal nerve injury (fundoplication, bariatric surgery, esophagectomy)</li>
                <li><strong>Medications:</strong> Opioids, anticholinergics, GLP-1 agonists, dopamine agonists</li>
                <li><strong>Neurologic:</strong> Parkinson's, MS, brainstem lesions</li>
                <li><strong>Connective tissue:</strong> Scleroderma, amyloidosis</li>
            </ul>
            
            <p><strong>Cardinal Symptoms:</strong></p>
            <ul>
                <li><strong>Nausea:</strong> Most common and bothersome symptom</li>
                <li><strong>Vomiting:</strong> Often partially digested food, may occur hours after eating</li>
                <li><strong>Early satiety / postprandial fullness</strong></li>
                <li><strong>Bloating / abdominal distension</strong></li>
                <li><strong>Abdominal pain:</strong> Present in 90%, often epigastric, can be severe</li>
                <li><strong>Weight loss / malnutrition</strong></li>
            </ul>
            
            <p><strong>Complications:</strong></p>
            <ul>
                <li>Malnutrition, weight loss</li>
                <li>Bezoar formation</li>
                <li>Erratic glycemic control in diabetics</li>
                <li>Aspiration pneumonia</li>
                <li>Electrolyte abnormalities (from vomiting)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Step 1 â€” Rule Out Mechanical Obstruction:</strong></p>
            <ul>
                <li><strong>EGD:</strong> Required before diagnosing gastroparesis. Rule out pyloric stenosis, gastric outlet obstruction, ulcer, malignancy, bezoar</li>
                <li><strong>CT or UGI series:</strong> If EGD incomplete or structural abnormality suspected</li>
            </ul>
            
            <p><strong>Step 2 â€” Confirm Delayed Gastric Emptying:</strong></p>
            <ul>
                <li><strong>Gastric Emptying Scintigraphy (Gold Standard):</strong>
                    <ul>
                        <li>Standardized low-fat meal with Tc-99m</li>
                        <li>Measure retention at 1, 2, and 4 hours</li>
                        <li><strong>Diagnostic:</strong> >60% retention at 2 hours OR >10% at 4 hours</li>
                        <li>Stop prokinetics 48-72 hr before, opioids 72 hr before</li>
                    </ul>
                </li>
                <li><strong>Wireless Motility Capsule (SmartPill):</strong> Alternative, measures pH, pressure, transit through entire GI tract</li>
                <li><strong>13C-Breath Test:</strong> Alternative, less available</li>
            </ul>
            
            <p><strong>Additional Workup:</strong></p>
            <ul>
                <li>HbA1c (glycemic control in diabetics)</li>
                <li>TSH (hypothyroidism can slow motility)</li>
                <li>ANA, SCL-70 if scleroderma suspected</li>
                <li>Review medications for offenders</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Acute Flare / Hospitalized Patient:</strong></p>
            <ul>
                <li><strong>NPO initially,</strong> then advance to small-volume clear liquids</li>
                <li><strong>IV fluids:</strong> Correct dehydration, electrolytes</li>
                <li><strong>Glycemic control:</strong> Critical in diabetics â€” hyperglycemia (>200 mg/dL) delays gastric emptying further</li>
                <li><strong>IV antiemetics:</strong> Ondansetron 4-8 mg IV q6-8h, promethazine, prochlorperazine</li>
                <li><strong>IV metoclopramide:</strong> 5-10 mg IV q6-8h (before meals and at bedtime)</li>
                <li><strong>NG tube decompression:</strong> If severe distension, obstruction, or refractory vomiting</li>
                <li><strong>Discontinue offending medications:</strong> Opioids, anticholinergics, GLP-1 agonists</li>
            </ul>
            
            <p><strong>Dietary Modifications:</strong></p>
            <ul>
                <li>Small, frequent meals (4-6/day)</li>
                <li>Low fat, low fiber (slows emptying)</li>
                <li>Liquids and pureed foods empty faster than solids</li>
                <li>Avoid carbonated beverages</li>
                <li>Walk after meals (promotes emptying)</li>
            </ul>
            
            <p><strong>Pharmacotherapy:</strong></p>
            <ul>
                <li><strong>Metoclopramide:</strong> 5-10 mg PO 15-30 min before meals + bedtime. Most effective but BLACK BOX WARNING for tardive dyskinesia. Limit to <12 weeks if possible</li>
                <li><strong>Domperidone:</strong> 10 mg TID-QID. Not FDA approved, available via FDA IND program. Fewer CNS effects (doesn't cross BBB)</li>
                <li><strong>Erythromycin:</strong> 40-250 mg PO before meals. Motilin agonist. Tolerance develops in weeks. Best for short-term/acute use</li>
                <li><strong>Prucalopride:</strong> 5-HT4 agonist, may help some patients</li>
                <li><strong>Antiemetics:</strong> Ondansetron, promethazine, prochlorperazine for symptom relief</li>
            </ul>
            
            <p><strong>Refractory Cases:</strong></p>
            <ul>
                <li><strong>Gastric electrical stimulation (Enterra):</strong> Implanted pacemaker, reduces nausea/vomiting in select patients</li>
                <li><strong>Pyloric interventions:</strong> Botox injection (temporary), G-POEM (gastric peroral endoscopic myotomy), pyloroplasty</li>
                <li><strong>Enteral feeding:</strong> J-tube (bypasses stomach) for nutrition in severe refractory cases</li>
                <li><strong>TPN:</strong> Last resort if enteral feeding fails</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Aspiration pneumonia with respiratory failure</li>
                <li>Severe electrolyte abnormalities (hypokalemia, hypochloremia)</li>
                <li>DKA in diabetic gastroparesis</li>
                <li>Severe malnutrition requiring TPN initiation</li>
                <li>Hemodynamic instability from dehydration</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Tolerating oral liquids/soft diet</li>
                <li>Nausea/vomiting controlled</li>
                <li>Electrolytes normalized</li>
                <li>Glycemic control optimized (diabetics)</li>
                <li>On effective antiemetic/prokinetic regimen</li>
                <li>Dietary education completed</li>
                <li>GI follow-up arranged</li>
                <li>Offending medications discontinued or alternatives provided</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>EGD before diagnosing:</strong> Must rule out mechanical obstruction. Don't diagnose gastroparesis without it</li>
            <li><strong>Hyperglycemia worsens emptying:</strong> Blood glucose >200 mg/dL delays gastric emptying independent of neuropathy. Control glucose first</li>
            <li><strong>Stop offending meds for testing:</strong> Opioids, metoclopramide must be stopped before gastric emptying study or results invalid</li>
            <li><strong>Metoclopramide has a black box:</strong> Risk of tardive dyskinesia. Use lowest effective dose, limit duration. Counsel patient</li>
            <li><strong>Erythromycin tolerance develops quickly:</strong> Best for acute flares, not long-term maintenance</li>
            <li><strong>Liquids empty by gravity:</strong> Liquids empty faster than solids. Prioritize liquid calories in severe cases</li>
            <li><strong>G-POEM is emerging:</strong> Endoscopic pyloric myotomy showing promise for refractory gastroparesis</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="serotonin-syndrome" class="condition-page">
    <div class="page-header">
        <h2>160. SEROTONIN SYNDROME</h2>
        <div class="subtitle">Drug-Induced Hyperserotonergic State â€¢ Clonus â€¢ Cyproheptadine â€¢ Hunter Criteria</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Potentially life-threatening drug-induced condition caused by excessive serotonergic activity in the CNS, typically from drug interactions or overdose. Onset usually within 24 hours of drug initiation, dose change, or adding another serotonergic agent</p>
            
            <p><strong>Classic Triad:</strong></p>
            <ul>
                <li><strong>Mental Status Changes:</strong> Agitation, anxiety, confusion, hypomania, hallucinations</li>
                <li><strong>Autonomic Instability:</strong> Hyperthermia, diaphoresis, tachycardia, hypertension, mydriasis, diarrhea</li>
                <li><strong>Neuromuscular Abnormalities:</strong> Clonus (spontaneous, inducible, or ocular), hyperreflexia, tremor, rigidity, ataxia</li>
            </ul>
            
            <p><strong>Key Clinical Features:</strong></p>
            <ul>
                <li><strong>Clonus:</strong> Most important diagnostic finding. Look for ankle clonus, patellar clonus, or ocular clonus (slow horizontal eye movements)</li>
                <li><strong>Hyperreflexia:</strong> More pronounced in lower extremities</li>
                <li><strong>Hyperthermia:</strong> May be severe (>41Â°C/106Â°F in severe cases)</li>
                <li><strong>Onset:</strong> Usually within 6-24 hours of causative agent; 60% within 6 hours</li>
            </ul>
            
            <p><strong>Causative Agents (Drug Classes):</strong></p>
            <ul>
                <li><strong>SSRIs:</strong> Fluoxetine, sertraline, paroxetine, citalopram, escitalopram</li>
                <li><strong>SNRIs:</strong> Venlafaxine, duloxetine, desvenlafaxine</li>
                <li><strong>MAOIs:</strong> Phenelzine, tranylcypromine, selegiline (highest risk combinations)</li>
                <li><strong>TCAs:</strong> Amitriptyline, nortriptyline, clomipramine</li>
                <li><strong>Opioids:</strong> Tramadol, meperidine, fentanyl, methadone (serotonin reuptake inhibition)</li>
                <li><strong>Triptans:</strong> Sumatriptan and other migraine medications</li>
                <li><strong>Antibiotics:</strong> Linezolid (weak MAOI), tedizolid</li>
                <li><strong>Antiemetics:</strong> Ondansetron, metoclopramide</li>
                <li><strong>Illicit Drugs:</strong> MDMA (ecstasy), cocaine, amphetamines</li>
                <li><strong>Supplements:</strong> St. John's wort, tryptophan</li>
                <li><strong>Other:</strong> Methylene blue (MAOI), dextromethorphan, lithium</li>
            </ul>
            
            <p><strong>High-Risk Combinations:</strong></p>
            <ul>
                <li><strong>MAOI + ANY serotonergic agent</strong> = highest risk (potentially fatal)</li>
                <li>SSRI + tramadol or meperidine</li>
                <li>SSRI + linezolid or methylene blue</li>
                <li>Multiple serotonergic agents at high doses</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Hunter Criteria (Most Accurate â€” Sensitivity 84%, Specificity 97%):</strong></p>
            <ul>
                <li>Must have taken a serotonergic agent AND one of the following:</li>
                <li>1. Spontaneous clonus</li>
                <li>2. Inducible clonus + agitation OR diaphoresis</li>
                <li>3. Ocular clonus + agitation OR diaphoresis</li>
                <li>4. Tremor + hyperreflexia</li>
                <li>5. Hypertonia + temperature >38Â°C + ocular clonus OR inducible clonus</li>
            </ul>
            
            <p><strong>Laboratory (Supportive, Not Diagnostic):</strong></p>
            <ul>
                <li><strong>CBC:</strong> Leukocytosis common</li>
                <li><strong>BMP:</strong> Electrolyte abnormalities, AKI if severe</li>
                <li><strong>CK:</strong> Elevated if rhabdomyolysis (from muscle rigidity, agitation)</li>
                <li><strong>LFTs:</strong> Transaminitis in severe cases</li>
                <li><strong>Coagulation:</strong> DIC in severe cases</li>
                <li><strong>Lactate:</strong> Elevated in severe cases</li>
                <li><strong>No specific diagnostic test</strong> â€” diagnosis is clinical</li>
            </ul>
            
            <p><strong>Differential Diagnosis:</strong></p>
            <table style="width:100%; border-collapse: collapse; margin-top: 10px; font-size: 9pt;">
                <tr style="background: #f0f0f0;">
                    <th style="border: 1px solid #ddd; padding: 6px;">Condition</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">Key Differentiating Features</th>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Neuroleptic Malignant Syndrome (NMS)</strong></td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Lead-pipe rigidity (not clonus), bradyreflexia, develops over days (not hours), caused by dopamine antagonists</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Malignant Hyperthermia</strong></td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Exposure to inhaled anesthetics or succinylcholine, OR setting</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Anticholinergic Toxicity</strong></td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Dry skin (not diaphoretic), urinary retention, decreased bowel sounds, mydriasis</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Sympathomimetic Toxicity</strong></td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Similar features but no clonus, often with significant hypertension</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Meningitis/Encephalitis</strong></td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Nuchal rigidity, focal neurologic findings, CSF abnormalities</td>
                </tr>
            </table>
            <p style="margin-top: 10px;"><strong>Key distinguishing feature of serotonin syndrome: CLONUS and hyperreflexia (vs rigidity and bradyreflexia in NMS)</strong></p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Management:</strong></p>
            <ul>
                <li><strong>Stop ALL serotonergic agents</strong> â€” most important step</li>
                <li><strong>Supportive care:</strong> IV fluids, continuous monitoring</li>
                <li><strong>Benzodiazepines:</strong> First-line for agitation, muscle rigidity, seizure prevention
                    <ul>
                        <li>Lorazepam 2-4 mg IV or diazepam 5-10 mg IV, repeat as needed</li>
                        <li>Controls agitation and reduces muscle hyperactivity</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Hyperthermia Management:</strong></p>
            <ul>
                <li><strong>External cooling:</strong> Ice packs, cooling blankets, evaporative cooling</li>
                <li><strong>Avoid antipyretics:</strong> Acetaminophen/NSAIDs ineffective (not prostaglandin-mediated fever)</li>
                <li><strong>If temp >41Â°C:</strong> Consider intubation and paralysis with non-depolarizing agent (stops muscle hyperactivity generating heat)</li>
            </ul>
            
            <p><strong>Cyproheptadine (Serotonin Antagonist):</strong></p>
            <ul>
                <li><strong>Mechanism:</strong> 5-HT2A receptor antagonist</li>
                <li><strong>Dose:</strong> 12 mg initial dose, then 2 mg q2h until improvement</li>
                <li><strong>Maintenance:</strong> 8 mg q6h once stabilized</li>
                <li><strong>Max:</strong> 32 mg/day</li>
                <li><strong>Route:</strong> PO only (can crush and give via NG if intubated)</li>
                <li><strong>Side effects:</strong> Sedation (often beneficial), anticholinergic effects</li>
                <li><strong>Note:</strong> Evidence is anecdotal but widely recommended</li>
            </ul>
            
            <p><strong>Severe Cases (ICU):</strong></p>
            <ul>
                <li>Intubation for airway protection or severe hyperthermia</li>
                <li>Paralysis (non-depolarizing NMB) for refractory hyperthermia</li>
                <li>Avoid succinylcholine (risk of hyperkalemia with rhabdomyolysis)</li>
                <li>Aggressive IV fluids for rhabdomyolysis</li>
                <li>Pressors if needed (avoid serotonergic agents like dopamine; use norepinephrine or phenylephrine)</li>
            </ul>
            
            <p><strong>What to Avoid:</strong></p>
            <ul>
                <li><strong>Physical restraints:</strong> Increase muscle rigidity â†’ worsen rhabdomyolysis and hyperthermia</li>
                <li><strong>Antipyretics:</strong> Ineffective</li>
                <li><strong>Succinylcholine:</strong> Hyperkalemia risk</li>
                <li><strong>Dopamine:</strong> Theoretical serotonergic activity</li>
                <li><strong>Bromocriptine/dantrolene:</strong> These are for NMS, not serotonin syndrome</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Temperature >40Â°C (104Â°F)</li>
                <li>Severe muscle rigidity</li>
                <li>Hemodynamic instability</li>
                <li>Altered mental status (GCS <13)</li>
                <li>Seizures</li>
                <li>Rhabdomyolysis with AKI</li>
                <li>DIC or multi-organ dysfunction</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Symptoms resolved (typically within 24-72 hours after stopping agent)</li>
                <li>Afebrile</li>
                <li>Mental status at baseline</li>
                <li>No clonus or hyperreflexia</li>
                <li>CK normalizing (if elevated)</li>
                <li>Clear plan for psychiatric medication management</li>
                <li>Offending agent(s) documented and patient educated</li>
                <li>Psychiatry or PCP follow-up arranged for medication reconciliation</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Clonus is the key:</strong> The most distinguishing feature from NMS. If you see clonus + serotonergic drug exposure = serotonin syndrome until proven otherwise</li>
            <li><strong>NMS is slow, SS is fast:</strong> NMS develops over days with gradual rigidity. Serotonin syndrome develops within hours with hyperreflexia/clonus</li>
            <li><strong>Stop the drug and most cases resolve:</strong> 70% resolve within 24 hours of stopping the offending agent. Supportive care is often sufficient</li>
            <li><strong>Cyproheptadine only works orally:</strong> No IV formulation. Crush and give via NG if patient intubated</li>
            <li><strong>Linezolid is a sneaky cause:</strong> Weak MAOI activity. Avoid with SSRIs/SNRIs if possible. Also methylene blue (used in methemoglobinemia, sentinel lymph node mapping)</li>
            <li><strong>Tramadol is a common culprit:</strong> Often overlooked as a serotonergic agent. Avoid with SSRIs/MAOIs</li>
            <li><strong>MAOI washout periods matter:</strong> MAOIs require 2-week washout before starting serotonergic agents. Fluoxetine requires 5-week washout before MAOI (long half-life)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="hypoglycemia" class="condition-page">
    <div class="page-header">
        <h2>161. HYPOGLYCEMIA</h2>
        <div class="subtitle">Glucose <70 mg/dL â€¢ Whipple's Triad â€¢ Insulin vs Sulfonylurea â€¢ Insulinoma</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Blood glucose <70 mg/dL. Severe hypoglycemia = requiring assistance from another person. Whipple's Triad: (1) Symptoms consistent with hypoglycemia, (2) Low plasma glucose, (3) Resolution with glucose correction</p>
            
            <p><strong>Autonomic (Adrenergic) Symptoms:</strong></p>
            <ul>
                <li>Tremor, palpitations, anxiety, diaphoresis, hunger, paresthesias</li>
                <li>Occur at glucose ~55-65 mg/dL</li>
                <li>May be blunted in diabetics with hypoglycemia unawareness, beta-blocker use</li>
            </ul>
            
            <p><strong>Neuroglycopenic Symptoms:</strong></p>
            <ul>
                <li>Confusion, difficulty concentrating, behavioral changes, slurred speech</li>
                <li>Visual disturbances, weakness, fatigue, dizziness</li>
                <li>Seizures, loss of consciousness, coma (severe)</li>
                <li>Occur at glucose ~50 mg/dL and below</li>
            </ul>
            
            <p><strong>Etiologies in Hospitalized Patients:</strong></p>
            <ul>
                <li><strong>Insulin excess (most common):</strong> Too much insulin for intake, missed meal, insulin stacking</li>
                <li><strong>Sulfonylureas:</strong> Glipizide, glyburide, glimepiride â€” long-acting, accumulate in renal failure</li>
                <li><strong>Reduced oral intake:</strong> NPO status without adjusting insulin, anorexia, N/V</li>
                <li><strong>Renal failure:</strong> Reduced insulin clearance, reduced gluconeogenesis</li>
                <li><strong>Hepatic failure:</strong> Impaired gluconeogenesis and glycogenolysis</li>
                <li><strong>Sepsis:</strong> Increased glucose utilization, hepatic dysfunction</li>
                <li><strong>Adrenal insufficiency:</strong> Cortisol is counter-regulatory hormone</li>
                <li><strong>Alcohol:</strong> Inhibits gluconeogenesis</li>
            </ul>
            
            <p><strong>Etiologies in Non-Diabetics (Rare):</strong></p>
            <ul>
                <li><strong>Insulinoma:</strong> Fasting hypoglycemia, elevated insulin/C-peptide, negative sulfonylurea screen</li>
                <li><strong>Factitious hypoglycemia:</strong> Exogenous insulin (high insulin, LOW C-peptide) or sulfonylurea ingestion</li>
                <li><strong>Non-islet cell tumor hypoglycemia:</strong> IGF-2 producing tumors (mesenchymal tumors)</li>
                <li><strong>Autoimmune:</strong> Anti-insulin antibodies, insulin receptor antibodies</li>
                <li><strong>Post-gastric bypass:</strong> Reactive/postprandial hypoglycemia</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Immediate:</strong></p>
            <ul>
                <li><strong>Point-of-care glucose</strong> â€” confirm hypoglycemia</li>
                <li><strong>If cause unclear, draw labs BEFORE treating:</strong> Glucose, insulin, C-peptide, proinsulin, Î²-hydroxybutyrate, sulfonylurea screen</li>
            </ul>
            
            <p><strong>Interpretation (drawn during hypoglycemia):</strong></p>
            <table style="width:100%; border-collapse: collapse; margin-top: 10px; font-size: 9pt;">
                <tr style="background: #f0f0f0;">
                    <th style="border: 1px solid #ddd; padding: 6px;">Diagnosis</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">Insulin</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">C-peptide</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">Proinsulin</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">SU Screen</th>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Insulinoma</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†‘</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†‘</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†‘</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Negative</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Sulfonylurea</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†‘</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†‘</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†‘</td>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Positive</strong></td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Exogenous Insulin</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†‘</td>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>â†“/Low</strong></td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†“</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Negative</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">IGF-2 tumor</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†“</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†“</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">â†“</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Negative</td>
                </tr>
            </table>
            
            <p><strong>Additional Workup (if etiology unclear):</strong></p>
            <ul>
                <li>Cortisol (8 AM or random if acute) â€” rule out adrenal insufficiency</li>
                <li>LFTs, renal function</li>
                <li>72-hour fast with serial glucose/insulin/C-peptide (for suspected insulinoma)</li>
                <li>CT/MRI pancreas if insulinoma suspected</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate Treatment:</strong></p>
            <ul>
                <li><strong>Conscious, able to swallow:</strong> 15-20g fast-acting carbs (4 oz juice, glucose tabs, 3-4 sugar packets). Recheck in 15 min, repeat if still <70</li>
                <li><strong>Altered/unable to swallow:</strong>
                    <ul>
                        <li><strong>D50:</strong> 25-50 mL (12.5-25g glucose) IV push. Can repeat</li>
                        <li><strong>D10:</strong> 100-250 mL if no D50 or prefer slower correction</li>
                        <li><strong>Glucagon:</strong> 1 mg IM/SQ if no IV access (less effective in alcoholics, liver failure)</li>
                    </ul>
                </li>
                <li><strong>Follow with complex carbs/meal</strong> once glucose >100 and patient alert</li>
            </ul>
            
            <p><strong>Sulfonylurea-Induced Hypoglycemia (CRITICAL):</strong></p>
            <ul>
                <li><strong>Prolonged hypoglycemia expected</strong> â€” sulfonylureas have long half-lives (12-24+ hours)</li>
                <li><strong>ADMIT for observation</strong> â€” minimum 24 hours, longer for glyburide or renal impairment</li>
                <li><strong>Continuous D10 infusion:</strong> Often required to maintain euglycemia</li>
                <li><strong>Octreotide:</strong> 50-100 mcg SQ q8h â€” inhibits insulin release, helps prevent recurrent hypoglycemia</li>
                <li><strong>Frequent glucose monitoring:</strong> q1h initially, can space if stable</li>
            </ul>
            
            <p><strong>Prevention in Hospitalized Diabetics:</strong></p>
            <ul>
                <li>Reduce/hold insulin if NPO or reduced intake</li>
                <li>Reduce insulin in AKI (decreased clearance)</li>
                <li>Avoid sliding-scale-only regimens (reactive, not preventive)</li>
                <li>Coordinate insulin with meal delivery</li>
                <li>Hypoglycemia protocol: nurse-driven treatment for glucose <70</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Refractory hypoglycemia requiring continuous dextrose infusion</li>
                <li>Seizures or prolonged altered mental status</li>
                <li>Sulfonylurea overdose (intentional)</li>
                <li>Recurrent hypoglycemia despite treatment</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Euglycemic for â‰¥24 hours off dextrose infusion</li>
                <li>Cause identified and addressed</li>
                <li>Diabetes regimen adjusted if needed</li>
                <li>Patient educated on recognition and treatment</li>
                <li>Follow-up arranged</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Sulfonylurea hypoglycemia = admit:</strong> Long half-life means recurrent hypoglycemia for 24-72 hours. Never discharge after single correction</li>
            <li><strong>Octreotide for sulfonylurea OD:</strong> Inhibits insulin release. Give 50-100 mcg SQ q8h. Game-changer for refractory cases</li>
            <li><strong>Draw labs BEFORE treating:</strong> If cause unclear, get insulin/C-peptide/SU screen before giving dextrose â€” opportunity lost once treated</li>
            <li><strong>Low C-peptide = exogenous insulin:</strong> Endogenous insulin secretion includes C-peptide. Exogenous insulin does not</li>
            <li><strong>Hypoglycemia unawareness:</strong> Diabetics with frequent hypoglycemia lose adrenergic warning symptoms. First sign may be neuroglycopenic (confusion, seizure)</li>
            <li><strong>Glucagon doesn't work in liver failure/alcoholics:</strong> Requires hepatic glycogen stores. These patients need IV dextrose</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="nms" class="condition-page">
    <div class="page-header">
        <h2>162. NEUROLEPTIC MALIGNANT SYNDROME (NMS)</h2>
        <div class="subtitle">Antipsychotic-Induced â€¢ Lead-Pipe Rigidity â€¢ Hyperthermia â€¢ Bromocriptine/Dantrolene</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Life-threatening idiosyncratic reaction to dopamine antagonists (antipsychotics, antiemetics) characterized by hyperthermia, muscle rigidity, altered mental status, and autonomic instability. Mortality 5-20% even with treatment</p>
            
            <p><strong>Classic Tetrad:</strong></p>
            <ul>
                <li><strong>Hyperthermia:</strong> Often >40Â°C (104Â°F), can exceed 41Â°C</li>
                <li><strong>Muscle Rigidity:</strong> "Lead-pipe" rigidity (constant resistance throughout ROM), NOT clonus</li>
                <li><strong>Altered Mental Status:</strong> Confusion, agitation, stupor, coma</li>
                <li><strong>Autonomic Instability:</strong> Tachycardia, labile BP (hyper- or hypotension), diaphoresis, tachypnea</li>
            </ul>
            
            <p><strong>Time Course:</strong></p>
            <ul>
                <li>Onset typically within 2 weeks of starting/increasing antipsychotic (90% within 10 days)</li>
                <li>Can occur after years of stable therapy (rare)</li>
                <li>Develops over 24-72 hours (slower than serotonin syndrome)</li>
                <li>Duration: Days to weeks even after stopping offending agent</li>
            </ul>
            
            <p><strong>Causative Agents:</strong></p>
            <ul>
                <li><strong>Typical Antipsychotics (Higher Risk):</strong> Haloperidol, fluphenazine, chlorpromazine</li>
                <li><strong>Atypical Antipsychotics:</strong> Risperidone, olanzapine, quetiapine, aripiprazole, clozapine (all can cause)</li>
                <li><strong>Antiemetics:</strong> Metoclopramide, prochlorperazine, promethazine</li>
                <li><strong>Dopamine Withdrawal:</strong> Abrupt discontinuation of levodopa/dopamine agonists in Parkinson's</li>
            </ul>
            
            <p><strong>Risk Factors:</strong></p>
            <ul>
                <li>High-potency typical antipsychotics</li>
                <li>Rapid dose escalation, IM administration</li>
                <li>Dehydration, agitation, exhaustion</li>
                <li>Prior NMS episode (17-30% recurrence risk)</li>
                <li>Organic brain disease</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Clinical Diagnosis â€” No Specific Test:</strong></p>
            <ul>
                <li>Recent dopamine antagonist exposure + classic tetrad</li>
                <li>Rule out other causes (infection, other drug toxicity)</li>
            </ul>
            
            <p><strong>Laboratory Findings (Supportive):</strong></p>
            <ul>
                <li><strong>CK:</strong> Markedly elevated (often >1000, can be >100,000) â€” from rigidity-induced rhabdomyolysis</li>
                <li><strong>WBC:</strong> Leukocytosis (10-40k) â€” not infection</li>
                <li><strong>LFTs:</strong> Often elevated</li>
                <li><strong>Metabolic acidosis</strong></li>
                <li><strong>Myoglobinuria</strong></li>
                <li><strong>Electrolytes:</strong> Hypocalcemia, hyper/hyponatremia</li>
                <li><strong>Iron:</strong> Low serum iron (acute phase reactant â€” sensitive early marker)</li>
            </ul>
            
            <p><strong>Differential Diagnosis (NMS vs Serotonin Syndrome):</strong></p>
            <table style="width:100%; border-collapse: collapse; margin-top: 10px; font-size: 9pt;">
                <tr style="background: #f0f0f0;">
                    <th style="border: 1px solid #ddd; padding: 6px;">Feature</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">NMS</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">Serotonin Syndrome</th>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Causative Agent</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Dopamine antagonists</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Serotonergic drugs</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Onset</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Days (24-72 hrs)</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Hours (<24 hrs)</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Muscle Findings</td>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Lead-pipe rigidity</strong></td>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Clonus, hyperreflexia</strong></td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Reflexes</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Normal or decreased</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Hyperreflexia</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Pupils</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Normal</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Mydriasis</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Bowel Sounds</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Decreased/absent</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Hyperactive</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Resolution</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Days to weeks</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">24-72 hours</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">Treatment</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Bromocriptine, dantrolene</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Cyproheptadine</td>
                </tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Immediate:</strong></p>
            <ul>
                <li><strong>STOP offending agent</strong> â€” most important step</li>
                <li><strong>ICU admission</strong></li>
                <li><strong>Supportive care:</strong> IV fluids, cooling, monitoring</li>
            </ul>
            
            <p><strong>Cooling:</strong></p>
            <ul>
                <li>External cooling (ice packs, cooling blankets, evaporative)</li>
                <li>Antipyretics NOT effective (not prostaglandin-mediated)</li>
                <li>Target temperature <38.5Â°C</li>
            </ul>
            
            <p><strong>Specific Pharmacotherapy:</strong></p>
            <ul>
                <li><strong>Bromocriptine (Dopamine Agonist):</strong>
                    <ul>
                        <li>2.5 mg PO/NG q8h, increase to 5 mg q8h as needed</li>
                        <li>Max 40 mg/day</li>
                        <li>Continue until symptoms resolve, then taper over 10 days</li>
                    </ul>
                </li>
                <li><strong>Dantrolene (Muscle Relaxant):</strong>
                    <ul>
                        <li>1-2.5 mg/kg IV q6h (max 10 mg/kg/day)</li>
                        <li>Reduces rigidity and heat production</li>
                        <li>Monitor for hepatotoxicity</li>
                    </ul>
                </li>
                <li><strong>Benzodiazepines:</strong> For agitation (lorazepam 1-2 mg IV q4-6h PRN)</li>
                <li><strong>Amantadine:</strong> 100 mg PO BID â€” alternative dopaminergic agent</li>
            </ul>
            
            <p><strong>Supportive Measures:</strong></p>
            <ul>
                <li>Aggressive IV fluids (prevent AKI from rhabdomyolysis)</li>
                <li>DVT prophylaxis</li>
                <li>Intubation if needed for airway protection or severe rigidity</li>
                <li>Avoid succinylcholine (hyperkalemia risk from rhabdo)</li>
                <li>ECT may be considered for refractory cases</li>
            </ul>
            
            <p><strong>Duration:</strong></p>
            <ul>
                <li>Symptoms resolve over 7-14 days with treatment</li>
                <li>Longer with depot antipsychotics (weeks)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>ALL NMS patients require ICU</li>
                <li>Hyperthermia >40Â°C</li>
                <li>Severe rigidity</li>
                <li>Rhabdomyolysis (CK >10,000)</li>
                <li>Respiratory compromise</li>
                <li>Hemodynamic instability</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Afebrile for >48 hours</li>
                <li>Rigidity resolved</li>
                <li>Mental status at baseline</li>
                <li>CK downtrending/normalized</li>
                <li>Renal function stable</li>
                <li>Psychiatric plan for alternative antipsychotic (if needed)</li>
                <li>May cautiously rechallenge with low-potency agent after 2+ weeks if psychiatrically necessary</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Lead-pipe rigidity, NOT clonus:</strong> Key distinction from serotonin syndrome. NMS = rigid. SS = hyperreflexic/clonus</li>
            <li><strong>NMS is slow, SS is fast:</strong> NMS develops over days. SS develops within hours</li>
            <li><strong>CK is massively elevated:</strong> Often >1000, frequently >10,000. Rhabdomyolysis is the rule, not the exception</li>
            <li><strong>Low iron is early marker:</strong> Serum iron drops before CK rises. Useful for early diagnosis</li>
            <li><strong>Metoclopramide can cause NMS:</strong> Often forgotten. It's a dopamine antagonist</li>
            <li><strong>Parkinson's patients at risk from dopamine withdrawal:</strong> Abruptly stopping levodopa can trigger NMS-like syndrome</li>
            <li><strong>17-30% recurrence:</strong> If antipsychotic needed in future, wait 2+ weeks, use low-potency atypical, start very low dose</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="osteomyelitis" class="condition-page">
    <div class="page-header">
        <h2>163. OSTEOMYELITIS</h2>
        <div class="subtitle">Vertebral â€¢ Diabetic Foot â€¢ Hematogenous â€¢ MRI Gold Standard</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Infection of bone, classified by mechanism (hematogenous vs contiguous vs direct inoculation), duration (acute <2 weeks vs chronic), and location</p>
            
            <p><strong>Vertebral Osteomyelitis:</strong></p>
            <ul>
                <li><strong>Presentation:</strong> Back pain (>90%), fever (50%), neurologic deficits (30% â€” epidural abscess)</li>
                <li><strong>Risk factors:</strong> IVDU, endocarditis, recent bacteremia, spinal procedures, immunosuppression</li>
                <li><strong>Location:</strong> Lumbar > thoracic > cervical</li>
                <li><strong>Organisms:</strong> S. aureus (50%), Strep species, gram-negatives (UTI source), TB (Pott's disease)</li>
                <li><strong>Complications:</strong> Epidural abscess (urgent), psoas abscess, spinal instability, cord compression</li>
            </ul>
            
            <p><strong>Diabetic Foot Osteomyelitis:</strong></p>
            <ul>
                <li><strong>Presentation:</strong> Non-healing ulcer, probe-to-bone positive, may lack systemic signs (neuropathy masks pain)</li>
                <li><strong>Organisms:</strong> Polymicrobial â€” S. aureus, streptococci, enterococci, Pseudomonas, anaerobes</li>
                <li><strong>Key question:</strong> Can probe touch bone through ulcer? â†’ ~85% predictive of osteomyelitis</li>
            </ul>
            
            <p><strong>Contiguous/Post-Traumatic:</strong></p>
            <ul>
                <li>Open fractures, surgical site infections, hardware infections</li>
                <li>Often polymicrobial including skin flora and gram-negatives</li>
            </ul>
            
            <p><strong>Hematogenous (Children > Adults):</strong></p>
            <ul>
                <li>Metaphysis of long bones in children</li>
                <li>Vertebrae in adults</li>
                <li>Usually monomicrobial (S. aureus dominant)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Labs:</strong></p>
            <ul>
                <li><strong>ESR and CRP:</strong> Elevated in >90%. CRP normalizes faster (good for monitoring treatment)</li>
                <li><strong>WBC:</strong> May be normal in chronic osteomyelitis</li>
                <li><strong>Blood cultures:</strong> Positive in 50% of vertebral, less in other types. GET BEFORE ANTIBIOTICS</li>
                <li><strong>Procalcitonin:</strong> May help distinguish soft tissue vs bone infection</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>Plain X-ray:</strong> First-line but insensitive early (changes take 10-14 days). Shows periosteal elevation, lytic lesions, sequestra</li>
                <li><strong>MRI with Contrast:</strong> GOLD STANDARD
                    <ul>
                        <li>Sensitivity 90-100%, Specificity 80-90%</li>
                        <li>Shows bone marrow edema, soft tissue involvement, abscesses</li>
                        <li>Essential for vertebral osteo (epidural abscess?)</li>
                    </ul>
                </li>
                <li><strong>CT:</strong> Good for cortical bone detail, sequestrum, surgical planning</li>
                <li><strong>Nuclear Medicine:</strong> Triple-phase bone scan if MRI contraindicated. WBC scan more specific but less sensitive</li>
            </ul>
            
            <p><strong>Bone Biopsy/Culture (CRITICAL):</strong></p>
            <ul>
                <li><strong>Obtain BEFORE antibiotics if possible</strong></li>
                <li><strong>CT-guided biopsy:</strong> For vertebral osteomyelitis â€” 75% yield if not on antibiotics</li>
                <li><strong>Surgical debridement specimens:</strong> Best yield</li>
                <li><strong>Diabetic foot:</strong> Bone biopsy through non-infected tissue (not through ulcer base)</li>
                <li><strong>Send for:</strong> Aerobic, anaerobic, fungal, mycobacterial cultures + histopathology</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Empiric Antibiotics (While Awaiting Culture):</strong></p>
            <ul>
                <li><strong>Vertebral:</strong> Vancomycin + ceftriaxone (or ciprofloxacin if gram-neg suspected)</li>
                <li><strong>Diabetic Foot:</strong> Vancomycin + piperacillin-tazobactam (or vancomycin + ceftriaxone + metronidazole)</li>
                <li><strong>Hardware-associated:</strong> Vancomycin + cefepime (cover Pseudomonas)</li>
            </ul>
            
            <p><strong>Duration:</strong></p>
            <ul>
                <li><strong>Vertebral osteomyelitis:</strong> 6 weeks IV minimum (some transition to oral after 2-3 weeks if appropriate agent, adherent patient)</li>
                <li><strong>Diabetic foot:</strong>
                    <ul>
                        <li>Soft tissue only: 1-2 weeks</li>
                        <li>Osteomyelitis with residual infected bone: 4-6 weeks</li>
                        <li>Osteomyelitis with amputation/complete resection: 2-5 days post-op</li>
                    </ul>
                </li>
                <li><strong>Chronic osteomyelitis:</strong> Often requires surgical debridement + 4-6 weeks antibiotics</li>
            </ul>
            
            <p><strong>Surgical Indications:</strong></p>
            <ul>
                <li><strong>Vertebral:</strong> Epidural abscess with neuro deficits (emergent), spinal instability, failure of medical therapy</li>
                <li><strong>Diabetic foot:</strong> Extensive necrosis, abscess, failure of antibiotics, exposed bone. Amputation if limb-threatening</li>
                <li><strong>Hardware-associated:</strong> Often requires hardware removal for cure</li>
            </ul>
            
            <p><strong>Monitoring:</strong></p>
            <ul>
                <li>CRP weekly â€” should decline by 2 weeks</li>
                <li>ESR slower to normalize (follows over months)</li>
                <li>Repeat imaging if not improving clinically</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Epidural abscess with neurologic compromise (SURGICAL EMERGENCY)</li>
                <li>Sepsis or septic shock</li>
                <li>Spinal cord compression</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Culture data available, on appropriate antibiotics</li>
                <li>CRP downtrending</li>
                <li>Afebrile, pain controlled</li>
                <li>PICC line placed (if IV antibiotics continuing)</li>
                <li>Outpatient IV antibiotic plan established</li>
                <li>ID and/or orthopedic surgery follow-up</li>
                <li>No surgical emergency</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>GET CULTURES BEFORE ANTIBIOTICS:</strong> Bone biopsy yield drops significantly after antibiotics started. Hold antibiotics for biopsy if patient stable</li>
            <li><strong>Probe-to-bone = osteomyelitis:</strong> If metal probe reaches bone through diabetic foot ulcer, PPV ~85% for osteomyelitis</li>
            <li><strong>MRI is essential for vertebral:</strong> Must rule out epidural abscess. Clinical exam cannot reliably exclude it</li>
            <li><strong>Staph aureus dominates:</strong> ~50% of all osteomyelitis. Get blood cultures â€” positive in half of hematogenous cases</li>
            <li><strong>Epidural abscess = emergency:</strong> Progressive neuro deficits need emergent surgical decompression. Don't wait</li>
            <li><strong>X-ray changes take 2 weeks:</strong> Normal X-ray doesn't rule out early osteomyelitis. MRI is far more sensitive</li>
            <li><strong>IVDU + back pain = vertebral osteo:</strong> Until proven otherwise. Get MRI, blood cultures, echocardiogram</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="septic-arthritis" class="condition-page">
    <div class="page-header">
        <h2>164. SEPTIC ARTHRITIS</h2>
        <div class="subtitle">Joint Emergency â€¢ Arthrocentesis â€¢ Synovial WBC >50,000 â€¢ Urgent Drainage</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Bacterial infection of a joint â€” orthopedic emergency requiring urgent diagnosis and drainage to prevent permanent joint destruction</p>
            
            <p><strong>Classic Presentation:</strong></p>
            <ul>
                <li><strong>Monoarticular</strong> (90%) â€” knee most common (50%), then hip, ankle, wrist, shoulder</li>
                <li><strong>Acute onset</strong> joint pain, swelling, warmth, erythema</li>
                <li><strong>Severely limited ROM</strong> â€” patient guards joint</li>
                <li><strong>Fever</strong> (50-75%)</li>
                <li><strong>Unable to bear weight</strong> (if lower extremity)</li>
            </ul>
            
            <p><strong>Risk Factors:</strong></p>
            <ul>
                <li>Pre-existing joint disease (RA, OA, gout)</li>
                <li>Prosthetic joint</li>
                <li>Recent joint surgery or injection</li>
                <li>Skin infection, bacteremia</li>
                <li>IVDU</li>
                <li>Immunosuppression (DM, steroids, biologics)</li>
                <li>Age >80</li>
            </ul>
            
            <p><strong>Organisms:</strong></p>
            <ul>
                <li><strong>S. aureus:</strong> Most common overall (40-50%), including MRSA</li>
                <li><strong>Streptococci:</strong> Group A, B, pneumococcus</li>
                <li><strong>N. gonorrhoeae:</strong> Young sexually active adults â€” often migratory polyarthralgia â†’ monoarthritis, rash, tenosynovitis</li>
                <li><strong>Gram-negatives:</strong> Elderly, immunocompromised, IVDU</li>
                <li><strong>Prosthetic joints:</strong> Coagulase-negative staph, Propionibacterium, S. aureus</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>ARTHROCENTESIS â€” MANDATORY:</strong></p>
            <ul>
                <li><strong>Do not delay for imaging</strong> â€” clinical diagnosis + tap</li>
                <li><strong>Send:</strong> Cell count with differential, Gram stain, culture, crystal analysis</li>
            </ul>
            
            <p><strong>Synovial Fluid Interpretation:</strong></p>
            <table style="width:100%; border-collapse: collapse; margin-top: 10px; font-size: 9pt;">
                <tr style="background: #f0f0f0;">
                    <th style="border: 1px solid #ddd; padding: 6px;">Finding</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">Normal</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">Non-inflammatory</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">Inflammatory</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">Septic</th>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">WBC/mmÂ³</td>
                    <td style="border: 1px solid #ddd; padding: 6px;"><200</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">200-2,000</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">2,000-50,000</td>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>>50,000</strong></td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;">PMN %</td>
                    <td style="border: 1px solid #ddd; padding: 6px;"><25%</td>
                    <td style="border: 1px solid #ddd; padding: 6px;"><25%</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">50-70%</td>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>>90%</strong></td>
                </tr>
            </table>
            
            <p><strong>Key Points:</strong></p>
            <ul>
                <li><strong>WBC >50,000 with >90% PMNs</strong> = septic until proven otherwise</li>
                <li><strong>WBC >100,000</strong> = almost always septic</li>
                <li><strong>Gram stain:</strong> Positive in only 50-75% (low sensitivity)</li>
                <li><strong>Culture:</strong> Positive in 80-90% (gold standard)</li>
                <li><strong>Crystals don't rule out infection:</strong> Gout and septic arthritis can coexist!</li>
            </ul>
            
            <p><strong>Additional Workup:</strong></p>
            <ul>
                <li><strong>Blood cultures:</strong> Positive in 50%</li>
                <li><strong>CBC, CRP, ESR:</strong> Usually elevated but non-specific</li>
                <li><strong>X-ray:</strong> Usually normal early. Shows soft tissue swelling. Late: joint space narrowing, erosions</li>
                <li><strong>MRI:</strong> If suspect adjacent osteomyelitis, or deep joint (hip, SI joint)</li>
                <li><strong>Gonococcal:</strong> NAAT from urethra, cervix, pharynx, rectum + blood/synovial culture</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Empiric Antibiotics (Start Immediately After Arthrocentesis):</strong></p>
            <ul>
                <li><strong>Standard:</strong> Vancomycin 15-20 mg/kg IV q8-12h (cover MRSA)</li>
                <li><strong>Add gram-negative coverage if:</strong> Immunocompromised, IVDU, elderly, recent surgery
                    <ul>
                        <li>Ceftriaxone 2g IV daily OR cefepime 2g IV q8h</li>
                    </ul>
                </li>
                <li><strong>Suspected gonococcal:</strong> Ceftriaxone 1g IV daily + azithromycin 1g PO Ã— 1</li>
            </ul>
            
            <p><strong>DRAINAGE â€” ESSENTIAL:</strong></p>
            <ul>
                <li><strong>Joint destruction occurs within days</strong> without adequate drainage</li>
                <li><strong>Options:</strong>
                    <ul>
                        <li><strong>Serial arthrocentesis:</strong> Daily needle drainage until effusion resolves (often adequate for accessible joints)</li>
                        <li><strong>Arthroscopic lavage:</strong> If fails serial taps, large joint, loculations</li>
                        <li><strong>Open arthrotomy:</strong> Hip (difficult to aspirate), shoulder, failed arthroscopy</li>
                    </ul>
                </li>
                <li><strong>HIP = SURGICAL EMERGENCY:</strong> Difficult to drain percutaneously, high risk of AVN. Early surgical drainage recommended</li>
            </ul>
            
            <p><strong>Duration of Antibiotics:</strong></p>
            <ul>
                <li><strong>Native joint:</strong> 2-4 weeks (2 weeks often adequate for uncomplicated)</li>
                <li><strong>Gonococcal:</strong> 7-14 days (often responds rapidly)</li>
                <li><strong>Prosthetic joint:</strong> 6 weeks + often requires hardware removal or exchange</li>
                <li><strong>Adjacent osteomyelitis:</strong> 6 weeks</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Sepsis or septic shock</li>
                <li>Hip septic arthritis (surgical emergency)</li>
                <li>Polyarticular septic arthritis (suggests bacteremia/endocarditis)</li>
                <li>Rapid joint destruction</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Joint adequately drained (no reaccumulation)</li>
                <li>Improving pain, ROM, swelling</li>
                <li>Afebrile</li>
                <li>CRP downtrending</li>
                <li>Culture results available, on appropriate antibiotics</li>
                <li>PICC line if continuing IV antibiotics</li>
                <li>PT/OT arranged for rehabilitation</li>
                <li>Orthopedic/ID follow-up</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Tap before antibiotics, but don't delay antibiotics for tap:</strong> If significant delay, start antibiotics. Joint damage is worse than slightly lower culture yield</li>
            <li><strong>WBC >50k, >90% PMNs = septic:</strong> This is the threshold. Don't wait for culture</li>
            <li><strong>Crystals â‰  not infected:</strong> Gout and septic arthritis coexist in 1.5% of gout flares. If high suspicion, treat for both</li>
            <li><strong>Hip = urgent surgery:</strong> Hard to drain, high AVN risk. Don't attempt serial aspiration â€” call ortho early</li>
            <li><strong>Gonococcal is different:</strong> Young, healthy, sexually active. Often polyarticular then localizes. Skin lesions, tenosynovitis. Responds well to antibiotics</li>
            <li><strong>Prosthetic joint infection needs ID + ortho:</strong> Often requires hardware removal. Long-term antibiotics. Complex management</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="epidural-abscess" class="condition-page">
    <div class="page-header">
        <h2>165. SPINAL EPIDURAL ABSCESS</h2>
        <div class="subtitle">Neurologic Emergency â€¢ Classic Triad â€¢ MRI Whole Spine â€¢ Urgent Decompression</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Pyogenic infection in the epidural space â€” neurologic emergency requiring urgent diagnosis and often surgical decompression to prevent permanent paralysis</p>
            
            <p><strong>Classic Triad (Present in Only 10-15%):</strong></p>
            <ul>
                <li>Fever</li>
                <li>Back pain</li>
                <li>Neurologic deficit</li>
            </ul>
            
            <p><strong>Clinical Stages (Progressive Over Days):</strong></p>
            <ol>
                <li><strong>Stage 1:</strong> Back pain (often severe, localized), fever</li>
                <li><strong>Stage 2:</strong> Radicular pain (nerve root irritation)</li>
                <li><strong>Stage 3:</strong> Motor weakness, sensory deficits, bowel/bladder dysfunction</li>
                <li><strong>Stage 4:</strong> Paralysis (often irreversible if >24-48 hours)</li>
            </ol>
            
            <p><strong>Risk Factors:</strong></p>
            <ul>
                <li><strong>IVDU</strong> (most common in many series)</li>
                <li>Diabetes mellitus</li>
                <li>Spinal procedures (epidural injection, surgery)</li>
                <li>Bacteremia from any source</li>
                <li>Immunosuppression</li>
                <li>Chronic renal failure</li>
                <li>Alcohol use disorder</li>
                <li>Adjacent vertebral osteomyelitis</li>
            </ul>
            
            <p><strong>Location:</strong></p>
            <ul>
                <li>Posterior epidural space (most common)</li>
                <li>Thoracolumbar > lumbar > cervical</li>
                <li>May span multiple vertebral levels</li>
            </ul>
            
            <p><strong>Organisms:</strong></p>
            <ul>
                <li><strong>S. aureus:</strong> 60-70% (including MRSA)</li>
                <li>Streptococci, gram-negatives (10-15% each)</li>
                <li>Coagulase-negative staph (post-procedure)</li>
                <li>TB (Pott's disease with epidural extension)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>MRI WITH GADOLINIUM â€” GOLD STANDARD:</strong></p>
            <ul>
                <li><strong>Image ENTIRE spine</strong> â€” can be multifocal</li>
                <li>Sensitivity >90%</li>
                <li>Shows epidural collection, cord compression, vertebral osteomyelitis, paraspinal abscess</li>
                <li><strong>Do NOT delay for MRI if clinical picture clear</strong> â€” emergent surgical consultation</li>
            </ul>
            
            <p><strong>CT Myelogram:</strong></p>
            <ul>
                <li>If MRI contraindicated (pacemaker, severe claustrophobia)</li>
                <li>Less sensitive than MRI</li>
            </ul>
            
            <p><strong>Labs:</strong></p>
            <ul>
                <li><strong>WBC:</strong> Elevated in 60-80%</li>
                <li><strong>ESR:</strong> Elevated in >95% (often >50)</li>
                <li><strong>CRP:</strong> Elevated in >90%</li>
                <li><strong>Blood cultures:</strong> Positive in 60% â€” GET BEFORE ANTIBIOTICS</li>
            </ul>
            
            <p><strong>Image-Guided Aspiration/Biopsy:</strong></p>
            <ul>
                <li>If blood cultures negative and diagnosis uncertain</li>
                <li>Don't delay treatment for culture</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Emergent Surgical Consultation:</strong></p>
            <ul>
                <li><strong>ANY neurologic deficit</strong> = emergent surgical decompression</li>
                <li><strong>Goal:</strong> Decompression within 24 hours (ideally <12 hours) of motor deficit</li>
                <li>Recovery correlates with pre-op neurologic status and time to surgery</li>
            </ul>
            
            <p><strong>Surgical Indications (Absolute):</strong></p>
            <ul>
                <li>Neurologic deficit (weakness, bowel/bladder dysfunction)</li>
                <li>Spinal instability</li>
                <li>Failure of medical therapy</li>
                <li>Large abscess with significant cord compression</li>
            </ul>
            
            <p><strong>Medical Management Alone (Select Cases):</strong></p>
            <ul>
                <li>No neurologic deficit</li>
                <li>High surgical risk</li>
                <li>Extensive multilevel disease</li>
                <li><strong>CLOSE monitoring:</strong> Neuro checks q4h, serial imaging, low threshold for surgery</li>
            </ul>
            
            <p><strong>Empiric Antibiotics:</strong></p>
            <ul>
                <li><strong>Vancomycin</strong> 15-20 mg/kg IV q8-12h (cover MRSA)</li>
                <li><strong>PLUS Ceftriaxone</strong> 2g IV q24h or Cefepime 2g IV q8h (cover gram-negatives)</li>
                <li>Adjust based on cultures</li>
            </ul>
            
            <p><strong>Duration:</strong></p>
            <ul>
                <li><strong>Epidural abscess alone:</strong> 4-6 weeks</li>
                <li><strong>With vertebral osteomyelitis:</strong> 6-8 weeks</li>
                <li>Transition to oral therapy possible with appropriate agents and good source control</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Any neurologic deficit (surgical emergency)</li>
                <li>Sepsis or septic shock</li>
                <li>Respiratory compromise (cervical involvement)</li>
                <li>Post-operative monitoring</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Neurologically stable or improving</li>
                <li>Post-surgical wound healing</li>
                <li>Afebrile</li>
                <li>CRP downtrending</li>
                <li>On appropriate IV antibiotics (PICC line)</li>
                <li>Rehab placement if neurologic deficits</li>
                <li>ID and neurosurgery/orthopedic follow-up</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Back pain + fever + IVDU = epidural abscess until proven otherwise:</strong> Get emergent MRI</li>
            <li><strong>Classic triad present in only 10-15%:</strong> Back pain is most consistent symptom. Don't wait for neuro deficits</li>
            <li><strong>Time is paralysis:</strong> Pre-op neurologic status predicts outcome. Surgery within 24 hours of motor deficit is critical</li>
            <li><strong>Image the WHOLE spine:</strong> Can have multiple non-contiguous abscesses</li>
            <li><strong>ESR almost always elevated:</strong> ESR >20 has 98% sensitivity. Normal ESR + CRP makes diagnosis very unlikely</li>
            <li><strong>Don't LP if you suspect epidural abscess:</strong> Risk of meningitis from seeding. MRI first</li>
            <li><strong>Medical management requires close monitoring:</strong> Neuro checks q4h. Any decline = emergent surgery</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="clabsi" class="condition-page">
    <div class="page-header">
        <h2>166. CATHETER-RELATED BLOODSTREAM INFECTION (CLABSI)</h2>
        <div class="subtitle">Central Line Infection â€¢ Line Removal â€¢ Differential Time to Positivity</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Bacteremia/fungemia in a patient with central venous catheter (CVC) where the catheter is the attributable source. One of the most common healthcare-associated infections</p>
            
            <p><strong>Clinical Features:</strong></p>
            <ul>
                <li>Fever, chills, rigors</li>
                <li>Hypotension, sepsis</li>
                <li>May have no localizing signs</li>
                <li><strong>Exit site findings (may or may not be present):</strong> Erythema, purulence, tenderness</li>
                <li><strong>Tunnel infection:</strong> Erythema/tenderness along subcutaneous tract (tunneled catheters)</li>
            </ul>
            
            <p><strong>Risk Factors:</strong></p>
            <ul>
                <li>Duration of catheterization (risk increases after day 5-7)</li>
                <li>Femoral > internal jugular > subclavian site</li>
                <li>TPN administration</li>
                <li>Multiple lumens</li>
                <li>Frequent manipulation</li>
                <li>Neutropenia, immunosuppression</li>
                <li>Poor insertion/maintenance technique</li>
            </ul>
            
            <p><strong>Common Organisms:</strong></p>
            <ul>
                <li><strong>Coagulase-negative staphylococci:</strong> Most common (30-40%), often low virulence</li>
                <li><strong>S. aureus:</strong> 15-20%, high virulence, metastatic complications</li>
                <li><strong>Enterococci:</strong> 10-15%</li>
                <li><strong>Gram-negatives:</strong> 15-20% (Klebsiella, E. coli, Pseudomonas, Enterobacter)</li>
                <li><strong>Candida:</strong> 5-10%, especially TPN, broad-spectrum antibiotics</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Blood Cultures:</strong></p>
            <ul>
                <li><strong>Paired cultures:</strong> One from catheter, one from peripheral vein (BEFORE antibiotics)</li>
                <li><strong>Differential time to positivity (DTTP):</strong> Catheter culture positive â‰¥2 hours before peripheral = catheter source (sensitivity 85%, specificity 90%)</li>
                <li><strong>If no peripheral access:</strong> Draw from two different lumens</li>
            </ul>
            
            <p><strong>Catheter Tip Culture (If Removed):</strong></p>
            <ul>
                <li>Roll-plate method (Maki technique)</li>
                <li>â‰¥15 CFU = colonization/infection</li>
                <li>Same organism in tip and blood = confirmed CLABSI</li>
            </ul>
            
            <p><strong>Definitions:</strong></p>
            <ul>
                <li><strong>Definite CLABSI:</strong> Same organism from catheter tip (â‰¥15 CFU) and peripheral blood</li>
                <li><strong>Probable CLABSI:</strong> Bacteremia with CVC, defervescence after removal, no other source</li>
                <li><strong>DTTP-defined:</strong> Catheter blood positive â‰¥2 hours before peripheral</li>
            </ul>
            
            <p><strong>Additional Workup Based on Organism:</strong></p>
            <ul>
                <li><strong>S. aureus bacteremia:</strong> Echocardiogram (TEE preferred), consider ophthalmology exam, repeat cultures until negative</li>
                <li><strong>Candida:</strong> Ophthalmology exam (endophthalmitis), echocardiogram</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Catheter Removal â€” Definite Indications:</strong></p>
            <ul>
                <li><strong>S. aureus</strong> â€” ALWAYS remove (high complication rate)</li>
                <li><strong>Candida</strong> â€” ALWAYS remove</li>
                <li><strong>Pseudomonas</strong> â€” usually remove</li>
                <li><strong>Tunnel infection or port pocket infection</strong></li>
                <li><strong>Septic shock</strong></li>
                <li><strong>Suppurative thrombophlebitis</strong></li>
                <li><strong>Persistent bacteremia (>72 hours on appropriate antibiotics)</strong></li>
                <li><strong>Metastatic infection</strong> (endocarditis, osteomyelitis)</li>
            </ul>
            
            <p><strong>Catheter Salvage (May Attempt in Select Cases):</strong></p>
            <ul>
                <li>Coagulase-negative staph (low virulence)</li>
                <li>No tunnel/pocket infection</li>
                <li>Limited vascular access</li>
                <li>Hemodynamically stable</li>
                <li><strong>Use antibiotic lock therapy</strong> + systemic antibiotics</li>
                <li>If persistent bacteremia >72 hours, REMOVE</li>
            </ul>
            
            <p><strong>Empiric Antibiotics:</strong></p>
            <ul>
                <li><strong>Vancomycin</strong> (cover MRSA, CoNS)</li>
                <li><strong>ADD gram-negative coverage</strong> if: Septic, immunocompromised, femoral catheter, known colonization
                    <ul>
                        <li>Cefepime 2g IV q8h OR piperacillin-tazobactam 4.5g IV q6h</li>
                    </ul>
                </li>
                <li><strong>ADD antifungal</strong> if: TPN, prolonged antibiotics, Candida colonization, immunocompromised
                    <ul>
                        <li>Micafungin 100mg IV daily or fluconazole 400mg IV daily</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Duration (From First Negative Culture):</strong></p>
            <ul>
                <li><strong>Coagulase-negative staph:</strong> 5-7 days (if catheter removed and uncomplicated)</li>
                <li><strong>S. aureus:</strong> Minimum 4 weeks (2 weeks only if TEE negative, no hardware, rapid clearance, catheter removed)</li>
                <li><strong>Gram-negatives:</strong> 7-14 days</li>
                <li><strong>Candida:</strong> 14 days after first negative culture</li>
                <li><strong>Complicated (endocarditis, septic thrombosis):</strong> 4-6 weeks</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Septic shock</li>
                <li>S. aureus bacteremia with hemodynamic instability</li>
                <li>Suppurative thrombophlebitis</li>
                <li>Endocarditis with acute decompensation</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Catheter removed (or salvaged with documented clearance)</li>
                <li>Blood cultures negative</li>
                <li>Afebrile</li>
                <li>Hemodynamically stable</li>
                <li>If S. aureus/Candida: Echo completed, no endocarditis</li>
                <li>PICC line for ongoing antibiotics if needed</li>
                <li>ID follow-up for duration guidance</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>S. aureus = remove the line:</strong> No exceptions. High rate of endocarditis and metastatic infection with retained catheter</li>
            <li><strong>Candida = remove the line:</strong> Fungal biofilms don't respond to antifungals. Also get ophthalmology consult</li>
            <li><strong>Coag-neg staph = can consider salvage:</strong> Low virulence, may try antibiotic lock. But if persistent >72h, remove</li>
            <li><strong>S. aureus needs echo:</strong> TEE preferred. 25% of S. aureus bacteremia has endocarditis. Changes duration dramatically</li>
            <li><strong>Repeat cultures until negative:</strong> For S. aureus and Candida. Persistent positivity = look for metastatic focus</li>
            <li><strong>DTTP helps when can't remove:</strong> Catheter culture positive â‰¥2 hours before peripheral confirms catheter source</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="diabetic-foot-infection" class="condition-page">
    <div class="page-header">
        <h2>167. DIABETIC FOOT INFECTION</h2>
        <div class="subtitle">IDSA/IWGDF Classification â€¢ Polymicrobial â€¢ Osteomyelitis â€¢ Limb Salvage vs Amputation</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Soft tissue and/or bone infection of the foot in a patient with diabetes, typically arising from neuropathic ulcers. Leading cause of non-traumatic amputation</p>
            
            <p><strong>Why Diabetic Feet Get Infected:</strong></p>
            <ul>
                <li><strong>Neuropathy:</strong> Loss of protective sensation â†’ unrecognized trauma â†’ ulcer</li>
                <li><strong>Vascular disease:</strong> Poor perfusion â†’ impaired healing, antibiotic delivery</li>
                <li><strong>Immune dysfunction:</strong> Impaired neutrophil function in hyperglycemia</li>
                <li><strong>Structural deformity:</strong> Charcot foot, hammertoes â†’ pressure points</li>
            </ul>
            
            <p><strong>Signs of Infection (May Be Subtle):</strong></p>
            <ul>
                <li>Purulent drainage</li>
                <li>Erythema, warmth, swelling, tenderness (may be masked by neuropathy)</li>
                <li>Foul odor</li>
                <li>Unexplained hyperglycemia</li>
                <li>Systemic signs (fever, chills) = severe infection</li>
            </ul>
            
            <p><strong>IDSA/IWGDF Severity Classification:</strong></p>
            <table style="width:100%; border-collapse: collapse; margin-top: 10px; font-size: 9pt;">
                <tr style="background: #f0f0f0;">
                    <th style="border: 1px solid #ddd; padding: 6px;">Grade</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">Clinical Features</th>
                    <th style="border: 1px solid #ddd; padding: 6px;">Setting</th>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Mild (1-2)</strong></td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Local infection, cellulitis <2 cm, no systemic signs</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Outpatient</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Moderate (3)</strong></td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Cellulitis >2 cm, lymphangitis, deep abscess, gangrene, muscle/bone involvement, no SIRS</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Inpatient</td>
                </tr>
                <tr>
                    <td style="border: 1px solid #ddd; padding: 6px;"><strong>Severe (4)</strong></td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Any foot infection + SIRS (fever, tachycardia, tachypnea, leukocytosis) or hemodynamic instability</td>
                    <td style="border: 1px solid #ddd; padding: 6px;">Inpatient/ICU</td>
                </tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Probe-to-Bone Test:</strong></p>
            <ul>
                <li>Insert sterile metal probe through ulcer</li>
                <li>If probe reaches bone = high probability of osteomyelitis (PPV 85%)</li>
            </ul>
            
            <p><strong>Labs:</strong></p>
            <ul>
                <li>CBC, BMP, HbA1c</li>
                <li>ESR, CRP (elevated in osteo, but non-specific)</li>
                <li>Blood cultures if systemic signs</li>
                <li>Procalcitonin (may help differentiate soft tissue vs bone infection)</li>
            </ul>
            
            <p><strong>Cultures:</strong></p>
            <ul>
                <li><strong>Superficial swabs are UNRELIABLE</strong> â€” don't guide therapy</li>
                <li><strong>Deep tissue/bone culture:</strong> Gold standard. Obtain at debridement</li>
                <li><strong>Bone biopsy:</strong> Through non-infected tissue if possible (not through ulcer base)</li>
            </ul>
            
            <p><strong>Imaging:</strong></p>
            <ul>
                <li><strong>X-ray:</strong> First-line. May show soft tissue gas, bony destruction, foreign body. Insensitive for early osteomyelitis</li>
                <li><strong>MRI:</strong> Gold standard for osteomyelitis (sensitivity 90%, specificity 80%). Can distinguish cellulitis from osteo</li>
                <li><strong>CT:</strong> Alternative if MRI contraindicated. Good for surgical planning</li>
            </ul>
            
            <p><strong>Vascular Assessment:</strong></p>
            <ul>
                <li><strong>ABI (Ankle-Brachial Index):</strong> <0.9 suggests PAD. May be falsely elevated if calcified</li>
                <li><strong>Toe pressures:</strong> More reliable in diabetics</li>
                <li><strong>Vascular surgery consult:</strong> If significant PAD â€” may need revascularization before wound will heal</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Empiric Antibiotics (Based on Severity):</strong></p>
            <ul>
                <li><strong>Mild:</strong> Oral â€” Amoxicillin-clavulanate, or TMP-SMX + cephalexin, or clindamycin</li>
                <li><strong>Moderate:</strong> IV â€” Ampicillin-sulbactam, or piperacillin-tazobactam, or ceftriaxone + metronidazole</li>
                <li><strong>Severe / MRSA risk:</strong> ADD Vancomycin</li>
                <li><strong>Pseudomonas risk (wet/macerated, prior treatment):</strong> Piperacillin-tazobactam or cefepime + metronidazole</li>
            </ul>
            
            <p><strong>Organisms to Cover:</strong></p>
            <ul>
                <li><strong>Acute, antibiotic-naive:</strong> Gram-positive cocci (Staph, Strep)</li>
                <li><strong>Chronic, previously treated:</strong> Polymicrobial â€” add gram-negatives, anaerobes</li>
                <li><strong>Wet/macerated/severe:</strong> Add Pseudomonas coverage</li>
            </ul>
            
            <p><strong>Duration:</strong></p>
            <ul>
                <li><strong>Soft tissue only:</strong> 1-2 weeks</li>
                <li><strong>Osteomyelitis with residual infected bone:</strong> 4-6 weeks</li>
                <li><strong>Osteomyelitis with amputation (no residual infected bone):</strong> 2-5 days post-op</li>
            </ul>
            
            <p><strong>Surgical Considerations:</strong></p>
            <ul>
                <li><strong>Debridement:</strong> Remove necrotic tissue, drain abscesses</li>
                <li><strong>Amputation:</strong> Consider if extensive necrosis, uncontrolled infection, non-reconstructable PAD, threatened life</li>
                <li><strong>Revascularization:</strong> If significant PAD, may be needed for wound healing</li>
            </ul>
            
            <p><strong>Wound Care:</strong></p>
            <ul>
                <li>Off-loading (total contact cast, removable walker)</li>
                <li>Regular debridement</li>
                <li>Moist wound environment</li>
                <li>Glycemic control</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Sepsis or septic shock</li>
                <li>Necrotizing fasciitis</li>
                <li>Wet gangrene with systemic toxicity</li>
                <li>Gas in deep tissues</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Systemic signs resolved (afebrile, WBC normalizing)</li>
                <li>Local infection controlled (decreasing erythema, drainage)</li>
                <li>Adequate debridement completed</li>
                <li>Appropriate oral antibiotic if continuing</li>
                <li>Off-loading device arranged</li>
                <li>Wound care plan established</li>
                <li>Vascular assessment completed (revascularization if needed)</li>
                <li>Podiatry/wound care/vascular follow-up</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Probe-to-bone = osteomyelitis:</strong> If sterile probe reaches bone through ulcer, PPV 85% for osteo</li>
            <li><strong>Superficial swabs are useless:</strong> They grow colonizers, not pathogens. Get deep tissue/bone cultures</li>
            <li><strong>Check the vessels:</strong> Wounds won't heal without adequate perfusion. Always assess vascular status</li>
            <li><strong>Antibiotics don't heal wounds:</strong> Off-loading, debridement, and perfusion heal wounds. Antibiotics treat infection</li>
            <li><strong>MRSA is common in diabetic foot:</strong> Especially if prior antibiotics, hospitalization, or chronic wound</li>
            <li><strong>Wet gangrene = emergency:</strong> Rapidly progressive, life-threatening. Needs emergent debridement/amputation</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="bb-ccb-toxicity" class="condition-page">
    <div class="page-header">
        <h2>168. BETA BLOCKER / CALCIUM CHANNEL BLOCKER TOXICITY</h2>
        <div class="subtitle">Bradycardia â€¢ Hypotension â€¢ High-Dose Insulin â€¢ Glucagon â€¢ Lipid Emulsion</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Life-threatening overdose of beta-blockers or calcium channel blockers causing cardiovascular collapse. Different mechanisms but similar hemodynamic effects</p>
            
            <p><strong>Beta Blocker Toxicity:</strong></p>
            <ul>
                <li><strong>Mechanism:</strong> Blocks Î²1 (cardiac) and Î²2 (vascular, metabolic) receptors</li>
                <li><strong>Cardiovascular:</strong> Bradycardia, hypotension, AV block, cardiogenic shock</li>
                <li><strong>CNS:</strong> Lethargy, seizures (especially propranolol â€” lipophilic, crosses BBB)</li>
                <li><strong>Metabolic:</strong> Hypoglycemia (blocks glycogenolysis), hyperkalemia</li>
                <li><strong>Respiratory:</strong> Bronchospasm (Î²2 blockade)</li>
                <li><strong>High-risk agents:</strong> Propranolol (lipophilic, Na-channel blockade), sotalol (QT prolongation)</li>
            </ul>
            
            <p><strong>Calcium Channel Blocker Toxicity:</strong></p>
            <ul>
                <li><strong>Mechanism:</strong> Blocks L-type Ca channels â†’ decreased cardiac contractility, vasodilation</li>
                <li><strong>Dihydropyridines (amlodipine, nifedipine):</strong> More vasodilation, reflex tachycardia (may be preserved initially)</li>
                <li><strong>Non-dihydropyridines (verapamil, diltiazem):</strong> More cardiodepression, bradycardia</li>
                <li><strong>Cardiovascular:</strong> Hypotension, bradycardia (non-DHP), heart block, cardiogenic shock</li>
                <li><strong>Metabolic:</strong> <strong>HYPERGLYCEMIA</strong> (distinguishes from BB â€” Ca needed for insulin release)</li>
                <li><strong>GI:</strong> Nausea, vomiting, ileus</li>
            </ul>
            
            <p><strong>Distinguishing BB vs CCB:</strong></p>
            <ul>
                <li>BB â†’ Hypoglycemia; CCB â†’ Hyperglycemia</li>
                <li>BB (propranolol) â†’ QRS widening, seizures; CCB â†’ usually not</li>
                <li>Both â†’ Bradycardia, hypotension (though DHP CCB may have tachycardia early)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>Initial Stabilization:</strong></p>
            <ul>
                <li>ABCs, IV access, continuous monitoring</li>
                <li><strong>Decontamination:</strong> Activated charcoal 1 g/kg if within 1-2 hours and airway protected. Consider whole bowel irrigation for sustained-release formulations</li>
                <li><strong>IV fluids:</strong> Bolus for hypotension (caution: may worsen pulmonary edema if cardiogenic)</li>
                <li><strong>Atropine:</strong> 0.5-1 mg IV for bradycardia (often ineffective in severe toxicity)</li>
            </ul>
            
            <p><strong>HIGH-DOSE INSULIN EUGLYCEMIA THERAPY (HIET) â€” First-Line for Severe Toxicity:</strong></p>
            <ul>
                <li><strong>Mechanism:</strong> Insulin has positive inotropic effects independent of glucose metabolism</li>
                <li><strong>Bolus:</strong> Regular insulin 1 unit/kg IV</li>
                <li><strong>Infusion:</strong> 0.5-1 unit/kg/hr, titrate to hemodynamic effect (may need up to 10 units/kg/hr)</li>
                <li><strong>Glucose supplementation:</strong> D10 or D25 infusion to maintain glucose 100-200 mg/dL</li>
                <li><strong>Potassium:</strong> Monitor closely, supplement to keep K >2.8-3.0</li>
                <li><strong>Why it works:</strong> Shocked heart preferentially uses glucose. Insulin improves myocardial glucose uptake and contractility</li>
            </ul>
            
            <p><strong>Glucagon (Primarily for BB):</strong></p>
            <ul>
                <li><strong>Mechanism:</strong> Bypasses Î²-receptor to activate adenylate cyclase</li>
                <li><strong>Dose:</strong> 3-5 mg IV bolus (50-150 mcg/kg), may repeat. Infusion: 3-5 mg/hr</li>
                <li><strong>Limitations:</strong> Limited supply, tachyphylaxis, causes vomiting</li>
            </ul>
            
            <p><strong>Calcium (Primarily for CCB):</strong></p>
            <ul>
                <li><strong>Calcium chloride:</strong> 1-2 g IV (via central line â€” caustic)</li>
                <li><strong>Calcium gluconate:</strong> 3-6 g IV (can give peripherally)</li>
                <li>May repeat q15-20 min or start infusion</li>
                <li>Helps temporarily but rarely sufficient alone</li>
            </ul>
            
            <p><strong>Vasopressors:</strong></p>
            <ul>
                <li><strong>Norepinephrine:</strong> First-line for hypotension</li>
                <li><strong>Epinephrine:</strong> If refractory, provides both inotropy and vasoconstriction</li>
                <li><strong>High doses often required</strong> due to receptor blockade</li>
            </ul>
            
            <p><strong>Lipid Emulsion Therapy (Intralipid):</strong></p>
            <ul>
                <li><strong>Indication:</strong> Refractory/peri-arrest, lipophilic agents (propranolol, verapamil)</li>
                <li><strong>Dose:</strong> 20% lipid emulsion 1.5 mL/kg IV bolus, then 0.25 mL/kg/min infusion</li>
                <li>May repeat bolus twice if persistent cardiovascular collapse</li>
            </ul>
            
            <p><strong>Advanced/Refractory:</strong></p>
            <ul>
                <li><strong>Pacing:</strong> Transcutaneous or transvenous for bradycardia</li>
                <li><strong>ECMO/VA-ECMO:</strong> Consider for refractory shock (bridge to recovery)</li>
                <li><strong>Methylene blue:</strong> For vasoplegic shock refractory to vasopressors (1-2 mg/kg IV)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>ALL significant BB/CCB overdose requires ICU</li>
                <li>Symptomatic bradycardia</li>
                <li>Hypotension</li>
                <li>Altered mental status</li>
                <li>Any cardiovascular effects</li>
                <li>Sustained-release ingestion (delayed toxicity)</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Asymptomatic >24 hours post-ingestion (longer for sustained-release)</li>
                <li>Normal vital signs off all supportive therapy</li>
                <li>Normal ECG</li>
                <li>Psychiatric evaluation if intentional</li>
                <li>Toxicology/poison center follow-up</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>High-dose insulin is first-line:</strong> Often more effective than glucagon or calcium. Don't be afraid of doses up to 10 units/kg/hr</li>
            <li><strong>Glucose distinguishes BB from CCB:</strong> Hypoglycemia = BB. Hyperglycemia = CCB</li>
            <li><strong>Sustained-release = prolonged observation:</strong> Toxicity may be delayed 12-24 hours. Observe at least 24 hours</li>
            <li><strong>Glucagon supply is limited:</strong> Pharmacy may not have enough for continuous infusion. Insulin is more available</li>
            <li><strong>Whole bowel irrigation for SR formulations:</strong> GoLYTELY until rectal effluent clear. Especially for verapamil SR</li>
            <li><strong>ECMO saves lives:</strong> Consider early for refractory shock. Bridge to drug elimination</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="digoxin-toxicity" class="condition-page">
    <div class="page-header">
        <h2>169. DIGOXIN TOXICITY</h2>
        <div class="subtitle">Narrow Therapeutic Index â€¢ DigiFab â€¢ Bidirectional VT â€¢ Visual Disturbances</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Toxicity from cardiac glycoside with narrow therapeutic window (therapeutic 0.8-2.0 ng/mL, toxic often >2.0). Acute overdose vs chronic toxicity have different presentations</p>
            
            <p><strong>Mechanism:</strong></p>
            <ul>
                <li>Inhibits Na/K-ATPase â†’ increased intracellular Ca â†’ positive inotropy</li>
                <li>Increases vagal tone (parasympathetic) â†’ slows AV conduction</li>
                <li>At toxic levels â†’ increased automaticity (ectopy) + AV block</li>
            </ul>
            
            <p><strong>Risk Factors for Toxicity:</strong></p>
            <ul>
                <li><strong>Renal impairment:</strong> Digoxin renally cleared (80%)</li>
                <li><strong>Hypokalemia:</strong> Increases myocardial sensitivity (K+ and digoxin compete for Na/K-ATPase)</li>
                <li><strong>Hypomagnesemia:</strong> Similar effect</li>
                <li><strong>Hypercalcemia:</strong> Potentiates digoxin effects</li>
                <li><strong>Drug interactions:</strong> Amiodarone, verapamil, quinidine (increase levels)</li>
                <li><strong>Hypothyroidism</strong></li>
                <li><strong>Advanced age</strong></li>
            </ul>
            
            <p><strong>Clinical Features:</strong></p>
            <ul>
                <li><strong>GI (Often First):</strong> Nausea, vomiting, anorexia, abdominal pain</li>
                <li><strong>Neurologic:</strong> Confusion, lethargy, weakness</li>
                <li><strong>Visual (Classic):</strong> Yellow-green halos (xanthopsia), blurred vision, photophobia</li>
                <li><strong>Cardiac:</strong> Virtually any arrhythmia except rapidly conducted atrial arrhythmias</li>
            </ul>
            
            <p><strong>Classic Arrhythmias:</strong></p>
            <ul>
                <li><strong>Bidirectional VT:</strong> Pathognomonic â€” alternating QRS axis</li>
                <li><strong>Regularized atrial fibrillation:</strong> AF with complete heart block and junctional escape</li>
                <li><strong>Atrial tachycardia with AV block</strong></li>
                <li><strong>Frequent PVCs, bigeminy</strong></li>
                <li><strong>Sinus bradycardia, AV block</strong></li>
                <li><strong>Accelerated junctional rhythm</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Digoxin Level:</strong></p>
            <ul>
                <li>Draw level at least 6 hours post-dose (for distribution)</li>
                <li>Therapeutic: 0.8-2.0 ng/mL (some use 0.5-1.0 for HF)</li>
                <li>Toxicity more likely >2.0 but can occur at "therapeutic" levels with hypokalemia</li>
                <li><strong>After Fab treatment:</strong> Level will be falsely elevated (measures bound digoxin)</li>
            </ul>
            
            <p><strong>Electrolytes:</strong></p>
            <ul>
                <li><strong>Potassium:</strong> Critical â€” hypokalemia increases toxicity. Hyperkalemia in acute massive overdose (Na/K-ATPase blocked systemically)</li>
                <li><strong>Magnesium:</strong> Check and replete</li>
                <li><strong>Calcium</strong></li>
                <li><strong>Renal function</strong></li>
            </ul>
            
            <p><strong>ECG:</strong></p>
            <ul>
                <li><strong>Digoxin effect (not toxicity):</strong> Scooped ST depression ("Salvador Dali mustache"), QT shortening</li>
                <li><strong>Digoxin toxicity:</strong> Arrhythmias as listed above</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>General Measures:</strong></p>
            <ul>
                <li><strong>Stop digoxin</strong></li>
                <li><strong>Activated charcoal:</strong> If within 1-2 hours of acute ingestion</li>
                <li><strong>Correct electrolytes:</strong>
                    <ul>
                        <li>Replete K+ to 4.0-5.0 (but avoid in hyperkalemia of acute overdose)</li>
                        <li>Replete Mg to >2.0</li>
                    </ul>
                </li>
                <li><strong>Continuous cardiac monitoring</strong></li>
            </ul>
            
            <p><strong>DIGOXIN-SPECIFIC ANTIBODY FRAGMENTS (DigiFab):</strong></p>
            <ul>
                <li><strong>Indications:</strong>
                    <ul>
                        <li>Life-threatening arrhythmias (VT, VF, high-grade AV block)</li>
                        <li>Hemodynamic instability</li>
                        <li>Potassium >5.5 in acute overdose</li>
                        <li>Acute ingestion >10 mg (adult) or >4 mg (child)</li>
                        <li>Digoxin level >15 ng/mL at any time or >10 ng/mL 6 hours post-ingestion</li>
                    </ul>
                </li>
                <li><strong>Dosing (Chronic Toxicity):</strong>
                    <ul>
                        <li>Known level: # vials = (level ng/mL Ã— weight kg) / 100</li>
                        <li>Empiric: 3-6 vials for life-threatening arrhythmia</li>
                    </ul>
                </li>
                <li><strong>Dosing (Acute Overdose):</strong>
                    <ul>
                        <li>Known amount ingested: # vials = (amount in mg Ã— 0.8) / 0.5</li>
                        <li>Empiric large ingestion: 10-20 vials</li>
                    </ul>
                </li>
                <li><strong>Response:</strong> Usually within 30-60 minutes</li>
            </ul>
            
            <p><strong>Arrhythmia Management:</strong></p>
            <ul>
                <li><strong>Bradycardia:</strong> Atropine (often ineffective). DigiFab. Pacing if refractory</li>
                <li><strong>Ventricular arrhythmias:</strong> DigiFab first. Lidocaine or phenytoin (don't prolong QT). Avoid amiodarone if possible</li>
                <li><strong>Avoid:</strong> Calcium (may worsen digoxin toxicity â€” "stone heart"), cardioversion for AFib (may precipitate VF â€” use only if unstable, lowest effective energy)</li>
            </ul>
            
            <p><strong>Hyperkalemia (Acute Overdose):</strong></p>
            <ul>
                <li>Treat with insulin/glucose, bicarb, albuterol</li>
                <li><strong>Avoid calcium:</strong> Controversial â€” may worsen digoxin cardiotoxicity (though used if life-threatening hyperkalemia)</li>
                <li>DigiFab will correct hyperkalemia (restores Na/K-ATPase function)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Any significant arrhythmia</li>
                <li>Hemodynamic instability</li>
                <li>Hyperkalemia (acute overdose)</li>
                <li>Symptomatic toxicity</li>
                <li>Level >4 ng/mL with symptoms</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Arrhythmias resolved</li>
                <li>Hemodynamically stable</li>
                <li>Electrolytes normalized</li>
                <li>Symptoms resolved</li>
                <li>Cause of toxicity identified (AKI, drug interaction, accidental)</li>
                <li>Medication reconciliation â€” safe to restart at lower dose?</li>
                <li>Cardiology/toxicology follow-up</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Bidirectional VT = digoxin until proven otherwise:</strong> Pathognomonic. Also seen in catecholaminergic polymorphic VT and aconitine poisoning</li>
            <li><strong>Hypokalemia kills:</strong> Even "therapeutic" digoxin levels can be toxic in hypokalemia. Replete K+ aggressively</li>
            <li><strong>Avoid calcium in digoxin toxicity:</strong> Historical concern for "stone heart" (refractory cardiac arrest). Though data is limited, avoid unless hyperkalemia is immediately life-threatening</li>
            <li><strong>DigiFab fixes hyperkalemia:</strong> In acute overdose, hyperkalemia is from Na/K-ATPase inhibition. Fab antibodies restore pump function</li>
            <li><strong>Level is falsely elevated after Fab:</strong> Assay measures total digoxin (bound + free). Only free digoxin is active</li>
            <li><strong>AF that becomes regular = complete heart block:</strong> Classic sign. AF with regularized ventricular response = AV block with junctional escape</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<div id="lithium-toxicity" class="condition-page">
    <div class="page-header">
        <h2>170. LITHIUM TOXICITY</h2>
        <div class="subtitle">Narrow Therapeutic Index â€¢ Nephrogenic DI â€¢ Dialysis Indications â€¢ SILENT Trial</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Toxicity from lithium, a mood stabilizer with narrow therapeutic window (0.6-1.2 mEq/L). Primarily neurologic toxicity with renal elimination</p>
            
            <p><strong>Types of Toxicity:</strong></p>
            <ul>
                <li><strong>Acute overdose:</strong> GI symptoms first, then neuro. Peak effects delayed (slow tissue distribution)</li>
                <li><strong>Chronic toxicity:</strong> Insidious neurologic symptoms at lower levels. More dangerous</li>
                <li><strong>Acute-on-chronic:</strong> Most common and most dangerous combination</li>
            </ul>
            
            <p><strong>Precipitants of Chronic Toxicity:</strong></p>
            <ul>
                <li><strong>Volume depletion:</strong> Diarrhea, vomiting, decreased intake</li>
                <li><strong>Renal impairment:</strong> AKI, CKD progression</li>
                <li><strong>Drug interactions:</strong>
                    <ul>
                        <li>NSAIDs (reduce renal Li clearance)</li>
                        <li>ACE inhibitors, ARBs (reduce clearance)</li>
                        <li>Thiazides (reduce clearance via Na depletion)</li>
                        <li>Loops less problematic but still caution</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Clinical Features by Severity:</strong></p>
            <ul>
                <li><strong>Mild (1.5-2.5 mEq/L):</strong> Nausea, vomiting, diarrhea, tremor, lethargy, ataxia</li>
                <li><strong>Moderate (2.5-3.5 mEq/L):</strong> Confusion, agitation, dysarthria, nystagmus, myoclonus, hyperreflexia</li>
                <li><strong>Severe (>3.5 mEq/L):</strong> Seizures, coma, hyperthermia, cardiovascular collapse</li>
            </ul>
            
            <p><strong>Chronic Effects of Lithium (Not Acute Toxicity):</strong></p>
            <ul>
                <li><strong>Nephrogenic DI:</strong> Polyuria, polydipsia (Li inhibits ADH action on collecting duct)</li>
                <li><strong>Hypothyroidism:</strong> Common, often subclinical</li>
                <li><strong>Hyperparathyroidism:</strong> Hypercalcemia</li>
                <li><strong>Chronic kidney disease</strong></li>
            </ul>
            
            <p><strong>SILENT (Syndrome of Irreversible Lithium-Effectuated Neurotoxicity):</strong></p>
            <ul>
                <li>Persistent neurologic deficits (cerebellar, cognitive, extrapyramidal) after lithium cleared</li>
                <li>Risk factors: Prolonged toxicity, high levels, delayed treatment</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><strong>Lithium Level:</strong></p>
            <ul>
                <li>Therapeutic: 0.6-1.2 mEq/L</li>
                <li>Check q4-6h until trending down (levels may rise in acute overdose)</li>
                <li><strong>Chronic toxicity can occur at lower levels</strong> (tissue saturation)</li>
            </ul>
            
            <p><strong>Additional Labs:</strong></p>
            <ul>
                <li><strong>BMP:</strong> Renal function, electrolytes (Na, K)</li>
                <li><strong>Calcium, TSH:</strong> Chronic lithium effects</li>
                <li><strong>Serum osmolality, urine osmolality:</strong> If DI suspected</li>
                <li><strong>ECG:</strong> T wave flattening/inversion, QT prolongation, bradycardia</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><strong>General Measures:</strong></p>
            <ul>
                <li><strong>Stop lithium</strong></li>
                <li><strong>IV fluids:</strong> Normal saline â€” restores volume, enhances renal clearance. Avoid hypotonic fluids</li>
                <li><strong>Activated charcoal:</strong> NOT effective (Li not adsorbed to charcoal)</li>
                <li><strong>Whole bowel irrigation:</strong> Consider for large acute ingestions or extended-release</li>
                <li><strong>Stop interacting drugs:</strong> NSAIDs, ACEi, ARBs, thiazides</li>
            </ul>
            
            <p><strong>HEMODIALYSIS â€” Indications (EXTRIP Guidelines):</strong></p>
            <ul>
                <li><strong>Recommended:</strong>
                    <ul>
                        <li>Decreased level of consciousness, seizures, life-threatening dysrhythmias</li>
                        <li>Level >4.0 mEq/L AND impaired kidney function</li>
                    </ul>
                </li>
                <li><strong>Suggested:</strong>
                    <ul>
                        <li>Confusion (not just lethargy)</li>
                        <li>Level >5.0 mEq/L</li>
                        <li>Expected time to Li <1.0 mEq/L exceeds 36 hours</li>
                    </ul>
                </li>
            </ul>
            
            <p><strong>Hemodialysis Specifics:</strong></p>
            <ul>
                <li>Lithium is ideal for dialysis: Low molecular weight, low protein binding, small volume of distribution</li>
                <li>HD reduces level by 1 mEq/L per hour</li>
                <li><strong>Rebound:</strong> Level may rise after HD (redistribution from tissues). Repeat level 6 hours post-HD</li>
                <li>May need repeated HD sessions</li>
                <li><strong>CRRT:</strong> Alternative if hemodynamically unstable, but less efficient</li>
            </ul>
            
            <p><strong>Seizure Management:</strong></p>
            <ul>
                <li>Benzodiazepines first-line</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ ESCALATE TO ICU IF:</div>
            <ul>
                <li>Altered mental status</li>
                <li>Seizures</li>
                <li>Level >2.5 mEq/L with symptoms</li>
                <li>Level >4.0 mEq/L regardless of symptoms</li>
                <li>Requires hemodialysis</li>
                <li>Hemodynamic instability</li>
            </ul>
        </div>
        
        <div class="box">
            <div class="box-title">âœ“ DISCHARGE CRITERIA</div>
            <ul>
                <li>Level <1.5 mEq/L and stable (no rebound)</li>
                <li>Neurologically at baseline</li>
                <li>Renal function stable</li>
                <li>Cause of toxicity identified and addressed</li>
                <li>Medication reconciliation (is lithium still indicated? dose adjustment?)</li>
                <li>Psychiatry follow-up</li>
                <li>Education on drug interactions, hydration</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž PEARLS</div>
        <ul>
            <li><strong>Chronic toxicity is worse than acute:</strong> Tissues are saturated. Neurologic toxicity at lower levels. Higher risk of SILENT</li>
            <li><strong>Charcoal doesn't work:</strong> Lithium is not adsorbed. Don't waste time with it</li>
            <li><strong>Volume, volume, volume:</strong> NS restores renal perfusion and enhances lithium clearance. First-line treatment</li>
            <li><strong>Check for drug interactions:</strong> NSAIDs, ACEi, ARBs, thiazides all increase lithium levels. Stop them</li>
            <li><strong>Expect rebound after HD:</strong> Lithium redistributes from tissues. Recheck level 6 hours post-dialysis</li>
            <li><strong>SILENT is preventable:</strong> Early, aggressive treatment reduces risk of permanent neurologic injury</li>
            <li><strong>Nephrogenic DI is common:</strong> Chronic lithium use causes polyuria. If hospitalized, monitor fluid balance carefully</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- NEW CONDITIONS FOR IMCRG -->

<!-- TICK-BORNE ILLNESS -->
<div id="tick-borne" class="condition-page">
    <div class="page-header">
        <h2>171. TICK-BORNE ILLNESS</h2>
        <div class="subtitle">Lyme Disease â€¢ Anaplasmosis â€¢ Ehrlichiosis â€¢ Babesiosis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Lyme Disease (Borrelia burgdorferi):</span></p>
            <ul>
                <li><strong>Early Localized (3-30 days):</strong> Erythema migrans (EM) - expanding red/pink patch â‰¥5cm, central clearing ("bull's eye") in 20%, warm but not painful. 70-80% have EM. Flu-like symptoms common</li>
                <li><strong>Early Disseminated (weeks-months):</strong> Multiple EM lesions, cranial neuropathy (especially VII - facial palsy, often bilateral), meningitis, AV block (can be high-grade), migratory arthralgias</li>
                <li><strong>Late (months-years):</strong> Lyme arthritis (large joint, especially knee - recurrent, brief attacks), chronic encephalopathy (rare)</li>
            </ul>
            
            <p><span class="label">Anaplasmosis (Anaplasma phagocytophilum):</span></p>
            <ul>
                <li><strong>Classic Triad:</strong> Fever + leukopenia + thrombocytopenia (1-2 weeks after tick bite)</li>
                <li><strong>Symptoms:</strong> High fever, severe headache, myalgias, malaise. NO RASH (unlike Lyme/RMSF)</li>
                <li><strong>Labs:</strong> Leukopenia, thrombocytopenia, elevated transaminases (70%), morulae in granulocytes (rare but pathognomonic)</li>
                <li><strong>Severity:</strong> Can be severe in elderly/immunocompromised. ICU admission in 5-7%</li>
            </ul>
            
            <p><span class="label">Ehrlichiosis (Ehrlichia chaffeensis):</span></p>
            <ul>
                <li><strong>Similar to Anaplasmosis:</strong> Fever, headache, myalgias, leukopenia, thrombocytopenia, elevated LFTs</li>
                <li><strong>Differences:</strong> More common in Southeast/South-central US (Lone Star tick). Rash in 30% (adults), 60% (children). More severe GI symptoms</li>
                <li><strong>Morulae:</strong> Found in monocytes (vs granulocytes in anaplasmosis)</li>
            </ul>
            
            <p><span class="label">Babesiosis (Babesia microti):</span></p>
            <ul>
                <li><strong>Presentation:</strong> Fever, fatigue, myalgias, hemolytic anemia (can be severe). Dark urine from hemoglobinuria</li>
                <li><strong>Risk for Severe Disease:</strong> Asplenia (can be fatal), elderly, immunocompromised, HIV</li>
                <li><strong>Labs:</strong> Hemolytic anemia, thrombocytopenia, elevated LDH, low haptoglobin. Parasitemia on smear (ring forms, "Maltese cross")</li>
            </ul>
            
            <p><span class="label">Geographic Distribution:</span> Lyme/Anaplasmosis/Babesiosis: Northeast + Upper Midwest (Ixodes scapularis tick). Ehrlichiosis: Southeast + South-central (Lone Star tick)</p>
            
            <p><span class="label">Co-infection:</span> 10-20% of Lyme patients co-infected with Anaplasma or Babesia. Consider if atypical features or poor response to Lyme treatment</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Lyme Disease:</span></p>
            <ul>
                <li><strong>Erythema Migrans:</strong> CLINICAL DIAGNOSIS - no testing needed. Treat empirically. Serology often negative early</li>
                <li><strong>Disseminated/Late Lyme:</strong> Two-tier serology: ELISA/EIA â†’ if positive/equivocal â†’ Western blot. Both must be positive</li>
                <li><strong>CSF:</strong> If meningitis suspected - lymphocytic pleocytosis, CSF Lyme antibody index</li>
                <li><strong>Cardiac:</strong> ECG for all (PR interval). Echo if AV block or myocarditis suspected</li>
            </ul>
            
            <p><span class="label">Anaplasmosis/Ehrlichiosis:</span></p>
            <ul>
                <li><strong>PCR:</strong> Most sensitive early in disease (first week). Order Anaplasma or Ehrlichia PCR based on geography</li>
                <li><strong>Serology:</strong> Acute and convalescent titers (4-fold rise). Often negative in first week</li>
                <li><strong>Blood Smear:</strong> Morulae in granulocytes (Anaplasma) or monocytes (Ehrlichia) - seen in 20-80% but specific</li>
                <li><strong>DO NOT WAIT for confirmatory tests - treat empirically if clinical suspicion high</strong></li>
            </ul>
            
            <p><span class="label">Babesiosis:</span></p>
            <ul>
                <li><strong>Blood Smear:</strong> Ring forms (similar to malaria), "Maltese cross" tetrads (pathognomonic but rare)</li>
                <li><strong>PCR:</strong> More sensitive than smear, especially low-level parasitemia</li>
                <li><strong>Serology:</strong> Babesia IgM/IgG (may take 2-4 weeks to become positive)</li>
                <li><strong>Hemolysis Labs:</strong> CBC (anemia, thrombocytopenia), retic count, LDH, haptoglobin, bilirubin</li>
            </ul>
            
            <p><span class="label">Standard Labs for All Tick-borne Illness:</span></p>
            <ul>
                <li>CBC with differential (leukopenia, thrombocytopenia)</li>
                <li>CMP including LFTs (transaminitis common)</li>
                <li>Blood smear if Babesiosis or Anaplasmosis suspected</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Lyme Disease:</span></p>
            <ul>
                <li><strong>Early Localized/Early Disseminated (EM, facial palsy, mild carditis):</strong> Doxycycline 100mg BID Ã— 10-14 days (preferred - also treats co-infection)</li>
                <li><strong>Alternatives:</strong> Amoxicillin 500mg TID Ã— 14 days (pregnancy, children <8), Cefuroxime 500mg BID Ã— 14 days</li>
                <li><strong>Lyme Arthritis:</strong> Doxycycline 100mg BID Ã— 28 days OR Amoxicillin 500mg TID Ã— 28 days</li>
                <li><strong>Lyme Meningitis/High-grade AV block:</strong> Ceftriaxone 2g IV daily Ã— 14-21 days. May need temporary pacemaker for heart block</li>
            </ul>
            
            <p><span class="label">Anaplasmosis/Ehrlichiosis:</span></p>
            <ul>
                <li><strong>First-line:</strong> Doxycycline 100mg BID until afebrile for â‰¥3 days (minimum 5-7 days total)</li>
                <li><strong>DO NOT DELAY treatment for confirmatory testing</strong></li>
                <li><strong>Pregnancy:</strong> Doxycycline still recommended (short course) - risk of severe disease outweighs fetal risk. Rifampin is alternative but less effective</li>
                <li><strong>Response:</strong> Dramatic improvement within 24-48 hours. If no response, reconsider diagnosis</li>
            </ul>
            
            <p><span class="label">Babesiosis:</span></p>
            <ul>
                <li><strong>Mild-Moderate:</strong> Atovaquone 750mg BID + Azithromycin 500-1000mg day 1, then 250-500mg daily Ã— 7-10 days</li>
                <li><strong>Severe (parasitemia >10%, significant hemolysis, organ dysfunction):</strong> Clindamycin 600mg IV q8h + Quinine 650mg PO q8h Ã— 7-10 days. Consider exchange transfusion if parasitemia >10% or severe hemolysis/end-organ damage</li>
                <li><strong>Asplenic/Immunocompromised:</strong> Treat for â‰¥6 weeks + 2 weeks after parasitemia clears. High relapse risk</li>
            </ul>
            
            <p><span class="label">Prophylaxis After Tick Bite (Lyme only):</span></p>
            <ul>
                <li><strong>Single dose Doxycycline 200mg</strong> if: Ixodes tick attached â‰¥36 hours, within 72 hours of removal, in endemic area</li>
                <li>Not recommended routinely - most tick bites don't transmit disease</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Erythema migrans = treat, don't test:</strong> Serology is often negative early. EM is a clinical diagnosis. Start doxycycline</li>
                <li><strong>No rash + fever + cytopenias:</strong> Think Anaplasmosis/Ehrlichiosis, not Lyme. Doxycycline covers all</li>
                <li><strong>Doxycycline is the answer:</strong> Treats Lyme, Anaplasmosis, Ehrlichiosis, and RMSF. When in doubt in endemic area, treat empirically</li>
                <li><strong>Hemolytic anemia after tick bite:</strong> Think Babesiosis. Check smear, especially in asplenic patients (can be fatal)</li>
                <li><strong>Co-infection is common:</strong> If patient not improving on Lyme treatment, consider Babesiosis (needs different regimen)</li>
                <li><strong>Bilateral facial palsy:</strong> Highly suggestive of Lyme disease. Check serology and treat</li>
                <li><strong>Heart block in young patient:</strong> Consider Lyme carditis. Usually resolves with antibiotics, but may need temporary pacing</li>
                <li><strong>Post-treatment Lyme disease syndrome:</strong> Fatigue, arthralgias persisting after treatment. NOT indication for prolonged antibiotics (no benefit in trials)</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PELVIC INFLAMMATORY DISEASE -->
<div id="pid" class="condition-page">
    <div class="page-header">
        <h2>172. PELVIC INFLAMMATORY DISEASE</h2>
        <div class="subtitle">Salpingitis â€¢ Endometritis â€¢ Tubo-ovarian Abscess</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Presentation:</span> Lower abdominal/pelvic pain (usually bilateral), vaginal discharge, fever, dyspareunia. May have irregular bleeding. Often subacute onset over days</p>
            
            <p><span class="label">Minimum Criteria for Diagnosis (CDC):</span> Sexually active woman with pelvic/lower abdominal pain AND at least ONE of:</p>
            <ul>
                <li>Cervical motion tenderness (CMT) - "chandelier sign"</li>
                <li>Uterine tenderness</li>
                <li>Adnexal tenderness</li>
            </ul>
            
            <p><span class="label">Additional Criteria (Increase Specificity):</span></p>
            <ul>
                <li>Oral temperature >101Â°F (38.3Â°C)</li>
                <li>Mucopurulent cervical discharge or cervical friability</li>
                <li>WBC on saline wet prep of vaginal fluid</li>
                <li>Elevated ESR or CRP</li>
                <li>Positive GC/CT NAAT</li>
            </ul>
            
            <p><span class="label">Causative Organisms:</span></p>
            <ul>
                <li><strong>Neisseria gonorrhoeae:</strong> Often more acute presentation</li>
                <li><strong>Chlamydia trachomatis:</strong> Often subclinical, more likely to cause tubal damage</li>
                <li><strong>Vaginal flora:</strong> Anaerobes, G. vaginalis, H. influenzae, enteric GNRs, Streptococcus</li>
                <li><strong>Mycoplasma genitalium:</strong> Increasingly recognized, may require specific testing</li>
            </ul>
            
            <p><span class="label">Risk Factors:</span> Age 15-25, multiple sexual partners, prior STI, prior PID, IUD insertion within 3 weeks (risk returns to baseline after), douching</p>
            
            <p><span class="label">Tubo-ovarian Abscess (TOA):</span> Complication in 15-30% of hospitalized PID. Palpable adnexal mass, higher fever, more toxic. Can rupture (surgical emergency). Higher risk of infertility</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Required Testing:</span></p>
            <ul>
                <li><strong>Pregnancy Test:</strong> ALWAYS - rule out ectopic pregnancy (similar presentation)</li>
                <li><strong>GC/CT NAAT:</strong> Cervical or urine. Positive in 30-40% of PID cases</li>
                <li><strong>Wet Mount:</strong> WBCs, clue cells (BV), trichomonads</li>
                <li><strong>HIV Testing:</strong> Offer to all patients with STI</li>
                <li><strong>RPR/VDRL:</strong> Syphilis screening</li>
            </ul>
            
            <p><span class="label">Additional Labs:</span></p>
            <ul>
                <li>CBC (leukocytosis common)</li>
                <li>ESR/CRP (elevated, can follow for response)</li>
                <li>UA (rule out UTI)</li>
            </ul>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>Pelvic Ultrasound:</strong> If TOA suspected, palpable mass, or not improving on therapy. Transvaginal preferred</li>
                <li><strong>CT Abdomen/Pelvis:</strong> If uncertain diagnosis or concern for other pathology (appendicitis)</li>
            </ul>
            
            <p><span class="label">Laparoscopy:</span> Gold standard but rarely needed. Consider if: diagnosis uncertain, no response to treatment, surgical emergency suspected</p>
            
            <p><span class="label">Differential Diagnosis:</span></p>
            <ul>
                <li>Ectopic pregnancy (always rule out!)</li>
                <li>Appendicitis (RLQ predominant, anorexia, migration of pain)</li>
                <li>Ovarian cyst rupture/torsion (sudden onset, unilateral)</li>
                <li>Endometriosis</li>
                <li>UTI/pyelonephritis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Outpatient Treatment (Mild-Moderate):</span></p>
            <ul>
                <li><strong>Preferred:</strong> Ceftriaxone 500mg IM Ã— 1 PLUS Doxycycline 100mg PO BID Ã— 14 days PLUS Metronidazole 500mg PO BID Ã— 14 days</li>
                <li><strong>Alternative (if ceftriaxone unavailable):</strong> Cefoxitin 2g IM Ã— 1 + Probenecid 1g PO PLUS Doxycycline 100mg PO BID Ã— 14 days + Metronidazole 500mg PO BID Ã— 14 days</li>
                <li><strong>Metronidazole:</strong> Recommended to cover anaerobes and BV (which often coexists)</li>
            </ul>
            
            <p><span class="label">Indications for Hospitalization:</span></p>
            <ul>
                <li>Surgical emergency cannot be excluded (appendicitis, ectopic)</li>
                <li>Tubo-ovarian abscess</li>
                <li>Pregnancy</li>
                <li>Severe illness (high fever, nausea/vomiting, peritoneal signs)</li>
                <li>Unable to tolerate or follow outpatient regimen</li>
                <li>No clinical response to oral therapy within 72 hours</li>
            </ul>
            
            <p><span class="label">Inpatient Treatment:</span></p>
            <ul>
                <li><strong>Preferred:</strong> Cefotetan 2g IV q12h OR Cefoxitin 2g IV q6h PLUS Doxycycline 100mg IV/PO q12h</li>
                <li><strong>Alternative:</strong> Clindamycin 900mg IV q8h PLUS Gentamicin 2mg/kg load, then 1.5mg/kg q8h (or 5mg/kg daily)</li>
                <li><strong>Alternative:</strong> Ampicillin-sulbactam 3g IV q6h PLUS Doxycycline 100mg IV/PO q12h</li>
                <li><strong>Transition to oral:</strong> After 24-48h of clinical improvement, complete 14 days with Doxycycline 100mg PO BID + Metronidazole 500mg PO BID</li>
            </ul>
            
            <p><span class="label">Tubo-ovarian Abscess:</span></p>
            <ul>
                <li>IV antibiotics as above</li>
                <li>If no improvement in 48-72h or abscess >9cm: consider IR drainage or surgical intervention</li>
                <li>Ruptured TOA: Surgical emergency - laparoscopy/laparotomy</li>
            </ul>
            
            <p><span class="label">Partner Management:</span> All sexual partners in past 60 days should be evaluated and treated empirically for GC/CT. Patient should abstain from intercourse until treatment complete and partners treated</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Low threshold to treat:</strong> Consequences of untreated PID (infertility, ectopic pregnancy, chronic pelvic pain) are severe. Treat empirically if clinical suspicion</li>
                <li><strong>Negative GC/CT doesn't rule out PID:</strong> Only 30-40% of PID is GC/CT positive. Treat regardless of NAAT result</li>
                <li><strong>Always rule out ectopic:</strong> Pregnancy test is mandatory. Ectopic can present identically to PID</li>
                <li><strong>IUD can stay in:</strong> No need to remove IUD unless no clinical improvement in 48-72h. Risk is mainly in first 3 weeks after insertion</li>
                <li><strong>Fitz-Hugh-Curtis syndrome:</strong> RUQ pain from perihepatitis. Can mimic cholecystitis. "Violin string" adhesions on laparoscopy</li>
                <li><strong>Infertility risk:</strong> ~10% after 1 episode, ~20% after 2, ~40% after 3 episodes. Emphasize treatment completion and partner treatment</li>
                <li><strong>Consider M. genitalium:</strong> If not improving on standard therapy, test and treat with Moxifloxacin if positive</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- EMPYEMA / PARAPNEUMONIC EFFUSION -->
<div id="empyema" class="condition-page">
    <div class="page-header">
        <h2>173. EMPYEMA / PARAPNEUMONIC EFFUSION</h2>
        <div class="subtitle">Complicated vs Uncomplicated â€¢ Pleural Space Infection</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definitions:</span></p>
            <ul>
                <li><strong>Simple Parapneumonic Effusion:</strong> Sterile exudative effusion adjacent to pneumonia. Often small, free-flowing, resolves with antibiotics alone</li>
                <li><strong>Complicated Parapneumonic Effusion:</strong> pH <7.2, glucose <60, LDH >1000, or positive Gram stain. Will NOT resolve without drainage</li>
                <li><strong>Empyema:</strong> Frank pus in pleural space OR positive pleural fluid culture. Requires drainage</li>
            </ul>
            
            <p><span class="label">Clinical Features:</span></p>
            <ul>
                <li>Persistent/worsening fever despite appropriate antibiotics for pneumonia</li>
                <li>Pleuritic chest pain (may decrease as fluid accumulates)</li>
                <li>Dyspnea (from lung compression)</li>
                <li>Dullness to percussion, decreased breath sounds, egophony at upper border</li>
                <li>Signs of sepsis in severe cases</li>
            </ul>
            
            <p><span class="label">Risk Factors:</span> Alcoholism, IVDU, aspiration, poor dentition, diabetes, immunosuppression, GERD, esophageal disorders</p>
            
            <p><span class="label">Common Organisms:</span></p>
            <ul>
                <li><strong>Community-acquired:</strong> Streptococcus pneumoniae (most common), other streptococci, S. aureus, anaerobes (especially if aspiration)</li>
                <li><strong>Hospital-acquired:</strong> S. aureus (including MRSA), gram-negative bacilli, anaerobes</li>
                <li><strong>Anaerobes:</strong> Often from aspiration. Foul-smelling pus is diagnostic</li>
            </ul>
            
            <p><span class="label">Stages of Empyema:</span></p>
            <ul>
                <li><strong>Exudative (Stage 1):</strong> Days 1-3. Free-flowing fluid, low WBC, normal pH/glucose. May resolve with antibiotics alone</li>
                <li><strong>Fibrinopurulent (Stage 2):</strong> Days 3-14. Loculations form, â†‘WBC, â†“pH, â†“glucose. Requires drainage</li>
                <li><strong>Organizing (Stage 3):</strong> Weeks. Thick fibrous peel ("rind") encases lung. May need decortication</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>CXR:</strong> Blunting of costophrenic angle (>200mL), meniscus sign, loculated fluid. Lateral decubitus shows layering vs loculation</li>
                <li><strong>CT Chest with Contrast:</strong> Gold standard. Shows loculations, lung abscess, "split pleura sign" (enhancing visceral and parietal pleura). Helps plan drainage</li>
                <li><strong>Ultrasound:</strong> Bedside, identifies septations/loculations, guides thoracentesis. Can distinguish simple from complex effusion</li>
            </ul>
            
            <p><span class="label">Thoracentesis (ALWAYS indicated if new effusion with pneumonia):</span></p>
            <ul>
                <li><strong>Appearance:</strong> Frank pus = empyema (no further analysis needed, go to drainage)</li>
                <li><strong>Cell count:</strong> WBC >50,000 strongly suggests infection</li>
                <li><strong>Chemistry:</strong> pH, glucose, LDH, protein</li>
                <li><strong>Microbiology:</strong> Gram stain, culture (aerobic + anaerobic), consider AFB/fungal if risk factors</li>
            </ul>
            
            <p><span class="label">Criteria for Complicated Effusion (ANY ONE = needs drainage):</span></p>
            <ul>
                <li>pH <7.2 (most important predictor)</li>
                <li>Glucose <60 mg/dL</li>
                <li>LDH >1000 IU/L or >3Ã— serum</li>
                <li>Positive Gram stain or culture</li>
                <li>Frank pus</li>
                <li>Loculated effusion</li>
            </ul>
            
            <p><span class="label">Blood Tests:</span> CBC, BMP, blood cultures, CRP/procalcitonin</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Antibiotics:</span></p>
            <ul>
                <li><strong>Community-acquired:</strong> Ceftriaxone 2g IV daily + Metronidazole 500mg IV q8h (covers anaerobes) OR Ampicillin-sulbactam 3g IV q6h</li>
                <li><strong>Hospital-acquired/MRSA risk:</strong> Vancomycin + Piperacillin-tazobactam OR Meropenem</li>
                <li><strong>Duration:</strong> Minimum 2-4 weeks, often longer (4-6 weeks) depending on clinical response. Transition to oral when afebrile, clinically improved</li>
            </ul>
            
            <p><span class="label">Drainage - Indications:</span></p>
            <ul>
                <li>Frank pus</li>
                <li>Positive Gram stain or culture</li>
                <li>pH <7.2</li>
                <li>Loculated effusion</li>
                <li>Large effusion (>Â½ hemithorax)</li>
            </ul>
            
            <p><span class="label">Drainage Options:</span></p>
            <ul>
                <li><strong>Chest Tube (Image-guided):</strong> First-line for most complicated effusions. Use large-bore (â‰¥24 Fr) or small-bore with fibrinolytics</li>
                <li><strong>Intrapleural Fibrinolytics (tPA/DNase):</strong> tPA 10mg + DNase 5mg in 30mL saline, instill via chest tube, clamp 1h, then drain. BID Ã— 3 days. Indicated for loculated effusions</li>
                <li><strong>VATS (Video-Assisted Thoracoscopic Surgery):</strong> If chest tube + fibrinolytics fail, multiloculated, or organizing stage. Can break adhesions and debride</li>
                <li><strong>Thoracotomy with Decortication:</strong> Stage 3 (organized) empyema with trapped lung. Major surgery</li>
            </ul>
            
            <p><span class="label">Monitoring:</span></p>
            <ul>
                <li>Daily chest tubes output (should decrease over time)</li>
                <li>Serial imaging to assess drainage</li>
                <li>Clinical improvement (fever, WBC, inflammatory markers)</li>
                <li>Remove tube when output <150mL/day and lung re-expanded</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Tap it early:</strong> Any patient with pneumonia and pleural effusion should have thoracentesis. Don't wait for antibiotics to fail</li>
                <li><strong>pH is the key:</strong> pH <7.2 is the single best predictor of need for drainage. Must be measured on ABG machine (not chemistry lab)</li>
                <li><strong>Don't send fluid in heparinized tube:</strong> Affects pH measurement. Use plain syringe, send immediately on ice</li>
                <li><strong>If in doubt, drain:</strong> The consequences of not draining a complicated effusion (lung entrapment, sepsis) far outweigh risks of chest tube</li>
                <li><strong>tPA/DNase works:</strong> MIST2 trial showed reduced surgery and hospital stay. Standard of care for loculated effusions</li>
                <li><strong>Poor dentition = anaerobes:</strong> Cover with metronidazole or use amp-sulbactam/pip-tazo</li>
                <li><strong>Trapped lung:</strong> If lung doesn't re-expand after drainage, consider organizing empyema or endobronchial obstruction</li>
                <li><strong>Pulmonary/thoracic surgery consult early:</strong> Complex cases benefit from multidisciplinary approach</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- LUNG ABSCESS -->
<div id="lung-abscess" class="condition-page">
    <div class="page-header">
        <h2>174. LUNG ABSCESS</h2>
        <div class="subtitle">Cavitary Pulmonary Infection â€¢ Aspiration-related</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Typical Presentation:</span> Indolent course (weeks) with fever, productive cough (often foul-smelling/putrid sputum if anaerobic), weight loss, night sweats. May have pleuritic chest pain, hemoptysis</p>
            
            <p><span class="label">Primary vs Secondary:</span></p>
            <ul>
                <li><strong>Primary (80%):</strong> Aspiration in patient with risk factors. Often polymicrobial with anaerobes</li>
                <li><strong>Secondary (20%):</strong> Complication of existing condition - pneumonia, septic emboli (endocarditis, IVDU), malignancy, bronchial obstruction</li>
            </ul>
            
            <p><span class="label">Risk Factors for Aspiration:</span></p>
            <ul>
                <li>Altered consciousness (alcoholism, seizures, overdose, anesthesia, stroke)</li>
                <li>Dysphagia (neurologic disease, esophageal disorders)</li>
                <li>Poor dental hygiene (anaerobic oral flora)</li>
                <li>GERD, gastroparesis</li>
                <li>Periodontal disease</li>
            </ul>
            
            <p><span class="label">Location:</span> Aspiration abscesses favor dependent segments: posterior segment RUL, superior segments of lower lobes (if supine during aspiration)</p>
            
            <p><span class="label">Microbiology:</span></p>
            <ul>
                <li><strong>Anaerobes (most common in aspiration):</strong> Peptostreptococcus, Prevotella, Fusobacterium, Bacteroides. Often polymicrobial</li>
                <li><strong>Aerobes:</strong> S. aureus (especially MRSA if recent healthcare), Klebsiella (alcoholics, diabetics - "currant jelly" sputum), Streptococcus, Pseudomonas</li>
                <li><strong>Consider if not responding:</strong> TB, Nocardia, fungi (Aspergillus, endemic mycoses), Actinomyces</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>CXR:</strong> Cavitary lesion with air-fluid level. Thick, irregular walls suggest abscess (vs thin-walled = bulla, cyst)</li>
                <li><strong>CT Chest with Contrast:</strong> Gold standard. Defines size, location, complications. Can distinguish abscess from empyema with air-fluid level ("split pleura" sign = empyema)</li>
            </ul>
            
            <p><span class="label">Microbiologic Workup:</span></p>
            <ul>
                <li><strong>Sputum Culture:</strong> Often contaminated with oral flora. Anaerobic culture difficult</li>
                <li><strong>Blood Cultures:</strong> Low yield but should be obtained</li>
                <li><strong>Bronchoscopy with BAL:</strong> Consider if: not responding to therapy, atypical presentation, immunocompromised, concern for malignancy/obstruction. Protected brush specimen best for anaerobes</li>
                <li><strong>CT-guided Aspiration:</strong> Can confirm diagnosis and get culture, but risk of pneumothorax, bronchopleural fistula</li>
            </ul>
            
            <p><span class="label">Additional Testing:</span></p>
            <ul>
                <li>CBC, BMP, LFTs</li>
                <li>HIV test (opportunistic causes)</li>
                <li>Sputum AFB Ã— 3, fungal cultures if risk factors</li>
                <li>Consider Nocardia (immunocompromised), Actinomyces (poor dentition, sulfur granules)</li>
            </ul>
            
            <p><span class="label">Rule Out Malignancy:</span> Cavitary lung cancer can mimic abscess. Higher risk if: age >45, smoker, no fever, not responding to antibiotics. Bronchoscopy or follow-up imaging to resolution</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Antibiotic Therapy (Mainstay of Treatment):</span></p>
            <ul>
                <li><strong>First-line:</strong> Ampicillin-sulbactam 3g IV q6h OR Piperacillin-tazobactam 4.5g IV q6h (covers anaerobes + aerobes)</li>
                <li><strong>Alternative:</strong> Meropenem 1g IV q8h OR Ceftriaxone 2g IV daily + Metronidazole 500mg IV q8h</li>
                <li><strong>MRSA coverage (if risk factors):</strong> Add Vancomycin 15-20mg/kg IV q8-12h or Linezolid 600mg IV/PO q12h</li>
                <li><strong>Clindamycin monotherapy:</strong> Previously standard but increasing resistance. Not recommended as sole agent</li>
            </ul>
            
            <p><span class="label">Duration:</span></p>
            <ul>
                <li>Minimum 4-6 weeks, often longer</li>
                <li>Continue until: afebrile, clinically improved, AND CXR shows resolution or stable small residual cavity</li>
                <li>IV â†’ PO transition when clinically improved (afebrile 3-5 days, tolerating PO)</li>
                <li>Oral options: Amoxicillin-clavulanate 875mg BID, or Clindamycin 450mg QID + Fluoroquinolone</li>
            </ul>
            
            <p><span class="label">Indications for Drainage/Surgery:</span></p>
            <ul>
                <li>Abscess >6 cm (poor response to antibiotics alone)</li>
                <li>No clinical improvement after 7-10 days of appropriate antibiotics</li>
                <li>Massive hemoptysis</li>
                <li>Suspected malignancy</li>
                <li>Bronchopleural fistula</li>
            </ul>
            
            <p><span class="label">Drainage Options:</span></p>
            <ul>
                <li><strong>Postural drainage:</strong> Position affected side down to promote drainage via bronchus</li>
                <li><strong>CT-guided percutaneous drainage:</strong> For peripheral abscesses not communicating with bronchus</li>
                <li><strong>Bronchoscopic drainage:</strong> Can position catheter in abscess cavity</li>
                <li><strong>Surgical resection:</strong> Reserved for complications, failed medical/drainage therapy, or malignancy concern</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Most resolve with antibiotics alone:</strong> Unlike empyema, lung abscess usually doesn't require drainage if <6cm</li>
                <li><strong>Putrid sputum = anaerobes:</strong> Foul-smelling sputum is pathognomonic for anaerobic infection. Ensure anaerobic coverage</li>
                <li><strong>Think aspiration:</strong> Ask about recent intoxication, seizure, procedure under anesthesia, dysphagia</li>
                <li><strong>Location matters:</strong> Right-sided and dependent segments favor aspiration. Left upper lobe or bilateral should raise concern for other causes</li>
                <li><strong>Klebsiella in alcoholics:</strong> "Currant jelly" sputum, bulging fissure sign on CXR. Can be rapidly progressive</li>
                <li><strong>Response takes time:</strong> Expect gradual improvement over 1-2 weeks. Cavity may persist for weeks after clinical cure</li>
                <li><strong>Always consider TB:</strong> Especially if upper lobe, immigrant, homeless, HIV. Get AFB smears before starting standard antibiotics</li>
                <li><strong>Follow to resolution:</strong> Repeat imaging to ensure cavity resolves. Persistent cavity after treatment â†’ bronchoscopy to rule out malignancy</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- HERPES ZOSTER -->
<div id="herpes-zoster" class="condition-page">
    <div class="page-header">
        <h2>175. HERPES ZOSTER (SHINGLES)</h2>
        <div class="subtitle">VZV Reactivation â€¢ Postherpetic Neuralgia</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Presentation:</span></p>
            <ul>
                <li><strong>Prodrome (2-4 days before rash):</strong> Pain, burning, tingling, or itching in dermatomal distribution. May be mistaken for other conditions (MI, renal colic, appendicitis)</li>
                <li><strong>Rash:</strong> Unilateral, dermatomal distribution. Erythematous macules â†’ papules â†’ vesicles â†’ pustules â†’ crusting over 7-10 days</li>
                <li><strong>Pain:</strong> Often severe, described as burning, stabbing, or electric. May persist after rash heals (PHN)</li>
            </ul>
            
            <p><span class="label">Common Dermatomes:</span> Thoracic (>50%), trigeminal (especially V1 - ophthalmic), cervical, lumbar</p>
            
            <p><span class="label">Special Presentations:</span></p>
            <ul>
                <li><strong>Herpes Zoster Ophthalmicus (HZO):</strong> V1 involvement. Hutchinson sign (vesicles on nose tip) = nasociliary nerve involvement = HIGH risk of ocular disease. Requires URGENT ophthalmology consult</li>
                <li><strong>Ramsay Hunt Syndrome:</strong> VZV involving geniculate ganglion. Facial palsy + vesicles in ear canal/pinna + hearing loss/vertigo. Poor prognosis for facial nerve recovery</li>
                <li><strong>Disseminated Zoster:</strong> >20 lesions outside primary dermatome, or visceral involvement. Indicates immunocompromise. Can involve lungs, liver, brain</li>
                <li><strong>Zoster Sine Herpete:</strong> Dermatomal pain without rash. Difficult diagnosis, may need PCR of skin or CSF</li>
            </ul>
            
            <p><span class="label">Risk Factors:</span> Age >50 (incidence increases with age), immunocompromise (HIV, transplant, chemo, steroids), prior history (can recur)</p>
            
            <p><span class="label">Postherpetic Neuralgia (PHN):</span> Pain persisting >90 days after rash. Risk factors: age >50, severe acute pain, severe rash, prodromal pain. May last months to years</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Clinical Diagnosis:</span> Usually straightforward based on characteristic dermatomal vesicular rash. Testing rarely needed for typical presentation</p>
            
            <p><span class="label">Testing (Consider if Atypical):</span></p>
            <ul>
                <li><strong>VZV PCR:</strong> Most sensitive. Swab base of vesicle. Useful for atypical presentations, disseminated disease, or CNS involvement</li>
                <li><strong>Direct Fluorescent Antibody (DFA):</strong> Rapid, specific, but less sensitive than PCR</li>
                <li><strong>Tzanck Smear:</strong> Shows multinucleated giant cells. Quick but cannot distinguish VZV from HSV</li>
            </ul>
            
            <p><span class="label">If CNS Involvement Suspected:</span></p>
            <ul>
                <li>LP: CSF VZV PCR and VZV IgG</li>
                <li>MRI brain if encephalitis/myelitis suspected</li>
            </ul>
            
            <p><span class="label">HIV Testing:</span> Consider in young patients (<50) or disseminated/recurrent zoster</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Antiviral Therapy (Most Effective if Started Within 72h of Rash):</span></p>
            <ul>
                <li><strong>Valacyclovir:</strong> 1g PO TID Ã— 7 days (preferred - better bioavailability)</li>
                <li><strong>Famciclovir:</strong> 500mg PO TID Ã— 7 days</li>
                <li><strong>Acyclovir:</strong> 800mg PO 5Ã— daily Ã— 7 days (less convenient dosing)</li>
            </ul>
            
            <p><span class="label">Indications for IV Acyclovir (10mg/kg IV q8h):</span></p>
            <ul>
                <li>Disseminated zoster</li>
                <li>Immunocompromised patients with severe disease</li>
                <li>CNS involvement (encephalitis, myelitis)</li>
                <li>Herpes zoster ophthalmicus with severe disease</li>
                <li>Unable to tolerate oral medications</li>
            </ul>
            
            <p><span class="label">Who to Treat (Even if >72h):</span></p>
            <ul>
                <li>New vesicles still forming</li>
                <li>Immunocompromised</li>
                <li>HZO (any stage)</li>
                <li>Age >50</li>
            </ul>
            
            <p><span class="label">Pain Management:</span></p>
            <ul>
                <li><strong>Acute:</strong> Acetaminophen, NSAIDs, opioids for severe pain</li>
                <li><strong>Neuropathic Pain/PHN:</strong>
                    <ul>
                        <li>Gabapentin: Start 300mg daily, titrate to 300-600mg TID</li>
                        <li>Pregabalin: Start 75mg BID, titrate to 150-300mg BID</li>
                        <li>TCAs (amitriptyline, nortriptyline): 10-25mg at bedtime, titrate up</li>
                        <li>Lidocaine 5% patch: Apply to affected area</li>
                        <li>Capsaicin 8% patch: Applied by specialist</li>
                    </ul>
                </li>
            </ul>
            
            <p><span class="label">Corticosteroids:</span> Prednisone 60mg Ã— 7 days, taper over 21 days. May improve acute pain and quality of life. Does NOT prevent PHN. Contraindicated if immunocompromised</p>
            
            <p><span class="label">Herpes Zoster Ophthalmicus:</span></p>
            <ul>
                <li>URGENT ophthalmology referral</li>
                <li>Antiviral therapy (may need prolonged course)</li>
                <li>Topical steroids under ophthalmology guidance</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Hutchinson sign:</strong> Vesicles on nose tip predicts ocular involvement. Get ophthalmology involved emergently</li>
                <li><strong>Treat early:</strong> Antivirals most effective within 72h but still beneficial later if new lesions forming</li>
                <li><strong>Pain before rash:</strong> Prodromal pain can mimic MI, appendicitis, renal colic. Keep zoster in differential for unexplained dermatomal pain</li>
                <li><strong>Immunocompromised patients:</strong> Higher risk of dissemination, complications. Lower threshold for IV therapy and hospitalization</li>
                <li><strong>Contagious:</strong> Can transmit VZV to non-immune contacts (causes primary varicella, not zoster). Cover lesions until crusted</li>
                <li><strong>HCW with zoster:</strong> Exclude from work until lesions crusted. If able to cover lesions completely, may work in non-high-risk areas</li>
                <li><strong>PHN is devastating:</strong> Can cause severe chronic pain. Early aggressive treatment of acute zoster may reduce risk</li>
                <li><strong>Shingrix vaccine:</strong> Recombinant vaccine, 2 doses. >90% effective. Recommended for all adults â‰¥50, even prior zoster or Zostavax</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PROSTATITIS -->
<div id="prostatitis" class="condition-page">
    <div class="page-header">
        <h2>176. ACUTE BACTERIAL PROSTATITIS</h2>
        <div class="subtitle">Prostatic Infection â€¢ Urinary Retention</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Presentation:</span> Acute onset fever, chills, dysuria, frequency, urgency, pelvic/perineal pain, low back pain. May have difficulty voiding or urinary retention</p>
            
            <p><span class="label">Physical Exam:</span></p>
            <ul>
                <li>Prostate: Exquisitely tender, boggy, warm on digital rectal exam</li>
                <li><strong>DO NOT massage prostate vigorously</strong> - risk of bacteremia</li>
                <li>May have suprapubic tenderness</li>
            </ul>
            
            <p><span class="label">NIH Classification:</span></p>
            <ul>
                <li><strong>Category I:</strong> Acute bacterial prostatitis (this section)</li>
                <li><strong>Category II:</strong> Chronic bacterial prostatitis (recurrent UTIs, prostatic focus)</li>
                <li><strong>Category III:</strong> Chronic pelvic pain syndrome (CPPS) - most common, no bacteria</li>
                <li><strong>Category IV:</strong> Asymptomatic inflammatory prostatitis</li>
            </ul>
            
            <p><span class="label">Common Organisms:</span></p>
            <ul>
                <li><strong>Gram-negatives (80%):</strong> E. coli (most common), Klebsiella, Proteus, Pseudomonas</li>
                <li><strong>Gram-positives:</strong> Enterococcus, S. aureus</li>
                <li><strong>STI-related:</strong> N. gonorrhoeae, C. trachomatis (especially younger patients)</li>
            </ul>
            
            <p><span class="label">Risk Factors:</span> UTI, urethral instrumentation (catheter, cystoscopy), prostatic biopsy, unprotected anal intercourse, BPH with urinary retention</p>
            
            <p><span class="label">Complications:</span> Prostatic abscess (especially diabetics, immunocompromised), chronic prostatitis, epididymitis, sepsis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Urinalysis:</strong> Pyuria, bacteriuria</li>
                <li><strong>Urine Culture:</strong> Essential - guides therapy</li>
                <li><strong>Blood Cultures:</strong> If febrile or septic</li>
                <li><strong>CBC:</strong> Leukocytosis common</li>
                <li><strong>PSA:</strong> Will be elevated (don't use for cancer screening during acute infection)</li>
            </ul>
            
            <p><span class="label">STI Testing:</span> GC/CT NAAT in sexually active patients, especially if <35 or STI risk factors</p>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li>Not routinely needed for uncomplicated acute prostatitis</li>
                <li><strong>CT or Transrectal US:</strong> If abscess suspected (no improvement after 48-72h, fluctuant prostate on exam, immunocompromised)</li>
                <li><strong>Post-void Residual:</strong> If urinary retention suspected</li>
            </ul>
            
            <p><span class="label">Do NOT Perform:</span> Vigorous prostatic massage - risk of bacteremia</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Outpatient (Mild-Moderate, Non-toxic):</span></p>
            <ul>
                <li><strong>Fluoroquinolone (preferred):</strong> Ciprofloxacin 500mg BID OR Levofloxacin 500-750mg daily Ã— 4-6 weeks</li>
                <li><strong>Alternative:</strong> TMP-SMX DS BID Ã— 4-6 weeks (if susceptible)</li>
                <li><strong>Long duration needed:</strong> Poor penetration into inflamed prostate. 4-6 weeks minimum to prevent chronic prostatitis</li>
            </ul>
            
            <p><span class="label">Inpatient (Severe, Septic, Urinary Retention):</span></p>
            <ul>
                <li><strong>Empiric IV:</strong> Ceftriaxone 2g daily OR Ciprofloxacin 400mg IV q12h PLUS Ampicillin 2g IV q6h (enterococcal coverage if risk factors)</li>
                <li><strong>If ESBL/MDR risk:</strong> Ertapenem or Meropenem</li>
                <li><strong>Transition to oral:</strong> After clinical improvement, complete 4-6 weeks total</li>
            </ul>
            
            <p><span class="label">If STI Suspected:</span></p>
            <ul>
                <li>Ceftriaxone 500mg IM Ã— 1 PLUS Doxycycline 100mg BID Ã— 10-14 days</li>
            </ul>
            
            <p><span class="label">Urinary Retention:</span></p>
            <ul>
                <li>Suprapubic catheter preferred (urethral catheter may worsen prostatitis)</li>
                <li>If urethral catheter used, remove as soon as possible</li>
            </ul>
            
            <p><span class="label">Prostatic Abscess:</span></p>
            <ul>
                <li>IV antibiotics</li>
                <li>Transrectal or transperineal drainage (usually by urology)</li>
            </ul>
            
            <p><span class="label">Supportive Care:</span> Hydration, NSAIDs/acetaminophen, stool softeners (defecation can be painful), alpha-blockers if retention</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Don't massage:</strong> Gentle palpation only on DRE. Vigorous massage can cause bacteremia</li>
                <li><strong>Long treatment course:</strong> 4-6 weeks is essential. Undertreated acute prostatitis becomes chronic prostatitis</li>
                <li><strong>Fluoroquinolones penetrate:</strong> FQs have excellent prostatic tissue penetration, making them first-line despite stewardship concerns</li>
                <li><strong>Elevated PSA:</strong> Will be elevated during infection. Don't use for cancer screening. Recheck 4-6 weeks after treatment</li>
                <li><strong>Consider abscess if not improving:</strong> Especially in diabetics. CT or transrectal US can diagnose</li>
                <li><strong>Sexual partners:</strong> Treat if GC/CT positive</li>
                <li><strong>Retention is common:</strong> Inflamed prostate causes obstruction. May need catheter</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- BRAIN ABSCESS -->
<div id="brain-abscess" class="condition-page">
    <div class="page-header">
        <h2>177. BRAIN ABSCESS</h2>
        <div class="subtitle">Intracranial Suppurative Infection</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Triad (present in <50%):</span> Headache + Fever + Focal neurologic deficit</p>
            
            <p><span class="label">Common Symptoms:</span></p>
            <ul>
                <li><strong>Headache:</strong> Most common (70%), often severe, may be localized or diffuse</li>
                <li><strong>Focal Deficits:</strong> Depend on location - hemiparesis, aphasia, visual field cuts (40-50%)</li>
                <li><strong>Fever:</strong> Present in only 50% (may be absent especially if on antibiotics)</li>
                <li><strong>Altered Mental Status:</strong> Confusion, lethargy, coma</li>
                <li><strong>Seizures:</strong> 25-35%, can be presenting symptom</li>
                <li><strong>Nausea/Vomiting:</strong> From increased ICP</li>
                <li><strong>Papilledema:</strong> Sign of elevated ICP</li>
            </ul>
            
            <p><span class="label">Sources/Routes of Infection:</span></p>
            <ul>
                <li><strong>Contiguous Spread (40-50%):</strong> Sinusitis, otitis media, mastoiditis, dental infection. Frontal lobe (sinusitis), temporal lobe/cerebellum (otitis)</li>
                <li><strong>Hematogenous (25%):</strong> Endocarditis, lung abscess, skin/soft tissue infection, congenital heart disease with R-to-L shunt. Often multiple abscesses</li>
                <li><strong>Post-traumatic/Neurosurgical:</strong> Penetrating trauma, craniotomy</li>
                <li><strong>Cryptogenic (25%):</strong> No source identified</li>
            </ul>
            
            <p><span class="label">Microbiology:</span></p>
            <ul>
                <li><strong>Streptococci:</strong> Viridans strep most common overall, S. anginosus group (milleri)</li>
                <li><strong>Staphylococci:</strong> Especially post-trauma/neurosurgery, MRSA if healthcare-associated</li>
                <li><strong>Anaerobes:</strong> Bacteroides, Fusobacterium, Peptostreptococcus (dental/sinus source)</li>
                <li><strong>Gram-negatives:</strong> Enterobacteriaceae, Pseudomonas (chronic otitis)</li>
                <li><strong>Immunocompromised:</strong> Nocardia, Toxoplasma, Aspergillus, Mucor, Listeria</li>
                <li><strong>Often polymicrobial</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Neuroimaging (URGENT):</span></p>
            <ul>
                <li><strong>MRI with Contrast:</strong> Gold standard. Ring-enhancing lesion with surrounding edema. Restricted diffusion on DWI (high signal) is highly specific for abscess vs tumor</li>
                <li><strong>CT with Contrast:</strong> Ring-enhancing hypodense lesion if MRI unavailable. Less sensitive for early cerebritis</li>
            </ul>
            
            <p><span class="label">Stages on Imaging:</span></p>
            <ul>
                <li><strong>Early Cerebritis (days 1-3):</strong> Ill-defined hypodense area, minimal enhancement</li>
                <li><strong>Late Cerebritis (days 4-9):</strong> Ring enhancement developing</li>
                <li><strong>Early Capsule (days 10-14):</strong> Well-defined ring enhancement</li>
                <li><strong>Late Capsule (>14 days):</strong> Thick capsule, decreased edema</li>
            </ul>
            
            <p><span class="label">Lumbar Puncture:</span></p>
            <ul>
                <li><strong>CONTRAINDICATED if:</strong> Mass effect, elevated ICP, posterior fossa abscess. Risk of herniation</li>
                <li>Low yield (positive culture in only 10-20%)</li>
                <li>CSF often shows elevated protein, mild pleocytosis, normal glucose</li>
            </ul>
            
            <p><span class="label">Identify Source:</span></p>
            <ul>
                <li>CT sinuses/mastoids (if sinus/otogenic suspected)</li>
                <li>Echocardiogram (TTE â†’ TEE if negative with high suspicion)</li>
                <li>CT chest (lung abscess, septic emboli)</li>
                <li>Dental evaluation</li>
                <li>Blood cultures (positive in 10-40%)</li>
            </ul>
            
            <p><span class="label">Aspiration/Biopsy:</span></p>
            <ul>
                <li>Stereotactic aspiration for diagnosis AND decompression</li>
                <li>Send for Gram stain, aerobic + anaerobic culture, fungal, AFB, Nocardia</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Empiric Antibiotic Therapy:</span></p>
            <ul>
                <li><strong>Standard:</strong> Ceftriaxone 2g IV q12h + Metronidazole 500mg IV q8h + Vancomycin 15-20mg/kg IV q8-12h</li>
                <li><strong>Covers:</strong> Streptococci, staphylococci (including MRSA), gram-negatives, anaerobes</li>
            </ul>
            
            <p><span class="label">Special Situations:</span></p>
            <ul>
                <li><strong>Post-neurosurgery/trauma:</strong> Vancomycin + Cefepime or Meropenem (Pseudomonas coverage)</li>
                <li><strong>HIV/Immunocompromised:</strong> Add coverage for Toxoplasma (Pyrimethamine + Sulfadiazine), consider Nocardia, fungal</li>
                <li><strong>Known source:</strong> Tailor to likely organisms (e.g., dental â†’ emphasize anaerobic coverage)</li>
            </ul>
            
            <p><span class="label">Duration:</span></p>
            <ul>
                <li>6-8 weeks IV therapy (minimum)</li>
                <li>May need longer if: poor drainage, immunocompromised, osteomyelitis</li>
                <li>Follow with serial imaging (MRI every 2-4 weeks initially)</li>
            </ul>
            
            <p><span class="label">Surgical Management:</span></p>
            <ul>
                <li><strong>Stereotactic Aspiration:</strong> Preferred for most abscesses. Diagnostic + therapeutic. May need repeat aspiration</li>
                <li><strong>Craniotomy/Excision:</strong> Consider if: multiloculated, posterior fossa (risk of hydrocephalus), failed aspiration, fungal abscess, traumatic abscess with foreign body</li>
            </ul>
            
            <p><span class="label">Indications for Surgery:</span></p>
            <ul>
                <li>Abscess >2.5 cm (poor response to antibiotics alone)</li>
                <li>Significant mass effect</li>
                <li>Neurologic deterioration</li>
                <li>No improvement after 1 week of antibiotics</li>
                <li>Intraventricular rupture</li>
            </ul>
            
            <p><span class="label">Adjunctive Therapy:</span></p>
            <ul>
                <li><strong>Corticosteroids:</strong> Consider if significant edema/mass effect. May slow capsule formation. Use short course</li>
                <li><strong>Antiepileptic Drugs:</strong> Prophylaxis controversial. Treat if seizures occur. Consider prophylaxis for frontal lobe abscess</li>
                <li><strong>ICP Management:</strong> Elevate head of bed, mannitol/hypertonic saline if elevated ICP</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>No LP with brain abscess:</strong> Risk of herniation. Imaging first, always</li>
                <li><strong>Fever is often absent:</strong> Don't rely on fever to make diagnosis. Headache + focal deficit should prompt imaging</li>
                <li><strong>DWI is key:</strong> Restricted diffusion distinguishes abscess (bright on DWI) from tumor (not restricted)</li>
                <li><strong>Find the source:</strong> Treat source (dental extraction, sinus surgery, etc.) or abscess will recur</li>
                <li><strong>Metronidazole is essential:</strong> Excellent CNS penetration and anaerobic coverage. Always include in regimen</li>
                <li><strong>Serial imaging:</strong> Abscess may enlarge initially despite appropriate treatment. Follow with MRI every 2-4 weeks</li>
                <li><strong>Long treatment:</strong> 6-8 weeks minimum. Stopping early leads to relapse</li>
                <li><strong>Multidisciplinary:</strong> Neurosurgery, infectious disease, and source specialists all involved</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PROSTHETIC JOINT INFECTION -->
<div id="prosthetic-joint-infection" class="condition-page">
    <div class="page-header">
        <h2>178. PROSTHETIC JOINT INFECTION</h2>
        <div class="subtitle">Periprosthetic Infection â€¢ Arthroplasty Infection</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classification by Timing:</span></p>
            <ul>
                <li><strong>Early (<3 months post-op):</strong> Typically virulent organisms (S. aureus, GNRs). Wound dehiscence, drainage, acute pain, fever. Often surgical site contamination</li>
                <li><strong>Delayed (3-12 months):</strong> Less virulent organisms (CoNS, Cutibacterium acnes). Insidious onset, chronic pain, implant loosening</li>
                <li><strong>Late (>12 months):</strong> Usually hematogenous seeding. Acute onset with pain, swelling, fever. Prior well-functioning joint</li>
            </ul>
            
            <p><span class="label">Clinical Features:</span></p>
            <ul>
                <li>Joint pain (most common) - may be only symptom in chronic infection</li>
                <li>Joint swelling, effusion</li>
                <li>Wound drainage, sinus tract (if present = definite infection)</li>
                <li>Fever (often absent in chronic infection)</li>
                <li>Implant loosening on imaging</li>
            </ul>
            
            <p><span class="label">Common Organisms:</span></p>
            <ul>
                <li><strong>Staphylococci (60%):</strong> CoNS (most common overall), S. aureus (virulent, worse outcomes)</li>
                <li><strong>Streptococci:</strong> Often hematogenous</li>
                <li><strong>Gram-negatives (10-20%):</strong> E. coli, Pseudomonas</li>
                <li><strong>Cutibacterium acnes:</strong> Especially shoulder arthroplasty. Slow-growing, needs prolonged culture incubation</li>
                <li><strong>Culture-negative (10-15%):</strong> Prior antibiotics, fastidious organisms</li>
            </ul>
            
            <p><span class="label">Risk Factors:</span> Prior revision surgery, rheumatoid arthritis, diabetes, immunosuppression, obesity, wound healing problems, prior PJI, bacteremia, dental procedures</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Serum Markers:</span></p>
            <ul>
                <li><strong>ESR and CRP:</strong> Both elevated suggests infection. CRP more specific. Normal values essentially rule out infection</li>
                <li><strong>D-dimer:</strong> Elevated in PJI (newer marker)</li>
            </ul>
            
            <p><span class="label">Joint Aspiration (CRITICAL - if any concern for PJI):</span></p>
            <ul>
                <li><strong>Hold antibiotics:</strong> At least 2 weeks before aspiration if patient stable</li>
                <li><strong>Synovial WBC:</strong> >3,000/Î¼L (chronic) or >10,000/Î¼L (acute) suggests infection</li>
                <li><strong>PMN %:</strong> >80% (acute) or >70% (chronic)</li>
                <li><strong>Culture:</strong> Aerobic + anaerobic, hold 14 days (Cutibacterium needs time)</li>
                <li><strong>Alpha-defensin:</strong> Highly sensitive and specific synovial marker for PJI</li>
                <li><strong>Leukocyte esterase:</strong> Urine dipstick on synovial fluid (++ = likely infection)</li>
            </ul>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>X-ray:</strong> Loosening (lucency around implant), periosteal reaction. Normal X-ray doesn't exclude infection</li>
                <li><strong>CT:</strong> Better for loosening, bone destruction</li>
                <li><strong>MRI:</strong> Limited by metal artifact but can show soft tissue collections</li>
                <li><strong>Nuclear Medicine:</strong> WBC-labeled scan if diagnosis uncertain</li>
            </ul>
            
            <p><span class="label">Intraoperative:</span></p>
            <ul>
                <li>â‰¥3 tissue cultures from different sites (most important for diagnosis)</li>
                <li>Histopathology (>5 PMNs per high-power field = infection)</li>
                <li>Sonication of explanted prosthesis improves culture yield</li>
            </ul>
            
            <p><span class="label">MSIS Criteria for PJI (2 major OR 4 minor):</span></p>
            <ul>
                <li><strong>Major:</strong> Sinus tract, 2 positive cultures with same organism</li>
                <li><strong>Minor:</strong> Elevated CRP/ESR, elevated synovial WBC, elevated PMN%, positive histology, single positive culture</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Treatment Strategy Depends on:</span></p>
            <ul>
                <li>Duration of symptoms</li>
                <li>Timing since implantation</li>
                <li>Implant stability</li>
                <li>Soft tissue condition</li>
                <li>Organism virulence</li>
                <li>Host factors</li>
            </ul>
            
            <p><span class="label">DAIR (Debridement, Antibiotics, Implant Retention):</span></p>
            <ul>
                <li><strong>Indications:</strong> Early infection (<4 weeks post-op) OR acute hematogenous (<3 weeks symptoms) AND stable implant AND good soft tissue AND susceptible organism</li>
                <li><strong>Procedure:</strong> Surgical debridement, exchange of modular components (poly liner, femoral head), irrigation, retain prosthesis</li>
                <li><strong>Success rate:</strong> 50-70% (higher for strep, lower for staph)</li>
            </ul>
            
            <p><span class="label">Two-Stage Exchange (Gold Standard):</span></p>
            <ul>
                <li><strong>Indications:</strong> Chronic infection, failed DAIR, difficult organism (MRSA, resistant GNR)</li>
                <li><strong>Stage 1:</strong> Remove all components, debride, place antibiotic-loaded cement spacer</li>
                <li><strong>Interim:</strong> 6 weeks IV antibiotics, then 2-8 week antibiotic holiday, confirm infection cleared</li>
                <li><strong>Stage 2:</strong> Reimplant new prosthesis</li>
                <li><strong>Success rate:</strong> >90%</li>
            </ul>
            
            <p><span class="label">One-Stage Exchange:</span> Remove and reimplant same surgery. Selected cases: healthy host, known susceptible organism, good bone stock. Success rate 80-90%</p>
            
            <p><span class="label">Antibiotic Therapy:</span></p>
            <ul>
                <li><strong>IV Phase:</strong> 4-6 weeks, organism-directed</li>
                <li><strong>Oral Phase:</strong> Often prolonged (3-6 months for DAIR)</li>
                <li><strong>Rifampin:</strong> Essential for staphylococcal PJI with retained implant. Add to backbone antibiotic. Prevents biofilm formation</li>
                <li><strong>Staphylococcal regimen (DAIR):</strong> IV Vancomycin or Daptomycin Ã— 2-6 weeks â†’ then oral Rifampin 300mg BID + companion drug (FQ, TMP-SMX, doxycycline) Ã— 3-6 months</li>
            </ul>
            
            <p><span class="label">Suppressive Therapy:</span> Lifelong oral antibiotics if: cannot undergo surgery, retained infected prosthesis. TMP-SMX or doxycycline commonly used</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Pain is the key symptom:</strong> Persistent or new pain in prosthetic joint should prompt PJI workup</li>
                <li><strong>Hold antibiotics before aspiration:</strong> Culture yield drops dramatically if patient recently on antibiotics</li>
                <li><strong>Rifampin is magic for staph:</strong> Penetrates biofilm. Never use as monotherapy (rapid resistance). Always add to backbone agent</li>
                <li><strong>CoNS is not a contaminant:</strong> In prosthetic joint, CoNS is a true pathogen. Treat it</li>
                <li><strong>Shoulders = think Cutibacterium:</strong> C. acnes common in shoulder PJI. Request extended culture incubation (14 days)</li>
                <li><strong>Sinus tract = definite infection:</strong> No aspiration needed. Plan for surgery</li>
                <li><strong>ID + Orthopedics partnership:</strong> Complex decisions require multidisciplinary approach</li>
                <li><strong>Two-stage is more reliable:</strong> Higher cure rate than DAIR. Choose based on patient factors and organism</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CIED/PACEMAKER INFECTION -->
<div id="cied-infection" class="condition-page">
    <div class="page-header">
        <h2>179. CIED INFECTION</h2>
        <div class="subtitle">Pacemaker â€¢ ICD â€¢ CRT Device Infection</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Types of CIED Infection:</span></p>
            <ul>
                <li><strong>Pocket Infection:</strong> Infection limited to generator pocket. Erythema, warmth, swelling, drainage, dehiscence over device. May or may not have fever</li>
                <li><strong>Lead Infection/Endocarditis:</strong> Bacteremia with lead vegetations. Fever, positive blood cultures, may have septic emboli (pulmonary if right-sided). Often no pocket changes</li>
                <li><strong>Combined:</strong> Pocket infection with secondary bacteremia and lead involvement</li>
            </ul>
            
            <p><span class="label">Clinical Features:</span></p>
            <ul>
                <li>Fever, chills (especially with lead infection)</li>
                <li>Pocket: erythema, swelling, pain, warmth, drainage</li>
                <li>Erosion: device or lead visible through skin</li>
                <li>Septic pulmonary emboli: dyspnea, cough, hypoxia (if lead vegetation)</li>
                <li>May have subtle presentation - chronically ill with low-grade fever</li>
            </ul>
            
            <p><span class="label">Timing:</span></p>
            <ul>
                <li><strong>Early (<1 year):</strong> Usually perioperative contamination. S. aureus common</li>
                <li><strong>Late (>1 year):</strong> Often hematogenous seeding. CoNS, other organisms</li>
            </ul>
            
            <p><span class="label">Common Organisms:</span></p>
            <ul>
                <li><strong>Staphylococci (60-80%):</strong> CoNS most common. S. aureus (more virulent, higher mortality)</li>
                <li><strong>Gram-negatives (10%):</strong> Especially healthcare-associated</li>
                <li><strong>Cutibacterium acnes:</strong> May cause indolent infection</li>
                <li><strong>Fungi:</strong> Rare, usually immunocompromised</li>
            </ul>
            
            <p><span class="label">Risk Factors:</span> Diabetes, renal failure, anticoagulation, repeat procedures, multiple leads, temporary pacing wire, longer procedure time, hematoma</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Blood Cultures:</span></p>
            <ul>
                <li>Minimum 2 sets from peripheral sites</li>
                <li>Multiple sets over time if subacute presentation</li>
                <li>Hold antibiotics before cultures if patient stable</li>
            </ul>
            
            <p><span class="label">Echocardiography:</span></p>
            <ul>
                <li><strong>TEE:</strong> Required for all suspected CIED infections. Much more sensitive than TTE for lead vegetations</li>
                <li><strong>Findings:</strong> Vegetations on leads, tricuspid valve involvement, pulmonary emboli</li>
            </ul>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>CT Chest:</strong> Pulmonary septic emboli (nodules, cavities)</li>
                <li><strong>PET-CT:</strong> Increasingly used. FDG uptake in pocket or along leads suggests infection. Useful when diagnosis uncertain</li>
            </ul>
            
            <p><span class="label">Pocket Assessment:</span></p>
            <ul>
                <li>Inspect for erythema, swelling, erosion, dehiscence</li>
                <li>If drainage present: Gram stain and culture</li>
                <li>Do NOT needle aspirate pocket (can introduce infection, damage leads)</li>
            </ul>
            
            <p><span class="label">Labs:</span> CBC, BMP, inflammatory markers (CRP, ESR)</p>
            
            <p><span class="label">Lead Tip Culture:</span> Most important culture. Send after extraction</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p class="highlight" style="background-color: #fee2e2; padding: 10px; border-radius: 5px;"><strong>âš ï¸ COMPLETE DEVICE AND LEAD EXTRACTION IS REQUIRED FOR CURE</strong><br>Antibiotics alone without extraction have very high failure rate</p>
            
            <p><span class="label">Device Extraction:</span></p>
            <ul>
                <li><strong>Indicated for:</strong> All definite CIED infections (pocket or lead)</li>
                <li><strong>Percutaneous extraction:</strong> Preferred. Done by experienced electrophysiologist</li>
                <li><strong>Surgical extraction:</strong> If percutaneous fails, large vegetations (>20mm relative contraindication to percutaneous), tricuspid valve destruction</li>
            </ul>
            
            <p><span class="label">Empiric Antibiotic Therapy:</span></p>
            <ul>
                <li><strong>Vancomycin:</strong> 15-20mg/kg IV q8-12h (covers MRSA, CoNS)</li>
                <li><strong>+ Cefepime or Pip-tazo:</strong> If gram-negative suspected or healthcare-associated</li>
                <li><strong>Tailor to cultures</strong></li>
            </ul>
            
            <p><span class="label">Duration of Antibiotics:</span></p>
            <ul>
                <li><strong>Pocket infection only, no bacteremia:</strong> 10-14 days after extraction</li>
                <li><strong>Bacteremia, no vegetation:</strong> At least 2 weeks after extraction</li>
                <li><strong>Lead vegetation:</strong> 4 weeks after extraction</li>
                <li><strong>Complicated (osteomyelitis, septic emboli, paravalvular abscess):</strong> 4-6 weeks or longer</li>
            </ul>
            
            <p><span class="label">Reimplantation:</span></p>
            <ul>
                <li><strong>Timing:</strong> Wait until blood cultures negative for at least 72 hours</li>
                <li><strong>S. aureus:</strong> Wait at least 14 days after first negative culture</li>
                <li><strong>Site:</strong> Contralateral side preferred</li>
                <li><strong>Reassess need:</strong> Some patients may no longer need device (recovered EF, transient bradycardia)</li>
            </ul>
            
            <p><span class="label">If Extraction Not Possible (Unacceptable Surgical Risk):</span></p>
            <ul>
                <li>Chronic suppressive antibiotics (oral, organism-directed)</li>
                <li>High failure rate, poor long-term outcomes</li>
                <li>Palliative approach</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Extraction is essential:</strong> Cannot cure CIED infection without removing all hardware. Antibiotics alone fail in >50%</li>
                <li><strong>TEE for everyone:</strong> TTE misses lead vegetations. All suspected CIED infections need TEE</li>
                <li><strong>Erosion = infection:</strong> Even if no purulence, device eroding through skin is infected. Extract</li>
                <li><strong>S. aureus bacteremia + CIED:</strong> Even without obvious pocket infection or vegetation, assume CIED infection. TEE and strongly consider extraction</li>
                <li><strong>PET-CT is helpful:</strong> When diagnosis is uncertain, FDG-PET can identify occult infection</li>
                <li><strong>Don't aspirate the pocket:</strong> Can introduce infection or damage leads. If drainage present, swab it</li>
                <li><strong>Extraction is safe in experienced hands:</strong> Major complication rate <2% at high-volume centers</li>
                <li><strong>ID + EP partnership:</strong> Complex management requires collaboration</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- TRANSFUSION REACTIONS -->
<div id="transfusion-reactions" class="condition-page">
    <div class="page-header">
        <h2>180. TRANSFUSION REACTIONS</h2>
        <div class="subtitle">TRALI â€¢ TACO â€¢ Hemolytic â€¢ Febrile</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Acute Hemolytic Transfusion Reaction (AHTR):</span></p>
            <ul>
                <li><strong>Cause:</strong> ABO incompatibility (usually clerical error)</li>
                <li><strong>Timing:</strong> Minutes to hours, often within first 15 mL</li>
                <li><strong>Symptoms:</strong> Fever, chills, rigors, flank/back pain, chest pain, hypotension, hemoglobinuria (dark urine), anxiety, "sense of doom"</li>
                <li><strong>Labs:</strong> â†“Hgb, â†‘LDH, â†‘bilirubin, â†“haptoglobin, positive DAT, hemoglobinuria</li>
                <li><strong>Complications:</strong> DIC, acute kidney injury, death</li>
            </ul>
            
            <p><span class="label">Febrile Non-Hemolytic Transfusion Reaction (FNHTR):</span></p>
            <ul>
                <li><strong>Cause:</strong> Cytokines in product, recipient antibodies to donor WBCs</li>
                <li><strong>Timing:</strong> During or within 4 hours</li>
                <li><strong>Symptoms:</strong> Fever (â‰¥1Â°C rise), chills, rigors. NO hemolysis, NO hypotension</li>
                <li><strong>Most common reaction overall</strong></li>
            </ul>
            
            <p><span class="label">TRALI (Transfusion-Related Acute Lung Injury):</span></p>
            <ul>
                <li><strong>Cause:</strong> Donor antibodies to recipient WBCs â†’ neutrophil activation â†’ lung injury</li>
                <li><strong>Timing:</strong> Within 6 hours of transfusion (usually 1-2 hours)</li>
                <li><strong>Symptoms:</strong> Acute respiratory distress, hypoxia, bilateral pulmonary infiltrates, fever. NO volume overload/cardiac failure</li>
                <li><strong>Leading cause of transfusion-related death</strong></li>
            </ul>
            
            <p><span class="label">TACO (Transfusion-Associated Circulatory Overload):</span></p>
            <ul>
                <li><strong>Cause:</strong> Volume overload, especially rapid transfusion or underlying cardiac/renal disease</li>
                <li><strong>Timing:</strong> During or within 6-12 hours</li>
                <li><strong>Symptoms:</strong> Dyspnea, orthopnea, JVD, peripheral edema, hypertension, elevated BNP</li>
                <li><strong>Risk factors:</strong> CHF, renal failure, elderly, multiple units, rapid infusion</li>
            </ul>
            
            <p><span class="label">Allergic Reactions:</span></p>
            <ul>
                <li><strong>Minor:</strong> Urticaria, pruritus, flushing (1-3% of transfusions)</li>
                <li><strong>Anaphylaxis:</strong> Rare. Hypotension, bronchospasm, angioedema. Often IgA deficiency</li>
            </ul>
            
            <p><span class="label">Delayed Hemolytic Transfusion Reaction:</span></p>
            <ul>
                <li><strong>Timing:</strong> 3-14 days post-transfusion</li>
                <li><strong>Cause:</strong> Anamnestic antibody response to minor RBC antigens</li>
                <li><strong>Symptoms:</strong> Falling Hgb, mild jaundice, positive DAT. Often asymptomatic</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Immediate Steps (Any Reaction):</span></p>
            <ul>
                <li><strong>STOP the transfusion</strong></li>
                <li>Maintain IV access with saline</li>
                <li>Verify patient ID and product label (clerical check)</li>
                <li>Notify blood bank</li>
                <li>Return blood product and tubing to blood bank</li>
            </ul>
            
            <p><span class="label">Labs for Suspected Hemolytic Reaction:</span></p>
            <ul>
                <li>Repeat type and screen, crossmatch</li>
                <li>Direct antiglobulin test (DAT/Coombs)</li>
                <li>Plasma free hemoglobin</li>
                <li>LDH, bilirubin, haptoglobin</li>
                <li>Urinalysis (hemoglobinuria)</li>
                <li>CBC, coagulation studies (DIC screen)</li>
            </ul>
            
            <p><span class="label">TRALI vs TACO - Key Distinctions:</span></p>
            <table>
                <thead><tr><th>Feature</th><th>TRALI</th><th>TACO</th></tr></thead>
                <tbody>
                    <tr><td>BNP</td><td>Normal or low</td><td>Elevated (>1.5Ã— baseline)</td></tr>
                    <tr><td>Blood pressure</td><td>Hypotension</td><td>Hypertension</td></tr>
                    <tr><td>JVD</td><td>Absent</td><td>Present</td></tr>
                    <tr><td>Response to diuretics</td><td>No improvement</td><td>Rapid improvement</td></tr>
                    <tr><td>Fever</td><td>Common</td><td>Uncommon</td></tr>
                    <tr><td>Echo</td><td>Normal EF</td><td>May show elevated filling pressures</td></tr>
                </tbody>
            </table>
            
            <p><span class="label">Imaging:</span> CXR for any respiratory symptoms (infiltrates in TRALI, pulmonary edema in TACO)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Acute Hemolytic Transfusion Reaction:</span></p>
            <ul>
                <li>STOP transfusion immediately</li>
                <li>Aggressive IV fluids to maintain urine output >1 mL/kg/hr (prevents renal failure)</li>
                <li>Vasopressors if hypotensive despite fluids</li>
                <li>Monitor for DIC, treat supportively</li>
                <li>May need dialysis if AKI develops</li>
            </ul>
            
            <p><span class="label">FNHTR:</span></p>
            <ul>
                <li>Stop transfusion, evaluate for hemolysis</li>
                <li>Acetaminophen for fever</li>
                <li>If hemolysis ruled out, may carefully restart transfusion</li>
                <li>Future: Use leukoreduced products, premedicate</li>
            </ul>
            
            <p><span class="label">TRALI:</span></p>
            <ul>
                <li>STOP transfusion</li>
                <li>Supportive care: O2, mechanical ventilation if needed (lung-protective)</li>
                <li>NO diuretics (not volume overloaded)</li>
                <li>Usually resolves within 48-96 hours with supportive care</li>
                <li>Report to blood bank (donor may need to be deferred)</li>
            </ul>
            
            <p><span class="label">TACO:</span></p>
            <ul>
                <li>STOP transfusion</li>
                <li>Sit patient upright</li>
                <li>Supplemental O2</li>
                <li>IV furosemide 20-40mg (diuresis is cornerstone)</li>
                <li>Future: Slower transfusion rate, diuretics between units, single-unit transfusions</li>
            </ul>
            
            <p><span class="label">Allergic Reactions:</span></p>
            <ul>
                <li><strong>Urticaria:</strong> Stop transfusion, diphenhydramine 25-50mg IV. If symptoms resolve, may restart slowly</li>
                <li><strong>Anaphylaxis:</strong> Epinephrine 0.3-0.5mg IM, aggressive resuscitation. Future transfusions: washed products, IgA-deficient donor if IgA deficiency</li>
            </ul>
            
            <p><span class="label">Prevention:</span></p>
            <ul>
                <li>Strict patient ID verification (prevents AHTR)</li>
                <li>Leukoreduced products (prevents FNHTR)</li>
                <li>Male-only plasma donors (reduces TRALI)</li>
                <li>Slow transfusion rate in at-risk patients (prevents TACO)</li>
                <li>Restrictive transfusion thresholds</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Stop the transfusion first:</strong> Any suspected reaction â†’ stop immediately. Can always restart if benign</li>
                <li><strong>Verify, verify, verify:</strong> Most fatal AHTR due to clerical errors. Check patient ID and product label at bedside</li>
                <li><strong>TRALI vs TACO:</strong> BNP is your friend. Elevated = TACO. Normal = think TRALI</li>
                <li><strong>Diuretics for TACO, NOT TRALI:</strong> TRALI is permeability problem, not volume. Diuretics make it worse</li>
                <li><strong>Fever â‰  always stop:</strong> FNHTR is common and benign. Rule out hemolysis, then may restart with premedication</li>
                <li><strong>Back pain during transfusion:</strong> Red flag for hemolysis. Stop and evaluate</li>
                <li><strong>Leukoreduction prevents FNHTR:</strong> Most products now leukoreduced. Significantly reduced FNHTR rates</li>
                <li><strong>Report to blood bank:</strong> All reactions should be reported. Critical for donor safety (TRALI) and patient safety</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- TOXIC MEGACOLON -->
<div id="toxic-megacolon" class="condition-page">
    <div class="page-header">
        <h2>181. TOXIC MEGACOLON</h2>
        <div class="subtitle">Acute Colonic Dilation â€¢ IBD Emergency</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Acute colonic dilation (>6 cm) with signs of systemic toxicity in the setting of colitis</p>
            
            <p><span class="label">Diagnostic Criteria (Jalan Criteria - 3 of 4 + 1 additional):</span></p>
            <ul>
                <li><strong>Fever >38.6Â°C (101.5Â°F)</strong></li>
                <li><strong>Heart rate >120 bpm</strong></li>
                <li><strong>WBC >10,500/Î¼L</strong></li>
                <li><strong>Anemia</strong></li>
                <li>PLUS at least one of: Dehydration, altered mental status, electrolyte abnormality, hypotension</li>
            </ul>
            
            <p><span class="label">Clinical Features:</span></p>
            <ul>
                <li>Abdominal distension and tenderness</li>
                <li>Decreased or absent bowel sounds</li>
                <li>Bloody diarrhea (may actually DECREASE as colon dilates)</li>
                <li>Fever, tachycardia, hypotension</li>
                <li>Signs of peritonitis if perforation occurs</li>
            </ul>
            
            <p><span class="label">Causes:</span></p>
            <ul>
                <li><strong>Inflammatory Bowel Disease:</strong> Ulcerative colitis (more common), Crohn's disease. Often first presentation or severe flare</li>
                <li><strong>Infectious Colitis:</strong> C. difficile (increasingly common cause), CMV (immunocompromised), Salmonella, Shigella, Campylobacter</li>
                <li><strong>Ischemic Colitis</strong></li>
                <li><strong>Medications:</strong> Opioids, anticholinergics, antidiarrheals (can precipitate in colitis)</li>
            </ul>
            
            <p><span class="label">Precipitating Factors in IBD:</span></p>
            <ul>
                <li>Hypokalemia (impairs colonic motility)</li>
                <li>Opioids, anticholinergics, antidiarrheals</li>
                <li>Barium enema, colonoscopy (instrumentation)</li>
                <li>Abrupt steroid withdrawal</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>Abdominal X-ray:</strong> Colonic dilation >6 cm (transverse colon), loss of haustral markings, "thumbprinting" (mucosal edema)</li>
                <li><strong>CT Abdomen/Pelvis:</strong> More sensitive. Shows dilation, wall thickening, pericolic fat stranding, free air if perforated</li>
                <li><strong>AVOID barium enema:</strong> Risk of perforation</li>
            </ul>
            
            <p><span class="label">Laboratory:</span></p>
            <ul>
                <li>CBC (leukocytosis, anemia)</li>
                <li>CMP (electrolytes - hypokalemia/hypomagnesemia worsen dilation)</li>
                <li>Albumin (low = poor prognosis)</li>
                <li>Blood cultures (if febrile)</li>
                <li>Stool studies: C. diff PCR, stool culture, O&P</li>
                <li>CMV PCR (if immunocompromised or refractory IBD)</li>
            </ul>
            
            <p><span class="label">Colonoscopy:</span></p>
            <ul>
                <li>Generally CONTRAINDICATED (risk of perforation)</li>
                <li>Limited flexible sigmoidoscopy may be done carefully if: diagnosis uncertain, need to rule out CMV/C. diff superinfection in IBD</li>
                <li>Minimal insufflation, do not advance past dilated segment</li>
            </ul>
            
            <p><span class="label">Surgical Consultation:</span> Get involved EARLY - may need emergent colectomy</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">General Supportive Measures:</span></p>
            <ul>
                <li><strong>NPO:</strong> Complete bowel rest</li>
                <li><strong>NG tube decompression:</strong> May help decompress proximal GI tract</li>
                <li><strong>IV fluids:</strong> Aggressive resuscitation, correct electrolytes</li>
                <li><strong>Correct hypokalemia and hypomagnesemia:</strong> Essential for colonic motility</li>
                <li><strong>STOP all motility-altering medications:</strong> Opioids, anticholinergics, antidiarrheals</li>
                <li><strong>DVT prophylaxis:</strong> SCDs (avoid anticoagulation if surgery imminent)</li>
                <li><strong>Position changes:</strong> Rolling patient may help decompress colon</li>
            </ul>
            
            <p><span class="label">Medical Therapy (IBD-related):</span></p>
            <ul>
                <li><strong>IV Corticosteroids:</strong> Methylprednisolone 60mg IV daily or Hydrocortisone 100mg IV q8h</li>
                <li><strong>Antibiotics:</strong> Broad-spectrum (Ciprofloxacin + Metronidazole OR Pip-tazo) - cover translocation</li>
                <li><strong>Cyclosporine or Infliximab:</strong> Consider as rescue therapy if no improvement on steroids (GI and surgery input)</li>
            </ul>
            
            <p><span class="label">Medical Therapy (C. diff-related):</span></p>
            <ul>
                <li><strong>Vancomycin 500mg PO/NG QID</strong> (high dose)</li>
                <li><strong>+ Metronidazole 500mg IV q8h</strong></li>
                <li><strong>Consider Vancomycin retention enemas</strong> if ileus prevents oral delivery</li>
                <li><strong>Consider Fidaxomicin or fecal transplant</strong> in appropriate settings</li>
            </ul>
            
            <p><span class="label">Indications for URGENT Surgery (Colectomy):</span></p>
            <ul>
                <li>Perforation (free air)</li>
                <li>Uncontrolled hemorrhage</li>
                <li>Increasing colonic dilation despite treatment</li>
                <li>No improvement after 24-72 hours of medical therapy</li>
                <li>Worsening clinical status (increasing WBC, fever, peritonitis)</li>
            </ul>
            
            <p><span class="label">Surgical Procedure:</span> Subtotal colectomy with end ileostomy. Preserves rectum for potential future IPAA (in UC)</p>
            
            <p><span class="label">Monitoring:</span></p>
            <ul>
                <li>Serial abdominal exams (q4-6h)</li>
                <li>Daily abdominal X-ray to assess colonic diameter</li>
                <li>Labs q12-24h (WBC, electrolytes, lactate)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Diarrhea may STOP:</strong> Paradoxically, as colon dilates, diarrhea may decrease. Don't be falsely reassured</li>
                <li><strong>Surgery saves lives:</strong> Don't delay colectomy if not improving. Mortality much higher with perforation</li>
                <li><strong>C. diff is increasingly common cause:</strong> Always test for C. diff, even in known IBD patients</li>
                <li><strong>Correct potassium and magnesium:</strong> Hypokalemia impairs colonic motility. Aggressive replacement essential</li>
                <li><strong>Stop the opioids:</strong> Opioids precipitate and worsen toxic megacolon. Use alternatives for pain</li>
                <li><strong>Colonoscopy is dangerous:</strong> Avoid unless absolutely necessary. Risk of perforation very high</li>
                <li><strong>24-72 hour window:</strong> If no improvement with medical therapy in 24-72h, surgery indicated</li>
                <li><strong>Multidisciplinary care:</strong> GI, surgery, and ID (if infectious) should all be involved early</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- POLYMYALGIA RHEUMATICA -->
<div id="pmr" class="condition-page">
    <div class="page-header">
        <h2>182. POLYMYALGIA RHEUMATICA</h2>
        <div class="subtitle">PMR â€¢ Giant Cell Arteritis Association</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Presentation:</span> Bilateral shoulder and hip girdle pain/stiffness in patient >50 years. Morning stiffness lasting >45 minutes. Difficulty with ADLs (combing hair, rising from chair)</p>
            
            <p><span class="label">Key Features:</span></p>
            <ul>
                <li><strong>Age:</strong> Almost always >50 years (peak 70-80)</li>
                <li><strong>Symmetric proximal pain:</strong> Shoulders (most common), neck, hips, thighs</li>
                <li><strong>Morning stiffness:</strong> Prolonged (>45 min), improves with activity</li>
                <li><strong>Sudden onset:</strong> Patients can often pinpoint when symptoms started</li>
                <li><strong>Constitutional symptoms:</strong> Fatigue, malaise, low-grade fever, weight loss (30-50%)</li>
                <li><strong>NO true muscle weakness:</strong> Weakness is from pain, not myopathy. Normal CK</li>
            </ul>
            
            <p><span class="label">Physical Exam:</span></p>
            <ul>
                <li>Limited active ROM of shoulders and hips (passive ROM preserved)</li>
                <li>Tenderness over shoulder and hip girdles</li>
                <li>No synovitis of small joints (unlike RA)</li>
                <li>Normal muscle strength on formal testing</li>
            </ul>
            
            <p><span class="label">Association with Giant Cell Arteritis (GCA):</span></p>
            <ul>
                <li>10-30% of PMR patients have GCA</li>
                <li>40-60% of GCA patients have PMR symptoms</li>
                <li><strong>RED FLAGS for GCA:</strong> New headache, jaw claudication, visual symptoms, scalp tenderness, temporal artery abnormality</li>
            </ul>
            
            <p><span class="label">Differential Diagnosis:</span></p>
            <ul>
                <li><strong>Late-onset RA:</strong> More small joint involvement, RF/CCP positive</li>
                <li><strong>Inflammatory myopathy:</strong> True weakness, elevated CK</li>
                <li><strong>Hypothyroidism:</strong> Check TSH</li>
                <li><strong>Malignancy:</strong> Consider if atypical features or not responding to steroids</li>
                <li><strong>Infection:</strong> Endocarditis, TB can mimic</li>
                <li><strong>Fibromyalgia:</strong> Tender points, normal inflammatory markers</li>
                <li><strong>RS3PE:</strong> Pitting edema of hands, good prognosis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Laboratory Findings:</span></p>
            <ul>
                <li><strong>ESR:</strong> Elevated (often >40-50, frequently >100). Normal ESR makes diagnosis unlikely</li>
                <li><strong>CRP:</strong> Elevated. May be more sensitive than ESR</li>
                <li><strong>CBC:</strong> Normocytic anemia (anemia of chronic disease), thrombocytosis</li>
                <li><strong>CK:</strong> NORMAL (distinguishes from myositis)</li>
                <li><strong>RF, Anti-CCP:</strong> Negative (distinguishes from RA)</li>
                <li><strong>ANA:</strong> Negative</li>
                <li><strong>Liver enzymes:</strong> Mild elevation (especially Alk phos) in some patients</li>
            </ul>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>Ultrasound:</strong> Biceps tenosynovitis, subacromial/subdeltoid bursitis, hip synovitis. Can support diagnosis</li>
                <li><strong>MRI:</strong> Shows bursitis and synovitis. Not routinely needed</li>
                <li><strong>PET-CT:</strong> Shows FDG uptake in shoulders, hips, spinous processes. Research tool, not standard</li>
            </ul>
            
            <p><span class="label">Evaluate for GCA (if any concerning features):</span></p>
            <ul>
                <li>Temporal artery biopsy</li>
                <li>Temporal artery ultrasound ("halo sign")</li>
            </ul>
            
            <p><span class="label">2012 ACR/EULAR Classification Criteria:</span></p>
            <ul>
                <li>Age â‰¥50 years</li>
                <li>Bilateral shoulder aching</li>
                <li>Abnormal ESR (>40) or CRP</li>
                <li>Plus scoring system including morning stiffness, hip involvement, absence of RF/CCP, absence of peripheral joint involvement</li>
            </ul>
            
            <p><span class="label">Response to Steroids:</span> DRAMATIC improvement within 24-72 hours of prednisone is virtually diagnostic. If no response, reconsider diagnosis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Initial Treatment - Prednisone:</span></p>
            <ul>
                <li><strong>Starting dose:</strong> Prednisone 12.5-25 mg daily (lower doses than GCA)</li>
                <li><strong>Response:</strong> Dramatic improvement expected within 24-72 hours</li>
                <li><strong>If no response in 1 week:</strong> Consider higher dose (up to 30mg) or alternative diagnosis</li>
            </ul>
            
            <p><span class="label">Tapering Schedule (Gradual - total duration 1-2 years):</span></p>
            <ul>
                <li><strong>Initial taper:</strong> After 2-4 weeks of symptom control, reduce by 2.5mg every 2-4 weeks until 10mg</li>
                <li><strong>Below 10mg:</strong> Reduce by 1mg every 4-8 weeks</li>
                <li><strong>Maintenance:</strong> Most patients need 5-10 mg for many months</li>
                <li><strong>Monitor:</strong> ESR/CRP with each taper. Symptoms should stay controlled</li>
            </ul>
            
            <p><span class="label">Relapse Management:</span></p>
            <ul>
                <li>Relapse common (30-50%) especially during taper below 10mg</li>
                <li>Increase to last effective dose, then taper more slowly</li>
                <li>Consider steroid-sparing agent if multiple relapses</li>
            </ul>
            
            <p><span class="label">Steroid-Sparing Agents:</span></p>
            <ul>
                <li><strong>Methotrexate:</strong> 7.5-15mg weekly. May allow lower steroid dose and faster taper. Mixed evidence</li>
                <li><strong>Tocilizumab:</strong> IL-6 inhibitor. Emerging evidence for refractory cases. GiACTA trial showed benefit in GCA</li>
            </ul>
            
            <p><span class="label">Monitoring and Prevention of Steroid Complications:</span></p>
            <ul>
                <li>Bone protection: Calcium 1000-1200mg + Vitamin D 800-1000 IU daily. DEXA scan. Consider bisphosphonate</li>
                <li>PPI if GI risk factors</li>
                <li>Monitor glucose, blood pressure</li>
                <li>Pneumococcal and influenza vaccination</li>
                <li>Consider PJP prophylaxis if high-dose steroids prolonged (controversial in PMR)</li>
            </ul>
            
            <p><span class="label">If GCA Suspected:</span></p>
            <ul>
                <li>START high-dose steroids immediately (prednisone 40-60mg or 1mg/kg) - don't wait for biopsy</li>
                <li>Add aspirin 81mg daily</li>
                <li>Urgent temporal artery biopsy or ultrasound</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PEARLS</div>
        <div class="section-content">
            <ul>
                <li><strong>Dramatic steroid response:</strong> If patient doesn't feel significantly better within 1-3 days of prednisone, reconsider the diagnosis</li>
                <li><strong>Always think about GCA:</strong> Ask about headache, jaw claudication, visual symptoms at every visit. PMR can evolve to GCA</li>
                <li><strong>Normal CK:</strong> Elevated CK means it's not PMR. Consider myositis</li>
                <li><strong>Age matters:</strong> PMR essentially doesn't occur before age 50. If <50, wrong diagnosis</li>
                <li><strong>Slow taper below 10mg:</strong> This is where relapses happen. Go slowly (1mg every 4-8 weeks)</li>
                <li><strong>Flares during taper:</strong> Common. Increase dose, control symptoms, then try slower taper</li>
                <li><strong>Can't get off steroids:</strong> If can't taper below 5mg after 2 years, consider alternative diagnosis or steroid-sparing agent</li>
                <li><strong>Screen for malignancy:</strong> Age-appropriate cancer screening. PMR can be paraneoplastic</li>
            </ul>
        </div>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- MAJOR DEPRESSIVE DISORDER -->
<div id="mdd" class="condition-page">
    <div class="page-header">
        <h2>183. MAJOR DEPRESSIVE DISORDER</h2>
        <div class="subtitle">SIG E CAPS Criteria â€¢ SSRIs First-Line â€¢ Screen for Bipolar</div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS (DSM-5)</div>
        <div class="section-content">
            <p><span class="label">Criteria:</span> â‰¥5 symptoms for â‰¥2 weeks (must include #1 or #2)</p>
            <p><span class="label">SIG E CAPS Mnemonic:</span></p>
            <ul>
                <li><strong>S</strong>leep disturbance (insomnia or hypersomnia)</li>
                <li><strong>I</strong>nterest loss (anhedonia) â€” REQUIRED</li>
                <li><strong>G</strong>uilt or worthlessness</li>
                <li><strong>E</strong>nergy loss / fatigue</li>
                <li><strong>C</strong>oncentration problems</li>
                <li><strong>A</strong>ppetite changes (increased or decreased)</li>
                <li><strong>P</strong>sychomotor agitation or retardation</li>
                <li><strong>S</strong>uicidal ideation</li>
            </ul>
            <p><span class="label">Plus:</span> Depressed mood â€” REQUIRED (one of the two)</p>
            
            <p><span class="label">Screening Tools:</span></p>
            <ul>
                <li><strong>PHQ-2:</strong> Depressed mood + anhedonia. Score â‰¥3 = positive â†’ do PHQ-9</li>
                <li><strong>PHQ-9:</strong> 5-9 mild, 10-14 moderate, 15-19 mod-severe, â‰¥20 severe</li>
            </ul>
            
            <p><span class="label">Rule Out:</span> Hypothyroidism, anemia, B12 deficiency, medications (Î²-blockers, steroids), substance use, BIPOLAR (screen before starting antidepressant!)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Mild:</span> Psychotherapy (CBT) OR medication (patient preference)</p>
            <p><span class="label">Moderate-Severe:</span> Medication + psychotherapy</p>
            
            <p><span class="label">First-Line Medications (SSRIs):</span></p>
            <ul>
                <li><strong>Sertraline 50mg daily</strong> â€” Good safety, fewer drug interactions</li>
                <li><strong>Escitalopram 10mg daily</strong> â€” Well tolerated</li>
                <li><strong>Fluoxetine 20mg daily</strong> â€” Long half-life, activating</li>
            </ul>
            
            <p><span class="label">Alternatives:</span></p>
            <ul>
                <li><strong>SNRIs:</strong> Venlafaxine, duloxetine (also for neuropathic pain)</li>
                <li><strong>Bupropion:</strong> No sexual side effects; good for fatigue; avoid in seizures/eating disorders</li>
                <li><strong>Mirtazapine:</strong> Sedating, weight gain; good for insomnia, poor appetite</li>
            </ul>
            
            <p><span class="label">Timeline:</span> 2-4 weeks for initial response; 6-8 weeks for full effect. Continue 6-9 months after remission (lifelong if recurrent)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
        <ul>
            <li><strong>Always screen for bipolar before starting antidepressant:</strong> "Have you ever had a period of unusually elevated mood, decreased need for sleep, racing thoughts?" Antidepressants can trigger mania</li>
            <li><strong>Black box warning &lt;25 years:</strong> Monitor closely for suicidal ideation in first weeks</li>
            <li><strong>Sexual dysfunction common with SSRIs:</strong> Switch to bupropion or mirtazapine, or add bupropion</li>
            <li><strong>QTc prolongation:</strong> Citalopram max 40mg (20mg if elderly or hepatic impairment)</li>
        </ul>
    </div>
    
    <div class="section">
        <div class="section-title">SUICIDE RISK ASSESSMENT</div>
        <div class="section-content">
            <p><span class="label">SAD PERSONS Risk Factors:</span> Sex (male), Age (elderly/young), Depression, Previous attempt (strongest), Ethanol/drugs, Rational thinking loss, Social support lacking, Organized plan, No spouse, Sickness</p>
            <p><span class="label">Ask Directly:</span> Ideation (passive vs active), plan, intent, access to means, protective factors</p>
            <p><span class="label">High Risk:</span> Plan + intent + means â†’ Psychiatric hospitalization</p>
        </div>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ANXIETY DISORDERS -->
<div id="anxiety" class="condition-page">
    <div class="page-header">
        <h2>184. ANXIETY DISORDERS (GAD / PANIC)</h2>
        <div class="subtitle">SSRIs/SNRIs First-Line â€¢ CBT Effective â€¢ Avoid Long-Term Benzos</div>
    </div>
    
    <div class="section">
        <div class="section-title">GENERALIZED ANXIETY DISORDER (GAD)</div>
        <div class="section-content">
            <p><span class="label">Criteria:</span> Excessive worry about multiple events, more days than not for â‰¥6 months, difficult to control</p>
            <p><span class="label">Plus â‰¥3 of:</span> Restlessness, fatigue, concentration difficulty, irritability, muscle tension, sleep disturbance</p>
            
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>First-line:</strong> SSRIs (escitalopram, sertraline) or SNRIs (venlafaxine XR, duloxetine)</li>
                <li><strong>CBT:</strong> Equally effective as medication; combination often best</li>
                <li><strong>Buspirone:</strong> Non-sedating, no dependence; takes 2-4 weeks; good adjunct</li>
                <li><strong>Avoid long-term benzodiazepines:</strong> Dependence, falls in elderly, cognitive impairment</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PANIC DISORDER</div>
        <div class="section-content">
            <p><span class="label">Panic Attack (â‰¥4 symptoms, peak within minutes):</span></p>
            <ul>
                <li>Palpitations, sweating, trembling, SOB, choking sensation</li>
                <li>Chest pain, nausea, dizziness, chills/hot flashes</li>
                <li>Paresthesias, derealization, fear of losing control, fear of dying</li>
            </ul>
            
            <p><span class="label">Panic Disorder:</span> Recurrent unexpected panic attacks + â‰¥1 month of concern about attacks OR maladaptive behavior</p>
            
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>First-line:</strong> SSRIs (sertraline, paroxetine) or SNRIs</li>
                <li><strong>CBT with exposure therapy:</strong> Highly effective</li>
                <li><strong>Acute attacks:</strong> Benzodiazepine PRN (lorazepam 0.5-1mg) â€” limit use</li>
            </ul>
            
            <p><span class="label">Rule Out:</span> Hyperthyroidism, pheochromocytoma, cardiac arrhythmia, PE, stimulant use</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PTSD</div>
        <div class="section-content">
            <p><span class="label">Criteria:</span> Exposure to trauma + symptoms &gt;1 month from each category:</p>
            <ul>
                <li><strong>Intrusion:</strong> Flashbacks, nightmares, distressing memories</li>
                <li><strong>Avoidance:</strong> Avoiding reminders</li>
                <li><strong>Negative cognition/mood:</strong> Detachment, anhedonia, negative beliefs</li>
                <li><strong>Arousal:</strong> Hypervigilance, exaggerated startle, sleep disturbance</li>
            </ul>
            <p><span class="label">Treatment:</span> Trauma-focused therapy (PE, CPT, EMDR); SSRIs (sertraline, paroxetine FDA-approved); Prazosin for nightmares. <strong>Avoid benzodiazepines (may worsen outcomes)</strong></p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
        <ul>
            <li><strong>Beta-blockers only for performance anxiety:</strong> Not effective for GAD or panic disorder</li>
            <li><strong>Benzodiazepines are NOT first-line:</strong> Use short-term only; risk of dependence, falls, cognitive impairment</li>
            <li><strong>SSRIs take 2-4 weeks:</strong> Warn patients; may initially worsen anxiety briefly</li>
        </ul>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- BIPOLAR DISORDER -->
<div id="bipolar" class="condition-page">
    <div class="page-header">
        <h2>185. BIPOLAR DISORDER</h2>
        <div class="subtitle">DIG FAST Criteria â€¢ Mood Stabilizers â€¢ NO Antidepressant Monotherapy</div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Bipolar I:</span> â‰¥1 manic episode (may have depressive episodes)</p>
            <p><span class="label">Bipolar II:</span> â‰¥1 hypomanic episode + â‰¥1 major depressive episode (no full mania)</p>
            
            <p><span class="label">Manic Episode â€” DIG FAST (â‰¥3 symptoms, â‰¥1 week or any duration if hospitalized):</span></p>
            <ul>
                <li><strong>D</strong>istractibility</li>
                <li><strong>I</strong>ndiscretion / impulsivity (risky behavior, spending sprees)</li>
                <li><strong>G</strong>randiosity</li>
                <li><strong>F</strong>light of ideas / racing thoughts</li>
                <li><strong>A</strong>ctivity/Agitation increased</li>
                <li><strong>S</strong>leep decreased (feels rested with little sleep)</li>
                <li><strong>T</strong>alkativeness (pressured speech)</li>
            </ul>
            
            <p><span class="label">Hypomania vs Mania:</span></p>
            <ul>
                <li><strong>Hypomania:</strong> â‰¥4 days, no marked impairment, no psychosis, no hospitalization</li>
                <li><strong>Mania:</strong> â‰¥7 days, marked impairment, may have psychosis, often hospitalized</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Acute Mania:</span></p>
            <ul>
                <li><strong>Mood stabilizers:</strong> Lithium, valproate</li>
                <li><strong>Atypical antipsychotics:</strong> Quetiapine, aripiprazole, olanzapine, risperidone</li>
                <li><strong>Benzodiazepines:</strong> Adjunct for agitation/insomnia</li>
            </ul>
            
            <p><span class="label">Bipolar Depression:</span></p>
            <ul>
                <li><strong>Quetiapine</strong> (monotherapy) â€” FDA-approved</li>
                <li><strong>Lurasidone</strong> (monotherapy or with mood stabilizer)</li>
                <li><strong>Lamotrigine</strong> (maintenance, depression prevention)</li>
                <li><strong>Olanzapine-fluoxetine combination (OFC)</strong></li>
            </ul>
            
            <div class="box warning-box">
                <div class="box-title">âš ï¸ NEVER USE ANTIDEPRESSANT MONOTHERAPY</div>
                <p>Can trigger mania or rapid cycling. If antidepressant needed, must use WITH mood stabilizer.</p>
            </div>
            
            <p><span class="label">Lithium Monitoring:</span></p>
            <ul>
                <li><strong>Therapeutic range:</strong> 0.6-1.2 mEq/L</li>
                <li><strong>Baseline:</strong> TSH, Cr, Ca, ECG, pregnancy test</li>
                <li><strong>Monitoring:</strong> Lithium level, TSH, Cr every 6 months</li>
                <li><strong>Toxicity:</strong> Tremor â†’ ataxia â†’ confusion â†’ seizures</li>
                <li><strong>Drug interactions:</strong> NSAIDs, ACEi, ARBs, thiazides INCREASE lithium levels</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
        <ul>
            <li><strong>Screen for mania before starting any antidepressant:</strong> "Have you ever had periods of elevated mood, decreased sleep, racing thoughts, impulsive behavior?"</li>
            <li><strong>Valproate is teratogenic:</strong> Neural tube defects â€” avoid in pregnancy</li>
            <li><strong>Lithium narrow therapeutic window:</strong> Dehydration, NSAIDs, ACEi can precipitate toxicity</li>
        </ul>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CHRONIC URTICARIA -->
<div id="chronic-urticaria" class="condition-page">
    <div class="page-header">
        <h2>186. CHRONIC URTICARIA</h2>
        <div class="subtitle">â‰¥6 Weeks Duration â€¢ Antihistamines First-Line â€¢ Omalizumab for Refractory</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION & WORKUP</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Wheals (hives) â€” raised, erythematous, pruritic plaques that blanch and resolve within 24 hours</p>
            
            <p><span class="label">Classification:</span></p>
            <ul>
                <li><strong>Acute:</strong> &lt;6 weeks (often identifiable cause: infection, drug, food)</li>
                <li><strong>Chronic spontaneous:</strong> â‰¥6 weeks, usually idiopathic</li>
                <li><strong>Chronic inducible:</strong> Physical trigger (cold, pressure, cholinergic, solar)</li>
            </ul>
            
            <p><span class="label">Chronic Spontaneous Urticaria:</span></p>
            <ul>
                <li>Cause identified in &lt;10%</li>
                <li>NOT typically allergic â€” extensive allergy testing not indicated</li>
                <li>May be associated with autoimmune thyroid disease</li>
            </ul>
            
            <p><span class="label">Limited Workup:</span> CBC, TSH, CRP/ESR. Avoid extensive testing without specific indications.</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Stepwise Approach:</span></p>
            <ol>
                <li><strong>Step 1:</strong> Second-generation H1 antihistamine daily (cetirizine, loratadine, fexofenadine)</li>
                <li><strong>Step 2:</strong> Increase to 2-4Ã— standard dose (guideline-recommended, off-label)</li>
                <li><strong>Step 3:</strong> Add H2 blocker OR leukotriene antagonist OR switch antihistamine</li>
                <li><strong>Step 4:</strong> Add <strong>omalizumab</strong> (anti-IgE; FDA-approved for chronic urticaria)</li>
                <li><strong>Step 5:</strong> Cyclosporine (refractory cases)</li>
            </ol>
            
            <p><span class="label">Avoid:</span></p>
            <ul>
                <li><strong>First-generation antihistamines:</strong> Sedation, anticholinergic effects (especially in elderly)</li>
                <li><strong>Long-term corticosteroids:</strong> Use only for short flares</li>
                <li><strong>NSAIDs:</strong> May exacerbate urticaria in some patients</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
        <ul>
            <li><strong>Up-dosing antihistamines is evidence-based:</strong> 2-4Ã— standard dose before adding other agents</li>
            <li><strong>Omalizumab (Xolair):</strong> Highly effective for chronic urticaria; works within weeks</li>
            <li><strong>Individual wheals lasting &gt;24 hours:</strong> Consider urticarial vasculitis â€” biopsy may be needed</li>
        </ul>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- HEREDITARY ANGIOEDEMA -->
<div id="hae" class="condition-page">
    <div class="page-header">
        <h2>187. HEREDITARY ANGIOEDEMA (HAE)</h2>
        <div class="subtitle">C1-INH Deficiency â€¢ Low C4 â€¢ Epinephrine/Antihistamines INEFFECTIVE</div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Types:</span></p>
            <ul>
                <li><strong>Type 1 (85%):</strong> Low C1-INH level AND function</li>
                <li><strong>Type 2 (15%):</strong> Normal level, LOW function</li>
                <li><strong>Type 3 (rare):</strong> Normal C1-INH; often Factor XII mutation</li>
            </ul>
            
            <p><span class="label">Clinical Features:</span></p>
            <ul>
                <li>Recurrent angioedema WITHOUT urticaria</li>
                <li>Affects face, lips, tongue, throat, extremities, genitalia, GI tract</li>
                <li>GI attacks: Severe abdominal pain, vomiting (can mimic surgical abdomen)</li>
                <li>Laryngeal edema can be fatal</li>
                <li>Family history often present</li>
            </ul>
            
            <p><span class="label">Laboratory Findings:</span></p>
            <ul>
                <li><strong>C4 LOW</strong> (screening test â€” low during AND between attacks)</li>
                <li>C1-INH level low (Type 1) or function low (Type 2)</li>
                <li>C3 is NORMAL (unlike acquired deficiency)</li>
            </ul>
            
            <p><span class="label">Triggers:</span> Trauma, surgery, dental procedures, stress, infections, estrogen (OCPs), ACE inhibitors (CONTRAINDICATED)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <div class="box warning-box">
                <div class="box-title">âš ï¸ EPINEPHRINE, ANTIHISTAMINES, STEROIDS DO NOT WORK</div>
                <p>HAE is bradykinin-mediated, NOT histamine-mediated. Standard anaphylaxis treatment is INEFFECTIVE.</p>
            </div>
            
            <p><span class="label">Acute Attack:</span></p>
            <ul>
                <li><strong>C1-INH concentrate:</strong> Berinert (plasma-derived), Ruconest (recombinant)</li>
                <li><strong>Icatibant:</strong> Bradykinin B2 receptor antagonist (SC injection)</li>
                <li><strong>Ecallantide:</strong> Kallikrein inhibitor</li>
                <li><strong>Fresh frozen plasma:</strong> If above unavailable (contains C1-INH)</li>
            </ul>
            
            <p><span class="label">Long-Term Prophylaxis:</span></p>
            <ul>
                <li><strong>Lanadelumab:</strong> Anti-kallikrein antibody (SC every 2 weeks)</li>
                <li><strong>Berotralstat:</strong> Oral kallikrein inhibitor (daily)</li>
                <li><strong>C1-INH concentrate:</strong> IV/SC prophylaxis</li>
            </ul>
            
            <p><span class="label">Short-Term Prophylaxis (before procedures):</span> C1-INH concentrate 1-6 hours before</p>
        </div>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">HAE vs ACE INHIBITOR ANGIOEDEMA</div>
            <ul>
                <li>Both bradykinin-mediated</li>
                <li>Both present WITHOUT urticaria</li>
                <li>ACEi: Can occur at any time (even after years)</li>
                <li>ACEi: 5Ã— more common in Black patients</li>
                <li>ACEi: Stop drug permanently; do NOT substitute ARB</li>
            </ul>
        </div>
        <div class="box">
            <div class="box-title">HAE vs ALLERGIC ANGIOEDEMA</div>
            <ul>
                <li>HAE: NO urticaria; C4 low</li>
                <li>Allergic: Often WITH urticaria; responds to epinephrine</li>
                <li>HAE: Family history common</li>
                <li>HAE: Recurrent without clear trigger</li>
            </ul>
        </div>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ALLERGIC RHINITIS -->
<div id="allergic-rhinitis" class="condition-page">
    <div class="page-header">
        <h2>188. ALLERGIC RHINITIS</h2>
        <div class="subtitle">Intranasal Steroids First-Line â€¢ Allergen Avoidance â€¢ Immunotherapy for Refractory</div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & CLASSIFICATION</div>
        <div class="section-content">
            <p><span class="label">Symptoms:</span> Nasal congestion, rhinorrhea (clear), sneezing, nasal pruritus, postnasal drip, ocular symptoms (itching, tearing)</p>
            
            <p><span class="label">Physical Exam:</span> Allergic shiners (dark circles), allergic salute (transverse nasal crease), pale/boggy turbinates</p>
            
            <p><span class="label">Classification:</span></p>
            <ul>
                <li><strong>Seasonal:</strong> Pollens (trees spring, grasses summer, weeds fall)</li>
                <li><strong>Perennial:</strong> Dust mites, mold, animal dander, cockroach</li>
                <li><strong>Intermittent:</strong> &lt;4 days/week or &lt;4 weeks</li>
                <li><strong>Persistent:</strong> â‰¥4 days/week AND â‰¥4 weeks</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Stepwise Approach:</span></p>
            <ol>
                <li><strong>Allergen avoidance</strong> (if feasible): HEPA filters, dust mite covers, pet removal</li>
                <li><strong>Intranasal corticosteroids</strong> â€” MOST EFFECTIVE for moderate-severe
                    <ul>
                        <li>Fluticasone, mometasone, budesonide</li>
                        <li>Use daily for best effect; takes days-weeks</li>
                    </ul>
                </li>
                <li><strong>Second-generation oral antihistamines</strong> â€” for mild or PRN
                    <ul>
                        <li>Cetirizine 10mg, loratadine 10mg, fexofenadine 180mg</li>
                    </ul>
                </li>
                <li><strong>Combination:</strong> Intranasal steroid + intranasal antihistamine (azelastine)</li>
                <li><strong>Add-ons:</strong> Leukotriene antagonist (montelukast), nasal saline irrigation</li>
                <li><strong>Allergen immunotherapy</strong> â€” for refractory cases (SCIT or SLIT)</li>
            </ol>
            
            <p><span class="label">Avoid:</span></p>
            <ul>
                <li><strong>Decongestant nasal sprays &gt;3-5 days:</strong> Rhinitis medicamentosa (rebound congestion)</li>
                <li><strong>First-generation antihistamines:</strong> Sedation, anticholinergic effects</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
        <ul>
            <li><strong>Intranasal steroids are most effective:</strong> Superior to antihistamines for nasal congestion</li>
            <li><strong>Allergen immunotherapy modifies disease:</strong> Only treatment that changes natural history; 3-5 years</li>
            <li><strong>Non-allergic rhinitis exists:</strong> Vasomotor rhinitis â€” triggered by irritants, temperature; treat with ipratropium nasal</li>
        </ul>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- FOOD ALLERGY -->
<div id="food-allergy" class="condition-page">
    <div class="page-header">
        <h2>189. FOOD ALLERGY</h2>
        <div class="subtitle">IgE-Mediated = Epinephrine â€¢ Big 9 Allergens â€¢ Oral Immunotherapy Emerging</div>
    </div>
    
    <div class="section">
        <div class="section-title">TYPES & DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">IgE-Mediated (Type I):</span> Minutes to 2 hours; urticaria, angioedema, anaphylaxis, vomiting</p>
            <p><span class="label">Non-IgE-Mediated:</span> Hours to days; enterocolitis (FPIES), eosinophilic esophagitis</p>
            <p><span class="label">Food Intolerance (Non-Immune):</span> Lactose intolerance â€” GI symptoms only, not allergic</p>
            
            <p><span class="label">"Big 9" Allergens:</span> Peanut, tree nuts, milk, egg, wheat, soy, fish, shellfish, sesame</p>
            
            <p><span class="label">Diagnosis:</span></p>
            <ul>
                <li><strong>History is most important:</strong> Timing, symptoms, reproducibility</li>
                <li><strong>Skin prick testing:</strong> High NPV; positive doesn't confirm clinical allergy</li>
                <li><strong>Specific IgE:</strong> Same limitations</li>
                <li><strong>Oral food challenge:</strong> Gold standard (supervised)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">All Patients with IgE-Mediated Food Allergy:</span></p>
            <ul>
                <li><strong>Strict avoidance</strong> of allergen</li>
                <li><strong>Epinephrine auto-injector (EpiPen)</strong> â€” carry at all times</li>
                <li>Education on label reading</li>
                <li>Anaphylaxis action plan</li>
                <li>Medic-Alert bracelet</li>
            </ul>
            
            <p><span class="label">Oral Immunotherapy (OIT):</span></p>
            <ul>
                <li>FDA-approved for peanut (Palforzia) in children/adolescents</li>
                <li>Reduces risk of severe reaction to accidental exposure</li>
                <li>Does NOT cure allergy; must continue avoidance</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
        <ul>
            <li><strong>Food-dependent exercise-induced anaphylaxis:</strong> Anaphylaxis occurs when exercise follows specific food (wheat, shellfish). Either alone doesn't cause symptoms</li>
            <li><strong>Oral allergy syndrome:</strong> Pollen-food cross-reactivity; oral tingling with raw fruits/vegetables; usually not systemic</li>
            <li><strong>Most children outgrow milk, egg, soy, wheat allergy:</strong> Peanut, tree nut, fish, shellfish usually lifelong</li>
        </ul>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- GERIATRIC SYNDROMES -->
<div id="geriatric-syndromes" class="condition-page">
    <div class="page-header">
        <h2>190. GERIATRIC SYNDROMES (FALLS / BEERS / ELDER ABUSE)</h2>
        <div class="subtitle">Multifactorial Falls Assessment â€¢ Beers Criteria â€¢ Mandatory Reporting</div>
    </div>
    
    <div class="section">
        <div class="section-title">FALL PREVENTION</div>
        <div class="section-content">
            <p><span class="label">Annual Screening:</span> "Have you fallen in the past year? Do you feel unsteady? Do you worry about falling?" â€” Yes to any â†’ Full assessment</p>
            
            <p><span class="label">Assessment:</span></p>
            <ul>
                <li><strong>Timed Up and Go (TUG):</strong> Rise, walk 3m, return, sit. â‰¥12 seconds = increased risk</li>
                <li><strong>Orthostatic vitals</strong></li>
                <li><strong>Vision screening</strong></li>
                <li><strong>Medication review</strong> (see Beers Criteria)</li>
                <li><strong>Footwear assessment</strong></li>
                <li><strong>Home safety evaluation</strong></li>
            </ul>
            
            <p><span class="label">Evidence-Based Interventions:</span></p>
            <ul>
                <li><strong>Exercise (balance + strength):</strong> Most effective (Tai Chi, PT)</li>
                <li><strong>Vitamin D 800-1000 IU daily</strong> if deficient</li>
                <li><strong>Medication reduction:</strong> Stop fall-risk medications</li>
                <li><strong>Home modifications:</strong> Remove rugs, improve lighting, grab bars</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">BEERS CRITERIA â€” MEDICATIONS TO AVOID</div>
        <div class="section-content">
            <p><span class="label">High-Risk Medications in Elderly:</span></p>
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Class</th><th>Examples</th><th>Concern</th></tr>
                <tr><td>First-gen antihistamines</td><td>Diphenhydramine, hydroxyzine</td><td>Anticholinergic; confusion, falls</td></tr>
                <tr><td>Benzodiazepines</td><td>All</td><td>Falls, fractures, cognitive impairment</td></tr>
                <tr><td>Non-benzo hypnotics</td><td>Zolpidem, eszopiclone</td><td>Falls, minimal benefit</td></tr>
                <tr><td>Muscle relaxants</td><td>Cyclobenzaprine, methocarbamol</td><td>Anticholinergic; poorly tolerated</td></tr>
                <tr><td>Long-acting sulfonylureas</td><td>Glyburide</td><td>Prolonged hypoglycemia</td></tr>
                <tr><td>NSAIDs (chronic)</td><td>All</td><td>GI bleed, AKI, CV events</td></tr>
                <tr><td>PPIs (&gt;8 weeks)</td><td>All without indication</td><td>C. diff, fractures, hypomagnesemia</td></tr>
                <tr><td>Anticholinergics</td><td>Oxybutynin, TCAs</td><td>Confusion, falls, constipation</td></tr>
            </table>
            
            <p><span class="label">Deprescribing Approach:</span> Review all medications â†’ Identify PIMs â†’ Assess ongoing indication â†’ Prioritize by harm â†’ Taper appropriately â†’ Monitor</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">ELDER ABUSE</div>
        <div class="section-content">
            <p><span class="label">Types:</span> Physical, emotional, sexual, financial, neglect, self-neglect</p>
            
            <p><span class="label">Red Flags:</span></p>
            <ul>
                <li>Unexplained injuries or injuries in various stages of healing</li>
                <li>Delay in seeking care</li>
                <li>Inconsistent history</li>
                <li>Poor hygiene, malnutrition, dehydration</li>
                <li>Fearful behavior around caregiver</li>
                <li>Caregiver speaks for patient, won't leave room</li>
            </ul>
            
            <div class="box warning-box">
                <div class="box-title">âš ï¸ MANDATORY REPORTING</div>
                <p>Most states require reporting suspected elder abuse to Adult Protective Services (APS). Document carefully. Report even if not certain.</p>
            </div>
        </div>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PREVENTIVE CARE & SCREENING -->
<div id="preventive-care" class="condition-page">
    <div class="page-header">
        <h2>191. PREVENTIVE CARE & CANCER SCREENING</h2>
        <div class="subtitle">USPSTF Grades â€¢ Age-Appropriate Screening â€¢ Know When to Stop</div>
    </div>
    
    <div class="section">
        <div class="section-title">USPSTF GRADING</div>
        <div class="section-content">
            <ul>
                <li><strong>Grade A:</strong> High certainty of substantial benefit â†’ RECOMMEND</li>
                <li><strong>Grade B:</strong> Moderate-high certainty of moderate benefit â†’ RECOMMEND</li>
                <li><strong>Grade C:</strong> Small benefit â†’ OFFER SELECTIVELY (shared decision-making)</li>
                <li><strong>Grade D:</strong> No benefit or harms outweigh â†’ DO NOT OFFER</li>
                <li><strong>Grade I:</strong> Insufficient evidence</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CANCER SCREENING (USPSTF A/B)</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Cancer</th><th>Population</th><th>Method</th><th>Interval</th></tr>
                <tr><td><strong>Colorectal</strong></td><td>Age 45-75</td><td>Colonoscopy OR FIT OR FIT-DNA</td><td>10y / 1y / 1-3y</td></tr>
                <tr><td><strong>Breast</strong></td><td>Women 40-74</td><td>Mammography</td><td>Every 2 years</td></tr>
                <tr><td><strong>Cervical</strong></td><td>Women 21-65</td><td>Pap Â± HPV</td><td>Every 3-5 years</td></tr>
                <tr><td><strong>Lung</strong></td><td>50-80, â‰¥20 pack-years, current/quit &lt;15y</td><td>Low-dose CT</td><td>Annual</td></tr>
            </table>
            
            <p><span class="label">When to STOP Screening:</span></p>
            <ul>
                <li>Life expectancy &lt;10 years</li>
                <li>Age &gt;75 for CRC (individualize 76-85; stop &gt;85)</li>
                <li>Age &gt;65 for cervical if adequate prior screening</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">OTHER SCREENINGS</div>
        <div class="section-content">
            <p><span class="label">Recommended:</span></p>
            <ul>
                <li><strong>AAA:</strong> Men 65-75 who ever smoked â€” ONE TIME ultrasound</li>
                <li><strong>Hepatitis C:</strong> All adults 18-79 at least once</li>
                <li><strong>Hepatitis B:</strong> All adults at least once</li>
                <li><strong>HIV:</strong> All adults 15-65 at least once</li>
                <li><strong>Diabetes:</strong> Adults 35-70 with overweight/obesity</li>
                <li><strong>Depression:</strong> All adults (PHQ-2)</li>
                <li><strong>Osteoporosis (DEXA):</strong> Women â‰¥65</li>
            </ul>
            
            <p><span class="label">Grade D (Do NOT Screen):</span></p>
            <ul>
                <li>Ovarian cancer (CA-125, ultrasound)</li>
                <li>Routine PSA (shared decision 55-69)</li>
                <li>Thyroid cancer (palpation, ultrasound)</li>
                <li>Carotid stenosis in asymptomatic</li>
                <li>Routine ECG in asymptomatic low-risk</li>
                <li><strong>Aspirin for primary prevention age â‰¥60</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">IMMUNIZATIONS (ADULTS)</div>
        <div class="section-content">
            <ul>
                <li><strong>Influenza:</strong> Annual, all adults (high-dose for â‰¥65)</li>
                <li><strong>COVID-19:</strong> Updated vaccine annually</li>
                <li><strong>Tdap:</strong> Once, then Td every 10 years</li>
                <li><strong>Pneumococcal:</strong> PCV20 OR PCV15â†’PPSV23 for all â‰¥65</li>
                <li><strong>Shingles (RZV):</strong> 2 doses, age â‰¥50</li>
                <li><strong>Hepatitis B:</strong> 3-dose series if not immune</li>
                <li><strong>RSV:</strong> Single dose, age â‰¥60 (shared decision)</li>
            </ul>
        </div>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- MEDICAL ETHICS & CAPACITY -->
<div id="ethics-capacity" class="condition-page">
    <div class="page-header">
        <h2>192. MEDICAL ETHICS & CAPACITY ASSESSMENT</h2>
        <div class="subtitle">Four Principles â€¢ Decision-Specific Capacity â€¢ Advance Directives</div>
    </div>
    
    <div class="section">
        <div class="section-title">FOUR PRINCIPLES OF MEDICAL ETHICS</div>
        <div class="section-content">
            <ul>
                <li><strong>Autonomy:</strong> Respect patient's right to make decisions (informed consent, right to refuse)</li>
                <li><strong>Beneficence:</strong> Act in patient's best interest</li>
                <li><strong>Non-maleficence:</strong> Do no harm</li>
                <li><strong>Justice:</strong> Fair distribution of resources</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">INFORMED CONSENT</div>
        <div class="section-content">
            <p><span class="label">Elements:</span></p>
            <ol>
                <li><strong>Disclosure:</strong> Nature of procedure, risks, benefits, alternatives</li>
                <li><strong>Understanding:</strong> Patient comprehends information</li>
                <li><strong>Voluntariness:</strong> Decision made without coercion</li>
                <li><strong>Competence:</strong> Patient has capacity to decide</li>
                <li><strong>Consent:</strong> Patient agrees to proceed</li>
            </ol>
            
            <p><span class="label">Exceptions:</span> Emergency (imminent threat, no surrogate), waiver, therapeutic privilege (rare), incapacity (surrogate consents)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CAPACITY ASSESSMENT</div>
        <div class="section-content">
            <p><span class="label">Capacity vs Competence:</span></p>
            <ul>
                <li><strong>Capacity:</strong> Clinical determination by physician; decision-specific</li>
                <li><strong>Competence:</strong> Legal determination by court; global</li>
            </ul>
            
            <p><span class="label">Four Elements of Capacity:</span></p>
            <ol>
                <li><strong>Understanding:</strong> Can state the medical problem and proposed treatment</li>
                <li><strong>Appreciation:</strong> Acknowledges how this applies to their situation</li>
                <li><strong>Reasoning:</strong> Can weigh risks/benefits and consider alternatives</li>
                <li><strong>Choice:</strong> Can clearly communicate a decision</li>
            </ol>
            
            <div class="box warning-box">
                <div class="box-title">âš ï¸ KEY PRINCIPLES</div>
                <ul>
                    <li>Capacity is <strong>decision-specific</strong> â€” patient may have capacity for some decisions but not others</li>
                    <li>Capacity can <strong>fluctuate</strong> (delirium, time of day)</li>
                    <li><strong>Disagreement with physician â‰  lack of capacity</strong></li>
                    <li>Patient WITH capacity can refuse any treatment, even life-saving</li>
                </ul>
            </div>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">ADVANCE DIRECTIVES</div>
        <div class="section-content">
            <p><span class="label">Types:</span></p>
            <ul>
                <li><strong>Living Will:</strong> Written preferences for specific situations (terminal illness, PVS)</li>
                <li><strong>Healthcare Proxy/Durable POA:</strong> Designates decision-maker if patient loses capacity</li>
                <li><strong>POLST/MOLST:</strong> Physician orders for life-sustaining treatment â€” actionable medical orders</li>
            </ul>
            
            <p><span class="label">DNR/DNI:</span></p>
            <ul>
                <li>DNR = No CPR; DNI = No intubation</li>
                <li>DNR/DNI does NOT mean "do not treat"</li>
                <li>Address before surgery â€” may suspend during procedure with consent</li>
            </ul>
            
            <p><span class="label">Surrogate Hierarchy (if no proxy):</span> Spouse â†’ Adult children â†’ Parents â†’ Siblings â†’ Other family</p>
            
            <p><span class="label">Decision Standards:</span></p>
            <ul>
                <li><strong>Substituted judgment:</strong> What would patient want? (preferred)</li>
                <li><strong>Best interest:</strong> If patient's wishes unknown</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž TEACHING PEARLS</div>
        <ul>
            <li><strong>Withholding = Withdrawing treatment:</strong> Ethically and legally equivalent</li>
            <li><strong>Palliative care â‰  Hospice:</strong> Palliative can be concurrent with curative treatment</li>
            <li><strong>Break confidentiality when:</strong> Imminent harm to identifiable third party, mandatory reporting (abuse, certain diseases), court order</li>
        </ul>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PCOS -->
<div id="pcos" class="condition-page">
    <div class="page-header">
        <h2>193. POLYCYSTIC OVARY SYNDROME (PCOS)</h2>
        <div class="subtitle">Rotterdam Criteria â€¢ Insulin Resistance â€¢ Metabolic Syndrome</div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS â€” ROTTERDAM CRITERIA (2 of 3)</div>
        <div class="section-content">
            <ol>
                <li><strong>Oligo/anovulation:</strong> Irregular menses (&lt;8 cycles/year or cycles &gt;35 days)</li>
                <li><strong>Clinical or biochemical hyperandrogenism:</strong> Hirsutism, acne, alopecia; elevated free testosterone</li>
                <li><strong>Polycystic ovaries on ultrasound:</strong> â‰¥12 follicles (2-9mm) per ovary OR ovarian volume &gt;10mL</li>
            </ol>
            <p><span class="label">Rule Out:</span> Thyroid disease (TSH), hyperprolactinemia, non-classic CAH (17-OH progesterone), Cushing's</p>
            <p><span class="label">Labs:</span> Total/free testosterone, DHEA-S, LH:FSH ratio often &gt;2:1 (not diagnostic), fasting glucose/insulin, lipid panel</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Lifestyle:</span> Weight loss (5-10% improves ovulation and metabolic parameters)</p>
            <p><span class="label">Menstrual Irregularity/Hyperandrogenism:</span></p>
            <ul>
                <li><strong>Combined OCPs:</strong> First-line for menstrual regulation and hirsutism</li>
                <li><strong>Spironolactone:</strong> Anti-androgen for hirsutism (teratogenic â€” requires contraception)</li>
                <li><strong>Metformin:</strong> Insulin sensitizer; second-line for metabolic features</li>
            </ul>
            <p><span class="label">Infertility:</span> Letrozole (first-line for ovulation induction), clomiphene (second-line)</p>
            <p><span class="label">Screen for:</span> Metabolic syndrome, T2DM (OGTT preferred), OSA, depression, endometrial hyperplasia (unopposed estrogen)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Letrozole &gt; clomiphene</strong> for ovulation induction (higher live birth rates)</li>
            <li><strong>Endometrial protection required:</strong> OCPs or cyclic progestins to prevent hyperplasia/cancer</li>
            <li><strong>OGTT preferred over fasting glucose</strong> for diabetes screening in PCOS</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- MONONUCLEOSIS -->
<div id="mononucleosis" class="condition-page">
    <div class="page-header">
        <h2>194. INFECTIOUS MONONUCLEOSIS</h2>
        <div class="subtitle">EBV â€¢ Heterophile Antibody â€¢ Avoid Contact Sports</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Classic Triad:</span> Fever, pharyngitis (exudative), lymphadenopathy (posterior cervical)</p>
            <p><span class="label">Other Features:</span> Fatigue (can be prolonged), splenomegaly (50%), hepatomegaly, palatal petechiae, periorbital edema</p>
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Atypical lymphocytosis</strong> (&gt;10% atypical lymphocytes)</li>
                <li><strong>Heterophile antibody (Monospot):</strong> 85% sensitive by week 2; may be negative early or in children</li>
                <li><strong>EBV-specific antibodies:</strong> VCA IgM (acute), VCA IgG (past), EBNA (appears later = past infection)</li>
                <li>Mild transaminitis common</li>
            </ul>
            <p><span class="label">Differential:</span> CMV (heterophile-negative mono), HIV acute infection, strep pharyngitis, toxoplasmosis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Supportive:</span> Rest, hydration, acetaminophen/NSAIDs for pain/fever</p>
            <p><span class="label">Avoid:</span></p>
            <ul>
                <li><strong>Contact sports for 3-4 weeks</strong> (splenic rupture risk) â€” some recommend until spleen normalizes</li>
                <li><strong>Amoxicillin/ampicillin:</strong> Causes diffuse maculopapular rash (not true allergy â€” do NOT label as penicillin allergic)</li>
            </ul>
            <p><span class="label">Steroids:</span> Only if airway obstruction from tonsillar enlargement</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Ampicillin rash â‰  penicillin allergy:</strong> EBV-specific phenomenon; don't mislabel</li>
            <li><strong>Heterophile-negative mono:</strong> Think CMV, HIV, or early EBV (check EBV-specific serology)</li>
            <li><strong>Splenic rupture:</strong> Rare but life-threatening; avoid contact sports Ã— 3-4 weeks minimum</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ADULT-ONSET STILL'S DISEASE -->
<div id="adult-still" class="condition-page">
    <div class="page-header">
        <h2>195. ADULT-ONSET STILL'S DISEASE (AOSD)</h2>
        <div class="subtitle">Quotidian Fever â€¢ Salmon-Colored Rash â€¢ Ferritin &gt;10,000</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES â€” YAMAGUCHI CRITERIA</div>
        <div class="section-content">
            <p><span class="label">Major Criteria:</span></p>
            <ul>
                <li><strong>Quotidian fever â‰¥39Â°C for â‰¥1 week:</strong> Daily spikes, returns to normal</li>
                <li><strong>Arthralgia/arthritis â‰¥2 weeks</strong></li>
                <li><strong>Typical rash:</strong> Salmon-colored, evanescent, maculopapular; appears with fever</li>
                <li><strong>Leukocytosis â‰¥10,000 with â‰¥80% granulocytes</strong></li>
            </ul>
            <p><span class="label">Minor Criteria:</span> Sore throat, lymphadenopathy/splenomegaly, liver dysfunction, negative ANA and RF</p>
            <p><span class="label">Diagnosis:</span> â‰¥5 criteria (â‰¥2 major) + exclusion of infection, malignancy, other rheumatic diseases</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">LABS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Characteristic Labs:</span></p>
            <ul>
                <li><strong>Ferritin markedly elevated</strong> (often &gt;10,000 ng/mL) â€” highly suggestive</li>
                <li><strong>Glycosylated ferritin &lt;20%</strong> (more specific)</li>
                <li>Elevated ESR/CRP, leukocytosis, anemia of chronic disease, elevated LFTs</li>
                <li><strong>ANA and RF typically NEGATIVE</strong></li>
            </ul>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>NSAIDs:</strong> Mild disease</li>
                <li><strong>Corticosteroids:</strong> Moderate-severe (prednisone 0.5-1 mg/kg)</li>
                <li><strong>IL-1 inhibitors (anakinra, canakinumab):</strong> Highly effective, often first-line steroid-sparing</li>
                <li><strong>IL-6 inhibitors (tocilizumab):</strong> Alternative</li>
                <li>Methotrexate for chronic arthritis</li>
            </ul>
            <p><span class="label">Complications:</span> Macrophage activation syndrome (MAS) â€” medical emergency</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Ferritin &gt;10,000:</strong> Think Still's disease (or MAS, HLH)</li>
            <li><strong>Quotidian fever + salmon rash + negative ANA/RF + sky-high ferritin = AOSD</strong></li>
            <li><strong>IL-1 inhibitors highly effective:</strong> Anakinra often dramatic response</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- BEHÃ‡ET'S DISEASE -->
<div id="behcet" class="condition-page">
    <div class="page-header">
        <h2>196. BEHÃ‡ET'S DISEASE</h2>
        <div class="subtitle">Oral + Genital Ulcers â€¢ Uveitis â€¢ Pathergy â€¢ Silk Road Disease</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Required:</span> <strong>Recurrent oral ulcers</strong> (â‰¥3 episodes/year) â€” painful aphthous ulcers</p>
            <p><span class="label">Plus â‰¥2 of:</span></p>
            <ul>
                <li><strong>Genital ulcers:</strong> Painful, scarring (scrotal/vulvar)</li>
                <li><strong>Eye involvement:</strong> Anterior/posterior uveitis, retinal vasculitis â€” can cause blindness</li>
                <li><strong>Skin lesions:</strong> Erythema nodosum, pseudofolliculitis, papulopustular lesions</li>
                <li><strong>Positive pathergy test:</strong> Papule/pustule at site of needle prick (24-48h)</li>
            </ul>
            <p><span class="label">Other Features:</span> CNS (neuro-BehÃ§et's â€” meningoencephalitis, sinus thrombosis), vascular (arterial aneurysms, DVT), GI (ileocecal ulcers like Crohn's), arthritis</p>
            <p><span class="label">Demographics:</span> "Silk Road" â€” Turkey, Middle East, East Asia; young adults; HLA-B51 associated</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Mucocutaneous:</span> Topical steroids, colchicine, apremilast</p>
            <p><span class="label">Ocular (sight-threatening):</span> High-dose steroids + azathioprine or <strong>anti-TNF (infliximab, adalimumab)</strong></p>
            <p><span class="label">Vascular/Neurologic:</span> High-dose steroids + immunosuppression (azathioprine, cyclophosphamide, anti-TNF)</p>
            <p><span class="label">Venous thrombosis:</span> Anticoagulation controversial; immunosuppression may be more important</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Oral + genital ulcers + uveitis = BehÃ§et's until proven otherwise</strong></li>
            <li><strong>Pathergy test:</strong> Pustule at needle stick site â€” fairly specific but not sensitive</li>
            <li><strong>Leading cause of blindness in BehÃ§et's:</strong> Posterior uveitis â€” requires aggressive treatment</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- RHEUMATOID ARTHRITIS -->
<div id="rheumatoid-arthritis" class="condition-page">
    <div class="page-header">
        <h2>197. RHEUMATOID ARTHRITIS</h2>
        <div class="subtitle">Symmetric Polyarthritis â€¢ RF/Anti-CCP â€¢ Early DMARD Therapy</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Classic Presentation:</span> Symmetric polyarthritis affecting small joints â€” MCP, PIP, wrists, MTP. <strong>Morning stiffness &gt;1 hour</strong> (inflammatory)</p>
            <p><span class="label">Joints Spared:</span> DIP joints (think OA, psoriatic), thoracolumbar spine</p>
            <p><span class="label">Deformities (Late):</span> Ulnar deviation, swan-neck, boutonniÃ¨re, Z-thumb</p>
            <p><span class="label">Extra-Articular:</span> Rheumatoid nodules (extensor surfaces), interstitial lung disease, pericarditis, Felty syndrome (RA + splenomegaly + neutropenia), scleritis, vasculitis</p>
            
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>RF:</strong> 70-80% sensitive; not specific (also in SjÃ¶gren's, HCV, elderly)</li>
                <li><strong>Anti-CCP:</strong> More specific (~95%); predicts erosive disease</li>
                <li>Elevated ESR/CRP, anemia of chronic disease</li>
            </ul>
            <p><span class="label">Imaging:</span> X-ray â€” periarticular osteopenia, joint space narrowing, erosions (marginal). MRI/US more sensitive early</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT â€” TREAT TO TARGET</div>
        <div class="section-content">
            <p><span class="label">Principle:</span> Early aggressive treatment prevents joint damage. Target = remission or low disease activity</p>
            <p><span class="label">First-Line:</span></p>
            <ul>
                <li><strong>Methotrexate:</strong> Anchor drug; 15-25mg weekly + folic acid</li>
                <li>Monitor: CBC, LFTs, creatinine; avoid alcohol; teratogenic</li>
            </ul>
            <p><span class="label">If Inadequate Response:</span></p>
            <ul>
                <li><strong>Add biologic DMARD:</strong> TNF inhibitors (adalimumab, etanercept), IL-6 inhibitors (tocilizumab), T-cell costimulation blocker (abatacept), B-cell depletion (rituximab)</li>
                <li><strong>JAK inhibitors:</strong> Tofacitinib, baricitinib, upadacitinib</li>
            </ul>
            <p><span class="label">Adjuncts:</span> NSAIDs (symptom control only), low-dose prednisone (bridge, â‰¤3 months)</p>
            <p><span class="label">Screening Before Biologics:</span> TB (quantiferon/PPD), hepatitis B/C, assess infection risk</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Anti-CCP + RF = high specificity and predicts erosive disease</strong></li>
            <li><strong>Methotrexate is first-line</strong> â€” start early to prevent joint destruction</li>
            <li><strong>Screen for latent TB before starting biologics</strong> (especially TNF inhibitors)</li>
            <li><strong>C-spine instability:</strong> Atlantoaxial subluxation â€” assess before intubation/surgery</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- SPONDYLOARTHROPATHIES -->
<div id="spondyloarthropathy" class="condition-page">
    <div class="page-header">
        <h2>198. SPONDYLOARTHROPATHIES</h2>
        <div class="subtitle">HLA-B27 â€¢ Axial Involvement â€¢ Enthesitis â€¢ RF-Negative</div>
    </div>
    
    <div class="section">
        <div class="section-title">OVERVIEW</div>
        <div class="section-content">
            <p><span class="label">Common Features:</span> Inflammatory back pain, sacroiliitis, enthesitis (tendon/ligament insertions), dactylitis ("sausage digit"), uveitis, HLA-B27 association, <strong>RF-negative</strong></p>
            <p><span class="label">Types:</span></p>
            <ul>
                <li><strong>Ankylosing Spondylitis:</strong> Axial predominant; young men; bamboo spine</li>
                <li><strong>Psoriatic Arthritis:</strong> Skin psoriasis + arthritis (DIP involvement, dactylitis, pencil-in-cup)</li>
                <li><strong>Reactive Arthritis:</strong> Post-infectious (Chlamydia, enteric); "can't see, can't pee, can't climb a tree"</li>
                <li><strong>Enteropathic Arthritis:</strong> Associated with IBD</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">ANKYLOSING SPONDYLITIS</div>
        <div class="section-content">
            <p><span class="label">Inflammatory Back Pain (â‰¥4 of 5):</span> Age onset &lt;40, insidious, improves with exercise, no improvement with rest, night pain</p>
            <p><span class="label">Imaging:</span> Sacroiliitis on X-ray (bilateral, symmetric) or MRI (bone marrow edema). Late: bamboo spine, squaring of vertebrae</p>
            <p><span class="label">Extra-Articular:</span> Acute anterior uveitis (30%), aortitis/AR, apical pulmonary fibrosis, IgA nephropathy</p>
            <p><span class="label">Treatment:</span> NSAIDs (first-line â€” continuous), physical therapy. If inadequate: <strong>TNF inhibitors</strong> or IL-17 inhibitors (secukinumab). Methotrexate NOT effective for axial disease</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PSORIATIC ARTHRITIS</div>
        <div class="section-content">
            <p><span class="label">Patterns:</span> DIP arthritis (classic), asymmetric oligoarthritis, symmetric polyarthritis (RA-like), spondylitis, arthritis mutilans</p>
            <p><span class="label">Clues:</span> Nail pitting/onycholysis, dactylitis, enthesitis, skin psoriasis (may be hidden â€” scalp, umbilicus, gluteal cleft)</p>
            <p><span class="label">X-ray:</span> Pencil-in-cup deformity, periostitis, DIP erosions</p>
            <p><span class="label">Treatment:</span> NSAIDs, DMARDs (methotrexate for peripheral), TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors (ustekinumab)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Inflammatory back pain + young male + HLA-B27 = ankylosing spondylitis</strong></li>
            <li><strong>DIP involvement:</strong> Psoriatic arthritis or OA (NOT RA)</li>
            <li><strong>TNF inhibitors first-line biologic</strong> for axial spondyloarthropathy</li>
            <li><strong>Methotrexate doesn't work for axial disease</strong> â€” only peripheral arthritis</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- OSTEOARTHRITIS -->
<div id="osteoarthritis" class="condition-page">
    <div class="page-header">
        <h2>199. OSTEOARTHRITIS</h2>
        <div class="subtitle">Degenerative â€¢ DIP/PIP/Knee/Hip â€¢ Osteophytes â€¢ Non-Inflammatory</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Presentation:</span> Joint pain worse with use, better with rest. <strong>Stiffness &lt;30 minutes</strong> (vs &gt;1 hour in RA)</p>
            <p><span class="label">Joints Affected:</span> DIP (Heberden's nodes), PIP (Bouchard's nodes), first CMC, knees, hips, cervical/lumbar spine. <strong>MCP spared</strong> (think RA)</p>
            <p><span class="label">Exam:</span> Bony enlargement, crepitus, reduced ROM, no warmth/erythema (non-inflammatory)</p>
            <p><span class="label">X-ray Findings:</span> Joint space narrowing (asymmetric), osteophytes, subchondral sclerosis, subchondral cysts</p>
            <p><span class="label">Labs:</span> Normal ESR/CRP, RF negative, synovial fluid non-inflammatory (WBC &lt;2000)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Non-Pharmacologic (First-Line):</span> Weight loss, exercise (strengthening, aerobic), physical therapy, assistive devices</p>
            <p><span class="label">Pharmacologic:</span></p>
            <ul>
                <li><strong>Topical NSAIDs:</strong> First-line for knee OA</li>
                <li><strong>Acetaminophen:</strong> Modest benefit; safer than oral NSAIDs</li>
                <li><strong>Oral NSAIDs:</strong> Effective but GI/CV/renal risks; use lowest dose, shortest duration</li>
                <li><strong>Intra-articular steroids:</strong> Short-term relief; limit frequency</li>
                <li><strong>Duloxetine:</strong> Adjunct for chronic OA pain</li>
            </ul>
            <p><span class="label">NOT Recommended:</span> Glucosamine/chondroitin (no proven benefit), hyaluronic acid injections (mixed evidence), opioids</p>
            <p><span class="label">Surgery:</span> Joint replacement for severe, refractory disease</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>DIP + PIP involvement = OA;</strong> MCP + PIP = RA</li>
            <li><strong>Topical NSAIDs first-line</strong> for knee OA (better safety profile)</li>
            <li><strong>Inflammatory OA of hands:</strong> Erosive OA â€” DIP/PIP erosions, more pain; can mimic inflammatory arthritis</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- LUPUS NEPHRITIS -->
<div id="lupus-nephritis" class="condition-page">
    <div class="page-header">
        <h2>200. LUPUS NEPHRITIS</h2>
        <div class="subtitle">ISN/RPS Classification â€¢ Class III/IV Most Severe â€¢ Biopsy Required</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION (ISN/RPS)</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Class</th><th>Description</th><th>Treatment</th></tr>
                <tr><td>I</td><td>Minimal mesangial</td><td>Supportive</td></tr>
                <tr><td>II</td><td>Mesangial proliferative</td><td>Supportive Â± low-dose steroids</td></tr>
                <tr><td><strong>III</strong></td><td>Focal proliferative (&lt;50% glomeruli)</td><td>Immunosuppression</td></tr>
                <tr><td><strong>IV</strong></td><td>Diffuse proliferative (&gt;50% glomeruli) â€” <strong>MOST COMMON, MOST SEVERE</strong></td><td>Aggressive immunosuppression</td></tr>
                <tr><td>V</td><td>Membranous</td><td>Immunosuppression if nephrotic</td></tr>
                <tr><td>VI</td><td>Sclerosing (&gt;90% sclerosed)</td><td>Supportive; consider transplant</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">When to Suspect:</span> SLE patient with proteinuria (&gt;500mg/day), hematuria, RBC casts, rising creatinine</p>
            <p><span class="label">Labs:</span> Low C3/C4 (consumed), positive anti-dsDNA (correlates with activity), elevated anti-dsDNA titers</p>
            <p><span class="label">Biopsy:</span> Required to determine class and guide treatment</p>
            
            <p><span class="label">Treatment (Class III/IV):</span></p>
            <ul>
                <li><strong>Induction:</strong> Mycophenolate mofetil (MMF) + glucocorticoids (preferred) OR cyclophosphamide + glucocorticoids</li>
                <li><strong>Maintenance:</strong> MMF or azathioprine + low-dose steroids</li>
                <li><strong>Add voclosporin or belimumab</strong> for enhanced response</li>
            </ul>
            <p><span class="label">Adjuncts:</span> Hydroxychloroquine (ALL SLE patients), ACEi/ARB for proteinuria, BP control</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Class IV = diffuse proliferative = worst prognosis</strong> without treatment</li>
            <li><strong>All SLE patients should be on hydroxychloroquine</strong> (reduces flares, mortality)</li>
            <li><strong>Anti-dsDNA and complement levels</strong> correlate with disease activity</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- DRUG-INDUCED LUPUS -->
<div id="drug-induced-lupus" class="condition-page">
    <div class="page-header">
        <h2>201. DRUG-INDUCED LUPUS</h2>
        <div class="subtitle">Anti-Histone Antibodies â€¢ Resolves with Drug Cessation â€¢ Renal/CNS Rare</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Common Culprits (HIGH RISK):</span></p>
            <ul>
                <li><strong>Hydralazine</strong> (most common)</li>
                <li><strong>Procainamide</strong> (highest incidence with chronic use)</li>
                <li><strong>Isoniazid</strong></li>
                <li>Minocycline, TNF inhibitors, methyldopa, quinidine</li>
            </ul>
            
            <p><span class="label">Clinical Features:</span> Arthralgia/arthritis, myalgia, serositis (pleuritis, pericarditis), fever, rash. Typically milder than SLE</p>
            <p><span class="label">Usually ABSENT:</span> Renal disease, CNS involvement, severe cytopenias (major distinguishing feature from SLE)</p>
            
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>ANA positive</strong> (usually homogeneous pattern)</li>
                <li><strong>Anti-histone antibodies positive</strong> (~95%) â€” most specific</li>
                <li><strong>Anti-dsDNA typically NEGATIVE</strong> (unlike SLE)</li>
                <li>Complement levels usually NORMAL</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Primary Treatment:</span> <strong>Discontinue offending drug</strong> â€” symptoms resolve within weeks to months</p>
            <p><span class="label">Symptomatic:</span> NSAIDs for arthralgia/myalgia; short-course steroids if severe</p>
            <p><span class="label">Serologies:</span> ANA may remain positive for months after drug cessation</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Anti-histone antibodies + drug exposure + no renal/CNS = drug-induced lupus</strong></li>
            <li><strong>Hydralazine #1 cause;</strong> procainamide highest incidence with prolonged use</li>
            <li><strong>Resolves with drug discontinuation</strong> â€” don't need long-term immunosuppression</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- SYSTEMIC SCLEROSIS -->
<div id="systemic-sclerosis" class="condition-page">
    <div class="page-header">
        <h2>202. SYSTEMIC SCLEROSIS (SCLERODERMA)</h2>
        <div class="subtitle">Limited (CREST) vs Diffuse â€¢ Anti-Scl-70 vs Anti-Centromere â€¢ Renal Crisis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Feature</th><th>Limited (CREST)</th><th>Diffuse</th></tr>
                <tr><td>Skin involvement</td><td>Distal to elbows/knees, face</td><td>Proximal (trunk, upper arms/thighs)</td></tr>
                <tr><td>Raynaud's</td><td>Years before skin changes</td><td>Within 1 year of skin changes</td></tr>
                <tr><td>Antibody</td><td><strong>Anti-centromere</strong></td><td><strong>Anti-Scl-70 (topoisomerase I)</strong></td></tr>
                <tr><td>Organ involvement</td><td>Pulmonary HTN (late), less ILD</td><td>ILD, renal crisis, cardiac</td></tr>
                <tr><td>Prognosis</td><td>Better (except PAH)</td><td>Worse</td></tr>
            </table>
            <p><span class="label">CREST:</span> Calcinosis, Raynaud's, Esophageal dysmotility, Sclerodactyly, Telangiectasias</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">Skin:</span> Tight, thickened skin; "salt and pepper" pigmentation; digital ulcers</p>
            <p><span class="label">GI:</span> Esophageal dysmotility (GERD, dysphagia), gastroparesis, small bowel dysmotility (bacterial overgrowth), watermelon stomach (GAVE)</p>
            <p><span class="label">Pulmonary:</span> ILD (ground-glass â†’ fibrosis on HRCT), pulmonary arterial hypertension (PAH)</p>
            
            <p><span class="label">Treatments by Manifestation:</span></p>
            <ul>
                <li><strong>Raynaud's:</strong> CCBs (nifedipine), avoid cold</li>
                <li><strong>GI:</strong> PPI, prokinetics, antibiotics for bacterial overgrowth</li>
                <li><strong>ILD:</strong> Mycophenolate, nintedanib, tocilizumab</li>
                <li><strong>PAH:</strong> PDE5 inhibitors, endothelin receptor antagonists, prostacyclins</li>
                <li><strong>Renal crisis:</strong> See below</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ SCLERODERMA RENAL CRISIS</div>
            <ul>
                <li><strong>Presentation:</strong> Acute HTN, AKI, microangiopathic hemolytic anemia</li>
                <li><strong>Risk factors:</strong> Diffuse disease, early disease, high-dose steroids, anti-RNA polymerase III</li>
                <li><strong>Treatment:</strong> <strong>ACE INHIBITORS</strong> (captopril) â€” even if creatinine rising</li>
                <li><strong>Do NOT use steroids</strong> â€” can precipitate crisis</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Anti-centromere = limited/CREST;</strong> Anti-Scl-70 = diffuse</li>
            <li><strong>ACE inhibitors for scleroderma renal crisis</strong> â€” continue even if Cr rises</li>
            <li><strong>High-dose steroids can precipitate renal crisis</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- INFLAMMATORY MYOPATHIES -->
<div id="inflammatory-myopathy" class="condition-page">
    <div class="page-header">
        <h2>203. INFLAMMATORY MYOPATHIES</h2>
        <div class="subtitle">Dermatomyositis vs Polymyositis â€¢ Proximal Weakness â€¢ CK Elevated</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION & FEATURES</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Feature</th><th>Dermatomyositis</th><th>Polymyositis</th><th>Inclusion Body Myositis</th></tr>
                <tr><td>Weakness</td><td>Proximal, symmetric</td><td>Proximal, symmetric</td><td>Asymmetric, distal (finger flexors, quads)</td></tr>
                <tr><td>Skin findings</td><td><strong>Heliotrope rash, Gottron's papules</strong></td><td>None</td><td>None</td></tr>
                <tr><td>CK</td><td>Elevated (10-50Ã—)</td><td>Elevated (10-50Ã—)</td><td>Normal or mildly elevated</td></tr>
                <tr><td>Malignancy risk</td><td><strong>HIGH (screen)</strong></td><td>Moderate</td><td>Low</td></tr>
                <tr><td>Treatment response</td><td>Good</td><td>Good</td><td>Poor</td></tr>
            </table>
            
            <p><span class="label">Dermatomyositis Skin Findings:</span></p>
            <ul>
                <li><strong>Heliotrope rash:</strong> Violaceous eyelid discoloration</li>
                <li><strong>Gottron's papules:</strong> Erythematous papules over MCP, PIP, DIP</li>
                <li><strong>V-sign:</strong> Rash on anterior chest/neck</li>
                <li><strong>Shawl sign:</strong> Rash on upper back/shoulders</li>
                <li><strong>Mechanic's hands:</strong> Cracked, fissured skin on fingers</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Diagnosis:</span></p>
            <ul>
                <li><strong>CK elevated</strong> (can be very high)</li>
                <li><strong>EMG:</strong> Myopathic pattern (short, small polyphasic potentials)</li>
                <li><strong>MRI:</strong> Muscle edema</li>
                <li><strong>Muscle biopsy:</strong> Gold standard (perifascicular atrophy in DM, endomysial inflammation in PM)</li>
                <li><strong>Myositis-specific antibodies:</strong> Anti-Jo-1 (antisynthetase syndrome â€” ILD, arthritis, Raynaud's, mechanic's hands)</li>
            </ul>
            
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>High-dose glucocorticoids</strong> (prednisone 1mg/kg) first-line</li>
                <li><strong>Steroid-sparing:</strong> Methotrexate, azathioprine, IVIG</li>
                <li><strong>Rituximab</strong> for refractory cases</li>
            </ul>
            
            <p><span class="label">Malignancy Screening (Dermatomyositis):</span> Age-appropriate cancer screening + CT chest/abdomen/pelvis; ovarian cancer screen in women</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Heliotrope + Gottron's = dermatomyositis</strong> â€” screen for malignancy</li>
            <li><strong>Anti-Jo-1:</strong> Antisynthetase syndrome â€” ILD + arthritis + mechanic's hands</li>
            <li><strong>Inclusion body myositis:</strong> Older men, asymmetric, distal weakness, poor treatment response</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- SJÃ–GREN'S SYNDROME -->
<div id="sjogren" class="condition-page">
    <div class="page-header">
        <h2>204. SJÃ–GREN'S SYNDROME</h2>
        <div class="subtitle">Sicca Symptoms â€¢ Anti-SSA/SSB â€¢ Lymphoma Risk</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Sicca Symptoms:</span></p>
            <ul>
                <li><strong>Dry eyes (keratoconjunctivitis sicca):</strong> Gritty sensation, burning</li>
                <li><strong>Dry mouth (xerostomia):</strong> Difficulty swallowing dry foods, dental caries</li>
            </ul>
            <p><span class="label">Extraglandular:</span> Arthralgia/arthritis, Raynaud's, interstitial nephritis (RTA type 1), peripheral neuropathy, ILD, parotid enlargement</p>
            <p><span class="label">Primary vs Secondary:</span> Secondary occurs with other autoimmune diseases (RA, SLE, scleroderma)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Anti-SSA (Ro):</strong> 70% â€” also seen in SLE; associated with neonatal lupus, congenital heart block</li>
                <li><strong>Anti-SSB (La):</strong> 40% â€” more specific for SjÃ¶gren's</li>
                <li>RF positive (common), ANA positive</li>
            </ul>
            <p><span class="label">Tests:</span> Schirmer test (tear production), salivary gland biopsy (focal lymphocytic infiltration â€” most specific)</p>
            
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Dry eyes:</strong> Artificial tears, cyclosporine drops (Restasis), punctal plugs</li>
                <li><strong>Dry mouth:</strong> Saliva substitutes, pilocarpine, cevimeline (muscarinic agonists), good dental care</li>
                <li><strong>Systemic:</strong> Hydroxychloroquine (fatigue, arthralgia), immunosuppression for severe organ involvement</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Anti-SSA in pregnancy:</strong> Risk of neonatal lupus and congenital heart block â€” monitor fetal heart</li>
            <li><strong>Lymphoma risk increased</strong> (especially MALT, marginal zone) â€” monitor for parotid enlargement, lymphadenopathy</li>
            <li><strong>Type 1 RTA:</strong> Distal RTA with hypokalemia â€” think SjÃ¶gren's</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- MCTD -->
<div id="mctd" class="condition-page">
    <div class="page-header">
        <h2>205. MIXED CONNECTIVE TISSUE DISEASE (MCTD)</h2>
        <div class="subtitle">Overlap Syndrome â€¢ High-Titer Anti-U1 RNP â€¢ Raynaud's Universal</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Overlap of features from SLE, scleroderma, and polymyositis with <strong>high-titer anti-U1 RNP antibodies</strong></p>
            <p><span class="label">Common Features:</span></p>
            <ul>
                <li><strong>Raynaud's phenomenon:</strong> Nearly universal</li>
                <li><strong>Swollen "sausage" fingers</strong></li>
                <li>Arthritis/arthralgia</li>
                <li>Myositis</li>
                <li>Esophageal dysmotility</li>
                <li><strong>Pulmonary HTN</strong> (leading cause of death)</li>
            </ul>
            <p><span class="label">Usually Spared:</span> Severe renal disease, CNS involvement (unlike SLE)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>High-titer anti-U1 RNP</strong> (required for diagnosis)</li>
                <li>ANA positive (speckled pattern)</li>
                <li>RF may be positive</li>
            </ul>
            <p><span class="label">Treatment:</span> Treat specific manifestations â€” NSAIDs/hydroxychloroquine for arthritis, steroids for myositis/serositis, CCBs for Raynaud's, PAH-specific therapy</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>High-titer anti-U1 RNP + Raynaud's + overlap features = MCTD</strong></li>
            <li><strong>Pulmonary HTN is major cause of morbidity/mortality</strong></li>
            <li>May evolve into a single defined CTD over time</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ANTIPHOSPHOLIPID SYNDROME -->
<div id="aps" class="condition-page">
    <div class="page-header">
        <h2>206. ANTIPHOSPHOLIPID SYNDROME (APS)</h2>
        <div class="subtitle">Thrombosis + Pregnancy Loss â€¢ Lupus Anticoagulant â€¢ Lifelong Anticoagulation</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL CRITERIA (SYDNEY)</div>
        <div class="section-content">
            <p><span class="label">Clinical (â‰¥1 required):</span></p>
            <ul>
                <li><strong>Vascular thrombosis:</strong> Arterial, venous, or small vessel (DVT, PE, stroke, MI)</li>
                <li><strong>Pregnancy morbidity:</strong> â‰¥1 unexplained fetal death â‰¥10 weeks, â‰¥1 premature birth &lt;34 weeks due to preeclampsia/placental insufficiency, â‰¥3 consecutive spontaneous abortions &lt;10 weeks</li>
            </ul>
            <p><span class="label">Laboratory (â‰¥1 required, positive on 2 occasions â‰¥12 weeks apart):</span></p>
            <ul>
                <li><strong>Lupus anticoagulant (LA):</strong> Most specific; prolongs PTT but is prothrombotic</li>
                <li><strong>Anticardiolipin antibodies</strong> (IgG or IgM, medium-high titer)</li>
                <li><strong>Anti-Î²2 glycoprotein I antibodies</strong> (IgG or IgM)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Thrombosis:</span></p>
            <ul>
                <li><strong>First venous thrombosis:</strong> Warfarin (INR 2-3) â€” lifelong if unprovoked</li>
                <li><strong>Arterial thrombosis:</strong> Warfarin (INR 2-3) Â± aspirin</li>
                <li><strong>Recurrent thrombosis on warfarin:</strong> Higher INR (3-4) or add aspirin or LMWH</li>
                <li><strong>DOACs:</strong> NOT recommended (inferior to warfarin in APS, especially triple-positive)</li>
            </ul>
            <p><span class="label">Pregnancy:</span> LMWH + low-dose aspirin</p>
            <p><span class="label">Primary Prevention (asymptomatic antibodies):</span> Low-dose aspirin if high-risk (triple positive)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="box warning-box">
            <div class="box-title">âš ï¸ CATASTROPHIC APS (CAPS)</div>
            <p>Multi-organ thrombosis over days-weeks. High mortality. Treat with anticoagulation + steroids + plasma exchange or IVIG.</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Prolonged PTT + thrombosis = think lupus anticoagulant</strong> (PTT doesn't correct with mixing study)</li>
            <li><strong>Warfarin preferred over DOACs</strong> in APS (especially triple-positive)</li>
            <li><strong>False-positive VDRL/RPR</strong> can occur with antiphospholipid antibodies</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- SARCOIDOSIS -->
<div id="sarcoidosis" class="condition-page">
    <div class="page-header">
        <h2>207. SARCOIDOSIS</h2>
        <div class="subtitle">Non-Caseating Granulomas â€¢ Bilateral Hilar LAD â€¢ Multi-Organ</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Demographics:</span> African Americans, Northern Europeans, women; age 25-45</p>
            <p><span class="label">Pulmonary (>90%):</span> Bilateral hilar lymphadenopathy (BHL), ILD, cough, dyspnea</p>
            <p><span class="label">Staging:</span> Stage 0 = normal CXR; I = BHL only; II = BHL + parenchymal; III = parenchymal only; IV = fibrosis</p>
            
            <p><span class="label">Extrapulmonary:</span></p>
            <ul>
                <li><strong>Skin:</strong> Erythema nodosum (good prognosis), lupus pernio (violaceous facial plaques â€” poor prognosis)</li>
                <li><strong>Eyes:</strong> Uveitis (anterior most common) â€” screen all patients</li>
                <li><strong>Cardiac:</strong> Heart block, cardiomyopathy, sudden death</li>
                <li><strong>Neuro:</strong> CN VII palsy (most common), meningitis, hypothalamic involvement</li>
                <li><strong>Renal:</strong> Hypercalcemia/hypercalciuria (granulomas produce 1,25-vitamin D), nephrolithiasis</li>
                <li><strong>Liver/spleen:</strong> Hepatomegaly, elevated ALP</li>
            </ul>
            <p><span class="label">LÃ¶fgren Syndrome:</span> BHL + erythema nodosum + ankle arthritis + fever â€” excellent prognosis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Labs:</span> ACE level (non-specific, not for diagnosis), hypercalcemia, elevated ALP</p>
            <p><span class="label">Diagnosis:</span> <strong>Biopsy showing non-caseating granulomas</strong> + compatible clinical/radiographic findings + exclusion of other causes (TB, fungal)</p>
            
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Observation:</strong> Stage I often resolves spontaneously</li>
                <li><strong>Corticosteroids:</strong> First-line for symptomatic pulmonary, cardiac, neuro, ocular, hypercalcemia</li>
                <li><strong>Steroid-sparing:</strong> Methotrexate, azathioprine; anti-TNF for refractory</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Bilateral hilar LAD on CXR in young adult = think sarcoidosis</strong></li>
            <li><strong>LÃ¶fgren syndrome:</strong> Erythema nodosum + BHL + arthritis = excellent prognosis, often resolves</li>
            <li><strong>Hypercalcemia:</strong> Granulomas convert 25-OH to 1,25-OH vitamin D</li>
            <li><strong>Lupus pernio = poor prognosis;</strong> erythema nodosum = good prognosis</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- IgG4-RELATED DISEASE -->
<div id="igg4" class="condition-page">
    <div class="page-header">
        <h2>208. IgG4-RELATED DISEASE</h2>
        <div class="subtitle">Tumefactive Lesions â€¢ Elevated Serum IgG4 â€¢ Autoimmune Pancreatitis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Overview:</span> Fibroinflammatory condition with tumefactive (mass-forming) lesions; can mimic malignancy</p>
            <p><span class="label">Organ Involvement:</span></p>
            <ul>
                <li><strong>Pancreas:</strong> Type 1 autoimmune pancreatitis (diffuse pancreatic enlargement "sausage pancreas")</li>
                <li><strong>Biliary:</strong> Sclerosing cholangitis (mimics cholangiocarcinoma)</li>
                <li><strong>Salivary/lacrimal glands:</strong> Mikulicz disease (bilateral gland enlargement)</li>
                <li><strong>Retroperitoneum:</strong> Retroperitoneal fibrosis</li>
                <li><strong>Kidney:</strong> Tubulointerstitial nephritis</li>
                <li><strong>Aorta:</strong> Periaortitis</li>
                <li><strong>Thyroid:</strong> Riedel's thyroiditis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Labs:</span> <strong>Elevated serum IgG4</strong> (>135 mg/dL) â€” not required for diagnosis; can be normal in 30%</p>
            <p><span class="label">Histology:</span> Dense lymphoplasmacytic infiltrate with IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Glucocorticoids:</strong> First-line â€” typically dramatic response</li>
                <li><strong>Rituximab:</strong> Steroid-sparing, relapsed/refractory</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Painless jaundice + "sausage pancreas" = autoimmune pancreatitis (IgG4-related)</strong></li>
            <li><strong>Can mimic pancreatic cancer</strong> â€” check IgG4, consider biopsy before Whipple</li>
            <li><strong>Responds dramatically to steroids</strong> â€” diagnostic and therapeutic</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- AMYLOIDOSIS -->
<div id="amyloidosis" class="condition-page">
    <div class="page-header">
        <h2>209. AMYLOIDOSIS</h2>
        <div class="subtitle">AL vs AA vs ATTR â€¢ Congo Red Birefringence â€¢ Multi-Organ</div>
    </div>
    
    <div class="section">
        <div class="section-title">TYPES</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Type</th><th>Precursor Protein</th><th>Associated Conditions</th><th>Key Features</th></tr>
                <tr><td><strong>AL (Primary)</strong></td><td>Immunoglobulin light chains</td><td>Multiple myeloma, plasma cell dyscrasias</td><td>Heart, kidney, nerve, liver, tongue</td></tr>
                <tr><td><strong>AA (Secondary)</strong></td><td>Serum amyloid A</td><td>Chronic inflammation (RA, IBD, chronic infections)</td><td>Kidney (nephrotic), liver, spleen</td></tr>
                <tr><td><strong>ATTR (hereditary)</strong></td><td>Transthyretin (mutant)</td><td>Familial (Val30Met common)</td><td>Neuropathy, cardiomyopathy</td></tr>
                <tr><td><strong>ATTR (wild-type)</strong></td><td>Transthyretin (wild-type)</td><td>Elderly men</td><td>Cardiomyopathy, carpal tunnel</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Clues to AL Amyloidosis:</span></p>
            <ul>
                <li><strong>Nephrotic syndrome</strong> (most common renal manifestation)</li>
                <li><strong>Restrictive cardiomyopathy</strong> with low-voltage ECG and "sparkling" myocardium on echo</li>
                <li><strong>Macroglossia</strong> (pathognomonic)</li>
                <li>Periorbital purpura ("raccoon eyes")</li>
                <li>Peripheral/autonomic neuropathy</li>
                <li>Hepatomegaly with elevated ALP</li>
                <li>Carpal tunnel syndrome (bilateral)</li>
            </ul>
            <p><span class="label">Diagnosis:</span></p>
            <ul>
                <li><strong>Tissue biopsy:</strong> Fat pad aspirate, bone marrow, or affected organ</li>
                <li><strong>Congo red stain:</strong> Apple-green birefringence under polarized light</li>
                <li><strong>Mass spectrometry:</strong> Identify amyloid type</li>
                <li><strong>Workup for AL:</strong> SPEP/UPEP, serum free light chains, bone marrow biopsy</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">AL Amyloidosis:</span> Treat underlying plasma cell dyscrasia â€” daratumumab + CyBorD, autologous stem cell transplant if eligible</p>
            <p><span class="label">AA Amyloidosis:</span> Treat underlying inflammatory condition</p>
            <p><span class="label">ATTR:</span> Tafamidis (TTR stabilizer) for cardiomyopathy; liver transplant (hereditary); patisiran/inotersen (gene silencers)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Nephrotic syndrome + cardiomyopathy + neuropathy = think AL amyloidosis</strong></li>
            <li><strong>Macroglossia is pathognomonic</strong> for AL amyloidosis</li>
            <li><strong>Low-voltage ECG + thick walls on echo = infiltrative cardiomyopathy</strong> (amyloid)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- OSTEOPOROSIS -->
<div id="osteoporosis" class="condition-page">
    <div class="page-header">
        <h2>210. OSTEOPOROSIS</h2>
        <div class="subtitle">T-Score â‰¤-2.5 â€¢ FRAX Risk â€¢ Bisphosphonates First-Line</div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & SCREENING</div>
        <div class="section-content">
            <p><span class="label">DEXA Screening:</span> Women â‰¥65, men â‰¥70, younger if risk factors</p>
            <p><span class="label">Definitions (T-score):</span></p>
            <ul>
                <li><strong>Normal:</strong> T-score â‰¥ -1.0</li>
                <li><strong>Osteopenia:</strong> T-score -1.0 to -2.5</li>
                <li><strong>Osteoporosis:</strong> T-score â‰¤ -2.5</li>
            </ul>
            <p><span class="label">FRAX:</span> 10-year fracture risk calculator. Treat if hip fracture risk â‰¥3% or major osteoporotic fracture risk â‰¥20%</p>
            <p><span class="label">Secondary Causes:</span> Vitamin D deficiency, hyperparathyroidism, hyperthyroidism, Cushing's, celiac, chronic steroids, hypogonadism</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Non-Pharmacologic:</span> Weight-bearing exercise, fall prevention, calcium 1000-1200mg/day, vitamin D 800-1000 IU/day</p>
            <p><span class="label">First-Line:</span></p>
            <ul>
                <li><strong>Bisphosphonates:</strong> Alendronate 70mg weekly, risedronate, zoledronic acid 5mg IV yearly</li>
                <li>Take on empty stomach, remain upright 30 min, adequate calcium/vitamin D</li>
                <li>Side effects: GI (oral), osteonecrosis of jaw (rare), atypical femur fractures (rare, with prolonged use)</li>
            </ul>
            <p><span class="label">Alternatives:</span></p>
            <ul>
                <li><strong>Denosumab:</strong> Anti-RANKL; 60mg SC q6 months (rapid bone loss if stopped â€” must transition)</li>
                <li><strong>Teriparatide/abaloparatide:</strong> Anabolic (PTH analog); for severe/refractory; max 2 years</li>
                <li><strong>Romosozumab:</strong> Anti-sclerostin; very high fracture risk (avoid if recent MI/stroke)</li>
            </ul>
            <p><span class="label">Drug Holiday:</span> Consider after 5 years oral or 3 years IV bisphosphonate in moderate-risk patients</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Bisphosphonates first-line;</strong> use FRAX if osteopenia to guide treatment</li>
            <li><strong>Denosumab: rebound bone loss if stopped</strong> â€” must transition to bisphosphonate</li>
            <li><strong>Zoledronic acid:</strong> Give after hip fracture repair (reduces future fractures and mortality)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PAGET'S DISEASE -->
<div id="paget" class="condition-page">
    <div class="page-header">
        <h2>211. PAGET'S DISEASE OF BONE</h2>
        <div class="subtitle">Elevated ALP â€¢ Normal Ca/Phos â€¢ Bisphosphonates</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Pathophysiology:</span> Increased osteoclast â†’ osteoblast activity; disorganized bone remodeling</p>
            <p><span class="label">Common Sites:</span> Pelvis, spine, skull, femur, tibia</p>
            <p><span class="label">Presentation:</span></p>
            <ul>
                <li><strong>Often asymptomatic</strong> (incidental elevated ALP)</li>
                <li>Bone pain (most common symptom)</li>
                <li>Skeletal deformities (bowing of tibia, skull enlargement)</li>
                <li>Hearing loss (skull involvement)</li>
            </ul>
            <p><span class="label">Complications:</span> Fractures, osteoarthritis (adjacent joints), high-output heart failure (rare, extensive disease), <strong>osteosarcoma</strong> (rare but serious â€” sudden pain increase)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Elevated alkaline phosphatase</strong> (reflects disease activity)</li>
                <li><strong>Normal calcium and phosphorus</strong></li>
                <li>Normal PTH</li>
            </ul>
            <p><span class="label">Imaging:</span> X-ray shows lytic and sclerotic lesions, cortical thickening, bone enlargement. Bone scan shows increased uptake</p>
            
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Bisphosphonates:</strong> Zoledronic acid 5mg IV Ã— 1 (first-line); alendronate</li>
                <li><strong>Indications:</strong> Symptoms, elevated ALP, involvement at high-risk sites (skull, spine, weight-bearing bones), before orthopedic surgery</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Isolated elevated ALP + normal Ca/Phos = Paget's disease</strong></li>
            <li><strong>Sudden increase in pain:</strong> Think fracture or osteosarcoma</li>
            <li><strong>Zoledronic acid single dose</strong> often sufficient for years</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- OSTEONECROSIS -->
<div id="osteonecrosis" class="condition-page">
    <div class="page-header">
        <h2>212. OSTEONECROSIS (AVASCULAR NECROSIS)</h2>
        <div class="subtitle">Hip Most Common â€¢ Steroids/Alcohol â€¢ MRI Most Sensitive</div>
    </div>
    
    <div class="section">
        <div class="section-title">ETIOLOGY & CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li><strong>Corticosteroids</strong> (most common non-traumatic cause)</li>
                <li><strong>Alcohol abuse</strong></li>
                <li>Sickle cell disease</li>
                <li>Hip fracture/dislocation (traumatic)</li>
                <li>SLE, antiphospholipid syndrome</li>
                <li>Radiation, Gaucher disease, decompression sickness (Caisson disease)</li>
            </ul>
            <p><span class="label">Common Sites:</span> Femoral head (hip) most common, humeral head, femoral condyles, talus</p>
            <p><span class="label">Presentation:</span> Gradual onset of joint pain, worse with weight-bearing; may be bilateral</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>X-ray:</strong> May be normal early; later shows crescent sign, subchondral collapse, sclerosis</li>
                <li><strong>MRI:</strong> Most sensitive for early detection â€” "double-line sign" (pathognomonic)</li>
            </ul>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Early (pre-collapse):</strong> Protected weight-bearing, bisphosphonates (limited evidence), core decompression</li>
                <li><strong>Late (collapse):</strong> Total joint arthroplasty</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Hip pain + steroid use = think AVN</strong> (MRI if X-ray negative)</li>
            <li><strong>MRI most sensitive</strong> â€” order if high suspicion and normal X-ray</li>
            <li><strong>Screen contralateral hip</strong> â€” often bilateral</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- FIBROMYALGIA -->
<div id="fibromyalgia" class="condition-page">
    <div class="page-header">
        <h2>213. FIBROMYALGIA</h2>
        <div class="subtitle">Widespread Pain â€¢ Normal Labs â€¢ Central Sensitization</div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Criteria (2010/2016):</span></p>
            <ul>
                <li><strong>Widespread pain index (WPI)</strong> + symptom severity scale (SSS)</li>
                <li>Symptoms present â‰¥3 months</li>
                <li>No other disorder that would explain symptoms</li>
            </ul>
            <p><span class="label">Clinical Features:</span></p>
            <ul>
                <li><strong>Widespread pain:</strong> Both sides, above and below waist</li>
                <li><strong>Fatigue</strong></li>
                <li><strong>Non-restorative sleep</strong></li>
                <li><strong>Cognitive symptoms ("fibro fog")</strong></li>
                <li>Associated: Headache, IBS, interstitial cystitis, depression, anxiety</li>
            </ul>
            <p><span class="label">Labs:</span> <strong>All normal</strong> â€” CBC, CMP, TSH, ESR/CRP. Order only to rule out other conditions</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Non-Pharmacologic (Cornerstone):</span></p>
            <ul>
                <li><strong>Exercise:</strong> Aerobic + strength training â€” most effective intervention</li>
                <li>Sleep hygiene</li>
                <li>Cognitive behavioral therapy</li>
            </ul>
            <p><span class="label">Pharmacologic:</span></p>
            <ul>
                <li><strong>Duloxetine (SNRI):</strong> FDA-approved; also helps depression</li>
                <li><strong>Milnacipran (SNRI):</strong> FDA-approved</li>
                <li><strong>Pregabalin:</strong> FDA-approved; helps pain and sleep</li>
                <li>Amitriptyline (low-dose): Helps pain and sleep</li>
                <li><strong>Avoid:</strong> Opioids (ineffective, harmful), NSAIDs (limited benefit)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Normal labs + widespread pain + fatigue + sleep problems = fibromyalgia</strong></li>
            <li><strong>Exercise is most effective treatment</strong></li>
            <li><strong>Avoid opioids</strong> â€” not effective and may worsen outcomes</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CAUDA EQUINA SYNDROME -->
<div id="cauda-equina" class="condition-page">
    <div class="page-header">
        <h2>214. CAUDA EQUINA SYNDROME</h2>
        <div class="subtitle">Surgical Emergency â€¢ Saddle Anesthesia â€¢ Urinary Retention</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Etiology:</span> Large central disc herniation (most common), tumor, abscess, hematoma, trauma</p>
            <p><span class="label">Red Flag Symptoms:</span></p>
            <ul>
                <li><strong>Saddle anesthesia:</strong> Numbness in perineum/perianal area</li>
                <li><strong>Urinary retention</strong> (most common) or incontinence</li>
                <li><strong>Fecal incontinence</strong></li>
                <li><strong>Bilateral leg weakness/numbness</strong></li>
                <li><strong>Sexual dysfunction</strong></li>
                <li>Low back pain with bilateral sciatica</li>
            </ul>
            <p><span class="label">Exam:</span> Decreased anal tone, absent bulbocavernosus reflex, post-void residual &gt;100-200mL</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <div class="box warning-box">
                <div class="box-title">âš ï¸ SURGICAL EMERGENCY</div>
                <p>Delay in decompression leads to permanent neurologic deficits. <strong>Emergent MRI + neurosurgical consultation</strong></p>
            </div>
            <p><span class="label">Imaging:</span> <strong>MRI lumbar spine</strong> (emergent) â€” CT myelogram if MRI unavailable</p>
            <p><span class="label">Treatment:</span> <strong>Emergent surgical decompression</strong> â€” ideally within 24-48 hours for best outcomes</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Back pain + saddle anesthesia + urinary retention = cauda equina until proven otherwise</strong></li>
            <li><strong>Check post-void residual</strong> â€” urinary retention is the most consistent finding</li>
            <li><strong>Emergent MRI and surgical decompression</strong> â€” delays worsen outcomes</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CUSHING SYNDROME -->
<div id="cushing" class="condition-page">
    <div class="page-header">
        <h2>215. CUSHING SYNDROME</h2>
        <div class="subtitle">Hypercortisolism â€¢ ACTH-Dependent vs Independent â€¢ Dexamethasone Suppression</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Classic Features:</span></p>
            <ul>
                <li><strong>Central obesity</strong> with thin extremities</li>
                <li><strong>Moon facies, buffalo hump, supraclavicular fat pads</strong></li>
                <li><strong>Purple striae</strong> (>1cm wide) â€” most specific</li>
                <li><strong>Proximal muscle weakness</strong></li>
                <li><strong>Easy bruising, thin skin</strong></li>
                <li>Hypertension, hyperglycemia, hypokalemia</li>
                <li>Osteoporosis, menstrual irregularities, hirsutism</li>
                <li>Depression, cognitive changes</li>
            </ul>
            <p><span class="label">Etiology:</span></p>
            <ul>
                <li><strong>Exogenous steroids:</strong> Most common cause overall</li>
                <li><strong>ACTH-dependent (80%):</strong> Pituitary adenoma (Cushing disease 70%), ectopic ACTH (lung cancer, carcinoid)</li>
                <li><strong>ACTH-independent (20%):</strong> Adrenal adenoma, adrenal carcinoma</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Step 1 â€” Confirm Hypercortisolism (â‰¥2 abnormal):</span></p>
            <ul>
                <li><strong>24-hour urine free cortisol</strong> (elevated)</li>
                <li><strong>Late-night salivary cortisol</strong> (elevated â€” loss of diurnal variation)</li>
                <li><strong>1mg overnight dexamethasone suppression test:</strong> Morning cortisol >1.8 Î¼g/dL = abnormal (fails to suppress)</li>
            </ul>
            
            <p><span class="label">Step 2 â€” Determine ACTH Dependence:</span></p>
            <ul>
                <li><strong>ACTH suppressed (&lt;5 pg/mL):</strong> ACTH-independent â†’ Adrenal imaging (CT)</li>
                <li><strong>ACTH normal/elevated:</strong> ACTH-dependent â†’ Pituitary MRI</li>
            </ul>
            
            <p><span class="label">Step 3 â€” Localize (if ACTH-dependent):</span></p>
            <ul>
                <li><strong>High-dose (8mg) dexamethasone suppression:</strong> Suppresses = pituitary; No suppression = ectopic</li>
                <li><strong>Inferior petrosal sinus sampling (IPSS):</strong> Gold standard to distinguish pituitary vs ectopic</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Pituitary (Cushing Disease):</span> Transsphenoidal surgery (first-line)</p>
            <p><span class="label">Adrenal Adenoma:</span> Adrenalectomy</p>
            <p><span class="label">Ectopic ACTH:</span> Resect tumor if possible; medical therapy if not</p>
            <p><span class="label">Medical Therapy:</span> Ketoconazole, metyrapone, osilodrostat (steroidogenesis inhibitors); mifepristone (glucocorticoid receptor antagonist); pasireotide (pituitary)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Wide purple striae most specific</strong> for Cushing (vs obesity)</li>
            <li><strong>Exogenous steroids most common cause</strong> â€” always ask about steroid use</li>
            <li><strong>Ectopic ACTH:</strong> Often severe, rapid onset, hypokalemia prominent (small cell lung cancer)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PRIMARY ALDOSTERONISM -->
<div id="primary-aldosteronism" class="condition-page">
    <div class="page-header">
        <h2>216. PRIMARY ALDOSTERONISM (CONN SYNDROME)</h2>
        <div class="subtitle">HTN + Hypokalemia â€¢ ARR Screening â€¢ Adrenal Adenoma vs Hyperplasia</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & SCREENING</div>
        <div class="section-content">
            <p><span class="label">Suspect When:</span></p>
            <ul>
                <li><strong>Resistant hypertension</strong> (uncontrolled on â‰¥3 drugs)</li>
                <li><strong>Hypertension + hypokalemia</strong> (spontaneous or diuretic-induced severe)</li>
                <li>Hypertension + adrenal incidentaloma</li>
                <li>Early-onset HTN or family history of early stroke</li>
                <li>Hypertension with OSA</li>
            </ul>
            <p><span class="label">Note:</span> Most patients are normokalemic â€” hypokalemia is specific but not sensitive</p>
            
            <p><span class="label">Screening â€” Aldosterone-to-Renin Ratio (ARR):</span></p>
            <ul>
                <li><strong>ARR >30 + aldosterone >15 ng/dL</strong> = positive screen</li>
                <li>Hold interfering meds: spironolactone (6 weeks), MRAs, ACEi/ARBs, diuretics (2-4 weeks)</li>
                <li>Can continue CCBs, alpha-blockers, hydralazine</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CONFIRMATORY TESTING & SUBTYPE</div>
        <div class="section-content">
            <p><span class="label">Confirmatory Tests (after positive ARR):</span></p>
            <ul>
                <li><strong>Oral sodium loading test</strong> or <strong>IV saline infusion test</strong></li>
                <li>Failure to suppress aldosterone confirms diagnosis</li>
            </ul>
            
            <p><span class="label">Subtype Differentiation:</span></p>
            <ul>
                <li><strong>Adrenal CT:</strong> First imaging study</li>
                <li><strong>Adrenal vein sampling (AVS):</strong> Gold standard to distinguish unilateral (adenoma) vs bilateral (hyperplasia) â€” required if surgery considered</li>
            </ul>
            
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Feature</th><th>Aldosterone-Producing Adenoma</th><th>Bilateral Hyperplasia</th></tr>
                <tr><td>Laterality</td><td>Unilateral</td><td>Bilateral</td></tr>
                <tr><td>Treatment</td><td>Adrenalectomy (curative)</td><td>MRA (spironolactone, eplerenone)</td></tr>
                <tr><td>Prevalence</td><td>~35%</td><td>~60%</td></tr>
            </table>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Most patients are normokalemic</strong> â€” screen based on resistant HTN</li>
            <li><strong>ARR >30 + aldo >15</strong> = positive screen â†’ confirm with salt loading</li>
            <li><strong>Adrenal vein sampling before surgery</strong> â€” CT alone insufficient</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PROLACTINOMA -->
<div id="prolactinoma" class="condition-page">
    <div class="page-header">
        <h2>217. PROLACTINOMA</h2>
        <div class="subtitle">Most Common Pituitary Tumor â€¢ Dopamine Agonists First-Line</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Hyperprolactinemia Effects:</span></p>
            <ul>
                <li><strong>Women:</strong> Amenorrhea, galactorrhea, infertility, decreased libido</li>
                <li><strong>Men:</strong> Decreased libido, erectile dysfunction, gynecomastia, infertility (often present late with large tumors)</li>
                <li><strong>Both:</strong> Osteoporosis (hypogonadism)</li>
            </ul>
            <p><span class="label">Mass Effects (macroadenoma >10mm):</span></p>
            <ul>
                <li><strong>Headache</strong></li>
                <li><strong>Visual field defects:</strong> Bitemporal hemianopia (optic chiasm compression)</li>
                <li>Hypopituitarism (compression of normal pituitary)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Labs:</span> <strong>Serum prolactin</strong></p>
            <ul>
                <li>Prolactin level generally correlates with tumor size</li>
                <li>>200 ng/mL almost always prolactinoma</li>
                <li>Mild elevation (25-100) â€” rule out other causes first</li>
            </ul>
            
            <p><span class="label">Rule Out Other Causes of Hyperprolactinemia:</span></p>
            <ul>
                <li><strong>Medications:</strong> Antipsychotics (most common), metoclopramide, SSRIs</li>
                <li><strong>Pregnancy</strong> (always check Î²-hCG)</li>
                <li><strong>Primary hypothyroidism</strong> (check TSH â€” TRH stimulates prolactin)</li>
                <li><strong>Stalk effect:</strong> Non-functioning pituitary mass compressing stalk (prolactin usually <100)</li>
            </ul>
            
            <p><span class="label">Imaging:</span> Pituitary MRI with gadolinium</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">First-Line â€” Dopamine Agonists (even for large tumors):</span></p>
            <ul>
                <li><strong>Cabergoline:</strong> Preferred â€” more effective, better tolerated, twice weekly</li>
                <li><strong>Bromocriptine:</strong> Alternative (daily dosing, more side effects)</li>
                <li>Normalize prolactin and shrink tumor in >90%</li>
            </ul>
            <p><span class="label">Surgery:</span> Only if medication intolerance/failure, CSF leak, or patient preference</p>
            <p><span class="label">Pregnancy:</span> Discontinue cabergoline once pregnant (for microprolactinomas); bromocriptine has more safety data</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Dopamine agonists first-line even for macroprolactinomas</strong> â€” NOT surgery</li>
            <li><strong>Prolactin >200 = prolactinoma;</strong> mild elevation = rule out meds, hypothyroid, pregnancy</li>
            <li><strong>Stalk effect:</strong> Large non-functioning adenoma with mild prolactin elevation (<100)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ACROMEGALY -->
<div id="acromegaly" class="condition-page">
    <div class="page-header">
        <h2>218. ACROMEGALY</h2>
        <div class="subtitle">GH Excess â€¢ IGF-1 Screening â€¢ Transsphenoidal Surgery</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Gradual Onset (often delayed diagnosis 7-10 years):</span></p>
            <ul>
                <li><strong>Acral enlargement:</strong> Hands (rings don't fit), feet (shoe size increases)</li>
                <li><strong>Facial changes:</strong> Frontal bossing, prognathism (jaw protrusion), coarsened features, macroglossia</li>
                <li><strong>Skin:</strong> Thickened, oily, hyperhidrosis, skin tags</li>
                <li><strong>Soft tissue:</strong> Carpal tunnel syndrome, deepening voice</li>
            </ul>
            <p><span class="label">Systemic Complications:</span></p>
            <ul>
                <li><strong>Cardiovascular:</strong> Hypertension, cardiomyopathy, arrhythmias (major cause of death)</li>
                <li><strong>Metabolic:</strong> Diabetes/glucose intolerance, hyperlipidemia</li>
                <li><strong>Respiratory:</strong> Sleep apnea (very common)</li>
                <li><strong>Rheumatologic:</strong> Arthropathy, osteoarthritis</li>
                <li><strong>Neoplastic:</strong> Increased colon polyps â†’ colonoscopy recommended</li>
            </ul>
            <p><span class="label">Local Mass Effects:</span> Headache, visual field defects, hypopituitarism</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Screening:</span> <strong>IGF-1 level</strong> (reflects integrated GH secretion; age/sex adjusted)</p>
            <p><span class="label">Confirmation:</span> <strong>Oral glucose tolerance test (OGTT)</strong> â€” GH should suppress to <1 ng/mL; failure to suppress confirms diagnosis</p>
            <p><span class="label">Imaging:</span> Pituitary MRI</p>
            
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>First-line:</strong> Transsphenoidal surgery â€” curative if complete resection</li>
                <li><strong>Medical therapy (if surgery fails/incomplete):</strong>
                    <ul>
                        <li>Somatostatin analogs: Octreotide LAR, lanreotide (first-line medical)</li>
                        <li>GH receptor antagonist: Pegvisomant (normalizes IGF-1)</li>
                        <li>Dopamine agonist: Cabergoline (if mild, co-secreting prolactin)</li>
                    </ul>
                </li>
                <li><strong>Radiation:</strong> For residual/recurrent disease</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>IGF-1 for screening; OGTT for confirmation</strong></li>
            <li><strong>Surgery first-line</strong> (unlike prolactinoma where meds are first)</li>
            <li><strong>Screen for colon polyps, sleep apnea, cardiac disease</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- MEN SYNDROMES -->
<div id="men-syndromes" class="condition-page">
    <div class="page-header">
        <h2>219. MULTIPLE ENDOCRINE NEOPLASIA (MEN) SYNDROMES</h2>
        <div class="subtitle">Autosomal Dominant â€¢ Screen Family Members â€¢ Prophylactic Thyroidectomy in MEN2</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Syndrome</th><th>Gene</th><th>Components (3 P's / 2 M's)</th></tr>
                <tr>
                    <td><strong>MEN1</strong><br>("3 P's")</td>
                    <td>MEN1 (menin)<br>Tumor suppressor</td>
                    <td>
                        <strong>P</strong>arathyroid hyperplasia (95%) â€” most common/earliest<br>
                        <strong>P</strong>ituitary adenomas (40%) â€” prolactinoma most common<br>
                        <strong>P</strong>ancreatic NETs (40%) â€” gastrinoma most common, insulinoma
                    </td>
                </tr>
                <tr>
                    <td><strong>MEN2A</strong><br>("2 M's + P")</td>
                    <td>RET proto-oncogene</td>
                    <td>
                        <strong>M</strong>edullary thyroid carcinoma (95%) â€” most lethal<br>
                        Pheochromocytoma (50%)<br>
                        <strong>P</strong>arathyroid hyperplasia (20-30%)
                    </td>
                </tr>
                <tr>
                    <td><strong>MEN2B</strong></td>
                    <td>RET proto-oncogene</td>
                    <td>
                        <strong>M</strong>edullary thyroid carcinoma (100%) â€” aggressive, early<br>
                        Pheochromocytoma (50%)<br>
                        <strong>M</strong>arfanoid habitus, mucosal neuromas (lips, tongue)<br>
                        NO hyperparathyroidism
                    </td>
                </tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">KEY MANAGEMENT POINTS</div>
        <div class="section-content">
            <p><span class="label">MEN1:</span></p>
            <ul>
                <li>Screen for hypercalcemia (PTH, calcium), prolactin, fasting glucose/insulin</li>
                <li>Gastrinoma: Check fasting gastrin; may cause Zollinger-Ellison syndrome</li>
            </ul>
            
            <p><span class="label">MEN2:</span></p>
            <ul>
                <li><strong>RET mutation testing</strong> for all family members</li>
                <li><strong>Prophylactic thyroidectomy</strong> in RET carriers (timing based on mutation risk category)</li>
                <li><strong>Always screen for pheochromocytoma BEFORE thyroid surgery</strong> (plasma/urine metanephrines)</li>
                <li>MTC: Check calcitonin, CEA</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>MEN1 = 3 P's:</strong> Parathyroid, Pituitary, Pancreas</li>
            <li><strong>MEN2 = MTC + Pheo Â± Parathyroid;</strong> MEN2B adds marfanoid + neuromas</li>
            <li><strong>Always rule out pheo before thyroid surgery</strong> in MEN2</li>
            <li><strong>Prophylactic thyroidectomy</strong> for RET mutation carriers</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PRIMARY BILIARY CHOLANGITIS -->
<div id="pbc" class="condition-page">
    <div class="page-header">
        <h2>220. PRIMARY BILIARY CHOLANGITIS (PBC)</h2>
        <div class="subtitle">Anti-Mitochondrial Antibody â€¢ Cholestatic LFTs â€¢ Ursodiol</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Demographics:</span> Middle-aged women (90%); often associated with other autoimmune diseases (SjÃ¶gren's, thyroiditis, scleroderma)</p>
            <p><span class="label">Presentation:</span></p>
            <ul>
                <li><strong>Fatigue</strong> (most common symptom)</li>
                <li><strong>Pruritus</strong> (often precedes jaundice by years)</li>
                <li>May be asymptomatic (detected by elevated ALP)</li>
                <li>Later: Jaundice, xanthomas/xanthelasmas, hepatomegaly</li>
            </ul>
            <p><span class="label">Complications:</span> Cirrhosis, portal hypertension, fat-soluble vitamin deficiency (A, D, E, K), osteoporosis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Cholestatic pattern:</strong> Elevated ALP (predominant), elevated GGT, bilirubin rises later</li>
                <li><strong>Anti-mitochondrial antibody (AMA):</strong> Positive in >95% â€” highly specific</li>
                <li>Elevated IgM</li>
                <li>Mildly elevated aminotransferases</li>
            </ul>
            <p><span class="label">Diagnosis Criteria (2 of 3):</span></p>
            <ol>
                <li>Cholestatic biochemistry (elevated ALP)</li>
                <li>Positive AMA (or PBC-specific ANA if AMA negative)</li>
                <li>Liver biopsy showing non-suppurative cholangitis (not required if AMA+ and cholestasis)</li>
            </ol>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">First-Line:</span></p>
            <ul>
                <li><strong>Ursodeoxycholic acid (UDCA):</strong> 13-15 mg/kg/day â€” slows progression, improves survival</li>
            </ul>
            <p><span class="label">Inadequate Response to UDCA:</span></p>
            <ul>
                <li><strong>Obeticholic acid:</strong> FXR agonist; add-on therapy (avoid in decompensated cirrhosis)</li>
                <li><strong>Elafibranor, seladelpar:</strong> Newer PPAR agonists</li>
            </ul>
            <p><span class="label">Symptom Management:</span></p>
            <ul>
                <li><strong>Pruritus:</strong> Cholestyramine (first-line), rifampin, naltrexone, sertraline</li>
                <li><strong>Osteoporosis:</strong> Calcium, vitamin D, bisphosphonates</li>
                <li><strong>Fat-soluble vitamins:</strong> Supplement A, D, E, K if deficient</li>
            </ul>
            <p><span class="label">Liver Transplant:</span> For decompensated cirrhosis, intractable pruritus</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>AMA >95% specific</strong> â€” diagnosis often doesn't require biopsy</li>
            <li><strong>Middle-aged woman + elevated ALP + pruritus = think PBC</strong></li>
            <li><strong>UDCA improves survival</strong> â€” start early</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- NAFLD / NASH -->
<div id="nafld" class="condition-page">
    <div class="page-header">
        <h2>221. NAFLD / NASH / MASLD</h2>
        <div class="subtitle">Metabolic Syndrome Association â€¢ FIB-4 Staging â€¢ Weight Loss Primary Treatment</div>
    </div>
    
    <div class="section">
        <div class="section-title">DEFINITIONS & SPECTRUM</div>
        <div class="section-content">
            <p><span class="label">Updated Nomenclature (2023):</span></p>
            <ul>
                <li><strong>MASLD</strong> (Metabolic dysfunction-Associated Steatotic Liver Disease): Replaces NAFLD</li>
                <li><strong>MASH</strong> (Metabolic dysfunction-Associated Steatohepatitis): Replaces NASH</li>
            </ul>
            <p><span class="label">Spectrum:</span></p>
            <ul>
                <li><strong>Simple steatosis (NAFL):</strong> Fat >5% hepatocytes; minimal inflammation; low progression risk</li>
                <li><strong>Steatohepatitis (NASH/MASH):</strong> Steatosis + inflammation + hepatocyte injury (ballooning); can progress to fibrosis</li>
                <li><strong>Cirrhosis:</strong> End-stage; HCC risk</li>
            </ul>
            <p><span class="label">Risk Factors:</span> Obesity, type 2 diabetes, metabolic syndrome, dyslipidemia, PCOS</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Clinical Suspicion:</span> Elevated ALT (often ALT > AST), metabolic risk factors, hepatic steatosis on imaging</p>
            <p><span class="label">Exclude Other Causes:</span> Alcohol (>21 drinks/week men, >14 women), viral hepatitis, autoimmune, Wilson's, hemochromatosis, medications</p>
            
            <p><span class="label">Non-Invasive Fibrosis Assessment:</span></p>
            <ul>
                <li><strong>FIB-4 Index:</strong> Age, AST, ALT, platelets â€” <1.3 low risk, >2.67 high risk</li>
                <li><strong>NAFLD Fibrosis Score (NFS)</strong></li>
                <li><strong>Transient elastography (FibroScan):</strong> Liver stiffness measurement</li>
                <li><strong>MR elastography:</strong> Most accurate non-invasive</li>
            </ul>
            <p><span class="label">Liver Biopsy:</span> Gold standard; indicated when diagnosis uncertain or to stage NASH</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Lifestyle (Cornerstone):</span></p>
            <ul>
                <li><strong>Weight loss:</strong> â‰¥5% improves steatosis; â‰¥7-10% can improve NASH/fibrosis</li>
                <li>Mediterranean diet, exercise</li>
                <li>Avoid alcohol</li>
            </ul>
            
            <p><span class="label">Pharmacotherapy (for NASH with fibrosis):</span></p>
            <ul>
                <li><strong>Resmetirom (Rezdiffra):</strong> FDA-approved 2024 for NASH with moderate-advanced fibrosis</li>
                <li><strong>GLP-1 agonists:</strong> Semaglutide â€” improves NASH, weight loss (not yet FDA-approved for NASH indication)</li>
                <li><strong>Pioglitazone:</strong> Improves NASH histology (weight gain, fracture risk)</li>
                <li><strong>Vitamin E (800 IU):</strong> For non-diabetic NASH (concern for long-term safety)</li>
            </ul>
            
            <p><span class="label">Manage Comorbidities:</span> Diabetes control (SGLT2i, GLP-1), statins for dyslipidemia (safe in NAFLD), hypertension</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>FIB-4 <1.3 rules out advanced fibrosis;</strong> >2.67 rules in</li>
            <li><strong>7-10% weight loss can reverse NASH</strong></li>
            <li><strong>Statins are SAFE in NAFLD</strong> â€” do not withhold for elevated LFTs</li>
            <li><strong>Screen for HCC</strong> in NASH cirrhosis (US Â± AFP every 6 months)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CHRONIC CORONARY DISEASE -->
<div id="chronic-cad" class="condition-page">
    <div class="page-header">
        <h2>222. CHRONIC CORONARY DISEASE</h2>
        <div class="subtitle">Stable Angina â€¢ GDMT â€¢ Revascularization Indications</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Stable Angina:</span> Predictable chest discomfort with exertion, relieved by rest or nitroglycerin within 5 minutes</p>
            <p><span class="label">Canadian Cardiovascular Society (CCS) Classification:</span></p>
            <ul>
                <li><strong>Class I:</strong> Angina with strenuous activity only</li>
                <li><strong>Class II:</strong> Slight limitation; angina walking >2 blocks or >1 flight stairs</li>
                <li><strong>Class III:</strong> Marked limitation; angina walking 1-2 blocks or 1 flight</li>
                <li><strong>Class IV:</strong> Angina at rest or minimal activity</li>
            </ul>
            <p><span class="label">Pretest Probability:</span> Use age, sex, symptoms to estimate CAD likelihood before testing</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">GUIDELINE-DIRECTED MEDICAL THERAPY (GDMT)</div>
        <div class="section-content">
            <p><span class="label">Anti-Anginal Therapy:</span></p>
            <ul>
                <li><strong>Beta-blockers:</strong> First-line; reduce HR and myocardial O2 demand</li>
                <li><strong>CCBs:</strong> Alternative or add-on (non-DHP for rate control, DHP for vasospasm)</li>
                <li><strong>Long-acting nitrates:</strong> Add if persistent symptoms; nitrate-free interval required</li>
                <li><strong>Ranolazine:</strong> Add-on for refractory angina (blocks late Na+ current)</li>
            </ul>
            <p><span class="label">Risk-Reducing Therapy:</span></p>
            <ul>
                <li><strong>Aspirin 81mg daily</strong> (clopidogrel if intolerant)</li>
                <li><strong>High-intensity statin</strong> (atorvastatin 40-80mg, rosuvastatin 20-40mg)</li>
                <li><strong>ACEi/ARB</strong> if EF â‰¤40%, HTN, DM, or CKD</li>
                <li><strong>BP goal &lt;130/80</strong></li>
                <li><strong>LDL goal &lt;70 mg/dL</strong> (consider &lt;55 if very high risk)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Beta-blockers improve mortality post-MI</strong> but benefit in stable CAD without prior MI is less clear</li>
            <li><strong>Ranolazine:</strong> No mortality benefit but reduces angina; prolongs QT</li>
            <li><strong>Nitrate tolerance:</strong> Requires 10-14 hour nitrate-free interval</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- STRESS TESTING -->
<div id="stress-testing" class="condition-page">
    <div class="page-header">
        <h2>223. STRESS TESTING SELECTION</h2>
        <div class="subtitle">Exercise vs Pharmacologic â€¢ Echo vs Nuclear â€¢ Appropriate Use</div>
    </div>
    
    <div class="section">
        <div class="section-title">MODALITY SELECTION</div>
        <div class="section-content">
            <p><span class="label">Exercise vs Pharmacologic:</span></p>
            <ul>
                <li><strong>Exercise preferred</strong> if patient can achieve â‰¥85% max HR (220 - age)</li>
                <li><strong>Pharmacologic if:</strong> Unable to exercise, LBBB, paced rhythm, severe deconditioning</li>
            </ul>
            
            <p><span class="label">Pharmacologic Agents:</span></p>
            <ul>
                <li><strong>Regadenoson/Adenosine/Dipyridamole:</strong> Vasodilators (nuclear imaging). AVOID in asthma/severe COPD, 2nd/3rd degree AV block, SBP &lt;90</li>
                <li><strong>Dobutamine:</strong> Î²1-agonist (echo). AVOID in severe HTN, arrhythmias, severe AS</li>
            </ul>
            
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Modality</th><th>Imaging</th><th>Best For</th><th>Avoid If</th></tr>
                <tr><td>Exercise ECG</td><td>None</td><td>Intermediate risk, can exercise, interpretable ECG</td><td>LBBB, paced, WPW, ST abnormalities, digoxin</td></tr>
                <tr><td>Exercise Echo</td><td>Echo</td><td>Can exercise, uninterpretable ECG</td><td>Poor acoustic windows</td></tr>
                <tr><td>Exercise Nuclear</td><td>SPECT/PET</td><td>Can exercise, uninterpretable ECG, need quantification</td><td>Recent nuclear study</td></tr>
                <tr><td>Pharm Echo (dobutamine)</td><td>Echo</td><td>Can't exercise, viability assessment</td><td>Arrhythmias, severe AS</td></tr>
                <tr><td>Pharm Nuclear (regadenoson)</td><td>SPECT/PET</td><td>Can't exercise, need quantification</td><td>Asthma, AV block</td></tr>
            </table>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>LBBB or paced rhythm:</strong> Use vasodilator stress (NOT dobutamine) â€” can cause false septal perfusion defects</li>
            <li><strong>Hold caffeine 12-24h</strong> before adenosine/regadenoson</li>
            <li><strong>Aminophylline reverses</strong> adenosine/regadenoson side effects</li>
            <li><strong>Duke Treadmill Score:</strong> Exercise time - (5 Ã— ST deviation) - (4 Ã— angina index)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PCI vs CABG -->
<div id="pci-cabg" class="condition-page">
    <div class="page-header">
        <h2>224. PCI vs CABG INDICATIONS</h2>
        <div class="subtitle">SYNTAX Score â€¢ Left Main â€¢ Multivessel Disease</div>
    </div>
    
    <div class="section">
        <div class="section-title">REVASCULARIZATION INDICATIONS</div>
        <div class="section-content">
            <p><span class="label">Indications for Revascularization:</span></p>
            <ul>
                <li>Unacceptable angina despite GDMT</li>
                <li>Left main stenosis â‰¥50%</li>
                <li>3-vessel disease with EF &lt;35%</li>
                <li>2-vessel disease with proximal LAD involvement</li>
                <li>Large area of ischemia (&gt;10% myocardium)</li>
            </ul>
            
            <p><span class="label">SYNTAX Score:</span> Anatomic complexity score based on coronary lesion characteristics</p>
            <ul>
                <li><strong>Low (0-22):</strong> PCI and CABG comparable</li>
                <li><strong>Intermediate (23-32):</strong> Heart Team discussion</li>
                <li><strong>High (&gt;32):</strong> CABG preferred</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PCI vs CABG COMPARISON</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Feature</th><th>Favors PCI</th><th>Favors CABG</th></tr>
                <tr><td>Anatomy</td><td>1-2 vessel, low SYNTAX</td><td>3-vessel, left main, high SYNTAX</td></tr>
                <tr><td>Diabetes</td><td>Non-diabetic</td><td>Diabetic with multivessel disease</td></tr>
                <tr><td>EF</td><td>Preserved EF</td><td>Reduced EF (&lt;35%)</td></tr>
                <tr><td>Surgical risk</td><td>High surgical risk (STS &gt;8%)</td><td>Low-moderate surgical risk</td></tr>
                <tr><td>Completeness</td><td>Complete revascularization achievable</td><td>Complete revascularization needed</td></tr>
                <tr><td>Life expectancy</td><td>Limited life expectancy</td><td>Long life expectancy</td></tr>
            </table>
            
            <p><span class="label">CABG Survival Benefit Established:</span></p>
            <ul>
                <li>Left main â‰¥50%</li>
                <li>3-vessel disease (especially with DM or LV dysfunction)</li>
                <li>2-vessel with proximal LAD + EF &lt;50%</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Diabetics with multivessel disease:</strong> CABG superior to PCI (FREEDOM trial)</li>
            <li><strong>LIMA to LAD:</strong> Best long-term patency; CABG advantage</li>
            <li><strong>Heart Team approach:</strong> Recommended for complex decisions</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ICD/CRT -->
<div id="icd-crt" class="condition-page">
    <div class="page-header">
        <h2>225. ICD / CRT DEVICE THERAPY</h2>
        <div class="subtitle">Primary vs Secondary Prevention â€¢ CRT Indications â€¢ EF Criteria</div>
    </div>
    
    <div class="section">
        <div class="section-title">ICD INDICATIONS</div>
        <div class="section-content">
            <p><span class="label">Secondary Prevention (survived SCD):</span></p>
            <ul>
                <li>Survived VF arrest or hemodynamically unstable VT not due to reversible cause</li>
                <li>Sustained VT with structural heart disease</li>
            </ul>
            
            <p><span class="label">Primary Prevention:</span></p>
            <ul>
                <li><strong>Ischemic cardiomyopathy:</strong> EF â‰¤35%, â‰¥40 days post-MI, â‰¥90 days post-revascularization, NYHA II-III on GDMT</li>
                <li><strong>Non-ischemic cardiomyopathy:</strong> EF â‰¤35%, NYHA II-III on GDMT, â‰¥3 months optimal therapy</li>
                <li><strong>Specific conditions:</strong> HCM with risk factors, ARVC, Long QT with syncope, Brugada with syncope</li>
            </ul>
            
            <p><span class="label">Wait periods:</span></p>
            <ul>
                <li>40 days post-MI (SCD-HeFT)</li>
                <li>90 days post-revascularization</li>
                <li>3 months of GDMT for new HF diagnosis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CRT INDICATIONS</div>
        <div class="section-content">
            <p><span class="label">CRT-D or CRT-P (Class I):</span></p>
            <ul>
                <li><strong>EF â‰¤35%</strong></li>
                <li><strong>NYHA II-IV (ambulatory)</strong> on GDMT</li>
                <li><strong>LBBB with QRS â‰¥150ms</strong> (strongest indication)</li>
                <li>Sinus rhythm</li>
            </ul>
            
            <p><span class="label">Weaker Indications (Class IIa):</span></p>
            <ul>
                <li>LBBB with QRS 120-149ms</li>
                <li>Non-LBBB with QRS â‰¥150ms</li>
                <li>AFib if expect &gt;70% biventricular pacing</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>LBBB + wide QRS benefits most from CRT;</strong> Non-LBBB benefit less clear</li>
            <li><strong>Wait 40 days post-MI</strong> â€” early ICD no benefit (DINAMIT, IRIS)</li>
            <li><strong>EF may recover:</strong> Reassess before implant; wearable defibrillator (LifeVest) can bridge</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- HCM -->
<div id="hcm" class="condition-page">
    <div class="page-header">
        <h2>226. HYPERTROPHIC CARDIOMYOPATHY</h2>
        <div class="subtitle">Asymmetric Septal Hypertrophy â€¢ LVOT Obstruction â€¢ SCD Risk</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> LV wall thickness â‰¥15mm (or â‰¥13mm with family history) not explained by loading conditions</p>
            <p><span class="label">Symptoms:</span> Dyspnea, angina, syncope (exertional), palpitations. Often asymptomatic</p>
            <p><span class="label">Physical Exam:</span></p>
            <ul>
                <li>Harsh crescendo-decrescendo systolic murmur at LLSB</li>
                <li><strong>Murmur increases with:</strong> Valsalva, standing (decreased preload)</li>
                <li><strong>Murmur decreases with:</strong> Squatting, handgrip (increased afterload/preload)</li>
                <li>Bifid carotid pulse ("spike and dome")</li>
            </ul>
            <p><span class="label">Echo:</span> Asymmetric septal hypertrophy (septum:posterior wall >1.3:1), SAM of mitral valve, LVOT gradient â‰¥30mmHg (obstructive)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Obstructive HCM (gradient â‰¥30mmHg):</span></p>
            <ul>
                <li><strong>First-line:</strong> Beta-blockers (negative inotropy, slows HR)</li>
                <li><strong>Second-line:</strong> Verapamil or diltiazem (if beta-blocker intolerant)</li>
                <li><strong>Add disopyramide</strong> if persistent symptoms (negative inotropy)</li>
                <li><strong>Mavacamten:</strong> Cardiac myosin inhibitor; FDA-approved for obstructive HCM</li>
                <li><strong>Septal reduction:</strong> Surgical myectomy (preferred) or alcohol septal ablation if refractory</li>
            </ul>
            
            <p><span class="label">AVOID:</span></p>
            <ul>
                <li>Vasodilators (nitrates, ACEi, ARBs) â€” worsen gradient</li>
                <li>Diuretics (unless volume overloaded)</li>
                <li>Digoxin, dobutamine (positive inotropes)</li>
                <li>High-intensity exercise</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">SCD RISK STRATIFICATION</div>
        <div class="section-content">
            <p><span class="label">Major Risk Factors for ICD:</span></p>
            <ul>
                <li>Prior cardiac arrest or sustained VT</li>
                <li>Family history of SCD from HCM</li>
                <li>Unexplained syncope</li>
                <li>Massive LVH (â‰¥30mm)</li>
                <li>NSVT on Holter</li>
                <li>Abnormal BP response to exercise</li>
                <li>LGE on CMR (extensive scarring)</li>
            </ul>
            <p><span class="label">Use HCM Risk-SCD Calculator:</span> â‰¥6% 5-year risk â†’ consider ICD</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Murmur dynamics:</strong> Only HCM and MVP increase with Valsalva/standing</li>
            <li><strong>Screen first-degree relatives</strong> with echo and/or genetic testing</li>
            <li><strong>Mavacamten:</strong> New therapy that reduces LVOT gradient</li>
            <li><strong>Athletes:</strong> Disqualify from competitive sports if diagnosed</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CARDIOMYOPATHIES -->
<div id="cardiomyopathies" class="condition-page">
    <div class="page-header">
        <h2>227. DILATED & RESTRICTIVE CARDIOMYOPATHY</h2>
        <div class="subtitle">DCM Causes â€¢ RCM vs Constrictive â€¢ Infiltrative Diseases</div>
    </div>
    
    <div class="section">
        <div class="section-title">DILATED CARDIOMYOPATHY (DCM)</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> LV dilation with reduced systolic function (EF &lt;40%) not explained by CAD or abnormal loading</p>
            <p><span class="label">Causes:</span></p>
            <ul>
                <li><strong>Idiopathic</strong> (30-40% â€” many genetic)</li>
                <li><strong>Ischemic</strong> (exclude with angiography)</li>
                <li><strong>Familial/Genetic:</strong> TTN, LMNA, MYH7</li>
                <li><strong>Toxic:</strong> Alcohol, cocaine, chemotherapy (anthracyclines, trastuzumab)</li>
                <li><strong>Infectious:</strong> Viral myocarditis, Chagas, HIV</li>
                <li><strong>Peripartum cardiomyopathy</strong></li>
                <li><strong>Tachycardia-induced</strong></li>
                <li><strong>Stress cardiomyopathy (Takotsubo)</strong></li>
            </ul>
            <p><span class="label">Treatment:</span> Standard HFrEF GDMT (ACEi/ARB/ARNI, beta-blocker, MRA, SGLT2i). ICD/CRT if indicated. Treat underlying cause</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">RESTRICTIVE CARDIOMYOPATHY (RCM)</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Impaired ventricular filling due to stiff, non-compliant ventricles; usually preserved EF</p>
            <p><span class="label">Causes:</span></p>
            <ul>
                <li><strong>Amyloidosis</strong> (AL, ATTR) â€” most common infiltrative</li>
                <li><strong>Sarcoidosis</strong></li>
                <li><strong>Hemochromatosis</strong></li>
                <li><strong>Radiation</strong></li>
                <li><strong>Storage diseases:</strong> Fabry, glycogen storage</li>
                <li><strong>Fibrosis:</strong> Scleroderma, endomyocardial fibrosis</li>
            </ul>
            <p><span class="label">Echo:</span> Biatrial enlargement, normal/small ventricles, preserved EF, diastolic dysfunction, "sparkling" myocardium (amyloid)</p>
            <p><span class="label">Low-voltage ECG + thick walls = amyloid</strong> (discordance)</p>
        </div>
    </div>
    
    <div class="two-column">
        <div class="box">
            <div class="box-title">RCM vs Constrictive Pericarditis</div>
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Feature</th><th>RCM</th><th>Constrictive</th></tr>
                <tr><td>Septal bounce</td><td>Absent</td><td>Present</td></tr>
                <tr><td>Respiratory variation</td><td>Absent</td><td>Present (&gt;25%)</td></tr>
                <tr><td>Pericardium</td><td>Normal</td><td>Thickened/calcified</td></tr>
                <tr><td>Kussmaul sign</td><td>Variable</td><td>Present</td></tr>
                <tr><td>BNP</td><td>Elevated</td><td>Normal/low</td></tr>
            </table>
        </div>
        <div class="box">
            <div class="box-title">Key Diagnostic Clues</div>
            <ul style="font-size: 9pt;">
                <li>Amyloid: Low voltage + thick walls, diastolic dysfunction</li>
                <li>Sarcoid: Heart block, VT, patchy LGE on CMR</li>
                <li>Hemochromatosis: Increased T2* on CMR, liver iron</li>
                <li>Fabry: LVH, angiokeratomas, Î±-galactosidase deficiency</li>
            </ul>
        </div>
    </div>
    
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONSTRICTIVE PERICARDITIS -->
<div id="constrictive-pericarditis" class="condition-page">
    <div class="page-header">
        <h2>228. CONSTRICTIVE PERICARDITIS</h2>
        <div class="subtitle">Post-Cardiac Surgery â€¢ Ventricular Interdependence â€¢ Pericardiectomy</div>
    </div>
    
    <div class="section">
        <div class="section-title">ETIOLOGY & CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Causes:</span></p>
            <ul>
                <li><strong>Idiopathic/viral</strong> (most common in developed countries)</li>
                <li><strong>Post-cardiac surgery</strong></li>
                <li><strong>Radiation therapy</strong></li>
                <li><strong>TB</strong> (common in endemic areas)</li>
                <li><strong>Connective tissue disease, uremia, malignancy</strong></li>
            </ul>
            <p><span class="label">Symptoms:</span> Dyspnea, fatigue, peripheral edema, ascites (often out of proportion to peripheral edema)</p>
            <p><span class="label">Physical Exam:</span></p>
            <ul>
                <li><strong>Elevated JVP</strong> with prominent y-descent</li>
                <li><strong>Kussmaul sign:</strong> JVP rises with inspiration (paradoxical)</li>
                <li><strong>Pericardial knock:</strong> High-pitched early diastolic sound</li>
                <li>Hepatomegaly, ascites, peripheral edema</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Echo:</span></p>
            <ul>
                <li><strong>Septal bounce</strong> (ventricular interdependence)</li>
                <li><strong>Respiratory variation</strong> in mitral/tricuspid inflow (&gt;25%)</li>
                <li>Dilated IVC without respiratory variation</li>
                <li>Preserved/increased medial e' velocity</li>
            </ul>
            <p><span class="label">CT/MRI:</span> Pericardial thickening (&gt;4mm), calcification</p>
            <p><span class="label">Cath:</span> Equalization of diastolic pressures, "square root" sign, discordant ventricular pressure changes with respiration</p>
            <p><span class="label">BNP:</span> Normal or mildly elevated (vs elevated in RCM)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Medical:</span> Diuretics for congestion; treat underlying cause; anti-inflammatory if transient/inflammatory</p>
            <p><span class="label">Definitive:</span> <strong>Pericardiectomy</strong> â€” surgical removal of pericardium; high morbidity/mortality but curative</p>
            <p><span class="label">Prognosis:</span> Poor without surgery; radiation-induced has worst surgical outcomes</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Kussmaul sign + pericardial knock + ascites = constrictive pericarditis</strong></li>
            <li><strong>Septal bounce on echo</strong> â€” key finding distinguishing from RCM</li>
            <li><strong>Normal BNP</strong> favors constriction over restriction</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- BRADYARRHYTHMIAS -->
<div id="bradyarrhythmias" class="condition-page">
    <div class="page-header">
        <h2>229. BRADYARRHYTHMIAS & PACING</h2>
        <div class="subtitle">Sick Sinus Syndrome â€¢ AV Blocks â€¢ Pacemaker Indications</div>
    </div>
    
    <div class="section">
        <div class="section-title">SICK SINUS SYNDROME</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> SA node dysfunction causing symptomatic bradycardia</p>
            <p><span class="label">Manifestations:</span></p>
            <ul>
                <li>Sinus bradycardia</li>
                <li>Sinus pauses/arrest</li>
                <li>Sinoatrial exit block</li>
                <li><strong>Tachy-brady syndrome:</strong> Alternating tachycardia (usually AFib) and bradycardia</li>
                <li>Chronotropic incompetence (inadequate HR response to exercise)</li>
            </ul>
            <p><span class="label">Treatment:</span> Pacemaker if symptomatic; treat tachycardia component after pacing secured</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">AV BLOCKS</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Type</th><th>ECG Finding</th><th>Treatment</th></tr>
                <tr><td><strong>First-degree</strong></td><td>PR &gt;200ms, all P waves conducted</td><td>None (usually benign)</td></tr>
                <tr><td><strong>Second-degree Type I (Wenckebach)</strong></td><td>Progressive PR prolongation â†’ dropped beat; grouped beating</td><td>Usually benign; pacing if symptomatic</td></tr>
                <tr><td><strong>Second-degree Type II</strong></td><td>Fixed PR interval â†’ sudden dropped beat</td><td>Pacemaker (high risk of progression)</td></tr>
                <tr><td><strong>Third-degree (Complete)</strong></td><td>AV dissociation; P waves and QRS independent</td><td>Pacemaker</td></tr>
                <tr><td><strong>High-grade AV block</strong></td><td>â‰¥2 consecutive non-conducted P waves</td><td>Pacemaker</td></tr>
            </table>
            
            <p><span class="label">Reversible Causes:</span> Drugs (beta-blockers, CCBs, digoxin, amiodarone), hyperkalemia, Lyme disease, ischemia (inferior MI), post-cardiac surgery</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PACEMAKER INDICATIONS & MODES</div>
        <div class="section-content">
            <p><span class="label">Class I Indications:</span></p>
            <ul>
                <li>Symptomatic bradycardia</li>
                <li>Third-degree or advanced second-degree AV block</li>
                <li>Alternating bundle branch block</li>
                <li>Post-AV node ablation</li>
            </ul>
            
            <p><span class="label">Pacemaker Mode Codes:</span> [Chamber Paced]-[Chamber Sensed]-[Response]</p>
            <ul>
                <li><strong>VVI:</strong> Paces ventricle, senses ventricle, inhibits when sensed (backup)</li>
                <li><strong>DDD:</strong> Dual chamber pacing and sensing; maintains AV synchrony</li>
                <li><strong>AAI:</strong> Paces atrium only; for SSS with intact AV conduction</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Mobitz II always needs pacemaker</strong> â€” high progression risk to complete block</li>
            <li><strong>Inferior MI + AV block:</strong> Often transient (AV nodal); may resolve</li>
            <li><strong>Anterior MI + AV block:</strong> Infranodal; worse prognosis, often needs pacing</li>
            <li><strong>Lyme disease:</strong> Can cause reversible heart block; treat with antibiotics first</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- SCD PREVENTION -->
<div id="scd-prevention" class="condition-page">
    <div class="page-header">
        <h2>230. SUDDEN CARDIAC DEATH PREVENTION</h2>
        <div class="subtitle">Channelopathies â€¢ Inherited Arrhythmias â€¢ Risk Stratification</div>
    </div>
    
    <div class="section">
        <div class="section-title">CHANNELOPATHIES</div>
        <div class="section-content">
            <p><span class="label">Long QT Syndrome (LQTS):</span></p>
            <ul>
                <li><strong>QTc:</strong> &gt;470ms (males), &gt;480ms (females)</li>
                <li><strong>LQT1:</strong> Exercise-triggered (swimming); responds to beta-blockers</li>
                <li><strong>LQT2:</strong> Emotional/auditory triggers; responds to beta-blockers</li>
                <li><strong>LQT3:</strong> Rest/sleep triggers; less responsive to beta-blockers</li>
                <li><strong>Treatment:</strong> Beta-blockers (all), ICD if high-risk, avoid QT-prolonging drugs</li>
            </ul>
            
            <p><span class="label">Brugada Syndrome:</span></p>
            <ul>
                <li>Type 1 pattern: Coved ST elevation â‰¥2mm in V1-V3 + spontaneous or provoked</li>
                <li>Associated with SCN5A mutation</li>
                <li>VF typically at rest or during sleep</li>
                <li><strong>Treatment:</strong> ICD for survivors or high-risk; quinidine; avoid fever, certain drugs</li>
            </ul>
            
            <p><span class="label">CPVT (Catecholaminergic Polymorphic VT):</span></p>
            <ul>
                <li>Exercise/stress-induced bidirectional or polymorphic VT</li>
                <li>Normal resting ECG and structurally normal heart</li>
                <li><strong>Treatment:</strong> Beta-blockers (nadolol), flecainide, ICD for refractory</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">OTHER SCD RISK CONDITIONS</div>
        <div class="section-content">
            <p><span class="label">ARVC (Arrhythmogenic RV Cardiomyopathy):</span></p>
            <ul>
                <li>Fibrofatty replacement of RV myocardium</li>
                <li>ECG: Epsilon wave (V1-V3), T-wave inversions V1-V3</li>
                <li>VT with LBBB morphology (RV origin)</li>
                <li>Common cause of SCD in young athletes</li>
            </ul>
            
            <p><span class="label">Commotio Cordis:</span> VF from blunt chest trauma during vulnerable repolarization phase</p>
            
            <p><span class="label">WPW with Preexcited AFib:</span></p>
            <ul>
                <li>Irregular wide-complex tachycardia</li>
                <li><strong>AVOID:</strong> AV nodal blockers (digoxin, CCB, beta-blockers, adenosine)</li>
                <li><strong>Treat with:</strong> Procainamide or cardioversion</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Long QT + syncope = high risk</strong> â€” needs ICD evaluation</li>
            <li><strong>Brugada can be unmasked by:</strong> Fever, class I antiarrhythmics, cocaine</li>
            <li><strong>Epsilon wave</strong> = ARVC</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PAD -->
<div id="pad" class="condition-page">
    <div class="page-header">
        <h2>231. PERIPHERAL ARTERY DISEASE</h2>
        <div class="subtitle">ABI â€¢ Claudication â€¢ Critical Limb Ischemia</div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li><strong>Intermittent claudication:</strong> Calf pain with walking, relieved by rest (within 10 min)</li>
                <li><strong>Critical limb ischemia (CLI):</strong> Rest pain, non-healing wounds, gangrene</li>
            </ul>
            
            <p><span class="label">Ankle-Brachial Index (ABI):</span></p>
            <ul>
                <li><strong>&gt;1.3:</strong> Non-compressible (calcified) â€” unreliable; use toe pressures</li>
                <li><strong>1.0-1.3:</strong> Normal</li>
                <li><strong>0.9-1.0:</strong> Borderline</li>
                <li><strong>&lt;0.9:</strong> PAD (diagnosis)</li>
                <li><strong>&lt;0.4:</strong> Severe PAD / CLI</li>
            </ul>
            
            <p><span class="label">Additional Testing:</span> Exercise ABI (if normal at rest but symptomatic), duplex ultrasound, CTA/MRA for revascularization planning</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">All PAD Patients:</span></p>
            <ul>
                <li><strong>Smoking cessation</strong> (most important modifiable risk factor)</li>
                <li><strong>Antiplatelet:</strong> Aspirin or clopidogrel (clopidogrel may be preferred)</li>
                <li><strong>Statin:</strong> High-intensity</li>
                <li><strong>BP control, diabetes management</strong></li>
                <li><strong>Supervised exercise therapy:</strong> First-line for claudication; 30-45 min, 3Ã—/week</li>
            </ul>
            
            <p><span class="label">Claudication:</span></p>
            <ul>
                <li><strong>Cilostazol:</strong> PDE3 inhibitor; improves walking distance; avoid in HF</li>
                <li>Revascularization if lifestyle-limiting despite medical therapy</li>
            </ul>
            
            <p><span class="label">Critical Limb Ischemia:</span></p>
            <ul>
                <li><strong>Revascularization urgent</strong> (endovascular or surgical)</li>
                <li>Wound care, pain management</li>
                <li>Amputation if non-revascularizable</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>ABI &lt;0.9 = PAD;</strong> ABI &gt;1.3 = calcified arteries (diabetics)</li>
            <li><strong>Cilostazol contraindicated in HF</strong></li>
            <li><strong>Supervised exercise therapy</strong> is first-line for claudication â€” as effective as revascularization</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- STATIN GUIDELINES -->
<div id="statin-guidelines" class="condition-page">
    <div class="page-header">
        <h2>232. STATIN THERAPY GUIDELINES</h2>
        <div class="subtitle">ASCVD Risk â€¢ Primary vs Secondary Prevention â€¢ LDL Goals</div>
    </div>
    
    <div class="section">
        <div class="section-title">STATIN BENEFIT GROUPS (2018 ACC/AHA)</div>
        <div class="section-content">
            <p><span class="label">Four Groups Who Benefit:</span></p>
            <ol>
                <li><strong>Clinical ASCVD:</strong> ACS, stable angina, prior MI/stroke/TIA, PAD</li>
                <li><strong>LDL â‰¥190 mg/dL</strong> (severe hypercholesterolemia)</li>
                <li><strong>Diabetes age 40-75</strong> with LDL 70-189</li>
                <li><strong>Primary prevention age 40-75</strong> with LDL 70-189 + 10-year ASCVD risk â‰¥7.5%</li>
            </ol>
            
            <p><span class="label">Statin Intensity:</span></p>
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Intensity</th><th>LDL Reduction</th><th>Drugs</th></tr>
                <tr><td><strong>High</strong></td><td>â‰¥50%</td><td>Atorvastatin 40-80mg, Rosuvastatin 20-40mg</td></tr>
                <tr><td><strong>Moderate</strong></td><td>30-49%</td><td>Atorvastatin 10-20mg, Rosuvastatin 5-10mg, Simvastatin 20-40mg, Pravastatin 40mg</td></tr>
                <tr><td><strong>Low</strong></td><td>&lt;30%</td><td>Simvastatin 10mg, Pravastatin 10-20mg</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">LDL GOALS & ADD-ON THERAPY</div>
        <div class="section-content">
            <p><span class="label">LDL Goals:</span></p>
            <ul>
                <li><strong>Very high-risk ASCVD:</strong> LDL &lt;70 mg/dL (consider &lt;55)</li>
                <li><strong>High-risk:</strong> LDL &lt;70 mg/dL</li>
                <li><strong>Primary prevention:</strong> â‰¥50% reduction; LDL &lt;100</li>
            </ul>
            
            <p><span class="label">Non-Statin Therapies (if LDL not at goal on max statin):</span></p>
            <ul>
                <li><strong>Ezetimibe:</strong> 10mg daily; reduces LDL ~15-20%</li>
                <li><strong>PCSK9 inhibitors:</strong> Evolocumab, alirocumab; reduce LDL ~60%; for very high-risk or familial hypercholesterolemia</li>
                <li><strong>Bempedoic acid:</strong> ACL inhibitor; for statin-intolerant</li>
                <li><strong>Inclisiran:</strong> siRNA targeting PCSK9; twice-yearly injection</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>High-intensity statin for all ASCVD</strong> (secondary prevention)</li>
            <li><strong>Statin + ezetimibe before PCSK9 inhibitor</strong></li>
            <li><strong>Statins safe in NAFLD/elevated LFTs</strong> â€” do not withhold</li>
            <li><strong>True statin intolerance rare</strong> (~5-10%); rechallenge with different statin or lower dose</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<!-- INPATIENT INSULIN MANAGEMENT -->
<div id="inpatient-insulin" class="condition-page">
    <div class="page-header">
        <h2>233. INPATIENT INSULIN MANAGEMENT</h2>
        <div class="subtitle">Basal-Bolus â€¢ Sliding Scale Pitfalls â€¢ Transition to Outpatient</div>
    </div>
    
    <div class="section">
        <div class="section-title">GLYCEMIC TARGETS</div>
        <div class="section-content">
            <p><span class="label">General Inpatient Goal:</span> 140-180 mg/dL (ADA 2024)</p>
            <p><span class="label">Tighter Control (110-140):</span> Select patients if achievable without hypoglycemia</p>
            <p><span class="label">Less Stringent (180-200):</span> Terminal illness, limited life expectancy, high hypoglycemia risk</p>
            <p><span class="label">Avoid:</span> BG &lt;70 (hypoglycemia) and &gt;250 (hyperglycemia)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">BASAL-BOLUS INSULIN PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Total Daily Dose (TDD) Calculation:</span></p>
            <ul>
                <li><strong>Insulin-naive:</strong> 0.4-0.5 units/kg/day</li>
                <li><strong>Insulin-sensitive (elderly, CKD, thin):</strong> 0.2-0.3 units/kg/day</li>
                <li><strong>Insulin-resistant (obese, high-dose steroids):</strong> 0.5-0.6 units/kg/day</li>
            </ul>
            
            <p><span class="label">Distribution:</span></p>
            <ul>
                <li><strong>50% Basal:</strong> Glargine or detemir once daily (or NPH BID)</li>
                <li><strong>50% Bolus:</strong> Divided among meals (rapid-acting: lispro, aspart, glulisine)</li>
            </ul>
            
            <p><span class="label">Correction Scale:</span> Added to meal-time insulin for hyperglycemia</p>
            <ul>
                <li>Correction factor = 1800 / TDD (how much 1 unit drops BG)</li>
                <li>Typically 1 unit per 50 mg/dL above target</li>
            </ul>
            
            <p><span class="label">NPO Patients:</span> Give basal insulin (reduce by 20-25%); hold bolus; use correction-only sliding scale</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">AVOID SLIDING SCALE ONLY</div>
        <div class="section-content">
            <div class="box warning-box">
                <div class="box-title">âš ï¸ SLIDING SCALE MONOTHERAPY IS REACTIVE, NOT PROACTIVE</div>
                <p>Treats hyperglycemia after it occurs; causes glucose variability; delays appropriate management. Always use scheduled basal insulin in hospitalized diabetics.</p>
            </div>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TRANSITION TO OUTPATIENT</div>
        <div class="section-content">
            <ul>
                <li>Give long-acting insulin the evening before or morning of discharge</li>
                <li>Overlap with IV insulin by 2-4 hours before discontinuing drip</li>
                <li>Resume home regimen if A1c at goal; adjust if not</li>
                <li>Hold metformin if receiving contrast; restart 48h later if renal function stable</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Never use sliding scale alone</strong> â€” always add basal insulin</li>
            <li><strong>Continue basal insulin even when NPO</strong> (reduce dose 20-25%)</li>
            <li><strong>Hold oral agents in hospital</strong> (except maybe SGLT2i in selected patients)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- INSULIN TYPES -->
<div id="insulin-types" class="condition-page">
    <div class="page-header">
        <h2>234. INSULIN TYPES & PHARMACOLOGY</h2>
        <div class="subtitle">Onset â€¢ Peak â€¢ Duration â€¢ Clinical Use</div>
    </div>
    
    <div class="section">
        <div class="section-title">INSULIN PHARMACOKINETICS</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Type</th><th>Examples</th><th>Onset</th><th>Peak</th><th>Duration</th><th>Use</th></tr>
                <tr><td><strong>Rapid-acting</strong></td><td>Lispro, Aspart, Glulisine</td><td>15 min</td><td>1-2 hr</td><td>3-5 hr</td><td>Bolus/meals</td></tr>
                <tr><td><strong>Ultra-rapid</strong></td><td>Fiasp, Lyumjev</td><td>5-10 min</td><td>1 hr</td><td>3-5 hr</td><td>Bolus/meals</td></tr>
                <tr><td><strong>Short-acting</strong></td><td>Regular (Humulin R)</td><td>30 min</td><td>2-4 hr</td><td>6-8 hr</td><td>IV drip, meals</td></tr>
                <tr><td><strong>Intermediate</strong></td><td>NPH</td><td>2-4 hr</td><td>4-10 hr</td><td>12-18 hr</td><td>Basal (BID)</td></tr>
                <tr><td><strong>Long-acting</strong></td><td>Glargine (Lantus), Detemir</td><td>2-4 hr</td><td>Minimal</td><td>20-24 hr</td><td>Basal (daily)</td></tr>
                <tr><td><strong>Ultra-long</strong></td><td>Degludec (Tresiba), Glargine U-300</td><td>1-2 hr</td><td>None</td><td>36-42 hr</td><td>Basal (daily)</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CONCENTRATED INSULINS</div>
        <div class="section-content">
            <ul>
                <li><strong>U-500 Regular:</strong> 5Ã— concentrated; for severe insulin resistance (&gt;200 units/day)</li>
                <li><strong>Glargine U-300 (Toujeo):</strong> 3Ã— concentrated; flatter profile than U-100</li>
                <li><strong>Lispro U-200 (Humalog):</strong> 2Ã— concentrated; same dosing, smaller volume</li>
            </ul>
            <p><span class="label">Caution:</span> High risk of dosing errors with concentrated insulins</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PREMIXED INSULINS</div>
        <div class="section-content">
            <ul>
                <li><strong>70/30:</strong> 70% NPH + 30% regular</li>
                <li><strong>75/25:</strong> 75% protamine lispro + 25% lispro</li>
                <li>Given BID (before breakfast and dinner)</li>
                <li>Less flexible; higher hypoglycemia risk</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Only Regular insulin can be given IV</strong></li>
            <li><strong>NPH has a peak</strong> â€” risk of nocturnal hypoglycemia if given at bedtime</li>
            <li><strong>Glargine/Detemir are "peakless"</strong> â€” lower hypoglycemia risk</li>
            <li><strong>Degludec has longest half-life</strong> â€” flexible dosing timing</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- EUGLYCEMIC DKA -->
<div id="euglycemic-dka" class="condition-page">
    <div class="page-header">
        <h2>235. EUGLYCEMIC DKA</h2>
        <div class="subtitle">SGLT2 Inhibitor-Associated â€¢ Normal Glucose DKA â€¢ Delayed Recognition</div>
    </div>
    
    <div class="section">
        <div class="section-title">DEFINITION & PATHOPHYSIOLOGY</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> DKA with blood glucose &lt;250 mg/dL (sometimes &lt;200)</p>
            <p><span class="label">Mechanism with SGLT2i:</span></p>
            <ul>
                <li>Glycosuria lowers blood glucose</li>
                <li>Decreased insulin secretion (lower glucose stimulus)</li>
                <li>Increased glucagon â†’ lipolysis â†’ ketogenesis</li>
                <li>Volume depletion from osmotic diuresis</li>
            </ul>
            <p><span class="label">Triggers:</span> Surgery, fasting, illness, reduced carbohydrate intake, dehydration, alcohol</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Diagnostic Criteria (same as DKA except glucose):</span></p>
            <ul>
                <li>pH &lt;7.3 or bicarb &lt;18</li>
                <li>Anion gap &gt;12</li>
                <li>Positive ketones (serum Î²-hydroxybutyrate)</li>
                <li><strong>Glucose may be normal or only mildly elevated</strong></li>
            </ul>
            
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Stop SGLT2 inhibitor</strong></li>
                <li>IV fluids (often more volume depleted than apparent)</li>
                <li><strong>Dextrose-containing fluids earlier</strong> (D5 + insulin to clear ketones)</li>
                <li>IV insulin infusion (same as standard DKA)</li>
                <li>Electrolyte replacement (K+, etc.)</li>
            </ul>
            
            <p><span class="label">Key Difference:</span> Need dextrose earlier in treatment since glucose already low; continue insulin until ketones clear</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PREVENTION</div>
        <div class="section-content">
            <ul>
                <li><strong>Hold SGLT2i 3-4 days before surgery</strong></li>
                <li>Hold during acute illness, fasting, or reduced oral intake</li>
                <li>Educate patients on symptoms (nausea, vomiting, abdominal pain, fatigue)</li>
                <li>Check ketones if symptomatic even with normal glucose</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Normal glucose doesn't rule out DKA</strong> â€” check ketones and anion gap</li>
            <li><strong>SGLT2i-associated DKA</strong> can occur in Type 2 diabetics</li>
            <li><strong>Hold SGLT2i perioperatively</strong> (3-4 days before)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- DIABETIC MICROVASCULAR COMPLICATIONS -->
<div id="diabetic-complications" class="condition-page">
    <div class="page-header">
        <h2>236. DIABETIC MICROVASCULAR COMPLICATIONS</h2>
        <div class="subtitle">Retinopathy â€¢ Nephropathy â€¢ Neuropathy</div>
    </div>
    
    <div class="section">
        <div class="section-title">DIABETIC RETINOPATHY</div>
        <div class="section-content">
            <p><span class="label">Screening:</span></p>
            <ul>
                <li><strong>Type 1:</strong> Annual dilated exam starting 5 years after diagnosis</li>
                <li><strong>Type 2:</strong> At diagnosis, then annually</li>
                <li><strong>Pregnancy:</strong> Before conception and each trimester</li>
            </ul>
            
            <p><span class="label">Classification:</span></p>
            <ul>
                <li><strong>Non-proliferative (NPDR):</strong> Microaneurysms, hemorrhages, cotton-wool spots, hard exudates</li>
                <li><strong>Proliferative (PDR):</strong> Neovascularization â€” sight-threatening; needs urgent referral</li>
                <li><strong>Diabetic macular edema:</strong> Can occur at any stage; leading cause of vision loss</li>
            </ul>
            
            <p><span class="label">Treatment:</span> Glycemic control, BP control, anti-VEGF injections (ranibizumab, aflibercept), laser photocoagulation for PDR</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIABETIC NEPHROPATHY</div>
        <div class="section-content">
            <p><span class="label">Screening:</span> Annual urine albumin-to-creatinine ratio (UACR) + eGFR</p>
            <ul>
                <li><strong>Normal:</strong> UACR &lt;30 mg/g</li>
                <li><strong>Moderately increased (microalbuminuria):</strong> 30-300 mg/g</li>
                <li><strong>Severely increased (macroalbuminuria):</strong> &gt;300 mg/g</li>
            </ul>
            
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>ACEi or ARB:</strong> First-line if UACR â‰¥30 (even if normotensive)</li>
                <li><strong>SGLT2 inhibitor:</strong> Add if eGFR â‰¥20 â€” nephroprotective</li>
                <li><strong>Finerenone:</strong> Non-steroidal MRA; add if persistent albuminuria on ACEi/ARB + SGLT2i</li>
                <li>BP goal &lt;130/80; glycemic control</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIABETIC NEUROPATHY</div>
        <div class="section-content">
            <p><span class="label">Types:</span></p>
            <ul>
                <li><strong>Distal symmetric polyneuropathy (DSPN):</strong> Most common; "stocking-glove" numbness, burning, tingling</li>
                <li><strong>Autonomic:</strong> Gastroparesis, orthostatic hypotension, erectile dysfunction, neurogenic bladder</li>
                <li><strong>Mononeuropathies:</strong> CN III palsy (pupil-sparing), carpal tunnel</li>
                <li><strong>Diabetic amyotrophy:</strong> Painful proximal weakness (femoral neuropathy)</li>
            </ul>
            
            <p><span class="label">Screening:</span> Annual monofilament testing + vibration sense</p>
            
            <p><span class="label">Painful Neuropathy Treatment:</span></p>
            <ul>
                <li><strong>First-line:</strong> Duloxetine, pregabalin, gabapentin</li>
                <li><strong>Second-line:</strong> TCAs (amitriptyline), tapentadol</li>
                <li><strong>Topical:</strong> Capsaicin, lidocaine patch</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Proliferative retinopathy = urgent ophthalmology referral</strong></li>
            <li><strong>SGLT2i + finerenone</strong> provide additive renal protection beyond ACEi/ARB</li>
            <li><strong>CN III palsy with pupil sparing = diabetic;</strong> pupil involved = aneurysm (urgent)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- SUBCLINICAL HYPOTHYROIDISM -->
<div id="subclinical-hypothyroid" class="condition-page">
    <div class="page-header">
        <h2>237. SUBCLINICAL HYPOTHYROIDISM</h2>
        <div class="subtitle">Elevated TSH â€¢ Normal T4 â€¢ When to Treat</div>
    </div>
    
    <div class="section">
        <div class="section-title">DEFINITION & CAUSES</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Elevated TSH (typically 4.5-10 mIU/L) with normal free T4</p>
            <p><span class="label">Causes:</span></p>
            <ul>
                <li>Early Hashimoto's thyroiditis (most common)</li>
                <li>Recovery from non-thyroidal illness</li>
                <li>Medications (lithium, amiodarone, immune checkpoint inhibitors)</li>
                <li>Post-radioactive iodine or thyroid surgery</li>
                <li>Iodine deficiency or excess</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">WHEN TO TREAT</div>
        <div class="section-content">
            <p><span class="label">Treat with Levothyroxine if:</span></p>
            <ul>
                <li><strong>TSH &gt;10 mIU/L</strong> (consensus to treat)</li>
                <li><strong>TSH 4.5-10 + symptoms</strong> consistent with hypothyroidism</li>
                <li><strong>Pregnancy or planning pregnancy</strong> (TSH goal &lt;2.5)</li>
                <li><strong>Positive TPO antibodies</strong> (higher progression risk)</li>
                <li><strong>Goiter</strong></li>
                <li><strong>Infertility</strong></li>
            </ul>
            
            <p><span class="label">Observation Appropriate if:</span></p>
            <ul>
                <li>TSH 4.5-10, asymptomatic, TPO negative</li>
                <li>Elderly (&gt;70-80 years) â€” higher TSH may be normal</li>
                <li>Recent illness (recheck in 6-8 weeks)</li>
            </ul>
            
            <p><span class="label">Follow-up if Not Treating:</span> Recheck TSH in 6-12 months</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Levothyroxine Dosing:</span></p>
            <ul>
                <li>Start low: 25-50 mcg daily</li>
                <li>Elderly or CAD: Start 12.5-25 mcg</li>
                <li>Take on empty stomach, 30-60 min before eating</li>
                <li>Separate from calcium, iron, PPIs by 4 hours</li>
            </ul>
            <p><span class="label">Monitoring:</span> Recheck TSH in 6-8 weeks; goal TSH 0.5-2.5</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>TSH &gt;10 = treat;</strong> TSH 4.5-10 = individualize</li>
            <li><strong>Elderly may not benefit from treatment</strong> â€” higher TSH may be protective</li>
            <li><strong>Always treat in pregnancy</strong> â€” goal TSH &lt;2.5 in first trimester</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- THYROID NODULES -->
<div id="thyroid-nodules" class="condition-page">
    <div class="page-header">
        <h2>238. THYROID NODULES</h2>
        <div class="subtitle">FNA Criteria â€¢ TI-RADS â€¢ Bethesda System</div>
    </div>
    
    <div class="section">
        <div class="section-title">INITIAL EVALUATION</div>
        <div class="section-content">
            <p><span class="label">First Step:</span> Check TSH</p>
            <ul>
                <li><strong>Low TSH:</strong> Thyroid scan â€” "hot" nodules rarely malignant; no FNA needed</li>
                <li><strong>Normal/High TSH:</strong> Ultrasound evaluation</li>
            </ul>
            
            <p><span class="label">Suspicious US Features:</span></p>
            <ul>
                <li>Hypoechoic</li>
                <li>Irregular margins</li>
                <li>Taller than wide</li>
                <li>Microcalcifications</li>
                <li>Extrathyroidal extension</li>
                <li>Abnormal cervical lymph nodes</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">FNA INDICATIONS (ATA Guidelines)</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>US Pattern</th><th>FNA Threshold</th></tr>
                <tr><td>High suspicion (solid hypoechoic + suspicious features)</td><td>â‰¥1 cm</td></tr>
                <tr><td>Intermediate suspicion (hypoechoic, smooth margins)</td><td>â‰¥1 cm</td></tr>
                <tr><td>Low suspicion (isoechoic/hyperechoic, partially cystic)</td><td>â‰¥1.5 cm</td></tr>
                <tr><td>Very low suspicion (spongiform, purely cystic)</td><td>â‰¥2 cm or observe</td></tr>
                <tr><td>Benign (purely cystic)</td><td>No FNA</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">BETHESDA SYSTEM (FNA RESULTS)</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Category</th><th>Malignancy Risk</th><th>Management</th></tr>
                <tr><td>I. Non-diagnostic</td><td>5-10%</td><td>Repeat FNA</td></tr>
                <tr><td>II. Benign</td><td>0-3%</td><td>Follow-up US</td></tr>
                <tr><td>III. AUS/FLUS</td><td>10-30%</td><td>Repeat FNA or molecular testing</td></tr>
                <tr><td>IV. Follicular neoplasm</td><td>25-40%</td><td>Molecular testing or lobectomy</td></tr>
                <tr><td>V. Suspicious for malignancy</td><td>50-75%</td><td>Lobectomy or total thyroidectomy</td></tr>
                <tr><td>VI. Malignant</td><td>97-99%</td><td>Total thyroidectomy</td></tr>
            </table>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Hot nodule on scan = benign;</strong> no FNA needed</li>
            <li><strong>Microcalcifications</strong> most specific for papillary thyroid cancer</li>
            <li><strong>Bethesda III/IV = indeterminate;</strong> molecular testing (Afirma, ThyroSeq) helps guide surgery</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- THYROIDITIS -->
<div id="thyroiditis" class="condition-page">
    <div class="page-header">
        <h2>239. THYROIDITIS</h2>
        <div class="subtitle">Subacute â€¢ Silent â€¢ Postpartum â€¢ Hashimoto's</div>
    </div>
    
    <div class="section">
        <div class="section-title">TYPES OF THYROIDITIS</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Type</th><th>Cause</th><th>Pain</th><th>RAIU</th><th>Clinical Course</th></tr>
                <tr><td><strong>Subacute (de Quervain)</strong></td><td>Post-viral</td><td>YES â€” tender thyroid</td><td>LOW</td><td>Hyper â†’ Hypo â†’ Recovery (weeks-months)</td></tr>
                <tr><td><strong>Silent/Painless</strong></td><td>Autoimmune</td><td>No</td><td>LOW</td><td>Hyper â†’ Hypo â†’ Recovery</td></tr>
                <tr><td><strong>Postpartum</strong></td><td>Autoimmune</td><td>No</td><td>LOW</td><td>Hyper (2-6mo) â†’ Hypo (4-8mo) â†’ Recovery (most)</td></tr>
                <tr><td><strong>Hashimoto's</strong></td><td>Autoimmune (TPO Ab)</td><td>No</td><td>Variable</td><td>Progressive hypothyroidism</td></tr>
                <tr><td><strong>Drug-induced</strong></td><td>Amiodarone, checkpoint inhibitors</td><td>Variable</td><td>Variable</td><td>Depends on type</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">SUBACUTE THYROIDITIS (de Quervain)</div>
        <div class="section-content">
            <p><span class="label">Presentation:</span> Painful, tender thyroid after viral URI; fever, fatigue, neck pain radiating to jaw/ear</p>
            <p><span class="label">Labs:</span> Elevated ESR (often &gt;50), low TSH initially (thyrotoxic phase), low RAIU</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>NSAIDs</strong> for mild pain</li>
                <li><strong>Prednisone 40mg</strong> tapering for severe pain (dramatic response)</li>
                <li><strong>Beta-blockers</strong> for thyrotoxic symptoms</li>
                <li><strong>No antithyroid drugs</strong> (not increased hormone synthesis)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">POSTPARTUM THYROIDITIS</div>
        <div class="section-content">
            <p><span class="label">Timing:</span> 2-6 months postpartum (hyperthyroid phase), 4-8 months (hypothyroid phase)</p>
            <p><span class="label">Risk Factors:</span> TPO antibody positive, Type 1 DM, prior postpartum thyroiditis</p>
            <p><span class="label">Management:</span></p>
            <ul>
                <li>Hyperthyroid phase: Beta-blockers (no thionamides)</li>
                <li>Hypothyroid phase: Levothyroxine if symptomatic</li>
                <li>Most recover; 20-30% develop permanent hypothyroidism</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Painful thyroid + elevated ESR + low RAIU = subacute thyroiditis</strong></li>
            <li><strong>Low RAIU distinguishes thyroiditis from Graves'</strong> (high RAIU)</li>
            <li><strong>Steroids dramatically improve subacute thyroiditis pain</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- MALE HYPOGONADISM -->
<div id="hypogonadism" class="condition-page">
    <div class="page-header">
        <h2>240. MALE HYPOGONADISM</h2>
        <div class="subtitle">Primary vs Secondary â€¢ Testosterone Replacement â€¢ Monitoring</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Type</th><th>Location</th><th>LH/FSH</th><th>Causes</th></tr>
                <tr><td><strong>Primary (Hypergonadotropic)</strong></td><td>Testicular failure</td><td>HIGH</td><td>Klinefelter (XXY), orchitis, trauma, radiation, chemotherapy</td></tr>
                <tr><td><strong>Secondary (Hypogonadotropic)</strong></td><td>Pituitary/hypothalamic</td><td>LOW/Normal</td><td>Pituitary tumor, hyperprolactinemia, Kallmann syndrome, opioids, obesity</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Symptoms:</span> Decreased libido, erectile dysfunction, fatigue, decreased muscle mass, increased body fat, mood changes, decreased bone density</p>
            <p><span class="label">Diagnosis:</span></p>
            <ul>
                <li><strong>Two morning testosterone levels</strong> (8-10 AM) both low (&lt;300 ng/dL)</li>
                <li>Check LH, FSH to differentiate primary vs secondary</li>
                <li>If secondary: Check prolactin, pituitary MRI if indicated</li>
                <li>Consider SHBG and free testosterone if total T borderline</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Testosterone Replacement Options:</span></p>
            <ul>
                <li><strong>IM injection:</strong> Testosterone cypionate/enanthate every 1-2 weeks</li>
                <li><strong>Topical gel:</strong> Daily application; risk of transfer</li>
                <li><strong>Transdermal patch:</strong> Daily</li>
                <li><strong>Nasal gel:</strong> TID dosing</li>
                <li><strong>SC pellets:</strong> Every 3-6 months</li>
            </ul>
            
            <p><span class="label">Contraindications:</span></p>
            <ul>
                <li>Prostate or breast cancer</li>
                <li>PSA &gt;4 or palpable nodule (without evaluation)</li>
                <li>Hematocrit &gt;50%</li>
                <li>Severe untreated sleep apnea</li>
                <li>Desire for fertility (suppresses spermatogenesis)</li>
            </ul>
            
            <p><span class="label">Monitoring:</span> Testosterone level, hematocrit (q3-6mo first year), PSA, lipids, BMD</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Two AM testosterone levels required</strong> before diagnosis</li>
            <li><strong>Testosterone replacement suppresses fertility</strong> â€” use hCG/clomiphene if fertility desired</li>
            <li><strong>Monitor hematocrit</strong> â€” polycythemia is common side effect</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<!-- ZOLLINGER-ELLISON -->
<div id="zes" class="condition-page">
    <div class="page-header">
        <h2>241. ZOLLINGER-ELLISON SYNDROME</h2>
        <div class="subtitle">Gastrinoma â€¢ Refractory PUD â€¢ MEN1 Association</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Presentation:</span></p>
            <ul>
                <li>Refractory or recurrent peptic ulcers (especially distal duodenum/jejunum)</li>
                <li>Multiple ulcers</li>
                <li>Diarrhea/steatorrhea (acid inactivates lipase)</li>
                <li>GERD symptoms</li>
            </ul>
            <p><span class="label">Location:</span> Gastrinoma triangle (pancreas, duodenum); 60-90% malignant; 25% associated with MEN1</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Fasting Serum Gastrin:</span> &gt;1000 pg/mL diagnostic (with gastric pH &lt;2)</p>
            <p><span class="label">Secretin Stimulation Test:</span> Paradoxical rise in gastrin (&gt;120 pg/mL increase) â€” confirms diagnosis</p>
            <p><span class="label">Must Confirm Gastric Acid Hypersecretion:</span> pH &lt;2 rules out achlorhydria/PPI effect</p>
            <p><span class="label">Localization:</span> CT/MRI, EUS, somatostatin receptor scintigraphy (Octreoscan)</p>
            <p><span class="label">Rule Out MEN1:</span> Calcium, PTH, prolactin, pituitary imaging</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>High-dose PPI:</strong> Control acid secretion (often 2-4Ã— standard dose)</li>
                <li><strong>Surgical resection:</strong> Curative if localized; not if metastatic or MEN1</li>
                <li><strong>Somatostatin analogs:</strong> For metastatic disease</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Gastrin &gt;1000 + pH &lt;2 = diagnostic</strong></li>
            <li><strong>Stop PPI before testing</strong> â€” PPIs elevate gastrin</li>
            <li><strong>Screen for MEN1</strong> in all ZES patients</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- SIBO -->
<div id="sibo" class="condition-page">
    <div class="page-header">
        <h2>242. SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO)</h2>
        <div class="subtitle">Malabsorption â€¢ Breath Testing â€¢ Rifaximin</div>
    </div>
    
    <div class="section">
        <div class="section-title">RISK FACTORS & PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li><strong>Anatomic:</strong> Blind loops, strictures, diverticula, post-surgical (Roux-en-Y)</li>
                <li><strong>Motility disorders:</strong> Scleroderma, diabetes gastroparesis, chronic intestinal pseudo-obstruction</li>
                <li><strong>Hypochlorhydria:</strong> Chronic PPI use, atrophic gastritis</li>
                <li><strong>Immune:</strong> IgA deficiency, HIV</li>
            </ul>
            <p><span class="label">Symptoms:</span> Bloating, flatulence, abdominal discomfort, diarrhea, weight loss, steatorrhea</p>
            <p><span class="label">Deficiencies:</span> B12 (bacteria consume), fat-soluble vitamins (A, D, E, K)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Diagnosis:</span></p>
            <ul>
                <li><strong>Glucose or lactulose hydrogen breath test:</strong> Most practical</li>
                <li><strong>Small bowel aspirate &gt;10Â³ CFU/mL:</strong> Gold standard but invasive</li>
            </ul>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Rifaximin 550mg TID Ã— 14 days:</strong> First-line (non-absorbable)</li>
                <li><strong>Alternatives:</strong> Metronidazole + fluoroquinolone, amoxicillin-clavulanate, doxycycline</li>
                <li><strong>Recurrence common:</strong> May need cyclic antibiotics</li>
                <li><strong>Treat underlying cause</strong> when possible</li>
                <li><strong>Nutritional supplementation:</strong> B12, fat-soluble vitamins</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>B12 deficiency (not folate)</strong> â€” bacteria consume B12 but produce folate</li>
            <li><strong>Rifaximin first-line</strong> â€” well-tolerated, minimal systemic absorption</li>
            <li><strong>Consider in scleroderma, post-surgical patients</strong> with GI symptoms</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- MALABSORPTION -->
<div id="malabsorption" class="condition-page">
    <div class="page-header">
        <h2>243. MALABSORPTION SYNDROMES</h2>
        <div class="subtitle">Fat vs Carbohydrate â€¢ Workup â€¢ Etiology-Specific Treatment</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">General Symptoms:</span> Diarrhea, weight loss, bloating, flatulence</p>
            <p><span class="label">Fat Malabsorption (Steatorrhea):</span> Greasy, foul-smelling, floating stools; fat-soluble vitamin deficiencies (A, D, E, K)</p>
            <p><span class="label">Carbohydrate Malabsorption:</span> Watery diarrhea, bloating, flatulence (osmotic)</p>
            <p><span class="label">Specific Deficiencies:</span></p>
            <ul>
                <li>Iron: Anemia (proximal small bowel)</li>
                <li>B12: Anemia, neuropathy (terminal ileum)</li>
                <li>Calcium/Vitamin D: Osteoporosis, hypocalcemia</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIFFERENTIAL DIAGNOSIS</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Location</th><th>Causes</th><th>Key Features</th></tr>
                <tr><td>Luminal (digestion)</td><td>Pancreatic insufficiency, bile salt deficiency</td><td>Steatorrhea, low fecal elastase</td></tr>
                <tr><td>Mucosal (absorption)</td><td>Celiac, tropical sprue, Whipple's, Crohn's, radiation</td><td>Villous atrophy, specific antibodies</td></tr>
                <tr><td>Post-mucosal (lymphatic)</td><td>Intestinal lymphangiectasia, lymphoma</td><td>Protein-losing enteropathy, chylous ascites</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">WORKUP</div>
        <div class="section-content">
            <ul>
                <li><strong>Qualitative fecal fat:</strong> Sudan stain (screening)</li>
                <li><strong>Quantitative fecal fat:</strong> &gt;7g/day on 100g fat diet (72-hour collection)</li>
                <li><strong>Fecal elastase:</strong> &lt;200 Î¼g/g suggests pancreatic insufficiency</li>
                <li><strong>D-xylose test:</strong> Normal = luminal problem; Abnormal = mucosal disease</li>
                <li><strong>Celiac serology:</strong> TTG-IgA (check total IgA)</li>
                <li><strong>Small bowel biopsy:</strong> If celiac suspected or unexplained</li>
                <li><strong>Imaging:</strong> CT/MRI enterography, capsule endoscopy</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Low fecal elastase = pancreatic insufficiency;</strong> treat with pancreatic enzymes</li>
            <li><strong>D-xylose normal = pancreatic/biliary;</strong> abnormal = mucosal disease</li>
            <li><strong>Check IgA level</strong> when ordering TTG-IgA (IgA deficiency gives false negative)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- MICROSCOPIC COLITIS -->
<div id="microscopic-colitis" class="condition-page">
    <div class="page-header">
        <h2>244. MICROSCOPIC COLITIS</h2>
        <div class="subtitle">Collagenous vs Lymphocytic â€¢ Normal Colonoscopy â€¢ Budesonide</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Presentation:</span></p>
            <ul>
                <li>Chronic watery, non-bloody diarrhea</li>
                <li>Typically middle-aged to elderly women</li>
                <li>Nocturnal diarrhea common</li>
                <li>Associated with autoimmune diseases (celiac, thyroid)</li>
            </ul>
            <p><span class="label">Drug Associations:</span> NSAIDs, PPIs, SSRIs, checkpoint inhibitors</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Colonoscopy:</span> <strong>Grossly normal</strong> (hence "microscopic")</p>
            <p><span class="label">Diagnosis requires random biopsies:</span></p>
            <ul>
                <li><strong>Collagenous colitis:</strong> Thickened subepithelial collagen band (&gt;10 Î¼m)</li>
                <li><strong>Lymphocytic colitis:</strong> Increased intraepithelial lymphocytes (&gt;20 per 100 epithelial cells)</li>
            </ul>
            <p><span class="label">Labs:</span> May have elevated inflammatory markers; rule out celiac disease</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Step 1:</span> Discontinue offending medications (NSAIDs, PPIs)</p>
            <p><span class="label">Step 2:</span> Antidiarrheals (loperamide) for mild symptoms</p>
            <p><span class="label">Step 3:</span> <strong>Budesonide 9mg daily Ã— 6-8 weeks</strong> â€” first-line for moderate-severe; high response rate</p>
            <p><span class="label">Maintenance:</span> Budesonide 6mg; relapses common after stopping</p>
            <p><span class="label">Refractory:</span> Bismuth subsalicylate, cholestyramine, immunomodulators, biologics (rare)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Normal colonoscopy + chronic watery diarrhea = biopsy for microscopic colitis</strong></li>
            <li><strong>Budesonide highly effective</strong> â€” topically active, low systemic absorption</li>
            <li><strong>Screen for celiac disease</strong> â€” commonly coexists</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- HEREDITARY CRC SYNDROMES -->
<div id="hereditary-crc" class="condition-page">
    <div class="page-header">
        <h2>245. HEREDITARY CRC SYNDROMES</h2>
        <div class="subtitle">Lynch Syndrome â€¢ FAP â€¢ Screening Protocols</div>
    </div>
    
    <div class="section">
        <div class="section-title">LYNCH SYNDROME (HNPCC)</div>
        <div class="section-content">
            <p><span class="label">Genetics:</span> Autosomal dominant; MLH1, MSH2, MSH6, PMS2 mutations (mismatch repair genes)</p>
            <p><span class="label">Features:</span></p>
            <ul>
                <li>Early-onset CRC (mean age 45)</li>
                <li>Right-sided predominance</li>
                <li>Synchronous/metachronous CRC</li>
                <li>Microsatellite instability (MSI-high)</li>
            </ul>
            <p><span class="label">Extra-Colonic Cancers:</span> Endometrial (most common), ovarian, gastric, urinary tract, small bowel, brain (Turcot), sebaceous tumors (Muir-Torre)</p>
            <p><span class="label">Amsterdam II Criteria (3-2-1 rule):</span> 3 relatives with Lynch-associated cancer, 2 generations, 1 diagnosed &lt;50</p>
            <p><span class="label">Screening:</span> Colonoscopy every 1-2 years starting age 20-25 (or 2-5 years before youngest case)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">FAMILIAL ADENOMATOUS POLYPOSIS (FAP)</div>
        <div class="section-content">
            <p><span class="label">Genetics:</span> Autosomal dominant; APC gene mutation</p>
            <p><span class="label">Features:</span></p>
            <ul>
                <li>&gt;100 colorectal adenomatous polyps (often thousands)</li>
                <li>100% CRC risk if untreated (by age 40)</li>
                <li>Polyps develop in teens</li>
            </ul>
            <p><span class="label">Extra-Colonic:</span> Duodenal adenomas/cancer (second most common cancer), desmoid tumors, thyroid cancer, osteomas (Gardner syndrome), brain tumors (Turcot)</p>
            <p><span class="label">Attenuated FAP:</span> 10-100 polyps, later onset</p>
            <p><span class="label">Screening:</span> Annual sigmoidoscopy/colonoscopy starting age 10-12</p>
            <p><span class="label">Treatment:</span> Prophylactic colectomy when polyps develop (usually late teens/20s)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">OTHER SYNDROMES</div>
        <div class="section-content">
            <ul>
                <li><strong>Peutz-Jeghers:</strong> Hamartomatous polyps + mucocutaneous pigmentation; STK11 mutation; GI/breast/pancreas/ovarian cancer risk</li>
                <li><strong>Juvenile Polyposis:</strong> &gt;5 juvenile polyps; SMAD4/BMPR1A; CRC risk</li>
                <li><strong>MUTYH-associated:</strong> Autosomal recessive; 10-100 adenomas; similar to attenuated FAP</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Lynch = MSI-high, right-sided, endometrial cancer</strong></li>
            <li><strong>FAP = thousands of polyps, 100% cancer risk, prophylactic colectomy</strong></li>
            <li><strong>Universal tumor testing</strong> for Lynch now recommended for all CRC</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PSC -->
<div id="psc" class="condition-page">
    <div class="page-header">
        <h2>246. PRIMARY SCLEROSING CHOLANGITIS (PSC)</h2>
        <div class="subtitle">IBD Association â€¢ Beading on MRCP â€¢ Cholangiocarcinoma Risk</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Demographics:</span> Young to middle-aged men; 70-80% have IBD (usually UC)</p>
            <p><span class="label">Presentation:</span></p>
            <ul>
                <li>Fatigue, pruritus</li>
                <li>RUQ pain, jaundice (later)</li>
                <li>May be asymptomatic (elevated ALP on labs)</li>
                <li>Recurrent cholangitis (fever, RUQ pain, jaundice)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li>Cholestatic pattern: Elevated ALP (predominant), GGT, bilirubin</li>
                <li>p-ANCA positive (70%) â€” non-specific</li>
                <li>AMA negative (unlike PBC)</li>
            </ul>
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>MRCP (first-line):</strong> Multifocal strictures and dilations ("beading") of intrahepatic and extrahepatic bile ducts</li>
                <li>ERCP: More invasive; used therapeutically</li>
            </ul>
            <p><span class="label">Biopsy:</span> "Onion-skin" periductal fibrosis (not required for diagnosis)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">COMPLICATIONS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Complications:</span></p>
            <ul>
                <li><strong>Cholangiocarcinoma:</strong> 10-15% lifetime risk; difficult to detect</li>
                <li>Cirrhosis, portal hypertension</li>
                <li>Dominant stricture (may need ERCP dilation/stenting)</li>
                <li>Fat-soluble vitamin deficiency</li>
                <li>Increased CRC risk (need annual colonoscopy if UC)</li>
            </ul>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>No proven medical therapy</strong> to slow progression</li>
                <li>UDCA: May improve labs but no survival benefit; high-dose harmful</li>
                <li>Pruritus management: Cholestyramine, rifampin</li>
                <li><strong>Liver transplant:</strong> Only curative option; can recur</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>PSC + UC:</strong> Must do colonoscopy even if colectomy (rectal stump cancer)</li>
            <li><strong>Beading on MRCP = PSC;</strong> AMA negative (unlike PBC)</li>
            <li><strong>No medical therapy slows progression</strong> â€” transplant only cure</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- WILSON DISEASE -->
<div id="wilson" class="condition-page">
    <div class="page-header">
        <h2>247. WILSON DISEASE</h2>
        <div class="subtitle">Copper Overload â€¢ Kayser-Fleischer Rings â€¢ Ceruloplasmin</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Age of Onset:</span> 5-35 years (hepatic earlier, neuropsych later)</p>
            <p><span class="label">Hepatic:</span> Ranges from asymptomatic elevated LFTs to cirrhosis to acute liver failure (Coombs-negative hemolytic anemia)</p>
            <p><span class="label">Neurologic:</span> Tremor, dystonia, dysarthria, parkinsonism, psychiatric symptoms (depression, personality change)</p>
            <p><span class="label">Ophthalmologic:</span> <strong>Kayser-Fleischer rings</strong> â€” copper deposits in Descemet's membrane (requires slit-lamp); present in 95% with neurologic disease</p>
            <p><span class="label">Other:</span> Coombs-negative hemolytic anemia, renal tubular acidosis, arthritis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Low serum ceruloplasmin</strong> (&lt;20 mg/dL) â€” 85% sensitive</li>
                <li><strong>Elevated 24-hour urine copper</strong> (&gt;100 Î¼g/day; &gt;40 Î¼g suggests)</li>
                <li><strong>Elevated hepatic copper</strong> on liver biopsy (&gt;250 Î¼g/g dry weight) â€” gold standard</li>
                <li>Low serum copper (bound to ceruloplasmin); high free copper</li>
            </ul>
            <p><span class="label">Genetic Testing:</span> ATP7B gene mutations (autosomal recessive)</p>
            <p><span class="label">Imaging:</span> Brain MRI may show basal ganglia changes</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>Chelation therapy:</strong> D-penicillamine (first-line) or trientine</li>
                <li><strong>Zinc:</strong> Blocks intestinal copper absorption; maintenance or mild disease</li>
                <li><strong>Low copper diet:</strong> Avoid shellfish, liver, nuts, chocolate, mushrooms</li>
                <li><strong>Liver transplant:</strong> Curative for liver failure; may improve neurologic symptoms</li>
                <li><strong>Screen siblings</strong> (25% risk)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Young patient + liver disease + neuropsych symptoms = Wilson</strong></li>
            <li><strong>Low ceruloplasmin + Kayser-Fleischer rings = diagnostic</strong></li>
            <li><strong>Acute liver failure + Coombs-negative hemolysis = Wilson until proven otherwise</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- HEMOCHROMATOSIS -->
<div id="hemochromatosis" class="condition-page">
    <div class="page-header">
        <h2>248. HEREDITARY HEMOCHROMATOSIS</h2>
        <div class="subtitle">Iron Overload â€¢ HFE Gene â€¢ Phlebotomy</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Classic Triad:</span> Cirrhosis, diabetes mellitus, skin hyperpigmentation ("bronze diabetes")</p>
            <p><span class="label">Other Manifestations:</span></p>
            <ul>
                <li><strong>Liver:</strong> Elevated LFTs, cirrhosis, HCC (leading cause of death)</li>
                <li><strong>Heart:</strong> Dilated cardiomyopathy, arrhythmias</li>
                <li><strong>Endocrine:</strong> Diabetes, hypogonadism</li>
                <li><strong>Joints:</strong> Arthropathy (2nd/3rd MCP â€” "iron fist"), chondrocalcinosis (pseudogout)</li>
                <li><strong>Skin:</strong> Bronze/gray pigmentation</li>
            </ul>
            <p><span class="label">Demographics:</span> Northern European descent; men symptomatic earlier (women protected by menses)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Initial Testing:</span></p>
            <ul>
                <li><strong>Transferrin saturation &gt;45%</strong> â€” most sensitive screening test</li>
                <li><strong>Ferritin elevated</strong> (but non-specific; acute phase reactant)</li>
            </ul>
            <p><span class="label">Confirmatory:</span></p>
            <ul>
                <li><strong>HFE gene testing:</strong> C282Y homozygosity (most common); C282Y/H63D compound heterozygosity</li>
                <li><strong>MRI:</strong> Quantify liver/cardiac iron (T2*)</li>
                <li><strong>Liver biopsy:</strong> If ferritin &gt;1000 or elevated LFTs (assess fibrosis)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>Phlebotomy:</strong> First-line; 500mL weekly until ferritin &lt;50-100; then maintenance q2-4 months</li>
                <li><strong>Goal:</strong> Ferritin 50-100 ng/mL, transferrin saturation &lt;50%</li>
                <li><strong>Chelation (deferasirox):</strong> If phlebotomy contraindicated</li>
                <li><strong>Avoid:</strong> Iron supplements, vitamin C (increases absorption), excess alcohol</li>
                <li><strong>Screen first-degree relatives</strong></li>
                <li><strong>HCC surveillance:</strong> If cirrhosis (US Â± AFP every 6 months)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Transferrin saturation &gt;45% = screen with HFE genotyping</strong></li>
            <li><strong>C282Y homozygous</strong> most common genotype in symptomatic patients</li>
            <li><strong>Arthropathy may not improve with phlebotomy</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- EOE -->
<div id="eoe" class="condition-page">
    <div class="page-header">
        <h2>249. EOSINOPHILIC ESOPHAGITIS (EoE)</h2>
        <div class="subtitle">Dysphagia â€¢ Food Impaction â€¢ Ringed Esophagus</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Demographics:</span> Young adults (20s-30s), predominantly male; often atopic history (asthma, allergies, eczema)</p>
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li><strong>Dysphagia to solids</strong> (most common)</li>
                <li><strong>Food impaction</strong> (may be presenting symptom)</li>
                <li>Heartburn (often PPI-refractory)</li>
                <li>Chest pain</li>
                <li>Children: Feeding difficulties, failure to thrive</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">EGD Findings:</span></p>
            <ul>
                <li><strong>Rings/trachealization</strong> ("feline esophagus")</li>
                <li>Linear furrows</li>
                <li>White exudates/plaques</li>
                <li>Strictures, narrow caliber</li>
                <li>May appear normal</li>
            </ul>
            <p><span class="label">Histology Required:</span></p>
            <ul>
                <li><strong>â‰¥15 eosinophils per high-power field</strong> on esophageal biopsy</li>
                <li>Multiple biopsies from proximal and distal esophagus (patchy)</li>
            </ul>
            <p><span class="label">Rule Out:</span> GERD (but can coexist), other causes of esophageal eosinophilia</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">First-Line Options:</span></p>
            <ul>
                <li><strong>PPI:</strong> Omeprazole 40mg BID Ã— 8 weeks (PPI-responsive EoE)</li>
                <li><strong>Topical corticosteroids:</strong> Swallowed fluticasone (from MDI, don't inhale) or budesonide slurry</li>
                <li><strong>Dietary elimination:</strong> 6-food elimination (milk, wheat, egg, soy, nuts, seafood) or elemental diet</li>
            </ul>
            <p><span class="label">Refractory:</span> Dupilumab (IL-4/IL-13 inhibitor) â€” FDA approved for EoE</p>
            <p><span class="label">Dilation:</span> For symptomatic strictures (careful â€” mucosal tears common)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Young atopic male + dysphagia + food impaction = EoE</strong></li>
            <li><strong>â‰¥15 eos/hpf required for diagnosis</strong></li>
            <li><strong>Swallowed topical steroids</strong> â€” not inhaled</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<!-- IPF -->
<div id="ipf" class="condition-page">
    <div class="page-header">
        <h2>250. IDIOPATHIC PULMONARY FIBROSIS (IPF)</h2>
        <div class="subtitle">UIP Pattern â€¢ Progressive Fibrosis â€¢ Antifibrotics</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Demographics:</span> Age &gt;50, male predominance, smoking history</p>
            <p><span class="label">Symptoms:</span> Progressive dyspnea, dry cough (months to years)</p>
            <p><span class="label">Exam:</span> Bibasilar inspiratory "Velcro" crackles, clubbing (25-50%)</p>
            <p><span class="label">PFTs:</span> Restrictive pattern (â†“FVC, â†“TLC), â†“DLCO (often early and disproportionate)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">HRCT Pattern â€” UIP (Usual Interstitial Pneumonia):</span></p>
            <ul>
                <li><strong>Honeycombing</strong> (clustered cystic airspaces) â€” most specific</li>
                <li>Reticular opacities</li>
                <li>Traction bronchiectasis</li>
                <li><strong>Basal and peripheral predominance</strong></li>
                <li>Absence of features inconsistent with UIP</li>
            </ul>
            <p><span class="label">Definite UIP on HRCT + compatible clinical = IPF</span> (no biopsy needed)</p>
            <p><span class="label">Surgical Lung Biopsy:</span> If HRCT indeterminate; shows UIP pattern histologically</p>
            <p><span class="label">Rule Out:</span> CTD-ILD, hypersensitivity pneumonitis, drug-induced, asbestosis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Antifibrotic Therapy (slow progression):</span></p>
            <ul>
                <li><strong>Nintedanib:</strong> Tyrosine kinase inhibitor; diarrhea common side effect</li>
                <li><strong>Pirfenidone:</strong> Anti-fibrotic/anti-inflammatory; GI side effects, photosensitivity</li>
            </ul>
            <p><span class="label">Neither is curative;</span> both slow FVC decline</p>
            <p><span class="label">Supportive:</span> Supplemental O2, pulmonary rehabilitation, vaccination</p>
            <p><span class="label">Lung Transplant:</span> Only curative option; refer early (median survival 3-5 years without)</p>
            <p><span class="label">AVOID:</span> Steroids and immunosuppressants (no benefit, may harm in IPF)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Honeycombing + basal/peripheral = UIP pattern = IPF</strong></li>
            <li><strong>Steroids don't help IPF</strong> (unlike other ILDs)</li>
            <li><strong>Early transplant referral</strong> â€” median survival only 3-5 years</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CYSTIC FIBROSIS -->
<div id="cystic-fibrosis" class="condition-page">
    <div class="page-header">
        <h2>251. CYSTIC FIBROSIS</h2>
        <div class="subtitle">CFTR Mutation â€¢ Bronchiectasis â€¢ CFTR Modulators</div>
    </div>
    
    <div class="section">
        <div class="section-title">PATHOPHYSIOLOGY & CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Genetics:</span> Autosomal recessive; CFTR gene mutations (F508del most common)</p>
            <p><span class="label">Pulmonary:</span></p>
            <ul>
                <li>Thick secretions, bronchiectasis, recurrent infections</li>
                <li>Pathogens: <strong>Pseudomonas aeruginosa</strong> (most significant), S. aureus, Burkholderia cepacia, NTM</li>
                <li>Progressive decline â†’ respiratory failure</li>
            </ul>
            <p><span class="label">GI:</span></p>
            <ul>
                <li><strong>Pancreatic insufficiency</strong> (85%) â€” steatorrhea, malnutrition</li>
                <li>Meconium ileus (neonates), DIOS (adults)</li>
                <li>CF-related diabetes (CFRD)</li>
                <li>Hepatobiliary disease</li>
            </ul>
            <p><span class="label">Other:</span> Male infertility (absent vas deferens), sinus disease, osteoporosis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <ul>
                <li><strong>Sweat chloride &gt;60 mEq/L</strong> â€” diagnostic</li>
                <li>Newborn screening (immunoreactive trypsinogen)</li>
                <li>CFTR genetic testing</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">CFTR Modulators (Disease-Modifying):</span></p>
            <ul>
                <li><strong>Elexacaftor/Tezacaftor/Ivacaftor (Trikafta):</strong> Highly effective for F508del (90% of patients); dramatically improves lung function and outcomes</li>
                <li>Ivacaftor alone for gating mutations (G551D)</li>
            </ul>
            <p><span class="label">Airway Clearance:</span></p>
            <ul>
                <li>Chest physiotherapy, oscillating devices</li>
                <li><strong>Dornase alfa (Pulmozyme):</strong> DNase; reduces mucus viscosity</li>
                <li><strong>Hypertonic saline:</strong> Nebulized 7%</li>
            </ul>
            <p><span class="label">Infections:</span> Aggressive treatment of exacerbations; chronic suppressive therapy for Pseudomonas (inhaled tobramycin, aztreonam)</p>
            <p><span class="label">Nutrition:</span> Pancreatic enzyme replacement, fat-soluble vitamins, high-calorie diet</p>
            <p><span class="label">Transplant:</span> For advanced disease</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Sweat chloride &gt;60 = CF;</strong> 30-59 = intermediate</li>
            <li><strong>Trikafta transformed CF care</strong> â€” now chronic disease with near-normal lifespan for many</li>
            <li><strong>Pseudomonas eradication</strong> attempted at first isolation</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ALPHA-1 ANTITRYPSIN -->
<div id="a1at" class="condition-page">
    <div class="page-header">
        <h2>252. ALPHA-1 ANTITRYPSIN DEFICIENCY</h2>
        <div class="subtitle">Early COPD â€¢ Panacinar Emphysema â€¢ Augmentation Therapy</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">When to Suspect:</span></p>
            <ul>
                <li><strong>COPD/emphysema at young age (&lt;45)</strong></li>
                <li>COPD in non-smoker or minimal smoking</li>
                <li><strong>Basilar-predominant emphysema</strong> (panacinar)</li>
                <li>Family history of emphysema or liver disease</li>
                <li>Unexplained liver disease</li>
                <li>Necrotizing panniculitis</li>
            </ul>
            <p><span class="label">Pulmonary:</span> Early-onset COPD; accelerated by smoking</p>
            <p><span class="label">Hepatic:</span> Cirrhosis (AAT polymers accumulate in liver); HCC risk</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <ul>
                <li><strong>Serum AAT level:</strong> &lt;11 Î¼M (or &lt;80 mg/dL) = severe deficiency</li>
                <li><strong>Phenotype/genotype testing:</strong> PI*ZZ most common severe; PI*MZ heterozygotes have intermediate levels</li>
            </ul>
            <p><span class="label">Who to Test:</span> All COPD patients should be tested at least once (ATS/ERS recommendation)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>Smoking cessation:</strong> Most important intervention</li>
                <li><strong>Standard COPD treatment:</strong> Bronchodilators, ICS if indicated</li>
                <li><strong>AAT augmentation therapy:</strong> IV pooled human AAT (Prolastin) weekly for severe deficiency with evidence of emphysema; slows FEV1 decline</li>
                <li><strong>Lung transplant:</strong> For advanced disease</li>
                <li><strong>Liver transplant:</strong> For end-stage liver disease (curative â€” liver produces normal AAT)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Test ALL COPD patients</strong> for AAT deficiency at least once</li>
            <li><strong>Basilar emphysema</strong> in young non-smoker = think AAT deficiency</li>
            <li><strong>PI*ZZ = severe deficiency;</strong> PI*MZ = carrier</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- BRONCHIECTASIS -->
<div id="bronchiectasis" class="condition-page">
    <div class="page-header">
        <h2>253. BRONCHIECTASIS</h2>
        <div class="subtitle">Chronic Productive Cough â€¢ Airway Clearance â€¢ NTM</div>
    </div>
    
    <div class="section">
        <div class="section-title">ETIOLOGY</div>
        <div class="section-content">
            <p><span class="label">Post-Infectious:</span> Childhood pneumonia, TB, NTM, pertussis</p>
            <p><span class="label">Immune:</span> CVID, IgA deficiency, HIV</p>
            <p><span class="label">Genetic:</span> Cystic fibrosis, primary ciliary dyskinesia, AAT deficiency</p>
            <p><span class="label">Aspiration/Obstruction:</span> Foreign body, tumor, ABPA</p>
            <p><span class="label">Autoimmune:</span> RA, SjÃ¶gren's, IBD</p>
            <p><span class="label">Idiopathic:</span> ~50% of cases</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Symptoms:</span> Chronic productive cough (purulent sputum), hemoptysis, recurrent infections, dyspnea</p>
            <p><span class="label">Exam:</span> Crackles, wheezing, clubbing</p>
            <p><span class="label">HRCT:</span> Bronchial dilation (internal diameter > adjacent pulmonary artery = "signet ring sign"), lack of tapering, bronchial wall thickening</p>
            <p><span class="label">Workup for Etiology:</span></p>
            <ul>
                <li>Immunoglobulins (IgG, IgA, IgM)</li>
                <li>CFTR testing (even in adults)</li>
                <li>Sputum for AFB and fungal cultures</li>
                <li>Aspergillus IgE, IgG (ABPA)</li>
                <li>Consider PCD testing if suggestive history</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Airway Clearance:</span> Chest physiotherapy, oscillating devices, hypertonic saline</p>
            <p><span class="label">Mucolytics:</span> Hypertonic saline (7%); dornase alfa only for CF</p>
            <p><span class="label">Antibiotics:</span></p>
            <ul>
                <li>Acute exacerbations: 14 days, culture-directed</li>
                <li><strong>Chronic macrolide therapy</strong> (azithromycin 3Ã—/week): Reduces exacerbations (rule out NTM first)</li>
                <li>Inhaled antibiotics for Pseudomonas colonization</li>
            </ul>
            <p><span class="label">Bronchodilators:</span> If coexisting airflow obstruction</p>
            <p><span class="label">Surgery:</span> Resection for localized disease with recurrent infections/hemoptysis</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Rule out NTM before starting chronic azithromycin</strong> (resistance)</li>
            <li><strong>Test immunoglobulins and consider CF</strong> even in adults</li>
            <li><strong>Signet ring sign on CT</strong> = bronchiectasis</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- HYPERSENSITIVITY PNEUMONITIS -->
<div id="hp" class="condition-page">
    <div class="page-header">
        <h2>254. HYPERSENSITIVITY PNEUMONITIS</h2>
        <div class="subtitle">Antigen Exposure â€¢ Acute vs Chronic â€¢ Ground Glass + Mosaic</div>
    </div>
    
    <div class="section">
        <div class="section-title">ETIOLOGY & CLASSIFICATION</div>
        <div class="section-content">
            <p><span class="label">Common Antigens:</span></p>
            <ul>
                <li><strong>Bird fancier's lung:</strong> Avian proteins (pigeons, parakeets)</li>
                <li><strong>Farmer's lung:</strong> Thermophilic actinomycetes (moldy hay)</li>
                <li><strong>Hot tub lung:</strong> Mycobacterium avium complex</li>
                <li><strong>Humidifier/AC lung:</strong> Bacteria, fungi in water reservoirs</li>
            </ul>
            
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Type</th><th>Onset</th><th>Features</th></tr>
                <tr><td><strong>Acute</strong></td><td>4-8 hours post-exposure</td><td>Flu-like symptoms, dyspnea, cough; resolves with avoidance</td></tr>
                <tr><td><strong>Subacute</strong></td><td>Weeks-months</td><td>Progressive dyspnea, cough, fatigue</td></tr>
                <tr><td><strong>Chronic</strong></td><td>Months-years</td><td>Progressive fibrosis, may be irreversible</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">History:</span> Exposure history crucial (occupational, hobbies, home environment)</p>
            <p><span class="label">Labs:</span> Serum precipitins (IgG to specific antigens) â€” supportive but not diagnostic</p>
            <p><span class="label">HRCT:</span></p>
            <ul>
                <li><strong>Acute/Subacute:</strong> Ground-glass opacities, centrilobular nodules, mosaic attenuation (air trapping)</li>
                <li><strong>Chronic:</strong> Fibrosis, traction bronchiectasis; upper/mid lung predominant</li>
            </ul>
            <p><span class="label">BAL:</span> Lymphocytosis (&gt;20-30%); CD4/CD8 ratio variable</p>
            <p><span class="label">Biopsy:</span> Poorly formed non-caseating granulomas, cellular bronchiolitis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>Antigen avoidance:</strong> Most important; often curative in acute/subacute</li>
                <li><strong>Corticosteroids:</strong> For severe or progressive disease (prednisone 0.5-1 mg/kg)</li>
                <li><strong>Immunosuppression:</strong> Mycophenolate, azathioprine for chronic progressive</li>
                <li><strong>Antifibrotics:</strong> Consider in fibrotic HP (nintedanib approved)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Detailed exposure history is key</strong> â€” birds, hot tubs, moldy environments</li>
            <li><strong>Upper/mid lung predominance</strong> (vs IPF which is basal)</li>
            <li><strong>BAL lymphocytosis</strong> supports diagnosis</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PULMONARY NODULE -->
<div id="pulm-nodule" class="condition-page">
    <div class="page-header">
        <h2>255. PULMONARY NODULE EVALUATION</h2>
        <div class="subtitle">Fleischner Criteria â€¢ Solid vs Ground-Glass â€¢ Malignancy Risk</div>
    </div>
    
    <div class="section">
        <div class="section-title">DEFINITIONS</div>
        <div class="section-content">
            <p><span class="label">Pulmonary Nodule:</span> &lt;3 cm; if &gt;3 cm = mass (higher malignancy risk)</p>
            <p><span class="label">Types:</span></p>
            <ul>
                <li><strong>Solid:</strong> Completely obscures lung parenchyma</li>
                <li><strong>Ground-glass (subsolid):</strong> Does not obscure lung; slower growing but higher malignancy rate</li>
                <li><strong>Part-solid:</strong> Both components; highest malignancy risk</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">RISK STRATIFICATION</div>
        <div class="section-content">
            <p><span class="label">Higher Malignancy Risk:</span></p>
            <ul>
                <li>Larger size (&gt;8mm especially concerning)</li>
                <li>Spiculated margins</li>
                <li>Upper lobe location</li>
                <li>Part-solid or ground-glass</li>
                <li>Smoking history, older age</li>
                <li>History of cancer</li>
                <li>Growth on serial imaging</li>
            </ul>
            <p><span class="label">Lower Malignancy Risk:</span></p>
            <ul>
                <li>Smooth margins</li>
                <li>Calcification patterns (central, popcorn, laminated)</li>
                <li>Stable for &gt;2 years</li>
                <li>Multiple nodules (often infectious/inflammatory)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">FLEISCHNER SOCIETY GUIDELINES (2017) â€” SOLID NODULES</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Size</th><th>Low Risk</th><th>High Risk</th></tr>
                <tr><td>&lt;6mm</td><td>No follow-up</td><td>Optional CT at 12 months</td></tr>
                <tr><td>6-8mm</td><td>CT at 6-12 months, then consider 18-24mo</td><td>CT at 6-12 months, then 18-24 months</td></tr>
                <tr><td>&gt;8mm</td><td colspan="2">CT at 3 months, PET/CT, or biopsy</td></tr>
            </table>
            <p><span class="label">Ground-Glass/Part-Solid:</span> More conservative approach; longer follow-up intervals but ultimately may need resection</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">EVALUATION OPTIONS</div>
        <div class="section-content">
            <ul>
                <li><strong>Serial CT:</strong> For low-intermediate risk</li>
                <li><strong>PET-CT:</strong> For nodules &gt;8mm; sensitivity ~90% for malignancy</li>
                <li><strong>Biopsy:</strong> CT-guided, bronchoscopy (navigational), surgical</li>
                <li><strong>Surgical resection:</strong> High-risk nodules or positive biopsy</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>&lt;6mm solid nodule in low-risk patient = no follow-up needed</strong></li>
            <li><strong>Part-solid nodules have highest malignancy risk</strong></li>
            <li><strong>Stability &gt;2 years suggests benign</strong> (but ground-glass needs longer follow-up)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<!-- THALASSEMIAS -->
<div id="thalassemia" class="condition-page">
    <div class="page-header">
        <h2>256. THALASSEMIAS</h2>
        <div class="subtitle">Alpha vs Beta â€¢ Microcytic Anemia â€¢ Iron Overload</div>
    </div>
    
    <div class="section">
        <div class="section-title">OVERVIEW</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Inherited disorders of reduced globin chain synthesis (Î± or Î² chains)</p>
            <p><span class="label">Result:</span> Microcytic anemia with ineffective erythropoiesis; hemolysis in severe forms</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">BETA-THALASSEMIA</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Type</th><th>Genotype</th><th>Clinical</th></tr>
                <tr><td><strong>Minor (trait)</strong></td><td>Î²/Î²âº or Î²/Î²â°</td><td>Mild microcytic anemia; usually asymptomatic</td></tr>
                <tr><td><strong>Intermedia</strong></td><td>Î²âº/Î²âº or Î²âº/Î²â°</td><td>Moderate anemia; occasional transfusions</td></tr>
                <tr><td><strong>Major (Cooley's)</strong></td><td>Î²â°/Î²â°</td><td>Severe transfusion-dependent anemia; presents in infancy</td></tr>
            </table>
            <p><span class="label">Labs:</span> Microcytic anemia, target cells, elevated HbA2 (&gt;3.5%) on electrophoresis</p>
            <p><span class="label">Complications (Major):</span> Iron overload (transfusions + increased absorption), extramedullary hematopoiesis, bone deformities, growth retardation</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">ALPHA-THALASSEMIA</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Genes Deleted</th><th>Name</th><th>Clinical</th></tr>
                <tr><td>1 (Î±Î±/Î±-)</td><td>Silent carrier</td><td>Normal</td></tr>
                <tr><td>2 (Î±-/Î±- or Î±Î±/--)</td><td>Trait</td><td>Mild microcytic anemia</td></tr>
                <tr><td>3 (Î±-/--)</td><td>HbH disease</td><td>Moderate hemolytic anemia; HbH (Î²4) on electrophoresis</td></tr>
                <tr><td>4 (--/--)</td><td>Hb Bart's hydrops fetalis</td><td>Fatal in utero</td></tr>
            </table>
            <p><span class="label">Note:</span> Î±-thalassemia trait has NORMAL hemoglobin electrophoresis (need genetic testing)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>Trait:</strong> No treatment; avoid unnecessary iron supplementation</li>
                <li><strong>Transfusion-dependent:</strong> Regular transfusions to maintain Hb 9-10</li>
                <li><strong>Iron chelation:</strong> Deferasirox (oral daily), deferoxamine (SC/IV), deferiprone</li>
                <li><strong>Splenectomy:</strong> If hypersplenism increasing transfusion needs</li>
                <li><strong>Curative:</strong> Allogeneic stem cell transplant; gene therapy (new)</li>
                <li><strong>Luspatercept:</strong> For transfusion-dependent Î²-thalassemia (reduces transfusion burden)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Î²-thal trait: elevated HbA2;</strong> Î±-thal trait: normal electrophoresis</li>
            <li><strong>Don't give iron</strong> for thalassemia trait (already iron-loaded)</li>
            <li><strong>Mentzer index &lt;13</strong> (MCV/RBC) suggests thalassemia over iron deficiency</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- MYELOPROLIFERATIVE NEOPLASMS -->
<div id="mpn" class="condition-page">
    <div class="page-header">
        <h2>257. MYELOPROLIFERATIVE NEOPLASMS</h2>
        <div class="subtitle">PV â€¢ ET â€¢ MF â€¢ JAK2 Mutation</div>
    </div>
    
    <div class="section">
        <div class="section-title">OVERVIEW</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Disease</th><th>Primary Finding</th><th>JAK2 V617F</th><th>Other Mutations</th></tr>
                <tr><td><strong>Polycythemia Vera (PV)</strong></td><td>Elevated RBC mass</td><td>95%</td><td>JAK2 exon 12</td></tr>
                <tr><td><strong>Essential Thrombocythemia (ET)</strong></td><td>Elevated platelets</td><td>50-60%</td><td>CALR, MPL</td></tr>
                <tr><td><strong>Primary Myelofibrosis (MF)</strong></td><td>Bone marrow fibrosis</td><td>50-60%</td><td>CALR, MPL</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">POLYCYTHEMIA VERA</div>
        <div class="section-content">
            <p><span class="label">Diagnosis:</span> Hb &gt;16.5 (M) or &gt;16 (F), OR Hct &gt;49%/48% + JAK2 mutation + low EPO</p>
            <p><span class="label">Symptoms:</span> Hyperviscosity (headache, visual changes, dizziness), aquagenic pruritus, erythromelalgia, splenomegaly, thrombosis (including unusual sites â€” Budd-Chiari, portal vein)</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Phlebotomy:</strong> Goal Hct &lt;45%</li>
                <li><strong>Aspirin 81mg</strong> (all patients unless contraindicated)</li>
                <li><strong>Cytoreduction if high-risk:</strong> Hydroxyurea first-line; ruxolitinib (JAK inhibitor) if refractory</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">ESSENTIAL THROMBOCYTHEMIA</div>
        <div class="section-content">
            <p><span class="label">Diagnosis:</span> Platelets â‰¥450K, bone marrow biopsy (megakaryocyte proliferation), JAK2/CALR/MPL mutation, exclusion of other causes</p>
            <p><span class="label">Complications:</span> Thrombosis AND bleeding (acquired vWD if platelets very high)</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Low-risk:</strong> Aspirin alone (or observation if CALR+ low-risk)</li>
                <li><strong>High-risk:</strong> Hydroxyurea + aspirin; anagrelide alternative</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PRIMARY MYELOFIBROSIS</div>
        <div class="section-content">
            <p><span class="label">Features:</span> Bone marrow fibrosis, cytopenias, massive splenomegaly, constitutional symptoms, leukoerythroblastic smear (teardrop cells, nucleated RBCs)</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Ruxolitinib:</strong> First-line for symptomatic splenomegaly/symptoms</li>
                <li><strong>Allogeneic SCT:</strong> Only curative option (for eligible high-risk patients)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>PV: Hct goal &lt;45%</strong> reduces thrombosis</li>
            <li><strong>Aquagenic pruritus</strong> classic for PV</li>
            <li><strong>Teardrop cells + nucleated RBCs = myelofibrosis</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CML -->
<div id="cml" class="condition-page">
    <div class="page-header">
        <h2>258. CHRONIC MYELOID LEUKEMIA</h2>
        <div class="subtitle">BCR-ABL â€¢ Philadelphia Chromosome â€¢ Tyrosine Kinase Inhibitors</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Presentation:</span> Often asymptomatic (incidental leukocytosis); fatigue, weight loss, early satiety, splenomegaly</p>
            <p><span class="label">Labs:</span></p>
            <ul>
                <li>Marked leukocytosis (often 50-200K) with left shift</li>
                <li><strong>Basophilia and eosinophilia</strong></li>
                <li>Low LAP (leukocyte alkaline phosphatase) score</li>
                <li>Anemia, thrombocytosis (or thrombocytopenia in advanced phase)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Philadelphia Chromosome:</span> t(9;22) â€” BCR-ABL1 fusion gene</p>
            <p><span class="label">Testing:</span></p>
            <ul>
                <li><strong>Bone marrow biopsy</strong> with cytogenetics</li>
                <li><strong>FISH</strong> for BCR-ABL</li>
                <li><strong>PCR</strong> for BCR-ABL (quantitative â€” used for monitoring)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PHASES & TREATMENT</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Phase</th><th>Features</th></tr>
                <tr><td><strong>Chronic</strong></td><td>&lt;10% blasts; most present here</td></tr>
                <tr><td><strong>Accelerated</strong></td><td>10-19% blasts, other criteria</td></tr>
                <tr><td><strong>Blast crisis</strong></td><td>â‰¥20% blasts; like acute leukemia</td></tr>
            </table>
            
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Tyrosine Kinase Inhibitors (TKIs):</strong> First-line for all patients
                    <ul>
                        <li>Imatinib: First-generation; well-tolerated</li>
                        <li>Dasatinib, Nilotinib, Bosutinib: Second-generation; more potent</li>
                        <li>Ponatinib: For T315I mutation (resistant to others)</li>
                    </ul>
                </li>
                <li><strong>Monitoring:</strong> Quantitative BCR-ABL PCR every 3 months; goal is major molecular response (MMR)</li>
                <li><strong>TKI discontinuation:</strong> Possible in select patients with deep molecular response</li>
                <li><strong>Allogeneic SCT:</strong> Reserved for TKI failure or blast crisis</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>BCR-ABL = Philadelphia chromosome = CML</strong></li>
            <li><strong>TKIs transformed CML</strong> â€” near-normal life expectancy in chronic phase</li>
            <li><strong>T315I mutation = resistance;</strong> use ponatinib</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CLL -->
<div id="cll" class="condition-page">
    <div class="page-header">
        <h2>259. CHRONIC LYMPHOCYTIC LEUKEMIA</h2>
        <div class="subtitle">CD5+ B-cells â€¢ Smudge Cells â€¢ Watch and Wait</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Demographics:</span> Median age 70; most common adult leukemia in Western countries</p>
            <p><span class="label">Presentation:</span> Often asymptomatic (incidental lymphocytosis); lymphadenopathy, splenomegaly, B symptoms</p>
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Lymphocytosis</strong> (â‰¥5000/Î¼L clonal B-lymphocytes)</li>
                <li><strong>Smudge cells</strong> on peripheral smear</li>
                <li>Flow cytometry: CD5+, CD19+, CD20 (dim), CD23+</li>
            </ul>
            <p><span class="label">Complications:</span> Autoimmune hemolytic anemia, ITP, infections (hypogammaglobulinemia), Richter transformation (to DLBCL)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">STAGING & PROGNOSIS</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Rai Stage</th><th>Features</th><th>Risk</th></tr>
                <tr><td>0</td><td>Lymphocytosis only</td><td>Low</td></tr>
                <tr><td>I</td><td>+ Lymphadenopathy</td><td>Intermediate</td></tr>
                <tr><td>II</td><td>+ Hepatosplenomegaly</td><td>Intermediate</td></tr>
                <tr><td>III</td><td>+ Anemia (Hb &lt;11)</td><td>High</td></tr>
                <tr><td>IV</td><td>+ Thrombocytopenia (&lt;100K)</td><td>High</td></tr>
            </table>
            <p><span class="label">Poor Prognostic Markers:</span> del(17p), TP53 mutation, unmutated IGHV, del(11q)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Early Stage (Rai 0-II) Asymptomatic:</span> <strong>Watch and wait</strong> â€” treatment doesn't improve survival</p>
            <p><span class="label">Indications to Treat:</span> Progressive cytopenias, massive/symptomatic splenomegaly/lymphadenopathy, B symptoms, AIHA/ITP refractory to steroids</p>
            <p><span class="label">First-Line Options:</span></p>
            <ul>
                <li><strong>BTK inhibitors:</strong> Ibrutinib, acalabrutinib, zanubrutinib â€” can be used regardless of del(17p)</li>
                <li><strong>BCL-2 inhibitor:</strong> Venetoclax (+ obinutuzumab for fixed duration)</li>
                <li>Chemoimmunotherapy (FCR, BR) less commonly used now</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Smudge cells + CD5+ B-cells = CLL</strong></li>
            <li><strong>Watch and wait for early-stage asymptomatic</strong></li>
            <li><strong>del(17p)/TP53 = poor prognosis;</strong> BTK inhibitors preferred</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- MULTIPLE MYELOMA -->
<div id="myeloma" class="condition-page">
    <div class="page-header">
        <h2>260. MULTIPLE MYELOMA</h2>
        <div class="subtitle">CRAB Criteria â€¢ M-Protein â€¢ Bone Disease</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES â€” CRAB</div>
        <div class="section-content">
            <ul>
                <li><strong>C â€” Calcium elevation</strong> (hypercalcemia)</li>
                <li><strong>R â€” Renal insufficiency</strong> (light chain cast nephropathy)</li>
                <li><strong>A â€” Anemia</strong> (normocytic)</li>
                <li><strong>B â€” Bone disease</strong> (lytic lesions, pathologic fractures, bone pain)</li>
            </ul>
            <p><span class="label">Other:</span> Recurrent infections, hyperviscosity (rare), amyloidosis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Diagnostic Criteria (â‰¥10% clonal plasma cells + end-organ damage OR biomarker):</span></p>
            <ul>
                <li>Bone marrow clonal plasma cells â‰¥10%</li>
                <li>PLUS: CRAB criteria OR biomarkers (sFLC ratio â‰¥100, bone marrow plasma cells â‰¥60%, &gt;1 focal lesion on MRI)</li>
            </ul>
            <p><span class="label">Workup:</span></p>
            <ul>
                <li><strong>SPEP/UPEP with immunofixation:</strong> M-protein (monoclonal spike)</li>
                <li><strong>Serum free light chains</strong></li>
                <li><strong>Bone marrow biopsy</strong></li>
                <li><strong>Skeletal survey</strong> or whole-body low-dose CT (lytic lesions)</li>
                <li>Î²2-microglobulin, LDH (prognosis)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Transplant-Eligible:</span></p>
            <ul>
                <li>Induction: VRd (bortezomib, lenalidomide, dexamethasone) Â± daratumumab</li>
                <li>Autologous stem cell transplant</li>
                <li>Maintenance: Lenalidomide</li>
            </ul>
            <p><span class="label">Transplant-Ineligible:</span> VRd or DRd (daratumumab, lenalidomide, dex) until progression</p>
            <p><span class="label">Supportive:</span></p>
            <ul>
                <li><strong>Bisphosphonates</strong> (zoledronic acid) or denosumab for bone disease</li>
                <li>Avoid NSAIDs (nephrotoxic)</li>
                <li>VTE prophylaxis with IMiDs</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Lytic lesions (not blastic)</strong> â€” bone scan often negative</li>
            <li><strong>Rouleaux formation</strong> on smear</li>
            <li><strong>MGUS â†’ smoldering â†’ myeloma</strong> progression spectrum</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- VON WILLEBRAND DISEASE -->
<div id="vwd" class="condition-page">
    <div class="page-header">
        <h2>261. VON WILLEBRAND DISEASE</h2>
        <div class="subtitle">Most Common Inherited Bleeding Disorder â€¢ DDAVP</div>
    </div>
    
    <div class="section">
        <div class="section-title">TYPES</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Type</th><th>Defect</th><th>Inheritance</th><th>Severity</th></tr>
                <tr><td><strong>Type 1</strong></td><td>Partial quantitative deficiency</td><td>AD</td><td>Mild-moderate (75%)</td></tr>
                <tr><td><strong>Type 2</strong></td><td>Qualitative defect (multiple subtypes)</td><td>AD</td><td>Moderate</td></tr>
                <tr><td><strong>Type 3</strong></td><td>Complete deficiency</td><td>AR</td><td>Severe (rare)</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES & DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Bleeding Pattern:</span> Mucocutaneous â€” epistaxis, easy bruising, menorrhagia, GI bleeding, prolonged bleeding after surgery/dental procedures</p>
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Prolonged PTT</strong> (vWF carries factor VIII)</li>
                <li><strong>Normal PT, platelets</strong></li>
                <li><strong>Prolonged bleeding time</strong> (or abnormal PFA-100)</li>
            </ul>
            <p><span class="label">Specific Tests:</span></p>
            <ul>
                <li>vWF antigen (vWF:Ag)</li>
                <li>vWF activity (ristocetin cofactor â€” vWF:RCo)</li>
                <li>Factor VIII level</li>
                <li>vWF multimer analysis (for Type 2 subtypes)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Type 1:</span></p>
            <ul>
                <li><strong>DDAVP (desmopressin):</strong> First-line; releases vWF from endothelial stores</li>
                <li>Test with DDAVP trial before planned procedures</li>
            </ul>
            <p><span class="label">Type 2 & 3 (or DDAVP-unresponsive):</span></p>
            <ul>
                <li><strong>vWF-containing factor concentrates</strong> (Humate-P)</li>
            </ul>
            <p><span class="label">Adjuncts:</span></p>
            <ul>
                <li><strong>Tranexamic acid:</strong> For mucosal bleeding, menorrhagia</li>
                <li>Avoid aspirin/NSAIDs</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Prolonged PTT + mucosal bleeding + normal platelets = vWD</strong></li>
            <li><strong>DDAVP for Type 1;</strong> contraindicated in Type 2B (worsens thrombocytopenia)</li>
            <li><strong>Most common inherited bleeding disorder</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- HEMOPHILIA -->
<div id="hemophilia" class="condition-page">
    <div class="page-header">
        <h2>262. HEMOPHILIA</h2>
        <div class="subtitle">Factor VIII (A) vs IX (B) â€¢ Hemarthrosis â€¢ Factor Replacement</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Type</th><th>Deficiency</th><th>Inheritance</th><th>Frequency</th></tr>
                <tr><td><strong>Hemophilia A</strong></td><td>Factor VIII</td><td>X-linked recessive</td><td>80-85%</td></tr>
                <tr><td><strong>Hemophilia B</strong></td><td>Factor IX</td><td>X-linked recessive</td><td>15-20%</td></tr>
            </table>
            <p><span class="label">Severity:</span></p>
            <ul>
                <li><strong>Severe:</strong> &lt;1% factor activity â€” spontaneous bleeding</li>
                <li><strong>Moderate:</strong> 1-5% â€” bleeding with minor trauma</li>
                <li><strong>Mild:</strong> 5-40% â€” bleeding with surgery/major trauma</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Bleeding Pattern:</span> Deep tissue/joint bleeding (unlike vWD)</p>
            <ul>
                <li><strong>Hemarthrosis</strong> (knees, elbows, ankles) â€” hallmark; leads to arthropathy</li>
                <li>Muscle hematomas (including iliopsoas)</li>
                <li>Intracranial hemorrhage</li>
                <li>Prolonged bleeding after circumcision, dental work, surgery</li>
            </ul>
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Prolonged PTT</strong></li>
                <li><strong>Normal PT, platelets, bleeding time</strong></li>
                <li>Mixing study corrects (factor deficiency, not inhibitor)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Factor Replacement:</span></p>
            <ul>
                <li><strong>On-demand:</strong> For acute bleeding</li>
                <li><strong>Prophylaxis:</strong> Regular infusions to prevent bleeding (severe patients)</li>
                <li>Recombinant factors preferred over plasma-derived</li>
                <li>Extended half-life products available</li>
            </ul>
            <p><span class="label">Hemophilia A with Inhibitors:</span></p>
            <ul>
                <li><strong>Emicizumab:</strong> Bispecific antibody mimicking factor VIII function; prophylaxis</li>
                <li>Bypassing agents: rFVIIa, FEIBA</li>
            </ul>
            <p><span class="label">DDAVP:</span> May work for mild Hemophilia A (releases vWF-bound FVIII)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Hemarthrosis = hemophilia;</strong> mucosal = vWD</li>
            <li><strong>Prolonged PTT that corrects with mixing</strong> = factor deficiency</li>
            <li><strong>Emicizumab revolutionized care</strong> for severe Hemophilia A</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<!-- MULTIPLE SCLEROSIS -->
<div id="ms" class="condition-page">
    <div class="page-header">
        <h2>263. MULTIPLE SCLEROSIS</h2>
        <div class="subtitle">Demyelinating â€¢ McDonald Criteria â€¢ Disease-Modifying Therapy</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Demographics:</span> Young adults (20-40), female predominance</p>
            <p><span class="label">Classic Presentations:</span></p>
            <ul>
                <li><strong>Optic neuritis:</strong> Unilateral vision loss, pain with eye movement, afferent pupillary defect</li>
                <li><strong>Transverse myelitis:</strong> Sensory level, weakness, bowel/bladder dysfunction</li>
                <li><strong>Internuclear ophthalmoplegia (INO):</strong> Impaired adduction, nystagmus in abducting eye</li>
                <li><strong>Lhermitte sign:</strong> Electric shock down spine with neck flexion</li>
                <li>Cerebellar symptoms, trigeminal neuralgia</li>
            </ul>
            <p><span class="label">Patterns:</span></p>
            <ul>
                <li><strong>Relapsing-remitting (RRMS):</strong> 85% at onset; discrete attacks with recovery</li>
                <li><strong>Secondary progressive (SPMS):</strong> Gradual progression after RRMS</li>
                <li><strong>Primary progressive (PPMS):</strong> Progressive from onset (15%)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS â€” McDONALD CRITERIA (2017)</div>
        <div class="section-content">
            <p><span class="label">Requires:</span> Dissemination in space (DIS) AND time (DIT)</p>
            <ul>
                <li><strong>DIS:</strong> â‰¥1 T2 lesion in â‰¥2 typical locations (periventricular, cortical/juxtacortical, infratentorial, spinal cord)</li>
                <li><strong>DIT:</strong> Simultaneous gadolinium-enhancing and non-enhancing lesions OR new T2/enhancing lesion on follow-up MRI OR CSF oligoclonal bands</li>
            </ul>
            <p><span class="label">CSF:</span> Oligoclonal bands (>90%), elevated IgG index</p>
            <p><span class="label">MRI:</span> T2/FLAIR hyperintense lesions, "Dawson's fingers" (periventricular)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Acute Relapse:</span> High-dose IV methylprednisolone (1g daily Ã— 3-5 days)</p>
            <p><span class="label">Disease-Modifying Therapy (DMT):</span></p>
            <ul>
                <li><strong>High-efficacy:</strong> Natalizumab, ocrelizumab, ofatumumab, alemtuzumab</li>
                <li><strong>Moderate-efficacy:</strong> Dimethyl fumarate, fingolimod, teriflunomide</li>
                <li><strong>Injectable:</strong> Interferons, glatiramer (less commonly used now)</li>
            </ul>
            <p><span class="label">PPMS:</span> Ocrelizumab (only FDA-approved DMT)</p>
            <p><span class="label">Symptomatic:</span> Fatigue (modafinil), spasticity (baclofen), bladder dysfunction</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>INO in young adult = MS until proven otherwise</strong></li>
            <li><strong>Oligoclonal bands can satisfy DIT</strong></li>
            <li><strong>Natalizumab risk:</strong> PML (check JC virus antibody)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PARKINSON DISEASE -->
<div id="parkinsons" class="condition-page">
    <div class="page-header">
        <h2>264. PARKINSON DISEASE</h2>
        <div class="subtitle">TRAP â€¢ Dopaminergic Therapy â€¢ Motor Fluctuations</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES â€” TRAP</div>
        <div class="section-content">
            <ul>
                <li><strong>T â€” Tremor:</strong> Resting, "pill-rolling," 4-6 Hz; improves with action</li>
                <li><strong>R â€” Rigidity:</strong> Cogwheel (with tremor) or lead-pipe</li>
                <li><strong>A â€” Akinesia/Bradykinesia:</strong> Slowness of movement; masked facies, micrographia</li>
                <li><strong>P â€” Postural instability:</strong> Later feature; falls</li>
            </ul>
            <p><span class="label">Asymmetric onset is typical</span></p>
            <p><span class="label">Non-Motor:</span> Anosmia (early), constipation, REM sleep behavior disorder, depression, cognitive impairment</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Dopaminergic Therapy:</span></p>
            <ul>
                <li><strong>Carbidopa-levodopa:</strong> Most effective; start when symptoms affect function</li>
                <li><strong>Dopamine agonists:</strong> Pramipexole, ropinirole, rotigotine â€” can use early; risk of impulse control disorders</li>
                <li><strong>MAO-B inhibitors:</strong> Selegiline, rasagiline â€” mild benefit; can be initial monotherapy</li>
                <li><strong>COMT inhibitors:</strong> Entacapone â€” extends levodopa effect</li>
            </ul>
            <p><span class="label">Motor Complications (after years of levodopa):</span></p>
            <ul>
                <li><strong>"Wearing off":</strong> End-of-dose deterioration â€” add COMT inhibitor, increase frequency</li>
                <li><strong>Dyskinesias:</strong> Peak-dose involuntary movements â€” reduce levodopa dose, add amantadine</li>
                <li><strong>"On-off" phenomenon:</strong> Unpredictable fluctuations</li>
            </ul>
            <p><span class="label">Advanced:</span> Deep brain stimulation (subthalamic nucleus)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Asymmetric resting tremor + bradykinesia = PD</strong></li>
            <li><strong>Dopamine agonists:</strong> Impulse control disorders (gambling, hypersexuality)</li>
            <li><strong>Drug-induced parkinsonism:</strong> Antipsychotics, metoclopramide â€” symmetric, no tremor</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ESSENTIAL TREMOR -->
<div id="essential-tremor" class="condition-page">
    <div class="page-header">
        <h2>265. ESSENTIAL TREMOR</h2>
        <div class="subtitle">Action Tremor â€¢ Alcohol-Responsive â€¢ Beta-Blockers</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Characteristics:</span></p>
            <ul>
                <li><strong>Action/postural tremor</strong> (opposite of PD resting tremor)</li>
                <li>Bilateral and symmetric (vs asymmetric in PD)</li>
                <li>Affects hands, head ("no-no" or "yes-yes"), voice</li>
                <li>Frequency 4-12 Hz</li>
                <li><strong>Improves with alcohol</strong></li>
                <li>Family history often positive (autosomal dominant)</li>
            </ul>
            <p><span class="label">No other neurologic findings</span> (vs PD which has bradykinesia, rigidity)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">First-Line:</span></p>
            <ul>
                <li><strong>Propranolol:</strong> 20-80mg BID (or long-acting)</li>
                <li><strong>Primidone:</strong> Start low (25mg), titrate slowly (sedation)</li>
            </ul>
            <p><span class="label">Second-Line:</span> Topiramate, gabapentin, benzodiazepines</p>
            <p><span class="label">Refractory:</span> Deep brain stimulation (VIM thalamus), focused ultrasound thalamotomy</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Action tremor + improves with alcohol = essential tremor</strong></li>
            <li><strong>Resting tremor + bradykinesia = Parkinson</strong></li>
            <li><strong>Propranolol or primidone first-line</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ALS -->
<div id="als" class="condition-page">
    <div class="page-header">
        <h2>266. AMYOTROPHIC LATERAL SCLEROSIS (ALS)</h2>
        <div class="subtitle">UMN + LMN Signs â€¢ Bulbar Symptoms â€¢ Riluzole</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Combined Upper AND Lower Motor Neuron Signs:</span></p>
            <ul>
                <li><strong>UMN:</strong> Spasticity, hyperreflexia, Babinski sign</li>
                <li><strong>LMN:</strong> Weakness, atrophy, fasciculations</li>
            </ul>
            <p><span class="label">Preserved:</span> Sensation, cognition (mostly), eye movements, bowel/bladder (early)</p>
            <p><span class="label">Onset Patterns:</span></p>
            <ul>
                <li><strong>Limb-onset (70%):</strong> Asymmetric weakness, often hand</li>
                <li><strong>Bulbar-onset (25%):</strong> Dysarthria, dysphagia â€” worse prognosis</li>
            </ul>
            <p><span class="label">Progression:</span> Relentless; respiratory failure is usual cause of death</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Clinical Diagnosis:</span> UMN + LMN signs in multiple regions, progressive course</p>
            <p><span class="label">El Escorial Criteria:</span> Definite, probable, possible ALS based on regions involved</p>
            <p><span class="label">EMG:</span> Widespread denervation (fibrillations, positive sharp waves, fasciculations) in multiple regions</p>
            <p><span class="label">Rule Out:</span> Cervical myelopathy, multifocal motor neuropathy, Kennedy disease</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>Riluzole:</strong> Glutamate antagonist; prolongs survival by ~3 months</li>
                <li><strong>Edaravone:</strong> Free radical scavenger; may slow functional decline</li>
                <li><strong>Multidisciplinary care:</strong> Pulmonology, nutrition, PT/OT, speech therapy</li>
                <li><strong>Non-invasive ventilation:</strong> Prolongs survival, improves quality of life</li>
                <li><strong>PEG tube:</strong> When dysphagia compromises nutrition</li>
            </ul>
            <p><span class="label">Prognosis:</span> Median survival 3-5 years; bulbar-onset worse</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>UMN + LMN signs without sensory loss = ALS</strong></li>
            <li><strong>Fasciculations + atrophy + hyperreflexia</strong> in same limb = classic</li>
            <li><strong>Riluzole is disease-modifying</strong> but effect is modest</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- NPH -->
<div id="nph" class="condition-page">
    <div class="page-header">
        <h2>267. NORMAL PRESSURE HYDROCEPHALUS</h2>
        <div class="subtitle">Wet â€¢ Wobbly â€¢ Wacky â€¢ LP Trial</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES â€” TRIAD</div>
        <div class="section-content">
            <ul>
                <li><strong>Gait disturbance:</strong> Magnetic/apraxic gait ("feet stuck to floor"), wide-based, shuffling â€” earliest and most responsive to treatment</li>
                <li><strong>Urinary incontinence:</strong> Urge incontinence; later frank incontinence</li>
                <li><strong>Dementia:</strong> Subcortical pattern; psychomotor slowing, executive dysfunction</li>
            </ul>
            <p><span class="label">Mnemonic:</span> "Wet, Wobbly, Wacky" (or "Wacky, Wobbly, Wet" â€” in order of appearance)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>CT/MRI:</strong> Ventriculomegaly out of proportion to sulcal enlargement</li>
                <li>Evans index &gt;0.3 (ratio of frontal horns to maximum brain width)</li>
                <li>Periventricular white matter changes</li>
            </ul>
            <p><span class="label">Lumbar Puncture:</span> Normal opening pressure (hence "normal pressure")</p>
            <p><span class="label">LP Trial (High-Volume Tap):</span></p>
            <ul>
                <li>Remove 30-50 mL CSF</li>
                <li>Assess gait before and after (video)</li>
                <li><strong>Improvement predicts response to shunting</strong></li>
            </ul>
            <p><span class="label">Extended Lumbar Drainage:</span> 3-day trial if LP inconclusive</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>VP (ventriculoperitoneal) shunt:</strong> Definitive treatment</li>
                <li>Gait improves most; dementia may improve less</li>
                <li>Risks: Infection, subdural hematoma, shunt malfunction</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Gait responds best to shunting;</strong> dementia may not improve</li>
            <li><strong>LP trial predicts surgical response</strong></li>
            <li><strong>Ventriculomegaly + triad + improvement with LP = NPH</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- HEADACHE SYNDROMES -->
<div id="headache-syndromes" class="condition-page">
    <div class="page-header">
        <h2>268. HEADACHE SYNDROMES</h2>
        <div class="subtitle">Migraine â€¢ Tension â€¢ Cluster â€¢ Trigeminal Neuralgia</div>
    </div>
    
    <div class="section">
        <div class="section-title">COMPARISON</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Feature</th><th>Migraine</th><th>Tension</th><th>Cluster</th></tr>
                <tr><td>Location</td><td>Unilateral (often)</td><td>Bilateral, band-like</td><td>Unilateral, periorbital</td></tr>
                <tr><td>Quality</td><td>Pulsating/throbbing</td><td>Pressing/tightening</td><td>Excruciating, stabbing</td></tr>
                <tr><td>Duration</td><td>4-72 hours</td><td>30 min - 7 days</td><td>15-180 minutes</td></tr>
                <tr><td>Associated</td><td>N/V, photophobia, phonophobia, aura</td><td>None typically</td><td>Lacrimation, rhinorrhea, ptosis, restlessness</td></tr>
                <tr><td>Behavior</td><td>Seeks quiet dark room</td><td>Continues activity</td><td>Pacing, agitated</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLUSTER HEADACHE</div>
        <div class="section-content">
            <p><span class="label">Features:</span> "Suicide headache" â€” severe; occurs in clusters (weeks-months) then remission; often nocturnal; male predominance</p>
            <p><span class="label">Autonomic Features:</span> Ipsilateral lacrimation, conjunctival injection, nasal congestion, ptosis, miosis</p>
            <p><span class="label">Abortive:</span> <strong>High-flow O2 (100%, 12-15 L/min)</strong> â€” first-line; sumatriptan SC/nasal</p>
            <p><span class="label">Preventive:</span> Verapamil (first-line), lithium, galcanezumab</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TRIGEMINAL NEURALGIA</div>
        <div class="section-content">
            <p><span class="label">Features:</span> Brief (seconds) electric shock-like pain in V2/V3 distribution; triggered by touch, chewing, talking</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Carbamazepine:</strong> First-line</li>
                <li>Oxcarbazepine, lamotrigine, baclofen</li>
                <li>Surgery: Microvascular decompression if refractory (often vascular loop compressing nerve)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Cluster:</strong> High-flow O2 and sumatriptan abortive; verapamil preventive</li>
            <li><strong>Trigeminal neuralgia:</strong> Carbamazepine first-line</li>
            <li><strong>Young woman + visual aura + migraine + OCP = increased stroke risk</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PERIPHERAL NEUROPATHY -->
<div id="peripheral-neuropathy" class="condition-page">
    <div class="page-header">
        <h2>269. PERIPHERAL NEUROPATHY</h2>
        <div class="subtitle">Length-Dependent â€¢ Workup â€¢ Treatable Causes</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION</div>
        <div class="section-content">
            <p><span class="label">By Pattern:</span></p>
            <ul>
                <li><strong>Length-dependent (distal symmetric):</strong> Stocking-glove; most common</li>
                <li><strong>Mononeuropathy:</strong> Single nerve (carpal tunnel, peroneal palsy)</li>
                <li><strong>Mononeuritis multiplex:</strong> Multiple individual nerves (vasculitis, diabetes)</li>
                <li><strong>Polyradiculopathy:</strong> Multiple nerve roots</li>
            </ul>
            <p><span class="label">By Fiber Type:</span></p>
            <ul>
                <li><strong>Large fiber:</strong> Vibration, proprioception, reflexes lost first</li>
                <li><strong>Small fiber:</strong> Pain, temperature; burning/stinging pain</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">COMMON CAUSES</div>
        <div class="section-content">
            <ul>
                <li><strong>Diabetes</strong> â€” most common in US</li>
                <li><strong>Alcohol</strong></li>
                <li><strong>B12 deficiency</strong> â€” can cause combined sensory + UMN signs</li>
                <li><strong>Chemotherapy</strong> â€” platinum, taxanes, vinca alkaloids</li>
                <li><strong>Chronic kidney disease</strong></li>
                <li><strong>Hereditary</strong> â€” Charcot-Marie-Tooth</li>
                <li><strong>Inflammatory</strong> â€” GBS, CIDP</li>
                <li><strong>Paraproteinemia</strong> â€” MGUS, myeloma, amyloid</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">WORKUP</div>
        <div class="section-content">
            <p><span class="label">Initial Labs:</span></p>
            <ul>
                <li>Fasting glucose / HbA1c</li>
                <li>B12 (with MMA if borderline)</li>
                <li>TSH</li>
                <li>CBC, CMP</li>
                <li>SPEP/UPEP with immunofixation</li>
            </ul>
            <p><span class="label">If Initial Negative:</span> ANA, HIV, hepatitis B/C, Lyme, heavy metals, genetic testing</p>
            <p><span class="label">EMG/NCS:</span> Confirms neuropathy; distinguishes axonal vs demyelinating; important for CIDP</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Diabetes + alcohol account for majority</strong></li>
            <li><strong>B12 deficiency can cause neuropathy + myelopathy</strong></li>
            <li><strong>Demyelinating pattern on EMG:</strong> Think GBS, CIDP, or hereditary</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- DEMENTIA -->
<div id="dementia" class="condition-page">
    <div class="page-header">
        <h2>270. DEMENTIA SYNDROMES</h2>
        <div class="subtitle">Alzheimer's â€¢ Vascular â€¢ Lewy Body â€¢ FTD</div>
    </div>
    
    <div class="section">
        <div class="section-title">COMPARISON</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Type</th><th>Key Features</th><th>Pathology</th></tr>
                <tr><td><strong>Alzheimer's</strong></td><td>Memory loss earliest; gradual decline</td><td>Amyloid plaques, tau tangles</td></tr>
                <tr><td><strong>Vascular</strong></td><td>Stepwise decline; focal signs; CV risk factors</td><td>Infarcts, white matter disease</td></tr>
                <tr><td><strong>Lewy Body</strong></td><td>Visual hallucinations, parkinsonism, fluctuations, REM sleep disorder</td><td>Î±-synuclein inclusions</td></tr>
                <tr><td><strong>Frontotemporal</strong></td><td>Early personality/behavior change OR language dysfunction; younger onset</td><td>Tau or TDP-43</td></tr>
                <tr><td><strong>Parkinson dementia</strong></td><td>PD for â‰¥1 year before dementia</td><td>Î±-synuclein</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">WORKUP</div>
        <div class="section-content">
            <p><span class="label">Rule Out Reversible Causes:</span></p>
            <ul>
                <li>B12 deficiency</li>
                <li>Thyroid disease (TSH)</li>
                <li>Depression ("pseudodementia")</li>
                <li>NPH</li>
                <li>Medication effect</li>
                <li>Neurosyphilis, HIV (if risk factors)</li>
            </ul>
            <p><span class="label">Imaging:</span> MRI (atrophy pattern, vascular changes, masses)</p>
            <p><span class="label">Biomarkers:</span> CSF AÎ²42/tau, amyloid PET (for Alzheimer's confirmation)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Alzheimer's:</span></p>
            <ul>
                <li><strong>Cholinesterase inhibitors:</strong> Donepezil, rivastigmine, galantamine â€” modest benefit</li>
                <li><strong>Memantine:</strong> NMDA antagonist â€” moderate-severe AD</li>
                <li><strong>Lecanemab, donanemab:</strong> Anti-amyloid monoclonals â€” early AD</li>
            </ul>
            <p><span class="label">Lewy Body:</span></p>
            <ul>
                <li>Cholinesterase inhibitors helpful</li>
                <li><strong>AVOID antipsychotics</strong> â€” severe sensitivity; use quetiapine if necessary</li>
            </ul>
            <p><span class="label">FTD:</span> No proven disease-modifying therapy; SSRIs for behavioral symptoms</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Visual hallucinations + parkinsonism + fluctuations = Lewy Body</strong></li>
            <li><strong>Antipsychotics contraindicated in Lewy Body</strong></li>
            <li><strong>Behavioral variant FTD:</strong> Disinhibition, apathy, loss of empathy â€” often misdiagnosed as psychiatric</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- VERTIGO -->
<div id="vertigo" class="condition-page">
    <div class="page-header">
        <h2>271. VERTIGO</h2>
        <div class="subtitle">Central vs Peripheral â€¢ BPPV â€¢ HINTS Exam</div>
    </div>
    
    <div class="section">
        <div class="section-title">CENTRAL VS PERIPHERAL</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Feature</th><th>Peripheral</th><th>Central</th></tr>
                <tr><td>Onset</td><td>Sudden</td><td>Gradual or sudden</td></tr>
                <tr><td>Nystagmus</td><td>Horizontal/torsional; inhibited by fixation</td><td>Any direction; not inhibited by fixation</td></tr>
                <tr><td>Hearing loss</td><td>May be present</td><td>Usually absent</td></tr>
                <tr><td>Neurologic signs</td><td>Absent</td><td>Present (diplopia, dysarthria, ataxia)</td></tr>
                <tr><td>Severity</td><td>Often more severe vertigo</td><td>May be less severe</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">HINTS EXAM (for Acute Vestibular Syndrome)</div>
        <div class="section-content">
            <ul>
                <li><strong>H</strong>ead <strong>I</strong>mpulse: Abnormal (corrective saccade) = peripheral; Normal = central (BAD)</li>
                <li><strong>N</strong>ystagmus: Direction-changing = central</li>
                <li><strong>T</strong>est of <strong>S</strong>kew: Vertical skew deviation = central</li>
            </ul>
            <p><span class="label">Central Pattern (any one):</span> Normal head impulse, direction-changing nystagmus, or skew â†’ MRI/stroke workup</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">COMMON PERIPHERAL CAUSES</div>
        <div class="section-content">
            <p><span class="label">BPPV:</span></p>
            <ul>
                <li>Brief episodes (&lt;1 min) triggered by position change</li>
                <li>Dix-Hallpike positive (torsional upbeat nystagmus with latency)</li>
                <li><strong>Treatment:</strong> Epley maneuver (canalith repositioning)</li>
            </ul>
            <p><span class="label">Vestibular Neuritis:</span></p>
            <ul>
                <li>Acute prolonged vertigo (days); often post-viral</li>
                <li>No hearing loss (vs labyrinthitis)</li>
                <li>Treatment: Supportive; vestibular rehabilitation; short-term meclizine</li>
            </ul>
            <p><span class="label">Meniere's Disease:</span></p>
            <ul>
                <li>Episodic vertigo (20 min - hours) + hearing loss + tinnitus + aural fullness</li>
                <li>Treatment: Low-sodium diet, diuretics</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>HINTS beats MRI</strong> for detecting stroke in acute vestibular syndrome</li>
            <li><strong>Normal head impulse test is concerning</strong> â€” suggests central cause</li>
            <li><strong>BPPV:</strong> Posterior canal most common; Epley maneuver curative</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<!-- ANCA VASCULITIS -->
<div id="anca-vasculitis" class="condition-page">
    <div class="page-header">
        <h2>272. ANCA VASCULITIS</h2>
        <div class="subtitle">GPA â€¢ MPA â€¢ EGPA â€¢ Pulmonary-Renal Syndrome</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Disease</th><th>ANCA</th><th>Key Features</th></tr>
                <tr><td><strong>GPA (Wegener's)</strong></td><td>PR3-ANCA (c-ANCA)</td><td>Upper airway (sinusitis, saddle nose), lung nodules/hemorrhage, glomerulonephritis</td></tr>
                <tr><td><strong>MPA</strong></td><td>MPO-ANCA (p-ANCA)</td><td>Glomerulonephritis (pauci-immune), pulmonary hemorrhage; NO upper airway</td></tr>
                <tr><td><strong>EGPA (Churg-Strauss)</strong></td><td>MPO-ANCA (50%)</td><td>Asthma, eosinophilia, neuropathy, cardiac involvement</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">GPA (GRANULOMATOSIS WITH POLYANGIITIS)</div>
        <div class="section-content">
            <p><span class="label">Classic Triad:</span></p>
            <ul>
                <li><strong>Upper airway:</strong> Chronic sinusitis, nasal crusting, saddle nose deformity, subglottic stenosis</li>
                <li><strong>Lungs:</strong> Nodules (may cavitate), infiltrates, hemorrhage</li>
                <li><strong>Kidneys:</strong> Rapidly progressive glomerulonephritis (pauci-immune crescentic)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Labs:</span> PR3-ANCA or MPO-ANCA; elevated ESR/CRP; urinalysis (RBC casts)</p>
            <p><span class="label">Induction (Severe):</span></p>
            <ul>
                <li><strong>Rituximab</strong> OR cyclophosphamide + glucocorticoids</li>
                <li><strong>Plasmapheresis:</strong> For severe renal disease or pulmonary hemorrhage</li>
            </ul>
            <p><span class="label">Maintenance:</span> Rituximab or azathioprine</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Pulmonary-renal syndrome:</strong> Think ANCA vasculitis or anti-GBM</li>
            <li><strong>PR3-ANCA = GPA;</strong> MPO-ANCA = MPA or EGPA</li>
            <li><strong>Saddle nose deformity</strong> is classic for GPA</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- POLYARTERITIS NODOSA -->
<div id="pan" class="condition-page">
    <div class="page-header">
        <h2>273. POLYARTERITIS NODOSA</h2>
        <div class="subtitle">Medium-Vessel Vasculitis â€¢ HBV Association â€¢ Microaneurysms</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Key Features:</span></p>
            <ul>
                <li><strong>Constitutional:</strong> Fever, weight loss, malaise</li>
                <li><strong>Neurologic:</strong> Mononeuritis multiplex (foot drop, wrist drop)</li>
                <li><strong>Renal:</strong> Hypertension, renal infarcts (NOT glomerulonephritis)</li>
                <li><strong>GI:</strong> Mesenteric ischemia, bowel perforation</li>
                <li><strong>Skin:</strong> Livedo reticularis, subcutaneous nodules</li>
            </ul>
            <p><span class="label">SPARES lungs</span> (unlike ANCA vasculitis)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Association:</span> Hepatitis B (10-30%)</p>
            <p><span class="label">ANCA:</span> Negative</p>
            <p><span class="label">Angiography:</span> Microaneurysms and stenoses</p>
            <p><span class="label">Treatment:</span> Glucocorticoids Â± cyclophosphamide; treat HBV if present</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Medium vessel + mononeuritis multiplex + spares lungs = PAN</strong></li>
            <li><strong>Always check Hepatitis B</strong></li>
            <li><strong>Microaneurysms on angiography</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- REACTIVE ARTHRITIS -->
<div id="reactive-arthritis" class="condition-page">
    <div class="page-header">
        <h2>274. REACTIVE ARTHRITIS</h2>
        <div class="subtitle">Post-Infectious â€¢ HLA-B27 â€¢ Can't See, Can't Pee, Can't Climb a Tree</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Classic Triad:</span> Arthritis + urethritis + conjunctivitis</p>
            <p><span class="label">Triggering Infections:</span> Chlamydia (GU); Salmonella, Shigella, Campylobacter, Yersinia (GI)</p>
            <p><span class="label">Arthritis:</span> Asymmetric oligoarthritis, lower extremity; 1-4 weeks post-infection</p>
            <p><span class="label">Other:</span> Enthesitis, dactylitis, keratoderma blennorrhagicum, circinate balanitis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>NSAIDs:</strong> First-line</li>
                <li><strong>Treat active Chlamydia</strong> if present</li>
                <li><strong>DMARDs:</strong> Sulfasalazine, MTX for chronic</li>
                <li><strong>TNF inhibitors:</strong> If DMARD failure</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Asymmetric oligoarthritis + recent GU/GI infection = reactive arthritis</strong></li>
            <li><strong>HLA-B27 associated</strong></li>
            <li><strong>Keratoderma blennorrhagicum</strong> looks like pustular psoriasis</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- RAYNAUD -->
<div id="raynaud" class="condition-page">
    <div class="page-header">
        <h2>275. RAYNAUD PHENOMENON</h2>
        <div class="subtitle">Primary vs Secondary â€¢ Tricolor Change â€¢ CCB Treatment</div>
    </div>
    
    <div class="section">
        <div class="section-title">PRIMARY VS SECONDARY</div>
        <div class="section-content">
            <p><span class="label">Tricolor Change:</span> White â†’ Blue â†’ Red</p>
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Feature</th><th>Primary</th><th>Secondary</th></tr>
                <tr><td>Age onset</td><td>15-30</td><td>>30</td></tr>
                <tr><td>Tissue damage</td><td>None</td><td>Ulcers, gangrene</td></tr>
                <tr><td>ANA</td><td>Negative</td><td>Often positive</td></tr>
                <tr><td>Nailfold capillaries</td><td>Normal</td><td>Abnormal</td></tr>
            </table>
            <p><span class="label">Secondary Causes:</span> Scleroderma (most common), SLE, MCTD</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>All:</strong> Avoid cold, smoking cessation</li>
                <li><strong>First-line:</strong> Dihydropyridine CCBs (nifedipine, amlodipine)</li>
                <li><strong>Severe:</strong> Phosphodiesterase inhibitors, prostacyclin</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Digital ulcers = secondary;</strong> think scleroderma</li>
            <li><strong>Abnormal nailfold capillaries</strong> predict CTD</li>
            <li><strong>CCBs are first-line</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CRYOGLOBULINEMIA -->
<div id="cryoglobulinemia" class="condition-page">
    <div class="page-header">
        <h2>276. CRYOGLOBULINEMIA</h2>
        <div class="subtitle">HCV Association â€¢ Palpable Purpura â€¢ MPGN</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Meltzer's Triad:</span> Palpable purpura + arthralgias + weakness</p>
            <p><span class="label">HCV causes 90% of mixed cryoglobulinemia</span></p>
            <p><span class="label">Other:</span> MPGN, peripheral neuropathy, Raynaud</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Labs:</span> Cryoglobulins (transport at 37Â°C), low C4, positive RF, HCV RNA</p>
            <p><span class="label">Treatment:</span> Treat HCV (DAAs); rituximab for severe disease</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>HCV causes 90% of mixed cryoglobulinemia</strong></li>
            <li><strong>Low C4 + positive RF + purpura = cryoglobulinemia</strong></li>
            <li><strong>Treat HCV first</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<!-- INVASIVE CANDIDIASIS -->
<div id="invasive-candida" class="condition-page">
    <div class="page-header">
        <h2>277. INVASIVE CANDIDIASIS</h2>
        <div class="subtitle">Candidemia â€¢ Echinocandins â€¢ Line Removal</div>
    </div>
    
    <div class="section">
        <div class="section-title">RISK FACTORS & PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Risk Factors:</span> Central lines, TPN, broad-spectrum antibiotics, immunosuppression, GI surgery, ICU stay</p>
            <p><span class="label">Presentation:</span> Fever unresponsive to antibiotics, sepsis</p>
            <p><span class="label">Metastatic Complications:</span> Endophthalmitis (fundoscopic exam required), endocarditis, osteomyelitis, hepatosplenic candidiasis</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Diagnosis:</span> Blood cultures (often low sensitivity); Î²-D-glucan (sensitive but not specific)</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Echinocandin first-line:</strong> Caspofungin, micafungin, anidulafungin</li>
                <li><strong>Fluconazole:</strong> Step-down if susceptible and clinically stable</li>
                <li><strong>Remove all central lines</strong></li>
                <li><strong>Dilated fundoscopic exam</strong> within first week</li>
                <li><strong>Duration:</strong> 14 days from first negative blood culture</li>
            </ul>
            <p><span class="label">Repeat blood cultures daily until negative</span></p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Echinocandin first-line;</strong> remove all lines</li>
            <li><strong>Fundoscopic exam required</strong> to rule out endophthalmitis</li>
            <li><strong>14 days from first negative culture</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PCP -->
<div id="pcp" class="condition-page">
    <div class="page-header">
        <h2>278. PNEUMOCYSTIS PNEUMONIA (PCP)</h2>
        <div class="subtitle">HIV/AIDS â€¢ TMP-SMX â€¢ Adjunctive Steroids</div>
    </div>
    
    <div class="section">
        <div class="section-title">RISK FACTORS & PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">At Risk:</span> HIV with CD4 &lt;200; solid organ transplant; high-dose steroids; hematologic malignancy</p>
            <p><span class="label">Presentation:</span></p>
            <ul>
                <li>Subacute progressive dyspnea (weeks)</li>
                <li>Dry cough, fever</li>
                <li>Hypoxemia, especially with exertion</li>
                <li>HIV patients: Indolent; Non-HIV: More acute/severe</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Imaging:</span> Bilateral diffuse ground-glass infiltrates; pneumatoceles; can be normal early</p>
            <p><span class="label">Labs:</span> Elevated LDH (nonspecific), Î²-D-glucan</p>
            <p><span class="label">Diagnosis:</span> Induced sputum or BAL for PCR or DFA staining</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>TMP-SMX:</strong> 15-20 mg/kg/day TMP divided q6-8h Ã— 21 days</li>
                <li><strong>Alternatives:</strong> Pentamidine IV, atovaquone, dapsone + TMP, clindamycin + primaquine</li>
                <li><strong>Adjunctive steroids if PaO2 &lt;70 or A-a gradient â‰¥35:</strong> Prednisone 40mg BID Ã— 5d, then taper</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PROPHYLAXIS</div>
        <div class="section-content">
            <ul>
                <li><strong>HIV:</strong> CD4 &lt;200 or CD4 &lt;14% or history of OI</li>
                <li><strong>TMP-SMX DS daily</strong> (or 3Ã—/week); alternatives: dapsone, atovaquone, pentamidine inhaled</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>TMP-SMX + steroids if hypoxic</strong></li>
            <li><strong>Elevated LDH + bilateral GGO in immunocompromised = PCP</strong></li>
            <li><strong>21 days treatment</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ASPERGILLOSIS -->
<div id="aspergillosis" class="condition-page">
    <div class="page-header">
        <h2>279. INVASIVE ASPERGILLOSIS</h2>
        <div class="subtitle">Neutropenia â€¢ Halo Sign â€¢ Voriconazole</div>
    </div>
    
    <div class="section">
        <div class="section-title">RISK FACTORS & PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">At Risk:</span> Prolonged neutropenia, HSCT, solid organ transplant, high-dose steroids, CGD</p>
            <p><span class="label">Pulmonary:</span> Fever unresponsive to antibiotics, cough, hemoptysis, pleuritic chest pain</p>
            <p><span class="label">Other Sites:</span> Sinuses, CNS, disseminated</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <p><span class="label">CT Findings:</span></p>
            <ul>
                <li><strong>Halo sign:</strong> Ground-glass surrounding nodule (early)</li>
                <li><strong>Air-crescent sign:</strong> Cavitation (later, with neutrophil recovery)</li>
            </ul>
            <p><span class="label">Biomarkers:</span> Galactomannan (serum, BAL), Î²-D-glucan</p>
            <p><span class="label">Definitive:</span> Culture/histopath from tissue (septate hyphae, acute angle branching)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>Voriconazole:</strong> First-line</li>
                <li><strong>Alternatives:</strong> Isavuconazole, liposomal amphotericin B</li>
                <li><strong>Duration:</strong> Minimum 6-12 weeks; until resolution + immune recovery</li>
                <li>Reduce immunosuppression if possible</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Halo sign on CT in neutropenic patient = aspergillosis</strong></li>
            <li><strong>Voriconazole first-line;</strong> check drug levels</li>
            <li><strong>Galactomannan useful for diagnosis and monitoring</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CRYPTOCOCCUS -->
<div id="cryptococcus" class="condition-page">
    <div class="page-header">
        <h2>280. CRYPTOCOCCAL MENINGITIS</h2>
        <div class="subtitle">HIV/AIDS â€¢ India Ink â€¢ Amphotericin + Flucytosine</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">At Risk:</span> HIV with CD4 &lt;100, solid organ transplant, prolonged steroids</p>
            <p><span class="label">Presentation:</span> Subacute meningitis â€” headache, fever, altered mental status; may lack meningismus</p>
            <p><span class="label">Elevated Intracranial Pressure:</span> Common; requires serial LPs or drain</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <ul>
                <li><strong>CSF cryptococcal antigen:</strong> Highly sensitive/specific</li>
                <li><strong>Serum cryptococcal antigen:</strong> Often positive</li>
                <li><strong>India ink:</strong> Encapsulated yeast (less sensitive)</li>
                <li><strong>CSF:</strong> Elevated opening pressure, lymphocytic pleocytosis, low glucose, elevated protein</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">HIV-associated (Induction):</span></p>
            <ul>
                <li><strong>Liposomal amphotericin B + flucytosine Ã— 2 weeks</strong></li>
                <li>Followed by fluconazole consolidation (8 weeks) then maintenance</li>
            </ul>
            <p><span class="label">ICP Management:</span> Serial therapeutic LPs (remove 20-30 mL) or lumbar drain; goal OP &lt;20 cm H2O</p>
            <p><span class="label">ART:</span> Delay 4-6 weeks to avoid IRIS</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Cryptococcal antigen is key diagnostic test</strong></li>
            <li><strong>Elevated ICP management critical</strong> â€” serial LPs</li>
            <li><strong>Delay ART 4-6 weeks</strong> to reduce IRIS risk</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ENDEMIC MYCOSES -->
<div id="endemic-mycoses" class="condition-page">
    <div class="page-header">
        <h2>281. ENDEMIC MYCOSES</h2>
        <div class="subtitle">Histoplasmosis â€¢ Blastomycosis â€¢ Coccidioidomycosis</div>
    </div>
    
    <div class="section">
        <div class="section-title">GEOGRAPHIC DISTRIBUTION</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Fungus</th><th>Region</th><th>Exposure</th></tr>
                <tr><td><strong>Histoplasma</strong></td><td>Ohio/Mississippi River valleys</td><td>Bird/bat droppings, caves</td></tr>
                <tr><td><strong>Blastomyces</strong></td><td>Great Lakes, Ohio/Mississippi valleys</td><td>Decaying wood, soil</td></tr>
                <tr><td><strong>Coccidioides</strong></td><td>Southwest US (Arizona, California)</td><td>Desert soil (dust storms)</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Histoplasmosis:</span></p>
            <ul>
                <li>Usually self-limited; can cause chronic pulmonary (mimics TB), disseminated in immunocompromised</li>
                <li>Mediastinal lymphadenopathy, fibrosing mediastinitis (rare)</li>
            </ul>
            <p><span class="label">Blastomycosis:</span></p>
            <ul>
                <li>Pulmonary, skin (verrucous lesions), bone, prostate</li>
                <li>Less likely to resolve spontaneously â€” usually treat</li>
            </ul>
            <p><span class="label">Coccidioidomycosis (Valley Fever):</span></p>
            <ul>
                <li>60% asymptomatic; can cause pneumonia, erythema nodosum, disseminated (meningitis, bone)</li>
                <li>Risk of dissemination: Filipinos, African Americans, immunocompromised, pregnancy</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Diagnosis:</span> Urine/serum antigen (Histo, Blasto), serology, culture, histopathology</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Mild-moderate:</strong> Itraconazole</li>
                <li><strong>Severe/disseminated:</strong> Amphotericin B â†’ itraconazole</li>
                <li><strong>Cocci meningitis:</strong> Lifelong fluconazole</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Know the geography:</strong> Histo=Midwest caves; Cocci=Southwest desert; Blasto=Great Lakes</li>
            <li><strong>Cocci meningitis requires lifelong fluconazole</strong></li>
            <li><strong>Always treat blastomycosis</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- SJS/TEN -->
<div id="sjs-ten" class="condition-page">
    <div class="page-header">
        <h2>282. STEVENS-JOHNSON SYNDROME / TEN</h2>
        <div class="subtitle">Drug Reaction â€¢ Mucosal Involvement â€¢ Burn Unit Care</div>
    </div>
    
    <div class="section">
        <div class="section-title">DEFINITION & CAUSES</div>
        <div class="section-content">
            <p><span class="label">Spectrum:</span></p>
            <ul>
                <li><strong>SJS:</strong> &lt;10% BSA detachment</li>
                <li><strong>SJS-TEN overlap:</strong> 10-30% BSA</li>
                <li><strong>TEN:</strong> &gt;30% BSA detachment</li>
            </ul>
            <p><span class="label">Common Drug Causes:</span></p>
            <ul>
                <li><strong>Sulfonamides</strong> (TMP-SMX)</li>
                <li><strong>Anticonvulsants:</strong> Carbamazepine, phenytoin, lamotrigine, phenobarbital</li>
                <li><strong>Allopurinol</strong></li>
                <li><strong>NSAIDs</strong> (especially piroxicam)</li>
                <li><strong>Antibiotics:</strong> Fluoroquinolones, penicillins</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Prodrome:</span> Fever, malaise, URI symptoms 1-3 weeks after drug exposure</p>
            <p><span class="label">Skin:</span> Painful erythema â†’ targetoid lesions â†’ bullae â†’ epidermal detachment; positive Nikolsky sign</p>
            <p><span class="label">Mucosal Involvement (â‰¥2 sites):</span> Oral, ocular (conjunctivitis, corneal ulceration), genital</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>Immediate drug withdrawal</strong></li>
                <li><strong>Transfer to burn unit/ICU</strong> for TEN</li>
                <li><strong>Supportive care:</strong> Fluids, wound care, temperature regulation, nutrition</li>
                <li><strong>Ophthalmology consultation</strong> (prevent scarring/blindness)</li>
                <li>Avoid systemic steroids (controversial; some use early)</li>
                <li>SCORTEN for prognosis</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Mucosal involvement distinguishes from other drug reactions</strong></li>
            <li><strong>Stop the drug immediately</strong></li>
            <li><strong>HLA-B*5801 + allopurinol = high SJS/TEN risk</strong> (screen in high-risk populations)</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- DRESS -->
<div id="dress" class="condition-page">
    <div class="page-header">
        <h2>283. DRESS SYNDROME</h2>
        <div class="subtitle">Drug Reaction with Eosinophilia and Systemic Symptoms</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Timing:</span> 2-8 weeks after drug initiation (longer latency than SJS/TEN)</p>
            <p><span class="label">Features:</span></p>
            <ul>
                <li><strong>Rash:</strong> Morbilliform, may become edematous; facial edema common</li>
                <li><strong>Fever</strong></li>
                <li><strong>Lymphadenopathy</strong></li>
                <li><strong>Eosinophilia and/or atypical lymphocytosis</strong></li>
                <li><strong>Internal organ involvement:</strong> Liver (most common), kidney, heart (myocarditis), lung, thyroid</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">COMMON CAUSES</div>
        <div class="section-content">
            <ul>
                <li><strong>Anticonvulsants:</strong> Carbamazepine, phenytoin, lamotrigine, phenobarbital</li>
                <li><strong>Allopurinol</strong></li>
                <li><strong>Sulfonamides</strong></li>
                <li><strong>Vancomycin, minocycline, dapsone</strong></li>
            </ul>
            <p><span class="label">HLA Associations:</span> HLA-B*5801 (allopurinol), HLA-A*3101 (carbamazepine)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>Stop offending drug</strong></li>
                <li><strong>Systemic corticosteroids:</strong> Prednisone 1 mg/kg with slow taper (weeks to months)</li>
                <li>Monitor for organ involvement</li>
                <li><strong>Late complications:</strong> Thyroiditis, autoimmune disease</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>2-8 week latency</strong> (longer than SJS/TEN)</li>
            <li><strong>Eosinophilia + liver involvement + facial edema = DRESS</strong></li>
            <li><strong>Slow steroid taper</strong> â€” rebound common</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PRIMARY IMMUNODEFICIENCIES -->
<div id="cvid" class="condition-page">
    <div class="page-header">
        <h2>284. PRIMARY IMMUNODEFICIENCIES</h2>
        <div class="subtitle">CVID â€¢ IgA Deficiency â€¢ When to Suspect</div>
    </div>
    
    <div class="section">
        <div class="section-title">WARNING SIGNS IN ADULTS</div>
        <div class="section-content">
            <ul>
                <li>â‰¥2 serious bacterial infections in one year</li>
                <li>â‰¥3 bacterial sinusitis or pneumonia in one year</li>
                <li>Infections requiring prolonged antibiotics</li>
                <li>Recurrent skin abscesses</li>
                <li>Opportunistic infections</li>
                <li>Unexplained bronchiectasis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">COMMON VARIABLE IMMUNODEFICIENCY (CVID)</div>
        <div class="section-content">
            <p><span class="label">Most common symptomatic primary immunodeficiency in adults</span></p>
            <p><span class="label">Features:</span></p>
            <ul>
                <li>Recurrent sinopulmonary infections</li>
                <li>Low IgG + low IgA and/or IgM</li>
                <li>Poor vaccine responses</li>
                <li>Autoimmune disease (ITP, AIHA)</li>
                <li>Increased lymphoma risk</li>
                <li>GI disease (chronic diarrhea, malabsorption)</li>
            </ul>
            <p><span class="label">Treatment:</span> IVIG or SCIG replacement</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">IgA DEFICIENCY</div>
        <div class="section-content">
            <p><span class="label">Most common immunodeficiency overall</span> (1:500)</p>
            <p><span class="label">Most asymptomatic;</span> some have recurrent sinopulmonary/GI infections</p>
            <p><span class="label">Associations:</span> Celiac disease, autoimmune disease</p>
            <p><span class="label">Caution:</span> Risk of anaphylaxis to blood products containing IgA</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>CVID:</strong> Low IgG + recurrent infections + poor vaccine response</li>
            <li><strong>IgA deficiency:</strong> Most common; usually asymptomatic</li>
            <li><strong>IVIG is treatment for CVID</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<!-- EATING DISORDERS -->
<div id="eating-disorders" class="condition-page">
    <div class="page-header">
        <h2>285. EATING DISORDERS</h2>
        <div class="subtitle">Anorexia Nervosa â€¢ Bulimia â€¢ Refeeding Syndrome</div>
    </div>
    
    <div class="section">
        <div class="section-title">ANOREXIA NERVOSA</div>
        <div class="section-content">
            <p><span class="label">DSM-5 Criteria:</span></p>
            <ul>
                <li>Restriction of intake leading to significantly low body weight</li>
                <li>Intense fear of gaining weight</li>
                <li>Distorted body image</li>
            </ul>
            <p><span class="label">Medical Complications:</span></p>
            <ul>
                <li><strong>Cardiac:</strong> Bradycardia, hypotension, QTc prolongation, arrhythmias</li>
                <li><strong>Metabolic:</strong> Hypothermia, hypoglycemia</li>
                <li><strong>Endocrine:</strong> Amenorrhea, low T3, elevated cortisol</li>
                <li><strong>Bone:</strong> Osteoporosis</li>
                <li><strong>GI:</strong> Constipation, gastroparesis</li>
                <li><strong>Heme:</strong> Pancytopenia</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">BULIMIA NERVOSA</div>
        <div class="section-content">
            <p><span class="label">Features:</span> Binge eating + compensatory behaviors (purging, laxatives, exercise); normal or elevated weight</p>
            <p><span class="label">Medical Complications:</span></p>
            <ul>
                <li><strong>Electrolytes:</strong> Hypokalemia, hypochloremic metabolic alkalosis</li>
                <li><strong>Dental:</strong> Enamel erosion</li>
                <li><strong>Parotid hypertrophy</strong></li>
                <li><strong>Russell's sign:</strong> Calluses on knuckles</li>
                <li><strong>Esophageal:</strong> Mallory-Weiss tears, rarely Boerhaave</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">REFEEDING SYNDROME</div>
        <div class="section-content">
            <p><span class="label">Risk:</span> Severely malnourished patients (BMI &lt;16, minimal intake &gt;10 days)</p>
            <p><span class="label">Pathophysiology:</span> Insulin surge with refeeding â†’ intracellular shift of phosphorus, potassium, magnesium</p>
            <p><span class="label">Complications:</span> Hypophosphatemia (most important), hypokalemia, hypomagnesemia â†’ arrhythmias, respiratory failure, cardiac failure</p>
            <p><span class="label">Prevention:</span></p>
            <ul>
                <li>Start low, go slow with calories</li>
                <li>Replace thiamine before feeding</li>
                <li>Monitor and replace electrolytes</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Hypokalemia + metabolic alkalosis = purging</strong></li>
            <li><strong>Refeeding syndrome:</strong> Hypophosphatemia is key; give thiamine first</li>
            <li><strong>Anorexia has highest mortality</strong> of psychiatric disorders</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- SLEEP DISORDERS -->
<div id="sleep-disorders" class="condition-page">
    <div class="page-header">
        <h2>286. SLEEP DISORDERS</h2>
        <div class="subtitle">Insomnia â€¢ OSA â€¢ Narcolepsy â€¢ Restless Legs</div>
    </div>
    
    <div class="section">
        <div class="section-title">INSOMNIA</div>
        <div class="section-content">
            <p><span class="label">Chronic Insomnia:</span> â‰¥3 nights/week for â‰¥3 months</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>CBT-I (Cognitive Behavioral Therapy for Insomnia):</strong> First-line</li>
                <li><strong>Pharmacotherapy:</strong> Z-drugs (zolpidem), low-dose trazodone, doxepin; melatonin for circadian disorders</li>
                <li>Avoid benzodiazepines long-term (dependence, falls in elderly)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">OBSTRUCTIVE SLEEP APNEA</div>
        <div class="section-content">
            <p><span class="label">Symptoms:</span> Snoring, witnessed apneas, daytime somnolence, morning headaches</p>
            <p><span class="label">Diagnosis:</span> Polysomnography or home sleep test; AHI â‰¥5 with symptoms</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>CPAP:</strong> First-line for moderate-severe</li>
                <li>Weight loss, positional therapy</li>
                <li>Oral appliances for mild-moderate</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">NARCOLEPSY</div>
        <div class="section-content">
            <p><span class="label">Type 1:</span> Excessive daytime sleepiness + cataplexy (sudden loss of muscle tone with emotion)</p>
            <p><span class="label">Type 2:</span> EDS without cataplexy</p>
            <p><span class="label">Other Features:</span> Sleep paralysis, hypnagogic/hypnopompic hallucinations</p>
            <p><span class="label">Diagnosis:</span> PSG + MSLT (mean sleep latency &lt;8 min, â‰¥2 SOREMPs); low CSF orexin in Type 1</p>
            <p><span class="label">Treatment:</span> Modafinil/armodafinil for EDS; sodium oxybate for cataplexy</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">RESTLESS LEGS SYNDROME</div>
        <div class="section-content">
            <p><span class="label">Features:</span> Urge to move legs, worse at rest/evening, relieved by movement</p>
            <p><span class="label">Associations:</span> Iron deficiency (check ferritin), pregnancy, CKD</p>
            <p><span class="label">Treatment:</span></p>
            <ul>
                <li><strong>Iron supplementation</strong> if ferritin &lt;75</li>
                <li><strong>First-line:</strong> Alpha-2-delta ligands (gabapentin, pregabalin)</li>
                <li>Dopamine agonists (pramipexole) â€” risk of augmentation with long-term use</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>CBT-I is first-line for chronic insomnia</strong></li>
            <li><strong>Cataplexy = narcolepsy Type 1</strong></li>
            <li><strong>Check ferritin in RLS</strong> â€” treat if &lt;75</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- GLOMERULAR DISEASES -->
<div id="glomerular-diseases" class="condition-page">
    <div class="page-header">
        <h2>287. GLOMERULAR DISEASES</h2>
        <div class="subtitle">IgA Nephropathy â€¢ FSGS â€¢ Minimal Change â€¢ Membranous</div>
    </div>
    
    <div class="section">
        <div class="section-title">NEPHRITIC VS NEPHROTIC</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Feature</th><th>Nephritic</th><th>Nephrotic</th></tr>
                <tr><td>Proteinuria</td><td>&lt;3.5 g/day</td><td>â‰¥3.5 g/day</td></tr>
                <tr><td>Hematuria</td><td>Present (RBC casts)</td><td>Minimal</td></tr>
                <tr><td>Edema</td><td>Mild</td><td>Severe (anasarca)</td></tr>
                <tr><td>Other</td><td>HTN, oliguria, AKI</td><td>Hyperlipidemia, lipiduria</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">KEY GLOMERULAR DISEASES</div>
        <div class="section-content">
            <p><span class="label">IgA Nephropathy:</span></p>
            <ul>
                <li>Most common GN worldwide</li>
                <li>Episodic gross hematuria with URI ("synpharyngitic")</li>
                <li>Biopsy: Mesangial IgA deposits</li>
                <li>Treatment: ACEi/ARB; steroids if progressive</li>
            </ul>
            
            <p><span class="label">Minimal Change Disease:</span></p>
            <ul>
                <li>Most common nephrotic syndrome in children</li>
                <li>Biopsy: Normal LM, podocyte effacement on EM</li>
                <li>Treatment: Highly steroid-responsive</li>
            </ul>
            
            <p><span class="label">FSGS:</span></p>
            <ul>
                <li>Most common cause of nephrotic syndrome in adults (especially African Americans)</li>
                <li>Primary vs secondary (HIV, heroin, obesity, reflux)</li>
                <li>Treatment: Steroids (less responsive); SGLT2i</li>
            </ul>
            
            <p><span class="label">Membranous Nephropathy:</span></p>
            <ul>
                <li>Most common nephrotic in white adults</li>
                <li>Primary: Anti-PLA2R antibodies (70%)</li>
                <li>Secondary: Malignancy, hepatitis B, lupus, drugs (NSAIDs, gold)</li>
                <li>High thrombosis risk (renal vein thrombosis)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>IgA nephropathy:</strong> Hematuria with URI (synpharyngitic)</li>
            <li><strong>Minimal change:</strong> Kids, steroid-responsive</li>
            <li><strong>Anti-PLA2R positive = primary membranous</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- ANTI-GBM / GOODPASTURE -->
<div id="goodpasture" class="condition-page">
    <div class="page-header">
        <h2>288. ANTI-GBM DISEASE / GOODPASTURE</h2>
        <div class="subtitle">Pulmonary-Renal Syndrome â€¢ Linear IF â€¢ Plasmapheresis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL FEATURES</div>
        <div class="section-content">
            <p><span class="label">Anti-GBM Disease:</span> Antibodies against type IV collagen in glomerular/alveolar basement membrane</p>
            <p><span class="label">Goodpasture Syndrome:</span> Anti-GBM disease with both lung and kidney involvement</p>
            <p><span class="label">Pulmonary:</span> Diffuse alveolar hemorrhage â€” hemoptysis, dyspnea, infiltrates</p>
            <p><span class="label">Renal:</span> Rapidly progressive glomerulonephritis â€” hematuria, AKI</p>
            <p><span class="label">Associations:</span> Smoking (exposes pulmonary basement membrane), hydrocarbons</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS</div>
        <div class="section-content">
            <ul>
                <li><strong>Anti-GBM antibodies</strong> (serum)</li>
                <li><strong>Kidney biopsy:</strong> Linear IgG staining on immunofluorescence (pathognomonic)</li>
                <li>Crescentic GN on light microscopy</li>
            </ul>
            <p><span class="label">Note:</span> ~30% are also ANCA-positive (double-positive)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <ul>
                <li><strong>Plasmapheresis:</strong> To remove anti-GBM antibodies (daily Ã— 14 days or until antibodies clear)</li>
                <li><strong>Cyclophosphamide + high-dose corticosteroids</strong></li>
                <li>Prognosis depends on creatinine at presentation</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Linear IF staining = anti-GBM</strong> (granular = immune complex)</li>
            <li><strong>Plasmapheresis essential</strong></li>
            <li><strong>Pulmonary-renal syndrome DDx:</strong> Anti-GBM, ANCA vasculitis, SLE</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- CONTRAST NEPHROPATHY -->
<div id="contrast-nephropathy" class="condition-page">
    <div class="page-header">
        <h2>289. CONTRAST-INDUCED NEPHROPATHY</h2>
        <div class="subtitle">AKI Prevention â€¢ IV Fluids â€¢ Risk Factors</div>
    </div>
    
    <div class="section">
        <div class="section-title">DEFINITION & RISK FACTORS</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> AKI within 48-72 hours of contrast exposure; Cr rise â‰¥0.3 or â‰¥50%</p>
            <p><span class="label">High-Risk Patients:</span></p>
            <ul>
                <li>Pre-existing CKD (eGFR &lt;45)</li>
                <li>Diabetes with CKD</li>
                <li>Heart failure</li>
                <li>Volume depletion</li>
                <li>High contrast volume</li>
                <li>Intra-arterial contrast</li>
                <li>Concurrent nephrotoxins</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PREVENTION</div>
        <div class="section-content">
            <p><span class="label">Pre-Procedure:</span></p>
            <ul>
                <li><strong>IV isotonic fluids:</strong> Normal saline or isotonic bicarbonate (1-1.5 mL/kg/hr starting 3-12h before and continuing 6-24h after)</li>
                <li><strong>Hold nephrotoxins:</strong> NSAIDs</li>
                <li><strong>Minimize contrast volume</strong></li>
                <li><strong>Use iso-osmolar or low-osmolar contrast</strong></li>
            </ul>
            <p><span class="label">Metformin:</span> Hold at time of contrast if eGFR &lt;30; restart 48h after if renal function stable</p>
            <p><span class="label">Not Proven Effective:</span> N-acetylcysteine, sodium bicarbonate (beyond isotonic fluids)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">If CI-AKI Occurs:</span></p>
            <ul>
                <li>Supportive care</li>
                <li>Usually self-limited (peaks 3-5 days, resolves 7-10 days)</li>
                <li>Avoid additional nephrotoxic insults</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>IV fluids are the only proven prevention</strong></li>
            <li><strong>NAC does not prevent CI-AKI</strong> (PRESERVE trial)</li>
            <li><strong>Don't delay emergent procedures</strong> for CI-AKI concerns</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- PERIOPERATIVE EVALUATION -->
<div id="perioperative" class="condition-page">
    <div class="page-header">
        <h2>290. PERIOPERATIVE EVALUATION</h2>
        <div class="subtitle">RCRI â€¢ Cardiac Risk â€¢ Medication Management</div>
    </div>
    
    <div class="section">
        <div class="section-title">CARDIAC RISK ASSESSMENT</div>
        <div class="section-content">
            <p><span class="label">Revised Cardiac Risk Index (RCRI) â€” 1 point each:</span></p>
            <ul>
                <li>High-risk surgery (intraperitoneal, intrathoracic, suprainguinal vascular)</li>
                <li>History of ischemic heart disease</li>
                <li>History of heart failure</li>
                <li>History of cerebrovascular disease</li>
                <li>Diabetes requiring insulin</li>
                <li>Creatinine &gt;2.0</li>
            </ul>
            <p><span class="label">Risk:</span> 0 points = 0.4%; 1 = 0.9%; 2 = 6.6%; â‰¥3 = 11%</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">STEPWISE APPROACH (ACC/AHA)</div>
        <div class="section-content">
            <ol>
                <li><strong>Emergency surgery?</strong> â†’ Proceed</li>
                <li><strong>Active cardiac condition?</strong> (ACS, decompensated HF, severe AS, significant arrhythmia) â†’ Evaluate/treat first</li>
                <li><strong>Low-risk surgery?</strong> â†’ Proceed without testing</li>
                <li><strong>Functional capacity â‰¥4 METs?</strong> â†’ Proceed</li>
                <li><strong>&lt;4 METs or unknown + elevated risk?</strong> â†’ Consider stress testing if it will change management</li>
            </ol>
            <p><span class="label">Preoperative Testing:</span> ECG if known CAD or risk factors; Echo if dyspnea of unknown etiology or worsening symptoms</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MEDICATION MANAGEMENT</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Drug</th><th>Perioperative Management</th></tr>
                <tr><td>Beta-blockers</td><td><strong>Continue</strong> if on chronically; do NOT start new high-dose</td></tr>
                <tr><td>Statins</td><td><strong>Continue</strong></td></tr>
                <tr><td>ACEi/ARBs</td><td>Hold morning of surgery (hypotension risk); restart postop</td></tr>
                <tr><td>Aspirin</td><td>Continue if recent stent; otherwise hold 7 days for major surgery</td></tr>
                <tr><td>Clopidogrel</td><td>Hold 5 days if safe; continue if recent stent</td></tr>
                <tr><td>Warfarin</td><td>Hold 5 days; bridge if high-risk (mechanical valve, recent VTE)</td></tr>
                <tr><td>DOACs</td><td>Hold 1-2 days (2-3 if renal impairment)</td></tr>
            </table>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Don't start beta-blockers day of surgery</strong></li>
            <li><strong>Continue statins perioperatively</strong></li>
            <li><strong>4 METs = climb flight of stairs</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- VTE PROPHYLAXIS -->
<div id="vte-prophylaxis" class="condition-page">
    <div class="page-header">
        <h2>291. VTE PROPHYLAXIS</h2>
        <div class="subtitle">Padua Score â€¢ Caprini Score â€¢ Medical vs Surgical</div>
    </div>
    
    <div class="section">
        <div class="section-title">MEDICAL PATIENTS â€” PADUA SCORE</div>
        <div class="section-content">
            <p><span class="label">High Risk (â‰¥4 points):</span> Pharmacologic prophylaxis indicated</p>
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Factor</th><th>Points</th></tr>
                <tr><td>Active cancer</td><td>3</td></tr>
                <tr><td>Previous VTE</td><td>3</td></tr>
                <tr><td>Reduced mobility</td><td>3</td></tr>
                <tr><td>Thrombophilia</td><td>3</td></tr>
                <tr><td>Recent trauma/surgery</td><td>2</td></tr>
                <tr><td>Age â‰¥70</td><td>1</td></tr>
                <tr><td>Heart failure or respiratory failure</td><td>1</td></tr>
                <tr><td>Acute MI or stroke</td><td>1</td></tr>
                <tr><td>Acute infection or rheumatic disorder</td><td>1</td></tr>
                <tr><td>Obesity (BMI â‰¥30)</td><td>1</td></tr>
                <tr><td>Hormonal therapy</td><td>1</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PROPHYLAXIS OPTIONS</div>
        <div class="section-content">
            <p><span class="label">Pharmacologic:</span></p>
            <ul>
                <li><strong>Enoxaparin 40mg SC daily</strong> (most common)</li>
                <li><strong>Heparin 5000 units SC q8h</strong></li>
                <li><strong>Fondaparinux 2.5mg SC daily</strong> (if HIT history)</li>
            </ul>
            <p><span class="label">Mechanical:</span> SCDs, IPC; use if bleeding risk high; combine with pharmacologic if very high VTE risk</p>
            <p><span class="label">Contraindications to Pharmacologic:</span> Active bleeding, severe thrombocytopenia, recent CNS bleed/surgery</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">SPECIAL POPULATIONS</div>
        <div class="section-content">
            <ul>
                <li><strong>Hip/knee replacement:</strong> Extended prophylaxis 35 days (LMWH, rivaroxaban, aspirin)</li>
                <li><strong>Cancer surgery:</strong> Extended prophylaxis 4 weeks</li>
                <li><strong>ICU:</strong> All patients should receive prophylaxis unless contraindicated</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Padua â‰¥4 = pharmacologic prophylaxis</strong></li>
            <li><strong>Extended prophylaxis for orthopedic and cancer surgery</strong></li>
            <li><strong>Mechanical + pharmacologic for highest risk</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- OBESITY MANAGEMENT -->
<div id="obesity-mgmt" class="condition-page">
    <div class="page-header">
        <h2>292. OBESITY MANAGEMENT</h2>
        <div class="subtitle">GLP-1 Agonists â€¢ Bariatric Surgery Criteria â€¢ Pharmacotherapy</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION & INDICATIONS</div>
        <div class="section-content">
            <p><span class="label">BMI Classification:</span></p>
            <ul>
                <li>Overweight: 25-29.9</li>
                <li>Class I obesity: 30-34.9</li>
                <li>Class II obesity: 35-39.9</li>
                <li>Class III obesity: â‰¥40</li>
            </ul>
            <p><span class="label">Pharmacotherapy Indicated:</span> BMI â‰¥30 OR BMI â‰¥27 with comorbidity</p>
            <p><span class="label">Bariatric Surgery Indicated:</span> BMI â‰¥40 OR BMI â‰¥35 with comorbidity; consider for BMI 30-35 with poorly controlled T2DM</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PHARMACOTHERAPY</div>
        <div class="section-content">
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Drug</th><th>Mechanism</th><th>Notes</th></tr>
                <tr><td><strong>Semaglutide (Wegovy)</strong></td><td>GLP-1 agonist</td><td>Most effective (~15% weight loss); weekly injection</td></tr>
                <tr><td><strong>Tirzepatide (Zepbound)</strong></td><td>GLP-1/GIP dual agonist</td><td>~20% weight loss; weekly injection</td></tr>
                <tr><td><strong>Phentermine-topiramate</strong></td><td>Appetite suppressant + anticonvulsant</td><td>Effective; contraindicated in pregnancy (teratogenic)</td></tr>
                <tr><td><strong>Naltrexone-bupropion</strong></td><td>Opioid antagonist + NDRI</td><td>Avoid in seizures, eating disorders</td></tr>
                <tr><td><strong>Orlistat</strong></td><td>Lipase inhibitor</td><td>GI side effects; modest efficacy</td></tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">BARIATRIC SURGERY</div>
        <div class="section-content">
            <p><span class="label">Types:</span></p>
            <ul>
                <li><strong>Sleeve gastrectomy:</strong> Most common now; restrictive</li>
                <li><strong>Roux-en-Y gastric bypass:</strong> Restrictive + malabsorptive; greater T2DM remission</li>
            </ul>
            <p><span class="label">Long-term Requirements:</span> Lifelong vitamin supplementation (B12, iron, calcium, vitamin D), protein intake, follow-up</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>GLP-1 agonists most effective for weight loss</strong></li>
            <li><strong>Bariatric surgery leads to T2DM remission</strong> in many patients</li>
            <li><strong>Lifelong vitamin supplementation</strong> after bypass</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- SMOKING CESSATION -->
<div id="smoking-cessation" class="condition-page">
    <div class="page-header">
        <h2>293. SMOKING CESSATION</h2>
        <div class="subtitle">5 A's â€¢ Varenicline â€¢ NRT</div>
    </div>
    
    <div class="section">
        <div class="section-title">5 A's FRAMEWORK</div>
        <div class="section-content">
            <ul>
                <li><strong>Ask</strong> about tobacco use</li>
                <li><strong>Advise</strong> to quit (clear, strong, personalized)</li>
                <li><strong>Assess</strong> willingness to quit</li>
                <li><strong>Assist</strong> with quit attempt (pharmacotherapy, counseling)</li>
                <li><strong>Arrange</strong> follow-up</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PHARMACOTHERAPY</div>
        <div class="section-content">
            <table style="width:100%; font-size: 9pt;">
                <tr><th>Drug</th><th>Mechanism</th><th>Notes</th></tr>
                <tr><td><strong>Varenicline</strong></td><td>Partial nicotinic agonist</td><td>Most effective; start 1 week before quit date; 12 weeks</td></tr>
                <tr><td><strong>Bupropion SR</strong></td><td>NDRI</td><td>Start 1-2 weeks before quit; avoid in seizure disorder</td></tr>
                <tr><td><strong>NRT (patch, gum, lozenge)</strong></td><td>Nicotine replacement</td><td>Can combine patch + short-acting (gum/lozenge)</td></tr>
            </table>
            <p><span class="label">Combination therapy:</span> Varenicline + NRT, or NRT patch + short-acting NRT = more effective than monotherapy</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">SPECIAL CONSIDERATIONS</div>
        <div class="section-content">
            <ul>
                <li><strong>Hospitalized patients:</strong> Use NRT for withdrawal; counsel before discharge</li>
                <li><strong>Pregnancy:</strong> Behavioral counseling first-line; NRT if needed (safer than smoking)</li>
                <li><strong>Psychiatric illness:</strong> Varenicline and bupropion safe; monitor mood</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Varenicline is most effective</strong></li>
            <li><strong>Combination NRT more effective than single agent</strong></li>
            <li><strong>Bupropion contraindicated in seizure disorder</strong></li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>

<!-- AUD/OUD -->
<div id="aud-oud" class="condition-page">
    <div class="page-header">
        <h2>294. ALCOHOL & OPIOID USE DISORDERS</h2>
        <div class="subtitle">MOUD â€¢ Naltrexone â€¢ Buprenorphine</div>
    </div>
    
    <div class="section">
        <div class="section-title">ALCOHOL USE DISORDER</div>
        <div class="section-content">
            <p><span class="label">Pharmacotherapy for AUD:</span></p>
            <ul>
                <li><strong>Naltrexone:</strong> Opioid antagonist; reduces craving and heavy drinking; PO daily or IM monthly (Vivitrol); contraindicated if on opioids</li>
                <li><strong>Acamprosate:</strong> GABA/glutamate modulator; reduces craving; renally cleared (avoid in CKD); safe in liver disease</li>
                <li><strong>Disulfiram:</strong> Causes aversive reaction with alcohol (flushing, nausea); requires high motivation/supervision</li>
            </ul>
            <p><span class="label">Gabapentin:</span> May help with craving and anxiety; useful if comorbid sleep or anxiety issues</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">OPIOID USE DISORDER â€” MOUD</div>
        <div class="section-content">
            <p><span class="label">Medications for Opioid Use Disorder (MOUD):</span></p>
            <table style="width:100%; font-size: 8pt;">
                <tr><th>Medication</th><th>Mechanism</th><th>Key Points</th></tr>
                <tr><td><strong>Buprenorphine</strong></td><td>Partial Î¼ agonist</td><td>Office-based; wait for withdrawal before starting (COWS â‰¥8-12); ceiling effect (safer)</td></tr>
                <tr><td><strong>Methadone</strong></td><td>Full Î¼ agonist</td><td>OTP (clinic) only for OUD; daily observed dosing initially; QTc prolongation risk</td></tr>
                <tr><td><strong>Naltrexone (XR)</strong></td><td>Î¼ antagonist</td><td>Must be opioid-free 7-10 days; monthly IM; prevents relapse but doesn't treat withdrawal</td></tr>
            </table>
            <p><span class="label">Buprenorphine Induction:</span> Patient must be in withdrawal (COWS score); start low, titrate to effect; can start in ED/hospital</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">HARM REDUCTION</div>
        <div class="section-content">
            <ul>
                <li><strong>Naloxone prescribing:</strong> All patients at risk for overdose</li>
                <li><strong>Syringe exchange programs</strong></li>
                <li><strong>Fentanyl test strips</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ’Ž BOARD PEARLS</div>
        <ul>
            <li><strong>Buprenorphine: Wait for withdrawal (COWS â‰¥8)</strong> to avoid precipitated withdrawal</li>
            <li><strong>Naltrexone for AUD or OUD:</strong> Cannot be on opioids</li>
            <li><strong>MOUD is gold standard for OUD</strong> â€” reduces mortality</li>
        </ul>
    </div>
    <a href="#toc" class="back-to-top">â†‘ Back to Table of Contents</a>
</div>
<!-- BUILD #26 - GI/HEPATOLOGY CONDITIONS (295-298) -->

<!-- VARICEAL BLEEDING -->
<div id="variceal-bleeding" class="condition-page">
    <div class="page-header">
        <h2>295. VARICEAL BLEEDING</h2>
        <div class="subtitle">Life-Threatening GI Hemorrhage in Portal Hypertension</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Hematemesis (bright red blood or coffee grounds), melena, signs of hypovolemic shock</p>
            <p><span class="label">Associated Findings:</span> Stigmata of chronic liver disease (spider angiomata, ascites, splenomegaly, caput medusae)</p>
            <p><span class="label">Risk Stratification:</span></p>
            <ul>
                <li><strong>High-risk features:</strong> Active bleeding at endoscopy, large varices, red wale marks, Child-Pugh C</li>
                <li><strong>Mortality:</strong> 15-20% per episode; 6-week mortality correlates with Child-Pugh class</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Labs:</span> CBC, CMP, LFTs, coagulation studies (PT/INR, fibrinogen), type & screen (crossmatch 6 units), lactate</p>
            <p><span class="label">Risk Scores:</span></p>
            <ul>
                <li><strong>Child-Pugh:</strong> Predicts mortality (Class A: 5-6 pts, B: 7-9 pts, C: 10-15 pts)</li>
                <li><strong>MELD:</strong> Predicts 90-day mortality; prioritizes transplant listing</li>
            </ul>
            <p><span class="label">Endoscopy:</span> EGD within 12 hours of presentation (after resuscitation and hemodynamic stability)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Resuscitation:</span></p>
            <ul>
                <li>2 large-bore IVs, crystalloid resuscitation</li>
                <li><strong>Restrictive transfusion:</strong> Target Hgb 7-8 g/dL (liberal transfusion increases portal pressure and rebleeding)</li>
                <li>Correct coagulopathy: FFP if INR >2.5, platelets if <50K, consider fibrinogen replacement</li>
            </ul>
            
            <p><span class="label">2. Pharmacologic Therapy (Start Immediately):</span></p>
            <ul>
                <li><strong>Octreotide:</strong> 50 mcg IV bolus, then 50 mcg/hr infusion Ã— 3-5 days (reduces splanchnic blood flow)</li>
                <li><strong>PPI:</strong> Pantoprazole 80 mg IV bolus, then 8 mg/hr infusion (for concurrent ulcer disease)</li>
                <li><strong>Antibiotics:</strong> Ceftriaxone 1g IV daily Ã— 7 days (reduces mortality, prevents SBP)</li>
            </ul>
            
            <p><span class="label">3. Endoscopic Therapy:</span></p>
            <ul>
                <li><strong>Esophageal varices:</strong> Endoscopic variceal ligation (EVL/banding) â€” first-line</li>
                <li><strong>Gastric varices:</strong> Cyanoacrylate glue injection or balloon-occluded retrograde transvenous obliteration (BRTO)</li>
                <li>Repeat EGD every 2-4 weeks until varices eradicated</li>
            </ul>
            
            <p><span class="label">4. Rescue Therapies (If Endoscopy Fails):</span></p>
            <ul>
                <li><strong>Balloon tamponade:</strong> Sengstaken-Blakemore or Minnesota tube (bridge to definitive therapy, max 24h)</li>
                <li><strong>TIPS:</strong> Transjugular intrahepatic portosystemic shunt â€” for refractory bleeding</li>
                <li><strong>Early TIPS:</strong> Consider within 72h for high-risk patients (Child-Pugh C or B with active bleeding)</li>
            </ul>
            
            <p><span class="label">5. Secondary Prophylaxis:</span></p>
            <ul>
                <li><strong>Non-selective beta-blocker:</strong> Propranolol or nadolol (target HR 55-60 or 25% reduction)</li>
                <li><strong>EVL:</strong> Repeat banding every 2-4 weeks until varices obliterated</li>
                <li>Combination therapy (beta-blocker + EVL) most effective</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Restrictive transfusion:</strong> Overtransfusion increases portal pressure â†’ more bleeding. Target Hgb 7-8</li>
            <li><strong>Antibiotics save lives:</strong> Prophylactic ceftriaxone reduces mortality by 20% â€” don't skip it!</li>
            <li><strong>Octreotide timing:</strong> Start BEFORE endoscopy. Works within minutes to reduce portal pressure</li>
            <li><strong>Balloon tamponade:</strong> Last resort bridge therapy only. High complication rate (aspiration, esophageal necrosis)</li>
            <li><strong>Early TIPS:</strong> New paradigm â€” consider within 72h for high-risk patients, improves survival</li>
        </ul>
    </div>
</div>

<!-- OGILVIE SYNDROME -->
<div id="ogilvie" class="condition-page">
    <div class="page-header">
        <h2>296. OGILVIE SYNDROME (Acute Colonic Pseudo-Obstruction)</h2>
        <div class="subtitle">Massive Colonic Dilation Without Mechanical Obstruction</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Massive abdominal distension, absent or hypoactive bowel sounds, nausea/vomiting</p>
            <p><span class="label">Key Features:</span> Often in hospitalized, post-operative, or critically ill patients</p>
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li>Recent surgery (especially orthopedic, cardiac, obstetric)</li>
                <li>Trauma, sepsis, respiratory failure</li>
                <li>Medications (opioids, anticholinergics, CCBs)</li>
                <li>Electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia)</li>
                <li>Neurologic conditions (Parkinson's, MS, spinal cord injury)</li>
            </ul>
            <p><span class="label">Warning Signs:</span> Cecal diameter >12 cm = high perforation risk; fever, peritoneal signs = possible ischemia/perforation</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>Abdominal X-ray:</strong> Massively dilated colon (cecum often >10 cm), air-fluid levels, no transition point</li>
                <li><strong>CT abdomen/pelvis:</strong> Confirms no mechanical obstruction, assesses for perforation/ischemia</li>
            </ul>
            <p><span class="label">Labs:</span> CBC, CMP (especially K, Mg, Ca), lactate, TSH</p>
            <p><span class="label">Critical Measurement:</span> Cecal diameter â€” risk of perforation increases significantly when >12 cm or >6 days duration</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Supportive Care (Initial 24-48h):</span></p>
            <ul>
                <li>NPO, NG tube decompression</li>
                <li>Correct electrolytes aggressively</li>
                <li>Discontinue offending medications (opioids, anticholinergics)</li>
                <li>Mobilization, knee-to-chest positioning</li>
                <li>Rectal tube for decompression</li>
            </ul>
            
            <p><span class="label">2. Neostigmine (If No Improvement in 24-48h or Cecum >12 cm):</span></p>
            <ul>
                <li><strong>Dose:</strong> 2 mg IV over 3-5 minutes</li>
                <li><strong>Monitoring:</strong> Continuous cardiac monitoring during administration (bradycardia risk)</li>
                <li><strong>Contraindications:</strong> Bradycardia, recent MI, mechanical obstruction, GI perforation</li>
                <li><strong>Success rate:</strong> 80-90% response</li>
                <li>Have atropine at bedside for symptomatic bradycardia</li>
                <li>May repeat Ã— 1 if inadequate response after 3-4 hours</li>
            </ul>
            
            <p><span class="label">3. Colonoscopic Decompression:</span></p>
            <ul>
                <li>If neostigmine fails or contraindicated</li>
                <li>Success rate ~70%; recurrence common</li>
                <li>Place decompression tube if possible</li>
            </ul>
            
            <p><span class="label">4. Surgery:</span></p>
            <ul>
                <li>Indications: Perforation, peritonitis, ischemia, failed conservative/endoscopic management</li>
                <li>Options: Cecostomy tube, subtotal colectomy</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Cecal diameter cutoff:</strong> >12 cm = high perforation risk. Measure on imaging and trend!</li>
            <li><strong>Neostigmine works:</strong> 80-90% effective but requires cardiac monitoring. Keep atropine ready</li>
            <li><strong>Duration matters:</strong> >6 days of dilation also increases perforation risk independent of diameter</li>
            <li><strong>Rule out mechanical obstruction:</strong> CT scan essential before treating as pseudo-obstruction</li>
            <li><strong>Fix the basics first:</strong> Electrolyte correction and stopping offending meds often sufficient</li>
        </ul>
    </div>
</div>

<!-- ACALCULOUS CHOLECYSTITIS -->
<div id="acalculous-cholecystitis" class="condition-page">
    <div class="page-header">
        <h2>297. ACALCULOUS CHOLECYSTITIS</h2>
        <div class="subtitle">Gallbladder Inflammation Without Stones â€¢ ICU-Associated</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> RUQ pain, fever, leukocytosis in critically ill patient WITHOUT gallstones</p>
            <p><span class="label">Challenge:</span> Often subtle in sedated/intubated ICU patients â€” may present only as unexplained sepsis</p>
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li>Critical illness (sepsis, trauma, burns, major surgery)</li>
                <li>Prolonged NPO status, TPN</li>
                <li>Mechanical ventilation</li>
                <li>Multiple transfusions</li>
                <li>Vasopressor support (gallbladder ischemia)</li>
                <li>Immunosuppression, HIV/AIDS</li>
            </ul>
            <p><span class="label">Pathophysiology:</span> Bile stasis + gallbladder ischemia â†’ inflammation â†’ necrosis/gangrene</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Labs:</span> Leukocytosis (may be absent in immunocompromised), elevated LFTs, elevated lipase (if concurrent pancreatitis)</p>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>RUQ Ultrasound:</strong> Gallbladder wall thickening >3.5 mm, pericholecystic fluid, distension, NO stones, positive sonographic Murphy's sign</li>
                <li><strong>CT Abdomen:</strong> Wall thickening, pericholecystic stranding, enhancement defects (gangrene)</li>
                <li><strong>HIDA Scan:</strong> Non-visualization of gallbladder = positive (but slow, less useful in ICU)</li>
            </ul>
            
            <p><span class="label">Diagnostic Criteria (â‰¥2 of):</span></p>
            <ul>
                <li>Gallbladder distension (>5 cm transverse)</li>
                <li>Wall thickening >3.5 mm</li>
                <li>Pericholecystic fluid</li>
                <li>Mucosal sloughing</li>
                <li>Intramural gas (gangrene)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Antibiotics:</span></p>
            <ul>
                <li><strong>Empiric:</strong> Piperacillin-tazobactam OR ceftriaxone + metronidazole</li>
                <li>Cover gram-negatives + anaerobes</li>
            </ul>
            
            <p><span class="label">2. Source Control:</span></p>
            <ul>
                <li><strong>Percutaneous cholecystostomy:</strong> Preferred in critically ill/high surgical risk patients</li>
                <li>Place drain under US or CT guidance</li>
                <li>Can be converted to cholecystectomy once patient stabilized</li>
                <li><strong>Cholecystectomy:</strong> Definitive treatment when patient stable enough for surgery</li>
            </ul>
            
            <p><span class="label">3. Supportive Care:</span></p>
            <ul>
                <li>NPO, IV fluids</li>
                <li>Optimize hemodynamics</li>
                <li>Monitor for complications (gangrene, perforation)</li>
            </ul>
            
            <p><span class="label">Complications:</span> Gangrenous cholecystitis (50% of cases!), perforation, emphysematous cholecystitis, sepsis</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Think of it:</strong> Unexplained sepsis in ICU patient + RUQ findings = consider acalculous cholecystitis</li>
            <li><strong>High mortality:</strong> 30-50% mortality (vs 1-4% for calculous cholecystitis) due to delayed diagnosis</li>
            <li><strong>Gangrene is common:</strong> 50% have gangrenous changes at intervention â€” don't delay!</li>
            <li><strong>Perc chole works:</strong> Percutaneous drainage is effective bridge in unstable patients</li>
            <li><strong>No stones needed:</strong> Absence of stones does NOT rule out cholecystitis in ICU patients</li>
        </ul>
    </div>
</div>

<!-- COAGULOPATHY OF LIVER DISEASE -->
<div id="liver-coagulopathy" class="condition-page">
    <div class="page-header">
        <h2>298. COAGULOPATHY OF LIVER DISEASE</h2>
        <div class="subtitle">Rebalanced Hemostasis â€¢ Complex Bleeding/Thrombosis Risk</div>
    </div>
    
    <div class="section">
        <div class="section-title">PATHOPHYSIOLOGY</div>
        <div class="section-content">
            <p><span class="label">Key Concept:</span> Liver disease affects BOTH pro-coagulant AND anti-coagulant factors â†’ "rebalanced hemostasis"</p>
            <p><span class="label">Decreased Pro-coagulants:</span> Factors II, V, VII, IX, X, XI, fibrinogen</p>
            <p><span class="label">Decreased Anti-coagulants:</span> Protein C, Protein S, Antithrombin III</p>
            <p><span class="label">Platelet Issues:</span> Thrombocytopenia (splenic sequestration), platelet dysfunction</p>
            <p><span class="label">Fibrinolysis:</span> Enhanced (decreased PAI-1, Î±2-antiplasmin) but also decreased plasminogen</p>
            <p><span class="label">Clinical Implication:</span> INR does NOT predict bleeding risk in cirrhosis â€” patients can bleed OR clot</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Standard Labs:</span> PT/INR, PTT, fibrinogen, platelet count, D-dimer</p>
            <p><span class="label">Advanced Testing:</span></p>
            <ul>
                <li><strong>TEG/ROTEM:</strong> Viscoelastic testing provides global hemostasis assessment</li>
                <li>More useful than PT/INR for predicting bleeding in cirrhosis</li>
                <li>Can guide targeted component therapy</li>
            </ul>
            <p><span class="label">Distinguish from DIC:</span></p>
            <ul>
                <li>DIC: Rapidly falling fibrinogen, rising D-dimer, schistocytes</li>
                <li>Chronic liver disease: Stable coagulopathy, no schistocytes</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MANAGEMENT</div>
        <div class="section-content">
            <p><span class="label">General Principles:</span></p>
            <ul>
                <li><strong>Do NOT routinely correct INR for procedures</strong> â€” INR doesn't predict bleeding in cirrhosis</li>
                <li>Correct only if actively bleeding or high-risk procedure</li>
                <li>Avoid excessive FFP (volume overload, transfusion reactions)</li>
            </ul>
            
            <p><span class="label">For Active Bleeding:</span></p>
            <ul>
                <li><strong>Fibrinogen <100-120:</strong> Cryoprecipitate (10 units) or fibrinogen concentrate</li>
                <li><strong>Platelets <50K with bleeding:</strong> Platelet transfusion</li>
                <li><strong>FFP:</strong> Only if significant bleeding; use TEG/ROTEM to guide if available</li>
                <li><strong>PCC (4-factor):</strong> Consider for life-threatening bleeding (lower volume than FFP)</li>
                <li><strong>Tranexamic acid:</strong> Consider for hyperfibrinolysis (topical or IV)</li>
            </ul>
            
            <p><span class="label">Procedure Thresholds (General Guidance):</span></p>
            <ul>
                <li>Paracentesis/thoracentesis: Usually safe regardless of INR if platelets >20-50K</li>
                <li>Central line: Platelets >20K, fibrinogen >100</li>
                <li>Liver biopsy: Platelets >50-60K, INR <1.5 (though INR threshold controversial)</li>
            </ul>
            
            <p><span class="label">VTE Prophylaxis:</span></p>
            <ul>
                <li>Cirrhotic patients ARE at VTE risk despite elevated INR</li>
                <li>Pharmacologic prophylaxis generally safe if no active bleeding, platelets >50K</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>INR is misleading:</strong> Elevated INR does NOT mean bleeding risk in cirrhosis â€” "rebalanced hemostasis"</li>
            <li><strong>Cirrhotics clot too:</strong> Portal vein thrombosis, DVT/PE occur. Don't withhold prophylaxis based on INR alone</li>
            <li><strong>Fibrinogen is key:</strong> Often the critical factor. Check and replace if <100-120</li>
            <li><strong>Paracentesis is safe:</strong> Large volume paracentesis safe even with INR 2-3, platelets >20K</li>
            <li><strong>TEG/ROTEM superior:</strong> Viscoelastic testing better predicts bleeding than INR in liver disease</li>
            <li><strong>Avoid FFP reflex:</strong> Giving FFP to "correct INR" before procedures often unnecessary and harmful (volume overload)</li>
        </ul>
    </div>
</div>
<!-- BUILD #26 - CARDIOLOGY CONDITIONS (299-302) -->

<!-- TAKOTSUBO CARDIOMYOPATHY -->
<div id="takotsubo" class="condition-page">
    <div class="page-header">
        <h2>299. TAKOTSUBO CARDIOMYOPATHY</h2>
        <div class="subtitle">Stress-Induced Cardiomyopathy â€¢ "Broken Heart Syndrome"</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Post-menopausal woman with acute chest pain and dyspnea following intense emotional or physical stress</p>
            <p><span class="label">Triggers:</span></p>
            <ul>
                <li><strong>Emotional:</strong> Death of loved one, divorce, job loss, argument</li>
                <li><strong>Physical:</strong> Surgery, sepsis, respiratory failure, SAH, pheochromocytoma</li>
                <li><strong>No trigger identified:</strong> ~30% of cases</li>
            </ul>
            <p><span class="label">Demographics:</span> 90% women, mean age 65-70, often without traditional cardiac risk factors</p>
            <p><span class="label">Important:</span> Can occur in men and younger patients â€” don't exclude based on demographics</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">ECG:</span> ST elevation (mimics STEMI), T-wave inversions, QTc prolongation</p>
            <p><span class="label">Biomarkers:</span> Troponin elevated but disproportionately LOW relative to degree of wall motion abnormality</p>
            
            <p><span class="label">Echocardiogram:</span></p>
            <ul>
                <li><strong>Classic "apical ballooning":</strong> Apical and mid-ventricular akinesis with hyperdynamic base</li>
                <li><strong>Variants:</strong> Mid-ventricular, basal (reverse takotsubo), focal</li>
                <li>Wall motion abnormality extends beyond single coronary distribution</li>
            </ul>
            
            <p><span class="label">Coronary Angiography:</span> No obstructive CAD (or stenosis doesn't explain wall motion abnormality)</p>
            
            <p><span class="label">Mayo Criteria (Modified InterTAK):</span></p>
            <ul>
                <li>Transient LV dysfunction (akinesis/dyskinesis) extending beyond single epicardial territory</li>
                <li>Absence of obstructive coronary disease or plaque rupture</li>
                <li>New ECG changes (ST elevation and/or T-wave inversion) or troponin elevation</li>
                <li>Absence of pheochromocytoma or myocarditis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Acute Management:</span></p>
            <ul>
                <li>Treat initially as ACS until diagnosis confirmed (cath often needed)</li>
                <li>Supportive care â€” monitor for complications</li>
                <li>Beta-blockers (if not in cardiogenic shock) â€” may blunt catecholamine effect</li>
                <li>ACE inhibitors if LV dysfunction</li>
            </ul>
            
            <p><span class="label">Cardiogenic Shock (10-15%):</span></p>
            <ul>
                <li><strong>Avoid inotropes</strong> (catecholamines worsen condition)</li>
                <li>Mechanical support: IABP, Impella, ECMO</li>
                <li>Levosimendan (if available) â€” inotrope without catecholamine effect</li>
            </ul>
            
            <p><span class="label">LVOT Obstruction (if present):</span></p>
            <ul>
                <li>Beta-blockers, IV fluids</li>
                <li>AVOID inotropes, vasodilators (worsen obstruction)</li>
                <li>Phenylephrine if hypotensive</li>
            </ul>
            
            <p><span class="label">Complications to Monitor:</span></p>
            <ul>
                <li>Cardiogenic shock, LV thrombus, arrhythmias (VT, VF)</li>
                <li>Mitral regurgitation, LVOT obstruction</li>
                <li>Torsades de pointes (QTc prolongation)</li>
            </ul>
            
            <p><span class="label">Prognosis:</span> Recovery of LV function within days to weeks; in-hospital mortality ~5%; recurrence 5-10%</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Troponin-wall motion mismatch:</strong> Low troponin relative to severe wall motion abnormality suggests takotsubo vs ACS</li>
            <li><strong>Goes to cath lab:</strong> Often diagnosed at angiography when no culprit lesion found in STEMI presentation</li>
            <li><strong>Avoid catecholamines:</strong> Dobutamine/dopamine can worsen condition â€” catecholamine excess is the problem!</li>
            <li><strong>Check for LVOT obstruction:</strong> SAM of mitral valve can cause hypotension; treat with beta-blockers, not inotropes</li>
            <li><strong>Consider LV thrombus:</strong> Anticoagulation if LV thrombus or severe apical akinesis</li>
            <li><strong>Can be fatal:</strong> 5% mortality â€” not a benign condition despite "stress-induced" name</li>
        </ul>
    </div>
</div>

<!-- MITRAL STENOSIS -->
<div id="mitral-stenosis" class="condition-page">
    <div class="page-header">
        <h2>300. MITRAL STENOSIS</h2>
        <div class="subtitle">Rheumatic Heart Disease â€¢ LA Pressure Overload</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Dyspnea on exertion, fatigue, palpitations (atrial fibrillation), hemoptysis</p>
            <p><span class="label">Precipitants of Decompensation:</span> Atrial fibrillation (loss of atrial kick + tachycardia), pregnancy, anemia, infection, thyrotoxicosis</p>
            <p><span class="label">Physical Exam:</span></p>
            <ul>
                <li><strong>Low-pitched diastolic rumble:</strong> Best heard at apex with bell in left lateral decubitus</li>
                <li><strong>Opening snap:</strong> Higher pitch, follows S2 (closer to S2 = more severe stenosis)</li>
                <li><strong>Loud S1:</strong> Due to abrupt closure of stenotic valve</li>
                <li><strong>Signs of RV failure:</strong> Late finding (JVD, edema, ascites)</li>
            </ul>
            <p><span class="label">Etiology:</span> Rheumatic heart disease (>90%), degenerative calcification, carcinoid, SLE</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">ECG:</span> Left atrial enlargement (P mitrale), atrial fibrillation (common), RVH (late)</p>
            <p><span class="label">CXR:</span> Left atrial enlargement (straightening of left heart border), pulmonary congestion, Kerley B lines</p>
            
            <p><span class="label">Echocardiography:</span></p>
            <ul>
                <li><strong>Mitral valve area (MVA):</strong> Normal 4-6 cmÂ²</li>
                <li>Mild: >1.5 cmÂ²</li>
                <li>Moderate: 1.0-1.5 cmÂ²</li>
                <li>Severe: <1.0 cmÂ²</li>
                <li><strong>Mean gradient:</strong> Severe if >10 mmHg</li>
                <li><strong>Valve morphology:</strong> Wilkins score for balloon candidacy</li>
            </ul>
            
            <p><span class="label">Wilkins Score (Echocardiographic):</span></p>
            <ul>
                <li>Leaflet mobility, thickening, calcification, subvalvular thickening (each 1-4 points)</li>
                <li>Score â‰¤8: Favorable for percutaneous balloon mitral valvotomy (PBMV)</li>
                <li>Score >8: Consider surgical mitral valve replacement</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Medical Management:</span></p>
            <ul>
                <li><strong>Rate control:</strong> Beta-blockers, CCBs (diltiazem, verapamil) â€” slower HR = longer diastolic filling time</li>
                <li><strong>Diuretics:</strong> For pulmonary congestion</li>
                <li><strong>Anticoagulation:</strong> Warfarin if AF, LA thrombus, prior embolism, or severe MS with LA enlargement</li>
                <li><strong>AF cardioversion:</strong> After 3 weeks anticoagulation or TEE-guided</li>
            </ul>
            
            <p><span class="label">Intervention Indications:</span></p>
            <ul>
                <li>Symptomatic severe MS (MVA â‰¤1.5 cmÂ²)</li>
                <li>Asymptomatic severe MS with PASP >50 mmHg or new-onset AF</li>
            </ul>
            
            <p><span class="label">Intervention Options:</span></p>
            <ul>
                <li><strong>PBMV (Balloon valvotomy):</strong> First-line if favorable anatomy (Wilkins â‰¤8), no LA thrombus, no significant MR</li>
                <li><strong>Surgical MVR:</strong> Unfavorable anatomy, significant MR, LA thrombus, or PBMV failure</li>
            </ul>
            
            <p><span class="label">Special Situations:</span></p>
            <ul>
                <li><strong>Pregnancy:</strong> PBMV can be performed if symptoms refractory to medical therapy</li>
                <li><strong>Acute decompensation:</strong> Rate control critical; diuretics; cardioversion if new AF</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Tachycardia is the enemy:</strong> Faster HR = less diastolic filling time = pulmonary edema. Control rate aggressively</li>
            <li><strong>Opening snap timing:</strong> Shorter S2-OS interval = more severe stenosis (higher LA pressure opens valve earlier)</li>
            <li><strong>Wilkins score â‰¤8:</strong> Favorable for PBMV â€” commissures split nicely</li>
            <li><strong>Anticoagulate:</strong> High stroke risk with AF + MS. Warfarin preferred (no DOAC data)</li>
            <li><strong>Think rheumatic:</strong> Still most common cause worldwide. Ask about childhood illness, endemic areas</li>
        </ul>
    </div>
</div>

<!-- AORTIC REGURGITATION -->
<div id="aortic-regurgitation" class="condition-page">
    <div class="page-header">
        <h2>301. AORTIC REGURGITATION</h2>
        <div class="subtitle">Acute vs Chronic â€¢ Wide Pulse Pressure</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Chronic AR:</span> May be asymptomatic for years â†’ exertional dyspnea, fatigue, palpitations, angina</p>
            <p><span class="label">Acute AR:</span> Fulminant pulmonary edema, cardiogenic shock â€” EMERGENCY</p>
            
            <p><span class="label">Physical Exam (Chronic Severe AR):</span></p>
            <ul>
                <li><strong>Wide pulse pressure:</strong> High systolic, low diastolic (e.g., 170/50)</li>
                <li><strong>Diastolic decrescendo murmur:</strong> Left sternal border, sitting up, leaning forward</li>
                <li><strong>Austin Flint murmur:</strong> Low-pitched diastolic rumble at apex (AR jet hitting anterior MV leaflet)</li>
                <li><strong>Eponymous signs:</strong> Corrigan's (water-hammer) pulse, de Musset's (head bobbing), Quincke's (nail bed pulsations), Traube's (pistol shot femorals)</li>
            </ul>
            
            <p><span class="label">Acute AR:</span> May NOT have classic findings â€” no wide pulse pressure (LV hasn't dilated), soft murmur, tachycardia</p>
            
            <p><span class="label">Etiology:</span></p>
            <ul>
                <li><strong>Chronic:</strong> Bicuspid aortic valve, rheumatic, degenerative, connective tissue disease (Marfan)</li>
                <li><strong>Acute:</strong> Infective endocarditis, aortic dissection, trauma</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">ECG:</span> LVH (chronic), may be normal in acute</p>
            <p><span class="label">CXR:</span> Cardiomegaly (chronic), pulmonary edema (acute)</p>
            
            <p><span class="label">Echocardiography:</span></p>
            <ul>
                <li><strong>Chronic severe AR:</strong> Holodiastolic flow reversal in descending aorta, vena contracta >6mm, regurgitant volume â‰¥60 mL, ERO â‰¥0.3 cmÂ²</li>
                <li><strong>Acute AR:</strong> Early mitral valve closure (pathognomonic), elevated LV filling pressures, normal LV size</li>
                <li>Assess etiology: Bicuspid valve, endocarditis, aortic root dilation</li>
            </ul>
            
            <p><span class="label">If Aortic Dissection Suspected:</span> CT angiography or TEE urgently</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Acute Severe AR (Emergency):</span></p>
            <ul>
                <li><strong>Surgery is definitive:</strong> Urgent AVR â€” medical therapy is bridge only</li>
                <li><strong>Vasodilators:</strong> Nitroprusside to reduce afterload (decreases regurgitant volume)</li>
                <li><strong>Inotropes:</strong> Dobutamine if cardiogenic shock</li>
                <li><strong>AVOID:</strong> Beta-blockers (removes compensatory tachycardia), IABP (worsens regurgitation during diastole)</li>
            </ul>
            
            <p><span class="label">Chronic AR â€” Indications for Surgery:</span></p>
            <ul>
                <li>Symptomatic severe AR</li>
                <li>Asymptomatic severe AR with LV dysfunction (LVEF â‰¤55%)</li>
                <li>Asymptomatic severe AR with LV dilation (LVESD >50mm or indexed >25mm/mÂ²)</li>
                <li>Undergoing other cardiac surgery</li>
            </ul>
            
            <p><span class="label">Medical Therapy (Chronic):</span></p>
            <ul>
                <li>Vasodilators (ACEi, ARB, dihydropyridine CCB) if hypertensive</li>
                <li>No proven benefit of vasodilators in normotensive asymptomatic patients</li>
                <li>Serial echo every 6-12 months for severe AR; yearly for moderate</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Acute AR is an emergency:</strong> LV can't compensate â†’ cardiogenic shock. Surgery ASAP</li>
            <li><strong>No IABP in AR:</strong> Balloon inflation in diastole worsens regurgitation!</li>
            <li><strong>Wide pulse pressure:</strong> Classic for chronic AR. Absent in acute AR (LV hasn't dilated yet)</li>
            <li><strong>Austin Flint â‰  MS:</strong> AR jet causes functional mitral stenosis physiology without actual stenosis</li>
            <li><strong>Early MV closure:</strong> Pathognomonic of acute severe AR on echo</li>
            <li><strong>Check the aorta:</strong> Aortic root dilation is common cause â€” screen for aneurysm, Marfan</li>
        </ul>
    </div>
</div>

<!-- PROSTHETIC VALVE DYSFUNCTION -->
<div id="prosthetic-valve" class="condition-page">
    <div class="page-header">
        <h2>302. PROSTHETIC VALVE DYSFUNCTION</h2>
        <div class="subtitle">Mechanical & Bioprosthetic Valve Complications</div>
    </div>
    
    <div class="section">
        <div class="section-title">VALVE TYPES</div>
        <div class="section-content">
            <p><span class="label">Mechanical Valves:</span> Durable (20+ years), require lifelong anticoagulation (INR 2.5-3.5 for mitral, 2-3 for aortic)</p>
            <p><span class="label">Bioprosthetic Valves:</span> Limited durability (10-15 years), typically no anticoagulation after 3-6 months</p>
            <p><span class="label">TAVR Valves:</span> Increasingly common for aortic stenosis, unique complications</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATIONS</div>
        <div class="section-content">
            <p><span class="label">Prosthetic Valve Obstruction:</span></p>
            <ul>
                <li><strong>Thrombosis:</strong> Usually mechanical valves with subtherapeutic INR; acute onset dyspnea, CHF</li>
                <li><strong>Pannus:</strong> Tissue ingrowth; more gradual onset</li>
                <li><strong>Exam:</strong> Muffled or absent valve clicks (mechanical), new murmur, CHF signs</li>
            </ul>
            
            <p><span class="label">Prosthetic Valve Regurgitation:</span></p>
            <ul>
                <li><strong>Paravalvular leak:</strong> Around the sewing ring; can be early (technical) or late (endocarditis, dehiscence)</li>
                <li><strong>Intrinsic regurgitation:</strong> Leaflet degeneration (bioprosthetic), disc malfunction (mechanical)</li>
                <li><strong>Symptoms:</strong> CHF, hemolytic anemia (from turbulent flow)</li>
            </ul>
            
            <p><span class="label">Prosthetic Valve Endocarditis (PVE):</span></p>
            <ul>
                <li><strong>Early (&lt;1 year):</strong> Staph aureus, coagulase-negative staph, gram-negatives</li>
                <li><strong>Late (&gt;1 year):</strong> Similar to native valve endocarditis pathogens</li>
                <li><strong>Higher risk:</strong> Mechanical > bioprosthetic; mitral > aortic</li>
            </ul>
            
            <p><span class="label">Structural Valve Deterioration (Bioprosthetic):</span></p>
            <ul>
                <li>Leaflet calcification, tearing, stenosis, regurgitation</li>
                <li>More rapid in younger patients, renal failure, calcium disorders</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">TTE:</span> Initial assessment â€” gradients, regurgitation, vegetation</p>
            <p><span class="label">TEE:</span> More sensitive for:</p>
            <ul>
                <li>Valve thrombosis</li>
                <li>Paravalvular abscess</li>
                <li>Vegetations (especially mechanical valves with acoustic shadowing)</li>
            </ul>
            <p><span class="label">Fluoroscopy:</span> Assess mechanical valve leaflet motion</p>
            <p><span class="label">CT:</span> Pannus vs thrombus differentiation, paravalvular leak localization</p>
            <p><span class="label">Labs:</span> INR, hemolysis labs (LDH, haptoglobin, reticulocyte count, peripheral smear), blood cultures</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Valve Thrombosis:</span></p>
            <ul>
                <li><strong>Non-obstructive, small thrombus:</strong> Optimize anticoagulation, serial imaging</li>
                <li><strong>Obstructive thrombosis â€” stable:</strong> Fibrinolysis (tPA) vs surgery based on surgical risk</li>
                <li><strong>Obstructive thrombosis â€” unstable:</strong> Surgery preferred if available; fibrinolysis if not</li>
            </ul>
            
            <p><span class="label">Prosthetic Valve Endocarditis:</span></p>
            <ul>
                <li>Prolonged antibiotics (6 weeks minimum)</li>
                <li><strong>Surgery indications:</strong> Heart failure, uncontrolled infection, paravalvular abscess, large/mobile vegetation, recurrent emboli</li>
                <li>Early PVE has high mortality â€” aggressive management</li>
            </ul>
            
            <p><span class="label">Paravalvular Leak:</span></p>
            <ul>
                <li>Small asymptomatic: Monitor</li>
                <li>Symptomatic or hemolysis: Percutaneous closure or surgical repair</li>
            </ul>
            
            <p><span class="label">Structural Deterioration:</span></p>
            <ul>
                <li>Redo surgery (SAVR) or valve-in-valve TAVR for failed bioprosthetic valves</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Absent clicks = obstruction:</strong> Mechanical valve clicks should be audible. Muffled/absent = suspect thrombosis</li>
            <li><strong>Check the INR:</strong> Most mechanical valve thromboses occur with subtherapeutic anticoagulation</li>
            <li><strong>TEE for endocarditis:</strong> TTE misses many prosthetic valve vegetations due to shadowing</li>
            <li><strong>Hemolysis = paravalvular leak:</strong> Unexplained anemia with elevated LDH/retics in prosthetic valve patient</li>
            <li><strong>Bioprosthetic durability:</strong> ~10-15 years â€” earlier failure in younger patients, dialysis patients</li>
            <li><strong>PVE is dangerous:</strong> Mortality 20-40%. Low threshold for surgery</li>
        </ul>
    </div>
</div>
<!-- BUILD #26 - NEUROLOGY CONDITIONS (303-306) -->

<!-- PRES -->
<div id="pres" class="condition-page">
    <div class="page-header">
        <h2>303. PRES (Posterior Reversible Encephalopathy Syndrome)</h2>
        <div class="subtitle">Hypertensive Emergency Neurologic Complication</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Tetrad:</span> Headache, altered mental status, seizures, visual disturbances</p>
            <p><span class="label">Visual Symptoms:</span> Cortical blindness, visual field deficits, blurred vision (posterior circulation involvement)</p>
            <p><span class="label">Seizures:</span> Occur in 60-75% of cases; may be presenting symptom</p>
            
            <p><span class="label">Risk Factors/Triggers:</span></p>
            <ul>
                <li><strong>Hypertension:</strong> Hypertensive emergency most common; but 20-30% have normal BP!</li>
                <li><strong>Preeclampsia/Eclampsia:</strong> Leading cause in pregnancy</li>
                <li><strong>Immunosuppressants:</strong> Cyclosporine, tacrolimus, sirolimus</li>
                <li><strong>Chemotherapy:</strong> Cisplatin, bevacizumab, tyrosine kinase inhibitors</li>
                <li><strong>Renal disease:</strong> Uremia, dialysis</li>
                <li><strong>Autoimmune:</strong> SLE, thrombotic microangiopathies (TTP, HUS)</li>
                <li><strong>Sepsis, organ transplantation</strong></li>
            </ul>
            
            <p><span class="label">Pathophysiology:</span> Endothelial dysfunction â†’ failure of cerebral autoregulation â†’ vasogenic edema (predominantly posterior circulation)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">MRI Brain (Diagnostic Standard):</span></p>
            <ul>
                <li><strong>Classic:</strong> Bilateral symmetric T2/FLAIR hyperintensities in parietal-occipital white matter</li>
                <li><strong>Other locations:</strong> Frontal, temporal, brainstem, cerebellum (not limited to posterior)</li>
                <li><strong>DWI:</strong> Usually normal or shows facilitated diffusion (vasogenic, not cytotoxic edema)</li>
                <li><strong>Important:</strong> Restricted diffusion = infarction = irreversible damage</li>
            </ul>
            
            <p><span class="label">CT Head:</span> May show hypodensities but less sensitive than MRI</p>
            
            <p><span class="label">Labs:</span> BMP, LFTs, CBC, UA, drug levels (cyclosporine, tacrolimus), uric acid (preeclampsia)</p>
            
            <p><span class="label">Differential:</span> CVA/stroke, venous sinus thrombosis, encephalitis, metabolic encephalopathy</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Blood Pressure Control:</span></p>
            <ul>
                <li>Goal: Reduce MAP by 20-25% over first few hours</li>
                <li><strong>IV agents:</strong> Nicardipine, labetalol, clevidipine</li>
                <li><strong>Eclampsia:</strong> Magnesium sulfate + hydralazine or labetalol + delivery</li>
                <li><strong>Avoid:</strong> Precipitous BP drops (can cause watershed infarcts)</li>
            </ul>
            
            <p><span class="label">2. Seizure Management:</span></p>
            <ul>
                <li>Benzodiazepines for acute seizures</li>
                <li>Levetiracetam, phenytoin, or lacosamide for seizure prophylaxis</li>
                <li>AEDs often not needed long-term once PRES resolves</li>
            </ul>
            
            <p><span class="label">3. Remove/Treat Underlying Cause:</span></p>
            <ul>
                <li>Discontinue or reduce offending immunosuppressant</li>
                <li>Deliver fetus in eclampsia</li>
                <li>Treat underlying infection, autoimmune condition</li>
            </ul>
            
            <p><span class="label">4. Supportive Care:</span></p>
            <ul>
                <li>ICU monitoring for severe cases</li>
                <li>Manage increased ICP if present</li>
            </ul>
            
            <p><span class="label">Prognosis:</span> Generally reversible with treatment within days to weeks; MRI normalizes. Permanent deficits if cytotoxic edema/infarction develops</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Not always posterior:</strong> Can involve frontal lobes, brainstem â€” "PRES" is a misnomer</li>
            <li><strong>Not always hypertensive:</strong> 20-30% have normal BP at presentation</li>
            <li><strong>DWI is key:</strong> Restricted diffusion = cytotoxic edema = worse prognosis (infarct, not reversible)</li>
            <li><strong>Think immunosuppressants:</strong> Calcineurin inhibitors (cyclosporine, tacrolimus) are common culprits</li>
            <li><strong>Eclampsia is PRES:</strong> Classic PRES trigger â€” treat with magnesium + delivery</li>
            <li><strong>Can recur:</strong> Especially if underlying condition not addressed</li>
        </ul>
    </div>
</div>

<!-- OSMOTIC DEMYELINATION SYNDROME -->
<div id="osmotic-demyelination" class="condition-page">
    <div class="page-header">
        <h2>304. OSMOTIC DEMYELINATION SYNDROME (ODS)</h2>
        <div class="subtitle">Central Pontine Myelinolysis (CPM) â€¢ Sodium Correction Injury</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Timeline:</span> Symptoms develop 2-6 days AFTER overly rapid sodium correction</p>
            <p><span class="label">Biphasic Course:</span></p>
            <ul>
                <li><strong>Phase 1:</strong> Initial improvement as hyponatremia corrects</li>
                <li><strong>Phase 2 (day 2-6):</strong> Neurologic deterioration â€” dysarthria, dysphagia, quadriparesis</li>
            </ul>
            
            <p><span class="label">Central Pontine Myelinolysis:</span></p>
            <ul>
                <li>Spastic quadriparesis, pseudobulbar palsy (dysarthria, dysphagia)</li>
                <li><strong>"Locked-in syndrome":</strong> Severe cases â€” awake but unable to move except eye movements</li>
            </ul>
            
            <p><span class="label">Extrapontine Myelinolysis (EPM):</span> Movement disorders, ataxia, cognitive changes (basal ganglia, thalamus involvement)</p>
            
            <p><span class="label">High-Risk Patients:</span></p>
            <ul>
                <li>Chronic alcoholism, malnutrition</li>
                <li>Liver transplantation</li>
                <li>Hypokalemia (concurrent)</li>
                <li>Severely hyponatremic (&lt;105 mEq/L) or chronic hyponatremia (&gt;48h)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">MRI Brain (Diagnostic Standard):</span></p>
            <ul>
                <li><strong>Classic "trident" or "bat wing":</strong> T2/FLAIR hyperintensity in central pons, sparing periphery</li>
                <li><strong>EPM:</strong> Symmetric lesions in basal ganglia, thalami, cerebral white matter</li>
                <li><strong>Timing:</strong> MRI may be NORMAL in first 2 weeks; repeat if clinical suspicion high</li>
                <li>DWI may show early changes before T2/FLAIR</li>
            </ul>
            
            <p><span class="label">Review Sodium Correction:</span> Calculate rate of sodium rise â€” was it too fast?</p>
            <p><span class="label">Safe Correction Rate:</span> â‰¤10 mEq/L in first 24h, â‰¤18 mEq/L in first 48h (some recommend â‰¤8 mEq/L in high-risk patients)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PREVENTION & TREATMENT</div>
        <div class="section-content">
            <p><span class="label">PREVENTION IS KEY:</span></p>
            <ul>
                <li><strong>Monitor sodium frequently</strong> during correction (q2-4h)</li>
                <li><strong>Goal:</strong> Raise sodium â‰¤10 mEq/L in 24 hours, â‰¤8 mEq/L in high-risk patients</li>
                <li><strong>If overcorrecting:</strong> D5W infusion Â± DDAVP to re-lower sodium</li>
            </ul>
            
            <p><span class="label">Rescue Therapy (If Overcorrection Detected):</span></p>
            <ul>
                <li><strong>D5W:</strong> 3 mL/kg/hr to lower sodium back</li>
                <li><strong>DDAVP:</strong> 2-4 mcg IV/SQ to prevent free water excretion</li>
                <li>Target: Re-lower sodium to stay within safe correction limits</li>
            </ul>
            
            <p><span class="label">Treatment of Established ODS:</span></p>
            <ul>
                <li>No proven specific treatment</li>
                <li>Supportive care, rehabilitation</li>
                <li><strong>Plasmapheresis:</strong> Anecdotal reports, not proven</li>
                <li><strong>Steroids:</strong> Sometimes used, no clear evidence</li>
            </ul>
            
            <p><span class="label">Prognosis:</span></p>
            <ul>
                <li>Previously considered uniformly fatal</li>
                <li>Now: Many patients improve over weeks to months with supportive care</li>
                <li>Full recovery possible in some; others have permanent deficits</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Prevention, prevention, prevention:</strong> ODS is almost entirely iatrogenic. Monitor sodium closely during correction</li>
            <li><strong>10 in 24, 18 in 48:</strong> Safe sodium correction limits. Use 8 in 24 for high-risk patients</li>
            <li><strong>Biphasic course is classic:</strong> Initial improvement then deterioration days later</li>
            <li><strong>MRI may be negative early:</strong> Changes may not appear for 2 weeks. Repeat MRI if suspicious</li>
            <li><strong>DDAVP rescue:</strong> If correcting too fast, give DDAVP + D5W to re-lower sodium</li>
            <li><strong>Not always fatal:</strong> With supportive care, many patients have meaningful recovery</li>
        </ul>
    </div>
</div>

<!-- IIH (PSEUDOTUMOR CEREBRI) -->
<div id="iih" class="condition-page">
    <div class="page-header">
        <h2>305. IIH (Idiopathic Intracranial Hypertension)</h2>
        <div class="subtitle">Pseudotumor Cerebri â€¢ Elevated ICP Without Mass</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Patient:</span> Obese woman of childbearing age with headache and papilledema</p>
            <p><span class="label">Headache:</span> Daily, generalized or retro-orbital, worse with Valsalva, may wake from sleep, positional component</p>
            
            <p><span class="label">Visual Symptoms:</span></p>
            <ul>
                <li><strong>Transient visual obscurations:</strong> Brief (seconds) episodes of vision loss, often with position changes</li>
                <li><strong>Diplopia:</strong> CN VI palsy (false localizing sign from elevated ICP)</li>
                <li><strong>Permanent vision loss:</strong> Can occur without treatment â€” optic nerve damage</li>
            </ul>
            
            <p><span class="label">Other Symptoms:</span> Pulsatile tinnitus (whooshing in ears), neck/back pain, nausea</p>
            
            <p><span class="label">Papilledema:</span> Bilateral in >95% â€” MUST examine fundi</p>
            
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li><strong>Obesity:</strong> 90%+ of patients; weight gain often precedes symptoms</li>
                <li><strong>Female sex, reproductive age</strong></li>
                <li><strong>Medications:</strong> Vitamin A, tetracyclines (minocycline, doxycycline), growth hormone, lithium</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC CRITERIA (Modified Dandy)</div>
        <div class="section-content">
            <p><span class="label">Required:</span></p>
            <ul>
                <li>Signs/symptoms of elevated ICP (headache, papilledema, CN VI palsy)</li>
                <li><strong>Elevated opening pressure on LP:</strong> >250 mm Hâ‚‚O (lateral decubitus)</li>
                <li>Normal CSF composition</li>
                <li>No other cause identified (normal neuroimaging, no mass, no venous thrombosis)</li>
            </ul>
            
            <p><span class="label">MRI Brain + MRV:</span></p>
            <ul>
                <li>Rule out mass, hydrocephalus, venous sinus thrombosis</li>
                <li><strong>IIH findings:</strong> Empty sella, flattened posterior globes, optic nerve sheath distension, transverse sinus stenosis</li>
            </ul>
            
            <p><span class="label">Lumbar Puncture:</span></p>
            <ul>
                <li>Opening pressure >250 mm Hâ‚‚O (some use >200 with symptoms)</li>
                <li>Normal CSF protein, glucose, cell count</li>
                <li>Diagnostic AND therapeutic (temporary symptom relief)</li>
            </ul>
            
            <p><span class="label">Visual Assessment:</span> Formal visual field testing (Humphrey), OCT â€” baseline and serial monitoring</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Weight Loss:</span></p>
            <ul>
                <li>Most effective long-term treatment</li>
                <li>5-10% weight loss often produces significant improvement</li>
                <li>Consider bariatric surgery referral for severe cases</li>
            </ul>
            
            <p><span class="label">2. Acetazolamide (First-Line Medical Therapy):</span></p>
            <ul>
                <li>Carbonic anhydrase inhibitor â€” decreases CSF production</li>
                <li><strong>Dose:</strong> Start 500 mg BID, titrate to 1-2 g/day (max 4 g/day)</li>
                <li><strong>Side effects:</strong> Paresthesias, dysgeusia, metabolic acidosis, nephrolithiasis</li>
            </ul>
            
            <p><span class="label">3. Topiramate (Alternative):</span></p>
            <ul>
                <li>Weak carbonic anhydrase inhibitor + promotes weight loss</li>
                <li>May be preferred if weight loss desired</li>
            </ul>
            
            <p><span class="label">4. Stop Offending Medications:</span> Vitamin A, tetracyclines, growth hormone</p>
            
            <p><span class="label">5. Surgical Options (Vision-Threatening or Refractory):</span></p>
            <ul>
                <li><strong>Optic nerve sheath fenestration:</strong> Directly protects optic nerve</li>
                <li><strong>CSF shunting:</strong> Ventriculoperitoneal or lumboperitoneal shunt</li>
                <li><strong>Venous sinus stenting:</strong> If significant transverse sinus stenosis</li>
            </ul>
            
            <p><span class="label">Monitoring:</span> Serial visual field testing and OCT â€” vision loss can be permanent!</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Check the fundi:</strong> Papilledema is the key finding â€” don't miss it!</li>
            <li><strong>Vision loss is real:</strong> Despite "benign" ICP elevation, permanent optic nerve damage occurs. Monitor closely</li>
            <li><strong>Transient visual obscurations:</strong> Classic symptom â€” brief blackouts of vision with position change</li>
            <li><strong>Weight loss works:</strong> Even 5-10% weight loss can resolve symptoms</li>
            <li><strong>Rule out venous thrombosis:</strong> MRV is essential â€” cerebral venous thrombosis mimics IIH</li>
            <li><strong>LP is diagnostic AND therapeutic:</strong> Provides immediate (temporary) relief</li>
        </ul>
    </div>
</div>

<!-- MEDICATION OVERUSE HEADACHE -->
<div id="medication-overuse-headache" class="condition-page">
    <div class="page-header">
        <h2>306. MEDICATION OVERUSE HEADACHE (MOH)</h2>
        <div class="subtitle">Rebound Headache â€¢ Analgesic Overuse</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Chronic daily headache (â‰¥15 days/month) in patient with pre-existing headache disorder who overuses acute medications</p>
            <p><span class="label">Pattern:</span> Worsening headache frequency â†’ increased medication use â†’ more headaches (vicious cycle)</p>
            <p><span class="label">Morning headache:</span> Often present upon waking (medication wearing off)</p>
            
            <p><span class="label">Medication Thresholds for Overuse:</span></p>
            <ul>
                <li><strong>Simple analgesics (acetaminophen, NSAIDs):</strong> â‰¥15 days/month</li>
                <li><strong>Triptans:</strong> â‰¥10 days/month</li>
                <li><strong>Opioids:</strong> â‰¥10 days/month</li>
                <li><strong>Combination analgesics (butalbital-containing):</strong> â‰¥10 days/month</li>
                <li><strong>Ergots:</strong> â‰¥10 days/month</li>
            </ul>
            
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li>Pre-existing migraine or tension-type headache</li>
                <li>History of anxiety, depression</li>
                <li>Escalating use of acute medications</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC CRITERIA (ICHD-3)</div>
        <div class="section-content">
            <p><span class="label">Criteria:</span></p>
            <ul>
                <li>Headache present â‰¥15 days/month</li>
                <li>Pre-existing headache disorder</li>
                <li>Regular overuse of acute headache medication for >3 months</li>
                <li>Headache not better accounted for by another diagnosis</li>
            </ul>
            
            <p><span class="label">Highest Risk Medications:</span></p>
            <ul>
                <li><strong>Opioids:</strong> Highest risk of MOH, hardest to withdraw</li>
                <li><strong>Butalbital combinations:</strong> Very high risk</li>
                <li><strong>Triptans:</strong> Moderate risk (but may be easier to withdraw)</li>
                <li><strong>NSAIDs/Acetaminophen:</strong> Lower risk but still occurs</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Education:</span></p>
            <ul>
                <li>Explain the cycle of medication overuse and rebound</li>
                <li>Set expectations: Initial worsening (1-2 weeks) before improvement</li>
                <li>Most patients improve within 2 months of withdrawal</li>
            </ul>
            
            <p><span class="label">2. Withdrawal Approaches:</span></p>
            <ul>
                <li><strong>Abrupt withdrawal:</strong> Preferred for most (triptans, NSAIDs, acetaminophen)</li>
                <li><strong>Gradual taper:</strong> Required for opioids, butalbital (withdrawal symptoms)</li>
                <li><strong>Inpatient detox:</strong> Consider for severe cases, opioid dependence, failed outpatient attempts</li>
            </ul>
            
            <p><span class="label">3. Bridge Therapy (During Withdrawal):</span></p>
            <ul>
                <li><strong>NSAIDs (scheduled):</strong> Naproxen 500 mg BID for 1-2 weeks (if not overusing NSAIDs)</li>
                <li><strong>Steroids:</strong> Prednisone 60-80 mg Ã— 2-5 days taper (limited evidence)</li>
                <li><strong>Anti-emetics:</strong> PRN for nausea</li>
                <li><strong>DHE infusion:</strong> Consider for inpatient protocol</li>
            </ul>
            
            <p><span class="label">4. Start Preventive Therapy:</span></p>
            <ul>
                <li>Begin during or shortly after withdrawal</li>
                <li>Options: Topiramate, amitriptyline, propranolol, CGRP monoclonal antibodies</li>
                <li>CGRP antagonists may be effective even before withdrawal complete</li>
            </ul>
            
            <p><span class="label">5. Limit Future Acute Medication Use:</span></p>
            <ul>
                <li>Restrict acute medications to â‰¤2 days/week</li>
                <li>Keep headache diary</li>
                <li>Avoid butalbital and opioids for primary headaches</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Ask about medication use:</strong> Many patients don't recognize overuse as the problem</li>
            <li><strong>Opioids are worst:</strong> Highest risk of MOH, hardest to withdraw, least effective for headache</li>
            <li><strong>Warn about worsening:</strong> First 1-2 weeks after withdrawal are usually worse before better</li>
            <li><strong>â‰¤2 days/week rule:</strong> After recovery, acute medications should be used â‰¤2 days/week to prevent recurrence</li>
            <li><strong>Preventive therapy is key:</strong> Must address underlying headache disorder, not just stop the overused medication</li>
            <li><strong>CGRP antibodies help:</strong> Newer agents (erenumab, fremanezumab) effective for MOH prevention</li>
        </ul>
    </div>
</div>
<!-- BUILD #26 - HEMATOLOGY/ONCOLOGY CONDITIONS (307-309) -->

<!-- HLH -->
<div id="hlh" class="condition-page">
    <div class="page-header">
        <h2>307. HLH (Hemophagocytic Lymphohistiocytosis)</h2>
        <div class="subtitle">Cytokine Storm Syndrome â€¢ Life-Threatening Hyperinflammation</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Persistent fever, cytopenias, hepatosplenomegaly, multi-organ dysfunction</p>
            <p><span class="label">Systemic Inflammation:</span> Often mimics sepsis or severe infection with rapid deterioration</p>
            
            <p><span class="label">Key Features:</span></p>
            <ul>
                <li><strong>Fever:</strong> Prolonged, high-grade, unresponsive to antibiotics</li>
                <li><strong>Hepatosplenomegaly:</strong> Present in >90%</li>
                <li><strong>Cytopenias:</strong> â‰¥2 cell lines affected (anemia, thrombocytopenia, neutropenia)</li>
                <li><strong>CNS involvement:</strong> Altered mental status, seizures (30-50%)</li>
                <li><strong>Coagulopathy:</strong> DIC-like picture, hypofibrinogenemia</li>
            </ul>
            
            <p><span class="label">Triggers (Secondary HLH in Adults):</span></p>
            <ul>
                <li><strong>Infections:</strong> EBV (most common), CMV, HIV, other viruses; bacterial, fungal</li>
                <li><strong>Malignancy:</strong> Lymphoma (especially T-cell, NK-cell), leukemia</li>
                <li><strong>Autoimmune:</strong> SLE, Adult-onset Still's disease, sJIA â†’ "MAS" (macrophage activation syndrome)</li>
                <li><strong>Medications:</strong> Immunosuppressants, checkpoint inhibitors</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">HLH-2004 Criteria (â‰¥5 of 8):</span></p>
            <ul>
                <li>Fever â‰¥38.5Â°C</li>
                <li>Splenomegaly</li>
                <li>Cytopenias (â‰¥2 lines): Hgb <9, Plt <100K, ANC <1K</li>
                <li><strong>Hypertriglyceridemia â‰¥265 mg/dL OR hypofibrinogenemia <150 mg/dL</strong></li>
                <li><strong>Hemophagocytosis</strong> in bone marrow, spleen, or lymph nodes</li>
                <li><strong>Low/absent NK-cell activity</strong></li>
                <li><strong>Ferritin â‰¥500 ng/mL</strong> (often >10,000 â€” very elevated ferritin is clue!)</li>
                <li><strong>Elevated soluble CD25 (sIL-2R) â‰¥2,400 U/mL</strong></li>
            </ul>
            
            <p><span class="label">H-Score Calculator:</span> Clinical scoring system; score >169 = 93% probability of HLH</p>
            
            <p><span class="label">Key Labs:</span></p>
            <ul>
                <li><strong>Ferritin:</strong> Often >10,000 (very high = think HLH); ferritin >500 is criterion</li>
                <li><strong>Triglycerides:</strong> Elevated</li>
                <li><strong>Fibrinogen:</strong> Low (unusual in other inflammatory states)</li>
                <li><strong>LDH:</strong> Very elevated</li>
                <li><strong>Soluble IL-2 receptor:</strong> Markedly elevated</li>
                <li><strong>D-dimer:</strong> Elevated</li>
            </ul>
            
            <p><span class="label">Bone Marrow Biopsy:</span> May show hemophagocytosis, but absence doesn't rule out HLH</p>
            
            <p><span class="label">Workup for Trigger:</span> EBV/CMV viral loads, HIV, CT for lymphoma, PET scan, autoimmune serologies</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Urgency:</span> HLH is rapidly fatal without treatment â€” mortality >50% untreated. Do not wait for all criteria</p>
            
            <p><span class="label">1. Treat Underlying Trigger:</span></p>
            <ul>
                <li>Treat infection (antivirals for EBV/CMV)</li>
                <li>Chemotherapy for malignancy-associated HLH</li>
                <li>Discontinue offending medications</li>
            </ul>
            
            <p><span class="label">2. Immunosuppression (HLH-94/2004 Protocol):</span></p>
            <ul>
                <li><strong>Dexamethasone:</strong> 10 mg/mÂ² (potent CNS penetration)</li>
                <li><strong>Etoposide:</strong> 150 mg/mÂ² twice weekly initially</li>
                <li><strong>Cyclosporine A:</strong> Added at week 9 or earlier</li>
                <li><strong>Intrathecal methotrexate + hydrocortisone:</strong> If CNS involvement</li>
            </ul>
            
            <p><span class="label">3. Alternative/Newer Therapies:</span></p>
            <ul>
                <li><strong>Anakinra:</strong> IL-1 receptor antagonist â€” especially for MAS/autoimmune HLH</li>
                <li><strong>Ruxolitinib:</strong> JAK inhibitor â€” increasing use for refractory HLH</li>
                <li><strong>Emapalumab:</strong> Anti-interferon-gamma â€” FDA approved for primary HLH</li>
            </ul>
            
            <p><span class="label">4. Supportive Care:</span></p>
            <ul>
                <li>ICU monitoring</li>
                <li>Transfusion support, coagulopathy management</li>
                <li>IVIG sometimes used (especially if infection-triggered)</li>
            </ul>
            
            <p><span class="label">5. Consider Allogeneic HSCT:</span> For primary/familial HLH or refractory cases</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Sky-high ferritin:</strong> Ferritin >10,000 is highly specific for HLH. Think HLH when ferritin very elevated</li>
            <li><strong>Low fibrinogen paradox:</strong> Inflammatory state with LOW fibrinogen is unusual â€” suggests HLH or DIC</li>
            <li><strong>Don't wait for hemophagocytosis:</strong> Bone marrow hemophagocytosis absent in 20-30% â€” treat based on clinical picture</li>
            <li><strong>Find the trigger:</strong> EBV and lymphoma are common in adults â€” PET scan, viral PCRs</li>
            <li><strong>HLH vs sepsis:</strong> Both cause cytopenias, organ failure; HLH has very high ferritin, low fibrinogen, splenomegaly</li>
            <li><strong>Rapid treatment:</strong> HLH is a medical emergency â€” mortality is high without immunosuppression</li>
        </ul>
    </div>
</div>

<!-- IRON DEFICIENCY ANEMIA -->
<div id="iron-deficiency-anemia" class="condition-page">
    <div class="page-header">
        <h2>308. IRON DEFICIENCY ANEMIA</h2>
        <div class="subtitle">Most Common Anemia Worldwide â€¢ GI Evaluation Required</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Symptoms:</span> Fatigue, dyspnea on exertion, palpitations, headache, dizziness</p>
            <p><span class="label">Specific to Iron Deficiency:</span></p>
            <ul>
                <li><strong>Pica:</strong> Craving non-food items (ice â€” pagophagia, dirt, starch)</li>
                <li><strong>Restless legs syndrome</strong></li>
                <li><strong>Koilonychia:</strong> Spoon-shaped nails (late finding)</li>
                <li><strong>Angular cheilitis, glossitis</strong></li>
                <li><strong>Plummer-Vinson syndrome:</strong> Esophageal web + IDA + dysphagia (rare)</li>
            </ul>
            
            <p><span class="label">Causes by Population:</span></p>
            <ul>
                <li><strong>Premenopausal women:</strong> Menstrual blood loss (most common)</li>
                <li><strong>Men and postmenopausal women:</strong> GI blood loss until proven otherwise</li>
                <li><strong>Dietary:</strong> Vegans, restrictive diets (less common in adults)</li>
                <li><strong>Malabsorption:</strong> Celiac disease, gastric bypass, H. pylori, PPI use</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">CBC:</span> Microcytic (low MCV), hypochromic anemia; elevated RDW</p>
            
            <p><span class="label">Iron Studies:</span></p>
            <ul>
                <li><strong>Serum iron:</strong> Low</li>
                <li><strong>Ferritin:</strong> Low (<30 ng/mL diagnostic; <15 very specific)</li>
                <li><strong>TIBC:</strong> Elevated (>400 mcg/dL)</li>
                <li><strong>Transferrin saturation:</strong> Low (<20%)</li>
            </ul>
            
            <p><span class="label">Ferritin Interpretation:</span></p>
            <ul>
                <li>Ferritin <15: Diagnostic for IDA</li>
                <li>Ferritin 15-30: Probable IDA</li>
                <li>Ferritin >100: IDA unlikely (but can occur with inflammation)</li>
                <li><strong>Note:</strong> Ferritin is acute phase reactant â€” can be "normal" in IDA + inflammation</li>
            </ul>
            
            <p><span class="label">Peripheral Smear:</span> Microcytic, hypochromic RBCs, pencil cells, target cells</p>
            
            <p><span class="label">Reticulocyte Count:</span> Inappropriately low for degree of anemia (inadequate response)</p>
            
            <p><span class="label">GI EVALUATION (Men and Postmenopausal Women):</span></p>
            <ul>
                <li><strong>Colonoscopy:</strong> Evaluate for colon cancer, polyps, angiodysplasia</li>
                <li><strong>EGD:</strong> Evaluate for gastric/esophageal pathology, H. pylori</li>
                <li><strong>Celiac serologies:</strong> TTG-IgA (malabsorption)</li>
                <li><strong>Consider capsule endoscopy:</strong> If upper and lower endoscopy negative (small bowel evaluation)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Oral Iron (First-Line for Mild-Moderate):</span></p>
            <ul>
                <li><strong>Ferrous sulfate:</strong> 325 mg (65 mg elemental iron) daily to TID</li>
                <li><strong>Every-other-day dosing:</strong> May improve absorption and tolerability</li>
                <li><strong>Take on empty stomach</strong> with vitamin C (enhances absorption)</li>
                <li><strong>Avoid:</strong> Antacids, PPIs, calcium, tea, coffee (inhibit absorption)</li>
                <li><strong>Duration:</strong> Continue 3-6 months after Hgb normalizes to replete stores</li>
            </ul>
            
            <p><span class="label">2. IV Iron (Indications):</span></p>
            <ul>
                <li>Oral iron intolerance or non-adherence</li>
                <li>Malabsorption (celiac, gastric bypass, IBD)</li>
                <li>Ongoing blood loss exceeding oral replacement</li>
                <li>CKD on dialysis or ESA therapy</li>
                <li>Need for rapid repletion (severe symptomatic anemia, preoperative)</li>
            </ul>
            
            <p><span class="label">IV Iron Formulations:</span></p>
            <ul>
                <li><strong>Iron sucrose:</strong> 200-300 mg per infusion, well tolerated</li>
                <li><strong>Ferric carboxymaltose (Injectafer):</strong> 750 mg Ã— 2 doses (can give full repletion in 2 visits)</li>
                <li><strong>Ferric derisomaltose (Monoferric):</strong> Single 1000 mg dose possible</li>
                <li><strong>Iron dextran:</strong> Test dose required, higher anaphylaxis risk</li>
            </ul>
            
            <p><span class="label">3. Treat Underlying Cause:</span></p>
            <ul>
                <li>Treat H. pylori if positive</li>
                <li>Gluten-free diet for celiac disease</li>
                <li>Manage menorrhagia (hormonal therapy, GYN evaluation)</li>
                <li>Surgical intervention for GI malignancy</li>
            </ul>
            
            <p><span class="label">Response Monitoring:</span></p>
            <ul>
                <li>Reticulocyte count rises in 3-5 days</li>
                <li>Hemoglobin rises 1-2 g/dL per month</li>
                <li>Recheck ferritin at 3 months (goal >100 for adequate stores)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>IDA in men = GI workup:</strong> Colon cancer until proven otherwise. Don't just give iron without investigating</li>
            <li><strong>Ferritin <30:</strong> Diagnostic for IDA in non-inflammatory states</li>
            <li><strong>Every-other-day dosing:</strong> Better absorbed than daily (hepcidin physiology)</li>
            <li><strong>Pica (especially ice craving):</strong> Highly specific for iron deficiency</li>
            <li><strong>Think celiac:</strong> Unexplained IDA, especially with diarrhea or family history â€” check TTG-IgA</li>
            <li><strong>IV iron is underused:</strong> Safe, effective, and faster than oral. Use it when indicated</li>
        </ul>
    </div>
</div>

<!-- PARANEOPLASTIC SYNDROMES -->
<div id="paraneoplastic" class="condition-page">
    <div class="page-header">
        <h2>309. PARANEOPLASTIC SYNDROMES</h2>
        <div class="subtitle">Remote Effects of Malignancy â€¢ Not Direct Tumor Invasion</div>
    </div>
    
    <div class="section">
        <div class="section-title">OVERVIEW</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Symptoms caused by tumor-secreted substances or immune cross-reactivity, NOT direct tumor invasion or metastasis</p>
            <p><span class="label">Importance:</span> May be presenting symptom of occult malignancy; can precede cancer diagnosis by months to years</p>
            <p><span class="label">Categories:</span> Endocrine, neurologic, hematologic, dermatologic, rheumatologic</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">ENDOCRINE PARANEOPLASTIC SYNDROMES</div>
        <div class="section-content">
            <p><span class="label">SIADH (Hyponatremia):</span></p>
            <ul>
                <li><strong>Cancer:</strong> Small cell lung cancer (most common), head/neck cancers</li>
                <li><strong>Mechanism:</strong> Ectopic ADH production</li>
                <li><strong>Treatment:</strong> Fluid restriction, treat underlying cancer</li>
            </ul>
            
            <p><span class="label">Hypercalcemia of Malignancy:</span></p>
            <ul>
                <li><strong>PTHrP:</strong> Squamous cell carcinomas (lung, head/neck, renal)</li>
                <li><strong>1,25-vitamin D:</strong> Lymphoma</li>
                <li><strong>Osteolytic metastases:</strong> Breast cancer, myeloma</li>
                <li><strong>Treatment:</strong> IV fluids, bisphosphonates, denosumab, calcitonin</li>
            </ul>
            
            <p><span class="label">Cushing Syndrome (Ectopic ACTH):</span></p>
            <ul>
                <li><strong>Cancer:</strong> Small cell lung cancer, carcinoid tumors, medullary thyroid</li>
                <li><strong>Features:</strong> Hypokalemia, hypertension, hyperglycemia (often without classic cushingoid features due to rapid onset)</li>
            </ul>
            
            <p><span class="label">Hypoglycemia (Non-islet Cell Tumor):</span></p>
            <ul>
                <li><strong>Cancer:</strong> Large mesenchymal tumors, hepatocellular carcinoma</li>
                <li><strong>Mechanism:</strong> IGF-2 secretion</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">NEUROLOGIC PARANEOPLASTIC SYNDROMES</div>
        <div class="section-content">
            <p><span class="label">Lambert-Eaton Myasthenic Syndrome (LEMS):</span></p>
            <ul>
                <li><strong>Cancer:</strong> Small cell lung cancer (60%)</li>
                <li><strong>Antibody:</strong> Anti-VGCC (voltage-gated calcium channel)</li>
                <li><strong>Features:</strong> Proximal weakness that IMPROVES with exercise, autonomic dysfunction, hyporeflexia</li>
                <li><strong>Diagnosis:</strong> EMG shows incremental response, anti-VGCC antibodies</li>
            </ul>
            
            <p><span class="label">Paraneoplastic Cerebellar Degeneration:</span></p>
            <ul>
                <li><strong>Cancer:</strong> Ovarian, breast, SCLC, Hodgkin lymphoma</li>
                <li><strong>Antibodies:</strong> Anti-Yo (ovarian/breast), Anti-Hu (SCLC)</li>
                <li><strong>Features:</strong> Rapidly progressive ataxia, dysarthria, nystagmus</li>
            </ul>
            
            <p><span class="label">Limbic Encephalitis:</span></p>
            <ul>
                <li><strong>Cancer:</strong> SCLC, testicular (seminoma), thymoma</li>
                <li><strong>Antibodies:</strong> Anti-Hu, Anti-NMDAR, Anti-LGI1</li>
                <li><strong>Features:</strong> Memory loss, seizures, psychiatric symptoms</li>
            </ul>
            
            <p><span class="label">Anti-NMDA Receptor Encephalitis:</span></p>
            <ul>
                <li><strong>Cancer:</strong> Ovarian teratoma (young women)</li>
                <li><strong>Features:</strong> Psychiatric symptoms â†’ seizures â†’ movement disorders â†’ autonomic instability</li>
                <li><strong>Treatment:</strong> Tumor removal, immunotherapy (IVIG, steroids, rituximab)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">OTHER PARANEOPLASTIC SYNDROMES</div>
        <div class="section-content">
            <p><span class="label">Dermatologic:</span></p>
            <ul>
                <li><strong>Acanthosis nigricans (malignant):</strong> GI adenocarcinomas (especially gastric)</li>
                <li><strong>Dermatomyositis:</strong> Various solid tumors (ovarian, lung, GI, breast)</li>
                <li><strong>Sweet syndrome:</strong> AML, MDS</li>
                <li><strong>Erythema gyratum repens:</strong> Lung, breast, GI cancers</li>
                <li><strong>Leser-TrÃ©lat sign:</strong> Explosive seborrheic keratoses â€” GI malignancy</li>
            </ul>
            
            <p><span class="label">Hematologic:</span></p>
            <ul>
                <li><strong>Polycythemia:</strong> Renal cell carcinoma, hepatocellular carcinoma (EPO production)</li>
                <li><strong>Thrombocytosis:</strong> Many solid tumors</li>
                <li><strong>Trousseau syndrome:</strong> Migratory superficial thrombophlebitis â€” pancreatic, lung cancer</li>
            </ul>
            
            <p><span class="label">Rheumatologic:</span></p>
            <ul>
                <li><strong>Hypertrophic osteoarthropathy:</strong> Lung cancer â€” digital clubbing, periostitis</li>
                <li><strong>Polymyalgia-like syndrome:</strong> Various malignancies</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Think cancer:</strong> Unexplained hyponatremia, hypercalcemia, or neurologic syndrome â†’ search for malignancy</li>
            <li><strong>SCLC is the "paraneoplastic cancer":</strong> Associated with SIADH, Cushing, LEMS, many neurologic syndromes</li>
            <li><strong>LEMS vs Myasthenia:</strong> LEMS improves with exercise, MG worsens. Check for SCLC in LEMS</li>
            <li><strong>Dermatomyositis:</strong> Cancer screening essential â€” CT chest/abdomen/pelvis, age-appropriate screening, consider PET</li>
            <li><strong>Anti-NMDAR encephalitis:</strong> Young woman with psychiatric symptoms â†’ check for ovarian teratoma</li>
            <li><strong>Treatment is cancer treatment:</strong> Paraneoplastic syndromes often improve with treatment of underlying malignancy</li>
        </ul>
    </div>
</div>
<!-- BUILD #26 - ENDOCRINE & PULMONARY CONDITIONS (310-313) -->

<!-- PRIMARY HYPERALDOSTERONISM -->
<div id="primary-hyperaldosteronism" class="condition-page">
    <div class="page-header">
        <h2>310. PRIMARY HYPERALDOSTERONISM</h2>
        <div class="subtitle">Conn Syndrome â€¢ Most Common Secondary Hypertension</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic:</span> Resistant hypertension + hypokalemia (but 50%+ have normal potassium)</p>
            <p><span class="label">Features:</span></p>
            <ul>
                <li>Resistant or severe hypertension (often requiring â‰¥3 medications)</li>
                <li>Hypokalemia (may be absent â€” don't exclude PA based on normal K)</li>
                <li>Metabolic alkalosis</li>
                <li>Muscle weakness, cramping (if significant hypokalemia)</li>
            </ul>
            
            <p><span class="label">Prevalence:</span> 5-10% of all hypertensive patients; 20% of resistant hypertension</p>
            
            <p><span class="label">Screening Indications (Endocrine Society Guidelines):</span></p>
            <ul>
                <li>Sustained BP >150/100 on 3 occasions</li>
                <li>Resistant hypertension (BP >140/90 despite 3 drugs including diuretic)</li>
                <li>Hypertension + hypokalemia (spontaneous or diuretic-induced)</li>
                <li>Hypertension + adrenal incidentaloma</li>
                <li>Hypertension + sleep apnea</li>
                <li>Family history of early-onset hypertension or stroke (<40 years)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Step 1: Screening â€” Aldosterone-to-Renin Ratio (ARR):</span></p>
            <ul>
                <li><strong>Positive screen:</strong> ARR >30 AND aldosterone >15 ng/dL</li>
                <li><strong>Conditions:</strong> Morning sample, seated, potassium repleted</li>
                <li><strong>Interfering medications:</strong></li>
                <ul>
                    <li>Stop spironolactone/eplerenone 4-6 weeks before</li>
                    <li>Stop other K-sparing diuretics, thiazides 2-4 weeks before</li>
                    <li>Beta-blockers lower renin â†’ false positive (continue if needed for BP)</li>
                    <li>ACEi/ARBs may cause false negatives (but can screen on them if ARR elevated)</li>
                </ul>
            </ul>
            
            <p><span class="label">Step 2: Confirmatory Testing (If Screening Positive):</span></p>
            <ul>
                <li><strong>Oral sodium loading test:</strong> 3 days high-salt diet, then 24h urine aldosterone (>12 mcg/24h = positive)</li>
                <li><strong>IV saline suppression test:</strong> 2L NS over 4 hours, then serum aldosterone (>10 ng/dL = positive)</li>
                <li><strong>Fludrocortisone suppression test:</strong> Alternative confirmatory test</li>
            </ul>
            
            <p><span class="label">Step 3: Subtype Differentiation:</span></p>
            <ul>
                <li><strong>CT Adrenals:</strong> Identify unilateral adenoma vs bilateral hyperplasia</li>
                <li><strong>Adrenal Vein Sampling (AVS):</strong> Gold standard for lateralization if surgery considered</li>
                <ul>
                    <li>Required if CT shows bilateral disease or normal adrenals</li>
                    <li>May skip if <35 years with clear unilateral adenoma</li>
                </ul>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Unilateral Disease (Adenoma/Unilateral Hyperplasia):</span></p>
            <ul>
                <li><strong>Laparoscopic adrenalectomy:</strong> Treatment of choice</li>
                <li>Cure/improvement of hypertension in 50-70%</li>
                <li>Pre-operative: MRA (spironolactone) to normalize potassium, improve BP</li>
            </ul>
            
            <p><span class="label">Bilateral Disease or Non-Surgical Candidates:</span></p>
            <ul>
                <li><strong>Mineralocorticoid receptor antagonists:</strong></li>
                <ul>
                    <li><strong>Spironolactone:</strong> 25-100 mg daily (start low, titrate); gynecomastia common</li>
                    <li><strong>Eplerenone:</strong> 25-50 mg BID; fewer anti-androgen effects, more expensive</li>
                </ul>
                <li>May need additional antihypertensives</li>
                <li>Monitor potassium (risk of hyperkalemia, especially with CKD)</li>
            </ul>
            
            <p><span class="label">Outcomes:</span></p>
            <ul>
                <li>Surgery cures hypokalemia in nearly all patients</li>
                <li>Hypertension cure rate depends on duration and severity pre-op</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Screen liberally:</strong> PA is underdiagnosed. Screen anyone with resistant HTN or HTN + hypokalemia</li>
            <li><strong>Normal K doesn't exclude PA:</strong> 50%+ of PA patients are normokalemic</li>
            <li><strong>ARR is a ratio:</strong> Low renin is the key finding â€” aldosterone may be only mildly elevated</li>
            <li><strong>Stop spironolactone before testing:</strong> Interferes with ARR for weeks</li>
            <li><strong>AVS before surgery:</strong> CT can miss small adenomas and misidentify incidentalomas â€” AVS confirms lateralization</li>
            <li><strong>Long-term CV benefit:</strong> Treating PA reduces CV events beyond BP control alone</li>
        </ul>
    </div>
</div>

<!-- CARCINOID SYNDROME -->
<div id="carcinoid" class="condition-page">
    <div class="page-header">
        <h2>311. CARCINOID SYNDROME</h2>
        <div class="subtitle">Neuroendocrine Tumor Hormone Excess â€¢ Serotonin-Mediated</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Triad:</span> Flushing, diarrhea, wheezing (but full triad uncommon)</p>
            
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li><strong>Flushing (90%):</strong> Episodic, dry (vs sweating), face/neck, triggered by alcohol, stress, tyramine-rich foods</li>
                <li><strong>Diarrhea (70%):</strong> Secretory, watery, can be severe</li>
                <li><strong>Bronchospasm (15%):</strong> Wheezing, dyspnea</li>
                <li><strong>Carcinoid heart disease (40-50%):</strong> Right-sided valvular disease (tricuspid regurgitation, pulmonic stenosis)</li>
            </ul>
            
            <p><span class="label">Key Point:</span> Carcinoid syndrome occurs only when tumor products reach systemic circulation</p>
            <ul>
                <li><strong>GI carcinoids:</strong> Syndrome occurs with LIVER METASTASES (hepatic metabolism normally clears serotonin)</li>
                <li><strong>Bronchial/ovarian carcinoids:</strong> Can cause syndrome without liver mets (drain directly to systemic circulation)</li>
            </ul>
            
            <p><span class="label">Carcinoid Crisis:</span></p>
            <ul>
                <li>Life-threatening release of vasoactive substances</li>
                <li>Triggers: Surgery, anesthesia, biopsy, chemoembolization</li>
                <li>Features: Severe hypotension/hypertension, flushing, bronchospasm, arrhythmias</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Biochemical Testing:</span></p>
            <ul>
                <li><strong>24-hour urine 5-HIAA:</strong> Serotonin metabolite; elevated in 70% with carcinoid syndrome</li>
                <li><strong>Plasma chromogranin A:</strong> Elevated in most NETs (not specific)</li>
                <li><strong>Serum serotonin:</strong> Less commonly used</li>
            </ul>
            
            <p><span class="label">Avoid Before Testing:</span> Tryptophan-rich foods (bananas, avocados, walnuts), medications (acetaminophen, cough syrups)</p>
            
            <p><span class="label">Localization:</span></p>
            <ul>
                <li><strong>CT/MRI:</strong> Identify primary tumor, liver metastases</li>
                <li><strong>Octreotide scan (Octreoscan):</strong> Somatostatin receptor scintigraphy</li>
                <li><strong>Ga-68 DOTATATE PET/CT:</strong> Superior sensitivity for somatostatin receptor-positive tumors</li>
            </ul>
            
            <p><span class="label">Cardiac Evaluation:</span></p>
            <ul>
                <li><strong>Echocardiogram:</strong> Screen for carcinoid heart disease (tricuspid/pulmonic valve thickening)</li>
                <li>Obtain in all patients with carcinoid syndrome</li>
                <li>NT-proBNP and 5-HIAA levels correlate with cardiac involvement</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Somatostatin Analogs (First-Line for Symptoms):</span></p>
            <ul>
                <li><strong>Octreotide LAR:</strong> 20-30 mg IM every 4 weeks (long-acting)</li>
                <li><strong>Lanreotide:</strong> 120 mg deep SQ every 4 weeks</li>
                <li>Also have antiproliferative effect (slow tumor growth)</li>
                <li>For breakthrough: Octreotide 100-500 mcg SQ PRN</li>
            </ul>
            
            <p><span class="label">2. Carcinoid Crisis Prevention:</span></p>
            <ul>
                <li><strong>Pre-operative octreotide:</strong> 250-500 mcg IV bolus before any procedure</li>
                <li>Continuous infusion during surgery (50-100 mcg/hr)</li>
                <li>Avoid: Catecholamines, morphine, succinylcholine (can trigger crisis)</li>
            </ul>
            
            <p><span class="label">3. Managing Refractory Symptoms:</span></p>
            <ul>
                <li><strong>Telotristat:</strong> Tryptophan hydroxylase inhibitor for refractory diarrhea</li>
                <li><strong>Hepatic-directed therapy:</strong> Embolization, ablation, surgical debulking</li>
            </ul>
            
            <p><span class="label">4. Tumor-Directed Therapy:</span></p>
            <ul>
                <li><strong>Surgery:</strong> Resection of primary and/or metastases when feasible</li>
                <li><strong>PRRT:</strong> Lutetium-177 DOTATATE for progressive disease</li>
                <li><strong>Everolimus, sunitinib:</strong> For progressive NETs</li>
                <li><strong>Liver-directed:</strong> TACE, radioembolization, ablation</li>
            </ul>
            
            <p><span class="label">5. Carcinoid Heart Disease:</span></p>
            <ul>
                <li>Medical optimization, diuretics</li>
                <li>Valve surgery for severe symptomatic disease</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Liver mets = syndrome:</strong> GI carcinoids cause syndrome only after hepatic metastasis (liver normally clears serotonin)</li>
            <li><strong>Flushing is dry:</strong> Unlike pheochromocytoma (sweating), carcinoid flushing is typically dry</li>
            <li><strong>Right heart involvement:</strong> Serotonin damages right-sided valves â†’ tricuspid regurgitation most common</li>
            <li><strong>Octreotide before surgery:</strong> Always give octreotide prophylaxis before procedures to prevent carcinoid crisis</li>
            <li><strong>5-HIAA for diagnosis:</strong> 24-hour urine 5-HIAA is key diagnostic test</li>
            <li><strong>PRRT is effective:</strong> Lutetium-177 DOTATATE improves survival in progressive NETs</li>
        </ul>
    </div>
</div>

<!-- HEMOTHORAX -->
<div id="hemothorax" class="condition-page">
    <div class="page-header">
        <h2>312. HEMOTHORAX</h2>
        <div class="subtitle">Blood in Pleural Space â€¢ Trauma vs Spontaneous</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Symptoms:</span> Chest pain, dyspnea, tachycardia, hypotension (if massive)</p>
            <p><span class="label">Physical Exam:</span> Decreased breath sounds, dullness to percussion, tracheal deviation (massive)</p>
            
            <p><span class="label">Classification by Size:</span></p>
            <ul>
                <li><strong>Small:</strong> <300 mL</li>
                <li><strong>Moderate:</strong> 300-1000 mL</li>
                <li><strong>Massive:</strong> >1000-1500 mL (or >200 mL/hr output)</li>
            </ul>
            
            <p><span class="label">Etiology:</span></p>
            <ul>
                <li><strong>Traumatic (most common):</strong> Blunt or penetrating chest trauma, rib fractures</li>
                <li><strong>Iatrogenic:</strong> Central line placement, thoracentesis, chest tube, cardiac surgery</li>
                <li><strong>Spontaneous:</strong></li>
                <ul>
                    <li>Anticoagulation (warfarin, DOACs)</li>
                    <li>Malignancy (primary or metastatic)</li>
                    <li>Pulmonary embolism with infarction</li>
                    <li>Aortic dissection/rupture</li>
                    <li>Arteriovenous malformation</li>
                    <li>Coagulopathy, thrombocytopenia</li>
                </ul>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">CXR:</span> Blunting of costophrenic angle (>200-300 mL to visualize), opacification, meniscus sign</p>
            <p><span class="label">Ultrasound:</span> Sensitive for small effusions; echogenic fluid suggests blood</p>
            <p><span class="label">CT Chest:</span> Quantifies volume, identifies source, associated injuries</p>
            
            <p><span class="label">Pleural Fluid Analysis:</span></p>
            <ul>
                <li><strong>Hematocrit:</strong> Pleural fluid Hct >50% of peripheral blood Hct = hemothorax</li>
                <li>Bloody effusion (Hct <50%) can be from malignancy, PE, parapneumonic</li>
            </ul>
            
            <p><span class="label">Labs:</span> CBC (trending Hgb), coagulation studies, type & screen</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Resuscitation:</span></p>
            <ul>
                <li>Large-bore IV access, crystalloid resuscitation</li>
                <li>Blood transfusion as needed</li>
                <li>Correct coagulopathy (reverse anticoagulation if applicable)</li>
            </ul>
            
            <p><span class="label">2. Tube Thoracostomy (Chest Tube):</span></p>
            <ul>
                <li><strong>Indication:</strong> Most hemothoraces require drainage</li>
                <li><strong>Size:</strong> Large-bore (28-36 Fr) preferred for blood (clots clog small tubes)</li>
                <li><strong>Position:</strong> Posterior-lateral, 5th intercostal space</li>
                <li>Connect to drainage system, monitor output</li>
            </ul>
            
            <p><span class="label">3. Indications for Surgery (VATS or Thoracotomy):</span></p>
            <ul>
                <li><strong>Immediate thoracotomy:</strong></li>
                <ul>
                    <li>Initial output >1500 mL</li>
                    <li>Ongoing output >200 mL/hr for 2-4 hours</li>
                    <li>Hemodynamic instability despite resuscitation</li>
                </ul>
                <li><strong>VATS (Video-Assisted Thoracoscopic Surgery):</strong></li>
                <ul>
                    <li>Retained/clotted hemothorax (incomplete drainage)</li>
                    <li>Early VATS (within 3-7 days) reduces empyema risk</li>
                </ul>
            </ul>
            
            <p><span class="label">4. Complications:</span></p>
            <ul>
                <li><strong>Retained hemothorax:</strong> Leads to empyema, fibrothorax</li>
                <li><strong>Empyema:</strong> Infected hemothorax â€” requires drainage, antibiotics, possibly decortication</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>1500 mL or 200 mL/hr:</strong> Thresholds for surgical intervention â€” memorize these numbers</li>
            <li><strong>Large-bore chest tube:</strong> Use 28-36 Fr for hemothorax â€” small tubes clot off</li>
            <li><strong>Early VATS for retained:</strong> Don't wait â€” early evacuation prevents empyema and fibrothorax</li>
            <li><strong>Check pleural Hct:</strong> Hct >50% of blood Hct confirms hemothorax</li>
            <li><strong>Spontaneous hemothorax:</strong> Think anticoagulation, malignancy, aortic pathology</li>
            <li><strong>Complete evacuation:</strong> Goal is complete drainage â€” retained blood causes complications</li>
        </ul>
    </div>
</div>

<!-- CHYLOTHORAX -->
<div id="chylothorax" class="condition-page">
    <div class="page-header">
        <h2>313. CHYLOTHORAX</h2>
        <div class="subtitle">Lymphatic Fluid in Pleural Space â€¢ Thoracic Duct Injury</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Symptoms:</span> Progressive dyspnea, chest discomfort (typically non-painful)</p>
            <p><span class="label">Course:</span> May accumulate rapidly; significant nutritional and immune consequences</p>
            
            <p><span class="label">Etiology:</span></p>
            <ul>
                <li><strong>Traumatic/Surgical (50%):</strong></li>
                <ul>
                    <li>Thoracic surgery (esophagectomy, lung resection, cardiac surgery)</li>
                    <li>Central line placement (especially left subclavian)</li>
                    <li>Blunt/penetrating trauma</li>
                </ul>
                <li><strong>Non-traumatic (50%):</strong></li>
                <ul>
                    <li>Malignancy (lymphoma most common, lung cancer, metastatic)</li>
                    <li>Lymphangioleiomyomatosis (LAM)</li>
                    <li>Sarcoidosis, tuberculosis</li>
                    <li>Superior vena cava thrombosis</li>
                    <li>Congenital lymphatic abnormalities</li>
                </ul>
            </ul>
            
            <p><span class="label">Complications:</span></p>
            <ul>
                <li>Malnutrition (loss of proteins, fats, vitamins)</li>
                <li>Immunodeficiency (loss of T lymphocytes, immunoglobulins)</li>
                <li>Electrolyte abnormalities</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Pleural Fluid Appearance:</span> Milky, white, or turbid (if patient fasting, may be less milky)</p>
            
            <p><span class="label">Pleural Fluid Analysis:</span></p>
            <ul>
                <li><strong>Triglycerides >110 mg/dL:</strong> Diagnostic of chylothorax</li>
                <li><strong>Triglycerides <50 mg/dL:</strong> Rules out chylothorax</li>
                <li><strong>Triglycerides 50-110 mg/dL:</strong> Check lipoprotein electrophoresis for chylomicrons (definitive)</li>
                <li><strong>Chylomicrons present:</strong> Confirms chylothorax</li>
            </ul>
            
            <p><span class="label">Other Fluid Features:</span></p>
            <ul>
                <li>Lymphocyte-predominant (>80% lymphocytes)</li>
                <li>Exudative by Light's criteria</li>
                <li>pH >7.4, glucose similar to serum</li>
            </ul>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li>CT chest: Identify mass, lymphadenopathy, thoracic duct injury</li>
                <li>Lymphangiography: Can localize leak (rarely needed)</li>
            </ul>
            
            <p><span class="label">DDx for Milky Effusion:</span></p>
            <ul>
                <li><strong>Chylothorax:</strong> High triglycerides, chylomicrons present</li>
                <li><strong>Pseudochylothorax:</strong> High cholesterol (>200 mg/dL), cholesterol crystals; seen in chronic effusions (TB, RA)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Conservative Management (First-Line, 2-4 weeks):</span></p>
            <ul>
                <li><strong>Drainage:</strong> Chest tube or repeated thoracentesis</li>
                <li><strong>Dietary modification:</strong></li>
                <ul>
                    <li>NPO or low-fat diet with medium-chain triglycerides (MCT)</li>
                    <li>MCTs absorbed directly into portal circulation, bypass thoracic duct</li>
                </ul>
                <li><strong>TPN:</strong> If NPO required or high-output chyle leak</li>
                <li><strong>Octreotide:</strong> Reduces chyle production (decreases splanchnic blood flow)</li>
            </ul>
            
            <p><span class="label">2. Interventional/Surgical (If Conservative Fails):</span></p>
            <ul>
                <li><strong>Thoracic duct embolization:</strong> Interventional radiology; first-line invasive option</li>
                <li><strong>Thoracic duct ligation:</strong> VATS or open; if embolization fails/unavailable</li>
                <li><strong>Pleurodesis:</strong> For malignant or recurrent chylothorax</li>
                <li><strong>Pleuroperitoneal shunt:</strong> Refractory cases</li>
            </ul>
            
            <p><span class="label">3. Treat Underlying Cause:</span></p>
            <ul>
                <li>Chemotherapy/radiation for lymphoma</li>
                <li>Anticoagulation for SVC thrombosis</li>
            </ul>
            
            <p><span class="label">Nutritional Support:</span></p>
            <ul>
                <li>Monitor albumin, prealbumin, lymphocyte count</li>
                <li>Replace immunoglobulins if significantly depleted</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Triglycerides >110:</strong> Diagnostic cutoff for chylothorax â€” always check on milky effusion</li>
            <li><strong>Post-surgical:</strong> Consider chylothorax after esophagectomy, cardiac surgery, or central line placement</li>
            <li><strong>Lymphoma:</strong> Most common non-traumatic cause â€” look for mediastinal lymphadenopathy</li>
            <li><strong>MCT diet works:</strong> Medium-chain triglycerides bypass thoracic duct â†’ reduce chyle flow</li>
            <li><strong>Nutritional emergency:</strong> Losing chyle = losing protein, fat, lymphocytes. Support aggressively</li>
            <li><strong>Pseudochylothorax:</strong> Chronic effusions with high cholesterol, NOT triglycerides â€” different entity</li>
        </ul>
    </div>
</div>
<!-- BUILD #26 - NEPHROLOGY, PSYCHIATRY, CRITICAL CARE CONDITIONS (314-317) -->

<!-- RENAL VEIN THROMBOSIS -->
<div id="renal-vein-thrombosis" class="condition-page">
    <div class="page-header">
        <h2>314. RENAL VEIN THROMBOSIS</h2>
        <div class="subtitle">Nephrotic Syndrome Complication â€¢ Hypercoagulable State</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Acute RVT:</span> Flank pain, hematuria, acute kidney injury, nausea/vomiting</p>
            <p><span class="label">Chronic RVT:</span> Often asymptomatic; may present with pulmonary embolism or progressive renal dysfunction</p>
            
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li><strong>Nephrotic syndrome (most common in adults):</strong> Especially membranous nephropathy (highest risk)</li>
                <li>Malignancy (renal cell carcinoma with IVC extension)</li>
                <li>Trauma, surgery</li>
                <li>Severe dehydration (neonates)</li>
                <li>Hypercoagulable states (factor V Leiden, antiphospholipid syndrome)</li>
                <li>Oral contraceptives, pregnancy</li>
            </ul>
            
            <p><span class="label">Nephrotic Syndrome & Thrombosis:</span></p>
            <ul>
                <li>Loss of antithrombin III in urine</li>
                <li>Increased hepatic synthesis of procoagulant factors</li>
                <li>Membranous nephropathy has highest thrombosis risk (25-35%)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li>Urinalysis: Hematuria, proteinuria</li>
                <li>BMP: Acute rise in creatinine (especially bilateral RVT)</li>
                <li>LDH: Elevated in acute thrombosis</li>
                <li>D-dimer: Elevated (non-specific)</li>
            </ul>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>CT venography:</strong> Test of choice; filling defect in renal vein, enlarged kidney</li>
                <li><strong>Doppler ultrasound:</strong> Absent or reversed diastolic flow; less sensitive than CT</li>
                <li><strong>MR venography:</strong> Alternative if CT contrast contraindicated</li>
            </ul>
            
            <p><span class="label">Evaluate for Underlying Cause:</span></p>
            <ul>
                <li>24-hour urine protein if not already known</li>
                <li>Hypercoagulability workup (if not nephrotic)</li>
                <li>Consider renal malignancy (CT with contrast)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Anticoagulation (Mainstay of Treatment):</span></p>
            <ul>
                <li><strong>Acute:</strong> Heparin (UFH or LMWH) initially</li>
                <li><strong>Transition:</strong> Warfarin (target INR 2-3) or DOAC</li>
                <li><strong>Duration:</strong> Minimum 6 months; longer if underlying risk persists (e.g., ongoing nephrotic syndrome)</li>
            </ul>
            
            <p><span class="label">Thrombolysis/Thrombectomy (Rare Indications):</span></p>
            <ul>
                <li>Acute bilateral RVT with severe AKI</li>
                <li>Extension into IVC</li>
                <li>Failure of anticoagulation</li>
            </ul>
            
            <p><span class="label">Treat Underlying Condition:</span></p>
            <ul>
                <li>Immunosuppression for nephrotic syndrome (steroids, CNI, rituximab depending on etiology)</li>
                <li>Surgical resection for renal cell carcinoma</li>
            </ul>
            
            <p><span class="label">Prophylaxis in Nephrotic Syndrome:</span></p>
            <ul>
                <li>Consider prophylactic anticoagulation in membranous nephropathy with albumin <2.5 g/dL</li>
                <li>Risk-benefit analysis required (bleeding vs thrombosis risk)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Membranous = highest risk:</strong> Up to 35% develop VTE. Consider prophylactic anticoagulation if albumin <2.5</li>
            <li><strong>Often asymptomatic:</strong> Many cases discovered incidentally or when PE occurs</li>
            <li><strong>Think RVT:</strong> Nephrotic syndrome + flank pain or unexplained AKI worsening</li>
            <li><strong>Bilateral = AKI:</strong> Unilateral usually compensated; bilateral causes acute kidney injury</li>
            <li><strong>Anticoagulation duration:</strong> Continue as long as nephrotic state persists</li>
            <li><strong>Antithrombin III loss:</strong> Heparin may be less effective in severe nephrotic syndrome (AT-III depleted)</li>
        </ul>
    </div>
</div>

<!-- ATHEROEMBOLIC RENAL DISEASE -->
<div id="atheroembolic-renal" class="condition-page">
    <div class="page-header">
        <h2>315. ATHEROEMBOLIC RENAL DISEASE</h2>
        <div class="subtitle">Cholesterol Crystal Embolization â€¢ Post-Procedural AKI</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Scenario:</span> Elderly patient with atherosclerosis develops AKI days to weeks after arterial catheterization, vascular surgery, or anticoagulation initiation</p>
            
            <p><span class="label">Renal Manifestations:</span></p>
            <ul>
                <li>Subacute AKI: Progressive over weeks (contrast nephropathy improves; atheroemboli worsen)</li>
                <li>May be acute or chronic/stuttering course</li>
                <li>Proteinuria (usually subnephrotic)</li>
                <li>Hypertension (new or worsening)</li>
            </ul>
            
            <p><span class="label">Extra-Renal Manifestations:</span></p>
            <ul>
                <li><strong>Skin:</strong> Livedo reticularis, blue toe syndrome, digital gangrene, ulceration</li>
                <li><strong>GI:</strong> Abdominal pain, GI bleeding, pancreatitis</li>
                <li><strong>CNS:</strong> Stroke, TIA, confusion (if cerebral emboli)</li>
                <li><strong>Retinal:</strong> Hollenhorst plaques (cholesterol crystals in retinal arteries)</li>
            </ul>
            
            <p><span class="label">Triggers:</span></p>
            <ul>
                <li>Arterial catheterization (cardiac cath, angiography)</li>
                <li>Vascular surgery</li>
                <li>Anticoagulation initiation (destabilizes plaque)</li>
                <li>Thrombolytic therapy</li>
                <li>Spontaneous (rare)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Eosinophilia:</strong> Present in 60-80% (key clue!)</li>
                <li><strong>Eosinophiluria:</strong> May be present</li>
                <li><strong>Hypocomplementemia:</strong> Low C3, C4 (transient)</li>
                <li><strong>Elevated ESR/CRP</strong></li>
                <li>Progressive rise in creatinine over days to weeks</li>
            </ul>
            
            <p><span class="label">Tissue Diagnosis (Gold Standard):</span></p>
            <ul>
                <li><strong>Skin biopsy:</strong> If livedo or skin lesions present (least invasive)</li>
                <li><strong>Renal biopsy:</strong> Needle-shaped cholesterol clefts in arterioles (pathognomonic)</li>
                <li>Biopsy shows empty clefts (cholesterol dissolved during processing)</li>
            </ul>
            
            <p><span class="label">Clinical Diagnosis Often Made Without Biopsy:</span></p>
            <ul>
                <li>Typical clinical setting (recent procedure)</li>
                <li>Characteristic skin findings</li>
                <li>Eosinophilia + progressive AKI</li>
            </ul>
            
            <p><span class="label">Differentiate from Contrast Nephropathy:</span></p>
            <ul>
                <li>Contrast: Peaks 2-3 days, improves by 7-10 days</li>
                <li>Atheroemboli: Progressive worsening over weeks, systemic signs</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">No Specific Treatment â€” Supportive Care:</span></p>
            <ul>
                <li>Supportive renal care; dialysis if needed</li>
                <li>Blood pressure control</li>
                <li>Wound care for skin lesions</li>
            </ul>
            
            <p><span class="label">Controversial Interventions:</span></p>
            <ul>
                <li><strong>Statins:</strong> May stabilize plaque, possibly beneficial</li>
                <li><strong>Anticoagulation:</strong> Controversial â€” may trigger more emboli, but needed if other indication (AF, mechanical valve)</li>
                <li><strong>Steroids:</strong> Anecdotal benefit, not proven</li>
            </ul>
            
            <p><span class="label">Prevention:</span></p>
            <ul>
                <li>Minimize arterial manipulation in high-risk patients</li>
                <li>Radial (vs femoral) access when possible</li>
                <li>Statin therapy before procedures</li>
            </ul>
            
            <p><span class="label">Prognosis:</span></p>
            <ul>
                <li>Poor: 1-year mortality 60-80% in older series</li>
                <li>~30-40% require dialysis</li>
                <li>Spontaneous improvement can occur in some cases</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Blue toes, livedo, eosinophilia:</strong> Classic triad after arterial procedure = atheroemboli</li>
            <li><strong>Timing distinguishes:</strong> Contrast nephropathy improves by day 7-10; atheroemboli worsen progressively</li>
            <li><strong>Eosinophilia is key:</strong> Present in 60-80%; helps differentiate from other causes of AKI</li>
            <li><strong>Hollenhorst plaques:</strong> Fundoscopy may show cholesterol crystals in retinal arteries</li>
            <li><strong>Anticoagulation paradox:</strong> Can actually trigger atheroemboli by destabilizing plaque</li>
            <li><strong>Poor prognosis:</strong> Significant mortality â€” prevention is key</li>
        </ul>
    </div>
</div>

<!-- CATATONIA -->
<div id="catatonia" class="condition-page">
    <div class="page-header">
        <h2>316. CATATONIA</h2>
        <div class="subtitle">Psychomotor Syndrome â€¢ Medical Emergency</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Core Features (DSM-5 â€” â‰¥3 required):</span></p>
            <ul>
                <li><strong>Stupor:</strong> No psychomotor activity, not relating to environment</li>
                <li><strong>Catalepsy:</strong> Passive induction and maintenance of postures</li>
                <li><strong>Waxy flexibility:</strong> Slight resistance to positioning by examiner</li>
                <li><strong>Mutism:</strong> No or minimal verbal response</li>
                <li><strong>Negativism:</strong> Opposition or no response to instructions</li>
                <li><strong>Posturing:</strong> Spontaneous maintenance of posture against gravity</li>
                <li><strong>Mannerisms:</strong> Odd, circumstantial caricature of normal actions</li>
                <li><strong>Stereotypy:</strong> Repetitive, non-goal-directed movements</li>
                <li><strong>Agitation:</strong> Not influenced by external stimuli</li>
                <li><strong>Grimacing</strong></li>
                <li><strong>Echolalia:</strong> Mimicking another's speech</li>
                <li><strong>Echopraxia:</strong> Mimicking another's movements</li>
            </ul>
            
            <p><span class="label">Subtypes:</span></p>
            <ul>
                <li><strong>Retarded (hypokinetic):</strong> Stupor, mutism, immobility â€” most common</li>
                <li><strong>Excited (hyperkinetic):</strong> Agitation, stereotypies, impulsivity â€” can be dangerous</li>
                <li><strong>Malignant catatonia:</strong> Fever, autonomic instability, rigidity â€” medical emergency</li>
            </ul>
            
            <p><span class="label">Underlying Causes:</span></p>
            <ul>
                <li><strong>Psychiatric:</strong> Mood disorders (most common), schizophrenia, autism</li>
                <li><strong>Medical:</strong> Encephalitis (anti-NMDAR), seizures, metabolic (hepatic, uremic), drugs/toxins</li>
                <li><strong>Medication-induced:</strong> Neuroleptics (NMS overlap), withdrawal (benzodiazepines)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Bush-Francis Catatonia Rating Scale (BFCRS):</span></p>
            <ul>
                <li>Screening: 14 items (presence/absence)</li>
                <li>Score â‰¥2 = likely catatonia</li>
                <li>Full scale rates severity (23 items)</li>
            </ul>
            
            <p><span class="label">Lorazepam Challenge Test:</span></p>
            <ul>
                <li><strong>Procedure:</strong> Lorazepam 1-2 mg IV</li>
                <li><strong>Positive response:</strong> Marked improvement within 5-10 minutes</li>
                <li><strong>Diagnostic and therapeutic:</strong> Response supports catatonia diagnosis</li>
            </ul>
            
            <p><span class="label">Medical Workup (Rule Out Organic Causes):</span></p>
            <ul>
                <li>CBC, CMP, LFTs, TFTs, ammonia</li>
                <li>Urine drug screen</li>
                <li>Lumbar puncture (encephalitis, anti-NMDAR)</li>
                <li>MRI brain, EEG (nonconvulsive status epilepticus)</li>
                <li>CPK (elevated in malignant catatonia)</li>
            </ul>
            
            <p><span class="label">Differentiate Catatonia vs NMS:</span></p>
            <ul>
                <li>Both have rigidity, fever, autonomic instability</li>
                <li>NMS: Recent neuroleptic exposure, lead-pipe rigidity</li>
                <li>Catatonia: May have waxy flexibility, responds to benzodiazepines</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Benzodiazepines (First-Line):</span></p>
            <ul>
                <li><strong>Lorazepam:</strong> 1-2 mg IV/IM/PO q4-8h, titrate up to 8-24 mg/day</li>
                <li>Response often rapid (within hours)</li>
                <li>~70% respond to benzodiazepines</li>
                <li>Continue for days to weeks, then taper slowly</li>
            </ul>
            
            <p><span class="label">2. ECT (Electroconvulsive Therapy):</span></p>
            <ul>
                <li><strong>Indications:</strong> Benzodiazepine-resistant, malignant catatonia, severe/life-threatening</li>
                <li>Highly effective (>80% response)</li>
                <li>Bilateral electrode placement, daily treatments initially</li>
                <li>Often needed urgently â€” don't delay if not responding to benzos</li>
            </ul>
            
            <p><span class="label">3. Supportive Care:</span></p>
            <ul>
                <li>DVT prophylaxis (immobility risk)</li>
                <li>Nutrition: NG tube or TPN if prolonged mutism/refusal</li>
                <li>Monitor for aspiration, pressure ulcers</li>
                <li>Hydration, temperature management</li>
            </ul>
            
            <p><span class="label">4. Stop Offending Agents:</span></p>
            <ul>
                <li>Discontinue antipsychotics if NMS suspected</li>
                <li>Hold neuroleptics until catatonia resolves</li>
            </ul>
            
            <p><span class="label">5. Treat Underlying Cause:</span></p>
            <ul>
                <li>Immunotherapy for anti-NMDAR encephalitis</li>
                <li>Mood stabilizers/antidepressants once catatonia resolves</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Lorazepam challenge:</strong> Rapid improvement with 1-2 mg IV lorazepam is diagnostic AND therapeutic</li>
            <li><strong>Mood disorders > schizophrenia:</strong> Catatonia is more often from depression/bipolar than schizophrenia</li>
            <li><strong>Avoid antipsychotics initially:</strong> Can worsen catatonia or precipitate NMS</li>
            <li><strong>Malignant catatonia = emergency:</strong> Fever + rigidity + autonomic instability â†’ needs urgent ECT if not responding to benzos</li>
            <li><strong>Don't miss anti-NMDAR:</strong> Young woman with psychiatric symptoms â†’ check for ovarian teratoma, send antibodies</li>
            <li><strong>ECT works:</strong> Highly effective, even in treatment-resistant cases. Don't delay if benzos fail</li>
        </ul>
    </div>
</div>

<!-- MALIGNANT HYPERTHERMIA -->
<div id="malignant-hyperthermia" class="condition-page">
    <div class="page-header">
        <h2>317. MALIGNANT HYPERTHERMIA</h2>
        <div class="subtitle">Anesthetic Emergency â€¢ Hypermetabolic Crisis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Setting:</span> Occurs during or shortly after general anesthesia with triggering agents</p>
            
            <p><span class="label">Triggering Agents:</span></p>
            <ul>
                <li><strong>Volatile anesthetics:</strong> Sevoflurane, isoflurane, desflurane, halothane</li>
                <li><strong>Succinylcholine:</strong> Depolarizing neuromuscular blocker</li>
            </ul>
            
            <p><span class="label">Safe Agents:</span> Propofol, opioids, benzodiazepines, nitrous oxide, non-depolarizing NMBs</p>
            
            <p><span class="label">Clinical Features (in Order of Appearance):</span></p>
            <ul>
                <li><strong>Early:</strong></li>
                <ul>
                    <li>Masseter muscle rigidity (especially after succinylcholine) â€” may be first sign</li>
                    <li>Unexplained tachycardia</li>
                    <li>Rising ETCOâ‚‚ (earliest and most sensitive sign)</li>
                    <li>Tachypnea (in spontaneously breathing patients)</li>
                </ul>
                <li><strong>Progressive:</strong></li>
                <ul>
                    <li>Hyperthermia (may rise 1-2Â°C every 5 minutes)</li>
                    <li>Generalized muscle rigidity</li>
                    <li>Mottled skin, diaphoresis</li>
                </ul>
                <li><strong>Late:</strong></li>
                <ul>
                    <li>Rhabdomyolysis (massively elevated CPK)</li>
                    <li>Hyperkalemia â†’ arrhythmias</li>
                    <li>DIC, myoglobinuria, renal failure</li>
                    <li>Cardiac arrest</li>
                </ul>
            </ul>
            
            <p><span class="label">Genetics:</span> Autosomal dominant; RYR1 gene mutations (ryanodine receptor) most common</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Clinical Diagnosis (During Crisis):</span> Recognize pattern â€” rising ETCOâ‚‚, tachycardia, rigidity, hyperthermia in OR setting</p>
            
            <p><span class="label">Labs (During Crisis):</span></p>
            <ul>
                <li>ABG: Respiratory AND metabolic acidosis, hypercarbia</li>
                <li>Potassium: Hyperkalemia (life-threatening)</li>
                <li>CPK: Massively elevated (>10,000 to >100,000)</li>
                <li>Myoglobin: Elevated (myoglobinuria â†’ AKI)</li>
                <li>Lactate: Elevated</li>
                <li>Coagulation studies: May show DIC</li>
            </ul>
            
            <p><span class="label">Definitive Diagnosis (Post-Crisis Susceptibility Testing):</span></p>
            <ul>
                <li><strong>Caffeine-halothane contracture test (CHCT):</strong> Gold standard; muscle biopsy required</li>
                <li><strong>Genetic testing:</strong> RYR1 mutation testing; if positive, confirms susceptibility</li>
                <li>Test patient AND family members</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL (EMERGENCY)</div>
        <div class="section-content">
            <p><span class="label">1. STOP TRIGGERING AGENTS IMMEDIATELY:</span></p>
            <ul>
                <li>Discontinue volatile anesthetics and succinylcholine</li>
                <li>Hyperventilate with 100% Oâ‚‚ at high flows (â‰¥10 L/min)</li>
                <li>Do NOT delay surgery termination if possible</li>
            </ul>
            
            <p><span class="label">2. DANTROLENE (CRITICAL â€” GIVE IMMEDIATELY):</span></p>
            <ul>
                <li><strong>Dose:</strong> 2.5 mg/kg IV bolus</li>
                <li>Repeat every 5 minutes until symptoms resolve (up to 10 mg/kg or more)</li>
                <li>Continue 1 mg/kg q4-6h for 24-48 hours (recrudescence risk)</li>
                <li>Dantrolene is the specific antidote â€” mechanism: blocks calcium release from sarcoplasmic reticulum</li>
            </ul>
            
            <p><span class="label">3. Treat Hyperkalemia:</span></p>
            <ul>
                <li>Calcium chloride or gluconate (cardiac stabilization)</li>
                <li>Insulin + glucose</li>
                <li>Sodium bicarbonate</li>
                <li><strong>Avoid calcium channel blockers</strong> (interaction with dantrolene â†’ cardiovascular collapse)</li>
            </ul>
            
            <p><span class="label">4. Active Cooling:</span></p>
            <ul>
                <li>Cold IV saline</li>
                <li>Ice packs to axillae, groin</li>
                <li>Cooling blankets</li>
                <li>Target: <38.5Â°C</li>
            </ul>
            
            <p><span class="label">5. Treat Arrhythmias:</span></p>
            <ul>
                <li>Standard ACLS protocols</li>
                <li>Avoid calcium channel blockers</li>
            </ul>
            
            <p><span class="label">6. Prevent Renal Failure:</span></p>
            <ul>
                <li>Aggressive IV fluids</li>
                <li>Maintain UOP >2 mL/kg/hr (force diuresis)</li>
                <li>Consider mannitol or sodium bicarbonate for myoglobinuria</li>
            </ul>
            
            <p><span class="label">7. Monitor:</span> ICU admission, serial CPK, K, renal function, coags</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Rising ETCOâ‚‚ is earliest sign:</strong> Unexplained hypercarbia during anesthesia = think MH</li>
            <li><strong>Dantrolene saves lives:</strong> Mortality dropped from 80% to <5% with dantrolene. Give early, give enough</li>
            <li><strong>Avoid CCBs:</strong> Calcium channel blockers + dantrolene = cardiovascular collapse</li>
            <li><strong>Fever may be late:</strong> Don't wait for fever â€” other signs appear first</li>
            <li><strong>Masseter rigidity:</strong> Especially after succinylcholine, may be early warning sign</li>
            <li><strong>Family screening:</strong> Autosomal dominant â€” test and warn family members</li>
            <li><strong>MH hotline:</strong> 1-800-644-9737 (MHAUS) â€” 24/7 expert consultation</li>
        </ul>
    </div>
</div>
<!-- BUILD #27 - GI/HEPATOLOGY CONDITIONS (318-322) -->

<!-- HEPATORENAL SYNDROME -->
<div id="hepatorenal-syndrome" class="condition-page">
    <div class="page-header">
        <h2>318. HEPATORENAL SYNDROME</h2>
        <div class="subtitle">Functional Renal Failure in Cirrhosis â€¢ Type 1 vs Type 2</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Functional renal failure in advanced cirrhosis due to splanchnic vasodilation and renal vasoconstriction</p>
            
            <p><span class="label">HRS-AKI (formerly Type 1):</span></p>
            <ul>
                <li>Rapid decline in kidney function (doubling of creatinine to â‰¥2.5 mg/dL in <2 weeks)</li>
                <li>Often precipitated by infection (SBP), GI bleeding, large volume paracentesis without albumin</li>
                <li>High mortality without treatment (median survival ~2 weeks)</li>
            </ul>
            
            <p><span class="label">HRS-NAKI (formerly Type 2):</span></p>
            <ul>
                <li>Gradual, steady decline in renal function</li>
                <li>Associated with refractory ascites</li>
                <li>Better short-term prognosis than HRS-AKI</li>
            </ul>
            
            <p><span class="label">Precipitants:</span> SBP (most common), GI bleeding, aggressive diuresis, large volume paracentesis without albumin replacement, nephrotoxins</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC CRITERIA (ICA-AKI 2015)</div>
        <div class="section-content">
            <p><span class="label">Required Criteria:</span></p>
            <ul>
                <li>Cirrhosis with ascites</li>
                <li>Diagnosis of AKI per ICA criteria (sCr increase â‰¥0.3 mg/dL within 48h OR â‰¥50% from baseline)</li>
                <li>No improvement after 2 days of diuretic withdrawal AND albumin challenge (1 g/kg/day, max 100g/day)</li>
                <li>Absence of shock</li>
                <li>No current or recent nephrotoxic drugs</li>
                <li>No parenchymal kidney disease (proteinuria <500 mg/day, no hematuria, normal renal ultrasound)</li>
            </ul>
            
            <p><span class="label">Key Point:</span> HRS is a diagnosis of EXCLUSION â€” must rule out other causes first</p>
            
            <p><span class="label">Urine Studies:</span></p>
            <ul>
                <li>Urine sodium typically <10 mEq/L (avid sodium retention)</li>
                <li>FENa <1% (prerenal pattern)</li>
                <li>Bland sediment (no casts, minimal protein)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. General Measures:</span></p>
            <ul>
                <li>Stop diuretics, nephrotoxins</li>
                <li>Volume expansion with albumin 1 g/kg (max 100g) Ã— 2 days</li>
                <li>Treat precipitating factors (antibiotics for SBP)</li>
            </ul>
            
            <p><span class="label">2. Vasoconstrictor Therapy + Albumin:</span></p>
            <ul>
                <li><strong>Terlipressin + Albumin:</strong> First-line where available</li>
                <ul>
                    <li>Terlipressin 0.5-1 mg IV q4-6h, titrate to max 2 mg q4h</li>
                    <li>FDA-approved 2022 in US</li>
                </ul>
                <li><strong>Norepinephrine + Albumin:</strong> ICU setting, equally effective</li>
                <ul>
                    <li>Start 0.5 mcg/kg/min, titrate to increase MAP by 10 mmHg</li>
                </ul>
                <li><strong>Midodrine + Octreotide + Albumin:</strong> Non-ICU alternative (less effective)</li>
                <ul>
                    <li>Midodrine 7.5-12.5 mg PO TID</li>
                    <li>Octreotide 100-200 mcg SQ TID</li>
                    <li>Albumin 25-50 g/day</li>
                </ul>
            </ul>
            
            <p><span class="label">3. Treatment Goals:</span></p>
            <ul>
                <li>Complete response: sCr <1.5 mg/dL</li>
                <li>Partial response: sCr decrease â‰¥50%</li>
                <li>Continue treatment until response or max 14 days</li>
            </ul>
            
            <p><span class="label">4. TIPS:</span> Consider for HRS-NAKI with refractory ascites; contraindicated in HRS-AKI with high MELD</p>
            
            <p><span class="label">5. Liver Transplantation:</span> Definitive treatment; evaluate all HRS patients for transplant candidacy</p>
            
            <p><span class="label">6. Renal Replacement Therapy:</span> Bridge to transplant only; not beneficial without transplant option</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Albumin challenge first:</strong> Must give albumin 1 g/kg Ã— 2 days before diagnosing HRS</li>
            <li><strong>SBP is #1 precipitant:</strong> Always rule out infection in cirrhotic with AKI</li>
            <li><strong>Terlipressin is here:</strong> FDA approved 2022 â€” first-line therapy with albumin</li>
            <li><strong>FENa is low:</strong> Despite being "renal failure," kidneys are working â€” just underperfused</li>
            <li><strong>Transplant is cure:</strong> HRS often reverses post-liver transplant</li>
            <li><strong>Dialysis without transplant:</strong> Generally futile â€” doesn't improve survival</li>
        </ul>
    </div>
</div>

<!-- DRUG-INDUCED LIVER INJURY -->
<div id="dili" class="condition-page">
    <div class="page-header">
        <h2>319. DRUG-INDUCED LIVER INJURY (DILI)</h2>
        <div class="subtitle">Hepatotoxicity â€¢ R-Ratio Classification</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Presentation:</span> Asymptomatic LFT elevation to fulminant hepatic failure</p>
            <p><span class="label">Symptoms (when present):</span> Fatigue, nausea, RUQ pain, jaundice, pruritus</p>
            
            <p><span class="label">Patterns by R-Ratio:</span></p>
            <ul>
                <li><strong>R = (ALT/ULN) Ã· (ALP/ULN)</strong></li>
                <li><strong>Hepatocellular (R â‰¥5):</strong> ALT predominant; acetaminophen, isoniazid, statins</li>
                <li><strong>Cholestatic (R â‰¤2):</strong> ALP predominant; amoxicillin-clavulanate, anabolic steroids</li>
                <li><strong>Mixed (R 2-5):</strong> Both elevated; phenytoin, sulfonamides</li>
            </ul>
            
            <p><span class="label">High-Risk Medications:</span></p>
            <ul>
                <li><strong>Antibiotics:</strong> Amoxicillin-clavulanate (#1 cause), isoniazid, fluoroquinolones, nitrofurantoin</li>
                <li><strong>NSAIDs:</strong> Diclofenac especially</li>
                <li><strong>Anticonvulsants:</strong> Phenytoin, carbamazepine, valproate</li>
                <li><strong>Statins:</strong> Usually mild, rarely severe</li>
                <li><strong>Acetaminophen:</strong> Dose-dependent, most common cause of ALF</li>
                <li><strong>Herbal/supplements:</strong> Green tea extract, kava, anabolic steroids</li>
                <li><strong>Immunotherapy:</strong> Checkpoint inhibitors (ipilimumab, nivolumab)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Key Principle:</span> DILI is a diagnosis of EXCLUSION</p>
            
            <p><span class="label">Rule Out Other Causes:</span></p>
            <ul>
                <li>Viral hepatitis: HAV IgM, HBsAg, HBV DNA, HCV Ab/RNA, HEV (if appropriate)</li>
                <li>Autoimmune hepatitis: ANA, ASMA, IgG levels</li>
                <li>Biliary obstruction: RUQ ultrasound, MRCP if needed</li>
                <li>Wilson disease: Ceruloplasmin (if <40 years)</li>
                <li>Ischemic hepatitis: Clinical context, rapid rise/fall pattern</li>
            </ul>
            
            <p><span class="label">Causality Assessment:</span></p>
            <ul>
                <li><strong>RUCAM Score:</strong> Roussel Uclaf Causality Assessment Method</li>
                <li>Considers: Timing, course, risk factors, concomitant drugs, exclusion of other causes, rechallenge</li>
                <li>Score >8: Highly probable; 6-8: Probable; 3-5: Possible</li>
            </ul>
            
            <p><span class="label">Hy's Law (Poor Prognosis):</span></p>
            <ul>
                <li>Hepatocellular injury (ALT >3Ã— ULN) PLUS</li>
                <li>Bilirubin >2Ã— ULN WITHOUT</li>
                <li>Biliary obstruction</li>
                <li>Indicates ~10% risk of fatal/transplant-requiring outcome</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Stop Offending Agent:</span> Most important intervention</p>
            
            <p><span class="label">2. Specific Antidotes:</span></p>
            <ul>
                <li><strong>Acetaminophen:</strong> N-acetylcysteine (NAC)</li>
                <li><strong>Valproate:</strong> L-carnitine</li>
                <li><strong>Amanita mushroom:</strong> Silibinin, NAC, penicillin G</li>
            </ul>
            
            <p><span class="label">3. NAC for Non-Acetaminophen DILI:</span></p>
            <ul>
                <li>Consider IV NAC for early acute liver failure from any DILI</li>
                <li>May improve transplant-free survival in early ALF</li>
            </ul>
            
            <p><span class="label">4. Corticosteroids:</span></p>
            <ul>
                <li>Consider for immune-mediated DILI (checkpoint inhibitors)</li>
                <li>DRESS syndrome with liver involvement</li>
                <li>Autoimmune-like DILI</li>
            </ul>
            
            <p><span class="label">5. Ursodeoxycholic Acid:</span> May help cholestatic DILI (limited evidence)</p>
            
            <p><span class="label">6. Liver Transplant Evaluation:</span> If progressing to acute liver failure</p>
            
            <p><span class="label">Prognosis:</span> Most DILI resolves with drug withdrawal; 10% progress to chronic liver disease</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>R-ratio guides pattern:</strong> Calculate (ALT/ULN)Ã·(ALP/ULN) to classify hepatocellular vs cholestatic</li>
            <li><strong>Amox-clav is #1:</strong> Most common cause of idiosyncratic DILI (not acetaminophen, which is dose-dependent)</li>
            <li><strong>Hy's Law = danger:</strong> Hepatocellular + jaundice without obstruction = ~10% fatal/transplant</li>
            <li><strong>Ask about supplements:</strong> Herbal products cause significant DILI â€” patients don't always report them</li>
            <li><strong>Latency varies:</strong> Days (acetaminophen) to months (amox-clav, isoniazid)</li>
            <li><strong>Never rechallenge:</strong> If severe DILI, do not re-expose to the drug</li>
        </ul>
    </div>
</div>

<!-- AUTOIMMUNE HEPATITIS -->
<div id="autoimmune-hepatitis" class="condition-page">
    <div class="page-header">
        <h2>320. AUTOIMMUNE HEPATITIS</h2>
        <div class="subtitle">Immune-Mediated Liver Inflammation â€¢ Steroid-Responsive</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Spectrum:</span> Asymptomatic LFT elevation â†’ acute hepatitis â†’ fulminant liver failure â†’ chronic cirrhosis</p>
            <p><span class="label">Symptoms:</span> Fatigue, malaise, jaundice, RUQ discomfort, arthralgias</p>
            
            <p><span class="label">Demographics:</span></p>
            <ul>
                <li>Bimodal: Young women (15-25) and perimenopausal (45-60)</li>
                <li>Female predominance (3-4:1)</li>
                <li>Associated with other autoimmune diseases (thyroiditis, celiac, UC, RA)</li>
            </ul>
            
            <p><span class="label">Types:</span></p>
            <ul>
                <li><strong>Type 1 (Classic):</strong> ANA and/or ASMA positive; most common</li>
                <li><strong>Type 2:</strong> Anti-LKM1 or anti-LC1 positive; more common in children</li>
            </ul>
            
            <p><span class="label">Overlap Syndromes:</span> AIH-PBC overlap, AIH-PSC overlap</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Simplified Diagnostic Criteria (â‰¥6 points = probable, â‰¥7 = definite):</span></p>
            <ul>
                <li><strong>ANA or ASMA â‰¥1:40:</strong> 1 point</li>
                <li><strong>ANA or ASMA â‰¥1:80:</strong> 2 points</li>
                <li><strong>Anti-LKM1 â‰¥1:40:</strong> 2 points</li>
                <li><strong>Anti-SLA positive:</strong> 2 points</li>
                <li><strong>IgG >ULN:</strong> 1 point</li>
                <li><strong>IgG >1.1Ã— ULN:</strong> 2 points</li>
                <li><strong>Liver histology compatible:</strong> 1 point</li>
                <li><strong>Liver histology typical:</strong> 2 points</li>
                <li><strong>Absence of viral hepatitis:</strong> 2 points</li>
            </ul>
            
            <p><span class="label">Laboratory Findings:</span></p>
            <ul>
                <li>Elevated ALT/AST (hepatocellular pattern)</li>
                <li>Elevated IgG (polyclonal hypergammaglobulinemia)</li>
                <li>Positive autoantibodies (ANA, ASMA, anti-LKM1, anti-SLA)</li>
            </ul>
            
            <p><span class="label">Liver Biopsy:</span></p>
            <ul>
                <li><strong>Typical:</strong> Interface hepatitis, lymphoplasmacytic infiltrate, hepatocyte rosettes</li>
                <li>Helps confirm diagnosis, assess severity, rule out other conditions</li>
            </ul>
            
            <p><span class="label">Exclude:</span> Viral hepatitis, DILI, Wilson disease, alpha-1 antitrypsin deficiency</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Indications for Treatment:</span></p>
            <ul>
                <li>AST/ALT â‰¥10Ã— ULN</li>
                <li>AST/ALT â‰¥5Ã— ULN with IgG â‰¥2Ã— ULN</li>
                <li>Bridging necrosis or multilobular necrosis on biopsy</li>
                <li>Symptoms attributable to AIH</li>
            </ul>
            
            <p><span class="label">Induction Therapy:</span></p>
            <ul>
                <li><strong>Prednisone monotherapy:</strong> 40-60 mg/day initially, taper over weeks</li>
                <li><strong>Prednisone + Azathioprine (preferred):</strong></li>
                <ul>
                    <li>Prednisone 30 mg/day + azathioprine 50 mg/day (or 1-2 mg/kg)</li>
                    <li>Allows lower steroid doses</li>
                </ul>
                <li><strong>Budesonide + azathioprine:</strong> Alternative for non-cirrhotic patients (fewer systemic steroid effects)</li>
            </ul>
            
            <p><span class="label">Maintenance Therapy:</span></p>
            <ul>
                <li>Azathioprine 1-2 mg/kg/day as monotherapy after remission</li>
                <li>Continue minimum 2-3 years after normalization</li>
                <li>Many patients require lifelong therapy</li>
            </ul>
            
            <p><span class="label">Treatment Goals:</span></p>
            <ul>
                <li>Biochemical remission: Normal ALT, AST, IgG</li>
                <li>Histologic remission: Resolution of inflammation on biopsy</li>
            </ul>
            
            <p><span class="label">Refractory Disease:</span> Mycophenolate mofetil, tacrolimus, rituximab</p>
            
            <p><span class="label">Liver Transplant:</span> For decompensated cirrhosis or fulminant AIH unresponsive to steroids</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Steroid-responsive:</strong> AIH typically responds dramatically to steroids â€” lack of response should prompt reconsideration</li>
            <li><strong>Check IgG:</strong> Elevated IgG is key; often >2Ã— ULN</li>
            <li><strong>ASMA is smooth muscle:</strong> Anti-smooth muscle antibody, not "asthma"</li>
            <li><strong>Azathioprine is steroid-sparing:</strong> Combination allows lower steroid doses and fewer side effects</li>
            <li><strong>Relapse is common:</strong> 50-90% relapse after stopping therapy; many need lifelong treatment</li>
            <li><strong>Can present as ALF:</strong> Acute severe AIH may require urgent transplant evaluation</li>
        </ul>
    </div>
</div>

<!-- BUDD-CHIARI SYNDROME -->
<div id="budd-chiari" class="condition-page">
    <div class="page-header">
        <h2>321. BUDD-CHIARI SYNDROME</h2>
        <div class="subtitle">Hepatic Vein Outflow Obstruction</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Triad:</span> Abdominal pain, hepatomegaly, ascites</p>
            
            <p><span class="label">Presentations:</span></p>
            <ul>
                <li><strong>Acute:</strong> Rapid onset RUQ pain, hepatomegaly, ascites, liver failure</li>
                <li><strong>Subacute:</strong> Gradual onset over weeks; most common presentation</li>
                <li><strong>Chronic:</strong> Complications of cirrhosis (variceal bleeding, encephalopathy)</li>
                <li><strong>Fulminant:</strong> Acute liver failure with encephalopathy (rare)</li>
            </ul>
            
            <p><span class="label">Etiology (Hypercoagulable States):</span></p>
            <ul>
                <li><strong>Myeloproliferative neoplasms:</strong> JAK2+ polycythemia vera, essential thrombocythemia (most common!)</li>
                <li><strong>Inherited thrombophilias:</strong> Factor V Leiden, prothrombin mutation, protein C/S deficiency</li>
                <li><strong>Antiphospholipid syndrome</strong></li>
                <li><strong>PNH (paroxysmal nocturnal hemoglobinuria)</strong></li>
                <li><strong>Oral contraceptives, pregnancy</strong></li>
                <li><strong>Malignancy:</strong> HCC, renal cell carcinoma with IVC invasion</li>
                <li><strong>Infections:</strong> Liver abscess, aspergillosis</li>
            </ul>
            
            <p><span class="label">Key Point:</span> Always look for underlying cause â€” often MPN even without elevated counts</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Doppler Ultrasound (First-Line):</span></p>
            <ul>
                <li>Absent or reversed flow in hepatic veins</li>
                <li>Intrahepatic collaterals ("spider web" pattern)</li>
                <li>Caudate lobe hypertrophy (drains directly to IVC)</li>
                <li>Sensitivity ~85%</li>
            </ul>
            
            <p><span class="label">CT/MRI with Venography:</span></p>
            <ul>
                <li>Confirms diagnosis, shows extent of thrombosis</li>
                <li>"Flip-flop" enhancement pattern on CT</li>
                <li>IVC involvement</li>
            </ul>
            
            <p><span class="label">Venography:</span> Gold standard but invasive; used if imaging equivocal or for intervention</p>
            
            <p><span class="label">Liver Biopsy:</span> Centrilobular congestion, necrosis; may help assess chronicity</p>
            
            <p><span class="label">Thrombophilia Workup:</span></p>
            <ul>
                <li><strong>JAK2 V617F mutation:</strong> Test in ALL patients (MPN is leading cause)</li>
                <li>Factor V Leiden, prothrombin G20210A</li>
                <li>Antithrombin, protein C/S (after acute phase)</li>
                <li>Antiphospholipid antibodies</li>
                <li>PNH flow cytometry</li>
                <li>Bone marrow biopsy if MPN suspected</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Stepwise Approach:</span></p>
            
            <p><span class="label">1. Anticoagulation (All Patients):</span></p>
            <ul>
                <li>LMWH â†’ warfarin (INR 2-3) or DOAC</li>
                <li>Lifelong if underlying thrombophilia persists</li>
            </ul>
            
            <p><span class="label">2. Treat Underlying Cause:</span></p>
            <ul>
                <li>Cytoreduction for MPN (hydroxyurea, ruxolitinib)</li>
                <li>Eculizumab for PNH</li>
            </ul>
            
            <p><span class="label">3. Medical Management of Complications:</span></p>
            <ul>
                <li>Diuretics for ascites</li>
                <li>Beta-blockers for varices</li>
            </ul>
            
            <p><span class="label">4. Angioplasty/Stenting:</span></p>
            <ul>
                <li>For short-segment hepatic vein or IVC stenosis/web</li>
                <li>Consider thrombolysis if acute</li>
            </ul>
            
            <p><span class="label">5. TIPS:</span></p>
            <ul>
                <li>For patients failing medical therapy</li>
                <li>Decompresses portal system by creating intrahepatic shunt</li>
                <li>70-80% long-term success</li>
            </ul>
            
            <p><span class="label">6. Liver Transplantation:</span></p>
            <ul>
                <li>Fulminant liver failure</li>
                <li>Failed TIPS</li>
                <li>Decompensated cirrhosis</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Check JAK2 in everyone:</strong> MPN is the most common cause â€” even with normal CBC</li>
            <li><strong>Caudate lobe hypertrophy:</strong> Classic finding â€” caudate drains directly to IVC, so it's spared</li>
            <li><strong>Stepwise treatment:</strong> Anticoagulation â†’ intervention â†’ TIPS â†’ transplant</li>
            <li><strong>Young woman with BCS:</strong> Think OCPs + underlying thrombophilia</li>
            <li><strong>Acute = thrombolysis:</strong> May try catheter-directed thrombolysis if caught early</li>
            <li><strong>Lifelong anticoagulation:</strong> Most patients need it indefinitely</li>
        </ul>
    </div>
</div>

<!-- HEPATOPULMONARY SYNDROME -->
<div id="hepatopulmonary" class="condition-page">
    <div class="page-header">
        <h2>322. HEPATOPULMONARY SYNDROME</h2>
        <div class="subtitle">Intrapulmonary Shunting in Liver Disease â€¢ Platypnea-Orthodeoxia</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Hypoxemia due to intrapulmonary vascular dilations (IPVDs) in the setting of liver disease</p>
            
            <p><span class="label">Classic Symptoms:</span></p>
            <ul>
                <li><strong>Dyspnea:</strong> Progressive, often insidious onset</li>
                <li><strong>Platypnea:</strong> Dyspnea worsening when upright (opposite of orthopnea!)</li>
                <li><strong>Orthodeoxia:</strong> Oxygen desaturation when upright (improves supine)</li>
            </ul>
            
            <p><span class="label">Physical Exam:</span></p>
            <ul>
                <li>Spider angiomata, clubbing, cyanosis</li>
                <li>Signs of chronic liver disease and portal hypertension</li>
            </ul>
            
            <p><span class="label">Pathophysiology:</span></p>
            <ul>
                <li>Intrapulmonary vascular dilations (IPVDs) at capillary and precapillary level</li>
                <li>Blood flows through dilated vessels without adequate gas exchange</li>
                <li>Ventilation-perfusion mismatch and true shunting</li>
                <li>Worse upright because dilations are basal (gravity-dependent)</li>
            </ul>
            
            <p><span class="label">Severity Classification:</span></p>
            <ul>
                <li>Mild: PaOâ‚‚ â‰¥80 mmHg</li>
                <li>Moderate: PaOâ‚‚ 60-79 mmHg</li>
                <li>Severe: PaOâ‚‚ 50-59 mmHg</li>
                <li>Very severe: PaOâ‚‚ <50 mmHg</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC CRITERIA</div>
        <div class="section-content">
            <p><span class="label">Triad Required:</span></p>
            <ul>
                <li>Liver disease (usually with portal hypertension)</li>
                <li>Hypoxemia: Elevated A-a gradient (â‰¥15 mmHg, or â‰¥20 if age >64) OR PaOâ‚‚ <80 mmHg on room air</li>
                <li>Evidence of intrapulmonary vascular dilations</li>
            </ul>
            
            <p><span class="label">Contrast-Enhanced Echocardiography (Diagnostic Test of Choice):</span></p>
            <ul>
                <li>Agitated saline ("bubble study")</li>
                <li><strong>Positive:</strong> Bubbles appear in left atrium 3-6 cardiac cycles after appearing in right atrium</li>
                <li><strong>Intracardiac shunt:</strong> Bubbles appear in <3 cycles (PFO, ASD)</li>
                <li>Sensitivity >95%</li>
            </ul>
            
            <p><span class="label">99mTc-MAA Lung Perfusion Scan:</span></p>
            <ul>
                <li>Quantifies shunt fraction</li>
                <li>Brain uptake >6% indicates significant shunting</li>
            </ul>
            
            <p><span class="label">Additional Workup:</span></p>
            <ul>
                <li>ABG: Hypoxemia, elevated A-a gradient</li>
                <li>PFTs: Often normal or mildly reduced DLCO</li>
                <li>CXR/CT: Usually normal; rule out other causes</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">No Effective Medical Therapy:</span></p>
            <ul>
                <li>No medications proven to improve HPS</li>
                <li>Pentoxifylline, garlic, mycophenolate â€” studied but not beneficial</li>
            </ul>
            
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li>Supplemental oxygen for hypoxemia</li>
                <li>Avoid hepatotoxins, optimize liver function</li>
            </ul>
            
            <p><span class="label">Liver Transplantation (Definitive Treatment):</span></p>
            <ul>
                <li>Only treatment that reverses HPS</li>
                <li>HPS is an indication for MELD exception points</li>
                <li>PaOâ‚‚ <60 mmHg qualifies for exception</li>
                <li>Resolution of HPS occurs in 85%+ post-transplant (may take 6-12 months)</li>
            </ul>
            
            <p><span class="label">Contraindication:</span> PaOâ‚‚ <50 mmHg associated with higher post-transplant mortality â€” controversial cutoff</p>
            
            <p><span class="label">TIPS:</span> Generally NOT effective for HPS (unlike portopulmonary hypertension)</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Platypnea-orthodeoxia:</strong> Pathognomonic â€” worse oxygenation when upright (opposite of heart failure!)</li>
            <li><strong>Bubble echo is diagnostic:</strong> Late appearance (3-6 cycles) of bubbles in left heart confirms IPVDs</li>
            <li><strong>HPS vs portopulmonary:</strong> HPS = vasodilation/shunting (low PVR); Portopulmonary = vasoconstriction (high PVR)</li>
            <li><strong>Transplant cures:</strong> HPS is a transplant indication; most resolve post-transplant</li>
            <li><strong>MELD exception:</strong> PaOâ‚‚ <60 qualifies for exception points</li>
            <li><strong>Spider angiomata = systemic vasodilation:</strong> Same process causes both cutaneous and pulmonary dilations</li>
        </ul>
    </div>
</div>
<!-- BUILD #27 - NEPHROLOGY & RHEUMATOLOGY CONDITIONS (323-326) -->

<!-- CONTRAST-INDUCED NEPHROPATHY -->
<div id="contrast-nephropathy" class="condition-page">
    <div class="page-header">
        <h2>323. CONTRAST-INDUCED NEPHROPATHY (CIN)</h2>
        <div class="subtitle">Contrast-Associated AKI â€¢ Prevention is Key</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> AKI occurring within 48-72 hours of contrast exposure</p>
            <ul>
                <li>Increase in serum creatinine â‰¥0.5 mg/dL OR â‰¥25% from baseline</li>
                <li>Peak creatinine typically at 3-5 days</li>
                <li>Usually recovers within 7-14 days</li>
            </ul>
            
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li><strong>Pre-existing CKD (eGFR <60):</strong> Most important risk factor</li>
                <li><strong>Diabetes mellitus</strong> (especially with CKD)</li>
                <li><strong>Heart failure, hypotension</strong></li>
                <li><strong>Volume depletion</strong></li>
                <li><strong>Age >75</strong></li>
                <li><strong>High contrast volume</strong> (>100-150 mL or >3Ã— eGFR mL)</li>
                <li><strong>Multiple contrast exposures</strong> within 72 hours</li>
                <li><strong>Intra-arterial > IV contrast</strong></li>
                <li><strong>High-osmolar > low-osmolar > iso-osmolar contrast</strong></li>
            </ul>
            
            <p><span class="label">Clinical Course:</span></p>
            <ul>
                <li>Usually non-oliguric</li>
                <li>Creatinine peaks day 3-5, returns to baseline by day 7-14</li>
                <li>Dialysis rarely needed (~1%)</li>
                <li>May accelerate progression of underlying CKD</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">RISK ASSESSMENT</div>
        <div class="section-content">
            <p><span class="label">Mehran Risk Score (for PCI):</span></p>
            <ul>
                <li>Hypotension: 5 points</li>
                <li>IABP: 5 points</li>
                <li>CHF: 5 points</li>
                <li>Age >75: 4 points</li>
                <li>Anemia: 3 points</li>
                <li>Diabetes: 3 points</li>
                <li>Contrast volume (1 point per 100 mL)</li>
                <li>eGFR 40-60: 2 points; 20-40: 4 points; <20: 6 points</li>
            </ul>
            
            <p><span class="label">Risk Categories:</span></p>
            <ul>
                <li>Low risk (â‰¤5): CIN risk 7.5%</li>
                <li>Moderate (6-10): CIN risk 14%</li>
                <li>High (11-15): CIN risk 26%</li>
                <li>Very high (â‰¥16): CIN risk 57%</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PREVENTION PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Volume Expansion (Most Important):</span></p>
            <ul>
                <li><strong>Isotonic saline:</strong> 1-1.5 mL/kg/hr for 6-12 hours before AND after contrast</li>
                <li><strong>Alternative:</strong> Sodium bicarbonate 154 mEq/L at 3 mL/kg/hr Ã— 1 hour before, then 1 mL/kg/hr Ã— 6 hours after</li>
                <li>IV hydration superior to oral</li>
            </ul>
            
            <p><span class="label">2. Minimize Contrast Volume:</span></p>
            <ul>
                <li>Use lowest effective dose</li>
                <li>Target: contrast volume (mL) < 3Ã— eGFR</li>
                <li>Use iso-osmolar or low-osmolar contrast agents</li>
            </ul>
            
            <p><span class="label">3. Hold Nephrotoxins:</span></p>
            <ul>
                <li>NSAIDs, aminoglycosides</li>
                <li>Hold metformin (risk of lactic acidosis if AKI develops â€” restart after 48h if creatinine stable)</li>
            </ul>
            
            <p><span class="label">4. Interventions NOT Proven Beneficial:</span></p>
            <ul>
                <li><strong>N-acetylcysteine (NAC):</strong> No longer recommended (PRESERVE trial negative)</li>
                <li><strong>Prophylactic dialysis:</strong> Not beneficial</li>
                <li><strong>Fenoldopam, theophylline:</strong> Not effective</li>
            </ul>
            
            <p><span class="label">5. Special Considerations:</span></p>
            <ul>
                <li><strong>Emergency procedures:</strong> Don't delay for hydration if life-threatening indication</li>
                <li><strong>CKD + urgent CT:</strong> Benefit of diagnosis often outweighs CIN risk</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Hydration is prevention:</strong> IV saline before and after contrast is the most effective strategy</li>
            <li><strong>NAC doesn't work:</strong> PRESERVE trial showed no benefit â€” stop ordering it</li>
            <li><strong>Don't delay necessary imaging:</strong> Risk of missed diagnosis often exceeds CIN risk</li>
            <li><strong>Peaks day 3-5:</strong> If creatinine still rising at day 7, consider other causes</li>
            <li><strong>Metformin is a passenger:</strong> Hold it because of lactic acidosis risk IF CIN develops, not because it causes CIN</li>
            <li><strong>CIN vs atheroemboli:</strong> CIN improves by day 7-14; atheroemboli progressively worsens</li>
        </ul>
    </div>
</div>

<!-- ACUTE INTERSTITIAL NEPHRITIS -->
<div id="acute-interstitial-nephritis" class="condition-page">
    <div class="page-header">
        <h2>324. ACUTE INTERSTITIAL NEPHRITIS (AIN)</h2>
        <div class="subtitle">Drug-Induced Tubulointerstitial Disease â€¢ Eosinophiluria</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Triad (Present in <10%):</span> Fever, rash, eosinophilia</p>
            <p><span class="label">More Common:</span> AKI without classic triad features</p>
            
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li>Often asymptomatic except for rising creatinine</li>
                <li>Flank pain, arthralgias, low-grade fever</li>
                <li>Maculopapular rash (especially with beta-lactams)</li>
            </ul>
            
            <p><span class="label">Causes:</span></p>
            <ul>
                <li><strong>Drugs (70-75%):</strong></li>
                <ul>
                    <li><strong>Antibiotics:</strong> Beta-lactams, fluoroquinolones, sulfonamides, rifampin</li>
                    <li><strong>NSAIDs:</strong> Can occur after months of use; often without systemic symptoms</li>
                    <li><strong>PPIs:</strong> Increasingly recognized; latency can be months</li>
                    <li><strong>Checkpoint inhibitors:</strong> Ipilimumab, nivolumab, pembrolizumab</li>
                    <li><strong>Others:</strong> Allopurinol, phenytoin, diuretics</li>
                </ul>
                <li><strong>Infections (15%):</strong> Legionella, Leptospira, CMV, EBV, Streptococcus</li>
                <li><strong>Autoimmune:</strong> Sarcoidosis, SjÃ¶gren's, TINU syndrome, SLE</li>
                <li><strong>Idiopathic</strong></li>
            </ul>
            
            <p><span class="label">Latency Period:</span></p>
            <ul>
                <li>Antibiotics: Days to weeks</li>
                <li>NSAIDs: Weeks to months</li>
                <li>PPIs: Weeks to months (median 10-11 weeks)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Urinalysis:</span></p>
            <ul>
                <li>WBC casts (hallmark)</li>
                <li>Sterile pyuria</li>
                <li>Hematuria (usually microscopic)</li>
                <li>Mild-moderate proteinuria (<1 g/day, unless NSAID-associated)</li>
            </ul>
            
            <p><span class="label">Eosinophiluria:</span></p>
            <ul>
                <li>Urine eosinophils by Hansel stain (Wright stain less sensitive)</li>
                <li>Sensitivity only 40-60% â€” ABSENCE does NOT rule out AIN</li>
                <li>Not specific (also seen in UTI, prostatitis, GN, atheroemboli)</li>
            </ul>
            
            <p><span class="label">Labs:</span></p>
            <ul>
                <li>Peripheral eosinophilia (present in ~35%)</li>
                <li>Elevated IgE (sometimes)</li>
                <li>FENa may be elevated (tubular dysfunction)</li>
            </ul>
            
            <p><span class="label">Kidney Biopsy (Gold Standard):</span></p>
            <ul>
                <li>Interstitial edema and inflammatory infiltrate</li>
                <li>Lymphocytes, plasma cells, eosinophils</li>
                <li>Tubulitis (inflammatory cells invading tubular epithelium)</li>
                <li>Consider if diagnosis uncertain or no improvement with drug withdrawal</li>
            </ul>
            
            <p><span class="label">Gallium-67 Scan:</span> Increased renal uptake; rarely used now</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">1. Remove Offending Agent:</span></p>
            <ul>
                <li>Most important intervention</li>
                <li>Review ALL medications including OTC and supplements</li>
            </ul>
            
            <p><span class="label">2. Supportive Care:</span></p>
            <ul>
                <li>Avoid nephrotoxins</li>
                <li>Monitor creatinine for improvement</li>
            </ul>
            
            <p><span class="label">3. Corticosteroids (Controversial):</span></p>
            <ul>
                <li><strong>Consider if:</strong> No improvement 3-7 days after drug withdrawal, severe AKI, biopsy-proven AIN</li>
                <li><strong>Regimen:</strong> Prednisone 1 mg/kg/day (max 60 mg) Ã— 2-4 weeks, then taper over 4-8 weeks</li>
                <li>Earlier steroid initiation (<2 weeks) may improve outcomes</li>
                <li>Benefit less clear with prolonged AKI or chronic changes on biopsy</li>
            </ul>
            
            <p><span class="label">4. Checkpoint Inhibitor AIN:</span></p>
            <ul>
                <li>Higher dose steroids often needed</li>
                <li>Prednisone 1-2 mg/kg/day</li>
                <li>May need to discontinue immunotherapy depending on severity</li>
            </ul>
            
            <p><span class="label">Prognosis:</span></p>
            <ul>
                <li>Most recover with drug withdrawal Â± steroids</li>
                <li>~40% have incomplete recovery (residual CKD)</li>
                <li>Poor prognostic factors: Prolonged AKI, interstitial fibrosis on biopsy</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Classic triad is rare:</strong> Fever + rash + eosinophilia present in <10% â€” don't rely on it</li>
            <li><strong>Eosinophiluria is insensitive:</strong> Absence does NOT rule out AIN</li>
            <li><strong>PPIs are underrecognized:</strong> Can cause AIN after months of use; increasing reports</li>
            <li><strong>WBC casts are key:</strong> Suggest tubulointerstitial inflammation</li>
            <li><strong>Early steroids may help:</strong> Consider if no improvement within 3-7 days of drug withdrawal</li>
            <li><strong>NSAID-AIN is different:</strong> Often has nephrotic-range proteinuria and lacks systemic symptoms</li>
        </ul>
    </div>
</div>

<!-- CPPD (PSEUDOGOUT) -->
<div id="cppd" class="condition-page">
    <div class="page-header">
        <h2>325. CPPD (Calcium Pyrophosphate Deposition Disease)</h2>
        <div class="subtitle">Pseudogout â€¢ Chondrocalcinosis</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Clinical Phenotypes:</span></p>
            <ul>
                <li><strong>Acute CPP Crystal Arthritis (Pseudogout):</strong></li>
                <ul>
                    <li>Acute monoarticular or oligoarticular arthritis</li>
                    <li>Knee most common (>50%), also wrist, ankle, shoulder</li>
                    <li>Mimics gout or septic arthritis</li>
                </ul>
                <li><strong>Chronic CPP Crystal Inflammatory Arthritis:</strong></li>
                <ul>
                    <li>Resembles rheumatoid arthritis</li>
                    <li>Symmetric polyarthritis, morning stiffness</li>
                </ul>
                <li><strong>Osteoarthritis with CPPD:</strong></li>
                <ul>
                    <li>Accelerated OA in atypical joints (wrists, MCPs, shoulders)</li>
                </ul>
                <li><strong>Asymptomatic Chondrocalcinosis:</strong> Incidental radiographic finding</li>
            </ul>
            
            <p><span class="label">Triggers for Acute Attacks:</span></p>
            <ul>
                <li>Surgery, illness, trauma</li>
                <li>Similar triggers to gout flares</li>
            </ul>
            
            <p><span class="label">Associated Conditions (Screen if <55 years or polyarticular):</span></p>
            <ul>
                <li><strong>Hyperparathyroidism</strong></li>
                <li><strong>Hemochromatosis</strong></li>
                <li><strong>Hypomagnesemia</strong></li>
                <li><strong>Hypophosphatasia</strong></li>
                <li><strong>Familial/hereditary CPPD</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Synovial Fluid Analysis (Gold Standard):</span></p>
            <ul>
                <li><strong>CPP crystals:</strong> Rhomboid or rod-shaped</li>
                <li><strong>Weakly positive birefringence</strong> under polarized light (blue when parallel to compensator axis)</li>
                <li>Inflammatory fluid: WBC 15,000-30,000/Î¼L (can be higher)</li>
                <li>Always rule out septic arthritis (can coexist!)</li>
            </ul>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>X-ray â€” Chondrocalcinosis:</strong></li>
                <ul>
                    <li>Linear calcifications in fibrocartilage and hyaline cartilage</li>
                    <li>Best seen: Knee menisci, triangular fibrocartilage of wrist, pubic symphysis</li>
                </ul>
                <li><strong>Ultrasound:</strong> Hyperechoic deposits within cartilage</li>
                <li><strong>CT:</strong> More sensitive for calcifications</li>
            </ul>
            
            <p><span class="label">Metabolic Workup (if <55 or polyarticular):</span></p>
            <ul>
                <li>Calcium, PTH (hyperparathyroidism)</li>
                <li>Iron studies, ferritin (hemochromatosis)</li>
                <li>Magnesium</li>
                <li>Alkaline phosphatase (hypophosphatasia)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Acute Attack:</span></p>
            <ul>
                <li><strong>NSAIDs:</strong> First-line if no contraindications</li>
                <li><strong>Colchicine:</strong> 1.2 mg then 0.6 mg one hour later (same as gout dosing)</li>
                <li><strong>Intra-articular corticosteroids:</strong> Effective for monoarticular disease</li>
                <li><strong>Systemic corticosteroids:</strong> Prednisone 30-40 mg/day Ã— 5-7 days if NSAIDs/colchicine contraindicated</li>
                <li><strong>IL-1 inhibitors (anakinra):</strong> For refractory cases</li>
            </ul>
            
            <p><span class="label">Prophylaxis:</span></p>
            <ul>
                <li>Low-dose colchicine 0.6 mg daily or BID</li>
                <li>Low-dose NSAIDs if tolerated</li>
            </ul>
            
            <p><span class="label">Key Differences from Gout:</span></p>
            <ul>
                <li>NO urate-lowering therapy equivalent for CPPD</li>
                <li>Cannot dissolve existing CPP crystite deposits</li>
                <li>Focus on treating acute attacks and prophylaxis</li>
            </ul>
            
            <p><span class="label">Treat Underlying Metabolic Condition:</span></p>
            <ul>
                <li>Parathyroidectomy for hyperparathyroidism</li>
                <li>Phlebotomy for hemochromatosis</li>
                <li>Magnesium replacement</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Weakly positive birefringence:</strong> Blue when parallel (vs gout: strongly negative, yellow when parallel)</li>
            <li><strong>Knee and wrist:</strong> Most common joints (gout favors 1st MTP)</li>
            <li><strong>No "allopurinol equivalent":</strong> Can't dissolve CPP crystals; only treat attacks and prevent recurrence</li>
            <li><strong>Screen for metabolic causes:</strong> Especially if young (<55) or polyarticular â€” check PTH, iron, Mg</li>
            <li><strong>Chondrocalcinosis â‰  CPPD disease:</strong> Many patients with radiographic CC are asymptomatic</li>
            <li><strong>Can coexist with septic arthritis:</strong> Always send fluid for culture; crystals don't rule out infection</li>
        </ul>
    </div>
</div>

<!-- ANGIOEDEMA -->
<div id="angioedema" class="condition-page">
    <div class="page-header">
        <h2>326. ANGIOEDEMA</h2>
        <div class="subtitle">Bradykinin vs Histamine-Mediated â€¢ ACEi-Induced</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Localized, non-pitting edema of deep dermis, subcutaneous tissue, or submucosa</p>
            
            <p><span class="label">Locations:</span></p>
            <ul>
                <li>Face (lips, eyelids, tongue)</li>
                <li>Oropharynx, larynx (AIRWAY EMERGENCY)</li>
                <li>Extremities, genitalia</li>
                <li>GI tract (abdominal pain, nausea â€” can mimic surgical abdomen)</li>
            </ul>
            
            <p><span class="label">Types:</span></p>
            <ul>
                <li><strong>Histamine-Mediated (Mast Cell):</strong></li>
                <ul>
                    <li>Associated with urticaria</li>
                    <li>Pruritic</li>
                    <li>Responds to antihistamines, epinephrine, steroids</li>
                    <li>Causes: Allergic reactions, chronic spontaneous urticaria</li>
                </ul>
                <li><strong>Bradykinin-Mediated:</strong></li>
                <ul>
                    <li>NO urticaria</li>
                    <li>NOT pruritic (may have burning/tingling)</li>
                    <li>Does NOT respond to antihistamines, epinephrine, steroids</li>
                    <li>Causes: ACEi, hereditary angioedema (HAE)</li>
                </ul>
            </ul>
            
            <p><span class="label">ACE Inhibitor-Induced Angioedema:</span></p>
            <ul>
                <li>0.1-0.7% of ACEi users</li>
                <li>Higher risk: African Americans (4-5Ã— higher)</li>
                <li>Can occur years after starting ACEi</li>
                <li>Typically affects face, lips, tongue, larynx</li>
            </ul>
            
            <p><span class="label">Hereditary Angioedema (HAE):</span></p>
            <ul>
                <li>C1 esterase inhibitor deficiency or dysfunction</li>
                <li>Type 1 (85%): Low C1-INH level and function</li>
                <li>Type 2 (15%): Normal C1-INH level, low function</li>
                <li>Family history, recurrent attacks since childhood</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Clinical Differentiation:</span></p>
            <table style="width:100%; border-collapse: collapse; margin: 10px 0;">
                <tr style="background:#f0f4f8;">
                    <th style="padding:8px; border:1px solid #ddd;">Feature</th>
                    <th style="padding:8px; border:1px solid #ddd;">Histamine-Mediated</th>
                    <th style="padding:8px; border:1px solid #ddd;">Bradykinin-Mediated</th>
                </tr>
                <tr>
                    <td style="padding:8px; border:1px solid #ddd;">Urticaria</td>
                    <td style="padding:8px; border:1px solid #ddd;">Present</td>
                    <td style="padding:8px; border:1px solid #ddd;">Absent</td>
                </tr>
                <tr>
                    <td style="padding:8px; border:1px solid #ddd;">Pruritus</td>
                    <td style="padding:8px; border:1px solid #ddd;">Yes</td>
                    <td style="padding:8px; border:1px solid #ddd;">No (burning/tingling)</td>
                </tr>
                <tr>
                    <td style="padding:8px; border:1px solid #ddd;">Response to epinephrine</td>
                    <td style="padding:8px; border:1px solid #ddd;">Yes</td>
                    <td style="padding:8px; border:1px solid #ddd;">No</td>
                </tr>
                <tr>
                    <td style="padding:8px; border:1px solid #ddd;">Response to antihistamines</td>
                    <td style="padding:8px; border:1px solid #ddd;">Yes</td>
                    <td style="padding:8px; border:1px solid #ddd;">No</td>
                </tr>
            </table>
            
            <p><span class="label">Labs for HAE Evaluation:</span></p>
            <ul>
                <li><strong>C4:</strong> Low during AND between attacks (screening test)</li>
                <li><strong>C1-INH level:</strong> Low in Type 1</li>
                <li><strong>C1-INH function:</strong> Low in Types 1 and 2</li>
                <li><strong>C1q:</strong> Normal in HAE; low in acquired C1-INH deficiency</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Airway Management (Priority):</span></p>
            <ul>
                <li>Assess for stridor, voice changes, tongue swelling</li>
                <li>Early intubation if airway compromise (may be difficult â€” call anesthesia/ENT early)</li>
                <li>Prepare for surgical airway</li>
            </ul>
            
            <p><span class="label">Histamine-Mediated Angioedema:</span></p>
            <ul>
                <li>Epinephrine 0.3-0.5 mg IM (if severe/anaphylaxis)</li>
                <li>H1-antihistamines: Diphenhydramine 25-50 mg IV</li>
                <li>H2-antihistamines: Famotidine 20 mg IV</li>
                <li>Corticosteroids: Methylprednisolone 125 mg IV</li>
            </ul>
            
            <p><span class="label">ACEi-Induced Angioedema:</span></p>
            <ul>
                <li><strong>Stop ACEi permanently</strong></li>
                <li>Standard therapy (epinephrine, antihistamines, steroids) â€” often ineffective but still given</li>
                <li><strong>Icatibant (Firazyr):</strong> Bradykinin B2 receptor antagonist, 30 mg SQ</li>
                <li><strong>C1-INH concentrate:</strong> May help (off-label)</li>
                <li><strong>Fresh frozen plasma:</strong> Contains ACE, may help degrade bradykinin (controversial)</li>
                <li>Do NOT switch to ARB immediately (cross-reactivity ~10%)</li>
            </ul>
            
            <p><span class="label">Hereditary Angioedema â€” Acute Attack:</span></p>
            <ul>
                <li><strong>C1-INH concentrate (Berinert, Cinryze):</strong> 20 units/kg IV</li>
                <li><strong>Icatibant:</strong> 30 mg SQ</li>
                <li><strong>Ecallantide (Kalbitor):</strong> Kallikrein inhibitor, 30 mg SQ</li>
            </ul>
            
            <p><span class="label">HAE â€” Prophylaxis:</span></p>
            <ul>
                <li>Lanadelumab (anti-kallikrein antibody)</li>
                <li>C1-INH concentrate</li>
                <li>Androgens (danazol) â€” less preferred due to side effects</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>No urticaria = think bradykinin:</strong> ACEi or HAE; won't respond to standard allergic treatment</li>
            <li><strong>ACEi can cause angioedema years later:</strong> Don't assume it's not the ACEi because patient has been on it for years</li>
            <li><strong>Epinephrine won't work for bradykinin:</strong> But still give it if uncertain â€” won't harm</li>
            <li><strong>C4 is the screening test:</strong> Low C4 between attacks suggests HAE â€” send C1-INH level and function</li>
            <li><strong>Icatibant for ACEi angioedema:</strong> Bradykinin receptor blocker; works when standard therapy fails</li>
            <li><strong>Avoid ARBs after ACEi angioedema:</strong> ~10% cross-reactivity; find alternative antihypertensive</li>
        </ul>
    </div>
</div>
<!-- BUILD #27 - TRANSFUSION, ID, PULMONARY CONDITIONS (327-331) -->

<!-- TRALI -->
<div id="trali" class="condition-page">
    <div class="page-header">
        <h2>327. TRALI (Transfusion-Related Acute Lung Injury)</h2>
        <div class="subtitle">Non-Cardiogenic Pulmonary Edema â€¢ Antibody-Mediated</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Acute lung injury occurring within 6 hours of transfusion, not explained by other ALI risk factors</p>
            
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li>Acute dyspnea, hypoxemia</li>
                <li>Fever, chills (common)</li>
                <li>Hypotension (more common than hypertension)</li>
                <li>Typically occurs 1-2 hours into or after transfusion</li>
            </ul>
            
            <p><span class="label">Diagnostic Criteria:</span></p>
            <ul>
                <li>Acute onset (within 6 hours of transfusion)</li>
                <li>Hypoxemia: PaOâ‚‚/FiOâ‚‚ â‰¤300 OR SpOâ‚‚ <90% on room air</li>
                <li>Bilateral infiltrates on CXR</li>
                <li>No evidence of left atrial hypertension (PAOP â‰¤18 or no clinical evidence of volume overload)</li>
                <li>No pre-existing ALI before transfusion</li>
            </ul>
            
            <p><span class="label">Pathophysiology:</span></p>
            <ul>
                <li><strong>Immune TRALI:</strong> Donor antibodies (anti-HLA or anti-HNA) react with recipient leukocytes</li>
                <li><strong>Non-immune TRALI:</strong> Bioactive lipids in stored blood products</li>
                <li>Results in neutrophil activation and pulmonary capillary leak</li>
            </ul>
            
            <p><span class="label">High-Risk Products:</span></p>
            <ul>
                <li>Products with high plasma content: FFP, platelets, whole blood</li>
                <li>Risk reduced with male-only plasma donors (fewer HLA antibodies)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT PROTOCOL</div>
        <div class="section-content">
            <p><span class="label">Immediate Actions:</span></p>
            <ul>
                <li><strong>Stop transfusion immediately</strong></li>
                <li>Supportive care with oxygen</li>
                <li>Mechanical ventilation if needed (lung-protective strategy)</li>
            </ul>
            
            <p><span class="label">Supportive Care:</span></p>
            <ul>
                <li>Oxygen supplementation</li>
                <li>Intubation/mechanical ventilation for severe hypoxemia</li>
                <li>Vasopressors for hypotension (not volume â€” avoid fluid overload)</li>
            </ul>
            
            <p><span class="label">NOT Beneficial:</span></p>
            <ul>
                <li>Diuretics (not cardiogenic â€” may worsen hypotension)</li>
                <li>Steroids (no proven benefit)</li>
            </ul>
            
            <p><span class="label">Prognosis:</span></p>
            <ul>
                <li>Mortality 5-10% (lower than ARDS from other causes)</li>
                <li>Most improve within 48-96 hours with supportive care</li>
                <li>Usually no long-term pulmonary sequelae</li>
            </ul>
            
            <p><span class="label">Reporting:</span></p>
            <ul>
                <li>Report to blood bank immediately</li>
                <li>Donor testing for HLA/HNA antibodies</li>
                <li>Implicated donor may be deferred from future donations</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Within 6 hours:</strong> TRALI occurs during or within 6 hours of transfusion</li>
            <li><strong>TRALI vs TACO:</strong> TRALI = hypotension, non-cardiogenic; TACO = hypertension, volume overload</li>
            <li><strong>No diuretics:</strong> Not cardiogenic edema â€” diuretics may worsen hypotension</li>
            <li><strong>Usually resolves:</strong> Most patients recover within 48-96 hours</li>
            <li><strong>Report to blood bank:</strong> Critical for donor management and future prevention</li>
            <li><strong>Plasma-rich products:</strong> Higher risk with FFP, platelets than PRBCs</li>
        </ul>
    </div>
</div>

<!-- TACO -->
<div id="taco" class="condition-page">
    <div class="page-header">
        <h2>328. TACO (Transfusion-Associated Circulatory Overload)</h2>
        <div class="subtitle">Cardiogenic Pulmonary Edema from Volume Overload</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Acute pulmonary edema due to volume overload from transfusion</p>
            
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li>Acute dyspnea, orthopnea</li>
                <li>Hypertension (key differentiator from TRALI)</li>
                <li>Tachycardia</li>
                <li>Elevated JVP</li>
                <li>Typically occurs during or within 6-12 hours of transfusion</li>
            </ul>
            
            <p><span class="label">Diagnostic Criteria:</span></p>
            <ul>
                <li>Acute or worsening respiratory distress within 12 hours of transfusion</li>
                <li>Evidence of positive fluid balance</li>
                <li>Elevated BNP/NT-proBNP</li>
                <li>Evidence of left heart failure (elevated PAOP, response to diuretics)</li>
                <li>Bilateral infiltrates on CXR</li>
            </ul>
            
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li>Pre-existing heart failure</li>
                <li>Renal insufficiency</li>
                <li>Age >70</li>
                <li>Low albumin</li>
                <li>Rapid transfusion rate</li>
                <li>Large transfusion volume</li>
                <li>Positive fluid balance</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIFFERENTIATING TACO vs TRALI</div>
        <div class="section-content">
            <table style="width:100%; border-collapse: collapse; margin: 10px 0;">
                <tr style="background:#f0f4f8;">
                    <th style="padding:8px; border:1px solid #ddd;">Feature</th>
                    <th style="padding:8px; border:1px solid #ddd;">TACO</th>
                    <th style="padding:8px; border:1px solid #ddd;">TRALI</th>
                </tr>
                <tr>
                    <td style="padding:8px; border:1px solid #ddd;">Blood pressure</td>
                    <td style="padding:8px; border:1px solid #ddd;">Hypertension</td>
                    <td style="padding:8px; border:1px solid #ddd;">Hypotension</td>
                </tr>
                <tr>
                    <td style="padding:8px; border:1px solid #ddd;">JVP</td>
                    <td style="padding:8px; border:1px solid #ddd;">Elevated</td>
                    <td style="padding:8px; border:1px solid #ddd;">Normal/low</td>
                </tr>
                <tr>
                    <td style="padding:8px; border:1px solid #ddd;">BNP</td>
                    <td style="padding:8px; border:1px solid #ddd;">Elevated (>1.5Ã— baseline)</td>
                    <td style="padding:8px; border:1px solid #ddd;">Normal or mildly elevated</td>
                </tr>
                <tr>
                    <td style="padding:8px; border:1px solid #ddd;">Response to diuretics</td>
                    <td style="padding:8px; border:1px solid #ddd;">Yes</td>
                    <td style="padding:8px; border:1px solid #ddd;">No</td>
                </tr>
                <tr>
                    <td style="padding:8px; border:1px solid #ddd;">Fever</td>
                    <td style="padding:8px; border:1px solid #ddd;">Uncommon</td>
                    <td style="padding:8px; border:1px solid #ddd;">Common</td>
                </tr>
                <tr>
                    <td style="padding:8px; border:1px solid #ddd;">Mechanism</td>
                    <td style="padding:8px; border:1px solid #ddd;">Volume overload</td>
                    <td style="padding:8px; border:1px solid #ddd;">Antibody-mediated</td>
                </tr>
            </table>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT & PREVENTION</div>
        <div class="section-content">
            <p><span class="label">Immediate Treatment:</span></p>
            <ul>
                <li>Stop or slow transfusion</li>
                <li>Sit patient upright</li>
                <li><strong>IV diuretics:</strong> Furosemide 20-40 mg IV</li>
                <li>Supplemental oxygen</li>
                <li>Non-invasive ventilation if needed</li>
            </ul>
            
            <p><span class="label">Prevention Strategies:</span></p>
            <ul>
                <li><strong>Slower transfusion rate:</strong> 1-2 mL/kg/hr in high-risk patients</li>
                <li><strong>Smaller aliquots:</strong> Split units, transfuse over longer time</li>
                <li><strong>Prophylactic diuretics:</strong> Furosemide between units in high-risk patients</li>
                <li><strong>Restrictive transfusion:</strong> Transfuse only when necessary</li>
                <li><strong>Monitor fluid balance</strong></li>
            </ul>
            
            <p><span class="label">Prognosis:</span></p>
            <ul>
                <li>Usually resolves with diuresis within 12-24 hours</li>
                <li>Mortality <5% with appropriate treatment</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>TACO is more common than TRALI:</strong> Most common cause of transfusion-related death</li>
            <li><strong>Hypertension = TACO:</strong> Key differentiator from TRALI (hypotensive)</li>
            <li><strong>Diuretics work:</strong> Unlike TRALI, TACO responds to diuresis</li>
            <li><strong>BNP helps differentiate:</strong> Elevated in TACO, normal/mildly elevated in TRALI</li>
            <li><strong>Prevention is key:</strong> Slow transfusion, prophylactic diuretics in high-risk patients</li>
            <li><strong>Can coexist:</strong> Some patients have features of both TACO and TRALI</li>
        </ul>
    </div>
</div>

<!-- ENDEMIC FUNGAL INFECTIONS -->
<div id="endemic-fungal" class="condition-page">
    <div class="page-header">
        <h2>329. ENDEMIC FUNGAL INFECTIONS</h2>
        <div class="subtitle">Histoplasmosis â€¢ Blastomycosis â€¢ Coccidioidomycosis</div>
    </div>
    
    <div class="section">
        <div class="section-title">GEOGRAPHIC DISTRIBUTION</div>
        <div class="section-content">
            <p><span class="label">Histoplasmosis (Histoplasma capsulatum):</span></p>
            <ul>
                <li>Ohio and Mississippi River valleys</li>
                <li>Soil contaminated with bird or bat droppings</li>
                <li>Cave exploration, demolition of old buildings</li>
            </ul>
            
            <p><span class="label">Blastomycosis (Blastomyces dermatitidis):</span></p>
            <ul>
                <li>Great Lakes, Ohio/Mississippi River valleys, Southeast</li>
                <li>Moist soil, decaying vegetation near waterways</li>
            </ul>
            
            <p><span class="label">Coccidioidomycosis (Coccidioides immitis/posadasii):</span></p>
            <ul>
                <li>Southwestern US (Arizona, California Central Valley), Northern Mexico</li>
                <li>"Valley fever"</li>
                <li>Dust storms, construction, earthquakes</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATIONS</div>
        <div class="section-content">
            <p><span class="label">Histoplasmosis:</span></p>
            <ul>
                <li><strong>Acute pulmonary:</strong> Self-limited flu-like illness; may see hilar lymphadenopathy</li>
                <li><strong>Chronic cavitary:</strong> Upper lobe disease resembling TB; in patients with COPD</li>
                <li><strong>Progressive disseminated:</strong> Immunocompromised (AIDS, TNF inhibitors); hepatosplenomegaly, pancytopenia, adrenal involvement</li>
            </ul>
            
            <p><span class="label">Blastomycosis:</span></p>
            <ul>
                <li><strong>Pulmonary:</strong> Pneumonia with mass-like lesions (can mimic malignancy)</li>
                <li><strong>Skin:</strong> Verrucous or ulcerative lesions (papulopustules â†’ crusted nodules)</li>
                <li><strong>Bone:</strong> Osteomyelitis (vertebrae, ribs, long bones)</li>
                <li><strong>GU:</strong> Prostatitis, epididymitis</li>
                <li>Can occur in immunocompetent hosts</li>
            </ul>
            
            <p><span class="label">Coccidioidomycosis:</span></p>
            <ul>
                <li><strong>Primary pulmonary:</strong> "Valley fever" â€” fever, cough, chest pain, arthralgias</li>
                <li><strong>Pulmonary nodules/cavities:</strong> Can be incidental findings</li>
                <li><strong>Disseminated:</strong> Skin, bones, meninges; higher risk in immunocompromised, pregnant women, Filipino/African American descent</li>
                <li><strong>Meningitis:</strong> Most serious complication; chronic basilar meningitis</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Histoplasmosis:</span></p>
            <ul>
                <li><strong>Urine/serum Histoplasma antigen:</strong> Sensitive for disseminated disease and acute pulmonary</li>
                <li><strong>Serology:</strong> Antibodies (complement fixation, immunodiffusion); less useful in immunocompromised</li>
                <li><strong>Culture/histopath:</strong> Small intracellular yeasts in macrophages</li>
            </ul>
            
            <p><span class="label">Blastomycosis:</span></p>
            <ul>
                <li><strong>Culture:</strong> Gold standard but slow (2-4 weeks)</li>
                <li><strong>Direct visualization:</strong> Broad-based budding yeast (8-15 Î¼m)</li>
                <li><strong>Urine Blastomyces antigen:</strong> Cross-reacts with Histoplasma</li>
            </ul>
            
            <p><span class="label">Coccidioidomycosis:</span></p>
            <ul>
                <li><strong>Serology:</strong> IgM (early), IgG (complement fixation titers correlate with disease severity)</li>
                <li><strong>Culture:</strong> HAZARDOUS â€” alert lab (biosafety concern)</li>
                <li><strong>Direct visualization:</strong> Spherules with endospores</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Histoplasmosis:</span></p>
            <ul>
                <li><strong>Mild-moderate acute:</strong> Observation or itraconazole Ã— 6-12 weeks</li>
                <li><strong>Moderate-severe/disseminated:</strong> Amphotericin B (liposomal) Ã— 1-2 weeks â†’ itraconazole Ã— 12 months</li>
                <li><strong>AIDS patients:</strong> Lifelong suppression with itraconazole until immune reconstitution</li>
            </ul>
            
            <p><span class="label">Blastomycosis:</span></p>
            <ul>
                <li><strong>Mild-moderate pulmonary:</strong> Itraconazole Ã— 6-12 months</li>
                <li><strong>Severe/disseminated/CNS:</strong> Amphotericin B â†’ itraconazole Ã— 12 months</li>
                <li>Always treat (higher mortality than other endemic mycoses)</li>
            </ul>
            
            <p><span class="label">Coccidioidomycosis:</span></p>
            <ul>
                <li><strong>Primary pulmonary (mild):</strong> Observation in healthy hosts OR fluconazole if symptoms >2 months</li>
                <li><strong>Severe/disseminated:</strong> Fluconazole (high dose) or itraconazole; amphotericin B for severe</li>
                <li><strong>Meningitis:</strong> Fluconazole 400-1200 mg/day LIFELONG (relapse common)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Geography matters:</strong> Ask about travel/residence in endemic areas</li>
            <li><strong>Histoplasma antigen:</strong> Best test for disseminated disease; also useful for monitoring treatment</li>
            <li><strong>Blasto skin lesions:</strong> Verrucous/ulcerative â€” can mimic squamous cell carcinoma</li>
            <li><strong>Cocci meningitis = lifelong azole:</strong> Relapse is common; don't stop therapy</li>
            <li><strong>Broad-based budding:</strong> Classic for Blastomycosis (vs narrow-based in other yeasts)</li>
            <li><strong>Alert lab for Cocci:</strong> Highly infectious in culture â€” biosafety hazard</li>
        </ul>
    </div>
</div>

<!-- PULMONARY HYPERTENSION -->
<div id="pulmonary-hypertension" class="condition-page">
    <div class="page-header">
        <h2>330. PULMONARY HYPERTENSION</h2>
        <div class="subtitle">WHO Groups 1-5 â€¢ Right Heart Catheterization Required</div>
    </div>
    
    <div class="section">
        <div class="section-title">DEFINITION & CLASSIFICATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Mean pulmonary artery pressure (mPAP) >20 mmHg at rest by right heart catheterization</p>
            
            <p><span class="label">WHO Classification:</span></p>
            <ul>
                <li><strong>Group 1 â€” Pulmonary Arterial Hypertension (PAH):</strong></li>
                <ul>
                    <li>Idiopathic PAH</li>
                    <li>Heritable (BMPR2 mutations)</li>
                    <li>Drug/toxin-induced (methamphetamines, anorexigens)</li>
                    <li>Associated: CTD (scleroderma), HIV, portal hypertension, CHD</li>
                </ul>
                <li><strong>Group 2 â€” Left Heart Disease:</strong> HFrEF, HFpEF, valvular disease (most common cause!)</li>
                <li><strong>Group 3 â€” Lung Disease/Hypoxia:</strong> COPD, ILD, OSA, high altitude</li>
                <li><strong>Group 4 â€” Chronic Thromboembolic (CTEPH):</strong> Organized thrombi; potentially curable</li>
                <li><strong>Group 5 â€” Multifactorial:</strong> Sarcoidosis, hematologic disorders, metabolic</li>
            </ul>
            
            <p><span class="label">Hemodynamic Definitions:</span></p>
            <ul>
                <li><strong>Pre-capillary PH:</strong> mPAP >20, PAWP â‰¤15, PVR â‰¥3 WU (Groups 1, 3, 4, 5)</li>
                <li><strong>Post-capillary PH:</strong> mPAP >20, PAWP >15 (Group 2)</li>
                <li><strong>Combined:</strong> mPAP >20, PAWP >15, PVR â‰¥3 WU</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li>Dyspnea on exertion (most common, early)</li>
                <li>Fatigue, weakness</li>
                <li>Chest pain (RV ischemia)</li>
                <li>Syncope, near-syncope (ominous â€” suggests severe disease)</li>
                <li>Peripheral edema, ascites (right heart failure)</li>
            </ul>
            
            <p><span class="label">Physical Exam:</span></p>
            <ul>
                <li>Loud P2, right-sided S4</li>
                <li>Tricuspid regurgitation murmur</li>
                <li>JVD, hepatomegaly, peripheral edema</li>
                <li>Signs of underlying disease (scleroderma, COPD)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Initial Evaluation:</span></p>
            <ul>
                <li><strong>Echocardiogram:</strong> Estimates RVSP, RV function, left heart disease</li>
                <li><strong>PFTs:</strong> Assess for lung disease</li>
                <li><strong>V/Q scan:</strong> Rule out CTEPH (more sensitive than CT for chronic PE)</li>
                <li><strong>CT chest:</strong> Parenchymal lung disease, PA enlargement</li>
                <li><strong>6-minute walk test:</strong> Functional assessment</li>
                <li><strong>BNP/NT-proBNP:</strong> Prognostic</li>
            </ul>
            
            <p><span class="label">Right Heart Catheterization (Required for Diagnosis):</span></p>
            <ul>
                <li>Confirms diagnosis</li>
                <li>Differentiates pre- vs post-capillary</li>
                <li>Vasoreactivity testing (Group 1): Response to inhaled NO, epoprostenol, or adenosine</li>
                <li>Positive vasoreactivity: â†“ mPAP â‰¥10 mmHg to â‰¤40 mmHg with stable/improved CO</li>
            </ul>
            
            <p><span class="label">Evaluate for Underlying Causes:</span></p>
            <ul>
                <li>ANA, Scl-70 (scleroderma)</li>
                <li>HIV testing</li>
                <li>LFTs (portal hypertension)</li>
                <li>Sleep study (OSA)</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT (GROUP 1 PAH)</div>
        <div class="section-content">
            <p><span class="label">General Measures:</span></p>
            <ul>
                <li>Diuretics for volume overload</li>
                <li>Oxygen to maintain SpOâ‚‚ >90%</li>
                <li>Avoid pregnancy (high mortality)</li>
                <li>Supervised exercise rehabilitation</li>
            </ul>
            
            <p><span class="label">Vasoreactivity-Positive Patients:</span></p>
            <ul>
                <li>Calcium channel blockers (nifedipine, diltiazem, amlodipine)</li>
                <li>Only ~10% of PAH patients are responders</li>
            </ul>
            
            <p><span class="label">PAH-Specific Therapies:</span></p>
            <ul>
                <li><strong>Endothelin receptor antagonists:</strong> Ambrisentan, bosentan, macitentan</li>
                <li><strong>PDE-5 inhibitors:</strong> Sildenafil, tadalafil</li>
                <li><strong>Soluble guanylate cyclase stimulator:</strong> Riociguat</li>
                <li><strong>Prostacyclin pathway:</strong> Epoprostenol (IV), treprostinil (IV/SQ/inhaled), iloprost (inhaled), selexipag (oral)</li>
            </ul>
            
            <p><span class="label">Combination Therapy:</span> Most patients started on upfront combination therapy (ERA + PDE-5i)</p>
            
            <p><span class="label">Group 2 (Left Heart):</span> Treat underlying heart failure; PAH-specific drugs may worsen outcomes</p>
            
            <p><span class="label">Group 3 (Lung Disease):</span> Optimize underlying disease; supplemental Oâ‚‚</p>
            
            <p><span class="label">Group 4 (CTEPH):</span> Pulmonary endarterectomy (potentially curative); riociguat or balloon angioplasty if inoperable</p>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>RHC is required:</strong> Echo suggests PH, but diagnosis requires right heart catheterization</li>
            <li><strong>Group 2 is most common:</strong> Left heart disease â€” don't give PAH drugs!</li>
            <li><strong>V/Q scan for CTEPH:</strong> More sensitive than CT; CTEPH is potentially curable with surgery</li>
            <li><strong>Syncope is ominous:</strong> Indicates severe disease with high mortality</li>
            <li><strong>Avoid pregnancy:</strong> Mortality 30-50% in PAH patients</li>
            <li><strong>Combination therapy upfront:</strong> Most Group 1 patients started on dual therapy</li>
        </ul>
    </div>
</div>

<!-- OBSTRUCTIVE SLEEP APNEA -->
<div id="osa" class="condition-page">
    <div class="page-header">
        <h2>331. OBSTRUCTIVE SLEEP APNEA (OSA)</h2>
        <div class="subtitle">Sleep-Disordered Breathing â€¢ Hypercapnic Respiratory Failure</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Classic Symptoms:</span></p>
            <ul>
                <li>Loud snoring with witnessed apneas</li>
                <li>Excessive daytime sleepiness</li>
                <li>Morning headaches</li>
                <li>Unrefreshing sleep, fatigue</li>
                <li>Nocturia</li>
                <li>Cognitive impairment, difficulty concentrating</li>
            </ul>
            
            <p><span class="label">Screening Tools:</span></p>
            <ul>
                <li><strong>STOP-BANG:</strong> Snoring, Tired, Observed apnea, Pressure (HTN), BMI >35, Age >50, Neck >40cm, Gender male</li>
                <li>Score â‰¥5: High probability of moderate-severe OSA</li>
                <li><strong>Epworth Sleepiness Scale:</strong> Quantifies daytime sleepiness</li>
            </ul>
            
            <p><span class="label">Complications:</span></p>
            <ul>
                <li>Resistant hypertension</li>
                <li>Atrial fibrillation (4Ã— increased risk)</li>
                <li>Stroke, cardiovascular disease</li>
                <li>Type 2 diabetes</li>
                <li>Pulmonary hypertension</li>
                <li>Obesity hypoventilation syndrome (OHS)</li>
                <li>Motor vehicle accidents</li>
            </ul>
            
            <p><span class="label">Obesity Hypoventilation Syndrome (OHS):</span></p>
            <ul>
                <li>BMI â‰¥30 + daytime hypercapnia (PaCOâ‚‚ >45) + sleep-disordered breathing</li>
                <li>After excluding other causes of hypoventilation</li>
                <li>Higher morbidity/mortality than OSA alone</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Polysomnography (Gold Standard):</span></p>
            <ul>
                <li>In-laboratory overnight sleep study</li>
                <li>Measures AHI, oxygen desaturation, sleep stages, arousals</li>
            </ul>
            
            <p><span class="label">Home Sleep Apnea Testing (HSAT):</span></p>
            <ul>
                <li>Appropriate for high pretest probability, uncomplicated patients</li>
                <li>May underestimate severity</li>
                <li>Not appropriate if: CHF, COPD, neuromuscular disease, suspected central apnea</li>
            </ul>
            
            <p><span class="label">Apnea-Hypopnea Index (AHI) Severity:</span></p>
            <ul>
                <li>Mild: 5-15 events/hour</li>
                <li>Moderate: 15-30 events/hour</li>
                <li>Severe: >30 events/hour</li>
            </ul>
            
            <p><span class="label">Additional Workup:</span></p>
            <ul>
                <li>ABG if OHS suspected (daytime hypercapnia)</li>
                <li>TFTs (hypothyroidism can worsen OSA)</li>
                <li>Consider echo if pulmonary hypertension suspected</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Positive Airway Pressure (First-Line):</span></p>
            <ul>
                <li><strong>CPAP:</strong> Continuous positive airway pressure; standard for OSA</li>
                <li><strong>BiPAP:</strong> For OHS, COPD-OSA overlap, CPAP intolerance</li>
                <li>Auto-titrating CPAP (APAP) often used</li>
            </ul>
            
            <p><span class="label">Alternatives (If CPAP Intolerant):</span></p>
            <ul>
                <li><strong>Oral appliances:</strong> Mandibular advancement devices; for mild-moderate OSA</li>
                <li><strong>Positional therapy:</strong> If predominantly supine OSA</li>
                <li><strong>Hypoglossal nerve stimulation (Inspire):</strong> For moderate-severe OSA, CPAP failure, BMI <32</li>
            </ul>
            
            <p><span class="label">Surgical Options:</span></p>
            <ul>
                <li>UPPP (uvulopalatopharyngoplasty): Variable success</li>
                <li>Maxillomandibular advancement</li>
                <li>Bariatric surgery: If BMI â‰¥35 with comorbidities</li>
            </ul>
            
            <p><span class="label">Lifestyle Modifications:</span></p>
            <ul>
                <li>Weight loss (10% weight loss can significantly improve AHI)</li>
                <li>Avoid alcohol and sedatives before bed</li>
                <li>Sleep position optimization</li>
            </ul>
            
            <p><span class="label">Inpatient Considerations:</span></p>
            <ul>
                <li>Continue CPAP/BiPAP during hospitalization</li>
                <li>Caution with opioids and sedatives</li>
                <li>Higher risk of difficult intubation</li>
                <li>Post-operative monitoring for respiratory complications</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Resistant HTN:</strong> Screen all patients with resistant hypertension for OSA</li>
            <li><strong>AF + OSA:</strong> Treating OSA improves AF outcomes and cardioversion success</li>
            <li><strong>OHS is worse:</strong> Daytime hypercapnia indicates more severe disease with higher mortality</li>
            <li><strong>Weight loss helps:</strong> 10% weight loss can reduce AHI by 20-50%</li>
            <li><strong>Continue CPAP inpatient:</strong> Bring patient's home device; reduces complications</li>
            <li><strong>STOP-BANG â‰¥5:</strong> High probability of moderate-severe OSA</li>
        </ul>
    </div>
</div>
<!-- BUILD #27 - ENDOCRINE & CARDIOLOGY CONDITIONS (332-336) -->

<!-- HYPERPARATHYROIDISM -->
<div id="hyperparathyroidism" class="condition-page">
    <div class="page-header">
        <h2>332. HYPERPARATHYROIDISM</h2>
        <div class="subtitle">Primary vs Secondary vs Tertiary â€¢ Hypercalcemia Workup</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLASSIFICATION</div>
        <div class="section-content">
            <p><span class="label">Primary Hyperparathyroidism:</span></p>
            <ul>
                <li>Autonomous PTH overproduction</li>
                <li><strong>Causes:</strong> Single adenoma (85%), hyperplasia (10-15%), carcinoma (<1%)</li>
                <li><strong>Labs:</strong> â†‘ Calcium, â†‘ PTH (or inappropriately normal)</li>
            </ul>
            
            <p><span class="label">Secondary Hyperparathyroidism:</span></p>
            <ul>
                <li>Appropriate PTH response to hypocalcemia</li>
                <li><strong>Causes:</strong> CKD (most common), vitamin D deficiency, malabsorption</li>
                <li><strong>Labs:</strong> â†“ or normal calcium, â†‘ PTH</li>
            </ul>
            
            <p><span class="label">Tertiary Hyperparathyroidism:</span></p>
            <ul>
                <li>Autonomous PTH after prolonged secondary hyperparathyroidism</li>
                <li>Typically post-renal transplant</li>
                <li><strong>Labs:</strong> â†‘ Calcium, â†‘ PTH</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">"Stones, Bones, Groans, Thrones, and Psychiatric Overtones":</span></p>
            <ul>
                <li><strong>Stones:</strong> Nephrolithiasis (calcium oxalate/phosphate), nephrocalcinosis</li>
                <li><strong>Bones:</strong> Osteoporosis, osteitis fibrosa cystica (brown tumors), fractures</li>
                <li><strong>Groans:</strong> Abdominal pain, constipation, pancreatitis, peptic ulcer</li>
                <li><strong>Thrones:</strong> Polyuria, polydipsia (nephrogenic DI from hypercalcemia)</li>
                <li><strong>Psychiatric:</strong> Depression, fatigue, cognitive dysfunction, anxiety</li>
            </ul>
            
            <p><span class="label">Many Patients Asymptomatic:</span> Discovered incidentally on routine labs</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Initial Labs:</span></p>
            <ul>
                <li>Serum calcium (correct for albumin or check ionized)</li>
                <li>Intact PTH</li>
                <li>25-OH vitamin D</li>
                <li>Phosphorus (low/low-normal in primary)</li>
                <li>24-hour urine calcium (distinguish from FHH)</li>
                <li>Creatinine, eGFR</li>
            </ul>
            
            <p><span class="label">Key Patterns:</span></p>
            <ul>
                <li><strong>Primary HPT:</strong> â†‘ Ca, â†‘ PTH (or inappropriately normal), â†“ phos, â†‘ urine Ca</li>
                <li><strong>FHH:</strong> â†‘ Ca, â†‘ PTH, LOW urine calcium (Ca/Cr clearance ratio <0.01)</li>
                <li><strong>Malignancy:</strong> â†‘ Ca, â†“ PTH, â†‘ PTHrP</li>
            </ul>
            
            <p><span class="label">Localization (If Surgery Planned):</span></p>
            <ul>
                <li><strong>Sestamibi scan:</strong> Identifies adenoma location</li>
                <li><strong>Neck ultrasound:</strong> Complementary to sestamibi</li>
                <li><strong>4D-CT:</strong> If sestamibi/US negative or discordant</li>
            </ul>
            
            <p><span class="label">Assess End-Organ Damage:</span></p>
            <ul>
                <li>DEXA scan (osteoporosis assessment)</li>
                <li>Renal imaging (stones, nephrocalcinosis)</li>
                <li>24-hour urine calcium, creatinine</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Indications for Parathyroidectomy:</span></p>
            <ul>
                <li>Symptomatic disease</li>
                <li>Serum calcium >1 mg/dL above normal</li>
                <li>eGFR <60 mL/min</li>
                <li>T-score â‰¤-2.5 at any site or vertebral fracture</li>
                <li>Age <50</li>
                <li>Kidney stones or nephrocalcinosis</li>
                <li>24-hour urine calcium >400 mg/day with stone risk</li>
            </ul>
            
            <p><span class="label">Surgical Options:</span></p>
            <ul>
                <li>Minimally invasive parathyroidectomy (if localized adenoma)</li>
                <li>Bilateral neck exploration (if localization fails or hyperplasia)</li>
                <li>Intraoperative PTH monitoring</li>
            </ul>
            
            <p><span class="label">Medical Management (If Surgery Not Pursued):</span></p>
            <ul>
                <li>Adequate hydration, avoid thiazides</li>
                <li>Vitamin D repletion (if deficient)</li>
                <li><strong>Cinacalcet:</strong> Calcimimetic; lowers Ca but not PTH levels; for hypercalcemia control</li>
                <li><strong>Bisphosphonates:</strong> For osteoporosis</li>
                <li>Monitor: Calcium, creatinine, DEXA annually</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>PTH should be LOW in hypercalcemia:</strong> If PTH elevated/normal with high Ca = primary HPT</li>
            <li><strong>Rule out FHH:</strong> Check urine calcium; FHH has low urine Ca (benign, no surgery needed)</li>
            <li><strong>Surgery is curative:</strong> 95%+ cure rate for adenoma with experienced surgeon</li>
            <li><strong>Hungry bone syndrome:</strong> Post-parathyroidectomy hypocalcemia (bones take up calcium)</li>
            <li><strong>Normocalcemic variant:</strong> Normal Ca but elevated PTH â€” early/mild disease</li>
            <li><strong>MEN syndromes:</strong> Consider in young patients or family history</li>
        </ul>
    </div>
</div>

<!-- HYPOPARATHYROIDISM -->
<div id="hypoparathyroidism" class="condition-page">
    <div class="page-header">
        <h2>333. HYPOPARATHYROIDISM</h2>
        <div class="subtitle">PTH Deficiency â€¢ Post-Surgical Hypocalcemia</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Symptoms of Hypocalcemia:</span></p>
            <ul>
                <li><strong>Neuromuscular:</strong> Paresthesias (perioral, fingertips), muscle cramps, tetany, seizures</li>
                <li><strong>Cardiac:</strong> QTc prolongation, heart failure (severe/chronic)</li>
                <li><strong>Neuropsychiatric:</strong> Anxiety, depression, cognitive impairment</li>
                <li><strong>Laryngospasm:</strong> Medical emergency</li>
            </ul>
            
            <p><span class="label">Physical Exam Signs:</span></p>
            <ul>
                <li><strong>Chvostek sign:</strong> Facial twitch when tapping facial nerve (anterior to ear)</li>
                <li><strong>Trousseau sign:</strong> Carpal spasm with BP cuff inflated above systolic for 3 minutes (more specific)</li>
            </ul>
            
            <p><span class="label">Etiology:</span></p>
            <ul>
                <li><strong>Post-surgical (most common):</strong> After thyroidectomy, parathyroidectomy, neck dissection</li>
                <li><strong>Autoimmune:</strong> Isolated or part of APS-1 (autoimmune polyglandular syndrome)</li>
                <li><strong>Genetic:</strong> DiGeorge syndrome (22q11 deletion), AIRE mutations</li>
                <li><strong>Infiltrative:</strong> Hemochromatosis, Wilson disease, metastatic disease</li>
                <li><strong>Radiation</strong></li>
                <li><strong>Hypomagnesemia:</strong> Impairs PTH secretion and action</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Labs:</span></p>
            <ul>
                <li><strong>Low calcium</strong> (ionized or albumin-corrected)</li>
                <li><strong>Low or inappropriately normal PTH</strong></li>
                <li><strong>Elevated phosphorus</strong> (PTH normally promotes phosphate excretion)</li>
                <li><strong>Low 1,25-OH vitamin D</strong> (PTH activates vitamin D)</li>
                <li><strong>Normal 25-OH vitamin D</strong> (unless concurrent deficiency)</li>
                <li><strong>Check magnesium</strong> â€” must be normal for PTH to work</li>
            </ul>
            
            <p><span class="label">ECG:</span> Prolonged QTc interval</p>
            
            <p><span class="label">24-hour Urine Calcium:</span> Low (due to lack of PTH effect on renal reabsorption)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Acute Symptomatic Hypocalcemia (Emergency):</span></p>
            <ul>
                <li><strong>IV Calcium gluconate:</strong> 1-2 g (10-20 mL of 10% solution) over 10-20 minutes</li>
                <li>Follow with continuous infusion: 0.5-1.5 mg/kg/hr elemental calcium</li>
                <li>Calcium chloride: More concentrated but irritating; use central line</li>
                <li>Monitor for arrhythmias during infusion</li>
                <li><strong>Correct hypomagnesemia</strong> (PTH won't work if Mg low)</li>
            </ul>
            
            <p><span class="label">Chronic Management:</span></p>
            <ul>
                <li><strong>Calcium supplements:</strong> Calcium carbonate or citrate 1-3 g/day (elemental Ca) in divided doses</li>
                <li><strong>Active vitamin D:</strong> Calcitriol 0.25-2 mcg/day (most important!)</li>
                <li>Goal: Low-normal calcium (8-8.5 mg/dL), avoid hypercalciuria</li>
            </ul>
            
            <p><span class="label">PTH Replacement Therapy:</span></p>
            <ul>
                <li><strong>Natpara (PTH 1-84):</strong> FDA-approved for refractory hypoparathyroidism</li>
                <li>Reserved for patients not controlled on standard therapy</li>
                <li>Black box warning: Osteosarcoma risk in animal studies</li>
            </ul>
            
            <p><span class="label">Monitoring:</span></p>
            <ul>
                <li>Serum calcium: Weekly initially, then every 3-6 months</li>
                <li>24-hour urine calcium: Annually (hypercalciuria risk â†’ stones)</li>
                <li>Renal function, phosphorus</li>
                <li>Renal ultrasound: Periodic screening for nephrocalcinosis</li>
            </ul>
            
            <p><span class="label">Avoid:</span></p>
            <ul>
                <li>Thiazide diuretics (increase calcium, but can cause hypercalcemia on treatment)</li>
                <li>Loop diuretics (increase calcium excretion)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Calcitriol is key:</strong> Without PTH, can't activate vitamin D â€” must give active form</li>
            <li><strong>Check magnesium:</strong> PTH won't work if Mg is low; must replete first</li>
            <li><strong>Post-thyroidectomy:</strong> Most common cause; monitor calcium closely post-op</li>
            <li><strong>Target low-normal Ca:</strong> Higher targets increase hypercalciuria and kidney stone risk</li>
            <li><strong>Trousseau > Chvostek:</strong> Trousseau is more specific for hypocalcemia</li>
            <li><strong>High phosphorus:</strong> Key differentiator from vitamin D deficiency (which has low phosphorus)</li>
        </ul>
    </div>
</div>

<!-- TRICUSPID REGURGITATION -->
<div id="tricuspid-regurgitation" class="condition-page">
    <div class="page-header">
        <h2>334. TRICUSPID REGURGITATION</h2>
        <div class="subtitle">Right Heart Failure â€¢ Secondary vs Primary</div>
    </div>
    
    <div class="section">
        <div class="section-title">ETIOLOGY</div>
        <div class="section-content">
            <p><span class="label">Secondary/Functional TR (Most Common):</span></p>
            <ul>
                <li>RV dilation from pulmonary hypertension</li>
                <li>Left heart disease (MR, MS, LV dysfunction)</li>
                <li>RV infarction</li>
                <li>Atrial fibrillation (annular dilation)</li>
            </ul>
            
            <p><span class="label">Primary/Organic TR:</span></p>
            <ul>
                <li><strong>Infective endocarditis:</strong> IV drug use, pacemaker/ICD leads</li>
                <li><strong>Rheumatic heart disease</strong></li>
                <li><strong>Carcinoid syndrome:</strong> Fibrous plaques on valve</li>
                <li><strong>Ebstein anomaly:</strong> Congenital apical displacement of tricuspid valve</li>
                <li><strong>Trauma:</strong> Blunt chest trauma, RV biopsy</li>
                <li><strong>Drugs:</strong> Ergot derivatives, cabergoline, fenfluramine</li>
                <li><strong>Pacemaker/ICD lead interference</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li>Often asymptomatic until severe</li>
                <li>Fatigue, weakness</li>
                <li>Peripheral edema, ascites</li>
                <li>Abdominal discomfort (hepatic congestion)</li>
                <li>Dyspnea (if associated left heart disease)</li>
            </ul>
            
            <p><span class="label">Physical Exam:</span></p>
            <ul>
                <li><strong>Holosystolic murmur:</strong> Left sternal border, increases with inspiration (Carvallo sign)</li>
                <li><strong>JVD:</strong> Prominent V waves ("CV" waves in severe TR)</li>
                <li><strong>Pulsatile liver:</strong> Hepatojugular reflux</li>
                <li><strong>Peripheral edema, ascites</strong></li>
                <li><strong>RV heave</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Echocardiography:</span></p>
            <ul>
                <li>Assess TR severity: Vena contracta, jet area, hepatic vein flow reversal</li>
                <li>RV size and function</li>
                <li>RVSP estimation</li>
                <li>Evaluate left heart and other valves</li>
                <li>Look for structural abnormalities (endocarditis, leads)</li>
            </ul>
            
            <p><span class="label">Severity Grading:</span></p>
            <ul>
                <li>Mild, Moderate, Severe, Massive, Torrential</li>
                <li>Severe: Vena contracta â‰¥7 mm, EROA â‰¥40 mmÂ², systolic hepatic vein reversal</li>
            </ul>
            
            <p><span class="label">Additional Testing:</span></p>
            <ul>
                <li>RHC if pulmonary hypertension suspected</li>
                <li>CT/MRI for complex anatomy</li>
                <li>Labs: BNP, liver function tests</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Medical Management:</span></p>
            <ul>
                <li><strong>Diuretics:</strong> Mainstay for right heart failure symptoms</li>
                <li>Treat underlying cause (pulmonary hypertension, left heart disease)</li>
                <li>Sodium restriction</li>
            </ul>
            
            <p><span class="label">Surgical Indications:</span></p>
            <ul>
                <li>Severe TR undergoing left-sided valve surgery</li>
                <li>Severe primary TR with symptoms or RV dilation/dysfunction</li>
                <li>Progressive RV dilation despite medical therapy</li>
            </ul>
            
            <p><span class="label">Surgical Options:</span></p>
            <ul>
                <li><strong>Annuloplasty:</strong> Ring repair for functional TR</li>
                <li><strong>Valve repair/replacement:</strong> For primary TR</li>
                <li>Bioprosthetic preferred if replacement needed (lower thrombogenicity)</li>
            </ul>
            
            <p><span class="label">Transcatheter Options (Emerging):</span></p>
            <ul>
                <li>TriClip (edge-to-edge repair)</li>
                <li>Transcatheter valve replacement</li>
                <li>For high surgical risk patients</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Secondary TR is most common:</strong> Fix the left heart disease or pulmonary hypertension first</li>
            <li><strong>Carvallo sign:</strong> Murmur increases with inspiration (right-sided murmurs increase with venous return)</li>
            <li><strong>Giant V waves:</strong> Classic JVP finding in severe TR</li>
            <li><strong>IVDU + TR + fever:</strong> Think right-sided endocarditis</li>
            <li><strong>Carcinoid TR:</strong> Fibrous plaques cause restricted leaflets with regurgitation AND stenosis</li>
            <li><strong>Repair at time of left heart surgery:</strong> Address significant TR when doing mitral/aortic surgery</li>
        </ul>
    </div>
</div>

<!-- LONG QT SYNDROME -->
<div id="long-qt" class="condition-page">
    <div class="page-header">
        <h2>335. LONG QT SYNDROME</h2>
        <div class="subtitle">QTc Prolongation â€¢ Torsades de Pointes Risk</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> QTc >450 ms in men, >460 ms in women (some use >470/480 ms for diagnosis)</p>
            
            <p><span class="label">Types:</span></p>
            <ul>
                <li><strong>Congenital LQTS:</strong> Ion channel mutations (17 subtypes identified)</li>
                <ul>
                    <li>LQT1: KCNQ1 â€” triggered by exercise (especially swimming)</li>
                    <li>LQT2: KCNH2 â€” triggered by emotional stress, auditory stimuli</li>
                    <li>LQT3: SCN5A â€” events during rest/sleep</li>
                </ul>
                <li><strong>Acquired LQTS:</strong> Drugs, electrolytes, structural heart disease</li>
            </ul>
            
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li>Syncope (from torsades)</li>
                <li>Seizures (often misdiagnosed as epilepsy)</li>
                <li>Sudden cardiac death</li>
                <li>Palpitations</li>
                <li>May be asymptomatic</li>
            </ul>
            
            <p><span class="label">Acquired Causes:</span></p>
            <ul>
                <li><strong>Drugs (CredibleMeds.org):</strong></li>
                <ul>
                    <li>Antiarrhythmics: Sotalol, dofetilide, amiodarone, procainamide</li>
                    <li>Antibiotics: Fluoroquinolones, macrolides, azoles</li>
                    <li>Antipsychotics: Haloperidol, ziprasidone, thioridazine</li>
                    <li>Antidepressants: TCAs, citalopram</li>
                    <li>Antiemetics: Ondansetron, droperidol</li>
                    <li>Others: Methadone, hydroxychloroquine</li>
                </ul>
                <li><strong>Electrolytes:</strong> Hypokalemia, hypomagnesemia, hypocalcemia</li>
                <li><strong>Bradycardia</strong></li>
                <li><strong>Structural:</strong> LVH, cardiomyopathy, myocardial ischemia</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">ECG:</span></p>
            <ul>
                <li>Measure QTc (Bazett formula: QTc = QT/âˆšRR)</li>
                <li>T-wave morphology (notched T waves in LQT2)</li>
                <li>Look for TWA (T-wave alternans)</li>
            </ul>
            
            <p><span class="label">Schwartz Score (Congenital LQTS):</span></p>
            <ul>
                <li>QTc, T-wave morphology, clinical history, family history</li>
                <li>â‰¥3.5 points: High probability</li>
            </ul>
            
            <p><span class="label">Additional Testing:</span></p>
            <ul>
                <li>Electrolytes (K, Mg, Ca)</li>
                <li>Medication review</li>
                <li>Exercise stress testing (paradoxical QT prolongation in LQT1)</li>
                <li>Genetic testing (if congenital suspected)</li>
                <li>Family screening with ECG</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Acute Torsades de Pointes:</span></p>
            <ul>
                <li><strong>IV Magnesium:</strong> 2 g IV over 2-5 minutes (first-line even if Mg normal)</li>
                <li><strong>Correct hypokalemia:</strong> Target K >4.0 mEq/L</li>
                <li><strong>Overdrive pacing:</strong> Temporary pacing to shorten QT (rate 90-110)</li>
                <li><strong>Isoproterenol:</strong> If pacing unavailable (increases HR)</li>
                <li><strong>Defibrillation:</strong> If unstable/pulseless</li>
                <li><strong>Stop QT-prolonging drugs</strong></li>
            </ul>
            
            <p><span class="label">Congenital LQTS â€” Long-Term:</span></p>
            <ul>
                <li><strong>Beta-blockers:</strong> First-line for LQT1 and LQT2 (nadolol or propranolol preferred)</li>
                <li><strong>Avoid triggers:</strong> Strenuous exercise in LQT1, startle/emotional stress in LQT2</li>
                <li><strong>ICD:</strong> Secondary prevention (survived arrest), high-risk patients, breakthrough events on beta-blockers</li>
                <li><strong>Left cardiac sympathetic denervation:</strong> Refractory cases</li>
            </ul>
            
            <p><span class="label">Acquired LQTS:</span></p>
            <ul>
                <li>Remove/avoid offending drugs</li>
                <li>Correct electrolytes</li>
                <li>Treat underlying condition</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Magnesium first for torsades:</strong> Give 2 g IV even if Mg level is normal</li>
            <li><strong>LQT1 = swimming:</strong> Exercise-triggered, responds well to beta-blockers</li>
            <li><strong>LQT2 = alarm clocks:</strong> Auditory startle trigger</li>
            <li><strong>LQT3 = sleep:</strong> Events at rest; may need pacemaker/ICD, mexiletine</li>
            <li><strong>Check CredibleMeds.org:</strong> Comprehensive list of QT-prolonging drugs</li>
            <li><strong>Keep K >4.0:</strong> Low K + QT drug = torsades waiting to happen</li>
        </ul>
    </div>
</div>

<!-- BRUGADA SYNDROME -->
<div id="brugada" class="condition-page">
    <div class="page-header">
        <h2>336. BRUGADA SYNDROME</h2>
        <div class="subtitle">Inherited Arrhythmia Syndrome â€¢ Coved ST Elevation</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Demographics:</span></p>
            <ul>
                <li>Male predominance (8:1)</li>
                <li>Asian descent (especially Southeast Asian)</li>
                <li>Typical onset: 30s-40s</li>
            </ul>
            
            <p><span class="label">Symptoms:</span></p>
            <ul>
                <li>Syncope (from polymorphic VT/VF)</li>
                <li>Sudden cardiac death (often during sleep or rest)</li>
                <li>Palpitations</li>
                <li>Many patients asymptomatic</li>
            </ul>
            
            <p><span class="label">Triggers:</span></p>
            <ul>
                <li>Fever (can unmask or worsen pattern)</li>
                <li>Vagal stimulation, large meals</li>
                <li>Cocaine, alcohol</li>
                <li>Certain drugs (sodium channel blockers, psychotropics)</li>
            </ul>
            
            <p><span class="label">Genetics:</span> SCN5A mutations (sodium channel) in ~20-30%; autosomal dominant</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">ECG PATTERNS</div>
        <div class="section-content">
            <p><span class="label">Type 1 (Diagnostic):</span></p>
            <ul>
                <li><strong>"Coved" ST elevation â‰¥2 mm</strong> in V1-V3</li>
                <li>Followed by inverted T wave</li>
                <li>This is the only diagnostic pattern</li>
            </ul>
            
            <p><span class="label">Type 2 (Suggestive but Not Diagnostic):</span></p>
            <ul>
                <li>"Saddleback" ST elevation â‰¥0.5 mm in V1-V3</li>
                <li>Positive or biphasic T wave</li>
            </ul>
            
            <p><span class="label">ECG Tips:</span></p>
            <ul>
                <li>Place V1-V2 in higher intercostal spaces (2nd-3rd) if standard ECG normal but suspicion high</li>
                <li>Pattern may be intermittent</li>
                <li>Fever can provoke Type 1 pattern</li>
            </ul>
            
            <p><span class="label">Drug Challenge (Provocative Testing):</span></p>
            <ul>
                <li>Ajmaline, flecainide, or procainamide</li>
                <li>Positive if Type 1 pattern appears</li>
                <li>Perform in monitored setting</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSIS & RISK STRATIFICATION</div>
        <div class="section-content">
            <p><span class="label">Diagnostic Criteria:</span></p>
            <ul>
                <li>Spontaneous or drug-induced Type 1 pattern PLUS</li>
                <li>One of: Documented VF/polymorphic VT, syncope, family history SCD <45, or Type 1 ECG in family member</li>
            </ul>
            
            <p><span class="label">High-Risk Features:</span></p>
            <ul>
                <li>Survived cardiac arrest</li>
                <li>Syncope (presumed arrhythmic)</li>
                <li>Spontaneous Type 1 pattern (vs drug-induced)</li>
                <li>Inducible VF on EP study (controversial)</li>
            </ul>
            
            <p><span class="label">Family Screening:</span> ECG for first-degree relatives; genetic testing if mutation identified</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">ICD (Implantable Cardioverter-Defibrillator):</span></p>
            <ul>
                <li><strong>Class I:</strong> Prior cardiac arrest, documented sustained VT</li>
                <li><strong>Class IIa:</strong> Spontaneous Type 1 pattern with syncope</li>
                <li><strong>Class IIb:</strong> Inducible VF on EP study (controversial)</li>
            </ul>
            
            <p><span class="label">Medical Therapy:</span></p>
            <ul>
                <li><strong>Quinidine:</strong> May prevent arrhythmias; used as adjunct or if ICD not feasible</li>
                <li><strong>Isoproterenol:</strong> For electrical storm</li>
            </ul>
            
            <p><span class="label">Catheter Ablation:</span></p>
            <ul>
                <li>Epicardial ablation of arrhythmogenic substrate</li>
                <li>For recurrent VF despite ICD</li>
            </ul>
            
            <p><span class="label">Lifestyle & Avoidance:</span></p>
            <ul>
                <li><strong>Avoid drugs that worsen Brugada:</strong> www.brugadadrugs.org</li>
                <li>Treat fever aggressively (acetaminophen)</li>
                <li>Avoid excessive alcohol</li>
                <li>Avoid large meals (vagal stimulation)</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Coved Type 1 is diagnostic:</strong> Saddleback (Type 2) is NOT diagnostic alone</li>
            <li><strong>Fever uncovers Brugada:</strong> Febrile patients may develop Type 1 pattern â€” treat fever aggressively</li>
            <li><strong>Asian males:</strong> Higher prevalence in Southeast Asian populations</li>
            <li><strong>Events at rest/sleep:</strong> Unlike LQT1 (exercise-triggered)</li>
            <li><strong>High leads may help:</strong> Try V1-V2 in 2nd-3rd intercostal space if suspicious but normal ECG</li>
            <li><strong>BrugadaDrugs.org:</strong> List of drugs to avoid in Brugada patients</li>
        </ul>
    </div>
</div>
<!-- BUILD #27 - CRITICAL CARE CONDITIONS (337-338) -->

<!-- VENTILATOR-ASSOCIATED PNEUMONIA -->
<div id="vap" class="condition-page">
    <div class="page-header">
        <h2>337. VENTILATOR-ASSOCIATED PNEUMONIA (VAP)</h2>
        <div class="subtitle">ICU-Acquired Pneumonia â€¢ Prevention Bundles</div>
    </div>
    
    <div class="section">
        <div class="section-title">DEFINITION & EPIDEMIOLOGY</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Pneumonia occurring >48 hours after endotracheal intubation</p>
            
            <p><span class="label">Incidence:</span> 5-15% of mechanically ventilated patients; risk increases with duration of ventilation</p>
            
            <p><span class="label">Mortality:</span> Attributable mortality 10-15%; increases ICU stay by 7-9 days</p>
            
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li>Prolonged mechanical ventilation</li>
                <li>Supine positioning</li>
                <li>Heavy sedation, paralysis</li>
                <li>Reintubation</li>
                <li>Prior antibiotic exposure</li>
                <li>Aspiration</li>
                <li>ARDS, COPD, immunosuppression</li>
            </ul>
            
            <p><span class="label">Pathogenesis:</span> Microaspiration of oropharyngeal secretions around ETT cuff; biofilm on ETT</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">MICROBIOLOGY</div>
        <div class="section-content">
            <p><span class="label">Early VAP (<5 days):</span></p>
            <ul>
                <li>S. pneumoniae, H. influenzae, MSSA</li>
                <li>Enteric gram-negatives</li>
            </ul>
            
            <p><span class="label">Late VAP (â‰¥5 days):</span></p>
            <ul>
                <li><strong>Pseudomonas aeruginosa</strong></li>
                <li><strong>MRSA</strong></li>
                <li><strong>Acinetobacter</strong></li>
                <li>ESBL-producing Enterobacteriaceae</li>
                <li>Stenotrophomonas maltophilia</li>
            </ul>
            
            <p><span class="label">MDR Risk Factors:</span></p>
            <ul>
                <li>Prior IV antibiotics within 90 days</li>
                <li>â‰¥5 days hospitalization before VAP</li>
                <li>Septic shock at time of VAP</li>
                <li>ARDS preceding VAP</li>
                <li>Acute renal replacement therapy before VAP</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC WORKUP</div>
        <div class="section-content">
            <p><span class="label">Clinical Suspicion (All Present):</span></p>
            <ul>
                <li>New/progressive infiltrate on CXR</li>
                <li>Fever (>38Â°C) or hypothermia</li>
                <li>Leukocytosis or leukopenia</li>
                <li>Purulent secretions</li>
                <li>Decline in oxygenation</li>
            </ul>
            
            <p><span class="label">Respiratory Sampling (Before Antibiotics if Possible):</span></p>
            <ul>
                <li><strong>Endotracheal aspirate (ETA):</strong> Easier to obtain; semi-quantitative</li>
                <li><strong>Bronchoalveolar lavage (BAL):</strong> More specific; threshold â‰¥10â´ CFU/mL</li>
                <li><strong>Protected specimen brush (PSB):</strong> Threshold â‰¥10Â³ CFU/mL</li>
            </ul>
            
            <p><span class="label">Clinical Pulmonary Infection Score (CPIS):</span></p>
            <ul>
                <li>Combines temperature, WBC, secretions, oxygenation, CXR, culture</li>
                <li>Score >6 suggests VAP</li>
                <li>Limited sensitivity/specificity; not routinely used for diagnosis</li>
            </ul>
            
            <p><span class="label">Blood Cultures:</span> Obtain before antibiotics; positive in 10-25%</p>
            
            <p><span class="label">Biomarkers:</span> Procalcitonin may help guide antibiotic duration (not diagnosis)</p>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Empiric Therapy â€” Low MDR Risk:</span></p>
            <ul>
                <li>Piperacillin-tazobactam OR</li>
                <li>Cefepime OR</li>
                <li>Levofloxacin OR</li>
                <li>Meropenem (if local ESBL prevalence high)</li>
            </ul>
            
            <p><span class="label">Empiric Therapy â€” High MDR Risk:</span></p>
            <ul>
                <li><strong>Anti-pseudomonal coverage (choose 2 from different classes):</strong></li>
                <ul>
                    <li>Piperacillin-tazobactam, cefepime, ceftazidime, carbapenem, aztreonam</li>
                    <li>PLUS fluoroquinolone (cipro/levo) OR aminoglycoside</li>
                </ul>
                <li><strong>Add MRSA coverage:</strong> Vancomycin or linezolid</li>
            </ul>
            
            <p><span class="label">De-escalation:</span></p>
            <ul>
                <li>Narrow therapy based on culture results (typically within 48-72h)</li>
                <li>Stop MRSA coverage if cultures negative</li>
            </ul>
            
            <p><span class="label">Duration:</span></p>
            <ul>
                <li>7 days for most VAP (non-fermenting GNRs may need longer)</li>
                <li>Procalcitonin-guided discontinuation reduces antibiotic exposure</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">PREVENTION (VAP Bundle)</div>
        <div class="section-content">
            <ul>
                <li><strong>Head of bed elevation 30-45Â°</strong></li>
                <li><strong>Daily sedation interruption</strong> ("sedation vacation")</li>
                <li><strong>Daily assessment of readiness to extubate</strong></li>
                <li><strong>DVT prophylaxis</strong></li>
                <li><strong>Stress ulcer prophylaxis</strong> (though may increase VAP risk)</li>
                <li><strong>Oral care with chlorhexidine</strong> (0.12% twice daily)</li>
                <li><strong>Subglottic secretion drainage</strong> (specialized ETT)</li>
                <li><strong>Avoid unnecessary intubation/reintubation</strong></li>
                <li><strong>Maintain ETT cuff pressure 20-30 cm Hâ‚‚O</strong></li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>Duration matters:</strong> Late VAP (â‰¥5 days) needs broader MDR coverage</li>
            <li><strong>7 days is enough:</strong> Shorter courses work for most VAP</li>
            <li><strong>De-escalate aggressively:</strong> Narrow to culture results within 48-72h</li>
            <li><strong>Bundle compliance:</strong> VAP prevention bundles reduce incidence by 50%+</li>
            <li><strong>Extubation is prevention:</strong> Every day on vent increases VAP risk</li>
            <li><strong>Don't overdiagnose:</strong> Many CXR infiltrates in ICU are not VAP (atelectasis, CHF, ARDS)</li>
        </ul>
    </div>
</div>

<!-- FAT EMBOLISM SYNDROME -->
<div id="fat-embolism" class="condition-page">
    <div class="page-header">
        <h2>338. FAT EMBOLISM SYNDROME</h2>
        <div class="subtitle">Post-Fracture Complication â€¢ Gurd Criteria</div>
    </div>
    
    <div class="section">
        <div class="section-title">CLINICAL PRESENTATION</div>
        <div class="section-content">
            <p><span class="label">Definition:</span> Multi-system dysfunction (pulmonary, neurologic, dermatologic) following fat emboli, typically after long bone fractures</p>
            
            <p><span class="label">Timeline:</span></p>
            <ul>
                <li>Typically 24-72 hours after injury/surgery</li>
                <li>Rarely presents immediately</li>
            </ul>
            
            <p><span class="label">Classic Triad:</span></p>
            <ul>
                <li><strong>Respiratory distress:</strong> Hypoxemia, tachypnea, ARDS-like picture</li>
                <li><strong>Neurologic changes:</strong> Confusion, agitation, altered consciousness, seizures</li>
                <li><strong>Petechial rash:</strong> Upper body (chest, axillae, neck, conjunctivae) â€” pathognomonic but present in only 20-50%</li>
            </ul>
            
            <p><span class="label">Risk Factors:</span></p>
            <ul>
                <li><strong>Long bone fractures</strong> (femur > tibia)</li>
                <li><strong>Pelvic fractures</strong></li>
                <li><strong>Multiple fractures</strong></li>
                <li><strong>Orthopedic procedures:</strong> Intramedullary nailing, arthroplasty</li>
                <li><strong>Non-traumatic:</strong> Pancreatitis, liposuction, bone marrow transplant, sickle cell crisis (rare)</li>
            </ul>
            
            <p><span class="label">Pathophysiology:</span></p>
            <ul>
                <li>Fat globules embolize to pulmonary circulation â†’ inflammatory cascade</li>
                <li>Mechanical obstruction + toxic free fatty acid effects</li>
                <li>Systemic inflammation â†’ multiorgan dysfunction</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">DIAGNOSTIC CRITERIA</div>
        <div class="section-content">
            <p><span class="label">Gurd Criteria (Need 1 Major + 4 Minor OR 2 Major):</span></p>
            
            <p><span class="label">Major Criteria:</span></p>
            <ul>
                <li>Petechial rash</li>
                <li>Respiratory symptoms + bilateral infiltrates</li>
                <li>CNS signs (unrelated to trauma or other cause)</li>
            </ul>
            
            <p><span class="label">Minor Criteria:</span></p>
            <ul>
                <li>Tachycardia >110 bpm</li>
                <li>Fever >38.5Â°C</li>
                <li>Retinal fat or petechiae on fundoscopy</li>
                <li>Fat in urine</li>
                <li>Sudden unexplained drop in Hct or platelets</li>
                <li>Elevated ESR</li>
                <li>Fat globules in sputum</li>
            </ul>
            
            <p><span class="label">Laboratory Findings:</span></p>
            <ul>
                <li>Thrombocytopenia (common)</li>
                <li>Anemia (hemolysis, bone marrow suppression)</li>
                <li>Hypoxemia (A-a gradient elevated)</li>
                <li>Elevated lipase (variable)</li>
            </ul>
            
            <p><span class="label">Imaging:</span></p>
            <ul>
                <li><strong>CXR:</strong> Bilateral alveolar infiltrates ("snowstorm" appearance)</li>
                <li><strong>CT chest:</strong> Ground-glass opacities, nodular opacities</li>
                <li><strong>MRI brain:</strong> Multiple hyperintense lesions on T2/FLAIR ("starfield" pattern) â€” sensitive but not specific</li>
            </ul>
        </div>
    </div>
    
    <div class="section">
        <div class="section-title">TREATMENT</div>
        <div class="section-content">
            <p><span class="label">Primarily Supportive:</span></p>
            <ul>
                <li><strong>Respiratory support:</strong> Oxygen, mechanical ventilation (lung-protective strategies)</li>
                <li><strong>Hemodynamic support:</strong> IV fluids, vasopressors if needed</li>
                <li><strong>Early fracture fixation:</strong> Reduces ongoing fat embolism (within 24h if possible)</li>
            </ul>
            
            <p><span class="label">Controversial/Unproven Therapies:</span></p>
            <ul>
                <li><strong>Corticosteroids:</strong> Some studies suggest benefit in prophylaxis; no clear benefit once established</li>
                <li><strong>Heparin:</strong> Theoretical benefit (stimulates lipase); not routinely used</li>
                <li><strong>Albumin:</strong> May bind free fatty acids; unproven</li>
            </ul>
            
            <p><span class="label">Prevention:</span></p>
            <ul>
                <li>Early surgical stabilization of long bone fractures (<24h)</li>
                <li>Gentle surgical technique (minimize intramedullary pressure)</li>
                <li>Avoid aggressive volume resuscitation with crystalloids alone</li>
                <li>Prophylactic corticosteroids? (methylprednisolone 7.5 mg/kg q8h Ã— 3 doses) â€” data mixed</li>
            </ul>
            
            <p><span class="label">Prognosis:</span></p>
            <ul>
                <li>Mortality 5-15% with supportive care</li>
                <li>Most survivors have complete neurologic recovery</li>
                <li>ARDS may require prolonged ventilation</li>
            </ul>
        </div>
    </div>
    
    <div class="pearl-box">
        <div class="pearl-title">ðŸ”‘ TEACHING PEARLS</div>
        <ul>
            <li><strong>24-72 hour delay:</strong> FES doesn't present immediately â€” watch for it in days following fracture</li>
            <li><strong>Petechiae = pathognomonic:</strong> But only present in 20-50%; upper body distribution</li>
            <li><strong>Think FES:</strong> Post-fracture patient with unexplained hypoxia, confusion, and petechiae</li>
            <li><strong>Early fixation prevents:</strong> Stabilize long bone fractures within 24h to reduce risk</li>
            <li><strong>Thrombocytopenia is common:</strong> Unexplained platelet drop post-fracture should raise suspicion</li>
            <li><strong>Supportive care works:</strong> Most patients recover fully with appropriate respiratory support</li>
        </ul>
    </div>
</div>
<!-- FOOTER -->
<div class="footer-section">
    <p><strong>Internal Medicine Clinical Reference Guide</strong></p>
    <p>338 Essential Conditions for Hospital Medicine</p>
    <p><strong style="color: #ff6b6b;">BUILD #27</strong></p>
    <p style="font-size: 9pt; margin-top: 15px;">For educational purposes only. Always use clinical judgment and consult current guidelines.</p>
</div>

</div>

<script>
// Wells Score Calculator for PE
function calculateWells() {
    let score = 0;
    if (document.getElementById('wells-dvt').checked) score += 3;
    if (document.getElementById('wells-alt').checked) score += 3;
    if (document.getElementById('wells-hr').checked) score += 1.5;
    if (document.getElementById('wells-immob').checked) score += 1.5;
    if (document.getElementById('wells-prior').checked) score += 1.5;
    if (document.getElementById('wells-hemo').checked) score += 1;
    if (document.getElementById('wells-cancer').checked) score += 1;
    
    const resultDiv = document.getElementById('wells-result');
    let interpretation = '';
    let riskClass = '';
    
    if (score <= 4) {
        interpretation = '<strong>PE Unlikely</strong> â€” Check D-dimer. If negative, PE excluded. If positive, proceed to CTPA.';
        riskClass = '';
    } else {
        interpretation = '<strong>PE Likely</strong> â€” Proceed directly to CTPA. Do not rely on D-dimer alone.';
        riskClass = 'high-risk';
    }
    
    resultDiv.style.display = 'block';
    resultDiv.className = 'calc-result ' + riskClass;
    resultDiv.innerHTML = `
        <div style="font-size: 1.2em; margin-bottom: 8px;">Wells Score = <strong>${score}</strong></div>
        <div>${interpretation}</div>
    `;
}

// PERC Rule Calculator
function calculatePERC() {
    let allNegative = true;
    const criteria = ['perc-age', 'perc-hr', 'perc-spo2', 'perc-hemo', 'perc-estrogen', 'perc-vte', 'perc-surgery', 'perc-leg'];
    
    criteria.forEach(id => {
        if (document.getElementById(id).checked) allNegative = false;
    });
    
    const resultDiv = document.getElementById('perc-result');
    
    if (allNegative) {
        resultDiv.style.display = 'block';
        resultDiv.className = 'calc-result';
        resultDiv.innerHTML = `
            <div style="font-size: 1.1em;"><strong>PERC Negative</strong></div>
            <div>If clinical suspicion is LOW, PE is effectively ruled out. No D-dimer or imaging needed.</div>
        `;
    } else {
        resultDiv.style.display = 'block';
        resultDiv.className = 'calc-result high-risk';
        resultDiv.innerHTML = `
            <div style="font-size: 1.1em;"><strong>PERC Positive</strong></div>
            <div>Cannot rule out PE by PERC alone. Proceed with D-dimer or Wells score to guide further workup.</div>
        `;
    }
}

// FENa Calculator
function calculateFENa() {
    const urineNa = parseFloat(document.getElementById('fena-urine-na').value);
    const serumNa = parseFloat(document.getElementById('fena-serum-na').value);
    const urineCr = parseFloat(document.getElementById('fena-urine-cr').value);
    const serumCr = parseFloat(document.getElementById('fena-serum-cr').value);
    const resultDiv = document.getElementById('fena-result');
    
    if (isNaN(urineNa) || isNaN(serumNa) || isNaN(urineCr) || isNaN(serumCr)) {
        resultDiv.style.display = 'block';
        resultDiv.className = 'calc-result high-risk';
        resultDiv.innerHTML = 'âš ï¸ Please enter all values';
        return;
    }
    
    if (urineCr === 0 || serumNa === 0) {
        resultDiv.style.display = 'block';
        resultDiv.className = 'calc-result high-risk';
        resultDiv.innerHTML = 'âš ï¸ Invalid values (division by zero)';
        return;
    }
    
    // FENa = (Urine Na Ã— Serum Cr) / (Serum Na Ã— Urine Cr) Ã— 100
    const fena = ((urineNa * serumCr) / (serumNa * urineCr)) * 100;
    
    let interpretation = '';
    let riskClass = '';
    
    if (fena < 1) {
        interpretation = '<strong>Prerenal AKI</strong> â€” Suggests volume depletion, decreased effective circulating volume, or early obstruction. Consider fluid challenge.';
        riskClass = '';
    } else if (fena >= 1 && fena <= 2) {
        interpretation = '<strong>Indeterminate</strong> â€” Could be prerenal or intrinsic. Consider clinical context, FEUrea if on diuretics, and urine microscopy.';
        riskClass = '';
    } else {
        interpretation = '<strong>Intrinsic Renal (ATN)</strong> â€” Suggests tubular injury. Common causes: ischemia, nephrotoxins, sepsis.';
        riskClass = 'high-risk';
    }
    
    resultDiv.style.display = 'block';
    resultDiv.className = 'calc-result ' + riskClass;
    resultDiv.innerHTML = `
        <div style="font-size: 1.2em; margin-bottom: 8px;">FENa = <strong>${fena.toFixed(2)}%</strong></div>
        <div>${interpretation}</div>
        <div style="font-size: 0.85em; color: #666; margin-top: 8px;">
            âš ï¸ <strong>Limitations:</strong> Not valid with diuretics (use FEUrea <35% for prerenal), CKD, contrast, or rhabdomyolysis.
        </div>
    `;
}

// HEART Score Calculator
function calculateHEART() {
    const history = document.getElementById('heart-history').value;
    const ecg = document.getElementById('heart-ecg').value;
    const age = document.getElementById('heart-age').value;
    const risk = document.getElementById('heart-risk').value;
    const trop = document.getElementById('heart-trop').value;
    
    const resultDiv = document.getElementById('heart-result');
    
    if (history === '' || ecg === '' || age === '' || risk === '' || trop === '') {
        resultDiv.style.display = 'block';
        resultDiv.className = 'calc-result high-risk';
        resultDiv.innerHTML = 'âš ï¸ Please select all values';
        return;
    }
    
    const score = parseInt(history) + parseInt(ecg) + parseInt(age) + parseInt(risk) + parseInt(trop);
    
    let interpretation = '';
    let riskClass = '';
    
    if (score <= 3) {
        interpretation = '<strong>Low Risk (0-3)</strong> â€” 1.7% risk of MACE at 6 weeks. Consider early discharge with outpatient follow-up.';
        riskClass = '';
    } else if (score <= 6) {
        interpretation = '<strong>Moderate Risk (4-6)</strong> â€” 12-16% risk of MACE. Admit for observation and serial troponins.';
        riskClass = '';
    } else {
        interpretation = '<strong>High Risk (7-10)</strong> â€” 50-65% risk of MACE. Admit, early cardiology consult, consider early invasive strategy.';
        riskClass = 'high-risk';
    }
    
    resultDiv.style.display = 'block';
    resultDiv.className = 'calc-result ' + riskClass;
    resultDiv.innerHTML = `
        <div style="font-size: 1.2em; margin-bottom: 8px;">HEART Score = <strong>${score}</strong></div>
        <div>${interpretation}</div>
    `;
}

// TIMI STEMI Score Calculator
function calculateTIMI_STEMI() {
    let score = 0;
    if (document.getElementById('timi-stemi-age65').checked) score += 2;
    if (document.getElementById('timi-stemi-age75').checked) score += 3;
    if (document.getElementById('timi-stemi-dm').checked) score += 1;
    if (document.getElementById('timi-stemi-bp').checked) score += 3;
    if (document.getElementById('timi-stemi-hr').checked) score += 2;
    if (document.getElementById('timi-stemi-killip').checked) score += 2;
    if (document.getElementById('timi-stemi-weight').checked) score += 1;
    if (document.getElementById('timi-stemi-anterior').checked) score += 1;
    if (document.getElementById('timi-stemi-time').checked) score += 1;
    
    const resultDiv = document.getElementById('timi-stemi-result');
    
    let mortality = '';
    let riskClass = '';
    
    if (score <= 2) {
        mortality = '~2% 30-day mortality';
        riskClass = '';
    } else if (score <= 4) {
        mortality = '~5% 30-day mortality';
        riskClass = '';
    } else if (score <= 6) {
        mortality = '~12% 30-day mortality';
        riskClass = 'high-risk';
    } else {
        mortality = '~30%+ 30-day mortality';
        riskClass = 'high-risk';
    }
    
    resultDiv.style.display = 'block';
    resultDiv.className = 'calc-result ' + riskClass;
    resultDiv.innerHTML = `
        <div style="font-size: 1.2em; margin-bottom: 8px;">TIMI STEMI Score = <strong>${score}</strong></div>
        <div>${mortality}</div>
    `;
}

// TIMI NSTEMI Score Calculator
function calculateTIMI_NSTEMI() {
    let score = 0;
    if (document.getElementById('timi-nstemi-age').checked) score += 1;
    if (document.getElementById('timi-nstemi-risk').checked) score += 1;
    if (document.getElementById('timi-nstemi-cad').checked) score += 1;
    if (document.getElementById('timi-nstemi-asa').checked) score += 1;
    if (document.getElementById('timi-nstemi-angina').checked) score += 1;
    if (document.getElementById('timi-nstemi-ecg').checked) score += 1;
    if (document.getElementById('timi-nstemi-trop').checked) score += 1;
    
    const resultDiv = document.getElementById('timi-nstemi-result');
    
    let risk = '';
    let riskClass = '';
    
    if (score <= 2) {
        risk = '<strong>Low Risk (0-2)</strong> â€” ~5% risk of death/MI/urgent revasc at 14 days.';
        riskClass = '';
    } else if (score <= 4) {
        risk = '<strong>Moderate Risk (3-4)</strong> â€” ~13% risk. Consider early invasive strategy.';
        riskClass = '';
    } else {
        risk = '<strong>High Risk (5-7)</strong> â€” ~41% risk. Early invasive strategy recommended.';
        riskClass = 'high-risk';
    }
    
    resultDiv.style.display = 'block';
    resultDiv.className = 'calc-result ' + riskClass;
    resultDiv.innerHTML = `
        <div style="font-size: 1.2em; margin-bottom: 8px;">TIMI NSTEMI Score = <strong>${score}</strong></div>
        <div>${risk}</div>
    `;
}

// GRACE Score Calculator
function calculateGRACE() {
    const age = parseFloat(document.getElementById('grace-age').value);
    const hr = parseFloat(document.getElementById('grace-hr').value);
    const sbp = parseFloat(document.getElementById('grace-sbp').value);
    const cr = parseFloat(document.getElementById('grace-cr').value);
    const killip = document.getElementById('grace-killip').value;
    
    const resultDiv = document.getElementById('grace-result');
    
    if (isNaN(age) || isNaN(hr) || isNaN(sbp) || isNaN(cr) || killip === '') {
        resultDiv.style.display = 'block';
        resultDiv.className = 'calc-result high-risk';
        resultDiv.innerHTML = 'âš ï¸ Please enter all values';
        return;
    }
    
    // Simplified GRACE score calculation
    let score = 0;
    
    // Age points
    if (age < 30) score += 0;
    else if (age < 40) score += 8;
    else if (age < 50) score += 25;
    else if (age < 60) score += 41;
    else if (age < 70) score += 58;
    else if (age < 80) score += 75;
    else if (age < 90) score += 91;
    else score += 100;
    
    // Heart rate points
    if (hr < 50) score += 0;
    else if (hr < 70) score += 3;
    else if (hr < 90) score += 9;
    else if (hr < 110) score += 15;
    else if (hr < 150) score += 24;
    else if (hr < 200) score += 38;
    else score += 46;
    
    // SBP points (inverse)
    if (sbp < 80) score += 58;
    else if (sbp < 100) score += 53;
    else if (sbp < 120) score += 43;
    else if (sbp < 140) score += 34;
    else if (sbp < 160) score += 24;
    else if (sbp < 200) score += 10;
    else score += 0;
    
    // Creatinine points
    if (cr < 0.4) score += 1;
    else if (cr < 0.8) score += 4;
    else if (cr < 1.2) score += 7;
    else if (cr < 1.6) score += 10;
    else if (cr < 2.0) score += 13;
    else if (cr < 4.0) score += 21;
    else score += 28;
    
    // Killip class
    score += parseInt(killip);
    
    let interpretation = '';
    let riskClass = '';
    
    if (score < 109) {
        interpretation = '<strong>Low Risk</strong> â€” <1% in-hospital mortality.';
        riskClass = '';
    } else if (score <= 140) {
        interpretation = '<strong>Intermediate Risk</strong> â€” 1-3% in-hospital mortality.';
        riskClass = '';
    } else {
        interpretation = '<strong>High Risk</strong> â€” >3% in-hospital mortality. Consider early invasive strategy.';
        riskClass = 'high-risk';
    }
    
    resultDiv.style.display = 'block';
    resultDiv.className = 'calc-result ' + riskClass;
    resultDiv.innerHTML = `
        <div style="font-size: 1.2em; margin-bottom: 8px;">GRACE Score = <strong>${score}</strong></div>
        <div>${interpretation}</div>
    `;
}

// qSOFA Calculator
function calculateQSOFA() {
    let score = 0;
    if (document.getElementById('qsofa-rr').checked) score += 1;
    if (document.getElementById('qsofa-ams').checked) score += 1;
    if (document.getElementById('qsofa-sbp').checked) score += 1;
    
    const resultDiv = document.getElementById('qsofa-result');
    
    let interpretation = '';
    let riskClass = '';
    
    if (score < 2) {
        interpretation = '<strong>qSOFA Negative (0-1)</strong> â€” Low risk for poor outcomes. Continue monitoring but sepsis not excluded.';
        riskClass = '';
    } else {
        interpretation = '<strong>qSOFA Positive (â‰¥2)</strong> â€” High risk for poor outcomes. Evaluate for organ dysfunction, consider ICU level care.';
        riskClass = 'high-risk';
    }
    
    resultDiv.style.display = 'block';
    resultDiv.className = 'calc-result ' + riskClass;
    resultDiv.innerHTML = `
        <div style="font-size: 1.2em; margin-bottom: 8px;">qSOFA Score = <strong>${score}</strong></div>
        <div>${interpretation}</div>
    `;
}

// ToC Search Functionality
(function() {
    const searchInput = document.getElementById('tocSearch');
    const searchClear = document.getElementById('tocSearchClear');
    const searchResults = document.getElementById('tocSearchResults');
    const tocGrid = document.getElementById('tocGrid');
    
    if (!searchInput || !tocGrid) return;
    
    const tocItems = tocGrid.querySelectorAll('.toc-item');
    const totalItems = tocItems.length;
    
    function filterToc(query) {
        const q = query.toLowerCase().trim();
        let visibleCount = 0;
        
        tocItems.forEach(item => {
            const text = item.textContent.toLowerCase();
            if (!q || text.includes(q)) {
                item.classList.remove('hidden');
                visibleCount++;
            } else {
                item.classList.add('hidden');
            }
        });
        
        // Update results text
        if (q) {
            searchResults.textContent = `Showing ${visibleCount} of ${totalItems} conditions`;
        } else {
            searchResults.textContent = '';
        }
        
        // Show/hide clear button
        searchClear.style.display = q ? 'flex' : 'none';
        
        // Show no results message
        let noResults = document.getElementById('noSearchResults');
        if (visibleCount === 0 && q) {
            if (!noResults) {
                noResults = document.createElement('div');
                noResults.id = 'noSearchResults';
                noResults.className = 'no-search-results';
                noResults.textContent = 'No conditions match your search.';
                tocGrid.parentNode.insertBefore(noResults, tocGrid.nextSibling);
            }
            noResults.style.display = 'block';
        } else if (noResults) {
            noResults.style.display = 'none';
        }
    }
    
    searchInput.addEventListener('input', (e) => filterToc(e.target.value));
    
    searchClear.addEventListener('click', () => {
        searchInput.value = '';
        filterToc('');
        searchInput.focus();
    });
    
    // Also filter condition pages if user scrolls to them
    searchInput.addEventListener('keydown', (e) => {
        if (e.key === 'Enter') {
            const visibleItems = Array.from(tocItems).filter(item => !item.classList.contains('hidden'));
            if (visibleItems.length === 1) {
                const link = visibleItems[0].querySelector('a');
                if (link) link.click();
            }
        }
    });
})();
</script>
</body>
</html>